<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">26098371</PMID><DateCompleted><Year>2015</Year><Month>08</Month><Day>20</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1476-4687</ISSN><JournalIssue CitedMedium="Internet"><Volume>523</Volume><Issue>7562</Issue><PubDate><Year>2015</Year><Month>Jul</Month><Day>30</Day></PubDate></JournalIssue><Title>Nature</Title><ISOAbbreviation>Nature</ISOAbbreviation></Journal><ArticleTitle>Impermanence of dendritic spines in live adult CA1 hippocampus.</ArticleTitle><Pagination><StartPage>592</StartPage><EndPage>596</EndPage><MedlinePgn>592-6</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/nature14467</ELocationID><Abstract><AbstractText>The mammalian hippocampus is crucial for episodic memory formation and transiently retains information for about 3-4 weeks in adult mice and longer in humans. Although neuroscientists widely believe that neural synapses are elemental sites of information storage, there has been no direct evidence that hippocampal synapses persist for time intervals commensurate with the duration of hippocampal-dependent memory. Here we tested the prediction that the lifetimes of hippocampal synapses match the longevity of hippocampal memory. By using time-lapse two-photon microendoscopy in the CA1 hippocampal area of live mice, we monitored the turnover dynamics of the pyramidal neurons' basal dendritic spines, postsynaptic structures whose turnover dynamics are thought to reflect those of excitatory synaptic connections. Strikingly, CA1 spine turnover dynamics differed sharply from those seen previously in the neocortex. Mathematical modelling revealed that the data best matched kinetic models with a single population of spines with a mean lifetime of approximately 1-2 weeks. This implies &#x223c;100% turnover in &#x223c;2-3 times this interval, a near full erasure of the synaptic connectivity pattern. Although N-methyl-d-aspartate (NMDA) receptor blockade stabilizes spines in the neocortex, in CA1 it transiently increased the rate of spine loss and thus lowered spine density. These results reveal that adult neocortical and hippocampal pyramidal neurons have divergent patterns of spine regulation and quantitatively support the idea that the transience of hippocampal-dependent memory directly reflects the turnover dynamics of hippocampal synapses.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Attardo</LastName><ForeName>Alessio</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>1] James H. Clark Center for Biomedical Engineering &amp;Sciences, Stanford University, Stanford, California 94305, USA [2] Howard Hughes Medical Institute, Stanford University, Stanford, California 94305, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fitzgerald</LastName><ForeName>James E</ForeName><Initials>JE</Initials><AffiliationInfo><Affiliation>James H. Clark Center for Biomedical Engineering &amp;Sciences, Stanford University, Stanford, California 94305, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schnitzer</LastName><ForeName>Mark J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>1] James H. Clark Center for Biomedical Engineering &amp;Sciences, Stanford University, Stanford, California 94305, USA [2] Howard Hughes Medical Institute, Stanford University, Stanford, California 94305, USA [3] CNC Program, Stanford University, Stanford, California 94305, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R21 AG038771</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 MH092809</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>06</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nature</MedlineTA><NlmUniqueID>0410462</NlmUniqueID><ISSNLinking>0028-0836</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016194">Receptors, N-Methyl-D-Aspartate</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Neuroscientist. 2015 Dec;21(6):576</RefSource></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D056547" MajorTopicYN="N">CA1 Region, Hippocampal</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="Y">cytology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D049229" MajorTopicYN="N">Dendritic Spines</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004724" MajorTopicYN="N">Endoscopy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007700" MajorTopicYN="N">Kinetics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D061212" MajorTopicYN="N">Memory, Episodic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019579" MajorTopicYN="N">Neocortex</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009473" MajorTopicYN="N">Neuronal Plasticity</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017785" MajorTopicYN="N">Photons</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017966" MajorTopicYN="N">Pyramidal Cells</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016194" MajorTopicYN="N">Receptors, N-Methyl-D-Aspartate</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013569" MajorTopicYN="N">Synapses</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>8</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>4</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>6</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>6</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>8</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2016</Year><Month>1</Month><Day>30</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26098371</ArticleId><ArticleId IdType="mid">NIHMS680456</ArticleId><ArticleId IdType="pmc">PMC4648621</ArticleId><ArticleId IdType="doi">10.1038/nature14467</ArticleId><ArticleId IdType="pii">nature14467</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Squire LR, Zola-Morgan S. The medial temporal lobe memory system. Science. 1991;253:1380&#x2013;1386.</Citation><ArticleIdList><ArticleId IdType="pubmed">1896849</ArticleId></ArticleIdList></Reference><Reference><Citation>Frankland PW, Bontempi B. The organization of recent and remote memories. Nat Rev Neurosci. 2005;6:119&#x2013;130. doi: 10.1038/nrn1607. nrn1607 [pii]</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrn1607</ArticleId><ArticleId IdType="pubmed">15685217</ArticleId></ArticleIdList></Reference><Reference><Citation>Frey U, Morris RG. Synaptic tagging and long-term potentiation. Nature. 1997;385:533&#x2013;536. doi: 10.1038/385533a0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/385533a0</ArticleId><ArticleId IdType="pubmed">9020359</ArticleId></ArticleIdList></Reference><Reference><Citation>Barretto RP, et al. Time-lapse imaging of disease progression in deep brain areas using fluorescence microendoscopy. Nat Med. 2011;17:223&#x2013;228. doi: 10.1038/nm.2292. nm.2292 [pii]</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.2292</ArticleId><ArticleId IdType="pmc">PMC3833825</ArticleId><ArticleId IdType="pubmed">21240263</ArticleId></ArticleIdList></Reference><Reference><Citation>Engert F, Bonhoeffer T. Dendritic spine changes associated with hippocampal long-term synaptic plasticity. Nature. 1999;399:66&#x2013;70. doi: 10.1038/19978.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/19978</ArticleId><ArticleId IdType="pubmed">10331391</ArticleId></ArticleIdList></Reference><Reference><Citation>Maletic-Savatic M, Malinow R, Svoboda K. Rapid dendritic morphogenesis in CA1 hippocampal dendrites induced by synaptic activity. Science. 1999;283:1923&#x2013;1927.</Citation><ArticleIdList><ArticleId IdType="pubmed">10082466</ArticleId></ArticleIdList></Reference><Reference><Citation>Holtmaat AJ, et al. Transient and persistent dendritic spines in the neocortex in vivo. Neuron. 2005;45:279&#x2013;291. doi: 10.1016/j.neuron.2005.01.003. S0896627305000048 [pii]</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2005.01.003</ArticleId><ArticleId IdType="pubmed">15664179</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu T, et al. Rapid formation and selective stabilization of synapses for enduring motor memories. Nature. 2009;462:915&#x2013;919. doi: 10.1038/nature08389. nature08389 [pii]</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature08389</ArticleId><ArticleId IdType="pmc">PMC2844762</ArticleId><ArticleId IdType="pubmed">19946267</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang G, Pan F, Gan WB. Stably maintained dendritic spines are associated with lifelong memories. Nature. 2009;462:920&#x2013;924. doi: 10.1038/nature08577. nature08577 [pii]</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature08577</ArticleId><ArticleId IdType="pmc">PMC4724802</ArticleId><ArticleId IdType="pubmed">19946265</ArticleId></ArticleIdList></Reference><Reference><Citation>Zuo Y, Yang G, Kwon E, Gan WB. Long-term sensory deprivation prevents dendritic spine loss in primary somatosensory cortex. Nature. 2005;436:261&#x2013;265. doi: 10.1038/nature03715. nature03715 [pii]</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature03715</ArticleId><ArticleId IdType="pubmed">16015331</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang G, et al. Sleep promotes branch-specific formation of dendritic spines after learning. Science. 2014;344:1173&#x2013;1178. doi: 10.1126/science.1249098.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1249098</ArticleId><ArticleId IdType="pmc">PMC4447313</ArticleId><ArticleId IdType="pubmed">24904169</ArticleId></ArticleIdList></Reference><Reference><Citation>Harris KM. Structure, development, and plasticity of dendritic spines. Curr Opin Neurobiol. 1999;9:343&#x2013;348.</Citation><ArticleIdList><ArticleId IdType="pubmed">10395574</ArticleId></ArticleIdList></Reference><Reference><Citation>Mizrahi A, Crowley JC, Shtoyerman E, Katz LC. High-resolution in vivo imaging of hippocampal dendrites and spines. J Neurosci. 2004;24:3147&#x2013;3151. doi: 10.1523/JNEUROSCI.5218-03.2004. 24/13/3147 [pii]</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.5218-03.2004</ArticleId><ArticleId IdType="pmc">PMC6730023</ArticleId><ArticleId IdType="pubmed">15056694</ArticleId></ArticleIdList></Reference><Reference><Citation>Barretto RP, Messerschmidt B, Schnitzer MJ. In vivo fluorescence imaging with high-resolution microlenses. Nat Methods. 2009;6:511&#x2013;512. doi: 10.1038/nmeth.1339. nmeth.1339 [pii]</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nmeth.1339</ArticleId><ArticleId IdType="pmc">PMC2849805</ArticleId><ArticleId IdType="pubmed">19525959</ArticleId></ArticleIdList></Reference><Reference><Citation>Gu L, et al. Long-term in vivo imaging of dendritic spines in the hippocampus reveals structural plasticity. J Neurosci. 2014;34:13948&#x2013;13953. doi: 10.1523/JNEUROSCI.1464-14.2014. 34/42/13948 [pii]</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.1464-14.2014</ArticleId><ArticleId IdType="pmc">PMC6705298</ArticleId><ArticleId IdType="pubmed">25319691</ArticleId></ArticleIdList></Reference><Reference><Citation>Ziv Y, et al. Long-term dynamics of CA1 hippocampal place codes. Nat Neurosci. 2013;16:264&#x2013;266. doi: 10.1038/nn.3329. nn.3329 [pii]</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.3329</ArticleId><ArticleId IdType="pmc">PMC3784308</ArticleId><ArticleId IdType="pubmed">23396101</ArticleId></ArticleIdList></Reference><Reference><Citation>Harris KM, Stevens JK. Dendritic spines of CA 1 pyramidal cells in the rat hippocampus: serial electron microscopy with reference to their biophysical characteristics. J Neurosci. 1989;9:2982&#x2013;2997.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6569708</ArticleId><ArticleId IdType="pubmed">2769375</ArticleId></ArticleIdList></Reference><Reference><Citation>Moser MB, Trommald M, Andersen P. An increase in dendritic spine density on hippocampal CA1 pyramidal cells following spatial learning in adult rats suggests the formation of new synapses. Proc Natl Acad Sci U S A. 1994;91:12673&#x2013;12675.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC45501</ArticleId><ArticleId IdType="pubmed">7809099</ArticleId></ArticleIdList></Reference><Reference><Citation>Rampon C, et al. Enrichment induces structural changes and recovery from nonspatial memory deficits in CA1 NMDAR1-knockout mice. Nat Neurosci. 2000;3:238&#x2013;244. doi: 10.1038/72945.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/72945</ArticleId><ArticleId IdType="pubmed">10700255</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanders J, Cowansage K, Baumgartel K, Mayford M. Elimination of dendritic spines with long-term memory is specific to active circuits. J Neurosci. 2012;32:12570&#x2013;12578. doi: 10.1523/JNEUROSCI.1131-12.2012. 32/36/12570 [pii]</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.1131-12.2012</ArticleId><ArticleId IdType="pmc">PMC3486631</ArticleId><ArticleId IdType="pubmed">22956846</ArticleId></ArticleIdList></Reference><Reference><Citation>Bourne JN, Harris KM. Coordination of size and number of excitatory and inhibitory synapses results in a balanced structural plasticity along mature hippocampal CA1 dendrites during LTP. Hippocampus. 2011;21:354&#x2013;373. doi: 10.1002/hipo.20768.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hipo.20768</ArticleId><ArticleId IdType="pmc">PMC2891364</ArticleId><ArticleId IdType="pubmed">20101601</ArticleId></ArticleIdList></Reference><Reference><Citation>Huerta PT, Sun LD, Wilson MA, Tonegawa S. Formation of temporal memory requires NMDA receptors within CA1 pyramidal neurons. Neuron. 2000;25:473&#x2013;480. S0896-6273(00)80909-5 [pii]</Citation><ArticleIdList><ArticleId IdType="pubmed">10719900</ArticleId></ArticleIdList></Reference><Reference><Citation>Yasumatsu N, Matsuzaki M, Miyazaki T, Noguchi J, Kasai H. Principles of long-term dynamics of dendritic spines. J Neurosci. 2008;28:13592&#x2013;13608. doi: 10.1523/JNEUROSCI.0603-08.2008. 28/50/13592 [pii]</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.0603-08.2008</ArticleId><ArticleId IdType="pmc">PMC2706274</ArticleId><ArticleId IdType="pubmed">19074033</ArticleId></ArticleIdList></Reference><Reference><Citation>Toni N, Buchs PA, Nikonenko I, Bron CR, Muller D. LTP promotes formation of multiple spine synapses between a single axon terminal and a dendrite. Nature. 1999;402:421&#x2013;425. doi: 10.1038/46574.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/46574</ArticleId><ArticleId IdType="pubmed">10586883</ArticleId></ArticleIdList></Reference><Reference><Citation>Goshen I, et al. Dynamics of retrieval strategies for remote memories. Cell. 2011;147:678&#x2013;689. doi: 10.1016/j.cell.2011.09.033. S0092-8674(11)01144-5 [pii]</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2011.09.033</ArticleId><ArticleId IdType="pubmed">22019004</ArticleId></ArticleIdList></Reference><Reference><Citation>Sorra KE, Harris KM. Stability in synapse number and size at 2 hr after long-term potentiation in hippocampal area CA1. J Neurosci. 1998;18:658&#x2013;671.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6792539</ArticleId><ArticleId IdType="pubmed">9425008</ArticleId></ArticleIdList></Reference><Reference><Citation>Fusi S, Drew PJ, Abbott LF. Cascade models of synaptically stored memories. Neuron. 2005;45:599&#x2013;611. doi: 10.1016/j.neuron.2005.02.001. S0896-6273(05)00117-0 [pii]</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2005.02.001</ArticleId><ArticleId IdType="pubmed">15721245</ArticleId></ArticleIdList></Reference><Reference><Citation>Abraham WC, Robins A. Memory retention--the synaptic stability versus plasticity dilemma. Trends Neurosci. 2005;28:73&#x2013;78. doi: 10.1016/j.tins.2004.12.003. S0166-2236(04)00370-4 [pii]</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tins.2004.12.003</ArticleId><ArticleId IdType="pubmed">15667929</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu XE, Mel BW. Capacity-enhancing synaptic learning rules in a medial temporal lobe online learning model. Neuron. 2009;62:31&#x2013;41. doi: 10.1016/j.neuron.2009.02.021. S0896-6273(09)00167-6 [pii]</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2009.02.021</ArticleId><ArticleId IdType="pmc">PMC2822782</ArticleId><ArticleId IdType="pubmed">19376065</ArticleId></ArticleIdList></Reference><Reference><Citation>Poirazi P, Mel BW. Impact of active dendrites and structural plasticity on the memory capacity of neural tissue. Neuron. 2001;29:779&#x2013;796. S0896-6273(01)00252-5 [pii]</Citation><ArticleIdList><ArticleId IdType="pubmed">11301036</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng G, et al. Imaging neuronal subsets in transgenic mice expressing multiple spectral variants of GFP. Neuron. 2000;28:41&#x2013;51. S0896-6273(00)00084-2 [pii]</Citation><ArticleIdList><ArticleId IdType="pubmed">11086982</ArticleId></ArticleIdList></Reference><Reference><Citation>Holtmaat A, et al. Long-term, high-resolution imaging in the mouse neocortex through a chronic cranial window. Nat Protoc. 2009;4:1128&#x2013;1144. doi: 10.1038/nprot.2009.89. nprot.2009.89 [pii]</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nprot.2009.89</ArticleId><ArticleId IdType="pmc">PMC3072839</ArticleId><ArticleId IdType="pubmed">19617885</ArticleId></ArticleIdList></Reference><Reference><Citation>Dombeck DA, Harvey CD, Tian L, Looger LL, Tank DW. Functional imaging of hippocampal place cells at cellular resolution during virtual navigation. Nat Neurosci. 2010;13:1433&#x2013;1440. doi: 10.1038/nn.2648. nn.2648 [pii]</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.2648</ArticleId><ArticleId IdType="pmc">PMC2967725</ArticleId><ArticleId IdType="pubmed">20890294</ArticleId></ArticleIdList></Reference><Reference><Citation>Mishchenko Y, et al. Ultrastructural analysis of hippocampal neuropil from the connectomics perspective. Neuron. 2010;67:1009&#x2013;1020. doi: 10.1016/j.neuron.2010.08.014. S0896-6273(10)00624-0 [pii]</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2010.08.014</ArticleId><ArticleId IdType="pmc">PMC3215280</ArticleId><ArticleId IdType="pubmed">20869597</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">26099047</PMID><DateCompleted><Year>2015</Year><Month>09</Month><Day>28</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1546-170X</ISSN><JournalIssue CitedMedium="Internet"><Volume>21</Volume><Issue>7</Issue><PubDate><Year>2015</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Nature medicine</Title><ISOAbbreviation>Nat Med</ISOAbbreviation></Journal><ArticleTitle>Inhibition of amyloid-&#x3b2; plaque formation by &#x3b1;-synuclein.</ArticleTitle><Pagination><StartPage>802</StartPage><EndPage>807</EndPage><MedlinePgn>802-7</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/nm.3885</ELocationID><Abstract><AbstractText>Amyloid-&#x3b2; (A&#x3b2;) plaques and &#x3b1;-synuclein (&#x3b1;-syn)-rich Lewy bodies are the major neuropathological hallmarks of Alzheimer's disease (AD) and Parkinson's disease, respectively. An overlap of pathologies is found in most individuals with dementia with Lewy bodies (DLB) and in more than 50% of AD cases. Their brains display substantial &#x3b1;-syn accumulation not only in Lewy bodies, but also in dystrophic neurites decorating A&#x3b2; plaques. Several studies report binding and coaggregation of A&#x3b2; and &#x3b1;-syn, yet the precise role of &#x3b1;-syn in amyloid plaque formation remains elusive. Here we performed intracerebral injections of &#x3b1;-syn-containing preparations into amyloid precursor protein (APP) transgenic mice (expressing APP695(KM670/671NL) and PSEN1(L166P) under the control of the neuron-specific Thy-1 promoter; referred to here as 'APPPS1'). Unexpectedly, &#x3b1;-syn failed to cross-seed A&#x3b2; plaques in vivo, but rather it inhibited plaque formation in APPPS1 mice coexpressing SNCA(A30P) (referred to here as 'APPPS1 &#xd7; [A30P]aSYN' double-transgenic mice). This was accompanied by increased A&#x3b2; levels in cerebrospinal fluid despite unchanged overall A&#x3b2; levels. Notably, the seeding activity of A&#x3b2;-containing brain homogenates was considerably reduced by &#x3b1;-syn, and A&#x3b2; deposition was suppressed in grafted tissue from [A30P]aSYN transgenic mice. Thus, we conclude that an interaction between A&#x3b2; and &#x3b1;-syn leads to inhibition of A&#x3b2; deposition and to reduced plaque formation.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bachhuber</LastName><ForeName>Teresa</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Adolf Butenandt Institute, Department of Biochemistry, Ludwig-Maximilians University, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Katzmarski</LastName><ForeName>Natalie</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>1] Neurocenter, Department of Neurology, University of Freiburg, Freiburg, Germany. [2] Faculty of Biology, University of Freiburg, Freiburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McCarter</LastName><ForeName>Joanna F</ForeName><Initials>JF</Initials><AffiliationInfo><Affiliation>Adolf Butenandt Institute, Department of Biochemistry, Ludwig-Maximilians University, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Loreth</LastName><ForeName>Desiree</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Neurocenter, Department of Neurology, University of Freiburg, Freiburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tahirovic</LastName><ForeName>Sabina</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kamp</LastName><ForeName>Frits</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Metabolic Biochemistry, Ludwig-Maximilians University, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abou-Ajram</LastName><ForeName>Claudia</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Adolf Butenandt Institute, Department of Biochemistry, Ludwig-Maximilians University, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nuscher</LastName><ForeName>Brigitte</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Metabolic Biochemistry, Ludwig-Maximilians University, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Serrano-Pozo</LastName><ForeName>Alberto</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>MassGeneral Institute for Neurodegenerative Disease, Massachusetts General Hospital and Harvard Medical School, Charlestown, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>M&#xfc;ller</LastName><ForeName>Alexandra</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Institute of Neuropathology, University of Freiburg, Freiburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prinz</LastName><ForeName>Marco</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>1] Institute of Neuropathology, University of Freiburg, Freiburg, Germany. [2] Centre for Biological Signalling Studies (BIOSS), University of Freiburg, Freiburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Steiner</LastName><ForeName>Harald</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>1] German Center for Neurodegenerative Diseases (DZNE), Munich, Germany. [2] Department of Metabolic Biochemistry, Ludwig-Maximilians University, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hyman</LastName><ForeName>Bradley T</ForeName><Initials>BT</Initials><AffiliationInfo><Affiliation>MassGeneral Institute for Neurodegenerative Disease, Massachusetts General Hospital and Harvard Medical School, Charlestown, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Haass</LastName><ForeName>Christian</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>1] German Center for Neurodegenerative Diseases (DZNE), Munich, Germany. [2] Department of Metabolic Biochemistry, Ludwig-Maximilians University, Munich, Germany. [3] Munich Cluster for Systems Neurology (SyNergy), Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meyer-Luehmann</LastName><ForeName>Melanie</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>1] Adolf Butenandt Institute, Department of Biochemistry, Ludwig-Maximilians University, Munich, Germany. [2] Neurocenter, Department of Neurology, University of Freiburg, Freiburg, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>06</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Med</MedlineTA><NlmUniqueID>9502015</NlmUniqueID><ISSNLinking>1078-8956</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053764">Presenilin-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051844">alpha-Synuclein</NameOfSubstance></Chemical><Chemical><RegistryNumber>147336-22-9</RegistryNumber><NameOfSubstance UI="D049452">Green Fluorescent Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Neurosci. 2015 Aug;16(8):443. doi: 10.1038/nrn3998.</RefSource><PMID Version="1">26189692</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049452" MajorTopicYN="N">Green Fluorescent Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058225" MajorTopicYN="N">Plaque, Amyloid</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053764" MajorTopicYN="N">Presenilin-1</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051844" MajorTopicYN="N">alpha-Synuclein</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>1</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>5</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>6</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>6</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>9</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26099047</ArticleId><ArticleId IdType="doi">10.1038/nm.3885</ArticleId><ArticleId IdType="pii">nm.3885</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>J Neurosci. 2001 Jan 15;21(2):372-81</Citation><ArticleIdList><ArticleId IdType="pubmed">11160418</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 1993 Dec 1;90(23):11282-6</Citation><ArticleIdList><ArticleId IdType="pubmed">8248242</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 2003 Apr 23-30;289(16):2094-103</Citation><ArticleIdList><ArticleId IdType="pubmed">12709467</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2008 Sep 04;3(9):e3135</Citation><ArticleIdList><ArticleId IdType="pubmed">18769546</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Neurosci. 2013 Jan;14 (1):38-48</Citation><ArticleIdList><ArticleId IdType="pubmed">23254192</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 2000 Sep 1;20(17):6365-73</Citation><ArticleIdList><ArticleId IdType="pubmed">10964942</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2003 Apr 25;300(5619):636-40</Citation><ArticleIdList><ArticleId IdType="pubmed">12714745</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell. 2012 Mar 16;148(6):1188-203</Citation><ArticleIdList><ArticleId IdType="pubmed">22424229</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 2012 Dec 12;32(50):18204-14</Citation><ArticleIdList><ArticleId IdType="pubmed">23238734</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 1998 Aug;51(2):351-7</Citation><ArticleIdList><ArticleId IdType="pubmed">9710002</ArticleId></ArticleIdList></Reference><Reference><Citation>Mov Disord. 2013 Mar;28(3):263-4</Citation><ArticleIdList><ArticleId IdType="pubmed">23307690</ArticleId></ArticleIdList></Reference><Reference><Citation>Sci Transl Med. 2013 Jul 17;5(194):194re2</Citation><ArticleIdList><ArticleId IdType="pubmed">23863834</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Neurol. 2006 Mar;59(3):512-9</Citation><ArticleIdList><ArticleId IdType="pubmed">16372280</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Pathol. 1998 Feb;152(2):367-72</Citation><ArticleIdList><ArticleId IdType="pubmed">9466562</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 2011 May 25;31(21):7604-18</Citation><ArticleIdList><ArticleId IdType="pubmed">21613474</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurol Neurosurg Psychiatry. 1998 May;64(5):653-6</Citation><ArticleIdList><ArticleId IdType="pubmed">9598683</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet Neurol. 2004 Jan;3(1):19-28</Citation><ArticleIdList><ArticleId IdType="pubmed">14693108</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neuropathol Exp Neurol. 1997 May;56(5):499-508</Citation><ArticleIdList><ArticleId IdType="pubmed">9143263</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain. 2006 May;129(Pt 5):1177-87</Citation><ArticleIdList><ArticleId IdType="pubmed">16600985</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 1999 Jun 10;52(9):1839-44</Citation><ArticleIdList><ArticleId IdType="pubmed">10371532</ArticleId></ArticleIdList></Reference><Reference><Citation>EMBO Rep. 2006 Sep;7(9):940-6</Citation><ArticleIdList><ArticleId IdType="pubmed">16906128</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochem J. 1995 Aug 15;310 ( Pt 1):91-4</Citation><ArticleIdList><ArticleId IdType="pubmed">7646476</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 2003 Feb 25;60(4):652-6</Citation><ArticleIdList><ArticleId IdType="pubmed">12601108</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochem J. 1997 Apr 15;323 ( Pt 2):539-46</Citation><ArticleIdList><ArticleId IdType="pubmed">9163350</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell. 2013 Jul 3;154(1):103-17</Citation><ArticleIdList><ArticleId IdType="pubmed">23827677</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Neurosci. 2003 Apr;6(4):370-7</Citation><ArticleIdList><ArticleId IdType="pubmed">12598899</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 1997 Nov 25;94(24):13287-92</Citation><ArticleIdList><ArticleId IdType="pubmed">9371838</ArticleId></ArticleIdList></Reference><Reference><Citation>J Exp Med. 2012 May 7;209(5):975-86</Citation><ArticleIdList><ArticleId IdType="pubmed">22508839</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuron. 2000 Oct;28(1):41-51</Citation><ArticleIdList><ArticleId IdType="pubmed">11086982</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Neurodegener. 2007 Mar 16;2:6</Citation><ArticleIdList><ArticleId IdType="pubmed">17367539</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neuropathol Exp Neurol. 1998 Oct;57(10):955-60</Citation><ArticleIdList><ArticleId IdType="pubmed">9786245</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Cell Biol. 2002 Feb;4(2):160-4</Citation><ArticleIdList><ArticleId IdType="pubmed">11813001</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Pathol. 2000 Jul;10(3):378-84</Citation><ArticleIdList><ArticleId IdType="pubmed">10885656</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 2000 May 15;20(10):3606-11</Citation><ArticleIdList><ArticleId IdType="pubmed">10804202</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2012 Nov 16;338(6109):949-53</Citation><ArticleIdList><ArticleId IdType="pubmed">23161999</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 2006 Apr 5;26(14):3821-8</Citation><ArticleIdList><ArticleId IdType="pubmed">16597736</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Neuropathol. 2013 Aug;126(2):179-88</Citation><ArticleIdList><ArticleId IdType="pubmed">23775142</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2006 Sep 22;313(5794):1781-4</Citation><ArticleIdList><ArticleId IdType="pubmed">16990547</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurochem. 2002 Apr;81(2):229-36</Citation><ArticleIdList><ArticleId IdType="pubmed">12064470</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuron. 2011 Oct 6;72(1):57-71</Citation><ArticleIdList><ArticleId IdType="pubmed">21982369</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Invest. 2002 Nov;110(10):1429-39</Citation><ArticleIdList><ArticleId IdType="pubmed">12438441</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 2005 Dec 27;65(12):1863-72</Citation><ArticleIdList><ArticleId IdType="pubmed">16237129</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">26054031</PMID><DateCompleted><Year>2015</Year><Month>11</Month><Day>02</Day></DateCompleted><DateRevised><Year>2021</Year><Month>05</Month><Day>03</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-6114</ISSN><JournalIssue CitedMedium="Internet"><Volume>175</Volume><Issue>8</Issue><PubDate><Year>2015</Year><Month>Aug</Month></PubDate></JournalIssue><Title>JAMA internal medicine</Title><ISOAbbreviation>JAMA Intern Med</ISOAbbreviation></Journal><ArticleTitle>Statin Therapy and Risk of Acute Memory Impairment.</ArticleTitle><Pagination><StartPage>1399</StartPage><EndPage>1405</EndPage><MedlinePgn>1399-405</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamainternmed.2015.2092</ELocationID><Abstract><AbstractText Label="IMPORTANCE" NlmCategory="OBJECTIVE">Reports on the association between statins and memory impairment are inconsistent.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To assess whether statin users show acute decline in memory compared with nonusers and with users of nonstatin lipid-lowering drugs (LLDs).</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS" NlmCategory="METHODS">Using The Health Improvement Network database during January 13, 1987, through December 16, 2013, a retrospective cohort study compared 482,543 statin users with 2 control groups: 482,543 matched nonusers of any LLDs and all 26,484 users of nonstatin LLDs. A case-crossover study of 68,028 patients with incident acute memory loss evaluated exposure to statins during the period immediately before the outcome vs 3 earlier periods. Analysis was conducted from July 7, 2013, through January 15, 2015.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">When compared with matched nonusers of any LLDs (using odds ratio [95% CI]), a strong association was present between first exposure to statins and incident acute memory loss diagnosed within 30 days immediately following exposure (fully adjusted, 4.40; 3.01-6.41). This association was not reproduced in the comparison of statins vs nonstatin LLDs (fully adjusted, 1.03; 0.63-1.66) but was also present when comparing nonstatin LLDs with matched nonuser controls (adjusted, 3.60; 1.34-9.70). The case-crossover analysis showed little association.</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE" NlmCategory="CONCLUSIONS">Both statin and nonstatin LLDs were strongly associated with acute memory loss in the first 30 days following exposure in users compared with nonusers but not when compared with each other. Thus, either all LLDs cause acute memory loss regardless of drug class or the association is the result of detection bias rather than a causal association.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Strom</LastName><ForeName>Brian L</ForeName><Initials>BL</Initials><AffiliationInfo><Affiliation>Rutgers Biomedical and Health Sciences, Rutgers University, Newark, New Jersey2Center for Clinical Epidemiology and Biostatistics, Department of Biostatistics and Epidemiology, University of Pennsylvania Perelman School of Medicine, Philadelphia3Center fo.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schinnar</LastName><ForeName>Rita</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Center for Clinical Epidemiology and Biostatistics, Department of Biostatistics and Epidemiology, University of Pennsylvania Perelman School of Medicine, Philadelphia3Center for Pharmacoepidemiology Research and Training, University of Pennsylvania Perelm.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Karlawish</LastName><ForeName>Jason</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Penn Memory Center, Department of Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia5Department of Medical Ethics and Health Policy, University of Pennsylvania Perelman School of Medicine, Philadelphia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hennessy</LastName><ForeName>Sean</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Center for Clinical Epidemiology and Biostatistics, Department of Biostatistics and Epidemiology, University of Pennsylvania Perelman School of Medicine, Philadelphia3Center for Pharmacoepidemiology Research and Training, University of Pennsylvania Perelm.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Teal</LastName><ForeName>Valerie</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Center for Clinical Epidemiology and Biostatistics, Department of Biostatistics and Epidemiology, University of Pennsylvania Perelman School of Medicine, Philadelphia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bilker</LastName><ForeName>Warren B</ForeName><Initials>WB</Initials><AffiliationInfo><Affiliation>Center for Clinical Epidemiology and Biostatistics, Department of Biostatistics and Epidemiology, University of Pennsylvania Perelman School of Medicine, Philadelphia3Center for Pharmacoepidemiology Research and Training, University of Pennsylvania Perelm.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>TL1 RR024133</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>TL1-RR024133</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Intern Med</MedlineTA><NlmUniqueID>101589534</NlmUniqueID><ISSNLinking>2168-6106</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019161">Hydroxymethylglutaryl-CoA Reductase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000960">Hypolipidemic Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000208" MajorTopicYN="N">Acute Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019161" MajorTopicYN="N">Hydroxymethylglutaryl-CoA Reductase Inhibitors</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006949" MajorTopicYN="N">Hyperlipidemias</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000960" MajorTopicYN="N">Hypolipidemic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016015" MajorTopicYN="N">Logistic Models</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008569" MajorTopicYN="N">Memory Disorders</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of Interest Disclosures:</b> Dr Strom reports receiving research funding from AstraZeneca and Bristol-Myers Squibb and serving as a consultant to Abbott, AstraZeneca, Bayer Healthcare LLC, Bristol-Myers Squibb, Novartis, and Pfizer. Dr Hennessy reports receiving research funding from AstraZeneca and Bristol-Myers Squibb and educational funds from Pfizer. He also reports acting as a consultant for AstraZeneca, Bayer Healthcare LLC, Bristol-Myers Squibb, and Merck. No other disclosures are reported.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>6</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>6</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2017</Year><Month>6</Month><Day>28</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26054031</ArticleId><ArticleId IdType="mid">NIHMS856256</ArticleId><ArticleId IdType="pmc">PMC5487843</ArticleId><ArticleId IdType="doi">10.1001/jamainternmed.2015.2092</ArticleId><ArticleId IdType="pii">2301148</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Orsi A, Sherman O, Woldeselassie Z. Simvastatin-associated memory loss. Pharmacotherapy. 2001;21(6):767&#x2013;769.</Citation><ArticleIdList><ArticleId IdType="pubmed">11401190</ArticleId></ArticleIdList></Reference><Reference><Citation>King DS, Wilburn AJ, Wofford MR, Harrell TK, Lindley BJ, Jones DW. Cognitive impairment associated with atorvastatin and simvastatin. Pharmacotherapy. 2003;23(12):1663&#x2013;1667.</Citation><ArticleIdList><ArticleId IdType="pubmed">14695047</ArticleId></ArticleIdList></Reference><Reference><Citation>Galatti L, Polimeni G, Salvo F, Romani M, Sessa A, Spina E. Short-term memory loss associated with rosuvastatin. Pharmacotherapy. 2006;26(8):1190&#x2013;1192.</Citation><ArticleIdList><ArticleId IdType="pubmed">16863497</ArticleId></ArticleIdList></Reference><Reference><Citation>Padala KP, Padala PR, Potter JF. Simvastatin-induced decline in cognition. Ann Pharmacother. 2006;40(10):1880&#x2013;1883.</Citation><ArticleIdList><ArticleId IdType="pubmed">16940411</ArticleId></ArticleIdList></Reference><Reference><Citation>Okeahialam BN, Isiguzoro I. Statin related memory dysfunction in a Nigerian woman: a case report. Curr Drug Saf. 2012;7(1):33&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">22663955</ArticleId></ArticleIdList></Reference><Reference><Citation>McDonagh J. Statin-related cognitive impairment in the real world: you&#x2019;ll live longer, but you might not like it. JAMA Intern Med. 2014;174(12):1889.</Citation><ArticleIdList><ArticleId IdType="pubmed">25347692</ArticleId></ArticleIdList></Reference><Reference><Citation>Wagstaff LR, Mitton MW, Arvik BM, Doraiswamy PM. Statin-associated memory loss: analysis of 60 case reports and review of the literature. Pharmacotherapy. 2003;23(7):871&#x2013;880.</Citation><ArticleIdList><ArticleId IdType="pubmed">12885101</ArticleId></ArticleIdList></Reference><Reference><Citation>Langsjoen PH, Langsjoen JO, Langsjoen AM, Lucas LA. Treatment of statin adverse effects with supplemental coenzyme Q10 and statin drug discontinuation. Biofactors. 2005;25(1&#x2013;4):147&#x2013;152.</Citation><ArticleIdList><ArticleId IdType="pubmed">16873939</ArticleId></ArticleIdList></Reference><Reference><Citation>Evans MA, Golomb BA. Statin-associated adverse cognitive effects: survey results from 171 patients. Pharmacotherapy. 2009;29(7):800&#x2013;811.</Citation><ArticleIdList><ArticleId IdType="pubmed">19558254</ArticleId></ArticleIdList></Reference><Reference><Citation>Rockwood K, Howlett S, Fisk J, et al. Lipid-lowering agents and the risk of cognitive impairment that does not meet criteria for dementia, in relation to apolipoprotein E status. Neuroepidemiology. 2007;29(3&#x2013;4):201&#x2013;207.</Citation><ArticleIdList><ArticleId IdType="pubmed">18043005</ArticleId></ArticleIdList></Reference><Reference><Citation>Bernick C, Katz R, Smith NL, et al. Cardiovascular Health Study Collaborative Research Group Statins and cognitive function in the elderly: the Cardiovascular Health Study. Neurology. 2005;65(9):1388&#x2013;1394.</Citation><ArticleIdList><ArticleId IdType="pubmed">16275825</ArticleId></ArticleIdList></Reference><Reference><Citation>Rojas-Fernandez CH, Cameron JC. Is statin-associated cognitive impairment clinically relevant? a narrative review and clinical recommendations. Ann Pharmacother. 2012;46(4):549&#x2013;557.</Citation><ArticleIdList><ArticleId IdType="pubmed">22474137</ArticleId></ArticleIdList></Reference><Reference><Citation>Richardson K, Schoen M, French B, et al. Statins and cognitive function: a systematic review. Ann Intern Med. 2013;159(10):688&#x2013;697.</Citation><ArticleIdList><ArticleId IdType="pubmed">24247674</ArticleId></ArticleIdList></Reference><Reference><Citation>Swiger KJ, Manalac RJ, Blumenthal RS, Blaha MJ, Martin SS. Statins and cognition: a systematic review and meta-analysis of short- and long-term cognitive effects. Mayo Clin Proc. 2013;88(11):1213&#x2013;1221.</Citation><ArticleIdList><ArticleId IdType="pubmed">24095248</ArticleId></ArticleIdList></Reference><Reference><Citation>Longenberger J, Shah ZA. Simvastatin and other HMG-CoA reductase inhibitors on brain cholesterol levels in Alzheimer&#x2019;s disease. Curr Alzheimer Res. 2011;8(4):434&#x2013;442.</Citation><ArticleIdList><ArticleId IdType="pubmed">21244355</ArticleId></ArticleIdList></Reference><Reference><Citation>Simons M, Keller P, Dichgans J, Schulz JB. Cholesterol and Alzheimer&#x2019;s disease: is there a link? Neurology. 2001;57(6):1089&#x2013;1093.</Citation><ArticleIdList><ArticleId IdType="pubmed">11571339</ArticleId></ArticleIdList></Reference><Reference><Citation>Tong XK, Nicolakakis N, Fernandes P, et al. Simvastatin improves cerebrovascular function and counters soluble amyloid-&#x3b2;, inflammation and oxidative stress in aged APP mice. Neurobiol Dis. 2009;35(3):406&#x2013;414.</Citation><ArticleIdList><ArticleId IdType="pubmed">19524673</ArticleId></ArticleIdList></Reference><Reference><Citation>Pallebage-Gamarallage MM, Galloway S, Johnsen R, Jian L, Dhaliwal S, Mamo JC. The effect of exogenous cholesterol and lipid-modulating agents on enterocytic amyloid-&#x3b2; abundance. Br J Nutr. 2009;101(3):340&#x2013;347.</Citation><ArticleIdList><ArticleId IdType="pubmed">18631412</ArticleId></ArticleIdList></Reference><Reference><Citation>Kurata T, Miyazaki K, Kozuki M, et al. Atorvastatin and pitavastatin reduce senile plaques and inflammatory responses in a mouse model of Alzheimer&#x2019;s disease. Neurol Res. 2012;34(6):601&#x2013;610.</Citation><ArticleIdList><ArticleId IdType="pubmed">22732109</ArticleId></ArticleIdList></Reference><Reference><Citation>Serrano-Pozo A, Vega GL, L&#xfc;tjohann D, et al. Effects of simvastatin on cholesterol metabolism and Alzheimer disease biomarkers. Alzheimer Dis Assoc Disord. 2010;24(3):220&#x2013;226.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3694274</ArticleId><ArticleId IdType="pubmed">20473136</ArticleId></ArticleIdList></Reference><Reference><Citation>Harris JR, Milton NG. Cholesterol in Alzheimer&#x2019;s disease and other amyloidogenic disorders. Subcell Biochem. 2010;51:47&#x2013;75.</Citation><ArticleIdList><ArticleId IdType="pubmed">20213540</ArticleId></ArticleIdList></Reference><Reference><Citation>Sierra S, Ramos MC, Molina P, Esteo C, V&#xe1;zquez JA, Burgos JS. Statins as neuroprotectants: a comparative in vitro study of lipophilicity, blood-brain-barrier penetration, lowering of brain cholesterol, and decrease of neuron cell death. J Alzheimers Dis. 2011;23(2):307&#x2013;318.</Citation><ArticleIdList><ArticleId IdType="pubmed">21098985</ArticleId></ArticleIdList></Reference><Reference><Citation>Klopfleisch S, Merkler D, Schmitz M, et al. Negative impact of statins on oligodendrocytes and myelin formation in vitro and in vivo. J Neurosci. 2008;28(50):13609&#x2013;13614.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6671750</ArticleId><ArticleId IdType="pubmed">19074034</ArticleId></ArticleIdList></Reference><Reference><Citation>Miron VE, Zehntner SP, Kuhlmann T, et al. Statin therapy inhibits remyelination in the central nervous system. Am J Pathol. 2009;174(5):1880&#x2013;1890.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2671276</ArticleId><ArticleId IdType="pubmed">19349355</ArticleId></ArticleIdList></Reference><Reference><Citation>Rockwood K. Epidemiological and clinical trials evidence about a preventive role for statins in Alzheimer&#x2019;s disease. Acta Neurol Scand Suppl. 2006;185:71&#x2013;77.</Citation><ArticleIdList><ArticleId IdType="pubmed">16866914</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang CC, Jick SS, Testa MA. Who receives lipid-lowering drugs: the effects of comorbidities and patient characteristics on treatment initiation. Br J Clin Pharmacol. 2003;55(3):288&#x2013;298.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1884220</ArticleId><ArticleId IdType="pubmed">12630980</ArticleId></ArticleIdList></Reference><Reference><Citation>Halava H, Helin-Salmivaara A, Junnila J, Huupponen R. Selective prescribing of simvastatin and atorvastatin by patient characteristics at treatment initiation over a 7-year period in Finland. Eur J Clin Pharmacol. 2009;65(9):927&#x2013;933.</Citation><ArticleIdList><ArticleId IdType="pubmed">19471912</ArticleId></ArticleIdList></Reference><Reference><Citation>The Health Improvement Network (THIN) database.   http://www.thin-uk.net/ Accessed April 22, 2015.</Citation></Reference><Reference><Citation>Horsfall L, Walters K, Petersen I. Identifying periods of acceptable computer usage in primary care research databases. Pharmacoepidemiol Drug Saf. 2013;22(1):64&#x2013;69.</Citation><ArticleIdList><ArticleId IdType="pubmed">23124958</ArticleId></ArticleIdList></Reference><Reference><Citation>Maclure M, Mittleman MA. Should we use a case-crossover design? Annu Rev Public Health. 2000;21:193&#x2013;221.</Citation><ArticleIdList><ArticleId IdType="pubmed">10884952</ArticleId></ArticleIdList></Reference><Reference><Citation>Hosmer DW, Jr, Lemeshow SA, Sturdivant RX. Applied Logistic Regression. 3rd. Hoboken, NJ: Wiley; 2013. Logistic regression for matched case-control studies; pp. 243&#x2013;267.</Citation></Reference><Reference><Citation>Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika. 1983;70:41&#x2013;55.</Citation></Reference><Reference><Citation>Seeger JD, Williams PL, Walker AM. An application of propensity score matching using claims data. Pharmacoepidemiol Drug Saf. 2005;14(7):465&#x2013;476.</Citation><ArticleIdList><ArticleId IdType="pubmed">15651087</ArticleId></ArticleIdList></Reference><Reference><Citation>Maclure M. The case-crossover design: a method for studying transient effects on the risk of acute events. Am J Epidemiol. 1991;133(2):144&#x2013;153.</Citation><ArticleIdList><ArticleId IdType="pubmed">1985444</ArticleId></ArticleIdList></Reference><Reference><Citation>Belmin J, Min L, Roth C, Reuben D, Wenger N. Assessment and management of patients with cognitive impairment and dementia in primary care. J Nutr Health Aging. 2012;16(5):462&#x2013;467.</Citation><ArticleIdList><ArticleId IdType="pubmed">22555792</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">26109656</PMID><DateCompleted><Year>2015</Year><Month>09</Month><Day>08</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>03</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>35</Volume><Issue>25</Issue><PubDate><Year>2015</Year><Month>Jun</Month><Day>24</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>The Progranulin Cleavage Products, Granulins, Exacerbate TDP-43 Toxicity and Increase TDP-43 Levels.</ArticleTitle><Pagination><StartPage>9315</StartPage><EndPage>9328</EndPage><MedlinePgn>9315-28</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.4808-14.2015</ELocationID><Abstract><AbstractText>Mutations in the human progranulin gene resulting in protein haploinsufficiency cause frontotemporal lobar degeneration with TDP-43 inclusions. Although progress has been made in understanding the normal functions of progranulin and TDP-43, the molecular interactions between these proteins remain unclear. Progranulin is proteolytically processed into granulins, but the role of granulins in the pathogenesis of neurodegenerative disease is unknown. We used a Caenorhabditis elegans model of neuronal TDP-43 proteinopathy to specifically interrogate the contribution of granulins to the neurodegenerative process. Complete loss of the progranulin gene did not worsen TDP-43 toxicity, whereas progranulin heterozygosity did. Interestingly, expression of individual granulins alone had little effect on behavior. In contrast, when granulins were coexpressed with TDP-43, they exacerbated its toxicity in a variety of behaviors including motor coordination. These same granulins increased TDP-43 levels via a post-translational mechanism. We further found that in human neurodegenerative disease subjects, granulin fragments accumulated specifically in diseased regions of brain. To our knowledge, this is the first demonstration of a toxic role for granulin fragments in a neurodegenerative disease model. These studies suggest that presence of cleaved granulins, rather than or in addition to loss of full-length progranulin, may contribute to disease in TDP-43 proteinopathies.</AbstractText><CopyrightInformation>Copyright &#xa9; 2015 the authors 0270-6474/15/359315-14$15.00/0.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Salazar</LastName><ForeName>Dominique A</ForeName><Initials>DA</Initials><Identifier Source="ORCID">0000-0002-6696-7527</Identifier><AffiliationInfo><Affiliation>Department of Neurology, University of California at San Francisco, San Francisco, California 94158, and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Butler</LastName><ForeName>Victoria J</ForeName><Initials>VJ</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of California at San Francisco, San Francisco, California 94158, and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Argouarch</LastName><ForeName>Andrea R</ForeName><Initials>AR</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of California at San Francisco, San Francisco, California 94158, and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hsu</LastName><ForeName>Tsung-Yuan</ForeName><Initials>TY</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of California at San Francisco, San Francisco, California 94158, and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mason</LastName><ForeName>Amanda</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Gladstone Institutes of Neurological Disease, San Francisco, California 94148.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nakamura</LastName><ForeName>Ayumi</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of California at San Francisco, San Francisco, California 94158, and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McCurdy</LastName><ForeName>Helen</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of California at San Francisco, San Francisco, California 94158, and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cox</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of California at San Francisco, San Francisco, California 94158, and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ng</LastName><ForeName>Rachel</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of California at San Francisco, San Francisco, California 94158, and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pan</LastName><ForeName>Gloria</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of California at San Francisco, San Francisco, California 94158, and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Seeley</LastName><ForeName>William W</ForeName><Initials>WW</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of California at San Francisco, San Francisco, California 94158, and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miller</LastName><ForeName>Bruce L</ForeName><Initials>BL</Initials><Identifier Source="ORCID">0000-0002-2152-4220</Identifier><AffiliationInfo><Affiliation>Department of Neurology, University of California at San Francisco, San Francisco, California 94158, and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kao</LastName><ForeName>Aimee W</ForeName><Initials>AW</Initials><Identifier Source="ORCID">0000-0002-7686-7968</Identifier><AffiliationInfo><Affiliation>Department of Neurology, University of California at San Francisco, San Francisco, California 94158, and akao@memory.ucsf.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P50 AG023501</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG19724</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 NS082709</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P40 OD010440</GrantID><Acronym>OD</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 GM007618</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG23501</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS095257</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG019724</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D036341">Intercellular Signaling Peptides and Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000077153">Progranulins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D029961">Zebrafish Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C509429">progranulin A, zebrafish</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D030801" MajorTopicYN="N">Animals, Genetically Modified</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017173" MajorTopicYN="N">Caenorhabditis elegans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004268" MajorTopicYN="N">DNA-Binding Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015151" MajorTopicYN="N">Immunoblotting</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D036341" MajorTopicYN="N">Intercellular Signaling Peptides and Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000077153" MajorTopicYN="N">Progranulins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D060888" MajorTopicYN="N">Real-Time Polymerase Chain Reaction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057177" MajorTopicYN="N">TDP-43 Proteinopathies</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D029961" MajorTopicYN="N">Zebrafish Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">C. elegans</Keyword><Keyword MajorTopicYN="N">TDP-43</Keyword><Keyword MajorTopicYN="N">frontotemporal lobar degeneration</Keyword><Keyword MajorTopicYN="N">granulin</Keyword><Keyword MajorTopicYN="N">neurodegenerative disease</Keyword><Keyword MajorTopicYN="N">progranulin</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>6</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>6</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>9</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2015</Year><Month>12</Month><Day>24</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26109656</ArticleId><ArticleId IdType="pmc">PMC4478251</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.4808-14.2015</ArticleId><ArticleId IdType="pii">35/25/9315</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Aggad D, V&#xe9;ri&#xe8;pe J, Tauffenberger A, Parker JA. TDP-43 toxicity proceeds via calcium dysregulation and necrosis in aging Caenorhabditis elegans motor neurons. J Neurosci. 2014;34:12093&#x2013;12103. doi: 10.1523/JNEUROSCI.2495-13.2014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.2495-13.2014</ArticleId><ArticleId IdType="pmc">PMC4262699</ArticleId><ArticleId IdType="pubmed">25186754</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmed Z, Sheng H, Xu YF, Lin WL, Innes AE, Gass J, Yu X, Wuertzer CA, Hou H, Chiba S, Yamanouchi K, Leissring M, Petrucelli L, Nishihara M, Hutton ML, McGowan E, Dickson DW, Lewis J. Accelerated lipofuscinosis and ubiquitination in granulin knockout mice suggests a role for progranulin in successful aging. Am J Pathol. 2010;177:311&#x2013;324. doi: 10.2353/ajpath.2010.090915.</Citation><ArticleIdList><ArticleId IdType="doi">10.2353/ajpath.2010.090915</ArticleId><ArticleId IdType="pmc">PMC2893674</ArticleId><ArticleId IdType="pubmed">20522652</ArticleId></ArticleIdList></Reference><Reference><Citation>Albertson DG, Thomson JN. The pharynx of Caenorhabditis elegans. Philos Trans R Soc Lond B Biol Sci. 1976;275:299&#x2013;325. doi: 10.1098/rstb.1976.0085.</Citation><ArticleIdList><ArticleId IdType="doi">10.1098/rstb.1976.0085</ArticleId><ArticleId IdType="pubmed">8805</ArticleId></ArticleIdList></Reference><Reference><Citation>Almeida S, Zhang Z, Coppola G, Mao W, Futai K, Karydas A, Geschwind MD, Tartaglia MC, Gao F, Gianni D, Sena-Esteves M, Geschwind DH, Miller BL, Farese RV, Jr, Gao FB. Induced pluripotent stem cell models of progranulin-deficient frontotemporal dementia uncover specific reversible neuronal defects. Cell Rep. 2012;2:789&#x2013;798. doi: 10.1016/j.celrep.2012.09.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2012.09.007</ArticleId><ArticleId IdType="pmc">PMC3532907</ArticleId><ArticleId IdType="pubmed">23063362</ArticleId></ArticleIdList></Reference><Reference><Citation>Ash PE, Zhang YJ, Roberts CM, Saldi T, Hutter H, Buratti E, Petrucelli L, Link CD. Neurotoxic effects of TDP-43 overexpression in C. elegans. Hum Mol Genet. 2010;19:3206&#x2013;3218. doi: 10.1093/hmg/ddq230.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddq230</ArticleId><ArticleId IdType="pmc">PMC2908471</ArticleId><ArticleId IdType="pubmed">20530643</ArticleId></ArticleIdList></Reference><Reference><Citation>Avery L, Horvitz HR. A cell that dies during wild-type C. elegans development can function as a neuron in a ced-3 mutant. Cell. 1987;51:1071&#x2013;1078. doi: 10.1016/0092-8674(87)90593-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0092-8674(87)90593-9</ArticleId><ArticleId IdType="pmc">PMC3773210</ArticleId><ArticleId IdType="pubmed">3690660</ArticleId></ArticleIdList></Reference><Reference><Citation>Avery L, You YJ. C. elegans feeding. WormBook. 2012;2012:1&#x2013;23. doi: 10.1895/wormbook.1.150.1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1895/wormbook.1.150.1</ArticleId><ArticleId IdType="pmc">PMC3590810</ArticleId><ArticleId IdType="pubmed">22628186</ArticleId></ArticleIdList></Reference><Reference><Citation>Bany IA, Dong MQ, Koelle MR. Genetic and cellular basis for acetylcholine inhibition of Caenorhabditis elegans egg-laying behavior. J Neurosci. 2003;23:8060&#x2013;8069.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6740490</ArticleId><ArticleId IdType="pubmed">12954868</ArticleId></ArticleIdList></Reference><Reference><Citation>Barmada SJ, Serio A, Arjun A, Bilican B, Daub A, Ando DM, Tsvetkov A, Pleiss M, Li X, Peisach D, Shaw C, Chandran S, Finkbeiner S. Autophagy induction enhances TDP43 turnover and survival in neuronal ALS models. Nat Chem Biol. 2014;10:677&#x2013;685. doi: 10.1038/nchembio.1563.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nchembio.1563</ArticleId><ArticleId IdType="pmc">PMC4106236</ArticleId><ArticleId IdType="pubmed">24974230</ArticleId></ArticleIdList></Reference><Reference><Citation>Brouwers N, Nuytemans K, van der Zee J, Gijselinck I, Engelborghs S, Theuns J, Kumar-Singh S, Pickut BA, Pals P, Dermaut B, Bogaerts V, De Pooter T, Serneels S, Van den Broeck M, Cuijt I, Mattheijssens M, Peeters K, Sciot R, Martin JJ, Cras P, et al. Alzheimer and Parkinson diagnoses in progranulin null mutation carriers in an extended founder family. Arch Neurol. 2007;64:1436&#x2013;1446. doi: 10.1001/archneur.64.10.1436.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneur.64.10.1436</ArticleId><ArticleId IdType="pubmed">17923627</ArticleId></ArticleIdList></Reference><Reference><Citation>Cenik B, Sephton CF, Kutluk Cenik B, Herz J, Yu G. Progranulin: a proteolytically processed protein at the crossroads of inflammation and neurodegeneration. J Biol Chem. 2012;287:32298&#x2013;32306. doi: 10.1074/jbc.R112.399170.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.R112.399170</ArticleId><ArticleId IdType="pmc">PMC3463300</ArticleId><ArticleId IdType="pubmed">22859297</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung S, Gumienny TL, Hengartner MO, Driscoll M. A common set of engulfment genes mediates removal of both apoptotic and necrotic cell corpses in C. elegans. Nat Cell Biol. 2000;2:931&#x2013;937. doi: 10.1038/35046585.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/35046585</ArticleId><ArticleId IdType="pubmed">11146658</ArticleId></ArticleIdList></Reference><Reference><Citation>Coppola G, Karydas A, Rademakers R, Wang Q, Baker M, Hutton M, Miller BL, Geschwind DH. Gene expression study on peripheral blood identifies progranulin mutations. Ann Neurol. 2008;64:92&#x2013;96. doi: 10.1002/ana.21397.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.21397</ArticleId><ArticleId IdType="pmc">PMC2773201</ArticleId><ArticleId IdType="pubmed">18551524</ArticleId></ArticleIdList></Reference><Reference><Citation>Dempsey CM, Mackenzie SM, Gargus A, Blanco G, Sze JY. Serotonin (5HT), fluoxetine, imipramine and dopamine target distinct 5HT receptor signaling to modulate Caenorhabditis elegans egg-laying behavior. Genetics. 2005;169:1425&#x2013;1436. doi: 10.1534/genetics.104.032540.</Citation><ArticleIdList><ArticleId IdType="doi">10.1534/genetics.104.032540</ArticleId><ArticleId IdType="pmc">PMC1449529</ArticleId><ArticleId IdType="pubmed">15654117</ArticleId></ArticleIdList></Reference><Reference><Citation>Desai C, Horvitz HR. Caenorhabditis elegans mutants defective in the functioning of the motor neurons responsible for egg laying. Genetics. 1989;121:703&#x2013;721.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1203655</ArticleId><ArticleId IdType="pubmed">2721931</ArticleId></ArticleIdList></Reference><Reference><Citation>Desai C, Garriga G, McIntire SL, Horvitz HR. A genetic pathway for the development of the Caenorhabditis elegans HSN motor neurons. Nature. 1988;336:638&#x2013;646. doi: 10.1038/336638a0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/336638a0</ArticleId><ArticleId IdType="pubmed">3200316</ArticleId></ArticleIdList></Reference><Reference><Citation>Filiano AJ, Martens LH, Young AH, Warmus BA, Zhou P, Diaz-Ramirez G, Jiao J, Zhang Z, Huang EJ, Gao FB, Farese RV, Jr, Roberson ED. Dissociation of frontotemporal dementia-related deficits and neuroinflammation in progranulin haploinsufficient mice. J Neurosci. 2013;33:5352&#x2013;5361. doi: 10.1523/JNEUROSCI.6103-11.2013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.6103-11.2013</ArticleId><ArticleId IdType="pmc">PMC3740510</ArticleId><ArticleId IdType="pubmed">23516300</ArticleId></ArticleIdList></Reference><Reference><Citation>Finch N, Baker M, Crook R, Swanson K, Kuntz K, Surtees R, Bisceglio G, Rovelet-Lecrux A, Boeve B, Petersen RC, Dickson DW, Younkin SG, Deramecourt V, Crook J, Graff-Radford NR, Rademakers R. Plasma progranulin levels predict progranulin mutation status in frontotemporal dementia patients and asymptomatic family members. Brain. 2009;132:583&#x2013;591. doi: 10.1093/brain/awn352.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awn352</ArticleId><ArticleId IdType="pmc">PMC2664450</ArticleId><ArticleId IdType="pubmed">19158106</ArticleId></ArticleIdList></Reference><Reference><Citation>Frank CA, Baum PD, Garriga G. HLH-14 is a C. elegans achaete-scute protein that promotes neurogenesis through asymmetric cell division. Development. 2003;130:6507&#x2013;6518. doi: 10.1242/dev.00894.</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/dev.00894</ArticleId><ArticleId IdType="pubmed">14627726</ArticleId></ArticleIdList></Reference><Reference><Citation>Gass J, Cannon A, Mackenzie IR, Boeve B, Baker M, Adamson J, Crook R, Melquist S, Kuntz K, Petersen R, Josephs K, Pickering-Brown SM, Graff-Radford N, Uitti R, Dickson D, Wszolek Z, Gonzalez J, Beach TG, Bigio E, Johnson N, et al. Mutations in progranulin are a major cause of ubiquitin-positive frontotemporal lobar degeneration. Hum Mol Genet. 2006;15:2988&#x2013;3001. doi: 10.1093/hmg/ddl241.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddl241</ArticleId><ArticleId IdType="pubmed">16950801</ArticleId></ArticleIdList></Reference><Reference><Citation>Gass J, Lee WC, Cook C, Finch N, Stetler C, Jansen-West K, Lewis J, Link CD, Rademakers R, Nykjaer A, Petrucelli L. Progranulin regulates neuronal outgrowth independent of sortilin. Mol Neurodegener. 2012;7:33. doi: 10.1186/1750-1326-7-33.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1750-1326-7-33</ArticleId><ArticleId IdType="pmc">PMC3508877</ArticleId><ArticleId IdType="pubmed">22781549</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghidoni R, Benussi L, Glionna M, Franzoni M, Binetti G. Low plasma progranulin levels predict progranulin mutations in frontotemporal lobar degeneration. Neurology. 2008;71:1235&#x2013;1239. doi: 10.1212/01.wnl.0000325058.10218.fc.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000325058.10218.fc</ArticleId><ArticleId IdType="pubmed">18768919</ArticleId></ArticleIdList></Reference><Reference><Citation>Hansen M, Taubert S, Crawford D, Libina N, Lee SJ, Kenyon C. Lifespan extension by conditions that inhibit translation in Caenorhabditis elegans. Aging Cell. 2007;6:95&#x2013;110. doi: 10.1111/j.1474-9726.2006.00267.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1474-9726.2006.00267.x</ArticleId><ArticleId IdType="pubmed">17266679</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanson KA, Kim SH, Wassarman DA, Tibbetts RS. Ubiquilin modifies TDP-43 toxicity in a Drosophila model of amyotrophic lateral sclerosis (ALS) J Biol Chem. 2010;285:11068&#x2013;11072. doi: 10.1074/jbc.C109.078527.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.C109.078527</ArticleId><ArticleId IdType="pmc">PMC2856981</ArticleId><ArticleId IdType="pubmed">20154090</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoogewijs D, Houthoofd K, Matthijssens F, Vandesompele J, Vanfleteren JR. Selection and validation of a set of reliable reference genes for quantitative sod gene expression analysis in C. elegans. BMC Mol Biol. 2008;9:9. doi: 10.1186/1471-2199-9-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2199-9-9</ArticleId><ArticleId IdType="pmc">PMC2254638</ArticleId><ArticleId IdType="pubmed">18211699</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu F, Padukkavidana T, V&#xe6;gter CB, Brady OA, Zheng Y, Mackenzie IR, Feldman HH, Nykjaer A, Strittmatter SM. Sortilin-mediated endocytosis determines levels of the frontotemporal dementia protein, progranulin. Neuron. 2010;68:654&#x2013;667. doi: 10.1016/j.neuron.2010.09.034.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2010.09.034</ArticleId><ArticleId IdType="pmc">PMC2990962</ArticleId><ArticleId IdType="pubmed">21092856</ArticleId></ArticleIdList></Reference><Reference><Citation>Igaz LM, Kwong LK, Lee EB, Chen-Plotkin A, Swanson E, Unger T, Malunda J, Xu Y, Winton MJ, Trojanowski JQ, Lee VM. Dysregulation of the ALS-associated gene TDP-43 leads to neuronal death and degeneration in mice. J Clin Invest. 2011;121:726&#x2013;738. doi: 10.1172/JCI44867.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI44867</ArticleId><ArticleId IdType="pmc">PMC3026736</ArticleId><ArticleId IdType="pubmed">21206091</ArticleId></ArticleIdList></Reference><Reference><Citation>Judy ME, Nakamura A, Huang A, Grant H, McCurdy H, Weiberth KF, Gao F, Coppola G, Kenyon C, Kao AW. A shift to organismal stress resistance in programmed cell death mutants. PLoS Genet. 2013;9:e1003714. doi: 10.1371/journal.pgen.1003714.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pgen.1003714</ArticleId><ArticleId IdType="pmc">PMC3778000</ArticleId><ArticleId IdType="pubmed">24068943</ArticleId></ArticleIdList></Reference><Reference><Citation>Kabashi E, Lin L, Tradewell ML, Dion PA, Bercier V, Bourgouin P, Rochefort D, Bel Hadj S, Durham HD, Vande Velde C, Rouleau GA, Drapeau P. Gain and loss of function of ALS-related mutations of TARDBP (TDP-43) cause motor deficits in vivo. Hum Mol Genet. 2010;19:671&#x2013;683. doi: 10.1093/hmg/ddp534.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddp534</ArticleId><ArticleId IdType="pubmed">19959528</ArticleId></ArticleIdList></Reference><Reference><Citation>Kao AW, Eisenhut RJ, Herl Martens L, Nakamura A, Huang A, Bagley JA, Zhou P, de Luis A, Neukomm LJ, Cabello J, Farese RV, Jr, Kenyon C. A neurodegenerative disease mutation that accelerates the clearance of apoptotic cells. Proc Natl Acad Sci U S A. 2011;108:4441&#x2013;4446. doi: 10.1073/pnas.1100650108.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1100650108</ArticleId><ArticleId IdType="pmc">PMC3060230</ArticleId><ArticleId IdType="pubmed">21368173</ArticleId></ArticleIdList></Reference><Reference><Citation>Kleinberger G, Wils H, Ponsaerts P, Joris G, Timmermans JP, Van Broeckhoven C, Kumar-Singh S. Increased caspase activation and decreased TDP-43 solubility in progranulin knockout cortical cultures. J Neurochem. 2010;115:735&#x2013;747. doi: 10.1111/j.1471-4159.2010.06961.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2010.06961.x</ArticleId><ArticleId IdType="pubmed">20731760</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee EB, Lee VM, Trojanowski JQ. Gains or losses: molecular mechanisms of TDP43-mediated neurodegeneration. Nat Rev Neurosci. 2012;13:38&#x2013;50. doi: 10.1038/nrn3121.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrn3121</ArticleId><ArticleId IdType="pmc">PMC3285250</ArticleId><ArticleId IdType="pubmed">22127299</ArticleId></ArticleIdList></Reference><Reference><Citation>Liachko NF, Guthrie CR, Kraemer BC. Phosphorylation promotes neurotoxicity in a Caenorhabditis elegans model of TDP-43 proteinopathy. J Neurosci. 2010;30:16208&#x2013;16219. doi: 10.1523/JNEUROSCI.2911-10.2010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.2911-10.2010</ArticleId><ArticleId IdType="pmc">PMC3075589</ArticleId><ArticleId IdType="pubmed">21123567</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y, Ray P, Rao EJ, Shi C, Guo W, Chen X, Woodruff EA, 3rd, Fushimi K, Wu JY. A Drosophila model for TDP-43 proteinopathy. Proc Natl Acad Sci U S A. 2010;107:3169&#x2013;3174. doi: 10.1073/pnas.0913602107.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0913602107</ArticleId><ArticleId IdType="pmc">PMC2840283</ArticleId><ArticleId IdType="pubmed">20133767</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackenzie IR, Rademakers R. The molecular genetics and neuropathology of frontotemporal lobar degeneration: recent developments. Neurogenetics. 2007;8:237&#x2013;248. doi: 10.1007/s10048-007-0102-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10048-007-0102-4</ArticleId><ArticleId IdType="pubmed">17805587</ArticleId></ArticleIdList></Reference><Reference><Citation>Martens LH, Zhang J, Barmada SJ, Zhou P, Kamiya S, Sun B, Mins SW, Gan L, Finkbeiner S, Huang EJ, Farese RV., Jr Progranulin deficiency promotes neuroinflammation and neuron loss following toxin-induced injury. J Clin Invest. 2012;122:3955&#x2013;3959. doi: 10.1172/JCI63113.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI63113</ArticleId><ArticleId IdType="pmc">PMC3484443</ArticleId><ArticleId IdType="pubmed">23041626</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsubara T, Mita A, Minami K, Hosooka T, Kitazawa S, Takahashi K, Tamori Y, Yokoi N, Watanabe M, Matsuo E, Nishimura O, Seino S. PGRN is a key adipokine mediating high fat diet-induced insulin resistance and obesity through IL-6 in adipose tissue. Cell Metab. 2012;15:38&#x2013;50. doi: 10.1016/j.cmet.2011.12.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmet.2011.12.002</ArticleId><ArticleId IdType="pubmed">22225875</ArticleId></ArticleIdList></Reference><Reference><Citation>McIntire SL, Jorgensen E, Horvitz HR. Genes required for GABA function in Caenorhabditis elegans. Nature. 1993;364:334&#x2013;337. doi: 10.1038/364334a0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/364334a0</ArticleId><ArticleId IdType="pubmed">8332190</ArticleId></ArticleIdList></Reference><Reference><Citation>Minami SS, Min SW, Krabbe G, Wang C, Zhou Y, Asgarov R, Li Y, Martens LH, Elia LP, Ward ME, Mucke L, Farese RV, Jr, Gan L. Progranulin protects against amyloid beta deposition and toxicity in Alzheimer's disease mouse models. Nat Med. 2014;20:1157&#x2013;1164. doi: 10.1038/nm.3672.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.3672</ArticleId><ArticleId IdType="pmc">PMC4196723</ArticleId><ArticleId IdType="pubmed">25261995</ArticleId></ArticleIdList></Reference><Reference><Citation>Murphy JM, Henry RG, Langmore S, Kramer JH, Miller BL, Lomen-Hoerth C. Continuum of frontal lobe impairment in amyotrophic lateral sclerosis. Arch Neurol. 2007;64:530&#x2013;534. doi: 10.1001/archneur.64.4.530.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneur.64.4.530</ArticleId><ArticleId IdType="pubmed">17420314</ArticleId></ArticleIdList></Reference><Reference><Citation>Neary D, Snowden JS, Gustafson L, Passant U, Stuss D, Black S, Freedman M, Kertesz A, Robert PH, Albert M, Boone K, Miller BL, Cummings J, Benson DF. Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology. 1998;51:1546&#x2013;1554. doi: 10.1212/WNL.51.6.1546.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.51.6.1546</ArticleId><ArticleId IdType="pubmed">9855500</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M, Sampathu DM, Kwong LK, Truax AC, Micsenyi MC, Chou TT, Bruce J, Schuck T, Grossman M, Clark CM, McCluskey LF, Miller BL, Masliah E, Mackenzie IR, Feldman H, Feiden W, Kretzschmar HA, Trojanowski JQ, Lee VM. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science. 2006;314:130&#x2013;133. doi: 10.1126/science.1134108.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1134108</ArticleId><ArticleId IdType="pubmed">17023659</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M, Kwong LK, Truax AC, Vanmassenhove B, Kretzschmar HA, Van Deerlin VM, Clark CM, Grossman M, Miller BL, Trojanowski JQ, Lee VM. TDP-43-positive white matter pathology in frontotemporal lobar degeneration with ubiquitin-positive inclusions. J Neuropathol Exp Neurol. 2007;66:177&#x2013;183. doi: 10.1097/01.jnen.0000248554.45456.58.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.jnen.0000248554.45456.58</ArticleId><ArticleId IdType="pubmed">17356379</ArticleId></ArticleIdList></Reference><Reference><Citation>Park B, Buti L, Lee S, Matsuwaki T, Spooner E, Brinkmann MM, Nishihara M, Ploegh HL. Granulin is a soluble cofactor for toll-like receptor 9 signaling. Immunity. 2011;34:505&#x2013;513. doi: 10.1016/j.immuni.2011.01.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2011.01.018</ArticleId><ArticleId IdType="pubmed">21497117</ArticleId></ArticleIdList></Reference><Reference><Citation>Perry DC, Lehmann M, Yokoyama JS, Karydas A, Lee JJ, Coppola G, Grinberg LT, Geschwind D, Seeley WW, Miller BL, Rosen H, Rabinovici G. Progranulin mutations as risk factors for Alzheimer disease. JAMA Neurol. 2013;70:774&#x2013;778. doi: 10.1001/2013.jamaneurol.393.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/2013.jamaneurol.393</ArticleId><ArticleId IdType="pmc">PMC3743672</ArticleId><ArticleId IdType="pubmed">23609919</ArticleId></ArticleIdList></Reference><Reference><Citation>Petkau TL, Leavitt BR. Progranulin in neurodegenerative disease. Trends Neurosci. 2014;37:388&#x2013;398. doi: 10.1016/j.tins.2014.04.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tins.2014.04.003</ArticleId><ArticleId IdType="pubmed">24800652</ArticleId></ArticleIdList></Reference><Reference><Citation>Pickford F, Marcus J, Camargo LM, Xiao Q, Graham D, Mo JR, Burkhardt M, Kulkarni V, Crispino J, Hering H, Hutton M. Progranulin is a chemoattractant for microglia and stimulates their endocytic activity. Am J Pathol. 2011;178:284&#x2013;295. doi: 10.1016/j.ajpath.2010.11.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajpath.2010.11.002</ArticleId><ArticleId IdType="pmc">PMC3070582</ArticleId><ArticleId IdType="pubmed">21224065</ArticleId></ArticleIdList></Reference><Reference><Citation>Raizen DM, Avery L. Electrical activity and behavior in the pharynx of Caenorhabditis elegans. Neuron. 1994;12:483&#x2013;495. doi: 10.1016/0896-6273(94)90207-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0896-6273(94)90207-0</ArticleId><ArticleId IdType="pmc">PMC4460247</ArticleId><ArticleId IdType="pubmed">8155316</ArticleId></ArticleIdList></Reference><Reference><Citation>Raizen DM, Lee RY, Avery L. Interacting genes required for pharyngeal excitation by motor neuron MC in Caenorhabditis elegans. Genetics. 1995;141:1365&#x2013;1382.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1206873</ArticleId><ArticleId IdType="pubmed">8601480</ArticleId></ArticleIdList></Reference><Reference><Citation>Riddle DL, Blumenthal T, Meyer BJ, Priess JR. Introduction to C. elegans. In: Riddle DL, Blumenthal T, Meyer BJ, Priess JR, editors. C. elegans II. New York: Cold Spring Harbor; 1997.</Citation></Reference><Reference><Citation>Sawin ER, Ranganathan R, Horvitz HR. C. elegans locomotory rate is modulated by the environment through a dopaminergic pathway and by experience through a serotonergic pathway. Neuron. 2000;26:619&#x2013;631. doi: 10.1016/S0896-6273(00)81199-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0896-6273(00)81199-X</ArticleId><ArticleId IdType="pubmed">10896158</ArticleId></ArticleIdList></Reference><Reference><Citation>Schafer WR, Kenyon CJ. A calcium-channel homologue required for adaptation to dopamine and serotonin in Caenorhabditis elegans. Nature. 1995;375:73&#x2013;78. doi: 10.1038/375073a0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/375073a0</ArticleId><ArticleId IdType="pubmed">7723846</ArticleId></ArticleIdList></Reference><Reference><Citation>Sleegers K, Brouwers N, Van Damme P, Engelborghs S, Gijselinck I, van der Zee J, Peeters K, Mattheijssens M, Cruts M, Vandenberghe R, De Deyn PP, Robberecht W, Van Broeckhoven C. Serum biomarker for progranulin-associated frontotemporal lobar degeneration. Ann Neurol. 2009;65:603&#x2013;609. doi: 10.1002/ana.21621.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.21621</ArticleId><ArticleId IdType="pubmed">19288468</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith KR, Damiano J, Franceschetti S, Carpenter S, Canafoglia L, Morbin M, Rossi G, Pareyson D, Mole SE, Staropoli JF, Sims KB, Lewis J, Lin WL, Dickson DW, Dahl HH, Bahlo M, Berkovic SF. Strikingly different clinicopathological phenotypes determined by progranulin-mutation dosage. Am J Hum Genet. 2012;90:1102&#x2013;1107. doi: 10.1016/j.ajhg.2012.04.021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajhg.2012.04.021</ArticleId><ArticleId IdType="pmc">PMC3370276</ArticleId><ArticleId IdType="pubmed">22608501</ArticleId></ArticleIdList></Reference><Reference><Citation>Stallings NR, Puttaparthi K, Luther CM, Burns DK, Elliott JL. Progressive motor weakness in transgenic mice expressing human TDP-43. Neurobiol Dis. 2010;40:404&#x2013;414. doi: 10.1016/j.nbd.2010.06.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2010.06.017</ArticleId><ArticleId IdType="pubmed">20621187</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanaka Y, Matsuwaki T, Yamanouchi K, Nishihara M. Increased lysosomal biogenesis in activated microglia and exacerbated neuronal damage after traumatic brain injury in progranulin-deficient mice. Neuroscience. 2013;250:8&#x2013;19. doi: 10.1016/j.neuroscience.2013.06.049.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroscience.2013.06.049</ArticleId><ArticleId IdType="pubmed">23830905</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang W, Lu Y, Tian QY, Zhang Y, Guo FJ, Liu GY, Syed NM, Lai Y, Lin EA, Kong L, Su J, Yin F, Ding AH, Zanin-Zhorov A, Dustin ML, Tao J, Craft J, Yin Z, Feng JQ, Abramson SB, et al. The growth factor progranulin binds to TNF receptors and is therapeutic against inflammatory arthritis in mice. Science. 2011;332:478&#x2013;484. doi: 10.1126/science.1199214.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1199214</ArticleId><ArticleId IdType="pmc">PMC3104397</ArticleId><ArticleId IdType="pubmed">21393509</ArticleId></ArticleIdList></Reference><Reference><Citation>Tao J, Ji F, Wang F, Liu B, Zhu Y. Neuroprotective effects of progranulin in ischemic mice. Brain Res. 2012;1436:130&#x2013;136. doi: 10.1016/j.brainres.2011.11.063.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2011.11.063</ArticleId><ArticleId IdType="pubmed">22221732</ArticleId></ArticleIdList></Reference><Reference><Citation>Tapia L, Milnerwood A, Guo A, Mills F, Yoshida E, Vasuta C, Mackenzie IR, Raymond L, Cynader M, Jia W, Bamji SX. Progranulin deficiency decreases gross neural connectivity but enhances transmission at individual synapses. J Neurosci. 2011;31:11126&#x2013;11132. doi: 10.1523/JNEUROSCI.6244-10.2011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.6244-10.2011</ArticleId><ArticleId IdType="pmc">PMC6623368</ArticleId><ArticleId IdType="pubmed">21813674</ArticleId></ArticleIdList></Reference><Reference><Citation>Tolkatchev D, Malik S, Vinogradova A, Wang P, Chen Z, Xu P, Bennett HP, Bateman A, Ni F. Structure dissection of human progranulin identifies well-folded granulin/epithelin modules with unique functional activities. Protein Sci. 2008;17:711&#x2013;724. doi: 10.1110/ps.073295308.</Citation><ArticleIdList><ArticleId IdType="doi">10.1110/ps.073295308</ArticleId><ArticleId IdType="pmc">PMC2271164</ArticleId><ArticleId IdType="pubmed">18359860</ArticleId></ArticleIdList></Reference><Reference><Citation>Trent C, Tsuing N, Horvitz HR. Egg-laying defective mutants of the nematode Caenorhabditis elegans. Genetics. 1983;104:619&#x2013;647.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1202130</ArticleId><ArticleId IdType="pubmed">11813735</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsai KJ, Yang CH, Fang YH, Cho KH, Chien WL, Wang WT, Wu TW, Lin CP, Fu WM, Shen CK. Elevated expression of TDP-43 in the forebrain of mice is sufficient to cause neurological and pathological phenotypes mimicking FTLD-U. J Exp Med. 2010;207:1661&#x2013;1673. doi: 10.1084/jem.20092164.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20092164</ArticleId><ArticleId IdType="pmc">PMC2916125</ArticleId><ArticleId IdType="pubmed">20660618</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccaro A, Tauffenberger A, Aggad D, Rouleau G, Drapeau P, Parker JA. Mutant TDP-43 and FUS cause age-dependent paralysis and neurodegeneration in C. elegans. PLoS One. 2012;7:e31321. doi: 10.1371/journal.pone.0031321.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0031321</ArticleId><ArticleId IdType="pmc">PMC3283630</ArticleId><ArticleId IdType="pubmed">22363618</ArticleId></ArticleIdList></Reference><Reference><Citation>Ward ME, Taubes A, Chen R, Miller BL, Sephton CF, Gelfand JM, Minami S, Boscardin J, Martens LH, Seeley WW, Yu G, Herz J, Filiano AJ, Arrant AE, Roberson ED, Kraft TW, Farese RV, Jr, Green A, Gan L. Early retinal neurodegeneration and impaired Ran-mediated nuclear import of TDP-43 in progranulin-deficient FTLD. J Exp Med. 2014;211:1937&#x2013;1945. doi: 10.1084/jem.20140214.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20140214</ArticleId><ArticleId IdType="pmc">PMC4172214</ArticleId><ArticleId IdType="pubmed">25155018</ArticleId></ArticleIdList></Reference><Reference><Citation>Wegorzewska I, Bell S, Cairns NJ, Miller TM, Baloh RH. TDP-43 mutant transgenic mice develop features of ALS and frontotemporal lobar degeneration. Proc Natl Acad Sci U S A. 2009;106:18809&#x2013;18814. doi: 10.1073/pnas.0908767106.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0908767106</ArticleId><ArticleId IdType="pmc">PMC2762420</ArticleId><ArticleId IdType="pubmed">19833869</ArticleId></ArticleIdList></Reference><Reference><Citation>Weinshenker D, Garriga G, Thomas JH. Genetic and pharmacological analysis of neurotransmitters controlling egg laying in C. elegans. J Neurosci. 1995;15:6975&#x2013;6985.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6577982</ArticleId><ArticleId IdType="pubmed">7472454</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu YF, Gendron TF, Zhang YJ, Lin WL, D'Alton S, Sheng H, Casey MC, Tong J, Knight J, Yu X, Rademakers R, Boylan K, Hutton M, McGowan E, Dickson DW, Lewis J, Petrucelli L. Wild-type human TDP-43 expression causes TDP-43 phosphorylation, mitochondrial aggregation, motor deficits, and early mortality in transgenic mice. J Neurosci. 2010;30:10851&#x2013;10859. doi: 10.1523/JNEUROSCI.1630-10.2010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.1630-10.2010</ArticleId><ArticleId IdType="pmc">PMC3056148</ArticleId><ArticleId IdType="pubmed">20702714</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu J, Xilouri M, Bruban J, Shioi J, Shao Z, Papazoglou I, Vekrellis K, Robakis NK. Extracellular progranulin protects cortical neurons from toxic insults by activating survival signaling. Neurobiol Aging. 2011;32:2326.e5&#x2013;16. doi: 10.1016/j.neurobiolaging.2011.06.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2011.06.017</ArticleId><ArticleId IdType="pmc">PMC3375317</ArticleId><ArticleId IdType="pubmed">21820214</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang T, Mullane PC, Periz G, Wang J. TDP-43 neurotoxicity and protein aggregation modulated by heat shock factor and insulin/IGF-1 signaling. Hum Mol Genet. 2011;20:1952&#x2013;1965. doi: 10.1093/hmg/ddr076.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddr076</ArticleId><ArticleId IdType="pmc">PMC3080607</ArticleId><ArticleId IdType="pubmed">21355045</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou H, Huang C, Chen H, Wang D, Landel CP, Xia PY, Bowser R, Liu YJ, Xia XG. Transgenic rat model of neurodegeneration caused by mutation in the TDP gene. PLoS Genet. 2010;6:e1000887. doi: 10.1371/journal.pgen.1000887.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pgen.1000887</ArticleId><ArticleId IdType="pmc">PMC2845661</ArticleId><ArticleId IdType="pubmed">20361056</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu J, Nathan C, Jin W, Sim D, Ashcroft GS, Wahl SM, Lacomis L, Erdjument-Bromage H, Tempst P, Wright CD, Ding A. Conversion of proepithelin to epithelins: roles of SLPI and elastase in host defense and wound repair. Cell. 2002;111:867&#x2013;878. doi: 10.1016/S0092-8674(02)01141-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0092-8674(02)01141-8</ArticleId><ArticleId IdType="pubmed">12526812</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">26119027</PMID><DateCompleted><Year>2015</Year><Month>09</Month><Day>15</Day></DateCompleted><DateRevised><Year>2024</Year><Month>03</Month><Day>23</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1097-4199</ISSN><JournalIssue CitedMedium="Internet"><Volume>87</Volume><Issue>1</Issue><PubDate><Year>2015</Year><Month>Jul</Month><Day>01</Day></PubDate></JournalIssue><Title>Neuron</Title><ISOAbbreviation>Neuron</ISOAbbreviation></Journal><ArticleTitle>Regional Blood Flow in the Normal and Ischemic Brain Is Controlled by Arteriolar Smooth Muscle Cell Contractility and Not by Capillary Pericytes.</ArticleTitle><Pagination><StartPage>95</StartPage><EndPage>110</EndPage><MedlinePgn>95-110</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.neuron.2015.06.001</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0896-6273(15)00514-0</ELocationID><Abstract><AbstractText>The precise regulation of cerebral blood flow is critical for normal brain function, and its disruption underlies many neuropathologies. The extent to which smooth muscle-covered arterioles or pericyte-covered capillaries control vasomotion during neurovascular coupling remains controversial. We found that capillary pericytes in mice and humans do not express smooth muscle actin and are morphologically and functionally distinct from adjacent precapillary smooth muscle cells (SMCs). Using optical imaging we investigated blood flow regulation at various sites on the vascular tree in living mice. Optogenetic, whisker stimulation, or cortical spreading depolarization caused microvascular diameter or flow changes in SMC but not pericyte-covered microvessels. During early stages of brain ischemia, transient SMC but not pericyte constrictions were a&#xa0;major cause of hypoperfusion leading to thrombosis and distal microvascular occlusions. Thus, capillary pericytes are not contractile, and regulation of cerebral blood flow in physiological and pathological conditions is mediated by arteriolar SMCs.</AbstractText><CopyrightInformation>Copyright &#xa9; 2015 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hill</LastName><ForeName>Robert A</ForeName><Initials>RA</Initials><AffiliationInfo><Affiliation>Department of Neurology, Yale School of Medicine, New Haven, CT 06510, USA; Department of Neurobiology, Yale School of Medicine, New Haven, CT 06510, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tong</LastName><ForeName>Lei</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Neurology, Yale School of Medicine, New Haven, CT 06510, USA; Department of Neurobiology, Yale School of Medicine, New Haven, CT 06510, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yuan</LastName><ForeName>Peng</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Neurology, Yale School of Medicine, New Haven, CT 06510, USA; Department of Neurobiology, Yale School of Medicine, New Haven, CT 06510, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Murikinati</LastName><ForeName>Sasidhar</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurology, Yale School of Medicine, New Haven, CT 06510, USA; Department of Neurobiology, Yale School of Medicine, New Haven, CT 06510, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gupta</LastName><ForeName>Shobhana</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurology, Yale School of Medicine, New Haven, CT 06510, USA; Department of Neurobiology, Yale School of Medicine, New Haven, CT 06510, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grutzendler</LastName><ForeName>Jaime</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurology, Yale School of Medicine, New Haven, CT 06510, USA; Department of Neurobiology, Yale School of Medicine, New Haven, CT 06510, USA. Electronic address: jaime.grutzendler@yale.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>F32 NS090820</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 AG048181</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 HL007950</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01-NS089734</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG027855</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS089734</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01-HL106815</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>F32-NS090820</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS089662</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 HL106815</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D059040">Video-Audio Media</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>06</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neuron</MedlineTA><NlmUniqueID>8809320</NlmUniqueID><ISSNLinking>0896-6273</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000199">Actins</NameOfSubstance></Chemical><Chemical><RegistryNumber>SY7Q814VUP</RegistryNumber><NameOfSubstance UI="D002118">Calcium</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Neuron. 2015 Jul 1;87(1):4-6. doi: 10.1016/j.neuron.2015.06.024.</RefSource><PMID Version="1">26139364</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000199" MajorTopicYN="N">Actins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001160" MajorTopicYN="N">Arterioles</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000098" MajorTopicYN="N">blood supply</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002545" MajorTopicYN="Y">Brain Ischemia</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002118" MajorTopicYN="N">Calcium</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002196" MajorTopicYN="N">Capillaries</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002540" MajorTopicYN="N">Cerebral Cortex</DescriptorName><QualifierName UI="Q000098" MajorTopicYN="Y">blood supply</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002560" MajorTopicYN="N">Cerebrovascular Circulation</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009119" MajorTopicYN="N">Muscle Contraction</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009131" MajorTopicYN="N">Muscle, Smooth, Vascular</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D032389" MajorTopicYN="N">Myocytes, Smooth Muscle</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020286" MajorTopicYN="N">Pericytes</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>1</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2015</Year><Month>4</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>5</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>6</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>6</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>9</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2016</Year><Month>7</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26119027</ArticleId><ArticleId IdType="mid">NIHMS697709</ArticleId><ArticleId IdType="pmc">PMC4487786</ArticleId><ArticleId IdType="doi">10.1016/j.neuron.2015.06.001</ArticleId><ArticleId IdType="pii">S0896-6273(15)00514-0</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Armstrong JJ, Larina IV, Dickinson ME, Zimmer WE, Hirschi KK. Characterization of bacterial artificial chromosome transgenic mice expressing mCherry fluorescent protein substituted for the murine smooth muscle alpha-actin gene. Genesis. 2010;48:457&#x2013;463.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2906650</ArticleId><ArticleId IdType="pubmed">20506352</ArticleId></ArticleIdList></Reference><Reference><Citation>Armulik A, Genov&#xe9; G, M&#xe4;e M, Nisancioglu MH, Wallgard E, Niaudet C, He L, Norlin J, Lindblom P, Strittmatter K, et al. Pericytes regulate the blood-brain barrier. Nature. 2010;468:557&#x2013;561.</Citation><ArticleIdList><ArticleId IdType="pubmed">20944627</ArticleId></ArticleIdList></Reference><Reference><Citation>Armulik A, Genov&#xe9; G, Betsholtz C. Pericytes: developmental, physiological, and pathological perspectives, problems, and promises. Dev Cell. 2011;21:193&#x2013;215.</Citation><ArticleIdList><ArticleId IdType="pubmed">21839917</ArticleId></ArticleIdList></Reference><Reference><Citation>Attwell D, Iadecola C. The neural basis of functional brain imaging signals. Trends Neurosci. 2002;25:621&#x2013;625.</Citation><ArticleIdList><ArticleId IdType="pubmed">12446129</ArticleId></ArticleIdList></Reference><Reference><Citation>Bell RD, Winkler EA, Sagare AP, Singh I, LaRue B, Deane R, Zlokovic BV. Pericytes control key neurovascular functions and neuronal phenotype in the adult brain and during brain aging. Neuron. 2010;68:409&#x2013;427.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3056408</ArticleId><ArticleId IdType="pubmed">21040844</ArticleId></ArticleIdList></Reference><Reference><Citation>Blinder P, Tsai PS, Kaufhold JP, Knutsen PM, Suhl H, Kleinfeld D. The cortical angiome: an interconnected vascular network with noncolumnar patterns of blood flow. Nat Neurosci. 2013;16:889&#x2013;897.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4141079</ArticleId><ArticleId IdType="pubmed">23749145</ArticleId></ArticleIdList></Reference><Reference><Citation>Borysova L, Wray S, Eisner Da, Burdyga T. How calcium signals in myocytes and pericytes are integrated across in situ microvascular networks and control microvascular tone. Cell Calcium. 2013;54:163&#x2013;174.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3775125</ArticleId><ArticleId IdType="pubmed">23867002</ArticleId></ArticleIdList></Reference><Reference><Citation>Brian JE, Faraci FM, Feuerstein G. Tumor Necrosis Factor- Induced Dilatation of Cerebral Arterioles Editorial Comment. Stroke. 1998;29:509&#x2013;515.</Citation><ArticleIdList><ArticleId IdType="pubmed">9472897</ArticleId></ArticleIdList></Reference><Reference><Citation>Chaigneau E, Oheim M, Audinat E, Charpak S. Two-photon imaging of capillary blood flow in olfactory bulb glomeruli. Proc Natl Acad Sci U S A. 2003;100:13081&#x2013;13086.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC240748</ArticleId><ArticleId IdType="pubmed">14569029</ArticleId></ArticleIdList></Reference><Reference><Citation>Cuevas P, Gutierrez-Diaz JA, Reimers D, Dujovny M, Diaz FG, Ausman JI. Pericyte endothelial gap junctions in human cerebral capillaries. Anat Embryol (Berl) 1984;170:155&#x2013;159.</Citation><ArticleIdList><ArticleId IdType="pubmed">6517350</ArticleId></ArticleIdList></Reference><Reference><Citation>Daneman R, Zhou L, Kebede AA, Barres BA. Pericytes are required for blood-brain barrier integrity during embryogenesis. Nature. 2010;468:562&#x2013;566.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3241506</ArticleId><ArticleId IdType="pubmed">20944625</ArticleId></ArticleIdList></Reference><Reference><Citation>Devor A, Tian P, Nishimura N, Teng IC, Hillman EMC, Narayanan SN, Ulbert I, Boas DA, Kleinfeld D, Dale AM. Suppressed neuronal activity and concurrent arteriolar vasoconstriction may explain negative blood oxygenation level-dependent signal. J Neurosci. 2007;27:4452&#x2013;4459.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2680207</ArticleId><ArticleId IdType="pubmed">17442830</ArticleId></ArticleIdList></Reference><Reference><Citation>Drew PJ, Shih AY, Kleinfeld D. Fluctuating and sensory-induced vasodynamics in rodent cortex extend arteriole capacity. Proc Natl Acad Sci U S A. 2011;108:8473&#x2013;8478.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3100929</ArticleId><ArticleId IdType="pubmed">21536897</ArticleId></ArticleIdList></Reference><Reference><Citation>Duan X, Krishnaswamy A, De la Huerta I, Sanes JR. Type II cadherins guide assembly of a direction-selective retinal circuit. Cell. 2014;158:793&#x2013;807.</Citation><ArticleIdList><ArticleId IdType="pubmed">25126785</ArticleId></ArticleIdList></Reference><Reference><Citation>Faraci FM. Protecting against vascular disease in brain. Am J Physiol Heart Circ Physiol. 2011;300:H1566&#x2013;H1582.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3094081</ArticleId><ArticleId IdType="pubmed">21335467</ArticleId></ArticleIdList></Reference><Reference><Citation>Farkas E, Luiten PG. Cerebral microvascular pathology in aging and Alzheimer&#x2019;s disease. Prog Neurobiol. 2001;64:575&#x2013;611.</Citation><ArticleIdList><ArticleId IdType="pubmed">11311463</ArticleId></ArticleIdList></Reference><Reference><Citation>Fern&#xe1;ndez-Klett F, Offenhauser N, Dirnagl U, Priller J, Lindauer U. Pericytes in capillaries are contractile in vivo, but arterioles mediate functional hyperemia in the mouse brain. Proc Natl Acad Sci U S A. 2010;107:22290&#x2013;22295.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3009761</ArticleId><ArticleId IdType="pubmed">21135230</ArticleId></ArticleIdList></Reference><Reference><Citation>Grinvald A, Lieke E, Frostig RD, Gilbert CD, Wiesel TN. Functional architecture of cortex revealed by optical imaging of intrinsic signals. Nature. 1986;324:361&#x2013;364.</Citation><ArticleIdList><ArticleId IdType="pubmed">3785405</ArticleId></ArticleIdList></Reference><Reference><Citation>Grutzendler J, Murikinati S, Hiner B, Ji L, Lam CK, Yoo T, Gupta S, Hafler BP, Adelman RA, Yuan P, et al. Angiophagy prevents early embolus washout but recanalizes microvessels through embolus extravasation. Sci Transl Med. 2014;6:226ra31.</Citation><ArticleIdList><ArticleId IdType="pubmed">24598589</ArticleId></ArticleIdList></Reference><Reference><Citation>Hall CN, Reynell C, Gesslein B, Hamilton NB, Mishra A, Sutherland Ba, O&#x2019;Farrell FM, Buchan AM, Lauritzen M, Attwell D. Capillary pericytes regulate cerebral blood flow in health and disease. Nature. 2014;508:55&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3976267</ArticleId><ArticleId IdType="pubmed">24670647</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamel E. Perivascular nerves and the regulation of cerebrovascular tone. J Appl Physiol. 2006;100:1059&#x2013;1064.</Citation><ArticleIdList><ArticleId IdType="pubmed">16467392</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamilton NB, Attwell D, Hall CN. Pericyte-mediated regulation of capillary diameter: a component of neurovascular coupling in health and disease. Front Neuroenergetics. 2010;2:1&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2912025</ArticleId><ArticleId IdType="pubmed">20725515</ArticleId></ArticleIdList></Reference><Reference><Citation>Harb R, Whiteus C, Freitas C, Grutzendler J. In vivo imaging of cerebral microvascular plasticity from birth to death. J Cereb Blood Flow Metab. 2012;106815:1&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3597363</ArticleId><ArticleId IdType="pubmed">23093067</ArticleId></ArticleIdList></Reference><Reference><Citation>Haydon PG, Carmignoto G. Astrocyte control of synaptic transmission and neurovascular coupling. Physiol Rev. 2006;86:1009&#x2013;1031.</Citation><ArticleIdList><ArticleId IdType="pubmed">16816144</ArticleId></ArticleIdList></Reference><Reference><Citation>Hill RA, Grutzendler J. In vivo imaging of oligodendrocytes with sulforhodamine 101. Nat Methods. 2014;11:1081&#x2013;1082.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4539948</ArticleId><ArticleId IdType="pubmed">25357236</ArticleId></ArticleIdList></Reference><Reference><Citation>Hill RA, Patel KD, Goncalves CM, Grutzendler J, Nishiyama A. Modulation of oligodendrocyte generation during a critical temporal window after NG2 cell division. Nat Neurosci. 2014;17:1518&#x2013;1527.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4275302</ArticleId><ArticleId IdType="pubmed">25262495</ArticleId></ArticleIdList></Reference><Reference><Citation>Iadecola C. Neurovascular regulation in the normal brain and in Alzheimer&#x2019;s disease. Nat Rev Neurosci. 2004;5:347&#x2013;360.</Citation><ArticleIdList><ArticleId IdType="pubmed">15100718</ArticleId></ArticleIdList></Reference><Reference><Citation>Iadecola C, Nedergaard M. Glial regulation of the cerebral microvasculature. Nat Neurosci. 2007;10:1369&#x2013;1376.</Citation><ArticleIdList><ArticleId IdType="pubmed">17965657</ArticleId></ArticleIdList></Reference><Reference><Citation>Iadecola C, Yang G, Ebner TJ, Chen G. Local and propagated vascular responses evoked by focal synaptic activity in cerebellar cortex. J Neurophysiol. 1997;78:651&#x2013;659.</Citation><ArticleIdList><ArticleId IdType="pubmed">9307102</ArticleId></ArticleIdList></Reference><Reference><Citation>Itoh Y, Suzuki N. Control of brain capillary blood flow. J Cereb Blood Flow Metab. 2012;32:1167&#x2013;1176.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3390803</ArticleId><ArticleId IdType="pubmed">22293984</ArticleId></ArticleIdList></Reference><Reference><Citation>Kety SS, Schmidt CF. The effects of altered arterial tensions of carbon dioxide and oxygen on cerebral blood flow and cerebral oxygen consumption of normal young men. J Clin Invest. 1948;27:484&#x2013;492.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC439519</ArticleId><ArticleId IdType="pubmed">16695569</ArticleId></ArticleIdList></Reference><Reference><Citation>Kornfield TE, Newman EA. Regulation of blood flow in the retinal trilaminar vascular network. J Neurosci. 2014;34:11504&#x2013;11513.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4138352</ArticleId><ArticleId IdType="pubmed">25143628</ArticleId></ArticleIdList></Reference><Reference><Citation>Krueger M, Bechmann I. CNS pericytes: concepts, misconceptions, and a way out. Glia. 2010;58:1&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pubmed">19533601</ArticleId></ArticleIdList></Reference><Reference><Citation>Lam CK, Yoo T, Hiner B, Liu Z, Grutzendler J. Embolus extravasation is an alternative mechanism for cerebral microvascular recanalization. Nature. 2010;465:478&#x2013;482.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2879083</ArticleId><ArticleId IdType="pubmed">20505729</ArticleId></ArticleIdList></Reference><Reference><Citation>Leao AAP. Spreading depression of activity in the cerebral cortex. J Neurophysiol. 1944;7:359&#x2013;390.</Citation><ArticleIdList><ArticleId IdType="pubmed">20268874</ArticleId></ArticleIdList></Reference><Reference><Citation>Logothetis NK, Wandell BA. Interpreting the BOLD signal. Annu Rev Physiol. 2004;66:735&#x2013;769.</Citation><ArticleIdList><ArticleId IdType="pubmed">14977420</ArticleId></ArticleIdList></Reference><Reference><Citation>Logothetis NK, Pauls J, Augath M, Trinath T, Oeltermann A. Neurophysiological investigation of the basis of the fMRI signal. Nature. 2001;412:150&#x2013;157.</Citation><ArticleIdList><ArticleId IdType="pubmed">11449264</ArticleId></ArticleIdList></Reference><Reference><Citation>Madisen L, Mao T, Koch H, Zhuo J, Berenyi A, Fujisawa S, Hsu YWA, Garcia AJ, Gu X, Zanella S, et al. A toolbox of Cre-dependent optogenetic transgenic mice for light-induced activation and silencing. Nat Neurosci. 2012;15:793&#x2013;802.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3337962</ArticleId><ArticleId IdType="pubmed">22446880</ArticleId></ArticleIdList></Reference><Reference><Citation>Motoike T, Loughna S, Perens E, Roman BL, Liao W, Chau TC, Richardson CD, Kawate T, Kuno J, Weinstein BM, et al. Universal GFP reporter for the study of vascular development. Genesis. 2000;28:75&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pubmed">11064424</ArticleId></ArticleIdList></Reference><Reference><Citation>Muzumdar MD, Tasic B, Miyamichi K, Li L, Luo L. A global double-fluorescent Cre reporter mouse. Genesis. 2007;45:593&#x2013;605.</Citation><ArticleIdList><ArticleId IdType="pubmed">17868096</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakayama A, Nakayama M, Turner CJ, H&#xf6;ing S, Lepore JJ, Adams RH. Ephrin-B2 controls PDGFR&#x3b2; internalization and signaling. Genes Dev. 2013;27:2576&#x2013;2589.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3861671</ArticleId><ArticleId IdType="pubmed">24298057</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishiyama A, Suzuki R, Zhu X. NG2 cells (polydendrocytes) in brain physiology and repair. Front Neurosci. 2014;8:133.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4072963</ArticleId><ArticleId IdType="pubmed">25018689</ArticleId></ArticleIdList></Reference><Reference><Citation>Noguchi H, Gompper G. Shape transitions of fluid vesicles and red blood cells in capillary flows. Proc Natl Acad Sci U S A. 2005;102:14159&#x2013;14164.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1242298</ArticleId><ArticleId IdType="pubmed">16186506</ArticleId></ArticleIdList></Reference><Reference><Citation>Novak A, Guo C, Yang W, Nagy A, Lobe CG. Z/EG, a double reporter mouse line that expresses enhanced green fluorescent protein upon Cre-mediated excision. Genesis. 2000;28:147&#x2013;155.</Citation><ArticleIdList><ArticleId IdType="pubmed">11105057</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Farrell FM, Attwell D. A role for pericytes in coronary no-reflow. Nat Rev Cardiol. 2014;11:427&#x2013;432.</Citation><ArticleIdList><ArticleId IdType="pubmed">24776704</ArticleId></ArticleIdList></Reference><Reference><Citation>Ogawa S, Lee TM, Kay AR, Tank DW. Brain magnetic resonance imaging with contrast dependent on blood oxygenation. Proc Natl Acad Sci U S A. 1990;87:9868&#x2013;9872.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC55275</ArticleId><ArticleId IdType="pubmed">2124706</ArticleId></ArticleIdList></Reference><Reference><Citation>Oku H, Kodama T, Sakagami K, Puro DG. Diabetes-induced disruption of gap junction pathways within the retinal microvasculature. Invest Ophthalmol Vis Sci. 2001;42:1915&#x2013;1920.</Citation><ArticleIdList><ArticleId IdType="pubmed">11431461</ArticleId></ArticleIdList></Reference><Reference><Citation>Pawlik G, Rackl A, Bing RJ. Quantitative capillary topography and blood flow in the cerebral cortex of cats: an in vivo microscopic study. Brain Res. 1981;208:35&#x2013;58.</Citation><ArticleIdList><ArticleId IdType="pubmed">7470927</ArticleId></ArticleIdList></Reference><Reference><Citation>Peppiatt CM, Howarth C, Mobbs P, Attwell D. Bidirectional control of CNS capillary diameter by pericytes. Nature. 2006;443:700&#x2013;704.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1761848</ArticleId><ArticleId IdType="pubmed">17036005</ArticleId></ArticleIdList></Reference><Reference><Citation>Puro DG. Physiology and pathobiology of the pericyte-containing retinal microvasculature: new developments. Microcirculation. 2007;14:1&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pubmed">17365657</ArticleId></ArticleIdList></Reference><Reference><Citation>Raichle ME, Mintun MA. Brain work and brain imaging. Annu Rev Neurosci. 2006;29:449&#x2013;476.</Citation><ArticleIdList><ArticleId IdType="pubmed">16776593</ArticleId></ArticleIdList></Reference><Reference><Citation>Rezkalla SH, Kloner RA. No-reflow phenomenon. Circulation. 2002;105:656&#x2013;662.</Citation><ArticleIdList><ArticleId IdType="pubmed">11827935</ArticleId></ArticleIdList></Reference><Reference><Citation>Rouget C. Note on the development of the contractile walls of blood vessels. C R Acad Sci. 1874;79:559&#x2013;562.</Citation></Reference><Reference><Citation>Roy CS, Sherrington CS. On the Regulation of the Blood-supply of the Brain. J Physiol. 1890;11:85&#x2013;158.17.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1514242</ArticleId><ArticleId IdType="pubmed">16991945</ArticleId></ArticleIdList></Reference><Reference><Citation>Sagare AP, Bell RD, Zhao Z, Ma Q, Winkler EA, Ramanathan A, Zlokovic BV. Pericyte loss influences Alzheimer-like neurodegeneration in mice. Nat Commun. 2013;4:2932.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3945879</ArticleId><ArticleId IdType="pubmed">24336108</ArticleId></ArticleIdList></Reference><Reference><Citation>Sakagami K, Wu DM, Puro DG. Physiology of rat retinal pericytes: modulation of ion channel activity by serum-derived molecules. J Physiol. 1999;521(Pt 3):637&#x2013;650.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2269681</ArticleId><ArticleId IdType="pubmed">10601495</ArticleId></ArticleIdList></Reference><Reference><Citation>Schain AJ, Hill RA, Grutzendler J. Label-free in vivo imaging of myelinated axons in health and disease with spectral confocal reflectance microscopy. Nat Med. 2014;20:443&#x2013;449.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3981936</ArticleId><ArticleId IdType="pubmed">24681598</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen Z, Lu Z, Chhatbar PY, O&#x2019;Herron P, Kara P. An artery-specific fluorescent dye for studying neurovascular coupling. Nat Methods. 2012;9:273&#x2013;276.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3392962</ArticleId><ArticleId IdType="pubmed">22266543</ArticleId></ArticleIdList></Reference><Reference><Citation>Simard M, Arcuino G, Takano T, Liu QS, Nedergaard M. Signaling at the Gliovascular Interface. J Neurosci. 2003;23:9254&#x2013;9262.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6740832</ArticleId><ArticleId IdType="pubmed">14534260</ArticleId></ArticleIdList></Reference><Reference><Citation>Skalak R, Branemark PI. Deformation of red blood cells in capillaries. Science. 1969;164:717&#x2013;719.</Citation><ArticleIdList><ArticleId IdType="pubmed">5778020</ArticleId></ArticleIdList></Reference><Reference><Citation>Snippert HJ, van der Flier LG, Sato T, van Es JH, van den Born M, Kroon-Veenboer C, Barker N, Klein AM, van Rheenen J, Simons BD, et al. Intestinal crypt homeostasis results from neutral competition between symmetrically dividing Lgr5 stem cells. Cell. 2010;143:134&#x2013;144.</Citation><ArticleIdList><ArticleId IdType="pubmed">20887898</ArticleId></ArticleIdList></Reference><Reference><Citation>Somjen GG. Mechanisms of spreading depression and hypoxic spreading depression-like depolarization. Physiol Rev. 2001;81:1065&#x2013;1096.</Citation><ArticleIdList><ArticleId IdType="pubmed">11427692</ArticleId></ArticleIdList></Reference><Reference><Citation>Uemura A, Ogawa M, Hirashima M, Fujiwara T, Koyama S, Takagi H, Honda Y, Wiegand SJ, Yancopoulos GD, Nishikawa SI. Recombinant angiopoietin-1 restores higher-order architecture of growing blood vessels in mice in the absence of mural cells. J Clin Invest. 2002;110:1619&#x2013;1628.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC151628</ArticleId><ArticleId IdType="pubmed">12464667</ArticleId></ArticleIdList></Reference><Reference><Citation>Vanzetta I, Hildesheim R, Grinvald A. Compartment-resolved imaging of activity-dependent dynamics of cortical blood volume and oximetry. J Neurosci. 2005;25:2233&#x2013;2244.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6726087</ArticleId><ArticleId IdType="pubmed">15745949</ArticleId></ArticleIdList></Reference><Reference><Citation>Vates GE, Takano T, Zlokovic B, Nedergaard M. Pericyte constriction after stroke: the jury is still out. Nat Med. 2010;16:959. author reply 960.</Citation><ArticleIdList><ArticleId IdType="pubmed">20823870</ArticleId></ArticleIdList></Reference><Reference><Citation>Wendling O, Bornert JM, Chambon P, Metzger D. Efficient temporally-controlled targeted mutagenesis in smooth muscle cells of the adult mouse. Genesis. 2009;47:14&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pubmed">18942088</ArticleId></ArticleIdList></Reference><Reference><Citation>Winkler EA, Bell RD, Zlokovic BV. Central nervous system pericytes in health and disease. Nat Neurosci. 2011;14:1398&#x2013;1405.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4020628</ArticleId><ArticleId IdType="pubmed">22030551</ArticleId></ArticleIdList></Reference><Reference><Citation>Winkler EA, Sagare AP, Zlokovic BV. The pericyte: a forgotten cell type with important implications for Alzheimer&#x2019;s disease? Brain Pathol. 2014;24:371&#x2013;386.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4423607</ArticleId><ArticleId IdType="pubmed">24946075</ArticleId></ArticleIdList></Reference><Reference><Citation>Yemisci M, Gursoy-Ozdemir Y, Vural A, Can A, Topalkara K, Dalkara T. Pericyte contraction induced by oxidative-nitrative stress impairs capillary reflow despite successful opening of an occluded cerebral artery. Nat Med. 2009;15:1031&#x2013;1037.</Citation><ArticleIdList><ArticleId IdType="pubmed">19718040</ArticleId></ArticleIdList></Reference><Reference><Citation>Zariwala HA, Borghuis BG, Hoogland TM, Madisen L, Tian L, De Zeeuw CI, Zeng H, Looger LL, Svoboda K, Chen TW. A Cre-dependent GCaMP3 reporter mouse for neuronal imaging in vivo. J Neurosci. 2012;32:3131&#x2013;3141.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3315707</ArticleId><ArticleId IdType="pubmed">22378886</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu X, Bergles DE, Nishiyama A. NG2 cells generate both oligodendrocytes and gray matter astrocytes. Development. 2008;135:145&#x2013;157.</Citation><ArticleIdList><ArticleId IdType="pubmed">18045844</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu X, Hill RA, Dietrich D, Komitova M, Suzuki R, Nishiyama A. Age-dependent fate and lineage restriction of single NG2 cells. Development. 2011;138:745&#x2013;753.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3026417</ArticleId><ArticleId IdType="pubmed">21266410</ArticleId></ArticleIdList></Reference><Reference><Citation>Del Zoppo GJ, Schmid-Sch&#xf6;nbein GW, Mori E, Copeland BR, Chang CM. Polymorphonuclear leukocytes occlude capillaries following middle cerebral artery occlusion and reperfusion in baboons. Stroke. 1991;22:1276&#x2013;1283.</Citation><ArticleIdList><ArticleId IdType="pubmed">1926239</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">26121081</PMID><DateCompleted><Year>2015</Year><Month>11</Month><Day>05</Day></DateCompleted><DateRevised><Year>2025</Year><Month>01</Month><Day>28</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-6157</ISSN><JournalIssue CitedMedium="Internet"><Volume>72</Volume><Issue>8</Issue><PubDate><Year>2015</Year><Month>Aug</Month></PubDate></JournalIssue><Title>JAMA neurology</Title><ISOAbbreviation>JAMA Neurol</ISOAbbreviation></Journal><ArticleTitle>Brain Imaging and Blood Biomarker Abnormalities in Children With Autosomal Dominant Alzheimer Disease: A Cross-Sectional Study.</ArticleTitle><Pagination><StartPage>912</StartPage><EndPage>919</EndPage><MedlinePgn>912-9</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamaneurol.2015.1099</ELocationID><Abstract><AbstractText Label="IMPORTANCE" NlmCategory="OBJECTIVE">Brain imaging and fluid biomarkers are characterized in children at risk for autosomal dominant Alzheimer disease (ADAD).</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To characterize and compare structural magnetic resonance imaging (MRI), resting-state and task-dependent functional MRI, and plasma amyloid-&#x3b2; (A&#x3b2;) measurements in presenilin 1 (PSEN1) E280A mutation-carrying and noncarrying children with ADAD.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS" NlmCategory="METHODS">Cross-sectional measures of structural and functional MRI and plasma A&#x3b2; assays were assessed in 18 PSEN1 E280A carriers and 19 noncarriers aged 9 to 17 years from a Colombian kindred with ADAD. Recruitment and data collection for this study were conducted at the University of Antioquia and the Hospital Pablo Tobon Uribe in Medell&#xed;n, Colombia, between August 2011 and June 2012.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES" NlmCategory="METHODS">All participants had blood sampling, structural MRI, and functional MRI during associative memory encoding and resting-state and cognitive assessments. Outcome measures included plasma A&#x3b2;1-42 concentrations and A&#x3b2;1-42:A&#x3b2;1-40 ratios, memory encoding-dependent activation changes, resting-state connectivity, and regional gray matter volumes. Structural and functional MRI data were compared using automated brain mapping algorithms and search regions related to AD.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Similar to findings in adult mutation carriers, in the later preclinical and clinical stages of ADAD, mutation-carrying children were distinguished from control individuals by significantly higher plasma A&#x3b2;1-42 levels (mean [SD]: carriers, 18.8 [5.1] pg/mL and noncarriers, 13.1 [3.2] pg/mL; P&#x2009;&lt;&#x2009;.001) and A&#x3b2;1-42:A&#x3b2;1-40 ratios (mean [SD]: carriers, 0.32 [0.06] and noncarriers, 0.21 [0.03]; P&#x2009;&lt;&#x2009;.001), as well as less memory encoding task-related deactivation in parietal regions (eg, mean [SD] parameter estimates for the right precuneus were -0.590 [0.50] for noncarriers and -0.087 [0.38] for carriers; P&#x2009;&lt;&#x2009;.005 uncorrected). Unlike carriers in the later stages, mutation-carrying children demonstrated increased functional connectivity of the posterior cingulate cortex with medial temporal lobe regions (mean [SD] parameter estimates were 0.038 [0.070] for noncarriers and 0.190 [0.057] for carriers), as well as greater gray matter volumes in temporal regions (eg, left parahippocampus; P&#x2009;&lt;&#x2009;. 049, corrected for multiple comparisons).</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE" NlmCategory="CONCLUSIONS">Children at genetic risk for ADAD have functional and structural brain changes and abnormal levels of plasma A&#x3b2;1-42. The extent to which the underlying brain changes are either neurodegenerative or developmental remains to be determined. This study provides additional information about the earliest known biomarker changes associated with ADAD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Quiroz</LastName><ForeName>Yakeel T</ForeName><Initials>YT</Initials><AffiliationInfo><Affiliation>Department of Neurology, Massachusetts General Hospital, Boston2Department of Psychiatry, Massachusetts General Hospital, Boston3Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Boston4Harvard Medical School, Boston, Ma.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schultz</LastName><ForeName>Aaron P</ForeName><Initials>AP</Initials><AffiliationInfo><Affiliation>Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Boston4Harvard Medical School, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Kewei</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Banner Alzheimer's Institute, Phoenix, Arizona7Arizona Alzheimer's Consortium, Phoenix8Department of Mathematics and Statistics, Arizona State University, Tempe.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Protas</LastName><ForeName>Hillary D</ForeName><Initials>HD</Initials><AffiliationInfo><Affiliation>Banner Alzheimer's Institute, Phoenix, Arizona7Arizona Alzheimer's Consortium, Phoenix.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brickhouse</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Boston4Harvard Medical School, Boston, Massachusetts9Frontotemporal Dementia Unit, Department of Neurology, Massachusetts General Hospital, Boston.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fleisher</LastName><ForeName>Adam S</ForeName><Initials>AS</Initials><AffiliationInfo><Affiliation>Banner Alzheimer's Institute, Phoenix, Arizona10Eli Lilly and Company, Indianapolis, Indiana11Department of Neurosciences, University of California, San Diego.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Langbaum</LastName><ForeName>Jessica B</ForeName><Initials>JB</Initials><AffiliationInfo><Affiliation>Banner Alzheimer's Institute, Phoenix, Arizona7Arizona Alzheimer's Consortium, Phoenix.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thiyyagura</LastName><ForeName>Pradeep</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Banner Alzheimer's Institute, Phoenix, Arizona7Arizona Alzheimer's Consortium, Phoenix.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fagan</LastName><ForeName>Anne M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St Louis, Missouri.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shah</LastName><ForeName>Aarti R</ForeName><Initials>AR</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St Louis, Missouri.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Muniz</LastName><ForeName>Martha</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Psychology Department, Boston University, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arboleda-Velasquez</LastName><ForeName>Joseph F</ForeName><Initials>JF</Initials><AffiliationInfo><Affiliation>Schepens Eye Research Institute, Massachusetts Eye and Ear Infirmary, Boston15Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Munoz</LastName><ForeName>Claudia</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Grupo de Neurociencias, Universidad de Antioquia, Medell&#xed;n, Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garcia</LastName><ForeName>Gloria</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Grupo de Neurociencias, Universidad de Antioquia, Medell&#xed;n, Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Acosta-Baena</LastName><ForeName>Natalia</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Grupo de Neurociencias, Universidad de Antioquia, Medell&#xed;n, Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Giraldo</LastName><ForeName>Margarita</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Grupo de Neurociencias, Universidad de Antioquia, Medell&#xed;n, Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tirado</LastName><ForeName>Victoria</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Grupo de Neurociencias, Universidad de Antioquia, Medell&#xed;n, Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ram&#xed;rez</LastName><ForeName>Dora L</ForeName><Initials>DL</Initials><AffiliationInfo><Affiliation>Grupo de Neurociencias, Universidad de Antioquia, Medell&#xed;n, Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tariot</LastName><ForeName>Pierre N</ForeName><Initials>PN</Initials><AffiliationInfo><Affiliation>Banner Alzheimer's Institute, Phoenix, Arizona7Arizona Alzheimer's Consortium, Phoenix16Department of Psychiatry, University of Arizona, Phoenix.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dickerson</LastName><ForeName>Bradford C</ForeName><Initials>BC</Initials><AffiliationInfo><Affiliation>Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Boston4Harvard Medical School, Boston, Massachusetts9Frontotemporal Dementia Unit, Department of Neurology, Massachusetts General Hospital, Boston.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sperling</LastName><ForeName>Reisa A</ForeName><Initials>RA</Initials><AffiliationInfo><Affiliation>Department of Neurology, Massachusetts General Hospital, Boston3Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Boston4Harvard Medical School, Boston, Massachusetts17Center for Alzheimer Research and Treatment, Departm.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lopera</LastName><ForeName>Francisco</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Grupo de Neurociencias, Universidad de Antioquia, Medell&#xed;n, Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reiman</LastName><ForeName>Eric M</ForeName><Initials>EM</Initials><AffiliationInfo><Affiliation>Banner Alzheimer's Institute, Phoenix, Arizona7Arizona Alzheimer's Consortium, Phoenix16Department of Psychiatry, University of Arizona, Phoenix18Division of Neurogenomics, Translational Genomics Research Institute, Phoenix, Arizona.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R00 EY021624</GrantID><Acronym>EY</Acronym><Agency>NEI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG031581</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG062421</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K99 EY021624</GrantID><Acronym>EY</Acronym><Agency>NEI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1AG041705</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>DP5OD019833</GrantID><Acronym>OD</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>2UF1 AG032438</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UF1 AG032438</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG19610</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG019610</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K24 AG035007</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG055444</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>EY021624</GrantID><Acronym>EY</Acronym><Agency>NEI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005134</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>DP5 OD019833</GrantID><Acronym>OD</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG041705</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Neurol</MedlineTA><NlmUniqueID>101589536</NlmUniqueID><ISSNLinking>2168-6149</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053764">Presenilin-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C078592">amyloid beta-protein (1-40)</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C075222">amyloid beta-protein (1-42)</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001931" MajorTopicYN="N">Brain Mapping</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009929" MajorTopicYN="N">Organ Size</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053764" MajorTopicYN="N">Presenilin-1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>6</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>6</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>11</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2016</Year><Month>8</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26121081</ArticleId><ArticleId IdType="mid">NIHMS706295</ArticleId><ArticleId IdType="pmc">PMC4625544</ArticleId><ArticleId IdType="doi">10.1001/jamaneurol.2015.1099</ArticleId><ArticleId IdType="pii">2337496</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Fleisher AS, Chen K, Quiroz YT, et al. Florbetapir PET analysis of amyloid-beta deposition in the presenilin 1 E280A autosomal dominant Alzheimer's disease kindred: a cross-sectional study. Lancet neurology. 2012;11:1057&#x2013;1065.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3515078</ArticleId><ArticleId IdType="pubmed">23137949</ArticleId></ArticleIdList></Reference><Reference><Citation>Quiroz YT, Budson AE, Celone K, et al. Hippocampal hyperactivation in presymptomatic familial Alzheimer's disease. Annals of neurology. 2010;68:865&#x2013;875.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3175143</ArticleId><ArticleId IdType="pubmed">21194156</ArticleId></ArticleIdList></Reference><Reference><Citation>Quiroz YT, Ally BA, Celone K, et al. Event-related potential markers of brain changes in preclinical familial Alzheimer disease. Neurology. 2011;77:469&#x2013;475.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3146305</ArticleId><ArticleId IdType="pubmed">21775732</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiman EM, Quiroz YT, Fleisher AS, et al. Brain imaging and fluid biomarker analysis in young adults at genetic risk for autosomal dominant Alzheimer's disease in the presenilin 1 E280A kindred: a case-control study. Lancet neurology. 2012;11:1048&#x2013;1056.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4181671</ArticleId><ArticleId IdType="pubmed">23137948</ArticleId></ArticleIdList></Reference><Reference><Citation>Dubois B, Feldman HH, Jacova C, et al. Revising the definition of Alzheimer's disease: a new lexicon. Lancet neurology. 2010;9:1118&#x2013;1127.</Citation><ArticleIdList><ArticleId IdType="pubmed">20934914</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperling RA, Aisen PS, Beckett LA, et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's &amp; dementia : the journal of the Alzheimer's Association. 2011;7:280&#x2013;292.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3220946</ArticleId><ArticleId IdType="pubmed">21514248</ArticleId></ArticleIdList></Reference><Reference><Citation>Dean DC, 3rd, Jerskey BA, Chen K, et al. Brain differences in infants at differential genetic risk for late-onset Alzheimer disease: a cross-sectional imaging study. JAMA neurology. 2014;71:11&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4056558</ArticleId><ArticleId IdType="pubmed">24276092</ArticleId></ArticleIdList></Reference><Reference><Citation>Karran E, Mercken M, De Strooper B. The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics. Nat Rev Drug Discov. 2011;10:698&#x2013;712.</Citation><ArticleIdList><ArticleId IdType="pubmed">21852788</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopera F, Ardilla A, Martinez A, et al. Clinical features of early-onset Alzheimer disease in a large kindred with an E280A presenilin-1 mutation. JAMA : the journal of the American Medical Association. 1997;277:793&#x2013;799.</Citation><ArticleIdList><ArticleId IdType="pubmed">9052708</ArticleId></ArticleIdList></Reference><Reference><Citation>Acosta-Baena N, Sepulveda-Falla D, Lopera-Gomez CM, et al. Pre-dementia clinical stages in presenilin 1 E280A familial early-onset Alzheimer's disease: a retrospective cohort study. Lancet neurology. 2011;10:213&#x2013;220.</Citation><ArticleIdList><ArticleId IdType="pubmed">21296022</ArticleId></ArticleIdList></Reference><Reference><Citation>Bateman RJ, Xiong C, Benzinger TL, et al. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. The New England journal of medicine. 2012;367:795&#x2013;804.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3474597</ArticleId><ArticleId IdType="pubmed">22784036</ArticleId></ArticleIdList></Reference><Reference><Citation>Fleisher AS, Chen K, Quiroz YT, et al. Associations Between Biomarkers and Age in the Presenilin 1 E280A Autosomal Dominant Alzheimer Disease Kindred: A Cross-sectional Study. JAMA neurology. 2015;72:316&#x2013;324.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4355261</ArticleId><ArticleId IdType="pubmed">25580592</ArticleId></ArticleIdList></Reference><Reference><Citation>Chouraki V, Beiser A, Younkin L, et al. Plasma amyloid-beta and risk of Alzheimer's disease in the Framingham Heart Study. Alzheimer's &amp; dementia : the journal of the Alzheimer's Association. 2015;11:249&#x2013;257. e241.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4362883</ArticleId><ArticleId IdType="pubmed">25217292</ArticleId></ArticleIdList></Reference><Reference><Citation>Rembach A, Watt AD, Wilson WJ, et al. Plasma amyloid-beta levels are significantly associated with a transition toward Alzheimer's disease as measured by cognitive decline and change in neocortical amyloid burden. Journal of Alzheimer's disease : JAD. 2014;40:95&#x2013;104.</Citation><ArticleIdList><ArticleId IdType="pubmed">24334723</ArticleId></ArticleIdList></Reference><Reference><Citation>Graff-Radford NR, Crook JE, Lucas J, et al. Association of low plasma Abeta42/Abeta40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease. Archives of neurology. 2007;64:354&#x2013;362.</Citation><ArticleIdList><ArticleId IdType="pubmed">17353377</ArticleId></ArticleIdList></Reference><Reference><Citation>Quiroz YT, Stern CE, Reiman EM, et al. Cortical atrophy in presymptomatic Alzheimer's disease presenilin 1 mutation carriers. Journal of neurology, neurosurgery, and psychiatry. 2013;84:556&#x2013;561.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3632663</ArticleId><ArticleId IdType="pubmed">23134660</ArticleId></ArticleIdList></Reference><Reference><Citation>Lendon CL, Martinez A, Behrens IM, et al. E280A PS-1 mutation causes Alzheimer's disease but age of onset is not modified by ApoE alleles. Human mutation. 1997;10:186&#x2013;195.</Citation><ArticleIdList><ArticleId IdType="pubmed">9298817</ArticleId></ArticleIdList></Reference><Reference><Citation>Freire L, Roche A, Mangin JF. What is the best similarity measure for motion correction in fMRI time series? IEEE transactions on medical imaging. 2002;21:470&#x2013;484.</Citation><ArticleIdList><ArticleId IdType="pubmed">12071618</ArticleId></ArticleIdList></Reference><Reference><Citation>Ashburner J. A fast diffeomorphic image registration algorithm. NeuroImage. 2007;38:95&#x2013;113.</Citation><ArticleIdList><ArticleId IdType="pubmed">17761438</ArticleId></ArticleIdList></Reference><Reference><Citation>Ashburner J, Andersson JL, Friston KJ. Image registration using a symmetric prior--in three dimensions. Human brain mapping. 2000;9:212&#x2013;225.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6871943</ArticleId><ArticleId IdType="pubmed">10770230</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomas JB, Brier MR, Bateman RJ, et al. Functional connectivity in autosomal dominant and late-onset Alzheimer disease. JAMA neurology. 2014;71:1111&#x2013;1122.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4240274</ArticleId><ArticleId IdType="pubmed">25069482</ArticleId></ArticleIdList></Reference><Reference><Citation>Chhatwal JP, Schultz AP, Johnson K, et al. Impaired default network functional connectivity in autosomal dominant Alzheimer disease. Neurology. 2013;81:736&#x2013;744.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3776464</ArticleId><ArticleId IdType="pubmed">23884042</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen G, Ward BD, Chen G, Li SJ. Decreased effective connectivity from cortices to the right parahippocampal gyrus in Alzheimer's disease subjects. Brain connectivity;2014;4:702&#x2013;708.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4238239</ArticleId><ArticleId IdType="pubmed">25132215</ArticleId></ArticleIdList></Reference><Reference><Citation>Fleisher A. JAMA neurology. In Press.</Citation></Reference><Reference><Citation>Knickmeyer RC, Wang J, Zhu H, et al. Common variants in psychiatric risk genes predict brain structure at birth. Cereb Cortex. 2014;24:1230&#x2013;1246.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3977618</ArticleId><ArticleId IdType="pubmed">23283688</ArticleId></ArticleIdList></Reference><Reference><Citation>Fortea J, Sala-Llonch R, Bartres-Faz D, et al. Increased cortical thickness and caudate volume precede atrophy in PSEN1 mutation carriers. Journal of Alzheimer's disease : JAD. 2010;22:909&#x2013;922.</Citation><ArticleIdList><ArticleId IdType="pubmed">20858974</ArticleId></ArticleIdList></Reference><Reference><Citation>Saura CA, Choi SY, Beglopoulos V, et al. Loss of presenilin function causes impairments of memory and synaptic plasticity followed by age-dependent neurodegeneration. Neuron. 2004;42:23&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pubmed">15066262</ArticleId></ArticleIdList></Reference><Reference><Citation>Louvi A, Artavanis-Tsakonas S. Notch signalling in vertebrate neural development. Nature reviews Neuroscience. 2006;7:93&#x2013;102.</Citation><ArticleIdList><ArticleId IdType="pubmed">16429119</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia D, Watanabe H, Wu B, et al. Presenilin-1 Knockin Mice Reveal Loss-of-Function Mechanism for Familial Alzheimer's Disease. Neuron. 2015;85:967&#x2013;981.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4358812</ArticleId><ArticleId IdType="pubmed">25741723</ArticleId></ArticleIdList></Reference><Reference><Citation>Bateman RJ, Aisen PS, De Strooper B, et al. Autosomal-dominant Alzheimer's disease: a review and proposal for the prevention of Alzheimer's disease. Alzheimer's research &amp; therapy. 2011;3:1.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3109410</ArticleId><ArticleId IdType="pubmed">21211070</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">26139022</PMID><DateCompleted><Year>2015</Year><Month>10</Month><Day>15</Day></DateCompleted><DateRevised><Year>2024</Year><Month>06</Month><Day>12</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1474-4465</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>8</Issue><PubDate><Year>2015</Year><Month>Aug</Month></PubDate></JournalIssue><Title>The Lancet. Neurology</Title><ISOAbbreviation>Lancet Neurol</ISOAbbreviation></Journal><ArticleTitle>Longitudinal assessment of neuroimaging and clinical markers in autosomal dominant Alzheimer's disease: a prospective cohort study.</ArticleTitle><Pagination><StartPage>804</StartPage><EndPage>813</EndPage><MedlinePgn>804-813</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/S1474-4422(15)00135-0</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1474-4422(15)00135-0</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The biomarker model of Alzheimer's disease postulates a dynamic sequence of amyloidosis, neurodegeneration, and cognitive decline as an individual progresses from preclinical Alzheimer's disease to dementia. Despite supportive evidence from cross-sectional studies, verification with long-term within-individual data is needed.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">For this prospective cohort study, carriers of autosomal dominant Alzheimer's disease mutations (aged &#x2265;21 years) were recruited from across the USA through referrals by physicians or from affected families. People with mutations in PSEN1, PSEN2, or APP were assessed at the University of Pittsburgh Alzheimer's Disease Research Center every 1-2 years, between March 23, 2003, and Aug 1, 2014. We measured global cerebral amyloid &#x3b2; (A&#x3b2;) load using (11)C-Pittsburgh Compound-B PET, posterior cortical metabolism with (18)F-fluorodeoxyglucose PET, hippocampal volume (age and sex corrected) with T1-weighted MRI, verbal memory with the ten-item Consortium to Establish a Registry for Alzheimer's Disease Word List Learning Delayed Recall Test, and general cognition with the Mini Mental State Examination. We estimated overall biomarker trajectories across estimated years from symptom onset using linear mixed models, and compared these estimates with cross-sectional data from cognitively normal control individuals (age 65-89 years) who were negative for amyloidosis, hypometabolism, and hippocampal atrophy. In the mutation carriers who had the longest follow-up, we examined the within-individual progression of amyloidosis, metabolism, hippocampal volume, and cognition to identify progressive within-individual changes (a significant change was defined as an increase or decrease of more than two Z scores standardised to controls).</AbstractText><AbstractText Label="FINDINGS" NlmCategory="RESULTS">16 people with mutations in PSEN1, PSEN2, or APP, aged 28-56 years, completed between two and eight assessments (a total of 83 assessments) over 2-11 years. Significant differences in mutation carriers compared with controls (p&lt;0&#xb7;01) were detected in the following order: increased amyloidosis (7&#xb7;5 years before expected onset), decreased metabolism (at time of expected onset), decreased hippocampal volume and verbal memory (7&#xb7;5 years after expected onset), and decreased general cognition (10 years after expected onset). Among the seven participants with longest follow-up (seven or eight assessments spanning 6-11 years), three individuals had active amyloidosis without progressive neurodegeneration or cognitive decline, two amyloid-positive individuals showed progressive neurodegeneration and cognitive decline without further progressive amyloidosis, and two amyloid-positive individuals showed neither active amyloidosis nor progressive neurodegeneration or cognitive decline.</AbstractText><AbstractText Label="INTERPRETATION" NlmCategory="CONCLUSIONS">Our results support amyloidosis as the earliest component of the biomarker model in autosomal dominant Alzheimer's disease. Our within-individual examination suggests three sequential phases in the development of autosomal dominant Alzheimer's disease-active amyloidosis, a stable amyloid-positive period, and progressive neurodegeneration and cognitive decline-indicating that A&#x3b2; accumulation is largely complete before progressive neurodegeneration and cognitive decline occur. These findings offer supportive evidence for efforts to target early A&#x3b2; deposition for secondary prevention in individuals with autosomal dominant Alzheimer's disease.</AbstractText><AbstractText Label="FUNDING" NlmCategory="BACKGROUND">National Institutes of Health and Howard Hughes Medical Institute.</AbstractText><CopyrightInformation>Copyright &#xa9; 2015 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yau</LastName><ForeName>Wai-Ying Wendy</ForeName><Initials>WW</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Pittsburgh, Pittsburgh, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tudorascu</LastName><ForeName>Dana L</ForeName><Initials>DL</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, University of Pittsburgh, Pittsburgh, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McDade</LastName><ForeName>Eric M</ForeName><Initials>EM</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Pittsburgh, Pittsburgh, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ikonomovic</LastName><ForeName>Snezana</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Pittsburgh, Pittsburgh, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>James</LastName><ForeName>Jeffrey A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Department of Radiology, University of Pittsburgh, Pittsburgh, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Minhas</LastName><ForeName>Davneet</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Radiology, University of Pittsburgh, Pittsburgh, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mowrey</LastName><ForeName>Wenzhu</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Division of Biostatistics, Department of Epidemiology and Population Health, Albert Einstein College of Medicine, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sheu</LastName><ForeName>Lei K</ForeName><Initials>LK</Initials><AffiliationInfo><Affiliation>Department of Psychology, University of Pittsburgh, Pittsburgh, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Snitz</LastName><ForeName>Beth E</ForeName><Initials>BE</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Pittsburgh, Pittsburgh, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weissfeld</LastName><ForeName>Lisa</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Statistics Collaborative, Inc, Washington, DC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gianaros</LastName><ForeName>Peter J</ForeName><Initials>PJ</Initials><AffiliationInfo><Affiliation>Department of Psychology, University of Pittsburgh, Pittsburgh, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aizenstein</LastName><ForeName>Howard J</ForeName><Initials>HJ</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Pittsburgh, Pittsburgh, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Price</LastName><ForeName>Julie C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Department of Radiology, University of Pittsburgh, Pittsburgh, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mathis</LastName><ForeName>Chester A</ForeName><Initials>CA</Initials><AffiliationInfo><Affiliation>Department of Radiology, University of Pittsburgh, Pittsburgh, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lopez</LastName><ForeName>Oscar L</ForeName><Initials>OL</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Pittsburgh, Pittsburgh, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Klunk</LastName><ForeName>William E</ForeName><Initials>WE</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Pittsburgh, Pittsburgh, PA, USA. Electronic address: klunkwe@upmc.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P50AG005133</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR000005</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG032438</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37 AG025516</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01HL089850</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005133</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><Acronym>HHMI</Acronym><Agency>Howard Hughes Medical Institute</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG025516</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG025516</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U19 AG032438</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 HL089850</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG025204</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>06</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lancet Neurol</MedlineTA><NlmUniqueID>101139309</NlmUniqueID><ISSNLinking>1474-4422</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C475519">2-(4'-(methylamino)phenyl)-6-hydroxybenzothiazole</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000814">Aniline Compounds</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013844">Thiazoles</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Lancet Neurol. 2015 Aug;14(8):781-783. doi: 10.1016/S1474-4422(15)00150-7.</RefSource><PMID Version="1">26139024</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000686" MajorTopicYN="N">Amyloidosis</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000814" MajorTopicYN="N">Aniline Compounds</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="Y">Biomarkers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002540" MajorTopicYN="Y">Cerebral Cortex</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="Y">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013844" MajorTopicYN="N">Thiazoles</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflicts of interest</b>. GE Healthcare holds a license agreement with the University of Pittsburgh based on the technology described in this manuscript. WEK and CAM are co-inventors of Pittsburgh Compound-B and, as such, have a financial interest in this license agreement. GE Healthcare provided no grant support for this study and had no role in the design or interpretation of results or preparation of this manuscript. EMM receives personal compensation for work on the Dominantly Inherited Alzheimer Network Trial Unit (DIAN-TU) therapeutics trial committee. OLL served as a consultant to Lundbeck and Grifols. All other authors have no conflicts of interest with this work. Once all clinical evaluations and image analyses were complete (each blinded to the other) and the data frozen, all authors had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis (with the exception of specific genetic testing results accessible only to WEK due to confidentiality reasons).</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>4</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2015</Year><Month>5</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>6</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>7</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>7</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>10</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2016</Year><Month>8</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26139022</ArticleId><ArticleId IdType="mid">NIHMS709422</ArticleId><ArticleId IdType="pmc">PMC4519011</ArticleId><ArticleId IdType="doi">10.1016/S1474-4422(15)00135-0</ArticleId><ArticleId IdType="pii">S1474-4422(15)00135-0</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Alzheimer&#x2019;s Association. 2014 Alzheimer&#x2019;s disease facts and figures. Alzheimers Dement. 2014;10:e47&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pubmed">24818261</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperling RA, Jack CR, Aisen PS. Testing the right target and right drug at the right stage. Science Translational Medicine. 2011;3:111cm33.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3752906</ArticleId><ArticleId IdType="pubmed">22133718</ArticleId></ArticleIdList></Reference><Reference><Citation>Bateman RJ, Xiong C, Benzinger TLS, et al. Clinical and biomarker changes in dominantly inherited Alzheimer&#x2019;s disease. N Engl J Med. 2012;367:795&#x2013;804.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3474597</ArticleId><ArticleId IdType="pubmed">22784036</ArticleId></ArticleIdList></Reference><Reference><Citation>Benzinger TLS, Blazey T, Jack CR, et al. Regional variability of imaging biomarkers in autosomal dominant Alzheimer&#x2019;s disease. Proceedings of the &#x2026;. 2013</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3839740</ArticleId><ArticleId IdType="pubmed">24194552</ArticleId></ArticleIdList></Reference><Reference><Citation>Villemagne VL, Burnham S, Bourgeat P, et al. Amyloid &#x3b2; deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer&#x2019;s disease: a prospective cohort study. Lancet Neurol. 2013;12:357&#x2013;67.</Citation><ArticleIdList><ArticleId IdType="pubmed">23477989</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Knopman DS, Jagust WJ, et al. Hypothetical model of dynamic biomarkers of the Alzheimer&#x2019;s pathological cascade. Lancet Neurol. 2010;9:119&#x2013;28.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2819840</ArticleId><ArticleId IdType="pubmed">20083042</ArticleId></ArticleIdList></Reference><Reference><Citation>Fleisher AS, Chen K, Quiroz YT, et al. Associations Between Biomarkers and Age in the Presenilin 1 E280A Autosomal Dominant Alzheimer Disease Kindred: A Cross-sectional Study. JAMA Neurol. 2015 doi: 10.1001/jamaneurol.2014.3314.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2014.3314</ArticleId><ArticleId IdType="pmc">PMC4355261</ArticleId><ArticleId IdType="pubmed">25580592</ArticleId></ArticleIdList></Reference><Reference><Citation>Fagan AM, Xiong C, Jasielec MS, et al. Longitudinal change in CSF biomarkers in autosomal-dominant Alzheimer&#x2019;s disease. Science Translational Medicine. 2014;6:226ra30.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4038930</ArticleId><ArticleId IdType="pubmed">24598588</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperling RA, Karlawish J, Johnson KA. Preclinical Alzheimer disease-the challenges ahead. Nat Rev Neurol. 2013;9:54&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3643203</ArticleId><ArticleId IdType="pubmed">23183885</ArticleId></ArticleIdList></Reference><Reference><Citation>Physicians AAOF, Association AP. Diagnostic and Statistical Manual of Mental Disorders. 4. American Psychiatric Pub; 1995.</Citation></Reference><Reference><Citation>Jack CR, Knopman DS, Weigand SD, et al. An operational approach to National Institute on Aging-Alzheimer&#x2019;s Association criteria for preclinical Alzheimer disease. Ann Neurol. 2012;71:765&#x2013;75.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3586223</ArticleId><ArticleId IdType="pubmed">22488240</ArticleId></ArticleIdList></Reference><Reference><Citation>Klunk WE, Price JC, Mathis CA, et al. Amyloid deposition begins in the striatum of presenilin-1 mutation carriers from two unrelated pedigrees. J Neurosci. 2007;27:6174&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3265970</ArticleId><ArticleId IdType="pubmed">17553989</ArticleId></ArticleIdList></Reference><Reference><Citation>Welsh KA, Butters N, Mohs RC, et al. The Consortium to Establish a Registry for Alzheimer&#x2019;s Disease (CERAD) Part V. A normative study of the neuropsychological battery. Neurology. 1994;44:609&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">8164812</ArticleId></ArticleIdList></Reference><Reference><Citation>Folstein MF, Folstein SE, McHugh PR. &#x2018;Mini-mental state&#x2019;. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="pubmed">1202204</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology. 1993;43:2412&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">8232972</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez OL, Becker JT, Klunk W, et al. Research evaluation and diagnosis of probable Alzheimer&#x2019;s disease over the last two decades: I. Neurology. 2000;55:1854&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pubmed">11134385</ArticleId></ArticleIdList></Reference><Reference><Citation>Patenaude B, Smith SM, Kennedy DN, Jenkinson M. A Bayesian model of shape and appearance for subcortical brain segmentation. NeuroImage. 2011;56:907&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3417233</ArticleId><ArticleId IdType="pubmed">21352927</ArticleId></ArticleIdList></Reference><Reference><Citation>Pfefferbaum A, Rohlfing T, Rosenbloom MJ, Sullivan EV. Combining atlas-based parcellation of regional brain data acquired across scanners at 1.5 T and 3. 0 T field strengths. NeuroImage. 2012;60:940&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3303927</ArticleId><ArticleId IdType="pubmed">22297204</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Petersen RC, Xu YC, et al. Medial temporal atrophy on MRI in normal aging and very mild Alzheimer&#x2019;s disease. Neurology. 1997;49:786&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2730601</ArticleId><ArticleId IdType="pubmed">9305341</ArticleId></ArticleIdList></Reference><Reference><Citation>Klunk WE, Engler H, Nordberg A, et al. Imaging brain amyloid in Alzheimer&#x2019;s disease with Pittsburgh Compound-B. Ann Neurol. 2004;55:306&#x2013;19.</Citation><ArticleIdList><ArticleId IdType="pubmed">14991808</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen AD, Price JC, Weissfeld LA, et al. Basal cerebral metabolism may modulate the cognitive effects of Abeta in mild cognitive impairment: an example of brain reserve. J Neurosci. 2009;29:14770&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2810461</ArticleId><ArticleId IdType="pubmed">19940172</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen AD, Mowrey W, Weissfeld LA, et al. Classification of amyloid-positivity in controls: comparison of visual read and quantitative approaches. NeuroImage. 2013;71:207&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3605888</ArticleId><ArticleId IdType="pubmed">23353602</ArticleId></ArticleIdList></Reference><Reference><Citation>Pedan A. Smoothing with SAS Proc Mixed. Seattle SAS Users Group International Proceedings; March 2003; p. 30.</Citation></Reference><Reference><Citation>Jack CR, Vemuri P, Wiste HJ, et al. Evidence for ordering of Alzheimer disease biomarkers. Arch Neurol. 2011;68:1526&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3387980</ArticleId><ArticleId IdType="pubmed">21825215</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Holtzman DM. Biomarker modeling of Alzheimer&#x2019;s disease. Neuron. 2013;80:1347&#x2013;58.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3928967</ArticleId><ArticleId IdType="pubmed">24360540</ArticleId></ArticleIdList></Reference><Reference><Citation>Mosconi L, Sorbi S, de Leon MJ, et al. Hypometabolism exceeds atrophy in presymptomatic early-onset familial Alzheimer&#x2019;s disease. J Nucl Med. 2006;47:1778&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="pubmed">17079810</ArticleId></ArticleIdList></Reference><Reference><Citation>Villemagne VL, Ataka S, Mizuno T, et al. High striatal amyloid beta-peptide deposition across different autosomal Alzheimer disease mutation types. Arch Neurol. 2009;66:1537&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">20008660</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Knopman DS, Jagust WJ, et al. Tracking pathophysiological processes in Alzheimer&#x2019;s disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 2013;12:207&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3622225</ArticleId><ArticleId IdType="pubmed">23332364</ArticleId></ArticleIdList></Reference><Reference><Citation>Fleisher AS, Chen K, Quiroz YT, et al. Florbetapir PET analysis of amyloid-&#x3b2; deposition in the presenilin 1 E280A autosomal dominant Alzheimer&#x2019;s disease kindred: a cross-sectional study. Lancet Neurol. 2012;11:1057&#x2013;65.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3515078</ArticleId><ArticleId IdType="pubmed">23137949</ArticleId></ArticleIdList></Reference><Reference><Citation>Caroli A, Frisoni GB. The dynamics of Alzheimer&#x2018;s disease biomarkers in the Alzheimer&#x2019;s Disease Neuroimaging Initiative cohort. Neurobiol Aging. 2010;31:1263&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3467365</ArticleId><ArticleId IdType="pubmed">20538373</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Wiste HJ, Lesnick TG, et al. Brain -amyloid load approaches a plateau. Neurology. 2013;80:890&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3653215</ArticleId><ArticleId IdType="pubmed">23446680</ArticleId></ArticleIdList></Reference><Reference><Citation>Ridha BH, Barnes J, Bartlett JW, et al. Tracking atrophy progression in familial Alzheimer&#x2019;s disease: a serial MRI study. Lancet Neurol. 2006;5:828&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">16987729</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryman DC, Acosta-Baena N, Aisen PS, et al. Symptom onset in autosomal dominant Alzheimer disease: a systematic review and meta-analysis. Neurology. 2014;83:253&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4117367</ArticleId><ArticleId IdType="pubmed">24928124</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">26141491</PMID><DateCompleted><Year>2015</Year><Month>11</Month><Day>16</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>17</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1460-2156</ISSN><JournalIssue CitedMedium="Internet"><Volume>138</Volume><Issue>Pt 9</Issue><PubDate><Year>2015</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Brain : a journal of neurology</Title><ISOAbbreviation>Brain</ISOAbbreviation></Journal><ArticleTitle>The behavioural/dysexecutive variant of Alzheimer's disease: clinical, neuroimaging and pathological features.</ArticleTitle><Pagination><StartPage>2732</StartPage><EndPage>2749</EndPage><MedlinePgn>2732-49</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/brain/awv191</ELocationID><Abstract><AbstractText>A 'frontal variant of Alzheimer's disease' has been described in patients with predominant behavioural or dysexecutive deficits caused by Alzheimer's disease pathology. The description of this rare Alzheimer's disease phenotype has been limited to case reports and small series, and many clinical, neuroimaging and neuropathological characteristics are not well understood. In this retrospective study, we included 55 patients with Alzheimer's disease with a behavioural-predominant presentation (behavioural Alzheimer's disease) and a neuropathological diagnosis of high-likelihood Alzheimer's disease (n = 17) and/or biomarker evidence of Alzheimer's disease pathology (n = 44). In addition, we included 29 patients with autopsy/biomarker-defined Alzheimer's disease with a dysexecutive-predominant syndrome (dysexecutive Alzheimer's disease). We performed structured chart reviews to ascertain clinical features. First symptoms were more often cognitive (behavioural Alzheimer's disease: 53%; dysexecutive Alzheimer's disease: 83%) than behavioural (behavioural Alzheimer's disease: 25%; dysexecutive Alzheimer's disease: 3%). Apathy was the most common behavioural feature, while hyperorality and perseverative/compulsive behaviours were less prevalent. Fifty-two per cent of patients with behavioural Alzheimer's disease met diagnostic criteria for possible behavioural-variant frontotemporal dementia. Overlap between behavioural and dysexecutive Alzheimer's disease was modest (9/75 patients). Sixty per cent of patients with behavioural Alzheimer's disease and 40% of those with the dysexecutive syndrome carried at least one APOE &#x3b5;4 allele. We also compared neuropsychological test performance and brain atrophy (applying voxel-based morphometry) with matched autopsy/biomarker-defined typical (amnestic-predominant) Alzheimer's disease (typical Alzheimer's disease, n = 58), autopsy-confirmed/Alzheimer's disease biomarker-negative behavioural variant frontotemporal dementia (n = 59), and controls (n = 61). Patients with behavioural Alzheimer's disease showed worse memory scores than behavioural variant frontotemporal dementia and did not differ from typical Alzheimer's disease, while executive function composite scores were lower compared to behavioural variant frontotemporal dementia and typical Alzheimer's disease. Voxel-wise contrasts between behavioural and dysexecutive Alzheimer's disease patients and controls revealed marked atrophy in bilateral temporoparietal regions and only limited atrophy in the frontal cortex. In direct comparison with behavioural and those with dysexecutive Alzheimer's disease, patients with behavioural variant frontotemporal dementia showed more frontal atrophy and less posterior involvement, whereas patients with typical Alzheimer's disease were slightly more affected posteriorly and showed less frontal atrophy (P &lt; 0.001 uncorrected). Among 24 autopsied behavioural Alzheimer's disease/dysexecutive Alzheimer's disease patients, only two had primary co-morbid FTD-spectrum pathology (progressive supranuclear palsy). In conclusion, behavioural Alzheimer's disease presentations are characterized by a milder and more restricted behavioural profile than in behavioural variant frontotemporal dementia, co-occurrence of memory dysfunction and high APOE &#x3b5;4 prevalence. Dysexecutive Alzheimer's disease presented as a primarily cognitive phenotype with minimal behavioural abnormalities and intermediate APOE &#x3b5;4 prevalence. Both behavioural Alzheimer's disease and dysexecutive Alzheimer's disease presentations are distinguished by temporoparietal-predominant atrophy. Based on the relative sparing of frontal grey matter, we propose to redefine these clinical syndromes as 'the behavioural/dysexecutive variant of Alzheimer's disease' rather than frontal variant Alzheimer's disease. Further work is needed to determine whether behavioural and dysexecutive-predominant presentations of Alzheimer's disease represent distinct phenotypes or a single continuum.</AbstractText><CopyrightInformation>&#xa9; The Author (2015). Published by Oxford University Press on behalf of the Guarantors of Brain. All rights reserved. For Permissions, please email: journals.permissions@oup.com.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ossenkoppele</LastName><ForeName>Rik</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>1 Memory and Aging Center, University of California San Francisco, San Francisco, USA 2 Helen Wills Neuroscience Institute, University of California Berkeley, Berkeley, USA 3 Department of Neurology and Alzheimer Center, VU University Medical Center, Amsterdam, The Netherlands 4 Department of Radiology and Nuclear Medicine, VU University Medical Center, Amsterdam, The Netherlands r.ossenkoppele@vumc.nl.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pijnenburg</LastName><ForeName>Yolande A L</ForeName><Initials>YA</Initials><AffiliationInfo><Affiliation>3 Department of Neurology and Alzheimer Center, VU University Medical Center, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Perry</LastName><ForeName>David C</ForeName><Initials>DC</Initials><AffiliationInfo><Affiliation>1 Memory and Aging Center, University of California San Francisco, San Francisco, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cohn-Sheehy</LastName><ForeName>Brendan I</ForeName><Initials>BI</Initials><AffiliationInfo><Affiliation>1 Memory and Aging Center, University of California San Francisco, San Francisco, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scheltens</LastName><ForeName>Nienke M E</ForeName><Initials>NM</Initials><AffiliationInfo><Affiliation>3 Department of Neurology and Alzheimer Center, VU University Medical Center, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vogel</LastName><ForeName>Jacob W</ForeName><Initials>JW</Initials><AffiliationInfo><Affiliation>2 Helen Wills Neuroscience Institute, University of California Berkeley, Berkeley, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kramer</LastName><ForeName>Joel H</ForeName><Initials>JH</Initials><AffiliationInfo><Affiliation>1 Memory and Aging Center, University of California San Francisco, San Francisco, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van der Vlies</LastName><ForeName>Annelies E</ForeName><Initials>AE</Initials><AffiliationInfo><Affiliation>3 Department of Neurology and Alzheimer Center, VU University Medical Center, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>La Joie</LastName><ForeName>Renaud</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>2 Helen Wills Neuroscience Institute, University of California Berkeley, Berkeley, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rosen</LastName><ForeName>Howard J</ForeName><Initials>HJ</Initials><AffiliationInfo><Affiliation>1 Memory and Aging Center, University of California San Francisco, San Francisco, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van der Flier</LastName><ForeName>Wiesje M</ForeName><Initials>WM</Initials><AffiliationInfo><Affiliation>3 Department of Neurology and Alzheimer Center, VU University Medical Center, Amsterdam, The Netherlands 5 Department of Epidemiology and Biostatistics VU University Medical Center, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grinberg</LastName><ForeName>Lea T</ForeName><Initials>LT</Initials><AffiliationInfo><Affiliation>1 Memory and Aging Center, University of California San Francisco, San Francisco, USA 6 Department of Pathology, University of California San Francisco, San Francisco, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rozemuller</LastName><ForeName>Annemieke J</ForeName><Initials>AJ</Initials><AffiliationInfo><Affiliation>3 Department of Neurology and Alzheimer Center, VU University Medical Center, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Eric J</ForeName><Initials>EJ</Initials><AffiliationInfo><Affiliation>6 Department of Pathology, University of California San Francisco, San Francisco, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Berckel</LastName><ForeName>Bart N M</ForeName><Initials>BN</Initials><AffiliationInfo><Affiliation>4 Department of Radiology and Nuclear Medicine, VU University Medical Center, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miller</LastName><ForeName>Bruce L</ForeName><Initials>BL</Initials><AffiliationInfo><Affiliation>1 Memory and Aging Center, University of California San Francisco, San Francisco, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barkhof</LastName><ForeName>Frederik</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>4 Department of Radiology and Nuclear Medicine, VU University Medical Center, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jagust</LastName><ForeName>William J</ForeName><Initials>WJ</Initials><AffiliationInfo><Affiliation>2 Helen Wills Neuroscience Institute, University of California Berkeley, Berkeley, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scheltens</LastName><ForeName>Philip</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>3 Department of Neurology and Alzheimer Center, VU University Medical Center, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Seeley</LastName><ForeName>William W</ForeName><Initials>WW</Initials><AffiliationInfo><Affiliation>1 Memory and Aging Center, University of California San Francisco, San Francisco, USA 6 Department of Pathology, University of California San Francisco, San Francisco, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rabinovici</LastName><ForeName>Gil D</ForeName><Initials>GD</Initials><AffiliationInfo><Affiliation>1 Memory and Aging Center, University of California San Francisco, San Francisco, USA 2 Helen Wills Neuroscience Institute, University of California Berkeley, Berkeley, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K23 AG045289</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG023501</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG003991</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50-AG023501</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01-AG1792403</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG019724</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG032306</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG045611</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01-AG027859</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01-AG045611</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>07</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Brain</MedlineTA><NlmUniqueID>0372537</NlmUniqueID><ISSNLinking>0006-8950</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001057">Apolipoproteins E</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000704" MajorTopicYN="N">Analysis of Variance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001057" MajorTopicYN="N">Apolipoproteins E</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D056344" MajorTopicYN="N">Executive Function</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007091" MajorTopicYN="N">Image Processing, Computer-Assisted</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001523" MajorTopicYN="N">Mental Disorders</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008609" MajorTopicYN="N">Mental Status Schedule</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="N">Positron-Emission Tomography</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer&#x2019;s disease</Keyword><Keyword MajorTopicYN="N">executive function</Keyword><Keyword MajorTopicYN="N">frontal, behaviour</Keyword><Keyword MajorTopicYN="N">frontotemporal dementia</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>1</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>5</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>7</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>7</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>11</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2016</Year><Month>9</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26141491</ArticleId><ArticleId IdType="pmc">PMC4623840</ArticleId><ArticleId IdType="doi">10.1093/brain/awv191</ArticleId><ArticleId IdType="pii">awv191</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer Dement 2011; 7: 270&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3312027</ArticleId><ArticleId IdType="pubmed">21514249</ArticleId></ArticleIdList></Reference><Reference><Citation>Alladi S, Xuereb J, Bak T, Nestor P, Knibb J, Patterson K, et al. Focal cortical presentations of Alzheimer's disease. Brain 2007; 130: 2636&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pubmed">17898010</ArticleId></ArticleIdList></Reference><Reference><Citation>Amador-Ortiz C, Lin WL, Ahmed Z, Personett D, Davies P, Duara R, et al. TDP-43 immunoreactivity in hippocampal sclerosis and Alzheimer's disease. Ann Neurol 2007; 61: 435&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2677204</ArticleId><ArticleId IdType="pubmed">17469117</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrade L, Caraveo-Anduaga JJ, Berglund P, Bijl RV, De Graaf R, Vollebergh W, et al. The epidemiology of major depressive episodes: results from the International Consortium of Psychiatric Epidemiology (ICPE) Surveys. Int J Methods Psychiatr Res 2003; 12: 3&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6878531</ArticleId><ArticleId IdType="pubmed">12830306</ArticleId></ArticleIdList></Reference><Reference><Citation>Attems J. Sporadic cerebral amyloid angiopathy: pathology, clinical implications, and possible pathomechanisms. Acta Neuropathol 2005; 110: 345&#x2013;59.</Citation><ArticleIdList><ArticleId IdType="pubmed">16170565</ArticleId></ArticleIdList></Reference><Reference><Citation>Back-Madruga C, Boone KB, Briere J, Cummings J, McPherson S, Fairbanks L, et al. Functional ability in executive variant Alzheimer's disease and typical Alzheimer's disease. Clin Neuropsych 2002; 16: 331&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">12607146</ArticleId></ArticleIdList></Reference><Reference><Citation>Balasa M, Gelpi E, Antonell A, Rey MJ, Sanchez-Valle R, Molinuevo JL, et al. Clinical features and APOE genotype of pathologically proven early-onset Alzheimer disease. Neurology 2011; 76: 1720&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">21576687</ArticleId></ArticleIdList></Reference><Reference><Citation>Beach TG, Monsell SE, Phillips LE, Kukull W. Accuracy of the clinical diagnosis of Alzheimer disease at National Institute on Aging Alzheimer Disease Centers, 2005-2010. J Neuropath Exp Neurol 2012; 71: 266&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3331862</ArticleId><ArticleId IdType="pubmed">22437338</ArticleId></ArticleIdList></Reference><Reference><Citation>Benson DF, Davis RJ, Snyder BD. Posterior cortical atrophy. Arch Neurol 1988; 45: 789&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pubmed">3390033</ArticleId></ArticleIdList></Reference><Reference><Citation>Binetti G, Magni E, Padovani A, Cappa SF, Bianchetti A, Trabucchi M. Executive dysfunction in early Alzheimer's disease. J Neurol Neurosurg Psychiatry 1996; 60: 91&#x2013;3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC486198</ArticleId><ArticleId IdType="pubmed">8558161</ArticleId></ArticleIdList></Reference><Reference><Citation>Blennerhassett R, Lillo P, Halliday GM, Hodges JR, Kril JJ. Distribution of pathology in frontal variant Alzheimer's disease. J Alzheimers Dis 2014; 39: 63&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pubmed">24121962</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Alafuzoff I, Arzberger T, Kretzschmar H, Del Tredici K. Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol 2006; 112: 389&#x2013;404.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3906709</ArticleId><ArticleId IdType="pubmed">16906426</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 1991; 82: 239&#x2013;59.</Citation><ArticleIdList><ArticleId IdType="pubmed">1759558</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E. Argyrophilic grain disease: frequency of occurrence in different age categories and neuropathological diagnostic criteria. J Neural Transm 1998; 105: 801&#x2013;19.</Citation><ArticleIdList><ArticleId IdType="pubmed">9869320</ArticleId></ArticleIdList></Reference><Reference><Citation>Bruen PD, McGeown WJ, Shanks MF, Venneri A. Neuroanatomical correlates of neuropsychiatric symptoms in Alzheimer's disease. Brain 2008; 131: 2455&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pubmed">18669506</ArticleId></ArticleIdList></Reference><Reference><Citation>Cairns NJ, Bigio EH, Mackenzie IR, Neumann M, Lee VM, Hatanpaa KJ, et al. Neuropathologic diagnostic and nosologic criteria for frontotemporal lobar degeneration: consensus of the Consortium for Frontotemporal Lobar Degeneration. Acta Neuropathol 2007; 114: 5&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2827877</ArticleId><ArticleId IdType="pubmed">17579875</ArticleId></ArticleIdList></Reference><Reference><Citation>Corrigan JD, Selassie AW, Orman JA. The epidemiology of traumatic brain injury. J Head Trauma Rehabil 2010; 25: 72&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pubmed">20234226</ArticleId></ArticleIdList></Reference><Reference><Citation>Crutch SJ, Lehmann M, Schott JM, Rabinovici GD, Rossor MN, Fox NC. Posterior cortical atrophy. Lancet Neurol 2012; 11: 170&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3740271</ArticleId><ArticleId IdType="pubmed">22265212</ArticleId></ArticleIdList></Reference><Reference><Citation>Damasio H, Grabowski T, Frank R, Galaburda AM, Damasio AR. The return of Phineas Gage: clues about the brain from the skull of a famous patient. Science 1994; 264: 1102&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">8178168</ArticleId></ArticleIdList></Reference><Reference><Citation>Devi G, Williamson J, Massoud F, Anderson K, Stern Y, Devanand DP, et al. A comparison of family history of psychiatric disorders among patients with early- and late-onset Alzheimer's disease. J Neuropsychiatry Clin Neurosci 2004; 16: 57&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pubmed">14990760</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickerson BC, Wolk DA.Alzheimer's Disease Neuroimaging I. Dysexecutive versus amnesic phenotypes of very mild Alzheimer's disease are associated with distinct clinical, genetic and cortical thinning characteristics. J Neurol Neurosurg Psychiatry 2011; 82: 45&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3023235</ArticleId><ArticleId IdType="pubmed">20562467</ArticleId></ArticleIdList></Reference><Reference><Citation>Duara R, Barker WW, Lopez-Alberola R, Loewenstein DA, Grau LB, Gilchrist D, et al. Alzheimer's disease: interaction of apolipoprotein E genotype, family history of dementia, gender, education, ethnicity, and age of onset. Neurology 1996; 46: 1575&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">8649551</ArticleId></ArticleIdList></Reference><Reference><Citation>Dubois B, Feldman HH, Jacova C, Hampel H, Molinuevo JL, Blennow K, et al. Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. Lancet Neurol 2014; 13: 614&#x2013;29.</Citation><ArticleIdList><ArticleId IdType="pubmed">24849862</ArticleId></ArticleIdList></Reference><Reference><Citation>Duits FH, Teunissen CE, Bouwman FH, Visser PJ, Mattsson N, Zetterberg H, et al. The cerebrospinal fluid &#x201c;Alzheimer profile&#x201d;: Easily said, but what does it mean? Alzheimer Dement 2014; 10: 713&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pubmed">24721526</ArticleId></ArticleIdList></Reference><Reference><Citation>Farrer LA, Cupples LA, Haines JL, Hyman B, Kukull WA, Mayeux R, et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA 1997; 278: 1349&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pubmed">9343467</ArticleId></ArticleIdList></Reference><Reference><Citation>Folstein MF, Folstein SE, McHugh PR. Mini-mental state. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="pubmed">1202204</ArticleId></ArticleIdList></Reference><Reference><Citation>Forman MS, Farmer J, Johnson JK, Clark CM, Arnold SE, Coslett HB, et al. Frontotemporal dementia: clinicopathological correlations. Ann Neurol 2006; 59: 952&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2629792</ArticleId><ArticleId IdType="pubmed">16718704</ArticleId></ArticleIdList></Reference><Reference><Citation>Gorno-Tempini ML, Hillis AE, Weintraub S, Kertesz A, Mendez M, Cappa SF, et al. Classification of primary progressive aphasia and its variants. Neurology 2011; 76: 1006&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3059138</ArticleId><ArticleId IdType="pubmed">21325651</ArticleId></ArticleIdList></Reference><Reference><Citation>Habek M, Hajnsek S, Zarkovic K, Chudy D, Mubrin Z. Frontal variant of Alzheimer's disease: clinico-CSF-pathological correlation. Can J Neurol Sci 2010; 37: 118&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">20169785</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamilton RL. Lewy bodies in Alzheimer's disease: a neuropathological review of 145 cases using alpha-synuclein immunohistochemistry. Brain Pathol 2000; 10: 378&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8098522</ArticleId><ArticleId IdType="pubmed">10885656</ArticleId></ArticleIdList></Reference><Reference><Citation>Hansen L, Salmon D, Galasko D, Masliah E, Katzman R, DeTeresa R, et al. The Lewy body variant of Alzheimer's disease: a clinical and pathologic entity. Neurology 1990; 40: 1&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">2153271</ArticleId></ArticleIdList></Reference><Reference><Citation>Herrero-San Martin A, Villarejo-Galende A, Rabano-Gutierrez A, Guerrero-Marquez C, Porta-Etessam J, Bermejo-Pareja F. Frontal variant of Alzheimer's disease. Two pathologically confirmed cases and a literature review [in Spanish]. Rev Neurol 2013; 57: 542&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">24288103</ArticleId></ArticleIdList></Reference><Reference><Citation>Hyman BT, Trojanowski JQ. Consensus recommendations for the postmortem diagnosis of Alzheimer disease from the National Institute on Aging and the Reagan Institute Working Group on diagnostic criteria for the neuropathological assessment of Alzheimer disease. J Neuropath Exp Neurol 1997; 56: 1095&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">9329452</ArticleId></ArticleIdList></Reference><Reference><Citation>Ikonomovic MD, Klunk WE, Abrahamson EE, Mathis CA, Price JC, Tsopelas ND, et al. Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease. Brain 2008; 131: 1630&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2408940</ArticleId><ArticleId IdType="pubmed">18339640</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr, Petersen RC, Xu YC, Waring SC, O'Brien PC, Tangalos EG, et al. Medial temporal atrophy on MRI in normal aging and very mild Alzheimer's disease. Neurology 1997; 49: 786&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2730601</ArticleId><ArticleId IdType="pubmed">9305341</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson JK, Head E, Kim R, Starr A, Cotman CW. Clinical and pathological evidence for a frontal variant of Alzheimer disease. Arch Neurol 1999; 56: 1233&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">10520939</ArticleId></ArticleIdList></Reference><Reference><Citation>Josephs KA, Whitwell JL, Weigand SD, Murray ME, Tosakulwong N, Liesinger AM, et al. TDP-43 is a key player in the clinical features associated with Alzheimer's disease. Acta Neuropathol 2014; 127: 811&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4172544</ArticleId><ArticleId IdType="pubmed">24659241</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalaria RN, Ballard C. Overlap between pathology of Alzheimer disease and vascular dementia. Alzheimer Dis Assoc Disord 1999; 13 (Suppl 3): S115&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pubmed">10609690</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaufer DI, Cummings JL, Ketchel P, Smith V, MacMillan A, Shelley T, et al. Validation of the NPI-Q, a brief clinical form of the Neuropsychiatric Inventory. J Neuropsychiatry Clin Neurosci 2000; 12: 233&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">11001602</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim HJ, Kang SJ, Kim C, Kim GH, Jeon S, Lee JM, et al. The effects of small vessel disease and amyloid burden on neuropsychiatric symptoms: a study among patients with subcortical vascular cognitive impairments. Neurobiol Aging 2013; 34: 1913&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">23414669</ArticleId></ArticleIdList></Reference><Reference><Citation>Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 2004; 55: 306&#x2013;19.</Citation><ArticleIdList><ArticleId IdType="pubmed">14991808</ArticleId></ArticleIdList></Reference><Reference><Citation>La Joie R, Perrotin A, Barre L, Hommet C, Mezenge F, Ibazizene M, et al. Region-specific hierarchy between atrophy, hypometabolism, and beta-amyloid (Abeta) load in Alzheimer's disease dementia. J Neurosci 2012; 32: 16265&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6794030</ArticleId><ArticleId IdType="pubmed">23152610</ArticleId></ArticleIdList></Reference><Reference><Citation>Landau SM, Lu M, Joshi AD, Pontecorvo M, Mintun MA, Trojanowski JQ, et al. Comparing positron emission tomography imaging and cerebrospinal fluid measurements of beta-amyloid. Ann Neurol 2013; 74: 826&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3748164</ArticleId><ArticleId IdType="pubmed">23536396</ArticleId></ArticleIdList></Reference><Reference><Citation>Larner AJ. Frontal variant Alzheimer's disease: a reappraisal. Clin Neurol Neurosurg 2006; 108: 705&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">16102893</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee SE, Rabinovici GD, Mayo MC, Wilson SM, Seeley WW, DeArmond SJ, et al. Clinicopathological correlations in corticobasal degeneration. Ann Neurol 2011; 70: 327&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3154081</ArticleId><ArticleId IdType="pubmed">21823158</ArticleId></ArticleIdList></Reference><Reference><Citation>Lehmann M, Ghosh PM, Madison C, Karydas A, Coppola G, O'Neil JP, et al. Greater medial temporal hypometabolism and lower cortical amyloid burden in ApoE4-positive AD patients. J Neurol Neurosurg Psychiatry 2014; 85: 266&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3946299</ArticleId><ArticleId IdType="pubmed">23965289</ArticleId></ArticleIdList></Reference><Reference><Citation>Lehmann M, Ghosh PM, Madison C, Laforce R, Jr, Corbetta-Rastelli C, Weiner MW, et al. Diverging patterns of amyloid deposition and hypometabolism in clinical variants of probable Alzheimer's disease. Brain 2013a; 136: 844&#x2013;58.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3580269</ArticleId><ArticleId IdType="pubmed">23358601</ArticleId></ArticleIdList></Reference><Reference><Citation>Lehmann M, Madison CM, Ghosh PM, Seeley WW, Mormino E, Greicius MD, et al. Intrinsic connectivity networks in healthy subjects explain clinical variability in Alzheimer's disease. Proc Nat Acad Sci 2013b; 110: 11606&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3710820</ArticleId><ArticleId IdType="pubmed">23798398</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackenzie IR, Neumann M, Bigio EH, Cairns NJ, Alafuzoff I, Kril J, et al. Nomenclature and nosology for neuropathologic subtypes of frontotemporal lobar degeneration: an update. Acta Neuropathol 2010; 119: 1&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2799633</ArticleId><ArticleId IdType="pubmed">19924424</ArticleId></ArticleIdList></Reference><Reference><Citation>Manning EN, Barnes J, Cash DM, Bartlett JW, Leung KK, Ourselin S, et al. APOE epsilon4 is associated with disproportionate progressive hippocampal atrophy in AD. PloS One 2014; 9: e97608.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4039513</ArticleId><ArticleId IdType="pubmed">24878738</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR, Jr, Kawas CH, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011; 7: 263&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3312024</ArticleId><ArticleId IdType="pubmed">21514250</ArticleId></ArticleIdList></Reference><Reference><Citation>Mendez MF, Lee AS, Joshi A, Shapira JS. Nonamnestic presentations of early-onset Alzheimer's disease. Am J Alzheimers Dis Other Dement 2012; 27: 413&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3625669</ArticleId><ArticleId IdType="pubmed">22871906</ArticleId></ArticleIdList></Reference><Reference><Citation>Mendez MF, Joshi A, Tassniyom K, Teng E, Shapira JS. Clinicopathologic differences among patients with behavioural variant frontotemporal dementia. Neurology 2013; 80: 561&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3589292</ArticleId><ArticleId IdType="pubmed">23325909</ArticleId></ArticleIdList></Reference><Reference><Citation>Mesulam M, Wicklund A, Johnson N, Rogalski E, Leger GC, Rademaker A, et al. Alzheimer and frontotemporal pathology in subsets of primary progressive aphasia. Ann Neurol 2008; 63: 709&#x2013;19.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2858311</ArticleId><ArticleId IdType="pubmed">18412267</ArticleId></ArticleIdList></Reference><Reference><Citation>Mez J, Cosentino S, Brickman AM, Huey ED, Manly JJ, Mayeux R. Dysexecutive versus amnestic Alzheimer disease subgroups: analysis of demographic, genetic, and vascular factors. Alzheimer Dis Assoc Disord 2013; 27: 218&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3748394</ArticleId><ArticleId IdType="pubmed">23954887</ArticleId></ArticleIdList></Reference><Reference><Citation>Michaelson DM. ApoE4: The most prevalent yet understudied risk factor for Alzheimer's disease. Alzheimer's Dement 2014; 10: 861&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">25217293</ArticleId></ArticleIdList></Reference><Reference><Citation>Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ, Brownlee LM, et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 1991; 41: 479&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="pubmed">2011243</ArticleId></ArticleIdList></Reference><Reference><Citation>Moller C, Vrenken H, Jiskoot L, Versteeg A, Barkhof F, Scheltens P, et al. Different patterns of gray matter atrophy in early- and late-onset Alzheimer's disease. Neurobiol Aging 2013; 34: 2014&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pubmed">23561509</ArticleId></ArticleIdList></Reference><Reference><Citation>Montine TJ, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Dickson DW, et al. National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease: a practical approach. Acta Neuropathol 2012; 123: 1&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3268003</ArticleId><ArticleId IdType="pubmed">22101365</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 1993; 43: 2412&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">8232972</ArticleId></ArticleIdList></Reference><Reference><Citation>Munoz DG, Woulfe J, Kertesz A. Argyrophilic thorny astrocyte clusters in association with Alzheimer's disease pathology in possible primary progressive aphasia. Acta Neuropathol 2007; 114: 347&#x2013;57.</Citation><ArticleIdList><ArticleId IdType="pubmed">17637999</ArticleId></ArticleIdList></Reference><Reference><Citation>Neary D, Snowden JS, Gustafson L, Passant U, Stuss D, Black S, et al. Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology 1998; 51: 1546&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pubmed">9855500</ArticleId></ArticleIdList></Reference><Reference><Citation>Neufang S, Akhrif A, Riedl V, Forstl H, Kurz A, Zimmer C, et al. Disconnection of frontal and parietal areas contributes to impaired attention in very early Alzheimer's disease. J Alzheimer Dis 2011; 25: 309&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">21422523</ArticleId></ArticleIdList></Reference><Reference><Citation>Nwankwo T, Yoon SS, Burt V, Gu Q. Hypertension among adults in the United States: National Health and Nutrition Examination Survey, 2011-2012. NCHS Data Brief 2013; 133: 1&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">24171916</ArticleId></ArticleIdList></Reference><Reference><Citation>Ossenkoppele R, Prins ND, Pijnenburg YA, Lemstra AW, van der Flier WM, Adriaanse SF, et al. Impact of molecular imaging on the diagnostic process in a memory clinic. Alzheimers Dement 2013a; 9: 414&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">23164552</ArticleId></ArticleIdList></Reference><Reference><Citation>Ossenkoppele R, Tolboom N, Foster-Dingley JC, Adriaanse SF, Boellaard R, Yaqub M, et al. Longitudinal imaging of Alzheimer pathology using [11C]PIB, [18F]FDDNP and [18F]FDG PET. Eur J Nuc Med Mol Imaging 2012a; 39: 990&#x2013;1000.</Citation><ArticleIdList><ArticleId IdType="pubmed">22441582</ArticleId></ArticleIdList></Reference><Reference><Citation>Ossenkoppele R, van der Flier WM, Zwan MD, Adriaanse SF, Boellaard R, Windhorst AD, et al. Differential effect of APOE genotype on amyloid load and glucose metabolism in AD dementia. Neurology 2013b; 80: 359&#x2013;65.</Citation><ArticleIdList><ArticleId IdType="pubmed">23255822</ArticleId></ArticleIdList></Reference><Reference><Citation>Ossenkoppele R, Zwan MD, Tolboom N, van Assema DM, Adriaanse SF, Kloet RW, et al. Amyloid burden and metabolic function in early-onset Alzheimer's disease: parietal lobe involvement. Brain 2012b; 135: 2115&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pubmed">22556189</ArticleId></ArticleIdList></Reference><Reference><Citation>Pa J, Boxer A, Chao LL, Gazzaley A, Freeman K, Kramer J, et al. Clinical-neuroimaging characteristics of dysexecutive mild cognitive impairment. Ann Neurol 2009; 65: 414&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2680500</ArticleId><ArticleId IdType="pubmed">19399879</ArticleId></ArticleIdList></Reference><Reference><Citation>Poirier J, Davignon J, Bouthillier D, Kogan S, Bertrand P, Gauthier S. Apolipoprotein E polymorphism and Alzheimer's disease. Lancet 1993; 342: 697&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">8103819</ArticleId></ArticleIdList></Reference><Reference><Citation>Rabinovici GD, Furst AJ, Alkalay A, Racine CA, O'Neil JP, Janabi M, et al. Increased metabolic vulnerability in early-onset Alzheimer's disease is not related to amyloid burden. Brain 2010; 133: 512&#x2013;28.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2858015</ArticleId><ArticleId IdType="pubmed">20080878</ArticleId></ArticleIdList></Reference><Reference><Citation>Rabinovici GD, Rosen HJ, Alkalay A, Kornak J, Furst AJ, Agarwal N, et al. Amyloid vs FDG-PET in the differential diagnosis of AD and FTLD. Neurology 2011; 77: 2034&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3236517</ArticleId><ArticleId IdType="pubmed">22131541</ArticleId></ArticleIdList></Reference><Reference><Citation>Rascovsky K, Hodges JR, Knopman D, Mendez MF, Kramer JH, Neuhaus J, et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain 2011; 134: 2456&#x2013;77.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3170532</ArticleId><ArticleId IdType="pubmed">21810890</ArticleId></ArticleIdList></Reference><Reference><Citation>Reed BR, Eberling JL, Mungas D, Weiner M, Kramer JH, Jagust WJ. Effects of white matter lesions and lacunes on cortical function. Arc Neurol 2004; 61: 1545&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pubmed">15477508</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider JA, Arvanitakis Z, Bang W, Bennett DA. Mixed brain pathologies account for most dementia cases in community-dwelling older persons. Neurology 2007; 69: 2197&#x2013;204.</Citation><ArticleIdList><ArticleId IdType="pubmed">17568013</ArticleId></ArticleIdList></Reference><Reference><Citation>Schoonenboom NS, Reesink FE, Verwey NA, Kester MI, Teunissen CE, van de Ven PM, et al. Cerebrospinal fluid markers for differential dementia diagnosis in a large memory clinic cohort. Neurology 2012; 78: 47&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pubmed">22170879</ArticleId></ArticleIdList></Reference><Reference><Citation>Sjobeck M, Elfgren C, Larsson EM, Brockstedt S, Latt J, Englund E, et al. Alzheimer's disease (AD) and executive dysfunction. A case-control study on the significance of frontal white matter changes detected by diffusion tensor imaging (DTI). Arch Gerontol Geriatr 2010; 50: 260&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">19419776</ArticleId></ArticleIdList></Reference><Reference><Citation>Sluimer JD, van der Flier WM, Karas GB, Fox NC, Scheltens P, Barkhof F, et al. Whole-brain atrophy rate and cognitive decline: longitudinal MR study of memory clinic patients. Radiology 2008; 248: 590&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">18574133</ArticleId></ArticleIdList></Reference><Reference><Citation>Snowden JS, Stopford CL, Julien CL, Thompson JC, Davidson Y, Gibbons L, et al. Cognitive phenotypes in Alzheimer's disease and genetic risk. Cortex 2007; 43: 835&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pubmed">17941342</ArticleId></ArticleIdList></Reference><Reference><Citation>Soldatos CR, Lugaresi E. Nosology and prevalence of sleep disorders. Sem Neurol 1987; 7: 236&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pubmed">3332458</ArticleId></ArticleIdList></Reference><Reference><Citation>Strozyk D, Blennow K, White LR, Launer LJ. CSF Abeta 42 levels correlate with amyloid-neuropathology in a population-based autopsy study. Neurology 2003; 60: 652&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">12601108</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor KI, Probst A, Miserez AR, Monsch AU, Tolnay M. Clinical course of neuropathologically confirmed frontal-variant Alzheimer's disease. Nat Clin Pract Neurol 2008; 4: 226&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pubmed">18285751</ArticleId></ArticleIdList></Reference><Reference><Citation>Thal DR, Rub U, Orantes M, Braak H. Phases of A beta-deposition in the human brain and its relevance for the development of AD. Neurology 2002; 58: 1791&#x2013;800.</Citation><ArticleIdList><ArticleId IdType="pubmed">12084879</ArticleId></ArticleIdList></Reference><Reference><Citation>Togo T, Sahara N, Yen SH, Cookson N, Ishizawa T, Hutton M, et al. Argyrophilic grain disease is a sporadic 4-repeat tauopathy. J Neuropath Exp Neurol 2002; 61: 547&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pubmed">12071638</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Flier WM, Pijnenburg YA, Fox NC, Scheltens P. Early-onset versus late-onset Alzheimer's disease: the case of the missing APOE varepsilon4 allele. Lancet Neurol 2011; 10: 280&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">21185234</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Flier WM, Pijnenburg YA, Prins N, Lemstra AW, Bouwman FH, Teunissen CE, et al. Optimizing patient care and research: the Amsterdam Dementia Cohort. J Alzheimer Dis 2014; 41: 313&#x2013;27.</Citation><ArticleIdList><ArticleId IdType="pubmed">24614907</ArticleId></ArticleIdList></Reference><Reference><Citation>Vandenberghe R, Van Laere K, Ivanoiu A, Salmon E, Bastin C, Triau E, et al. 18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial. Ann Neurol 2010; 68: 319&#x2013;29.</Citation><ArticleIdList><ArticleId IdType="pubmed">20687209</ArticleId></ArticleIdList></Reference><Reference><Citation>Varma AR, Snowden JS, Lloyd JJ, Talbot PR, Mann DM, Neary D. Evaluation of the NINCDS-ADRDA criteria in the differentiation of Alzheimer's disease and frontotemporal dementia. J Neurol Neurosurg Psychiatry 1999; 66: 184&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1736233</ArticleId><ArticleId IdType="pubmed">10071097</ArticleId></ArticleIdList></Reference><Reference><Citation>Verpillat P, Camuzat A, Hannequin D, Thomas-Anterion C, Puel M, Belliard S, et al. Apolipoprotein E gene in frontotemporal dementia: an association study and meta-analysis. Eur J Hum Genet 2002; 10: 399&#x2013;405.</Citation><ArticleIdList><ArticleId IdType="pubmed">12107813</ArticleId></ArticleIdList></Reference><Reference><Citation>Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004; 27: 1047&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pubmed">15111519</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolk DA, Dickerson BC.Alzheimer's Disease Neuroimaging I. Apolipoprotein E (APOE) genotype has dissociable effects on memory and attentional-executive network function in Alzheimer's disease. Proc Nat Acad Sci 2010; 107: 10256&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2890481</ArticleId><ArticleId IdType="pubmed">20479234</ArticleId></ArticleIdList></Reference><Reference><Citation>Woodward M, Jacova C, Black SE, Kertesz A, Mackenzie IR, Feldman H, et al. Differentiating the frontal variant of Alzheimer's disease. Int J Ger Psychiatry 2010; 25: 732&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">19823987</ArticleId></ArticleIdList></Reference><Reference><Citation>Woodward MC, Rowe CC, Jones G, Villemagne VL, Varos TA. Differentiating the frontal presentation of Alzheimer's disease with FDG-PET. J Alzheimer Dis 2014; 44: 233&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pubmed">25261443</ArticleId></ArticleIdList></Reference><Reference><Citation>Yesavage JA, Brink TL, Rose TL, Lum O, Huang V, Adey M, et al. Development and validation of a geriatric depression screening scale: a preliminary report. J Psychiatr Res 1982; 17: 37&#x2013;49.</Citation><ArticleIdList><ArticleId IdType="pubmed">7183759</ArticleId></ArticleIdList></Reference><Reference><Citation>Zwan M, van Harten A, Ossenkoppele R, Bouwman F, Teunissen C, Adriaanse S, et al. Concordance between cerebrospinal fluid biomarkers and [11C]PIB PET in a memory clinic cohort. J Alzheimer Dis 2014; 41: 801&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">24705549</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">26147946</PMID><DateCompleted><Year>2015</Year><Month>12</Month><Day>02</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>08</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-6157</ISSN><JournalIssue CitedMedium="Internet"><Volume>72</Volume><Issue>9</Issue><PubDate><Year>2015</Year><Month>Sep</Month></PubDate></JournalIssue><Title>JAMA neurology</Title><ISOAbbreviation>JAMA Neurol</ISOAbbreviation></Journal><ArticleTitle>Longitudinal Cerebrospinal Fluid Biomarker Changes in Preclinical Alzheimer Disease During Middle Age.</ArticleTitle><Pagination><StartPage>1029</StartPage><EndPage>1042</EndPage><MedlinePgn>1029-42</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamaneurol.2015.1285</ELocationID><Abstract><AbstractText Label="IMPORTANCE" NlmCategory="OBJECTIVE">Individuals in the presymptomatic stage of Alzheimer disease (AD) are increasingly being targeted for AD secondary prevention trials. How early during the normal life span underlying AD pathologies begin to develop, their patterns of change over time, and their relationship with future cognitive decline remain to be determined.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To characterize the within-person trajectories of cerebrospinal fluid (CSF) biomarkers of AD over time and their association with changes in brain amyloid deposition and cognitive decline in cognitively normal middle-aged individuals.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS" NlmCategory="METHODS">As part of a cohort study, cognitively normal (Clinical Dementia Rating [CDR] of 0) middle-aged research volunteers (n&#x2009;=&#x2009;169) enrolled in the Adult Children Study at Washington University, St Louis, Missouri, had undergone serial CSF collection and longitudinal clinical assessment (mean, 6 years; range, 0.91-11.3 years) at 3-year intervals at the time of analysis, between January 2003 and November 2013. A subset (n&#x2009;=&#x2009;74) had also undergone longitudinal amyloid positron emission tomographic imaging with Pittsburgh compound B (PiB) in the same period. Serial CSF samples were analyzed for &#x3b2;-amyloid 40 (A&#x3b2;40), A&#x3b2;42, total tau, tau phosphorylated at threonine 181 (P-tau181), visinin-like protein 1 (VILIP-1), and chitinase-3-like protein 1 (YKL-40). Within-person measures were plotted according to age and AD risk defined by APOE genotype (&#x3b5;4 carriers vs noncarriers). Linear mixed models were used to compare estimated biomarker slopes among middle-age bins at baseline (early, 45-54 years; mid, 55-64 years; late, 65-74 years) and between risk groups. Within-person changes in CSF biomarkers were also compared with changes in cortical PiB binding and progression to a CDR higher than 0 at follow-up.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES" NlmCategory="METHODS">Changes in A&#x3b2;40, A&#x3b2;42, total tau, P-tau181, VILIP-1, and YKL-40 and, in a subset of participants, changes in cortical PiB binding.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">While there were no consistent longitudinal patterns in A&#x3b2;40 (P&#x2009;=&#x2009;.001-.97), longitudinal reductions in A&#x3b2;42 were observed in some individuals as early as early middle age (P&#x2009;&#x2264;&#x2009;.05) and low A&#x3b2;42 levels were associated with the development of cortical PiB-positive amyloid plaques (area under receiver operating characteristic curve&#x2009;=&#x2009;0.9352; 95% CI, 0.8895-0.9808), especially in mid middle age (P&#x2009;&lt;&#x2009;.001). Markers of neuronal injury (total tau, P-tau181, and VILIP-1) dramatically increased in some individuals in mid and late middle age (P&#x2009;&#x2264;&#x2009;.02), whereas the neuroinflammation marker YKL-40 increased consistently throughout middle age (P&#x2009;&#x2264;&#x2009;.003). These patterns were more apparent in at-risk &#x3b5;4 carriers (A&#x3b2;42 in an allele dose-dependent manner) and appeared to be associated with future cognitive deficits as determined by CDR.</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE" NlmCategory="CONCLUSIONS">Longitudinal CSF biomarker patterns consistent with AD are first detectable during early middle age and are associated with later amyloid positivity and cognitive decline. Such measures may be useful for targeting middle-aged, asymptomatic individuals for therapeutic trials designed to prevent cognitive decline.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sutphen</LastName><ForeName>Courtney L</ForeName><Initials>CL</Initials><AffiliationInfo><Affiliation>Knight Alzheimer's Disease Research Center, Washington University, St Louis, Missouri2Department of Neurology, Washington University, St Louis, Missouri3Hope Center for Neurodegenerative Disorders, Washington University, St Louis, Missouri.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jasielec</LastName><ForeName>Mateusz S</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>Knight Alzheimer's Disease Research Center, Washington University, St Louis, Missouri4Division of Biostatistics, Washington University, St Louis, Missouri.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shah</LastName><ForeName>Aarti R</ForeName><Initials>AR</Initials><AffiliationInfo><Affiliation>Knight Alzheimer's Disease Research Center, Washington University, St Louis, Missouri2Department of Neurology, Washington University, St Louis, Missouri3Hope Center for Neurodegenerative Disorders, Washington University, St Louis, Missouri.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Macy</LastName><ForeName>Elizabeth M</ForeName><Initials>EM</Initials><AffiliationInfo><Affiliation>Department of Pathology and Immunology, Washington University, St Louis, Missouri.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xiong</LastName><ForeName>Chengjie</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Knight Alzheimer's Disease Research Center, Washington University, St Louis, Missouri4Division of Biostatistics, Washington University, St Louis, Missouri.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vlassenko</LastName><ForeName>Andrei G</ForeName><Initials>AG</Initials><AffiliationInfo><Affiliation>Knight Alzheimer's Disease Research Center, Washington University, St Louis, Missouri6Department of Radiology, Washington University, St Louis, Missouri.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Benzinger</LastName><ForeName>Tammie L S</ForeName><Initials>TL</Initials><AffiliationInfo><Affiliation>Knight Alzheimer's Disease Research Center, Washington University, St Louis, Missouri6Department of Radiology, Washington University, St Louis, Missouri.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stoops</LastName><ForeName>Erik E J</ForeName><Initials>EE</Initials><AffiliationInfo><Affiliation>ADx NeuroSciences, Ghent, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vanderstichele</LastName><ForeName>Hugo M J</ForeName><Initials>HM</Initials><AffiliationInfo><Affiliation>ADx NeuroSciences, Ghent, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brix</LastName><ForeName>Britta</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>EUROIMMUN, L&#xfc;beck, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Darby</LastName><ForeName>Heather D</ForeName><Initials>HD</Initials><AffiliationInfo><Affiliation>Fujirebio US, Malvern, Pennsylvania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vandijck</LastName><ForeName>Manu L J</ForeName><Initials>ML</Initials><AffiliationInfo><Affiliation>Fujirebio Europe, Ghent, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ladenson</LastName><ForeName>Jack H</ForeName><Initials>JH</Initials><AffiliationInfo><Affiliation>Department of Pathology and Immunology, Washington University, St Louis, Missouri.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morris</LastName><ForeName>John C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Knight Alzheimer's Disease Research Center, Washington University, St Louis, Missouri2Department of Neurology, Washington University, St Louis, Missouri3Hope Center for Neurodegenerative Disorders, Washington University, St Louis, Missouri.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Holtzman</LastName><ForeName>David M</ForeName><Initials>DM</Initials><AffiliationInfo><Affiliation>Knight Alzheimer's Disease Research Center, Washington University, St Louis, Missouri2Department of Neurology, Washington University, St Louis, Missouri3Hope Center for Neurodegenerative Disorders, Washington University, St Louis, Missouri.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fagan</LastName><ForeName>Anne M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Knight Alzheimer's Disease Research Center, Washington University, St Louis, Missouri2Department of Neurology, Washington University, St Louis, Missouri3Hope Center for Neurodegenerative Disorders, Washington University, St Louis, Missouri.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P01AG026276</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG003991</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG026276</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>5P30 NS048056</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 NS048056</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Neurol</MedlineTA><NlmUniqueID>101589536</NlmUniqueID><ISSNLinking>2168-6149</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C475519">2-(4'-(methylamino)phenyl)-6-hydroxybenzothiazole</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D054392">Adipokines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000814">Aniline Compounds</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C084533">CHI3L1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000071451">Chitinase-3-Like Protein 1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D037102">Lectins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051596">Neurocalcin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013844">Thiazoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C496688">VSNL1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C078592">amyloid beta-protein (1-40)</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C075222">amyloid beta-protein (1-42)</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Neurol. 2015 Aug;11(8):427. doi: 10.1038/nrneurol.2015.129.</RefSource><PMID Version="1">26215625</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D054392" MajorTopicYN="N">Adipokines</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000814" MajorTopicYN="N">Aniline Compounds</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058070" MajorTopicYN="Y">Asymptomatic Diseases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000071451" MajorTopicYN="N">Chitinase-3-Like Protein 1</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D060005" MajorTopicYN="N">Genotyping Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D037102" MajorTopicYN="N">Lectins</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051596" MajorTopicYN="N">Neurocalcin</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="N">Positron-Emission Tomography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013844" MajorTopicYN="N">Thiazoles</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of Interest Disclosures:</b> Dr Benzinger reported being a member of the advisory board for Eli Lilly and Co (2011); receiving research funding from Avid Radiopharmaceuticals; providing expert testimony and receiving compensation from Kujawaski and Associates (2011); and participating in clinical trials sponsored by Eli Lilly and Co, Avid Radiopharmaceuticals, and Roche. Mr Stoops reported being a shareholder of ADx NeuroSciences and BioMARIC NV. Dr Vanderstichele reported being a cofounder and shareholder of ADx NeuroSciences and founder of Biomarkable bvba. Dr Ladenson reported being named on patents related to use of VILIP-1; these are being managed by Washington University in accordance with university policy. Dr Morris reported having participated in or currently participating in clinical trials of antidementia drugs sponsored by Janssen Immunotherapy, Pfizer, Eli Lilly and Co/Avid Radiopharmaceuticals, SNIFF (Study of Nasal Insulin to Fight Forgetfulness), and A4 Study (Anti-Amyloid Treatment in Asymptomatic Alzheimer&#x2019;s Disease) and serving as a consultant for Lilly USA, ISIS Pharmaceuticals, and the Charles Dana Foundation. Dr Holtzman reported being a cofounder of C2N Diagnostics LLC; serving on the scientific advisory boards of AstraZeneca, Genentech, Neurophage, and C2N Diagnostics; and serving as a consultant for Eli Lilly and Co. Washington University receives grants to the laboratory of Dr Holtzman from the Tau Consortium, Cure Alzheimer&#x2019;s Fund, the JPB Foundation, Eli Lilly and Co, Janssen, and C2N Diagnostics. Dr Fagan reported serving on the scientific advisory boards of IBL International and Roche and serving as a consultant for AbbVie and Novartis. No other disclosures were reported.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>7</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>7</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2015</Year><Month>9</Month><Day>15</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26147946</ArticleId><ArticleId IdType="mid">NIHMS712976</ArticleId><ArticleId IdType="pmc">PMC4570860</ArticleId><ArticleId IdType="doi">10.1001/jamaneurol.2015.1285</ArticleId><ArticleId IdType="pii">2368726</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>James BD, Leurgans SE, Hebert LE, Scherr PA, Yaffe K, Bennett DA. Contribution of Alzheimer disease to mortality in the United States. Neurology. 2014;82(12):1045&#x2013;1050.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3962992</ArticleId><ArticleId IdType="pubmed">24598707</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider LS, Mangialasche F, Andreasen N, et al. Clinical trials and late-stage drug development for Alzheimer&#x2019;s disease: an appraisal from 1984 to 2014. J Intern Med. 2014;275(3):251&#x2013;283.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3956752</ArticleId><ArticleId IdType="pubmed">24605808</ArticleId></ArticleIdList></Reference><Reference><Citation>G&#xf3;mez-Isla T, Price JL, McKeel DW, Jr, Morris JC, Growdon JH, Hyman BT. Profound loss of layer II entorhinal cortex neurons occurs in very mild Alzheimer&#x2019;s disease. J Neurosci. 1996;16(14):4491&#x2013;4500.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6578866</ArticleId><ArticleId IdType="pubmed">8699259</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E. Diagnostic criteria for neuropathologic assessment of Alzheimer&#x2019;s disease. Neurobiol Aging. 1997;18(4 suppl):S85&#x2013;S88.</Citation><ArticleIdList><ArticleId IdType="pubmed">9330992</ArticleId></ArticleIdList></Reference><Reference><Citation>Hulette CM, Welsh-Bohmer KA, Murray MG, Saunders AM, Mash DC, McIntyre LM. Neuropathological and neuropsychological changes in &#x201c;normal&#x201d; aging: evidence for preclinical Alzheimer disease in cognitively normal individuals. J Neuropathol Exp Neurol. 1998;57(12):1168&#x2013;1174.</Citation><ArticleIdList><ArticleId IdType="pubmed">9862640</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC, Price JL. Pathologic correlates of nondemented aging, mild cognitive impairment, and early-stage Alzheimer&#x2019;s disease. J Mol Neurosci. 2001;17(2):101&#x2013;118.</Citation><ArticleIdList><ArticleId IdType="pubmed">11816784</ArticleId></ArticleIdList></Reference><Reference><Citation>Price JL, Ko AI, Wade MJ, Tsou SK, McKeel DW, Morris JC. Neuron number in the entorhinal cortex and CA1 in preclinical Alzheimer disease. Arch Neurol. 2001;58(9):1395&#x2013;1402.</Citation><ArticleIdList><ArticleId IdType="pubmed">11559310</ArticleId></ArticleIdList></Reference><Reference><Citation>Markesbery WR, Schmitt FA, Kryscio RJ, Davis DG, Smith CD, Wekstein DR. Neuropathologic substrate of mild cognitive impairment. Arch Neurol. 2006;63(1):38&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pubmed">16401735</ArticleId></ArticleIdList></Reference><Reference><Citation>Bateman RJ, Xiong C, Benzinger TL, et al. Dominantly Inherited Alzheimer Network. Clinical and biomarker changes in dominantly inherited Alzheimer&#x2019;s disease. N Engl J Med. 2012;367(9):795&#x2013;804.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3474597</ArticleId><ArticleId IdType="pubmed">22784036</ArticleId></ArticleIdList></Reference><Reference><Citation>Fagan AM, Xiong C, Jasielec MS, et al. Dominantly Inherited Alzheimer Network. Longitudinal change in CSF biomarkers in autosomal-dominant Alzheimer&#x2019;s disease. Sci Transl Med. 2014;6(226):226ra30.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4038930</ArticleId><ArticleId IdType="pubmed">24598588</ArticleId></ArticleIdList></Reference><Reference><Citation>Villemagne VL, Burnham S, Bourgeat P, et al. Australian Imaging Biomarkers and Lifestyle (AIBL) Research Group. Amyloid &#x3b2; deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer&#x2019;s disease: a prospective cohort study. Lancet Neurol. 2013;12(4):357&#x2013;367.</Citation><ArticleIdList><ArticleId IdType="pubmed">23477989</ArticleId></ArticleIdList></Reference><Reference><Citation>Rafii MS. Preclinical Alzheimer&#x2019;s disease therapeutics. J Alzheimers Dis. 2014;42(suppl 4):S545&#x2013;S549.</Citation><ArticleIdList><ArticleId IdType="pubmed">25079804</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiong C, Roe CM, Buckles V, et al. Role of family history for Alzheimer biomarker abnormalities in the adult children study. Arch Neurol. 2011;68(10):1313&#x2013;1319.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3327304</ArticleId><ArticleId IdType="pubmed">21987546</ArticleId></ArticleIdList></Reference><Reference><Citation>Ros&#xe9;n C, Hansson O, Blennow K, Zetterberg H. Fluid biomarkers in Alzheimer&#x2019;s disease: current concepts. Mol Neurodegener. 2013;8:20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3691925</ArticleId><ArticleId IdType="pubmed">23800368</ArticleId></ArticleIdList></Reference><Reference><Citation>Bjerke M, Portelius E, Minthon L, et al. Confounding factors influencing amyloid beta concentration in cerebrospinal fluid. Int J Alzheimers Dis. doi: 10.4061/2010/986310. published online July 15, 2010.</Citation><ArticleIdList><ArticleId IdType="doi">10.4061/2010/986310</ArticleId><ArticleId IdType="pmc">PMC2925386</ArticleId><ArticleId IdType="pubmed">20798852</ArticleId></ArticleIdList></Reference><Reference><Citation>Craig-Schapiro R, Perrin RJ, Roe CM, et al. YKL-40: a novel prognostic fluid biomarker for preclinical Alzheimer&#x2019;s disease. Biol Psychiatry. 2010;68(10):903&#x2013;912.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3011944</ArticleId><ArticleId IdType="pubmed">21035623</ArticleId></ArticleIdList></Reference><Reference><Citation>Tarawneh R, D&#x2019;Angelo G, Macy E, et al. Visinin-like protein-1: diagnostic and prognostic biomarker in Alzheimer disease. Ann Neurol. 2011;70(2):274&#x2013;285.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3154071</ArticleId><ArticleId IdType="pubmed">21823155</ArticleId></ArticleIdList></Reference><Reference><Citation>Tarawneh R, Lee JM, Ladenson JH, Morris JC, Holtzman DM. CSF VILIP-1 predicts rates of cognitive decline in early Alzheimer disease. Neurology. 2012;78(10):709&#x2013;719.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3306162</ArticleId><ArticleId IdType="pubmed">22357717</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo X, Hou L, Shi H, et al. CSF levels of the neuronal injury biomarker visinin-like protein-1 in Alzheimer&#x2019;s disease and dementia with Lewy bodies. J Neurochem. 2013;127(5):681&#x2013;690.</Citation><ArticleIdList><ArticleId IdType="pubmed">23800322</ArticleId></ArticleIdList></Reference><Reference><Citation>Ros&#xe9;n C, Andersson CH, Andreasson U, et al. Increased levels of chitotriosidase and YKL-40 in cerebrospinal fluid from patients with Alzheimer&#x2019;s disease. Dement Geriatr Cogn Dis Extra. 2014;4(2):297&#x2013;304.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4164083</ArticleId><ArticleId IdType="pubmed">25254036</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology. 1993;43(11):2412&#x2013;2414.</Citation><ArticleIdList><ArticleId IdType="pubmed">8232972</ArticleId></ArticleIdList></Reference><Reference><Citation>Berg L, McKeel DW, Jr, Miller JP, et al. Clinicopathologic studies in cognitively healthy aging and Alzheimer&#x2019;s disease: relation of histologic markers to dementia severity, age, sex, and apolipoprotein E genotype. Arch Neurol. 1998;55 (3):326&#x2013;335.</Citation><ArticleIdList><ArticleId IdType="pubmed">9520006</ArticleId></ArticleIdList></Reference><Reference><Citation>Pastor P, Roe CM, Villegas A, et al. Apolipoprotein E&#x3b5;4 modifies Alzheimer&#x2019;s disease onset in an E280A PS1 kindred. Ann Neurol. 2003;54(2):163&#x2013;169.</Citation><ArticleIdList><ArticleId IdType="pubmed">12891668</ArticleId></ArticleIdList></Reference><Reference><Citation>Fagan AM, Mintun MA, Mach RH, et al. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann Neurol. 2006;59(3):512&#x2013;519.</Citation><ArticleIdList><ArticleId IdType="pubmed">16372280</ArticleId></ArticleIdList></Reference><Reference><Citation>Wiltfang J, Esselmann H, Bibl M, et al. Amyloid beta peptide ratio 42/40 but not A beta 42 correlates with phosphotau in patients with low-and high-CSF A beta 40 load. J Neurochem. 2007;101(4):1053&#x2013;1059.</Citation><ArticleIdList><ArticleId IdType="pubmed">17254013</ArticleId></ArticleIdList></Reference><Reference><Citation>Hansson O, Zetterberg H, Buchhave P, et al. Prediction of Alzheimer&#x2019;s disease using the CSF Abeta42/Abeta40 ratio in patients with mild cognitive impairment. Dement Geriatr Cogn Disord. 2007;23(5):316&#x2013;320.</Citation><ArticleIdList><ArticleId IdType="pubmed">17374949</ArticleId></ArticleIdList></Reference><Reference><Citation>Spies PE, Verbeek MM, van Groen T, Claassen JA. Reviewing reasons for the decreased CSF Abeta42 concentration in Alzheimer disease. Front Biosci (Landmark Ed) 2012;17:2024&#x2013;2034.</Citation><ArticleIdList><ArticleId IdType="pubmed">22652762</ArticleId></ArticleIdList></Reference><Reference><Citation>Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L. Association between CSF biomarkers and incipient Alzheimer&#x2019;s disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol. 2006;5(3):228&#x2013;234.</Citation><ArticleIdList><ArticleId IdType="pubmed">16488378</ArticleId></ArticleIdList></Reference><Reference><Citation>Fagan AM, Roe CM, Xiong C, Mintun MA, Morris JC, Holtzman DM. Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. Arch Neurol. 2007;64(3):343&#x2013;349.</Citation><ArticleIdList><ArticleId IdType="pubmed">17210801</ArticleId></ArticleIdList></Reference><Reference><Citation>Li G, Sokal I, Quinn JF, et al. CSF tau/Abeta42 ratio for increased risk of mild cognitive impairment: a follow-up study. Neurology. 2007;69 (7):631&#x2013;639.</Citation><ArticleIdList><ArticleId IdType="pubmed">17698783</ArticleId></ArticleIdList></Reference><Reference><Citation>Mintun MA, Larossa GN, Sheline YI, et al. [11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology. 2006;67(3):446&#x2013;452.</Citation><ArticleIdList><ArticleId IdType="pubmed">16894106</ArticleId></ArticleIdList></Reference><Reference><Citation>Su Y, D&#x2019;Angelo GM, Vlassenko AG, et al. Quantitative analysis of PiB-PET with FreeSurfer ROIs. PLoS One. 2013;8(11):e73377.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3819320</ArticleId><ArticleId IdType="pubmed">24223109</ArticleId></ArticleIdList></Reference><Reference><Citation>Vlassenko AG, Mintun MA, Xiong C, et al. Amyloid-beta plaque growth in cognitively normal adults: longitudinal [11C]Pittsburgh compound B data. Ann Neurol. 2011;70(5):857&#x2013;861.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3243969</ArticleId><ArticleId IdType="pubmed">22162065</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischl B, Salat DH, Busa E, et al. Whole brain segmentation: automated labeling of neuroanatomical structures in the human brain. Neuron. 2002;33(3):341&#x2013;355.</Citation><ArticleIdList><ArticleId IdType="pubmed">11832223</ArticleId></ArticleIdList></Reference><Reference><Citation>Desikan RS, S&#xe9;gonne F, Fischl B, et al. An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest. Neuroimage. 2006;31(3):968&#x2013;980.</Citation><ArticleIdList><ArticleId IdType="pubmed">16530430</ArticleId></ArticleIdList></Reference><Reference><Citation>Su Y, Blazey TM, Snyder AZ, et al. Dominantly Inherited Alzheimer Network. Partial volume correction in quantitative amyloid imaging. Neuroimage. 2015;107:55&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4300252</ArticleId><ArticleId IdType="pubmed">25485714</ArticleId></ArticleIdList></Reference><Reference><Citation>Satterthwaite FE. Synthesis of variance. Psychometrika. 1941;16(5):309&#x2013;316. doi: 10.1007/BF02288586.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF02288586</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim J, Basak JM, Holtzman DM. The role of apolipoprotein E in Alzheimer&#x2019;s disease. Neuron. 2009;63(3):287&#x2013;303.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3044446</ArticleId><ArticleId IdType="pubmed">19679070</ArticleId></ArticleIdList></Reference><Reference><Citation>Castellano JM, Kim J, Stewart FR, et al. Human apoE isoforms differentially regulate brain amyloid-&#x3b2; peptide clearance. Sci Transl Med. 2011;3 (89):89ra57.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3192364</ArticleId><ArticleId IdType="pubmed">21715678</ArticleId></ArticleIdList></Reference><Reference><Citation>Corder EH, Saunders AM, Strittmatter WJ, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer&#x2019;s disease in late onset families. Science. 1993;261(5123):921&#x2013;923.</Citation><ArticleIdList><ArticleId IdType="pubmed">8346443</ArticleId></ArticleIdList></Reference><Reference><Citation>Fleisher AS, Chen K, Quiroz YT, et al. Associations between biomarkers and age in the presenilin 1 E280A autosomal dominant Alzheimer disease kindred: a cross-sectional study. JAMA Neurol. 2015;72(3):316&#x2013;324.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4355261</ArticleId><ArticleId IdType="pubmed">25580592</ArticleId></ArticleIdList></Reference><Reference><Citation>Cairns NJ, Ikonomovic MD, Benzinger T, et al. Absence of Pittsburgh compound B detection of cerebral amyloid beta in a patient with clinical, cognitive, and cerebrospinal fluid markers of Alzheimer disease: a case report. Arch Neurol. 2009;66(12):1557&#x2013;1562.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2796200</ArticleId><ArticleId IdType="pubmed">20008664</ArticleId></ArticleIdList></Reference><Reference><Citation>Fagan AM, Mintun MA, Shah AR, et al. Cerebrospinal fluid tau and ptau(181) increase with cortical amyloid deposition in cognitively normal individuals: implications for future clinical trials of Alzheimer&#x2019;s disease. EMBO Mol Med. 2009;1(8&#x2013;9):371&#x2013;380.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2806678</ArticleId><ArticleId IdType="pubmed">20049742</ArticleId></ArticleIdList></Reference><Reference><Citation>Tapiola T, Alafuzoff I, Herukka SK, et al. Cerebrospinal fluid &#x3b2;-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. Arch Neurol. 2009;66(3):382&#x2013;389.</Citation><ArticleIdList><ArticleId IdType="pubmed">19273758</ArticleId></ArticleIdList></Reference><Reference><Citation>Toledo JB, Xie SX, Trojanowski JQ, Shaw LM. Longitudinal change in CSF tau and A&#x3b2; biomarkers for up to 48 months in ADNI. Acta Neuropathol. 2013;126(5):659&#x2013;670.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3875373</ArticleId><ArticleId IdType="pubmed">23812320</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperling RA, Aisen PS, Beckett LA, et al. Toward defining the preclinical stages of Alzheimer&#x2019;s disease: recommendations from the National Institute on Aging-Alzheimer&#x2019;s Association workgroups on diagnostic guidelines for Alzheimer&#x2019;s disease. Alzheimers Dement. 2011;7(3):280&#x2013;292.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3220946</ArticleId><ArticleId IdType="pubmed">21514248</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">26147761</PMID><DateCompleted><Year>2015</Year><Month>11</Month><Day>04</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1546-170X</ISSN><JournalIssue CitedMedium="Internet"><Volume>21</Volume><Issue>8</Issue><PubDate><Year>2015</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Nature medicine</Title><ISOAbbreviation>Nat Med</ISOAbbreviation></Journal><ArticleTitle>&#x3b2;2-microglobulin is a systemic pro-aging factor that impairs cognitive function and neurogenesis.</ArticleTitle><Pagination><StartPage>932</StartPage><EndPage>937</EndPage><MedlinePgn>932-7</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/nm.3898</ELocationID><Abstract><AbstractText>Aging drives cognitive and regenerative impairments in the adult brain, increasing susceptibility to neurodegenerative disorders in healthy individuals. Experiments using heterochronic parabiosis, in which the circulatory systems of young and old animals are joined, indicate that circulating pro-aging factors in old blood drive aging phenotypes in the brain. Here we identify &#x3b2;2-microglobulin (B2M), a component of major histocompatibility complex class 1 (MHC I) molecules, as a circulating factor that negatively regulates cognitive and regenerative function in the adult hippocampus in an age-dependent manner. B2M is elevated in the blood of aging humans and mice, and it is increased within the hippocampus of aged mice and young heterochronic parabionts. Exogenous B2M injected systemically, or locally in the hippocampus, impairs hippocampal-dependent cognitive function and neurogenesis in young mice. The negative effects of B2M and heterochronic parabiosis are, in part, mitigated in the hippocampus of young transporter associated with antigen processing 1 (Tap1)-deficient mice with reduced cell surface expression of MHC I. The absence of endogenous B2M expression abrogates age-related cognitive decline and enhances neurogenesis in aged mice. Our data indicate that systemic B2M accumulation in aging blood promotes age-related cognitive dysfunction and impairs neurogenesis, in part via MHC I, suggesting that B2M may be targeted therapeutically in old age.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Smith</LastName><ForeName>Lucas K</ForeName><Initials>LK</Initials><AffiliationInfo><Affiliation>1] Department of Anatomy, University of California San Francisco, San Francisco, California, USA. [2] The Eli and Edythe Broad Center for Regeneration Medicine and Stem Cell Research, San Francisco, California, USA. [3] Biomedical Sciences Graduate Program, University of California San Francisco, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>He</LastName><ForeName>Yingbo</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Jeong-Soo</ForeName><Initials>JS</Initials><AffiliationInfo><Affiliation>1] Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, California, USA. [2] Department of Biochemistry, Dankook University College of Medicine, Cheonan, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bieri</LastName><ForeName>Gregor</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>1] Department of Anatomy, University of California San Francisco, San Francisco, California, USA. [2] The Eli and Edythe Broad Center for Regeneration Medicine and Stem Cell Research, San Francisco, California, USA. [3] Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, California, USA. [4] Neuroscience Graduate Program, Stanford University School of Medicine, Stanford, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Snethlage</LastName><ForeName>Cedric E</ForeName><Initials>CE</Initials><AffiliationInfo><Affiliation>1] Department of Anatomy, University of California San Francisco, San Francisco, California, USA. [2] The Eli and Edythe Broad Center for Regeneration Medicine and Stem Cell Research, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Karin</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>1] Department of Anatomy, University of California San Francisco, San Francisco, California, USA. [2] The Eli and Edythe Broad Center for Regeneration Medicine and Stem Cell Research, San Francisco, California, USA. [3] Neuroscience Graduate Program, University of California San Francisco, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gontier</LastName><ForeName>Geraldine</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>1] Department of Anatomy, University of California San Francisco, San Francisco, California, USA. [2] The Eli and Edythe Broad Center for Regeneration Medicine and Stem Cell Research, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wabl</LastName><ForeName>Rafael</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Plambeck</LastName><ForeName>Kristopher E</ForeName><Initials>KE</Initials><AffiliationInfo><Affiliation>1] Department of Anatomy, University of California San Francisco, San Francisco, California, USA. [2] The Eli and Edythe Broad Center for Regeneration Medicine and Stem Cell Research, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Udeochu</LastName><ForeName>Joe</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>1] Department of Anatomy, University of California San Francisco, San Francisco, California, USA. [2] The Eli and Edythe Broad Center for Regeneration Medicine and Stem Cell Research, San Francisco, California, USA. [3] Biomedical Sciences Graduate Program, University of California San Francisco, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wheatley</LastName><ForeName>Elizabeth G</ForeName><Initials>EG</Initials><AffiliationInfo><Affiliation>1] Department of Anatomy, University of California San Francisco, San Francisco, California, USA. [2] The Eli and Edythe Broad Center for Regeneration Medicine and Stem Cell Research, San Francisco, California, USA. [3] Developmental and Stem Cell Biology Graduate Program, University of California San Francisco, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bouchard</LastName><ForeName>Jill</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>1] Department of Anatomy, University of California San Francisco, San Francisco, California, USA. [2] The Eli and Edythe Broad Center for Regeneration Medicine and Stem Cell Research, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eggel</LastName><ForeName>Alexander</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Rheumatology, Immunology and Allergology, University Hospital Bern, Bern, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Narasimha</LastName><ForeName>Ramya</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grant</LastName><ForeName>Jacqueline L</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>1] Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, California, USA. [2] Neuroscience Graduate Program, Stanford University School of Medicine, Stanford, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Luo</LastName><ForeName>Jian</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000000220648467</Identifier><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wyss-Coray</LastName><ForeName>Tony</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>1] Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, California, USA. [2] Neuroscience Graduate Program, Stanford University School of Medicine, Stanford, California, USA. [3] Center for Tissue Regeneration, Repair and Restoration, Veterans' Affairs (VA) Palo Alto Health Care System, Palo Alto, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Villeda</LastName><ForeName>Saul A</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>1] Department of Anatomy, University of California San Francisco, San Francisco, California, USA. [2] The Eli and Edythe Broad Center for Regeneration Medicine and Stem Cell Research, San Francisco, California, USA. [3] Biomedical Sciences Graduate Program, University of California San Francisco, San Francisco, California, USA. [4] Neuroscience Graduate Program, University of California San Francisco, San Francisco, California, USA. [5] Developmental and Stem Cell Biology Graduate Program, University of California San Francisco, San Francisco, California, USA. [6] California Institute for Quantitative Biosciences (QB3), San Francisco, California, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG045034</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1-TR000004</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>DP5-OD12178</GrantID><Acronym>OD</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 MH020016</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>DP5 OD012178</GrantID><Acronym>OD</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG027505</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>1F31-AG050415</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG027505</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 GM008568</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 HD007470</GrantID><Acronym>HD</Acronym><Agency>NICHD NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR000004</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>F31 AG050415</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>07</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Med</MedlineTA><NlmUniqueID>9502015</NlmUniqueID><ISSNLinking>1078-8956</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000071181">ATP Binding Cassette Transporter, Subfamily B, Member 2</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018528">ATP-Binding Cassette Transporters</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C486171">Tap1 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001613">beta 2-Microglobulin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Med. 2015 Aug;21(8):844-5. doi: 10.1038/nm.3926.</RefSource><PMID Version="1">26248266</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000071181" MajorTopicYN="N">ATP Binding Cassette Transporter, Subfamily B, Member 2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018528" MajorTopicYN="N">ATP-Binding Cassette Transporters</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="Y">Aging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="Y">Cognition</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008285" MajorTopicYN="N">Major Histocompatibility Complex</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055495" MajorTopicYN="Y">Neurogenesis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001613" MajorTopicYN="N">beta 2-Microglobulin</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading></MeshHeadingList><CoiStatement><b>Competing financial interests</b>. The authors declare that they have no competing financial interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>5</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>6</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>7</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>7</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>11</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2016</Year><Month>2</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26147761</ArticleId><ArticleId IdType="mid">NIHMS698774</ArticleId><ArticleId IdType="pmc">PMC4529371</ArticleId><ArticleId IdType="doi">10.1038/nm.3898</ArticleId><ArticleId IdType="pii">nm.3898</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hedden T, Gabrieli JD. Insights into the ageing mind: a view from cognitive neuroscience. Nature reviews. Neuroscience. 2004;5:87&#x2013;96.</Citation><ArticleIdList><ArticleId IdType="pubmed">14735112</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattson MP, Magnus T. Ageing and neuronal vulnerability. Nature reviews. Neuroscience. 2006;7:278&#x2013;294.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3710114</ArticleId><ArticleId IdType="pubmed">16552414</ArticleId></ArticleIdList></Reference><Reference><Citation>Small SA, Schobel SA, Buxton RB, Witter MP, Barnes CA. A pathophysiological framework of hippocampal dysfunction in ageing and disease. Nature reviews. Neuroscience. 2011;12:585&#x2013;601.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3312472</ArticleId><ArticleId IdType="pubmed">21897434</ArticleId></ArticleIdList></Reference><Reference><Citation>Rao MS, Hattiangady B, Shetty AK. The window and mechanisms of major age-related decline in the production of new neurons within the dentate gyrus of the hippocampus. Aging cell. 2006;5:545&#x2013;558.</Citation><ArticleIdList><ArticleId IdType="pubmed">17129216</ArticleId></ArticleIdList></Reference><Reference><Citation>Katsimpardi L, et al. Vascular and neurogenic rejuvenation of the aging mouse brain by young systemic factors. Science. 2014;344:630&#x2013;634.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4123747</ArticleId><ArticleId IdType="pubmed">24797482</ArticleId></ArticleIdList></Reference><Reference><Citation>Villeda SA, et al. The ageing systemic milieu negatively regulates neurogenesis and cognitive function. Nature. 2011;477:90&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3170097</ArticleId><ArticleId IdType="pubmed">21886162</ArticleId></ArticleIdList></Reference><Reference><Citation>Villeda SA, et al. Young blood reverses age-related impairments in cognitive function and synaptic plasticity in mice. Nature medicine. 2014;20:659&#x2013;663.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4224436</ArticleId><ArticleId IdType="pubmed">24793238</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruckh JM, et al. Rejuvenation of regeneration in the aging central nervous system. Cell stem cell. 2012;10:96&#x2013;103.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3714794</ArticleId><ArticleId IdType="pubmed">22226359</ArticleId></ArticleIdList></Reference><Reference><Citation>Conboy IM, et al. Rejuvenation of aged progenitor cells by exposure to a young systemic environment. Nature. 2005;433:760&#x2013;764.</Citation><ArticleIdList><ArticleId IdType="pubmed">15716955</ArticleId></ArticleIdList></Reference><Reference><Citation>Brack AS, et al. Increased Wnt signaling during aging alters muscle stem cell fate and increases fibrosis. Science. 2007;317:807&#x2013;810.</Citation><ArticleIdList><ArticleId IdType="pubmed">17690295</ArticleId></ArticleIdList></Reference><Reference><Citation>Laviano A. Young blood. The New England journal of medicine. 2014;371:573&#x2013;575.</Citation><ArticleIdList><ArticleId IdType="pubmed">25099584</ArticleId></ArticleIdList></Reference><Reference><Citation>Bouchard J, Villeda SA. Aging and brain rejuvenation as systemic events. Journal of neurochemistry. 2014</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4301186</ArticleId><ArticleId IdType="pubmed">25327899</ArticleId></ArticleIdList></Reference><Reference><Citation>Zijlstra M, et al. Beta 2-microglobulin deficient mice lack CD4-8+ cytolytic T cells. Nature. 1990;344:742&#x2013;746.</Citation><ArticleIdList><ArticleId IdType="pubmed">2139497</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee H, et al. Synapse elimination and learning rules co-regulated by MHC class I H2-Db. Nature. 2014;509:195&#x2013;200.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4016165</ArticleId><ArticleId IdType="pubmed">24695230</ArticleId></ArticleIdList></Reference><Reference><Citation>Loconto J, et al. Functional expression of murine V2R pheromone receptors involves selective association with the M10 and M1 families of MHC class Ib molecules. Cell. 2003;112:607&#x2013;618.</Citation><ArticleIdList><ArticleId IdType="pubmed">12628182</ArticleId></ArticleIdList></Reference><Reference><Citation>Boulanger LM, Shatz CJ. Immune signalling in neural development, synaptic plasticity and disease. Nature reviews. Neuroscience. 2004;5:521&#x2013;531.</Citation><ArticleIdList><ArticleId IdType="pubmed">15208694</ArticleId></ArticleIdList></Reference><Reference><Citation>Shatz CJ. MHC class I: an unexpected role in neuronal plasticity. Neuron. 2009;64:40&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2773547</ArticleId><ArticleId IdType="pubmed">19840547</ArticleId></ArticleIdList></Reference><Reference><Citation>Huh GS, et al. Functional requirement for class I MHC in CNS development and plasticity. Science. 2000;290:2155&#x2013;2159.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2175035</ArticleId><ArticleId IdType="pubmed">11118151</ArticleId></ArticleIdList></Reference><Reference><Citation>Goddard CA, Butts DA, Shatz CJ. Regulation of CNS synapses by neuronal MHC class I. Proceedings of the National Academy of Sciences of the United States of America. 2007;104:6828&#x2013;6833.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1871870</ArticleId><ArticleId IdType="pubmed">17420446</ArticleId></ArticleIdList></Reference><Reference><Citation>Glynn MW, et al. MHCI negatively regulates synapse density during the establishment of cortical connections. Nature neuroscience. 2011;14:442&#x2013;451.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3251641</ArticleId><ArticleId IdType="pubmed">21358642</ArticleId></ArticleIdList></Reference><Reference><Citation>Murray AM. Cognitive impairment in the aging dialysis and chronic kidney disease populations: an occult burden. Advances in chronic kidney disease. 2008;15:123&#x2013;132.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2504691</ArticleId><ArticleId IdType="pubmed">18334236</ArticleId></ArticleIdList></Reference><Reference><Citation>Corlin DB, et al. Quantification of cleaved beta2-microglobulin in serum from patients undergoing chronic hemodialysis. Clinical chemistry. 2005;51:1177&#x2013;1184.</Citation><ArticleIdList><ArticleId IdType="pubmed">15890888</ArticleId></ArticleIdList></Reference><Reference><Citation>McArthur JC, et al. The diagnostic utility of elevation in cerebrospinal fluid beta 2-microglobulin in HIV-1 dementia. Multicenter AIDS Cohort Study. Neurology. 1992;42:1707&#x2013;1712.</Citation><ArticleIdList><ArticleId IdType="pubmed">1355286</ArticleId></ArticleIdList></Reference><Reference><Citation>Brew BJ, Dunbar N, Pemberton L, Kaldor J. Predictive markers of AIDS dementia complex: CD4 cell count and cerebrospinal fluid concentrations of beta 2-microglobulin and neopterin. The Journal of infectious diseases. 1996;174:294&#x2013;298.</Citation><ArticleIdList><ArticleId IdType="pubmed">8699058</ArticleId></ArticleIdList></Reference><Reference><Citation>Carrette O, et al. A panel of cerebrospinal fluid potential biomarkers for the diagnosis of Alzheimer&#x2019;s disease. Proteomics. 2003;3:1486&#x2013;1494.</Citation><ArticleIdList><ArticleId IdType="pubmed">12923774</ArticleId></ArticleIdList></Reference><Reference><Citation>Clelland CD, et al. A functional role for adult hippocampal neurogenesis in spatial pattern separation. Science. 2009;325:210&#x2013;213.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2997634</ArticleId><ArticleId IdType="pubmed">19590004</ArticleId></ArticleIdList></Reference><Reference><Citation>Kitamura T, et al. Adult neurogenesis modulates the hippocampus-dependent period of associative fear memory. Cell. 2009;139:814&#x2013;827.</Citation><ArticleIdList><ArticleId IdType="pubmed">19914173</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang CL, Zou Y, He W, Gage FH, Evans RM. A role for adult TLX-positive neural stem cells in learning and behaviour. Nature. 2008;451:1004&#x2013;1007.</Citation><ArticleIdList><ArticleId IdType="pubmed">18235445</ArticleId></ArticleIdList></Reference><Reference><Citation>Drapeau E, et al. Spatial memory performances of aged rats in the water maze predict levels of hippocampal neurogenesis. Proceedings of the National Academy of Sciences of the United States of America. 2003;100:14385&#x2013;14390.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC283601</ArticleId><ArticleId IdType="pubmed">14614143</ArticleId></ArticleIdList></Reference><Reference><Citation>Merrill DA, Karim R, Darraq M, Chiba AA, Tuszynski MH. Hippocampal cell genesis does not correlate with spatial learning ability in aged rats. The Journal of comparative neurology. 2003;459:201&#x2013;207.</Citation><ArticleIdList><ArticleId IdType="pubmed">12640670</ArticleId></ArticleIdList></Reference><Reference><Citation>Bizon JL, Gallagher M. Production of new cells in the rat dentate gyrus over the lifespan: relation to cognitive decline. The European journal of neuroscience. 2003;18:215&#x2013;219.</Citation><ArticleIdList><ArticleId IdType="pubmed">12859354</ArticleId></ArticleIdList></Reference><Reference><Citation>Seib DR, et al. Loss of Dickkopf-1 restores neurogenesis in old age and counteracts cognitive decline. Cell stem cell. 2013;12:204&#x2013;214.</Citation><ArticleIdList><ArticleId IdType="pubmed">23395445</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Kaer L, Ashton-Rickardt PG, Ploegh HL, Tonegawa S. TAP1 mutant mice are deficient in antigen presentation, surface class I molecules, and CD4-8+ T cells. Cell. 1992;71:1205&#x2013;1214.</Citation><ArticleIdList><ArticleId IdType="pubmed">1473153</ArticleId></ArticleIdList></Reference><Reference><Citation>Laguna Goya R, Tyers P, Barker RA. Adult neurogenesis is unaffected by a functional knock-out of MHC class I in mice. Neuroreport. 2010;21:349&#x2013;353.</Citation><ArticleIdList><ArticleId IdType="pubmed">20147861</ArticleId></ArticleIdList></Reference><Reference><Citation>Adelson JD, et al. Neuroprotection from stroke in the absence of MHCI or PirB. Neuron. 2012;73:1100&#x2013;1107.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3314229</ArticleId><ArticleId IdType="pubmed">22445338</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeck WR, Siebold AP, Sharpless NE. Review: a meta-analysis of GWAS and age-associated diseases. Aging cell. 2012;11:727&#x2013;731.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3444649</ArticleId><ArticleId IdType="pubmed">22888763</ArticleId></ArticleIdList></Reference><Reference><Citation>Couillard-Despres S, et al. In vivo optical imaging of neurogenesis: watching new neurons in the intact brain. Molecular imaging. 2008;7:28&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">18384721</ArticleId></ArticleIdList></Reference><Reference><Citation>Mosher KI, et al. Neural progenitor cells regulate microglia functions and activity. Nature neuroscience. 2012;15:1485&#x2013;1487.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3495979</ArticleId><ArticleId IdType="pubmed">23086334</ArticleId></ArticleIdList></Reference><Reference><Citation>Alamed J, Wilcock DM, Diamond DM, Gordon MN, Morgan D. Two-day radial-arm water maze learning and memory task; robust resolution of amyloid-related memory deficits in transgenic mice. Nature protocols. 2006;1:1671&#x2013;1679.</Citation><ArticleIdList><ArticleId IdType="pubmed">17487150</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang J, et al. CSF multianalyte profile distinguishes Alzheimer and Parkinson diseases. American journal of clinical pathology. 2008;129:526&#x2013;529.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2688655</ArticleId><ArticleId IdType="pubmed">18343778</ArticleId></ArticleIdList></Reference><Reference><Citation>Li G, et al. Cerebrospinal fluid concentration of brain-derived neurotrophic factor and cognitive function in non-demented subjects. PloS one. 2009;4:e5424.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2671606</ArticleId><ArticleId IdType="pubmed">19412541</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">26153422</PMID><DateCompleted><Year>2015</Year><Month>11</Month><Day>17</Day></DateCompleted><DateRevised><Year>2020</Year><Month>04</Month><Day>24</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1091-6490</ISSN><JournalIssue CitedMedium="Internet"><Volume>112</Volume><Issue>31</Issue><PubDate><Year>2015</Year><Month>Aug</Month><Day>04</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>KTKEGV repeat motifs are key mediators of normal &#x3b1;-synuclein tetramerization: Their mutation causes excess monomers and neurotoxicity.</ArticleTitle><Pagination><StartPage>9596</StartPage><EndPage>9601</EndPage><MedlinePgn>9596-601</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1073/pnas.1505953112</ELocationID><Abstract><AbstractText>&#x3b1;-Synuclein (&#x3b1;S) is a highly abundant neuronal protein that aggregates into &#x3b2;-sheet-rich inclusions in Parkinson's disease (PD). &#x3b1;S was long thought to occur as a natively unfolded monomer, but recent work suggests it also occurs normally in &#x3b1;-helix-rich tetramers and related multimers. To elucidate the fundamental relationship between &#x3b1;S multimers and monomers in living neurons, we performed systematic mutagenesis to abolish self-interactions and learn which structural determinants underlie native multimerization. Unexpectedly, tetramers/multimers still formed in cells expressing each of 14 sequential 10-residue deletions across the 140-residue polypeptide. We postulated compensatory effects among the six highly conserved and one to three additional &#x3b1;S repeat motifs (consensus: KTKEGV), consistent with &#x3b1;S and its homologs &#x3b2;- and &#x3b3;-synuclein all forming tetramers while sharing only the repeats. Upon inserting in-register missense mutations into six or more &#x3b1;S repeats, certain mutations abolished tetramer formation, shown by intact-cell cross-linking and independently by fluorescent-protein complementation. For example, altered repeat motifs KLKEGV, KTKKGV, KTKEIV, or KTKEGW did not support tetramerization, indicating the importance of charged or small residues. When we expressed numerous different in-register repeat mutants in human neural cells, all multimer-abolishing but no multimer-neutral mutants caused frank neurotoxicity akin to the proapoptotic protein Bax. The multimer-abolishing variants became enriched in buffer-insoluble cell fractions and formed round cytoplasmic inclusions in primary cortical neurons. We conclude that the &#x3b1;S repeat motifs mediate physiological tetramerization, and perturbing them causes PD-like neurotoxicity. Moreover, the mutants we describe are valuable tools for studying normal and pathological properties of &#x3b1;S and screening for tetramer-stabilizing therapeutics.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Dettmer</LastName><ForeName>Ulf</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Newman</LastName><ForeName>Andrew J</ForeName><Initials>AJ</Initials><AffiliationInfo><Affiliation>Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>von Saucken</LastName><ForeName>Victoria E</ForeName><Initials>VE</Initials><AffiliationInfo><Affiliation>Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bartels</LastName><ForeName>Tim</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Selkoe</LastName><ForeName>Dennis</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115 dselkoe@partners.org.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>RF1 NS083845</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NSNS083845</GrantID><Agency>PHS HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>07</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D003432">Cross-Linking Reagents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D050505">Mutant Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051844">alpha-Synuclein</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Proc Natl Acad Sci U S A. 2015 Aug 4;112(31):9502-3. doi: 10.1073/pnas.1512077112.</RefSource><PMID Version="1">26204916</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D020816" MajorTopicYN="N">Amino Acid Motifs</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000595" MajorTopicYN="N">Amino Acid Sequence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016923" MajorTopicYN="N">Cell Death</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017124" MajorTopicYN="N">Conserved Sequence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003432" MajorTopicYN="N">Cross-Linking Reagents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002479" MajorTopicYN="N">Inclusion Bodies</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008856" MajorTopicYN="N">Microscopy, Fluorescence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008969" MajorTopicYN="N">Molecular Sequence Data</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D050505" MajorTopicYN="N">Mutant Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055503" MajorTopicYN="Y">Protein Multimerization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017207" MajorTopicYN="N">Rats, Sprague-Dawley</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020449" MajorTopicYN="Y">Repetitive Sequences, Amino Acid</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017384" MajorTopicYN="N">Sequence Deletion</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013329" MajorTopicYN="N">Structure-Activity Relationship</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051844" MajorTopicYN="N">alpha-Synuclein</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000633" MajorTopicYN="Y">toxicity</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Parkinson's disease</Keyword><Keyword MajorTopicYN="N">alpha-synuclein</Keyword><Keyword MajorTopicYN="N">multimer</Keyword><Keyword MajorTopicYN="N">neurotoxicity</Keyword><Keyword MajorTopicYN="N">tetramer</Keyword></KeywordList><CoiStatement>Conflict of interest statement: D.S. is a director and consultant to Prothena Biosciences.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>7</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>7</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>11</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2016</Year><Month>2</Month><Day>4</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26153422</ArticleId><ArticleId IdType="pmc">PMC4534262</ArticleId><ArticleId IdType="doi">10.1073/pnas.1505953112</ArticleId><ArticleId IdType="pii">1505953112</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Chandra S, et al. Double-knockout mice for alpha- and beta-synucleins: Effect on synaptic functions. Proc Natl Acad Sci USA. 2004;101(41):14966&#x2013;14971.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC522043</ArticleId><ArticleId IdType="pubmed">15465911</ArticleId></ArticleIdList></Reference><Reference><Citation>Scott D, Roy S. &#x3b1;-Synuclein inhibits intersynaptic vesicle mobility and maintains recycling-pool homeostasis. J Neurosci. 2012;32(30):10129&#x2013;10135.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3426499</ArticleId><ArticleId IdType="pubmed">22836248</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang L, et al. &#x3b1;-synuclein multimers cluster synaptic vesicles and attenuate recycling. Curr Biol. 2014;24(19):2319&#x2013;2326.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4190006</ArticleId><ArticleId IdType="pubmed">25264250</ArticleId></ArticleIdList></Reference><Reference><Citation>Spillantini MG, et al. Alpha-synuclein in Lewy bodies. Nature. 1997;388(6645):839&#x2013;840.</Citation><ArticleIdList><ArticleId IdType="pubmed">9278044</ArticleId></ArticleIdList></Reference><Reference><Citation>Kr&#xfc;ger R, et al. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson&#x2019;s disease. Nat Genet. 1998;18(2):106&#x2013;108.</Citation><ArticleIdList><ArticleId IdType="pubmed">9462735</ArticleId></ArticleIdList></Reference><Reference><Citation>Polymeropoulos MH, et al. Mutation in the alpha-synuclein gene identified in families with Parkinson&#x2019;s disease. Science. 1997;276(5321):2045&#x2013;2047.</Citation><ArticleIdList><ArticleId IdType="pubmed">9197268</ArticleId></ArticleIdList></Reference><Reference><Citation>Zarranz JJ, et al. The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann Neurol. 2004;55(2):164&#x2013;173.</Citation><ArticleIdList><ArticleId IdType="pubmed">14755719</ArticleId></ArticleIdList></Reference><Reference><Citation>Singleton AB, et al. alpha-Synuclein locus triplication causes Parkinson&#x2019;s disease. Science. 2003;302(5646):841.</Citation><ArticleIdList><ArticleId IdType="pubmed">14593171</ArticleId></ArticleIdList></Reference><Reference><Citation>Bartels T, Choi JG, Selkoe DJ. &#x3b1;-Synuclein occurs physiologically as a helically folded tetramer that resists aggregation. Nature. 2011;477(7362):107&#x2013;110.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3166366</ArticleId><ArticleId IdType="pubmed">21841800</ArticleId></ArticleIdList></Reference><Reference><Citation>Dettmer U, Newman AJ, Luth ES, Bartels T, Selkoe D. In vivo cross-linking reveals principally oligomeric forms of &#x3b1;-synuclein and &#x3b2;-synuclein in neurons and non-neural cells. J Biol Chem. 2013;288(9):6371&#x2013;6385.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3585072</ArticleId><ArticleId IdType="pubmed">23319586</ArticleId></ArticleIdList></Reference><Reference><Citation>Newman AJ, Selkoe D, Dettmer U. A new method for quantitative immunoblotting of endogenous &#x3b1;-synuclein. PLoS One. 2013;8(11):e81314.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3835431</ArticleId><ArticleId IdType="pubmed">24278419</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang W, et al. A soluble &#x3b1;-synuclein construct forms a dynamic tetramer. Proc Natl Acad Sci USA. 2011;108(43):17797&#x2013;17802.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3203798</ArticleId><ArticleId IdType="pubmed">22006323</ArticleId></ArticleIdList></Reference><Reference><Citation>Westphal CH, Chandra SS. Monomeric synucleins generate membrane curvature. J Biol Chem. 2013;288(3):1829&#x2013;1840.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3548493</ArticleId><ArticleId IdType="pubmed">23184946</ArticleId></ArticleIdList></Reference><Reference><Citation>Burr&#xe9; J, Sharma M, S&#xfc;dhof TC. &#x3b1;-Synuclein assembles into higher-order multimers upon membrane binding to promote SNARE complex formation. Proc Natl Acad Sci USA. 2014;111(40):E4274&#x2013;E4283.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4210039</ArticleId><ArticleId IdType="pubmed">25246573</ArticleId></ArticleIdList></Reference><Reference><Citation>Gurry T, et al. The dynamic structure of &#x3b1;-synuclein multimers. J Am Chem Soc. 2013;135(10):3865&#x2013;3872.</Citation><ArticleIdList><ArticleId IdType="pubmed">23398399</ArticleId></ArticleIdList></Reference><Reference><Citation>Gould N, et al. Evidence of native &#x3b1;-synuclein conformers in the human brain. J Biol Chem. 2014;289(11):7929&#x2013;7934.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3953303</ArticleId><ArticleId IdType="pubmed">24474688</ArticleId></ArticleIdList></Reference><Reference><Citation>Manning LR, et al. Human embryonic, fetal, and adult hemoglobins have different subunit interface strengths. Correlation with lifespan in the red cell. Protein Sci. 2007;16(8):1641&#x2013;1658.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2203358</ArticleId><ArticleId IdType="pubmed">17656582</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaglia G, Guan Y, Shah JV, Lahav G. Activation and control of p53 tetramerization in individual living cells. Proc Natl Acad Sci USA. 2013;110(38):15497&#x2013;15501.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3780836</ArticleId><ArticleId IdType="pubmed">24006363</ArticleId></ArticleIdList></Reference><Reference><Citation>Cole NB, et al. Lipid droplet binding and oligomerization properties of the Parkinson&#x2019;s disease protein alpha-synuclein. J Biol Chem. 2002;277(8):6344&#x2013;6352.</Citation><ArticleIdList><ArticleId IdType="pubmed">11744721</ArticleId></ArticleIdList></Reference><Reference><Citation>Burr&#xe9; J, et al. Properties of native brain &#x3b1;-synuclein. Nature. 2013;498(7453):E4&#x2013;E6; discussion E6&#x2013;E7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4255827</ArticleId><ArticleId IdType="pubmed">23765500</ArticleId></ArticleIdList></Reference><Reference><Citation>Fauvet B, et al. &#x3b1;-Synuclein in central nervous system and from erythrocytes, mammalian cells, and Escherichia coli exists predominantly as disordered monomer. J Biol Chem. 2012;287(19):15345&#x2013;15364.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3346117</ArticleId><ArticleId IdType="pubmed">22315227</ArticleId></ArticleIdList></Reference><Reference><Citation>Michell AW, et al. The effect of truncated human alpha-synuclein (1-120) on dopaminergic cells in a transgenic mouse model of Parkinson&#x2019;s disease. Cell Transplant. 2007;16(5):461&#x2013;474.</Citation><ArticleIdList><ArticleId IdType="pubmed">17708336</ArticleId></ArticleIdList></Reference><Reference><Citation>Outeiro TF, et al. Formation of toxic oligomeric alpha-synuclein species in living cells. PloS One. 2008;3(4):e1867.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2270899</ArticleId><ArticleId IdType="pubmed">18382657</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolfe MS, et al. Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and gamma-secretase activity. Nature. 1999;398(6727):513&#x2013;517.</Citation><ArticleIdList><ArticleId IdType="pubmed">10206644</ArticleId></ArticleIdList></Reference><Reference><Citation>Kara E, et al. &#x3b1;-Synuclein mutations cluster around a putative protein loop. Neurosci Lett. 2013;546:67&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3694303</ArticleId><ArticleId IdType="pubmed">23669636</ArticleId></ArticleIdList></Reference><Reference><Citation>Golebiewska U, Zurawsky C, Scarlata S. Defining the oligomerization state of &#x3b3;-synuclein in solution and in cells. Biochemistry. 2014;53(2):293&#x2013;299.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3932107</ArticleId><ArticleId IdType="pubmed">24367999</ArticleId></ArticleIdList></Reference><Reference><Citation>Pranke IM, et al. &#x3b1;-Synuclein and ALPS motifs are membrane curvature sensors whose contrasting chemistry mediates selective vesicle binding. J Cell Biol. 2011;194(1):89&#x2013;103.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3135411</ArticleId><ArticleId IdType="pubmed">21746853</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung CY, et al. Identification and rescue of &#x3b1;-synuclein toxicity in Parkinson patient-derived neurons. Science. 2013;342(6161):983&#x2013;987.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4022187</ArticleId><ArticleId IdType="pubmed">24158904</ArticleId></ArticleIdList></Reference><Reference><Citation>Davidson WS, Jonas A, Clayton DF, George JM. Stabilization of alpha-synuclein secondary structure upon binding to synthetic membranes. J Biol Chem. 1998;273(16):9443&#x2013;9449.</Citation><ArticleIdList><ArticleId IdType="pubmed">9545270</ArticleId></ArticleIdList></Reference><Reference><Citation>Burr&#xe9; J, Sharma M, S&#xfc;dhof TC. Definition of a molecular pathway mediating &#x3b1;-synuclein neurotoxicity. J Neurosci. 2015;35(13):5221&#x2013;5232.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4380997</ArticleId><ArticleId IdType="pubmed">25834048</ArticleId></ArticleIdList></Reference><Reference><Citation>Fonseca-Ornelas L, et al. Small molecule-mediated stabilization of vesicle-associated helical &#x3b1;-synuclein inhibits pathogenic misfolding and aggregation. Nat Commun. 2014;5:5857.</Citation><ArticleIdList><ArticleId IdType="pubmed">25524885</ArticleId></ArticleIdList></Reference><Reference><Citation>Galvagnion C, et al. Lipid vesicles trigger &#x3b1;-synuclein aggregation by stimulating primary nucleation. Nat Chem Biol. 2015;11(3):229&#x2013;234.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5019199</ArticleId><ArticleId IdType="pubmed">25643172</ArticleId></ArticleIdList></Reference><Reference><Citation>Dettmer U, et al. Transmembrane protein 147 (TMEM147) is a novel component of the Nicalin-NOMO protein complex. J Biol Chem. 2010;285(34):26174&#x2013;26181.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2924024</ArticleId><ArticleId IdType="pubmed">20538592</ArticleId></ArticleIdList></Reference><Reference><Citation>Kahle PJ, et al. Subcellular localization of wild-type and Parkinson&#x2019;s disease-associated mutant alpha -synuclein in human and transgenic mouse brain. J Neurosci. 2000;20(17):6365&#x2013;6373.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6772969</ArticleId><ArticleId IdType="pubmed">10964942</ArticleId></ArticleIdList></Reference><Reference><Citation>Baulac S, LaVoie MJ, Strahle J, Schlossmacher MG, Xia W. Dimerization of Parkinson&#x2019;s disease-causing DJ-1 and formation of high molecular weight complexes in human brain. Mol Cell Neurosci. 2004;27(3):236&#x2013;246.</Citation><ArticleIdList><ArticleId IdType="pubmed">15519239</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">26152694</PMID><DateCompleted><Year>2016</Year><Month>04</Month><Day>18</Day></DateCompleted><DateRevised><Year>2021</Year><Month>12</Month><Day>03</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1937-9145</ISSN><JournalIssue CitedMedium="Internet"><Volume>8</Volume><Issue>384</Issue><PubDate><Year>2015</Year><Month>Jul</Month><Day>07</Day></PubDate></JournalIssue><Title>Science signaling</Title><ISOAbbreviation>Sci Signal</ISOAbbreviation></Journal><ArticleTitle>Reelin protects against amyloid &#x3b2; toxicity in vivo.</ArticleTitle><Pagination><StartPage>ra67</StartPage><MedlinePgn>ra67</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1126/scisignal.aaa6674</ELocationID><Abstract><AbstractText>Alzheimer's disease (AD) is a currently incurable neurodegenerative disorder and is the most common form of dementia in people over the age of 65 years. The predominant genetic risk factor for AD is the &#x3b5;4 allele encoding apolipoprotein E (ApoE4). The secreted glycoprotein Reelin enhances synaptic plasticity by binding to the multifunctional ApoE receptors apolipoprotein E receptor 2 (Apoer2) and very low density lipoprotein receptor (Vldlr). We have previously shown that the presence of ApoE4 renders neurons unresponsive to Reelin by impairing the recycling of the receptors, thereby decreasing its protective effects against amyloid &#x3b2; (A&#x3b2;) oligomer-induced synaptic toxicity in vitro. We showed that when Reelin was knocked out in adult mice, these mice behaved normally without overt learning or memory deficits. However, they were strikingly sensitive to amyloid-induced synaptic suppression and had profound memory and learning disabilities with very low amounts of amyloid deposition. Our findings highlight the physiological importance of Reelin in protecting the brain against A&#x3b2;-induced synaptic dysfunction and memory impairment.</AbstractText><CopyrightInformation>Copyright &#xa9; 2015, American Association for the Advancement of Science.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lane-Donovan</LastName><ForeName>Courtney</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Molecular Genetics, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA. Department of Neuroscience, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA. Center for Translational Neurodegeneration Research, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA. joachim.herz@utsouthwestern.edu courtney.lane@utsouthwestern.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Philips</LastName><ForeName>Gary T</ForeName><Initials>GT</Initials><AffiliationInfo><Affiliation>Center for Neural Science, New York University, New York, NY 10003, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wasser</LastName><ForeName>Catherine R</ForeName><Initials>CR</Initials><AffiliationInfo><Affiliation>Department of Molecular Genetics, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA. Center for Translational Neurodegeneration Research, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Durakoglugil</LastName><ForeName>Murat S</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>Department of Molecular Genetics, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA. Center for Translational Neurodegeneration Research, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Masiulis</LastName><ForeName>Irene</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Molecular Genetics, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Upadhaya</LastName><ForeName>Ajeet</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Molecular Genetics, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA. Center for Translational Neurodegeneration Research, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pohlkamp</LastName><ForeName>Theresa</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Molecular Genetics, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA. Center for Translational Neurodegeneration Research, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA. Center for Neuroscience, Department of Neuroanatomy, Albert-Ludwigs-University, Freiburg 79085, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Coskun</LastName><ForeName>Cagil</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Molecular Genetics, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kotti</LastName><ForeName>Tiina</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Molecular Genetics, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Steller</LastName><ForeName>Laura</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Institute for Structural Neurobiology, Center for Molecular Neurobiology, Hamburg 20251, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hammer</LastName><ForeName>Robert E</ForeName><Initials>RE</Initials><AffiliationInfo><Affiliation>Department of Biochemistry, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Frotscher</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute for Structural Neurobiology, Center for Molecular Neurobiology, Hamburg 20251, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bock</LastName><ForeName>Hans H</ForeName><Initials>HH</Initials><AffiliationInfo><Affiliation>Clinic for Gastroenterology, Hepatology and Infectiology, Heinrich-Heine-University, D&#xfc;sseldorf 40225, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Herz</LastName><ForeName>Joachim</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Molecular Genetics, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA. Department of Neuroscience, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA. Center for Translational Neurodegeneration Research, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA. Center for Neuroscience, Department of Neuroanatomy, Albert-Ludwigs-University, Freiburg 79085, Germany. Department of Neurology and Neurotherapeutics, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA. joachim.herz@utsouthwestern.edu courtney.lane@utsouthwestern.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>F30 AG047799</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37 HL063762</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37 HL63762</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>07</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Sci Signal</MedlineTA><NlmUniqueID>101465400</NlmUniqueID><ISSNLinking>1945-0877</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015816">Cell Adhesion Molecules, Neuronal</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016326">Extracellular Matrix Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D026502">LDL-Receptor Related Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009419">Nerve Tissue Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011973">Receptors, LDL</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000091042">Reelin Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C036053">VLDL receptor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C098773">low density lipoprotein receptor-related protein 8</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.21.-</RegistryNumber><NameOfSubstance UI="C000717127">RELN protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.21.-</RegistryNumber><NameOfSubstance UI="C000717128">Reln protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.21.-</RegistryNumber><NameOfSubstance UI="D012697">Serine Endopeptidases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Neurosci. 2015 Sep;16(9):509. doi: 10.1038/nrn4006.</RefSource><PMID Version="1">26220482</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015153" MajorTopicYN="N">Blotting, Western</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015816" MajorTopicYN="N">Cell Adhesion Molecules, Neuronal</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016326" MajorTopicYN="N">Extracellular Matrix Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007150" MajorTopicYN="N">Immunohistochemistry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D026502" MajorTopicYN="N">LDL-Receptor Related Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017774" MajorTopicYN="N">Long-Term Potentiation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018782" MajorTopicYN="N">Maze Learning</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008569" MajorTopicYN="N">Memory Disorders</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009043" MajorTopicYN="N">Motor Activity</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009419" MajorTopicYN="N">Nerve Tissue Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011973" MajorTopicYN="N">Receptors, LDL</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000091042" MajorTopicYN="N">Reelin Protein</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012697" MajorTopicYN="N">Serine Endopeptidases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>7</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>7</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>4</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2016</Year><Month>1</Month><Day>7</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26152694</ArticleId><ArticleId IdType="mid">NIHMS738334</ArticleId><ArticleId IdType="pmc">PMC4652952</ArticleId><ArticleId IdType="doi">10.1126/scisignal.aaa6674</ArticleId><ArticleId IdType="pii">8/384/ra67</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, Roses AD, Haines JL, Pericak-Vance MA. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science. 1993;261:921&#x2013;923.</Citation><ArticleIdList><ArticleId IdType="pubmed">8346443</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y, Durakoglugil MS, Xian X, Herz J. ApoE4 reduces glutamate receptor function and synaptic plasticity by selectively impairing ApoE receptor recycling. Proceedings of the National Academy of Sciences of the United States of America. 2010;107:12011&#x2013;12016.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2900641</ArticleId><ArticleId IdType="pubmed">20547867</ArticleId></ArticleIdList></Reference><Reference><Citation>Hiesberger T, Trommsdorff M, Howell BW, Goffinet A, Mumby MC, Cooper JA, Herz J. Direct binding of Reelin to VLDL receptor and ApoE receptor 2 induces tyrosine phosphorylation of disabled-1 and modulates tau phosphorylation. Neuron. 1999;24:481&#x2013;489.</Citation><ArticleIdList><ArticleId IdType="pubmed">10571241</ArticleId></ArticleIdList></Reference><Reference><Citation>Wasser CR, Masiulis I, Durakoglugil MS, Lane-Donovan C, Xian X, Beffert U, Agarwala A, Hammer RE, Herz J. Differential splicing and glycosylation of Apoer2 alters synaptic plasticity and fear learning. Science signaling. 2014;7:ra113.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4355955</ArticleId><ArticleId IdType="pubmed">25429077</ArticleId></ArticleIdList></Reference><Reference><Citation>Strasser V, Fasching D, Hauser C, Mayer H, Bock HH, Hiesberger T, Herz J, Weeber EJ, Sweatt JD, Pramatarova A, Howell B, Schneider WJ, Nimpf J. Receptor clustering is involved in Reelin signaling. Molecular and cellular biology. 2004;24:1378&#x2013;1386.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC321426</ArticleId><ArticleId IdType="pubmed">14729980</ArticleId></ArticleIdList></Reference><Reference><Citation>Beffert U, Morfini G, Bock HH, Reyna H, Brady ST, Herz J. Reelin-mediated signaling locally regulates protein kinase B/Akt and glycogen synthase kinase 3beta. The Journal of biological chemistry. 2002;277:49958&#x2013;49964.</Citation><ArticleIdList><ArticleId IdType="pubmed">12376533</ArticleId></ArticleIdList></Reference><Reference><Citation>Bock HH, Herz J. Reelin activates SRC family tyrosine kinases in neurons. Current biology : CB. 2003;13:18&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pubmed">12526740</ArticleId></ArticleIdList></Reference><Reference><Citation>Grayson DR, Jia X, Chen Y, Sharma RP, Mitchell CP, Guidotti A, Costa E. Reelin promoter hypermethylation in schizophrenia. Proceedings of the National Academy of Sciences of the United States of America. 2005;102:9341&#x2013;9346.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1166626</ArticleId><ArticleId IdType="pubmed">15961543</ArticleId></ArticleIdList></Reference><Reference><Citation>Takasu MA, Dalva MB, Zigmond RE, Greenberg ME. Modulation of NMDA receptor-dependent calcium influx and gene expression through EphB receptors. Science. 2002;295:491&#x2013;495.</Citation><ArticleIdList><ArticleId IdType="pubmed">11799243</ArticleId></ArticleIdList></Reference><Reference><Citation>Snyder EM, Nong Y, Almeida CG, Paul S, Moran T, Choi EY, Nairn AC, Salter MW, Lombroso PJ, Gouras GK, Greengard P. Regulation of NMDA receptor trafficking by amyloid-beta. Nature neuroscience. 2005;8:1051&#x2013;1058.</Citation><ArticleIdList><ArticleId IdType="pubmed">16025111</ArticleId></ArticleIdList></Reference><Reference><Citation>Weeber EJ, Beffert U, Jones C, Christian JM, Forster E, Sweatt JD, Herz J. Reelin and ApoE receptors cooperate to enhance hippocampal synaptic plasticity and learning. The Journal of biological chemistry. 2002;277:39944&#x2013;39952.</Citation><ArticleIdList><ArticleId IdType="pubmed">12167620</ArticleId></ArticleIdList></Reference><Reference><Citation>Durakoglugil MS, Chen Y, White CL, Kavalali ET, Herz J. Reelin signaling antagonizes beta-amyloid at the synapse. Proceedings of the National Academy of Sciences of the United States of America. 2009;106:15938&#x2013;15943.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2747222</ArticleId><ArticleId IdType="pubmed">19805234</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, Wolfe MS, Rowan MJ, Selkoe DJ. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature. 2002;416:535&#x2013;539.</Citation><ArticleIdList><ArticleId IdType="pubmed">11932745</ArticleId></ArticleIdList></Reference><Reference><Citation>Rogers JT, Rusiana I, Trotter J, Zhao L, Donaldson E, Pak DT, Babus LW, Peters M, Banko JL, Chavis P, Rebeck GW, Hoe HS, Weeber EJ. Reelin supplementation enhances cognitive ability, synaptic plasticity, and dendritic spine density. Learn Mem. 2011;18:558&#x2013;564.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3166788</ArticleId><ArticleId IdType="pubmed">21852430</ArticleId></ArticleIdList></Reference><Reference><Citation>Pujadas L, Rossi D, Andres R, Teixeira CM, Serra-Vidal B, Parcerisas A, Maldonado R, Giralt E, Carulla N, Soriano E. Reelin delays amyloid-beta fibril formation and rescues cognitive deficits in a model of Alzheimer's disease. Nature communications. 2014;5:3443.</Citation><ArticleIdList><ArticleId IdType="pubmed">24599114</ArticleId></ArticleIdList></Reference><Reference><Citation>D'Arcangelo G, Homayouni R, Keshvara L, Rice DS, Sheldon M, Curran T. Reelin is a ligand for lipoprotein receptors. Neuron. 1999;24:471&#x2013;479.</Citation><ArticleIdList><ArticleId IdType="pubmed">10571240</ArticleId></ArticleIdList></Reference><Reference><Citation>D'Arcangelo G, Miao GG, Chen SC, Soares HD, Morgan JI, Curran T. A protein related to extracellular matrix proteins deleted in the mouse mutant reeler. Nature. 1995;374:719&#x2013;723.</Citation><ArticleIdList><ArticleId IdType="pubmed">7715726</ArticleId></ArticleIdList></Reference><Reference><Citation>Falconer DS. Two new mutants, 'trembler' and 'reeler', with neurological actions in the house mouse (Mus musculus L.) Journal of genetics. 1951;50:192&#x2013;201.</Citation><ArticleIdList><ArticleId IdType="pubmed">24539699</ArticleId></ArticleIdList></Reference><Reference><Citation>Qiu S, Korwek KM, Pratt-Davis AR, Peters M, Bergman MY, Weeber EJ. Cognitive disruption and altered hippocampus synaptic function in Reelin haploinsufficient mice. Neurobiology of learning and memory. 2006;85:228&#x2013;242.</Citation><ArticleIdList><ArticleId IdType="pubmed">16376115</ArticleId></ArticleIdList></Reference><Reference><Citation>Tueting P, Costa E, Dwivedi Y, Guidotti A, Impagnatiello F, Manev R, Pesold C. The phenotypic characteristics of heterozygous reeler mouse. Neuroreport. 1999;10:1329&#x2013;1334.</Citation><ArticleIdList><ArticleId IdType="pubmed">10363948</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayashi S, McMahon AP. Efficient recombination in diverse tissues by a tamoxifen-inducible form of Cre: a tool for temporally regulated gene activation/inactivation in the mouse. Developmental biology. 2002;244:305&#x2013;318.</Citation><ArticleIdList><ArticleId IdType="pubmed">11944939</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnaud L, Ballif BA, Forster E, Cooper JA. Fyn tyrosine kinase is a critical regulator of disabled-1 during brain development. Current biology : CB. 2003;13:9&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pubmed">12526739</ArticleId></ArticleIdList></Reference><Reference><Citation>Bock HH, Jossin Y, May P, Bergner O, Herz J. Apolipoprotein E receptors are required for reelin-induced proteasomal degradation of the neuronal adaptor protein Disabled-1. The Journal of biological chemistry. 2004;279:33471&#x2013;33479.</Citation><ArticleIdList><ArticleId IdType="pubmed">15175346</ArticleId></ArticleIdList></Reference><Reference><Citation>Tallquist MD, Soriano P. Epiblast-restricted Cre expression in MORE mice: a tool to distinguish embryonic vs. extra-embryonic gene function. Genesis. 2000;26:113&#x2013;115.</Citation><ArticleIdList><ArticleId IdType="pubmed">10686601</ArticleId></ArticleIdList></Reference><Reference><Citation>Trotter J, Lee GH, Kazdoba TM, Crowell B, Domogauer J, Mahoney HM, Franco SJ, Muller U, Weeber EJ, D'Arcangelo G. Dab1 is required for synaptic plasticity and associative learning. The Journal of neuroscience : the official journal of the Society for Neuroscience. 2013;33:15652&#x2013;15668.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3782631</ArticleId><ArticleId IdType="pubmed">24068831</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee GH, Chhangawala Z, von Daake S, Savas JN, Yates JR, 3rd, Comoletti D, D'Arcangelo G. Reelin induces Erk1/2 signaling in cortical neurons through a non-canonical pathway. The Journal of biological chemistry. 2014;289:20307&#x2013;20317.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4106344</ArticleId><ArticleId IdType="pubmed">24876378</ArticleId></ArticleIdList></Reference><Reference><Citation>Isosaka T, Hattori K, Yagi T. NMDA-receptor proteins are upregulated in the hippocampus of postnatal heterozygous reeler mice. Brain research. 2006;1073&#x2013;1074:11&#x2013;19.</Citation><ArticleIdList><ArticleId IdType="pubmed">16438943</ArticleId></ArticleIdList></Reference><Reference><Citation>Brich J, Shie FS, Howell BW, Li R, Tus K, Wakeland EK, Jin LW, Mumby M, Churchill G, Herz J, Cooper JA. Genetic modulation of tau phosphorylation in the mouse. The Journal of neuroscience : the official journal of the Society for Neuroscience. 2003;23:187&#x2013;192.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6742161</ArticleId><ArticleId IdType="pubmed">12514215</ArticleId></ArticleIdList></Reference><Reference><Citation>Haas CA, Frotscher M. Reelin deficiency causes granule cell dispersion in epilepsy. Experimental brain research. 2010;200:141&#x2013;149.</Citation><ArticleIdList><ArticleId IdType="pubmed">19633980</ArticleId></ArticleIdList></Reference><Reference><Citation>Heinrich C, Nitta N, Flubacher A, Muller M, Fahrner A, Kirsch M, Freiman T, Suzuki F, Depaulis A, Frotscher M, Haas CA. Reelin deficiency and displacement of mature neurons, but not neurogenesis, underlie the formation of granule cell dispersion in the epileptic hippocampus. The Journal of neuroscience : the official journal of the Society for Neuroscience. 2006;26:4701&#x2013;4713.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6674063</ArticleId><ArticleId IdType="pubmed">16641251</ArticleId></ArticleIdList></Reference><Reference><Citation>Bouche E, Romero-Ortega MI, Henkemeyer M, Catchpole T, Leemhuis J, Frotscher M, May P, Herz J, Bock HH. Reelin induces EphB activation. Cell research. 2013;23:473&#x2013;490.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3616423</ArticleId><ArticleId IdType="pubmed">23318582</ArticleId></ArticleIdList></Reference><Reference><Citation>Utsunomiya-Tate N, Kubo K, Tate S, Kainosho M, Katayama E, Nakajima K, Mikoshiba K. Reelin molecules assemble together to form a large protein complex, which is inhibited by the function-blocking CR-50 antibody. Proceedings of the National Academy of Sciences of the United States of America. 2000;97:9729&#x2013;9734.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC16933</ArticleId><ArticleId IdType="pubmed">10920200</ArticleId></ArticleIdList></Reference><Reference><Citation>Dulabon L, Olson EC, Taglienti MG, Eisenhuth S, McGrath B, Walsh CA, Kreidberg JA, Anton ES. Reelin binds alpha3beta1 integrin and inhibits neuronal migration. Neuron. 2000;27:33&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">10939329</ArticleId></ArticleIdList></Reference><Reference><Citation>Niu S, Yabut O, D'Arcangelo G. The Reelin signaling pathway promotes dendritic spine development in hippocampal neurons. The Journal of neuroscience : the official journal of the Society for Neuroscience. 2008;28:10339&#x2013;10348.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2572775</ArticleId><ArticleId IdType="pubmed">18842893</ArticleId></ArticleIdList></Reference><Reference><Citation>Rogers JT, Zhao L, Trotter JH, Rusiana I, Peters MM, Li Q, Donaldson E, Banko JL, Keenoy KE, Rebeck GW, Hoe HS, D'Arcangelo G, Weeber EJ. Reelin supplementation recovers sensorimotor gating, synaptic plasticity and associative learning deficits in the heterozygous reeler mouse. Journal of psychopharmacology. 2013;27:386&#x2013;395.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3820099</ArticleId><ArticleId IdType="pubmed">23104248</ArticleId></ArticleIdList></Reference><Reference><Citation>Podhorna J, Didriksen M. The heterozygous reeler mouse: behavioural phenotype. Behavioural brain research. 2004;153:43&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pubmed">15219705</ArticleId></ArticleIdList></Reference><Reference><Citation>Ognibene E, Adriani W, Granstrem O, Pieretti S, Laviola G. Impulsivity-anxiety-related behavior and profiles of morphine-induced analgesia in heterozygous reeler mice. Brain research. 2007;1131:173&#x2013;180.</Citation><ArticleIdList><ArticleId IdType="pubmed">17174287</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, Yang F, Cole G. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science. 1996;274:99&#x2013;102.</Citation><ArticleIdList><ArticleId IdType="pubmed">8810256</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon MN, King DL, Diamond DM, Jantzen PT, Boyett KV, Hope CE, Hatcher JM, DiCarlo G, Gottschall WP, Morgan D, Arendash GW. Correlation between cognitive deficits and Abeta deposits in transgenic APP+PS1 mice. Neurobiology of aging. 2001;22:377&#x2013;385.</Citation><ArticleIdList><ArticleId IdType="pubmed">11378242</ArticleId></ArticleIdList></Reference><Reference><Citation>Kocherhans S, Madhusudan A, Doehner J, Breu KS, Nitsch RM, Fritschy JM, Knuesel I. Reduced Reelin expression accelerates amyloid-beta plaque formation and tau pathology in transgenic Alzheimer's disease mice. The Journal of neuroscience : the official journal of the Society for Neuroscience. 2010;30:9228&#x2013;9240.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6632461</ArticleId><ArticleId IdType="pubmed">20610758</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim KS, Miller DM, Sapienza VJ, Chen CJ, Bai C, Grundke-Iqbal I, Currie JR, H.M. W. Production and characterization of monoclonal antibodies reactive to synthetic cerebrovascular amyloid peptide. Neurosci. Res. Commun. 1988;2:121&#x2013;130.</Citation></Reference><Reference><Citation>Kawarabayashi T, Younkin LH, Saido TC, Shoji M, Ashe KH, Younkin SG. Age-dependent changes in brain, CSF, and plasma amyloid (beta) protein in the Tg2576 transgenic mouse model of Alzheimer's disease. The Journal of neuroscience : the official journal of the Society for Neuroscience. 2001;21:372&#x2013;381.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6763819</ArticleId><ArticleId IdType="pubmed">11160418</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoe HS, Lee KJ, Carney RS, Lee J, Markova A, Lee JY, Howell BW, Hyman BT, Pak DT, Bu G, Rebeck GW. Interaction of reelin with amyloid precursor protein promotes neurite outgrowth. The Journal of neuroscience : the official journal of the Society for Neuroscience. 2009;29:7459&#x2013;7473.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2759694</ArticleId><ArticleId IdType="pubmed">19515914</ArticleId></ArticleIdList></Reference><Reference><Citation>Leeb C, Eresheim C, Nimpf J. Clusterin is a ligand for apolipoprotein E receptor 2 (ApoER2) and very low density lipoprotein receptor (VLDLR) and signals via the Reelin-signaling pathway. The Journal of biological chemistry. 2014;289:4161&#x2013;4172.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3924281</ArticleId><ArticleId IdType="pubmed">24381170</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim DH, Iijima H, Goto K, Sakai J, Ishii H, Kim HJ, Suzuki H, Kondo H, Saeki S, Yamamoto T. Human apolipoprotein E receptor 2. A novel lipoprotein receptor of the low density lipoprotein receptor family predominantly expressed in brain. The Journal of biological chemistry. 1996;271:8373&#x2013;8380.</Citation><ArticleIdList><ArticleId IdType="pubmed">8626535</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoe HS, Wessner D, Beffert U, Becker AG, Matsuoka Y, Rebeck GW. F-spondin interaction with the apolipoprotein E receptor ApoEr2 affects processing of amyloid precursor protein. Molecular and cellular biology. 2005;25:9259&#x2013;9268.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1265841</ArticleId><ArticleId IdType="pubmed">16227578</ArticleId></ArticleIdList></Reference><Reference><Citation>Trommsdorff M, Borg JP, Margolis B, Herz J. Interaction of cytosolic adaptor proteins with neuronal apolipoprotein E receptors and the amyloid precursor protein. The Journal of biological chemistry. 1998;273:33556&#x2013;33560.</Citation><ArticleIdList><ArticleId IdType="pubmed">9837937</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmid RS, Jo R, Shelton S, Kreidberg JA, Anton ES. Reelin, integrin and DAB1 interactions during embryonic cerebral cortical development. Cerebral cortex. 2005;15:1632&#x2013;1636.</Citation><ArticleIdList><ArticleId IdType="pubmed">15703255</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwon OY, Hwang K, Kim JA, Kim K, Kwon IC, Song HK, Jeon H. Dab1 binds to Fe65 and diminishes the effect of Fe65 or LRP1 on APP processing. Journal of cellular biochemistry. 2010;111:508&#x2013;519.</Citation><ArticleIdList><ArticleId IdType="pubmed">20568118</ArticleId></ArticleIdList></Reference><Reference><Citation>Homayouni R, Rice DS, Sheldon M, Curran T. Disabled-1 binds to the cytoplasmic domain of amyloid precursor-like protein 1. The Journal of neuroscience : the official journal of the Society for Neuroscience. 1999;19:7507&#x2013;7515.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6782519</ArticleId><ArticleId IdType="pubmed">10460257</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert JC, Heath S, Even G, Campion D, Sleegers K, Hiltunen M, Combarros O, Zelenika D, Bullido MJ, Tavernier B, Letenneur L, Bettens K, Berr C, Pasquier F, Fievet N, Barberger-Gateau P, Engelborghs S, De Deyn P, Mateo I, Franck A, Helisalmi S, Porcellini E, Hanon O, I. European Alzheimer's Disease Initiative. de Pancorbo MM, Lendon C, Dufouil C, Jaillard C, Leveillard T, Alvarez V, Bosco P, Mancuso M, Panza F, Nacmias B, Bossu P, Piccardi P, Annoni G, Seripa D, Galimberti D, Hannequin D, Licastro F, Soininen H, Ritchie K, Blanche H, Dartigues JF, Tzourio C, Gut I, Van Broeckhoven C, Alperovitch A, Lathrop M, Amouyel P. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nature genetics. 2009;41:1094&#x2013;1099.</Citation><ArticleIdList><ArticleId IdType="pubmed">19734903</ArticleId></ArticleIdList></Reference><Reference><Citation>Houser CR. Granule cell dispersion in the dentate gyrus of humans with temporal lobe epilepsy. Brain research. 1990;535:195&#x2013;204.</Citation><ArticleIdList><ArticleId IdType="pubmed">1705855</ArticleId></ArticleIdList></Reference><Reference><Citation>Suzuki F, Junier MP, Guilhem D, Sorensen JC, Onteniente B. Morphogenetic effect of kainate on adult hippocampal neurons associated with a prolonged expression of brain-derived neurotrophic factor. Neuroscience. 1995;64:665&#x2013;674.</Citation><ArticleIdList><ArticleId IdType="pubmed">7715779</ArticleId></ArticleIdList></Reference><Reference><Citation>Muller MC, Osswald M, Tinnes S, Haussler U, Jacobi A, Forster E, Frotscher M, Haas CA. Exogenous reelin prevents granule cell dispersion in experimental epilepsy. Experimental neurology. 2009;216:390&#x2013;397.</Citation><ArticleIdList><ArticleId IdType="pubmed">19185570</ArticleId></ArticleIdList></Reference><Reference><Citation>Chai X, Munzner G, Zhao S, Tinnes S, Kowalski J, Haussler U, Young C, Haas CA, Frotscher M. Epilepsy-induced motility of differentiated neurons. Cerebral cortex. 2014;24:2130&#x2013;2140.</Citation><ArticleIdList><ArticleId IdType="pubmed">23505288</ArticleId></ArticleIdList></Reference><Reference><Citation>Korwek KM, Trotter JH, Ladu MJ, Sullivan PM, Weeber EJ. ApoE isoform-dependent changes in hippocampal synaptic function. Molecular neurodegeneration. 2009;4:21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2695436</ArticleId><ArticleId IdType="pubmed">19725929</ArticleId></ArticleIdList></Reference><Reference><Citation>Levenga J, Krishnamurthy P, Rajamohamedsait H, Wong H, Franke TF, Cain P, Sigurdsson EM, Hoeffer CA. Tau pathology induces loss of GABAergic interneurons leading to altered synaptic plasticity and behavioral impairments. Acta neuropathologica communications. 2013;1:34.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3893396</ArticleId><ArticleId IdType="pubmed">24252661</ArticleId></ArticleIdList></Reference><Reference><Citation>Groc L, Choquet D, Stephenson FA, Verrier D, Manzoni OJ, Chavis P. NMDA receptor surface trafficking and synaptic subunit composition are developmentally regulated by the extracellular matrix protein Reelin. The Journal of neuroscience : the official journal of the Society for Neuroscience. 2007;27:10165&#x2013;10175.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672660</ArticleId><ArticleId IdType="pubmed">17881522</ArticleId></ArticleIdList></Reference><Reference><Citation>Sinagra M, Verrier D, Frankova D, Korwek KM, Blahos J, Weeber EJ, Manzoni OJ, Chavis P. Reelin, very-low-density lipoprotein receptor, and apolipoprotein E receptor 2 control somatic NMDA receptor composition during hippocampal maturation in vitro. The Journal of neuroscience : the official journal of the Society for Neuroscience. 2005;25:6127&#x2013;6136.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725049</ArticleId><ArticleId IdType="pubmed">15987942</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang YP, Shimizu E, Dube GR, Rampon C, Kerchner GA, Zhuo M, Liu G, Tsien JZ. Genetic enhancement of learning and memory in mice. Nature. 1999;401:63&#x2013;69.</Citation><ArticleIdList><ArticleId IdType="pubmed">10485705</ArticleId></ArticleIdList></Reference><Reference><Citation>Zurhove K, Nakajima C, Herz J, Bock HH, May P. Gamma-secretase limits the inflammatory response through the processing of LRP1. Science signaling. 2008;1:ra15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2694618</ArticleId><ArticleId IdType="pubmed">19036715</ArticleId></ArticleIdList></Reference><Reference><Citation>Telese F, Ma Q, Perez PM, Notani D, Oh S, Li W, Comoletti D, Ohgi KA, Taylor H, Rosenfeld MG. LRP8-Reelin-Regulated Neuronal Enhancer Signature Underlying Learning and Memory Formation. Neuron. 2015</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4486257</ArticleId><ArticleId IdType="pubmed">25892301</ArticleId></ArticleIdList></Reference><Reference><Citation>Impagnatiello F, Guidotti AR, Pesold C, Dwivedi Y, Caruncho H, Pisu MG, Uzunov DP, Smalheiser NR, Davis JM, Pandey GN, Pappas GD, Tueting P, Sharma RP, Costa E. A decrease of reelin expression as a putative vulnerability factor in schizophrenia. Proceedings of the National Academy of Sciences of the United States of America. 1998;95:15718&#x2013;15723.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC28110</ArticleId><ArticleId IdType="pubmed">9861036</ArticleId></ArticleIdList></Reference><Reference><Citation>Botella-Lopez A, Burgaya F, Gavin R, Garcia-Ayllon MS, Gomez-Tortosa E, Pena-Casanova J, Urena JM, Del Rio JA, Blesa R, Soriano E, Saez-Valero J. Reelin expression and glycosylation patterns are altered in Alzheimer's disease. Proceedings of the National Academy of Sciences of the United States of America. 2006;103:5573&#x2013;5578.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1414634</ArticleId><ArticleId IdType="pubmed">16567613</ArticleId></ArticleIdList></Reference><Reference><Citation>Seripa D, Matera MG, Franceschi M, Daniele A, Bizzarro A, Rinaldi M, Panza F, Fazio VM, Gravina C, D'Onofrio G, Solfrizzi V, Masullo C, Pilotto A. The RELN locus in Alzheimer's disease. Journal of Alzheimer's disease : JAD. 2008;14:335&#x2013;344.</Citation><ArticleIdList><ArticleId IdType="pubmed">18599960</ArticleId></ArticleIdList></Reference><Reference><Citation>Kramer PL, Xu H, Woltjer RL, Westaway SK, Clark D, Erten-Lyons D, Kaye JA, Welsh-Bohmer KA, Troncoso JC, Markesbery WR, Petersen RC, Turner RS, Kukull WA, Bennett DA, Galasko D, Morris JC, Ott J. Alzheimer disease pathology in cognitively healthy elderly: a genome-wide study. Neurobiology of aging. 2011;32:2113&#x2013;2122.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2990809</ArticleId><ArticleId IdType="pubmed">20452100</ArticleId></ArticleIdList></Reference><Reference><Citation>Holtzman DM, Herz J, Bu G. Apolipoprotein E and apolipoprotein E receptors: normal biology and roles in Alzheimer disease. Cold Spring Harbor perspectives in medicine. 2012;2:a006312.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3282491</ArticleId><ArticleId IdType="pubmed">22393530</ArticleId></ArticleIdList></Reference><Reference><Citation>Westerman MA, Cooper-Blacketer D, Mariash A, Kotilinek L, Kawarabayashi T, Younkin LH, Carlson GA, Younkin SG, Ashe KH. The relationship between Abeta and memory in the Tg2576 mouse model of Alzheimer's disease. The Journal of neuroscience : the official journal of the Society for Neuroscience. 2002;22:1858&#x2013;1867.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6758862</ArticleId><ArticleId IdType="pubmed">11880515</ArticleId></ArticleIdList></Reference><Reference><Citation>Braybrooke JP, Spink KG, Thacker J, Hickson ID. The RAD51 family member, RAD51L3, is a DNA-stimulated ATPase that forms a complex with XRCC2. The Journal of biological chemistry. 2000;275:29100&#x2013;29106.</Citation><ArticleIdList><ArticleId IdType="pubmed">10871607</ArticleId></ArticleIdList></Reference><Reference><Citation>Beffert U, Durudas A, Weeber EJ, Stolt PC, Giehl KM, Sweatt JD, Hammer RE, Herz J. Functional dissection of Reelin signaling by site-directed disruption of Disabled-1 adaptor binding to apolipoprotein E receptor 2: distinct roles in development and synaptic plasticity. The Journal of neuroscience : the official journal of the Society for Neuroscience. 2006;26:2041&#x2013;2052.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6674917</ArticleId><ArticleId IdType="pubmed">16481437</ArticleId></ArticleIdList></Reference><Reference><Citation>Trommsdorff M, Gotthardt M, Hiesberger T, Shelton J, Stockinger W, Nimpf J, Hammer RE, Richardson JA, Herz J. Reeler/Disabled-like disruption of neuronal migration in knockout mice lacking the VLDL receptor and ApoE receptor 2. Cell. 1999;97:689&#x2013;701.</Citation><ArticleIdList><ArticleId IdType="pubmed">10380922</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">26174152</PMID><DateCompleted><Year>2015</Year><Month>12</Month><Day>30</Day></DateCompleted><DateRevised><Year>2017</Year><Month>11</Month><Day>16</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1531-8249</ISSN><JournalIssue CitedMedium="Internet"><Volume>78</Volume><Issue>4</Issue><PubDate><Year>2015</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Annals of neurology</Title><ISOAbbreviation>Ann Neurol</ISOAbbreviation></Journal><ArticleTitle>Isoform-specific antibodies reveal distinct subcellular localizations of C9orf72 in amyotrophic lateral sclerosis.</ArticleTitle><Pagination><StartPage>568</StartPage><EndPage>583</EndPage><MedlinePgn>568-83</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/ana.24469</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">A noncoding hexanucleotide repeat expansion in C9orf72 is the most common cause of amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD). It has been reported that the repeat expansion causes a downregulation of C9orf72 transcripts, suggesting that haploinsufficiency may contribute to disease pathogenesis. Two protein isoforms are generated from three alternatively spliced transcripts of C9orf72; a long form (C9-L) and a short form (C9-S), and their function(s) are largely unknown owing to lack of specific antibodies.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">To investigate C9orf72 protein properties, we developed novel antibodies that recognize either C9-L or C9-S. Multiple techniques, including Western blot, immunohistochemistry, and coimmunoprecipitation, were used to determine the expression levels and subcellular localizations of C9-L and C9-S.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Investigation of expression of C9-L and C9-S demonstrated distinct biochemical profiles, region-specific changes, and distinct subcellular localizations in ALS tissues. In particular, C9-L antibody exhibited a diffuse cytoplasmic staining in neurons and labeled large speckles in cerebellar Purkinje cells. In contrast, C9-S antibody gave very specific labeling of the nuclear membrane in healthy neurons, with apparent relocalization to the plasma membrane of diseased motor neurons in ALS. Coimmunoprecipitation experiments revealed an interaction of the C9-isoforms with both Importin &#x3b2;1 and Ran-GTPase, components of the nuclear pore complex.</AbstractText><AbstractText Label="INTERPRETATION" NlmCategory="CONCLUSIONS">Using these antibodies, we have shown that C9orf72 may be involved in nucleocytoplasmic shuttling and this may have relevance to pathophysiology of ALS/FTLD. Our antibodies have provided improved detection of C9orf72 protein isoforms, which will help elucidate its physiological function and role in ALS/FTLD.</AbstractText><CopyrightInformation>&#xa9; 2015 The Authors Annals of Neurology published by Wiley Periodicals, Inc. on behalf of American Neurological Association.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Xiao</LastName><ForeName>Shangxi</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Tanz Center for Research in Neurodegenerative Diseases, University of Toronto, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>MacNair</LastName><ForeName>Laura</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Tanz Center for Research in Neurodegenerative Diseases, University of Toronto, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McGoldrick</LastName><ForeName>Philip</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Tanz Center for Research in Neurodegenerative Diseases, University of Toronto, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McKeever</LastName><ForeName>Paul M</ForeName><Initials>PM</Initials><AffiliationInfo><Affiliation>Tanz Center for Research in Neurodegenerative Diseases, University of Toronto, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McLean</LastName><ForeName>Jesse R</ForeName><Initials>JR</Initials><AffiliationInfo><Affiliation>Tanz Center for Research in Neurodegenerative Diseases, University of Toronto, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Ming</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Tanz Center for Research in Neurodegenerative Diseases, University of Toronto, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Keith</LastName><ForeName>Julia</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Sunnybrook Health Sciences Center, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zinman</LastName><ForeName>Lorne</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Sunnybrook Health Sciences Center, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rogaeva</LastName><ForeName>Ekaterina</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Tanz Center for Research in Neurodegenerative Diseases, University of Toronto, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Robertson</LastName><ForeName>Janice</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Tanz Center for Research in Neurodegenerative Diseases, University of Toronto, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>JNM-90963</GrantID><Agency>Canadian Institutes of Health Research</Agency><Country>Canada</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>08</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Ann Neurol</MedlineTA><NlmUniqueID>7707449</NlmUniqueID><ISSNLinking>0364-5134</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000906">Antibodies</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000073885">C9orf72 Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C568651">C9orf72 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D020033">Protein Isoforms</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011506">Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000595" MajorTopicYN="N">Amino Acid Sequence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000906" MajorTopicYN="N">Antibodies</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="Y">analysis</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000073885" MajorTopicYN="N">C9orf72 Protein</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002531" MajorTopicYN="N">Cerebellum</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008969" MajorTopicYN="N">Molecular Sequence Data</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009046" MajorTopicYN="N">Motor Neurons</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020033" MajorTopicYN="N">Protein Isoforms</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName><QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011506" MajorTopicYN="N">Proteins</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="Y">analysis</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>2</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2015</Year><Month>6</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>6</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>7</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>7</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>12</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26174152</ArticleId><ArticleId IdType="doi">10.1002/ana.24469</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">26176913</PMID><DateCompleted><Year>2015</Year><Month>08</Month><Day>06</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1476-4687</ISSN><JournalIssue CitedMedium="Internet"><Volume>523</Volume><Issue>7561</Issue><PubDate><Year>2015</Year><Month>Jul</Month><Day>23</Day></PubDate></JournalIssue><Title>Nature</Title><ISOAbbreviation>Nature</ISOAbbreviation></Journal><ArticleTitle>Antibody against early driver of neurodegeneration cis P-tau blocks brain injury and tauopathy.</ArticleTitle><Pagination><StartPage>431</StartPage><EndPage>436</EndPage><MedlinePgn>431-436</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/nature14658</ELocationID><Abstract><AbstractText>Traumatic brain injury (TBI), characterized by acute neurological dysfunction, is one of the best known environmental risk factors for chronic traumatic encephalopathy and Alzheimer's disease, the defining pathologic features of which include tauopathy made of phosphorylated tau protein (P-tau). However, tauopathy has not been detected in the early stages after TBI, and how TBI leads to tauopathy is unknown. Here we find robust cis P-tau pathology after TBI in humans and mice. After TBI in mice and stress in vitro, neurons acutely produce cis P-tau, which disrupts axonal microtubule networks and mitochondrial transport, spreads to other neurons, and leads to apoptosis. This process, which we term 'cistauosis', appears long before other tauopathy. Treating TBI mice with cis antibody blocks cistauosis, prevents tauopathy development and spread, and restores many TBI-related structural and functional sequelae. Thus, cis P-tau is a major early driver of disease after TBI and leads to tauopathy in chronic traumatic encephalopathy and Alzheimer's disease. The cis antibody may be further developed to detect and treat TBI, and prevent progressive neurodegeneration after injury.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Kondo</LastName><ForeName>Asami</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Translational Therapeutics, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cancer Research Institute, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Shahpasand</LastName><ForeName>Koorosh</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Division of Translational Therapeutics, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cancer Research Institute, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mannix</LastName><ForeName>Rebekah</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Division of Emergency Medicine, Children's Hospital Boston, Harvard Medical School, Boston, MA 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qiu</LastName><ForeName>Jianhua</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Division of Emergency Medicine, Children's Hospital Boston, Harvard Medical School, Boston, MA 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moncaster</LastName><ForeName>Juliet</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Alzheimer's Disease Center, CTE Program, Boston University School of Medicine, Boston, MA, 02118, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Chun-Hau</ForeName><Initials>CH</Initials><AffiliationInfo><Affiliation>Division of Translational Therapeutics, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cancer Research Institute, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yao</LastName><ForeName>Yandan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Division of Translational Therapeutics, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cancer Research Institute, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Yu-Min</ForeName><Initials>YM</Initials><AffiliationInfo><Affiliation>Division of Translational Therapeutics, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cancer Research Institute, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Driver</LastName><ForeName>Jane A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Division of Translational Therapeutics, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Geriatric Research Education and Clinical Center, VA Boston Healthcare System, Harvard Medical School, Boston, MA, 02130.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Yan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Neurology, Children's Hospital Boston, Harvard Medical School, Boston, MA 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wei</LastName><ForeName>Shuo</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Division of Translational Therapeutics, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cancer Research Institute, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Luo</LastName><ForeName>Man-Li</ForeName><Initials>ML</Initials><AffiliationInfo><Affiliation>Division of Translational Therapeutics, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cancer Research Institute, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Albayram</LastName><ForeName>Onder</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Division of Translational Therapeutics, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cancer Research Institute, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Pengyu</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Division of Translational Therapeutics, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cancer Research Institute, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rotenberg</LastName><ForeName>Alexander</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurology, Children's Hospital Boston, Harvard Medical School, Boston, MA 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ryo</LastName><ForeName>Akihide</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Microbiology, Yokohama City University School of Medicine, Yokohama 236-0004, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goldstein</LastName><ForeName>Lee E</ForeName><Initials>LE</Initials><AffiliationInfo><Affiliation>Alzheimer's Disease Center, CTE Program, Boston University School of Medicine, Boston, MA, 02118, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pascual-Leone</LastName><ForeName>Alvaro</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McKee</LastName><ForeName>Ann C</ForeName><Initials>AC</Initials><AffiliationInfo><Affiliation>Alzheimer's Disease Center, CTE Program, Boston University School of Medicine, Boston, MA, 02118, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meehan</LastName><ForeName>William</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Micheli Center for Sports Injury Prevention, Children's Hospital Boston, Harvard Medical School, Boston, MA 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Xiao Zhen</ForeName><Initials>XZ</Initials><AffiliationInfo><Affiliation>Division of Translational Therapeutics, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cancer Research Institute, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Kun Ping</ForeName><Initials>KP</Initials><AffiliationInfo><Affiliation>Division of Translational Therapeutics, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cancer Research Institute, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 CA167677</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01NS086659-01</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01CA167677</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG029385</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>S10 RR017927</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 HL111430</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01AG046319</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>S10RR017927</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 NS086659</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01AG029385</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG013846</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG046319</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32HD040128</GrantID><Acronym>HD</Acronym><Agency>NICHD NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 HD040128</GrantID><Acronym>HD</Acronym><Agency>NICHD NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30AG13846</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01HL111430</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>07</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nature</MedlineTA><NlmUniqueID>0410462</NlmUniqueID><ISSNLinking>0028-0836</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000939">Epitopes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010750">Phosphoproteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Drug Discov. 2015 Sep;14(9):599. doi: 10.1038/nrd4713.</RefSource><PMID Version="1">26323539</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000911" MajorTopicYN="N">Antibodies, Monoclonal</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000915" MajorTopicYN="N">Antibody Affinity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001369" MajorTopicYN="N">Axons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001930" MajorTopicYN="N">Brain Injuries</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000939" MajorTopicYN="N">Epitopes</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010750" MajorTopicYN="N">Phosphoproteins</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000633" MajorTopicYN="N">toxicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013312" MajorTopicYN="N">Stress, Physiological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D024801" MajorTopicYN="N">Tauopathies</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000633" MajorTopicYN="N">toxicity</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>6</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>6</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>7</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>7</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>8</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2016</Year><Month>1</Month><Day>23</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26176913</ArticleId><ArticleId IdType="mid">NIHMS700022</ArticleId><ArticleId IdType="pmc">PMC4718588</ArticleId><ArticleId IdType="doi">10.1038/nature14658</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Faul M, Xu L, Wald MM, Coronado VG.  Traumatic brain injury in the United States: emergency department visits, hospitalizations, and deaths, 2002&#x2013;2006. Centers for Disease Control and Prevention [online]; 2010.   http://www.cdc.gov/traumaticbraininjury/tbi_ed.html.</Citation></Reference><Reference><Citation>Centers for Disease Control and Prevention  CDC grand rounds: reducing severe traumatic brain injury in the United States. MMWR Morb Mortal Wkly Rep. 2013;62:549&#x2013;552.  http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6227a6222.htm.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4604943</ArticleId><ArticleId IdType="pubmed">23842444</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanielian T, et al.   Invisible Wounds of War: Psychological and Cognitive Injuries, Their Consequences, and Services to Assist Recovery. RAND Corporation; Santa Monica, CA: 2008.  2008,  http://www.rand.org/pubs/monographs/MG720.</Citation></Reference><Reference><Citation>Omalu BI, et al. Chronic traumatic encephalopathy in a National Football League player. Neurosurgery. 2005;57:128&#x2013;134.</Citation><ArticleIdList><ArticleId IdType="pubmed">15987548</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldstein LE, et al. Chronic traumatic encephalopathy in blast-exposed military veterans and a blast neurotrauma mouse model. Sci Transl Med. 2012;4:134ra160.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3739428</ArticleId><ArticleId IdType="pubmed">22593173</ArticleId></ArticleIdList></Reference><Reference><Citation>McKee AC, et al. The spectrum of disease in chronic traumatic encephalopathy. Brain. 2013;136:43&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3624697</ArticleId><ArticleId IdType="pubmed">23208308</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith DH, Johnson VE, Stewart W. Chronic neuropathologies of single and repetitive TBI: substrates of dementia? Nat Rev Neurol. 2013;9:211&#x2013;221.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4513655</ArticleId><ArticleId IdType="pubmed">23458973</ArticleId></ArticleIdList></Reference><Reference><Citation>DeKosky ST, Blennow K, Ikonomovic MD, Gandy S. Acute and chronic traumatic encephalopathies: pathogenesis and biomarkers. Nat Rev Neurol. 2013;9:192&#x2013;200.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4006940</ArticleId><ArticleId IdType="pubmed">23558985</ArticleId></ArticleIdList></Reference><Reference><Citation>Blennow K, Hardy J, Zetterberg H. The neuropathology and neurobiology of traumatic brain injury. Neuron. 2012;76:886&#x2013;899.</Citation><ArticleIdList><ArticleId IdType="pubmed">23217738</ArticleId></ArticleIdList></Reference><Reference><Citation>Mortimer JA, et al. Head trauma as a risk factor for Alzheimer's disease: a collaborative re-analysis of case-control studies. EURODEM Risk Factors Research Group. Int J Epidemiol. 1991;20(Suppl 2):S28&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pubmed">1833351</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo Z, et al. Head injury and the risk of AD in the MIRAGE study. Neurology. 2000;54:1316&#x2013;1323.</Citation><ArticleIdList><ArticleId IdType="pubmed">10746604</ArticleId></ArticleIdList></Reference><Reference><Citation>Nordstrom P, Michaelsson K, Gustafson Y, Nordstrom A. Traumatic brain injury and young onset dementia: a nationwide cohort study. Ann Neurol. 2014;75:374&#x2013;381.</Citation><ArticleIdList><ArticleId IdType="pubmed">24812697</ArticleId></ArticleIdList></Reference><Reference><Citation>Ballatore C, Lee VM, Trojanowski JQ. Tau-mediated neurodegeneration in Alzheimer's disease and related disorders. Nat Rev Neurosci. 2007;8:663&#x2013;672.</Citation><ArticleIdList><ArticleId IdType="pubmed">17684513</ArticleId></ArticleIdList></Reference><Reference><Citation>Mandelkow EM, Mandelkow E. Biochemistry and cell biology of tau protein in neurofibrillary degeneration. Cold Spring Harb Perspect Med. 2012;2:a006247.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3385935</ArticleId><ArticleId IdType="pubmed">22762014</ArticleId></ArticleIdList></Reference><Reference><Citation>Clavaguera F, et al. Transmission and spreading of tauopathy in transgenic mouse brain. Nat Cell Biol. 2009;11:909&#x2013;913.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2726961</ArticleId><ArticleId IdType="pubmed">19503072</ArticleId></ArticleIdList></Reference><Reference><Citation>de Calignon A, et al. Propagation of tau pathology in a model of early Alzheimer's disease. Neuron. 2012;73:685&#x2013;697.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3292759</ArticleId><ArticleId IdType="pubmed">22365544</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu L, et al. Trans-synaptic spread of tau pathology in vivo. PLoS ONE. 2012;7:e31302.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3270029</ArticleId><ArticleId IdType="pubmed">22312444</ArticleId></ArticleIdList></Reference><Reference><Citation>Clavaguera F, et al. Peripheral administration of tau aggregates triggers intracerebral tauopathy in transgenic mice. Acta Neuropathol. 2014;127:299&#x2013;301.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4253855</ArticleId><ArticleId IdType="pubmed">24362441</ArticleId></ArticleIdList></Reference><Reference><Citation>Clavaguera F, Hench J, Goedert M, Tolnay M. Invited review: Prion-like transmission and spreading of tau pathology. Neuropathol Appl Neurobiol. 2015;41:47&#x2013;58.</Citation><ArticleIdList><ArticleId IdType="pubmed">25399729</ArticleId></ArticleIdList></Reference><Reference><Citation>Asuni AA, Boutajangout A, Quartermain D, Sigurdsson EM. Immunotherapy targeting pathological tau conformers in a tangle mouse model reduces brain pathology with associated functional improvements. J Neurosci. 2007;27:9115&#x2013;9129.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672191</ArticleId><ArticleId IdType="pubmed">17715348</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenmann H. Immunotherapy for targeting tau pathology in Alzheimer's disease and tauopathies. Curr Alzheimer Res. 2013;10:217&#x2013;228.</Citation><ArticleIdList><ArticleId IdType="pubmed">23534533</ArticleId></ArticleIdList></Reference><Reference><Citation>Sigurdsson EM. Tau Immunotherapy and Imaging. Neurodegener Dis. 2014;13:103&#x2013;106.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3946316</ArticleId><ArticleId IdType="pubmed">24029727</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith C, Graham DI, Murray LS, Nicoll JA. Tau immunohistochemistry in acute brain injury. Neuropathol Appl Neurobiol. 2003;29:496&#x2013;502.</Citation><ArticleIdList><ArticleId IdType="pubmed">14507341</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson VE, Stewart W, Smith DH. Widespread tau and amyloid-beta pathology many years after a single traumatic brain injury in humans. Brain Pathol. 2012;22:142&#x2013;149.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3979351</ArticleId><ArticleId IdType="pubmed">21714827</ArticleId></ArticleIdList></Reference><Reference><Citation>Mannix R, et al. Clinical Correlates in an Experimental Model of Repetitive Mild Brain Injury. Ann Neurol. 2013;74:65&#x2013;75.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6312716</ArticleId><ArticleId IdType="pubmed">23922306</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu KP, Hanes SD, Hunter T. A human peptidyl-prolyl isomerase essential for regulation of mitosis. Nature. 1996;380:544&#x2013;547.</Citation><ArticleIdList><ArticleId IdType="pubmed">8606777</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu PJ, Wulf G, Zhou XZ, Davies P, Lu KP. The prolyl isomerase Pin1 restores the function of Alzheimer-associated phosphorylated tau protein. Nature. 1999;399:784&#x2013;788.</Citation><ArticleIdList><ArticleId IdType="pubmed">10391244</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou XZ, et al. Pin1-dependent prolyl isomerization regulates dephosphorylation of Cdc25C and tau proteins. Mol Cell. 2000;6:873&#x2013;883.</Citation><ArticleIdList><ArticleId IdType="pubmed">11090625</ArticleId></ArticleIdList></Reference><Reference><Citation>Liou Y-C, et al. Role of the prolyl isomerase Pin1 in protecting against age-dependent neurodegeneration. Nature. 2003;424:556&#x2013;561.</Citation><ArticleIdList><ArticleId IdType="pubmed">12891359</ArticleId></ArticleIdList></Reference><Reference><Citation>Pastorino L, et al. The prolyl isomerase Pin1 regulates amyloid precursor protein processing and amyloid-beta production. Nature. 2006;440:528&#x2013;534.</Citation><ArticleIdList><ArticleId IdType="pubmed">16554819</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu KP, Zhou XZ. The prolyl isomerase PIN1: a pivotal new twist in phosphorylation signalling and human disease. Nat Rev Mol Cell Biol. 2007;8:904&#x2013;916.</Citation><ArticleIdList><ArticleId IdType="pubmed">17878917</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim J, et al. Pin1 has opposite effects on wild-type and P301L tau stability and tauopathy. J. Clin. Invest. 2008;118:1877&#x2013;1889.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2323189</ArticleId><ArticleId IdType="pubmed">18431510</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee TH, Pastorino L, Lu KP. Peptidyl-prolyl cis-trans isomerase Pin1 in aging, cancer and Alzheimer's disease. Expet Rev Mol Med. 2011;13:e21.</Citation><ArticleIdList><ArticleId IdType="pubmed">21682951</ArticleId></ArticleIdList></Reference><Reference><Citation>Driver JA, Zhou XZ, Lu KP. Pin1 dysregulation helps to explain the inverse association between cancer and Alzheimer's disease. Biochim Biophys Acta. 2015</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4499009</ArticleId><ArticleId IdType="pubmed">25583562</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen CH, et al. Pin1 cysteine-113 oxidation inhibits its catalytic activity and cellular function in Alzheimer's disease. Neurobiol Dis. 2015;76:13&#x2013;23. The cover story.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4423621</ArticleId><ArticleId IdType="pubmed">25576397</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee TH, et al. Death associated protein kinase 1 phosphorylates Pin1 and inhibits its prolyl isomerase activity and cellular function. Mol Cell. 2011;22:147&#x2013;159.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3088080</ArticleId><ArticleId IdType="pubmed">21497122</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim BM, et al. Death-associated protein kinase 1 has a critical role in aberrant tau protein regulation and function. Cell Death Dis. 2014;5:e1237.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4047864</ArticleId><ArticleId IdType="pubmed">24853415</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma SL, et al. A PIN1 polymorphism that prevents its suppression by AP4 associates with delayed onset of Alzheimer's disease. Neurobiol Aging. 2012;33:804&#x2013;813.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2988914</ArticleId><ArticleId IdType="pubmed">20580132</ArticleId></ArticleIdList></Reference><Reference><Citation>Wijsman EM, et al. Evidence for a novel late-onset Alzheimer disease locus on chromosome 19p13.2. Am J Hum Genet. 2004;75:398&#x2013;409.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1182019</ArticleId><ArticleId IdType="pubmed">15248153</ArticleId></ArticleIdList></Reference><Reference><Citation>Luna-Munoz J, Chavez-Macias L, Garcia-Sierra F, Mena R. Earliest stages of tau conformational changes are related to the appearance of a sequence of specific phospho-dependent tau epitopes in Alzheimer's disease. J Alzheimers Dis. 2007;12:365&#x2013;375.</Citation><ArticleIdList><ArticleId IdType="pubmed">18198423</ArticleId></ArticleIdList></Reference><Reference><Citation>Hampel H, et al. Total and phosphorylated tau protein as biological markers of Alzheimer's disease. Exp Gerontol. 2010;45:30&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2815003</ArticleId><ArticleId IdType="pubmed">19853650</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakamura K, et al. Proline isomer-specific antibodies reveal the early pathogenic tau conformation in Alzheimer's disease. Cell. 2012;149:232&#x2013;244.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3601591</ArticleId><ArticleId IdType="pubmed">22464332</ArticleId></ArticleIdList></Reference><Reference><Citation>Lasagna-Reeves CA, et al. Identification of oligomers at early stages of tau aggregation in Alzheimer's disease. FASEB J. 2012;26:1946&#x2013;1959.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4046102</ArticleId><ArticleId IdType="pubmed">22253473</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson VE, Stewart W, Smith DH. Axonal pathology in traumatic brain injury. Exp Neurol. 2013;246:35&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3979341</ArticleId><ArticleId IdType="pubmed">22285252</ArticleId></ArticleIdList></Reference><Reference><Citation>Congdon EE, Gu J, Sait HB, Sigurdsson EM. Antibody uptake into neurons occurs primarily via clathrin-dependent Fcgamma receptor endocytosis and is a prerequisite for acute tau protein clearance. J Biol Chem. 2013;288:35452&#x2013;35465.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3853292</ArticleId><ArticleId IdType="pubmed">24163366</ArticleId></ArticleIdList></Reference><Reference><Citation>Mallery DL, et al. Antibodies mediate intracellular immunity through tripartite motif- containing 21 (TRIM21). Proc Natl Acad Sci U S A. 2010;107:19985&#x2013;19990.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2993423</ArticleId><ArticleId IdType="pubmed">21045130</ArticleId></ArticleIdList></Reference><Reference><Citation>Cruz JC, Tseng HC, Goldman JA, Shih H, Tsai LH. Aberrant Cdk5 activation by p25 triggers pathological events leading to neurodegeneration and neurofibrillary tangles. Neuron. 2003;40:471&#x2013;483.</Citation><ArticleIdList><ArticleId IdType="pubmed">14642273</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams S, et al. In situ DNA fragmentation occurs in white matter up to 12 months after head injury in man. Acta Neuropathol. 2001;102:581&#x2013;590.</Citation><ArticleIdList><ArticleId IdType="pubmed">11761718</ArticleId></ArticleIdList></Reference><Reference><Citation>Adhikari A, Topiwala MA, Gordon JA. Single units in the medial prefrontal cortex with anxiety-related firing patterns are preferentially influenced by ventral hippocampal activity. Neuron. 2011;71:898&#x2013;910.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3201792</ArticleId><ArticleId IdType="pubmed">21903082</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwarzbold ML, et al. Effects of traumatic brain injury of different severities on emotional, cognitive, and oxidative stress-related parameters in mice. J Neurotrauma. 2010;27:1883&#x2013;1893.</Citation><ArticleIdList><ArticleId IdType="pubmed">20649482</ArticleId></ArticleIdList></Reference><Reference><Citation>Tokuoka H, et al. Brain-derived neurotrophic factor-induced phosphorylation of neurofilament-H subunit in primary cultures of embryo rat cortical neurons. J Cell Sci. 2000;113(Pt 6):1059&#x2013;1068.</Citation><ArticleIdList><ArticleId IdType="pubmed">10683153</ArticleId></ArticleIdList></Reference><Reference><Citation>Shahpasand K, et al. Regulation of mitochondrial transport and inter-microtubule spacing by tau phosphorylation at the sites hyperphosphorylated in Alzheimer's disease. J Neurosci. 2012;32:2430&#x2013;2441.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6621814</ArticleId><ArticleId IdType="pubmed">22396417</ArticleId></ArticleIdList></Reference><Reference><Citation>Farah CA, et al. Tau interacts with Golgi membranes and mediates their association with microtubules. Cell Motil Cytoskeleton. 2006;63:710&#x2013;724.</Citation><ArticleIdList><ArticleId IdType="pubmed">16960886</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishihara T, et al. Age-dependent emergence and progression of a tauopathy in transgenic mice overexpressing the shortest human tau isoform. Neuron. 1999;24:751&#x2013;762.</Citation><ArticleIdList><ArticleId IdType="pubmed">10595524</ArticleId></ArticleIdList></Reference><Reference><Citation>Dawson HN, et al. Inhibition of neuronal maturation in primary hippocampal neurons from tau deficient mice. J Cell Sci. 2001;114:1179&#x2013;1187.</Citation><ArticleIdList><ArticleId IdType="pubmed">11228161</ArticleId></ArticleIdList></Reference><Reference><Citation>Meehan WP, 3rd, Zhang J, Mannix R, Whalen MJ. Increasing recovery time between injuries improves cognitive outcome after repetitive mild concussive brain injuries in mice. Neurosurgery. 2012;71:885&#x2013;891.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5815628</ArticleId><ArticleId IdType="pubmed">22743360</ArticleId></ArticleIdList></Reference><Reference><Citation>Walf AA, Frye CA. The use of the elevated plus maze as an assay of anxiety-related behavior in rodents. Nat Protoc. 2007;2:322&#x2013;328.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3623971</ArticleId><ArticleId IdType="pubmed">17406592</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris R. Developments of a water-maze procedure for studying spatial learning in the rat. J Neurosci Methods. 1984;11:47&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pubmed">6471907</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">26182420</PMID><DateCompleted><Year>2015</Year><Month>09</Month><Day>28</Day></DateCompleted><DateRevised><Year>2016</Year><Month>11</Month><Day>25</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1097-4199</ISSN><JournalIssue CitedMedium="Internet"><Volume>87</Volume><Issue>2</Issue><PubDate><Year>2015</Year><Month>Jul</Month><Day>15</Day></PubDate></JournalIssue><Title>Neuron</Title><ISOAbbreviation>Neuron</ISOAbbreviation></Journal><ArticleTitle>Dysregulated ADAM10-Mediated Processing of APP during a Critical Time Window Leads to Synaptic Deficits in Fragile X Syndrome.</ArticleTitle><Pagination><StartPage>382</StartPage><EndPage>398</EndPage><MedlinePgn>382-98</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.neuron.2015.06.032</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0896-6273(15)00595-4</ELocationID><Abstract><AbstractText>The Fragile X mental retardation protein (FMRP) regulates neuronal RNA metabolism, and its absence or mutations leads to the Fragile X syndrome (FXS). The &#x3b2;-amyloid precursor protein (APP) is involved in Alzheimer's disease, plays a role in synapse formation, and is upregulated in intellectual disabilities. Here, we show that during mouse synaptogenesis and in human FXS fibroblasts, a dual dysregulation of APP and the &#x3b1;-secretase ADAM10 leads to the production of an excess of soluble APP&#x3b1; (sAPP&#x3b1;). In FXS, sAPP&#x3b1; signals through the metabotropic receptor that, activating the MAP kinase pathway, leads to synaptic and behavioral deficits. Modulation of ADAM10 activity in FXS reduces sAPP&#x3b1; levels, restoring translational control, synaptic morphology, and behavioral plasticity. Thus, proper control of ADAM10-mediated APP processing during a specific developmental postnatal stage is crucial for healthy spine formation and function(s). Downregulation of ADAM10 activity at synapses may be an effective strategy for ameliorating FXS phenotypes.</AbstractText><CopyrightInformation>Copyright &#xa9; 2015 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pasciuto</LastName><ForeName>Emanuela</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Center for Human Genetics and Leuven Research Institute for Neuroscience and Disease (LIND), KU Leuven, 3000 Leuven, Belgium; VIB Center for the Biology of Disease, 3000 Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ahmed</LastName><ForeName>Tariq</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Faculty of Psychology and Educational Sciences, Laboratory of Biological Psychology, KU Leuven, 3000 Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wahle</LastName><ForeName>Tina</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Center for Human Genetics and Leuven Research Institute for Neuroscience and Disease (LIND), KU Leuven, 3000 Leuven, Belgium; VIB Center for the Biology of Disease, 3000 Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gardoni</LastName><ForeName>Fabrizio</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Dipartimento di Scienze Farmacologiche e Biomolecolari and Centre of Excellence on Neurodegenerative Diseases, Universit&#xe0; degli Studi di Milano, 20133 Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>D'Andrea</LastName><ForeName>Laura</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Biomedicine and Prevention, University of Rome Tor Vergata, 00133 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pacini</LastName><ForeName>Laura</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Biomedicine and Prevention, University of Rome Tor Vergata, 00133 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jacquemont</LastName><ForeName>S&#xe9;bastien</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Service de G&#xe9;n&#xe9;tique M&#xe9;dicale, Centre Hospitalier Universitaire Vaudois, 1011 Lausanne, Switzerland; Department of Psychiatry, University of Montreal, QC H3T 1C5, Canada; Centre de Recherche, Centre Hospitalier Universitaire Sainte Justine, Montr&#xe9;al, QC H3T 1C4, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tassone</LastName><ForeName>Flora</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Biochemistry and Molecular Medicine, UC Davis, Sacramento, CA 95817, USA; MIND Institute, UC Davis Medical Center, Sacramento, CA 95817, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Balschun</LastName><ForeName>Detlef</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Faculty of Psychology and Educational Sciences, Laboratory of Biological Psychology, KU Leuven, 3000 Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dotti</LastName><ForeName>Carlos G</ForeName><Initials>CG</Initials><AffiliationInfo><Affiliation>Center for Human Genetics and Leuven Research Institute for Neuroscience and Disease (LIND), KU Leuven, 3000 Leuven, Belgium; VIB Center for the Biology of Disease, 3000 Leuven, Belgium; Centro de Biolog&#xed;a Molecular Severo Ochoa, CSIC/UAM, 28049 Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Callaerts-Vegh</LastName><ForeName>Zsuzsanna</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Faculty of Psychology and Educational Sciences, Laboratory of Biological Psychology, KU Leuven, 3000 Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>D'Hooge</LastName><ForeName>Rudi</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Faculty of Psychology and Educational Sciences, Laboratory of Biological Psychology, KU Leuven, 3000 Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>M&#xfc;ller</LastName><ForeName>Ulrike C</ForeName><Initials>UC</Initials><AffiliationInfo><Affiliation>Institute for Pharmacy and Molecular Biotechnology, University of Heidelberg, 69120 Heidelberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Di Luca</LastName><ForeName>Monica</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Dipartimento di Scienze Farmacologiche e Biomolecolari and Centre of Excellence on Neurodegenerative Diseases, Universit&#xe0; degli Studi di Milano, 20133 Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Strooper</LastName><ForeName>Bart</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Center for Human Genetics and Leuven Research Institute for Neuroscience and Disease (LIND), KU Leuven, 3000 Leuven, Belgium; VIB Center for the Biology of Disease, 3000 Leuven, Belgium; UCL Institute of Neurology, Queen Square, WC1N 3BG London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bagni</LastName><ForeName>Claudia</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Center for Human Genetics and Leuven Research Institute for Neuroscience and Disease (LIND), KU Leuven, 3000 Leuven, Belgium; VIB Center for the Biology of Disease, 3000 Leuven, Belgium; Department of Biomedicine and Prevention, University of Rome Tor Vergata, 00133 Rome, Italy. Electronic address: claudia.bagni@cme.vib-kuleuven.be.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neuron</MedlineTA><NlmUniqueID>8809320</NlmUniqueID><ISSNLinking>0896-6273</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008565">Membrane Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C485184">enhanced green fluorescent protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>147336-22-9</RegistryNumber><NameOfSubstance UI="D049452">Green Fluorescent Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.24.-</RegistryNumber><NameOfSubstance UI="D051722">ADAM Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.24.81</RegistryNumber><NameOfSubstance UI="D000072197">ADAM10 Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.24.81</RegistryNumber><NameOfSubstance UI="C491236">ADAM10 protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>Neuron. 2015 Aug 19;87(4):908</RefSource></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D051722" MajorTopicYN="N">ADAM Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000072197" MajorTopicYN="N">ADAM10 Protein</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053829" MajorTopicYN="N">Amyloid Precursor Protein Secretases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000831" MajorTopicYN="N">Animals, Newborn</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002540" MajorTopicYN="N">Cerebral Cortex</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005600" MajorTopicYN="N">Fragile X Syndrome</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005786" MajorTopicYN="N">Gene Expression Regulation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D049452" MajorTopicYN="N">Green Fluorescent Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008565" MajorTopicYN="N">Membrane Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013569" MajorTopicYN="N">Synapses</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2013</Year><Month>11</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2015</Year><Month>4</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>6</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>7</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>7</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>9</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26182420</ArticleId><ArticleId IdType="doi">10.1016/j.neuron.2015.06.032</ArticleId><ArticleId IdType="pii">S0896-6273(15)00595-4</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">10880397</PMID><DateCompleted><Year>2000</Year><Month>08</Month><Day>08</Day></DateCompleted><DateRevised><Year>2024</Year><Month>12</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0002-9440</ISSN><JournalIssue CitedMedium="Print"><Volume>157</Volume><Issue>1</Issue><PubDate><Year>2000</Year><Month>Jul</Month></PubDate></JournalIssue><Title>The American journal of pathology</Title><ISOAbbreviation>Am J Pathol</ISOAbbreviation></Journal><ArticleTitle>Endocytic pathway abnormalities precede amyloid beta deposition in sporadic Alzheimer's disease and Down syndrome: differential effects of APOE genotype and presenilin mutations.</ArticleTitle><Pagination><StartPage>277</StartPage><EndPage>286</EndPage><MedlinePgn>277-86</MedlinePgn></Pagination><Abstract><AbstractText>Endocytosis is critical to the function and fate of molecules important to Alzheimer's disease (AD) etiology, including the beta protein precursor (betaPP), amyloid beta (Abeta) peptide, and apolipoprotein E (ApoE). Early endosomes, a major site of Abeta peptide generation, are markedly enlarged within neurons in the Alzheimer brain, suggesting altered endocytic pathway (EP) activity. Here, we show that neuronal EP activation is a specific and very early response in AD. To evaluate endocytic activation, we used markers of internalization (rab5, rabaptin 5) and recycling (rab4), and found that enlargement of rab5-positive early endosomes in the AD brain was associated with elevated levels of rab4 immunoreactive protein and translocation of rabaptin 5 to endosomes, implying that both endocytic uptake and recycling are activated. These abnormalities were evident in pyramidal neurons of the neocortex at preclinical stages of disease when Alzheimer-like neuropathology, such as Abeta deposition, was restricted to the entorhinal region. In Down syndrome, early endosomes were significantly enlarged in some pyramidal neurons as early as 28 weeks of gestation, decades before classical AD neuropathology develops. Markers of EP activity were only minimally influenced by normal aging and other neurodegenerative diseases studied. Inheritance of the epsilon4 allele of APOE, however, accentuated early endosome enlargement at preclinical stages of AD. By contrast, endosomes were normal in size at advanced stages of familial AD caused by mutations of presenilin 1 or 2, indicating that altered endocytosis is not a consequence of Abeta deposition. These results identify EP activation as the earliest known intraneuronal change to occur in sporadic AD, the most common form of AD. Given the important role of the EP in Abeta peptide generation and ApoE function, early endosomal abnormalities provide a mechanistic link between EP alterations, genetic susceptibility factors, and Abeta generation and suggest differences that may be involved in Abeta generation and beta amyloidogenesis in subtypes of AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cataldo</LastName><ForeName>A M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Nathan S. Kline Institute for Psychiatric Research, Orangeburg, NY 10962, USA. catalado@nki.rfmh.org</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peterhoff</LastName><ForeName>C M</ForeName><Initials>CM</Initials></Author><Author ValidYN="Y"><LastName>Troncoso</LastName><ForeName>J C</ForeName><Initials>JC</Initials></Author><Author ValidYN="Y"><LastName>Gomez-Isla</LastName><ForeName>T</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Hyman</LastName><ForeName>B T</ForeName><Initials>BT</Initials></Author><Author ValidYN="Y"><LastName>Nixon</LastName><ForeName>R A</ForeName><Initials>RA</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>AG 10916</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG14762</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Pathol</MedlineTA><NlmUniqueID>0370502</NlmUniqueID><ISSNLinking>0002-9440</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001057">Apolipoproteins E</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008565">Membrane Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C508853">PSEN1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C508861">PSEN2 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053764">Presenilin-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053766">Presenilin-2</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.6.5.2</RegistryNumber><NameOfSubstance UI="D020696">rab5 GTP-Binding Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001057" MajorTopicYN="N">Apolipoproteins E</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004314" MajorTopicYN="N">Down Syndrome</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004705" MajorTopicYN="Y">Endocytosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011992" MajorTopicYN="N">Endosomes</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005333" MajorTopicYN="N">Fetus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005865" MajorTopicYN="N">Gestational Age</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007150" MajorTopicYN="N">Immunohistochemistry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007231" MajorTopicYN="N">Infant, Newborn</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008565" MajorTopicYN="N">Membrane Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="N">Neurodegenerative Diseases</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053764" MajorTopicYN="N">Presenilin-1</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053766" MajorTopicYN="N">Presenilin-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020696" MajorTopicYN="N">rab5 GTP-Binding Proteins</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2000</Year><Month>7</Month><Day>6</Day><Hour>11</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2000</Year><Month>8</Month><Day>12</Day><Hour>11</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2000</Year><Month>7</Month><Day>6</Day><Hour>11</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2001</Year><Month>1</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10880397</ArticleId><ArticleId IdType="pmc">PMC1850219</ArticleId><ArticleId IdType="doi">10.1016/s0002-9440(10)64538-5</ArticleId><ArticleId IdType="pii">S0002-9440(10)64538-5</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Chyung ASC, Greenberg BD, Cook DG, Doms RW, Lee VM: Novel beta-secretase cleavage of beta-amyloid precursor protein in the endoplasmic reticulum/intermediate compartment of NT2N cells. J Cell Biol 1997, 138:671-680</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2141643</ArticleId><ArticleId IdType="pubmed">9245794</ArticleId></ArticleIdList></Reference><Reference><Citation>Cook DG, Forman MS, Sung JC, Leight S, Kolson DL, Iwatsubo T, Lee VM, Doms RW: Alzheimer&#x2019;s A beta(1&#x2013;42) is generated in the endoplasmic reticulum/intermediate compartment of NT2N cells. Nat Med 1997, 3:1021-1023</Citation><ArticleIdList><ArticleId IdType="pubmed">9288730</ArticleId></ArticleIdList></Reference><Reference><Citation>Hartmann H, Busciglio J, Baumann KH, Staufenbiel M, Yankner BA: Developmental regulation of presenilin-1 processing in the brain suggests a role in neuronal differentiation. J Biol Chem 1997, 272:14505-14508</Citation><ArticleIdList><ArticleId IdType="pubmed">9169406</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia W, Zhang J, Ostaszewski BL, Kimberly WT, Seubert P, Koo EH, Shen J, Selkoe DJ: Presenilin 1 regulates the processing of beta-amyloid precursor protein C-terminal fragments and the generation of amyloid beta-protein in endoplasmic reticulum and Golgi. Biochemistry 1998, 37:16465-16471</Citation><ArticleIdList><ArticleId IdType="pubmed">9843412</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu H, Sweeney D, Wang R, Thinakaran G, Lo AC, Sisodia SS, Greengard P, Gandy S: Generation of Alzheimer beta-amyloid protein in the trans-Golgi network in the apparent absence of vesicle formation. Proc Natl Acad Sci USA 1997, 94:3748-3752</Citation><ArticleIdList><ArticleId IdType="pmc">PMC20512</ArticleId><ArticleId IdType="pubmed">9108049</ArticleId></ArticleIdList></Reference><Reference><Citation>Tomita S, Kirino Y, Suzuki T: Cleavage of Alzheimer&#x2019;s amyloid precursor protein (APP) by secretases occurs after O-glycosylation of APP in the protein secretory pathway. Identification of intracellular compartments in which APP cleavage occurs without using toxic agents that interfere with protein metabolism. J Biol Chem 1998, 273:6277-6284</Citation><ArticleIdList><ArticleId IdType="pubmed">9497354</ArticleId></ArticleIdList></Reference><Reference><Citation>Thinakaran G, Borchelt DR, Lee MK, Slunt HH, Spitzer L, Kim G, Ratovitsky T, Davenport F, Nordstedt C, Seeger M, Hardy J, Levey AI, Gandy SE, Jenkins NA, Copeland NG, Price DL, Sisodia SS: Endoproteolysis of presenilin 1 and accumulation of processed derivatives in vivo. Neuron 1996, 17:181-190</Citation><ArticleIdList><ArticleId IdType="pubmed">8755489</ArticleId></ArticleIdList></Reference><Reference><Citation>Peraus GC, Masters CL, Beyreuther K: Late compartments of amyloid precursor protein transport in SY5Y cells are involved in beta-amyloid secretion. J Neurosci 1997, 17:7714-7724</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6793894</ArticleId><ArticleId IdType="pubmed">9315893</ArticleId></ArticleIdList></Reference><Reference><Citation>Haass C, Koo EH, Mellon A, Hung AY, Selkoe DJ: Targeting of cell-surface beta-amyloid precursor protein to lysosomes: alternative processing into amyloid-bearing fragments. Nature 1992, 357:500-503</Citation><ArticleIdList><ArticleId IdType="pubmed">1608449</ArticleId></ArticleIdList></Reference><Reference><Citation>Koo EH, Squazzo SL: Evidence that production and release of amyloid beta-protein involves the endocytic pathway. J Biol Chem 1994, 269:17386-17389</Citation><ArticleIdList><ArticleId IdType="pubmed">8021238</ArticleId></ArticleIdList></Reference><Reference><Citation>Soriano S, Chyung AS, Chen X, Stokin GB, Lee VM, Koo EH: Expression of beta-amyloid precursor protein-CD3gamma chimeras to demonstrate the selective generation of amyloid beta(1&#x2013;40) and amyloid beta(1&#x2013;42) peptides within secretory and endocytic compartments. J Biol Chem 1999, 274:32295-32300</Citation><ArticleIdList><ArticleId IdType="pubmed">10542269</ArticleId></ArticleIdList></Reference><Reference><Citation>Stokin GB, Chyung ASC, Perez RG, Lee VMY, Koo E: The Pathway of Alpha-Beta 42 Production in APP with Codon 717 Mutation. 1998. Sixth International Conference on Alzheimer&#x2019;s Disease, Amsterdam</Citation></Reference><Reference><Citation>Gorvel JP, Chavrier P, Zerial M, Gruenberg J: rab5 controls early endosome fusion in vitro. Cell 1991, 64:915-925</Citation><ArticleIdList><ArticleId IdType="pubmed">1900457</ArticleId></ArticleIdList></Reference><Reference><Citation>Bucci C, Parton RG, Mather IH, Stunnenberg H, Simons K, Hoflack B, Zerial M: The small GTPase rab5 functions as a regulatory factor in the early endocytic pathway. Cell 1992, 70:715-728</Citation><ArticleIdList><ArticleId IdType="pubmed">1516130</ArticleId></ArticleIdList></Reference><Reference><Citation>Cataldo AM, Barnett JL, Pieroni C, Nixon RA: Increased neuronal endocytosis and protease delivery to early endosomes in sporadic Alzheimer&#x2019;s disease: neuropathologic evidence for a mechanism of increased beta-amyloidogenesis. J Neurosci 1997, 17:6142-6151</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6568334</ArticleId><ArticleId IdType="pubmed">9236226</ArticleId></ArticleIdList></Reference><Reference><Citation>Chevallier N, Vizzavona J, Marambaud P, Baur CP, Spillantini M, Fulcrand P, Martinez J, Goedert M, Vincent JP, Checler F: Cathepsin D displays in vitro beta-secretase-like specificity. Brain Res 1997, 750:11-19</Citation><ArticleIdList><ArticleId IdType="pubmed">9098524</ArticleId></ArticleIdList></Reference><Reference><Citation>Dreyer RN, Bausch KM, Fracasso P, Hammond LJ, Wunderlich D, Wirak DO, Davis G, Brini CM, Buckholz TM, Konig G, Kamarck ME, Tamburini PP: Processing of the pre-beta-amyloid protein by cathepsin D is enhanced by a familial Alzheimer&#x2019;s disease mutation. Eur J Biochem 1994, 224:265-271</Citation><ArticleIdList><ArticleId IdType="pubmed">7523115</ArticleId></ArticleIdList></Reference><Reference><Citation>Evin G, Cappai R, Li QX, Culvenor JG, Small DH, Beyreuther K, Masters CL: Candidate gamma-secretases in the generation of the carboxyl terminus of the Alzheimer&#x2019;s disease beta A4 amyloid: possible involvement of cathepsin D. Biochemistry 1995, 34:14185-14192</Citation><ArticleIdList><ArticleId IdType="pubmed">7578016</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackay EA, Ehrhard A, Moniatte M, Guenet C, Tardif C, Tarnus C, Sorokine O, Heintzelmann B, Nay C, Remy JM, Higaki J, Van Dorsselaer A, Wagner J, Danzin C, Mamont P: A possible role for ca-thepsins D, E, and B in the processing of beta-amyloid precursor protein in Alzheimer&#x2019;s disease. Eur J Biochem 1997, 244:414-425</Citation><ArticleIdList><ArticleId IdType="pubmed">9119007</ArticleId></ArticleIdList></Reference><Reference><Citation>Nixon RA, Cataldo AM, Paskevich PA, Hamilton DJ, Wheelock TR, Kanaley-Andrews L: The lysosomal system in neurons. Involvement at multiple stages of Alzheimer&#x2019;s disease pathogenesis. Ann N Y Acad Sci 1992, 674:65-88</Citation><ArticleIdList><ArticleId IdType="pubmed">1288372</ArticleId></ArticleIdList></Reference><Reference><Citation>Cataldo AM, Hamilton DJ, Nixon RA: Lysosomal abnormalities in degenerating neurons link neuronal compromise to senile plaque development in Alzheimer disease. Brain Res 1994, 640:68-80</Citation><ArticleIdList><ArticleId IdType="pubmed">8004466</ArticleId></ArticleIdList></Reference><Reference><Citation>Cataldo AM, Hamilton DJ, Barnett JL, Paskevich PA, Nixon RA: Properties of the endosomal-lysosomal system in the human central nervous system: disturbances mark most neurons in populations at risk to degenerate in Alzheimer&#x2019;s disease. J Neurosci 1996, 16:186-199</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6578706</ArticleId><ArticleId IdType="pubmed">8613784</ArticleId></ArticleIdList></Reference><Reference><Citation>Cataldo AM, Barnett JL, Mann DA, Nixon RA: Colocalization of lysosomal hydrolase and &#x3b2;-amyloid diffuse plaques of Alzheimer&#x2019;s disease and Down&#x2019;s syndrome brains. J Neuropath Exp Neurol 1996, 55:704-715</Citation><ArticleIdList><ArticleId IdType="pubmed">8642396</ArticleId></ArticleIdList></Reference><Reference><Citation>Nixon RA, Cataldo AM, Mathews PM, Mohan P: Abnormalities of the endosomal-lysosomal system in Alzheimer&#x2019;s disease as potential therapeutic targets. Neurobiol Aging 1998, 19:S136</Citation></Reference><Reference><Citation>Borchelt DR, Thinarkaran G, Eckman CB, Lee MK, Davenport F, Ratovitsky T, Prada CM, Kim G, Seekins S, Yager D, Slunt HH, Wang R, Seeger M, Levey AI, Gandy SE, Copeland NG, Jenkins NA, Price DL, Younkin SG, Sisodia SS: Familial Alzheimer&#x2019;s disease-linked presenilin 1 variants elevate Abeta1&#x2013;42/1&#x2013;40 ratio in vitro and in vivo. Neuron 1996, 17:1005-1013</Citation><ArticleIdList><ArticleId IdType="pubmed">8938131</ArticleId></ArticleIdList></Reference><Reference><Citation>Mann DM, Iwatsubo T, Cairns NJ, Lantos PL, Nochlin D, Sumi SM, Bird TD, Poorkaj P, Hardy J, Hutton M, Prihar G, Crook R, Rossor MN, Haltia M: Amyloid beta protein (Abeta) deposition in chromosome 14-linked Alzheimer&#x2019;s disease: predominance of Abeta42(43). Ann Neurol 1996, 40:149-156</Citation><ArticleIdList><ArticleId IdType="pubmed">8773595</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang AJ, Chandswangbhuvava D, Margol L, Glabe CG: Loss of endosomal/lysosomal membrane impermeability is an early event in amyloid Abeta1&#x2013;42 pathogenesis. J Neurosci Res 1998, 52:691-698</Citation><ArticleIdList><ArticleId IdType="pubmed">9669318</ArticleId></ArticleIdList></Reference><Reference><Citation>Lai F, Kammann E, Rebeck GW, Anderson A, Chen Y, Nixon RA: APOE genotype and gender effects on Alzheimer disease in 100 adults with Down syndrome. Neurology 1999, 53:331-336</Citation><ArticleIdList><ArticleId IdType="pubmed">10430422</ArticleId></ArticleIdList></Reference><Reference><Citation>Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, Roses AD, Haines JL, Pericak-Vance MA: Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer&#x2019;s disease in late onset families [see comments]. Science 1993, 261:921-923</Citation><ArticleIdList><ArticleId IdType="pubmed">8346443</ArticleId></ArticleIdList></Reference><Reference><Citation>Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ, Brownlee LM, Vogel FS, Hughes JP, van Belle G, Berg L: The Consortium to Establish a Registry for Alzheimer&#x2019;s Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer&#x2019;s disease. Neurology 1991, 41:479-486</Citation><ArticleIdList><ArticleId IdType="pubmed">2011243</ArticleId></ArticleIdList></Reference><Reference><Citation>Mirra SS, Hart MN, Terry RD: Making the diagnosis of Alzheimer&#x2019;s disease. Arch Path Lab Med 1993, 117:132-144</Citation><ArticleIdList><ArticleId IdType="pubmed">8427562</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E: Neuropathological staging of Alzheimer-related changes. Acta Neuropathol 1991, 82:239-259</Citation><ArticleIdList><ArticleId IdType="pubmed">1759558</ArticleId></ArticleIdList></Reference><Reference><Citation>Hyman BT, West HL, Rebeck GW, Lai F, Mann DA: Neuropathological changes in Down syndrome hippocampal formation: effect of age and apolipoprotein E genotype. Arch Neurol 1995, 52:373-378</Citation><ArticleIdList><ArticleId IdType="pubmed">7710373</ArticleId></ArticleIdList></Reference><Reference><Citation>Cataldo AM, Thayer CY, Bird ED, Wheelock TR, Nixon RA: Lysosomal proteinase antigens are prominently localized within senile plaques of Alzheimer&#x2019;s disease: evidence for a neuronal origin. Brain Res 1990, 513:181-192</Citation><ArticleIdList><ArticleId IdType="pubmed">2350688</ArticleId></ArticleIdList></Reference><Reference><Citation>Jicha GA, Bowser R, Kazam IG, Davies P: Alz-50 and MC-1, a new monoclonal antibody raised to paired helical filaments, recognize conformational epitopes on recombinant tau. J Neurosci Res 1997, 48:128-132</Citation><ArticleIdList><ArticleId IdType="pubmed">9130141</ArticleId></ArticleIdList></Reference><Reference><Citation>Lai MM, Cavanagh D: The molecular biology of coronaviruses. Adv Virus Res 1997, 48:1-100</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7130985</ArticleId><ArticleId IdType="pubmed">9233431</ArticleId></ArticleIdList></Reference><Reference><Citation>Chavrier P, Parton RG, Hauri HP, Simons K, Zerial M: Localization of low molecular weight GTP binding proteins to exocytic and endocytic compartments. Cell 1990, 62:317-329</Citation><ArticleIdList><ArticleId IdType="pubmed">2115402</ArticleId></ArticleIdList></Reference><Reference><Citation>de Hoop MJ, Huber LA, Stenmark H, Williamson E, Zerial M, Parton RG, Dotti CG: The involvement of the small GTP-binding protein Rab5a in neuronal endocytosis. Neuron 1994, 13:11-22</Citation><ArticleIdList><ArticleId IdType="pubmed">8043272</ArticleId></ArticleIdList></Reference><Reference><Citation>Stenmark H, Vitale G, Ullrich O, Zerial M: Rabaptin-5 is a direct effector of the small GTPase Rab5 in endocytic membrane fusion. Cell 1995, 83:423-432</Citation><ArticleIdList><ArticleId IdType="pubmed">8521472</ArticleId></ArticleIdList></Reference><Reference><Citation>Simonsen A, Lippe R, Christoforidis S, Gaullier JM, Brech A, Callaghan J, Toh BH, Murphy C, Zerial M, Stenmark H: EEA1 links PI(3)K function to Rab5 regulation of endosome fusion [see comments]. Nature 1998, 394:494-498</Citation><ArticleIdList><ArticleId IdType="pubmed">9697774</ArticleId></ArticleIdList></Reference><Reference><Citation>Gournier H, Stenmark H, Rybin V, Lippe R, Zerial M: Two distinct effectors of the small GTPase Rab5 cooperate in endocytic membrane fusion. Embo J 1998, 17:1930-1940</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1170539</ArticleId><ArticleId IdType="pubmed">9524116</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Sluijs P, Hull M, Webster P, Male P, Goud B, Mellman I: The small GTP-binding protein rab4 controls an early sorting event on the endocytic pathway. Cell 1992, 70:729-740</Citation><ArticleIdList><ArticleId IdType="pubmed">1516131</ArticleId></ArticleIdList></Reference><Reference><Citation>Slooter AJ, Houwing-Duistermaat JJ, van Harskamp F, Cruts M, Van Broeckhoven C, Breteler MM, Hofman A, Stijnen T, van Duijn CM: Apolipoprotein E genotype and progression of Alzheimer&#x2019;s disease: the Rotterdam Study. J Neurol 1999, 246:304-308</Citation><ArticleIdList><ArticleId IdType="pubmed">10367700</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohm TG, Scharnagl H, Marz W, Bohl J: Apolipoprotein E isoforms and the development of low and high Braak stages of Alzheimer&#x2019;s disease-related lesions. Acta Neuropathol (Berl) 1999, 98:273-280</Citation><ArticleIdList><ArticleId IdType="pubmed">10483785</ArticleId></ArticleIdList></Reference><Reference><Citation>Bucci C, Wandinger-Ness A, Lutcke A, Chiariello M, Bruni CB, Zerial M: Rab5a is a common component of the apical and basolateral endocytic machinery in polarized epithelial cells. Proc Natl Acad Sci USA 1994, 91:5061-5065</Citation><ArticleIdList><ArticleId IdType="pmc">PMC43931</ArticleId><ArticleId IdType="pubmed">8197185</ArticleId></ArticleIdList></Reference><Reference><Citation>Daro E, van der Sluijs P, Galli T, Mellman I: Rab4 and cellubrevin define different early endosome populations on the pathway of transferrin receptor recycling. Proc Natl Acad Sci USA 1996, 93:9559-9564</Citation><ArticleIdList><ArticleId IdType="pmc">PMC38467</ArticleId><ArticleId IdType="pubmed">8790369</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams KR, Saunders AM, Roses AD, Armati PJ: Uptake and internalization of exogenous apolipoprotein E3 by cultured human central nervous system neurons. Neurobiol Dis 1998, 5:271-279</Citation><ArticleIdList><ArticleId IdType="pubmed">9848097</ArticleId></ArticleIdList></Reference><Reference><Citation>Trommsdorff M, Borg JP, Margolis B, Herz J: Interaction of cytosolic adaptor proteins with neuronal apolipoprotein E receptors and the amyloid precursor protein. J Biol Chem 1998, 273:33556-33560</Citation><ArticleIdList><ArticleId IdType="pubmed">9837937</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo Q, Sopher BL, Furukawa K, Pham DG, Robinson N, Martin GM, Mattson MP: Alzheimer&#x2019;s presenilin mutation sensitizes neural cells to apoptosis induced by trophic factor withdrawal and amyloid beta-peptide: involvement of calcium and oxyradicals. J Neurosci 1997, 17:4212-4222</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6573527</ArticleId><ArticleId IdType="pubmed">9151738</ArticleId></ArticleIdList></Reference><Reference><Citation>Begley JG, Duan W, Chan S, Duff K, Mattson MP: Altered calcium homeostasis and mitochondrial dysfunction in cortical synaptic compartments of presenilin-1 mutant mice. J Neurochem 1999, 72:1030-1039</Citation><ArticleIdList><ArticleId IdType="pubmed">10037474</ArticleId></ArticleIdList></Reference><Reference><Citation>Buxbaum JD, Choi EK, Luo Y, Lilliehook C, Crowley AC, Merriam DE, Wasco W: Calsenilin: a calcium-binding protein that interacts with the presenilins and regulates the levels of a presenilin fragment [see comments]. Nat Med 1998, 4:1177-1181</Citation><ArticleIdList><ArticleId IdType="pubmed">9771752</ArticleId></ArticleIdList></Reference><Reference><Citation>Gibson GE, Vestling M, Zhang H, Szolosi S, Alkon D, Lannfelt L, Gandy S, Cowburn RF: Abnormalities in Alzheimer&#x2019;s disease fibroblasts bearing the APP670/671 mutation. Neurobiol Aging 1997, 18:573-580</Citation><ArticleIdList><ArticleId IdType="pubmed">9461055</ArticleId></ArticleIdList></Reference><Reference><Citation>van Broeckhoven C: Presenilins and Alzheimer disease. Nat Genet 1995, 11:230-232</Citation><ArticleIdList><ArticleId IdType="pubmed">7581440</ArticleId></ArticleIdList></Reference><Reference><Citation>Houlden H, Crook R, Backhovens H, Prihar G, Baker M, Hutton M, Rossor M, Martin JJ, Van Broeckhoven C, Hardy J: ApoE genotype is a risk factor in nonpresenilin early-onset Alzheimer&#x2019;s disease families. Am J Med Genet 1998, 81:117-121</Citation><ArticleIdList><ArticleId IdType="pubmed">9514597</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattson MP, Guo Q: Cell and molecular neurobiology of presenilins: a role for the endoplasmic reticulum in the pathogenesis of Alzheimer&#x2019;s disease? J Neurosci Res 1997, 50:505-513</Citation><ArticleIdList><ArticleId IdType="pubmed">9404712</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Uden E, Carlson G, St. George-Hyslop P, Westaway D, Orlando R, Mallory M, Rockenstein E, Masliah E: Aberrant presenilin-1 expression downregulates LDL receptor-related protein (LRP): is LRP central to Alzheimer&#x2019;s disease pathogenesis? Mol Cell Neurosci 1999, 14:129-140</Citation><ArticleIdList><ArticleId IdType="pubmed">10479411</ArticleId></ArticleIdList></Reference><Reference><Citation>Gomez-Isla T, Growden WB, McNamara MJ, Nochlin D, Bird TD, Arango JC, Lopera F, Kosik K, Lantos PL, Cairns NJ, Hyman BT: The impact of different presenilin 1 and presenilin 2 mutations on amyloid deposition, neurofibrillary changes and neuronal loss in the familial Alzheimer&#x2019;s disease brain: evidence for other phenotype-modifying factors. Brain 1999, 122:1709-1719</Citation><ArticleIdList><ArticleId IdType="pubmed">10468510</ArticleId></ArticleIdList></Reference><Reference><Citation>Simpson IA, Chundu KR, Davies-Hill T, Honer WG, Davies P: Decreased concentrations of GLUT1 and GLUT3 glucose transporters in the brains of patients with Alzheimer&#x2019;s disease [see comments]. Ann Neurol 1994, 35:546-551</Citation><ArticleIdList><ArticleId IdType="pubmed">8179300</ArticleId></ArticleIdList></Reference><Reference><Citation>Vannucci SJ, Reinhart R, Maher F, Bondy CA, Lee WH, Vannucci RC, Simpson IA: Alterations in GLUT1 and GLUT3 glucose transporter gene expression following unilateral hypoxia-ischemia in the immature rat brain. Brain Res Dev Brain Res 1998, 107:255-264</Citation><ArticleIdList><ArticleId IdType="pubmed">9593925</ArticleId></ArticleIdList></Reference><Reference><Citation>Frautschy SA, Horn DL, Sigel JJ, Harris-White ME, Mendoza JJ, Yang F, Saido TC, Cole GM: Protease inhibitor coinfusion with amyloid beta-protein results in enhanced deposition and toxicity in rat brain. J Neurosci 1998, 18:8311-8321</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6792856</ArticleId><ArticleId IdType="pubmed">9763475</ArticleId></ArticleIdList></Reference><Reference><Citation>Maher F, Simpson IA: The GLUT3 glucose transporter is the predominant isoform in primary cultured neurons: assessment by biosynthetic and photoaffinity labelling. Biochem J 1994, 301:379-384</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1137091</ArticleId><ArticleId IdType="pubmed">8042980</ArticleId></ArticleIdList></Reference><Reference><Citation>Nixon RA, Cataldo AM: The lysosomal system in neuronal cell death: a review. Ann N Y Acad Sci 1993, 679:87-109</Citation><ArticleIdList><ArticleId IdType="pubmed">8512210</ArticleId></ArticleIdList></Reference><Reference><Citation>Brunk UT, Dalen H, Roberg K, Hellquist HB: Photo-oxidative disruption of lysosomal membranes causes apoptosis of cultured human fibroblasts. Free Radic Biol Med 1997, 23:616-626</Citation><ArticleIdList><ArticleId IdType="pubmed">9215807</ArticleId></ArticleIdList></Reference><Reference><Citation>Fossel ET, Zanella CL, Fletcher JG, Hui KK: Cell death induced by peroxidized low-density lipoprotein: endopepsis. Cancer Res 1994, 54:1240-1248</Citation><ArticleIdList><ArticleId IdType="pubmed">8118812</ArticleId></ArticleIdList></Reference><Reference><Citation>Horner HC, Packan DR, Sapolsky RM: Glucocorticoids inhibit glucose transport in cultured hippocampal neurons and glia. Neuroendocrinology 1990, 52:57-64</Citation><ArticleIdList><ArticleId IdType="pubmed">2118608</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberg K, Ollinger K: Oxidative stress causes relocation of the lysosomal enzyme cathepsin D with ensuing apoptosis in neonatal rat cardiomyocytes. Am J Pathol 1998, 152:1151-1156</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1858594</ArticleId><ArticleId IdType="pubmed">9588882</ArticleId></ArticleIdList></Reference><Reference><Citation>Vassar R, Bennett BD, Babu-Khan S, Khan S, Mendiaz EA, Denis P, Teplow D, Ross S, Amarante P, Loeloff R, Luo Y, Fisher S, Fuller J, Edenson S, Lile J, Jarosinski MA, Biere AL, Curran E, Burgess T, Louis J-C, Collins F, Treanor J, Rogers G, Citron M: &#x3b2;-Secretase cleavage of Alzheimer&#x2019;s amyloid precursor protein by the transmembrane aspartic protease BACE. Science 1999, 286:735-741</Citation><ArticleIdList><ArticleId IdType="pubmed">10531052</ArticleId></ArticleIdList></Reference><Reference><Citation>Nixon RA, Mathews PM, Mohan P, Beard M, Guerra CB, Duff K, Yang A, Cataldo AM: Endosomal-Lysosomal System Abnormalities Differentiate Subtypes of Alzheimer&#x2019;s Disease: Lysosomal System Activation in Trangenic Mouse Models of Familial AD. 1999. New Mexico, Keystone Conference, Taos</Citation></Reference><Reference><Citation>Sinha S, Lieberburg I: Cellular mechanisms of beta-amyloid production and secretion. Proc Natl Acad Sci USA 1999, 96:11049-11053</Citation><ArticleIdList><ArticleId IdType="pmc">PMC34239</ArticleId><ArticleId IdType="pubmed">10500121</ArticleId></ArticleIdList></Reference><Reference><Citation>Siman R: Proteolytic mechanism for the neurodegeneration of Alzheimer&#x2019;s disease. Ann N Y Acad Sci 1992, 674:193-202</Citation><ArticleIdList><ArticleId IdType="pubmed">1288364</ArticleId></ArticleIdList></Reference><Reference><Citation>Siman R, Mistretta S, Durkin JT, Savage MJ, Loh T, Trusko S, Scott RW: Processing of the beta-amyloid precursor. Multiple proteases generate and degrade potentially amyloidogenic fragments. J Biol Chem 1993, 268:16602-16609</Citation><ArticleIdList><ArticleId IdType="pubmed">8344942</ArticleId></ArticleIdList></Reference><Reference><Citation>Schrader-Fischer G, Paganetti PA: Effect of alkalizing agents on the processing of the beta-amyloid precursor protein. Brain Res 1996, 716:91-100</Citation><ArticleIdList><ArticleId IdType="pubmed">8738224</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ, Yamazaki T, Citron M, Podlisny MB, Koo EH, Teplow DB, Haass C: The role of APP processing and trafficking pathways in the formation of amyloid beta-protein. Ann N Y Acad Sci 1996, 777:57-64</Citation><ArticleIdList><ArticleId IdType="pubmed">8624127</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">26194181</PMID><DateCompleted><Year>2017</Year><Month>01</Month><Day>10</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1476-5578</ISSN><JournalIssue CitedMedium="Internet"><Volume>21</Volume><Issue>5</Issue><PubDate><Year>2016</Year><Month>May</Month></PubDate></JournalIssue><Title>Molecular psychiatry</Title><ISOAbbreviation>Mol Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Evidence that the rab5 effector APPL1 mediates APP-&#x3b2;CTF-induced dysfunction of endosomes in Down syndrome and Alzheimer's disease.</ArticleTitle><Pagination><StartPage>707</StartPage><EndPage>716</EndPage><MedlinePgn>707-16</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/mp.2015.97</ELocationID><Abstract><AbstractText>&#x3b2;-Amyloid precursor protein (APP) and its cleaved products are strongly implicated in Alzheimer's disease (AD). Endosomes are highly active APP processing sites, and endosome anomalies associated with upregulated expression of early endosomal regulator, rab5, are the earliest known disease-specific neuronal response in AD. Here, we show that the rab5 effector APPL1 (adaptor protein containing pleckstrin homology domain, phosphotyrosine binding domain and leucine zipper motif) mediates rab5 overactivation in Down syndrome (DS) and AD, which is caused by elevated levels of the &#x3b2;-cleaved carboxy-terminal fragment of APP (&#x3b2;CTF). &#x3b2;CTF recruits APPL1 to rab5 endosomes, where it stabilizes active GTP-rab5, leading to pathologically accelerated endocytosis, endosome swelling and selectively impaired axonal transport of rab5 endosomes. In DS fibroblasts, APPL1 knockdown corrects these endosomal anomalies. &#x3b2;CTF levels are also elevated in AD brain, which is accompanied by abnormally high recruitment of APPL1 to rab5 endosomes as seen in DS fibroblasts. These studies indicate that persistent rab5 overactivation through &#x3b2;CTF-APPL1 interactions constitutes a novel APP-dependent pathogenic pathway in AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>S</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Cellular and Molecular Biology Training Program, New York University School of Medicine, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sato</LastName><ForeName>Y</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Center for Dementia Research, Nathan S Kline Institute for Psychiatric Research, Orangeburg, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mohan</LastName><ForeName>P S</ForeName><Initials>PS</Initials><AffiliationInfo><Affiliation>Center for Dementia Research, Nathan S Kline Institute for Psychiatric Research, Orangeburg, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, New York University School of Medicine, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peterhoff</LastName><ForeName>C</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Center for Dementia Research, Nathan S Kline Institute for Psychiatric Research, Orangeburg, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pensalfini</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Center for Dementia Research, Nathan S Kline Institute for Psychiatric Research, Orangeburg, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rigoglioso</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Cell Biology, New York University School of Medicine, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jiang</LastName><ForeName>Y</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Center for Dementia Research, Nathan S Kline Institute for Psychiatric Research, Orangeburg, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, New York University School of Medicine, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nixon</LastName><ForeName>R A</ForeName><Initials>RA</Initials><AffiliationInfo><Affiliation>Center for Dementia Research, Nathan S Kline Institute for Psychiatric Research, Orangeburg, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, New York University School of Medicine, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cell Biology, New York University School of Medicine, New York, NY, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P01 AG017617</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R24 MH068855</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>5R24MH068855</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01AG017617</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>07</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Mol Psychiatry</MedlineTA><NlmUniqueID>9607835</NlmUniqueID><ISSNLinking>1359-4184</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C545487">APP protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C464801">APPL1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D048868">Adaptor Proteins, Signal Transducing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>86-01-1</RegistryNumber><NameOfSubstance UI="D006160">Guanosine Triphosphate</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.6.1.-</RegistryNumber><NameOfSubstance UI="C427755">RAB5C protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.6.5.2</RegistryNumber><NameOfSubstance UI="D020696">rab5 GTP-Binding Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D048868" MajorTopicYN="N">Adaptor Proteins, Signal Transducing</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004314" MajorTopicYN="N">Down Syndrome</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011992" MajorTopicYN="N">Endosomes</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005347" MajorTopicYN="N">Fibroblasts</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055785" MajorTopicYN="N">Gene Knockdown Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006160" MajorTopicYN="N">Guanosine Triphosphate</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057809" MajorTopicYN="N">HEK293 Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020696" MajorTopicYN="N">rab5 GTP-Binding Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>1</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2015</Year><Month>5</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>6</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>7</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>7</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>1</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2017</Year><Month>5</Month><Day>3</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26194181</ArticleId><ArticleId IdType="mid">NIHMS696690</ArticleId><ArticleId IdType="pmc">PMC4721948</ArticleId><ArticleId IdType="doi">10.1038/mp.2015.97</ArticleId><ArticleId IdType="pii">mp201597</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Pimplikar SW, Nixon RA, Robakis NK, Shen J, Tsai LH. Amyloid-independent mechanisms in Alzheimer's disease pathogenesis. J Neurosci 2010; 30: 14946&#x2013;14954.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3426835</ArticleId><ArticleId IdType="pubmed">21068297</ArticleId></ArticleIdList></Reference><Reference><Citation>Krstic D, Knuesel I. Deciphering the mechanism underlying late-onset Alzheimer disease. Nat Rev Neurol 2013; 9: 25&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">23183882</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang Y, Mullaney KA, Peterhoff CM, Che S, Schmidt SD, Boyer-Boiteau A et al. Alzheimer's-related endosome dysfunction in Down syndrome is A{beta}-independent but requires APP and is reversed by BACE-1 inhibition. Proc Natl Acad Sci USA 2010; 107: 1630&#x2013;1635.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2824382</ArticleId><ArticleId IdType="pubmed">20080541</ArticleId></ArticleIdList></Reference><Reference><Citation>Israel MA, Yuan SH, Bardy C, Reyna SM, Mu Y, Herrera C et al. Probing sporadic and familial Alzheimer's disease using induced pluripotent stem cells. Nature 2012; 482: 216&#x2013;220.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3338985</ArticleId><ArticleId IdType="pubmed">22278060</ArticleId></ArticleIdList></Reference><Reference><Citation>Rhinn H, Fujita R, Qiang L, Cheng R, Lee JH, Abeliovich A. Integrative genomics identifies APOE epsilon4 effectors in Alzheimer's disease. Nature 2013; 500: 45&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pubmed">23883936</ArticleId></ArticleIdList></Reference><Reference><Citation>Nixon RA. The role of autophagy in neurodegenerative disease. Nat Med 2013; 19: 983&#x2013;997.</Citation><ArticleIdList><ArticleId IdType="pubmed">23921753</ArticleId></ArticleIdList></Reference><Reference><Citation>Ginsberg SD, Alldred MJ, Counts SE, Cataldo AM, Neve RL, Jiang Y et al. Microarray analysis of hippocampal CA1 neurons implicates early endosomal dysfunction during Alzheimer's disease progression. Biol Psychiatry 2010; 68: 885&#x2013;893.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2965820</ArticleId><ArticleId IdType="pubmed">20655510</ArticleId></ArticleIdList></Reference><Reference><Citation>Cataldo AM, Peterhoff CM, Troncoso JC, Gomez-Isla T, Hyman BT, Nixon RA. Endocytic pathway abnormalities precede amyloid beta deposition in sporadic Alzheimer's disease and Down syndrome: differential effects of APOE genotype and presenilin mutations. Am J Pathol 2000; 157: 277&#x2013;286.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1850219</ArticleId><ArticleId IdType="pubmed">10880397</ArticleId></ArticleIdList></Reference><Reference><Citation>Cataldo AM, Mathews PM, Boiteau AB, Hassinger LC, Peterhoff CM, Jiang Y et al. Down syndrome fibroblast model of Alzheimer-related endosome pathology: accelerated endocytosis promotes late endocytic defects. Am J Pathol 2008; 173: 370&#x2013;384.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2475775</ArticleId><ArticleId IdType="pubmed">18535180</ArticleId></ArticleIdList></Reference><Reference><Citation>Laifenfeld D, Patzek LJ, McPhie DL, Chen Y, Levites Y, Cataldo AM et al. Rab5 mediates an amyloid precursor protein signaling pathway that leads to apoptosis. J Neurosci 2007; 27: 7141&#x2013;7153.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6794581</ArticleId><ArticleId IdType="pubmed">17611268</ArticleId></ArticleIdList></Reference><Reference><Citation>Salehi A, Delcroix JD, Belichenko PV, Zhan K, Wu C, Valletta JS et al. Increased App expression in a mouse model of Down's syndrome disrupts NGF transport and causes cholinergic neuron degeneration. Neuron 2006; 51: 29&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pubmed">16815330</ArticleId></ArticleIdList></Reference><Reference><Citation>Ng EL, Tang BL. Rab GTPases and their roles in brain neurons and glia. Brain Res Rev 2008; 58: 236&#x2013;246.</Citation><ArticleIdList><ArticleId IdType="pubmed">18485483</ArticleId></ArticleIdList></Reference><Reference><Citation>Miaczynska M, Christoforidis S, Giner A, Shevchenko A, Uttenweiler-Joseph S, Habermann B et al. APPL proteins link Rab5 to nuclear signal transduction via an endosomal compartment. Cell 2004; 116: 445&#x2013;456.</Citation><ArticleIdList><ArticleId IdType="pubmed">15016378</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu G, Chen J, Liu J, Brunzelle JS, Huang B, Wakeham N et al. Structure of the APPL1 BAR-PH domain and characterization of its interaction with Rab5. EMBO J 2007; 26: 3484&#x2013;3493.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1933402</ArticleId><ArticleId IdType="pubmed">17581628</ArticleId></ArticleIdList></Reference><Reference><Citation>Zoncu R, Perera RM, Balkin DM, Pirruccello M, Toomre D, De Camilli P. A phosphoinositide switch controls the maturation and signaling properties of APPL endosomes. Cell 2009; 136: 1110&#x2013;1121.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2705806</ArticleId><ArticleId IdType="pubmed">19303853</ArticleId></ArticleIdList></Reference><Reference><Citation>Hupalowska A, Pyrzynska B, Miaczynska M. APPL1 regulates basal NF-kappaB activity by stabilizing NIK. J Cell Sci 2012; 125: 4090&#x2013;4102.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3482318</ArticleId><ArticleId IdType="pubmed">22685329</ArticleId></ArticleIdList></Reference><Reference><Citation>Bohdanowicz M, Balkin DM, De Camilli P, Grinstein S. Recruitment of OCRL and Inpp5B to phagosomes by Rab5 and APPL1 depletes phosphoinositides and attenuates Akt signaling. Mol Biol Cell 2012; 23: 176&#x2013;187.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3248896</ArticleId><ArticleId IdType="pubmed">22072788</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee JR, Hahn HS, Kim YH, Nguyen HH, Yang JM, Kang JS et al. Adaptor protein containing PH domain, PTB domain and leucine zipper (APPL1) regulates the protein level of EGFR by modulating its trafficking. Biochem Biophys Res Commun 2011; 415: 206&#x2013;211.</Citation><ArticleIdList><ArticleId IdType="pubmed">22037462</ArticleId></ArticleIdList></Reference><Reference><Citation>Stenmark H. Rab GTPases as coordinators of vesicle traffic. Nat Rev Mol Cell Biol 2009; 10: 513&#x2013;525.</Citation><ArticleIdList><ArticleId IdType="pubmed">19603039</ArticleId></ArticleIdList></Reference><Reference><Citation>Cossec JC, Simon A, Marquer C, Moldrich RX, Leterrier C, Rossier J et al. Clathrin-dependent APP endocytosis and Abeta secretion are highly sensitive to the level of plasma membrane cholesterol. Biochim Biophys Acta 2010; 1801: 846&#x2013;852.</Citation><ArticleIdList><ArticleId IdType="pubmed">20580937</ArticleId></ArticleIdList></Reference><Reference><Citation>Engidawork E, Gulesserian T, Seidl R, Cairns N, Lubec G. Expression of apoptosis related proteins: RAIDD, ZIP kinase, Bim/BOD, p21, Bax, Bcl-2 and NF-kappaB in brains of patients with Down syndrome. J Neural Transm Suppl 2001; 61: 181&#x2013;192.</Citation><ArticleIdList><ArticleId IdType="pubmed">11771742</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee S, Sato Y, Nixon RA. Lysosomal proteolysis inhibition selectively disrupts axonal transport of degradative organelles and causes an Alzheimer's-like axonal dystrophy. J Neurosci 2011; 31: 7817&#x2013;7830.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3351137</ArticleId><ArticleId IdType="pubmed">21613495</ArticleId></ArticleIdList></Reference><Reference><Citation>Vieira OV, Bucci C, Harrison RE, Trimble WS, Lanzetti L, Gruenberg J et al. Modulation of Rab5 and Rab7 recruitment to phagosomes by phosphatidylinositol 3-kinase. Mol Cell Biol 2003; 23: 2501&#x2013;2514.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC150733</ArticleId><ArticleId IdType="pubmed">12640132</ArticleId></ArticleIdList></Reference><Reference><Citation>Bucci C, Parton RG, Mather IH, Stunnenberg H, Simons K, Hoflack B et al. The small GTPase rab5 functions as a regulatory factor in the early endocytic pathway. Cell 1992; 70: 715&#x2013;728.</Citation><ArticleIdList><ArticleId IdType="pubmed">1516130</ArticleId></ArticleIdList></Reference><Reference><Citation>Stenmark H, Parton RG, Steele-Mortimer O, Lutcke A, Gruenberg J, Zerial M. Inhibition of rab5 GTPase activity stimulates membrane fusion in endocytosis. Embo J 1994; 13: 1287&#x2013;1296.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC394944</ArticleId><ArticleId IdType="pubmed">8137813</ArticleId></ArticleIdList></Reference><Reference><Citation>Citron M, Teplow DB, Selkoe DJ. Generation of amyloid beta protein from its precursor is sequence specific. Neuron 1995; 14: 661&#x2013;670.</Citation><ArticleIdList><ArticleId IdType="pubmed">7695913</ArticleId></ArticleIdList></Reference><Reference><Citation>Cataldo AM, Barnett JL, Pieroni C, Nixon RA. Increased neuronal endocytosis and protease delivery to early endosomes in sporadic Alzheimer's disease: neuropathologic evidence for a mechanism of increased beta-amyloidogenesis. J Neurosci 1997; 17: 6142&#x2013;6151.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6568334</ArticleId><ArticleId IdType="pubmed">9236226</ArticleId></ArticleIdList></Reference><Reference><Citation>Tamayev R, Zhou D, D'Adamio L. The interactome of the amyloid beta precursor protein family members is shaped by phosphorylation of their intracellular domains. Mol Neurodegener 2009; 4: 28.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2723102</ArticleId><ArticleId IdType="pubmed">19602287</ArticleId></ArticleIdList></Reference><Reference><Citation>Chial HJ, Wu R, Ustach CV, McPhail LC, Mobley WC, Chen YQ. Membrane targeting by APPL1 and APPL2: dynamic scaffolds that oligomerize and bind phosphoinositides. Traffic 2008; 9: 215&#x2013;229.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3810297</ArticleId><ArticleId IdType="pubmed">18034774</ArticleId></ArticleIdList></Reference><Reference><Citation>Ogawa A, Yamazaki Y, Nakamori M, Takahashi T, Kurashige T, Hiji M et al. Characterization and distribution of adaptor protein containing a PH domain, PTB domain and leucine zipper motif (APPL1) in Alzheimer's disease hippocampus: an immunohistochemical study. Brain Res 2012; 1494: 118&#x2013;124.</Citation><ArticleIdList><ArticleId IdType="pubmed">23246927</ArticleId></ArticleIdList></Reference><Reference><Citation>Perez RG, Soriano S, Hayes JD, Ostaszewski B, Xia W, Selkoe DJ et al. Mutagenesis identifies new signals for beta-amyloid precursor protein endocytosis, turnover, and the generation of secreted fragments, including Abeta42. J Biol Chem 1999; 274: 18851&#x2013;18856.</Citation><ArticleIdList><ArticleId IdType="pubmed">10383380</ArticleId></ArticleIdList></Reference><Reference><Citation>Young-Pearse TL, Bai J, Chang R, Zheng JB, LoTurco JJ, Selkoe DJ. A critical function for beta-amyloid precursor protein in neuronal migration revealed by in utero RNA interference. J Neurosci 2007; 27: 14459&#x2013;14469.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6673432</ArticleId><ArticleId IdType="pubmed">18160654</ArticleId></ArticleIdList></Reference><Reference><Citation>Borg JP, Ooi J, Levy E, Margolis B. The phosphotyrosine interaction domains of X11 and FE65 bind to distinct sites on the YENPTY motif of amyloid precursor protein. Mol Cell Biol 1996; 16: 6229&#x2013;6241.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC231626</ArticleId><ArticleId IdType="pubmed">8887653</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y, Liu W, McPhie DL, Hassinger L, Neve RL. APP-BP1 mediates APP-induced apoptosis and DNA synthesis and is increased in Alzheimer's disease brain. J Cell Biol 2003; 163: 27&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2173435</ArticleId><ArticleId IdType="pubmed">14557245</ArticleId></ArticleIdList></Reference><Reference><Citation>Beel AJ, Sakakura M, Barrett PJ, Sanders CR. Direct binding of cholesterol to the amyloid precursor protein: an important interaction in lipid-Alzheimer's disease relationships? Biochim Biophys Acta 2010; 1801: 975&#x2013;982.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2886191</ArticleId><ArticleId IdType="pubmed">20304095</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu L, Su M, Lucast L, Liu L, Netzer WJ, Gandy SE et al. Dynamin 1 regulates amyloid generation through modulation of BACE-1. PLoS One 2012; 7: e45033.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3443198</ArticleId><ArticleId IdType="pubmed">23024787</ArticleId></ArticleIdList></Reference><Reference><Citation>Sisodia SS. Beta-amyloid precursor protein cleavage by a membrane-bound protease. Proc Natl Acad Sci USA 1992; 89: 6075&#x2013;6079.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC49440</ArticleId><ArticleId IdType="pubmed">1631093</ArticleId></ArticleIdList></Reference><Reference><Citation>Minopoli G, de Candia P, Bonetti A, Faraonio R, Zambrano N, Russo T. The beta-amyloid precursor protein functions as a cytosolic anchoring site that prevents Fe65 nuclear translocation. J Biol Chem 2001; 276: 6545&#x2013;6550.</Citation><ArticleIdList><ArticleId IdType="pubmed">11085987</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan Y, You H, Wu C, Altomare DA, Testa JR. Appl1 is dispensable for mouse development, and loss of Appl1 has growth factor-selective effects on Akt signaling in murine embryonic fibroblasts. J Biol Chem 2010; 285: 6377&#x2013;6389.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2825433</ArticleId><ArticleId IdType="pubmed">20040596</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryu J, Galan AK, Xin X, Dong F, Abdul-Ghani MA, Zhou L et al. APPL1 potentiates insulin sensitivity by facilitating the binding of IRS1/2 to the insulin receptor. Cell Rep 2014; 7: 1227&#x2013;1238.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4380268</ArticleId><ArticleId IdType="pubmed">24813896</ArticleId></ArticleIdList></Reference><Reference><Citation>Erdmann KS, Mao Y, McCrea HJ, Zoncu R, Lee S, Paradise S et al. A role of the Lowe syndrome protein OCRL in early steps of the endocytic pathway. Dev Cell 2007; 13: 377&#x2013;390.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2025683</ArticleId><ArticleId IdType="pubmed">17765681</ArticleId></ArticleIdList></Reference><Reference><Citation>Deinhardt K, Salinas S, Verastegui C, Watson R, Worth D, Hanrahan S et al. Rab5 and Rab7 control endocytic sorting along the axonal retrograde transport pathway. Neuron 2006; 52: 293&#x2013;305.</Citation><ArticleIdList><ArticleId IdType="pubmed">17046692</ArticleId></ArticleIdList></Reference><Reference><Citation>Allen RD, Metuzals J, Tasaki I, Brady ST, Gilbert SP. Fast axonal transport in squid giant axon. Science 1982; 218: 1127&#x2013;1129.</Citation><ArticleIdList><ArticleId IdType="pubmed">6183744</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaasik A, Safiulina D, Choubey V, Kuum M, Zharkovsky A, Veksler V. Mitochondrial swelling impairs the transport of organelles in cerebellar granule neurons. J Biol Chem 2007; 282: 32821&#x2013;32826.</Citation><ArticleIdList><ArticleId IdType="pubmed">17785462</ArticleId></ArticleIdList></Reference><Reference><Citation>Yi JY, Ori-McKenney KM, McKenney RJ, Vershinin M, Gross SP, Vallee RB. High-resolution imaging reveals indirect coordination of opposite motors and a role for LIS1 in high-load axonal transport. J Cell Biol 2011; 195: 193&#x2013;201.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3198168</ArticleId><ArticleId IdType="pubmed">22006948</ArticleId></ArticleIdList></Reference><Reference><Citation>Stokin GB, Lillo C, Falzone TL, Brusch RG, Rockenstein E, Mount SL et al. Axonopathy and transport deficits early in the pathogenesis of Alzheimer's disease. Science 2005; 307: 1282&#x2013;1288.</Citation><ArticleIdList><ArticleId IdType="pubmed">15731448</ArticleId></ArticleIdList></Reference><Reference><Citation>Tilstra JS, Clauson CL, Niedernhofer LJ, Robbins PD. NF-kappaB in Aging and Disease. Aging Dis 2011; 2: 449&#x2013;465.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3295063</ArticleId><ArticleId IdType="pubmed">22396894</ArticleId></ArticleIdList></Reference><Reference><Citation>Olsson A, Hoglund K, Sjogren M, Andreasen N, Minthon L, Lannfelt L et al. Measurement of alpha- and beta-secretase cleaved amyloid precursor protein in cerebrospinal fluid from Alzheimer patients. Exp Neurol 2003; 183: 74&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pubmed">12957490</ArticleId></ArticleIdList></Reference><Reference><Citation>Fukumoto H, Cheung BS, Hyman BT, Irizarry MC. Beta-secretase protein and activity are increased in the neocortex in Alzheimer disease. Arch Neurol 2002; 59: 1381&#x2013;1389.</Citation><ArticleIdList><ArticleId IdType="pubmed">12223024</ArticleId></ArticleIdList></Reference><Reference><Citation>Devi L, Ohno M. Mitochondrial dysfunction and accumulation of the beta-secretase-cleaved C-terminal fragment of APP in Alzheimer's disease transgenic mice. Neurobiol Dis 2012; 45: 417&#x2013;424.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3225635</ArticleId><ArticleId IdType="pubmed">21933711</ArticleId></ArticleIdList></Reference><Reference><Citation>McPhie DL, Golde T, Eckman CB, Yager D, Brant JB, Neve RL. Beta-secretase cleavage of the amyloid precursor protein mediates neuronal apoptosis caused by familial Alzheimer's disease mutations. Brain Res Mol Brain Res 2001; 97: 103&#x2013;113.</Citation><ArticleIdList><ArticleId IdType="pubmed">11744168</ArticleId></ArticleIdList></Reference><Reference><Citation>Tamayev R, Matsuda S, Arancio O, D'Adamio L. Beta- but not gamma-secretase proteolysis of APP causes synaptic and memory deficits in a mouse model of dementia. EMBO Mol Med 2012; 4: 171&#x2013;179.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3376850</ArticleId><ArticleId IdType="pubmed">22170863</ArticleId></ArticleIdList></Reference><Reference><Citation>Oster-Granite ML, McPhie DL, Greenan J, Neve RL. Age-dependent neuronal and synaptic degeneration in mice transgenic for the C terminus of the amyloid precursor protein. J Neurosci 1996; 16: 6732&#x2013;6741.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6579256</ArticleId><ArticleId IdType="pubmed">8824314</ArticleId></ArticleIdList></Reference><Reference><Citation>Berger-Sweeney J, McPhie DL, Arters JA, Greenan J, Oster-Granite ML, Neve RL. Impairments in learning and memory accompanied by neurodegeneration in mice transgenic for the carboxyl-terminus of the amyloid precursor protein. Brain Res Mol Brain Res 1999; 66: 150&#x2013;162.</Citation><ArticleIdList><ArticleId IdType="pubmed">10095087</ArticleId></ArticleIdList></Reference><Reference><Citation>Rockenstein E, Mante M, Alford M, Adame A, Crews L, Hashimoto M et al. High beta-secretase activity elicits neurodegeneration in transgenic mice despite reductions in amyloid-beta levels: implications for the treatment of Alzheimer disease. J Biol Chem 2005; 280: 32957&#x2013;32967.</Citation><ArticleIdList><ArticleId IdType="pubmed">16027115</ArticleId></ArticleIdList></Reference><Reference><Citation>Stockley JH, O'Neill C. The proteins BACE1 and BACE2 and beta-secretase activity in normal and Alzheimer's disease brain. Biochem Soc Trans 2007; 35: 574&#x2013;576.</Citation><ArticleIdList><ArticleId IdType="pubmed">17511655</ArticleId></ArticleIdList></Reference><Reference><Citation>Coulson DT, Beyer N, Quinn JG, Brockbank S, Hellemans J, Irvine GB et al. BACE1 mRNA expression in Alzheimer's disease postmortem brain tissue. J Alzheimer's Dis 2010; 22: 1111&#x2013;1122.</Citation><ArticleIdList><ArticleId IdType="pubmed">20930286</ArticleId></ArticleIdList></Reference><Reference><Citation>Small SA, Kent K, Pierce A, Leung C, Kang MS, Okada H et al. Model-guided microarray implicates the retromer complex in Alzheimer's disease. Ann Neurol 2005; 58: 909&#x2013;919.</Citation><ArticleIdList><ArticleId IdType="pubmed">16315276</ArticleId></ArticleIdList></Reference><Reference><Citation>Refolo LM, Malester B, LaFrancois J, Bryant-Thomas T, Wang R, Tint GS et al. Hypercholesterolemia accelerates the Alzheimer's amyloid pathology in a transgenic mouse model. Neurobiol Dis 2000; 7: 321&#x2013;331.</Citation><ArticleIdList><ArticleId IdType="pubmed">10964604</ArticleId></ArticleIdList></Reference><Reference><Citation>Mastrocola R, Guglielmotto M, Medana C, Catalano MG, Cutrupi S, Borghi R et al. Dysregulation of SREBP2 induces BACE1 expression. Neurobiol Dis 2011; 44: 116&#x2013;124.</Citation><ArticleIdList><ArticleId IdType="pubmed">21726644</ArticleId></ArticleIdList></Reference><Reference><Citation>Marquer C, Devauges V, Cossec JC, Liot G, Lecart S, Saudou F et al. Local cholesterol increase triggers amyloid precursor protein-Bace1 clustering in lipid rafts and rapid endocytosis. FASEB J 2011; 25: 1295&#x2013;1305.</Citation><ArticleIdList><ArticleId IdType="pubmed">21257714</ArticleId></ArticleIdList></Reference><Reference><Citation>Wen L, Tang FL, Hong Y, Luo SW, Wang CL, He W et al. VPS35 haploinsufficiency increases Alzheimer's disease neuropathology. J Cell Biol 2011; 195: 765&#x2013;779.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3257571</ArticleId><ArticleId IdType="pubmed">22105352</ArticleId></ArticleIdList></Reference><Reference><Citation>Nixon RA. Autophagy, amyloidogenesis and Alzheimer disease. J Cell Sci 2007; 120: 4081&#x2013;4091.</Citation><ArticleIdList><ArticleId IdType="pubmed">18032783</ArticleId></ArticleIdList></Reference><Reference><Citation>Cossec JC, Lavaur J, Berman DE, Rivals I, Hoischen A, Stora S et al. Trisomy for synaptojanin1 in Down syndrome is functionally linked to the enlargement of early endosomes. Hum Mol Genet 2012; 21: 3156&#x2013;3172.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3384382</ArticleId><ArticleId IdType="pubmed">22511594</ArticleId></ArticleIdList></Reference><Reference><Citation>Morel E, Chamoun Z, Lasiecka ZM, Chan RB, Williamson RL, Vetanovetz C et al. Phosphatidylinositol-3-phosphate regulates sorting and processing of amyloid precursor protein through the endosomal system. Nat Commun 2013; 4: 2250.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3905799</ArticleId><ArticleId IdType="pubmed">23907271</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee MS, Kao SC, Lemere CA, Xia W, Tseng HC, Zhou Y et al. APP processing is regulated by cytoplasmic phosphorylation. J Cell Biol 2003; 163: 83&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2173445</ArticleId><ArticleId IdType="pubmed">14557249</ArticleId></ArticleIdList></Reference><Reference><Citation>Grimm MO, Mett J, Stahlmann CP, Haupenthal VJ, Zimmer VC, Hartmann T. Neprilysin and Abeta clearance: impact of the APP intracellular domain in NEP regulation and implications in Alzheimer's disease. Front Aging Neurosci 2013; 5: 98.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3870290</ArticleId><ArticleId IdType="pubmed">24391587</ArticleId></ArticleIdList></Reference><Reference><Citation>Granic I, Dolga AM, Nijholt IM, van Dijk G, Eisel UL. Inflammation and NF-kappaB in Alzheimer's disease and diabetes. J Alzheimers Dis 2009; 16: 809&#x2013;821.</Citation><ArticleIdList><ArticleId IdType="pubmed">19387114</ArticleId></ArticleIdList></Reference><Reference><Citation>Trager U, Andre R, Lahiri N, Magnusson-Lind A, Weiss A, Grueninger S et al. HTT-lowering reverses Huntington's disease immune dysfunction caused by NFkappaB pathway dysregulation. Brain 2014; 137: 819&#x2013;833.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3983408</ArticleId><ArticleId IdType="pubmed">24459107</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghosh A, Roy A, Liu X, Kordower JH, Mufson EJ, Hartley DM et al. Selective inhibition of NF-kappaB activation prevents dopaminergic neuronal loss in a mouse model of Parkinson's disease. Proc Natl Acad Sci USA 2007; 104: 18754&#x2013;18759.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2141849</ArticleId><ArticleId IdType="pubmed">18000063</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">26192747</PMID><DateCompleted><Year>2015</Year><Month>10</Month><Day>21</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>31</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1546-1726</ISSN><JournalIssue CitedMedium="Internet"><Volume>18</Volume><Issue>8</Issue><PubDate><Year>2015</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Nature neuroscience</Title><ISOAbbreviation>Nat Neurosci</ISOAbbreviation></Journal><ArticleTitle>Tau post-translational modifications in wild-type and human amyloid precursor protein transgenic mice.</ArticleTitle><Pagination><StartPage>1183</StartPage><EndPage>1189</EndPage><MedlinePgn>1183-9</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/nn.4067</ELocationID><Abstract><AbstractText>The microtubule-associated protein tau has been implicated in the pathogenesis of Alzheimer's disease (AD) and other neurodegenerative disorders. Reducing tau levels ameliorates AD-related synaptic, network, and behavioral abnormalities in transgenic mice expressing human amyloid precursor protein (hAPP). We used mass spectrometry to characterize the post-translational modification of endogenous tau isolated from wild-type and hAPP mice. We identified seven types of tau modifications at 63 sites in wild-type mice. Wild-type and hAPP mice had similar modifications, supporting the hypothesis that neuronal dysfunction in hAPP mice is enabled by physiological forms of tau. Our findings provide clear evidence for acetylation and ubiquitination of the same lysine residues; some sites were also targeted by lysine methylation. Our findings refute the hypothesis of extensive O-linked N-acetylglucosamine (O-GlcNAc) modification of endogenous tau. The complex post-translational modification of physiological tau suggests that tau is regulated by diverse mechanisms.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Morris</LastName><ForeName>Meaghan</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>1] Gladstone Institute of Neurological Disease, San Francisco, California, USA. [2] Biochemistry, Cellular and Molecular Biology Graduate Program, Department of Biological Chemistry, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Knudsen</LastName><ForeName>Giselle M</ForeName><Initials>GM</Initials><AffiliationInfo><Affiliation>Mass Spectrometry Facility, Department of Pharmaceutical Chemistry, University of California, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maeda</LastName><ForeName>Sumihiro</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000000207016860</Identifier><AffiliationInfo><Affiliation>1] Gladstone Institute of Neurological Disease, San Francisco, California, USA. [2] Department of Neurology, University of California, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Trinidad</LastName><ForeName>Jonathan C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Mass Spectrometry Facility, Department of Pharmaceutical Chemistry, University of California, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ioanoviciu</LastName><ForeName>Alexandra</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Mass Spectrometry Facility, Department of Pharmaceutical Chemistry, University of California, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Burlingame</LastName><ForeName>Alma L</ForeName><Initials>AL</Initials><AffiliationInfo><Affiliation>Mass Spectrometry Facility, Department of Pharmaceutical Chemistry, University of California, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mucke</LastName><ForeName>Lennart</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>1] Gladstone Institute of Neurological Disease, San Francisco, California, USA. [2] Department of Neurology, University of California, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P41 GM103481</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS041787</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>GM103481</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS041787</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>07</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Neurosci</MedlineTA><NlmUniqueID>9809671</NlmUniqueID><ISSNLinking>1097-6256</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000107" MajorTopicYN="N">Acetylation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013058" MajorTopicYN="N">Mass Spectrometry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008745" MajorTopicYN="N">Methylation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011499" MajorTopicYN="N">Protein Processing, Post-Translational</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D054875" MajorTopicYN="N">Ubiquitination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>1</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>6</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>7</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>7</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>10</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>4</Month><Day>15</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26192747</ArticleId><ArticleId IdType="mid">NIHMS702155</ArticleId><ArticleId IdType="pmc">PMC8049446</ArticleId><ArticleId IdType="doi">10.1038/nn.4067</ArticleId><ArticleId IdType="pii">nn.4067</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Morris M, Maeda S, Vossel K, Mucke L. The many faces of tau. Neuron. 2011;70:410&#x2013;426.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3319390</ArticleId><ArticleId IdType="pubmed">21555069</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang Y, Mucke L. Alzheimer mechanisms and therapeutic strategies. Cell. 2012;148:1204&#x2013;1222.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3319071</ArticleId><ArticleId IdType="pubmed">22424230</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberson ED, et al. Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model. Science. 2007;316:750&#x2013;754.</Citation><ArticleIdList><ArticleId IdType="pubmed">17478722</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberson ED, et al. Amyloid-&#x3b2;/Fyn-induced synaptic, network, and cognitive impairments depend on tau levels in multiple mouse models of Alzheimer's disease. J. Neurosci. 2011;31:700&#x2013;711.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3325794</ArticleId><ArticleId IdType="pubmed">21228179</ArticleId></ArticleIdList></Reference><Reference><Citation>Ittner LM, et al. Dendritic function of tau mediates amyloid-beta toxicity in Alzheimer's disease mouse models. Cell. 2010;142:387&#x2013;397.</Citation><ArticleIdList><ArticleId IdType="pubmed">20655099</ArticleId></ArticleIdList></Reference><Reference><Citation>Seward ME, et al. Amyloid-&#x3b2; signals through tau to drive ectopic neuronal cell cycle re-entry in Alzheimer's disease. J Cell Sci. 2013;126:1278&#x2013;1286.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3635465</ArticleId><ArticleId IdType="pubmed">23345405</ArticleId></ArticleIdList></Reference><Reference><Citation>Suberbielle E, et al. Physiologic brain activity causes DNA double-strand breaks in neurons, with exacerbation by amyloid-&#x3b2;. Nat. Neurosci. 2013;16:613&#x2013;621.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3637871</ArticleId><ArticleId IdType="pubmed">23525040</ArticleId></ArticleIdList></Reference><Reference><Citation>DeVos SL, et al. Antisense reduction of tau in adult mice protects against seizures. J. Neurosci. 2013;33:12887&#x2013;12897.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3728694</ArticleId><ArticleId IdType="pubmed">23904623</ArticleId></ArticleIdList></Reference><Reference><Citation>Gheyara AL, et al. Tau reduction prevents disease in a mouse model of Dravet syndrome. Ann. Neurol. 2014;76:443&#x2013;456.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4338764</ArticleId><ArticleId IdType="pubmed">25042160</ArticleId></ArticleIdList></Reference><Reference><Citation>Holth JK, et al. Tau loss attenuates neuronal network hyperexcitability in mouse and Drosophila genetic models of epilepsy. J. Neurosci. 2013;33:1651&#x2013;1659.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3711605</ArticleId><ArticleId IdType="pubmed">23345237</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Z, Hall AM, Kelinske M, Roberson ED. Seizure resistance without parkinsonism in aged mice after tau reduction. Neurobiol. Aging. 2014;35:2617&#x2013;2624.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4171213</ArticleId><ArticleId IdType="pubmed">24908165</ArticleId></ArticleIdList></Reference><Reference><Citation>Zempel H, et al. Amyloid-&#x3b2; oligomers induce synaptic damage via Tau-dependent microtubule severing by TTLL6 and spastin. EMBO J. 2013;32:2920&#x2013;2937.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3831312</ArticleId><ArticleId IdType="pubmed">24065130</ArticleId></ArticleIdList></Reference><Reference><Citation>Zempel H, Thies E, Mandelkow E, Mandelkow E-M. Abeta oligomers cause localized Ca2+ elevation, missorting of endogenous Tau into dendrites, Tau phosphorylation, and destruction of microtubules and spines. J. Neurosci. 2010;30:11938&#x2013;11950.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6633549</ArticleId><ArticleId IdType="pubmed">20826658</ArticleId></ArticleIdList></Reference><Reference><Citation>Funk KE, et al. Lysine methylation is an endogenous post-translational modification of tau protein in human brain and a modulator of aggregation propensity. Biochem. J. 2014;462:77&#x2013;88.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4292886</ArticleId><ArticleId IdType="pubmed">24869773</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo A, et al. Immunoaffinity enrichment and mass spectrometry analysis of protein methylation. Mol. Cell Proteomics. 2014;13:372&#x2013;387.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3879628</ArticleId><ArticleId IdType="pubmed">24129315</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomas SN, et al. Dual modification of Alzheimer's disease PHF-tau protein by lysine methylation and ubiquitylation: a mass spectrometry approach. Acta Neuropathol. 2012;123:105&#x2013;117.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3249157</ArticleId><ArticleId IdType="pubmed">22033876</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu F, Iqbal K, Grundke-Iqbal I, Hart GW, Gong C-X. O-GlcNAcylation regulates phosphorylation of tau: a mechanism involved in Alzheimer's disease. Proc. Natl. Acad. Sci. U.S.A. 2004;101:10804&#x2013;10809.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC490015</ArticleId><ArticleId IdType="pubmed">15249677</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuzwa SA, et al. A potent mechanism-inspired O-GlcNAcase inhibitor that blocks phosphorylation of tau in vivo. Nat. Chem. Biol. 2008;4:483&#x2013;490.</Citation><ArticleIdList><ArticleId IdType="pubmed">18587388</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnold CS, et al. The microtubule-associated protein tau is extensively modified with O-linked N-acetylglucosamine. J. Biol. Chem. 1996;271:28741&#x2013;28744.</Citation><ArticleIdList><ArticleId IdType="pubmed">8910513</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Z, et al. Enrichment and site mapping of O-linked N-acetylglucosamine by a combination of chemical/enzymatic tagging, photochemical cleavage, and electron transfer dissociation mass spectrometry. Mol. Cell Proteomics. 2010;9:153&#x2013;160.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2808261</ArticleId><ArticleId IdType="pubmed">19692427</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanger DP, et al. Novel phosphorylation sites in tau from Alzheimer brain support a role for casein kinase 1 in disease pathogenesis. J. Biol. Chem. 2007;282:23645&#x2013;23654.</Citation><ArticleIdList><ArticleId IdType="pubmed">17562708</ArticleId></ArticleIdList></Reference><Reference><Citation>Cripps D, et al. Alzheimer disease-specific conformation of hyperphosphorylated paired helical filament-Tau is polyubiquitinated through Lys-48, Lys-11, and Lys-6 ubiquitin conjugation. J. Biol. Chem. 2006;281:10825&#x2013;10838.</Citation><ArticleIdList><ArticleId IdType="pubmed">16443603</ArticleId></ArticleIdList></Reference><Reference><Citation>Morishima-Kawashima M, et al. Ubiquitin is conjugated with amino-terminally processed tau in paired helical filaments. Neuron. 1993;10:1151&#x2013;1160.</Citation><ArticleIdList><ArticleId IdType="pubmed">8391280</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen TJ, et al. The acetylation of tau inhibits its function and promotes pathological tau aggregation. Nat Commun. 2011;2:252.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3120096</ArticleId><ArticleId IdType="pubmed">21427723</ArticleId></ArticleIdList></Reference><Reference><Citation>Cook C, et al. Acetylation of the KXGS motifs in tau is a critical determinant in modulation of tau aggregation and clearance. Hum. Mol. Genet. 2014;23:104&#x2013;116.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3857946</ArticleId><ArticleId IdType="pubmed">23962722</ArticleId></ArticleIdList></Reference><Reference><Citation>Min S-W, et al. Acetylation of tau inhibits its degradation and contributes to tauopathy. Neuron. 2010;67:953&#x2013;966.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3035103</ArticleId><ArticleId IdType="pubmed">20869593</ArticleId></ArticleIdList></Reference><Reference><Citation>Baker PR, Trinidad JC, Chalkley RJ. Modification site localization scoring integrated into a search engine. Mol. Cell Proteomics. 2011;10:M111.008078.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3134073</ArticleId><ArticleId IdType="pubmed">21490164</ArticleId></ArticleIdList></Reference><Reference><Citation>Beausoleil SA, Vill&#xe9;n J, Gerber SA, Rush J, Gygi SP. A probability-based approach for high-throughput protein phosphorylation analysis and site localization. Nat. Biotechnol. 2006;24:1285&#x2013;1292.</Citation><ArticleIdList><ArticleId IdType="pubmed">16964243</ArticleId></ArticleIdList></Reference><Reference><Citation>Hornbeck PV, et al. PhosphoSitePlus: a comprehensive resource for investigating the structure and function of experimentally determined post-translational modifications in man and mouse. Nucleic Acids Res. 2012;40:D261&#x2013;270.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3245126</ArticleId><ArticleId IdType="pubmed">22135298</ArticleId></ArticleIdList></Reference><Reference><Citation>Bradshaw RA, Medzihradszky KF, Chalkley RJ. Protein PTMs: post-translational modifications or pesky trouble makers? J. Mass Spectrom. 2010;45:1095&#x2013;1097.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3133960</ArticleId><ArticleId IdType="pubmed">20635432</ArticleId></ArticleIdList></Reference><Reference><Citation>Biggar KK, Li SS-C. Non-histone protein methylation as a regulator of cellular signalling and function. Nat. Rev. Mol. Cell Biol. 2015;16:5&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pubmed">25491103</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuzwa SA, et al. Increasing O-GlcNAc slows neurodegeneration and stabilizes tau against aggregation. Nat. Chem. Biol. 2012;8:393&#x2013;399.</Citation><ArticleIdList><ArticleId IdType="pubmed">22366723</ArticleId></ArticleIdList></Reference><Reference><Citation>Borghgraef P, et al. Increasing brain protein O-GlcNAc-ylation mitigates breathing defects and mortality of Tau.P301L mice. PLoS One. 2013;8:e84442.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3871570</ArticleId><ArticleId IdType="pubmed">24376810</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu F, et al. Reduced O-GlcNAcylation links lower brain glucose metabolism and tau pathology in Alzheimer's disease. Brain. 2009;132:1820&#x2013;1832.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2702834</ArticleId><ArticleId IdType="pubmed">19451179</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuzwa SA, et al. Mapping O-GlcNAc modification sites on tau and generation of a site-specific OGlcNAc tau antibody. Amino Acids. 2011;40:857&#x2013;868.</Citation><ArticleIdList><ArticleId IdType="pubmed">20706749</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoover BR, et al. Tau mislocalization to dendritic spines mediates synaptic dysfunction independently of neurodegeneration. Neuron. 2010;68:1067&#x2013;1081.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3026458</ArticleId><ArticleId IdType="pubmed">21172610</ArticleId></ArticleIdList></Reference><Reference><Citation>Goedert M, Jakes R. Expression of separate isoforms of human tau protein: correlation with the tau pattern in brain and effects on tubulin polymerization. EMBO J. 1990;9:4225&#x2013;4230.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC552204</ArticleId><ArticleId IdType="pubmed">2124967</ArticleId></ArticleIdList></Reference><Reference><Citation>McMillan P, et al. Tau isoform regulation is region- and cell-specific in mouse brain. J. Comp. Neurol. 2008;511:788&#x2013;803.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2845852</ArticleId><ArticleId IdType="pubmed">18925637</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang X-J, Seto E. Lysine acetylation: codified crosstalk with other posttranslational modifications. Mol. Cell. 2008;31:449&#x2013;461.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2551738</ArticleId><ArticleId IdType="pubmed">18722172</ArticleId></ArticleIdList></Reference><Reference><Citation>Biernat J, Mandelkow EM. The development of cell processes induced by tau protein requires phosphorylation of serine 262 and 356 in the repeat domain and is inhibited by phosphorylation in the proline-rich domains. Mol. Biol. Cell. 1999;10:727&#x2013;740.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC25198</ArticleId><ArticleId IdType="pubmed">10069814</ArticleId></ArticleIdList></Reference><Reference><Citation>Biernat J, Gustke N, Drewes G, Mandelkow EM, Mandelkow E. Phosphorylation of Ser262 strongly reduces binding of tau to microtubules: distinction between PHF-like immunoreactivity and microtubule binding. Neuron. 1993;11:153&#x2013;163.</Citation><ArticleIdList><ArticleId IdType="pubmed">8393323</ArticleId></ArticleIdList></Reference><Reference><Citation>Von Bergen M, et al. Assembly of tau protein into Alzheimer paired helical filaments depends on a local sequence motif ((306)VQIVYK(311)) forming beta structure. Proc. Natl. Acad. Sci. USA. 2000;97:5129&#x2013;5134.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC25793</ArticleId><ArticleId IdType="pubmed">10805776</ArticleId></ArticleIdList></Reference><Reference><Citation>Von Bergen M, et al. Mutations of tau protein in frontotemporal dementia promote aggregation of paired helical filaments by enhancing local beta-structure. J. Biol. Chem. 2001;276:48165&#x2013;48174.</Citation><ArticleIdList><ArticleId IdType="pubmed">11606569</ArticleId></ArticleIdList></Reference><Reference><Citation>Brandt R, L&#xe9;ger J, Lee G. Interaction of tau with the neural plasma membrane mediated by tau's amino-terminal projection domain. J. Cell Biol. 1995;131:1327&#x2013;1340.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2120645</ArticleId><ArticleId IdType="pubmed">8522593</ArticleId></ArticleIdList></Reference><Reference><Citation>Reynolds CH, et al. Phosphorylation regulates tau interactions with Src homology 3 domains of phosphatidylinositol 3-kinase, phospholipase Cgamma1, Grb2, and Src family kinases. J. Biol. Chem. 2008;283:18177&#x2013;18186.</Citation><ArticleIdList><ArticleId IdType="pubmed">18467332</ArticleId></ArticleIdList></Reference><Reference><Citation>Sultan A, et al. Nuclear tau, a key player in neuronal DNA protection. J. Biol. Chem. 2011;286:4566&#x2013;4575.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3039398</ArticleId><ArticleId IdType="pubmed">21131359</ArticleId></ArticleIdList></Reference><Reference><Citation>Mandelkow EM, et al. Tau domains, phosphorylation, and interactions with microtubules. Neurobiol. Aging. 1995;16:355&#x2013;362.</Citation><ArticleIdList><ArticleId IdType="pubmed">7566345</ArticleId></ArticleIdList></Reference><Reference><Citation>Sturchler-Pierrat C, et al. Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. Proc. Natl. Acad. Sci. USA. 1997;94:13287&#x2013;13292.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC24301</ArticleId><ArticleId IdType="pubmed">9371838</ArticleId></ArticleIdList></Reference><Reference><Citation>Sim&#xf3;n A-M, et al. Overexpression of wild-type human APP in mice causes cognitive deficits and pathological features unrelated to Abeta levels. Neurobiol. Dis. 2009;33:369&#x2013;378.</Citation><ArticleIdList><ArticleId IdType="pubmed">19101630</ArticleId></ArticleIdList></Reference><Reference><Citation>K&#xf6;pke E, et al. Microtubule-associated protein tau. Abnormal phosphorylation of a non-paired helical filament pool in Alzheimer disease. J. Biol. Chem. 1993;268:24374&#x2013;24384.</Citation><ArticleIdList><ArticleId IdType="pubmed">8226987</ArticleId></ArticleIdList></Reference><Reference><Citation>Mucke L, et al. High-level neuronal expression of A&#x3b2;1&#x2013;42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J. Neurosci. 2000;20:4050&#x2013;4058.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6772621</ArticleId><ArticleId IdType="pubmed">10818140</ArticleId></ArticleIdList></Reference><Reference><Citation>Dawson HN, et al. Inhibition of neuronal maturation in primary hippocampal neurons from tau deficient mice. J. Cell. Sci. 2001;114:1179&#x2013;1187.</Citation><ArticleIdList><ArticleId IdType="pubmed">11228161</ArticleId></ArticleIdList></Reference><Reference><Citation>Planel E, et al. Anesthesia leads to tau hyperphosphorylation through inhibition of phosphatase activity by hypothermia. J. Neurosci. 2007;27:3090&#x2013;3097.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672474</ArticleId><ArticleId IdType="pubmed">17376970</ArticleId></ArticleIdList></Reference><Reference><Citation>Ivanovova N, Handzusova M, Hanes J, Kontsekova E, Novak M. High-yield purification of fetal tau preserving its structure and phosphorylation pattern. J. Immunol. Methods. 2008;339:17&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pubmed">18713639</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris M, et al. Age-appropriate cognition and subtle dopamine-independent motor deficits in aged tau knockout mice. Neurobiol. Aging. 2013;34:1523&#x2013;1529.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3596503</ArticleId><ArticleId IdType="pubmed">23332171</ArticleId></ArticleIdList></Reference><Reference><Citation>Trinidad JC, Thalhammer A, Specht CG, Schoepfer R, Burlingame AL. Phosphorylation state of postsynaptic density proteins. J. Neurochem. 2005;92:1306&#x2013;1316.</Citation><ArticleIdList><ArticleId IdType="pubmed">15748150</ArticleId></ArticleIdList></Reference><Reference><Citation>Trinidad JC, Specht CG, Thalhammer A, Schoepfer R, Burlingame AL. Comprehensive Identification of Phosphorylation Sites in Postsynaptic Density Preparations. Mol. Cell Proteomics. 2006;5:914&#x2013;922.</Citation><ArticleIdList><ArticleId IdType="pubmed">16452087</ArticleId></ArticleIdList></Reference><Reference><Citation>Vossel KA, et al. Tau reduction prevents A&#x3b2;-induced axonal transport deficits by blocking activation of GSK3&#x3b2;. J. Cell Biol. 2015;209:419&#x2013;433.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4427789</ArticleId><ArticleId IdType="pubmed">25963821</ArticleId></ArticleIdList></Reference><Reference><Citation>Chalkley RJ, Thalhammer A, Schoepfer R, Burlingame AL. Identification of protein OGlcNAcylation sites using electron transfer dissociation mass spectrometry on native peptides. Proc. Natl. Acad. Sci. USA. 2009;106:8894&#x2013;8899.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2690010</ArticleId><ArticleId IdType="pubmed">19458039</ArticleId></ArticleIdList></Reference><Reference><Citation>Trinidad JC, et al. Global identification and characterization of both O-GlcNAcylation and phosphorylation at the murine synapse. Mol. Cell Proteomics. 2012;11:215&#x2013;229.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3412957</ArticleId><ArticleId IdType="pubmed">22645316</ArticleId></ArticleIdList></Reference><Reference><Citation>Vosseller K, et al. O-linked N-acetylglucosamine proteomics of postsynaptic density preparations using lectin weak affinity chromatography and mass spectrometry. Mol. Cell Proteomics. 2006;5:923&#x2013;934.</Citation><ArticleIdList><ArticleId IdType="pubmed">16452088</ArticleId></ArticleIdList></Reference><Reference><Citation>Olsen JV, et al. Parts per million mass accuracy on an Orbitrap mass spectrometer via lock mass injection into a C-trap. Mol. Cell Proteomics. 2005;4:2010&#x2013;2021.</Citation><ArticleIdList><ArticleId IdType="pubmed">16249172</ArticleId></ArticleIdList></Reference><Reference><Citation>Chalkley RJ, Baker PR, Medzihradszky KF, Lynn AJ, Burlingame AL. In-depth analysis of tandem mass spectrometry data from disparate instrument types. Mol. Cell Proteomics. 2008;7:2386&#x2013;2398.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2596346</ArticleId><ArticleId IdType="pubmed">18653769</ArticleId></ArticleIdList></Reference><Reference><Citation>Elias JE, Gygi SP. Target-decoy search strategy for increased confidence in large-scale protein identifications by mass spectrometry. Nat. Methods. 2007;4:207&#x2013;214.</Citation><ArticleIdList><ArticleId IdType="pubmed">17327847</ArticleId></ArticleIdList></Reference><Reference><Citation>Guan S, Price JC, Prusiner SB, Ghaemmaghami S, Burlingame AL. A data processing pipeline for mammalian proteome dynamics studies using stable isotope metabolic labeling. Mol. Cell Proteomics. 2011;10:M111.010728.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3237081</ArticleId><ArticleId IdType="pubmed">21937731</ArticleId></ArticleIdList></Reference><Reference><Citation>Rudrabhatla P, Jaffe H, Pant HC. Direct evidence of phosphorylated neuronal intermediate filament proteins in neurofibrillary tangles (NFTs): phosphoproteomics of Alzheimer's NFTs. FASEB J. 2011;25:3896&#x2013;3905.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3205835</ArticleId><ArticleId IdType="pubmed">21828286</ArticleId></ArticleIdList></Reference><Reference><Citation>Tavares IA, et al. Prostate-derived sterile 20-like kinases (PSKs/TAOKs) phosphorylate tau protein and are activated in tangle-bearing neurons in Alzheimer disease. J. Biol. Chem. 2013;288:15418&#x2013;15429.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3663559</ArticleId><ArticleId IdType="pubmed">23585562</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">26203081</PMID><DateCompleted><Year>2016</Year><Month>04</Month><Day>18</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1946-6242</ISSN><JournalIssue CitedMedium="Internet"><Volume>7</Volume><Issue>297</Issue><PubDate><Year>2015</Year><Month>Jul</Month><Day>22</Day></PubDate></JournalIssue><Title>Science translational medicine</Title><ISOAbbreviation>Sci Transl Med</ISOAbbreviation></Journal><ArticleTitle>The prodrug DHED selectively delivers 17&#x3b2;-estradiol to the brain for treating estrogen-responsive disorders.</ArticleTitle><Pagination><StartPage>297ra113</StartPage><MedlinePgn>297ra113</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1126/scitranslmed.aab1290</ELocationID><Abstract><AbstractText>Many neurological and psychiatric maladies originate from the deprivation of the human brain from estrogens. However, current hormone therapies cannot be used safely to treat these conditions commonly associated with menopause because of detrimental side effects in the periphery. The latter also prevents the use of the hormone for neuroprotection. We show that a small-molecule bioprecursor prodrug, 10&#x3b2;,17&#x3b2;-dihydroxyestra-1,4-dien-3-one (DHED), converts to 17&#x3b2;-estradiol in the brain after systemic administration but remains inert in the rest of the body. The localized and rapid formation of estrogen from the prodrug was revealed by a series of in vivo bioanalytical assays and through in vivo imaging in rodents. DHED treatment efficiently alleviated symptoms that originated from brain estrogen deficiency in animal models of surgical menopause and provided neuroprotection in a rat stroke model. Concomitantly, we determined that 17&#x3b2;-estradiol formed in the brain from DHED elicited changes in gene expression and neuronal morphology identical to those obtained after direct 17&#x3b2;-estradiol treatment. Together, complementary functional and mechanistic data show that our approach is highly relevant therapeutically, because administration of the prodrug selectively produces estrogen in the brain independently from the route of administration and treatment regimen. Therefore, peripheral responses associated with the use of systemic estrogens, such as stimulation of the uterus and estrogen-responsive tumor growth, were absent. Collectively, our brain-selective prodrug approach may safely provide estrogen neuroprotection and medicate neurological and psychiatric symptoms developing from estrogen deficiency, particularly those encountered after surgical menopause, without the adverse side effects of current hormone therapies.</AbstractText><CopyrightInformation>Copyright &#xa9; 2015, American Association for the Advancement of Science.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Prokai</LastName><ForeName>Laszlo</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Pharmacology and Neuroscience, University of North Texas Health Science Center, Fort Worth, TX 76107, USA. AgyPharma LLC, Mansfield, TX 76063, USA. laszlo.prokai@unthsc.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nguyen</LastName><ForeName>Vien</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Pharmacology and Neuroscience, University of North Texas Health Science Center, Fort Worth, TX 76107, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Szarka</LastName><ForeName>Szabolcs</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Pharmacology and Neuroscience, University of North Texas Health Science Center, Fort Worth, TX 76107, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garg</LastName><ForeName>Puja</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Pharmacology and Neuroscience, University of North Texas Health Science Center, Fort Worth, TX 76107, USA. Vision Research Center and Departments of Ophthalmology and Basic Medical Science, University of Missouri-Kansas City, School of Medicine, Kansas City, MO 64108, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sabnis</LastName><ForeName>Gauri</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Pharmacology, University of Maryland School of Medicine, Baltimore, MD 21201, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bimonte-Nelson</LastName><ForeName>Heather A</ForeName><Initials>HA</Initials><AffiliationInfo><Affiliation>Department of Psychology, Arizona State University, Tempe, AZ 85287, USA. Arizona Alzheimer's Consortium, Tempe, AZ 85014, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McLaughlin</LastName><ForeName>Katie J</ForeName><Initials>KJ</Initials><AffiliationInfo><Affiliation>Department of Psychology, Arizona State University, Tempe, AZ 85287, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Talboom</LastName><ForeName>Joshua S</ForeName><Initials>JS</Initials><AffiliationInfo><Affiliation>Department of Psychology, Arizona State University, Tempe, AZ 85287, USA. Arizona Alzheimer's Consortium, Tempe, AZ 85014, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Conrad</LastName><ForeName>Cheryl D</ForeName><Initials>CD</Initials><AffiliationInfo><Affiliation>Department of Psychology, Arizona State University, Tempe, AZ 85287, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shughrue</LastName><ForeName>Paul J</ForeName><Initials>PJ</Initials><AffiliationInfo><Affiliation>Department of Pharmacology, Elan Pharmaceuticals Inc., South San Francisco, CA 94080, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gould</LastName><ForeName>Todd D</ForeName><Initials>TD</Initials><AffiliationInfo><Affiliation>Department of Pharmacology, University of Maryland School of Medicine, Baltimore, MD 21201, USA. Department of Psychiatry, University of Maryland School of Medicine, Baltimore, MD 21201, USA. Department of Anatomy and Neurobiology, University of Maryland School of Medicine, Baltimore, MD 21201, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brodie</LastName><ForeName>Angela</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Pharmacology, University of Maryland School of Medicine, Baltimore, MD 21201, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Merchenthaler</LastName><ForeName>Istvan</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Anatomy and Neurobiology, University of Maryland School of Medicine, Baltimore, MD 21201, USA. Department of Epidemiology and Public Health, University of Maryland School of Medicine, Baltimore, MD 21201, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Koulen</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Vision Research Center and Departments of Ophthalmology and Basic Medical Science, University of Missouri-Kansas City, School of Medicine, Kansas City, MO 64108, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prokai-Tatrai</LastName><ForeName>Katalin</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Pharmacology and Neuroscience, University of North Texas Health Science Center, Fort Worth, TX 76107, USA. AgyPharma LLC, Mansfield, TX 76063, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R21 AG031421</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS044765</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG027956</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 MH100700</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG028084</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>S10 RR012023</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG031535</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Sci Transl Med</MedlineTA><NlmUniqueID>101505086</NlmUniqueID><ISSNLinking>1946-6234</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000734">Androstenediols</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000928">Antidepressive Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004967">Estrogens</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011355">Prodrugs</NameOfSubstance></Chemical><Chemical><RegistryNumber>131061-48-8</RegistryNumber><NameOfSubstance UI="C066747">3,16-dihydroxyandrost-5-ene-17,19-dione</NameOfSubstance></Chemical><Chemical><RegistryNumber>4TI98Z838E</RegistryNumber><NameOfSubstance UI="D004958">Estradiol</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000734" MajorTopicYN="N">Androstenediols</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000928" MajorTopicYN="N">Antidepressive Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002545" MajorTopicYN="N">Brain Ischemia</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001943" MajorTopicYN="N">Breast Neoplasms</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004958" MajorTopicYN="N">Estradiol</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004967" MajorTopicYN="N">Estrogens</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D061986" MajorTopicYN="N">MCF-7 Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000066829" MajorTopicYN="N">Neuroprotection</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011355" MajorTopicYN="N">Prodrugs</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020521" MajorTopicYN="N">Stroke</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014599" MajorTopicYN="N">Uterus</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading></MeshHeadingList><CoiStatement><b>Competing interests</b>: L.P. and K.P.-T. have equity interests in AgyPharma LLC. L.P. and K.P.-T. hold US Patents 7,026,306 and 7,300,926 on the use of DHED.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>7</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>7</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>4</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2016</Year><Month>7</Month><Day>22</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26203081</ArticleId><ArticleId IdType="mid">NIHMS724359</ArticleId><ArticleId IdType="pmc">PMC4591937</ArticleId><ArticleId IdType="doi">10.1126/scitranslmed.aab1290</ArticleId><ArticleId IdType="pii">7/297/297ra113</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Rocca WA, Shuster LT, Grossardt BR, Maraganore DM, Gostout BS, Geda YE, Melton LJ., III Long-term effects of bilateral oophorectomy on brain aging: unanswered questions from the Mayo Clinic Cohort Study of Oophorectomy and Aging. Women&#x2019;s Health. 2009;5:39&#x2013;48.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2716666</ArticleId><ArticleId IdType="pubmed">19102639</ArticleId></ArticleIdList></Reference><Reference><Citation>Nachtigall L. Does combined hormone replacement therapy improve the health-related quality of life of postmenopausal women? Nat Clin Pract Endocrinol Metab. 2009;5:136&#x2013;137.</Citation><ArticleIdList><ArticleId IdType="pubmed">19229231</ArticleId></ArticleIdList></Reference><Reference><Citation>McEwen BC. Genome and hormones: Gender differences in physiology - Invited review: Estrogens effects on the brain: multiple sites and molecular mechanisms. J Appl Physiol. 2001;91:2785&#x2013;2801.</Citation><ArticleIdList><ArticleId IdType="pubmed">11717247</ArticleId></ArticleIdList></Reference><Reference><Citation>Prentice RL, Anderson GL. The Women&#x2019;s Health Initiative: Lessons learned. Annu Rev Public Health. 2007;29:131&#x2013;150.</Citation><ArticleIdList><ArticleId IdType="pubmed">18348708</ArticleId></ArticleIdList></Reference><Reference><Citation>Rocca WA, Grossardt BR, Miller VM, Shuster LT, Brown RD. Premature menopause or early menopause and risk of ischemic stroke. Menopause. 2012;19:272&#x2013;277.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3258468</ArticleId><ArticleId IdType="pubmed">21993082</ArticleId></ArticleIdList></Reference><Reference><Citation>Bailey ME, Wang ACJ, Hao J, Janssen WGM, Hara Y, Dumitriu D, Hof PR, Morrison JH. Interactive effects of age and estrogen on cortical neurons: implications for cognitive aging. Neuroscience. 2011;191:148&#x2013;158.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3166405</ArticleId><ArticleId IdType="pubmed">21664255</ArticleId></ArticleIdList></Reference><Reference><Citation>Files JA, Ko MG, Pruthi S. Bioidentical hormone therapy. Mayo Clin Proc. 2010;86:673&#x2013;680.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3127562</ArticleId><ArticleId IdType="pubmed">21531972</ArticleId></ArticleIdList></Reference><Reference><Citation>Yao J, Zhao LQ, Mao ZS, Chen SH, Wong KC, To J, Brinton RD. Potentiation of brain mitochondrial function by S-equol and R/S-equol estrogen receptor beta-selective phytoSERM treatments. Brain Res. 2013;1514:128&#x2013;141.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3672394</ArticleId><ArticleId IdType="pubmed">23428542</ArticleId></ArticleIdList></Reference><Reference><Citation>de Cremoux P, This P, Leclercq G, Jacquot Y. Controversies concerning the use of phytoestrogens in menopause management: Bioavailability and metabolism. Maturitas. 2010;65:334&#x2013;339.</Citation><ArticleIdList><ArticleId IdType="pubmed">20080366</ArticleId></ArticleIdList></Reference><Reference><Citation>Finan B, Yang B, Ottaway N, Stemmer K, Muller TD, Yi CX, Habegger K, Schriever SC, Garcia-Caceres C, Kabra DG, Hembree J, Holland J, Raver C, Seeley RJ, Hans W, Irmler M, Beckers J, de Angelis MH, Tiano JP, Mauvais-Jarvis F, Perez-Tilve D, Pfluger P, Zhang LS, Gelfanov V, DiMarchi TD, Tschoep MH. Targeted estrogen delivery reverses the metabolic syndrome. Nat Medicine. 2012;18:1847&#x2013;1856.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3757949</ArticleId><ArticleId IdType="pubmed">23142820</ArticleId></ArticleIdList></Reference><Reference><Citation>&#xd6;sterlund MK. Underlying mechanisms mediating the antidepressant effects of estrogens. Biochim Biophys Acta Gen Subj. 2010;1800:1136&#x2013;1144.</Citation><ArticleIdList><ArticleId IdType="pubmed">19900508</ArticleId></ArticleIdList></Reference><Reference><Citation>Ettmayer P, Amidon GL, Clement B, Testa B. Lessons learned from marketed and investigational prodrugs. J Med Chem. 2003;47:2393&#x2013;2404.</Citation><ArticleIdList><ArticleId IdType="pubmed">15115379</ArticleId></ArticleIdList></Reference><Reference><Citation>Tapfer MK, Sebestyen L, Kurucz I, Horvath K, Szelenyi I, Bodor N. New evidence for the selective, long-lasting central effects of the brain-targeted estradiol, Estredox. Pharmacol Biochem Behav. 2004;77:423&#x2013;429.</Citation><ArticleIdList><ArticleId IdType="pubmed">15006452</ArticleId></ArticleIdList></Reference><Reference><Citation>Sarkar DK, Friedman SJ, Yen SS, Frautschy SA. Chronic inhibition of hypothalamic-pituitary-ovarian axis and body weight gain by brain-directed delivery of estradiol-17&#x3b2; in female rats. Neuroendocrinology. 1989;50:204&#x2013;210.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4352090</ArticleId><ArticleId IdType="pubmed">2674763</ArticleId></ArticleIdList></Reference><Reference><Citation>Prokai-Tatrai K, Szarka S, Nguyen V, Sahyouni F, Walker C, White S, Talamantes T, Prokai L. &#x201c;All in the mind&#x201d;? Brain-targeting chemical delivery system of 17&#x3b2;-estradiol (Estredox) produces significant uterotrophic side effect. Pharm Anal Acta. 2013;S7:002. doi: 10.4172/2153-2435.S7-002.</Citation><ArticleIdList><ArticleId IdType="doi">10.4172/2153-2435.S7-002</ArticleId><ArticleId IdType="pmc">PMC3874273</ArticleId><ArticleId IdType="pubmed">24380028</ArticleId></ArticleIdList></Reference><Reference><Citation>Prokai L, Prokai-Tatrai K, Perjesi P, Zharikova AD, Perez E, Liu R, Simpkins JW. Quinol-based cyclic antioxidant mechanism in estrogen neuroprotection. Proc Natl Acad Sci USA. 2003;100:11741&#x2013;11746.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC208828</ArticleId><ArticleId IdType="pubmed">14504383</ArticleId></ArticleIdList></Reference><Reference><Citation>Bray JE, Marsden BD, Oppermann U. The human short-chain dehydrogenase/reductase (SDR) superfamily: A bioinformatics summary. Chem Biol Interact. 2009;178:99&#x2013;109.</Citation><ArticleIdList><ArticleId IdType="pubmed">19061874</ArticleId></ArticleIdList></Reference><Reference><Citation>Maser E. Neuroprotective role for carbonyl reductase? Biochem Biophys Res Commun. 2006;340:1019&#x2013;1022.</Citation><ArticleIdList><ArticleId IdType="pubmed">16406002</ArticleId></ArticleIdList></Reference><Reference><Citation>Grogan J, Shou M, Zhou D, Chen S, Korzekwa KR. Use of aromatase (CYP 19) metabolite ratios to characterize electron transfer from NADPH-Cytochrome P450 reductase. Biochemistry. 1993;32:12007&#x2013;12012.</Citation><ArticleIdList><ArticleId IdType="pubmed">8218277</ArticleId></ArticleIdList></Reference><Reference><Citation>Ciana P, Raviscioni M, Mussi P, Vegeto E, Que I, Parker MG, Lowik C, Maggi A. In vivo imaging of transcriptionally active estrogen receptors. Nat Med. 2003;9:82&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="pubmed">12483206</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuster LT, Rhodes DJ, Gostout BS, Grossardt BR, Rocca WA. Premature menopause or early menopause: Long-term health consequences. Maturitas. 2010;65:161&#x2013;166.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2815011</ArticleId><ArticleId IdType="pubmed">19733988</ArticleId></ArticleIdList></Reference><Reference><Citation>Merchenthaler I, Shughrue PJ. Neuroprotection by estrogen in animal models of ischemia and Parkinson&#x2019;s disease. Drug Dev Res. 2006;66:172&#x2013;181.</Citation></Reference><Reference><Citation>Bekku N, Yoshimura H. Animal model of menopausal depressive-like state in female mice: prolongation of immobility time in the forced swimming test following ovariectomy. Psychopharmacol. 2005;183:300&#x2013;307.</Citation><ArticleIdList><ArticleId IdType="pubmed">16228195</ArticleId></ArticleIdList></Reference><Reference><Citation>Alfinito PD, Chen X, Atherton J, Cosmi S, Deecher DC. ICI 182,780 penetrates brain and hypothalamic tissue and has functional effects in the brain after systemic dosing. Endocrinology. 2008;149:5219&#x2013;5226.</Citation><ArticleIdList><ArticleId IdType="pubmed">18599545</ArticleId></ArticleIdList></Reference><Reference><Citation>Merchenthaler I, Funkhouser JM, Carver JM, Lundeen SG, Ghosh K, Winneker RC. The effect of estrogens and antiestrogens in a rat model for hot flush. Maturitas. 1998;30:307&#x2013;316.</Citation><ArticleIdList><ArticleId IdType="pubmed">9881331</ArticleId></ArticleIdList></Reference><Reference><Citation>Bimonte-Nelson HA, Acosta JI, Talboom JS. Neuroscientists as cartographers: Mapping the crossroads of gonadal hormones, memory and age using animal models. Molecules. 2010;15:6050&#x2013;6105.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3126862</ArticleId><ArticleId IdType="pubmed">20877209</ArticleId></ArticleIdList></Reference><Reference><Citation>Shughrue PJ, Lane MV, Merchenthaler I. Regulation of progesterone receptor messenger ribonucleic acid in the rat medial preoptic nucleus by estrogenic and antiestrogenic compounds: An in situ hybridization study. Endocrinology. 1997;138:5476&#x2013;5484.</Citation><ArticleIdList><ArticleId IdType="pubmed">9389534</ArticleId></ArticleIdList></Reference><Reference><Citation>Conrad CD, McLaughlin KJ, Huynh TN, El-Ashmawy M, Sparks M. Chronic stress and a cyclic regimen of estradiol administration separately facilitate spatial memory: Relationship with hippocampal CA1 spine density and dendritic complexity. Behav Neurosci. 2012;126:142&#x2013;156.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3262896</ArticleId><ArticleId IdType="pubmed">22004264</ArticleId></ArticleIdList></Reference><Reference><Citation>Owens JW, Ashby J. Critical review and evaluation of the uterotrophic bioassay for the identification of possible estrogen agonists and antagonists: In support of the validation of the OECD uterotrophic protocols for the laboratory rodent. Crit Rev Toxicol. 2002;32:445&#x2013;520.</Citation><ArticleIdList><ArticleId IdType="pubmed">12487363</ArticleId></ArticleIdList></Reference><Reference><Citation>Prokai L, Stevens SM, Jr, Rauniyar N, Nguyen V. Rapid label-free identification of estrogen-induced differential protein expression in vivo from mouse brain and uterine tissue. J Proteome Res. 2009;8:3862&#x2013;3871.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2771330</ArticleId><ArticleId IdType="pubmed">19545149</ArticleId></ArticleIdList></Reference><Reference><Citation>Yue W, Zhou D, Chen S, Brodie A. A new nude mouse model for postmenopausal breast cancer using MCF-7 cells transfected with the human aromatase gene. Cancer Res. 1994;54:5092&#x2013;5095.</Citation><ArticleIdList><ArticleId IdType="pubmed">7923123</ArticleId></ArticleIdList></Reference><Reference><Citation>Finch A, Metcalfe KA, Chiang JK, Elit L, McLaughlin J, Springate C, Demsky R, Murphy J, Rosen B, Narod SA. The impact of prophylactic salpingo-oophorectomy on menopausal symptoms and sexual function in women who carry a BRCA mutation. Gyn Oncol. 2011;121:163&#x2013;168.</Citation><ArticleIdList><ArticleId IdType="pubmed">21216453</ArticleId></ArticleIdList></Reference><Reference><Citation>Rocca WA, Brandon BR, Grossardt R, Shusterd LT. Oophorectomy, menopause, estrogen treatment, and cognitive aging: Clinical evidence for a window of opportunity. Brain Res. 2011;1379:188&#x2013;198.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3046246</ArticleId><ArticleId IdType="pubmed">20965156</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson HD. Menopause. Lancet. 2008;371:760&#x2013;770.</Citation><ArticleIdList><ArticleId IdType="pubmed">18313505</ArticleId></ArticleIdList></Reference><Reference><Citation>Avis NE, Crawford SL, Greendale G, Bromberger JT, Everson-Rose SA, Gold EB, Hess R, Joffe H, Kravitz HM, Tepper PG, Thurston RC. Study of Women&#x2019;s Health Across the Nation (SWAN), Duration of menopausal vasomotor symptoms over the menopause transition. JAMA Internal Med. 2015;175:531&#x2013;539.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4433164</ArticleId><ArticleId IdType="pubmed">25686030</ArticleId></ArticleIdList></Reference><Reference><Citation>Vierk R, Brandt N, Rune GM. Hippocampal estradiol synthesis and its significance for hippocampal synaptic stability in male and female animals. Neuroscience. 2014;274:24&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pubmed">24846612</ArticleId></ArticleIdList></Reference><Reference><Citation>Braden BB, Talboom JS, Crain ID, Simard AR, Lukas RJ, Prokai L, Scheldrup MR, Bowman BL, Bimonte-Nelson HA. Medroxyprogesterone acetate impairs memory and alters the GABAergic system in aged surgically menopausal rats. Neurobiol Learn Mem. 2011;93:444&#x2013;453.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3397202</ArticleId><ArticleId IdType="pubmed">20074654</ArticleId></ArticleIdList></Reference><Reference><Citation>Solaja BA, Milic DR, Gasic MJ. A novel m-CPBA oxidation: p-quinols and epoxyquinols from phenols. Tetrahedron Lett. 1996;37:3765&#x2013;3768.</Citation></Reference><Reference><Citation>Prokai-Tatrai K, Rivera-Portalatin NM, Rauniyar N, Prokai L. A facile microwave-assisted synthesis of p-quinols by lead(IV)acetate oxidation. Lett Org Chem. 2007;4:265&#x2013;267.</Citation></Reference><Reference><Citation>Rivera-Portalatin NM, Serano-Vera JL, Prokai-Tatrai K, Prokai L. Comparison of estrogen-derived ortho-quinone and para-quinol concerning induction of oxidative stress. J Steroid Biochem Mol Biol. 2007;105:71&#x2013;75.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2752863</ArticleId><ArticleId IdType="pubmed">17582759</ArticleId></ArticleIdList></Reference><Reference><Citation>Hurwitz AR, Liu ST. Determination of aqueous solubility and pKa values of estrogens. J Pharm Sci. 1977;66:624&#x2013;627.</Citation><ArticleIdList><ArticleId IdType="pubmed">17710</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldman JM, Murr AS, Cooper RL. The rodent estrous cycle: Characterization of vaginal cytology and its utility in toxicological studies. Birth Defects Res B Dev Reprod Toxicol. 2007;80:84&#x2013;97.</Citation><ArticleIdList><ArticleId IdType="pubmed">17342777</ArticleId></ArticleIdList></Reference><Reference><Citation>Stell A, Belcredito S, Ciana P, Maggi A. Molecular imaging provides novel insights on estrogen receptor activity in mouse brain. Mol Imaging. 2008;7:283&#x2013;292.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2744878</ArticleId><ArticleId IdType="pubmed">19123998</ArticleId></ArticleIdList></Reference><Reference><Citation>Prokai L, Prokai-Tatrai K, Zharikova AD, Nguyen V, Perjesi P, Stevens SM., Jr Centrally-acting and metabolically stable thyrotropin-releasing hormone analogues upon replacement of histidine with substituted pyridinium. J Med Chem. 2004;47:6025&#x2013;6033.</Citation><ArticleIdList><ArticleId IdType="pubmed">15537357</ArticleId></ArticleIdList></Reference><Reference><Citation>Szarka S, Nguyen V, Prokai L, Prokai-Tatrai K. Separation of dansylated 17&#x3b1;-estradiol, 17&#x3b2;-estradiol, and estrone on a single HPLC column for simultaneous quantitation by LC-MS/MS. Anal Bioanal Chem. 2013;405:3399&#x2013;3406.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3600063</ArticleId><ArticleId IdType="pubmed">23371528</ArticleId></ArticleIdList></Reference><Reference><Citation>Gibaldi M, Perrier D. Pharmacokinetics. 2. Marcel Dekker; New York: 1982.</Citation></Reference><Reference><Citation>Garg P, Duncan RS, Kaja S, Zabaneh A, Chapman KD, Koulen P. Lauroylethanolamide and linoleoylethanolamide improve functional outcome in a rodent model for stroke. Neurosci Lett. 2011;492:134&#x2013;138.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3057422</ArticleId><ArticleId IdType="pubmed">21296126</ArticleId></ArticleIdList></Reference><Reference><Citation>Stewart JJP. Optimization of parameters for semiempirical methods V: Modification of NDDO approximations and application to 70 elements. J Mol Model. 2007;13:1173&#x2013;1213.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2039871</ArticleId><ArticleId IdType="pubmed">17828561</ArticleId></ArticleIdList></Reference><Reference><Citation>Klamt A, Sch&#xfc;&#xfc;rmann G. COSMO: A new approach to dielectric screening in solvents with explicit expressions for the screening energy and its gradient. J Chem Soc Perkin Trans. 1993;2:799&#x2013;805.</Citation></Reference><Reference><Citation>Keppel G, Wickens TD. Design and Analysis: A Researcher&#x2019;s Handbook. 4. Pearson Prentice Hall; Upper Saddle River, NJ: 2004.</Citation></Reference><Reference><Citation>Acosta JI, Mayer L, Talboom JS, Zay C, Scheldrup M, Castillo J, Demers LM, Enders CK, Bimonte-Nelson HA. Premarin improves memory, prevents scopolamine-induced amnesia and increases number of basal forebrain choline acetyltransferase positive cells in middle-aged surgically menopausal rats. Horm Behav. 2009;55:454&#x2013;464.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2775815</ArticleId><ArticleId IdType="pubmed">19101559</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">26214837</PMID><DateCompleted><Year>2015</Year><Month>11</Month><Day>04</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1546-170X</ISSN><JournalIssue CitedMedium="Internet"><Volume>21</Volume><Issue>8</Issue><PubDate><Year>2015</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Nature medicine</Title><ISOAbbreviation>Nat Med</ISOAbbreviation></Journal><ArticleTitle>Neutrophils promote Alzheimer's disease-like pathology and cognitive decline via LFA-1 integrin.</ArticleTitle><Pagination><StartPage>880</StartPage><EndPage>886</EndPage><MedlinePgn>880-6</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/nm.3913</ELocationID><Abstract><AbstractText>Inflammation is a pathological hallmark of Alzheimer's disease, and innate immune cells have been shown to contribute to disease pathogenesis. In two transgenic models of Alzheimer's disease (5xFAD and 3xTg-AD mice), neutrophils extravasated and were present in areas with amyloid-&#x3b2; (A&#x3b2;) deposits, where they released neutrophil extracellular traps (NETs) and IL-17. A&#x3b2;42 peptide triggered the LFA-1 integrin high-affinity state and rapid neutrophil adhesion to integrin ligands. In vivo, LFA-1 integrin controlled neutrophil extravasation into the CNS and intraparenchymal motility. In transgenic Alzheimer's disease models, neutrophil depletion or inhibition of neutrophil trafficking via LFA-1 blockade reduced Alzheimer's disease-like neuropathology and improved memory in mice already showing cognitive dysfunction. Temporary depletion of neutrophils for 1 month at early stages of disease led to sustained improvements in memory. Transgenic Alzheimer's disease model mice lacking LFA-1 were protected from cognitive decline and had reduced gliosis. In humans with Alzheimer's disease, neutrophils adhered to and spread inside brain venules and were present in the parenchyma, along with NETs. Our results demonstrate that neutrophils contribute to Alzheimer's disease pathogenesis and cognitive impairment and suggest that the inhibition of neutrophil trafficking may be beneficial in Alzheimer's disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zenaro</LastName><ForeName>Elena</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Pathology and Diagnostics, University of Verona, Verona, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pietronigro</LastName><ForeName>Enrica</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Pathology and Diagnostics, University of Verona, Verona, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Della Bianca</LastName><ForeName>Vittorina</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Pathology and Diagnostics, University of Verona, Verona, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Piacentino</LastName><ForeName>Gennj</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Pathology and Diagnostics, University of Verona, Verona, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marongiu</LastName><ForeName>Laura</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Pathology and Diagnostics, University of Verona, Verona, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Budui</LastName><ForeName>Simona</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Pathology and Diagnostics, University of Verona, Verona, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Turano</LastName><ForeName>Ermanna</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Neurological and Movement Sciences, Neurology Section, University of Verona, Verona, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rossi</LastName><ForeName>Barbara</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Pathology and Diagnostics, University of Verona, Verona, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Angiari</LastName><ForeName>Stefano</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Pathology and Diagnostics, University of Verona, Verona, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dusi</LastName><ForeName>Silvia</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Pathology and Diagnostics, University of Verona, Verona, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Montresor</LastName><ForeName>Alessio</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>1] Department of Pathology and Diagnostics, University of Verona, Verona, Italy. [2] The Center for Biomedical Computing (CBMC), University of Verona, Verona, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carlucci</LastName><ForeName>Tommaso</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Pathology and Diagnostics, University of Verona, Verona, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nan&#xec;</LastName><ForeName>Sara</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Pathology and Diagnostics, University of Verona, Verona, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tosadori</LastName><ForeName>Gabriele</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>1] Department of Pathology and Diagnostics, University of Verona, Verona, Italy. [2] The Center for Biomedical Computing (CBMC), University of Verona, Verona, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Calciano</LastName><ForeName>Lucia</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Public Health and Community Medicine, University of Verona, Verona, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Catalucci</LastName><ForeName>Daniele</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>National Research Council (CNR), Institute of Genetic and Biomedical Research (IRGB), and Humanitas Research Hospital, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Berton</LastName><ForeName>Giorgio</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Pathology and Diagnostics, University of Verona, Verona, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bonetti</LastName><ForeName>Bruno</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Neurological and Movement Sciences, Neurology Section, University of Verona, Verona, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Constantin</LastName><ForeName>Gabriela</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>1] Department of Pathology and Diagnostics, University of Verona, Verona, Italy. [2] The Center for Biomedical Computing (CBMC), University of Verona, Verona, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>07</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Med</MedlineTA><NlmUniqueID>9502015</NlmUniqueID><ISSNLinking>1078-8956</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D020381">Interleukin-17</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016169">Lymphocyte Function-Associated Antigen-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C075222">amyloid beta-protein (1-42)</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Neurosci. 2015 Sep;16(9):510. doi: 10.1038/nrn4014.</RefSource><PMID Version="1">26289569</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002448" MajorTopicYN="N">Cell Adhesion</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002465" MajorTopicYN="N">Cell Movement</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D065206" MajorTopicYN="N">Extracellular Traps</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020381" MajorTopicYN="N">Interleukin-17</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016169" MajorTopicYN="N">Lymphocyte Function-Associated Antigen-1</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009504" MajorTopicYN="N">Neutrophils</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>12</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>6</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>7</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>7</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>11</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26214837</ArticleId><ArticleId IdType="doi">10.1038/nm.3913</ArticleId><ArticleId IdType="pii">nm.3913</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>N Engl J Med. 2010 Jan 28;362(4):329-44</Citation><ArticleIdList><ArticleId IdType="pubmed">20107219</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 2001 Jan 15;21(2):372-81</Citation><ArticleIdList><ArticleId IdType="pubmed">11160418</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurobiol Aging. 2010 Apr;31(4):605-13</Citation><ArticleIdList><ArticleId IdType="pubmed">18603329</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuron. 2005 Mar 3;45(5):675-88</Citation><ArticleIdList><ArticleId IdType="pubmed">15748844</ArticleId></ArticleIdList></Reference><Reference><Citation>J Leukoc Biol. 2010 May;87(5):805-13</Citation><ArticleIdList><ArticleId IdType="pubmed">20110444</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Med. 2007 Oct;13(10):1173-5</Citation><ArticleIdList><ArticleId IdType="pubmed">17828272</ArticleId></ArticleIdList></Reference><Reference><Citation>BMC Neurosci. 2008 Aug 12;9:81</Citation><ArticleIdList><ArticleId IdType="pubmed">18700006</ArticleId></ArticleIdList></Reference><Reference><Citation>J Cell Mol Med. 2009 Sep;13(9A):2911-25</Citation><ArticleIdList><ArticleId IdType="pubmed">18657226</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neuroimmunol. 2002 Mar;124(1-2):83-92</Citation><ArticleIdList><ArticleId IdType="pubmed">11958825</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2010 Mar 15;67(6):513-21</Citation><ArticleIdList><ArticleId IdType="pubmed">19664757</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroscience. 1994 Jun;60(3):607-19</Citation><ArticleIdList><ArticleId IdType="pubmed">7936190</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell Rep. 2013 Nov 14;5(3):646-53</Citation><ArticleIdList><ArticleId IdType="pubmed">24210819</ArticleId></ArticleIdList></Reference><Reference><Citation>Blood. 2010 Jan 14;115(2):418-29</Citation><ArticleIdList><ArticleId IdType="pubmed">19901262</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2013 Jan 10;368(2):107-16</Citation><ArticleIdList><ArticleId IdType="pubmed">23150908</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Brain. 2013 Nov 05;6:43</Citation><ArticleIdList><ArticleId IdType="pubmed">24228616</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Res. 2010 Aug 12;1348:149-55</Citation><ArticleIdList><ArticleId IdType="pubmed">20558146</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Invest. 2012 Apr;122(4):1156-63</Citation><ArticleIdList><ArticleId IdType="pubmed">22466657</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 2013 Nov 6;33(45):17587-96</Citation><ArticleIdList><ArticleId IdType="pubmed">24198349</ArticleId></ArticleIdList></Reference><Reference><Citation>FASEB J. 2003 Jan;17(1):118-20</Citation><ArticleIdList><ArticleId IdType="pubmed">12424218</ArticleId></ArticleIdList></Reference><Reference><Citation>J Exp Med. 2000 Jun 5;191(11):1829-39</Citation><ArticleIdList><ArticleId IdType="pubmed">10839800</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2001 Aug 11;358(9280):461-7</Citation><ArticleIdList><ArticleId IdType="pubmed">11513911</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2002 Oct 25;298(5594):789-91</Citation><ArticleIdList><ArticleId IdType="pubmed">12399581</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann N Y Acad Sci. 1999;893:113-25</Citation><ArticleIdList><ArticleId IdType="pubmed">10672233</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 2006 Aug 30;26(35):9047-56</Citation><ArticleIdList><ArticleId IdType="pubmed">16943563</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Immunol. 2009 Feb;10(2):185-94</Citation><ArticleIdList><ArticleId IdType="pubmed">19136961</ArticleId></ArticleIdList></Reference><Reference><Citation>Immunity. 2010 Sep 24;33(3):424-36</Citation><ArticleIdList><ArticleId IdType="pubmed">20870176</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 2012 Jun 27;32(26):8845-54</Citation><ArticleIdList><ArticleId IdType="pubmed">22745485</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Neuropathol. 2013 Oct;126(4):461-77</Citation><ArticleIdList><ArticleId IdType="pubmed">24224195</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 2006 Oct 4;26(40):10129-40</Citation><ArticleIdList><ArticleId IdType="pubmed">17021169</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Neurol. 2013 Jan;9(1):25-34</Citation><ArticleIdList><ArticleId IdType="pubmed">23183882</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Opin Neurol. 2013 Jun;26(3):318-23</Citation><ArticleIdList><ArticleId IdType="pubmed">23493158</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Genet. 2011 May;43(5):429-35</Citation><ArticleIdList><ArticleId IdType="pubmed">21460840</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurobiol Dis. 2007 Apr;26(1):212-20</Citation><ArticleIdList><ArticleId IdType="pubmed">17306982</ArticleId></ArticleIdList></Reference><Reference><Citation>J Immunol. 2013 Apr 1;190(7):3648-60</Citation><ArticleIdList><ArticleId IdType="pubmed">23447687</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Med. 2006 Sep;12(9):1005-15</Citation><ArticleIdList><ArticleId IdType="pubmed">16960575</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Med. 2011 Nov 07;17(11):1381-90</Citation><ArticleIdList><ArticleId IdType="pubmed">22064428</ArticleId></ArticleIdList></Reference><Reference><Citation>J Immunol. 2012 Jul 1;189(1):381-92</Citation><ArticleIdList><ArticleId IdType="pubmed">22661091</ArticleId></ArticleIdList></Reference><Reference><Citation>J Alzheimers Dis. 2010;22(2):619-29</Citation><ArticleIdList><ArticleId IdType="pubmed">20847401</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neuroinflammation. 2005 Oct 18;2:23</Citation><ArticleIdList><ArticleId IdType="pubmed">16232318</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Genet. 2013 Dec;45(12):1452-8</Citation><ArticleIdList><ArticleId IdType="pubmed">24162737</ArticleId></ArticleIdList></Reference><Reference><Citation>Free Radic Biol Med. 1996;20(6):785-92</Citation><ArticleIdList><ArticleId IdType="pubmed">8728025</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurobiol Aging. 2014 Jun;35(6):1286-92</Citation><ArticleIdList><ArticleId IdType="pubmed">24485508</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 2005 Sep 28;25(39):8843-53</Citation><ArticleIdList><ArticleId IdType="pubmed">16192374</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Immunol. 2013 Mar;13(3):159-75</Citation><ArticleIdList><ArticleId IdType="pubmed">23435331</ArticleId></ArticleIdList></Reference><Reference><Citation>Trends Immunol. 2009 Nov;30(11):547-56</Citation><ArticleIdList><ArticleId IdType="pubmed">19783480</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Immunol. 2007 Sep;7(9):678-89</Citation><ArticleIdList><ArticleId IdType="pubmed">17717539</ArticleId></ArticleIdList></Reference><Reference><Citation>J Leukoc Biol. 2011 Apr;89(4):539-56</Citation><ArticleIdList><ArticleId IdType="pubmed">21169520</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Immunol. 2010 Jun;10(6):427-39</Citation><ArticleIdList><ArticleId IdType="pubmed">20498669</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Neurosci. 2011 Nov 03;12(12):723-38</Citation><ArticleIdList><ArticleId IdType="pubmed">22048062</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2001 Nov 22;345(21):1515-21</Citation><ArticleIdList><ArticleId IdType="pubmed">11794217</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Neurosci. 2007 Jan;8(1):57-69</Citation><ArticleIdList><ArticleId IdType="pubmed">17180163</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurobiol Aging. 2003 Dec;24(8):1063-70</Citation><ArticleIdList><ArticleId IdType="pubmed">14643377</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuron. 2003 Jul 31;39(3):409-21</Citation><ArticleIdList><ArticleId IdType="pubmed">12895417</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Med. 2009 Jun;15(6):623-5</Citation><ArticleIdList><ArticleId IdType="pubmed">19448636</ArticleId></ArticleIdList></Reference><Reference><Citation>CNS Neurol Disord Drug Targets. 2010 Apr;9(2):132-9</Citation><ArticleIdList><ArticleId IdType="pubmed">20205647</ArticleId></ArticleIdList></Reference><Reference><Citation>Sci Transl Med. 2011 Mar 9;3(73):73ra20</Citation><ArticleIdList><ArticleId IdType="pubmed">21389264</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroscience. 2009 Dec 15;164(3):1334-46</Citation><ArticleIdList><ArticleId IdType="pubmed">19772895</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroscience. 1998 Oct;86(4):1245-57</Citation><ArticleIdList><ArticleId IdType="pubmed">9697130</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">26250685</PMID><DateCompleted><Year>2015</Year><Month>09</Month><Day>03</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>30</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1095-9203</ISSN><JournalIssue CitedMedium="Internet"><Volume>349</Volume><Issue>6248</Issue><PubDate><Year>2015</Year><Month>Aug</Month><Day>07</Day></PubDate></JournalIssue><Title>Science (New York, N.Y.)</Title><ISOAbbreviation>Science</ISOAbbreviation></Journal><ArticleTitle>TDP-43 repression of nonconserved cryptic exons is compromised in ALS-FTD.</ArticleTitle><Pagination><StartPage>650</StartPage><EndPage>655</EndPage><MedlinePgn>650-5</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1126/science.aab0983</ELocationID><Abstract><AbstractText>Cytoplasmic aggregation of TDP-43, accompanied by its nuclear clearance, is a key common pathological hallmark of amyotrophic lateral sclerosis and frontotemporal dementia (ALS-FTD). However, a limited understanding of this RNA-binding protein (RBP) impedes the clarification of pathogenic mechanisms underlying TDP-43 proteinopathy. In contrast to RBPs that regulate splicing of conserved exons, we found that TDP-43 repressed the splicing of nonconserved cryptic exons, maintaining intron integrity. When TDP-43 was depleted from mouse embryonic stem cells, these cryptic exons were spliced into messenger RNAs, often disrupting their translation and promoting nonsense-mediated decay. Moreover, enforced repression of cryptic exons prevented cell death in TDP-43-deficient cells. Furthermore, repression of cryptic exons was impaired in ALS-FTD cases, suggesting that this splicing defect could potentially underlie TDP-43 proteinopathy.</AbstractText><CopyrightInformation>Copyright &#xa9; 2015, American Association for the Advancement of Science.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ling</LastName><ForeName>Jonathan P</ForeName><Initials>JP</Initials><AffiliationInfo><Affiliation>Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD 21205-2196, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pletnikova</LastName><ForeName>Olga</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD 21205-2196, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Troncoso</LastName><ForeName>Juan C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD 21205-2196, USA. Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD 21205-2196, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wong</LastName><ForeName>Philip C</ForeName><Initials>PC</Initials><AffiliationInfo><Affiliation>Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD 21205-2196, USA. Department of Neuroscience, Johns Hopkins University School of Medicine, Baltimore, MD 21205-2196, USA. wong@jhmi.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>SRA</DataBankName><AccessionNumberList><AccessionNumber>SRP057819</AccessionNumber><AccessionNumber>SRP057948</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>P50 AG005146</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50AG05146</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Science</MedlineTA><NlmUniqueID>0404511</NlmUniqueID><ISSNLinking>0036-8075</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000071183">Autophagy-Related Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D020033">Protein Isoforms</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000598624">TARDBP protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C578077">TDP-43 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.22.-</RegistryNumber><NameOfSubstance UI="C507524">ATG4B protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.22.-</RegistryNumber><NameOfSubstance UI="D003546">Cysteine Endopeptidases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000071183" MajorTopicYN="N">Autophagy-Related Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001483" MajorTopicYN="N">Base Sequence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003546" MajorTopicYN="N">Cysteine Endopeptidases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004268" MajorTopicYN="N">DNA-Binding Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053595" MajorTopicYN="N">Embryonic Stem Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005091" MajorTopicYN="N">Exons</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057180" MajorTopicYN="N">Frontotemporal Dementia</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055786" MajorTopicYN="N">Gene Knockout Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006367" MajorTopicYN="N">HeLa Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008969" MajorTopicYN="N">Molecular Sequence Data</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020033" MajorTopicYN="N">Protein Isoforms</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012326" MajorTopicYN="Y">RNA Splicing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020871" MajorTopicYN="N">RNA Stability</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012333" MajorTopicYN="N">RNA, Messenger</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017422" MajorTopicYN="N">Sequence Analysis, DNA</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>8</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>8</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>9</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2016</Year><Month>4</Month><Day>8</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26250685</ArticleId><ArticleId IdType="mid">NIHMS772498</ArticleId><ArticleId IdType="pmc">PMC4825810</ArticleId><ArticleId IdType="doi">10.1126/science.aab0983</ArticleId><ArticleId IdType="pii">349/6248/650</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Lee EB, Lee VM, Trojanowski JQ. Nat. Rev. Neurosci. 2012;13:38&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3285250</ArticleId><ArticleId IdType="pubmed">22127299</ArticleId></ArticleIdList></Reference><Reference><Citation>Ling S-C, Polymenidou M, Cleveland DW. Neuron. 2013;79:416&#x2013;438.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4411085</ArticleId><ArticleId IdType="pubmed">23931993</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M, et al. Science. 2006;314:130&#x2013;133.</Citation><ArticleIdList><ArticleId IdType="pubmed">17023659</ArticleId></ArticleIdList></Reference><Reference><Citation>Sreedharan J, et al. Science. 2008;319:1668&#x2013;1672.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7116650</ArticleId><ArticleId IdType="pubmed">18309045</ArticleId></ArticleIdList></Reference><Reference><Citation>Kabashi E, et al. Nat. Genet. 2008;40:572&#x2013;574.</Citation><ArticleIdList><ArticleId IdType="pubmed">18372902</ArticleId></ArticleIdList></Reference><Reference><Citation>Janssens J, Van Broeckhoven C. Hum. Mol. Genet. 2013;22(R1):R77&#x2013;R87.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3782069</ArticleId><ArticleId IdType="pubmed">23900071</ArticleId></ArticleIdList></Reference><Reference><Citation>Renton AE, Chi&#xf2; A, Traynor BJ. Nat. Neurosci. 2014;17:17&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4544832</ArticleId><ArticleId IdType="pubmed">24369373</ArticleId></ArticleIdList></Reference><Reference><Citation>Freischmidt A, et al. Nat. Neurosci. 2015;18:631&#x2013;636.</Citation><ArticleIdList><ArticleId IdType="pubmed">25803835</ArticleId></ArticleIdList></Reference><Reference><Citation>Cirulli ET, et al. Science. 2015;347:1436&#x2013;1441.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4437632</ArticleId><ArticleId IdType="pubmed">25700176</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayala YM, et al. EMBO J. 2011;30:277&#x2013;288.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3025456</ArticleId><ArticleId IdType="pubmed">21131904</ArticleId></ArticleIdList></Reference><Reference><Citation>Sephton CF, et al. J. Biol. Chem. 2010;285:6826&#x2013;6834.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2825476</ArticleId><ArticleId IdType="pubmed">20040602</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiang P-M, et al. Proc. Natl. Acad. Sci. U.S.A. 2010;107:16320&#x2013;16324.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2941284</ArticleId><ArticleId IdType="pubmed">20660762</ArticleId></ArticleIdList></Reference><Reference><Citation>Kraemer BC, et al. Acta Neuropathol. 2010;119:409&#x2013;419.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2880609</ArticleId><ArticleId IdType="pubmed">20198480</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang C, et al. Proc. Natl. Acad. Sci. U.S.A. 2014;111:E1121&#x2013;E1129.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3970502</ArticleId><ArticleId IdType="pubmed">24616503</ArticleId></ArticleIdList></Reference><Reference><Citation>Feiguin F, et al. FEBS Lett. 2009;583:1586&#x2013;1592.</Citation><ArticleIdList><ArticleId IdType="pubmed">19379745</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmid B, et al. Proc. Natl. Acad. Sci. U.S.A. 2013;110:4986&#x2013;4991.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3612625</ArticleId><ArticleId IdType="pubmed">23457265</ArticleId></ArticleIdList></Reference><Reference><Citation>Lukavsky PJ, et al. Nat. Struct. Mol. Biol. 2013;20:1443&#x2013;1449.</Citation><ArticleIdList><ArticleId IdType="pubmed">24240615</ArticleId></ArticleIdList></Reference><Reference><Citation>Tollervey JR, et al. Nat. Neurosci. 2011;14:452&#x2013;458.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3108889</ArticleId><ArticleId IdType="pubmed">21358640</ArticleId></ArticleIdList></Reference><Reference><Citation>Polymenidou M, et al. Nat. Neurosci. 2011;14:459&#x2013;468.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3094729</ArticleId><ArticleId IdType="pubmed">21358643</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuo P-H, Doudeva LG, Wang Y-T, Shen C-KJ, Yuan HS. Nucleic Acids Res. 2009;37:1799&#x2013;1808.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2665213</ArticleId><ArticleId IdType="pubmed">19174564</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y-J, et al. Hum. Mol. Genet. 2013;22:3112&#x2013;3122.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3699067</ArticleId><ArticleId IdType="pubmed">23575225</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayala YM, et al. J. Mol. Biol. 2005;348:575&#x2013;588.</Citation><ArticleIdList><ArticleId IdType="pubmed">15826655</ArticleId></ArticleIdList></Reference><Reference><Citation>D'Ambrogio A, et al. Nucleic Acids Res. 2009;37:4116&#x2013;4126.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2709582</ArticleId><ArticleId IdType="pubmed">19429692</ArticleId></ArticleIdList></Reference><Reference><Citation>Nonaka T, et al. Cell Reports. 2013;4:124&#x2013;134.</Citation><ArticleIdList><ArticleId IdType="pubmed">23831027</ArticleId></ArticleIdList></Reference><Reference><Citation>Gromak N, et al. EMBO J. 2003;22:6356&#x2013;6364.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC291850</ArticleId><ArticleId IdType="pubmed">14633994</ArticleId></ArticleIdList></Reference><Reference><Citation>Rideau AP, et al. Nat. Struct. Mol. Biol. 2006;13:839&#x2013;848.</Citation><ArticleIdList><ArticleId IdType="pubmed">16936729</ArticleId></ArticleIdList></Reference><Reference><Citation>Fu X-D, Ares Jr M. Nat. Rev. Genet. 2014;15:689&#x2013;701.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4440546</ArticleId><ArticleId IdType="pubmed">25112293</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">26258692</PMID><DateCompleted><Year>2016</Year><Month>01</Month><Day>30</Day></DateCompleted><DateRevised><Year>2021</Year><Month>05</Month><Day>03</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-6157</ISSN><JournalIssue CitedMedium="Internet"><Volume>72</Volume><Issue>10</Issue><PubDate><Year>2015</Year><Month>Oct</Month></PubDate></JournalIssue><Title>JAMA neurology</Title><ISOAbbreviation>JAMA Neurol</ISOAbbreviation></Journal><ArticleTitle>Cerebrospinal Fluid Patterns and the Risk of Future Dementia in Early, Incident Parkinson Disease.</ArticleTitle><Pagination><StartPage>1175</StartPage><EndPage>1182</EndPage><MedlinePgn>1175-82</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamaneurol.2015.1449</ELocationID><Abstract><AbstractText Label="IMPORTANCE" NlmCategory="OBJECTIVE">Alterations in cerebrospinal fluid (CSF) have been found in Parkinson disease (PD) and in PD dementia (PDD), but the prognostic importance of such changes is not well known. In vivo biomarkers for disease processes in PD are important for future development of disease-modifying therapies.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To assess the diagnostic and prognostic value of a panel of CSF biomarkers in patients with early PD and related disorders.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS" NlmCategory="METHODS">Regional population-based, prospective cohort study of idiopathic parkinsonism that included patients diagnosed between January 1, 2004, and April 30, 2009, by a movement disorder team at a university hospital that represented the only neurology clinic in the region. Participants were 128 nondemented patients with new-onset parkinsonism (104 with PD, 11 with multiple system atrophy, and 13 with progressive supranuclear palsy) who were followed up for 5 to 9 years. At baseline, CSF from 30 healthy control participants was obtained for comparison.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES" NlmCategory="METHODS">Cerebrospinal fluid concentrations of neurofilament light chain protein, A&#x3b2;1-42, total tau, phosphorylated tau, &#x3b1;-synuclein, and heart fatty acid-binding protein were quantified by 2 blinded measurements (at baseline and after 1 year). Follow-up included an extensive neuropsychological assessment. As PD outcome variables, mild cognitive impairment and incident PDD were diagnosed based on published criteria.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Among the 128 study participants, the 104 patients with early PD had a different CSF pattern compared with the 13 patients with progressive supranuclear palsy (baseline area under the receiver operating characteristic curve, 0.87; P&#x2009;&lt;&#x2009;.0001) and the 30 control participants (baseline area under the receiver operating characteristic curve, 0.69; P&#x2009;=&#x2009;.0021). A CSF biomarker pattern associated with the development of PDD was observed. In PD, high neurofilament light chain protein, low A&#x3b2;1-42, and high heart fatty acid-binding protein at baseline were related to future PDD as analyzed by Cox proportional hazards regression models. Combined, these early biomarkers predicted PDD with high accuracy (hazard ratio, 11.8; 95% CI, 3.3-42.1; P&#x2009;=&#x2009;.0001) after adjusting for possible confounders.</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE" NlmCategory="CONCLUSIONS">The analyzed CSF biomarkers have potential usefulness as a diagnostic tool in patients with parkinsonism. In PD, high neurofilament light chain protein, low A&#x3b2;1-42, and high heart fatty acid-binding protein were related to future PDD, providing new insights into the etiology of PDD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>B&#xe4;ckstr&#xf6;m</LastName><ForeName>David C</ForeName><Initials>DC</Initials><AffiliationInfo><Affiliation>Department of Pharmacology and Clinical Neuroscience, Ume&#xe5; University, Ume&#xe5;, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eriksson Domell&#xf6;f</LastName><ForeName>Magdalena</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Pharmacology and Clinical Neuroscience, Ume&#xe5; University, Ume&#xe5;, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Linder</LastName><ForeName>Jan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Pharmacology and Clinical Neuroscience, Ume&#xe5; University, Ume&#xe5;, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Olsson</LastName><ForeName>Bob</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy at University of Gothenburg, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>&#xd6;hrfelt</LastName><ForeName>Annika</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy at University of Gothenburg, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Trupp</LastName><ForeName>Miles</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Pharmacology and Clinical Neuroscience, Ume&#xe5; University, Ume&#xe5;, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zetterberg</LastName><ForeName>Henrik</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy at University of Gothenburg, M&#xf6;lndal, Sweden3University College London Institute of Neurology, Queen Square, London, England.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blennow</LastName><ForeName>Kaj</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy at University of Gothenburg, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Forsgren</LastName><ForeName>Lars</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Pharmacology and Clinical Neuroscience, Ume&#xe5; University, Ume&#xe5;, Sweden.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Neurol</MedlineTA><NlmUniqueID>101589536</NlmUniqueID><ISSNLinking>2168-6149</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D042241" MajorTopicYN="Y">Early Diagnosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012306" MajorTopicYN="N">Risk</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>8</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>8</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>1</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26258692</ArticleId><ArticleId IdType="doi">10.1001/jamaneurol.2015.1449</ArticleId><ArticleId IdType="pii">2422446</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">26246168</PMID><DateCompleted><Year>2016</Year><Month>05</Month><Day>10</Day></DateCompleted><DateRevised><Year>2015</Year><Month>08</Month><Day>06</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1946-6242</ISSN><JournalIssue CitedMedium="Internet"><Volume>7</Volume><Issue>299</Issue><PubDate><Year>2015</Year><Month>Aug</Month><Day>05</Day></PubDate></JournalIssue><Title>Science translational medicine</Title><ISOAbbreviation>Sci Transl Med</ISOAbbreviation></Journal><ArticleTitle>Structure-based drug design identifies polythiophenes as antiprion compounds.</ArticleTitle><Pagination><StartPage>299ra123</StartPage><MedlinePgn>299ra123</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1126/scitranslmed.aab1923</ELocationID><Abstract><AbstractText>Prions cause transmissible spongiform encephalopathies for which no treatment exists. Prions consist of PrP(Sc), a misfolded and aggregated form of the cellular prion protein (PrP(C)). We explore the antiprion properties of luminescent conjugated polythiophenes (LCPs) that bind and stabilize ordered protein aggregates. By administering a library of structurally diverse LCPs to the brains of prion-infected mice via osmotic minipumps, we found that antiprion activity required a minimum of five thiophene rings bearing regularly spaced carboxyl side groups. Solid-state nuclear magnetic resonance analyses and molecular dynamics simulations revealed that anionic side chains interacted with complementary, regularly spaced cationic amyloid residues of model prions. These findings allowed us to extract structural rules governing the interaction between LCPs and protein aggregates, which we then used to design a new set of LCPs with optimized binding. The new set of LCPs showed robust prophylactic and therapeutic potency in prion-infected mice, with the lead compound extending survival by &gt;80% and showing activity against both mouse and hamster prions as well as efficacy upon intraperitoneal administration into mice. These results demonstrate the feasibility of targeted chemical design of compounds that may be useful for treating diseases of aberrant protein aggregation such as prion disease.</AbstractText><CopyrightInformation>Copyright &#xa9; 2015, American Association for the Advancement of Science.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Herrmann</LastName><ForeName>Uli S</ForeName><Initials>US</Initials><AffiliationInfo><Affiliation>Institute of Neuropathology, University Hospital of Z&#xfc;rich, University of Z&#xfc;rich, 8091 Z&#xfc;rich, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sch&#xfc;tz</LastName><ForeName>Anne K</ForeName><Initials>AK</Initials><AffiliationInfo><Affiliation>Physical Chemistry, Eidgen&#xf6;ssische Technische Hochschule (ETH) Z&#xfc;rich, 8093 Z&#xfc;rich, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shirani</LastName><ForeName>Hamid</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Physics, Chemistry and Biology (IFM), Link&#xf6;ping University, 58183 Link&#xf6;ping, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Danzhi</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Biochemistry, University of Z&#xfc;rich, 8057 Z&#xfc;rich, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saban</LastName><ForeName>Dino</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Institute of Neuropathology, University Hospital of Z&#xfc;rich, University of Z&#xfc;rich, 8091 Z&#xfc;rich, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nuvolone</LastName><ForeName>Mario</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute of Neuropathology, University Hospital of Z&#xfc;rich, University of Z&#xfc;rich, 8091 Z&#xfc;rich, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Bei</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Institute of Neuropathology, University Hospital of Z&#xfc;rich, University of Z&#xfc;rich, 8091 Z&#xfc;rich, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ballmer</LastName><ForeName>Boris</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Institute of Neuropathology, University Hospital of Z&#xfc;rich, University of Z&#xfc;rich, 8091 Z&#xfc;rich, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>&#xc5;slund</LastName><ForeName>Andreas K O</ForeName><Initials>AK</Initials><AffiliationInfo><Affiliation>Department of Physics, Chemistry and Biology (IFM), Link&#xf6;ping University, 58183 Link&#xf6;ping, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mason</LastName><ForeName>Jeffrey J</ForeName><Initials>JJ</Initials><AffiliationInfo><Affiliation>Department of Physics, Chemistry and Biology (IFM), Link&#xf6;ping University, 58183 Link&#xf6;ping, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rushing</LastName><ForeName>Elisabeth</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Institute of Neuropathology, University Hospital of Z&#xfc;rich, University of Z&#xfc;rich, 8091 Z&#xfc;rich, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Budka</LastName><ForeName>Herbert</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Institute of Neuropathology, University Hospital of Z&#xfc;rich, University of Z&#xfc;rich, 8091 Z&#xfc;rich, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nystr&#xf6;m</LastName><ForeName>Sofie</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Physics, Chemistry and Biology (IFM), Link&#xf6;ping University, 58183 Link&#xf6;ping, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hammarstr&#xf6;m</LastName><ForeName>Per</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Physics, Chemistry and Biology (IFM), Link&#xf6;ping University, 58183 Link&#xf6;ping, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>B&#xf6;ckmann</LastName><ForeName>Anja</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Institut de Biologie et Chimie des Prot&#xe9;ines, UMR 5086 CNRS/Universit&#xe9; de Lyon 1, 69367 Lyon, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Caflisch</LastName><ForeName>Amedeo</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Biochemistry, University of Z&#xfc;rich, 8057 Z&#xfc;rich, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meier</LastName><ForeName>Beat H</ForeName><Initials>BH</Initials><AffiliationInfo><Affiliation>Physical Chemistry, Eidgen&#xf6;ssische Technische Hochschule (ETH) Z&#xfc;rich, 8093 Z&#xfc;rich, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nilsson</LastName><ForeName>K Peter R</ForeName><Initials>KP</Initials><AffiliationInfo><Affiliation>Department of Physics, Chemistry and Biology (IFM), Link&#xf6;ping University, 58183 Link&#xf6;ping, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hornemann</LastName><ForeName>Simone</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Institute of Neuropathology, University Hospital of Z&#xfc;rich, University of Z&#xfc;rich, 8091 Z&#xfc;rich, Switzerland. adriano.aguzzi@usz.ch simone.hornemann@usz.ch.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aguzzi</LastName><ForeName>Adriano</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Institute of Neuropathology, University Hospital of Z&#xfc;rich, University of Z&#xfc;rich, 8091 Z&#xfc;rich, Switzerland. adriano.aguzzi@usz.ch simone.hornemann@usz.ch.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Sci Transl Med</MedlineTA><NlmUniqueID>101505086</NlmUniqueID><ISSNLinking>1946-6234</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011108">Polymers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013876">Thiophenes</NameOfSubstance></Chemical><Chemical><RegistryNumber>25233-34-5</RegistryNumber><NameOfSubstance UI="C066730">polythiophene</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Drug Discov. 2015 Oct;14(10):679. doi: 10.1038/nrd4743.</RefSource><PMID Version="1">26388230</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006224" MajorTopicYN="N">Cricetinae</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015195" MajorTopicYN="Y">Drug Design</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009682" MajorTopicYN="N">Magnetic Resonance Spectroscopy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D056004" MajorTopicYN="N">Molecular Dynamics Simulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011108" MajorTopicYN="Y">Polymers</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017096" MajorTopicYN="N">Prion Diseases</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013329" MajorTopicYN="N">Structure-Activity Relationship</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013876" MajorTopicYN="Y">Thiophenes</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>8</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>8</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>5</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26246168</ArticleId><ArticleId IdType="doi">10.1126/scitranslmed.aab1923</ArticleId><ArticleId IdType="pii">7/299/299ra123</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">26280335</PMID><DateCompleted><Year>2015</Year><Month>10</Month><Day>14</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1476-4687</ISSN><JournalIssue CitedMedium="Internet"><Volume>525</Volume><Issue>7568</Issue><PubDate><Year>2015</Year><Month>Sep</Month><Day>10</Day></PubDate></JournalIssue><Title>Nature</Title><ISOAbbreviation>Nature</ISOAbbreviation></Journal><ArticleTitle>An atomic structure of human &#x3b3;-secretase.</ArticleTitle><Pagination><StartPage>212</StartPage><EndPage>217</EndPage><MedlinePgn>212-217</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/nature14892</ELocationID><Abstract><AbstractText>Dysfunction of the intramembrane protease &#x3b3;-secretase is thought to cause Alzheimer's disease, with most mutations derived from Alzheimer's disease mapping to the catalytic subunit presenilin 1 (PS1). Here we report an atomic structure of human &#x3b3;-secretase at 3.4 &#xc5; resolution, determined by single-particle cryo-electron microscopy. Mutations derived from Alzheimer's disease affect residues at two hotspots in PS1, each located at the centre of a distinct four transmembrane segment (TM) bundle. TM2 and, to a lesser extent, TM6 exhibit considerable flexibility, yielding a plastic active site and adaptable surrounding elements. The active site of PS1 is accessible from the convex side of the TM horseshoe, suggesting considerable conformational changes in nicastrin extracellular domain after substrate recruitment. Component protein APH-1 serves as a scaffold, anchoring the lone transmembrane helix from nicastrin and supporting the flexible conformation of PS1. Ordered phospholipids stabilize the complex inside the membrane. Our structure serves as a molecular basis for mechanistic understanding of &#x3b3;-secretase function.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Bai</LastName><ForeName>Xiao-Chen</ForeName><Initials>XC</Initials><AffiliationInfo><Affiliation>MRC Laboratory of Molecular Biology, Cambridge Biomedical Campus, Cambridge CB2 0QH, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Yan</LastName><ForeName>Chuangye</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Ministry of Education Key Laboratory of Protein Science, Tsinghua-Peking Joint Center for Life Sciences, Center for Structural Biology, School of Life Sciences, Tsinghua University, Beijing 100084, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Yang</LastName><ForeName>Guanghui</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Ministry of Education Key Laboratory of Protein Science, Tsinghua-Peking Joint Center for Life Sciences, Center for Structural Biology, School of Life Sciences, Tsinghua University, Beijing 100084, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Peilong</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Ministry of Education Key Laboratory of Protein Science, Tsinghua-Peking Joint Center for Life Sciences, Center for Structural Biology, School of Life Sciences, Tsinghua University, Beijing 100084, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ma</LastName><ForeName>Dan</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Ministry of Education Key Laboratory of Protein Science, Tsinghua-Peking Joint Center for Life Sciences, Center for Structural Biology, School of Life Sciences, Tsinghua University, Beijing 100084, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Linfeng</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Ministry of Education Key Laboratory of Protein Science, Tsinghua-Peking Joint Center for Life Sciences, Center for Structural Biology, School of Life Sciences, Tsinghua University, Beijing 100084, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Rui</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Ministry of Education Key Laboratory of Protein Science, Tsinghua-Peking Joint Center for Life Sciences, Center for Structural Biology, School of Life Sciences, Tsinghua University, Beijing 100084, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scheres</LastName><ForeName>Sjors H W</ForeName><Initials>SHW</Initials><AffiliationInfo><Affiliation>MRC Laboratory of Molecular Biology, Cambridge Biomedical Campus, Cambridge CB2 0QH, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shi</LastName><ForeName>Yigong</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Ministry of Education Key Laboratory of Protein Science, Tsinghua-Peking Joint Center for Life Sciences, Center for Structural Biology, School of Life Sciences, Tsinghua University, Beijing 100084, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>PDB</DataBankName><AccessionNumberList><AccessionNumber>5A63</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>MC_UP_A025_1013</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MC_UP_A025_101</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>08</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nature</MedlineTA><NlmUniqueID>0410462</NlmUniqueID><ISSNLinking>0028-0836</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008562">Membrane Glycoproteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053764">Presenilin-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D021122">Protein Subunits</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C413604">nicastrin protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053829" MajorTopicYN="N">Amyloid Precursor Protein Secretases</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000648" MajorTopicYN="Y">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001665" MajorTopicYN="N">Binding Sites</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020285" MajorTopicYN="Y">Cryoelectron Microscopy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008562" MajorTopicYN="N">Membrane Glycoproteins</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000648" MajorTopicYN="Y">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008958" MajorTopicYN="N">Models, Molecular</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053764" MajorTopicYN="N">Presenilin-1</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000648" MajorTopicYN="Y">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017434" MajorTopicYN="N">Protein Structure, Tertiary</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D021122" MajorTopicYN="N">Protein Subunits</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><OtherID Source="NLM">EMS64147</OtherID></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>5</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>7</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>8</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>8</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>10</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2016</Year><Month>3</Month><Day>10</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26280335</ArticleId><ArticleId IdType="mid">EMS64147</ArticleId><ArticleId IdType="pmc">PMC4568306</ArticleId><ArticleId IdType="doi">10.1038/nature14892</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Alzheimer A. About a peculiar disease of the cerebral cortex. Centralblatt f&#xfc;r Nervenheilkunde Psychiatrie. 1907;30:177&#x2013;179.</Citation></Reference><Reference><Citation>Hardy JA, Higgins GA. Alzheimer&#x2019;s disease: the amyloid cascade hypothesis. Science. 1992;256:184&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">1566067</ArticleId></ArticleIdList></Reference><Reference><Citation>De Strooper B, Iwatsubo T, Wolfe MS. Presenilins and gamma-Secretase: Structure, Function, and Role in Alzheimer Disease. Cold Spring Harbor perspectives in medicine. 2012;2:a006304.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3253024</ArticleId><ArticleId IdType="pubmed">22315713</ArticleId></ArticleIdList></Reference><Reference><Citation>Goate A, Hardy J. Twenty years of Alzheimer&#x2019;s disease-causing mutations. J Neurochem. 2012;120(Suppl 1):3&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">22122678</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanzi RE, Bertram L. Twenty years of the Alzheimer&#x2019;s disease amyloid hypothesis: a genetic perspective. Cell. 2005;120:545&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pubmed">15734686</ArticleId></ArticleIdList></Reference><Reference><Citation>Kimberly WT, et al. Gamma-secretase is a membrane protein complex comprised of presenilin, nicastrin, Aph-1, and Pen-2. Proc Natl Acad Sci U S A. 2003;100:6382&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC164455</ArticleId><ArticleId IdType="pubmed">12740439</ArticleId></ArticleIdList></Reference><Reference><Citation>De Strooper B, et al. Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein. Nature. 1998;391:387&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pubmed">9450754</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolfe MS, et al. Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and gamma-secretase activity. Nature. 1999;398:513&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">10206644</ArticleId></ArticleIdList></Reference><Reference><Citation>Thinakaran G, et al. Endoproteolysis of presenilin 1 and accumulation of processed derivatives in vivo. Neuron. 1996;17:181&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pubmed">8755489</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu G, et al. Nicastrin modulates presenilin-mediated notch/glp-1 signal transduction and betaAPP processing. Nature. 2000;407:48&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pubmed">10993067</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah S, et al. Nicastrin functions as a gamma-secretase-substrate receptor. Cell. 2005;122:435&#x2013;47.</Citation><ArticleIdList><ArticleId IdType="pubmed">16096062</ArticleId></ArticleIdList></Reference><Reference><Citation>Dries DR, et al. Glu-333 of nicastrin directly participates in gamma-secretase activity. J Biol Chem. 2009;284:29714&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2785603</ArticleId><ArticleId IdType="pubmed">19729449</ArticleId></ArticleIdList></Reference><Reference><Citation>Goo JS, et al. Nicastrin overexpression in transgenic mice induces aberrant behavior and APP processing. Mol Neurobiol. 2013;48:232&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pubmed">23595812</ArticleId></ArticleIdList></Reference><Reference><Citation>Francis R, et al. aph-1 and pen-2 are required for Notch pathway signaling, gamma-secretase cleavage of betaAPP, and presenilin protein accumulation. Dev Cell. 2002;3:85&#x2013;97.</Citation><ArticleIdList><ArticleId IdType="pubmed">12110170</ArticleId></ArticleIdList></Reference><Reference><Citation>Takasugi N, et al. The role of presenilin cofactors in the gamma-secretase complex. Nature. 2003;422:438&#x2013;441.</Citation><ArticleIdList><ArticleId IdType="pubmed">12660785</ArticleId></ArticleIdList></Reference><Reference><Citation>Goutte C, Tsunozaki M, Hale VA, Priess JR. APH-1 is a multipass membrane protein essential for the Notch signaling pathway in Caenorhabditis elegans embryos. Proc Natl Acad Sci U S A. 2002;99:775&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC117381</ArticleId><ArticleId IdType="pubmed">11792846</ArticleId></ArticleIdList></Reference><Reference><Citation>Gu Y, et al. APH-1 interacts with mature and immature forms of presenilins and nicastrin and may play a role in maturation of presenilin.nicastrin complexes. J Biol Chem. 2003;278:7374&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pubmed">12471034</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu P, et al. Three-dimensional structure of human gamma-secretase. Nature. 2014;512:166&#x2013;170.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4134323</ArticleId><ArticleId IdType="pubmed">25043039</ArticleId></ArticleIdList></Reference><Reference><Citation>Li X, et al. Structure of a presenilin family intramembrane aspartate protease. Nature. 2013;493:56&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pubmed">23254940</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie T, et al. Crystal structure of the gamma-secretase component nicastrin. Proc Natl Acad Sci U S A. 2014;111:13349&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4169925</ArticleId><ArticleId IdType="pubmed">25197054</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun L, et al. Structural basis of human gamma-secretase assembly. Proc Natl Acad Sci U S A. 2015</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4434707</ArticleId><ArticleId IdType="pubmed">25918421</ArticleId></ArticleIdList></Reference><Reference><Citation>Cooper JB, Khan G, Taylor G, Tickle IJ, Blundell TL. X-ray analyses of aspartic proteinases. II. Three-dimensional structure of the hexagonal crystal form of porcine pepsin at 2.3 A resolution. J Mol Biol. 1990;214:199&#x2013;222.</Citation><ArticleIdList><ArticleId IdType="pubmed">2115088</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J, Brunkan AL, Hecimovic S, Walker E, Goate A. Conserved &#x201c;PAL&#x201d; sequence in presenilins is essential for gamma-secretase activity, but not required for formation or stabilization of gamma-secretase complexes. Neurobiol Dis. 2004;15:654&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pubmed">15056474</ArticleId></ArticleIdList></Reference><Reference><Citation>Sato C, Takagi S, Tomita T, Iwatsubo T. The C-terminal PAL motif and transmembrane domain 9 of presenilin 1 are involved in the formation of the catalytic pore of the gamma-secretase. Journal of Neuroscience. 2008;28:6264&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6670534</ArticleId><ArticleId IdType="pubmed">18550769</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J, et al. C-terminal PAL motif of presenilin and presenilin homologues required for normal active site conformation. J Neurochem. 2006;96:218&#x2013;27.</Citation><ArticleIdList><ArticleId IdType="pubmed">16305624</ArticleId></ArticleIdList></Reference><Reference><Citation>Dang S, et al. Cleavage of amyloid precursor protein by an archaeal presenilin homologue PSH. Proc Natl Acad Sci U S A. 2015;112:3344&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4371958</ArticleId><ArticleId IdType="pubmed">25733893</ArticleId></ArticleIdList></Reference><Reference><Citation>Schedin-Weiss S, Winblad B, Tjernberg LO. The role of protein glycosylation in Alzheimer disease. FEBS J. 2014;281:46&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pubmed">24279329</ArticleId></ArticleIdList></Reference><Reference><Citation>Pardossi-Piquard R, et al. APH1 polar transmembrane residues regulate the assembly and activity of presenilin complexes. J Biol Chem. 2009;284:16298&#x2013;307.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2713549</ArticleId><ArticleId IdType="pubmed">19369254</ArticleId></ArticleIdList></Reference><Reference><Citation>Esselens C, et al. Peptides based on the presenilin-APP binding domain inhibit APP processing and Abeta production through interfering with the APP transmembrane domain. FASEB J. 2012;26:3765&#x2013;78.</Citation><ArticleIdList><ArticleId IdType="pubmed">22661005</ArticleId></ArticleIdList></Reference><Reference><Citation>Elad N, et al. The dynamic conformational landscape of gamma-secretase. J Cell Sci. 2014</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4311135</ArticleId><ArticleId IdType="pubmed">25501811</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y, et al. Structural Interactions between Inhibitor and Substrate Docking Sites Give Insight into Mechanisms of Human PS1 Complexes. Structure. 2014;22:125&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3887256</ArticleId><ArticleId IdType="pubmed">24210759</ArticleId></ArticleIdList></Reference><Reference><Citation>Takagi-Niidome S, et al. Cooperative roles of hydrophilic loop 1 and the C-terminus of presenilin 1 in the substrate-gating mechanism of gamma-secretase. J Neurosci. 2015;35:2646&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6605612</ArticleId><ArticleId IdType="pubmed">25673856</ArticleId></ArticleIdList></Reference><Reference><Citation>Takeo K, Watanabe N, Tomita T, Iwatsubo T. Contribution of the gamma-secretase subunits to the formation of catalytic pore of presenilin 1 protein. J Biol Chem. 2012;287:25834&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3406669</ArticleId><ArticleId IdType="pubmed">22689582</ArticleId></ArticleIdList></Reference><Reference><Citation>De Strooper B. Lessons from a failed &#x3b3;-secretase Alzheimer trial. Cell. 2014;159:721&#x2013;726.</Citation><ArticleIdList><ArticleId IdType="pubmed">25417150</ArticleId></ArticleIdList></Reference><Reference><Citation>Pettersen EF, et al. UCSF Chimera--a visualization system for exploratory research and analysis. J Comput Chem. 2004;25:1605&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">15264254</ArticleId></ArticleIdList></Reference><Reference><Citation>DeLano WL. The PyMOL Molecular Graphics System. on World Wide Web. 2002  http://www.pymol.org.</Citation></Reference><Reference><Citation>Li X, et al. Electron counting and beam-induced motion correction enable near-atomic-resolution single-particle cryo-EM. Nat Methods. 2013;10:584&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3684049</ArticleId><ArticleId IdType="pubmed">23644547</ArticleId></ArticleIdList></Reference><Reference><Citation>Mindell JA, Grigorieff N. Accurate determination of local defocus and specimen tilt in electron microscopy. J Struct Biol. 2003;142:334&#x2013;47.</Citation><ArticleIdList><ArticleId IdType="pubmed">12781660</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheres SH. RELION: Implementation of a Bayesian approach to cryo-EM structure determination. J Struct Biol. 2012;180:519&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3690530</ArticleId><ArticleId IdType="pubmed">23000701</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheres SH. Semi-automated selection of cryo-EM particles in RELION-1.3. J Struct Biol. 2015;189:114&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4318617</ArticleId><ArticleId IdType="pubmed">25486611</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheres SH. Beam-induced motion correction for sub-megadalton cryo-EM particles. Elife. 2014;3:e03665.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4130160</ArticleId><ArticleId IdType="pubmed">25122622</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen S, et al. High-resolution noise substitution to measure overfitting and validate resolution in 3D structure determination by single particle electron cryomicroscopy. Ultramicroscopy. 2013;135:24&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3834153</ArticleId><ArticleId IdType="pubmed">23872039</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenthal PB, Henderson R. Optimal determination of particle orientation, absolute hand, and contrast loss in single-particle electron cryomicroscopy. J Mol Biol. 2003;333:721&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pubmed">14568533</ArticleId></ArticleIdList></Reference><Reference><Citation>Kucukelbir A, Sigworth FJ, Tagare HD. Quantifying the local resolution of cryo-EM density maps. Nat Methods. 2014;11:63&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3903095</ArticleId><ArticleId IdType="pubmed">24213166</ArticleId></ArticleIdList></Reference><Reference><Citation>Stein N. CHAINSAW: a program for mutating pdb files used as templates in molecular replacement. Journal of Applied Crystallography. 2008;41:641&#x2013;643.</Citation></Reference><Reference><Citation>Adams PD, et al. PHENIX: building new software for automated crystallographic structure determination. Acta Crystallographica Section D-Biological Crystallography. 2002;58:1948&#x2013;1954.</Citation><ArticleIdList><ArticleId IdType="pubmed">12393927</ArticleId></ArticleIdList></Reference><Reference><Citation>Emsley P, Cowtan K. Coot: model-building tools for molecular graphics. Acta Crystallogr. D. 2004;60:2126&#x2013;2132.</Citation><ArticleIdList><ArticleId IdType="pubmed">15572765</ArticleId></ArticleIdList></Reference><Reference><Citation>Murshudov GN, Vagin AA, Dodson EJ. Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr D Biol Crystallogr. 1997;53:240&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pubmed">15299926</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown A, et al. Tools for macromolecular model building and refinement into electron cryo-microscopy reconstructions. Acta Crystallogr D Biol Crystallogr. 2015;71:136&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4304694</ArticleId><ArticleId IdType="pubmed">25615868</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicholls RA, Fischer M, McNicholas S, Murshudov GN. Conformation-independent structural comparison of macromolecules with ProSMART. Acta Crystallogr D Biol Crystallogr. 2014;70:2487&#x2013;99.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4157452</ArticleId><ArticleId IdType="pubmed">25195761</ArticleId></ArticleIdList></Reference><Reference><Citation>Amunts A, et al. Structure of the yeast mitochondrial large ribosomal subunit. Science. 2014;343:1485&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4046073</ArticleId><ArticleId IdType="pubmed">24675956</ArticleId></ArticleIdList></Reference><Reference><Citation>Crystal AS, et al. Membrane topology of gamma-secretase component PEN-2. J Biol Chem. 2003;278:20117&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pubmed">12639958</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">26284939</PMID><DateCompleted><Year>2016</Year><Month>05</Month><Day>09</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2041-1723</ISSN><JournalIssue CitedMedium="Internet"><Volume>6</Volume><PubDate><Year>2015</Year><Month>Aug</Month><Day>18</Day></PubDate></JournalIssue><Title>Nature communications</Title><ISOAbbreviation>Nat Commun</ISOAbbreviation></Journal><ArticleTitle>Breaking immune tolerance by targeting Foxp3(+) regulatory T cells mitigates Alzheimer's disease pathology.</ArticleTitle><Pagination><StartPage>7967</StartPage><MedlinePgn>7967</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">7967</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/ncomms8967</ELocationID><Abstract><AbstractText>Alzheimer's disease (AD) is a neurodegenerative disorder in which chronic neuroinflammation contributes to disease escalation. Nevertheless, while immunosuppressive drugs have repeatedly failed in treating this disease, recruitment of myeloid cells to the CNS was shown to play a reparative role in animal models. Here we show, using the 5XFAD AD mouse model, that transient depletion of Foxp3(+) regulatory T cells (Tregs), or pharmacological inhibition of their activity, is followed by amyloid-&#x3b2; plaque clearance, mitigation of the neuroinflammatory response and reversal of cognitive decline. We further show that transient Treg depletion affects the brain's choroid plexus, a selective gateway for immune cell trafficking to the CNS, and is associated with subsequent recruitment of immunoregulatory cells, including monocyte-derived macrophages and Tregs, to cerebral sites of plaque pathology. Our findings suggest targeting Treg-mediated systemic immunosuppression for treating AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Baruch</LastName><ForeName>Kuti</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Neurobiology, Weizmann Institute of Science, 234 Herzl Street, Rehovot 76100, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rosenzweig</LastName><ForeName>Neta</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Neurobiology, Weizmann Institute of Science, 234 Herzl Street, Rehovot 76100, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kertser</LastName><ForeName>Alexander</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurobiology, Weizmann Institute of Science, 234 Herzl Street, Rehovot 76100, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deczkowska</LastName><ForeName>Aleksandra</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurobiology, Weizmann Institute of Science, 234 Herzl Street, Rehovot 76100, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sharif</LastName><ForeName>Alaa Mohammad</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Department of Neurobiology, Weizmann Institute of Science, 234 Herzl Street, Rehovot 76100, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Spinrad</LastName><ForeName>Amit</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurobiology, Weizmann Institute of Science, 234 Herzl Street, Rehovot 76100, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tsitsou-Kampeli</LastName><ForeName>Afroditi</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurobiology, Weizmann Institute of Science, 234 Herzl Street, Rehovot 76100, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sarel</LastName><ForeName>Ayelet</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurobiology, Weizmann Institute of Science, 234 Herzl Street, Rehovot 76100, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cahalon</LastName><ForeName>Liora</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Neurobiology, Weizmann Institute of Science, 234 Herzl Street, Rehovot 76100, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schwartz</LastName><ForeName>Michal</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurobiology, Weizmann Institute of Science, 234 Herzl Street, Rehovot 76100, Israel.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>232835</GrantID><Acronym>ERC_</Acronym><Agency>European Research Council</Agency><Country>International</Country></Grant><Grant><GrantID>MR/L022656/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>08</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nat Commun</MedlineTA><NlmUniqueID>101528555</NlmUniqueID><ISSNLinking>2041-1723</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051858">Forkhead Transcription Factors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C498833">Foxp3 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>5M691HL4BO</RegistryNumber><NameOfSubstance UI="D000068717">Glatiramer Acetate</NameOfSubstance></Chemical><Chemical><RegistryNumber>63231-63-0</RegistryNumber><NameOfSubstance UI="D012313">RNA</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018891" MajorTopicYN="N">Dentate Gyrus</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051858" MajorTopicYN="N">Forkhead Transcription Factors</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005786" MajorTopicYN="N">Gene Expression Regulation</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000068717" MajorTopicYN="N">Glatiramer Acetate</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007108" MajorTopicYN="N">Immune Tolerance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D056747" MajorTopicYN="N">Immunomodulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012313" MajorTopicYN="N">RNA</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D050378" MajorTopicYN="N">T-Lymphocytes, Regulatory</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>4</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>7</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>8</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>8</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>5</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2015</Year><Month>9</Month><Day>2</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26284939</ArticleId><ArticleId IdType="pmc">PMC4557123</ArticleId><ArticleId IdType="doi">10.1038/ncomms8967</ArticleId><ArticleId IdType="pii">ncomms8967</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Akiyama H. et al.. Inflammation and Alzheimer's disease. Neurobiol. Aging 21, 383&#x2013;421 (2000).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3887148</ArticleId><ArticleId IdType="pubmed">10858586</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy J. &amp; Selkoe D. J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297, 353&#x2013;356 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">12130773</ArticleId></ArticleIdList></Reference><Reference><Citation>Weiner H. L. &amp; Frenkel D. Immunology and immunotherapy of Alzheimer's disease. Nat. Rev. Immunol. 6, 404&#x2013;416 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16639431</ArticleId></ArticleIdList></Reference><Reference><Citation>Anti-inflammatory drugs fall short in Alzheimer's disease. Nat. Med. 14, 916 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18776882</ArticleId></ArticleIdList></Reference><Reference><Citation>Group A. R. et al.. Naproxen and celecoxib do not prevent AD in early results from a randomized controlled trial. Neurology 68, 1800&#x2013;1808 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17460158</ArticleId></ArticleIdList></Reference><Reference><Citation>Breitner J. C. et al.. Risk of dementia and AD with prior exposure to NSAIDs in an elderly community-based cohort. Neurology 72, 1899&#x2013;1905 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2690966</ArticleId><ArticleId IdType="pubmed">19386997</ArticleId></ArticleIdList></Reference><Reference><Citation>Wyss-Coray T. &amp; Rogers J. Inflammation in Alzheimer disease-a brief review of the basic science and clinical literature. Cold Spring Harb. Perspect. Med. 2, a006346 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3253025</ArticleId><ArticleId IdType="pubmed">22315714</ArticleId></ArticleIdList></Reference><Reference><Citation>Britschgi M. &amp; Wyss-Coray T. Immune cells may fend off Alzheimer disease. Nat. Med. 13, 408&#x2013;409 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17415372</ArticleId></ArticleIdList></Reference><Reference><Citation>Cameron B. &amp; Landreth G. E. Inflammation, microglia, and Alzheimer's disease. Neurobiol. Dis. 37, 503&#x2013;509 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2823849</ArticleId><ArticleId IdType="pubmed">19833208</ArticleId></ArticleIdList></Reference><Reference><Citation>Lai A. Y. &amp; McLaurin J. Clearance of amyloid-beta peptides by microglia and macrophages: the issue of what, when and where. Future Neurol. 7, 165&#x2013;176 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3380064</ArticleId><ArticleId IdType="pubmed">22737039</ArticleId></ArticleIdList></Reference><Reference><Citation>Simard A. R., Soulet D., Gowing G., Julien J. P. &amp; Rivest S. Bone marrow-derived microglia play a critical role in restricting senile plaque formation in Alzheimer's disease. Neuron 49, 489&#x2013;502 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16476660</ArticleId></ArticleIdList></Reference><Reference><Citation>Butovsky O., Kunis G., Koronyo-Hamaoui M. &amp; Schwartz M. Selective ablation of bone marrow-derived dendritic cells increases amyloid plaques in a mouse Alzheimer's disease model. Eur. J. Neurosci. 26, 413&#x2013;416 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17623022</ArticleId></ArticleIdList></Reference><Reference><Citation>Town T. et al.. Blocking TGF-beta-Smad2/3 innate immune signalling mitigates Alzheimer-like pathology. Nat. Med. 14, 681&#x2013;687 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2649699</ArticleId><ArticleId IdType="pubmed">18516051</ArticleId></ArticleIdList></Reference><Reference><Citation>Koronyo-Hamaoui M. et al.. Attenuation of AD-like neuropathology by harnessing peripheral immune cells: local elevation of IL-10 and MMP-9. J. Neurochem. 111, 1409&#x2013;1424 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19780903</ArticleId></ArticleIdList></Reference><Reference><Citation>Mildner A. et al.. Distinct and non-redundant roles of microglia and myeloid subsets in mouse models of Alzheimer's disease. J. Neurosci. 31, 11159&#x2013;11171 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6623351</ArticleId><ArticleId IdType="pubmed">21813677</ArticleId></ArticleIdList></Reference><Reference><Citation>Koronyo Y. et al.. Therapeutic effects of glatiramer acetate and grafted CD115+ monocytes in a mouse model of Alzheimer's disease. Brain 138, 2399&#x2013;2422 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4840949</ArticleId><ArticleId IdType="pubmed">26049087</ArticleId></ArticleIdList></Reference><Reference><Citation>Kunis G. et al.. IFN-gamma-dependent activation of the brain's choroid plexus for CNS immune surveillance and repair. Brain 136, 3427&#x2013;3440 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">24088808</ArticleId></ArticleIdList></Reference><Reference><Citation>Shechter R. et al.. Recruitment of beneficial M2 macrophages to injured spinal cord is orchestrated by remote brain choroid plexus. Immunity 38, 555&#x2013;569 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4115271</ArticleId><ArticleId IdType="pubmed">23477737</ArticleId></ArticleIdList></Reference><Reference><Citation>Baruch K., Kertser A., Porat Z. &amp; Schwartz M. Cerebral nitric oxide represses choroid plexus NFkappaB-dependent gateway activity for leukocyte trafficking. EMBO J. 34, 1816&#x2013;1828 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4516433</ArticleId><ArticleId IdType="pubmed">25940071</ArticleId></ArticleIdList></Reference><Reference><Citation>Kunis G., Baruch K., Miller O. &amp; Schwartz M. Immunization with a myelin-derived antigen activates the brain's choroid plexus for recruitment of immunoregulatory cells to the CNS and attenuates disease progression in a mouse model of ALS. J. Neurosci. 35, 6381&#x2013;6393 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6605216</ArticleId><ArticleId IdType="pubmed">25904790</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwartz M. &amp; Ziv Y. Immunity to self and self-maintenance: what can tumor immunology teach us about ALS and Alzheimer's disease? Trends Pharmacol. Sci. 29, 287&#x2013;293 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18453002</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwartz M. &amp; Baruch K. The resolution of neuroinflammation in neurodegeneration: leukocyte recruitment via the choroid plexus. EMBO J. 33, 7&#x2013;22 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3990679</ArticleId><ArticleId IdType="pubmed">24357543</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwartz M. &amp; Baruch K. Breaking peripheral immune tolerance to CNS antigens in neurodegenerative diseases: boosting autoimmunity to fight-off chronic neuroinflammation. J. Autoimmun. 54, 8&#x2013;14 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">25199710</ArticleId></ArticleIdList></Reference><Reference><Citation>Oakley H. et al.. Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer's disease mutations: potential factors in amyloid plaque formation. J. Neurosci. 26, 10129&#x2013;10140 (2006).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6674618</ArticleId><ArticleId IdType="pubmed">17021169</ArticleId></ArticleIdList></Reference><Reference><Citation>Baruch K. et al.. Aging. Aging-induced type I interferon response at the choroid plexus negatively affects brain function. Science 346, 89&#x2013;93 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4869326</ArticleId><ArticleId IdType="pubmed">25147279</ArticleId></ArticleIdList></Reference><Reference><Citation>Baruch K. et al.. CNS-specific immunity at the choroid plexus shifts toward destructive Th2 inflammation in brain aging. Proc. Natl Acad. Sci. USA 110, 2264&#x2013;2269 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3568380</ArticleId><ArticleId IdType="pubmed">23335631</ArticleId></ArticleIdList></Reference><Reference><Citation>Sakaguchi S., Yamaguchi T., Nomura T. &amp; Ono M. Regulatory T cells and immune tolerance. Cell 133, 775&#x2013;787 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18510923</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenkranz D. et al.. Higher frequency of regulatory T cells in the elderly and increased suppressive activity in neurodegeneration. J. Neuroimmunol. 188, 117&#x2013;127 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17582512</ArticleId></ArticleIdList></Reference><Reference><Citation>Saresella M. et al.. PD1 negative and PD1 positive CD4+ T regulatory cells in mild cognitive impairment and Alzheimer's disease. J. Alzheimers Dis. 21, 927&#x2013;938 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20634592</ArticleId></ArticleIdList></Reference><Reference><Citation>Torres K. C. et al.. Increased frequency of T cells expressing IL-10 in Alzheimer disease but not in late-onset depression patients. Prog. Neuropsychopharmacol. Biol. Psychiatry 47, 40&#x2013;45 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23954740</ArticleId></ArticleIdList></Reference><Reference><Citation>Mayer C. T. et al.. Advantages of Foxp3(+) regulatory T cell depletion using DEREG mice. Immun. Inflamm. Dis. 2, 162&#x2013;165 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4257761</ArticleId><ArticleId IdType="pubmed">25505550</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim S. et al.. Differential expression of IL-10 receptor by epithelial cells and alveolar macrophages. Allergy 59, 505&#x2013;514 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15080831</ArticleId></ArticleIdList></Reference><Reference><Citation>Butovsky O. et al.. Glatiramer acetate fights against Alzheimer's disease by inducing dendritic-like microglia expressing insulin-like growth factor 1. Proc. Natl Acad. Sci. USA 103, 11784&#x2013;11789 (2006).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1544247</ArticleId><ArticleId IdType="pubmed">16864778</ArticleId></ArticleIdList></Reference><Reference><Citation>Agrawal S. et al.. Dystroglycan is selectively cleaved at the parenchymal basement membrane at sites of leukocyte extravasation in experimental autoimmune encephalomyelitis. J. Exp. Med. 203, 1007&#x2013;1019 (2006).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2118280</ArticleId><ArticleId IdType="pubmed">16585265</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong J., Li N., Zhang X., Zheng B. &amp; Zhang J. Z. Induction of CD4+CD25+ regulatory T cells by copolymer-I through activation of transcription factor Foxp3. Proc. Natl Acad. Sci. USA 102, 6449&#x2013;6454 (2005).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1088385</ArticleId><ArticleId IdType="pubmed">15851684</ArticleId></ArticleIdList></Reference><Reference><Citation>Weber M. S., Hohlfeld R. &amp; Zamvil S. S. Mechanism of action of glatiramer acetate in treatment of multiple sclerosis. Neurotherapeutics 4, 647&#x2013;653 (2007).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7479674</ArticleId><ArticleId IdType="pubmed">17920545</ArticleId></ArticleIdList></Reference><Reference><Citation>Haas J. et al.. Glatiramer acetate improves regulatory T-cell function by expansion of naive CD4(+)CD25(+)FOXP3(+)CD31(+) T-cells in patients with multiple sclerosis. J. Neuroimmunol. 216, 113&#x2013;117 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19646767</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishikawa H. &amp; Sakaguchi S. Regulatory T cells in tumor immunity. Int. J. Cancer 127, 759&#x2013;767 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20518016</ArticleId></ArticleIdList></Reference><Reference><Citation>Byrne W. L., Mills K. H., Lederer J. A. &amp; O'Sullivan G. C. Targeting regulatory T cells in cancer. Cancer. Res. 71, 6915&#x2013;6920 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4287207</ArticleId><ArticleId IdType="pubmed">22068034</ArticleId></ArticleIdList></Reference><Reference><Citation>Bos P. D. &amp; Rudensky A. Y. Treg cells in cancer: a case of multiple personality disorder. Sci. Transl. Med. 4, 164fs144 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">23241741</ArticleId></ArticleIdList></Reference><Reference><Citation>Bowers E. M. et al.. Virtual ligand screening of the p300/CBP histone acetyltransferase: identification of a selective small molecule inhibitor. Chem. Biol. 17, 471&#x2013;482 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2884008</ArticleId><ArticleId IdType="pubmed">20534345</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaub P. et al.. The histone acetyltransferase p300 promotes intrinsic axonal regeneration. Brain 134, 2134&#x2013;2148 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21705428</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y. et al.. Inhibition of p300 impairs Foxp3(+) T regulatory cell function and promotes antitumor immunity. Nat. Med. 19, 1173&#x2013;1177 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3793393</ArticleId><ArticleId IdType="pubmed">23955711</ArticleId></ArticleIdList></Reference><Reference><Citation>Shankar G. M. et al.. Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat. Med. 14, 837&#x2013;842 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2772133</ArticleId><ArticleId IdType="pubmed">18568035</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou X. et al.. Instability of the transcription factor Foxp3 leads to the generation of pathogenic memory T cells in vivo. Nat. Immunol. 10, 1000&#x2013;1007 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2729804</ArticleId><ArticleId IdType="pubmed">19633673</ArticleId></ArticleIdList></Reference><Reference><Citation>Mucida D. et al.. Reciprocal TH17 and regulatory T cell differentiation mediated by retinoic acid. Science 317, 256&#x2013;260 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17569825</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou X. et al.. Cutting edge: all-trans retinoic acid sustains the stability and function of natural regulatory T cells in an inflammatory milieu. J. Immunol. 185, 2675&#x2013;2679 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3098624</ArticleId><ArticleId IdType="pubmed">20679534</ArticleId></ArticleIdList></Reference><Reference><Citation>Ding Y. et al.. Retinoic acid attenuates beta-amyloid deposition and rescues memory deficits in an Alzheimer's disease transgenic mouse model. J. Neurosci. 28, 11622&#x2013;11634 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3844785</ArticleId><ArticleId IdType="pubmed">18987198</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim J. M., Rasmussen J. P. &amp; Rudensky A. Y. Regulatory T cells prevent catastrophic autoimmunity throughout the lifespan of mice. Nat. Immunol. 8, 191&#x2013;197 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17136045</ArticleId></ArticleIdList></Reference><Reference><Citation>Ziv Y. et al.. Immune cells contribute to the maintenance of neurogenesis and spatial learning abilities in adulthood. Nat. Neurosci. 9, 268&#x2013;275 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16415867</ArticleId></ArticleIdList></Reference><Reference><Citation>Derecki N. C. et al.. Regulation of learning and memory by meningeal immunity: a key role for IL-4. J. Exp. Med. 207, 1067&#x2013;1080 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2867291</ArticleId><ArticleId IdType="pubmed">20439540</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim R., Emi M. &amp; Tanabe K. Cancer immunoediting from immune surveillance to immune escape. Immunology 121, 1&#x2013;14 (2007).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2265921</ArticleId><ArticleId IdType="pubmed">17386080</ArticleId></ArticleIdList></Reference><Reference><Citation>Lesokhin A. M., Callahan M. K., Postow M. A. &amp; Wolchok J. D. On being less tolerant: enhanced cancer immunosurveillance enabled by targeting checkpoints and agonists of T cell activation. Sci. Transl. Med. 7, 280sr281 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25810313</ArticleId></ArticleIdList></Reference><Reference><Citation>Kipnis J. et al.. Neuroprotective autoimmunity: naturally occurring CD4+CD25+ regulatory T cells suppress the ability to withstand injury to the central nervous system. Proc. Natl Acad. Sci. USA 99, 15620&#x2013;15625 (2002).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC137766</ArticleId><ArticleId IdType="pubmed">12429857</ArticleId></ArticleIdList></Reference><Reference><Citation>Reynolds A. D., Banerjee R., Liu J., Gendelman H. E. &amp; Mosley R. L. Neuroprotective activities of CD4+CD25+ regulatory T cells in an animal model of Parkinson's disease. J. Leukoc. Biol. 82, 1083&#x2013;1094 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17675560</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang H., Yang H., Xie Z., Wei L. &amp; Bi J. Systemic transplantation of human umbilical cord derived mesenchymal stem cells-educated T regulatory cells improved the impaired cognition in AbetaPPswe/PS1dE9 transgenic mice. PloS ONE 8, e69129 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3723739</ArticleId><ArticleId IdType="pubmed">23935936</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh J. T. &amp; Kipnis J. Regulatory T cells in CNS injury: the simple, the complex and the confused. Trends Mol. Med. 17, 541&#x2013;547 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3189297</ArticleId><ArticleId IdType="pubmed">21741881</ArticleId></ArticleIdList></Reference><Reference><Citation>He F. &amp; Balling R. The role of regulatory T cells in neurodegenerative diseases. Wiley Interdiscip. Rev. Syst. Biol. Med. 5, 153&#x2013;180 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">22899644</ArticleId></ArticleIdList></Reference><Reference><Citation>Raposo C. et al.. CNS repair requires both effector and regulatory T cells with distinct temporal and spatial profiles. J. Neurosci. 34, 10141&#x2013;10155 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6608271</ArticleId><ArticleId IdType="pubmed">25080578</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh J. T. et al.. Regulatory T cells in central nervous system injury: a double-edged sword. J. Immunol. 193, 5013&#x2013;5022 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4225170</ArticleId><ArticleId IdType="pubmed">25320276</ArticleId></ArticleIdList></Reference><Reference><Citation>Appel S. H., Beers D. R. &amp; Henkel J. S. T cell-microglial dialogue in Parkinson's disease and amyotrophic lateral sclerosis: are we listening? Trends Immunol. 31, 7&#x2013;17 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4126423</ArticleId><ArticleId IdType="pubmed">19879804</ArticleId></ArticleIdList></Reference><Reference><Citation>Moalem G. et al.. Autoimmune T cells protect neurons from secondary degeneration after central nervous system axotomy. Nat. Med. 5, 49&#x2013;55 (1999).</Citation><ArticleIdList><ArticleId IdType="pubmed">9883839</ArticleId></ArticleIdList></Reference><Reference><Citation>Michaud J. P., Bellavance M. A., Prefontaine P. &amp; Rivest S. Real-time in vivo imaging reveals the ability of monocytes to clear vascular amyloid beta. Cell Rep. 5, 646&#x2013;653 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">24210819</ArticleId></ArticleIdList></Reference><Reference><Citation>Asseman C., Mauze S., Leach M. W., Coffman R. L. &amp; Powrie F. An essential role for interleukin 10 in the function of regulatory T cells that inhibit intestinal inflammation. J. Exp. Med. 190, 995&#x2013;1004 (1999).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2195650</ArticleId><ArticleId IdType="pubmed">10510089</ArticleId></ArticleIdList></Reference><Reference><Citation>Guillot-Sestier M. V. et al.. Il10 deficiency rebalances innate immunity to mitigate Alzheimer-like pathology. Neuron 85, 534&#x2013;548 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4352138</ArticleId><ArticleId IdType="pubmed">25619654</ArticleId></ArticleIdList></Reference><Reference><Citation>Chakrabarty P. et al.. IL-10 alters immunoproteostasis in APP mice, increasing plaque burden and worsening cognitive behavior. Neuron 85, 519&#x2013;533 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4320003</ArticleId><ArticleId IdType="pubmed">25619653</ArticleId></ArticleIdList></Reference><Reference><Citation>Borchelt D. R. et al.. Accelerated amyloid deposition in the brains of transgenic mice coexpressing mutant presenilin 1 and amyloid precursor proteins. Neuron 19, 939&#x2013;945 (1997).</Citation><ArticleIdList><ArticleId IdType="pubmed">9354339</ArticleId></ArticleIdList></Reference><Reference><Citation>Jung S. et al.. Analysis of fractalkine receptor CX(3)CR1 function by targeted deletion and green fluorescent protein reporter gene insertion. Mol. Cell. Biol. 20, 4106&#x2013;4114 (2000).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC85780</ArticleId><ArticleId IdType="pubmed">10805752</ArticleId></ArticleIdList></Reference><Reference><Citation>Suffner J. et al.. Dendritic cells support homeostatic expansion of Foxp3+ regulatory T cells in Foxp3.LuciDTR mice. J. Immunol. 184, 1810&#x2013;1820 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20083650</ArticleId></ArticleIdList></Reference><Reference><Citation>Burgess A. et al.. Loss of human Greatwall results in G2 arrest and multiple mitotic defects due to deregulation of the cyclin B-Cdc2/PP2A balance. Proc. Natl Acad. Sci. USA 107, 12564&#x2013;12569 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2906566</ArticleId><ArticleId IdType="pubmed">20538976</ArticleId></ArticleIdList></Reference><Reference><Citation>Alamed J., Wilcock D. M., Diamond D. M., Gordon M. N. &amp; Morgan D. Two-day radial-arm water maze learning and memory task; robust resolution of amyloid-related memory deficits in transgenic mice. Nat. Protoc. 1, 1671&#x2013;1679 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">17487150</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt S. D., Nixon R. A. &amp; Mathews P. M. ELISA method for measurement of amyloid-beta levels. Methods Mol. Biol. 299, 279&#x2013;297 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">15980612</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">26280122</PMID><DateCompleted><Year>2015</Year><Month>12</Month><Day>08</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1546-170X</ISSN><JournalIssue CitedMedium="Internet"><Volume>21</Volume><Issue>9</Issue><PubDate><Year>2015</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Nature medicine</Title><ISOAbbreviation>Nat Med</ISOAbbreviation></Journal><ArticleTitle>APP intracellular domain-WAVE1 pathway reduces amyloid-&#x3b2; production.</ArticleTitle><Pagination><StartPage>1054</StartPage><EndPage>1059</EndPage><MedlinePgn>1054-9</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/nm.3924</ELocationID><Abstract><AbstractText>An increase in amyloid-&#x3b2; (A&#x3b2;) production is a major pathogenic mechanism associated with Alzheimer's disease (AD), but little is known about possible homeostatic control of the amyloidogenic pathway. Here we report that the amyloid precursor protein (APP) intracellular domain (AICD) downregulates Wiskott-Aldrich syndrome protein (WASP)-family verprolin homologous protein 1 (WAVE1 or WASF1) as part of a negative feedback mechanism to limit A&#x3b2; production. The AICD binds to the Wasf1 promoter, negatively regulates its transcription and downregulates Wasf1 mRNA and protein expression in Neuro 2a (N2a) cells. WAVE1 interacts and colocalizes with APP in the Golgi apparatus. Experimentally reducing WAVE1 in N2a cells decreased the budding of APP-containing vesicles and reduced cell-surface APP, thereby reducing the production of A&#x3b2;. WAVE1 downregulation was observed in mouse models of AD. Reduction of Wasf1 gene expression dramatically reduced A&#x3b2; levels and restored memory deficits in a mouse model of AD. A decrease in amounts of WASF1 mRNA was also observed in human AD brains, suggesting clinical relevance of the negative feedback circuit involved in homeostatic regulation of A&#x3b2; production.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ceglia</LastName><ForeName>Ilaria</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Laboratory of Molecular and Cellular Neuroscience, The Rockefeller University, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reitz</LastName><ForeName>Christiane</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>The Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University, New York, New York, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Gertrude H. Sergievsky Center, Columbia University, New York, New York, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Columbia University, New York, New York, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Epidemiology, Columbia University, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gresack</LastName><ForeName>Jodi</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Laboratory of Molecular and Cellular Neuroscience, The Rockefeller University, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ahn</LastName><ForeName>Jung-Hyuck</ForeName><Initials>JH</Initials><AffiliationInfo><Affiliation>Department of Biochemistry, Ewha Womans University, Seoul, South Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Tissue Injury Defense Research Center, School of Medicine, Ewha Womans University, Seoul, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bustos</LastName><ForeName>Victor</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Laboratory of Molecular and Cellular Neuroscience, The Rockefeller University, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bleck</LastName><ForeName>Marina</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Laboratory of Cellular Biophysics, The Rockefeller University, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Xiaozhu</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Laboratory of Molecular and Cellular Neuroscience, The Rockefeller University, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martin</LastName><ForeName>Grant</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Laboratory of Molecular and Cellular Neuroscience, The Rockefeller University, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Simon</LastName><ForeName>Sanford M</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>Laboratory of Cellular Biophysics, The Rockefeller University, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nairn</LastName><ForeName>Angus C</ForeName><Initials>AC</Initials><AffiliationInfo><Affiliation>Laboratory of Molecular and Cellular Neuroscience, The Rockefeller University, New York, New York, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, Yale University School of Medicine, New Haven, Connecticut, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Greengard</LastName><ForeName>Paul</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Laboratory of Molecular and Cellular Neuroscience, The Rockefeller University, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Yong</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Laboratory of Molecular and Cellular Neuroscience, The Rockefeller University, New York, New York, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P01 AG009464</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG047270</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG009464</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG047270</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>08</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Med</MedlineTA><NlmUniqueID>9502015</NlmUniqueID><ISSNLinking>1078-8956</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051300">Wiskott-Aldrich Syndrome Protein Family</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="Y">biosynthesis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001483" MajorTopicYN="N">Base Sequence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008969" MajorTopicYN="N">Molecular Sequence Data</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017434" MajorTopicYN="N">Protein Structure, Tertiary</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051300" MajorTopicYN="N">Wiskott-Aldrich Syndrome Protein Family</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>1</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>7</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>8</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>8</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2016</Year><Month>3</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26280122</ArticleId><ArticleId IdType="mid">NIHMS708325</ArticleId><ArticleId IdType="pmc">PMC4560977</ArticleId><ArticleId IdType="doi">10.1038/nm.3924</ArticleId><ArticleId IdType="pii">nm.3924</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Tanzi RE, Bertram L. Twenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective. Cell. 2005;120:545&#x2013;555.</Citation><ArticleIdList><ArticleId IdType="pubmed">15734686</ArticleId></ArticleIdList></Reference><Reference><Citation>Ballard C, et al. Alzheimer's disease. Lancet. 2011;377:1019&#x2013;1031.</Citation><ArticleIdList><ArticleId IdType="pubmed">21371747</ArticleId></ArticleIdList></Reference><Reference><Citation>Takenawa T, Suetsugu S. The WASP-WAVE protein network: connecting the membrane to the cytoskeleton. Nat. Rev. Mol. Cell Biol. 2007;8:37&#x2013;48.</Citation><ArticleIdList><ArticleId IdType="pubmed">17183359</ArticleId></ArticleIdList></Reference><Reference><Citation>Soderling SH, et al. Loss of WAVE-1 causes sensorimotor retardation and reduced learning and memory in mice. Proc. Natl. Acad. Sci. USA. 2003;100:1723&#x2013;1728.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC149900</ArticleId><ArticleId IdType="pubmed">12578964</ArticleId></ArticleIdList></Reference><Reference><Citation>Eden S, Rohatgi R, Podtelejnikov AV, Mann M, Kirschner MW. Mechanism of regulation of WAVE1-induced actin nucleation by Rac1 and Nck. Nature. 2002;418:790&#x2013;793.</Citation><ArticleIdList><ArticleId IdType="pubmed">12181570</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim Y, et al. Phosphorylation of WAVE1 regulates actin polymerization and dendritic spine morphology. Nature. 2006;442:814&#x2013;817.</Citation><ArticleIdList><ArticleId IdType="pubmed">16862120</ArticleId></ArticleIdList></Reference><Reference><Citation>Suzuki T, et al. Molecular cloning of a novel apoptosis-related gene, human Nap1 (NCKAP1), and its possible relation to Alzheimer disease. Genomics. 2000;63:246&#x2013;254.</Citation><ArticleIdList><ArticleId IdType="pubmed">10673335</ArticleId></ArticleIdList></Reference><Reference><Citation>Oddo S, et al. Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron. 2003;39:409&#x2013;421.</Citation><ArticleIdList><ArticleId IdType="pubmed">12895417</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsiao K, et al. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science. 1996;274:99&#x2013;102.</Citation><ArticleIdList><ArticleId IdType="pubmed">8810256</ArticleId></ArticleIdList></Reference><Reference><Citation>Lo AC, Haass C, Wagner SL, Teplow DB, Sisodia SS. Metabolism of the &#x201c;Swedish&#x201d; amyloid precursor protein variant in Madin-Darby canine kidney cells. J. Biol. Chem. 1994;269:30966&#x2013;30973.</Citation><ArticleIdList><ArticleId IdType="pubmed">7983032</ArticleId></ArticleIdList></Reference><Reference><Citation>Muller T, Meyer HE, Egensperger R, Marcus K. The amyloid precursor protein intracellular domain (AICD) as modulator of gene expression, apoptosis, and cytoskeletal dynamics-relevance for Alzheimer's disease. Prog. Neurobiol. 2008;85:393&#x2013;406.</Citation><ArticleIdList><ArticleId IdType="pubmed">18603345</ArticleId></ArticleIdList></Reference><Reference><Citation>Haass C, Kaether C, Thinakaran G, Sisodia S. Trafficking and proteolytic processing of APP. Cold Spring Harb. Perspect. Med. 2012;2:a006270.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3331683</ArticleId><ArticleId IdType="pubmed">22553493</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao X, Sudhof TC. A transcriptionally [correction of transcriptively] active complex of APP with Fe65 and histone acetyltransferase Tip60. Science. 2001;293:115&#x2013;120.</Citation><ArticleIdList><ArticleId IdType="pubmed">11441186</ArticleId></ArticleIdList></Reference><Reference><Citation>Goodger ZV, et al. Nuclear signaling by the APP intracellular domain occurs predominantly through the amyloidogenic processing pathway. J. Cell Sci. 2009;122:3703&#x2013;3714.</Citation><ArticleIdList><ArticleId IdType="pubmed">19773363</ArticleId></ArticleIdList></Reference><Reference><Citation>Belyaev ND, et al. The transcriptionally active amyloid precursor protein (APP) intracellular domain is preferentially produced from the 695 isoform of APP in a {beta}-secretase-dependent pathway. J. Biol. Chem. 2010;285:41443&#x2013;41454.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3009870</ArticleId><ArticleId IdType="pubmed">20961856</ArticleId></ArticleIdList></Reference><Reference><Citation>Flammang B, et al. Evidence that the amyloid-beta protein precursor intracellular domain, AICD, derives from beta-secretase-generated C-terminal fragment. J. Alzheimers Dis. 2012;30:145&#x2013;153.</Citation><ArticleIdList><ArticleId IdType="pubmed">22406447</ArticleId></ArticleIdList></Reference><Reference><Citation>Pardossi-Piquard R, Checler F. The physiology of the beta-amyloid precursor protein intracellular domain AICD. J. Neurochem. 2012;120(Suppl 1):109&#x2013;124.</Citation><ArticleIdList><ArticleId IdType="pubmed">22122663</ArticleId></ArticleIdList></Reference><Reference><Citation>Belyaev ND, Nalivaeva NN, Makova NZ, Turner AJ. Neprilysin gene expression requires binding of the amyloid precursor protein intracellular domain to its promoter: implications for Alzheimer disease. EMBO Rep. 2009;10:94&#x2013;100.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2613207</ArticleId><ArticleId IdType="pubmed">19057576</ArticleId></ArticleIdList></Reference><Reference><Citation>Jankowsky JL, et al. Mutant presenilins specifically elevate the levels of the 42 residue beta-amyloid peptide in vivo: evidence for augmentation of a 42-specific gamma secretase. Hum. Mol. Genet. 2004;13:159&#x2013;170.</Citation><ArticleIdList><ArticleId IdType="pubmed">14645205</ArticleId></ArticleIdList></Reference><Reference><Citation>Rajendran L, Annaert W. Membrane trafficking pathways in Alzheimer's disease. Traffic. 2012;13:759&#x2013;770.</Citation><ArticleIdList><ArticleId IdType="pubmed">22269004</ArticleId></ArticleIdList></Reference><Reference><Citation>Suetsugu S, Gautreau A. Synergistic BAR-NPF interactions in actin-driven membrane remodeling. Trends Cell. Biol. 2012;22:141&#x2013;150.</Citation><ArticleIdList><ArticleId IdType="pubmed">22306177</ArticleId></ArticleIdList></Reference><Reference><Citation>Anitei M, Hoflack B. Bridging membrane and cytoskeleton dynamics in the secretory and endocytic pathways. Nat. Cell Biol. 2012;14:11&#x2013;19.</Citation><ArticleIdList><ArticleId IdType="pubmed">22193159</ArticleId></ArticleIdList></Reference><Reference><Citation>Webster JA, et al. Genetic control of human brain transcript expression in Alzheimer disease. Am. J. Hum. Genet. 2009;84:445&#x2013;458.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2667989</ArticleId><ArticleId IdType="pubmed">19361613</ArticleId></ArticleIdList></Reference><Reference><Citation>Ceglia I, Kim Y, Nairn AC, Greengard P. Signaling pathways controlling the phosphorylation state of WAVE1, a regulator of actin polymerization. J. Neurochem. 2010;114:182&#x2013;190.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2945298</ArticleId><ArticleId IdType="pubmed">20403076</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamenetz F, et al. APP processing and synaptic function. Neuron. 2003;37:925&#x2013;937.</Citation><ArticleIdList><ArticleId IdType="pubmed">12670422</ArticleId></ArticleIdList></Reference><Reference><Citation>Lesne S, et al. NMDA receptor activation inhibits alpha-secretase and promotes neuronal amyloid-beta production. J. Neurosci. 2005;25:9367&#x2013;9377.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725703</ArticleId><ArticleId IdType="pubmed">16221845</ArticleId></ArticleIdList></Reference><Reference><Citation>Cirrito JR, et al. Synaptic activity regulates interstitial fluid amyloid-beta levels in vivo. Neuron. 2005;48:913&#x2013;922.</Citation><ArticleIdList><ArticleId IdType="pubmed">16364896</ArticleId></ArticleIdList></Reference><Reference><Citation>Konietzko U. AICD nuclear signaling and its possible contribution to Alzheimer's disease. Curr. Alzheimer Res. 2012;9:200&#x2013;216.</Citation><ArticleIdList><ArticleId IdType="pubmed">21605035</ArticleId></ArticleIdList></Reference><Reference><Citation>Nalivaeva NN, Turner AJ. The amyloid precursor protein: a biochemical enigma in brain development, function and disease. FEBS Lett. 2013;587:2046&#x2013;2054.</Citation><ArticleIdList><ArticleId IdType="pubmed">23684647</ArticleId></ArticleIdList></Reference><Reference><Citation>Gasparini L, et al. Stimulation of beta-amyloid precursor protein trafficking by insulin reduces intraneuronal beta-amyloid and requires mitogen-activated protein kinase signaling. J Neurosci. 2001;21:2561&#x2013;2570.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6762523</ArticleId><ArticleId IdType="pubmed">11306609</ArticleId></ArticleIdList></Reference><Reference><Citation>He G, et al. Gamma-secretase activating protein is a therapeutic target for Alzheimer's disease. Nature. 2010;467:95&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2936959</ArticleId><ArticleId IdType="pubmed">20811458</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai D, et al. Presenilin-1 uses phospholipase D1 as a negative regulator of beta-amyloid formation. Proc Natl Acad Sci U S A. 2006;103:1941&#x2013;1946.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1413665</ArticleId><ArticleId IdType="pubmed">16449386</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai D, et al. Presenilin-1 regulates intracellular trafficking and cell surface delivery of beta-amyloid precursor protein. J Biol Chem. 2003;278:3446&#x2013;3454.</Citation><ArticleIdList><ArticleId IdType="pubmed">12435726</ArticleId></ArticleIdList></Reference><Reference><Citation>Suetsugu S, Yamazaki D, Kurisu S, Takenawa T. Differential roles of WAVE1 and WAVE2 in dorsal and peripheral ruffle formation for fibroblast cell migration. Dev Cell. 2003;5:595&#x2013;609.</Citation><ArticleIdList><ArticleId IdType="pubmed">14536061</ArticleId></ArticleIdList></Reference><Reference><Citation>Thinakaran G, et al. Endoproteolysis of presenilin 1 and accumulation of processed derivatives in vivo. Neuron. 1996;17:181&#x2013;190.</Citation><ArticleIdList><ArticleId IdType="pubmed">8755489</ArticleId></ArticleIdList></Reference><Reference><Citation>Buxbaum JD, et al. Processing of Alzheimer beta/A4 amyloid precursor protein: modulation by agents that regulate protein phosphorylation. Proc Natl Acad Sci U S A. 1990;87:6003&#x2013;6006.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC54458</ArticleId><ArticleId IdType="pubmed">2116015</ArticleId></ArticleIdList></Reference><Reference><Citation>Soderling SH, et al. The WRP component of the WAVE-1 complex attenuates Rac-mediated signalling. Nat Cell Biol. 2002;4:970&#x2013;975.</Citation><ArticleIdList><ArticleId IdType="pubmed">12447388</ArticleId></ArticleIdList></Reference><Reference><Citation>Thinakaran G, Teplow DB, Siman R, Greenberg B, Sisodia SS. Metabolism of the &#x201c;Swedish&#x201d; amyloid precursor protein variant in neuro2a (N2a) cells. Evidence that cleavage at the &#x201c;beta-secretase&#x201d; site occurs in the golgi apparatus. J Biol Chem. 1996;271:9390&#x2013;9397.</Citation><ArticleIdList><ArticleId IdType="pubmed">8621605</ArticleId></ArticleIdList></Reference><Reference><Citation>Urmoneit B, Turner J, Dyrks T. Pulse-chase experiments revealed beta-secretase cleavage from immature full-length amyloid precursor protein harboring the Swedish mutation. Implications for distinct pathways. J Mol Neurosci. 1998;11:141&#x2013;150.</Citation><ArticleIdList><ArticleId IdType="pubmed">10096041</ArticleId></ArticleIdList></Reference><Reference><Citation>Gresack JE, Kerr KM, Frick KM. Life-long environmental enrichment differentially affects the mnemonic response to estrogen in young, middle-aged, and aged female mice. Neurobiol Learn Mem. 2007;88:393&#x2013;408.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2098878</ArticleId><ArticleId IdType="pubmed">17869132</ArticleId></ArticleIdList></Reference><Reference><Citation>Harburger LL, Lambert TJ, Frick KM. Age-dependent effects of environmental enrichment on spatial reference memory in male mice. Behav Brain Res. 2007;185:43&#x2013;48.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2603144</ArticleId><ArticleId IdType="pubmed">17707521</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">26299962</PMID><DateCompleted><Year>2016</Year><Month>06</Month><Day>17</Day></DateCompleted><DateRevised><Year>2019</Year><Month>12</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2211-1247</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><Issue>9</Issue><PubDate><Year>2015</Year><Month>Sep</Month><Day>01</Day></PubDate></JournalIssue><Title>Cell reports</Title><ISOAbbreviation>Cell Rep</ISOAbbreviation></Journal><ArticleTitle>Antagonistic Effects of BACE1 and APH1B-&#x3b3;-Secretase Control Axonal Guidance by Regulating Growth Cone Collapse.</ArticleTitle><Pagination><StartPage>1367</StartPage><EndPage>1376</EndPage><MedlinePgn>1367-76</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.celrep.2015.07.059</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2211-1247(15)00849-9</ELocationID><Abstract><AbstractText>&#x392;ACE1 is the major drug target for Alzheimer's disease, but we know surprisingly little about its normal function in the CNS. Here, we show that this protease is critically involved in semaphorin 3A (Sema3A)-mediated axonal guidance processes in thalamic and hippocampal neurons. An active membrane-bound proteolytic CHL1 fragment is generated by BACE1 upon Sema3A binding. This fragment relays the Sema3A signal via ezrin-radixin-moesin (ERM) proteins to the neuronal cytoskeleton. APH1B-&#x3b3;-secretase-mediated degradation of this fragment stops the Sema3A-induced collapse and sensitizes the growth cone for the next axonal guidance cue. Thus, we reveal a cycle of proteolytic activity underlying growth cone collapse and restoration used by axons to find their correct trajectory in the brain. Our data also suggest that BACE1 and &#x3b3;-secretase inhibition have physiologically opposite effects in this process, supporting the idea that combination therapy might attenuate some of the side effects associated with these drugs.</AbstractText><CopyrightInformation>Copyright &#xa9; 2015 The Authors. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bar&#xe3;o</LastName><ForeName>Soraia</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>VIB Center for the Biology of Disease, VIB-Leuven 3000, Belgium; Center for Human Genetics, Universitaire ziekenhuizen and LIND, KU Leuven, Leuven 3000, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>G&#xe4;rtner</LastName><ForeName>Annette</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>VIB Center for the Biology of Disease, VIB-Leuven 3000, Belgium; Center for Human Genetics, Universitaire ziekenhuizen and LIND, KU Leuven, Leuven 3000, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leyva-D&#xed;az</LastName><ForeName>Eduardo</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Instituto de Neurociencias, Universidad Miguel Hernandez-Consejo Superior de Investigaciones Cient&#xed;ficas (UMH-CSIC), 03550 San Joan d'Alacant, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Demyanenko</LastName><ForeName>Galina</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Biochemistry and Biophysics, University of North Carolina (UNC), Chapel Hill, NC 27599, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Munck</LastName><ForeName>Sebastian</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>VIB Center for the Biology of Disease, VIB-Leuven 3000, Belgium; Center for Human Genetics, Universitaire ziekenhuizen and LIND, KU Leuven, Leuven 3000, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vanhoutvin</LastName><ForeName>Tine</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>VIB Center for the Biology of Disease, VIB-Leuven 3000, Belgium; Center for Human Genetics, Universitaire ziekenhuizen and LIND, KU Leuven, Leuven 3000, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Lujia</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>VIB Center for the Biology of Disease, VIB-Leuven 3000, Belgium; Center for Human Genetics, Universitaire ziekenhuizen and LIND, KU Leuven, Leuven 3000, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schachner</LastName><ForeName>Melitta</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>W.M. Keck Center for Collaborative Neuroscience, Department of Cell Biology and Neuroscience, Rutgers University, Piscataway, NJ&#xa0;08854-8082, USA; Center for Neuroscience, Shantou University Medical College, Shantou, Guangdong 515041, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>L&#xf3;pez-Bendito</LastName><ForeName>Guillermina</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Instituto de Neurociencias, Universidad Miguel Hernandez-Consejo Superior de Investigaciones Cient&#xed;ficas (UMH-CSIC), 03550 San Joan d'Alacant, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maness</LastName><ForeName>Patricia F</ForeName><Initials>PF</Initials><AffiliationInfo><Affiliation>Department of Biochemistry and Biophysics, University of North Carolina (UNC), Chapel Hill, NC 27599, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Strooper</LastName><ForeName>Bart</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>VIB Center for the Biology of Disease, VIB-Leuven 3000, Belgium; Center for Human Genetics, Universitaire ziekenhuizen and LIND, KU Leuven, Leuven 3000, Belgium; Institute of Neurology, University College London, Queen Square, WC1N 3BG London, UK. Electronic address: bart.destrooper@cme.vib-kuleuven.be.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 MH101605</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH113280</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>08</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cell Rep</MedlineTA><NlmUniqueID>101573691</NlmUniqueID></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008565">Membrane Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C488217">Sema3a protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D040121">Semaphorin-3A</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D010450">Endopeptidases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.-</RegistryNumber><NameOfSubstance UI="D016282">Aspartic Acid Endopeptidases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.46</RegistryNumber><NameOfSubstance UI="C509282">Bace1 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.99.-</RegistryNumber><NameOfSubstance UI="C498195">Aph1b protein, mouse</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D053829" MajorTopicYN="N">Amyloid Precursor Protein Secretases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016282" MajorTopicYN="N">Aspartic Acid Endopeptidases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010450" MajorTopicYN="N">Endopeptidases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020439" MajorTopicYN="N">Growth Cones</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008565" MajorTopicYN="N">Membrane Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059748" MajorTopicYN="N">Proteolysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D040121" MajorTopicYN="N">Semaphorin-3A</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>3</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2015</Year><Month>7</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>7</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>8</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>8</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>6</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2016</Year><Month>4</Month><Day>4</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26299962</ArticleId><ArticleId IdType="mid">NIHMS760930</ArticleId><ArticleId IdType="pmc">PMC4820248</ArticleId><ArticleId IdType="doi">10.1016/j.celrep.2015.07.059</ArticleId><ArticleId IdType="pii">S2211-1247(15)00849-9</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Acx H, Ch&#xb4;vez-Guti&#xe9;rrez L, Serneels L, Lismont S, Benurwar M, Elad N, De Strooper B. Signature amyloid &#x3b2; profiles are produced by different &#x3b3;-secretase complexes. J Biol Chem. 2014;289:4346&#x2013;4355.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3924297</ArticleId><ArticleId IdType="pubmed">24338474</ArticleId></ArticleIdList></Reference><Reference><Citation>Annaert WG, Esselens C, Baert V, Boeve C, Snellings G, Cupers P, Craessaerts K, De Strooper B. Interaction with telencephalin and the amyloid precursor protein predicts a ring structure for presenilins. Neuron. 2001;32:579&#x2013;589.</Citation><ArticleIdList><ArticleId IdType="pubmed">11719200</ArticleId></ArticleIdList></Reference><Reference><Citation>Bagnard D, Chounlamountri N, P&#xfc;schel AW, Bolz J. Axonal surface molecules act in combination with semaphorin 3a during the establishment of corticothalamic projections. Cereb Cortex. 2001;11:278&#x2013;285.</Citation><ArticleIdList><ArticleId IdType="pubmed">11230099</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao L, Rickenbacher GT, Rodriguez S, Moulia TW, Albers MW. The precision of axon targeting of mouse olfactory sensory neurons requires the BACE1 protease. Sci Rep. 2012;2:231.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3262176</ArticleId><ArticleId IdType="pubmed">22355745</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheret C, Willem M, Fricker FR, Wende H, Wulf-Goldenberg A, Tahirovic S, Nave KA, Saftig P, Haass C, Garratt AN, et al. Bace1 and Neuregulin-1 cooperate to control formation and maintenance of muscle spindles. EMBO J. 2013;32:2015&#x2013;2028.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3715864</ArticleId><ArticleId IdType="pubmed">23792428</ArticleId></ArticleIdList></Reference><Reference><Citation>De Strooper B. Lessons from a failed &#x3b3;-secretase Alzheimer trial. Cell. 2014;159:721&#x2013;726.</Citation><ArticleIdList><ArticleId IdType="pubmed">25417150</ArticleId></ArticleIdList></Reference><Reference><Citation>De Strooper B, Saftig P, Craessaerts K, Vanderstichele H, Guhde G, Annaert W, Von Figura K, Van Leuven F. Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein. Nature. 1998;391:387&#x2013;390.</Citation><ArticleIdList><ArticleId IdType="pubmed">9450754</ArticleId></ArticleIdList></Reference><Reference><Citation>Dominguez D, Tournoy J, Hartmann D, Huth T, Cryns K, Deforce S, Serneels L, Camacho IE, Marjaux E, Craessaerts K, et al. Phenotypic and biochemical analyses of BACE1- and BACE2-deficient mice. J Biol Chem. 2005;280:30797&#x2013;30806.</Citation><ArticleIdList><ArticleId IdType="pubmed">15987683</ArticleId></ArticleIdList></Reference><Reference><Citation>Fazzari P, Snellinx A, Sabanov V, Ahmed T, Serneels L, Gartner A, Shariati SA, Balschun D, De Strooper B. Cell autonomous regulation of hippocampal circuitry via Aph1b-&#x3b3;-secretase/neuregulin 1 signalling. eLife. 2014;3:e02196.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4073283</ArticleId><ArticleId IdType="pubmed">24891237</ArticleId></ArticleIdList></Reference><Reference><Citation>Fournier AE, Nakamura F, Kawamoto S, Goshima Y, Kalb RG, Strittmatter SM. Semaphorin3A enhances endocytosis at sites of receptor-F-actin colocalization during growth cone collapse. J Cell Biol. 2000;149:411&#x2013;422.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2175148</ArticleId><ArticleId IdType="pubmed">10769032</ArticleId></ArticleIdList></Reference><Reference><Citation>Harrison SM, Harper AJ, Hawkins J, Duddy G, Grau E, Pugh PL, Winter PH, Shilliam CS, Hughes ZA, Dawson LA, et al. BACE1 (beta-secretase) transgenic and knockout mice: identification of neurochemical deficits and behavioral changes. Mol Cell Neurosci. 2003;24:646&#x2013;655.</Citation><ArticleIdList><ArticleId IdType="pubmed">14664815</ArticleId></ArticleIdList></Reference><Reference><Citation>Hitt B, Riordan SM, Kukreja L, Eimer WA, Rajapaksha TW, Vassar R. &#x3b2;-Site amyloid precursor protein (APP)-cleaving enzyme 1 (BACE1)-deficient mice exhibit a close homolog of L1 (CHL1) loss-of-function phenotype involving axon guidance defects. J Biol Chem. 2012;287:38408&#x2013;38425.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3493884</ArticleId><ArticleId IdType="pubmed">22988240</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu X, Hicks CW, He W, Wong P, Macklin WB, Trapp BD, Yan R. Bace1 modulates myelination in the central and peripheral nervous system. Nat Neurosci. 2006;9:1520&#x2013;1525.</Citation><ArticleIdList><ArticleId IdType="pubmed">17099708</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuhn PH, Koroniak K, Hogl S, Colombo A, Zeitschel U, Willem M, Volbracht C, Schepers U, Imhof A, Hoffmeister A, et al. Secretome protein enrichment identifies physiological BACE1 protease substrates in neurons. EMBO J. 2012;31:3157&#x2013;3168.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3400020</ArticleId><ArticleId IdType="pubmed">22728825</ArticleId></ArticleIdList></Reference><Reference><Citation>Laird FM, Cai H, Savonenko AV, Farah MH, He K, Melnikova T, Wen H, Chiang HC, Xu G, Koliatsos VE, et al. BACE1, a major determinant of selective vulnerability of the brain to amyloid-beta amyloidogenesis, is essential for cognitive, emotional, and synaptic functions. J Neurosci. 2005;25:11693&#x2013;11709.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2564291</ArticleId><ArticleId IdType="pubmed">16354928</ArticleId></ArticleIdList></Reference><Reference><Citation>Leyva-D&#xed;az E, del Toro D, Menal MJ, Cambray S, Sus&#xed;n R, Tessier-Lavigne M, Klein R, Egea J, L&#xf3;pez-Bendito G. FLRT3 is a Robo1-nteracting protein that determines Netrin-1 attraction in developing axons. Curr Biol. 2014;24:494&#x2013;508.</Citation><ArticleIdList><ArticleId IdType="pubmed">24560577</ArticleId></ArticleIdList></Reference><Reference><Citation>Mintz CD, Carcea I, McNickle DG, Dickson TC, Ge Y, Salton SR, Benson DL. ERM proteins regulate growth cone responses to Sema3A. J Comp Neurol. 2008;510:351&#x2013;366.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2691689</ArticleId><ArticleId IdType="pubmed">18651636</ArticleId></ArticleIdList></Reference><Reference><Citation>Montag-Sallaz M, Schachner M, Montag D. Misguided axonal projections, neural cell adhesion molecule 180 mRNA upregulation, and altered behavior in mice deficient for the close homolog of L1. Mol Cell Biol. 2002;22:7967&#x2013;7981.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC134725</ArticleId><ArticleId IdType="pubmed">12391163</ArticleId></ArticleIdList></Reference><Reference><Citation>Naus S, Richter M, Wildeboer D, Moss M, Schachner M, Bartsch JW. Ectodomain shedding of the neural recognition molecule CHL1 by the metalloprotease-disintegrin ADAM8 promotes neurite outgrowth and suppresses neuronal cell death. J Biol Chem. 2004;279:16083&#x2013;16090.</Citation><ArticleIdList><ArticleId IdType="pubmed">14761956</ArticleId></ArticleIdList></Reference><Reference><Citation>Pozas E, Pascual M, Nguyen Ba-Charvet KT, Guijarro P, Sotelo C, Ch&#xe9;dotal A, Del R&#xed;o JA, Soriano E. Age-dependent effects of secreted semaphorins 3A, 3F, and 3E on developing hippocampal axons: n vitro effects and phenotype of semaphorin 3A (&#x2212;/&#x2212;) mice. Mol Cell Neurosci. 2001;18:26&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pubmed">11461151</ArticleId></ArticleIdList></Reference><Reference><Citation>Pratte M, Rougon G, Schachner M, Jamon M. Mice deficient for the close homologue of the neural adhesion cell L1 (CHL1) display alterations in emotional reactivity and motor coordination. Behav Brain Res. 2003;147:31&#x2013;39.</Citation><ArticleIdList><ArticleId IdType="pubmed">14659567</ArticleId></ArticleIdList></Reference><Reference><Citation>Rajapaksha TW, Eimer WA, Bozza TC, Vassar R. The Alzheimer's &#x3b2;-secretase enzyme BACE1 is required for accurate axon guidance of olfactory sensory neurons and normal glomerulus formation in the olfactory bulb. Mol Neurodegener. 2011;6:88.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3269394</ArticleId><ArticleId IdType="pubmed">22204380</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramesh V. Merlin and the ERM proteins in Schwann cells, neurons and growth cones. Nat Rev Neurosci. 2004;5:462&#x2013;470.</Citation><ArticleIdList><ArticleId IdType="pubmed">15152196</ArticleId></ArticleIdList></Reference><Reference><Citation>Romi E, Gokhman I, Wong E, Antonovsky N, Ludwig A, Sagi I, Saftig P, Tessier-Lavigne M, Yaron A. ADAM metalloproteases promote a developmental switch in responsiveness to the axonal repellant Sema3A. Nat Commun. 2014;5:4058.</Citation><ArticleIdList><ArticleId IdType="pubmed">24898499</ArticleId></ArticleIdList></Reference><Reference><Citation>Sahay A, Molliver ME, Ginty DD, Kolodkin AL. Semaphorin 3F is critical for development of limbic system circuitry and is required in neurons for selective CNS axon guidance events. J Neurosci. 2003;23:6671&#x2013;6680.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6740712</ArticleId><ArticleId IdType="pubmed">12890759</ArticleId></ArticleIdList></Reference><Reference><Citation>Sahay A, Kim CH, Sepkuty JP, Cho E, Huganir RL, Ginty DD, Kolodkin AL. Secreted semaphorins modulate synaptic transmission in the adult hippocampus. J Neurosci. 2005;25:3613&#x2013;3620.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725392</ArticleId><ArticleId IdType="pubmed">15814792</ArticleId></ArticleIdList></Reference><Reference><Citation>Savonenko AV, Melnikova T, Laird FM, Stewart KA, Price DL, Wong PC. Alteration of BACE1-dependent NRG1/ErbB4 signaling and schizophrenia-like phenotypes in BACE1-null mice. Proc Natl Acad Sci USA. 2008;105:5585&#x2013;5590.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2291091</ArticleId><ArticleId IdType="pubmed">18385378</ArticleId></ArticleIdList></Reference><Reference><Citation>Schlatter MC, Buhusi M, Wright AG, Maness PF. CHL1 promotes Sema3A-induced growth cone collapse and neurite elaboration through a motif required for recruitment of ERM proteins to the plasma membrane. J Neurochem. 2008;104:731&#x2013;744.</Citation><ArticleIdList><ArticleId IdType="pubmed">17995939</ArticleId></ArticleIdList></Reference><Reference><Citation>Serneels L, Dejaegere T, Craessaerts K, Horr&#xe9; K, Jorissen E, Tousseyn T, H&#xe9;bert S, Coolen M, Martens G, Zwijsen A, et al. Differential contribution of the three Aph1 genes to gamma-secretase activity in vivo. Proc Natl Acad Sci USA. 2005;102:1719&#x2013;1724.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC547495</ArticleId><ArticleId IdType="pubmed">15665098</ArticleId></ArticleIdList></Reference><Reference><Citation>Serneels L, Van Biervliet J, Craessaerts K, Dejaegere T, Horr&#xe9; K, Van Houtvin T, Esselmann H, Paul S, Sch&#xe4;fer MK, Berezovska O, et al. gamma-Secretase heterogeneity in the Aph1 subunit: relevance for Alzheimer's disease. Science. 2009;324:639&#x2013;642.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2740474</ArticleId><ArticleId IdType="pubmed">19299585</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi T, Fournier A, Nakamura F, Wang LH, Murakami Y, Kalb RG, Fujisawa H, Strittmatter SM. Plexin-neuropilin-1 complexes form functional semaphorin-3A receptors. Cell. 1999;99:59&#x2013;69.</Citation><ArticleIdList><ArticleId IdType="pubmed">10520994</ArticleId></ArticleIdList></Reference><Reference><Citation>Tamagnone L, Artigiani S, Chen H, He Z, Ming GI, Song H, Chedotal A, Winberg ML, Goodman CS, Poo M, et al. Plexins are a large family of receptors for transmembrane, secreted, and GPI-anchored semaphorins in vertebrates. Cell. 1999;99:71&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pubmed">10520995</ArticleId></ArticleIdList></Reference><Reference><Citation>Vassar R, Bennett BD, Babu-Khan S, Kahn S, Mendiaz EA, Denis P, Teplow DB, Ross S, Amarante P, Loeloff R, et al. Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science. 1999;286:735&#x2013;741.</Citation><ArticleIdList><ArticleId IdType="pubmed">10531052</ArticleId></ArticleIdList></Reference><Reference><Citation>Willem M, Garratt AN, Novak B, Citron M, Kaufmann S, Rittger A, DeStrooper B, Saftig P, Birchmeier C, Haass C. Control of peripheral nerve myelination by the beta-secretase BACE1. Science. 2006;314:664&#x2013;666.</Citation><ArticleIdList><ArticleId IdType="pubmed">16990514</ArticleId></ArticleIdList></Reference><Reference><Citation>Wright AG, Demyanenko GP, Powell A, Schachner M, Enriquez-Barreto L, Tran TS, Polleux F, Maness PF. Close homolog of L1 and neuropilin 1 mediate guidance of thalamocortical axons at the ventral telencephalon. J Neurosci. 2007;27:13667&#x2013;13679.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6673613</ArticleId><ArticleId IdType="pubmed">18077678</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou L, Bar&#xe3;o S, Laga M, Bockstael K, Borgers M, Gijsen H, Annaert W, Moechars D, Mercken M, Gevaert K, De Strooper B. The neural cell adhesion molecules L1 and CHL1 are cleaved by BACE1 protease in vivo. J Biol Chem. 2012;287:25927&#x2013;25940.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3406677</ArticleId><ArticleId IdType="pubmed">22692213</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">26299959</PMID><DateCompleted><Year>2016</Year><Month>06</Month><Day>17</Day></DateCompleted><DateRevised><Year>2023</Year><Month>08</Month><Day>15</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2211-1247</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><Issue>9</Issue><PubDate><Year>2015</Year><Month>Sep</Month><Day>01</Day></PubDate></JournalIssue><Title>Cell reports</Title><ISOAbbreviation>Cell Rep</ISOAbbreviation></Journal><ArticleTitle>Presenilin 1 Maintains Lysosomal Ca(2+) Homeostasis via TRPML1 by Regulating vATPase-Mediated Lysosome Acidification.</ArticleTitle><Pagination><StartPage>1430</StartPage><EndPage>1444</EndPage><MedlinePgn>1430-44</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.celrep.2015.07.050</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2211-1247(15)00828-1</ELocationID><Abstract><AbstractText>Presenilin 1 (PS1) deletion or Alzheimer's disease (AD)-linked mutations disrupt lysosomal acidification and proteolysis, which inhibits autophagy. Here, we establish that this phenotype stems from impaired glycosylation and instability of vATPase V0a1 subunit, causing deficient lysosomal vATPase assembly and function. We further demonstrate that elevated lysosomal pH in Presenilin 1 knockout (PS1KO) cells induces abnormal Ca(2+) efflux from lysosomes mediated by TRPML1 and elevates cytosolic Ca(2+). In WT cells, blocking vATPase activity or knockdown of either PS1 or the V0a1 subunit of vATPase reproduces all of these abnormalities. Normalizing lysosomal pH in PS1KO cells using acidic nanoparticles restores normal lysosomal proteolysis, autophagy, and Ca(2+) homeostasis, but correcting lysosomal Ca(2+) deficits alone neither re-acidifies lysosomes nor reverses proteolytic and autophagic deficits. Our results indicate that vATPase deficiency in PS1 loss-of-function states causes lysosomal/autophagy deficits and contributes to abnormal cellular Ca(2+) homeostasis, thus linking two AD-related pathogenic processes through a common molecular mechanism.</AbstractText><CopyrightInformation>Copyright &#xa9; 2015 The Authors. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Ju-Hyun</ForeName><Initials>JH</Initials><AffiliationInfo><Affiliation>Center for Dementia Research, Nathan S. Kline Institute, Orangeburg, NY 10962, USA; Department of Psychiatry, New York University, New York, NY 10016, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McBrayer</LastName><ForeName>Mary Kate</ForeName><Initials>MK</Initials><AffiliationInfo><Affiliation>Center for Dementia Research, Nathan S. Kline Institute, Orangeburg, NY 10962, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wolfe</LastName><ForeName>Devin M</ForeName><Initials>DM</Initials><AffiliationInfo><Affiliation>Center for Dementia Research, Nathan S. Kline Institute, Orangeburg, NY 10962, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Haslett</LastName><ForeName>Luke J</ForeName><Initials>LJ</Initials><AffiliationInfo><Affiliation>Division of Pathophysiology and Repair, Cardiff University, Cardiff CF10 3XQ, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kumar</LastName><ForeName>Asok</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Center for Dementia Research, Nathan S. Kline Institute, Orangeburg, NY 10962, USA; Department of Pathology, New York University, New York, NY 10016, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sato</LastName><ForeName>Yutaka</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Center for Dementia Research, Nathan S. Kline Institute, Orangeburg, NY 10962, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lie</LastName><ForeName>Pearl P Y</ForeName><Initials>PP</Initials><AffiliationInfo><Affiliation>Center for Dementia Research, Nathan S. Kline Institute, Orangeburg, NY 10962, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mohan</LastName><ForeName>Panaiyur</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Center for Dementia Research, Nathan S. Kline Institute, Orangeburg, NY 10962, USA; Department of Psychiatry, New York University, New York, NY 10016, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Coffey</LastName><ForeName>Erin E</ForeName><Initials>EE</Initials><AffiliationInfo><Affiliation>Department of Anatomy and Cell Biology, University of Pennsylvania, Philadelphia, PA 19104, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kompella</LastName><ForeName>Uday</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>Pharmaceutical Science and Ophthalmology, University of Colorado, Aurora, CO 80045, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mitchell</LastName><ForeName>Claire H</ForeName><Initials>CH</Initials><AffiliationInfo><Affiliation>Department of Anatomy and Cell Biology, University of Pennsylvania, Philadelphia, PA 19104, USA; Department of Physiology, University of Pennsylvania, Philadelphia, PA 19104, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lloyd-Evans</LastName><ForeName>Emyr</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Division of Pathophysiology and Repair, Cardiff University, Cardiff CF10 3XQ, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nixon</LastName><ForeName>Ralph A</ForeName><Initials>RA</Initials><AffiliationInfo><Affiliation>Center for Dementia Research, Nathan S. Kline Institute, Orangeburg, NY 10962, USA; Department of Psychiatry, New York University, New York, NY 10016, USA; Department of Cell Biology, New York University, New York, NY 10016, USA. Electronic address: nixon@nki.rfmh.org.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P01AG017617</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><Agency>Biotechnology and Biological Sciences Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>R01 EY015537</GrantID><Acronym>EY</Acronym><Agency>NEI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG017617</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 EY013434</GrantID><Acronym>EY</Acronym><Agency>NEI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>08</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cell Rep</MedlineTA><NlmUniqueID>101573691</NlmUniqueID></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C512321">Mcoln1 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053764">Presenilin-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D050051">Transient Receptor Potential Channels</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.6.1.-</RegistryNumber><NameOfSubstance UI="D025262">Vacuolar Proton-Translocating ATPases</NameOfSubstance></Chemical><Chemical><RegistryNumber>SY7Q814VUP</RegistryNumber><NameOfSubstance UI="D002118">Calcium</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001343" MajorTopicYN="N">Autophagy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002118" MajorTopicYN="N">Calcium</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006706" MajorTopicYN="N">Homeostasis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006863" MajorTopicYN="N">Hydrogen-Ion Concentration</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008247" MajorTopicYN="N">Lysosomes</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053764" MajorTopicYN="N">Presenilin-1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D059748" MajorTopicYN="N">Proteolysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D050051" MajorTopicYN="N">Transient Receptor Potential Channels</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D025262" MajorTopicYN="N">Vacuolar Proton-Translocating ATPases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>9</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2015</Year><Month>4</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>7</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>8</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>8</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>6</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2016</Year><Month>9</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26299959</ArticleId><ArticleId IdType="mid">NIHMS712149</ArticleId><ArticleId IdType="pmc">PMC4558203</ArticleId><ArticleId IdType="doi">10.1016/j.celrep.2015.07.050</ArticleId><ArticleId IdType="pii">S2211-1247(15)00828-1</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Avrahami L, Farfara D, Shaham-Kol M, Vassar R, Frenkel D, Eldar-Finkelman H. Inhibition of glycogen synthase kinase-3 ameliorates beta-amyloid pathology and restores lysosomal acidification and mammalian target of rapamycin activity in the Alzheimer disease mouse model: in vivo and in vitro studies. J Biol Chem. 2013;288:1295&#x2013;1306.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3543013</ArticleId><ArticleId IdType="pubmed">23155049</ArticleId></ArticleIdList></Reference><Reference><Citation>Baltazar GC, Guha S, Lu W, Lim J, Boesze-Battaglia K, Laties AM, Tyagi P, Kompella UB, Mitchell CH. Acidic nanoparticles are trafficked to lysosomes and restore an acidic lysosomal pH and degradative function to compromised ARPE-19 cells. PLoS One. 2012;7:e49635.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3525582</ArticleId><ArticleId IdType="pubmed">23272048</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhargava A, Voronov I, Wang Y, Glogauer M, Kartner N, Manolson MF. Osteopetrosis mutation R444L causes endoplasmic reticulum retention and misprocessing of vacuolar H+-ATPase a3 subunit. J Biol Chem. 2012;287:26829&#x2013;26839.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3411020</ArticleId><ArticleId IdType="pubmed">22685294</ArticleId></ArticleIdList></Reference><Reference><Citation>Butler D, Hwang J, Estick C, Nishiyama A, Kumar SS, Baveghems C, Young-Oxendine HB, Wisniewski ML, Charalambides A, Bahr BA. Protective effects of positive lysosomal modulation in Alzheimer&#x2019;s disease transgenic mouse models. PLoS One. 2011;6:e20501.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3112200</ArticleId><ArticleId IdType="pubmed">21695208</ArticleId></ArticleIdList></Reference><Reference><Citation>Calcraft PJ, Ruas M, Pan Z, Cheng X, Arredouani A, Hao X, Tang J, Rietdorf K, Teboul L, Chuang KT, et al. NAADP mobilizes calcium from acidic organelles through two-pore channels. Nature. 2009;459:596&#x2013;600.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2761823</ArticleId><ArticleId IdType="pubmed">19387438</ArticleId></ArticleIdList></Reference><Reference><Citation>Cesen MH, Pegan K, Spes A, Turk B. Lysosomal pathways to cell death and their therapeutic applications. ExpCell Res. 2012;318:1245&#x2013;1251.</Citation><ArticleIdList><ArticleId IdType="pubmed">22465226</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan SL, Mayne M, Holden CP, Geiger JD, Mattson MP. Presenilin-1 mutations increase levels of ryanodine receptors and calcium release in PC12 cells and cortical neurons. J Biol Chem. 2000;275:18195&#x2013;18200.</Citation><ArticleIdList><ArticleId IdType="pubmed">10764737</ArticleId></ArticleIdList></Reference><Reference><Citation>Chavez-Gutierrez L, Bammens L, Benilova I, Vandersteen A, Benurwar M, Borgers M, Lismont S, Zhou L, Van Cleynenbreugel S, Esselmann H, et al. The mechanism of gamma-Secretase dysfunction in familial Alzheimer disease. EMBO J. 2012;31:2261&#x2013;2274.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3364747</ArticleId><ArticleId IdType="pubmed">22505025</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheung KH, Mei L, Mak DO, Hayashi I, Iwatsubo T, Kang DE, Foskett JK. Gain-of-function enhancement of IP3 receptor modal gating by familial Alzheimer&#x2019;s disease-linked presenilin mutants in human cells and mouse neurons. Sci Signal. 2010;3:ra22.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2898196</ArticleId><ArticleId IdType="pubmed">20332427</ArticleId></ArticleIdList></Reference><Reference><Citation>Christensen KA, Myers JT, Swanson JA. pH-dependent regulation of lysosomal calcium in macrophages. J Cell Sci. 2002;115:599&#x2013;607.</Citation><ArticleIdList><ArticleId IdType="pubmed">11861766</ArticleId></ArticleIdList></Reference><Reference><Citation>Churchill GC, Okada Y, Thomas JM, Genazzani AA, Patel S, Galione A. NAADP mobilizes Ca(2+) from reserve granules, lysosome-related organelles, in sea urchin eggs. Cell. 2002;111:703&#x2013;708.</Citation><ArticleIdList><ArticleId IdType="pubmed">12464181</ArticleId></ArticleIdList></Reference><Reference><Citation>Coen K, Flannagan R, Baron S, Carraro-Lacroix L, Wang D, Vermeire W, Michiels C, Munck S, Baert V, Sugita S, et al. Lysosomal calcium homeostasis defects, not proton pump defects, cause endo-lysosomal dysfunction in PSEN-deficient cells. J Cell Biol. 2012;198:23&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3392942</ArticleId><ArticleId IdType="pubmed">22753898</ArticleId></ArticleIdList></Reference><Reference><Citation>Coffey EE, Beckel JM, Laties AM, Mitchell CH. Lysosomal alkalization and dysfunction in human fibroblasts with the Alzheimer&#x2019;s disease-linked presenilin 1 A246E mutation can be reversed with cAMP. Neuroscience. 2014;263:111&#x2013;124.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4028113</ArticleId><ArticleId IdType="pubmed">24418614</ArticleId></ArticleIdList></Reference><Reference><Citation>De Strooper B, Annaert W. Novel research horizons for presenilins and gamma-secretases in cell biology and disease. AnnuRevCell DevBiol. 2010;26:235&#x2013;260.</Citation><ArticleIdList><ArticleId IdType="pubmed">20604710</ArticleId></ArticleIdList></Reference><Reference><Citation>Dobrowolski R, Vick P, Ploper D, Gumper I, Snitkin H, Sabatini DD, De Robertis EM. Presenilin Deficiency or Lysosomal Inhibition Enhances Wnt Signaling through Relocalization of GSK3 to the Late-Endosomal Compartment. Cell Rep. 2012;2:1316&#x2013;1328.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3538832</ArticleId><ArticleId IdType="pubmed">23122960</ArticleId></ArticleIdList></Reference><Reference><Citation>Dong XP, Shen D, Wang X, Dawson T, Li X, Zhang Q, Cheng X, Zhang Y, Weisman LS, Delling M, et al. PI(3,5)P(2) controls membrane trafficking by direct activation of mucolipin Ca(2+) release channels in the endolysosome. Nat Commun. 2010;1:38.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2928581</ArticleId><ArticleId IdType="pubmed">20802798</ArticleId></ArticleIdList></Reference><Reference><Citation>Dong XP, Wang X, Shen D, Chen S, Liu M, Wang Y, Mills E, Cheng X, Delling M, Xu H. Activating mutations of the TRPML1 channel revealed by proline-scanning mutagenesis. J Biol Chem. 2009;284:32040&#x2013;32052.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2797275</ArticleId><ArticleId IdType="pubmed">19638346</ArticleId></ArticleIdList></Reference><Reference><Citation>Esselens C, Oorschot V, Baert V, Raemaekers T, Spittaels K, Serneels L, Zheng H, Saftig P, De Strooper B, Klumperman J, et al. Presenilin 1 mediates the turnover of telencephalin in hippocampal neurons via an autophagic degradative pathway. J Cell Biol. 2004;166:1041&#x2013;1054.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2172014</ArticleId><ArticleId IdType="pubmed">15452145</ArticleId></ArticleIdList></Reference><Reference><Citation>Fameli N, Ogunbayo OA, van Breemen C, Evans AM. Cytoplasmic nanojunctions between lysosomes and sarcoplasmic reticulum are required for specific calcium signaling. F1000Res. 2014;3:93.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4126599</ArticleId><ArticleId IdType="pubmed">25126414</ArticleId></ArticleIdList></Reference><Reference><Citation>Frakes AE, Ferraiuolo L, Haidet-Phillips AM, Schmelzer L, Braun L, Miranda CJ, Ladner KJ, Bevan AK, Foust KD, Godbout JP, et al. Microglia induce motor neuron death via the classical NF-kappaB pathway in amyotrophic lateral sclerosis. Neuron. 2014;81:1009&#x2013;1023.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3978641</ArticleId><ArticleId IdType="pubmed">24607225</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghavami S, Shojaei S, Yeganeh B, Ande SR, Jangamreddy JR, Mehrpour M, Christoffersson J, Chaabane W, Moghadam AR, Kashani HH, et al. Autophagy and apoptosis dysfunction in neurodegenerative disorders. ProgNeurobiol. 2014;112:24&#x2013;49.</Citation><ArticleIdList><ArticleId IdType="pubmed">24211851</ArticleId></ArticleIdList></Reference><Reference><Citation>Gillespie J, Ozanne S, Tugal B, Percy J, Warren M, Haywood J, Apps D. The vacuolar H(+)-translocating ATPase of renal tubules contains a 115-kDa glycosylated subunit. FEBS Lett. 1991;282:69&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pubmed">1827413</ArticleId></ArticleIdList></Reference><Reference><Citation>Grimm C, Jors S, Saldanha SA, Obukhov AG, Pan B, Oshima K, Cuajungco MP, Chase P, Hodder P, Heller S. Small molecule activators of TRPML3. Chem Biol. 2010;17:135&#x2013;148.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2834294</ArticleId><ArticleId IdType="pubmed">20189104</ArticleId></ArticleIdList></Reference><Reference><Citation>Jha A, Ahuja M, Patel S, Brailoiu E, Muallem S. Convergent regulation of the lysosomal two-pore channel-2 by Mg(2)(+), NAADP, PI(3,5)P(2) and multiple protein kinases. EMBO J. 2014;33:501&#x2013;511.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3989630</ArticleId><ArticleId IdType="pubmed">24502975</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang DE, Soriano S, Frosch MP, Collins T, Naruse S, Sisodia SS, Leibowitz G, Levine F, Koo EH. Presenilin 1 facilitates the constitutive turnover of beta-catenin: differential activity of Alzheimer&#x2019;s disease-linked PS1 mutants in the beta-catenin-signaling pathway. J Neurosci. 1999;19:4229&#x2013;4237.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6782616</ArticleId><ArticleId IdType="pubmed">10341227</ArticleId></ArticleIdList></Reference><Reference><Citation>Kilpatrick BS, Eden ER, Schapira AH, Futter CE, Patel S. Direct mobilisation of lysosomal Ca2+ triggers complex Ca2+ signals. J Cell Sci. 2013;126:60&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4208295</ArticleId><ArticleId IdType="pubmed">23108667</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee JH, Yu WH, Kumar A, Lee S, Mohan PS, Peterhoff CM, Wolf DM, Marinez-Vicente M, Massey AG, Sovak G, et al. Lysosomal proteolysis and autophagy require presenilin 1 and are disrupted by Alzheimer-related PS1 mutations. Cell. 2010;141:1146&#x2013;1158.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3647462</ArticleId><ArticleId IdType="pubmed">20541250</ArticleId></ArticleIdList></Reference><Reference><Citation>Lloyd-Evans E, Morgan AJ, He X, Smith DA, Elliot-Smith E, Sillence DJ, Churchill GC, Schuchman EH, Galione A, Platt FM. Niemann-Pick disease type C1 is a sphingosine storage disease that causes deregulation of lysosomal calcium. Nat Med. 2008;14:1247&#x2013;1255.</Citation><ArticleIdList><ArticleId IdType="pubmed">18953351</ArticleId></ArticleIdList></Reference><Reference><Citation>Menzies FM, Fleming A, Rubinsztein DC. Compromised autophagy and neurodegenerative diseases. Nat Rev Neurosci. 2015;16:345&#x2013;357.</Citation><ArticleIdList><ArticleId IdType="pubmed">25991442</ArticleId></ArticleIdList></Reference><Reference><Citation>Mindell JA. Lysosomal acidification mechanisms. Annu Rev Physiol. 2012;74:69&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="pubmed">22335796</ArticleId></ArticleIdList></Reference><Reference><Citation>Naylor E, Arredouani A, Vasudevan SR, Lewis AM, Parkesh R, Mizote A, Rosen D, Thomas JM, Izumi M, Ganesan A, et al. Identification of a chemical probe for NAADP by virtual screening. NatChemBiol. 2009;5:220&#x2013;226.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2659327</ArticleId><ArticleId IdType="pubmed">19234453</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishi T, Forgac M. Molecular Cloning and Expression of Three Isoforms of the 100-kDa a Subunit of the Mouse Vacuolar Proton-translocating ATPase. J Biol Chem. 2000;275:6824&#x2013;6830.</Citation><ArticleIdList><ArticleId IdType="pubmed">10702241</ArticleId></ArticleIdList></Reference><Reference><Citation>Nixon RA. Autophagy, amyloidogenesis and Alzheimer disease. J Cell Sci. 2007;120:4081&#x2013;4091.</Citation><ArticleIdList><ArticleId IdType="pubmed">18032783</ArticleId></ArticleIdList></Reference><Reference><Citation>Nixon RA. The role of autophagy in neurodegenerative disease. Nat Med. 2013;19:983&#x2013;997.</Citation><ArticleIdList><ArticleId IdType="pubmed">23921753</ArticleId></ArticleIdList></Reference><Reference><Citation>Nixon RA, Yang D. Autophagy and neuronal cell death in neurological disorders. Cold Spring Harb Perspect Biol. 2012;4 pii: a008839.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3475163</ArticleId><ArticleId IdType="pubmed">22983160</ArticleId></ArticleIdList></Reference><Reference><Citation>Nixon RA, Yang DS. Autophagy failure in Alzheimer&#x2019;s disease-locating the primary defect. NeurobiolDis. 2011;43:38&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3096679</ArticleId><ArticleId IdType="pubmed">21296668</ArticleId></ArticleIdList></Reference><Reference><Citation>Penny CJ, Kilpatrick BS, Han JM, Sneyd J, Patel S. A computational model of lysosome-ER Ca2+ microdomains. J Cell Sci. 2014;127:2934&#x2013;2943.</Citation><ArticleIdList><ArticleId IdType="pubmed">24706947</ArticleId></ArticleIdList></Reference><Reference><Citation>Pitt SJ, Funnell TM, Sitsapesan M, Venturi E, Rietdorf K, Ruas M, Ganesan A, Gosain R, Churchill GC, Zhu MX, et al. TPC2 is a novel NAADP-sensitive Ca2+ release channel, operating as a dual sensor of luminal pH and Ca2+ J Biol Chem. 2010;285:35039&#x2013;35046.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2966118</ArticleId><ArticleId IdType="pubmed">20720007</ArticleId></ArticleIdList></Reference><Reference><Citation>Raines SM, Rane HS, Bernardo SM, Binder JL, Lee SA, Parra KJ. Deletion of vacuolar proton-translocating ATPase V(o)a isoforms clarifies the role of vacuolar pH as a determinant of virulence-associated traits in Candida albicans. J Biol Chem. 2013;288:6190&#x2013;6201.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3585055</ArticleId><ArticleId IdType="pubmed">23316054</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramirez-Montealegre D, Pearce DA. Defective lysosomal arginine transport in juvenile Batten disease. HumMolGenet. 2005;14:3759&#x2013;3773.</Citation><ArticleIdList><ArticleId IdType="pubmed">16251196</ArticleId></ArticleIdList></Reference><Reference><Citation>Raychowdhury MK, Gonzalez-Perrett S, Montalbetti N, Timpanaro GA, Chasan B, Goldmann WH, Stahl S, Cooney A, Goldin E, Cantiello HF. Molecular pathophysiology of mucolipidosis type IV: pH dysregulation of the mucolipin-1 cation channel. HumMolGenet. 2004;13:617&#x2013;627.</Citation><ArticleIdList><ArticleId IdType="pubmed">14749347</ArticleId></ArticleIdList></Reference><Reference><Citation>Saw N, Kang S, Parsaud L, Han G, Jiang T, Grzegorczyk K, Surkont M, Sun-Wada G, Wada Y, Li L, et al. Vacuolar H(+)-ATPase subunits Voa1 and Voa2 cooperatively regulate secretory vesicle acidification, transmitter uptake, and storage. Mol Biol Cell. 2011;22:3394&#x2013;3409.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3172264</ArticleId><ArticleId IdType="pubmed">21795392</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ, Wolfe MS. Presenilin: Running with Scissors in the Membrane. Cell. 2007;131:215&#x2013;221.</Citation><ArticleIdList><ArticleId IdType="pubmed">17956719</ArticleId></ArticleIdList></Reference><Reference><Citation>Shilling D, Muller M, Takano H, Mak DO, Abel T, Coulter DA, Foskett JK. Suppression of InsP3 receptor-mediated Ca2+ signaling alleviates mutant presenilin-linked familial Alzheimer&#x2019;s disease pathogenesis. JNeurosci. 2014;34:6910&#x2013;6923.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4019804</ArticleId><ArticleId IdType="pubmed">24828645</ArticleId></ArticleIdList></Reference><Reference><Citation>Steiner H, Haass C. Intramembrane proteolysis by presenilins. Nat Rev Mol Cell Biol. 2000;1:217&#x2013;224.</Citation><ArticleIdList><ArticleId IdType="pubmed">11252897</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun B, Zhou Y, Halabisky B, Lo I, Cho SH, Mueller-Steiner S, Devidze N, Wang X, Grubb A, Gan L. Cystatin C-cathepsin B axis regulates amyloid beta levels and associated neuronal deficits in an animal model of Alzheimer&#x2019;s disease. Neuron. 2008;60:247&#x2013;257.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2755563</ArticleId><ArticleId IdType="pubmed">18957217</ArticleId></ArticleIdList></Reference><Reference><Citation>Torres M, Jimenez S, Sanchez-Varo R, Navarro V, Trujillo-Estrada L, Sanchez-Mejias E, Carmona I, Davila JC, Vizuete M, Gutierrez A, et al. Defective lysosomal proteolysis and axonal transport are early pathogenic events that worsen with age leading to increased APP metabolism and synaptic Abeta in transgenic APP/PS1 hippocampus. Mol Neurodegener. 2012;7:59.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3575255</ArticleId><ArticleId IdType="pubmed">23173743</ArticleId></ArticleIdList></Reference><Reference><Citation>Tu H, Nelson O, Bezprozvanny A, Wang Z, Lee SF, Hao YH, Serneels L, De Strooper B, Yu G, Bezprozvanny I. Presenilins form ER Ca2+ leak channels, a function disrupted by familial Alzheimer&#x2019;s disease-linked mutations. Cell. 2006;126:981&#x2013;993.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3241869</ArticleId><ArticleId IdType="pubmed">16959576</ArticleId></ArticleIdList></Reference><Reference><Citation>Walker MW, Lloyd-Evans E. A rapid method for the preparation of ultrapure, functional lysosomes using functionalized superparamagnetic iron oxide nanoparticles. Methods Cell Biol. 2015;126:21&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pubmed">25665439</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson CA, Murphy DD, Giasson BI, Zhang B, Trojanowski JQ, Lee VM. Degradative organelles containing mislocalized a- and b-synuclein proliferate in presenilin-1 null neurons. J Cell Biol. 2004;165:335&#x2013;346.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2172178</ArticleId><ArticleId IdType="pubmed">15123735</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolfe DM, Lee JH, Kumar A, Lee S, Orenstein SJ, Nixon RA. Autophagy failure in Alzheimer&#x2019;s disease and the role of defective lysosomal acidification. EurJNeurosci. 2013;37:1949&#x2013;1961.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3694736</ArticleId><ArticleId IdType="pubmed">23773064</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamaguchi S, Jha A, Li Q, Soyombo AA, Dickinson GD, Churamani D, Brailoiu E, Patel S, Muallem S. Transient receptor potential mucolipin 1 (TRPML1) and two-pore channels are functionally independent organellar ion channels. J Biol Chem. 2011;286:22934&#x2013;22942.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3123061</ArticleId><ArticleId IdType="pubmed">21540176</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang DS, Stavrides P, Mohan PS, Kaushik S, Kumar A, Ohno M, Schmidt SD, Wesson D, Bandyopadhyay U, Jiang Y, et al. Reversal of autophagy dysfunction in the TgCRND8 mouse model of Alzheimer&#x2019;s disease ameliorates amyloid pathologies and memory deficits. Brain. 2011;134:258&#x2013;277.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3009842</ArticleId><ArticleId IdType="pubmed">21186265</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang F, Jin S, Yi F, Li PL. TRP-ML1 functions as a lysosomal NAADP-sensitive Ca2+ release channel in coronary arterial myocytes. J Cell Mol Med. 2009;13:3174&#x2013;3185.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3752374</ArticleId><ArticleId IdType="pubmed">18754814</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X, Garbett K, Veeraraghavalu K, Wilburn B, Gilmore R, Mirnics K, Sisodia S. A Role for Presenilins in Autophagy Revisited: Normal Acidification of Lysosomes in Cells Lacking PSEN1 and PSEN2. JNeurosci. 2012a;32:8633&#x2013;8648.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3467018</ArticleId><ArticleId IdType="pubmed">22723704</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X, Li X, Xu H. Phosphoinositide isoforms determine compartment-specific ion channel activity. Proc Natl Acad Sci U S A. 2012b;109:11384&#x2013;11389.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3396495</ArticleId><ArticleId IdType="pubmed">22733759</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">26300044</PMID><DateCompleted><Year>2016</Year><Month>04</Month><Day>27</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1474-4465</ISSN><JournalIssue CitedMedium="Internet"><Volume>15</Volume><Issue>1</Issue><PubDate><Year>2016</Year><Month>Jan</Month></PubDate></JournalIssue><Title>The Lancet. Neurology</Title><ISOAbbreviation>Lancet Neurol</ISOAbbreviation></Journal><ArticleTitle>Dementia in western Europe: epidemiological evidence and implications for policy making.</ArticleTitle><Pagination><StartPage>116</StartPage><EndPage>124</EndPage><MedlinePgn>116-24</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/S1474-4422(15)00092-7</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1474-4422(15)00092-7</ELocationID><Abstract><AbstractText>Dementia is receiving increasing attention from governments and politicians. Epidemiological research based on western European populations done 20 years ago provided key initial evidence for dementia policy making, but these estimates are now out of date because of changes in life expectancy, living conditions, and health profiles. To assess whether dementia occurrence has changed during the past 20-30 years, investigators of five different studies done in western Europe (Sweden [Stockholm and Gothenburg], the Netherlands [Rotterdam], the UK [England], and Spain [Zaragoza]) have compared dementia occurrence using consistent research methods between two timepoints in well-defined geographical areas. Findings from four of the five studies showed non-significant changes in overall dementia occurrence. The only significant reduction in overall prevalence was found in the study done in the UK, powered and designed explicitly from its outset to detect change across generations (decrease in prevalence of 22%; p=0.003). Findings from the study done in Zaragoza (Spain) showed a significant reduction in dementia prevalence in men (43%; p=0.0002). The studies estimating incidence done in Stockholm and Rotterdam reported non-significant reductions. Such reductions could be the outcomes from earlier population-level investments such as improved education and living conditions, and better prevention and treatment of vascular and chronic conditions. This evidence suggests that attention to optimum health early in life might benefit cognitive health late in life. Policy planning and future research should be balanced across primary (policies reducing risk and increasing cognitive reserve), secondary (early detection and screening), and tertiary (once dementia is present) prevention. Each has their place, but upstream primary prevention has the largest effect on reduction of later dementia occurrence and disability.</AbstractText><CopyrightInformation>Copyright &#xa9; 2016 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Yu-Tzu</ForeName><Initials>YT</Initials><AffiliationInfo><Affiliation>Department of Public Health and Primary Care, Cambridge Institute of Public Health, School of Clinical Medicine, University of Cambridge, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fratiglioni</LastName><ForeName>Laura</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Aging Research Center, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet-Stockholm University, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Matthews</LastName><ForeName>Fiona E</ForeName><Initials>FE</Initials><AffiliationInfo><Affiliation>Medical Research Council Biostatistics Unit, Institute of Public Health, Cambridge, UK; Institute of Health and Society, Newcastle University, Newcastle, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lobo</LastName><ForeName>Antonio</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Universidad de Zaragoza, and Instituto de Investigaci&#xf3;n Sanitaria Arag&#xf3;n, Zaragoza, and Centro de Investigaci&#xf3;n Biom&#xe9;dica En Red de Salud Mental, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Breteler</LastName><ForeName>Monique M B</ForeName><Initials>MM</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases, Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Skoog</LastName><ForeName>Ingmar</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Centre for Ageing and Health, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brayne</LastName><ForeName>Carol</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Public Health and Primary Care, Cambridge Institute of Public Health, School of Clinical Medicine, University of Cambridge, Cambridge, UK. Electronic address: carol.brayne@medschl.cam.ac.uk.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MC_U105292687</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>08</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lancet Neurol</MedlineTA><NlmUniqueID>101139309</NlmUniqueID><ISSNLinking>1474-4422</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Lancet Neurol. 2016 Jun;15(7):659. doi: 10.1016/S1474-4422(16)30042-4.</RefSource><PMID Version="1">27302229</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Lancet Neurol. 2016 Jun;15(7):659. doi: 10.1016/S1474-4422(16)30041-2.</RefSource><PMID Version="1">27302230</PMID></CommentsCorrections><CommentsCorrections RefType="ErratumIn"><RefSource>Lancet Neurol. 2016 Feb;15(2):135. doi: 10.1016/S1474-4422(15)00387-7.</RefSource><PMID Version="1">28463116</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005060" MajorTopicYN="N" Type="Geographic">Europe</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006291" MajorTopicYN="N">Health Policy</DescriptorName><QualifierName UI="Q000639" MajorTopicYN="Y">trends</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011050" MajorTopicYN="Y">Policy Making</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>3</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2015</Year><Month>4</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>5</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>8</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>8</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>4</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26300044</ArticleId><ArticleId IdType="doi">10.1016/S1474-4422(15)00092-7</ArticleId><ArticleId IdType="pii">S1474-4422(15)00092-7</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">26305649</PMID><DateCompleted><Year>2015</Year><Month>08</Month><Day>31</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1538-3598</ISSN><JournalIssue CitedMedium="Internet"><Volume>314</Volume><Issue>8</Issue><PubDate><Year>2015</Year><Month>Aug</Month><Day>25</Day></PubDate></JournalIssue><Title>JAMA</Title><ISOAbbreviation>JAMA</ISOAbbreviation></Journal><ArticleTitle>Effect of Omega-3 Fatty Acids, Lutein/Zeaxanthin, or Other Nutrient Supplementation on Cognitive Function: The AREDS2 Randomized Clinical Trial.</ArticleTitle><Pagination><StartPage>791</StartPage><EndPage>801</EndPage><MedlinePgn>791-801</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jama.2015.9677</ELocationID><Abstract><AbstractText Label="IMPORTANCE" NlmCategory="OBJECTIVE">Observational data have suggested that high dietary intake of saturated fat and low intake of vegetables may be associated with increased risk of Alzheimer disease.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To test the effects of oral supplementation with nutrients on cognitive function.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS" NlmCategory="METHODS">In a double-masked randomized clinical trial (the Age-Related Eye Disease Study 2 [AREDS2]), retinal specialists in 82 US academic and community medical centers enrolled and observed participants who were at risk for developing late age-related macular degeneration (AMD) from October 2006 to December 2012. In addition to annual eye examinations, several validated cognitive function tests were administered via telephone by trained personnel at baseline and every 2 years during the 5-year study.</AbstractText><AbstractText Label="INTERVENTIONS" NlmCategory="METHODS">Long-chain polyunsaturated fatty acids (LCPUFAs) (1 g) and/or lutein (10 mg)/zeaxanthin (2 mg) vs placebo were tested in a factorial design. All participants were also given varying combinations of vitamins C, E, beta carotene, and zinc.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES" NlmCategory="METHODS">The main outcome was the yearly change in composite scores determined from a battery of cognitive function tests from baseline. The analyses, which were adjusted for baseline age, sex, race, history of hypertension, education, cognitive score, and depression score, evaluated the differences in the composite score between the treated vs untreated groups. The composite score provided an overall score for the battery, ranging from -22 to 17, with higher scores representing better function.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 89% (3741/4203) of AREDS2 participants consented to the ancillary cognitive function study and 93.6% (3501/3741) underwent cognitive function testing. The mean (SD) age of the participants was 72.7 (7.7) years and 57.5% were women. There were no statistically significant differences in change of scores for participants randomized to receive supplements vs those who were not. The yearly change in the composite cognitive function score was -0.19 (99% CI, -0.25 to -0.13) for participants randomized to receive LCPUFAs vs -0.18 (99% CI, -0.24 to -0.12) for those randomized to no LCPUFAs (difference in yearly change, -0.03 [99% CI, -0.20 to 0.13]; P&#x2009;=&#x2009;.63). Similarly, the yearly change in the composite cognitive function score was -0.18 (99% CI, -0.24 to -0.11) for participants randomized to receive lutein/zeaxanthin vs -0.19 (99% CI, -0.25 to -0.13) for those randomized to not receive lutein/zeaxanthin (difference in yearly change, 0.03 [99% CI, -0.14 to 0.19]; P&#x2009;=&#x2009;.66). Analyses were also conducted to assess for potential interactions between LCPUFAs and lutein/zeaxanthin and none were found to be significant.</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE" NlmCategory="CONCLUSIONS">Among older persons with AMD, oral supplementation with LCPUFAs or lutein/zeaxanthin had no statistically significant effect on cognitive function.</AbstractText><AbstractText Label="TRIAL REGISTRATION" NlmCategory="BACKGROUND">clinicaltrials.gov Identifier: NCT00345176.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chew</LastName><ForeName>Emily Y</ForeName><Initials>EY</Initials><AffiliationInfo><Affiliation>Division of Epidemiology and Clinical Applications, Clinical Trials Branch, National Eye Institute/National Institutes of Health, Bethesda, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Clemons</LastName><ForeName>Traci E</ForeName><Initials>TE</Initials><AffiliationInfo><Affiliation>The EMMES Corporation, Rockville, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Agr&#xf3;n</LastName><ForeName>Elvira</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Division of Epidemiology and Clinical Applications, Clinical Trials Branch, National Eye Institute/National Institutes of Health, Bethesda, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Launer</LastName><ForeName>Lenore J</ForeName><Initials>LJ</Initials><AffiliationInfo><Affiliation>Neuroepidemiology Section, National Institute on Aging/National Institutes of Health, Bethesda, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grodstein</LastName><ForeName>Francine</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts5Department of Epidemiology, Harvard School of Public Health, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bernstein</LastName><ForeName>Paul S</ForeName><Initials>PS</Initials><AffiliationInfo><Affiliation>Moran Eye Center, University of Utah, Salt Lake City.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>Age-Related Eye Disease Study 2 (AREDS2) Research Group</CollectiveName></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT00345176</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>Z99 EY999999</GrantID><Acronym>ImNIH</Acronym><Agency>Intramural NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>ZIA EY000485</GrantID><Acronym>ImNIH</Acronym><Agency>Intramural NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HHS-N-260-2005-00007-C</GrantID><Agency>PHS HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>N01-EY-5-0007</GrantID><Acronym>EY</Acronym><Agency>NEI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D052060">Research Support, N.I.H., Intramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA</MedlineTA><NlmUniqueID>7501160</NlmUniqueID><ISSNLinking>0098-7484</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015525">Fatty Acids, Omega-3</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014815">Vitamins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D065146">Zeaxanthins</NameOfSubstance></Chemical><Chemical><RegistryNumber>01YAE03M7J</RegistryNumber><NameOfSubstance UI="D019207">beta Carotene</NameOfSubstance></Chemical><Chemical><RegistryNumber>25167-62-8</RegistryNumber><NameOfSubstance UI="D004281">Docosahexaenoic Acids</NameOfSubstance></Chemical><Chemical><RegistryNumber>789U1901C5</RegistryNumber><NameOfSubstance UI="D003300">Copper</NameOfSubstance></Chemical><Chemical><RegistryNumber>AAN7QOV9EA</RegistryNumber><NameOfSubstance UI="D015118">Eicosapentaenoic Acid</NameOfSubstance></Chemical><Chemical><RegistryNumber>PQ6CK8PD0R</RegistryNumber><NameOfSubstance UI="D001205">Ascorbic Acid</NameOfSubstance></Chemical><Chemical><RegistryNumber>SOI2LOH54Z</RegistryNumber><NameOfSubstance UI="D015034">Zinc Oxide</NameOfSubstance></Chemical><Chemical><RegistryNumber>V1XJQ704R4</RegistryNumber><NameOfSubstance UI="C030973">cupric oxide</NameOfSubstance></Chemical><Chemical><RegistryNumber>X72A60C9MT</RegistryNumber><NameOfSubstance UI="D014975">Lutein</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>JAMA. 2015 Aug 25;314(8):774-5. doi: 10.1001/jama.2015.9526.</RefSource><PMID Version="1">26305645</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>JAMA. 2016 Feb 2;315(5):515-6. doi: 10.1001/jama.2015.16443.</RefSource><PMID Version="1">26836737</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>JAMA. 2016 Feb 2;315(5):516. doi: 10.1001/jama.2015.16452.</RefSource><PMID Version="1">26836738</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>JAMA. 2016 Feb 2;315(5):516-7. doi: 10.1001/jama.2015.16467.</RefSource><PMID Version="1">26836739</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>MMW Fortschr Med. 2015 Dec 14;157(21-22):52. doi: 10.1007/s15006-015-7616-8.</RefSource><PMID Version="1">26960871</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000465" MajorTopicYN="N">Algorithms</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001205" MajorTopicYN="N">Ascorbic Acid</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="Y">Cognition</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003300" MajorTopicYN="N">Copper</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019587" MajorTopicYN="Y">Dietary Supplements</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004281" MajorTopicYN="N">Docosahexaenoic Acids</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015118" MajorTopicYN="N">Eicosapentaenoic Acid</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015525" MajorTopicYN="N">Fatty Acids, Omega-3</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006630" MajorTopicYN="N">Hispanic or Latino</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059012" MajorTopicYN="N">Lost to Follow-Up</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014975" MajorTopicYN="N">Lutein</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008268" MajorTopicYN="N">Macular Degeneration</DescriptorName><QualifierName UI="Q000208" MajorTopicYN="N">ethnology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055118" MajorTopicYN="N">Medication Adherence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017063" MajorTopicYN="N">Outcome Assessment, Health Care</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D044469" MajorTopicYN="N">Racial Groups</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014815" MajorTopicYN="N">Vitamins</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D065146" MajorTopicYN="N">Zeaxanthins</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015034" MajorTopicYN="N">Zinc Oxide</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019207" MajorTopicYN="N">beta Carotene</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of Interest</b>. Emily Y. Chew, Elvira Agr&#xf3;n, and Lenore Launer, are employees of the National Institutes of Health that sponsored the study. Emily Y. Chew, Elvira Agr&#xf3;n, Traci E. Clemons, Lenore Launer, and Fran Grodstein have no financial or other conflicts of interest. Paul Bernstein: reported serving as a consultant for Kemin Health, Kalsec, DSM, and Science Based Health.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>8</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>8</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>9</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2017</Year><Month>3</Month><Day>28</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26305649</ArticleId><ArticleId IdType="mid">NIHMS850016</ArticleId><ArticleId IdType="pmc">PMC5369607</ArticleId><ArticleId IdType="doi">10.1001/jama.2015.9677</ArticleId><ArticleId IdType="pii">2429713</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>2013 Alzheimer&#x2019;s disease facts and figures. Alzheimer&#x2019;s &amp; dementia : the journal of the Alzheimer&#x2019;s Association. 2013;9:208&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pubmed">23507120</ArticleId></ArticleIdList></Reference><Reference><Citation>Dangour AD, Allen E, Elbourne D, Fletcher A, Richards M, Uauy R. Fish consumption and cognitive function among older people in the UK: baseline data from the OPAL study. The journal of nutrition, health &amp; aging. 2009;13:198&#x2013;202.</Citation><ArticleIdList><ArticleId IdType="pubmed">19262951</ArticleId></ArticleIdList></Reference><Reference><Citation>Tully AM, Roche HM, Doyle R, et al. Low serum cholesteryl ester-docosahexaenoic acid levels in Alzheimer&#x2019;s disease: a case-control study. The British journal of nutrition. 2003;89:483&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">12654166</ArticleId></ArticleIdList></Reference><Reference><Citation>Quinn JF, Raman R, Thomas RG, et al. Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial. Jama. 2010;304:1903&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3259852</ArticleId><ArticleId IdType="pubmed">21045096</ArticleId></ArticleIdList></Reference><Reference><Citation>Dangour AD, Allen E, Elbourne D, et al. Effect of 2-y n-3 long-chain polyunsaturated fatty acid supplementation on cognitive function in older people: a randomized, double-blind, controlled trial. The American journal of clinical nutrition. 2010;91:1725&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pubmed">20410089</ArticleId></ArticleIdList></Reference><Reference><Citation>Jama JW, Launer LJ, Witteman JC, et al. Dietary antioxidants and cognitive function in a population-based sample of older persons. The Rotterdam Study. American journal of epidemiology. 1996;144:275&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pubmed">8686696</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalmijn S, Feskens EJ, Launer LJ, Kromhout D. Polyunsaturated fatty acids, antioxidants, and cognitive function in very old men. American journal of epidemiology. 1997;145:33&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pubmed">8982020</ArticleId></ArticleIdList></Reference><Reference><Citation>Grodstein F, Chen J, Willett WC. High-dose antioxidant supplements and cognitive function in community-dwelling elderly women. The American journal of clinical nutrition. 2003;77:975&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">12663300</ArticleId></ArticleIdList></Reference><Reference><Citation>Yaffe K, Clemons TE, McBee WL, Lindblad AS. Impact of antioxidants, zinc, and copper on cognition in the elderly: a randomized, controlled trial. Neurology. 2004;63:1705&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1473037</ArticleId><ArticleId IdType="pubmed">15534261</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang JH, Cook N, Manson J, Buring JE, Grodstein F. A randomized trial of vitamin E supplementation and cognitive function in women. Archives of internal medicine. 2006;166:2462&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">17159011</ArticleId></ArticleIdList></Reference><Reference><Citation>Grodstein F, Kang JH, Glynn RJ, Cook NR, Gaziano JM. A randomized trial of beta carotene supplementation and cognitive function in men: the Physicians&#x2019; Health Study II. Archives of internal medicine. 2007;167:2184&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pubmed">17998490</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson EJ, McDonald K, Caldarella SM, Chung HY, Troen AM, Snodderly DM. Cognitive findings of an exploratory trial of docosahexaenoic acid and lutein supplementation in older women. Nutritional neuroscience. 2008;11:75&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pubmed">18510807</ArticleId></ArticleIdList></Reference><Reference><Citation>Chew EY, Clemons T, SanGiovanni JP, et al. The Age-Related Eye Disease Study 2 (AREDS2): study design and baseline characteristics (AREDS2 report number 1) Ophthalmology. 2012;119:2282&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3485447</ArticleId><ArticleId IdType="pubmed">22840421</ArticleId></ArticleIdList></Reference><Reference><Citation>Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial. Jama. 2013;309:2005&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pubmed">23644932</ArticleId></ArticleIdList></Reference><Reference><Citation>Albanes D, Heinonen OP, Huttunen JK, et al. Effects of alpha-tocopherol and beta-carotene supplements on cancer incidence in the Alpha-Tocopherol Beta-Carotene Cancer Prevention Study. The American journal of clinical nutrition. 1995;62:1427S&#x2013;30S.</Citation><ArticleIdList><ArticleId IdType="pubmed">7495243</ArticleId></ArticleIdList></Reference><Reference><Citation>Omenn GS, Goodman GE, Thornquist MD, et al. Risk factors for lung cancer and for intervention effects in CARET, the Beta-Carotene and Retinol Efficacy Trial. Journal of the National Cancer Institute. 1996;88:1550&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">8901853</ArticleId></ArticleIdList></Reference><Reference><Citation>Rankin MW, Clemons TE, McBee WL. Correlation analysis of the in-clinic and telephone batteries from the AREDS cognitive function ancillary study. AREDS Report No. 15. Ophthalmic epidemiology. 2005;12:271&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1473214</ArticleId><ArticleId IdType="pubmed">16033748</ArticleId></ArticleIdList></Reference><Reference><Citation>Newman CW, Weinstein BE, Jacobson GP, Hug GA. Test-retest reliability of the hearing handicap inventory for adults. Ear and hearing. 1991;12:355&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">1783240</ArticleId></ArticleIdList></Reference><Reference><Citation>Radloff LS. The CES-D Scale: a self-report depression scale for research in the general population. Appl Psychol Meas. 1977;1:385&#x2013;401.</Citation></Reference><Reference><Citation>Brandt J, Spencer M, Folstein M. The telephone interview for cognitive status. Neuropsychiatry, Neuropsychology and Behavioral Neurology. 1988;1:111&#x2013;7.</Citation></Reference><Reference><Citation>Rosen WG. Verbal fluency in aging and dementia. J Clinical Neuropsychology. 1980;2:135&#x2013;46.</Citation></Reference><Reference><Citation>Weschler D. A standardized memory scale for clinical use. J of Psychology. 1945;19:87&#x2013;95.</Citation></Reference><Reference><Citation>Myerson J, Hale S, Wagstaff D, Poon LW, Smith GA. The information-loss model: a mathematical theory of age-related cognitive slowing. Psychological review. 1990;97:475&#x2013;87.</Citation><ArticleIdList><ArticleId IdType="pubmed">2247538</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang JH, Grodstein F. Regular use of nonsteroidal anti-inflammatory drugs and cognitive function in aging women. Neurology. 2003;60:1591&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">12771247</ArticleId></ArticleIdList></Reference><Reference><Citation>Samra SK, Giordani B, Caveney AF, et al. Recovery of cognitive function after surgery for aneurysmal subarachnoid hemorrhage. Stroke; a journal of cerebral circulation. 2007;38:1864&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pubmed">17431208</ArticleId></ArticleIdList></Reference><Reference><Citation>Samieri C, Grodstein F, Rosner BA, et al. Mediterranean diet and cognitive function in older age. Epidemiology (Cambridge, Mass) 2013;24:490&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3674216</ArticleId><ArticleId IdType="pubmed">23676264</ArticleId></ArticleIdList></Reference><Reference><Citation>Evans DA, Grodstein F, Loewenstein D, Kaye J, Weintraub S. Reducing case ascertainment costs in U.S. population studies of Alzheimer&#x2019;s disease, dementia, and cognitive impairment-Part 2. Alzheimer&#x2019;s &amp; dementia : the journal of the Alzheimer&#x2019;s Association. 2011;7:110&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3033654</ArticleId><ArticleId IdType="pubmed">21255748</ArticleId></ArticleIdList></Reference><Reference><Citation>Age-Related Eye Disease Study 2 Research G. Chew EY, Clemons TE, et al. Secondary analyses of the effects of lutein/zeaxanthin on age-related macular degeneration progression: AREDS2 report No. 3. JAMA ophthalmology. 2014;132:142&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4636082</ArticleId><ArticleId IdType="pubmed">24310343</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonds DE, Harrington M, Worrall BB, et al. Effect of long-chain omega-3 fatty acids and lutein + zeaxanthin supplements on cardiovascular outcomes: results of the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial. JAMA internal medicine. 2014;174:763&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pubmed">24638908</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">26305648</PMID><DateCompleted><Year>2015</Year><Month>08</Month><Day>31</Day></DateCompleted><DateRevised><Year>2024</Year><Month>06</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1538-3598</ISSN><JournalIssue CitedMedium="Internet"><Volume>314</Volume><Issue>8</Issue><PubDate><Year>2015</Year><Month>Aug</Month><Day>25</Day></PubDate></JournalIssue><Title>JAMA</Title><ISOAbbreviation>JAMA</ISOAbbreviation></Journal><ArticleTitle>Effect of a 24-Month Physical Activity Intervention vs Health Education on Cognitive Outcomes in Sedentary Older Adults: The LIFE Randomized Trial.</ArticleTitle><Pagination><StartPage>781</StartPage><EndPage>790</EndPage><MedlinePgn>781-90</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jama.2015.9617</ELocationID><Abstract><AbstractText Label="IMPORTANCE" NlmCategory="OBJECTIVE">Epidemiological evidence suggests that physical activity benefits cognition, but results from randomized trials are limited and mixed.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To determine whether a 24-month physical activity program results in better cognitive function, lower risk of mild cognitive impairment (MCI) or dementia, or both, compared with a health education program.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS" NlmCategory="METHODS">A randomized clinical trial, the Lifestyle Interventions and Independence for Elders (LIFE) study, enrolled 1635 community-living participants at 8 US centers from February 2010 until December 2011. Participants were sedentary adults aged 70 to 89 years who were at risk for mobility disability but able to walk 400 m.</AbstractText><AbstractText Label="INTERVENTIONS" NlmCategory="METHODS">A structured, moderate-intensity physical activity program (n&#x2009;=&#x2009;818) that included walking, resistance training, and flexibility exercises or a health education program (n&#x2009;=&#x2009;817) of educational workshops and upper-extremity stretching.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES" NlmCategory="METHODS">Prespecified secondary outcomes of the LIFE study included cognitive function measured by the Digit Symbol Coding (DSC) task subtest of the Wechsler Adult Intelligence Scale (score range: 0-133; higher scores indicate better function) and the revised Hopkins Verbal Learning Test (HVLT-R; 12-item word list recall task) assessed in 1476 participants (90.3%). Tertiary outcomes included global and executive cognitive function and incident MCI or dementia at 24 months.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">At 24 months, DSC task and HVLT-R scores (adjusted for clinic site, sex, and baseline values) were not different between groups. The mean DSC task scores were 46.26 points for the physical activity group vs 46.28 for the health education group (mean difference, -0.01 points [95% CI, -0.80 to 0.77 points], P&#x2009;=&#x2009;.97). The mean HVLT-R delayed recall scores were 7.22 for the physical activity group vs 7.25 for the health education group (mean difference, -0.03 words [95% CI, -0.29 to 0.24 words], P&#x2009;=&#x2009;.84). No differences for any other cognitive or composite measures were observed. Participants in the physical activity group who were 80 years or older (n&#x2009;=&#x2009;307) and those with poorer baseline physical performance (n&#x2009;=&#x2009;328) had better changes in executive function composite scores compared with the health education group (P&#x2009;=&#x2009;.01 for interaction for both comparisons). Incident MCI or dementia occurred in 98 participants (13.2%) in the physical activity group and 91 participants (12.1%) in the health education group (odds ratio, 1.08 [95% CI, 0.80 to 1.46]).</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE" NlmCategory="CONCLUSIONS">Among sedentary older adults, a 24-month moderate-intensity physical activity program compared with a health education program did not result in improvements in global or domain-specific cognitive function.</AbstractText><AbstractText Label="TRIAL REGISTRATION" NlmCategory="BACKGROUND">clinicaltrials.gov Identifier: NCT01072500.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sink</LastName><ForeName>Kaycee M</ForeName><Initials>KM</Initials><AffiliationInfo><Affiliation>Section on Gerontology and Geriatric Medicine, Department of Internal Medicine, Wake Forest University School of Medicine, Winston-Salem, North Carolina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Espeland</LastName><ForeName>Mark A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Department of Biostatistical Sciences, Wake Forest University School of Medicine, Winston-Salem, North Carolina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Castro</LastName><ForeName>Cynthia M</ForeName><Initials>CM</Initials><AffiliationInfo><Affiliation>Stanford Prevention Research Center, Stanford University School of Medicine, Palo Alto, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Church</LastName><ForeName>Timothy</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Pennington Biomedical Research Center, Baton Rouge, Louisiana.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cohen</LastName><ForeName>Ron</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>College of Medicine, University of Florida, Gainesville.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dodson</LastName><ForeName>John A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Leon H. Charney Division of Cardiology, Department of Medicine, New York University School of Medicine, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guralnik</LastName><ForeName>Jack</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Division of Gerontology, Department of Epidemiology and Public Health, University of Maryland School of Medicine, Baltimore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hendrie</LastName><ForeName>Hugh C</ForeName><Initials>HC</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Center for Aging Research, Indiana University, Indianapolis.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jennings</LastName><ForeName>Janine</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Psychology, Wake Forest University, Winston-Salem, North Carolina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Katula</LastName><ForeName>Jeffery</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Health and Exercise Sciences, Wake Forest University, Winston-Salem, North Carolina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lopez</LastName><ForeName>Oscar L</ForeName><Initials>OL</Initials><AffiliationInfo><Affiliation>Departments of Neurology and Psychiatry, University of Pittsburgh, Pittsburgh, Pennsylvania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McDermott</LastName><ForeName>Mary M</ForeName><Initials>MM</Initials><AffiliationInfo><Affiliation>Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois13Senior Editor, JAMA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pahor</LastName><ForeName>Marco</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>College of Medicine, University of Florida, Gainesville.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reid</LastName><ForeName>Kieran F</ForeName><Initials>KF</Initials><AffiliationInfo><Affiliation>Nutrition, Exercise Physiology and Sarcopenia Laboratory, Jean Mayer USDA Human Nutrition Research Center on Aging, Tufts University, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rushing</LastName><ForeName>Julia</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Biostatistical Sciences, Wake Forest University School of Medicine, Winston-Salem, North Carolina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Verghese</LastName><ForeName>Joe</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Departments of Neurology and Medicine, Albert Einstein College of Medicine, Bronx, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rapp</LastName><ForeName>Stephen</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Wake Forest University School of Medicine, Winston-Salem, North Carolina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Williamson</LastName><ForeName>Jeff D</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>Section on Gerontology and Geriatric Medicine, Department of Internal Medicine, Wake Forest University School of Medicine, Winston-Salem, North Carolina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>LIFE Study Investigators</CollectiveName></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT01072500</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>P30 AG024827</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG031679</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>3U01AG022376-05A2S</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30AG021342</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><Acronym>ImNIH</Acronym><Agency>Intramural NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>1 P30 AG21332</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG022376</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG021332</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG028740</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UO1 AG22376</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG021342</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>1P30AG031679</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>1 P30 AG028740</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D052060">Research Support, N.I.H., Intramural</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA</MedlineTA><NlmUniqueID>7501160</NlmUniqueID><ISSNLinking>0098-7484</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>JAMA. 2015 Aug 25;314(8):774-5. doi: 10.1001/jama.2015.9526.</RefSource><PMID Version="1">26305645</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>JAMA. 2016 Jan 26;315(4):415. doi: 10.1001/jama.2015.16005.</RefSource><PMID Version="1">26813216</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>JAMA. 2016 Jan 26;315(4):415-6. doi: 10.1001/jama.2015.16008.</RefSource><PMID Version="1">26813217</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>J Physiother. 2016 Apr;62(2):115; discussion 115. doi: 10.1016/j.jphys.2015.12.008.</RefSource><PMID Version="1">26944524</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D060825" MajorTopicYN="N">Cognitive Dysfunction</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D056344" MajorTopicYN="Y">Executive Function</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005081" MajorTopicYN="N">Exercise Therapy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006266" MajorTopicYN="N">Health Education</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006293" MajorTopicYN="Y">Health Promotion</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D052580" MajorTopicYN="N">Muscle Stretching Exercises</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055070" MajorTopicYN="N">Resistance Training</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057185" MajorTopicYN="Y">Sedentary Behavior</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D034941" MajorTopicYN="N">Upper Extremity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016138" MajorTopicYN="N">Walking</DescriptorName></MeshHeading></MeshHeadingList><InvestigatorList><Investigator ValidYN="Y"><LastName>McDermott</LastName><ForeName>Mary M</ForeName><Initials>MM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Spring</LastName><ForeName>Bonnie</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hauser</LastName><ForeName>Joshua</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gulati</LastName><ForeName>Martha</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shah</LastName><ForeName>Sanjiv</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Domanchuk</LastName><ForeName>Kathryn</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Graff</LastName><ForeName>Rex</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kadela</LastName><ForeName>Kasia</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rego</LastName><ForeName>Alvito</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Church</LastName><ForeName>Timothy</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Blair</LastName><ForeName>Steven</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Myers</LastName><ForeName>Valerie</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Monce</LastName><ForeName>Ron</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Britt</LastName><ForeName>Nathan</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nauta</LastName><ForeName>Melissa</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Parks</LastName><ForeName>Ami</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rodarte</LastName><ForeName>Ruben</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Millet</LastName><ForeName>Heidi</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tudor-Locke</LastName><ForeName>Catrine</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Butitta</LastName><ForeName>Ben</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Donatto</LastName><ForeName>Sheletta</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bonds</LastName><ForeName>Denise</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hadley</LastName><ForeName>Evan C</ForeName><Initials>EC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Patel</LastName><ForeName>Kushang V</ForeName><Initials>KV</Initials></Investigator><Investigator ValidYN="Y"><LastName>Romashkan</LastName><ForeName>Sergei</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kaplan</LastName><ForeName>Robert M</ForeName><Initials>RM</Initials></Investigator><Investigator ValidYN="Y"><LastName>King</LastName><ForeName>Abby C</ForeName><Initials>AC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Castro</LastName><ForeName>Cynthia M</ForeName><Initials>CM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Haskell</LastName><ForeName>William L</ForeName><Initials>WL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stafford</LastName><ForeName>Randall S</ForeName><Initials>RS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yank</LastName><ForeName>Veronica</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pruitt</LastName><ForeName>Leslie A</ForeName><Initials>LA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Berra</LastName><ForeName>Kathy</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bell</LastName><ForeName>Carol</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thiessen</LastName><ForeName>Rosita</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Youngman</LastName><ForeName>Kate P</ForeName><Initials>KP</Initials></Investigator><Investigator ValidYN="Y"><LastName>Virgen</LastName><ForeName>Selene B</ForeName><Initials>SB</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tarin</LastName><ForeName>Kristina N</ForeName><Initials>KN</Initials></Investigator><Investigator ValidYN="Y"><LastName>Klaftenegger</LastName><ForeName>Heather</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Prosak</LastName><ForeName>Carolyn A</ForeName><Initials>CA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Campero</LastName><ForeName>Ines</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Garcia</LastName><ForeName>Dulce M</ForeName><Initials>DM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Soto</LastName><ForeName>Jos&#xe9;</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chio</LastName><ForeName>Linda</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hoskins</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fielding</LastName><ForeName>Roger</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nelson</LastName><ForeName>Miriam</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Folta</LastName><ForeName>Sara</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Phillips</LastName><ForeName>Edward</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Liu</LastName><ForeName>Christine</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cifarelli</LastName><ForeName>Erica</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Reid</LastName><ForeName>Kieran</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lacasse</LastName><ForeName>Paige</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kirn</LastName><ForeName>Dylan</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pasha</LastName><ForeName>Evan</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ribourg</LastName><ForeName>Sonnly</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ruais</LastName><ForeName>Karen</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kim</LastName><ForeName>Won</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cloutier</LastName><ForeName>Gregory</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Manini</LastName><ForeName>Todd</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pahor</LastName><ForeName>Marco</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Anton</LastName><ForeName>Stephen</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Buford</LastName><ForeName>Thomas</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nayfield</LastName><ForeName>Susan</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nocera</LastName><ForeName>Joe</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Marsiske</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sandesara</LastName><ForeName>Bhanu</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lee</LastName><ForeName>Jocelyn</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hiatt-Jensen</LastName><ForeName>Deborah</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Black</LastName><ForeName>Mieniecia</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Case</LastName><ForeName>Kimberly</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Herring</LastName><ForeName>Katherine</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schwier-Delvisco</LastName><ForeName>Amber</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Burk</LastName><ForeName>Bill</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hoover</LastName><ForeName>Brian</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Knaggs</LastName><ForeName>Jeffrey</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Martin</LastName><ForeName>Allison</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Xie</LastName><ForeName>Chonglun</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Morris</LastName><ForeName>Holly</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Singletary</LastName><ForeName>Flo</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Causer</LastName><ForeName>Jackie</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yonce</LastName><ForeName>Susan</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Del Boccio</LastName><ForeName>Christine</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gay</LastName><ForeName>Charles</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Alexander</LastName><ForeName>Tangerica Peavy</ForeName><Initials>TP</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pahor</LastName><ForeName>Marco</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Anton</LastName><ForeName>Stephen</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Buford</LastName><ForeName>Thomas</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Leeuwenburgh</LastName><ForeName>Christiaan</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nayfield</LastName><ForeName>Susan</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Manini</LastName><ForeName>Todd</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Caudle</LastName><ForeName>Connie</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Crump</LastName><ForeName>Lauren</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Holmes</LastName><ForeName>Latonia</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lee</LastName><ForeName>Jocelyn</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lester</LastName><ForeName>Ronald</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lu</LastName><ForeName>Ching-ju</ForeName><Initials>CJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>O'Mara</LastName><ForeName>Ryan</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pepine</LastName><ForeName>Carl J</ForeName><Initials>CJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ariet</LastName><ForeName>Mario</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Handberg</LastName><ForeName>Eileen</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Deluca</LastName><ForeName>Daniel</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hill</LastName><ForeName>James</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Guralnik</LastName><ForeName>Jack M</ForeName><Initials>JM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Newman</LastName><ForeName>Anne B</ForeName><Initials>AB</Initials></Investigator><Investigator ValidYN="Y"><LastName>Studenski</LastName><ForeName>Stephanie A</ForeName><Initials>SA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Goodpaster</LastName><ForeName>Bret H</ForeName><Initials>BH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lopez</LastName><ForeName>Oscar</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Glynn</LastName><ForeName>Nancy W</ForeName><Initials>NW</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bonk</LastName><ForeName>Janet T</ForeName><Initials>JT</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rush</LastName><ForeName>Jennifer</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kost</LastName><ForeName>Piera</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gerger</LastName><ForeName>Allison</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vincent</LastName><ForeName>Pamela</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Davis</LastName><ForeName>LaTisha</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Newman</LastName><ForeName>Mark A</ForeName><Initials>MA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Grove</LastName><ForeName>George</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Williams</LastName><ForeName>Kathy</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Groessl</LastName><ForeName>Erik J</ForeName><Initials>EJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kritchevsky</LastName><ForeName>Stephen B</ForeName><Initials>SB</Initials></Investigator><Investigator ValidYN="Y"><LastName>Marsh</LastName><ForeName>Anthony</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brinkley</LastName><ForeName>Tina</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Demons</LastName><ForeName>Jamehl</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sink</LastName><ForeName>Kaycee</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kennedy</LastName><ForeName>Kimberly</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shertzer-Skinner</LastName><ForeName>Rachel</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wrights</LastName><ForeName>Abbie</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fries</LastName><ForeName>Rose</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Barr</LastName><ForeName>Deborah</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Williamson</LastName><ForeName>Jeff</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sink</LastName><ForeName>Kaycee M</ForeName><Initials>KM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hendrie</LastName><ForeName>Hugh C</ForeName><Initials>HC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rapp</LastName><ForeName>Stephen R</ForeName><Initials>SR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Verghese</LastName><ForeName>Joe</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Woolard</LastName><ForeName>Nancy</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wilson</LastName><ForeName>Valerie K</ForeName><Initials>VK</Initials></Investigator><Investigator ValidYN="Y"><LastName>Miller</LastName><ForeName>Michael E</ForeName><Initials>ME</Initials></Investigator><Investigator ValidYN="Y"><LastName>Espeland</LastName><ForeName>Mark</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ambrosius</LastName><ForeName>Walter</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Babcock</LastName><ForeName>Don</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Beavers</LastName><ForeName>Daniel</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Byington</LastName><ForeName>Robert P</ForeName><Initials>RP</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cook</LastName><ForeName>Delilah</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Furberg</LastName><ForeName>Curt</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Goode</LastName><ForeName>Candace</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Griffin</LastName><ForeName>Jason</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Harvin</LastName><ForeName>Lea</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Henkin</LastName><ForeName>Leora</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hepler</LastName><ForeName>John</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hsu</LastName><ForeName>Fang-Chi</ForeName><Initials>FC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Joyce</LastName><ForeName>Kathy</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lovato</LastName><ForeName>Laura</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Roberson</LastName><ForeName>Wesley</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Robertson</LastName><ForeName>Julia</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rushing</LastName><ForeName>Julia</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rushing</LastName><ForeName>Scott</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stowe</LastName><ForeName>Cynthia L</ForeName><Initials>CL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Walkup</LastName><ForeName>Michael P</ForeName><Initials>MP</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hire</LastName><ForeName>Don</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rejeski</LastName><ForeName>Jack</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Katula</LastName><ForeName>Jeff</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brubaker</LastName><ForeName>Peter H</ForeName><Initials>PH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mihalko</LastName><ForeName>Shannon</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jennings</LastName><ForeName>Janine M</ForeName><Initials>JM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lane</LastName><ForeName>Kathy</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gill</LastName><ForeName>Thomas M</ForeName><Initials>TM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Axtell</LastName><ForeName>Robert S</ForeName><Initials>RS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kashaf</LastName><ForeName>Susan S</ForeName><Initials>SS</Initials></Investigator><Investigator ValidYN="Y"><LastName>de Renekeire</LastName><ForeName>Nathalie</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>McGloin</LastName><ForeName>Joanne M</ForeName><Initials>JM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mautner</LastName><ForeName>Raeleen</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Huie-White</LastName><ForeName>Sharon M</ForeName><Initials>SM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bianco</LastName><ForeName>Luann</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zocher</LastName><ForeName>Janice</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shepard</LastName><ForeName>Denise M</ForeName><Initials>DM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fennelly</LastName><ForeName>Barbara</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Halpin</LastName><ForeName>Sean</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Barnett</LastName><ForeName>Theresa</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wu</LastName><ForeName>Karen C</ForeName><Initials>KC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Iannone</LastName><ForeName>Lynne P</ForeName><Initials>LP</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bugaj</LastName><ForeName>Julie A</ForeName><Initials>JA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bailey</LastName><ForeName>Christine</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chupp</LastName><ForeName>Geoffrey</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Flynn</LastName><ForeName>Gail</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gill</LastName><ForeName>Thomas M</ForeName><Initials>TM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hankinson</LastName><ForeName>John</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fragoso</LastName><ForeName>Carlos A Vaz</ForeName><Initials>CA</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>8</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>8</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>9</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2016</Year><Month>8</Month><Day>25</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26305648</ArticleId><ArticleId IdType="mid">NIHMS736824</ArticleId><ArticleId IdType="pmc">PMC4698980</ArticleId><ArticleId IdType="doi">10.1001/jama.2015.9617</ArticleId><ArticleId IdType="pii">2429712</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Burdette JH, Laurienti PJ, Espeland MA, et al. Using network science to evaluate exercise-associated brain changes in older adults. Front Aging Neurosci. 2010;2:23.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2893375</ArticleId><ArticleId IdType="pubmed">20589103</ArticleId></ArticleIdList></Reference><Reference><Citation>Colcombe SJ, Erickson KI, Scalf PE, et al. Aerobic exercise training increases brain volume in aging humans. J Gerontol A Biol Sci Med Sci. 2006;61:1166&#x2013;1170.</Citation><ArticleIdList><ArticleId IdType="pubmed">17167157</ArticleId></ArticleIdList></Reference><Reference><Citation>Erickson KI, Leckie RL, Weinstein AM. Physical activity, fitness, and gray matter volume. Neurobiol Aging. 2014;35(Suppl 2):S20&#x2013;S28.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4094356</ArticleId><ArticleId IdType="pubmed">24952993</ArticleId></ArticleIdList></Reference><Reference><Citation>Coelho FG, Gobbi S, Andreatto CA, Corazza DI, Pedroso RV, Santos-Galduroz RF. Physical exercise modulates peripheral levels of brain-derived neurotrophic factor (BDNF): a systematic review of experimental studies in the elderly. Arch Gerontol Geriatr. 2013;56:10&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pubmed">22749404</ArticleId></ArticleIdList></Reference><Reference><Citation>Erickson KI, Gildengers AG, Butters MA. Physical activity and brain plasticity in late adulthood. Dialogues Clin Neurosci. 2013;15:99&#x2013;108.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3622473</ArticleId><ArticleId IdType="pubmed">23576893</ArticleId></ArticleIdList></Reference><Reference><Citation>Adlard PA, Perreau VM, Pop V, Cotman CW. Voluntary exercise decreases amyloid load in a transgenic model of Alzheimer&#x2019;s disease. J Neurosci. 2005;25:4217&#x2013;4221.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725122</ArticleId><ArticleId IdType="pubmed">15858047</ArticleId></ArticleIdList></Reference><Reference><Citation>Snowden M, Steinman L, Mochan K, et al. Effect of exercise on cognitive performance in community-dwelling older adults: review of intervention trials and recommendations for public health practice and research. J Am Geriatr Soc. 2011;59:704&#x2013;716.</Citation><ArticleIdList><ArticleId IdType="pubmed">21438861</ArticleId></ArticleIdList></Reference><Reference><Citation>Denkinger MD, Nikolaus T, Denkinger C, Lukas A. Physical activity for the prevention of cognitive decline: current evidence from observational and controlled studies. Z Gerontol Geriatr. 2012;45:11&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pubmed">22278001</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith PJ, Blumenthal JA, Hoffman BM, et al. Aerobic exercise and neurocognitive performance: a meta-analytic review of randomized controlled trials. Psychosom Med. 2010;72:239&#x2013;252.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2897704</ArticleId><ArticleId IdType="pubmed">20223924</ArticleId></ArticleIdList></Reference><Reference><Citation>Barnes DE, Santos-Modesitt W, Poelke G, et al. The Mental Activity and eXercise (MAX) trial: a randomized controlled trial to enhance cognitive function in older adults. JAMA Intern Med. 2013;173:797&#x2013;804.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5921904</ArticleId><ArticleId IdType="pubmed">23545598</ArticleId></ArticleIdList></Reference><Reference><Citation>Legault C, Jennings JM, Katula JA, et al. Designing clinical trials for assessing the effects of cognitive training and physical activity interventions on cognitive outcomes: the Seniors Health and Activity Research Program Pilot (SHARP-P) study, a randomized controlled trial. BMC Geriatr. 2011;11:27.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3126708</ArticleId><ArticleId IdType="pubmed">21615936</ArticleId></ArticleIdList></Reference><Reference><Citation>Lautenschlager NT, Cox KL, Flicker L, et al. Effect of physical activity on cognitive function in older adults at risk for Alzheimer disease: a randomized trial. JAMA. 2008;300:1027&#x2013;1037.</Citation><ArticleIdList><ArticleId IdType="pubmed">18768414</ArticleId></ArticleIdList></Reference><Reference><Citation>Williamson JD, Espeland M, Kritchevsky SB, et al. Changes in cognitive function in a randomized trial of physical activity: results of the lifestyle interventions and independence for elders pilot study. J Gerontol A Biol Sci Med Sci. 2009;64:688&#x2013;694.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2679423</ArticleId><ArticleId IdType="pubmed">19244157</ArticleId></ArticleIdList></Reference><Reference><Citation>Pahor M, Guralnik JM, Ambrosius WT, et al. Effect of structured physical activity on prevention of major mobility disability in older adults: the LIFE study randomized clinical trial. JAMA. 2014;311:2387&#x2013;2396.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4266388</ArticleId><ArticleId IdType="pubmed">24866862</ArticleId></ArticleIdList></Reference><Reference><Citation>Fielding RA, Rejeski WJ, Blair SN, et al. The Lifestyle Interventions and Independence for Elders (LIFE) Study: Design and Methods. J Gerontol A Biol Sci Med Sci. 2011;66:1226&#x2013;1237.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3193523</ArticleId><ArticleId IdType="pubmed">21825283</ArticleId></ArticleIdList></Reference><Reference><Citation>Guralnik JM, Ferrucci L, Simonsick EM, Salive ME, Wallace RB. Lower-extremity function in persons over the age of 70 years as a predictor of subsequent disability. N Engl J Med. 1995;332:556&#x2013;561.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9828188</ArticleId><ArticleId IdType="pubmed">7838189</ArticleId></ArticleIdList></Reference><Reference><Citation>Teng EL, Chui HC. The Modified Mini-Mental State (3MS) examination. J Clin Psychiatry. 1987;48:314&#x2013;318.</Citation><ArticleIdList><ArticleId IdType="pubmed">3611032</ArticleId></ArticleIdList></Reference><Reference><Citation>Rejeski WJ, Fielding RA, Blair SN, et al. The Lifestyle Interventions and Independence for Elders (LIFE) Pilot Study: Design and Methods. Contemp Clin Trials. 2005;26:141&#x2013;154.</Citation><ArticleIdList><ArticleId IdType="pubmed">15837437</ArticleId></ArticleIdList></Reference><Reference><Citation>Stewart AL, Verboncoeur CJ, McLellan BY, et al. Physical activity outcomes of CHAMPS II: a physical activity promotion program for older adults. J Gerontol A Biol Sci Med Sci. 2001;56:M465&#x2013;M470.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1780022</ArticleId><ArticleId IdType="pubmed">11487597</ArticleId></ArticleIdList></Reference><Reference><Citation>Sink KM, Espeland MA, Rushing J, et al. The LIFE Cognition Study: design and baseline characteristics. Clin Interv Aging. 2014;9:1425&#x2013;1436.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4154884</ArticleId><ArticleId IdType="pubmed">25210447</ArticleId></ArticleIdList></Reference><Reference><Citation>Wechsler D. WAIS-III manual. New York: Psychological Corporation; 1997.</Citation></Reference><Reference><Citation>Brandt J, Benedict RHB. Hopkins Verbal Learning Test-Revised Professional manual. Lutz, FL: Psychological Assessment Resources, Inc; 2001.</Citation></Reference><Reference><Citation>Kaplan E, Goodglass H, Weintraub S. The Boston Naming Test. 2nd. Philadelphia, PA: 1983.</Citation></Reference><Reference><Citation>Reitan R. Trail Making Test. Manual for administration and scoring. Tucson, AZ: Neuropsychological Laboratory; 1992.</Citation></Reference><Reference><Citation>Kirchner WK. Age differences in short-term retention of rapidly changing information. J Exp Psychol. 1958;55:352&#x2013;358.</Citation><ArticleIdList><ArticleId IdType="pubmed">13539317</ArticleId></ArticleIdList></Reference><Reference><Citation>Eriksen B, Eriksen CW. Effects of noise letters upon the identificaiton of a target letter in a nonsearch task. Perception &amp; Psychophysics. 1974;16:143&#x2013;149.</Citation></Reference><Reference><Citation>Rogers R, Monsell S. Costs of a predictable switch between simple cognitive tasks. J Exp Psychol Gen. 1995;124:207&#x2013;231.</Citation></Reference><Reference><Citation>Weissman MM, Sholomskas D, Pottenger M, Prusoff BA, Locke BZ. Assessing depressive symptoms in five psychiatric populations: a validation study. Am J Epidemiol. 1977;106:203&#x2013;214.</Citation><ArticleIdList><ArticleId IdType="pubmed">900119</ArticleId></ArticleIdList></Reference><Reference><Citation>Pfeffer RI, Kurosaki TT, Harrah CH, Jr, Chance JM, Filos S. Measurement of functional activities in older adults in the community. J Gerontol. 1982;37:323&#x2013;329.</Citation><ArticleIdList><ArticleId IdType="pubmed">7069156</ArticleId></ArticleIdList></Reference><Reference><Citation>Albert MS, DeKosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due to Alzheimer&#x2019;s disease: recommendations from the National Institute on Aging-Alzheimer&#x2019;s Association workgroups on diagnostic guidelines for Alzheimer&#x2019;s disease. Alzheimers Dement. 2011;7:270&#x2013;279.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3312027</ArticleId><ArticleId IdType="pubmed">21514249</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer&#x2019;s disease: recommendations from the National Institute on Aging-Alzheimer&#x2019;s Association workgroups on diagnostic guidelines for Alzheimer&#x2019;s disease. Alzheimers Dement. 2011;7:263&#x2013;269.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3312024</ArticleId><ArticleId IdType="pubmed">21514250</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan Y. Multiple Imputation Using SAS Software. J Statistical Software. 2011;45:1&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3267837</ArticleId><ArticleId IdType="pubmed">22289957</ArticleId></ArticleIdList></Reference><Reference><Citation>Espeland MA, Rapp SR, Bray GA, et al. Long-term impact of behavioral weight loss intervention on cognitive function. J Gerontol A Biol Sci Med Sci. 2014;69:1101&#x2013;1108.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4158413</ArticleId><ArticleId IdType="pubmed">24619151</ArticleId></ArticleIdList></Reference><Reference><Citation>Ngandu T, Lehtisalo J, Solomon A, et al. A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial. Lancet. 2015;385:2255&#x2013;2263.</Citation><ArticleIdList><ArticleId IdType="pubmed">25771249</ArticleId></ArticleIdList></Reference><Reference><Citation>Robertson DA, Savva GM, Coen RF, Kenny RA. Cognitive function in the prefrailty and frailty syndrome. J Am Geriatr Soc. 2014;62:2118&#x2013;2124.</Citation><ArticleIdList><ArticleId IdType="pubmed">25370593</ArticleId></ArticleIdList></Reference><Reference><Citation>Mielke MM, Roberts RO, Savica R, et al. Assessing the temporal relationship between cognition and gait: slow gait predicts cognitive decline in the Mayo Clinic Study of Aging. J Gerontol A Biol Sci Med Sci. 2013;68:929&#x2013;937.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3712358</ArticleId><ArticleId IdType="pubmed">23250002</ArticleId></ArticleIdList></Reference><Reference><Citation>Verghese J, Lipton RB, Katz MJ, et al. Leisure activities and the risk of dementia in the elderly. N Engl J Med. 2003;348:2508&#x2013;2516.</Citation><ArticleIdList><ArticleId IdType="pubmed">12815136</ArticleId></ArticleIdList></Reference><Reference><Citation>Etnier JL, Nowell PM, Landers DM, Sibley BA. A meta-regression to examine the relationship between aerobic fitness and cognitive performance. Brain Res Rev. 2006;52:119&#x2013;130.</Citation><ArticleIdList><ArticleId IdType="pubmed">16490256</ArticleId></ArticleIdList></Reference><Reference><Citation>Stern Y. Cognitive reserve in ageing and Alzheimer&#x2019;s disease. Lancet Neurol. 2012;11:1006&#x2013;1012.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3507991</ArticleId><ArticleId IdType="pubmed">23079557</ArticleId></ArticleIdList></Reference><Reference><Citation>Colcombe S, Kramer AF. Fitness effects on the cognitive function of older adults: a meta-analytic study. Psychol Sci. 2003;14:125&#x2013;130.</Citation><ArticleIdList><ArticleId IdType="pubmed">12661673</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">26308899</PMID><DateCompleted><Year>2015</Year><Month>10</Month><Day>01</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1476-4687</ISSN><JournalIssue CitedMedium="Internet"><Volume>525</Volume><Issue>7567</Issue><PubDate><Year>2015</Year><Month>Sep</Month><Day>03</Day></PubDate></JournalIssue><Title>Nature</Title><ISOAbbreviation>Nature</ISOAbbreviation></Journal><ArticleTitle>GGGGCC repeat expansion in C9orf72 compromises nucleocytoplasmic transport.</ArticleTitle><Pagination><StartPage>129</StartPage><EndPage>133</EndPage><MedlinePgn>129-33</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/nature14974</ELocationID><Abstract><AbstractText>The GGGGCC (G4C2) repeat expansion in a noncoding region of C9orf72 is the most common cause of sporadic and familial forms of amyotrophic lateral sclerosis and frontotemporal dementia. The basis for pathogenesis is unknown. To elucidate the consequences of G4C2 repeat expansion in a tractable genetic system, we generated transgenic fly lines expressing 8, 28 or 58 G4C2-repeat-containing transcripts that do not have a translation start site (AUG) but contain an open-reading frame for green fluorescent protein to detect repeat-associated non-AUG (RAN) translation. We show that these transgenic animals display dosage-dependent, repeat-length-dependent degeneration in neuronal tissues and RAN translation of dipeptide repeat (DPR) proteins, as observed in patients with C9orf72-related disease. This model was used in a large-scale, unbiased genetic screen, ultimately leading to the identification of 18 genetic modifiers that encode components of the nuclear pore complex (NPC), as well as the machinery that coordinates the export of nuclear RNA and the import of nuclear proteins. Consistent with these results, we found morphological abnormalities in the architecture of the nuclear envelope in cells expressing expanded G4C2 repeats in vitro and in vivo. Moreover, we identified a substantial defect in RNA export resulting in retention of RNA in the nuclei of Drosophila cells expressing expanded G4C2 repeats and also in mammalian cells, including aged induced pluripotent stem-cell-derived neurons from patients with C9orf72-related disease. These studies show that a primary consequence of G4C2 repeat expansion is the compromise of nucleocytoplasmic transport through the nuclear pore, revealing a novel mechanism of neurodegeneration.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Freibaum</LastName><ForeName>Brian D</ForeName><Initials>BD</Initials><AffiliationInfo><Affiliation>Department of Cell and Molecular Biology, St Jude Children's Research Hospital, Memphis, Tennessee 38105, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Yubing</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Massachusetts Medical School, Worcester, Massachusetts 01605, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lopez-Gonzalez</LastName><ForeName>Rodrigo</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Massachusetts Medical School, Worcester, Massachusetts 01605, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Nam Chul</ForeName><Initials>NC</Initials><AffiliationInfo><Affiliation>Department of Cell and Molecular Biology, St Jude Children's Research Hospital, Memphis, Tennessee 38105, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Almeida</LastName><ForeName>Sandra</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Massachusetts Medical School, Worcester, Massachusetts 01605, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Kyung-Ha</ForeName><Initials>KH</Initials><AffiliationInfo><Affiliation>Department of Cell and Molecular Biology, St Jude Children's Research Hospital, Memphis, Tennessee 38105, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Badders</LastName><ForeName>Nisha</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Cell and Molecular Biology, St Jude Children's Research Hospital, Memphis, Tennessee 38105, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Valentine</LastName><ForeName>Marc</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Cell and Molecular Biology, St Jude Children's Research Hospital, Memphis, Tennessee 38105, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miller</LastName><ForeName>Bruce L</ForeName><Initials>BL</Initials><AffiliationInfo><Affiliation>Memory and Aging Center, Department of Neurology, University of California San Francisco, San Francisco, California 94158, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wong</LastName><ForeName>Philip C</ForeName><Initials>PC</Initials><AffiliationInfo><Affiliation>Department of Pathology, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Petrucelli</LastName><ForeName>Leonard</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic Florida, Jacksonville, Florida 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Hong Joo</ForeName><Initials>HJ</Initials><AffiliationInfo><Affiliation>Department of Cell and Molecular Biology, St Jude Children's Research Hospital, Memphis, Tennessee 38105, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gao</LastName><ForeName>Fen-Biao</ForeName><Initials>FB</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Massachusetts Medical School, Worcester, Massachusetts 01605, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Taylor</LastName><ForeName>J Paul</ForeName><Initials>JP</Initials><AffiliationInfo><Affiliation>Howard Hughes Medical Institute, Department of Cell and Molecular Biology, St Jude Children's Research Hospital, Memphis, Tennessee 38105, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>NS079725</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005146</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG019724</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 CA021765</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG019724</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><Agency>Howard Hughes Medical Institute</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS057553</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>N079725</GrantID><Agency>PHS HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS079725</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>08</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nature</MedlineTA><NlmUniqueID>0410462</NlmUniqueID><ISSNLinking>0028-0836</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000073885">C9orf72 Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C568651">C9orf72 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011506">Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>63231-63-0</RegistryNumber><NameOfSubstance UI="D012313">RNA</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nature. 2015 Sep 3;525(7567):36-7. doi: 10.1038/nature15208.</RefSource><PMID Version="1">26308896</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Neurol. 2015 Dec;11(12):670-2. doi: 10.1038/nrneurol.2015.219.</RefSource><PMID Version="1">26526532</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D021581" MajorTopicYN="N">Active Transport, Cell Nucleus</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D030801" MajorTopicYN="N">Animals, Genetically Modified</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000073885" MajorTopicYN="N">C9orf72 Protein</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D042622" MajorTopicYN="N">DNA Repeat Expansion</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004331" MajorTopicYN="N">Drosophila melanogaster</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="Y">cytology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005123" MajorTopicYN="N">Eye</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057180" MajorTopicYN="N">Frontotemporal Dementia</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006367" MajorTopicYN="N">HeLa Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057026" MajorTopicYN="N">Induced Pluripotent Stem Cells</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009132" MajorTopicYN="N">Muscles</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D022022" MajorTopicYN="N">Nuclear Pore</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016366" MajorTopicYN="N">Open Reading Frames</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014176" MajorTopicYN="N">Protein Biosynthesis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011506" MajorTopicYN="N">Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012313" MajorTopicYN="N">RNA</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D034443" MajorTopicYN="N">RNA Transport</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012469" MajorTopicYN="N">Salivary Glands</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>12</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>7</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>8</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>8</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>10</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2016</Year><Month>3</Month><Day>3</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26308899</ArticleId><ArticleId IdType="mid">NIHMS731778</ArticleId><ArticleId IdType="pmc">PMC4631399</ArticleId><ArticleId IdType="doi">10.1038/nature14974</ArticleId><ArticleId IdType="pii">nature14974</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>DeJesus-Hernandez M, et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron. 2011;72:245&#x2013;256. doi:S0896-6273(11)00828-2[pii]10.1016/j.neuron.2011.09.011.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3202986</ArticleId><ArticleId IdType="pubmed">21944778</ArticleId></ArticleIdList></Reference><Reference><Citation>Renton AE, et al. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron. 2011;72:257&#x2013;268. doi: 10.1016/j.neuron.2011.09.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2011.09.010</ArticleId><ArticleId IdType="pmc">PMC3200438</ArticleId><ArticleId IdType="pubmed">21944779</ArticleId></ArticleIdList></Reference><Reference><Citation>Mizielinska S, et al. C9orf72 repeat expansions cause neurodegeneration in Drosophila through arginine-rich proteins. Science. 2014;345:1192&#x2013;1194. doi: 10.1126/science.1256800.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1256800</ArticleId><ArticleId IdType="pmc">PMC4944841</ArticleId><ArticleId IdType="pubmed">25103406</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu Z, et al. Expanded GGGGCC repeat RNA associated with amyotrophic lateral sclerosis and frontotemporal dementia causes neurodegeneration. Proc Natl Acad Sci U S A. 2013;110:7778&#x2013;7783. doi: 10.1073/pnas.1219643110.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1219643110</ArticleId><ArticleId IdType="pmc">PMC3651485</ArticleId><ArticleId IdType="pubmed">23553836</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwon I, et al. Poly-dipeptides encoded by the C9orf72 repeats bind nucleoli, impede RNA biogenesis, and kill cells. Science. 2014;345:1139&#x2013;1145. doi: 10.1126/science.1254917.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1254917</ArticleId><ArticleId IdType="pmc">PMC4459787</ArticleId><ArticleId IdType="pubmed">25081482</ArticleId></ArticleIdList></Reference><Reference><Citation>Wen X, et al. Antisense proline-arginine RAN dipeptides linked to C9ORF72-ALS/FTD form toxic nuclear aggregates that initiate in vitro and in vivo neuronal death. Neuron. 2014;84:1213&#x2013;1225. doi: 10.1016/j.neuron.2014.12.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2014.12.010</ArticleId><ArticleId IdType="pmc">PMC4632245</ArticleId><ArticleId IdType="pubmed">25521377</ArticleId></ArticleIdList></Reference><Reference><Citation>Makise M, et al. The Nup153-Nup50 protein interface and its role in nuclear import. J Biol Chem. 2012;287:38515&#x2013;38522. doi: 10.1074/jbc.M112.378893.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M112.378893</ArticleId><ArticleId IdType="pmc">PMC3493896</ArticleId><ArticleId IdType="pubmed">23007389</ArticleId></ArticleIdList></Reference><Reference><Citation>Cesario J, McKim KS. RanGTP is required for meiotic spindle organization and the initiation of embryonic development in Drosophila. J Cell Sci. 2011;124:3797&#x2013;3810. doi: 10.1242/jcs.084855.</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/jcs.084855</ArticleId><ArticleId IdType="pmc">PMC3225268</ArticleId><ArticleId IdType="pubmed">22100918</ArticleId></ArticleIdList></Reference><Reference><Citation>Reed R. Coupling transcription, splicing and mRNA export. Curr Opin Cell Biol. 2003;15:326&#x2013;331.</Citation><ArticleIdList><ArticleId IdType="pubmed">12787775</ArticleId></ArticleIdList></Reference><Reference><Citation>Viphakone N, et al. TREX exposes the RNA-binding domain of Nxf1 to enable mRNA export. Nat Commun. 2012;3:1006. doi: 10.1038/ncomms2005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms2005</ArticleId><ArticleId IdType="pmc">PMC3654228</ArticleId><ArticleId IdType="pubmed">22893130</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Z, et al. The protein Aly links pre-messenger-RNA splicing to nuclear export in metazoans. Nature. 2000;407:401&#x2013;405. doi: 10.1038/35030160.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/35030160</ArticleId><ArticleId IdType="pubmed">11014198</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang CT, et al. Chtop is a component of the dynamic TREX mRNA export complex. The EMBO journal. 2013;32:473&#x2013;486. doi: 10.1038/emboj.2012.342.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/emboj.2012.342</ArticleId><ArticleId IdType="pmc">PMC3567497</ArticleId><ArticleId IdType="pubmed">23299939</ArticleId></ArticleIdList></Reference><Reference><Citation>Wan J, et al. Mutations in the RNA exosome component gene EXOSC3 cause pontocerebellar hypoplasia and spinal motor neuron degeneration. Nat Genet. 2012;44:704&#x2013;708. doi: 10.1038/ng.2254.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.2254</ArticleId><ArticleId IdType="pmc">PMC3366034</ArticleId><ArticleId IdType="pubmed">22544365</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng H, et al. Human mRNA export machinery recruited to the 5 end of mRNA. Cell. 2006;127:1389&#x2013;1400. doi: 10.1016/j.cell.2006.10.044.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2006.10.044</ArticleId><ArticleId IdType="pubmed">17190602</ArticleId></ArticleIdList></Reference><Reference><Citation>Boehmer T, Enninga J, Dales S, Blobel G, Zhong H. Depletion of a single nucleoporin, Nup107, prevents the assembly of a subset of nucleoporins into the nuclear pore complex. Proc Natl Acad Sci U S A. 2003;100:981&#x2013;985. doi: 10.1073/pnas.252749899.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.252749899</ArticleId><ArticleId IdType="pmc">PMC298712</ArticleId><ArticleId IdType="pubmed">12552102</ArticleId></ArticleIdList></Reference><Reference><Citation>Vasu S, et al. Novel vertebrate nucleoporins Nup133 and Nup160 play a role in mRNA export. J Cell Biol. 2001;155:339&#x2013;354. doi: 10.1083/jcb.200108007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1083/jcb.200108007</ArticleId><ArticleId IdType="pmc">PMC2150853</ArticleId><ArticleId IdType="pubmed">11684705</ArticleId></ArticleIdList></Reference><Reference><Citation>Walther TC, et al. The conserved Nup107-160 complex is critical for nuclear pore complex assembly. Cell. 2003;113:195&#x2013;206.</Citation><ArticleIdList><ArticleId IdType="pubmed">12705868</ArticleId></ArticleIdList></Reference><Reference><Citation>Murphy R, Wente SR. An RNA-export mediator with an essential nuclear export signal. Nature. 1996;383:357&#x2013;360. doi: 10.1038/383357a0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/383357a0</ArticleId><ArticleId IdType="pubmed">8848052</ArticleId></ArticleIdList></Reference><Reference><Citation>Nousiainen HO, et al. Mutations in mRNA export mediator GLE1 result in a fetal motoneuron disease. Nat Genet. 2008;40:155&#x2013;157. doi: 10.1038/ng.2007.65.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.2007.65</ArticleId><ArticleId IdType="pmc">PMC2684619</ArticleId><ArticleId IdType="pubmed">18204449</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaneb HM, et al. Deleterious mutations in the essential mRNA metabolism factor, hGle1, in amyotrophic lateral sclerosis. Hum Mol Genet. 2015;24:1363&#x2013;1373. doi: 10.1093/hmg/ddu545.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddu545</ArticleId><ArticleId IdType="pmc">PMC4321443</ArticleId><ArticleId IdType="pubmed">25343993</ArticleId></ArticleIdList></Reference><Reference><Citation>Han SS, Williams LA, Eggan KC. Constructing and deconstructing stem cell models of neurological disease. Neuron. 2011;70:626&#x2013;644. doi: 10.1016/j.neuron.2011.05.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2011.05.003</ArticleId><ArticleId IdType="pubmed">21609821</ArticleId></ArticleIdList></Reference><Reference><Citation>van Blitterswijk M, DeJesus-Hernandez M, Rademakers R. How do C9ORF72 repeat expansions cause amyotrophic lateral sclerosis and frontotemporal dementia: can we learn from other noncoding repeat expansion disorders? Curr Opin Neurol. 2012;25:689&#x2013;700. doi: 10.1097/WCO.0b013e32835a3efb.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/WCO.0b013e32835a3efb</ArticleId><ArticleId IdType="pmc">PMC3923493</ArticleId><ArticleId IdType="pubmed">23160421</ArticleId></ArticleIdList></Reference><Reference><Citation>Almeida S, et al. Modeling key pathological features of frontotemporal dementia with C9ORF72 repeat expansion in iPSC-derived human neurons. Acta Neuropathol. 2013;126:385&#x2013;399. doi: 10.1007/s00401-013-1149-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-013-1149-y</ArticleId><ArticleId IdType="pmc">PMC3753484</ArticleId><ArticleId IdType="pubmed">23836290</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Z, et al. Downregulation of microRNA-9 in iPSC-derived neurons of FTD/ALS patients with TDP-43 mutations. PLoS One. 2013;8:e76055. doi: 10.1371/journal.pone.0076055.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0076055</ArticleId><ArticleId IdType="pmc">PMC3797144</ArticleId><ArticleId IdType="pubmed">24143176</ArticleId></ArticleIdList></Reference><Reference><Citation>Sareen D, et al. Targeting RNA foci in iPSC-derived motor neurons from ALS patients with a C9ORF72 repeat expansion. Sci Transl Med. 2013;5:208ra149. doi: 10.1126/scitranslmed.3007529.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.3007529</ArticleId><ArticleId IdType="pmc">PMC4090945</ArticleId><ArticleId IdType="pubmed">24154603</ArticleId></ArticleIdList></Reference><Reference><Citation>Cronshaw JM, Matunis MJ. The nuclear pore complex: disease associations and functional correlations. Trends Endocrinol Metab. 2004;15:34&#x2013;39.</Citation><ArticleIdList><ArticleId IdType="pubmed">14693424</ArticleId></ArticleIdList></Reference><Reference><Citation>Savas JN, Toyama BH, Xu T, Yates JR, 3rd, Hetzer MW. Extremely long-lived nuclear pore proteins in the rat brain. Science. 2012;335:942. doi: 10.1126/science.1217421.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1217421</ArticleId><ArticleId IdType="pmc">PMC3296478</ArticleId><ArticleId IdType="pubmed">22300851</ArticleId></ArticleIdList></Reference><Reference><Citation>Mor A, White MA, Fontoura BM. Nuclear trafficking in health and disease. Curr Opin Cell Biol. 2014;28:28&#x2013;35. doi: 10.1016/j.ceb.2014.01.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ceb.2014.01.007</ArticleId><ArticleId IdType="pmc">PMC4061247</ArticleId><ArticleId IdType="pubmed">24530809</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonnet A, Palancade B. Regulation of mRNA trafficking by nuclear pore complexes. Genes (Basel) 2014;5:767&#x2013;791. doi: 10.3390/genes5030767.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/genes5030767</ArticleId><ArticleId IdType="pmc">PMC4198930</ArticleId><ArticleId IdType="pubmed">25184662</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang YJ, et al. Aggregation-prone c9FTD/ALS poly(GA) RAN-translated proteins cause neurotoxicity by inducing ER stress. Acta Neuropathol. 2014;128:505&#x2013;524. doi: 10.1007/s00401-014-1336-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-014-1336-5</ArticleId><ArticleId IdType="pmc">PMC4159567</ArticleId><ArticleId IdType="pubmed">25173361</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim NC, et al. VCP is essential for mitochondrial quality control by PINK1/Parkin and this function is impaired by VCP mutations. Neuron. 2013;78:65&#x2013;80. doi: 10.1016/j.neuron.2013.02.029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2013.02.029</ArticleId><ArticleId IdType="pmc">PMC3683300</ArticleId><ArticleId IdType="pubmed">23498974</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith R, Taylor JP. Dissection and imaging of active zones in the Drosophila neuromuscular junction. Journal of visualized experiments: JoVE. 2011 doi: 10.3791/2676.</Citation><ArticleIdList><ArticleId IdType="doi">10.3791/2676</ArticleId><ArticleId IdType="pmc">PMC3169289</ArticleId><ArticleId IdType="pubmed">21559003</ArticleId></ArticleIdList></Reference><Reference><Citation>Gendron TF, et al. Antisense transcripts of the expanded C9ORF72 hexanucleotide repeat form nuclear RNA foci and undergo repeat-associated non-ATG translation in c9FTD/ALS. Acta neuropathologica. 2013;126:829&#x2013;844. doi: 10.1007/s00401-013-1192-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-013-1192-8</ArticleId><ArticleId IdType="pmc">PMC3830741</ArticleId><ArticleId IdType="pubmed">24129584</ArticleId></ArticleIdList></Reference><Reference><Citation>Ash PE, et al. Unconventional translation of C9ORF72 GGGGCC expansion generates insoluble polypeptides specific to c9FTD/ALS. Neuron. 2013;77:639&#x2013;646. doi: 10.1016/j.neuron.2013.02.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2013.02.004</ArticleId><ArticleId IdType="pmc">PMC3593233</ArticleId><ArticleId IdType="pubmed">23415312</ArticleId></ArticleIdList></Reference><Reference><Citation>Almeida S, et al. Induced pluripotent stem cell models of deficient frontotemporal dementia uncover specific reversible neuronal defects. Cell Rep. 2012;2:789&#x2013;798. doi: 10.1016/j.celrep.2012.09.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2012.09.007</ArticleId><ArticleId IdType="pmc">PMC3532907</ArticleId><ArticleId IdType="pubmed">23063362</ArticleId></ArticleIdList></Reference><Reference><Citation>Okita K, et al. A more efficient method to generate integration-free human iPS cells. Nat Methods. 2011;8:409&#x2013;412. doi: 10.1038/nmeth.1591.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nmeth.1591</ArticleId><ArticleId IdType="pubmed">21460823</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">26308983</PMID><DateCompleted><Year>2015</Year><Month>11</Month><Day>16</Day></DateCompleted><DateRevised><Year>2024</Year><Month>06</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1546-1726</ISSN><JournalIssue CitedMedium="Internet"><Volume>18</Volume><Issue>9</Issue><PubDate><Year>2015</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Nature neuroscience</Title><ISOAbbreviation>Nat Neurosci</ISOAbbreviation></Journal><ArticleTitle>Modifiers of C9orf72 dipeptide repeat toxicity connect nucleocytoplasmic transport defects to FTD/ALS.</ArticleTitle><Pagination><StartPage>1226</StartPage><EndPage>1229</EndPage><MedlinePgn>1226-9</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/nn.4085</ELocationID><Abstract><AbstractText>C9orf72 mutations are the most common cause of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). Dipeptide repeat proteins (DPRs) produced by unconventional translation of the C9orf72 repeat expansions cause neurodegeneration in cell culture and in animal models. We performed two unbiased screens in Saccharomyces cerevisiae and identified potent modifiers of DPR toxicity, including karyopherins and effectors of Ran-mediated nucleocytoplasmic transport, providing insight into potential disease mechanisms and therapeutic targets.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jovi&#x10d;i&#x107;</LastName><ForeName>Ana</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Genetics, Stanford University School of Medicine, Stanford, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mertens</LastName><ForeName>Jerome</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Salk Institute for Biological Studies, Sanford Consortium for Regenerative Medicine, La Jolla, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boeynaems</LastName><ForeName>Steven</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>KU Leuven-University of Leuven, Department of Neurosciences, Experimental Neurology and Leuven Research Institute for Neuroscience and Disease (LIND), Leuven, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Vlaams Instituut voor Biotechnologie (VIB), Vesalius Research Center, Laboratory of Neurobiology, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bogaert</LastName><ForeName>Elke</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>KU Leuven-University of Leuven, Department of Neurosciences, Experimental Neurology and Leuven Research Institute for Neuroscience and Disease (LIND), Leuven, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Vlaams Instituut voor Biotechnologie (VIB), Vesalius Research Center, Laboratory of Neurobiology, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chai</LastName><ForeName>Noori</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Genetics, Stanford University School of Medicine, Stanford, California, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neurosciences Graduate Program, Stanford University School of Medicine, Stanford, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yamada</LastName><ForeName>Shizuka B</ForeName><Initials>SB</Initials><AffiliationInfo><Affiliation>Department of Genetics, Stanford University School of Medicine, Stanford, California, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biology, Stanford University, Stanford, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Paul</LastName><ForeName>Joseph W</ForeName><Initials>JW</Initials><Suffix>3rd</Suffix><AffiliationInfo><Affiliation>Department of Genetics, Stanford University School of Medicine, Stanford, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Shuying</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Ludwig Institute for Cancer Research, Departments of Cellular and Molecular Medicine and of Neurosciences, University of California at San Diego, La Jolla, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Herdy</LastName><ForeName>Joseph R</ForeName><Initials>JR</Initials><AffiliationInfo><Affiliation>Salk Institute for Biological Studies, Sanford Consortium for Regenerative Medicine, La Jolla, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bieri</LastName><ForeName>Gregor</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Genetics, Stanford University School of Medicine, Stanford, California, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neurosciences Graduate Program, Stanford University School of Medicine, Stanford, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kramer</LastName><ForeName>Nicholas J</ForeName><Initials>NJ</Initials><AffiliationInfo><Affiliation>Department of Genetics, Stanford University School of Medicine, Stanford, California, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neurosciences Graduate Program, Stanford University School of Medicine, Stanford, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gage</LastName><ForeName>Fred H</ForeName><Initials>FH</Initials><AffiliationInfo><Affiliation>Salk Institute for Biological Studies, Sanford Consortium for Regenerative Medicine, La Jolla, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Van Den Bosch</LastName><ForeName>Ludo</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>KU Leuven-University of Leuven, Department of Neurosciences, Experimental Neurology and Leuven Research Institute for Neuroscience and Disease (LIND), Leuven, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Vlaams Instituut voor Biotechnologie (VIB), Vesalius Research Center, Laboratory of Neurobiology, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Robberecht</LastName><ForeName>Wim</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>KU Leuven-University of Leuven, Department of Neurosciences, Experimental Neurology and Leuven Research Institute for Neuroscience and Disease (LIND), Leuven, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Vlaams Instituut voor Biotechnologie (VIB), Vesalius Research Center, Laboratory of Neurobiology, Leuven, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University Hospitals Leuven, Department of Neurology, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gitler</LastName><ForeName>Aaron D</ForeName><Initials>AD</Initials><AffiliationInfo><Affiliation>Department of Genetics, Stanford University School of Medicine, Stanford, California, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 NS069375</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R00 NS091538</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS065317</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>1R01NS073660</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>1R01NS065317</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS069375</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 HG000044</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K99 NS091538</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS091538</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS073660</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Neurosci</MedlineTA><NlmUniqueID>9809671</NlmUniqueID><ISSNLinking>1097-6256</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000073885">C9orf72 Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C568651">C9orf72 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004151">Dipeptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011506">Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Neurol. 2015 Dec;11(12):670-2. doi: 10.1038/nrneurol.2015.219.</RefSource><PMID Version="1">26526532</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D021581" MajorTopicYN="N">Active Transport, Cell Nucleus</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000073885" MajorTopicYN="N">C9orf72 Protein</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002467" MajorTopicYN="N">Cell Nucleus</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D042622" MajorTopicYN="N">DNA Repeat Expansion</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004151" MajorTopicYN="N">Dipeptides</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057180" MajorTopicYN="N">Frontotemporal Dementia</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017353" MajorTopicYN="N">Gene Deletion</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011506" MajorTopicYN="N">Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015003" MajorTopicYN="N">Yeasts</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>4</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>7</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>8</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>8</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>11</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2016</Year><Month>3</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26308983</ArticleId><ArticleId IdType="mid">NIHMS708035</ArticleId><ArticleId IdType="pmc">PMC4552077</ArticleId><ArticleId IdType="doi">10.1038/nn.4085</ArticleId><ArticleId IdType="pii">nn.4085</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>DeJesus-Hernandez M, et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron. 2011;72:245&#x2013;256.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3202986</ArticleId><ArticleId IdType="pubmed">21944778</ArticleId></ArticleIdList></Reference><Reference><Citation>Renton AE, et al. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron. 2011;72:257&#x2013;268.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3200438</ArticleId><ArticleId IdType="pubmed">21944779</ArticleId></ArticleIdList></Reference><Reference><Citation>Ash PE, et al. Unconventional translation of C9ORF72 GGGGCC expansion generates insoluble polypeptides specific to c9FTD/ALS. Neuron. 2013;77:639&#x2013;646.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3593233</ArticleId><ArticleId IdType="pubmed">23415312</ArticleId></ArticleIdList></Reference><Reference><Citation>Mori K, et al. The C9orf72 GGGGCC repeat is translated into aggregating dipeptide-repeat proteins in FTLD/ALS. Science. 2013;339:1335&#x2013;1338.</Citation><ArticleIdList><ArticleId IdType="pubmed">23393093</ArticleId></ArticleIdList></Reference><Reference><Citation>Zu T, et al. RAN proteins and RNA foci from antisense transcripts in C9ORF72 ALS and frontotemporal dementia. Proc. Natl. Acad. Sci. U.S.A. 2013;110:E4968&#x2013;E4977.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3870665</ArticleId><ArticleId IdType="pubmed">24248382</ArticleId></ArticleIdList></Reference><Reference><Citation>Mizielinska S, et al. C9orf72 repeat expansions cause neurodegeneration in Drosophila through arginine-rich proteins. Science. 2014;345:1192&#x2013;1194.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4944841</ArticleId><ArticleId IdType="pubmed">25103406</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwon I, et al. Poly-dipeptides encoded by the C9orf72 repeats bind nucleoli, impede RNA biogenesis, and kill cells. Science. 2014;345:1139&#x2013;1145.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4459787</ArticleId><ArticleId IdType="pubmed">25081482</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang YJ, et al. Aggregation-prone c9FTD/ALS poly(GA) RAN-translated proteins cause neurotoxicity by inducing ER stress. Acta. Neuropathol. 2014;128:505&#x2013;524.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4159567</ArticleId><ArticleId IdType="pubmed">25173361</ArticleId></ArticleIdList></Reference><Reference><Citation>May S, et al. C9orf72 FTLD/ALS-associated Gly-Ala dipeptide repeat proteins cause neuronal toxicity and Unc119 sequestration. Acta. Neuropathol. 2014;128:485&#x2013;503.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4159571</ArticleId><ArticleId IdType="pubmed">25120191</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamakawa M, et al. Characterization of the dipeptide repeat protein in the molecular pathogenesis of c9FTD/ALS. Hum. Mol. Genet. 2014</Citation><ArticleIdList><ArticleId IdType="pubmed">25398948</ArticleId></ArticleIdList></Reference><Reference><Citation>Wen X, et al. Antisense Proline-Arginine RAN Dipeptides Linked to C9ORF72-ALS/FTD Form Toxic Nuclear Aggregates that Initiate In Vitro and In Vivo Neuronal Death. Neuron. 2014;84:1213&#x2013;1225.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4632245</ArticleId><ArticleId IdType="pubmed">25521377</ArticleId></ArticleIdList></Reference><Reference><Citation>Elden AC, et al. Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALS. Nature. 2010;466:1069&#x2013;1075.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2965417</ArticleId><ArticleId IdType="pubmed">20740007</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun Z, et al. Molecular determinants and genetic modifiers of aggregation and toxicity for the ALS disease protein FUS/TLS. PLoS Biol. 2011;9:e1000614.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3082519</ArticleId><ArticleId IdType="pubmed">21541367</ArticleId></ArticleIdList></Reference><Reference><Citation>Armakola M, et al. Inhibition of RNA lariat debranching enzyme suppresses TDP-43 toxicity in ALS disease models. Nat. Genet. 2012;44:1302&#x2013;1309.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3510335</ArticleId><ArticleId IdType="pubmed">23104007</ArticleId></ArticleIdList></Reference><Reference><Citation>Krebber H, Taura T, Lee MS, Silver PA. Uncoupling of the hnRNP Npl3p from mRNAs during the stress-induced block in mRNA export. Genes Dev. 1999;13:1994&#x2013;2004.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC316916</ArticleId><ArticleId IdType="pubmed">10444597</ArticleId></ArticleIdList></Reference><Reference><Citation>Dormann D, et al. ALS-associated fused in sarcoma (FUS) mutations disrupt Transportin-mediated nuclear import. EMBO J. 2010;29:2841&#x2013;2857.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2924641</ArticleId><ArticleId IdType="pubmed">20606625</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M, et al. FET proteins TAF15 and EWS are selective markers that distinguish FTLD with FUS pathology from amyotrophic lateral sclerosis with FUS mutations. Brain. 2011;134:2595&#x2013;2609.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3170539</ArticleId><ArticleId IdType="pubmed">21856723</ArticleId></ArticleIdList></Reference><Reference><Citation>Bardy C, et al. Neuronal medium that supports basic synaptic functions and activity of human neurons in vitro. Proc. Natl. Acad. Sci. U.S.A. 2015;112:E2725&#x2013;E2734.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4443325</ArticleId><ArticleId IdType="pubmed">25870293</ArticleId></ArticleIdList></Reference><Reference><Citation>Chew J, et al. C9ORF72 repeat expansions in mice cause TDP-43 pathology, neuronal loss, and behavioral deficits. Science. 2015;348:1151&#x2013;1154.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4692360</ArticleId><ArticleId IdType="pubmed">25977373</ArticleId></ArticleIdList></Reference><Reference><Citation>Haeusler AR, et al. C9orf72 nucleotide repeat structures initiate molecular cascades of disease. Nature. 2014;507:195&#x2013;200.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4046618</ArticleId><ArticleId IdType="pubmed">24598541</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Online References</Title><Reference><Citation>Hu Y, et al. Approaching a complete repository of sequence-verified protein-encoding clones for Saccharomyces cerevisiae. Genome Res. 2007;17:536&#x2013;543.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1832101</ArticleId><ArticleId IdType="pubmed">17322287</ArticleId></ArticleIdList></Reference><Reference><Citation>Tong AH, et al. Systematic genetic analysis with ordered arrays of yeast deletion mutants. Science. 2001;294:2364&#x2013;2368.</Citation><ArticleIdList><ArticleId IdType="pubmed">11743205</ArticleId></ArticleIdList></Reference><Reference><Citation>Collins SR, Schuldiner M, Krogan NJ, Weissman JS. A strategy for extracting and analyzing large-scale quantitative epistatic interaction data. Genome Biol. 2006;7:R63.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1779568</ArticleId><ArticleId IdType="pubmed">16859555</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang da W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat. Protoc. 2009;4:44&#x2013;57.</Citation><ArticleIdList><ArticleId IdType="pubmed">19131956</ArticleId></ArticleIdList></Reference><Reference><Citation>Lagier-Tourenne C, et al. Targeted degradation of sense and antisense C9orf72 RNA foci as therapy for ALS and frontotemporal degeneration. Proc. Natl. Acad. Sci. U.S.A. 2013;110:E4530&#x2013;E4539.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3839752</ArticleId><ArticleId IdType="pubmed">24170860</ArticleId></ArticleIdList></Reference><Reference><Citation>Ladewig J, et al. Small molecules enable highly efficient neuronal conversion of human fibroblasts. Nat. Methods. 2012;9:575&#x2013;578.</Citation><ArticleIdList><ArticleId IdType="pubmed">22484851</ArticleId></ArticleIdList></Reference><Reference><Citation>Mertens J, et al. Embryonic stem cell-based modeling of tau pathology in human neurons. Am. J. Pathol. 2013;182:1769&#x2013;1779.</Citation><ArticleIdList><ArticleId IdType="pubmed">23499461</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">26308891</PMID><DateCompleted><Year>2015</Year><Month>10</Month><Day>01</Day></DateCompleted><DateRevised><Year>2023</Year><Month>07</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1476-4687</ISSN><JournalIssue CitedMedium="Internet"><Volume>525</Volume><Issue>7567</Issue><PubDate><Year>2015</Year><Month>Sep</Month><Day>03</Day></PubDate></JournalIssue><Title>Nature</Title><ISOAbbreviation>Nature</ISOAbbreviation></Journal><ArticleTitle>The C9orf72 repeat expansion disrupts nucleocytoplasmic transport.</ArticleTitle><Pagination><StartPage>56</StartPage><EndPage>61</EndPage><MedlinePgn>56-61</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/nature14973</ELocationID><Abstract><AbstractText>The hexanucleotide repeat expansion (HRE) GGGGCC (G4C2) in C9orf72 is the most common cause of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). Recent studies support an HRE RNA gain-of-function mechanism of neurotoxicity, and we previously identified protein interactors for the G4C2 RNA including RanGAP1. A candidate-based genetic screen in Drosophila expressing 30 G4C2 repeats identified RanGAP (Drosophila orthologue of human RanGAP1), a key regulator of nucleocytoplasmic transport, as a potent suppressor of neurodegeneration. Enhancing nuclear import or suppressing nuclear export of proteins also suppresses neurodegeneration. RanGAP physically interacts with HRE RNA and is mislocalized in HRE-expressing flies, neurons from C9orf72 ALS patient-derived induced pluripotent stem cells (iPSC-derived neurons), and in C9orf72 ALS patient brain tissue. Nuclear import is impaired as a result of HRE expression in the fly model and in C9orf72 iPSC-derived neurons, and these deficits are rescued by small molecules and antisense oligonucleotides targeting the HRE G-quadruplexes. Nucleocytoplasmic transport defects may be a fundamental pathway for ALS and FTD that is amenable to pharmacotherapeutic intervention.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Zhang</LastName><ForeName>Ke</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Neurology, School of Medicine, Johns Hopkins University.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Donnelly</LastName><ForeName>Christopher J</ForeName><Initials>CJ</Initials><AffiliationInfo><Affiliation>Brain Science Institute, School of Medicine, Johns Hopkins University.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Haeusler</LastName><ForeName>Aaron R</ForeName><Initials>AR</Initials><AffiliationInfo><Affiliation>Biochemistry and Molecular Biology, Bloomberg School of Public Health, Johns Hopkins University.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grima</LastName><ForeName>Jonathan C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Brain Science Institute, School of Medicine, Johns Hopkins University.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neuroscience, School of Medicine, Johns Hopkins University.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Machamer</LastName><ForeName>James B</ForeName><Initials>JB</Initials><AffiliationInfo><Affiliation>Department of Neurology, School of Medicine, Johns Hopkins University.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Steinwald</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Biochemistry and Molecular Biology, Bloomberg School of Public Health, Johns Hopkins University.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Daley</LastName><ForeName>Elizabeth L</ForeName><Initials>EL</Initials><AffiliationInfo><Affiliation>Brain Science Institute, School of Medicine, Johns Hopkins University.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miller</LastName><ForeName>Sean J</ForeName><Initials>SJ</Initials><AffiliationInfo><Affiliation>Brain Science Institute, School of Medicine, Johns Hopkins University.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cunningham</LastName><ForeName>Kathleen M</ForeName><Initials>KM</Initials><AffiliationInfo><Affiliation>Department of Neurology, School of Medicine, Johns Hopkins University.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vidensky</LastName><ForeName>Svetlana</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Brain Science Institute, School of Medicine, Johns Hopkins University.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gupta</LastName><ForeName>Saksham</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurology, School of Medicine, Johns Hopkins University.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thomas</LastName><ForeName>Michael A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Brain Science Institute, School of Medicine, Johns Hopkins University.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hong</LastName><ForeName>Ingie</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, School of Medicine, Johns Hopkins University.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chiu</LastName><ForeName>Shu-Ling</ForeName><Initials>SL</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, School of Medicine, Johns Hopkins University.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huganir</LastName><ForeName>Richard L</ForeName><Initials>RL</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, School of Medicine, Johns Hopkins University.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ostrow</LastName><ForeName>Lyle W</ForeName><Initials>LW</Initials><AffiliationInfo><Affiliation>Department of Neurology, School of Medicine, Johns Hopkins University.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Matunis</LastName><ForeName>Michael J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Biochemistry and Molecular Biology, Bloomberg School of Public Health, Johns Hopkins University.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Jiou</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Biochemistry and Molecular Biology, Bloomberg School of Public Health, Johns Hopkins University.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sattler</LastName><ForeName>Rita</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Brain Science Institute, School of Medicine, Johns Hopkins University.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Lloyd</LastName><ForeName>Thomas E</ForeName><Initials>TE</Initials><AffiliationInfo><Affiliation>Department of Neurology, School of Medicine, Johns Hopkins University.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neuroscience, School of Medicine, Johns Hopkins University.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Rothstein</LastName><ForeName>Jeffrey D</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>Brain Science Institute, School of Medicine, Johns Hopkins University.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neuroscience, School of Medicine, Johns Hopkins University.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 NS094239</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RC2 NS069395</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 CA009110</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS074324</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS082563</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P40OD018537</GrantID><Acronym>OD</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K99 NS091486</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U24 NS078736</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>CA009110</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS089616</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS085207</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 GM060980</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01NS085207</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P40 OD018537</GrantID><Acronym>OD</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R00 NS091486</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG012992</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS091046</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 NS091046</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 GM084947</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS089616</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01-GM084947</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>08</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nature</MedlineTA><NlmUniqueID>0410462</NlmUniqueID><ISSNLinking>0028-0836</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000073885">C9orf72 Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C568651">C9orf72 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D029721">Drosophila Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D020690">GTPase-Activating Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009687">Nuclear Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016376">Oligonucleotides, Antisense</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011506">Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C092317">RANGAP1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C118002">RanGAP protein, Drosophila</NameOfSubstance></Chemical><Chemical><RegistryNumber>63231-63-0</RegistryNumber><NameOfSubstance UI="D012313">RNA</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nature. 2015 Sep 3;525(7567):36-7. doi: 10.1038/nature15208.</RefSource><PMID Version="1">26308896</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Neurol. 2015 Dec;11(12):670-2. doi: 10.1038/nrneurol.2015.219.</RefSource><PMID Version="1">26526532</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D021581" MajorTopicYN="N">Active Transport, Cell Nucleus</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000073885" MajorTopicYN="N">C9orf72 Protein</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002467" MajorTopicYN="N">Cell Nucleus</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D042622" MajorTopicYN="N">DNA Repeat Expansion</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D029721" MajorTopicYN="N">Drosophila Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004331" MajorTopicYN="N">Drosophila melanogaster</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057180" MajorTopicYN="N">Frontotemporal Dementia</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D054856" MajorTopicYN="N">G-Quadruplexes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020690" MajorTopicYN="N">GTPase-Activating Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057026" MajorTopicYN="N">Induced Pluripotent Stem Cells</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D022022" MajorTopicYN="N">Nuclear Pore</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009687" MajorTopicYN="N">Nuclear Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016376" MajorTopicYN="N">Oligonucleotides, Antisense</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016366" MajorTopicYN="N">Open Reading Frames</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011506" MajorTopicYN="N">Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012313" MajorTopicYN="N">RNA</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>12</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>7</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>8</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>8</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>10</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2016</Year><Month>3</Month><Day>21</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26308891</ArticleId><ArticleId IdType="mid">NIHMS761496</ArticleId><ArticleId IdType="pmc">PMC4800742</ArticleId><ArticleId IdType="doi">10.1038/nature14973</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Majounie E, et al. Frequency of the C9orf72 hexanucleotide repeat expansion in patients with amyotrophic lateral sclerosis and frontotemporal dementia: a cross-sectional study. Lancet Neurol. 2012;11:323&#x2013;330.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3322422</ArticleId><ArticleId IdType="pubmed">22406228</ArticleId></ArticleIdList></Reference><Reference><Citation>Dejesus-Hernandez M, et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron. 2011;72:245&#x2013;256.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3202986</ArticleId><ArticleId IdType="pubmed">21944778</ArticleId></ArticleIdList></Reference><Reference><Citation>Renton AE, et al. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron. 2011;72:257&#x2013;268.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3200438</ArticleId><ArticleId IdType="pubmed">21944779</ArticleId></ArticleIdList></Reference><Reference><Citation>Ash PE, et al. Unconventional translation of C9ORF72 GGGGCC expansion generates insoluble polypeptides specific to c9FTD/ALS. Neuron. 2013;77:639&#x2013;646.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3593233</ArticleId><ArticleId IdType="pubmed">23415312</ArticleId></ArticleIdList></Reference><Reference><Citation>Mori K, et al. The C9orf72 GGGGCC repeat is translated into aggregating dipeptide-repeat proteins in FTLD/ALS. Science. 2013;339:1335&#x2013;1338.</Citation><ArticleIdList><ArticleId IdType="pubmed">23393093</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwon I, et al. Poly-dipeptides encoded by the C9orf72 repeats bind nucleoli, impede RNA biogenesis, and kill cells. Science. 2014;345:1139&#x2013;1145.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4459787</ArticleId><ArticleId IdType="pubmed">25081482</ArticleId></ArticleIdList></Reference><Reference><Citation>Mizielinska S, et al. C9orf72 repeat expansions cause neurodegeneration in Drosophila through arginine-rich proteins. Science. 2014;345:1192&#x2013;1194.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4944841</ArticleId><ArticleId IdType="pubmed">25103406</ArticleId></ArticleIdList></Reference><Reference><Citation>Donnelly CJ, et al. RNA toxicity from the ALS/FTD C9ORF72 expansion is mitigated by antisense intervention. Neuron. 2013;80:415&#x2013;428.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4098943</ArticleId><ArticleId IdType="pubmed">24139042</ArticleId></ArticleIdList></Reference><Reference><Citation>Haeusler AR, et al. C9orf72 nucleotide repeat structures initiate molecular cascades of disease. Nature. 2014</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4046618</ArticleId><ArticleId IdType="pubmed">24598541</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu Z, et al. Expanded GGGGCC repeat RNA associated with amyotrophic lateral sclerosis and frontotemporal dementia causes neurodegeneration. Proc. Natl. Acad. Sci. U. S. A. 2013;110:7778&#x2013;7783.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3651485</ArticleId><ArticleId IdType="pubmed">23553836</ArticleId></ArticleIdList></Reference><Reference><Citation>Kusano A, Staber C, Ganetzky B. Segregation distortion induced by wild-type RanGAP in Drosophila. Proc. Natl. Acad. Sci. U. S. A. 2002;99:6866&#x2013;6870.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC124495</ArticleId><ArticleId IdType="pubmed">11997467</ArticleId></ArticleIdList></Reference><Reference><Citation>Kusano A, Staber C, Ganetzky B. Nuclear mislocalization of enzymatically active RanGAP causes segregation distortion in Drosophila. Dev. Cell. 2001;1:351&#x2013;361.</Citation><ArticleIdList><ArticleId IdType="pubmed">11702947</ArticleId></ArticleIdList></Reference><Reference><Citation>Merrill C, Bayraktaroglu L, Kusano A, Ganetzky B. Truncated RanGAP encoded by the Segregation Distorter locus of Drosophila. Science. 1999;283:1742&#x2013;1745.</Citation><ArticleIdList><ArticleId IdType="pubmed">10073941</ArticleId></ArticleIdList></Reference><Reference><Citation>Bischoff FR, Krebber H, Kempf T, Hermes I, Ponstingl H. Human RanGTPase-activating protein RanGAP1 is a homologue of yeast Rna1p involved in mRNA processing and transport. Proc. Natl. Acad. Sci. U. S. A. 1995;92:1749&#x2013;1753.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC42597</ArticleId><ArticleId IdType="pubmed">7878053</ArticleId></ArticleIdList></Reference><Reference><Citation>Bischoff FR, Klebe C, Kretschmer J, Wittinghofer A, Ponstingl H. RanGAP1 induces GTPase activity of nuclear Ras-related Ran. Proc. Natl. Acad. Sci. U. S. A. 1994;91:2587&#x2013;2591.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC43414</ArticleId><ArticleId IdType="pubmed">8146159</ArticleId></ArticleIdList></Reference><Reference><Citation>Steggerda SM, Paschal BM. Regulation of nuclear import and export by the GTPase Ran. Int. Rev. Cytol. 2002;217:41&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pubmed">12019565</ArticleId></ArticleIdList></Reference><Reference><Citation>Mor A, White MA, Fontoura BM. Nuclear Trafficking in Health and Disease. Curr. Opin. Cell Biol. 2014;28C:28&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4061247</ArticleId><ArticleId IdType="pubmed">24530809</ArticleId></ArticleIdList></Reference><Reference><Citation>Corbett AH, Krebber H. Hot trends erupting in the nuclear transport field. Workshop on mechanisms of nuclear transport. EMBO Rep. 2004;5:453&#x2013;458.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1299058</ArticleId><ArticleId IdType="pubmed">15105827</ArticleId></ArticleIdList></Reference><Reference><Citation>Frasch M. The maternally expressed Drosophila gene encoding the chromatin-binding protein BJ1 is a homolog of the vertebrate gene Regulator of Chromatin Condensation, RCC1. EMBO J. 1991;10:1225&#x2013;1236.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC452777</ArticleId><ArticleId IdType="pubmed">2022188</ArticleId></ArticleIdList></Reference><Reference><Citation>Toyama BH, et al. Identification of long-lived proteins reveals exceptional stability of essential cellular structures. Cell. 2013;154:971&#x2013;982.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3788602</ArticleId><ArticleId IdType="pubmed">23993091</ArticleId></ArticleIdList></Reference><Reference><Citation>Galy V, Mattaj IW, Askjaer P. Caenorhabditis elegans nucleoporins Nup93 and Nup205 determine the limit of nuclear pore complex size exclusion in vivo. Mol. Biol. Cell. 2003;14:5104&#x2013;5115.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC284812</ArticleId><ArticleId IdType="pubmed">12937276</ArticleId></ArticleIdList></Reference><Reference><Citation>Ribbeck K, Lipowsky G, Kent HM, Stewart M, Gorlich D. NTF2 mediates nuclear import of Ran. EMBO J. 1998;17:6587&#x2013;6598.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1171005</ArticleId><ArticleId IdType="pubmed">9822603</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith AE, Slepchenko BM, Schaff JC, Loew LM, Macara IG. Systems analysis of Ran transport. Science. 2002;295:488&#x2013;491.</Citation><ArticleIdList><ArticleId IdType="pubmed">11799242</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith A, Brownawell A, Macara IG. Nuclear import of Ran is mediated by the transport factor NTF2. Curr. Biol. 1998;8:1403&#x2013;1406.</Citation><ArticleIdList><ArticleId IdType="pubmed">9889103</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M, et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science. 2006;314:130&#x2013;133.</Citation><ArticleIdList><ArticleId IdType="pubmed">17023659</ArticleId></ArticleIdList></Reference><Reference><Citation>Ward ME, et al. Early retinal neurodegeneration and impaired Ran-mediated nuclear import of TDP-43 in progranulin-deficient FTLD. J. Exp. Med. 2014;211:1937&#x2013;1945.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4172214</ArticleId><ArticleId IdType="pubmed">25155018</ArticleId></ArticleIdList></Reference><Reference><Citation>D'Angelo MA, Gomez-Cavazos JS, Mei A, Lackner DH, Hetzer MW. A change in nuclear pore complex composition regulates cell differentiation. Dev. Cell. 2012;22:446&#x2013;458.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3288503</ArticleId><ArticleId IdType="pubmed">22264802</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishimura AL, et al. Nuclear import impairment causes cytoplasmic trans-activation response DNA-binding protein accumulation and is associated with frontotemporal lobar degeneration. Brain. 2010;133:1763&#x2013;1771.</Citation><ArticleIdList><ArticleId IdType="pubmed">20472655</ArticleId></ArticleIdList></Reference><Reference><Citation>Sareen D, et al. Targeting RNA foci in iPSC-derived motor neurons from ALS patients with a C9ORF72 repeat expansion. Sci. Transl. Med. 2013;5:208ra149.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4090945</ArticleId><ArticleId IdType="pubmed">24154603</ArticleId></ArticleIdList></Reference><Reference><Citation>Lagier-Tourenne C, et al. Targeted degradation of sense and antisense C9orf72 RNA foci as therapy for ALS and frontotemporal degeneration. Proc. Natl. Acad. Sci. U. S. A. 2013;110:E4530&#x2013;E4539.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3839752</ArticleId><ArticleId IdType="pubmed">24170860</ArticleId></ArticleIdList></Reference><Reference><Citation>Zamiri B, Reddy K, Macgregor RB, Jr., Pearson CE. TMPyP4 porphyrin distorts RNA G-quadruplex structures of the disease-associated r(GGGGCC)n repeat of the C9orf72 gene and blocks interaction of RNA-binding proteins. J. Biol. Chem. 2014;289:4653&#x2013;4659.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3931028</ArticleId><ArticleId IdType="pubmed">24371143</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt J, et al. Genome-wide studies in multiple myeloma identify XPO1/CRM1 as a critical target validated using the selective nuclear export inhibitor KPT-276. Leukemia. 2013;27:2357&#x2013;2365.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3922416</ArticleId><ArticleId IdType="pubmed">23752175</ArticleId></ArticleIdList></Reference><Reference><Citation>Nousiainen HO, et al. Mutations in mRNA export mediator GLE1 result in a fetal motoneuron disease. Nat. Genet. 2008;40:155&#x2013;157.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2684619</ArticleId><ArticleId IdType="pubmed">18204449</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaneb HM, et al. Deleterious mutations in the essential mRNA metabolism factor, hGle1, in amyotrophic lateral sclerosis. Hum. Mol. Genet. 2014</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4321443</ArticleId><ArticleId IdType="pubmed">25343993</ArticleId></ArticleIdList></Reference><Reference><Citation>Kinoshita Y, et al. Nuclear contour irregularity and abnormal transporter protein distribution in anterior horn cells in amyotrophic lateral sclerosis. J. Neuropathol. Exp. Neurol. 2009;68:1184&#x2013;1192.</Citation><ArticleIdList><ArticleId IdType="pubmed">19816199</ArticleId></ArticleIdList></Reference><Reference><Citation>D'Angelo MA, Raices M, Panowski SH, Hetzer MW. Age-dependent deterioration of nuclear pore complexes causes a loss of nuclear integrity in postmitotic cells. Cell. 2009;136:284&#x2013;295.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2805151</ArticleId><ArticleId IdType="pubmed">19167330</ArticleId></ArticleIdList></Reference><Reference><Citation>Ni JQ, et al. A Drosophila resource of transgenic RNAi lines for neurogenetics. Genetics. 2009;182:1089&#x2013;1100.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2728850</ArticleId><ArticleId IdType="pubmed">19487563</ArticleId></ArticleIdList></Reference><Reference><Citation>Ritson GP, et al. TDP-43 mediates degeneration in a novel Drosophila model of disease caused by mutations in VCP/p97. J. Neurosci. 2010;30:7729&#x2013;7739.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2890254</ArticleId><ArticleId IdType="pubmed">20519548</ArticleId></ArticleIdList></Reference><Reference><Citation>Osterwalder T, Yoon KS, White BH, Keshishian H. A conditional tissue-specific transgene expression system using inducible GAL4. Proc. Natl. Acad. Sci. U. S. A. 2001;98:12596&#x2013;12601.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC60099</ArticleId><ArticleId IdType="pubmed">11675495</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson HB, et al. Calmodulin point mutations affect Drosophila development and behavior. Genetics. 1997;147:1783&#x2013;1798.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1208346</ArticleId><ArticleId IdType="pubmed">9409836</ArticleId></ArticleIdList></Reference><Reference><Citation>Machamer JB, Collins SE, Lloyd TE. The ALS gene FUS regulates synaptic transmission at the Drosophila neuromuscular junction. Hum. Mol. Genet. 2014;23:3810&#x2013;3822.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4065154</ArticleId><ArticleId IdType="pubmed">24569165</ArticleId></ArticleIdList></Reference><Reference><Citation>Son EY, et al. Conversion of mouse and human fibroblasts into functional spinal motor neurons. Cell Stem Cell. 2011;9:205&#x2013;218.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3188987</ArticleId><ArticleId IdType="pubmed">21852222</ArticleId></ArticleIdList></Reference><Reference><Citation>Rubin GM, et al. A Drosophila complementary DNA resource. Science. 2000;287:2222&#x2013;2224.</Citation><ArticleIdList><ArticleId IdType="pubmed">10731138</ArticleId></ArticleIdList></Reference><Reference><Citation>Bischof J, Maeda RK, Hediger M, Karch F, Basler K. An optimized transgenesis system for Drosophila using germ-line-specific phiC31 integrases. Proc. Natl. Acad. Sci. U. S. A. 2007;104:3312&#x2013;3317.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1805588</ArticleId><ArticleId IdType="pubmed">17360644</ArticleId></ArticleIdList></Reference><Reference><Citation>Venken KJ, He Y, Hoskins RA, Bellen HJ. P[acman]: a BAC transgenic platform for targeted insertion of large DNA fragments in D. melanogaster. Science. 2006;314:1747&#x2013;1751.</Citation><ArticleIdList><ArticleId IdType="pubmed">17138868</ArticleId></ArticleIdList></Reference><Reference><Citation>Brand AH, Perrimon N. Targeted gene expression as a means of altering cell fates and generating dominant phenotypes. Development. 1993;118:401&#x2013;415.</Citation><ArticleIdList><ArticleId IdType="pubmed">8223268</ArticleId></ArticleIdList></Reference><Reference><Citation>Diaper DC, et al. Loss and gain of Drosophila TDP-43 impair synaptic efficacy and motor control leading to age-related neurodegeneration by loss-of-function phenotypes. Hum. Mol. Genet. 2013;22:1539&#x2013;1557.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3605831</ArticleId><ArticleId IdType="pubmed">23307927</ArticleId></ArticleIdList></Reference><Reference><Citation>Devlin AC, et al. Human iPSC-derived motoneurons harbouring TARDBP or C9ORF72 ALS mutations are dysfunctional despite maintaining viability. Nat. Commun. 2015;6:5999.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4338554</ArticleId><ArticleId IdType="pubmed">25580746</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">26322584</PMID><DateCompleted><Year>2016</Year><Month>04</Month><Day>28</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1476-4687</ISSN><JournalIssue CitedMedium="Internet"><Volume>526</Volume><Issue>7573</Issue><PubDate><Year>2015</Year><Month>Oct</Month><Day>15</Day></PubDate></JournalIssue><Title>Nature</Title><ISOAbbreviation>Nature</ISOAbbreviation></Journal><ArticleTitle>&#x3b7;-Secretase processing of APP inhibits neuronal activity in the hippocampus.</ArticleTitle><Pagination><StartPage>443</StartPage><EndPage>447</EndPage><MedlinePgn>443-7</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/nature14864</ELocationID><Abstract><AbstractText>Alzheimer disease (AD) is characterized by the accumulation of amyloid plaques, which are predominantly composed of amyloid-&#x3b2; peptide. Two principal physiological pathways either prevent or promote amyloid-&#x3b2; generation from its precursor, &#x3b2;-amyloid precursor protein (APP), in a competitive manner. Although APP processing has been studied in great detail, unknown proteolytic events seem to hinder stoichiometric analyses of APP metabolism in vivo. Here we describe a new physiological APP processing pathway, which generates proteolytic fragments capable of inhibiting neuronal activity within the hippocampus. We identify higher molecular mass carboxy-terminal fragments (CTFs) of APP, termed CTF-&#x3b7;, in addition to the long-known CTF-&#x3b1; and CTF-&#x3b2; fragments generated by the &#x3b1;- and &#x3b2;-secretases ADAM10 (a disintegrin and metalloproteinase 10) and BACE1 (&#x3b2;-site APP cleaving enzyme 1), respectively. CTF-&#x3b7; generation is mediated in part by membrane-bound matrix metalloproteinases such as MT5-MMP, referred to as &#x3b7;-secretase activity. &#x3b7;-Secretase cleavage occurs primarily at amino acids 504-505 of APP695, releasing a truncated ectodomain. After shedding of this ectodomain, CTF-&#x3b7; is further processed by ADAM10 and BACE1 to release long and short A&#x3b7; peptides (termed A&#x3b7;-&#x3b1; and A&#x3b7;-&#x3b2;). CTFs produced by &#x3b7;-secretase are enriched in dystrophic neurites in an AD mouse model and in human AD brains. Genetic and pharmacological inhibition of BACE1 activity results in robust accumulation of CTF-&#x3b7; and A&#x3b7;-&#x3b1;. In mice treated with a potent BACE1 inhibitor, hippocampal long-term potentiation was reduced. Notably, when recombinant or synthetic A&#x3b7;-&#x3b1; was applied on hippocampal slices ex vivo, long-term potentiation was lowered. Furthermore, in vivo single-cell two-photon calcium imaging showed that hippocampal neuronal activity was attenuated by A&#x3b7;-&#x3b1;. These findings not only demonstrate a major functionally relevant APP processing pathway, but may also indicate potential translational relevance for therapeutic strategies targeting APP processing.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Willem</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Biomedical Center (BMC), Ludwig-Maximilians-University Munich, 81377 Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tahirovic</LastName><ForeName>Sabina</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE) Munich, 81377 Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Busche</LastName><ForeName>Marc Aurel</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Psychotherapy, Technische Universit&#xe4;t M&#xfc;nchen, 81675 Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Neuroscience, Technische Universit&#xe4;t M&#xfc;nchen, 80802 Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Munich Cluster for Systems Neurology (SyNergy), Ludwig-Maximilians-University Munich, 81377 Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ovsepian</LastName><ForeName>Saak V</ForeName><Initials>SV</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE) Munich, 81377 Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chafai</LastName><ForeName>Magda</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institut de Pharmacologie Mol&#xe9;culaire et Cellulaire (IPMC), Centre National de la Recherche Scientifique (CNRS), Universit&#xe9; de Nice Sophia Antipolis, UMR 7275, 06560 Valbonne, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kootar</LastName><ForeName>Scherazad</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Institut de Pharmacologie Mol&#xe9;culaire et Cellulaire (IPMC), Centre National de la Recherche Scientifique (CNRS), Universit&#xe9; de Nice Sophia Antipolis, UMR 7275, 06560 Valbonne, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hornburg</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Max Planck Institute of Biochemistry, Martinsried 82152, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Evans</LastName><ForeName>Lewis D B</ForeName><Initials>LD</Initials><AffiliationInfo><Affiliation>Gurdon Institute, Cambridge Stem Cell Institute &amp;Department of Biochemistry, University of Cambridge, Cambridge CB2 1QN, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moore</LastName><ForeName>Steven</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Gurdon Institute, Cambridge Stem Cell Institute &amp;Department of Biochemistry, University of Cambridge, Cambridge CB2 1QN, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Daria</LastName><ForeName>Anna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Biomedical Center (BMC), Ludwig-Maximilians-University Munich, 81377 Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hampel</LastName><ForeName>Heike</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Biomedical Center (BMC), Ludwig-Maximilians-University Munich, 81377 Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>M&#xfc;ller</LastName><ForeName>Veronika</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Biomedical Center (BMC), Ludwig-Maximilians-University Munich, 81377 Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Giudici</LastName><ForeName>Camilla</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Biomedical Center (BMC), Ludwig-Maximilians-University Munich, 81377 Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nuscher</LastName><ForeName>Brigitte</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Biomedical Center (BMC), Ludwig-Maximilians-University Munich, 81377 Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wenninger-Weinzierl</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE) Munich, 81377 Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kremmer</LastName><ForeName>Elisabeth</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE) Munich, 81377 Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Munich Cluster for Systems Neurology (SyNergy), Ludwig-Maximilians-University Munich, 81377 Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Molecular Immunology, German Research Center for Environmental Health, 81377 Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Heneka</LastName><ForeName>Michael T</ForeName><Initials>MT</Initials><AffiliationInfo><Affiliation>Department of Neurology, Clinical Neuroscience Unit, University of Bonn, 53127 Bonn, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE) Bonn, 53175 Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thal</LastName><ForeName>Dietmar R</ForeName><Initials>DR</Initials><AffiliationInfo><Affiliation>Institute of Pathology - Laboratory for Neuropathology, University of Ulm, 89081 Ulm, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Giedraitis</LastName><ForeName>Vilmantas</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Public Health/Geriatrics, Uppsala University, 751 85 Uppsala, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lannfelt</LastName><ForeName>Lars</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Public Health/Geriatrics, Uppsala University, 751 85 Uppsala, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>M&#xfc;ller</LastName><ForeName>Ulrike</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>Institute for Pharmacy and Molecular Biotechnology IPMB, Functional Genomics, University of Heidelberg, 69120 Heidelberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Livesey</LastName><ForeName>Frederick J</ForeName><Initials>FJ</Initials><AffiliationInfo><Affiliation>Gurdon Institute, Cambridge Stem Cell Institute &amp;Department of Biochemistry, University of Cambridge, Cambridge CB2 1QN, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meissner</LastName><ForeName>Felix</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Max Planck Institute of Biochemistry, Martinsried 82152, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Herms</LastName><ForeName>Jochen</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE) Munich, 81377 Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Konnerth</LastName><ForeName>Arthur</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Institute of Neuroscience, Technische Universit&#xe4;t M&#xfc;nchen, 80802 Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Munich Cluster for Systems Neurology (SyNergy), Ludwig-Maximilians-University Munich, 81377 Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marie</LastName><ForeName>H&#xe9;l&#xe8;ne</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Institut de Pharmacologie Mol&#xe9;culaire et Cellulaire (IPMC), Centre National de la Recherche Scientifique (CNRS), Universit&#xe9; de Nice Sophia Antipolis, UMR 7275, 06560 Valbonne, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Haass</LastName><ForeName>Christian</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Biomedical Center (BMC), Ludwig-Maximilians-University Munich, 81377 Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE) Munich, 81377 Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Munich Cluster for Systems Neurology (SyNergy), Ludwig-Maximilians-University Munich, 81377 Munich, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>101052</GrantID><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/L023784/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/L023784/2</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>08</Month><Day>31</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nature</MedlineTA><NlmUniqueID>0410462</NlmUniqueID><ISSNLinking>0028-0836</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C545487">APP protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008565">Membrane Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.-</RegistryNumber><NameOfSubstance UI="D016282">Aspartic Acid Endopeptidases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.46</RegistryNumber><NameOfSubstance UI="C509280">BACE1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.46</RegistryNumber><NameOfSubstance UI="C509282">Bace1 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.24.-</RegistryNumber><NameOfSubstance UI="D051722">ADAM Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.24.-</RegistryNumber><NameOfSubstance UI="D053504">Matrix Metalloproteinases, Membrane-Associated</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.24.-</RegistryNumber><NameOfSubstance UI="C118502">Mmp24 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.24.81</RegistryNumber><NameOfSubstance UI="D000072197">ADAM10 Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.24.81</RegistryNumber><NameOfSubstance UI="C491236">ADAM10 protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Cell Res. 2015 Nov;25(11):1185-6. doi: 10.1038/cr.2015.125.</RefSource><PMID Version="1">26503171</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D051722" MajorTopicYN="N">ADAM Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000072197" MajorTopicYN="N">ADAM10 Protein</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053829" MajorTopicYN="N">Amyloid Precursor Protein Secretases</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000172" MajorTopicYN="N">deficiency</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016282" MajorTopicYN="N">Aspartic Acid Endopeptidases</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000172" MajorTopicYN="N">deficiency</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020013" MajorTopicYN="N">Calcium Signaling</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="Y">cytology</QualifierName><QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D066298" MajorTopicYN="N">In Vitro Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017774" MajorTopicYN="N">Long-Term Potentiation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053504" MajorTopicYN="N">Matrix Metalloproteinases, Membrane-Associated</DescriptorName><QualifierName UI="Q000172" MajorTopicYN="N">deficiency</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008565" MajorTopicYN="N">Membrane Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008970" MajorTopicYN="N">Molecular Weight</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016501" MajorTopicYN="N">Neurites</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058225" MajorTopicYN="N">Plaque, Amyloid</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011499" MajorTopicYN="N">Protein Processing, Post-Translational</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059748" MajorTopicYN="Y">Proteolysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059010" MajorTopicYN="N">Single-Cell Analysis</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement><b>Competing financial interests</b>. The authors declare no competing financial interests. A patent is pending.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>3</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>6</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>9</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>9</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>4</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2019</Year><Month>6</Month><Day>14</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26322584</ArticleId><ArticleId IdType="mid">EMS83348</ArticleId><ArticleId IdType="pmc">PMC6570618</ArticleId><ArticleId IdType="doi">10.1038/nature14864</ArticleId><ArticleId IdType="pii">nature14864</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Haass C, Selkoe DJ. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nat Rev Mol Cell Biol. 2007;8:101&#x2013;112.</Citation><ArticleIdList><ArticleId IdType="pubmed">17245412</ArticleId></ArticleIdList></Reference><Reference><Citation>Nygaard HB. Current and Emerging Therapies for Alzheimer's Disease. Clin Ther. 2013;35:1480&#x2013;1489.</Citation><ArticleIdList><ArticleId IdType="pubmed">24139420</ArticleId></ArticleIdList></Reference><Reference><Citation>Dobrowolska JA, et al. CNS amyloid-beta, soluble APP-alpha and -beta kinetics during BACE inhibition. J Neurosci. 2014;34:8336&#x2013;8346.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4051982</ArticleId><ArticleId IdType="pubmed">24920637</ArticleId></ArticleIdList></Reference><Reference><Citation>Portelius E, et al. Mass spectrometric characterization of amyloid-beta species in the 7PA2 cell model of Alzheimer's disease. J Alzheimers Dis. 2013;33:85&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pubmed">22886024</ArticleId></ArticleIdList></Reference><Reference><Citation>Welzel AT, et al. Secreted amyloid beta-proteins in a cell culture model include N-terminally extended peptides that impair synaptic plasticity. Biochemistry (Mosc) 2014;53:3908&#x2013;3921.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4070750</ArticleId><ArticleId IdType="pubmed">24840308</ArticleId></ArticleIdList></Reference><Reference><Citation>Sekine-Aizawa Y, et al. Matrix metalloproteinase (MMP) system in brain: identification and characterization of brain-specific MMP highly expressed in cerebellum. Eur J Neurosci. 2001;13:935&#x2013;948.</Citation><ArticleIdList><ArticleId IdType="pubmed">11264666</ArticleId></ArticleIdList></Reference><Reference><Citation>Haass C. Take five--BACE and the gamma-secretase quartet conduct Alzheimer's amyloid beta-peptide generation. EMBO J. 2004;23:483&#x2013;488.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1271800</ArticleId><ArticleId IdType="pubmed">14749724</ArticleId></ArticleIdList></Reference><Reference><Citation>Willem M, Lammich S, Haass C. Function, regulation and therapeutic properties of beta-secretase (BACE1) Semin Cell Dev Biol. 2009;20:175&#x2013;182.</Citation><ArticleIdList><ArticleId IdType="pubmed">19429494</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan R, Vassar R. Targeting the beta secretase BACE1 for Alzheimer's disease therapy. Lancet Neurol. 2014;13:319&#x2013;329.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4086426</ArticleId><ArticleId IdType="pubmed">24556009</ArticleId></ArticleIdList></Reference><Reference><Citation>McConlogue L, et al. Partial reduction of BACE1 has dramatic effects on Alzheimer plaque and synaptic pathology in APP Transgenic Mice. J Biol Chem. 2007;282:26326&#x2013;26334.</Citation><ArticleIdList><ArticleId IdType="pubmed">17616527</ArticleId></ArticleIdList></Reference><Reference><Citation>Postina R, et al. A disintegrin-metalloproteinase prevents amyloid plaque formation and hippocampal defects in an Alzheimer disease mouse model. J Clin Invest. 2004;113:1456&#x2013;1464.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC406531</ArticleId><ArticleId IdType="pubmed">15146243</ArticleId></ArticleIdList></Reference><Reference><Citation>Simons M, et al. Amyloidogenic processing of the human amyloid precursor protein in primary cultures of rat hippocampal neurons. J Neurosci. 1996;16:899&#x2013;908.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6578819</ArticleId><ArticleId IdType="pubmed">8558258</ArticleId></ArticleIdList></Reference><Reference><Citation>Nikolaev A, McLaughlin T, O'Leary DD, Tessier-Lavigne M. APP binds DR6 to trigger axon pruning and neuron death via distinct caspases. Nature. 2009;457:981&#x2013;989.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2677572</ArticleId><ArticleId IdType="pubmed">19225519</ArticleId></ArticleIdList></Reference><Reference><Citation>Jefferson T, et al. Metalloprotease meprin beta generates nontoxic N-terminal amyloid precursor protein fragments in vivo. J Biol Chem. 2011;286:27741&#x2013;27750.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3149364</ArticleId><ArticleId IdType="pubmed">21646356</ArticleId></ArticleIdList></Reference><Reference><Citation>Vella LJ, Cappai R. Identification of a novel amyloid precursor protein processing pathway that generates secreted N-terminal fragments. FASEB J. 2012</Citation><ArticleIdList><ArticleId IdType="pubmed">22490781</ArticleId></ArticleIdList></Reference><Reference><Citation>Haass C, Koo EH, Mellon A, Hung AY, Selkoe DJ. Targeting of cell-surface beta-amyloid precursor protein to lysosomes: alternative processing into amyloid-bearing fragments. Nature. 1992;357:500&#x2013;503.</Citation><ArticleIdList><ArticleId IdType="pubmed">1608449</ArticleId></ArticleIdList></Reference><Reference><Citation>Estus S, et al. Potentially amyloidogenic, carboxyl-terminal derivatives of the amyloid protein precursor. Science. 1992;255:726&#x2013;728.</Citation><ArticleIdList><ArticleId IdType="pubmed">1738846</ArticleId></ArticleIdList></Reference><Reference><Citation>Haass C, et al. b-Amyloid peptide and a 3-kDa fragment are derived by distinct cellular mechanisms. J Biol Chem. 1993;268:3021&#x2013;3024.</Citation><ArticleIdList><ArticleId IdType="pubmed">8428976</ArticleId></ArticleIdList></Reference><Reference><Citation>Muller U, et al. Behavioral and Anatomical Deficits in Mice Homozygous for a Modified Beta-Amyloid Precursor Protein Gene. Cell. 1994;79:755&#x2013;765.</Citation><ArticleIdList><ArticleId IdType="pubmed">8001115</ArticleId></ArticleIdList></Reference><Reference><Citation>Haass C, et al. Amyloid beta-peptide is produced by cultured cells during normal metabolism. Nature. 1992;359:322&#x2013;325.</Citation><ArticleIdList><ArticleId IdType="pubmed">1383826</ArticleId></ArticleIdList></Reference><Reference><Citation>Golde TE, Estus S, Younkin LH, Selkoe DJ, Younkin SG. Processing of the amyloid protein precursor to potentially amyloidogenic derivatives. Science. 1992;255:728&#x2013;730.</Citation><ArticleIdList><ArticleId IdType="pubmed">1738847</ArticleId></ArticleIdList></Reference><Reference><Citation>Radde R, et al. Abeta42-driven cerebral amyloidosis in transgenic mice reveals early and robust pathology. EMBO Rep. 2006;7:940&#x2013;946.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1559665</ArticleId><ArticleId IdType="pubmed">16906128</ArticleId></ArticleIdList></Reference><Reference><Citation>Haass C, et al. The Swedish Mutation Causes Early-Onset Alzheimers-Disease by Beta-Secretase Cleavage within the Secretory Pathway. Nat Med. 1995;1:1291&#x2013;1296.</Citation><ArticleIdList><ArticleId IdType="pubmed">7489411</ArticleId></ArticleIdList></Reference><Reference><Citation>Lannfelt L, et al. Amyloid beta-peptide in cerebrospinal fluid in individuals with the Swedish Alzheimer amyloid precursor protein mutation. Neurosci Lett. 1995;199:203&#x2013;206.</Citation><ArticleIdList><ArticleId IdType="pubmed">8577398</ArticleId></ArticleIdList></Reference><Reference><Citation>Higashi S, Miyazaki K. Novel processing of beta-amyloid precursor protein catalyzed by membrane type 1 matrix metalloproteinase releases a fragment lacking the inhibitor domain against gelatinase A. Biochemistry (Mosc) 2003;42:6514&#x2013;6526.</Citation><ArticleIdList><ArticleId IdType="pubmed">12767235</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmad M, et al. Cleavage of amyloid-beta precursor protein (APP) by membrane-type matrix metalloproteinases. J Biochem. 2006;139:517&#x2013;526.</Citation><ArticleIdList><ArticleId IdType="pubmed">16567416</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheltema RA, et al. The Q Exactive HF, a Benchtop mass spectrometer with a pre-filter, high-performance quadrupole and an ultra-high-field Orbitrap analyzer. Mol Cell Proteomics. 2014;13:3698&#x2013;3708.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4256516</ArticleId><ArticleId IdType="pubmed">25360005</ArticleId></ArticleIdList></Reference><Reference><Citation>Folgueras AR, et al. Metalloproteinase MT5-MMP is an essential modulator of neuro-immune interactions in thermal pain stimulation. Proc Natl Acad Sci U S A. 2009;106:16451&#x2013;16456.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2752566</ArticleId><ArticleId IdType="pubmed">19805319</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Z, et al. Impaired endochondral ossification and angiogenesis in mice deficient in membrane-type matrix metalloproteinase I. Proc Natl Acad Sci U S A. 2000;97:4052&#x2013;4057.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC18145</ArticleId><ArticleId IdType="pubmed">10737763</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi Y, Kirwan P, Livesey FJ. Directed differentiation of human pluripotent stem cells to cerebral cortex neurons and neural networks. Nat Protoc. 2012;7:1836&#x2013;1846.</Citation><ArticleIdList><ArticleId IdType="pubmed">22976355</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacobsen H, et al. Combined treatment with a BACE inhibitor and anti-Abeta antibody gantenerumab enhances amyloid reduction in APPLondon mice. J Neurosci. 2014;34:11621&#x2013;11630.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4145168</ArticleId><ArticleId IdType="pubmed">25164658</ArticleId></ArticleIdList></Reference><Reference><Citation>Moechars D, et al. Early phenotypic changes in transgenic mice that overexpress different mutants of amyloid precursor protein in brain. J Biol Chem. 1999;274:6483&#x2013;6492.</Citation><ArticleIdList><ArticleId IdType="pubmed">10037741</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai H, et al. BACE1 is the major beta-secretase for generation of Abeta peptides by neurons. Nat Neurosci. 2001;4:233&#x2013;234.</Citation><ArticleIdList><ArticleId IdType="pubmed">11224536</ArticleId></ArticleIdList></Reference><Reference><Citation>Radde R, et al. A beta 42-driven cerebral amyloidosis in transgenic mice reveals early and robust pathology. EMBO Rep. 2006;7:940&#x2013;946.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1559665</ArticleId><ArticleId IdType="pubmed">16906128</ArticleId></ArticleIdList></Reference><Reference><Citation>Nabavi S, et al. Engineering a memory with LTD and LTP. Nature. 2014;511:348&#x2013;352.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4210354</ArticleId><ArticleId IdType="pubmed">24896183</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh DM, et al. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature. 2002;416:535&#x2013;539.</Citation><ArticleIdList><ArticleId IdType="pubmed">11932745</ArticleId></ArticleIdList></Reference><Reference><Citation>Shankar GM, et al. Natural oligomers of the Alzheimer amyloid-beta protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway. J Neurosci. 2007;27:2866&#x2013;2875.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672572</ArticleId><ArticleId IdType="pubmed">17360908</ArticleId></ArticleIdList></Reference><Reference><Citation>Shankar GM, et al. Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med. 2008;14:837&#x2013;842.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2772133</ArticleId><ArticleId IdType="pubmed">18568035</ArticleId></ArticleIdList></Reference><Reference><Citation>Filser S, et al. Pharmacological Inhibition of BACE1 Impairs Synaptic Plasticity and Cognitive Functions. Biol Psychiatry. 2014</Citation><ArticleIdList><ArticleId IdType="pubmed">25599931</ArticleId></ArticleIdList></Reference><Reference><Citation>Busche MA, et al. Clusters of hyperactive neurons near amyloid plaques in a mouse model of Alzheimer's disease. Science. 2008;321:1686&#x2013;1689.</Citation><ArticleIdList><ArticleId IdType="pubmed">18802001</ArticleId></ArticleIdList></Reference><Reference><Citation>Busche MA, et al. Critical role of soluble amyloid-beta for early hippocampal hyperactivity in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A. 2012;109:8740&#x2013;8745.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3365221</ArticleId><ArticleId IdType="pubmed">22592800</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science. 2002;297:353&#x2013;356.</Citation><ArticleIdList><ArticleId IdType="pubmed">12130773</ArticleId></ArticleIdList></Reference><Reference><Citation>Jonsson T, et al. A mutation in APP protects against Alzheimer's disease and age-related cognitive decline. Nature. 2012;488:96&#x2013;99.</Citation><ArticleIdList><ArticleId IdType="pubmed">22801501</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuhn PH, et al. Secretome protein enrichment identifies physiological BACE1 protease substrates in neurons. EMBO J. 2012;31:3157&#x2013;3168.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3400020</ArticleId><ArticleId IdType="pubmed">22728825</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou L, et al. The neural cell adhesion molecules L1 and CHL1 are cleaved by BACE1 protease in vivo. The Journal of biological chemistry. 2012;287:25927&#x2013;25940.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3406677</ArticleId><ArticleId IdType="pubmed">22692213</ArticleId></ArticleIdList></Reference><Reference><Citation>Blennow K, Zetterberg H, Haass C, Finucane T. Semagacestat's fall: where next for AD therapies? Nat Med. 2013;19:1214&#x2013;1215.</Citation><ArticleIdList><ArticleId IdType="pubmed">24100981</ArticleId></ArticleIdList></Reference><Reference><Citation>Nolan RL, Teller JK. Diethylamine extraction of proteins and peptides isolated with a mono-phasic solution of phenol and guanidine isothiocyanate. J Biochem Biophys Methods. 2006;68:127&#x2013;131.</Citation><ArticleIdList><ArticleId IdType="pubmed">16750859</ArticleId></ArticleIdList></Reference><Reference><Citation>Westmeyer GG, et al. Dimerization of beta-site beta-amyloid precursor protein-cleaving enzyme. J Biol Chem. 2004;279:53205&#x2013;53212.</Citation><ArticleIdList><ArticleId IdType="pubmed">15485862</ArticleId></ArticleIdList></Reference><Reference><Citation>Fleck D, et al. Dual cleavage of neuregulin 1 type III by BACE1 and ADAM17 liberates its EGF-like domain and allows paracrine signaling. J Neurosci. 2013;33:7856&#x2013;7869.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6618983</ArticleId><ArticleId IdType="pubmed">23637177</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacobsen H, et al. Combined treatment with a BACE inhibitor and anti-Ab antibody gantenerumab enhances amyloid reduction in APPLondon mice. J Neurosci. 2014 in press.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4145168</ArticleId><ArticleId IdType="pubmed">25164658</ArticleId></ArticleIdList></Reference><Reference><Citation>Houeland G, et al. Transgenic mice with chronic NGF deprivation and Alzheimer's disease-like pathology display hippocampal region-specific impairments in short- and long-term plasticities. J Neurosci. 2010;30:13089&#x2013;13094.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6633528</ArticleId><ArticleId IdType="pubmed">20881126</ArticleId></ArticleIdList></Reference><Reference><Citation>Townsend M, Shankar GM, Mehta T, Walsh DM, Selkoe DJ. Effects of secreted oligomers of amyloid beta-protein on hippocampal synaptic plasticity: a potent role for trimers. J Physiol. 2006;572:477&#x2013;492.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1779683</ArticleId><ArticleId IdType="pubmed">16469784</ArticleId></ArticleIdList></Reference><Reference><Citation>Dombeck DA, Harvey CD, Tian L, Looger LL, Tank DW. Functional imaging of hippocampal place cells at cellular resolution during virtual navigation. Nat Neurosci. 2010;13:1433&#x2013;U1180.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2967725</ArticleId><ArticleId IdType="pubmed">20890294</ArticleId></ArticleIdList></Reference><Reference><Citation>Mizrahi A, Crowley JC, Shtoyerman E, Katz LC. High-resolution in vivo imaging of hippocampal dendrites and spines. J Neurosci. 2004;24:3147&#x2013;3151.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6730023</ArticleId><ArticleId IdType="pubmed">15056694</ArticleId></ArticleIdList></Reference><Reference><Citation>Grienberger C, Chen X, Konnerth A. NMDA receptor-dependent multidendrite Ca(2+) spikes required for hippocampal burst firing in vivo. Neuron. 2014;81:1274&#x2013;1281.</Citation><ArticleIdList><ArticleId IdType="pubmed">24560703</ArticleId></ArticleIdList></Reference><Reference><Citation>Stosiek C, Garaschuk O, Holthoff K, Konnerth A. In vivo two-photon calcium imaging of neuronal networks. Proc Natl Acad Sci U S A. 2003;100:7319&#x2013;7324.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC165873</ArticleId><ArticleId IdType="pubmed">12777621</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">26317470</PMID><DateCompleted><Year>2015</Year><Month>11</Month><Day>24</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>30</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1097-4172</ISSN><JournalIssue CitedMedium="Internet"><Volume>162</Volume><Issue>5</Issue><PubDate><Year>2015</Year><Month>Aug</Month><Day>27</Day></PubDate></JournalIssue><Title>Cell</Title><ISOAbbreviation>Cell</ISOAbbreviation></Journal><ArticleTitle>A Liquid-to-Solid Phase Transition of the ALS Protein FUS Accelerated by Disease Mutation.</ArticleTitle><Pagination><StartPage>1066</StartPage><EndPage>1077</EndPage><MedlinePgn>1066-77</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.cell.2015.07.047</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0092-8674(15)00963-0</ELocationID><Abstract><AbstractText>Many proteins contain disordered regions of low-sequence complexity, which cause aging-associated diseases because they are prone to aggregate. Here, we study FUS, a prion-like protein containing intrinsically disordered domains associated with the neurodegenerative disease ALS. We show that, in cells, FUS forms liquid compartments at sites of DNA damage and in the cytoplasm upon stress. We confirm this by reconstituting liquid FUS compartments in vitro. Using an in vitro "aging" experiment, we demonstrate that liquid droplets of FUS protein convert with time from a liquid to an aggregated state, and this conversion is accelerated by patient-derived mutations. We conclude that the physiological role of FUS requires forming dynamic liquid-like compartments. We propose that liquid-like compartments carry the trade-off between functionality and risk of aggregation and that aberrant phase transitions within liquid-like compartments lie at the heart of ALS and, presumably, other age-related diseases.</AbstractText><CopyrightInformation>Copyright &#xa9; 2015 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Patel</LastName><ForeName>Avinash</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Max Planck Institute of Molecular Cell Biology and Genetics, 01307 Dresden, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Hyun O</ForeName><Initials>HO</Initials><AffiliationInfo><Affiliation>Max Planck Institute of Molecular Cell Biology and Genetics, 01307 Dresden, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jawerth</LastName><ForeName>Louise</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Max Planck Institute of Molecular Cell Biology and Genetics, 01307 Dresden, Germany; Max Planck Institute for the Physics of Complex Systems, 01187 Dresden, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maharana</LastName><ForeName>Shovamayee</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Max Planck Institute of Molecular Cell Biology and Genetics, 01307 Dresden, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jahnel</LastName><ForeName>Marcus</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Max Planck Institute of Molecular Cell Biology and Genetics, 01307 Dresden, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hein</LastName><ForeName>Marco Y</ForeName><Initials>MY</Initials><AffiliationInfo><Affiliation>Department of Proteomics and Signal Transduction, Max Planck Institute of Biochemistry, 82152 Martinsried, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stoynov</LastName><ForeName>Stoyno</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Institute of Molecular Biology, Bulgarian Academy of Sciences, 21, G. Bontchev Str., Sofia 1113, Bulgaria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mahamid</LastName><ForeName>Julia</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Molecular Structural Biology, Max Planck Institute of Biochemistry, 82152 Martinsried, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saha</LastName><ForeName>Shambaditya</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Max Planck Institute of Molecular Cell Biology and Genetics, 01307 Dresden, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Franzmann</LastName><ForeName>Titus M</ForeName><Initials>TM</Initials><AffiliationInfo><Affiliation>Max Planck Institute of Molecular Cell Biology and Genetics, 01307 Dresden, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pozniakovski</LastName><ForeName>Andrej</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Max Planck Institute of Molecular Cell Biology and Genetics, 01307 Dresden, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Poser</LastName><ForeName>Ina</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Max Planck Institute of Molecular Cell Biology and Genetics, 01307 Dresden, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maghelli</LastName><ForeName>Nicola</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Max Planck Institute of Molecular Cell Biology and Genetics, 01307 Dresden, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Royer</LastName><ForeName>Loic A</ForeName><Initials>LA</Initials><AffiliationInfo><Affiliation>Max Planck Institute of Molecular Cell Biology and Genetics, 01307 Dresden, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weigert</LastName><ForeName>Martin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Max Planck Institute of Molecular Cell Biology and Genetics, 01307 Dresden, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Myers</LastName><ForeName>Eugene W</ForeName><Initials>EW</Initials><AffiliationInfo><Affiliation>Max Planck Institute of Molecular Cell Biology and Genetics, 01307 Dresden, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grill</LastName><ForeName>Stephan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Max Planck Institute of Molecular Cell Biology and Genetics, 01307 Dresden, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Drechsel</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Max Planck Institute of Molecular Cell Biology and Genetics, 01307 Dresden, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hyman</LastName><ForeName>Anthony A</ForeName><Initials>AA</Initials><AffiliationInfo><Affiliation>Max Planck Institute of Molecular Cell Biology and Genetics, 01307 Dresden, Germany. Electronic address: hyman@mpi-cbg.de.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alberti</LastName><ForeName>Simon</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Max Planck Institute of Molecular Cell Biology and Genetics, 01307 Dresden, Germany. Electronic address: alberti@mpi-cbg.de.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cell</MedlineTA><NlmUniqueID>0413066</NlmUniqueID><ISSNLinking>0092-8674</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000599550">FUS protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011328">Prions</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D066329">Protein Aggregates</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D034702">RNA-Binding Protein FUS</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002467" MajorTopicYN="N">Cell Nucleus</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003593" MajorTopicYN="N">Cytoplasm</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="Y">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011328" MajorTopicYN="N">Prions</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D066329" MajorTopicYN="N">Protein Aggregates</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017434" MajorTopicYN="N">Protein Structure, Tertiary</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D034702" MajorTopicYN="N">RNA-Binding Protein FUS</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>1</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2015</Year><Month>5</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>7</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>8</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>9</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26317470</ArticleId><ArticleId IdType="doi">10.1016/j.cell.2015.07.047</ArticleId><ArticleId IdType="pii">S0092-8674(15)00963-0</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">26324905</PMID><DateCompleted><Year>2016</Year><Month>01</Month><Day>01</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1091-6490</ISSN><JournalIssue CitedMedium="Internet"><Volume>112</Volume><Issue>38</Issue><PubDate><Year>2015</Year><Month>Sep</Month><Day>22</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>Evidence for &#x3b1;-synuclein prions causing multiple system atrophy in humans with parkinsonism.</ArticleTitle><Pagination><StartPage>E5308</StartPage><EndPage>E5317</EndPage><MedlinePgn>E5308-17</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1073/pnas.1514475112</ELocationID><Abstract><AbstractText>Prions are proteins that adopt alternative conformations that become self-propagating; the PrP(Sc) prion causes the rare human disorder Creutzfeldt-Jakob disease (CJD). We report here that multiple system atrophy (MSA) is caused by a different human prion composed of the &#x3b1;-synuclein protein. MSA is a slowly evolving disorder characterized by progressive loss of autonomic nervous system function and often signs of parkinsonism; the neuropathological hallmark of MSA is glial cytoplasmic inclusions consisting of filaments of &#x3b1;-synuclein. To determine whether human &#x3b1;-synuclein forms prions, we examined 14 human brain homogenates for transmission to cultured human embryonic kidney (HEK) cells expressing full-length, mutant human &#x3b1;-synuclein fused to yellow fluorescent protein (&#x3b1;-syn140*A53T-YFP) and TgM83(+/-) mice expressing &#x3b1;-synuclein (A53T). The TgM83(+/-) mice that were hemizygous for the mutant transgene did not develop spontaneous illness; in contrast, the TgM83(+/+) mice that were homozygous developed neurological dysfunction. Brain extracts from 14 MSA cases all transmitted neurodegeneration to TgM83(+/-) mice after incubation periods of &#x223c;120 d, which was accompanied by deposition of &#x3b1;-synuclein within neuronal cell bodies and axons. All of the MSA extracts also induced aggregation of &#x3b1;-syn*A53T-YFP in cultured cells, whereas none of six Parkinson's disease (PD) extracts or a control sample did so. Our findings argue that MSA is caused by a unique strain of &#x3b1;-synuclein prions, which is different from the putative prions causing PD and from those causing spontaneous neurodegeneration in TgM83(+/+) mice. Remarkably, &#x3b1;-synuclein is the first new human prion to be identified, to our knowledge, since the discovery a half century ago that CJD was transmissible.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Prusiner</LastName><ForeName>Stanley B</ForeName><Initials>SB</Initials><AffiliationInfo><Affiliation>Institute for Neurodegenerative Diseases, University of California, San Francisco, CA 94143; Department of Neurology, University of California, San Francisco, CA 94143; Department of Biochemistry and Biophysics, University of California, San Francisco, CA 94143; stanley@ind.ucsf.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Woerman</LastName><ForeName>Amanda L</ForeName><Initials>AL</Initials><AffiliationInfo><Affiliation>Institute for Neurodegenerative Diseases, University of California, San Francisco, CA 94143;</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mordes</LastName><ForeName>Daniel A</ForeName><Initials>DA</Initials><AffiliationInfo><Affiliation>C. S. Kubik Laboratory for Neuropathology, Department of Pathology, Massachusetts General Hospital, Boston, MA 02114;</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Watts</LastName><ForeName>Joel C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Institute for Neurodegenerative Diseases, University of California, San Francisco, CA 94143; Department of Neurology, University of California, San Francisco, CA 94143;</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rampersaud</LastName><ForeName>Ryan</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Institute for Neurodegenerative Diseases, University of California, San Francisco, CA 94143;</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Berry</LastName><ForeName>David B</ForeName><Initials>DB</Initials><AffiliationInfo><Affiliation>Institute for Neurodegenerative Diseases, University of California, San Francisco, CA 94143;</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Patel</LastName><ForeName>Smita</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Institute for Neurodegenerative Diseases, University of California, San Francisco, CA 94143;</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oehler</LastName><ForeName>Abby</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Pathology, University of California, San Francisco, CA 94143;</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lowe</LastName><ForeName>Jennifer K</ForeName><Initials>JK</Initials><AffiliationInfo><Affiliation>Center for Neurobehavioral Genetics, Center for Autism Research and Treatment, and Department of Neurology, University of California, Los Angeles, CA 90095;</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kravitz</LastName><ForeName>Stephanie N</ForeName><Initials>SN</Initials><AffiliationInfo><Affiliation>Center for Neurobehavioral Genetics, Center for Autism Research and Treatment, and Department of Neurology, University of California, Los Angeles, CA 90095;</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Geschwind</LastName><ForeName>Daniel H</ForeName><Initials>DH</Initials><AffiliationInfo><Affiliation>Center for Neurobehavioral Genetics, Center for Autism Research and Treatment, and Department of Neurology, University of California, Los Angeles, CA 90095; Department of Human Genetics, University of California, Los Angeles, CA 90095;</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Glidden</LastName><ForeName>David V</ForeName><Initials>DV</Initials><AffiliationInfo><Affiliation>Department of Epidemiology and Biostatistics, University of California, San Francisco, CA 94143;</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Halliday</LastName><ForeName>Glenda M</ForeName><Initials>GM</Initials><AffiliationInfo><Affiliation>School of Medical Science, Faculty of Medicine, University of New South Wales, and Neuroscience Research Australia, Randwick, NSW 2031, Australia;</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Middleton</LastName><ForeName>Lefkos T</ForeName><Initials>LT</Initials><AffiliationInfo><Affiliation>Ageing Research Unit, School of Public Health, Imperial College London, London SW7 2AZ, United Kingdom;</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gentleman</LastName><ForeName>Steve M</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>Centre for Neuroinflammation and Neurodegeneration, Department of Medicine, Imperial College London, London SW7 2AZ, United Kingdom;</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grinberg</LastName><ForeName>Lea T</ForeName><Initials>LT</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of California, San Francisco, CA 94143; Memory and Aging Center, University of California, San Francisco, CA 94143.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Giles</LastName><ForeName>Kurt</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Institute for Neurodegenerative Diseases, University of California, San Francisco, CA 94143; Department of Neurology, University of California, San Francisco, CA 94143;</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>AG002132</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG005134</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG002132</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37 AG031220</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG010770</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG021601</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG021601</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005134</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>G-0909</GrantID><Acronym>PUK_</Acronym><Agency>Parkinson's UK</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>AG031220</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG010770</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG003991</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005681</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>08</Month><Day>31</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011328">Prions</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C497604">SNCA protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051844">alpha-Synuclein</NameOfSubstance></Chemical><Chemical><RegistryNumber>1339-63-5</RegistryNumber><NameOfSubstance UI="D014451">Ubiquinone</NameOfSubstance></Chemical><Chemical><RegistryNumber>EJ27X76M46</RegistryNumber><NameOfSubstance UI="C024989">coenzyme Q10</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Proc Natl Acad Sci U S A. 2015 Sep 22;112(38):11748-9. doi: 10.1073/pnas.1515143112.</RefSource><PMID Version="1">26330608</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Mov Disord. 2016 Mar;31(3):300. doi: 10.1002/mds.26537.</RefSource><PMID Version="1">26833797</PMID></CommentsCorrections><CommentsCorrections RefType="ErratumIn"><RefSource>Proc Natl Acad Sci U S A. 2024 Jun 11;121(24):e2408899121. doi: 10.1073/pnas.2408899121.</RefSource><PMID Version="1">38830111</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005091" MajorTopicYN="N">Exons</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057809" MajorTopicYN="N">HEK293 Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007150" MajorTopicYN="N">Immunohistochemistry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008856" MajorTopicYN="N">Microscopy, Fluorescence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019578" MajorTopicYN="N">Multiple System Atrophy</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="N">Neurodegenerative Diseases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020734" MajorTopicYN="N">Parkinsonian Disorders</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020641" MajorTopicYN="N">Polymorphism, Single Nucleotide</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011328" MajorTopicYN="N">Prions</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014451" MajorTopicYN="N">Ubiquinone</DescriptorName><QualifierName UI="Q000031" MajorTopicYN="N">analogs &amp; derivatives</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051844" MajorTopicYN="N">alpha-Synuclein</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Parkinson's disease</Keyword><Keyword MajorTopicYN="N">neurodegeneration</Keyword><Keyword MajorTopicYN="N">strains</Keyword><Keyword MajorTopicYN="N">synucleinopathies</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>9</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>9</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>1</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2016</Year><Month>3</Month><Day>22</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26324905</ArticleId><ArticleId IdType="pmc">PMC4586853</ArticleId><ArticleId IdType="doi">10.1073/pnas.1514475112</ArticleId><ArticleId IdType="pii">1514475112</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Gajdusek DC, Gibbs CJ, Jr, Alpers M. Experimental transmission of a Kuru-like syndrome to chimpanzees. Nature. 1966;209(5025):794&#x2013;796.</Citation><ArticleIdList><ArticleId IdType="pubmed">5922150</ArticleId></ArticleIdList></Reference><Reference><Citation>Gibbs CJ, Jr, Gajdusek DC. An update on long-term in vivo and in vitro studies designed to identify a virus as the cause of amyotrophic lateral sclerosis, parkinsonism dementia, and Parkinson&#x2019;s disease. Adv Neurol. 1982;36:343&#x2013;353.</Citation><ArticleIdList><ArticleId IdType="pubmed">6817614</ArticleId></ArticleIdList></Reference><Reference><Citation>Graham JG, Oppenheimer DR. Orthostatic hypotension and nicotine sensitivity in a case of multiple system atrophy. J Neurol Neurosurg Psychiatry. 1969;32(1):28&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC493381</ArticleId><ArticleId IdType="pubmed">5774131</ArticleId></ArticleIdList></Reference><Reference><Citation>Papp MI, Kahn JE, Lantos PL. Glial cytoplasmic inclusions in the CNS of patients with multiple system atrophy (striatonigral degeneration, olivopontocerebellar atrophy and Shy-Drager syndrome) J Neurol Sci. 1989;94(1-3):79&#x2013;100.</Citation><ArticleIdList><ArticleId IdType="pubmed">2559165</ArticleId></ArticleIdList></Reference><Reference><Citation>Spillantini MG, et al. Filamentous &#x3b1;-synuclein inclusions link multiple system atrophy with Parkinson&#x2019;s disease and dementia with Lewy bodies. Neurosci Lett. 1998;251(3):205&#x2013;208.</Citation><ArticleIdList><ArticleId IdType="pubmed">9726379</ArticleId></ArticleIdList></Reference><Reference><Citation>Tu PH, et al. Glial cytoplasmic inclusions in white matter oligodendrocytes of multiple system atrophy brains contain insoluble &#x3b1;-synuclein. Ann Neurol. 1998;44(3):415&#x2013;422.</Citation><ArticleIdList><ArticleId IdType="pubmed">9749615</ArticleId></ArticleIdList></Reference><Reference><Citation>Wakabayashi K, Yoshimoto M, Tsuji S, Takahashi H. &#x3b1;-Synuclein immunoreactivity in glial cytoplasmic inclusions in multiple system atrophy. Neurosci Lett. 1998;249(2-3):180&#x2013;182.</Citation><ArticleIdList><ArticleId IdType="pubmed">9682846</ArticleId></ArticleIdList></Reference><Reference><Citation>Spillantini MG, et al. Alpha-synuclein in Lewy bodies. Nature. 1997;388(6645):839&#x2013;840.</Citation><ArticleIdList><ArticleId IdType="pubmed">9278044</ArticleId></ArticleIdList></Reference><Reference><Citation>Polymeropoulos MH, et al. Mutation in the &#x3b1;-synuclein gene identified in families with Parkinson&#x2019;s disease. Science. 1997;276(5321):2045&#x2013;2047.</Citation><ArticleIdList><ArticleId IdType="pubmed">9197268</ArticleId></ArticleIdList></Reference><Reference><Citation>Schrag A, Ben-Shlomo Y, Quinn NP. Prevalence of progressive supranuclear palsy and multiple system atrophy: A cross-sectional study. Lancet. 1999;354(9192):1771&#x2013;1775.</Citation><ArticleIdList><ArticleId IdType="pubmed">10577638</ArticleId></ArticleIdList></Reference><Reference><Citation>Bower JH, Maraganore DM, McDonnell SK, Rocca WA. Incidence of progressive supranuclear palsy and multiple system atrophy in Olmsted County, Minnesota, 1976 to 1990. Neurology. 1997;49(5):1284&#x2013;1288.</Citation><ArticleIdList><ArticleId IdType="pubmed">9371909</ArticleId></ArticleIdList></Reference><Reference><Citation>Gilman S, et al. Consensus statement on the diagnosis of multiple system atrophy. J Neurol Sci. 1999;163(1):94&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="pubmed">10223419</ArticleId></ArticleIdList></Reference><Reference><Citation>Watts JC, et al. Transmission of multiple system atrophy prions to transgenic mice. Proc Natl Acad Sci USA. 2013;110(48):19555&#x2013;19560.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3845125</ArticleId><ArticleId IdType="pubmed">24218576</ArticleId></ArticleIdList></Reference><Reference><Citation>Woerman AL, et al. Propagation of prions causing synucleinopathies in cultured cells. Proc Natl Acad Sci USA. 2015 112(35):E4949&#x2013;E4958.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4568231</ArticleId><ArticleId IdType="pubmed">26286986</ArticleId></ArticleIdList></Reference><Reference><Citation>Gilman S, et al. Second consensus statement on the diagnosis of multiple system atrophy. Neurology. 2008;71(9):670&#x2013;676.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2676993</ArticleId><ArticleId IdType="pubmed">18725592</ArticleId></ArticleIdList></Reference><Reference><Citation>Wenning GK, Braune S. Multiple system atrophy: Pathophysiology and management. CNS Drugs. 2001;15(11):839&#x2013;852.</Citation><ArticleIdList><ArticleId IdType="pubmed">11700149</ArticleId></ArticleIdList></Reference><Reference><Citation>Yabe I, et al. MSA-C is the predominant clinical phenotype of MSA in Japan: Analysis of 142 patients with probable MSA. J Neurol Sci. 2006;249(2):115&#x2013;121.</Citation><ArticleIdList><ArticleId IdType="pubmed">16828805</ArticleId></ArticleIdList></Reference><Reference><Citation>W&#xfc;llner U, et al. Features of probable multiple system atrophy patients identified among 4770 patients with parkinsonism enrolled in the multicentre registry of the German Competence Network on Parkinson&#x2019;s disease. J Neural Transm. 2007;114(9):1161&#x2013;1165.</Citation><ArticleIdList><ArticleId IdType="pubmed">17510732</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Sullivan SS, et al. Clinical outcomes of progressive supranuclear palsy and multiple system atrophy. Brain. 2008;131(Pt 5):1362&#x2013;1372.</Citation><ArticleIdList><ArticleId IdType="pubmed">18385183</ArticleId></ArticleIdList></Reference><Reference><Citation>Nuytemans K, Theuns J, Cruts M, Van Broeckhoven C. Genetic etiology of Parkinson disease associated with mutations in the SNCA, PARK2, PINK1, PARK7, and LRRK2 genes: A mutation update. Hum Mutat. 2010;31(7):763&#x2013;780.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3056147</ArticleId><ArticleId IdType="pubmed">20506312</ArticleId></ArticleIdList></Reference><Reference><Citation>Scholz SW, et al. SNCA variants are associated with increased risk for multiple system atrophy. Ann Neurol. 2009;65(5):610&#x2013;614.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3520128</ArticleId><ArticleId IdType="pubmed">19475667</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiely AP, et al. &#x3b1;-Synucleinopathy associated with G51D SNCA mutation: A link between Parkinson&#x2019;s disease and multiple system atrophy? Acta Neuropathol. 2013;125(5):753&#x2013;769.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3681325</ArticleId><ArticleId IdType="pubmed">23404372</ArticleId></ArticleIdList></Reference><Reference><Citation>Lesage S, et al. French Parkinson&#x2019;s Disease Genetics Study Group G51D &#x3b1;-synuclein mutation causes a novel parkinsonian-pyramidal syndrome. Ann Neurol. 2013;73(4):459&#x2013;471.</Citation><ArticleIdList><ArticleId IdType="pubmed">23526723</ArticleId></ArticleIdList></Reference><Reference><Citation>Pasanen P, et al. Novel &#x3b1;-synuclein mutation A53E associated with atypical multiple system atrophy and Parkinson&#x2019;s disease-type pathology. Neurobiol Aging. 2014;35(9):2180.e1&#x2013;2180.e5.</Citation><ArticleIdList><ArticleId IdType="pubmed">24746362</ArticleId></ArticleIdList></Reference><Reference><Citation>Multiple-System Atrophy Research Collaboration Mutations in COQ2 in familial and sporadic multiple-system atrophy. N Engl J Med. 2013;369(3):233&#x2013;244.</Citation><ArticleIdList><ArticleId IdType="pubmed">23758206</ArticleId></ArticleIdList></Reference><Reference><Citation>Combarros O, Infante J, Llorca J, Berciano J. Interleukin-1A (-889) genetic polymorphism increases the risk of multiple system atrophy. Mov Disord. 2003;18(11):1385&#x2013;1386.</Citation><ArticleIdList><ArticleId IdType="pubmed">14639688</ArticleId></ArticleIdList></Reference><Reference><Citation>Infante J, Llorca J, Berciano J, Combarros O. Interleukin-8, intercellular adhesion molecule-1 and tumour necrosis factor-alpha gene polymorphisms and the risk for multiple system atrophy. J Neurol Sci. 2005;228(1):11&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pubmed">15607204</ArticleId></ArticleIdList></Reference><Reference><Citation>Telling GC, et al. Prion propagation in mice expressing human and chimeric PrP transgenes implicates the interaction of cellular PrP with another protein. Cell. 1995;83(1):79&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pubmed">7553876</ArticleId></ArticleIdList></Reference><Reference><Citation>Sacino AN, et al. Intramuscular injection of &#x3b1;-synuclein induces CNS &#x3b1;-synuclein pathology and a rapid-onset motor phenotype in transgenic mice. Proc Natl Acad Sci USA. 2014;111(29):10732&#x2013;10737.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4115570</ArticleId><ArticleId IdType="pubmed">25002524</ArticleId></ArticleIdList></Reference><Reference><Citation>Bartz JC, Kincaid AE, Bessen RA. Rapid prion neuroinvasion following tongue infection. J Virol. 2003;77(1):583&#x2013;591.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC140623</ArticleId><ArticleId IdType="pubmed">12477862</ArticleId></ArticleIdList></Reference><Reference><Citation>Gajdusek DC. Unconventional viruses and the origin and disappearance of kuru. Science. 1977;197(4307):943&#x2013;960.</Citation><ArticleIdList><ArticleId IdType="pubmed">142303</ArticleId></ArticleIdList></Reference><Reference><Citation>Prusiner SB. Novel proteinaceous infectious particles cause scrapie. Science. 1982;216(4542):136&#x2013;144.</Citation><ArticleIdList><ArticleId IdType="pubmed">6801762</ArticleId></ArticleIdList></Reference><Reference><Citation>Prusiner SB. Madness and Memory. Yale Univ Press; New Haven, CT: 2014. p. 344.</Citation></Reference><Reference><Citation>Walker LC, Jucker M. Neurodegenerative diseases: Expanding the prion concept. Annu Rev Neurosci. 2015;38:87&#x2013;103.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4803040</ArticleId><ArticleId IdType="pubmed">25840008</ArticleId></ArticleIdList></Reference><Reference><Citation>Prusiner SB, et al. Scrapie prions aggregate to form amyloid-like birefringent rods. Cell. 1983;35(2 Pt 1):349&#x2013;358.</Citation><ArticleIdList><ArticleId IdType="pubmed">6418385</ArticleId></ArticleIdList></Reference><Reference><Citation>Han H, Weinreb PH, Lansbury PT., Jr The core Alzheimer&#x2019;s peptide NAC forms amyloid fibrils which seed and are seeded by beta-amyloid: Is NAC a common trigger or target in neurodegenerative disease? Chem Biol. 1995;2(3):163&#x2013;169.</Citation><ArticleIdList><ArticleId IdType="pubmed">9383418</ArticleId></ArticleIdList></Reference><Reference><Citation>Kordower JH, Chu Y, Hauser RA, Freeman TB, Olanow CW. Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson&#x2019;s disease. Nat Med. 2008;14(5):504&#x2013;506.</Citation><ArticleIdList><ArticleId IdType="pubmed">18391962</ArticleId></ArticleIdList></Reference><Reference><Citation>Li JY, et al. Lewy bodies in grafted neurons in subjects with Parkinson&#x2019;s disease suggest host-to-graft disease propagation. Nat Med. 2008;14(5):501&#x2013;503.</Citation><ArticleIdList><ArticleId IdType="pubmed">18391963</ArticleId></ArticleIdList></Reference><Reference><Citation>Olanow CW, Prusiner SB. Is Parkinson&#x2019;s disease a prion disorder? Proc Natl Acad Sci USA. 2009;106(31):12571&#x2013;12572.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2722298</ArticleId><ArticleId IdType="pubmed">19666621</ArticleId></ArticleIdList></Reference><Reference><Citation>Mougenot A-L, et al. Prion-like acceleration of a synucleinopathy in a transgenic mouse model. Neurobiol Aging. 2012;33(9):2225&#x2013;2228.</Citation><ArticleIdList><ArticleId IdType="pubmed">21813214</ArticleId></ArticleIdList></Reference><Reference><Citation>Luk KC, et al. Intracerebral inoculation of pathological &#x3b1;-synuclein initiates a rapidly progressive neurodegenerative &#x3b1;-synucleinopathy in mice. J Exp Med. 2012;209(5):975&#x2013;986.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3348112</ArticleId><ArticleId IdType="pubmed">22508839</ArticleId></ArticleIdList></Reference><Reference><Citation>Luk KC, et al. Pathological &#x3b1;-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science. 2012;338(6109):949&#x2013;953.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3552321</ArticleId><ArticleId IdType="pubmed">23161999</ArticleId></ArticleIdList></Reference><Reference><Citation>Sacino AN, et al. Amyloidogenic &#x3b1;-synuclein seeds do not invariably induce rapid, widespread pathology in mice. Acta Neuropathol. 2014;127(5):645&#x2013;665.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4869357</ArticleId><ArticleId IdType="pubmed">24659240</ArticleId></ArticleIdList></Reference><Reference><Citation>Peelaerts W, et al. &#x3b1;-Synuclein strains cause distinct synucleinopathies after local and systemic administration. Nature. 2015;522(7556):340&#x2013;344.</Citation><ArticleIdList><ArticleId IdType="pubmed">26061766</ArticleId></ArticleIdList></Reference><Reference><Citation>Recasens A, et al. Lewy body extracts from Parkinson disease brains trigger &#x3b1;-synuclein pathology and neurodegeneration in mice and monkeys. Ann Neurol. 2014;75(3):351&#x2013;362.</Citation><ArticleIdList><ArticleId IdType="pubmed">24243558</ArticleId></ArticleIdList></Reference><Reference><Citation>Masuda-Suzukake M, et al. Prion-like spreading of pathological &#x3b1;-synuclein in brain. Brain. 2013;136(Pt 4):1128&#x2013;1138.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3613715</ArticleId><ArticleId IdType="pubmed">23466394</ArticleId></ArticleIdList></Reference><Reference><Citation>Giasson BI, et al. Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. Science. 2000;290(5493):985&#x2013;989.</Citation><ArticleIdList><ArticleId IdType="pubmed">11062131</ArticleId></ArticleIdList></Reference><Reference><Citation>Shimura H, et al. Ubiquitination of a new form of &#x3b1;-synuclein by parkin from human brain: Implications for Parkinson&#x2019;s disease. Science. 2001;293(5528):263&#x2013;269.</Citation><ArticleIdList><ArticleId IdType="pubmed">11431533</ArticleId></ArticleIdList></Reference><Reference><Citation>Fujiwara H, et al. alpha-Synuclein is phosphorylated in synucleinopathy lesions. Nat Cell Biol. 2002;4(2):160&#x2013;164.</Citation><ArticleIdList><ArticleId IdType="pubmed">11813001</ArticleId></ArticleIdList></Reference><Reference><Citation>Krumova P, et al. Sumoylation inhibits &#x3b1;-synuclein aggregation and toxicity. J Cell Biol. 2011;194(1):49&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3135405</ArticleId><ArticleId IdType="pubmed">21746851</ArticleId></ArticleIdList></Reference><Reference><Citation>Telling GC, et al. Interactions between wild-type and mutant prion proteins modulate neurodegeneration in transgenic mice. Genes Dev. 1996;10(14):1736&#x2013;1750.</Citation><ArticleIdList><ArticleId IdType="pubmed">8698234</ArticleId></ArticleIdList></Reference><Reference><Citation>Giles K, et al. Identification of I137M and other mutations that modulate incubation periods for two human prion strains. J Virol. 2012;86(11):6033&#x2013;6041.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3372217</ArticleId><ArticleId IdType="pubmed">22438549</ArticleId></ArticleIdList></Reference><Reference><Citation>Bernoulli C, et al. Danger of accidental person-to-person transmission of Creutzfeldt-Jakob disease by surgery. Lancet. 1977;1(8009):478&#x2013;479.</Citation><ArticleIdList><ArticleId IdType="pubmed">65575</ArticleId></ArticleIdList></Reference><Reference><Citation>Gibbs CJ, Jr, et al. Transmission of Creutzfeldt-Jakob disease to a chimpanzee by electrodes contaminated during neurosurgery. J Neurol Neurosurg Psychiatry. 1994;57(6):757&#x2013;758.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1072988</ArticleId><ArticleId IdType="pubmed">8006664</ArticleId></ArticleIdList></Reference><Reference><Citation>Flechsig E, et al. Transmission of scrapie by steel-surface-bound prions. Mol Med. 2001;7(10):679&#x2013;684.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1949999</ArticleId><ArticleId IdType="pubmed">11713367</ArticleId></ArticleIdList></Reference><Reference><Citation>Giles K, et al. Resistance of bovine spongiform encephalopathy (BSE) prions to inactivation. PLoS Pathog. 2008;4(11):e1000206.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2576443</ArticleId><ArticleId IdType="pubmed">19008948</ArticleId></ArticleIdList></Reference><Reference><Citation>Cotzias GC, Van Woert MH, Schiffer LM. Aromatic amino acids and modification of parkinsonism. N Engl J Med. 1967;276(7):374&#x2013;379.</Citation><ArticleIdList><ArticleId IdType="pubmed">5334614</ArticleId></ArticleIdList></Reference><Reference><Citation>National Research Council (2011) Guide for the Care and Use of Laboratory Animals (National Academies Press, Washington, DC), 8th Ed.</Citation></Reference><Reference><Citation>Alafuzoff I, et al. Staging/typing of Lewy body related alpha-synuclein pathology: A study of the BrainNet Europe Consortium. Acta Neuropathol. 2009;117(6):635&#x2013;652.</Citation><ArticleIdList><ArticleId IdType="pubmed">19330340</ArticleId></ArticleIdList></Reference><Reference><Citation>Giasson BI, et al. Neuronal &#x3b1;-synucleinopathy with severe movement disorder in mice expressing A53T human &#x3b1;-synuclein. Neuron. 2002;34(4):521&#x2013;533.</Citation><ArticleIdList><ArticleId IdType="pubmed">12062037</ArticleId></ArticleIdList></Reference><Reference><Citation>Cabin DE, et al. Synaptic vesicle depletion correlates with attenuated synaptic responses to prolonged repetitive stimulation in mice lacking alpha-synuclein. J Neurosci. 2002;22(20):8797&#x2013;8807.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6757677</ArticleId><ArticleId IdType="pubmed">12388586</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuo YM, et al. Extensive enteric nervous system abnormalities in mice transgenic for artificial chromosomes containing Parkinson disease-associated alpha-synuclein gene mutations precede central nervous system changes. Hum Mol Genet. 2010;19(9):1633&#x2013;1650.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2850613</ArticleId><ArticleId IdType="pubmed">20106867</ArticleId></ArticleIdList></Reference><Reference><Citation>Carlson GA, et al. Linkage of prion protein and scrapie incubation time genes. Cell. 1986;46(4):503&#x2013;511.</Citation><ArticleIdList><ArticleId IdType="pubmed">3015416</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">26324099</PMID><DateCompleted><Year>2017</Year><Month>09</Month><Day>25</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1476-5578</ISSN><JournalIssue CitedMedium="Internet"><Volume>21</Volume><Issue>7</Issue><PubDate><Year>2016</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Molecular psychiatry</Title><ISOAbbreviation>Mol Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Midlife adiposity predicts earlier onset of Alzheimer's dementia, neuropathology and presymptomatic cerebral amyloid accumulation.</ArticleTitle><Pagination><StartPage>910</StartPage><EndPage>915</EndPage><MedlinePgn>910-5</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/mp.2015.129</ELocationID><Abstract><AbstractText>Understanding how midlife risk factors influence age at onset (AAO) of Alzheimer's disease (AD) may provide clues to delay disease expression. Although midlife adiposity predicts increased incidence of AD, it is unclear whether it affects AAO and severity of Alzheimer's neuropathology. Using a prospective population-based cohort, Baltimore Longitudinal Study of Aging (BLSA), this study aims to examine the relationships between midlife body mass index (BMI) and (1) AAO of AD (2) severity of Alzheimer's neuropathology and (3) fibrillar brain amyloid deposition during aging. We analyzed data on 1394 cognitively normal individuals at baseline (8643 visits; average follow-up interval 13.9 years), among whom 142 participants developed incident AD. In two subsamples of BLSA, 191 participants underwent autopsy and neuropathological assessment, and 75 non-demented individuals underwent brain amyloid imaging. Midlife adiposity was derived from BMI data at 50 years of age. We find that each unit increase in midlife BMI predicts earlier onset of AD by 6.7 months (P=0.013). Higher midlife BMI was associated with greater Braak neurofibrillary but not CERAD (Consortium to Establish a Registry for Alzheimer's Disease) neuritic plaque scores at autopsy overall. Associations between midlife BMI and brain amyloid burden approached statistical significance. Thus, higher midlife BMI was also associated with greater fibrillar amyloid measured by global mean cortical distribution volume ratio (P=0.075) and within the precuneus (left, P=0.061; right, P=0.079). In conclusion, midlife overweight predicts earlier onset of AD and greater burden of Alzheimer's neuropathology. A healthy BMI at midlife may delay the onset of AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chuang</LastName><ForeName>Y-F</ForeName><Initials>YF</Initials><AffiliationInfo><Affiliation>Clinical and Translational Neuroscience Unit, Laboratory of Behavioral Neuroscience, National Institute on Aging (NIA), National Institutes of Health (NIH), Baltimore, MD, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Public Health, National Yang-Ming University, Taipei, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, Far Eastern Memorial Hospital, New Taipei City, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>An</LastName><ForeName>Y</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Intramural Research Program, National Institute on Aging, Baltimore, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bilgel</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Intramural Research Program, National Institute on Aging, Baltimore, MD, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biomedical Engineering, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wong</LastName><ForeName>D F</ForeName><Initials>DF</Initials><AffiliationInfo><Affiliation>Russell H. Morgan Department of Radiology and Radiological Science, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry and Behavioral Science and Neuroscience, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Troncoso</LastName><ForeName>J C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Department of Pathology, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>O'Brien</LastName><ForeName>R J</ForeName><Initials>RJ</Initials><AffiliationInfo><Affiliation>Department of Neurology, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Breitner</LastName><ForeName>J C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Centre for Studies on Prevention of Alzheimer's Disease, Douglas Mental Health University Institute Research Centre, Montreal, QC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ferruci</LastName><ForeName>L</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Intramural Research Program, National Institute on Aging, Baltimore, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Resnick</LastName><ForeName>S M</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>Intramural Research Program, National Institute on Aging, Baltimore, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thambisetty</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Clinical and Translational Neuroscience Unit, Laboratory of Behavioral Neuroscience, National Institute on Aging (NIA), National Institutes of Health (NIH), Baltimore, MD, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P50 AG005146</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>Z99 AG999999</GrantID><Acronym>ImNIH</Acronym><Agency>Intramural NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052060">Research Support, N.I.H., Intramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>09</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Mol Psychiatry</MedlineTA><NlmUniqueID>9607835</NlmUniqueID><ISSNLinking>1359-4184</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>Mol Psychiatry. 2023 Oct;28(10):4486. doi: 10.1038/s41380-023-02210-z.</RefSource><PMID Version="1">37563279</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D050154" MajorTopicYN="N">Adiposity</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015992" MajorTopicYN="N">Body Mass Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005544" MajorTopicYN="N">Forecasting</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016874" MajorTopicYN="N">Neurofibrillary Tangles</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000069338" MajorTopicYN="N">Neuropathology</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009765" MajorTopicYN="N">Obesity</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058225" MajorTopicYN="N">Plaque, Amyloid</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="N">Positron-Emission Tomography</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of Interest:</b> The authors confirm that they do not have any conflicts of interest to disclose.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>3</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2015</Year><Month>7</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>7</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>9</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>9</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>9</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2018</Year><Month>2</Month><Day>13</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26324099</ArticleId><ArticleId IdType="mid">NIHMS939599</ArticleId><ArticleId IdType="pmc">PMC5811225</ArticleId><ArticleId IdType="doi">10.1038/mp.2015.129</ArticleId><ArticleId IdType="pii">mp2015129</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Barnes DE, Yaffe K. The projected effect of risk factor reduction on Alzheimer&#x2019;s disease prevalence. Lancet Neurol. 2011;10(9):819&#x2013;828.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3647614</ArticleId><ArticleId IdType="pubmed">21775213</ArticleId></ArticleIdList></Reference><Reference><Citation>Brookmeyer R, Johnson E, Ziegler-Graham K, Arrighi HM. Forecasting the global burden of Alzheimer&#x2019;s disease. Alzheimers Dement. 2007;3(3):186&#x2013;191.</Citation><ArticleIdList><ArticleId IdType="pubmed">19595937</ArticleId></ArticleIdList></Reference><Reference><Citation>Brookmeyer R, Gray S, Kawas C. Projections of Alzheimer&#x2019;s disease in the United States and the public health impact of delaying disease onset. Am J Public Health. 1998;88(9):1337&#x2013;1342.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1509089</ArticleId><ArticleId IdType="pubmed">9736873</ArticleId></ArticleIdList></Reference><Reference><Citation>Lourida I, Soni M, Thompson-Coon J, Purandare N, Lang IA, Ukoumunne OC, et al. Mediterranean diet, cognitive function, and dementia: a systematic review. Epidemiology. 2013;24(4):479&#x2013;489.</Citation><ArticleIdList><ArticleId IdType="pubmed">23680940</ArticleId></ArticleIdList></Reference><Reference><Citation>Radak Z, Hart N, Sarga L, Koltai E, Atalay M, Ohno H, et al. Exercise plays a preventive role against Alzheimer&#x2019;s disease. J Alzheimers Dis. 2010;20(3):777&#x2013;783.</Citation><ArticleIdList><ArticleId IdType="pubmed">20182027</ArticleId></ArticleIdList></Reference><Reference><Citation>Hassing LB, Dahl AK, Thorvaldsson V, Berg S, Gatz M, Pedersen NL, et al. Overweight in midlife and risk of dementia: a 40-year follow-up study. Int J Obes (Lond) 2009;33(8):893&#x2013;898.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3025291</ArticleId><ArticleId IdType="pubmed">19506566</ArticleId></ArticleIdList></Reference><Reference><Citation>Anstey KJ, Cherbuin N, Budge M, Young J. Body mass index in midlife and late-life as a risk factor for dementia: a meta-analysis of prospective studies. Obes Rev. 2011;12(5):e426&#x2013;437.</Citation><ArticleIdList><ArticleId IdType="pubmed">21348917</ArticleId></ArticleIdList></Reference><Reference><Citation>Beydoun MA, Beydoun HA, Wang Y. Obesity and central obesity as risk factors for incident dementia and its subtypes: a systematic review and meta-analysis. Obes Rev. 2008;9(3):204&#x2013;218.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4887143</ArticleId><ArticleId IdType="pubmed">18331422</ArticleId></ArticleIdList></Reference><Reference><Citation>Beydoun MA, Lhotsky A, Wang Y, Dal Forno G, An Y, Metter EJ, et al. Association of adiposity status and changes in early to mid-adulthood with incidence of Alzheimer&#x2019;s disease. Am J Epidemiol. 2008;168(10):1179&#x2013;1189.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2582058</ArticleId><ArticleId IdType="pubmed">18835864</ArticleId></ArticleIdList></Reference><Reference><Citation>Fitzpatrick AL, Kuller LH, Lopez OL, Diehr P, O&#x2019;Meara ES, Longstreth WT, Jr, et al. Midlife and late-life obesity and the risk of dementia: cardiovascular health study. Arch Neurol. 2009;66(3):336&#x2013;342.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3513375</ArticleId><ArticleId IdType="pubmed">19273752</ArticleId></ArticleIdList></Reference><Reference><Citation>Tolppanen AM, Ngandu T, Kareholt I, Laatikainen T, Rusanen M, Soininen H, et al. Midlife and late-life body mass index and late-life dementia: results from a prospective population-based cohort. J Alzheimers Dis. 2014;38(1):201&#x2013;209.</Citation><ArticleIdList><ArticleId IdType="pubmed">23948937</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitmer RA, Gunderson EP, Barrett-Connor E, Quesenberry CP, Jr, Yaffe K. Obesity in middle age and future risk of dementia: a 27 year longitudinal population based study. BMJ. 2005;330(7504):1360.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC558283</ArticleId><ArticleId IdType="pubmed">15863436</ArticleId></ArticleIdList></Reference><Reference><Citation>Ford ES, Mokdad AH. Epidemiology of obesity in the Western Hemisphere. J Clin Endocrinol Metab. 2008;93(11 Suppl 1):S1&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">18987267</ArticleId></ArticleIdList></Reference><Reference><Citation>Kelly T, Yang W, Chen CS, Reynolds K, He J. Global burden of obesity in 2005 and projections to 2030. Int J Obes (Lond) 2008;32(9):1431&#x2013;1437.</Citation><ArticleIdList><ArticleId IdType="pubmed">18607383</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Beydoun MA, Liang L, Caballero B, Kumanyika SK. Will all Americans become overweight or obese? estimating the progression and cost of the US obesity epidemic. Obesity (Silver Spring) 2008;16(10):2323&#x2013;2330.</Citation><ArticleIdList><ArticleId IdType="pubmed">18719634</ArticleId></ArticleIdList></Reference><Reference><Citation>Shock NW, Gruelich R, Andres R, Arenberg D, Costa PT, Lakatta E, et al. The Baltimore Longitudinal Study of Aging. Washington, DC: US Government Printing Office; 1984. Normal human aging.</Citation></Reference><Reference><Citation>Ferrucci L. The Baltimore Longitudinal Study of Aging (BLSA): a 50-year-long journey and plans for the future. J Gerontol A Biol Sci Med Sci. 2008;63(12):1416&#x2013;1419.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5004590</ArticleId><ArticleId IdType="pubmed">19126858</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawas C, Gray S, Brookmeyer R, Fozard J, Zonderman A. Age-specific incidence rates of Alzheimer&#x2019;s disease: the Baltimore Longitudinal Study of Aging. Neurology. 2000;54(11):2072&#x2013;2077.</Citation><ArticleIdList><ArticleId IdType="pubmed">10851365</ArticleId></ArticleIdList></Reference><Reference><Citation>American Psychiatric Association APAWGtRDSM, III. Diagnostic and statistical manual of mental disorders: DSM-III-R. American Psychiatric Association; Washington, DC: 1987.</Citation></Reference><Reference><Citation>McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer&#x2019;s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer&#x2019;s Disease. Neurology. 1984;34(7):939&#x2013;944.</Citation><ArticleIdList><ArticleId IdType="pubmed">6610841</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen RC. Mild cognitive impairment as a diagnostic entity. Journal of internal medicine. 2004;256(3):183&#x2013;194.</Citation><ArticleIdList><ArticleId IdType="pubmed">15324362</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Brien RJ, Resnick SM, Zonderman AB, Ferrucci L, Crain BJ, Pletnikova O, et al. Neuropathologic studies of the Baltimore Longitudinal Study of Aging (BLSA) J Alzheimers Dis. 2009;18(3):665&#x2013;675.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2978421</ArticleId><ArticleId IdType="pubmed">19661626</ArticleId></ArticleIdList></Reference><Reference><Citation>Gamaldo A, Moghekar A, Kilada S, Resnick SM, Zonderman AB, O&#x2019;Brien R. Effect of a clinical stroke on the risk of dementia in a prospective cohort. Neurology. 2006;67(8):1363&#x2013;1369.</Citation><ArticleIdList><ArticleId IdType="pubmed">17060561</ArticleId></ArticleIdList></Reference><Reference><Citation>Troncoso JC, Zonderman AB, Resnick SM, Crain B, Pletnikova O, O&#x2019;Brien RJ. Effect of infarcts on dementia in the Baltimore longitudinal study of aging. Ann Neurol. 2008;64(2):168&#x2013;176.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2694129</ArticleId><ArticleId IdType="pubmed">18496870</ArticleId></ArticleIdList></Reference><Reference><Citation>Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ, Brownlee LM, et al. The Consortium to Establish a Registry for Alzheimer&#x2019;s Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer&#x2019;s disease. Neurology. 1991;41(4):479&#x2013;486.</Citation><ArticleIdList><ArticleId IdType="pubmed">2011243</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82(4):239&#x2013;259.</Citation><ArticleIdList><ArticleId IdType="pubmed">1759558</ArticleId></ArticleIdList></Reference><Reference><Citation>Sojkova J, Zhou Y, An Y, Kraut MA, Ferrucci L, Wong DF, et al. Longitudinal patterns of beta-amyloid deposition in nondemented older adults. Arch Neurol. 2011;68(5):644&#x2013;649.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3136195</ArticleId><ArticleId IdType="pubmed">21555640</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischl B. FreeSurfer. Neuroimage. 2012;62(2):774&#x2013;781.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3685476</ArticleId><ArticleId IdType="pubmed">22248573</ArticleId></ArticleIdList></Reference><Reference><Citation>McAuliffe MJ, LF, McGarry D, Gandler W, Csaky K, Trus BL. Medical image processing, analysis and visualization in clinical research. Fourteenth IEEE symposium on computer-based medical systems; Washington, DC. 2001.</Citation></Reference><Reference><Citation>Lucas BC, Bogovic JA, Carass A, Bazin PL, Prince JL, Pham DL, et al. The Java Image Science Toolkit (JIST) for rapid prototyping and publishing of neuroimaging software. Neuroinformatics. 2010;8(1):5&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2860951</ArticleId><ArticleId IdType="pubmed">20077162</ArticleId></ArticleIdList></Reference><Reference><Citation>Ashburner J., FK . Spatial transformation of images. In: Frackowiak RSJ FK, Frith C, Dolan R, Mazziotta JC, editors. Human Brain Function. Academic Press; USA: 1997. pp. 43&#x2013;58.</Citation></Reference><Reference><Citation>Jenkinson M, Bannister P, Brady M, Smith S. Improved optimization for the robust and accurate linear registration and motion correction of brain images. Neuroimage. 2002;17(2):825&#x2013;841.</Citation><ArticleIdList><ArticleId IdType="pubmed">12377157</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Y, Endres CJ, Brasic JR, Huang SC, Wong DF. Linear regression with spatial constraint to generate parametric images of ligand-receptor dynamic PET studies with a simplified reference tissue model. Neuroimage. 2003;18(4):975&#x2013;989.</Citation><ArticleIdList><ArticleId IdType="pubmed">12725772</ArticleId></ArticleIdList></Reference><Reference><Citation>Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, et al. Imaging brain amyloid in Alzheimer&#x2019;s disease with Pittsburgh Compound-B. Ann Neurol. 2004;55(3):306&#x2013;319.</Citation><ArticleIdList><ArticleId IdType="pubmed">14991808</ArticleId></ArticleIdList></Reference><Reference><Citation>Mintun MA, Larossa GN, Sheline YI, Dence CS, Lee SY, Mach RH, et al. [11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology. 2006;67(3):446&#x2013;452.</Citation><ArticleIdList><ArticleId IdType="pubmed">16894106</ArticleId></ArticleIdList></Reference><Reference><Citation>Carroll RJ. Measurement error in nonlinear models: a modern perspective. Chapman &amp; Hall/CRC; London: 2006.</Citation></Reference><Reference><Citation>Swindell WR. Accelerated failure time models provide a useful statistical framework for aging research. Exp Gerontol. 2009;44(3):190&#x2013;200.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2718836</ArticleId><ArticleId IdType="pubmed">19007875</ArticleId></ArticleIdList></Reference><Reference><Citation>Carlson MC, Helms MJ, Steffens DC, Burke JR, Potter GG, Plassman BL. Midlife activity predicts risk of dementia in older male twin pairs. Alzheimers Dement. 2008;4(5):324&#x2013;331.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3673771</ArticleId><ArticleId IdType="pubmed">18790459</ArticleId></ArticleIdList></Reference><Reference><Citation>Farrell SW, Finley CE, Radford NB, Haskell WL. Cardiorespiratory fitness, body mass index, and heart failure mortality in men: Cooper Center Longitudinal Study. Circ Heart Fail. 2013;6(5):898&#x2013;905.</Citation><ArticleIdList><ArticleId IdType="pubmed">23873472</ArticleId></ArticleIdList></Reference><Reference><Citation>Rovio S, Kareholt I, Helkala EL, Viitanen M, Winblad B, Tuomilehto J, et al. Leisure-time physical activity at midlife and the risk of dementia and Alzheimer&#x2019;s disease. Lancet Neurol. 2005;4(11):705&#x2013;711.</Citation><ArticleIdList><ArticleId IdType="pubmed">16239176</ArticleId></ArticleIdList></Reference><Reference><Citation>Sabia S, Singh-Manoux A, Hagger-Johnson G, Cambois E, Brunner EJ, Kivimaki M. Influence of individual and combined healthy behaviours on successful aging. CMAJ. 2012;184(18):1985&#x2013;1992.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3519184</ArticleId><ArticleId IdType="pubmed">23091184</ArticleId></ArticleIdList></Reference><Reference><Citation>Akushevich I, Kravchenko J, Ukraintseva S, Arbeev K, Kulminski A, Yashin AI. Morbidity risks among older adults with pre-existing age-related diseases. Exp Gerontol. 2013;48(12):1395&#x2013;1401.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3895485</ArticleId><ArticleId IdType="pubmed">24064264</ArticleId></ArticleIdList></Reference><Reference><Citation>Gillette-Guyonnet S, Nourhashemi F, Andrieu S, de Glisezinski I, Ousset PJ, Riviere D, et al. Weight loss in Alzheimer disease. Am J Clin Nutr. 2000;71(2):637S&#x2013;642S.</Citation><ArticleIdList><ArticleId IdType="pubmed">10681272</ArticleId></ArticleIdList></Reference><Reference><Citation>Driscoll I, Beydoun MA, An Y, Davatzikos C, Ferrucci L, Zonderman AB, et al. Midlife obesity and trajectories of brain volume changes in older adults. Hum Brain Mapp. 2012;33(9):2204&#x2013;2210.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3419372</ArticleId><ArticleId IdType="pubmed">22887828</ArticleId></ArticleIdList></Reference><Reference><Citation>Das UN. Is obesity an inflammatory condition? Nutrition. 2001;17(11&#x2013;12):953&#x2013;966.</Citation><ArticleIdList><ArticleId IdType="pubmed">11744348</ArticleId></ArticleIdList></Reference><Reference><Citation>Purkayastha S, Cai D. Neuroinflammatory basis of metabolic syndrome. Mol Metab. 2013;2(4):356&#x2013;363.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3854982</ArticleId><ArticleId IdType="pubmed">24327952</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">26163429</PMID><DateCompleted><Year>2016</Year><Month>01</Month><Day>12</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>16</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1526-632X</ISSN><JournalIssue CitedMedium="Internet"><Volume>85</Volume><Issue>13</Issue><PubDate><Year>2015</Year><Month>Sep</Month><Day>29</Day></PubDate></JournalIssue><Title>Neurology</Title><ISOAbbreviation>Neurology</ISOAbbreviation></Journal><ArticleTitle>Postmenopausal hormone therapy, type 2 diabetes mellitus, and brain volumes.</ArticleTitle><Pagination><StartPage>1131</StartPage><EndPage>1138</EndPage><MedlinePgn>1131-8</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1212/WNL.0000000000001816</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To examine whether the effect of postmenopausal hormone therapy (HT) on brain volumes in women aged 65-79 years differs depending on type 2 diabetes status during postintervention follow-up of a randomized controlled clinical trial.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">The Women's Health Initiative randomized clinical trials assigned women to HT (0.625 mg/day conjugated equine estrogens with or without 2.5 mg/day medroxyprogesterone acetate) or placebo for an average of 5.6 years. A total of 1,402 trial participants underwent brain MRI 2.4 years after the trials; these were repeated in 699 women 4.7 years later. General linear models were used to assess the interaction between diabetes status and HT assignment on brain volumes.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Women with diabetes at baseline or during follow-up who had been assigned to HT compared to placebo had mean decrement in total brain volume of -18.6 mL (95% confidence interval [CI] -29.6, -7.6). For women without diabetes, this mean decrement was -0.4 (95% CI -3.8, 3.0) (interaction p=0.002). This interaction was evident for total gray matter (p&lt;0.001) and hippocampal (p=0.006) volumes. It was not evident for changes in brain volumes over follow-up or for ischemic lesion volumes and was not influenced by diabetes duration or oral medications.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">For women aged 65 years or older who are at increased risk for brain atrophy due to type 2 diabetes, prescription of postmenopausal HT is associated with lower gray matter (total and hippocampal) volumes. Interactions with diabetes and insulin resistance may explain divergent findings on how estrogen influences brain volume among older women.</AbstractText><CopyrightInformation>&#xa9; 2015 American Academy of Neurology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Espeland</LastName><ForeName>Mark A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>From the Departments of Biostatistical Sciences (M.A.E., R.C.), Internal Medicine (C.H., S.C.), and Social Sciences and Health Policy (L.V.), Wake Forest School of Medicine, Winston-Salem, NC; Departments of Pharmacology and Pharmaceutical Sciences, Biomedical Engineering, and Neurology (R.D.B.), University of Southern California, Los Angeles, CA; Division of Preventive Medicine (J.E.M.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA; Departments of Epidemiology and Biostatistics, Psychiatry, and Neurology (K.Y.), University of California, San Francisco; Department of Internal Medicine (B.J.E.), The University of Texas MD Anderson Cancer Center, Houston, TX; Department of Geriatric Medicine (K.M.), University of Hawaii at Manoa, Honolulu, HI; and Laboratory of Behavioral Neuroscience (S.M.R.), Intramural Research Program, National Institute on Aging, NIH, Baltimore, MD. mespelan@wakehealth.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brinton</LastName><ForeName>Roberta Diaz</ForeName><Initials>RD</Initials><AffiliationInfo><Affiliation>From the Departments of Biostatistical Sciences (M.A.E., R.C.), Internal Medicine (C.H., S.C.), and Social Sciences and Health Policy (L.V.), Wake Forest School of Medicine, Winston-Salem, NC; Departments of Pharmacology and Pharmaceutical Sciences, Biomedical Engineering, and Neurology (R.D.B.), University of Southern California, Los Angeles, CA; Division of Preventive Medicine (J.E.M.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA; Departments of Epidemiology and Biostatistics, Psychiatry, and Neurology (K.Y.), University of California, San Francisco; Department of Internal Medicine (B.J.E.), The University of Texas MD Anderson Cancer Center, Houston, TX; Department of Geriatric Medicine (K.M.), University of Hawaii at Manoa, Honolulu, HI; and Laboratory of Behavioral Neuroscience (S.M.R.), Intramural Research Program, National Institute on Aging, NIH, Baltimore, MD.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Manson</LastName><ForeName>JoAnn E</ForeName><Initials>JE</Initials><AffiliationInfo><Affiliation>From the Departments of Biostatistical Sciences (M.A.E., R.C.), Internal Medicine (C.H., S.C.), and Social Sciences and Health Policy (L.V.), Wake Forest School of Medicine, Winston-Salem, NC; Departments of Pharmacology and Pharmaceutical Sciences, Biomedical Engineering, and Neurology (R.D.B.), University of Southern California, Los Angeles, CA; Division of Preventive Medicine (J.E.M.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA; Departments of Epidemiology and Biostatistics, Psychiatry, and Neurology (K.Y.), University of California, San Francisco; Department of Internal Medicine (B.J.E.), The University of Texas MD Anderson Cancer Center, Houston, TX; Department of Geriatric Medicine (K.M.), University of Hawaii at Manoa, Honolulu, HI; and Laboratory of Behavioral Neuroscience (S.M.R.), Intramural Research Program, National Institute on Aging, NIH, Baltimore, MD.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yaffe</LastName><ForeName>Kristine</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>From the Departments of Biostatistical Sciences (M.A.E., R.C.), Internal Medicine (C.H., S.C.), and Social Sciences and Health Policy (L.V.), Wake Forest School of Medicine, Winston-Salem, NC; Departments of Pharmacology and Pharmaceutical Sciences, Biomedical Engineering, and Neurology (R.D.B.), University of Southern California, Los Angeles, CA; Division of Preventive Medicine (J.E.M.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA; Departments of Epidemiology and Biostatistics, Psychiatry, and Neurology (K.Y.), University of California, San Francisco; Department of Internal Medicine (B.J.E.), The University of Texas MD Anderson Cancer Center, Houston, TX; Department of Geriatric Medicine (K.M.), University of Hawaii at Manoa, Honolulu, HI; and Laboratory of Behavioral Neuroscience (S.M.R.), Intramural Research Program, National Institute on Aging, NIH, Baltimore, MD.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hugenschmidt</LastName><ForeName>Christina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>From the Departments of Biostatistical Sciences (M.A.E., R.C.), Internal Medicine (C.H., S.C.), and Social Sciences and Health Policy (L.V.), Wake Forest School of Medicine, Winston-Salem, NC; Departments of Pharmacology and Pharmaceutical Sciences, Biomedical Engineering, and Neurology (R.D.B.), University of Southern California, Los Angeles, CA; Division of Preventive Medicine (J.E.M.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA; Departments of Epidemiology and Biostatistics, Psychiatry, and Neurology (K.Y.), University of California, San Francisco; Department of Internal Medicine (B.J.E.), The University of Texas MD Anderson Cancer Center, Houston, TX; Department of Geriatric Medicine (K.M.), University of Hawaii at Manoa, Honolulu, HI; and Laboratory of Behavioral Neuroscience (S.M.R.), Intramural Research Program, National Institute on Aging, NIH, Baltimore, MD.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vaughan</LastName><ForeName>Leslie</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>From the Departments of Biostatistical Sciences (M.A.E., R.C.), Internal Medicine (C.H., S.C.), and Social Sciences and Health Policy (L.V.), Wake Forest School of Medicine, Winston-Salem, NC; Departments of Pharmacology and Pharmaceutical Sciences, Biomedical Engineering, and Neurology (R.D.B.), University of Southern California, Los Angeles, CA; Division of Preventive Medicine (J.E.M.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA; Departments of Epidemiology and Biostatistics, Psychiatry, and Neurology (K.Y.), University of California, San Francisco; Department of Internal Medicine (B.J.E.), The University of Texas MD Anderson Cancer Center, Houston, TX; Department of Geriatric Medicine (K.M.), University of Hawaii at Manoa, Honolulu, HI; and Laboratory of Behavioral Neuroscience (S.M.R.), Intramural Research Program, National Institute on Aging, NIH, Baltimore, MD.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Craft</LastName><ForeName>Suzanne</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>From the Departments of Biostatistical Sciences (M.A.E., R.C.), Internal Medicine (C.H., S.C.), and Social Sciences and Health Policy (L.V.), Wake Forest School of Medicine, Winston-Salem, NC; Departments of Pharmacology and Pharmaceutical Sciences, Biomedical Engineering, and Neurology (R.D.B.), University of Southern California, Los Angeles, CA; Division of Preventive Medicine (J.E.M.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA; Departments of Epidemiology and Biostatistics, Psychiatry, and Neurology (K.Y.), University of California, San Francisco; Department of Internal Medicine (B.J.E.), The University of Texas MD Anderson Cancer Center, Houston, TX; Department of Geriatric Medicine (K.M.), University of Hawaii at Manoa, Honolulu, HI; and Laboratory of Behavioral Neuroscience (S.M.R.), Intramural Research Program, National Institute on Aging, NIH, Baltimore, MD.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Edwards</LastName><ForeName>Beatrice J</ForeName><Initials>BJ</Initials><AffiliationInfo><Affiliation>From the Departments of Biostatistical Sciences (M.A.E., R.C.), Internal Medicine (C.H., S.C.), and Social Sciences and Health Policy (L.V.), Wake Forest School of Medicine, Winston-Salem, NC; Departments of Pharmacology and Pharmaceutical Sciences, Biomedical Engineering, and Neurology (R.D.B.), University of Southern California, Los Angeles, CA; Division of Preventive Medicine (J.E.M.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA; Departments of Epidemiology and Biostatistics, Psychiatry, and Neurology (K.Y.), University of California, San Francisco; Department of Internal Medicine (B.J.E.), The University of Texas MD Anderson Cancer Center, Houston, TX; Department of Geriatric Medicine (K.M.), University of Hawaii at Manoa, Honolulu, HI; and Laboratory of Behavioral Neuroscience (S.M.R.), Intramural Research Program, National Institute on Aging, NIH, Baltimore, MD.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Casanova</LastName><ForeName>Ramon</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>From the Departments of Biostatistical Sciences (M.A.E., R.C.), Internal Medicine (C.H., S.C.), and Social Sciences and Health Policy (L.V.), Wake Forest School of Medicine, Winston-Salem, NC; Departments of Pharmacology and Pharmaceutical Sciences, Biomedical Engineering, and Neurology (R.D.B.), University of Southern California, Los Angeles, CA; Division of Preventive Medicine (J.E.M.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA; Departments of Epidemiology and Biostatistics, Psychiatry, and Neurology (K.Y.), University of California, San Francisco; Department of Internal Medicine (B.J.E.), The University of Texas MD Anderson Cancer Center, Houston, TX; Department of Geriatric Medicine (K.M.), University of Hawaii at Manoa, Honolulu, HI; and Laboratory of Behavioral Neuroscience (S.M.R.), Intramural Research Program, National Institute on Aging, NIH, Baltimore, MD.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Masaki</LastName><ForeName>Kamal</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>From the Departments of Biostatistical Sciences (M.A.E., R.C.), Internal Medicine (C.H., S.C.), and Social Sciences and Health Policy (L.V.), Wake Forest School of Medicine, Winston-Salem, NC; Departments of Pharmacology and Pharmaceutical Sciences, Biomedical Engineering, and Neurology (R.D.B.), University of Southern California, Los Angeles, CA; Division of Preventive Medicine (J.E.M.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA; Departments of Epidemiology and Biostatistics, Psychiatry, and Neurology (K.Y.), University of California, San Francisco; Department of Internal Medicine (B.J.E.), The University of Texas MD Anderson Cancer Center, Houston, TX; Department of Geriatric Medicine (K.M.), University of Hawaii at Manoa, Honolulu, HI; and Laboratory of Behavioral Neuroscience (S.M.R.), Intramural Research Program, National Institute on Aging, NIH, Baltimore, MD.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Resnick</LastName><ForeName>Susan M</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>From the Departments of Biostatistical Sciences (M.A.E., R.C.), Internal Medicine (C.H., S.C.), and Social Sciences and Health Policy (L.V.), Wake Forest School of Medicine, Winston-Salem, NC; Departments of Pharmacology and Pharmaceutical Sciences, Biomedical Engineering, and Neurology (R.D.B.), University of Southern California, Los Angeles, CA; Division of Preventive Medicine (J.E.M.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA; Departments of Epidemiology and Biostatistics, Psychiatry, and Neurology (K.Y.), University of California, San Francisco; Department of Internal Medicine (B.J.E.), The University of Texas MD Anderson Cancer Center, Houston, TX; Department of Geriatric Medicine (K.M.), University of Hawaii at Manoa, Honolulu, HI; and Laboratory of Behavioral Neuroscience (S.M.R.), Intramural Research Program, National Institute on Aging, NIH, Baltimore, MD.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>WHIMS-MRI2 Study Group</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Agency>Intramural NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K01 AG043547</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HHSN268200464221C</GrantID><Agency>PHS HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>N01-WH-4-4221</GrantID><Acronym>WH</Acronym><Agency>WHI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D052060">Research Support, N.I.H., Intramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>07</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurology</MedlineTA><NlmUniqueID>0401060</NlmUniqueID><ISSNLinking>0028-3878</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004966">Estrogens, Conjugated (USP)</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003924" MajorTopicYN="Y">Diabetes Mellitus, Type 2</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015914" MajorTopicYN="N">Estrogen Replacement Therapy</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004966" MajorTopicYN="N">Estrogens, Conjugated (USP)</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D066128" MajorTopicYN="N">Gray Matter</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017698" MajorTopicYN="N">Postmenopause</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading></MeshHeadingList><InvestigatorList><Investigator ValidYN="Y"><LastName>Shumaker</LastName><ForeName>Sally</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Coker</LastName><ForeName>Laura</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Legault</LastName><ForeName>Claudine</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rapp</LastName><ForeName>Steve</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dailey</LastName><ForeName>Maggie</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Felton</LastName><ForeName>Debbie</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gleiser</LastName><ForeName>Lee Ann</ForeName><Initials>LA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Desiderio</LastName><ForeName>Lisa</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wassertheil-Smoller</LastName><ForeName>Sylvia</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Goodwin</LastName><ForeName>Mimi</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kotchen</LastName><ForeName>Jane Morley</ForeName><Initials>JM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ulmer</LastName><ForeName>John</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Matusewic</LastName><ForeName>Tracy</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dellenbach</LastName><ForeName>Sally</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Loebel</LastName><ForeName>Holly</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stefanick</LastName><ForeName>Marcia</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Downey</LastName><ForeName>Sherrill</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jackson</LastName><ForeName>Rebecca</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kochis</LastName><ForeName>Amanda</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Robbins</LastName><ForeName>John</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zaragoza</LastName><ForeName>Sophia</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nathan</LastName><ForeName>Lauren</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Perryman</LastName><ForeName>Adele</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Limacher</LastName><ForeName>Marian</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Toombs</LastName><ForeName>Mary Ellen</ForeName><Initials>ME</Initials></Investigator><Investigator ValidYN="Y"><LastName>Clarke</LastName><ForeName>Candy</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ockene</LastName><ForeName>Judith</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Churchill</LastName><ForeName>Linda</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jackson</LastName><ForeName>Sharon</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sepavich</LastName><ForeName>Deidre</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Grimm</LastName><ForeName>Richard</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Truwitt</LastName><ForeName>Chip</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Camarena</LastName><ForeName>Alexa</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brunner</LastName><ForeName>Robert</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hammons</LastName><ForeName>Jane</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Murphy</LastName><ForeName>Carol</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Johnson</LastName><ForeName>Stephanie</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nauth</LastName><ForeName>Angela</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lucas</LastName><ForeName>Kim</ForeName><Initials>K</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>1</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>6</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>7</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>7</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>1</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2016</Year><Month>9</Month><Day>29</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26163429</ArticleId><ArticleId IdType="pmc">PMC4603880</ArticleId><ArticleId IdType="doi">10.1212/WNL.0000000000001816</ArticleId><ArticleId IdType="pii">WNL.0000000000001816</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Carcaillon L, Brailly-Tabard S, Ancelin ML, et al. High plasma estradiol interacts with diabetes on risk of dementia in older postmenopausal women. Neurology 2014;82:504&#x2013;511.</Citation><ArticleIdList><ArticleId IdType="pubmed">24477111</ArticleId></ArticleIdList></Reference><Reference><Citation>Rolandsson O, Backestrom A, Eriksson S, Hallmans G, Nilsson LG. Increased glucose levels are associated with episodic memory in nondiabetic women. Diabetes 2008;57:440&#x2013;443.</Citation><ArticleIdList><ArticleId IdType="pubmed">17977953</ArticleId></ArticleIdList></Reference><Reference><Citation>Dahle CL, Jacobs BS, Raz N. Aging, vascular risk and cognition: blood glucose, pulse pressure, and cognitive performance in healthy adults. Psychol Aging 2009;24:154&#x2013;162.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2754117</ArticleId><ArticleId IdType="pubmed">19290746</ArticleId></ArticleIdList></Reference><Reference><Citation>Yaffe K, Barnes D, Lindquist K, et al. Endogenous sex hormone levels and risk of cognitive decline in an older biracial cohort. Neurobiol Aging 2007;28:171&#x2013;178.</Citation><ArticleIdList><ArticleId IdType="pubmed">17097195</ArticleId></ArticleIdList></Reference><Reference><Citation>Laughlin GA, Kritz-Silverstein D, Barrett-Connor E. Endogenous oestrogens predict 4-year decline in verbal fluency in postmenopausal women: the Rancho Bernardo Study. Clin Endocrinol (Oxf) 2010;72:99&#x2013;106.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2805055</ArticleId><ArticleId IdType="pubmed">19508596</ArticleId></ArticleIdList></Reference><Reference><Citation>Geerlings MI, Launer LJ, de Jong FH, et al. ; Rotterdam Study. Endogenous estrogen and risk of dementia in women and men: the Rotterdam Study. Ann Neurol 2003;53:607&#x2013;615.</Citation><ArticleIdList><ArticleId IdType="pubmed">12730994</ArticleId></ArticleIdList></Reference><Reference><Citation>Espeland MA, Miller ME, Goveas JS, et al. ; Whisca Study Group. Cognitive function and fine motor speed in older women with diabetes mellitus: results from the women's health initiative study of cognitive aging. J Womens Health (Larchmt) 2011;20:1435&#x2013;1443.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3186442</ArticleId><ArticleId IdType="pubmed">21819251</ArticleId></ArticleIdList></Reference><Reference><Citation>Espeland MA, Bryan RN, Goveas JS, et al. ; WHIMS-MRI Study Group. Influence of type 2 diabetes on brain volumes and changes in brain volumes: results from the Women's Health Initiative Magnetic Resonance Imaging studies. Diabetes Care 2013;36:90&#x2013;97.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3526228</ArticleId><ArticleId IdType="pubmed">22933440</ArticleId></ArticleIdList></Reference><Reference><Citation>Shumaker SA, Legault C, Kuller L, et al. ; Women's Health Initiative Memory Study. Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study. JAMA 2004;291:2947&#x2013;2958.</Citation><ArticleIdList><ArticleId IdType="pubmed">15213206</ArticleId></ArticleIdList></Reference><Reference><Citation>Espeland MA, Rapp SR, Shumaker SA, et al. Conjugated equine estrogens and global cognitive function in postmenopausal women. JAMA 2004;291:2959&#x2013;2968.</Citation><ArticleIdList><ArticleId IdType="pubmed">15213207</ArticleId></ArticleIdList></Reference><Reference><Citation>Resnick SM, Espeland MA, Jaramillo SA, et al. Postmenopausal hormone therapy and regional brain volume: the WHIMS-MRI Study. Neurology 2009;72:135&#x2013;142.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2677493</ArticleId><ArticleId IdType="pubmed">19139364</ArticleId></ArticleIdList></Reference><Reference><Citation>Espeland MA, Tindle HA, Bushnell CA, et al. Brain volumes, cognitive impairment, and conjugated equine estrogens. J Gerontol A Biol Sci Med Sci 2009;64:1243&#x2013;1250.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2773813</ArticleId><ArticleId IdType="pubmed">19729392</ArticleId></ArticleIdList></Reference><Reference><Citation>Casanova R, Espeland MA, Goveas JS, et al. ; Women's Health Initiative Memory Study. Application of machine learning methods to describe the effects of conjugated equine estrogens on region-specific brain volumes. Magn Reson Imaging 2011;29:546&#x2013;553.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3079024</ArticleId><ArticleId IdType="pubmed">21292420</ArticleId></ArticleIdList></Reference><Reference><Citation>Coker LH, Espeland MA, Hogan PE, et al. ; WHIMS-MRI Study Group. Change in brain and lesion volumes after CEE therapies: the WHIMS-MRI studies. Neurology 2014;82:427&#x2013;434.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3917682</ArticleId><ArticleId IdType="pubmed">24384646</ArticleId></ArticleIdList></Reference><Reference><Citation>Shumaker SA, Reboussin BA, Espeland MA, et al. The Women's Health Initiative Memory Study (WHIMS): a trial of the effect of estrogen therapy in preventing and slowing the progression of dementia. Control Clin Trials 1998;19:604&#x2013;621.</Citation><ArticleIdList><ArticleId IdType="pubmed">9875839</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaramillo SA, Felton D, Andrews LA, et al. ; Women's Health Initiative Memory Study Research Group. Enrollment in a brain magnetic resonance study: results from the Women's Health Initiative Memory Study Magnetic Resonance Imaging Study. Acad Radiol 2007;14:603&#x2013;612.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1934046</ArticleId><ArticleId IdType="pubmed">17434074</ArticleId></ArticleIdList></Reference><Reference><Citation>Margolis KL, Qi L, Brzyski R, et al. ; Women Health Initiative Investigators. Validity of diabetes self-reports in the Women's Health Initiative: comparison with medication inventories and fasting glucose measurements. Clin Trials 2008;5:240&#x2013;247.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2757268</ArticleId><ArticleId IdType="pubmed">18559413</ArticleId></ArticleIdList></Reference><Reference><Citation>The Women's Health Initiative Study Group. Design of the Women's Health Initiative clinical trial and observational study. Control Clin Trials 1998;19:61&#x2013;109.</Citation><ArticleIdList><ArticleId IdType="pubmed">9492970</ArticleId></ArticleIdList></Reference><Reference><Citation>Teng EL, Chui HC. The Modified Mini-Mental State (3MS) examination. J Clin Psychiatry 1987;48:314&#x2013;318.</Citation><ArticleIdList><ArticleId IdType="pubmed">3611032</ArticleId></ArticleIdList></Reference><Reference><Citation>Howie B, Fuchsberger C, Stephens M, Marchini J, Abecasis GR. Fast and accurate genotype imputation in genome-wide association studies through pre-phasing. Nat Genet 2012;44:955&#x2013;959.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3696580</ArticleId><ArticleId IdType="pubmed">22820512</ArticleId></ArticleIdList></Reference><Reference><Citation>Lao Z, Shen D, Liu D, et al. Computer-assisted segmentation of white matter lesions in 3D MR images using support vector machine. Acad Radiol 2008;15:300&#x2013;313.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2528894</ArticleId><ArticleId IdType="pubmed">18280928</ArticleId></ArticleIdList></Reference><Reference><Citation>Coker LH, Hogan PE, Bryan NR, et al. Postmenopausal hormone therapy and subclinical cerebrovascular disease: the WHIMS-MRI Study. Neurology 2009;72:125&#x2013;134.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2677498</ArticleId><ArticleId IdType="pubmed">19139363</ArticleId></ArticleIdList></Reference><Reference><Citation>Launer LJ, Miller ME, Williamson JD, et al. ; ACCORD MIND investigators. Effects of intensive glucose lowering on brain structure in people with type 2 diabetes (ACCORD MIND): a randomised open-label substudy. Lancet Neurol 2011;10:969&#x2013;977.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3333485</ArticleId><ArticleId IdType="pubmed">21958949</ArticleId></ArticleIdList></Reference><Reference><Citation>Littell RC, Milliken GA, Stroup WW, Wolfinger RD. SAS System for Mixed Models. Cary, NC: SAS Institute, Inc.; 1996.</Citation></Reference><Reference><Citation>Maki PM. Critical window hypothesis of hormone therapy and cognition: a scientific update on clinical studies. Menopause 2013;20:695&#x2013;709.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3780981</ArticleId><ArticleId IdType="pubmed">23715379</ArticleId></ArticleIdList></Reference><Reference><Citation>Wnuk A, Korol DL, Erickson KI. Estrogens, hormone therapy, and hippocampal volume in postmenopausal women. Maturitas 2012;73:186&#x2013;190.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3576699</ArticleId><ArticleId IdType="pubmed">22858056</ArticleId></ArticleIdList></Reference><Reference><Citation>Rasgon NL, Kenna HA, Wroolie TE, et al. Insulin resistance and medial prefrontal gyrus metabolism in women receiving hormone therapy. Psychiatr Res 2014;223:28&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pubmed">24819305</ArticleId></ArticleIdList></Reference><Reference><Citation>Espeland MA, Shumaker SA, Leng I, et al. ; WHIMSY Study Group. Long-term effects on cognitive function of postmenopausal hormone therapy prescribed to women aged 50 to 55 years. JAMA Intern Med 2013;173:1429&#x2013;1436.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3844547</ArticleId><ArticleId IdType="pubmed">23797469</ArticleId></ArticleIdList></Reference><Reference><Citation>Hankinson SE, Willett WC, Manson JE, et al. Alcohol, height, and adiposity in relation to estrogen and prolactin levels in postmenopausal women. J Natl Cancer Instit 1995;87:1297&#x2013;1302.</Citation><ArticleIdList><ArticleId IdType="pubmed">7658481</ArticleId></ArticleIdList></Reference><Reference><Citation>Driscoll I, Espeland MA, Wassertheil-Smoller S, et al. ; Women's Health Initiative Study of Cognitive Aging. Weight change and cognitive function: findings from the Women's Health Initiative Study of Cognitive Aging. Obesity (Silver Spring) 2011;19:1595&#x2013;1600.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3175491</ArticleId><ArticleId IdType="pubmed">21394095</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryan J, Artero S, Carriere I, et al. Brain volumes in late life: gender, hormone treatment, and estrogen receptor variants. Neurobiol Aging 2014;35;645&#x2013;654.</Citation><ArticleIdList><ArticleId IdType="pubmed">24269019</ArticleId></ArticleIdList></Reference><Reference><Citation>Moran C, Phan TG, Chen J, et al. Brain atrophy in type 2 diabetes: regional distribution and influence on cognition. Diabetes Care 2013;36:4036&#x2013;4042.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3836136</ArticleId><ArticleId IdType="pubmed">23939539</ArticleId></ArticleIdList></Reference><Reference><Citation>Manschot SM, Biessels GJ, de Valk H, et al. ; Utrecht Diabetic Encephalopathy Study Group. Metabolic and vascular determinants of impaired cognitive performance and abnormalities on brain magnetic resonance imaging in patients with type 2 diabetes. Diabetologia 2007;50:2388&#x2013;2397.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2039826</ArticleId><ArticleId IdType="pubmed">17764005</ArticleId></ArticleIdList></Reference><Reference><Citation>Williamson JD, Miller ME, Bryan RN, et al. ; ACCORD Study Group. The Action to Control Cardiovascular Risk in Diabetes Memory in Diabetes Study (ACCORD-MIND): rationale, design, and methods. Am J Cardiol 2007;99:112i&#x2013;122i.</Citation><ArticleIdList><ArticleId IdType="pubmed">17599421</ArticleId></ArticleIdList></Reference><Reference><Citation>Willette AA, Xu G, Johnson SC, et al. Insulin resistance, brain atrophy, and cognitive performance in late middle-aged adults. Diabetes Care 2013;36:443&#x2013;449.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3554303</ArticleId><ArticleId IdType="pubmed">23069842</ArticleId></ArticleIdList></Reference><Reference><Citation>Rettberg JR, Yao J, Brinton RD. Estrogen: a master regulator of bioenergetic systems in the brain and body. Front Neuroendocrinol 2014;35:8&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4024050</ArticleId><ArticleId IdType="pubmed">23994581</ArticleId></ArticleIdList></Reference><Reference><Citation>Brinton RD. Estrogen regulation of glucose metabolism and mitochondrial function: therapeutic implications for prevention of Alzheimer's disease. Adv Drug Deliv Rev 2008;60:1504&#x2013;1511.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2993571</ArticleId><ArticleId IdType="pubmed">18647624</ArticleId></ArticleIdList></Reference><Reference><Citation>Brinton RD. The healthy cell bias of estrogen action: mitochondrial bioenergetics and neurological implications. Trends Neurosci 2008;31:529&#x2013;537.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10124615</ArticleId><ArticleId IdType="pubmed">18774188</ArticleId></ArticleIdList></Reference><Reference><Citation>Bansal S, Chopra K. Distinct role of estrogen receptor-alpha and beta on postmenopausal diabetes-induced vascular dysfunction. Gen Compar Endocrinol 2014;206:51&#x2013;59.</Citation><ArticleIdList><ArticleId IdType="pubmed">24967951</ArticleId></ArticleIdList></Reference><Reference><Citation>Pratchayasakul W, Chattipakorn N, Chattipakorn SC. Estrogen restores brain insulin sensitivity in ovariectomized non-obese rats, but not in ovariectomized obese rats. Metabolism 2014;63:851&#x2013;859.</Citation><ArticleIdList><ArticleId IdType="pubmed">24742706</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">26335643</PMID><DateCompleted><Year>2015</Year><Month>11</Month><Day>23</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1097-4199</ISSN><JournalIssue CitedMedium="Internet"><Volume>87</Volume><Issue>5</Issue><PubDate><Year>2015</Year><Month>Sep</Month><Day>02</Day></PubDate></JournalIssue><Title>Neuron</Title><ISOAbbreviation>Neuron</ISOAbbreviation></Journal><ArticleTitle>Appoptosin-Mediated Caspase Cleavage of Tau Contributes to Progressive Supranuclear Palsy Pathogenesis.</ArticleTitle><Pagination><StartPage>963</StartPage><EndPage>975</EndPage><MedlinePgn>963-75</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.neuron.2015.08.020</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0896-6273(15)00714-X</ELocationID><Abstract><AbstractText>Progressive supranuclear palsy (PSP) is a movement disorder characterized by tau neuropathology where the underlying mechanism is unknown. An SNP (rs1768208 C/T) has been identified as a strong risk factor for PSP. Here, we identified a much higher T-allele occurrence and increased levels of the pro-apoptotic protein appoptosin in PSP patients. Elevations in appoptosin correlate with activated caspase-3 and caspase-cleaved tau levels. Appoptosin overexpression increased caspase-mediated tau cleavage, tau aggregation, and synaptic dysfunction, whereas appoptosin deficiency reduced tau cleavage and aggregation. Appoptosin transduction impaired multiple motor functions and exacerbated neuropathology in tau-transgenic mice in a manner dependent on caspase-3 and tau. Increased appoptosin and caspase-3-cleaved tau were also observed in brain samples of patients with Alzheimer's disease and frontotemporal dementia with tau inclusions. Our findings reveal a novel role for appoptosin in neurological disorders with tau neuropathology, linking caspase-3-mediated tau cleavage to synaptic dysfunction and behavioral/motor defects.</AbstractText><CopyrightInformation>Copyright &#xa9; 2015 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Yingjun</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Fujian Provincial Key Laboratory of Neurodegenerative Disease and Aging Research, Institute of Neuroscience, College of Medicine, Xiamen University, Xiamen, Fujian 361102, China; Degenerative Diseases Program, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA 92037, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tseng</LastName><ForeName>I-Chu</ForeName><Initials>IC</Initials><AffiliationInfo><Affiliation>Degenerative Diseases Program, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA 92037, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Heyser</LastName><ForeName>Charles J</ForeName><Initials>CJ</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, University of California San Diego, La Jolla, CA 92093, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rockenstein</LastName><ForeName>Edward</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, University of California San Diego, La Jolla, CA 92093, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mante</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, University of California San Diego, La Jolla, CA 92093, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Adame</LastName><ForeName>Anthony</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, University of California San Diego, La Jolla, CA 92093, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zheng</LastName><ForeName>Qiuyang</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Fujian Provincial Key Laboratory of Neurodegenerative Disease and Aging Research, Institute of Neuroscience, College of Medicine, Xiamen University, Xiamen, Fujian 361102, China; Degenerative Diseases Program, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA 92037, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Timothy</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Degenerative Diseases Program, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA 92037, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Xin</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Fujian Provincial Key Laboratory of Neurodegenerative Disease and Aging Research, Institute of Neuroscience, College of Medicine, Xiamen University, Xiamen, Fujian 361102, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arslan</LastName><ForeName>Pharhad E</ForeName><Initials>PE</Initials><AffiliationInfo><Affiliation>Tanz Centre for Research in Neurodegenerative Diseases, Krembil Discovery Tower, Toronto, ON M5T 2S8, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chakrabarty</LastName><ForeName>Paramita</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Center for Translational Research in Neurodegenerative Diseases, University of Florida, Gainesville, FL&#xa0;32610,&#xa0;USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Chengbiao</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, University of California San Diego, La Jolla, CA 92093, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bu</LastName><ForeName>Guojun</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Fujian Provincial Key Laboratory of Neurodegenerative Disease and Aging Research, Institute of Neuroscience, College of Medicine, Xiamen University, Xiamen, Fujian 361102, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mobley</LastName><ForeName>William C</ForeName><Initials>WC</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, University of California San Diego, La Jolla, CA 92093, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Yun-Wu</ForeName><Initials>YW</Initials><AffiliationInfo><Affiliation>Fujian Provincial Key Laboratory of Neurodegenerative Disease and Aging Research, Institute of Neuroscience, College of Medicine, Xiamen University, Xiamen, Fujian 361102, China; Degenerative Diseases Program, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA 92037, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>St George-Hyslop</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Tanz Centre for Research in Neurodegenerative Diseases, Krembil Discovery Tower, Toronto, ON M5T 2S8, Canada; Department of Medical Biophysics and Medicine (Neurology), University of Toronto, Toronto, ON M5S 3H2, Canada; Department of Clinical Neurosciences, Cambridge Institute for Medical Research, University of Cambridge, Cambridge, CB2 0XY, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Masliah</LastName><ForeName>Eliezer</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, University of California San Diego, La Jolla, CA 92093, USA; Department of Pathology, University of California San Diego, La Jolla, CA 92093, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fraser</LastName><ForeName>Paul</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Tanz Centre for Research in Neurodegenerative Diseases, Krembil Discovery Tower, Toronto, ON M5T 2S8, Canada; Department of Medical Biophysics and Medicine (Neurology), University of Toronto, Toronto, ON M5S 3H2, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Huaxi</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Fujian Provincial Key Laboratory of Neurodegenerative Disease and Aging Research, Institute of Neuroscience, College of Medicine, Xiamen University, Xiamen, Fujian 361102, China; Degenerative Diseases Program, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA 92037, USA. Electronic address: xuh@sbpdiscovery.org.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG035355</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01AG11385</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG011385</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG016574</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01AG021173</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG021173</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG044420</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>089703</GrantID><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>R01NS046673</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01AG18440</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>PN2 EY016525</GrantID><Acronym>EY</Acronym><Agency>NEI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS046673</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01NS076411</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>081864</GrantID><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>R01NS66072</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>PN1 EY016525</GrantID><Acronym>EY</Acronym><Agency>NEI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005131</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG038710</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01AG5131</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 NS076411</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01AG038710</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 NS074969</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG027924</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG018440</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS066072</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG046205</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MC_G1000734</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>R01AG044420</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neuron</MedlineTA><NlmUniqueID>8809320</NlmUniqueID><ISSNLinking>0896-6273</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051017">Apoptosis Regulatory Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C560487">MOBP protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009185">Myelin Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.22.-</RegistryNumber><NameOfSubstance UI="D053148">Caspase 3</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>Neuron. 2024 Dec 4;112(23):3984-3985. doi: 10.1016/j.neuron.2024.11.001.</RefSource><PMID Version="1">39520984</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051017" MajorTopicYN="N">Apoptosis Regulatory Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053148" MajorTopicYN="N">Caspase 3</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004622" MajorTopicYN="N">Embryo, Mammalian</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005786" MajorTopicYN="N">Gene Expression Regulation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018737" MajorTopicYN="N">Hand Strength</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009185" MajorTopicYN="N">Myelin Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020641" MajorTopicYN="N">Polymorphism, Single Nucleotide</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013494" MajorTopicYN="N">Supranuclear Palsy, Progressive</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>3</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2015</Year><Month>7</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>8</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>9</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>9</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2016</Year><Month>9</Month><Day>2</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26335643</ArticleId><ArticleId IdType="mid">NIHMS717322</ArticleId><ArticleId IdType="pmc">PMC4575284</ArticleId><ArticleId IdType="doi">10.1016/j.neuron.2015.08.020</ArticleId><ArticleId IdType="pii">S0896-6273(15)00714-X</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Baker M, Litvan I, Houlden H, Adamson J, Dickson D, Perez-Tur J, Hardy J, Lynch T, Bigio E, Hutton M. Association of an extended haplotype in the tau gene with progressive supranuclear palsy. Hum Mol Genet. 1999;8:711&#x2013;715.</Citation><ArticleIdList><ArticleId IdType="pubmed">10072441</ArticleId></ArticleIdList></Reference><Reference><Citation>Ballatore C, Lee VM, Trojanowski JQ. Tau-mediated neurodegeneration in Alzheimer&#x2019;s disease and related disorders. Nature Rev Neurosci. 2007;8:663&#x2013;672.</Citation><ArticleIdList><ArticleId IdType="pubmed">17684513</ArticleId></ArticleIdList></Reference><Reference><Citation>Blin N, Stafford DW. A general method for isolation of high molecular weight DNA from eukaryotes. Nucleic Acids Res. 1976;3:2303&#x2013;2308.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC343085</ArticleId><ArticleId IdType="pubmed">987581</ArticleId></ArticleIdList></Reference><Reference><Citation>Borroni B, Agosti C, Magnani E, Di Luca M, Padovani A. Genetic bases of Progressive Supranuclear Palsy: the MAPT tau disease. Curr Med Chem. 2011;18:2655&#x2013;2660.</Citation><ArticleIdList><ArticleId IdType="pubmed">21568901</ArticleId></ArticleIdList></Reference><Reference><Citation>Conrad C, Andreadis A, Trojanowski JQ, Dickson DW, Kang D, Chen X, Wiederholt W, Hansen L, Masliah E, Thal LJ, et al. Genetic evidence for the involvement of tau in progressive supranuclear palsy. Ann Neurol. 1997;41:277&#x2013;281.</Citation><ArticleIdList><ArticleId IdType="pubmed">9029080</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#x2019;Amelio M, Cavallucci V, Middei S, Marchetti C, Pacioni S, Ferri A, Diamantini A, De Zio D, Carrara P, Battistini L, et al. Caspase-3 triggers early synaptic dysfunction in a mouse model of Alzheimer&#x2019;s disease. Nat Neurosci. 2011;14:69&#x2013;76.</Citation><ArticleIdList><ArticleId IdType="pubmed">21151119</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#x2019;Amelio M, Sheng M, Cecconi F. Caspase-3 in the central nervous system: beyond apoptosis. Trends Neurosci. 2012;35:700&#x2013;709.</Citation><ArticleIdList><ArticleId IdType="pubmed">22796265</ArticleId></ArticleIdList></Reference><Reference><Citation>de Calignon A, Fox LM, Pitstick R, Carlson GA, Bacskai BJ, Spires-Jones TL, Hyman BT. Caspase activation precedes and leads to tangles. Nature. 2010;464:1201&#x2013;1204.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3091360</ArticleId><ArticleId IdType="pubmed">20357768</ArticleId></ArticleIdList></Reference><Reference><Citation>Ding H, Matthews TA, Johnson GV. Site-specific phosphorylation and caspase cleavage differentially impact tau-microtubule interactions and tau aggregation. J Biol Chem. 2006;281:19107&#x2013;19114.</Citation><ArticleIdList><ArticleId IdType="pubmed">16687396</ArticleId></ArticleIdList></Reference><Reference><Citation>Dou F, Netzer WJ, Tanemura K, Li F, Hartl FU, Takashima A, Gouras GK, Greengard P, Xu H. Chaperones increase association of tau protein with microtubules. Proc Natl Acad Sci U S A. 2003;100:721&#x2013;726.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC141063</ArticleId><ArticleId IdType="pubmed">12522269</ArticleId></ArticleIdList></Reference><Reference><Citation>Drechsel DN, Hyman AA, Cobb MH, Kirschner MW. Modulation of the dynamic instability of tubulin assembly by the microtubule-associated protein tau. Mol Biol Cell. 1992;3:1141&#x2013;1154.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC275678</ArticleId><ArticleId IdType="pubmed">1421571</ArticleId></ArticleIdList></Reference><Reference><Citation>Egerton T, Williams DR, Iansek R. Comparison of gait in progressive supranuclear palsy, Parkinson&#x2019;s disease and healthy older adults. BMC Neurol. 2012;12:116.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3517411</ArticleId><ArticleId IdType="pubmed">23031506</ArticleId></ArticleIdList></Reference><Reference><Citation>Fasulo L, Ugolini G, Cattaneo A. Apoptotic effect of caspase-3 cleaved tau in hippocampal neurons and its potentiation by tau FTDP-mutation N279K. J Alzheimer&#x2019;s Dis. 2005;7:3&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pubmed">15750210</ArticleId></ArticleIdList></Reference><Reference><Citation>Fasulo L, Ugolini G, Visintin M, Bradbury A, Brancolini C, Verzillo V, Novak M, Cattaneo A. The neuronal microtubule-associated protein tau is a substrate for caspase-3 and an effector of apoptosis. J Neurochem. 2000;75:624&#x2013;633.</Citation><ArticleIdList><ArticleId IdType="pubmed">10899937</ArticleId></ArticleIdList></Reference><Reference><Citation>Gamblin TC, Chen F, Zambrano A, Abraha A, Lagalwar S, Guillozet AL, Lu M, Fu Y, Garcia-Sierra F, LaPointe N, et al. Caspase cleavage of tau: linking amyloid and neurofibrillary tangles in Alzheimer&#x2019;s disease. Proc Natl Acad Sci U S A. 2003;100:10032&#x2013;10037.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC187753</ArticleId><ArticleId IdType="pubmed">12888622</ArticleId></ArticleIdList></Reference><Reference><Citation>Guernsey DL, Jiang H, Campagna DR, Evans SC, Ferguson M, Kellogg MD, Lachance M, Matsuoka M, Nightingale M, Rideout A, et al. Mutations in mitochondrial carrier family gene SLC25A38 cause nonsyndromic autosomal recessive congenital sideroblastic anemia. Nat Genet. 2009;41:651&#x2013;653.</Citation><ArticleIdList><ArticleId IdType="pubmed">19412178</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer&#x2019;s disease: progress and problems on the road to therapeutics. Science. 2002;297:353&#x2013;356.</Citation><ArticleIdList><ArticleId IdType="pubmed">12130773</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoglinger GU, Melhem NM, Dickson DW, Sleiman PM, Wang LS, Klei L, Rademakers R, de Silva R, Litvan I, Riley DE, et al. Identification of common variants influencing risk of the tauopathy progressive supranuclear palsy. Nat Genet. 2011;43:699&#x2013;705.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3125476</ArticleId><ArticleId IdType="pubmed">21685912</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoover BR, Reed MN, Su J, Penrod RD, Kotilinek LA, Grant MK, Pitstick R, Carlson GA, Lanier LM, Yuan LL, et al. Tau mislocalization to dendritic spines mediates synaptic dysfunction independently of neurodegeneration. Neuron. 2010;68:1067&#x2013;1081.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3026458</ArticleId><ArticleId IdType="pubmed">21172610</ArticleId></ArticleIdList></Reference><Reference><Citation>Hyman BT, Yuan J. Apoptotic and non-apoptotic roles of caspases in neuronal physiology and pathophysiology. Nat Rev Neurosci. 2012;13:395&#x2013;406.</Citation><ArticleIdList><ArticleId IdType="pubmed">22595785</ArticleId></ArticleIdList></Reference><Reference><Citation>Ikeda M, Shoji M, Kawarai T, Kawarabayashi T, Matsubara E, Murakami T, Sasaki A, Tomidokoro Y, Ikarashi Y, Kuribara H, et al. Accumulation of filamentous tau in the cerebral cortex of human tau R406W transgenic mice. Am J Pathol. 2005;166:521&#x2013;531.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1602315</ArticleId><ArticleId IdType="pubmed">15681835</ArticleId></ArticleIdList></Reference><Reference><Citation>Ittner LM, Ke YD, Delerue F, Bi M, Gladbach A, van Eersel J, Wolfing H, Chieng BC, Christie MJ, Napier IA, et al. Dendritic function of tau mediates amyloid-beta toxicity in Alzheimer&#x2019;s disease mouse models. Cell. 2010;142:387&#x2013;397.</Citation><ArticleIdList><ArticleId IdType="pubmed">20655099</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewis J, McGowan E, Rockwood J, Melrose H, Nacharaju P, Van Slegtenhorst M, Gwinn-Hardy K, Paul Murphy M, Baker M, Yu X, et al. Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein. Nat Genet. 2000;25:402&#x2013;405.</Citation><ArticleIdList><ArticleId IdType="pubmed">10932182</ArticleId></ArticleIdList></Reference><Reference><Citation>Mandelkow E, von Bergen M, Biernat J, Mandelkow EM. Structural principles of tau and the paired helical filaments of Alzheimer&#x2019;s disease. Brain Pathol. 2007;17:83&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8095506</ArticleId><ArticleId IdType="pubmed">17493042</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazanetz MP, Fischer PM. Untangling tau hyperphosphorylation in drug design for neurodegenerative diseases. Nat Rev Drug Discov. 2007;6:464&#x2013;479.</Citation><ArticleIdList><ArticleId IdType="pubmed">17541419</ArticleId></ArticleIdList></Reference><Reference><Citation>Pastor P, Pastor E, Carnero C, Vela R, Garcia T, Amer G, Tolosa E, Oliva R. Familial atypical progressive supranuclear palsy associated with homozigosity for the delN296 mutation in the tau gene. Ann Neurol. 2001;49:263&#x2013;267.</Citation><ArticleIdList><ArticleId IdType="pubmed">11220749</ArticleId></ArticleIdList></Reference><Reference><Citation>Poorkaj P, Muma NA, Zhukareva V, Cochran EJ, Shannon KM, Hurtig H, Koller WC, Bird TD, Trojanowski JQ, Lee VM, et al. An R5L tau mutation in a subject with a progressive supranuclear palsy phenotype. Ann Neurol. 2002;52:511&#x2013;516.</Citation><ArticleIdList><ArticleId IdType="pubmed">12325083</ArticleId></ArticleIdList></Reference><Reference><Citation>Quintanilla RA, Matthews-Roberson TA, Dolan PJ, Johnson GV. Caspase-cleaved tau expression induces mitochondrial dysfunction in immortalized cortical neurons: implications for the pathogenesis of Alzheimer disease. J Biol Chem. 2009;284:18754&#x2013;18766.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2707209</ArticleId><ArticleId IdType="pubmed">19389700</ArticleId></ArticleIdList></Reference><Reference><Citation>Rissman RA, Poon WW, Blurton-Jones M, Oddo S, Torp R, Vitek MP, LaFerla FM, Rohn TT, Cotman CW. Caspase-cleavage of tau is an early event in Alzheimer disease tangle pathology. J Clin Invest. 2004;114:121&#x2013;130.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC437967</ArticleId><ArticleId IdType="pubmed">15232619</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberson ED, Scearce-Levie K, Palop JJ, Yan F, Cheng IH, Wu T, Gerstein H, Yu GQ, Mucke L. Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer&#x2019;s disease mouse model. Science. 2007;316:750&#x2013;754.</Citation><ArticleIdList><ArticleId IdType="pubmed">17478722</ArticleId></ArticleIdList></Reference><Reference><Citation>Rohrer JD, Paviour D, Vandrovcova J, Hodges J, de Silva R, Rossor MN. Novel L284R MAPT mutation in a family with an autosomal dominant progressive supranuclear palsy syndrome. Neurodegener Dis. 2011;8:149&#x2013;152.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3078284</ArticleId><ArticleId IdType="pubmed">20838030</ArticleId></ArticleIdList></Reference><Reference><Citation>Ros R, Gomez Garre P, Hirano M, Tai YF, Ampuero I, Vidal L, Rojo A, Fontan A, Vazquez A, Fanjul S, et al. Genetic linkage of autosomal dominant progressive supranuclear palsy to 1q31.1. Ann Neurol. 2005;57:634&#x2013;641.</Citation><ArticleIdList><ArticleId IdType="pubmed">15852377</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossi G, Gasparoli E, Pasquali C, Di Fede G, Testa D, Albanese A, Bracco F, Tagliavini F. Progressive supranuclear palsy and Parkinson&#x2019;s disease in a family with a new mutation in the tau gene. Ann Neurol. 2004;55:448.</Citation><ArticleIdList><ArticleId IdType="pubmed">14991829</ArticleId></ArticleIdList></Reference><Reference><Citation>Shipton OA, Leitz JR, Dworzak J, Acton CE, Tunbridge EM, Denk F, Dawson HN, Vitek MP, Wade-Martins R, Paulsen O, et al. Tau protein is required for amyloid {beta}-induced impairment of hippocampal long-term potentiation. J Neurosci. 2011;31:1688&#x2013;1692.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3836238</ArticleId><ArticleId IdType="pubmed">21289177</ArticleId></ArticleIdList></Reference><Reference><Citation>Stamelou M, de Silva R, Arias-Carrion O, Boura E, Hollerhage M, Oertel WH, Muller U, Hoglinger GU. Rational therapeutic approaches to progressive supranuclear palsy. Brain. 2010;133:1578&#x2013;1590.</Citation><ArticleIdList><ArticleId IdType="pubmed">20472654</ArticleId></ArticleIdList></Reference><Reference><Citation>Stancu IC, Vasconcelos B, Terwel D, Dewachter I. Models of &#x3b2;-amyloid induced Tau-pathology: the long and &#x201c;folded&#x201d; road to understand the mechanism. Mol Neurodegener. 2014;9:51.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4255655</ArticleId><ArticleId IdType="pubmed">25407337</ArticleId></ArticleIdList></Reference><Reference><Citation>Stanford PM, Halliday GM, Brooks WS, Kwok JB, Storey CE, Creasey H, Morris JG, Fulham MJ, Schofield PR. Progressive supranuclear palsy pathology caused by a novel silent mutation in exon 10 of the tau gene: expansion of the disease phenotype caused by tau gene mutations. Brain. 2000;123(Pt 5):880&#x2013;893.</Citation><ArticleIdList><ArticleId IdType="pubmed">10775534</ArticleId></ArticleIdList></Reference><Reference><Citation>Steele JC, Richardson JC, Olszewski J. Progressive Supranuclear Palsy. A Heterogeneous Degeneration Involving the Brain Stem, Basal Ganglia and Cerebellum with Vertical Gaze and Pseudobulbar Palsy, Nuchal Dystonia and Dementia. Arch Neurol. 1964;10:333&#x2013;359.</Citation><ArticleIdList><ArticleId IdType="pubmed">14107684</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanemura K, Akagi T, Murayama M, Kikuchi N, Murayama O, Hashikawa T, Yoshiike Y, Park JM, Matsuda K, Nakao S, et al. Formation of filamentous tau aggregations in transgenic mice expressing V337M human tau. Neurobiol Dis. 2001;8:1036&#x2013;1045.</Citation><ArticleIdList><ArticleId IdType="pubmed">11741399</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson LG, Mosley-Thompson E, Davis ME, Henderson KA, Brecher HH, Zagorodnov VS, Mashiotta TA, Lin PN, Mikhalenko VN, Hardy DR, et al. Kilimanjaro ice core records: evidence of holocene climate change in tropical Africa. Science. 2002;298:589&#x2013;593.</Citation><ArticleIdList><ArticleId IdType="pubmed">12386332</ArticleId></ArticleIdList></Reference><Reference><Citation>Vogelsberg-Ragaglia V, Bruce J, Richter-Landsberg C, Zhang B, Hong M, Trojanowski JQ, Lee VM. Distinct FTDP-17 missense mutations in tau produce tau aggregates and other pathological phenotypes in transfected CHO cells. Mol Biol Cell. 2000;11:4093&#x2013;4104.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC15059</ArticleId><ArticleId IdType="pubmed">11102510</ArticleId></ArticleIdList></Reference><Reference><Citation>Vossel KA, Zhang K, Brodbeck J, Daub AC, Sharma P, Finkbeiner S, Cui B, Mucke L. Tau reduction prevents Abeta-induced defects in axonal transport. Science. 2010;330:198.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3024010</ArticleId><ArticleId IdType="pubmed">20829454</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X, Zhao Y, Zhang X, Badie H, Zhou Y, Mu Y, Loo LS, Cai L, Thompson RC, Yang B, et al. Loss of sorting nexin 27 contributes to excitatory synaptic dysfunction by modulating glutamate receptor recycling in Down&#x2019;s syndrome. Nat Med. 2013;19:473&#x2013;480.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3911880</ArticleId><ArticleId IdType="pubmed">23524343</ArticleId></ArticleIdList></Reference><Reference><Citation>Ward A, Crean S, Mercaldi CJ, Collins JM, Boyd D, Cook MN, Arrighi HM. Prevalence of apolipoprotein E4 genotype and homozygotes (APOE e4/4) among patients diagnosed with Alzheimer&#x2019;s disease: a systematic review and meta-analysis. Neuroepidemiology. 2012;38:1&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pubmed">22179327</ArticleId></ArticleIdList></Reference><Reference><Citation>Waxman EA, Giasson BI. Induction of intracellular tau aggregation is promoted by alpha-synuclein seeds and provides novel insights into the hyperphosphorylation of tau. J Neurosci. 2011;31:7604&#x2013;7618.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3122484</ArticleId><ArticleId IdType="pubmed">21613474</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams DR, Lees AJ. Progressive supranuclear palsy: clinicopathological concepts and diagnostic challenges. Lancet Neurol. 2009;8:270&#x2013;279.</Citation><ArticleIdList><ArticleId IdType="pubmed">19233037</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshiyama Y, Higuchi M, Zhang B, Huang SM, Iwata N, Saido TC, Maeda J, Suhara T, Trojanowski JQ, Lee VM. Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron. 2007;53:337&#x2013;351.</Citation><ArticleIdList><ArticleId IdType="pubmed">17270732</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang H, Zhang YW, Chen Y, Huang X, Zhou F, Wang W, Xian B, Zhang X, Masliah E, Chen Q, et al. Appoptosin is a novel pro-apoptotic protein and mediates cell death in neurodegeneration. J Neurosci. 2012;32:15565&#x2013;15576.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3509748</ArticleId><ArticleId IdType="pubmed">23115192</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X, Li F, Bulloj A, Zhang YW, Tong G, Zhang Z, Liao FF, Xu H. Tumor-suppressor PTEN affects tau phosphorylation, aggregation, and binding to microtubules. FASEB J. 2006;20:1272&#x2013;1274.</Citation><ArticleIdList><ArticleId IdType="pubmed">16645045</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao Y, Wang Y, Hu J, Zhang X, Zhang YW. CutA divalent cation tolerance homolog (Escherichia coli) (CUTA) regulates beta-cleavage of beta-amyloid precursor protein (APP) through interacting with beta-site APP cleaving protein 1 (BACE1) J Biol Chem. 2012;287:11141&#x2013;11150.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3322838</ArticleId><ArticleId IdType="pubmed">22351782</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">2810583</PMID><DateCompleted><Year>1989</Year><Month>11</Month><Day>29</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>09</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0098-7484</ISSN><JournalIssue CitedMedium="Print"><Volume>262</Volume><Issue>18</Issue><PubDate><Year>1989</Year><Month>Nov</Month><Day>10</Day></PubDate></JournalIssue><Title>JAMA</Title><ISOAbbreviation>JAMA</ISOAbbreviation></Journal><ArticleTitle>Prevalence of Alzheimer's disease in a community population of older persons. Higher than previously reported.</ArticleTitle><Pagination><StartPage>2551</StartPage><EndPage>2556</EndPage><MedlinePgn>2551-6</MedlinePgn></Pagination><Abstract><AbstractText>Clinically diagnosed Alzheimer's disease and other dementing illnesses were assessed in a geographically defined US community. Of 3623 persons (80.8% of all community residents over 65 years of age) who had brief memory testing in their homes, a stratified sample of 467 persons underwent neurological, neuropsychological, and laboratory examination. Prevalence rates of Alzheimer's disease were calculated for the community population from the sample undergoing clinical evaluation. Of those over the age of 65 years, an estimated 10.3% (95% confidence limits, 8.1% and 12.5%) had probable Alzheimer's disease. This prevalence rate was strongly associated with age. Of those 65 to 74 years old, 3.0% (95% confidence limits, 0.8 and 5.2) had probable Alzheimer's disease, compared with 18.7% (95% confidence limits, 13.2 and 24.2) of those 75 to 84 years old and 47.2% (95% confidence limits, 37.0 and 63.2) of those over 85 years. Other dementing conditions were uncommon. Of community residents with moderate or severe cognitive impairment, 84.1% had clinically diagnosed Alzheimer's disease as the only probable diagnosis. These data suggest that clinically diagnosed Alzheimer's disease is a common condition and that its public health impact will continue to increase with increasing longevity of the population.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Evans</LastName><ForeName>D A</ForeName><Initials>DA</Initials><AffiliationInfo><Affiliation>Channing Laboratory, Department of Medicine, Brigham and Women's Hospital, Boston, Mass 02115.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Funkenstein</LastName><ForeName>H H</ForeName><Initials>HH</Initials></Author><Author ValidYN="Y"><LastName>Albert</LastName><ForeName>M S</ForeName><Initials>MS</Initials></Author><Author ValidYN="Y"><LastName>Scherr</LastName><ForeName>P A</ForeName><Initials>PA</Initials></Author><Author ValidYN="Y"><LastName>Cook</LastName><ForeName>N R</ForeName><Initials>NR</Initials></Author><Author ValidYN="Y"><LastName>Chown</LastName><ForeName>M J</ForeName><Initials>MJ</Initials></Author><Author ValidYN="Y"><LastName>Hebert</LastName><ForeName>L E</ForeName><Initials>LE</Initials></Author><Author ValidYN="Y"><LastName>Hennekens</LastName><ForeName>C H</ForeName><Initials>CH</Initials></Author><Author ValidYN="Y"><LastName>Taylor</LastName><ForeName>J O</ForeName><Initials>JO</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>AG 06789</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>N01-AG-0-2107</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>N01-AG-1-2106</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA</MedlineTA><NlmUniqueID>7501160</NlmUniqueID><ISSNLinking>0098-7484</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>JAMA. 1990 May 9;263(18):2447-9.</RefSource><PMID Version="1">2103723</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>JAMA. 1990 Dec 19;264(23):2996. doi: 10.1001/jama.1990.03450230028021.</RefSource><PMID Version="1">2243426</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001900" MajorTopicYN="N" Type="Geographic">Boston</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007407" MajorTopicYN="N">Interviews as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016015" MajorTopicYN="N">Logistic Models</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012494" MajorTopicYN="N">Sampling Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1989</Year><Month>11</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1989</Year><Month>11</Month><Day>10</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1989</Year><Month>11</Month><Day>10</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">2810583</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">16207391</PMID><DateCompleted><Year>2006</Year><Month>08</Month><Day>03</Day></DateCompleted><DateRevised><Year>2025</Year><Month>03</Month><Day>26</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0033-2917</ISSN><JournalIssue CitedMedium="Print"><Volume>36</Volume><Issue>4</Issue><PubDate><Year>2006</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Psychological medicine</Title><ISOAbbreviation>Psychol Med</ISOAbbreviation></Journal><ArticleTitle>Brain reserve and dementia: a systematic review.</ArticleTitle><Pagination><StartPage>441</StartPage><EndPage>454</EndPage><MedlinePgn>441-54</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Behavioural brain reserve is a property of the central nervous system related to sustained and complex mental activity which can lead to differential expression of brain injury. Behavioural brain reserve has been assessed using autobiographical data such as education levels, occupational complexity and mentally stimulating lifestyle pursuits. So far there have been several epidemiological reports but no systematic review to put conflicting results into context. Our aim was to quantitatively review evidence for the effect of brain reserve on incident dementia.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">Cohort studies of the effects of education, occupation, premorbid IQ and mental activities on dementia risk were of interest. Abstracts were identified in MEDLINE (1966-September 2004), CURRENT CONTENTS (to September, 2004), PsychINFO (1984-September 2004), Cochrane Library Databases and reference lists from relevant articles. Twenty-two studies met inclusion criteria. Key information was extracted by both reviewers onto a standard template with a high level of agreement. Studies were combined through a quantitative random-effects meta-analysis.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Higher brain reserve was associated with a lowered risk for incident dementia (summary odds ratio, 0.54; 95% confidence interval, 0.49-0.59). This effect was found over a median of 7.1 years follow-up and resulted from integrating data across more than 29000 individuals. Notably, increased complex mental activity in late life was associated with lower dementia rates independent of other predictors; a dose-response relationship was also evident between extent of complex mental activities in late life and dementia risk.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">This study demonstrates robust evidence that complex patterns of mental activity in the early, mid- and late-life stages is associated with a significant reduction in dementia incidence. Randomized control trials based on brain-reserve principles are now required.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Valenzuela</LastName><ForeName>Michael J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>The Neuropsychiatric Institute, Prince of Wales Hospital, Sydney, Australia. michael@dancenetwork.com.au</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sachdev</LastName><ForeName>Perminder</ForeName><Initials>P</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2005</Year><Month>10</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Psychol Med</MedlineTA><NlmUniqueID>1254142</NlmUniqueID><ISSNLinking>0033-2917</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000033" MajorTopicYN="Y">anatomy &amp; histology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007899" MajorTopicYN="N">Leisure Activities</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011634" MajorTopicYN="N">Public Health</DescriptorName></MeshHeading></MeshHeadingList><NumberOfReferences>62</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>10</Month><Day>7</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>8</Month><Day>4</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>10</Month><Day>7</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16207391</ArticleId><ArticleId IdType="doi">10.1017/S0033291705006264</ArticleId><ArticleId IdType="pii">S0033291705006264</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">26354483</PMID><DateCompleted><Year>2015</Year><Month>10</Month><Day>14</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1476-4687</ISSN><JournalIssue CitedMedium="Internet"><Volume>525</Volume><Issue>7568</Issue><PubDate><Year>2015</Year><Month>Sep</Month><Day>10</Day></PubDate></JournalIssue><Title>Nature</Title><ISOAbbreviation>Nature</ISOAbbreviation></Journal><ArticleTitle>Evidence for human transmission of amyloid-&#x3b2; pathology and cerebral amyloid angiopathy.</ArticleTitle><Pagination><StartPage>247</StartPage><EndPage>250</EndPage><MedlinePgn>247-50</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/nature15369</ELocationID><Abstract><AbstractText>More than two hundred individuals developed Creutzfeldt-Jakob disease (CJD) worldwide as a result of treatment, typically in childhood, with human cadaveric pituitary-derived growth hormone contaminated with prions. Although such treatment ceased in 1985, iatrogenic CJD (iCJD) continues to emerge because of the prolonged incubation periods seen in human prion infections. Unexpectedly, in an autopsy study of eight individuals with iCJD, aged 36-51 years, in four we found moderate to severe grey matter and vascular amyloid-&#x3b2; (A&#x3b2;) pathology. The A&#x3b2; deposition in the grey matter was typical of that seen in Alzheimer's disease and A&#x3b2; in the blood vessel walls was characteristic of cerebral amyloid angiopathy and did not co-localize with prion protein deposition. None of these patients had pathogenic mutations, APOE &#x3b5;4 or other high-risk alleles associated with early-onset Alzheimer's disease. Examination of a series of 116 patients with other prion diseases from a prospective observational cohort study showed minimal or no A&#x3b2; pathology in cases of similar age range, or a decade older, without APOE &#x3b5;4 risk alleles. We also analysed pituitary glands from individuals with A&#x3b2; pathology and found marked A&#x3b2; deposition in multiple cases. Experimental seeding of A&#x3b2; pathology has been previously demonstrated in primates and transgenic mice by central nervous system or peripheral inoculation with Alzheimer's disease brain homogenate. The marked deposition of parenchymal and vascular A&#x3b2; in these relatively young patients with iCJD, in contrast with other prion disease patients and population controls, is consistent with iatrogenic transmission of A&#x3b2; pathology in addition to CJD and suggests that healthy exposed individuals may also be at risk of iatrogenic Alzheimer's disease and cerebral amyloid angiopathy. These findings should also prompt investigation of whether other known iatrogenic routes of prion transmission may also be relevant to A&#x3b2; and other proteopathic seeds associated with neurodegenerative and other human diseases.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jaunmuktane</LastName><ForeName>Zane</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Division of Neuropathology, The National Hospital for Neurology and Neurosurgery, Queen Square, London WC1N 3BG, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mead</LastName><ForeName>Simon</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Medical Research Council Prion Unit, Queen Square, London WC1N 3BG, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square, London WC1N 3BG, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Prion Clinic, The National Hospital for Neurology and Neurosurgery, Queen Square, London WC1N 3BG, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ellis</LastName><ForeName>Matthew</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square, London WC1N 3BG, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wadsworth</LastName><ForeName>Jonathan D F</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>Medical Research Council Prion Unit, Queen Square, London WC1N 3BG, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square, London WC1N 3BG, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nicoll</LastName><ForeName>Andrew J</ForeName><Initials>AJ</Initials><AffiliationInfo><Affiliation>Medical Research Council Prion Unit, Queen Square, London WC1N 3BG, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square, London WC1N 3BG, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kenny</LastName><ForeName>Joanna</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Medical Research Council Prion Unit, Queen Square, London WC1N 3BG, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Prion Clinic, The National Hospital for Neurology and Neurosurgery, Queen Square, London WC1N 3BG, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Launchbury</LastName><ForeName>Francesca</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square, London WC1N 3BG, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Linehan</LastName><ForeName>Jacqueline</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Medical Research Council Prion Unit, Queen Square, London WC1N 3BG, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Richard-Loendt</LastName><ForeName>Angela</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square, London WC1N 3BG, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Walker</LastName><ForeName>A Sarah</ForeName><Initials>AS</Initials><AffiliationInfo><Affiliation>MRC Clinical Trials Unit at University College London, 125 Kingsway, London WC2B 6NH, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rudge</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Medical Research Council Prion Unit, Queen Square, London WC1N 3BG, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Prion Clinic, The National Hospital for Neurology and Neurosurgery, Queen Square, London WC1N 3BG, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Collinge</LastName><ForeName>John</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Medical Research Council Prion Unit, Queen Square, London WC1N 3BG, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square, London WC1N 3BG, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Prion Clinic, The National Hospital for Neurology and Neurosurgery, Queen Square, London WC1N 3BG, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brandner</LastName><ForeName>Sebastian</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Division of Neuropathology, The National Hospital for Neurology and Neurosurgery, Queen Square, London WC1N 3BG, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Medical Research Council Prion Unit, Queen Square, London WC1N 3BG, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square, London WC1N 3BG, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MC_U123160657</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MC_U123192748</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MC_UU_12023/22</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nature</MedlineTA><NlmUniqueID>0410462</NlmUniqueID><ISSNLinking>0028-0836</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011328">Prions</NameOfSubstance></Chemical><Chemical><RegistryNumber>12629-01-5</RegistryNumber><NameOfSubstance UI="D019382">Human Growth Hormone</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nature. 2015 Sep 10;525(7568):193-4. doi: 10.1038/525193a.</RefSource><PMID Version="1">26354478</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>BMJ. 2015 Sep 09;351:h4831. doi: 10.1136/bmj.h4831.</RefSource><PMID Version="1">26359439</PMID></CommentsCorrections><CommentsCorrections RefType="ErratumIn"><RefSource>Nature. 2015 Oct 22;526(7574):595. doi: 10.1038/nature15704.</RefSource><PMID Version="1">26375001</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Neurol. 2015 Nov;11(11):612. doi: 10.1038/nrneurol.2015.190.</RefSource><PMID Version="1">26416538</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Neurosurgery. 2016 Jun;78(6):N17-8. doi: 10.1227/01.neu.0000484057.12676.e3.</RefSource><PMID Version="1">27191810</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Nature. 2016 Jul 13;535(7611):E1-2. doi: 10.1038/nature18602.</RefSource><PMID Version="1">27411637</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Nature. 2016 Jul 13;535(7611):E2-3. doi: 10.1038/nature18603.</RefSource><PMID Version="1">27411638</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Neurosurgery. 2019 Aug 1;85(2):E185-E187. doi: 10.1093/neuros/nyz035.</RefSource><PMID Version="1">30839069</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000483" MajorTopicYN="N">Alleles</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001344" MajorTopicYN="N">Autopsy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001808" MajorTopicYN="N">Blood Vessels</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016657" MajorTopicYN="N">Cerebral Amyloid Angiopathy</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007562" MajorTopicYN="N">Creutzfeldt-Jakob Syndrome</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004340" MajorTopicYN="Y">Drug Contamination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004730" MajorTopicYN="N">Endothelium, Vascular</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D066128" MajorTopicYN="N">Gray Matter</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019382" MajorTopicYN="N">Human Growth Hormone</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007049" MajorTopicYN="Y">Iatrogenic Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011328" MajorTopicYN="N">Prions</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>4</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>8</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>9</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>9</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>10</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26354483</ArticleId><ArticleId IdType="doi">10.1038/nature15369</ArticleId><ArticleId IdType="pii">nature15369</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Annu Rev Neurosci. 2001;24:519-50</Citation><ArticleIdList><ArticleId IdType="pubmed">11283320</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Neuropathol. 2006 Oct;112(4):389-404</Citation><ArticleIdList><ArticleId IdType="pubmed">16906426</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Neuropathol. 1998 Aug;96(2):116-22</Citation><ArticleIdList><ArticleId IdType="pubmed">9705125</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Neurobiol. 1994 Feb;8(1):25-39</Citation><ArticleIdList><ArticleId IdType="pubmed">8086126</ArticleId></ArticleIdList></Reference><Reference><Citation>Methods Mol Biol. 2008;459:197-227</Citation><ArticleIdList><ArticleId IdType="pubmed">18576157</ArticleId></ArticleIdList></Reference><Reference><Citation>J Gen Virol. 2005 Sep;86(Pt 9):2635-44</Citation><ArticleIdList><ArticleId IdType="pubmed">16099923</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neuroimmunol. 1988 Dec;20(2-3):95-110</Citation><ArticleIdList><ArticleId IdType="pubmed">3143742</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Neuropathol. 2012 Jan;123(1):31-7</Citation><ArticleIdList><ArticleId IdType="pubmed">22101366</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Neuropathol. 2014 Oct;128(4):477-84</Citation><ArticleIdList><ArticleId IdType="pubmed">25193240</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Neuropathol. 2014 Feb;127(2):299-301</Citation><ArticleIdList><ArticleId IdType="pubmed">24362441</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroepidemiology. 1997;16(2):86-93</Citation><ArticleIdList><ArticleId IdType="pubmed">9057170</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Pathol. 2007 Dec;171(6):2012-20</Citation><ArticleIdList><ArticleId IdType="pubmed">18055549</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurobiol Aging. 2014 Jan;35(1):261-5</Citation><ArticleIdList><ArticleId IdType="pubmed">23998997</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2010 Nov 12;330(6006):980-2</Citation><ArticleIdList><ArticleId IdType="pubmed">20966215</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropathol Appl Neurobiol. 2008 Aug;34(4):446-56</Citation><ArticleIdList><ArticleId IdType="pubmed">18657254</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 2003 Sep 23;61(6):783-91</Citation><ArticleIdList><ArticleId IdType="pubmed">14504321</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2007 Nov 9;318(5852):930-6</Citation><ArticleIdList><ArticleId IdType="pubmed">17991853</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2009 Aug 4;106(31):12926-31</Citation><ArticleIdList><ArticleId IdType="pubmed">19622727</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain. 2015 Nov;138(Pt 11):3386-99</Citation><ArticleIdList><ArticleId IdType="pubmed">26268531</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Neuropathol. 2012 Oct;124(4):517-29</Citation><ArticleIdList><ArticleId IdType="pubmed">22744790</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurobiol Aging. 1997 Jul-Aug;18(4):351-7</Citation><ArticleIdList><ArticleId IdType="pubmed">9330961</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 1991 Apr;41(4):479-86</Citation><ArticleIdList><ArticleId IdType="pubmed">2011243</ArticleId></ArticleIdList></Reference><Reference><Citation>EMBO Rep. 2013 Nov;14(11):1017-22</Citation><ArticleIdList><ArticleId IdType="pubmed">23999102</ArticleId></ArticleIdList></Reference><Reference><Citation>Alzheimers Dement. 2012 Jan;8(1):1-13</Citation><ArticleIdList><ArticleId IdType="pubmed">22265587</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2006 Jun 24;367 (9528):2068-74</Citation><ArticleIdList><ArticleId IdType="pubmed">16798390</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Neuropathol. 2014 Oct;128(4):463-76</Citation><ArticleIdList><ArticleId IdType="pubmed">25073522</ArticleId></ArticleIdList></Reference><Reference><Citation>Emerg Infect Dis. 2012 Jun;18(6):901-7</Citation><ArticleIdList><ArticleId IdType="pubmed">22607808</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurol Neurosurg Psychiatry. 2006 Mar;77(3):413-6</Citation><ArticleIdList><ArticleId IdType="pubmed">16484658</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet Neurol. 2008 Feb;7(2):129-35</Citation><ArticleIdList><ArticleId IdType="pubmed">18191617</ArticleId></ArticleIdList></Reference><Reference><Citation>Philos Trans R Soc Lond B Biol Sci. 2008 Nov 27;363(1510):3755-63</Citation><ArticleIdList><ArticleId IdType="pubmed">18849292</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Neurol. 2011 Sep;68(9):1185-90</Citation><ArticleIdList><ArticleId IdType="pubmed">21555601</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2006 Sep 22;313(5794):1781-4</Citation><ArticleIdList><ArticleId IdType="pubmed">16990547</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 2002 Jun 25;58(12):1791-800</Citation><ArticleIdList><ArticleId IdType="pubmed">12084879</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Endocrinol Metab. 2011 Oct;96(10):E1666-9</Citation><ArticleIdList><ArticleId IdType="pubmed">21816775</ArticleId></ArticleIdList></Reference><Reference><Citation>Aging (Milano). 1990 Dec;2(4):415-24</Citation><ArticleIdList><ArticleId IdType="pubmed">2094382</ArticleId></ArticleIdList></Reference><Reference><Citation>Cytometry. 2000 Apr 1;39(4):275-84</Citation><ArticleIdList><ArticleId IdType="pubmed">10738280</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Neurol. 1991 Nov;30(5):637-49</Citation><ArticleIdList><ArticleId IdType="pubmed">1763890</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA Neurol. 2013 Apr;70(4):462-8</Citation><ArticleIdList><ArticleId IdType="pubmed">23380910</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">26352792</PMID><DateCompleted><Year>2016</Year><Month>02</Month><Day>09</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1546-1726</ISSN><JournalIssue CitedMedium="Internet"><Volume>18</Volume><Issue>11</Issue><PubDate><Year>2015</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Nature neuroscience</Title><ISOAbbreviation>Nat Neurosci</ISOAbbreviation></Journal><ArticleTitle>Persistence of A&#x3b2; seeds in APP null mouse brain.</ArticleTitle><Pagination><StartPage>1559</StartPage><EndPage>1561</EndPage><MedlinePgn>1559-61</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/nn.4117</ELocationID><Abstract><AbstractText>Cerebral &#x3b2;-amyloidosis is induced by inoculation of A&#x3b2; seeds into APP transgenic mice, but not into App(-/-) (APP null) mice. We found that brain extracts from APP null mice that had been inoculated with A&#x3b2; seeds up to 6 months previously still induced &#x3b2;-amyloidosis in APP transgenic hosts following secondary transmission. Thus, A&#x3b2; seeds can persist in the brain for months, and they regain propagative and pathogenic activity in the presence of host A&#x3b2;.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ye</LastName><ForeName>Lan</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Cellular Neurology, Hertie Institute for Clinical Brain Research, University of T&#xfc;bingen, T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), T&#xfc;bingen, T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Graduate School of Cellular and Molecular Neuroscience, University of T&#xfc;bingen, T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fritschi</LastName><ForeName>Sarah K</ForeName><Initials>SK</Initials><AffiliationInfo><Affiliation>Department of Cellular Neurology, Hertie Institute for Clinical Brain Research, University of T&#xfc;bingen, T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), T&#xfc;bingen, T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schelle</LastName><ForeName>Juliane</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Cellular Neurology, Hertie Institute for Clinical Brain Research, University of T&#xfc;bingen, T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), T&#xfc;bingen, T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Graduate School of Cellular and Molecular Neuroscience, University of T&#xfc;bingen, T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oberm&#xfc;ller</LastName><ForeName>Ulrike</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>Department of Cellular Neurology, Hertie Institute for Clinical Brain Research, University of T&#xfc;bingen, T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), T&#xfc;bingen, T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Degenhardt</LastName><ForeName>Karoline</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Cellular Neurology, Hertie Institute for Clinical Brain Research, University of T&#xfc;bingen, T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), T&#xfc;bingen, T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Graduate School of Cellular and Molecular Neuroscience, University of T&#xfc;bingen, T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kaeser</LastName><ForeName>Stephan A</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>Department of Cellular Neurology, Hertie Institute for Clinical Brain Research, University of T&#xfc;bingen, T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), T&#xfc;bingen, T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eisele</LastName><ForeName>Yvonne S</ForeName><Initials>YS</Initials><AffiliationInfo><Affiliation>Department of Cellular Neurology, Hertie Institute for Clinical Brain Research, University of T&#xfc;bingen, T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), T&#xfc;bingen, T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Walker</LastName><ForeName>Lary C</ForeName><Initials>LC</Initials><AffiliationInfo><Affiliation>Yerkes National Primate Research Center and Department of Neurology, Emory University, Atlanta, Georgia, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baumann</LastName><ForeName>Frank</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Cellular Neurology, Hertie Institute for Clinical Brain Research, University of T&#xfc;bingen, T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), T&#xfc;bingen, T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Staufenbiel</LastName><ForeName>Matthias</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Cellular Neurology, Hertie Institute for Clinical Brain Research, University of T&#xfc;bingen, T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), T&#xfc;bingen, T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jucker</LastName><ForeName>Mathias</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Cellular Neurology, Hertie Institute for Clinical Brain Research, University of T&#xfc;bingen, T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), T&#xfc;bingen, T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>09</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Neurosci</MedlineTA><NlmUniqueID>9809671</NlmUniqueID><ISSNLinking>1097-6256</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000172" MajorTopicYN="N">deficiency</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000686" MajorTopicYN="N">Amyloidosis</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058225" MajorTopicYN="N">Plaque, Amyloid</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>7</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>8</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>9</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>9</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>2</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26352792</ArticleId><ArticleId IdType="doi">10.1038/nn.4117</ArticleId><ArticleId IdType="pii">nn.4117</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Cell. 1993 Jul 2;73(7):1339-47</Citation><ArticleIdList><ArticleId IdType="pubmed">8100741</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 2014 Jul 30;34(31):10264-73</Citation><ArticleIdList><ArticleId IdType="pubmed">25080588</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Res. 1983 Jun 6;268(2):249-54</Citation><ArticleIdList><ArticleId IdType="pubmed">6191831</ArticleId></ArticleIdList></Reference><Reference><Citation>Virus Res. 2015 Sep 2;207:106-12</Citation><ArticleIdList><ArticleId IdType="pubmed">25575736</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Neuropathol. 2014 Oct;128(4):477-84</Citation><ArticleIdList><ArticleId IdType="pubmed">25193240</ArticleId></ArticleIdList></Reference><Reference><Citation>Annu Rev Genet. 2013;47:601-23</Citation><ArticleIdList><ArticleId IdType="pubmed">24274755</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2013 Sep 5;501(7465):45-51</Citation><ArticleIdList><ArticleId IdType="pubmed">24005412</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurobiol Aging. 2011 Dec;32(12):2324.e1-6</Citation><ArticleIdList><ArticleId IdType="pubmed">20970889</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2010 Nov 12;330(6006):980-2</Citation><ArticleIdList><ArticleId IdType="pubmed">20966215</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 2011 Oct 12;31(41):14488-95</Citation><ArticleIdList><ArticleId IdType="pubmed">21994365</ArticleId></ArticleIdList></Reference><Reference><Citation>Sci Transl Med. 2013 Jul 17;5(194):194re2</Citation><ArticleIdList><ArticleId IdType="pubmed">23863834</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 1993 Apr 1;90(7):2793-7</Citation><ArticleIdList><ArticleId IdType="pubmed">8464892</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 1999 Nov 23;96(24):14088-93</Citation><ArticleIdList><ArticleId IdType="pubmed">10570203</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 2015 May 19;313(19):1924-38</Citation><ArticleIdList><ArticleId IdType="pubmed">25988462</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2009 Aug 4;106(31):12926-31</Citation><ArticleIdList><ArticleId IdType="pubmed">19622727</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurobiol Aging. 1995 Sep-Oct;16(5):797-804</Citation><ArticleIdList><ArticleId IdType="pubmed">8532113</ArticleId></ArticleIdList></Reference><Reference><Citation>J Gen Virol. 2005 Oct;86(Pt 10):2913-23</Citation><ArticleIdList><ArticleId IdType="pubmed">16186247</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuron. 2013 Dec 18;80(6):1347-58</Citation><ArticleIdList><ArticleId IdType="pubmed">24360540</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Neurosci. 2012 Jun 26;15(7):936-9</Citation><ArticleIdList><ArticleId IdType="pubmed">22735515</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Pathol. 1999 Jun;154(6):1673-84</Citation><ArticleIdList><ArticleId IdType="pubmed">10362792</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell. 1994 Jul 1;77(7):967-8</Citation><ArticleIdList><ArticleId IdType="pubmed">7912659</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2006 Sep 22;313(5794):1781-4</Citation><ArticleIdList><ArticleId IdType="pubmed">16990547</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 2002 Jun 25;58(12):1791-800</Citation><ArticleIdList><ArticleId IdType="pubmed">12084879</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">26352473</PMID><DateCompleted><Year>2015</Year><Month>10</Month><Day>19</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1476-4687</ISSN><JournalIssue CitedMedium="Internet"><Volume>525</Volume><Issue>7570</Issue><PubDate><Year>2015</Year><Month>Sep</Month><Day>24</Day></PubDate></JournalIssue><Title>Nature</Title><ISOAbbreviation>Nature</ISOAbbreviation></Journal><ArticleTitle>Structure of the toxic core of &#x3b1;-synuclein from invisible crystals.</ArticleTitle><Pagination><StartPage>486</StartPage><EndPage>490</EndPage><MedlinePgn>486-90</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/nature15368</ELocationID><Abstract><AbstractText>The protein &#x3b1;-synuclein is the main component of Lewy bodies, the neuron-associated aggregates seen in Parkinson disease and other neurodegenerative pathologies. An 11-residue segment, which we term NACore, appears to be responsible for amyloid formation and cytotoxicity of human &#x3b1;-synuclein. Here we describe crystals of NACore that have dimensions smaller than the wavelength of visible light and thus are invisible by optical microscopy. As the crystals are thousands of times too small for structure determination by synchrotron X-ray diffraction, we use micro-electron diffraction to determine the structure at atomic resolution. The 1.4 &#xc5; resolution structure demonstrates that this method can determine previously unknown protein structures and here yields, to our knowledge, the highest resolution achieved by any cryo-electron microscopy method to date. The structure exhibits protofibrils built of pairs of face-to-face &#x3b2;-sheets. X-ray fibre diffraction patterns show the similarity of NACore to toxic fibrils of full-length &#x3b1;-synuclein. The NACore structure, together with that of a second segment, inspires a model for most of the ordered portion of the toxic, full-length &#x3b1;-synuclein fibril, presenting opportunities for the design of inhibitors of &#x3b1;-synuclein fibrils.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rodriguez</LastName><ForeName>Jose A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Howard Hughes Medical Institute, UCLA-DOE Institute, Departments of Biological Chemistry and Chemistry and Biochemistry, Box 951570, UCLA, Los Angeles, California 90095-1570, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ivanova</LastName><ForeName>Magdalena I</ForeName><Initials>MI</Initials><AffiliationInfo><Affiliation>Howard Hughes Medical Institute, UCLA-DOE Institute, Departments of Biological Chemistry and Chemistry and Biochemistry, Box 951570, UCLA, Los Angeles, California 90095-1570, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sawaya</LastName><ForeName>Michael R</ForeName><Initials>MR</Initials><AffiliationInfo><Affiliation>Howard Hughes Medical Institute, UCLA-DOE Institute, Departments of Biological Chemistry and Chemistry and Biochemistry, Box 951570, UCLA, Los Angeles, California 90095-1570, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cascio</LastName><ForeName>Duilio</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Howard Hughes Medical Institute, UCLA-DOE Institute, Departments of Biological Chemistry and Chemistry and Biochemistry, Box 951570, UCLA, Los Angeles, California 90095-1570, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reyes</LastName><ForeName>Francis E</ForeName><Initials>FE</Initials><AffiliationInfo><Affiliation>Howard Hughes Medical Institute, Janelia Research Campus, 19700 Helix Drive, Ashburn, Virginia 20147, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shi</LastName><ForeName>Dan</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Howard Hughes Medical Institute, Janelia Research Campus, 19700 Helix Drive, Ashburn, Virginia 20147, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sangwan</LastName><ForeName>Smriti</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Howard Hughes Medical Institute, UCLA-DOE Institute, Departments of Biological Chemistry and Chemistry and Biochemistry, Box 951570, UCLA, Los Angeles, California 90095-1570, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guenther</LastName><ForeName>Elizabeth L</ForeName><Initials>EL</Initials><AffiliationInfo><Affiliation>Howard Hughes Medical Institute, UCLA-DOE Institute, Departments of Biological Chemistry and Chemistry and Biochemistry, Box 951570, UCLA, Los Angeles, California 90095-1570, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Johnson</LastName><ForeName>Lisa M</ForeName><Initials>LM</Initials><AffiliationInfo><Affiliation>Howard Hughes Medical Institute, UCLA-DOE Institute, Departments of Biological Chemistry and Chemistry and Biochemistry, Box 951570, UCLA, Los Angeles, California 90095-1570, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Meng</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Howard Hughes Medical Institute, UCLA-DOE Institute, Departments of Biological Chemistry and Chemistry and Biochemistry, Box 951570, UCLA, Los Angeles, California 90095-1570, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jiang</LastName><ForeName>Lin</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Howard Hughes Medical Institute, UCLA-DOE Institute, Departments of Biological Chemistry and Chemistry and Biochemistry, Box 951570, UCLA, Los Angeles, California 90095-1570, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arbing</LastName><ForeName>Mark A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Howard Hughes Medical Institute, UCLA-DOE Institute, Departments of Biological Chemistry and Chemistry and Biochemistry, Box 951570, UCLA, Los Angeles, California 90095-1570, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nannenga</LastName><ForeName>Brent L</ForeName><Initials>BL</Initials><AffiliationInfo><Affiliation>Howard Hughes Medical Institute, Janelia Research Campus, 19700 Helix Drive, Ashburn, Virginia 20147, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hattne</LastName><ForeName>Johan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Howard Hughes Medical Institute, Janelia Research Campus, 19700 Helix Drive, Ashburn, Virginia 20147, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Whitelegge</LastName><ForeName>Julian</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Box 42, NPI-Semel Institute, 760 Westwood Plaza, UCLA, Los Angeles, California 90024, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brewster</LastName><ForeName>Aaron S</ForeName><Initials>AS</Initials><AffiliationInfo><Affiliation>Physical Biosciences Division, Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Messerschmidt</LastName><ForeName>Marc</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Linac Coherent Light Source, SLAC National Accelerator Laboratory, Menlo Park, California 94025, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boutet</LastName><ForeName>S&#xe9;bastien</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Linac Coherent Light Source, SLAC National Accelerator Laboratory, Menlo Park, California 94025, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sauter</LastName><ForeName>Nicholas K</ForeName><Initials>NK</Initials><AffiliationInfo><Affiliation>Physical Biosciences Division, Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gonen</LastName><ForeName>Tamir</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Howard Hughes Medical Institute, Janelia Research Campus, 19700 Helix Drive, Ashburn, Virginia 20147, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eisenberg</LastName><ForeName>David S</ForeName><Initials>DS</Initials><AffiliationInfo><Affiliation>Howard Hughes Medical Institute, UCLA-DOE Institute, Departments of Biological Chemistry and Chemistry and Biochemistry, Box 951570, UCLA, Los Angeles, California 90095-1570, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>PDB</DataBankName><AccessionNumberList><AccessionNumber>4RIK</AccessionNumber><AccessionNumber>4RIL</AccessionNumber><AccessionNumber>4ZNN</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG029430</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 GM102520</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P41 GM103403</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG016570</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>GM095887</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 GM095887</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 DK063491</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG016570</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 GM007185</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><Acronym>HHMI</Acronym><Agency>Howard Hughes Medical Institute</Agency><Country>United States</Country></Grant><Grant><GrantID>GM102520</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>1R01-AG029430</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>09</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nature</MedlineTA><NlmUniqueID>0410462</NlmUniqueID><ISSNLinking>0028-0836</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000682">Amyloid</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C497604">SNCA protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051844">alpha-Synuclein</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nature. 2015 Sep 24;525(7570):458-9. doi: 10.1038/nature15630.</RefSource><PMID Version="1">26352470</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Mov Disord. 2016 Jan;31(1):44. doi: 10.1002/mds.26465.</RefSource><PMID Version="1">26748962</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000682" MajorTopicYN="N">Amyloid</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020285" MajorTopicYN="N">Cryoelectron Microscopy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004583" MajorTopicYN="N">Electrons</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016631" MajorTopicYN="N">Lewy Bodies</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008958" MajorTopicYN="N">Models, Molecular</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053758" MajorTopicYN="N">Nanoparticles</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName><QualifierName UI="Q000633" MajorTopicYN="Y">toxicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017434" MajorTopicYN="N">Protein Structure, Tertiary</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012542" MajorTopicYN="N">Scattering, Radiation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051844" MajorTopicYN="N">alpha-Synuclein</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName><QualifierName UI="Q000633" MajorTopicYN="Y">toxicity</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>10</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>8</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>9</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>9</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>10</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2016</Year><Month>3</Month><Day>24</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26352473</ArticleId><ArticleId IdType="mid">NIHMS721816</ArticleId><ArticleId IdType="pmc">PMC4791177</ArticleId><ArticleId IdType="doi">10.1038/nature15368</ArticleId><ArticleId IdType="pii">nature15368</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Spillantini MG, et al. Alpha-synuclein in Lewy bodies. Nature. 1997;388:839&#x2013;840.</Citation><ArticleIdList><ArticleId IdType="pubmed">9278044</ArticleId></ArticleIdList></Reference><Reference><Citation>Goedert M, Spillantini MG, Del Tredici K, Braak H. 100 years of Lewy pathology. Nat. Rev. Neurol. 2013;9:13&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pubmed">23183883</ArticleId></ArticleIdList></Reference><Reference><Citation>Polymeropoulos MH, et al. Mutation in the alpha-synuclein gene identified in families with Parkinson&#x2019;s disease. Science. 1997;276:2045&#x2013;2047.</Citation><ArticleIdList><ArticleId IdType="pubmed">9197268</ArticleId></ArticleIdList></Reference><Reference><Citation>Kr&#xfc;ger R. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson&#x2019;s disease. Nat. Genet. 1998;18:106&#x2013;108.</Citation><ArticleIdList><ArticleId IdType="pubmed">9462735</ArticleId></ArticleIdList></Reference><Reference><Citation>Zarranz JJ, et al. The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann. Neurol. 2004;55:164&#x2013;173.</Citation><ArticleIdList><ArticleId IdType="pubmed">14755719</ArticleId></ArticleIdList></Reference><Reference><Citation>Ib&#xe1;&#xf1;ez P. Causal relation between alpha-synuclein gene duplication and familial Parkinson&#x2019;s disease. Lancet. 2004;364:1169&#x2013;1171.</Citation><ArticleIdList><ArticleId IdType="pubmed">15451225</ArticleId></ArticleIdList></Reference><Reference><Citation>Singleton AB, et al. alpha-Synuclein locus triplication causes Parkinson&#x2019;s disease. Science. 2003;302:841.</Citation><ArticleIdList><ArticleId IdType="pubmed">14593171</ArticleId></ArticleIdList></Reference><Reference><Citation>U&#xe9;da K, et al. Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease. Proc. Natl. Acad. Sci. U. S. A. 1993;90:11282&#x2013;11286.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC47966</ArticleId><ArticleId IdType="pubmed">8248242</ArticleId></ArticleIdList></Reference><Reference><Citation>Biere AL, et al. Parkinson&#x2019;s disease-associated alpha-synuclein is more fibrillogenic than beta- and gamma-synuclein and cannot cross-seed its homologs. J. Biol. Chem. 2000;275:34574&#x2013;34579.</Citation><ArticleIdList><ArticleId IdType="pubmed">10942772</ArticleId></ArticleIdList></Reference><Reference><Citation>Giasson BI, Murray IVJ, Trojanowski JQ, Lee VM-Y. A Hydrophobic Stretch of 12 Amino Acid Residues in the Middle of &#x3b1;-Synuclein Is Essential for Filament Assembly. J. Biol. Chem. 2001;276:2380&#x2013;2386.</Citation><ArticleIdList><ArticleId IdType="pubmed">11060312</ArticleId></ArticleIdList></Reference><Reference><Citation>Du H-N, et al. A peptide motif consisting of glycine, alanine, and valine is required for the fibrillization and cytotoxicity of human alpha-synuclein. Biochemistry (Mosc.) 2003;42:8870&#x2013;8878.</Citation><ArticleIdList><ArticleId IdType="pubmed">12873148</ArticleId></ArticleIdList></Reference><Reference><Citation>Periquet M, Fulga T, Myllykangas L, Schlossmacher MG, Feany MB. Aggregated &#x3b1;-Synuclein Mediates Dopaminergic Neurotoxicity In Vivo. J. Neurosci. 2007;27:3338&#x2013;3346.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672466</ArticleId><ArticleId IdType="pubmed">17376994</ArticleId></ArticleIdList></Reference><Reference><Citation>Han H, Weinreb PH, Lansbury PT. The core Alzheimer&#x2019;s peptide NAC forms amyloid fibrils, which seed and are seeded by beta-amyloid: is NAC a common trigger or target in neurodegenerative disease? Chem. Biol. 1995;2:163&#x2013;169.</Citation><ArticleIdList><ArticleId IdType="pubmed">9383418</ArticleId></ArticleIdList></Reference><Reference><Citation>El-Agnaf OM, et al. Aggregates from mutant and wild-type alpha-synuclein proteins and NAC peptide induce apoptotic cell death in human neuroblastoma cells by formation of beta-sheet and amyloid-like filaments. FEBS Lett. 1998;440:71&#x2013;75.</Citation><ArticleIdList><ArticleId IdType="pubmed">9862428</ArticleId></ArticleIdList></Reference><Reference><Citation>Crowther RA, Daniel SE, Goedert M. Characterisation of isolated alpha-synuclein filaments from substantia nigra of Parkinson&#x2019;s disease brain. Neurosci. Lett. 2000;292:128&#x2013;130.</Citation><ArticleIdList><ArticleId IdType="pubmed">10998565</ArticleId></ArticleIdList></Reference><Reference><Citation>Der-Sarkissian A, Jao CC, Chen J, Langen R. Structural organization of alpha-synuclein fibrils studied by site-directed spin labeling. J. Biol. Chem. 2003;278:37530&#x2013;37535.</Citation><ArticleIdList><ArticleId IdType="pubmed">12815044</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen M, Margittai M, Chen J, Langen R. Investigation of alpha-synuclein fibril structure by site-directed spin labeling. J. Biol. Chem. 2007;282:24970&#x2013;24979.</Citation><ArticleIdList><ArticleId IdType="pubmed">17573347</ArticleId></ArticleIdList></Reference><Reference><Citation>Miake H, Mizusawa H, Iwatsubo T, Hasegawa M. Biochemical Characterization of the Core Structure of &#x3b1;-Synuclein Filaments. J. Biol. Chem. 2002;277:19213&#x2013;19219.</Citation><ArticleIdList><ArticleId IdType="pubmed">11893734</ArticleId></ArticleIdList></Reference><Reference><Citation>Conway KA, Harper JD, Lansbury PT. Accelerated in vitro fibril formation by a mutant alpha-synuclein linked to early-onset Parkinson disease. Nat. Med. 1998;4:1318&#x2013;1320.</Citation><ArticleIdList><ArticleId IdType="pubmed">9809558</ArticleId></ArticleIdList></Reference><Reference><Citation>Polymeropoulos MH, et al. Mutation in the alpha-synuclein gene identified in families with Parkinson&#x2019;s disease. Science. 1997;276:2045&#x2013;2047.</Citation><ArticleIdList><ArticleId IdType="pubmed">9197268</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson R, et al. Structure of the cross-beta spine of amyloid-like fibrils. Nature. 2005;435:773&#x2013;778.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1479801</ArticleId><ArticleId IdType="pubmed">15944695</ArticleId></ArticleIdList></Reference><Reference><Citation>Sawaya MR, et al. Atomic structures of amyloid cross-beta spines reveal varied steric zippers. Nature. 2007;447:453&#x2013;457.</Citation><ArticleIdList><ArticleId IdType="pubmed">17468747</ArticleId></ArticleIdList></Reference><Reference><Citation>Bodles AM, Guthrie DJ, Greer B, Irvine GB. Identification of the region of non-Abeta component (NAC) of Alzheimer&#x2019;s disease amyloid responsible for its aggregation and toxicity. J. Neurochem. 2001;78:384&#x2013;395.</Citation><ArticleIdList><ArticleId IdType="pubmed">11461974</ArticleId></ArticleIdList></Reference><Reference><Citation>Nannenga BL, Gonen T. Protein structure determination by MicroED. Curr. Opin. Struct. Biol. 2014;27C:24&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5656570</ArticleId><ArticleId IdType="pubmed">24709395</ArticleId></ArticleIdList></Reference><Reference><Citation>Nannenga BL, Shi D, Leslie AGW, Gonen T. High-resolution structure determination by continuous-rotation data collection in MicroED. Nat. Methods. 2014;11:927&#x2013;930.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4149488</ArticleId><ArticleId IdType="pubmed">25086503</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi D, Nannenga BL, Iadanza MG, Gonen T. Three-dimensional electron crystallography of protein microcrystals. eLife. 2013;2:e01345.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3831942</ArticleId><ArticleId IdType="pubmed">24252878</ArticleId></ArticleIdList></Reference><Reference><Citation>Nannenga BL, Shi D, Hattne J, Reyes FE, Gonen T. Structure of catalase determined by MicroED. eLife. 2014;3:e03600.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4359365</ArticleId><ArticleId IdType="pubmed">25303172</ArticleId></ArticleIdList></Reference><Reference><Citation>Yonekura K, Kato K, Ogasawara M, Tomita M, Toyoshima C. Electron crystallography of ultrathin 3D protein crystals: atomic model with charges. Proc. Natl. Acad. Sci. U. S. A. 2015;112:3368&#x2013;3373.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4372003</ArticleId><ArticleId IdType="pubmed">25730881</ArticleId></ArticleIdList></Reference><Reference><Citation>Doyle PA, Turner PS. Relativistic Hartree&#x2013;Fock X-ray and electron scattering factors. Acta Crystallogr. Sect. A. 1968;24:390&#x2013;397.</Citation></Reference><Reference><Citation>Sarafian TA, et al. Impairment of mitochondria in adult mouse brain overexpressing predominantly full-length, N-terminally acetylated human &#x3b1;-synuclein. PloS One. 2013;8:e63557.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3646806</ArticleId><ArticleId IdType="pubmed">23667637</ArticleId></ArticleIdList></Reference><Reference><Citation>Caughey B, Lansbury PT. Protofibrils, pores, fibrils, and neurodegeneration: separating the responsible protein aggregates from the innocent bystanders. Annu. Rev. Neurosci. 2003;26:267&#x2013;298.</Citation><ArticleIdList><ArticleId IdType="pubmed">12704221</ArticleId></ArticleIdList></Reference><Reference><Citation>Danzer KM, Schnack C, Sutcliffe A, Hengerer B, Gillardon F. Functional protein kinase arrays reveal inhibition of p-21-activated kinase 4 by alpha-synuclein oligomers. J. Neurochem. 2007;103:2401&#x2013;2407.</Citation><ArticleIdList><ArticleId IdType="pubmed">17883396</ArticleId></ArticleIdList></Reference><Reference><Citation>Karpinar DP, et al. Pre-fibrillar alpha-synuclein variants with impaired beta-structure increase neurotoxicity in Parkinson&#x2019;s disease models. EMBO J. 2009;28:3256&#x2013;3268.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2771093</ArticleId><ArticleId IdType="pubmed">19745811</ArticleId></ArticleIdList></Reference><Reference><Citation>Winner B, et al. In vivo demonstration that alpha-synuclein oligomers are toxic. Proc. Natl. Acad. Sci. U. S. A. 2011;108:4194&#x2013;4199.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3053976</ArticleId><ArticleId IdType="pubmed">21325059</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen SW, et al. Structural characterization of toxic oligomers that are kinetically trapped during &#x3b1;-synuclein fibril formation. Proc. Natl. Acad. Sci. U. S. A. 2015;112:E1994&#x2013;E2003.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4413268</ArticleId><ArticleId IdType="pubmed">25855634</ArticleId></ArticleIdList></Reference><Reference><Citation>Bousset L, et al. Structural and functional characterization of two alpha-synuclein strains. Nat. Commun. 2013;4:2575.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3826637</ArticleId><ArticleId IdType="pubmed">24108358</ArticleId></ArticleIdList></Reference><Reference><Citation>Auluck PK, Caraveo G, Lindquist S. &#x3b1;-Synuclein: membrane interactions and toxicity in Parkinson&#x2019;s disease. Annu. Rev. Cell Dev. Biol. 2010;26:211&#x2013;233.</Citation><ArticleIdList><ArticleId IdType="pubmed">20500090</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee JC, Langen R, Hummel PA, Gray HB, Winkler JR. Alpha-synuclein structures from fluorescence energy-transfer kinetics: implications for the role of the protein in Parkinson&#x2019;s disease. Proc. Natl. Acad. Sci. U. S. A. 2004;101:16466&#x2013;16471.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC534538</ArticleId><ArticleId IdType="pubmed">15536128</ArticleId></ArticleIdList></Reference><Reference><Citation>Sievers SA, et al. Structure-based design of non-natural amino-acid inhibitors of amyloid fibril formation. Nature. 2011;475:96&#x2013;100.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4073670</ArticleId><ArticleId IdType="pubmed">21677644</ArticleId></ArticleIdList></Reference><Reference><Citation>Comellas G, et al. Structured regions of &#x3b1;-synuclein fibrils include the early-onset Parkinson&#x2019;s disease mutation sites. J. Mol. Biol. 2011;411:881&#x2013;895.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3157309</ArticleId><ArticleId IdType="pubmed">21718702</ArticleId></ArticleIdList></Reference><Reference><Citation>Vilar M, et al. The fold of alpha-synuclein fibrils. Proc. Natl. Acad. Sci. U. S. A. 2008;105:8637&#x2013;8642.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2438424</ArticleId><ArticleId IdType="pubmed">18550842</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldschmidt L, Teng PK, Riek R, Eisenberg D. Identifying the amylome, proteins capable of forming amyloid-like fibrils. Proc. Natl. Acad. Sci. 2010;107:3487&#x2013;3492.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2840437</ArticleId><ArticleId IdType="pubmed">20133726</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Extended References</Title><Reference><Citation>Otwinowski Z, Minor W. In: Methods in Enzymology. Charles W, Carter J, editors. Vol. 276. Academic Press; 1997. pp. 307&#x2013;326.</Citation><ArticleIdList><ArticleId IdType="pubmed">27754618</ArticleId></ArticleIdList></Reference><Reference><Citation>Weierstall U, Spence JCH, Doak RB. Injector for scattering measurements on fully solvated biospecies. Rev. Sci. Instrum. 2012;83:035108.</Citation><ArticleIdList><ArticleId IdType="pubmed">22462961</ArticleId></ArticleIdList></Reference><Reference><Citation>Hattne J, et al. Accurate macromolecular structures using minimal measurements from X-ray free-electron lasers. Nat. Methods. 2014;11:545&#x2013;548.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4008696</ArticleId><ArticleId IdType="pubmed">24633409</ArticleId></ArticleIdList></Reference><Reference><Citation>Sauter NK, Hattne J, Grosse-Kunstleve RW, Echols N. New Python-based methods for data processing. Acta Crystallogr. D Biol. Crystallogr. 2013;69:1274&#x2013;1282.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3689530</ArticleId><ArticleId IdType="pubmed">23793153</ArticleId></ArticleIdList></Reference><Reference><Citation>Kabsch W. XDS. Acta Crystallogr. D Biol. Crystallogr. 2010;66:125&#x2013;132.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2815665</ArticleId><ArticleId IdType="pubmed">20124692</ArticleId></ArticleIdList></Reference><Reference><Citation>McCoy AJ, et al. Phaser crystallographic software. J. Appl. Crystallogr. 2007;40:658&#x2013;674.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2483472</ArticleId><ArticleId IdType="pubmed">19461840</ArticleId></ArticleIdList></Reference><Reference><Citation>Murshudov GN, Vagin AA, Dodson EJ. Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr. D Biol. Crystallogr. 1997;53:240&#x2013;255.</Citation><ArticleIdList><ArticleId IdType="pubmed">15299926</ArticleId></ArticleIdList></Reference><Reference><Citation>Afonine PV, et al. Towards automated crystallographic structure refinement with phenix.refine. Acta Crystallogr. D Biol. Crystallogr. 2012;68:352&#x2013;367.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3322595</ArticleId><ArticleId IdType="pubmed">22505256</ArticleId></ArticleIdList></Reference><Reference><Citation>Blanc E, et al. Refinement of severely incomplete structures with maximum likelihood in BUSTER-TNT. Acta Crystallogr. D Biol. Crystallogr. 2004;60:2210&#x2013;2221.</Citation><ArticleIdList><ArticleId IdType="pubmed">15572774</ArticleId></ArticleIdList></Reference><Reference><Citation>Emsley P, Lohkamp B, Scott WG, Cowtan K. Features and development of Coot. Acta Crystallogr. D Biol. Crystallogr. 2010;66:486&#x2013;501.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2852313</ArticleId><ArticleId IdType="pubmed">20383002</ArticleId></ArticleIdList></Reference><Reference><Citation>Delano W, et al.   In: The PyMOL Molecular Graphics System. Schr&#xf6;dinger LLC, editor.  at&lt; http://www.pymol.org&gt;.</Citation></Reference><Reference><Citation>Jakes R, Spillantini MG, Goedert M. Identification of two distinct synucleins from human brain. FEBS Lett. 1994;345:27&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pubmed">8194594</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson M, Coulton AT, Geeves MA, Mulvihill DP. Targeted amino-terminal acetylation of recombinant proteins in E. coli. PloS One. 2010;5:e15801.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3009751</ArticleId><ArticleId IdType="pubmed">21203426</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitelegge JP, Zhang H, Aguilera R, Taylor RM, Cramer WA. Full subunit coverage liquid chromatography electrospray ionization mass spectrometry (LCMS+) of an oligomeric membrane protein: cytochrome b(6)f complex from spinach and the cyanobacterium Mastigocladus laminosus. Mol. Cell. Proteomics MCP. 2002;1:816&#x2013;827.</Citation><ArticleIdList><ArticleId IdType="pubmed">12438564</ArticleId></ArticleIdList></Reference><Reference><Citation>Arvai A. Adxv - A Program to Display X-ray Diffraction Images. 2015 at&lt; http://www.scripps.edu/tainer/arvai/adxv.html&gt;.</Citation></Reference><Reference><Citation>Rao JN, Jao CC, Hegde BG, Langen R, Ulmer TS. A combinatorial NMR and EPR approach for evaluating the structural ensemble of partially folded proteins. J. Am. Chem. Soc. 2010;132:8657&#x2013;8668.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2903201</ArticleId><ArticleId IdType="pubmed">20524659</ArticleId></ArticleIdList></Reference><Reference><Citation>Brunger AT. Version 1.2 of the Crystallography and NMR system. Nat. Protoc. 2007;2:2728&#x2013;2733.</Citation><ArticleIdList><ArticleId IdType="pubmed">18007608</ArticleId></ArticleIdList></Reference><Reference><Citation>Fabiola F, Bertram R, Korostelev A, Chapman MS. An improved hydrogen bond potential: impact on medium resolution protein structures. Protein Sci. Publ. Protein Soc. 2002;11:1415&#x2013;1423.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2373622</ArticleId><ArticleId IdType="pubmed">12021440</ArticleId></ArticleIdList></Reference><Reference><Citation>Read RJ. Improved Fourier coefficients for maps using phases from partial structures with errors. Acta Crystallogr. A. 1986;42:140&#x2013;149.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">26351699</PMID><DateCompleted><Year>2015</Year><Month>12</Month><Day>21</Day></DateCompleted><DateRevised><Year>2019</Year><Month>01</Month><Day>08</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1091-6490</ISSN><JournalIssue CitedMedium="Internet"><Volume>112</Volume><Issue>38</Issue><PubDate><Year>2015</Year><Month>Sep</Month><Day>22</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>Peptide dimer structure in an A&#x3b2;(1-42) fibril visualized with cryo-EM.</ArticleTitle><Pagination><StartPage>11858</StartPage><EndPage>11863</EndPage><MedlinePgn>11858-63</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1073/pnas.1503455112</ELocationID><Abstract><AbstractText>Alzheimer's disease (AD) is a fatal neurodegenerative disorder in humans and the main cause of dementia in aging societies. The disease is characterized by the aberrant formation of &#x3b2;-amyloid (A&#x3b2;) peptide oligomers and fibrils. These structures may damage the brain and give rise to cerebral amyloid angiopathy, neuronal dysfunction, and cellular toxicity. Although the connection between AD and A&#x3b2; fibrillation is extensively documented, much is still unknown about the formation of these A&#x3b2; aggregates and their structures at the molecular level. Here, we combined electron cryomicroscopy, 3D reconstruction, and integrative structural modeling methods to determine the molecular architecture of a fibril formed by A&#x3b2;(1-42), a particularly pathogenic variant of A&#x3b2; peptide. Our model reveals that the individual layers of the A&#x3b2; fibril are formed by peptide dimers with face-to-face packing. The two peptides forming the dimer possess identical tilde-shaped conformations and interact with each other by packing of their hydrophobic C-terminal &#x3b2;-strands. The peptide C termini are located close to the main fibril axis, where they produce a hydrophobic core and are surrounded by the structurally more flexible and charged segments of the peptide N termini. The observed molecular architecture is compatible with the general chemical properties of A&#x3b2; peptide and provides a structural basis for various biological observations that illuminate the molecular underpinnings of AD. Moreover, the structure provides direct evidence for a steric zipper within a fibril formed by full-length A&#x3b2; peptide.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Schmidt</LastName><ForeName>Matthias</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute for Pharmaceutical Biotechnology, Ulm University, 89081 Ulm, Germany; Rosenstiel Basic Medical Sciences Research Center, Brandeis University, Waltham, MA 02454-9110;</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rohou</LastName><ForeName>Alexis</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Rosenstiel Basic Medical Sciences Research Center, Brandeis University, Waltham, MA 02454-9110; Janelia Research Campus, Howard Hughes Medical Institute, Ashburn, VA 20147;</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lasker</LastName><ForeName>Keren</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Developmental Biology, Stanford University School of Medicine, Stanford, CA 94305;</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yadav</LastName><ForeName>Jay K</ForeName><Initials>JK</Initials><AffiliationInfo><Affiliation>Institute for Pharmaceutical Biotechnology, Ulm University, 89081 Ulm, Germany;</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schiene-Fischer</LastName><ForeName>Cordelia</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Institute for Biochemistry and Biotechnology, Martin Luther University Halle-Wittenberg, 06120 Halle (Saale), Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>F&#xe4;ndrich</LastName><ForeName>Marcus</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute for Pharmaceutical Biotechnology, Ulm University, 89081 Ulm, Germany; marcus.faendrich@uni-ulm.de niko@grigorieff.org.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grigorieff</LastName><ForeName>Nikolaus</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Rosenstiel Basic Medical Sciences Research Center, Brandeis University, Waltham, MA 02454-9110; Janelia Research Campus, Howard Hughes Medical Institute, Ashburn, VA 20147; marcus.faendrich@uni-ulm.de niko@grigorieff.org.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>PDB</DataBankName><AccessionNumberList><AccessionNumber>5AEF</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>P01 GM062580</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>1 P01 GM-62580</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>09</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000682">Amyloid</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007140">Immunoglobulin Fab Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010455">Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C075222">amyloid beta-protein (1-42)</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000595" MajorTopicYN="N">Amino Acid Sequence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000682" MajorTopicYN="N">Amyloid</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000648" MajorTopicYN="Y">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000648" MajorTopicYN="Y">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020285" MajorTopicYN="Y">Cryoelectron Microscopy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018604" MajorTopicYN="N">Epitope Mapping</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007091" MajorTopicYN="N">Image Processing, Computer-Assisted</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007140" MajorTopicYN="N">Immunoglobulin Fab Fragments</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008958" MajorTopicYN="N">Models, Molecular</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008969" MajorTopicYN="N">Molecular Sequence Data</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000648" MajorTopicYN="Y">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010455" MajorTopicYN="N">Peptides</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055503" MajorTopicYN="Y">Protein Multimerization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017433" MajorTopicYN="N">Protein Structure, Secondary</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Frealix</Keyword><Keyword MajorTopicYN="N">cross-&#x3b2;</Keyword><Keyword MajorTopicYN="N">protein aggregation</Keyword><Keyword MajorTopicYN="N">protein folding</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>9</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>9</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>12</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2015</Year><Month>9</Month><Day>8</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26351699</ArticleId><ArticleId IdType="pmc">PMC4586870</ArticleId><ArticleId IdType="doi">10.1073/pnas.1503455112</ArticleId><ArticleId IdType="pii">1503455112</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Walsh DM, Selkoe DJ. A beta oligomers - A decade of discovery. J Neurochem. 2007;101(5):1172&#x2013;1184.</Citation><ArticleIdList><ArticleId IdType="pubmed">17286590</ArticleId></ArticleIdList></Reference><Reference><Citation>Spires-Jones TL, Hyman BT. The intersection of amyloid beta and tau at synapses in Alzheimer&#x2019;s disease. Neuron. 2014;82(4):756&#x2013;771.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4135182</ArticleId><ArticleId IdType="pubmed">24853936</ArticleId></ArticleIdList></Reference><Reference><Citation>Haass C, Selkoe DJ. Soluble protein oligomers in neurodegeneration: Lessons from the Alzheimer&#x2019;s amyloid beta-peptide. Nat Rev Mol Cell Biol. 2007;8(2):101&#x2013;112.</Citation><ArticleIdList><ArticleId IdType="pubmed">17245412</ArticleId></ArticleIdList></Reference><Reference><Citation>Cukalevski R, et al. The A&#x3b2;40 and A&#x3b2;42 peptides self-assemble into separate homomolecular fibrils in binary reactions but cross-react during primary nucleation. Chem Sci. 2015;6(7):4215&#x2013;4233.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5707514</ArticleId><ArticleId IdType="pubmed">29218188</ArticleId></ArticleIdList></Reference><Reference><Citation>Finder VH, Glockshuber R. Amyloid-beta aggregation. Neurodegener Dis. 2007;4(1):13&#x2013;27.</Citation><ArticleIdList><ArticleId IdType="pubmed">17429215</ArticleId></ArticleIdList></Reference><Reference><Citation>Fradinger EA, et al. C-terminal peptides coassemble into Abeta42 oligomers and protect neurons against Abeta42-induced neurotoxicity. Proc Natl Acad Sci USA. 2008;105(37):14175&#x2013;14180.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2544597</ArticleId><ArticleId IdType="pubmed">18779585</ArticleId></ArticleIdList></Reference><Reference><Citation>H&#xe4;rd T, Lendel C. Inhibition of amyloid formation. J Mol Biol. 2012;421(4-5):441&#x2013;465.</Citation><ArticleIdList><ArticleId IdType="pubmed">22244855</ArticleId></ArticleIdList></Reference><Reference><Citation>Grigorieff N. Direct detection pays off for electron cryo-microscopy. eLife. 2013;2:e00573.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3576708</ArticleId><ArticleId IdType="pubmed">23426864</ArticleId></ArticleIdList></Reference><Reference><Citation>Jim&#xe9;nez JL, et al. Cryo-electron microscopy structure of an SH3 amyloid fibril and model of the molecular packing. EMBO J. 1999;18(4):815&#x2013;821.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1171174</ArticleId><ArticleId IdType="pubmed">10022824</ArticleId></ArticleIdList></Reference><Reference><Citation>Fitzpatrick AW, et al. Atomic structure and hierarchical assembly of a cross-&#x3b2; amyloid fibril. Proc Natl Acad Sci USA. 2013;110(14):5468&#x2013;5473.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3619355</ArticleId><ArticleId IdType="pubmed">23513222</ArticleId></ArticleIdList></Reference><Reference><Citation>White HE, et al. Globular tetramers of beta(2)-microglobulin assemble into elaborate amyloid fibrils. J Mol Biol. 2009;389(1):48&#x2013;57.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2726924</ArticleId><ArticleId IdType="pubmed">19345691</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt M, et al. Comparison of Alzheimer Abeta(1-40) and Abeta(1-42) amyloid fibrils reveals similar protofilament structures. Proc Natl Acad Sci USA. 2009;106(47):19813&#x2013;19818.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2764733</ArticleId><ArticleId IdType="pubmed">19843697</ArticleId></ArticleIdList></Reference><Reference><Citation>Sachse C, F&#xe4;ndrich M, Grigorieff N. Paired beta-sheet structure of an Abeta(1-40) amyloid fibril revealed by electron microscopy. Proc Natl Acad Sci USA. 2008;105(21):7462&#x2013;7466.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2396686</ArticleId><ArticleId IdType="pubmed">18483195</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang R, et al. Interprotofilament interactions between Alzheimer&#x2019;s Abeta1-42 peptides in amyloid fibrils revealed by cryoEM. Proc Natl Acad Sci USA. 2009;106(12):4653&#x2013;4658.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2660777</ArticleId><ArticleId IdType="pubmed">19264960</ArticleId></ArticleIdList></Reference><Reference><Citation>F&#xe4;ndrich M, Schmidt M, Grigorieff N. Recent progress in understanding Alzheimer&#x2019;s &#x3b2;-amyloid structures. Trends Biochem Sci. 2011;36(6):338&#x2013;345.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3144754</ArticleId><ArticleId IdType="pubmed">21411326</ArticleId></ArticleIdList></Reference><Reference><Citation>Rohou A, Grigorieff N. Frealix: Model-based refinement of helical filament structures from electron micrographs. J Struct Biol. 2014;186(2):234&#x2013;244.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4067737</ArticleId><ArticleId IdType="pubmed">24657230</ArticleId></ArticleIdList></Reference><Reference><Citation>Miles LA, et al. Amyloid-beta-anti-amyloid-beta complex structure reveals an extended conformation in the immunodominant B-cell epitope. J Mol Biol. 2008;377(1):181&#x2013;192.</Citation><ArticleIdList><ArticleId IdType="pubmed">18237744</ArticleId></ArticleIdList></Reference><Reference><Citation>L&#xfc;hrs T, et al. 3D structure of Alzheimer&#x2019;s amyloid-beta(1-42) fibrils. Proc Natl Acad Sci USA. 2005;102(48):17342&#x2013;17347.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1297669</ArticleId><ArticleId IdType="pubmed">16293696</ArticleId></ArticleIdList></Reference><Reference><Citation>Sawaya MR, et al. Atomic structures of amyloid cross-beta spines reveal varied steric zippers. Nature. 2007;447(7143):453&#x2013;457.</Citation><ArticleIdList><ArticleId IdType="pubmed">17468747</ArticleId></ArticleIdList></Reference><Reference><Citation>Colletier JP, et al. Molecular basis for amyloid-beta polymorphism. Proc Natl Acad Sci USA. 2011;108(41):16938&#x2013;16943.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3193189</ArticleId><ArticleId IdType="pubmed">21949245</ArticleId></ArticleIdList></Reference><Reference><Citation>Roychaudhuri R, et al. C-terminal turn stability determines assembly differences between A&#x3b2;40 and A&#x3b2;42. J Mol Biol. 2013;425(2):292&#x2013;308.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3540122</ArticleId><ArticleId IdType="pubmed">23154165</ArticleId></ArticleIdList></Reference><Reference><Citation>Tycko R. Solid-state NMR studies of amyloid fibril structure. Annu Rev Phys Chem. 2011;62:279&#x2013;299.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3191906</ArticleId><ArticleId IdType="pubmed">21219138</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez del Amo JM, et al. An asymmetric dimer as the basic subunit in Alzheimer&#x2019;s disease amyloid &#x3b2; fibrils. Angew Chem Int Ed Engl. 2012;51(25):6136&#x2013;6139.</Citation><ArticleIdList><ArticleId IdType="pubmed">22565601</ArticleId></ArticleIdList></Reference><Reference><Citation>Schutz AK, et al. Atomic-resolution three-dimensional structure of amyloid &#x3b2; fibrils bearing the Osaka mutation. Angew Chem Int Ed Engl. 2015;54(1):331&#x2013;335.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4502972</ArticleId><ArticleId IdType="pubmed">25395337</ArticleId></ArticleIdList></Reference><Reference><Citation>Kheterpal I, Williams A, Murphy C, Bledsoe B, Wetzel R. Structural features of the Abeta amyloid fibril elucidated by limited proteolysis. Biochemistry. 2001;40(39):11757&#x2013;11767.</Citation><ArticleIdList><ArticleId IdType="pubmed">11570876</ArticleId></ArticleIdList></Reference><Reference><Citation>T&#xf6;r&#xf6;k M, et al. Structural and dynamic features of Alzheimer&#x2019;s Abeta peptide in amyloid fibrils studied by site-directed spin labeling. J Biol Chem. 2002;277(43):40810&#x2013;40815.</Citation><ArticleIdList><ArticleId IdType="pubmed">12181315</ArticleId></ArticleIdList></Reference><Reference><Citation>Garzon-Rodriguez W, Sepulveda-Becerra M, Milton S, Glabe CG. Soluble amyloid Abeta-(1-40) exists as a stable dimer at low concentrations. J Biol Chem. 1997;272(34):21037&#x2013;21044.</Citation><ArticleIdList><ArticleId IdType="pubmed">9261105</ArticleId></ArticleIdList></Reference><Reference><Citation>Sachse C, et al. High-resolution electron microscopy of helical specimens: A fresh look at tobacco mosaic virus. J Mol Biol. 2007;371(3):812&#x2013;835.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2025690</ArticleId><ArticleId IdType="pubmed">17585939</ArticleId></ArticleIdList></Reference><Reference><Citation>Ludtke SJ, Baldwin PR, Chiu W. EMAN: Semiautomated software for high-resolution single-particle reconstructions. J Struct Biol. 1999;128(1):82&#x2013;97.</Citation><ArticleIdList><ArticleId IdType="pubmed">10600563</ArticleId></ArticleIdList></Reference><Reference><Citation>Mindell JA, Grigorieff N. Accurate determination of local defocus and specimen tilt in electron microscopy. J Struct Biol. 2003;142(3):334&#x2013;347.</Citation><ArticleIdList><ArticleId IdType="pubmed">12781660</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenthal PB, Henderson R. Optimal determination of particle orientation, absolute hand, and contrast loss in single-particle electron cryomicroscopy. J Mol Biol. 2003;333(4):721&#x2013;745.</Citation><ArticleIdList><ArticleId IdType="pubmed">14568533</ArticleId></ArticleIdList></Reference><Reference><Citation>Pettersen EF, et al. UCSF Chimera--A visualization system for exploratory research and analysis. J Comput Chem. 2004;25(13):1605&#x2013;1612.</Citation><ArticleIdList><ArticleId IdType="pubmed">15264254</ArticleId></ArticleIdList></Reference><Reference><Citation>Rotkiewicz P, Skolnick J. Fast procedure for reconstruction of full-atom protein models from reduced representations. J Comput Chem. 2008;29(9):1460&#x2013;1465.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2692024</ArticleId><ArticleId IdType="pubmed">18196502</ArticleId></ArticleIdList></Reference><Reference><Citation>Schr&#xf6;der GF, Brunger AT, Levitt M. Combining efficient conformational sampling with a deformable elastic network model facilitates structure refinement at low resolution. Structure. 2007;15(12):1630&#x2013;1641.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2213367</ArticleId><ArticleId IdType="pubmed">18073112</ArticleId></ArticleIdList></Reference><Reference><Citation>Bekker H, Berendsen HJC, Vangunsteren WF. Force and virial of torsional-angle-dependent potentials. J Comput Chem. 1995;16(5):527&#x2013;533.</Citation></Reference><Reference><Citation>Chen VB, et al. MolProbity: All-atom structure validation for macromolecular crystallography. Acta Crystallogr D Biol Crystallogr. 2010;66(Pt 1):12&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2803126</ArticleId><ArticleId IdType="pubmed">20057044</ArticleId></ArticleIdList></Reference><Reference><Citation>Berendsen HJC, Vanderspoel D, Vandrunen R. GROMACS: A message-passing parallel molecular dynamics implementation. Comput Phys Commun. 1995;91(1-3):43&#x2013;56.</Citation></Reference><Reference><Citation>Duan Y, et al. A point-charge force field for molecular mechanics simulations of proteins based on condensed-phase quantum mechanical calculations. J Comput Chem. 2003;24(16):1999&#x2013;2012.</Citation><ArticleIdList><ArticleId IdType="pubmed">14531054</ArticleId></ArticleIdList></Reference><Reference><Citation>Frank J, et al. SPIDER and WEB: Processing and visualization of images in 3D electron microscopy and related fields. J Struct Biol. 1996;116(1):190&#x2013;199.</Citation><ArticleIdList><ArticleId IdType="pubmed">8742743</ArticleId></ArticleIdList></Reference><Reference><Citation>Word JM, Lovell SC, Richardson JS, Richardson DC. Asparagine and glutamine: Using hydrogen atom contacts in the choice of side-chain amide orientation. J Mol Biol. 1999;285(4):1735&#x2013;1747.</Citation><ArticleIdList><ArticleId IdType="pubmed">9917408</ArticleId></ArticleIdList></Reference><Reference><Citation>Jahn TR, et al. The common architecture of cross-beta amyloid. J Mol Biol. 2010;395(4):717&#x2013;727.</Citation><ArticleIdList><ArticleId IdType="pubmed">19781557</ArticleId></ArticleIdList></Reference><Reference><Citation> ZipperDB. Available at  services.mbi.ucla.edu/zipperdb/intro. Accessed November 5th, 2013.</Citation></Reference><Reference><Citation>Goldschmidt L, Teng PK, Riek R, Eisenberg D. Identifying the amylome, proteins capable of forming amyloid-like fibrils. Proc Natl Acad Sci USA. 2010;107(8):3487&#x2013;3492.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2840437</ArticleId><ArticleId IdType="pubmed">20133726</ArticleId></ArticleIdList></Reference><Reference><Citation>Harper JD, Lansbury PT., Jr Models of amyloid seeding in Alzheimer&#x2019;s disease and scrapie: Mechanistic truths and physiological consequences of the time-dependent solubility of amyloid proteins. Annu Rev Biochem. 1997;66:385&#x2013;407.</Citation><ArticleIdList><ArticleId IdType="pubmed">9242912</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirkitadze MD, Condron MM, Teplow DB. Identification and characterization of key kinetic intermediates in amyloid beta-protein fibrillogenesis. J Mol Biol. 2001;312(5):1103&#x2013;1119.</Citation><ArticleIdList><ArticleId IdType="pubmed">11580253</ArticleId></ArticleIdList></Reference><Reference><Citation>Nilsberth C, et al. The &#x2018;Arctic&#x2019; APP mutation (E693G) causes Alzheimer&#x2019;s disease by enhanced Abeta protofibril formation. Nat Neurosci. 2001;4(9):887&#x2013;893.</Citation><ArticleIdList><ArticleId IdType="pubmed">11528419</ArticleId></ArticleIdList></Reference><Reference><Citation>Murakami K, et al. Neurotoxicity and physicochemical properties of Abeta mutant peptides from cerebral amyloid angiopathy: Implication for the pathogenesis of cerebral amyloid angiopathy and Alzheimer&#x2019;s disease. J Biol Chem. 2003;278(46):46179&#x2013;46187.</Citation><ArticleIdList><ArticleId IdType="pubmed">12944403</ArticleId></ArticleIdList></Reference><Reference><Citation>Perchiacca JM, Ladiwala AR, Bhattacharya M, Tessier PM. Structure-based design of conformation- and sequence-specific antibodies against amyloid &#x3b2;. Proc Natl Acad Sci USA. 2012;109(1):84&#x2013;89.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3252897</ArticleId><ArticleId IdType="pubmed">22171009</ArticleId></ArticleIdList></Reference><Reference><Citation>Shankar GM, et al. Amyloid-beta protein dimers isolated directly from Alzheimer&#x2019;s brains impair synaptic plasticity and memory. Nat Med. 2008;14(8):837&#x2013;842.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2772133</ArticleId><ArticleId IdType="pubmed">18568035</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">8624133</PMID><DateCompleted><Year>1996</Year><Month>06</Month><Day>14</Day></DateCompleted><DateRevised><Year>2019</Year><Month>06</Month><Day>16</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0077-8923</ISSN><JournalIssue CitedMedium="Print"><Volume>777</Volume><PubDate><Year>1996</Year><Month>Jan</Month><Day>17</Day></PubDate></JournalIssue><Title>Annals of the New York Academy of Sciences</Title><ISOAbbreviation>Ann N Y Acad Sci</ISOAbbreviation></Journal><ArticleTitle>Structure, microtubule interactions, and phosphorylation of tau protein.</ArticleTitle><Pagination><StartPage>96</StartPage><EndPage>106</EndPage><MedlinePgn>96-106</MedlinePgn></Pagination><Abstract><AbstractText>This paper summarizes recent structural and functional studies on tau protein, its interactions with microtubules, its self-assembly into paired helical filaments (PHF)-like fibers, and its modification by phosphorylation. The structure of tau in solution resembles that of a random coil. Both tau and Alzheimer PHFs have very little secondary structure, making it improbable that the assembly of tau into PHFs is based on interacting beta sheets. Tau's binding to microtubules can be described by a "jaws" effect. The domain containing the repeats binds very weakly, while the flanking regions (jaws) bind strongly, even without the repeats. However, only the combination of flanking regions and repeats makes binding productive in terms of microtubule nucleation and assembly. Although the majority of Alzheimer-like phosphorylation sites are outside the repeats they have only a weak influence on binding, whereas the phosphorylation at Ser262 inside the repeats inhibits binding and makes microtubules dynamically unstable. This site can be phosphorylated by kinases present in brain tissue, and it is uniquely phosphorylated in Alzheimer brain.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mandelkow</LastName><ForeName>E M</ForeName><Initials>EM</Initials><AffiliationInfo><Affiliation>Max-Planck-Unit for Structural Molecular Biology, Hamburg, Germany. mand@mpasmb.desy.de</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schweers</LastName><ForeName>O</ForeName><Initials>O</Initials></Author><Author ValidYN="Y"><LastName>Drewes</LastName><ForeName>G</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Biernat</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Gustke</LastName><ForeName>N</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Trinczek</LastName><ForeName>B</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Mandelkow</LastName><ForeName>E</ForeName><Initials>E</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Ann N Y Acad Sci</MedlineTA><NlmUniqueID>7506858</NlmUniqueID><ISSNLinking>0077-8923</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D008870" MajorTopicYN="N">Microtubules</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008968" MajorTopicYN="N">Molecular Conformation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012091" MajorTopicYN="N">Repetitive Sequences, Nucleic Acid</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>51</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1996</Year><Month>1</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1996</Year><Month>1</Month><Day>17</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1996</Year><Month>1</Month><Day>17</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">8624133</ArticleId><ArticleId IdType="doi">10.1111/j.1749-6632.1996.tb34407.x</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">26366630</PMID><DateCompleted><Year>2016</Year><Month>03</Month><Day>11</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>30</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-6157</ISSN><JournalIssue CitedMedium="Internet"><Volume>72</Volume><Issue>11</Issue><PubDate><Year>2015</Year><Month>Nov</Month></PubDate></JournalIssue><Title>JAMA neurology</Title><ISOAbbreviation>JAMA Neurol</ISOAbbreviation></Journal><ArticleTitle>Neurogranin as a Cerebrospinal Fluid Biomarker for Synaptic Loss in Symptomatic Alzheimer Disease.</ArticleTitle><Pagination><StartPage>1275</StartPage><EndPage>1280</EndPage><MedlinePgn>1275-80</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamaneurol.2015.1867</ELocationID><Abstract><AbstractText Label="IMPORTANCE" NlmCategory="OBJECTIVE">Neurogranin (NGRN) seems to be a promising novel cerebrospinal fluid (CSF) biomarker for synaptic loss; however, clinical, and especially longitudinal, data are sparse.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To examine the utility of NGRN, with repeated CSF sampling, for diagnosis, prognosis, and monitoring of Alzheimer disease (AD).</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS" NlmCategory="METHODS">Longitudinal study of consecutive patients who underwent 2 lumbar punctures between the beginning of 1995 and the end of 2010 within the memory clinic-based Amsterdam Dementia Cohort. The study included 163 patients: 37 cognitively normal participants (mean [SE] age, 64 [2] years; 38% female; and mean [SE] Mini-Mental State Examination [MMSE] score, 28 [0.3]), 61 patients with mild cognitive impairment (MCI) (mean [SE] age, 68 [1] years; 38% female; and mean [SE] MMSE score, 27 [0.3]), and 65 patients with AD (mean [SE] age, 65 [1] years; 45% female; and mean [SE] MMSE score, 22 [0.7]). The mean (SE) interval between lumbar punctures was 2.0 (0.1) years, and the mean (SE) duration of cognitive follow-up was 3.8 (0.2) years. Measurements of CSF NGRN levels were obtained in January and February 2014.</AbstractText><AbstractText Label="MAIN OUTCOME AND MEASURE" NlmCategory="METHODS">Levels of NGRN in CSF samples.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Baseline CSF levels of NGRN in patients with AD (median level, 2381 pg/mL [interquartile range, 1651-3416 pg/mL]) were higher than in cognitively normal participants (median level, 1712 pg/mL [interquartile range, 1206-2724 pg/mL]) (P&#x2009;=&#x2009;.04). Baseline NGRN levels were highly correlated with total tau and tau phosphorylated at threonine 181 in all patient groups (all P&#x2009;&lt;&#x2009;.001), but not with A&#x3b2;42. Baseline CSF levels of NGRN were also higher in patients with MCI who progressed to AD (median level, 2842 pg/mL [interquartile range, 1882-3950 pg/mL]) compared with those with stable MCI (median level, 1752 pg/mL [interquartile range, 1024-2438 pg/mL]) (P&#x2009;=&#x2009;.004), and they were predictive of progression from MCI to AD (hazard ratio, 1.8 [95% CI, 1.1-2.9]; stratified by tertiles). Linear mixed-model analyses demonstrated that within-person levels of NGRN increased over time in cognitively normal participants (mean [SE] level, 90 [45] pg/mL per year; P&#x2009;&lt;&#x2009;.05) but not in patients with MCI or AD.</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE" NlmCategory="CONCLUSIONS">Neurogranin is a promising biomarker for AD because levels were elevated in patients with AD compared with cognitively normal participants and predicted progression from MCI to AD. Within-person levels of NGRN increased in cognitively normal participants but not in patients with later stage MCI or AD, which suggests that NGRN may reflect presymptomatic synaptic dysfunction or loss.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kester</LastName><ForeName>Maartje I</ForeName><Initials>MI</Initials><AffiliationInfo><Affiliation>Alzheimer Center and Department of Neurology, VU University Medical Center, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Teunissen</LastName><ForeName>Charlotte E</ForeName><Initials>CE</Initials><AffiliationInfo><Affiliation>Department of Clinical Chemistry, VU University Medical Center, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Crimmins</LastName><ForeName>Daniel L</ForeName><Initials>DL</Initials><AffiliationInfo><Affiliation>Department of Pathology and Immunology, Washington University School of Medicine, St Louis, Missouri.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Herries</LastName><ForeName>Elizabeth M</ForeName><Initials>EM</Initials><AffiliationInfo><Affiliation>Department of Pathology and Immunology, Washington University School of Medicine, St Louis, Missouri.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ladenson</LastName><ForeName>Jack H</ForeName><Initials>JH</Initials><AffiliationInfo><Affiliation>Department of Pathology and Immunology, Washington University School of Medicine, St Louis, Missouri.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scheltens</LastName><ForeName>Philip</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Alzheimer Center and Department of Neurology, VU University Medical Center, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van der Flier</LastName><ForeName>Wiesje M</ForeName><Initials>WM</Initials><AffiliationInfo><Affiliation>Alzheimer Center and Department of Neurology, VU University Medical Center, Amsterdam, the Netherlands4Department of Epidemiology and Biostatistics, VU University Medical Center, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morris</LastName><ForeName>John C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>The Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St Louis, Missouri6Department of Neurology, Washington University School of Medicine, St Louis, Missouri7Hope Center for Neurological Disorders, Washington Universit.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Holtzman</LastName><ForeName>David M</ForeName><Initials>DM</Initials><AffiliationInfo><Affiliation>The Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St Louis, Missouri6Department of Neurology, Washington University School of Medicine, St Louis, Missouri7Hope Center for Neurological Disorders, Washington Universit.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fagan</LastName><ForeName>Anne M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>The Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St Louis, Missouri6Department of Neurology, Washington University School of Medicine, St Louis, Missouri7Hope Center for Neurological Disorders, Washington Universit.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P01 AG026276</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Neurol</MedlineTA><NlmUniqueID>101589536</NlmUniqueID><ISSNLinking>2168-6149</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>132654-77-4</RegistryNumber><NameOfSubstance UI="D051579">Neurogranin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>JAMA Neurol. 2015 Nov;72(11):1237-8. doi: 10.1001/jamaneurol.2015.2075.</RefSource><PMID Version="1">26368650</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Neurol. 2015 Nov;11(11):609. doi: 10.1038/nrneurol.2015.178.</RefSource><PMID Version="1">26416540</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D060825" MajorTopicYN="N">Cognitive Dysfunction</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="Y">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051579" MajorTopicYN="N">Neurogranin</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013569" MajorTopicYN="N">Synapses</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>9</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>9</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>3</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2015</Year><Month>12</Month><Day>29</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26366630</ArticleId><ArticleId IdType="mid">NIHMS742417</ArticleId><ArticleId IdType="pmc">PMC4694558</ArticleId><ArticleId IdType="doi">10.1001/jamaneurol.2015.1867</ArticleId><ArticleId IdType="pii">2436595</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Blennow K, Hampel H. CSF markers for incipient Alzheimer's disease. Lancet Neurol. 2003;2(10):605&#x2013;613.</Citation><ArticleIdList><ArticleId IdType="pubmed">14505582</ArticleId></ArticleIdList></Reference><Reference><Citation>Kester MI, Scheffer PG, Koel-Simmelink MJ, et al. Serial CSF sampling in Alzheimer's disease: specific versus non-specific markers. Neurobiol Aging. 2012;33(8):1591&#x2013;1598.</Citation><ArticleIdList><ArticleId IdType="pubmed">21741127</ArticleId></ArticleIdList></Reference><Reference><Citation>Perrin RJ, Fagan AM, Holtzman DM. Multimodal techniques for diagnosis and prognosis of Alzheimer's disease. Nature. 2009;461(7266):916&#x2013;922.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2810658</ArticleId><ArticleId IdType="pubmed">19829371</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou B, Teramukai S, Yoshimura K, Fukushima M. Validity of cerebrospinal fluid biomarkers as endpoints in early-phase clinical trials for Alzheimer's disease. J Alzheimers Dis. 2009;18(1):89&#x2013;102.</Citation><ArticleIdList><ArticleId IdType="pubmed">19542628</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheff SW, Price DA, Schmitt FA, Mufson EJ. Hippocampal synaptic loss in early Alzheimer's disease and mild cognitive impairment. Neurobiol Aging. 2006;27(10):1372&#x2013;1384.</Citation><ArticleIdList><ArticleId IdType="pubmed">16289476</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheff SW, Price DA, Schmitt FA, DeKosky ST, Mufson EJ. Synaptic alterations in CA1 in mild Alzheimer disease and mild cognitive impairment. Neurology. 2007;68(18):1501&#x2013;1508.</Citation><ArticleIdList><ArticleId IdType="pubmed">17470753</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang JW, Schumacher E, Coulter PM, II, Vinters HV, Watson JB. Dendritic translocation of RC3/neurogranin mRNA in normal aging, Alzheimer disease and fronto-temporal dementia. J Neuropathol Exp Neurol. 1997;56(10):1105&#x2013;1118.</Citation><ArticleIdList><ArticleId IdType="pubmed">9329454</ArticleId></ArticleIdList></Reference><Reference><Citation>Slemmon JR, Feng B, Erhardt JA. Small proteins that modulate calmodulin-dependent signal transduction: effects of PEP-19, neuromodulin, and neurogranin on enzyme activation and cellular homeostasis. Mol Neurobiol. 2000;22(1-3):99&#x2013;113.</Citation><ArticleIdList><ArticleId IdType="pubmed">11414283</ArticleId></ArticleIdList></Reference><Reference><Citation>Davidsson P, Blennow K. Neurochemical dissection of synaptic pathology in Alzheimer's disease. Int Psychogeriatr. 1998;10(1):11&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pubmed">9629521</ArticleId></ArticleIdList></Reference><Reference><Citation>Reddy PH, Mani G, Park BS, et al. Differential loss of synaptic proteins in Alzheimer's disease: implications for synaptic dysfunction. J Alzheimers Dis. 2005;7(2):103&#x2013;117.</Citation><ArticleIdList><ArticleId IdType="pubmed">15851848</ArticleId></ArticleIdList></Reference><Reference><Citation>Thorsell A, Bjerke M, Gobom J, et al. Neurogranin in cerebrospinal fluid as a marker of synaptic degeneration in Alzheimer's disease. Brain Res. 2010;1362:13&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pubmed">20875798</ArticleId></ArticleIdList></Reference><Reference><Citation>Kvartsberg H, Duits FH, Ingelsson M, et al. Cerebrospinal fluid levels of the synaptic protein neurogranin correlates with cognitive decline in prodromal Alzheimer's disease [published online December 19, 2014]. Alzheimers Dement. doi:10.1016/j.jalz.2014.10.009.</Citation><ArticleIdList><ArticleId IdType="pubmed">25533203</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34(7):939&#x2013;944.</Citation><ArticleIdList><ArticleId IdType="pubmed">6610841</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol. 1999;56(3):303&#x2013;308.</Citation><ArticleIdList><ArticleId IdType="pubmed">10190820</ArticleId></ArticleIdList></Reference><Reference><Citation>Neary D, Snowden JS, Gustafson L, et al. Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology. 1998;51(6):1546&#x2013;1554.</Citation><ArticleIdList><ArticleId IdType="pubmed">9855500</ArticleId></ArticleIdList></Reference><Reference><Citation>Rom&#xe1;n GC, Tatemichi TK, Erkinjuntti T, et al. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology. 1993;43(2):250&#x2013;260.</Citation><ArticleIdList><ArticleId IdType="pubmed">8094895</ArticleId></ArticleIdList></Reference><Reference><Citation>McKeith IG, Dickson DW, Lowe J, et al. Consortium on DLB Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology. 2005;65(12):1863&#x2013;1872.</Citation><ArticleIdList><ArticleId IdType="pubmed">16237129</ArticleId></ArticleIdList></Reference><Reference><Citation>Bouwman FH, Schoonenboom NS, Verwey NA, et al. CSF biomarker levels in early and late onset Alzheimer's disease. Neurobiol Aging. 2009;30(12):1895&#x2013;1901.</Citation><ArticleIdList><ArticleId IdType="pubmed">18403055</ArticleId></ArticleIdList></Reference><Reference><Citation>Bouwman FH, van der Flier WM, Schoonenboom NS, et al. Usefulness of longitudinal measurements of &#x3b2;-amyloid1-42 in cerebrospinal fluid of patients with various cognitive and neurologic disorders. Clin Chem. 2006;52(8):1604&#x2013;1606.</Citation><ArticleIdList><ArticleId IdType="pubmed">16873300</ArticleId></ArticleIdList></Reference><Reference><Citation>Verwey NA, Bouwman FH, van der Flier WM, Veerhuis R, Scheltens P, Blankenstein MA. Variability in longitudinal cerebrospinal fluid tau and phosphorylated tau measurements. Clin Chem Lab Med. 2008;46(9):1300&#x2013;1304.</Citation><ArticleIdList><ArticleId IdType="pubmed">18601592</ArticleId></ArticleIdList></Reference><Reference><Citation>Twisk JW. Applied Longitudinal Data Analysis for Epidemiology. Cambridge University Press; Cambridge, England: 2003.</Citation></Reference><Reference><Citation>George AJ, Gordon L, Beissbarth T, et al. A serial analysis of gene expression profile of the Alzheimer's disease Tg2576 mouse model. Neurotox Res. 2010;17(4):360&#x2013;379.</Citation><ArticleIdList><ArticleId IdType="pubmed">19760337</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheff SW, Price DA, Ansari MA, et al. Synaptic change in the posterior cingulate gyrus in the progression of Alzheimer's disease. J Alzheimers Dis. 2015;43(3):1073&#x2013;1090.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4313125</ArticleId><ArticleId IdType="pubmed">25147118</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr, Knopman DS, Jagust WJ, et al. Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 2013;12(2):207&#x2013;216.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3622225</ArticleId><ArticleId IdType="pubmed">23332364</ArticleId></ArticleIdList></Reference><Reference><Citation>Koob AO, Shaked GM, Bender A, Bisquertt A, Rockenstein E, Masliah E. Neurogranin binds &#x3b1;-synuclein in the human superior temporal cortex and interaction is decreased in Parkinson's disease. Brain Res. 2014;1591:102&#x2013;110.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4943923</ArticleId><ArticleId IdType="pubmed">25446004</ArticleId></ArticleIdList></Reference><Reference><Citation>Ingelsson M, Fukumoto H, Newell KL, et al. Early A&#x3b2; accumulation and progressive synaptic loss, gliosis, and tangle formation in AD brain. Neurology. 2004;62(6):925&#x2013;931.</Citation><ArticleIdList><ArticleId IdType="pubmed">15037694</ArticleId></ArticleIdList></Reference><Reference><Citation>Blennow K, Bogdanovic N, Alafuzoff I, Ekman R, Davidsson P. Synaptic pathology in Alzheimer's disease: relation to severity of dementia, but not to senile plaques, neurofibrillary tangles, or the ApoE4 allele. J Neural Transm. 1996;103(5):603&#x2013;618.</Citation><ArticleIdList><ArticleId IdType="pubmed">8811505</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82(4):239&#x2013;259.</Citation><ArticleIdList><ArticleId IdType="pubmed">1759558</ArticleId></ArticleIdList></Reference><Reference><Citation>Buerger K, Otto M, Teipel SJ, et al. Dissociation between CSF total tau and tau protein phosphorylated at threonine 231 in Creutzfeldt-Jakob disease. Neurobiol Aging. 2006;27(1):10&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pubmed">16298235</ArticleId></ArticleIdList></Reference><Reference><Citation>Riemenschneider M, Wagenpfeil S, Vanderstichele H, et al. Phospho-tau/total tau ratio in cerebrospinal fluid discriminates Creutzfeldt-Jakob disease from other dementias. Mol Psychiatry. 2003;8(3):343&#x2013;347.</Citation><ArticleIdList><ArticleId IdType="pubmed">12660807</ArticleId></ArticleIdList></Reference><Reference><Citation>Kester MI, van der Vlies AE, Blankenstein MA, et al. CSF biomarkers predict rate of cognitive decline in Alzheimer disease. Neurology. 2009;73(17):1353&#x2013;1358.</Citation><ArticleIdList><ArticleId IdType="pubmed">19858456</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">26491725</PMID><DateRevised><Year>2024</Year><Month>03</Month><Day>24</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">2375-2548</ISSN><JournalIssue CitedMedium="Print"><Volume>1</Volume><Issue>8</Issue><PubDate><Year>2015</Year><Month>Sep</Month><Day>04</Day></PubDate></JournalIssue><Title>Science advances</Title><ISOAbbreviation>Sci Adv</ISOAbbreviation></Journal><ArticleTitle>Autoregulated paracellular clearance of amyloid-&#x3b2; across the blood-brain barrier.</ArticleTitle><Pagination><StartPage>e1500472</StartPage><MedlinePgn>e1500472</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e1500472</ELocationID><Abstract><AbstractText>The blood-brain barrier (BBB) is essential for maintaining brain homeostasis and protecting neural tissue from damaging blood-borne agents. The barrier is characterized by endothelial tight junctions that limit passive paracellular diffusion of polar solutes and macromolecules from blood to brain. Decreased brain clearance of the neurotoxic amyloid-&#x3b2; (A&#x3b2;) peptide is a central event in the pathogenesis of Alzheimer's disease (AD). Whereas transport of A&#x3b2; across the BBB can occur via transcellular endothelial receptors, the paracellular movement of A&#x3b2; has not been described. We show that soluble human A&#x3b2;(1-40) monomers can diffuse across the paracellular pathway of the BBB in tandem with a decrease in the tight junction proteins claudin-5 and occludin in the cerebral vascular endothelium. In a murine model of AD (Tg2576), plasma A&#x3b2;(1-40) levels were significantly increased, brain A&#x3b2;(1-40) levels were decreased, and cognitive function was enhanced when both claudin-5 and occludin were suppressed. Furthermore, A&#x3b2; can cause a transient down-regulation of claudin-5 and occludin, allowing for its own paracellular clearance across the BBB. Our results show, for the first time, the involvement of the paracellular pathway in autoregulated A&#x3b2; movement across the BBB and identify both claudin-5 and occludin as potential therapeutic targets for AD. These findings also indicate that controlled modulation of tight junction components at the BBB can enhance the clearance of A&#x3b2; from the brain.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Keaney</LastName><ForeName>James</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Smurfit Institute of Genetics, Lincoln Place Gate, Trinity College Dublin, Dublin 2, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Walsh</LastName><ForeName>Dominic M</ForeName><Initials>DM</Initials><AffiliationInfo><Affiliation>Laboratory for Neurodegenerative Research, Center for Neurological Diseases, Brigham and Women's Hospital, Harvard Institute of Medicine, 77 Avenue Louis Pasteur, Boston, MA 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>O'Malley</LastName><ForeName>Tiernan</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Laboratory for Neurodegenerative Research, Center for Neurological Diseases, Brigham and Women's Hospital, Harvard Institute of Medicine, 77 Avenue Louis Pasteur, Boston, MA 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hudson</LastName><ForeName>Natalie</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Smurfit Institute of Genetics, Lincoln Place Gate, Trinity College Dublin, Dublin 2, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Crosbie</LastName><ForeName>Darragh E</ForeName><Initials>DE</Initials><AffiliationInfo><Affiliation>Smurfit Institute of Genetics, Lincoln Place Gate, Trinity College Dublin, Dublin 2, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Loftus</LastName><ForeName>Teresa</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Neuropathology, Beaumont Hospital, Dublin 9, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sheehan</LastName><ForeName>Florike</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Neuropathology, Beaumont Hospital, Dublin 9, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McDaid</LastName><ForeName>Jacqueline</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Smurfit Institute of Genetics, Lincoln Place Gate, Trinity College Dublin, Dublin 2, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Humphries</LastName><ForeName>Marian M</ForeName><Initials>MM</Initials><AffiliationInfo><Affiliation>Smurfit Institute of Genetics, Lincoln Place Gate, Trinity College Dublin, Dublin 2, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Callanan</LastName><ForeName>John J</ForeName><Initials>JJ</Initials><AffiliationInfo><Affiliation>UCD School of Veterinary Medicine and Conway Institute of Biomolecular and Biomedical Research, University College Dublin, Belfield, Dublin 4, Ireland. ; Ross University School of Veterinary Medicine, P. O. Box 334, Basseterre, St. Kitts, West Indies.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brett</LastName><ForeName>Francesca M</ForeName><Initials>FM</Initials><AffiliationInfo><Affiliation>Department of Neuropathology, Beaumont Hospital, Dublin 9, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Farrell</LastName><ForeName>Michael A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Department of Neuropathology, Beaumont Hospital, Dublin 9, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Humphries</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Smurfit Institute of Genetics, Lincoln Place Gate, Trinity College Dublin, Dublin 2, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Campbell</LastName><ForeName>Matthew</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Smurfit Institute of Genetics, Lincoln Place Gate, Trinity College Dublin, Dublin 2, Ireland.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG046275</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Sci Adv</MedlineTA><NlmUniqueID>101653440</NlmUniqueID><ISSNLinking>2375-2548</ISSNLinking></MedlineJournalInfo></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>10</Month><Day>23</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>10</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>10</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2015</Year><Month>9</Month><Day>18</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26491725</ArticleId><ArticleId IdType="mid">NIHMS725256</ArticleId><ArticleId IdType="pmc">PMC4610013</ArticleId><ArticleId IdType="doi">10.1126/sciadv.1500472</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Prince M., Bryce R., Albanese E., Wimo A., Ribeiro W., Ferri C. P., The global prevalence of dementia: A systematic review and metaanalysis. Alzheimers Dement. 9, 63&#x2013;75.e2 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23305823</ArticleId></ArticleIdList></Reference><Reference><Citation>Dicksen D. W., The pathogenesis of senile plaques. J. Neuropathol. Exp. Neurol. 56, 321&#x2013;339 (1997).</Citation><ArticleIdList><ArticleId IdType="pubmed">9100663</ArticleId></ArticleIdList></Reference><Reference><Citation>Roher A. E., Palmer K. C., Chau V., Ball M. J., Isolation and chemical characterization of Alzheimer&#x2019;s disease paired helical filament cytoskeletons: Differentiation from amyloid plaque core protein. J. Cell Biol. 107, 2703&#x2013;2716 (1988).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2115630</ArticleId><ArticleId IdType="pubmed">3060472</ArticleId></ArticleIdList></Reference><Reference><Citation>Shankar G. M., Li S., Mehta T. H., Garcia-Munoz A., Shepardson N. E., Smith I., Brett F. M., Farrell M. A., Rowan M. J., Lemere C. A., Regan C. M., Walsh D. M., Sabatini B. L., Selkoe D. J., Amyloid-&#x3b2; protein dimers isolated directly from Alzheimer&#x2019;s brains impair synaptic plasticity and memory. Nat. Med. 14, 837&#x2013;842 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2772133</ArticleId><ArticleId IdType="pubmed">18568035</ArticleId></ArticleIdList></Reference><Reference><Citation>Mawuenyega K. G., Sigurdson W., Ovod V., Munsell L., Kasten T., Morris J. C., Yarasheski K. E., Bateman R. J., Decreased clearance of CNS &#x3b2;-amyloid in Alzheimer&#x2019;s disease. Science 330, 1774 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3073454</ArticleId><ArticleId IdType="pubmed">21148344</ArticleId></ArticleIdList></Reference><Reference><Citation>Sagare A. P., Bell R. D., Zlokovic B. V., Neurovascular defects and faulty amyloid-&#x3b2; vascular clearance in Alzheimer&#x2019;s disease. J. Alzheimers Dis. 33 (Suppl. 1), S87&#x2013;S100 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4416477</ArticleId><ArticleId IdType="pubmed">22751174</ArticleId></ArticleIdList></Reference><Reference><Citation>Auriel E., Greenberg S. M., The pathophysiology and clinical presentation of cerebral amyloid angiopathy. Curr. Atheroscler. Rep. 14, 343&#x2013;350 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22565298</ArticleId></ArticleIdList></Reference><Reference><Citation>Abbott N. J., Patabendige A. A. K., Dolman D. E. M., Yusof S. R., Begley D. J., Structure and function of the blood-brain barrier. Neurobiol. Dis. 37, 13&#x2013;25 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">19664713</ArticleId></ArticleIdList></Reference><Reference><Citation>Obermeier B., Daneman R., Ransohoff R. M., Development, maintenance and disruption of the blood-brain barrier. Nat. Med. 19, 1584&#x2013;1596 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4080800</ArticleId><ArticleId IdType="pubmed">24309662</ArticleId></ArticleIdList></Reference><Reference><Citation>Daneman R., Zhou L., Agalliu D., Cahoy J. D., Kaushal A., Barres B. A., The mouse blood-brain barrier transcriptome: A new resource for understanding the development and function of brain endothelial cells. PLOS One 5, e13741 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2966423</ArticleId><ArticleId IdType="pubmed">21060791</ArticleId></ArticleIdList></Reference><Reference><Citation>Saunders N. R., Daneman R., Dziegielewska K. M., Liddelow S. A., Transporters of the blood&#x2013;brain and blood&#x2013;CSF interfaces in development and in the adult. Mol. Aspects Med. 34, 742&#x2013;752 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23506907</ArticleId></ArticleIdList></Reference><Reference><Citation>Deane R., Yan S. D., Submamaryan R. K., LaRue B., Jovanovic S., Hogg E., Welch D., Manness L., Lin C., Yu J., Zhu H., Ghiso J., Frangione B., Stern A., Schmidt A. M., Armstrong D. L., Arnold B., Liliensiek B., Nawroth P., Hofman F., Kindy M., Stern D., Zlokovic B., RAGE mediates amyloid-&#x3b2; peptide transport across the blood-brain barrier and accumulation in brain. Nat. Med. 9, 907&#x2013;913 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">12808450</ArticleId></ArticleIdList></Reference><Reference><Citation>Deane R., Wu Z., Sagare A., Davis J., Yan S. D., Hamm K., Xu F., Parisi M., LaRue B., Hu H. W., Spijkers P., Guo H., Song X., Lenting P. J., Van Nostrand W. E., Zlokovic B. V., LRP/amyloid &#x3b2;-peptide interaction mediates differential brain efflux of A&#x3b2; isoforms. Neuron 43, 333&#x2013;344 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15294142</ArticleId></ArticleIdList></Reference><Reference><Citation>Carrano A., Hoozemans J. J. M., van der Vies S. M., Rozemuller A. J. M., van Horssen J., de Vries H. E., Amyloid beta induces oxidative stress-mediated blood&#x2013;brain barrier changes in capillary amyloid angiopathy. Antioxid. Redox Signal. 15, 1167&#x2013;1178 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21294650</ArticleId></ArticleIdList></Reference><Reference><Citation>Biron K. E., Dickstein D. L., Gopaul R., Jeffries W. A., Amyloid triggers extensive cerebral angiogenesis causing blood brain barrier permeability and hypervascularity in Alzheimer&#x2019;s disease. PLOS One 6, e23789 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3166122</ArticleId><ArticleId IdType="pubmed">21909359</ArticleId></ArticleIdList></Reference><Reference><Citation>Hartz A. M., Bauer B., Soldner E. L., Wolf A., Boy S., Backhaus R., Mihaljevic I., Bogdahn U., Kl&#xfc;nemann H. H., Schuierer G., Schlachetzki F., Amyloid-&#x3b2; contributes to blood&#x2013;brain barrier leakage in transgenic human amyloid precursor protein mice and in humans with cerebral amyloid angiopathy. Stroke 43, 514&#x2013;523 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5761312</ArticleId><ArticleId IdType="pubmed">22116809</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh D. M., Lomakin A., Benedek G. B., Condron M. M., Teplow D. B., Amyloid &#x3b2;-protein fibrillogenesis: Detection of a protofibrillar intermediate. J. Biol. Chem. 272, 22364&#x2013;22372 (1997).</Citation><ArticleIdList><ArticleId IdType="pubmed">9268388</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Malley T. T., Oktaviani N. A., Zhang D., Lomakin A., O&#x2019;Nuallain B., Linse S., Benedek G. B., Rowan M. J., Mulder F. A. A., Walsh D. M., A&#x3b2; dimers differ from monomers in structural propensity, aggregation paths, and population of synaptotoxic assemblies. Biochem. J. 461, 413&#x2013;426 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24785004</ArticleId></ArticleIdList></Reference><Reference><Citation>Campbell M., Kiang A.-S., Kenna P. F., Kerskens C., Blau C., O&#x2019;Dwyer L., Tivnan A., Kelly J. A., Brankin B., Farrar G.-J., Humphries P., RNAi-mediated reversible opening of the blood-brain barrier. J. Gene Med. 10, 930&#x2013;947 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18509865</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawarabayashi T., Younkin L. H., Saido T. C., Shoji M., Ashe K. H., Younkin S. G., Age-dependent changes in brain, CSF, and plasma amyloid &#x3b2; protein in the Tg2576 transgenic mouse model of Alzheimer&#x2019;s disease. J. Neurosci. 21, 372&#x2013;381 (2001).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6763819</ArticleId><ArticleId IdType="pubmed">11160418</ArticleId></ArticleIdList></Reference><Reference><Citation>Deacon R. M. J., Rawlins J. N. P., T-maze alternation in the rodent. Nat. Protoc. 1, 7&#x2013;12 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">17406205</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldblum D., Kipfer-Kauer A., Sarra G.-M., Wolf S., Frueh B. E., Distribution of amyloid precursor protein and amyloid-&#x3b2; immunoreactivity in DBA/2J glaucomatous mouse retinas. Invest. Ophthalmol. Vis. Sci. 48, 5085&#x2013;5090 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17962460</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanekiyo T., Xu H., Bu G., ApoE and A&#x3b2; in Alzheimer&#x2019;s disease: Accidental encounters or partners? Neuron 81, 740&#x2013;754 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3983361</ArticleId><ArticleId IdType="pubmed">24559670</ArticleId></ArticleIdList></Reference><Reference><Citation>Goate A., Chartier-Harlin M.-C., Mullan M., Brown J., Crawford F., Fidani L., Giuffra L., Haynes A., Irving N., James L., Mant R., Newton P., Rooke K., Roques P., Talbot C., Pericak-Vance M., Roses A., Williamson R., Rossor M., Owen M., Hardy J., Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer&#x2019;s disease. Nature 349, 706&#x2013;707 (1991).</Citation><ArticleIdList><ArticleId IdType="pubmed">1671712</ArticleId></ArticleIdList></Reference><Reference><Citation>Gandy S., Lifelong management of amyloid-beta metabolism to prevent Alzheimer&#x2019;s disease. N. Engl. J. Med. 367, 864&#x2013;865 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6464107</ArticleId><ArticleId IdType="pubmed">22931321</ArticleId></ArticleIdList></Reference><Reference><Citation>Nitta T., Hata M., Gotoh S., Seo Y., Sasaki H., Hashimoto N., Furuse M., Tsukita S., Size-selective loosening of the blood-brain barrier in claudin-5&#x2013;deficient mice. J. Cell Biol. 161, 653&#x2013;660 (2003).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2172943</ArticleId><ArticleId IdType="pubmed">12743111</ArticleId></ArticleIdList></Reference><Reference><Citation>Campbell M., Hanrahan F., Gobbo O. L., Kelly M. E., Kiang A.-S., Humphries M. M., Nguyen A. T. H., Ozaki E., Keaney J., Blau C. W., Kerskens C. M., Cahalan S. D., Callanan J. J., Wallace E., Grant G. A., Doherty C. P., Humphries P., Targeted suppression of claudin-5 decreases cerebral oedema and improves cognitive outcome following traumatic brain injury. Nat. Commun. 3, 849 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22617289</ArticleId></ArticleIdList></Reference><Reference><Citation>Tai L. M., Holloway K. A., Male D. K., Loughlin A. J., Romero I. A., Amyloid-&#x3b2;-induced occludin down-regulation and increased permeability in human brain endothelial cells is mediated by MAPK activation. J. Cell. Mol. Med. 14, 1101&#x2013;1112 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3822747</ArticleId><ArticleId IdType="pubmed">19438816</ArticleId></ArticleIdList></Reference><Reference><Citation>Karran E., Mercken M., De Strooper B., The amyloid cascade hypothesis for Alzheimer&#x2019;s disease: An appraisal for the development of therapeutics. Nat. Rev. Drug Discov. 10, 698&#x2013;712 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21852788</ArticleId></ArticleIdList></Reference><Reference><Citation>Toyn J. H., Ahlijanian M. K., Interpreting Alzheimer&#x2019;s disease clinical trials in light of the effects on amyloid-&#x3b2;. Alzheimers Res. Ther. 6, 14 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4014014</ArticleId><ArticleId IdType="pubmed">25031632</ArticleId></ArticleIdList></Reference><Reference><Citation>McDonald J. M., Cairns N. J., Taylor-Reinwald L., Holtzman D., Walsh D. M., The levels of water-soluble and triton-soluble A&#x3b2; are increased in Alzheimer&#x2019;s disease brain. Brain Res. 1450, 138&#x2013;147 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3319647</ArticleId><ArticleId IdType="pubmed">22440675</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">26377465</PMID><DateCompleted><Year>2016</Year><Month>01</Month><Day>04</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>09</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>35</Volume><Issue>37</Issue><PubDate><Year>2015</Year><Month>Sep</Month><Day>16</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Amyloid &#x3b2; Oligomers Disrupt Blood-CSF Barrier Integrity by Activating Matrix Metalloproteinases.</ArticleTitle><Pagination><StartPage>12766</StartPage><EndPage>12778</EndPage><MedlinePgn>12766-78</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.0006-15.2015</ELocationID><Abstract><AbstractText Label="UNLABELLED">The blood-CSF barrier (BCSFB) consists of a monolayer of choroid plexus epithelial (CPE) cells that maintain CNS homeostasis by producing CSF and restricting the passage of undesirable molecules and pathogens into the brain. Alzheimer's disease is the most common progressive neurodegenerative disorder and is characterized by the presence of amyloid &#x3b2; (A&#x3b2;) plaques and neurofibrillary tangles in the brain. Recent research shows that Alzheimer's disease is associated with morphological changes in CPE cells and compromised production of CSF. Here, we studied the direct effects of A&#x3b2; on the functionality of the BCSFB. Intracerebroventricular injection of A&#x3b2;1-42 oligomers into the cerebral ventricles of mice, a validated Alzheimer's disease model, caused induction of a cascade of detrimental events, including increased inflammatory gene expression in CPE cells and increased levels of proinflammatory cytokines and chemokines in the CSF. It also rapidly affected CPE cell morphology and tight junction protein levels. These changes were associated with loss of BCSFB integrity, as shown by an increase in BCSFB leakage. A&#x3b2;1-42 oligomers also increased matrix metalloproteinase (MMP) gene expression in the CPE and its activity in CSF. Interestingly, BCSFB disruption induced by A&#x3b2;1-42 oligomers did not occur in the presence of a broad-spectrum MMP inhibitor or in MMP3-deficient mice. These data provide evidence that MMPs are essential for the BCSFB leakage induced by A&#x3b2;1-42 oligomers. Our results reveal that Alzheimer's disease-associated soluble A&#x3b2;1-42 oligomers induce BCSFB dysfunction and suggest MMPs as a possible therapeutic target.</AbstractText><AbstractText Label="SIGNIFICANCE STATEMENT" NlmCategory="CONCLUSIONS">No treatments are yet available to cure Alzheimer's disease; however, soluble A&#x3b2; oligomers are believed to play a crucial role in the neuroinflammation that is observed in this disease. Here, we studied the effect of A&#x3b2; oligomers on the often neglected barrier between blood and brain, called the blood-CSF barrier (BCSFB). This BCSFB is formed by the choroid plexus epithelial cells and is important in maintaining brain homeostasis. We observed A&#x3b2; oligomer-induced changes in morphology and loss of BCSFB integrity that might play a role in Alzheimer's disease progression. Strikingly, both inhibition of matrix metalloproteinase (MMP) activity and MMP3 deficiency could protect against the detrimental effects of A&#x3b2; oligomer. Clearly, our results suggest that MMP inhibition might have therapeutic potential.</AbstractText><CopyrightInformation>Copyright &#xa9; 2015 the authors 0270-6474/15/3512767-13$15.00/0.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Brkic</LastName><ForeName>Marjana</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Inflammation Research Center, VIB, B-9052 Ghent, Belgium, Department of Biomedical Molecular Biology, Ghent University, B-9052 Ghent, Belgium, Department of Neurobiology, Institute for Biological Research, University of Belgrade, 11060 Belgrade, Republic of Serbia, and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Balusu</LastName><ForeName>Sriram</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0003-1424-0577</Identifier><AffiliationInfo><Affiliation>Inflammation Research Center, VIB, B-9052 Ghent, Belgium, Department of Biomedical Molecular Biology, Ghent University, B-9052 Ghent, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Van Wonterghem</LastName><ForeName>Elien</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Inflammation Research Center, VIB, B-9052 Ghent, Belgium, Department of Biomedical Molecular Biology, Ghent University, B-9052 Ghent, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gorl&#xe9;</LastName><ForeName>Nina</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Inflammation Research Center, VIB, B-9052 Ghent, Belgium, Department of Biomedical Molecular Biology, Ghent University, B-9052 Ghent, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Benilova</LastName><ForeName>Iryna</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Center for the Biology of Disease, VIB, B-3000 Leuven, Belgium, Center for Human Genetics and Leuven Institute of Neuroscience and Disease, KU Leuven, B-3000 Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kremer</LastName><ForeName>Anna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Inflammation Research Center, VIB, B-9052 Ghent, Belgium, Department of Biomedical Molecular Biology, Ghent University, B-9052 Ghent, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Van Hove</LastName><ForeName>Inge</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Laboratory of Neural Circuit Development and Regeneration, KU Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moons</LastName><ForeName>Lieve</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Laboratory of Neural Circuit Development and Regeneration, KU Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Strooper</LastName><ForeName>Bart</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Center for the Biology of Disease, VIB, B-3000 Leuven, Belgium, Center for Human Genetics and Leuven Institute of Neuroscience and Disease, KU Leuven, B-3000 Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kanazir</LastName><ForeName>Selma</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurobiology, Institute for Biological Research, University of Belgrade, 11060 Belgrade, Republic of Serbia, and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Libert</LastName><ForeName>Claude</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Inflammation Research Center, VIB, B-9052 Ghent, Belgium, Department of Biomedical Molecular Biology, Ghent University, B-9052 Ghent, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vandenbroucke</LastName><ForeName>Roosmarijn E</ForeName><Initials>RE</Initials><Identifier Source="ORCID">0000-0002-8327-620X</Identifier><AffiliationInfo><Affiliation>Inflammation Research Center, VIB, B-9052 Ghent, Belgium, Department of Biomedical Molecular Biology, Ghent University, B-9052 Ghent, Belgium, Roosmarijn.Vandenbroucke@irc.VIB-UGent.be.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001704">Biopolymers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018925">Chemokines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016207">Cytokines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018696">Neuroprotective Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011480">Protease Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C075222">amyloid beta-protein (1-42)</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.24.-</RegistryNumber><NameOfSubstance UI="D020782">Matrix Metalloproteinases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.24.17</RegistryNumber><NameOfSubstance UI="D019278">Matrix Metalloproteinase 3</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.24.17</RegistryNumber><NameOfSubstance UI="C511769">Mmp3 protein, mouse</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001704" MajorTopicYN="N">Biopolymers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001812" MajorTopicYN="N">Blood-Brain Barrier</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002199" MajorTopicYN="N">Capillary Permeability</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D048430" MajorTopicYN="N">Cell Shape</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018925" MajorTopicYN="N">Chemokines</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002831" MajorTopicYN="N">Choroid Plexus</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004789" MajorTopicYN="N">Enzyme Activation</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004847" MajorTopicYN="N">Epithelial Cells</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007276" MajorTopicYN="N">Injections, Intraventricular</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019278" MajorTopicYN="N">Matrix Metalloproteinase 3</DescriptorName><QualifierName UI="Q000172" MajorTopicYN="N">deficiency</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020782" MajorTopicYN="N">Matrix Metalloproteinases</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018696" MajorTopicYN="N">Neuroprotective Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011480" MajorTopicYN="N">Protease Inhibitors</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013047" MajorTopicYN="N">Specific Pathogen-Free Organisms</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019108" MajorTopicYN="N">Tight Junctions</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer's disease</Keyword><Keyword MajorTopicYN="N">amyloid &#x3b2; toxicity</Keyword><Keyword MajorTopicYN="N">blood&#x2013;CSF barrier</Keyword><Keyword MajorTopicYN="N">choroid plexus</Keyword><Keyword MajorTopicYN="N">matrix metalloproteinases</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>9</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>9</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>1</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2016</Year><Month>3</Month><Day>16</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26377465</ArticleId><ArticleId IdType="pmc">PMC6795210</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.0006-15.2015</ArticleId><ArticleId IdType="pii">35/37/12766</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, Cole GM, Cooper NR, Eikelenboom P, Emmerling M, Fiebich BL, Finch CE, Frautschy S, Griffin WS, Hampel H, Hull M, Landreth G, Lue L, Mrak R, Mackenzie IR, McGeer PL, et al. Inflammation and Alzheimer's disease. Neurobiol Aging. 2000;21:383&#x2013;421. doi: 10.1016/S0197-4580(00)00124-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0197-4580(00)00124-X</ArticleId><ArticleId IdType="pmc">PMC3887148</ArticleId><ArticleId IdType="pubmed">10858586</ArticleId></ArticleIdList></Reference><Reference><Citation>Alvira-Botero X, Carro EM. Clearance of amyloid-beta peptide across the choroid plexus in Alzheimer's disease. Curr Aging Sci. 2010;3:219&#x2013;229. doi: 10.2174/1874609811003030219.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1874609811003030219</ArticleId><ArticleId IdType="pubmed">20735345</ArticleId></ArticleIdList></Reference><Reference><Citation>Barichello T, Pereira JS, Savi GD, Generoso JS, Cipriano AL, Silvestre C, Petronilho F, Dal-Pizzol F, Vilela MC, Teixeira AL. A kinetic study of the cytokine/chemokines levels and disruption of blood-brain barrier in infant rats after pneumococcal meningitis. J Neuroimmunol. 2011;233:12&#x2013;17. doi: 10.1016/j.jneuroim.2010.10.035.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jneuroim.2010.10.035</ArticleId><ArticleId IdType="pubmed">21109308</ArticleId></ArticleIdList></Reference><Reference><Citation>Batra A, Latour LL, Ruetzler CA, Hallenbeck JM, Spatz M, Warach S, Henning EC. Increased plasma and tissue MMP levels are associated with BCSFB and BBB disruption evident on post-contrast FLAIR after experimental stroke. J Cereb Blood Flow Metab. 2010;30:1188&#x2013;1199. doi: 10.1038/jcbfm.2010.1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/jcbfm.2010.1</ArticleId><ArticleId IdType="pmc">PMC2879459</ArticleId><ArticleId IdType="pubmed">20197780</ArticleId></ArticleIdList></Reference><Reference><Citation>Biron KE, Dickstein DL, Gopaul R, Jefferies WA. Amyloid triggers extensive cerebral angiogenesis causing blood brain barrier permeability and hypervascularity in Alzheimer's disease. PLoS One. 2011;6:e23789. doi: 10.1371/journal.pone.0023789.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0023789</ArticleId><ArticleId IdType="pmc">PMC3166122</ArticleId><ArticleId IdType="pubmed">21909359</ArticleId></ArticleIdList></Reference><Reference><Citation>Brouillette J, Caillierez R, Zommer N, Alves-Pires C, Benilova I, Blum D, De Strooper B, Bu&#xe9;e L. Neurotoxicity and memory deficits induced by soluble low-molecular-weight amyloid-beta1&#x2013;42 oligomers are revealed in vivo by using a novel animal model. J Neurosci. 2012;32:7852&#x2013;7861. doi: 10.1523/JNEUROSCI.5901-11.2012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.5901-11.2012</ArticleId><ArticleId IdType="pmc">PMC6620963</ArticleId><ArticleId IdType="pubmed">22674261</ArticleId></ArticleIdList></Reference><Reference><Citation>Carrano A, Hoozemans JJ, van der Vies SM, Rozemuller AJ, van Horssen J, de Vries HE. Amyloid Beta induces oxidative stress-mediated blood-brain barrier changes in capillary amyloid angiopathy. Antioxid Redox Signal. 2011;15:1167&#x2013;1178. doi: 10.1089/ars.2011.3895.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/ars.2011.3895</ArticleId><ArticleId IdType="pubmed">21294650</ArticleId></ArticleIdList></Reference><Reference><Citation>Cetin F, Yazihan N, Dincer S, Akbulut G. The effect of intracerebroventricular injection of beta amyloid peptide (1&#x2013;42) on caspase-3 activity, lipid peroxidation, nitric oxide and NOS expression in young adult and aged rat brain. Turk Neurosurg. 2013;23:144&#x2013;150.</Citation><ArticleIdList><ArticleId IdType="pubmed">23546897</ArticleId></ArticleIdList></Reference><Reference><Citation>Chai Q, He WQ, Zhou M, Lu H, Fu ZF. Enhancement of blood-brain barrier permeability and reduction of tight junction protein expression are modulated by chemokines/cytokines induced by rabies virus infection. J Virol. 2014;88:4698&#x2013;4710. doi: 10.1128/JVI.03149-13.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.03149-13</ArticleId><ArticleId IdType="pmc">PMC3993813</ArticleId><ArticleId IdType="pubmed">24522913</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiu PS, Lai SC. Matrix metalloproteinase-9 leads to claudin-5 degradation via the NF-kappaB pathway in BALB/c mice with eosinophilic meningoencephalitis caused by Angiostrongylus cantonensis. PLoS One. 2013;8:e53370. doi: 10.1371/journal.pone.0053370.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0053370</ArticleId><ArticleId IdType="pmc">PMC3591436</ArticleId><ArticleId IdType="pubmed">23505411</ArticleId></ArticleIdList></Reference><Reference><Citation>Coisne C, Engelhardt B. Tight junctions in brain barriers during central nervous system inflammation. Antioxid Redox Signal. 2011;15:1285&#x2013;1303. doi: 10.1089/ars.2011.3929.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/ars.2011.3929</ArticleId><ArticleId IdType="pubmed">21338320</ArticleId></ArticleIdList></Reference><Reference><Citation>Crossgrove JS, Li GJ, Zheng W. The choroid plexus removes beta-amyloid from brain cerebrospinal fluid. Exp Biol Med (Maywood) 2005;230:771&#x2013;776.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3982214</ArticleId><ArticleId IdType="pubmed">16246905</ArticleId></ArticleIdList></Reference><Reference><Citation>Crossgrove JS, Smith EL, Zheng W. Macromolecules involved in production and metabolism of beta-amyloid at the brain barriers. Brain Res. 2007;1138:187&#x2013;195. doi: 10.1016/j.brainres.2006.12.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2006.12.022</ArticleId><ArticleId IdType="pmc">PMC1950938</ArticleId><ArticleId IdType="pubmed">17276414</ArticleId></ArticleIdList></Reference><Reference><Citation>Czerniawski J, Guzowski JF. Acute neuroinflammation impairs context discrimination memory and disrupts pattern separation processes in hippocampus. J Neurosci. 2014;34:12470&#x2013;12480. doi: 10.1523/JNEUROSCI.0542-14.2014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.0542-14.2014</ArticleId><ArticleId IdType="pmc">PMC4160778</ArticleId><ArticleId IdType="pubmed">25209285</ArticleId></ArticleIdList></Reference><Reference><Citation>Deane R, Bell RD, Sagare A, Zlokovic BV. Clearance of amyloid-beta peptide across the blood-brain barrier: implication for therapies in Alzheimer's disease. CNS Neurol Disord Drug Targets. 2009;8:16&#x2013;30. doi: 10.2174/187152709787601867.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/187152709787601867</ArticleId><ArticleId IdType="pmc">PMC2872930</ArticleId><ArticleId IdType="pubmed">19275634</ArticleId></ArticleIdList></Reference><Reference><Citation>Demeestere D, Libert C, Vandenbroucke RE. Clinical implications of leukocyte infiltration at the choroid plexus in (neuro)inflammatory disorders. Drug discovery today. 2015</Citation><ArticleIdList><ArticleId IdType="pubmed">25979470</ArticleId></ArticleIdList></Reference><Reference><Citation>Denk W, Horstmann H. Serial block-face scanning electron microscopy to reconstruct three-dimensional tissue nanostructure. PLoS Biol. 2004;2:e329. doi: 10.1371/journal.pbio.0020329.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pbio.0020329</ArticleId><ArticleId IdType="pmc">PMC524270</ArticleId><ArticleId IdType="pubmed">15514700</ArticleId></ArticleIdList></Reference><Reference><Citation>Emerich DF, Skinner SJ, Borlongan CV, Vasconcellos AV, Thanos CG. The choroid plexus in the rise, fall and repair of the brain. Bioessays. 2005;27:262&#x2013;274. doi: 10.1002/bies.20193.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/bies.20193</ArticleId><ArticleId IdType="pubmed">15714561</ArticleId></ArticleIdList></Reference><Reference><Citation>Engelhart MJ, Geerlings MI, Meijer J, Kiliaan A, Ruitenberg A, van Swieten JC, Stijnen T, Hofman A, Witteman JC, Breteler MM. Inflammatory proteins in plasma and the risk of dementia: the rotterdam study. Arch Neurol. 2004;61:668&#x2013;672. doi: 10.1001/archneur.61.5.668.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneur.61.5.668</ArticleId><ArticleId IdType="pubmed">15148142</ArticleId></ArticleIdList></Reference><Reference><Citation>Erickson MA, Banks WA. Blood-brain barrier dysfunction as a cause and consequence of Alzheimer's disease. J Cereb Blood Flow Metab. 2013;33:1500&#x2013;1513. doi: 10.1038/jcbfm.2013.135.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/jcbfm.2013.135</ArticleId><ArticleId IdType="pmc">PMC3790938</ArticleId><ArticleId IdType="pubmed">23921899</ArticleId></ArticleIdList></Reference><Reference><Citation>Floden AM, Li S, Combs CK. Beta-amyloid-stimulated microglia induce neuron death via synergistic stimulation of tumor necrosis factor alpha and NMDA receptors. J Neurosci. 2005;25:2566&#x2013;2575. doi: 10.1523/JNEUROSCI.4998-04.2005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.4998-04.2005</ArticleId><ArticleId IdType="pmc">PMC6725188</ArticleId><ArticleId IdType="pubmed">15758166</ArticleId></ArticleIdList></Reference><Reference><Citation>Grammas P, Ovase R. Inflammatory factors are elevated in brain microvessels in Alzheimer's disease. Neurobiol Aging. 2001;22:837&#x2013;842. doi: 10.1016/S0197-4580(01)00276-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0197-4580(01)00276-7</ArticleId><ArticleId IdType="pubmed">11754990</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo S, Wang S, Kim WJ, Lee SR, Frosch MP, Bacskai BJ, Greenberg SM, Lo EH. Effects of apoE isoforms on beta-amyloid-induced matrix metalloproteinase-9 in rat astrocytes. Brain Res. 2006;1111:222&#x2013;226. doi: 10.1016/j.brainres.2006.06.041.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2006.06.041</ArticleId><ArticleId IdType="pubmed">16919608</ArticleId></ArticleIdList></Reference><Reference><Citation>Hains BC, Waxman SG. Activated microglia contribute to the maintenance of chronic pain after spinal cord injury. J Neurosci. 2006;26:4308&#x2013;4317. doi: 10.1523/JNEUROSCI.0003-06.2006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.0003-06.2006</ArticleId><ArticleId IdType="pmc">PMC6674010</ArticleId><ArticleId IdType="pubmed">16624951</ArticleId></ArticleIdList></Reference><Reference><Citation>Halliday MR, Pomara N, Sagare AP, Mack WJ, Frangione B, Zlokovic BV. Relationship between cyclophilin a levels and matrix metalloproteinase 9 activity in cerebrospinal fluid of cognitively normal apolipoprotein e4 carriers and blood-brain barrier breakdown. JAMA Neurol. 2013;70:1198&#x2013;1200. doi: 10.1001/jamaneurol.2013.3841.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2013.3841</ArticleId><ArticleId IdType="pmc">PMC4047029</ArticleId><ArticleId IdType="pubmed">24030206</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanzel CE, Iulita MF, Eyjolfsdottir H, Hjorth E, Schultzberg M, Eriksdotter M, Cuello AC. Analysis of matrix metallo-proteases and the plasminogen system in mild cognitive impairment and Alzheimer's disease cerebrospinal fluid. J Alzheimers Dis. 2014;40:667&#x2013;678.</Citation><ArticleIdList><ArticleId IdType="pubmed">24531161</ArticleId></ArticleIdList></Reference><Reference><Citation>Hartz AM, Bauer B, Soldner EL, Wolf A, Boy S, Backhaus R, Mihaljevic I, Bogdahn U, Kl&#xfc;nemann HH, Schuierer G, Schlachetzki F. Amyloid-beta contributes to blood-brain barrier leakage in transgenic human amyloid precursor protein mice and in humans with cerebral amyloid angiopathy. Stroke. 2012;43:514&#x2013;523. doi: 10.1161/STROKEAHA.111.627562.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/STROKEAHA.111.627562</ArticleId><ArticleId IdType="pmc">PMC5761312</ArticleId><ArticleId IdType="pubmed">22116809</ArticleId></ArticleIdList></Reference><Reference><Citation>Horstmann S, Budig L, Gardner H, Koziol J, Deuschle M, Schilling C, Wagner S. Matrix metalloproteinases in peripheral blood and cerebrospinal fluid in patients with Alzheimer's disease. Int Psychogeriatr. 2010;22:966&#x2013;972. doi: 10.1017/S1041610210000827.</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S1041610210000827</ArticleId><ArticleId IdType="pubmed">20561382</ArticleId></ArticleIdList></Reference><Reference><Citation>Johanson CE, Duncan JA, 3rd, Klinge PM, Brinker T, Stopa EG, Silverberg GD. Multiplicity of cerebrospinal fluid functions: New challenges in health and disease. Cerebrospinal Fluid Res. 2008;5:10. doi: 10.1186/1743-8454-5-10.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1743-8454-5-10</ArticleId><ArticleId IdType="pmc">PMC2412840</ArticleId><ArticleId IdType="pubmed">18479516</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnstone M, Gearing AJ, Miller KM. A central role for astrocytes in the inflammatory response to beta-amyloid; chemokines, cytokines and reactive oxygen species are produced. J Neuroimmunol. 1999;93:182&#x2013;193. doi: 10.1016/S0165-5728(98)00226-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0165-5728(98)00226-4</ArticleId><ArticleId IdType="pubmed">10378882</ArticleId></ArticleIdList></Reference><Reference><Citation>Kauwe JS, Bailey MH, Ridge PG, Perry R, Wadsworth ME, Hoyt KL, Staley LA, Karch CM, Harari O, Cruchaga C, Ainscough BJ, Bales K, Pickering EH, Bertelsen S, Bertelsen S, Fagan AM, Holtzman DM, Morris JC, Goate AM. Genome-wide association study of CSF levels of 59 alzheimer's disease candidate proteins: significant associations with proteins involved in amyloid processing and inflammation. PLoS Genet. 2014;10:e1004758. doi: 10.1371/journal.pgen.1004758.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pgen.1004758</ArticleId><ArticleId IdType="pmc">PMC4207667</ArticleId><ArticleId IdType="pubmed">25340798</ArticleId></ArticleIdList></Reference><Reference><Citation>Kong LN, Zuo PP, Mu L, Liu YY, Yang N. Gene expression profile of amyloid beta protein-injected mouse model for Alzheimer disease. Acta Pharmacol Sin. 2005;26:666&#x2013;672. doi: 10.1111/j.1745-7254.2005.00129.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1745-7254.2005.00129.x</ArticleId><ArticleId IdType="pubmed">15916731</ArticleId></ArticleIdList></Reference><Reference><Citation>Kopec KK, Carroll RT. Alzheimer's beta-amyloid peptide 1&#x2013;42 induces a phagocytic response in murine microglia. J Neurochem. 1998;71:2123&#x2013;2131.</Citation><ArticleIdList><ArticleId IdType="pubmed">9798938</ArticleId></ArticleIdList></Reference><Reference><Citation>Krzyzanowska A, Carro E. Pathological alteration in the choroid plexus of Alzheimer's disease: implication for new therapy approaches. Front Pharmacol. 2012;3:75.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3342675</ArticleId><ArticleId IdType="pubmed">22563316</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuperstein I, Broersen K, Benilova I, Rozenski J, Jonckheere W, Debulpaep M, Vandersteen A, Segers-Nolten I, Van Der Werf K, Subramaniam V, Braeken D, Callewaert G, Bartic C, D'Hooge R, Martins IC, Rousseau F, Schymkowitz J, De Strooper B. Neurotoxicity of Alzheimer's disease Abeta peptides is induced by small changes in the Abeta42 to Abeta40 ratio. EMBO J. 2010;29:3408&#x2013;3420. doi: 10.1038/emboj.2010.211.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/emboj.2010.211</ArticleId><ArticleId IdType="pmc">PMC2957213</ArticleId><ArticleId IdType="pubmed">20818335</ArticleId></ArticleIdList></Reference><Reference><Citation>Ledo JH, Azevedo EP, Clarke JR, Ribeiro FC, Figueiredo CP, Foguel D, De Felice FG, Ferreira ST. Amyloid-beta oligomers link depressive-like behavior and cognitive deficits in mice. Mol Psychiatry. 2013;18:1053&#x2013;1054. doi: 10.1038/mp.2012.168.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mp.2012.168</ArticleId><ArticleId IdType="pmc">PMC3781315</ArticleId><ArticleId IdType="pubmed">23183490</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee JY, Choi HY, Ahn HJ, Ju BG, Yune TY. Matrix metalloproteinase-3 promotes early blood-spinal cord barrier disruption and hemorrhage and impairs long-term neurological recovery after spinal cord injury. Am J Pathol. 2014;184:2985&#x2013;3000. doi: 10.1016/j.ajpath.2014.07.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajpath.2014.07.016</ArticleId><ArticleId IdType="pubmed">25325922</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee YB, Nagai A, Kim SU. Cytokines, chemokines, and cytokine receptors in human microglia. J Neurosci Res. 2002;69:94&#x2013;103. doi: 10.1002/jnr.10253.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jnr.10253</ArticleId><ArticleId IdType="pubmed">12111820</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu L, Duff K. A technique for serial collection of cerebrospinal fluid from the cisterna magna in mouse. J Vis Exp. 2008;pii:960. doi: 10.3791/960.</Citation><ArticleIdList><ArticleId IdType="doi">10.3791/960</ArticleId><ArticleId IdType="pmc">PMC2762909</ArticleId><ArticleId IdType="pubmed">19066529</ArticleId></ArticleIdList></Reference><Reference><Citation>Maezawa I, Zimin PI, Wulff H, Jin LW. Amyloid-beta protein oligomer at low nanomolar concentrations activates microglia and induces microglial neurotoxicity. J Biol Chem. 2011;286:3693&#x2013;3706. doi: 10.1074/jbc.M110.135244.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M110.135244</ArticleId><ArticleId IdType="pmc">PMC3030372</ArticleId><ArticleId IdType="pubmed">20971854</ArticleId></ArticleIdList></Reference><Reference><Citation>Maia LF, Kaeser SA, Reichwald J, Hruscha M, Martus P, Staufenbiel M, Jucker M. Changes in amyloid-beta and Tau in the cerebrospinal fluid of transgenic mice overexpressing amyloid precursor protein. Sci Transl Med. 2013;5:194re192. doi: 10.1126/scitranslmed.3006446.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.3006446</ArticleId><ArticleId IdType="pubmed">23863834</ArticleId></ArticleIdList></Reference><Reference><Citation>Marco S, Skaper SD. Amyloid beta-peptide1&#x2013;42 alters tight junction protein distribution and expression in brain microvessel endothelial cells. Neurosci Lett. 2006;401:219&#x2013;224. doi: 10.1016/j.neulet.2006.03.047.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neulet.2006.03.047</ArticleId><ArticleId IdType="pubmed">16644119</ArticleId></ArticleIdList></Reference><Reference><Citation>Marques F, Sousa JC, Correia-Neves M, Oliveira P, Sousa N, Palha JA. The choroid plexus response to peripheral inflammatory stimulus. Neuroscience. 2007;144:424&#x2013;430. doi: 10.1016/j.neuroscience.2006.09.029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroscience.2006.09.029</ArticleId><ArticleId IdType="pubmed">17069984</ArticleId></ArticleIdList></Reference><Reference><Citation>Marques F, Sousa JC, Coppola G, Falcao AM, Rodrigues AJ, Geschwind DH, Sousa N, Correia-Neves M, Palha JA. Kinetic profile of the transcriptome changes induced in the choroid plexus by peripheral inflammation. J Cereb Blood Flow Metab. 2009a;29:921&#x2013;932. doi: 10.1038/jcbfm.2009.15.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/jcbfm.2009.15</ArticleId><ArticleId IdType="pubmed">19240744</ArticleId></ArticleIdList></Reference><Reference><Citation>Marques F, Sousa JC, Coppola G, Geschwind DH, Sousa N, Palha JA, Correia-Neves M. The choroid plexus response to a repeated peripheral inflammatory stimulus. BMC Neurosci. 2009b;10:135. doi: 10.1186/1471-2202-10-135.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2202-10-135</ArticleId><ArticleId IdType="pmc">PMC2784788</ArticleId><ArticleId IdType="pubmed">19922669</ArticleId></ArticleIdList></Reference><Reference><Citation>Marques F, Sousa JC, Sousa N, Palha JA. Blood-brain-barriers in aging and in Alzheimer's disease. Mol Neurodegener. 2013;8:38. doi: 10.1186/1750-1326-8-38.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1750-1326-8-38</ArticleId><ArticleId IdType="pmc">PMC4015275</ArticleId><ArticleId IdType="pubmed">24148264</ArticleId></ArticleIdList></Reference><Reference><Citation>McLean CA, Cherny RA, Fraser FW, Fuller SJ, Smith MJ, Beyreuther K, Bush AI, Masters CL. Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann Neurol. 1999;46:860&#x2013;866. doi: 10.1002/1531-8249(199912)46:6&lt;860::AID-ANA8&gt;3.0.CO;2-M.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/1531-8249(199912)46:6&lt;860::AID-ANA8&gt;3.0.CO;2-M</ArticleId><ArticleId IdType="pubmed">10589538</ArticleId></ArticleIdList></Reference><Reference><Citation>Minagar A, Alexander JS. Blood-brain barrier disruption in multiple sclerosis. Mult Scler. 2003;9:540&#x2013;549. doi: 10.1191/1352458503ms965oa.</Citation><ArticleIdList><ArticleId IdType="doi">10.1191/1352458503ms965oa</ArticleId><ArticleId IdType="pubmed">14664465</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitchell K, Yang HY, Berk JD, Tran JH, Iadarola MJ. Monocyte chemoattractant protein-1 in the choroid plexus: a potential link between vascular pro-inflammatory mediators and the CNS during peripheral tissue inflammation. Neuroscience. 2009;158:885&#x2013;895. doi: 10.1016/j.neuroscience.2008.10.047.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroscience.2008.10.047</ArticleId><ArticleId IdType="pmc">PMC2668531</ArticleId><ArticleId IdType="pubmed">19032979</ArticleId></ArticleIdList></Reference><Reference><Citation>Mroczko B, Groblewska M, Zboch M, Kulczy&#x144;ska A, Koper OM, Szmitkowski M, Kornhuber J, Lewczuk P. Concentrations of matrix metalloproteinases and their tissue inhibitors in the cerebrospinal fluid of patients with Alzheimer's disease. J Alzheimers Dis. 2014;40:351&#x2013;357.</Citation><ArticleIdList><ArticleId IdType="pubmed">24448781</ArticleId></ArticleIdList></Reference><Reference><Citation>Mudgett JS, Hutchinson NI, Chartrain NA, Forsyth AJ, McDonnell J, Singer II, Bayne EK, Flanagan J, Kawka D, Shen CF, Stevens K, Chen H, Trumbauer M, Visco DM. Susceptibility of stromelysin 1-deficient mice to collagen-induced arthritis and cartilage destruction. Arthritis Rheum. 1998;41:110&#x2013;121.</Citation><ArticleIdList><ArticleId IdType="pubmed">9433876</ArticleId></ArticleIdList></Reference><Reference><Citation>Nava P, Kamekura R, Nusrat A. Cleavage of transmembrane junction proteins and their role in regulating epithelial homeostasis. Tissue Barriers. 2013;1:e24783. doi: 10.4161/tisb.24783.</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/tisb.24783</ArticleId><ArticleId IdType="pmc">PMC3879235</ArticleId><ArticleId IdType="pubmed">24665393</ArticleId></ArticleIdList></Reference><Reference><Citation>Nery LR, Eltz NS, Hackman C, Fonseca R, Altenhofen S, Guerra HN, Freitas VM, Bonan CD, Vianna MR. Brain intraventricular injection of amyloid-beta in zebrafish embryo impairs cognition and increases tau phosphorylation, effects reversed by lithium. PLoS One. 2014;9:e105862. doi: 10.1371/journal.pone.0105862.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0105862</ArticleId><ArticleId IdType="pmc">PMC4154875</ArticleId><ArticleId IdType="pubmed">25187954</ArticleId></ArticleIdList></Reference><Reference><Citation>Nitta A, Fukuta T, Hasegawa T, Nabeshima T. Continuous infusion of beta-amyloid protein into the rat cerebral ventricle induces learning impairment and neuronal and morphological degeneration. Jpn J Pharmacol. 1997;73:51&#x2013;57. doi: 10.1254/jjp.73.51.</Citation><ArticleIdList><ArticleId IdType="doi">10.1254/jjp.73.51</ArticleId><ArticleId IdType="pubmed">9032134</ArticleId></ArticleIdList></Reference><Reference><Citation>Redzic Z. Molecular biology of the blood-brain and the blood-cerebrospinal fluid barriers: similarities and differences. Fluids Barriers CNS. 2011;8:3. doi: 10.1186/2045-8118-8-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/2045-8118-8-3</ArticleId><ArticleId IdType="pmc">PMC3045361</ArticleId><ArticleId IdType="pubmed">21349151</ArticleId></ArticleIdList></Reference><Reference><Citation>Romanitan MO, Popescu BO, Spulber S, B&#x103;jenaru O, Popescu LM, Winblad B, Bogdanovic N. Altered expression of claudin family proteins in Alzheimer's disease and vascular dementia brains. J Cell Mol Med. 2010;14:1088&#x2013;1100.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3822746</ArticleId><ArticleId IdType="pubmed">20041969</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenberg GA. Matrix metalloproteinases and their multiple roles in neurodegenerative diseases. Lancet Neurol. 2009;8:205&#x2013;216. doi: 10.1016/S1474-4422(09)70016-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(09)70016-X</ArticleId><ArticleId IdType="pubmed">19161911</ArticleId></ArticleIdList></Reference><Reference><Citation>Sagare AP, Bell RD, Zhao Z, Ma Q, Winkler EA, Ramanathan A, Zlokovic BV. Pericyte loss influences Alzheimer-like neurodegeneration in mice. Nat Commun. 2013;4:2932.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3945879</ArticleId><ArticleId IdType="pubmed">24336108</ArticleId></ArticleIdList></Reference><Reference><Citation>Schindelin J, Arganda-Carreras I, Frise E, Kaynig V, Longair M, Pietzsch T, Preibisch S, Rueden C, Saalfeld S, Schmid B, Tinevez JY, White DJ, Hartenstein V, Eliceiri K, Tomancak P, Cardona A. Fiji: an open-source platform for biological-image analysis. Nat Methods. 2012;9:676&#x2013;682. doi: 10.1038/nmeth.2019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nmeth.2019</ArticleId><ArticleId IdType="pmc">PMC3855844</ArticleId><ArticleId IdType="pubmed">22743772</ArticleId></ArticleIdList></Reference><Reference><Citation>Schubert-Unkmeir A, Slanina H, Frosch M. Mammalian cell transcriptome in response to meningitis-causing pathogens. Expert Rev Mol Diagn. 2009;9:833&#x2013;842. doi: 10.1586/erm.09.68.</Citation><ArticleIdList><ArticleId IdType="doi">10.1586/erm.09.68</ArticleId><ArticleId IdType="pubmed">19895228</ArticleId></ArticleIdList></Reference><Reference><Citation>Serot JM, B&#xe9;n&#xe9; MC, Foliguet B, Faure GC. Morphological alterations of the choroid plexus in late-onset Alzheimer's disease. Acta Neuropathol. 2000;99:105&#x2013;108. doi: 10.1007/PL00007412.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/PL00007412</ArticleId><ArticleId IdType="pubmed">10672315</ArticleId></ArticleIdList></Reference><Reference><Citation>Serot JM, B&#xe9;n&#xe9; MC, Faure GC. Choroid plexus, aging of the brain, and Alzheimer's disease. Front Biosci. 2003;8:s515&#x2013;s521. doi: 10.2741/1085.</Citation><ArticleIdList><ArticleId IdType="doi">10.2741/1085</ArticleId><ArticleId IdType="pubmed">12700093</ArticleId></ArticleIdList></Reference><Reference><Citation>Serot JM, Zmudka J, Jouanny P. A possible role for CSF turnover and choroid plexus in the pathogenesis of late onset Alzheimer's disease. J Alzheimers Dis. 2012;30:17&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pubmed">22349684</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharma HS, Zimmermann-Meinzingen S, Johanson CE. Cerebrolysin reduces blood-cerebrospinal fluid barrier permeability change, brain pathology, and functional deficits following traumatic brain injury in the rat. Ann N Y Acad Sci. 2010;1199:125&#x2013;137. doi: 10.1111/j.1749-6632.2009.05329.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1749-6632.2009.05329.x</ArticleId><ArticleId IdType="pubmed">20633118</ArticleId></ArticleIdList></Reference><Reference><Citation>Simard PF, Tosun C, Melnichenko L, Ivanova S, Gerzanich V, Simard JM. Inflammation of the choroid plexus and ependymal layer of the ventricle following intraventricular hemorrhage. Transl Stroke Res. 2011;2:227&#x2013;231. doi: 10.1007/s12975-011-0070-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12975-011-0070-8</ArticleId><ArticleId IdType="pmc">PMC3128335</ArticleId><ArticleId IdType="pubmed">21731590</ArticleId></ArticleIdList></Reference><Reference><Citation>Smits HA, Rijsmus A, van Loon JH, Wat JW, Verhoef J, Boven LA, Nottet HS. Amyloid-beta-induced chemokine production in primary human macrophages and astrocytes. J Neuroimmunol. 2002;127:160&#x2013;168. doi: 10.1016/S0165-5728(02)00112-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0165-5728(02)00112-1</ArticleId><ArticleId IdType="pubmed">12044988</ArticleId></ArticleIdList></Reference><Reference><Citation>Solito E, Sastre M. Microglia function in Alzheimer's disease. Front Pharmacol. 2012;3:14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3277080</ArticleId><ArticleId IdType="pubmed">22363284</ArticleId></ArticleIdList></Reference><Reference><Citation>Spector R, Johanson CE. Sustained choroid plexus function in human elderly and Alzheimer's disease patients. Fluids Barriers CNS. 2013;10:28. doi: 10.1186/2045-8118-10-28.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/2045-8118-10-28</ArticleId><ArticleId IdType="pmc">PMC3849253</ArticleId><ArticleId IdType="pubmed">24059870</ArticleId></ArticleIdList></Reference><Reference><Citation>Thouvenot E, Lafon-Cazal M, Demettre E, Jouin P, Bockaert J, Marin P. The proteomic analysis of mouse choroid plexus secretome reveals a high protein secretion capacity of choroidal epithelial cells. Proteomics. 2006;6:5941&#x2013;5952. doi: 10.1002/pmic.200600096.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pmic.200600096</ArticleId><ArticleId IdType="pubmed">17051638</ArticleId></ArticleIdList></Reference><Reference><Citation>Tripathy D, Thirumangalakudi L, Grammas P. Expression of macrophage inflammatory protein 1-alpha is elevated in Alzheimer's vessels and is regulated by oxidative stress. J Alzheimers Dis. 2007;11:447&#x2013;455.</Citation><ArticleIdList><ArticleId IdType="pubmed">17656823</ArticleId></ArticleIdList></Reference><Reference><Citation>Vandenbroucke RE, Libert C. Is there new hope for therapeutic matrix metalloproteinase inhibition? Nat Rev Drug Discov. 2014;13:904&#x2013;927. doi: 10.1038/nrd4390.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrd4390</ArticleId><ArticleId IdType="pubmed">25376097</ArticleId></ArticleIdList></Reference><Reference><Citation>Vandenbroucke RE, Dejonckheere E, Van Lint P, Demeestere D, Van Wonterghem E, Vanlaere I, Puim&#xe8;ge L, Van Hauwermeiren F, De Rycke R, Mc Guire C, Campestre C, L&#xf3;pez-Otin C, Matthys P, Leclercq G, Libert C. Matrix metalloprotease 8-dependent extracellular matrix cleavage at the blood-CSF barrier contributes to lethality during systemic inflammatory diseases. J Neurosci. 2012;32:9805&#x2013;9816. doi: 10.1523/JNEUROSCI.0967-12.2012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.0967-12.2012</ArticleId><ArticleId IdType="pmc">PMC6621276</ArticleId><ArticleId IdType="pubmed">22815495</ArticleId></ArticleIdList></Reference><Reference><Citation>Vandenbroucke RE, Dejonckheere E, Van Hauwermeiren F, Lodens S, De Rycke R, Van Wonterghem E, Staes A, Gevaert K, L&#xf3;pez-Otin C, Libert C. Matrix metalloproteinase 13 modulates intestinal epithelial barrier integrity in inflammatory diseases by activating TNF. EMBO Mol Med. 2013;5:932&#x2013;948.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3721470</ArticleId><ArticleId IdType="pubmed">23723167</ArticleId></ArticleIdList></Reference><Reference><Citation>Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A, Speleman F. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol. 2002;3:RESEARCH0034.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC126239</ArticleId><ArticleId IdType="pubmed">12184808</ArticleId></ArticleIdList></Reference><Reference><Citation>von Bernhardi R, Eugen&#xed;n J. Microglial reactivity to beta-amyloid is modulated by astrocytes and proinflammatory factors. Brain Res. 2004;1025:186&#x2013;193. doi: 10.1016/j.brainres.2004.07.084.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2004.07.084</ArticleId><ArticleId IdType="pubmed">15464759</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang XX, Tan MS, Yu JT, Tan L. Matrix metalloproteinases and their multiple roles in Alzheimer's disease. BioMed Res Int. 2014;2014:908636.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4094696</ArticleId><ArticleId IdType="pubmed">25050378</ArticleId></ArticleIdList></Reference><Reference><Citation>Winkler EA, Sagare AP, Zlokovic BV. The pericyte: a forgotten cell type with important implications for Alzheimer's disease? Brain Pathol. 2014;24:371&#x2013;386. doi: 10.1111/bpa.12152.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bpa.12152</ArticleId><ArticleId IdType="pmc">PMC4423607</ArticleId><ArticleId IdType="pubmed">24946075</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolburg H, Paulus W. Choroid plexus: biology and pathology. Acta Neuropathol. 2010;119:75&#x2013;88. doi: 10.1007/s00401-009-0627-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-009-0627-8</ArticleId><ArticleId IdType="pubmed">20033190</ArticleId></ArticleIdList></Reference><Reference><Citation>Wright AL, Zinn R, Hohensinn B, Konen LM, Beynon SB, Tan RP, Clark IA, Abdipranoto A, Vissel B. Neuroinflammation and neuronal loss precede Abeta plaque deposition in the hAPP-J20 mouse model of Alzheimer's disease. PLoS One. 2013;8:e59586. doi: 10.1371/journal.pone.0059586.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0059586</ArticleId><ArticleId IdType="pmc">PMC3613362</ArticleId><ArticleId IdType="pubmed">23560052</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan P, Hu X, Song H, Yin K, Bateman RJ, Cirrito JR, Xiao Q, Hsu FF, Turk JW, Xu J, Hsu CY, Holtzman DM, Lee JM. Matrix metalloproteinase-9 degrades amyloid-beta fibrils in vitro and compact plaques in situ. J Biol Chem. 2006;281:24566&#x2013;24574. doi: 10.1074/jbc.M602440200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M602440200</ArticleId><ArticleId IdType="pubmed">16787929</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin KJ, Cirrito JR, Yan P, Hu X, Xiao Q, Pan X, Bateman R, Song H, Hsu FF, Turk J, Xu J, Hsu CY, Mills JC, Holtzman DM, Lee JM. Matrix metalloproteinases expressed by astrocytes mediate extracellular amyloid-beta peptide catabolism. J Neurosci. 2006;26:10939&#x2013;10948. doi: 10.1523/JNEUROSCI.2085-06.2006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.2085-06.2006</ArticleId><ArticleId IdType="pmc">PMC6674654</ArticleId><ArticleId IdType="pubmed">17065436</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshiyama Y, Asahina M, Hattori T. Selective distribution of matrix metalloproteinase-3 (MMP-3) in Alzheimer's disease brain. Acta Neuropathol. 2000;99:91&#x2013;95. doi: 10.1007/PL00007428.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/PL00007428</ArticleId><ArticleId IdType="pubmed">10672313</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeni P, Doepker E, Schulze-Topphoff U, Huewel S, Tenenbaum T, Galla HJ. MMPs contribute to TNF-alpha-induced alteration of the blood-cerebrospinal fluid barrier in vitro. Am J Physiol Cell Physiol. 2007;293:C855&#x2013;C864. doi: 10.1152/ajpcell.00470.2006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajpcell.00470.2006</ArticleId><ArticleId IdType="pubmed">17507431</ArticleId></ArticleIdList></Reference><Reference><Citation>Zlokovic BV. The blood-brain barrier in health and chronic neurodegenerative disorders. Neuron. 2008;57:178&#x2013;201. doi: 10.1016/j.neuron.2008.01.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2008.01.003</ArticleId><ArticleId IdType="pubmed">18215617</ArticleId></ArticleIdList></Reference><Reference><Citation>Zlokovic BV. Neurovascular pathways to neurodegeneration in Alzheimer's disease and other disorders. Nat Rev Neurosci. 2011;12:723&#x2013;738.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4036520</ArticleId><ArticleId IdType="pubmed">22048062</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">26373605</PMID><DateCompleted><Year>2016</Year><Month>02</Month><Day>09</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1460-2156</ISSN><JournalIssue CitedMedium="Internet"><Volume>138</Volume><Issue>Pt 11</Issue><PubDate><Year>2015</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Brain : a journal of neurology</Title><ISOAbbreviation>Brain</ISOAbbreviation></Journal><ArticleTitle>Cerebrospinal fluid neurogranin: relation to cognition and neurodegeneration in Alzheimer's disease.</ArticleTitle><Pagination><StartPage>3373</StartPage><EndPage>3385</EndPage><MedlinePgn>3373-85</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/brain/awv267</ELocationID><Abstract><AbstractText>Synaptic dysfunction is linked to cognitive symptoms in Alzheimer's disease. Thus, measurement of synapse proteins in cerebrospinal fluid may be useful biomarkers to monitor synaptic degeneration. Cerebrospinal fluid levels of the postsynaptic protein neurogranin are increased in Alzheimer's disease, including in the predementia stage of the disease. Here, we tested the performance of cerebrospinal fluid neurogranin to predict cognitive decline and brain injury in the Alzheimer's Disease Neuroimaging Initiative study. An in-house immunoassay was used to analyse neurogranin in cerebrospinal fluid samples from a cohort of patients who at recruitment were diagnosed as having Alzheimer's disease with dementia (n = 95) or mild cognitive impairment (n = 173), as well as in cognitively normal subjects (n = 110). Patients with mild cognitive impairment were grouped into those that remained cognitively stable for at least 2 years (stable mild cognitive impairment) and those who progressed to Alzheimer's disease dementia during follow-up (progressive mild cognitive impairment). Correlations were tested between baseline cerebrospinal fluid neurogranin levels and baseline and longitudinal cognitive impairment, brain atrophy and glucose metabolism within each diagnostic group. Cerebrospinal fluid neurogranin was increased in patients with Alzheimer's disease dementia (P &lt; 0.001), progressive mild cognitive impairment (P &lt; 0.001) and stable mild cognitive impairment (P &lt; 0.05) compared with controls, and in Alzheimer's disease dementia (P &lt; 0.01) and progressive mild cognitive impairment (P &lt; 0.05) compared with stable mild cognitive impairment. In the mild cognitive impairment group, high baseline cerebrospinal fluid neurogranin levels predicted cognitive decline as reflected by decreased Mini-Mental State Examination (P &lt; 0.001) and increased Alzheimer's Disease Assessment Scale-cognitive subscale (P &lt; 0.001) scores at clinical follow-up. In addition, high baseline cerebrospinal fluid neurogranin levels in the mild cognitive impairment group correlated with longitudinal reductions in cortical glucose metabolism (P &lt; 0.001) and hippocampal volume (P &lt; 0.001) at clinical follow-up. Furthermore, within the progressive mild cognitive impairment group, elevated cerebrospinal fluid neurogranin levels were associated with accelerated deterioration in Alzheimer's Disease Assessment Scale-cognitive subscale (&#x3b2; = 0.0017, P = 0.01). These data demonstrate that cerebrospinal fluid neurogranin is increased already at the early clinical stage of Alzheimer's disease and predicts cognitive deterioration and disease-associated changes in metabolic and structural biomarkers over time.</AbstractText><CopyrightInformation>&#xa9; The Author (2015). Published by Oxford University Press on behalf of the Guarantors of Brain. All rights reserved. For Permissions, please email: journals.permissions@oup.com.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Portelius</LastName><ForeName>Erik</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>1 Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, the Sahlgrenska Academy at the University of Gothenburg, M&#xf6;lndal, Sweden erik.portelius@neuro.gu.se.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zetterberg</LastName><ForeName>Henrik</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>1 Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, the Sahlgrenska Academy at the University of Gothenburg, M&#xf6;lndal, Sweden 2 Department of Molecular Neuroscience, UCL Institute of Neurology, London WC1N 3BG, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Skillb&#xe4;ck</LastName><ForeName>Tobias</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>1 Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, the Sahlgrenska Academy at the University of Gothenburg, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>T&#xf6;rnqvist</LastName><ForeName>Ulrika</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>1 Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, the Sahlgrenska Academy at the University of Gothenburg, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Andreasson</LastName><ForeName>Ulf</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>1 Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, the Sahlgrenska Academy at the University of Gothenburg, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Trojanowski</LastName><ForeName>John Q</ForeName><Initials>JQ</Initials><AffiliationInfo><Affiliation>3 Department of Pathology and Laboratory Medicine, Institute on Aging, Center for Neurodegenerative Disease Research, University of Pennsylvania School of Medicine, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weiner</LastName><ForeName>Michael W</ForeName><Initials>MW</Initials><AffiliationInfo><Affiliation>4 Department of Veterans Affairs Medical Center, Center for Imaging of Neurodegenerative Diseases and Department of Radiology and Biomedical Imaging, University of California, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shaw</LastName><ForeName>Leslie M</ForeName><Initials>LM</Initials><AffiliationInfo><Affiliation>3 Department of Pathology and Laboratory Medicine, Institute on Aging, Center for Neurodegenerative Disease Research, University of Pennsylvania School of Medicine, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mattsson</LastName><ForeName>Niklas</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>5 Clinical Memory Research Unit, Lund University, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blennow</LastName><ForeName>Kaj</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><CollectiveName>Alzheimer&#x2019;s Disease Neuroimaging Initiative</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 AG010124</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K01 AG030514</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG010129</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG024904</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>09</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Brain</MedlineTA><NlmUniqueID>0372537</NlmUniqueID><ISSNLinking>0006-8950</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C496649">NRGN protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>132654-77-4</RegistryNumber><NameOfSubstance UI="D051579">Neurogranin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Neurol. 2015 Nov;11(11):609. doi: 10.1038/nrneurol.2015.178.</RefSource><PMID Version="1">26416540</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002540" MajorTopicYN="N">Cerebral Cortex</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="Y">Cognition</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D060825" MajorTopicYN="N">Cognitive Dysfunction</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051579" MajorTopicYN="N">Neurogranin</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009929" MajorTopicYN="N">Organ Size</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="N">Positron-Emission Tomography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer&#x2019;s disease</Keyword><Keyword MajorTopicYN="N">biomarker</Keyword><Keyword MajorTopicYN="N">cerebrospinal fluid</Keyword><Keyword MajorTopicYN="N">mild cognitive impairment</Keyword><Keyword MajorTopicYN="N">neurogranin</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>3</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>7</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>9</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>9</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>2</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2016</Year><Month>11</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26373605</ArticleId><ArticleId IdType="pmc">PMC4643642</ArticleId><ArticleId IdType="doi">10.1093/brain/awv267</ArticleId><ArticleId IdType="pii">awv267</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Alvarez-Bolado G, Rodriguez-Sanchez P, Tejero-Diez P, Fairen A, Diez-Guerra FJ. Neurogranin in the development of the rat telencephalon. Neuroscience 1996; 73: 565&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pubmed">8783271</ArticleId></ArticleIdList></Reference><Reference><Citation>Baudier J, Deloulme JC, Van Dorsselaer A, Black D, Matthes HW. Purification and characterization of a brain-specific protein kinase C substrate, neurogranin (p17). Identification of a consensus amino acid sequence between neurogranin and neuromodulin (GAP43) that corresponds to the protein kinase C phosphorylation site and the calmodulin-binding domain. J Biol Chem 1991; 266: 229&#x2013;37.</Citation><ArticleIdList><ArticleId IdType="pubmed">1824695</ArticleId></ArticleIdList></Reference><Reference><Citation>Bertoni-Freddari C, Fattoretti P, Casoli T, Caselli U, Meier-Ruge W. Deterioration threshold of synaptic morphology in aging and senile dementia of Alzheimer&#x2019;s type. Anal Quant Cytol Histol 1996; 18: 209&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pubmed">8790834</ArticleId></ArticleIdList></Reference><Reference><Citation>Blennow K, Bogdanovic N, Alafuzoff I, Ekman R, Davidsson P. Synaptic pathology in Alzheimer&#x2019;s disease: relation to severity of dementia, but not to senile plaques, neurofibrillary tangles, or the ApoE4 allele. J Neural Transm 1996; 103: 603&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pubmed">8811505</ArticleId></ArticleIdList></Reference><Reference><Citation>Blennow K, Hampel H, Weiner M, Zetterberg H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol 2010; 6: 131&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">20157306</ArticleId></ArticleIdList></Reference><Reference><Citation>Curtis C, Gamez JE, Singh U, Sadowsky CH, Villena T, Sabbagh MN, et al. Phase 3 trial of flutemetamol labeled with radioactive fluorine 18 imaging and neuritic plaque density. JAMA Neurol 2015; 72: 287&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pubmed">25622185</ArticleId></ArticleIdList></Reference><Reference><Citation>Davidsson P, Jahn R, Bergquist J, Ekman R, Blennow K. Synaptotagmin, a synaptic vesicle protein, is present in human cerebrospinal fluid: a new biochemical marker for synaptic pathology in Alzheimer disease?. Mol Chem Neuropathol 1996; 27: 195&#x2013;210.</Citation><ArticleIdList><ArticleId IdType="pubmed">8962603</ArticleId></ArticleIdList></Reference><Reference><Citation>Davidsson P, Puchades M, Blennow K. Identification of synaptic vesicle, pre- and postsynaptic proteins in human cerebrospinal fluid using liquid-phase isoelectric focusing. Electrophoresis 1999; 20: 431&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">10217148</ArticleId></ArticleIdList></Reference><Reference><Citation>Davies CA, Mann DM, Sumpter PQ, Yates PO. A quantitative morphometric analysis of the neuronal and synaptic content of the frontal and temporal cortex in patients with Alzheimer&#x2019;s disease. J Neurol Sci 1987; 78: 151&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pubmed">3572454</ArticleId></ArticleIdList></Reference><Reference><Citation>DeKosky ST, Scheff SW. Synapse loss in frontal cortex biopsies in Alzheimer&#x2019;s disease: correlation with cognitive severity. Ann Neurol 1990; 27: 457&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pubmed">2360787</ArticleId></ArticleIdList></Reference><Reference><Citation>Diez-Guerra FJ. Neurogranin, a link between calcium/calmodulin and protein kinase C signaling in synaptic plasticity. IUBMB Life 2010; 62: 597&#x2013;606.</Citation><ArticleIdList><ArticleId IdType="pubmed">20665622</ArticleId></ArticleIdList></Reference><Reference><Citation>Dubois B, Feldman HH, Jacova C, Hampel H, Molinuevo JL, Blennow K, et al. Advancing research diagnostic criteria for Alzheimer&#x2019;s disease: the IWG-2 criteria. Lancet Neurol 2014; 13: 614&#x2013;29.</Citation><ArticleIdList><ArticleId IdType="pubmed">24849862</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischl B, Salat DH, Busa E, Albert M, Dieterich M, Haselgrove C, et al. Whole brain segmentation: automated labeling of neuroanatomical structures in the human brain. Neuron 2002; 33: 341&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pubmed">11832223</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischl B, van der Kouwe A, Destrieux C, Halgren E, Segonne F, Salat DH, et al. Automatically parcellating the human cerebral cortex. Cereb Cortex 2004; 14: 11&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pubmed">14654453</ArticleId></ArticleIdList></Reference><Reference><Citation>Folstein MF, Folstein SE, McHugh PR. &#x201c;Mini-mental state&#x201d;. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="pubmed">1202204</ArticleId></ArticleIdList></Reference><Reference><Citation>Gerendasy DD, Sutcliffe JG. RC3/neurogranin, a postsynaptic calpacitin for setting the response threshold to calcium influxes. Mol Neurobiol 1997; 15: 131&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pubmed">9396008</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayashi Y. Long-term potentiation: two pathways meet at neurogranin. EMBO J 2009; 28: 2859&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2760120</ArticleId><ArticleId IdType="pubmed">19809472</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang KP, Huang FL, Chen HC. Characterization of a 7.5-kDa protein kinase C substrate (RC3 protein, neurogranin) from rat brain. Arch Biochem Biophys 1993; 305: 570&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pubmed">8080473</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang KP, Huang FL, Jager T, Li J, Reymann KG, Balschun D. Neurogranin/RC3 enhances long-term potentiation and learning by promoting calcium-mediated signaling. J Neurosci 2004; 24: 10660&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6730132</ArticleId><ArticleId IdType="pubmed">15564582</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr, Bernstein MA, Fox NC, Thompson P, Alexander G, Harvey D, et al. The Alzheimer&#x2019;s Disease Neuroimaging Initiative (ADNI): MRI methods. J Magn Reson Imaging 2008; 27: 685&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2544629</ArticleId><ArticleId IdType="pubmed">18302232</ArticleId></ArticleIdList></Reference><Reference><Citation>Kovacs GG, Milenkovic I, Wohrer A, Hoftberger R, Gelpi E, Haberler C, et al. Non-Alzheimer neurodegenerative pathologies and their combinations are more frequent than commonly believed in the elderly brain: a community-based autopsy series. Acta Neuropathol 2013; 126: 365&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">23900711</ArticleId></ArticleIdList></Reference><Reference><Citation>Kvartsberg H, Duits FH, Ingelsson M, Andreasen N, &#xd6;hrfelt A, Andersson K, et al. 
Cerebrospinal fluid levels of the synaptic protein neurogranin correlated with cognitive decline in prodromal Alzheime&#x155;s disease. Alzheime&#x155;s Dement
2014. 
http://dx.doi.org/10.1016/j.jalz.2014.10.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2014.10.009</ArticleId><ArticleId IdType="pubmed">25533203</ArticleId></ArticleIdList></Reference><Reference><Citation>Landau SM, Mintun MA, Joshi AD, Koeppe RA, Petersen RC, Aisen PS, et al. Amyloid deposition, hypometabolism, and longitudinal cognitive decline. Ann Neurol 2012; 72: 578&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3786871</ArticleId><ArticleId IdType="pubmed">23109153</ArticleId></ArticleIdList></Reference><Reference><Citation>Masliah E, Mallory M, Alford M, DeTeresa R, Hansen LA, McKeel DW, Jr, et al. Altered expression of synaptic proteins occurs early during progression of Alzheimer&#x2019;s disease. Neurology 2001; 56: 127&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">11148253</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattsson N, Insel PS, Landau S, Jagust W, Donohue M, Shaw LM, et al. Diagnostic accuracy of CSF Ab42 and florbetapir PET for Alzheimer&#x2019;s disease. Ann Clin Transl Neurol 2014; 1: 534&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4184556</ArticleId><ArticleId IdType="pubmed">25356425</ArticleId></ArticleIdList></Reference><Reference><Citation>Mosconi L, Pupi A, De Leon MJ. Brain glucose hypometabolism and oxidative stress in preclinical Alzheimer&#x2019;s disease. Ann N Y Acad Sci 2008; 1147: 180&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2661241</ArticleId><ArticleId IdType="pubmed">19076441</ArticleId></ArticleIdList></Reference><Reference><Citation>Pak JH, Huang FL, Li J, Balschun D, Reymann KG, Chiang C, et al. Involvement of neurogranin in the modulation of calcium/calmodulin-dependent protein kinase II, synaptic plasticity, and spatial learning: a study with knockout mice. Proc Natl Acad Sci USA 2000; 97: 11232&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC17183</ArticleId><ArticleId IdType="pubmed">11016969</ArticleId></ArticleIdList></Reference><Reference><Citation>Represa A, Deloulme JC, Sensenbrenner M, Ben-Ari Y, Baudier J. Neurogranin: immunocytochemical localization of a brain-specific protein kinase C substrate. J Neurosci 1990; 10: 3782&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6570038</ArticleId><ArticleId IdType="pubmed">2269883</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer&#x2019;s disease. Am J Psychiatry 1984; 141: 1356&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pubmed">6496779</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheff SW, Price DA, Schmitt FA, DeKosky ST, Mufson EJ. Synaptic alterations in CA1 in mild Alzheimer disease and mild cognitive impairment. Neurology 2007; 68: 1501&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">17470753</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaw LM, Vanderstichele H, Knapik-Czajka M, Clark CM, Aisen PS, Petersen RC, et al. Cerebrospinal fluid biomarker signature in Alzheimer&#x2019;s disease neuroimaging initiative subjects. Ann Neurol 2009; 65: 403&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2696350</ArticleId><ArticleId IdType="pubmed">19296504</ArticleId></ArticleIdList></Reference><Reference><Citation>Sze CI, Troncoso JC, Kawas C, Mouton P, Price DL, Martin LJ. Loss of the presynaptic vesicle protein synaptophysin in hippocampus correlates with cognitive decline in Alzheimer disease. J Neuropathol Exp Neurol 1997; 56: 933&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">9258263</ArticleId></ArticleIdList></Reference><Reference><Citation>Thorsell A, Bjerke M, Gobom J, Brunhage E, Vanmechelen E, Andreasen N, et al. Neurogranin in cerebrospinal fluid as a marker of synaptic degeneration in Alzheimer&#x2019;s disease. Brain Res 2010; 1362: 13&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pubmed">20875798</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">26393847</PMID><DateCompleted><Year>2015</Year><Month>10</Month><Day>01</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>09</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1538-3598</ISSN><JournalIssue CitedMedium="Internet"><Volume>314</Volume><Issue>12</Issue><PubDate><MedlineDate>2015 Sep 22-29</MedlineDate></PubDate></JournalIssue><Title>JAMA</Title><ISOAbbreviation>JAMA</ISOAbbreviation></Journal><ArticleTitle>Effect of Dextromethorphan-Quinidine on Agitation in Patients With Alzheimer Disease Dementia: A Randomized Clinical Trial.</ArticleTitle><Pagination><StartPage>1242</StartPage><EndPage>1254</EndPage><MedlinePgn>1242-54</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jama.2015.10214</ELocationID><Abstract><AbstractText Label="IMPORTANCE" NlmCategory="OBJECTIVE">Agitation is common among patients with Alzheimer disease; safe, effective treatments are lacking.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To assess the efficacy, safety, and tolerability of dextromethorphan hydrobromide-quinidine sulfate for Alzheimer disease-related agitation.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS" NlmCategory="METHODS">Phase 2 randomized, multicenter, double-blind, placebo-controlled trial using a sequential parallel comparison design with 2 consecutive 5-week treatment stages conducted August 2012-August 2014. Patients with probable Alzheimer disease, clinically significant agitation (Clinical Global Impressions-Severity agitation score &#x2265;4), and a Mini-Mental State Examination score of 8 to 28 participated at 42 US study sites. Stable dosages of antidepressants, antipsychotics, hypnotics, and antidementia medications were allowed.</AbstractText><AbstractText Label="INTERVENTIONS" NlmCategory="METHODS">In stage 1, 220 patients were randomized in a 3:4 ratio to receive dextromethorphan-quinidine (n&#x2009;=&#x2009;93) or placebo (n&#x2009;=&#x2009;127). In stage 2, patients receiving dextromethorphan-quinidine continued; those receiving placebo were stratified by response and rerandomized in a 1:1 ratio to dextromethorphan-quinidine (n&#x2009;=&#x2009;59) or placebo (n&#x2009;=&#x2009;60).</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES" NlmCategory="METHODS">The primary end point was change from baseline on the Neuropsychiatric Inventory (NPI) Agitation/Aggression domain (scale range, 0 [absence of symptoms] to 12 [symptoms occur daily and with marked severity]).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 194 patients (88.2%) completed the study. With the sequential parallel comparison design, 152 patients received dextromethorphan-quinidine and 127 received placebo during the study. Analysis combining stages 1 (all patients) and 2 (rerandomized placebo nonresponders) showed significantly reduced NPI Agitation/Aggression scores for dextromethorphan-quinidine vs placebo (ordinary least squares z statistic, -3.95; P&#x2009;&lt;&#x2009;.001). In stage 1, mean NPI Agitation/Aggression scores were reduced from 7.1 to 3.8 with dextromethorphan-quinidine and from 7.0 to 5.3 with placebo. Between-group treatment differences were significant in stage 1 (least squares mean, -1.5; 95% CI, -2.3 to -0.7; P&lt;.001). In stage 2, NPI Agitation/Aggression scores were reduced from 5.8 to 3.8 with dextromethorphan-quinidine and from 6.7 to 5.8 with placebo. Between-group treatment differences were also significant in stage 2 (least squares mean, -1.6; 95% CI, -2.9 to -0.3; P=.02). Adverse events included falls (8.6% for dextromethorphan-quinidine vs 3.9% for placebo), diarrhea (5.9% vs 3.1% respectively), and urinary tract infection (5.3% vs 3.9% respectively). Serious adverse events occurred in 7.9% with dextromethorphan-quinidine vs 4.7% with placebo. Dextromethorphan-quinidine was not associated with cognitive impairment, sedation, or clinically significant QTc prolongation.</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE" NlmCategory="CONCLUSIONS">In this preliminary 10-week phase 2 randomized clinical trial of patients with probable Alzheimer disease, combination dextromethorphan-quinidine demonstrated clinically relevant efficacy for agitation and was generally well tolerated.</AbstractText><AbstractText Label="TRIAL REGISTRATION" NlmCategory="BACKGROUND">clinicaltrials.gov Identifier: NCT01584440.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cummings</LastName><ForeName>Jeffrey L</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, Nevada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lyketsos</LastName><ForeName>Constantine G</ForeName><Initials>CG</Initials><AffiliationInfo><Affiliation>Johns Hopkins Memory and Alzheimer's Treatment Center, Johns Hopkins Bayview, Baltimore, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peskind</LastName><ForeName>Elaine R</ForeName><Initials>ER</Initials><AffiliationInfo><Affiliation>VA Puget Sound Health Care System, University of Washington School of Medicine, Seattle.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Porsteinsson</LastName><ForeName>Anton P</ForeName><Initials>AP</Initials><AffiliationInfo><Affiliation>University of Rochester School of Medicine and Dentistry, Rochester, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mintzer</LastName><ForeName>Jacobo E</ForeName><Initials>JE</Initials><AffiliationInfo><Affiliation>Clinical Biotechnology Research Institute, Roper St Francis Hospital, Charleston, South Carolina6Ralph H. Johnson VA Medical Center, Charleston, South Carolina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scharre</LastName><ForeName>Douglas W</ForeName><Initials>DW</Initials><AffiliationInfo><Affiliation>Ohio State University, Columbus.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De La Gandara</LastName><ForeName>Jose E</ForeName><Initials>JE</Initials><AffiliationInfo><Affiliation>Quantum Laboratories Inc, West Palm Beach, Florida.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Agronin</LastName><ForeName>Marc</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Miami Jewish Health Systems, Miami, Florida.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Davis</LastName><ForeName>Charles S</ForeName><Initials>CS</Initials><AffiliationInfo><Affiliation>CSD Biostatistics Inc, Tucson, Arizona.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nguyen</LastName><ForeName>Uyen</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>Avanir Pharmaceuticals Inc, Aliso Viejo, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shin</LastName><ForeName>Paul</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Avanir Pharmaceuticals Inc, Aliso Viejo, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tariot</LastName><ForeName>Pierre N</ForeName><Initials>PN</Initials><AffiliationInfo><Affiliation>Banner Alzheimer's Institute, Phoenix, Arizona.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Siffert</LastName><ForeName>Jo&#xe3;o</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Avanir Pharmaceuticals Inc, Aliso Viejo, California.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT01584440</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D017427">Clinical Trial, Phase II</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA</MedlineTA><NlmUniqueID>7501160</NlmUniqueID><ISSNLinking>0098-7484</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004338">Drug Combinations</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010919">Placebos</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C507057">dextromethorphan - quinidine combination</NameOfSubstance></Chemical><Chemical><RegistryNumber>7355X3ROTS</RegistryNumber><NameOfSubstance UI="D003915">Dextromethorphan</NameOfSubstance></Chemical><Chemical><RegistryNumber>ITX08688JL</RegistryNumber><NameOfSubstance UI="D011802">Quinidine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>JAMA. 2015 Sep 22-29;314(12):1233-5. doi: 10.1001/jama.2015.10215.</RefSource><PMID Version="1">26393843</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>BMJ. 2015 Sep 22;351:h5015. doi: 10.1136/bmj.h5015.</RefSource><PMID Version="1">26400972</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Evid Based Med. 2016 Feb;21(1):25. doi: 10.1136/ebmed-2015-110324.</RefSource><PMID Version="1">26701197</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>JAMA. 2016 Mar 15;315(11):1166. doi: 10.1001/jama.2015.18286.</RefSource><PMID Version="1">26978214</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>JAMA. 2016 Mar 15;315(11):1166-7. doi: 10.1001/jama.2015.18289.</RefSource><PMID Version="1">26978215</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000374" MajorTopicYN="N">Aggression</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003915" MajorTopicYN="N">Dextromethorphan</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004338" MajorTopicYN="N">Drug Combinations</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010919" MajorTopicYN="N">Placebos</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011595" MajorTopicYN="N">Psychomotor Agitation</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011802" MajorTopicYN="N">Quinidine</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>9</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>9</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>10</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26393847</ArticleId><ArticleId IdType="doi">10.1001/jama.2015.10214</ArticleId><ArticleId IdType="pii">2442936</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">26389654</PMID><DateCompleted><Year>2016</Year><Month>03</Month><Day>11</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>19</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-6157</ISSN><JournalIssue CitedMedium="Internet"><Volume>72</Volume><Issue>11</Issue><PubDate><Year>2015</Year><Month>Nov</Month></PubDate></JournalIssue><Title>JAMA neurology</Title><ISOAbbreviation>JAMA Neurol</ISOAbbreviation></Journal><ArticleTitle>Association Between Atrial Fibrillation and Dementia in the General Population.</ArticleTitle><Pagination><StartPage>1288</StartPage><EndPage>1294</EndPage><MedlinePgn>1288-94</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamaneurol.2015.2161</ELocationID><Abstract><AbstractText Label="IMPORTANCE" NlmCategory="OBJECTIVE">Atrial fibrillation (AF) has been suggested as a risk factor for dementia since it may lead to chronic cerebral hypoperfusion and stroke. However, longitudinal studies assessing the association between AF and dementia have shown inconsistent results.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To determine the effect of AF on the risk of developing dementia during 20 years of follow-up.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS" NlmCategory="METHODS">The association of prevalent and incident AF with incident dementia was assessed from July 6, 1989, to February 4, 2010, in 6514 dementia-free participants in the prospective population-based Rotterdam Study. Data analysis was conducted from September 18, 2014, to April 17, 2015. Cox proportional hazards regression models adjusting for age, sex, and cardiovascular risk factors; censored for stroke; and stratified by median age were used. In addition, we investigated whether the association between incident AF and dementia varied according to the duration of exposure, categorized in 6-year time bands.</AbstractText><AbstractText Label="EXPOSURES" NlmCategory="METHODS">Prevalent and incident AF.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES" NlmCategory="METHODS">Incident dementia, determined according to the Diagnostic and Statistical Manual of Mental Disorders (Third Edition Revised) and the National Institute of Neurological and Communicative Disorders and Stroke-Alzheimer's Disease and Related Disorders Association criteria.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">At baseline, 318 of 6514 participants (4.9%) had prevalent AF, and during 81&#x202f;483 person-years of follow-up, 994 participants (15.3%) developed incident dementia. With findings presented as adjusted hazard ratio (95% CI), prevalent AF was related to an increased risk of dementia (1.33; 1.02-1.73). Among 6196 participants without prevalent AF during 79&#x202f;003 person-years of follow-up, 723 participants (11.7%) developed incident AF and 932 individuals (15.0%) developed incident dementia. Incident AF was associated with an increased risk of dementia in younger participants (&lt;67 years: 1.81; 1.11-2.94 vs &#x2265;67 years: 1.12; 0.85-1.46; P&#x2009;=&#x2009;.02 for interaction). The risk of dementia was strongly associated with duration of exposure to AF in the younger participants (in the highest stratum: 3.30; 1.16-9.38; P&#x2009;=&#x2009;.003 for trend) but not in the elder participants (0.25; 0.04-1.86; P&#x2009;=&#x2009;.94 for trend).</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE" NlmCategory="CONCLUSIONS">Atrial fibrillation is associated with an increased risk of dementia, independent of clinical stroke. This association was strongest for younger participants with the longest duration of AF. Future studies should investigate whether optimal treatment of AF can prevent or postpone dementia.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>de Bruijn</LastName><ForeName>Ren&#xe9;e F A G</ForeName><Initials>RF</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, Erasmus Medical Center, Rotterdam, the Netherlands2Department of Neurology, Erasmus Medical Center, Rotterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Heeringa</LastName><ForeName>Jan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, Erasmus Medical Center, Rotterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wolters</LastName><ForeName>Frank J</ForeName><Initials>FJ</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, Erasmus Medical Center, Rotterdam, the Netherlands2Department of Neurology, Erasmus Medical Center, Rotterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Franco</LastName><ForeName>Oscar H</ForeName><Initials>OH</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, Erasmus Medical Center, Rotterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stricker</LastName><ForeName>Bruno H C</ForeName><Initials>BH</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, Erasmus Medical Center, Rotterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hofman</LastName><ForeName>Albert</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, Erasmus Medical Center, Rotterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Koudstaal</LastName><ForeName>Peter J</ForeName><Initials>PJ</Initials><AffiliationInfo><Affiliation>Department of Neurology, Erasmus Medical Center, Rotterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ikram</LastName><ForeName>M Arfan</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, Erasmus Medical Center, Rotterdam, the Netherlands3Department of Radiology, Erasmus Medical Center, Rotterdam, the Netherlands.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Neurol</MedlineTA><NlmUniqueID>101589536</NlmUniqueID><ISSNLinking>2168-6149</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>JAMA Neurol. 2016 May 1;73(5):607. doi: 10.1001/jamaneurol.2015.5066.</RefSource><PMID Version="1">26998790</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001281" MajorTopicYN="N">Atrial Fibrillation</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="Y">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009426" MajorTopicYN="N" Type="Geographic">Netherlands</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012306" MajorTopicYN="N">Risk</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>9</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>9</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>3</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26389654</ArticleId><ArticleId IdType="doi">10.1001/jamaneurol.2015.2161</ArticleId><ArticleId IdType="pii">2442471</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">26390242</PMID><DateCompleted><Year>2016</Year><Month>01</Month><Day>19</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>31</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1546-170X</ISSN><JournalIssue CitedMedium="Internet"><Volume>21</Volume><Issue>10</Issue><PubDate><Year>2015</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Nature medicine</Title><ISOAbbreviation>Nat Med</ISOAbbreviation></Journal><ArticleTitle>Critical role of acetylation in tau-mediated neurodegeneration and cognitive deficits.</ArticleTitle><Pagination><StartPage>1154</StartPage><EndPage>1162</EndPage><MedlinePgn>1154-62</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/nm.3951</ELocationID><Abstract><AbstractText>Tauopathies, including frontotemporal dementia (FTD) and Alzheimer's disease (AD), are neurodegenerative diseases in which tau fibrils accumulate. Recent evidence supports soluble tau species as the major toxic species. How soluble tau accumulates and causes neurodegeneration remains unclear. Here we identify tau acetylation at Lys174 (K174) as an early change in AD brains and a critical determinant in tau homeostasis and toxicity in mice. The acetyl-mimicking mutant K174Q slows tau turnover and induces cognitive deficits in vivo. Acetyltransferase p300-induced tau acetylation is inhibited by salsalate and salicylate, which enhance tau turnover and reduce tau levels. In the PS19 transgenic mouse model of FTD, administration of salsalate after disease onset inhibited p300 activity, lowered levels of total tau and tau acetylated at K174, rescued tau-induced memory deficits and prevented hippocampal atrophy. The tau-lowering and protective effects of salsalate were diminished in neurons expressing K174Q tau. Targeting tau acetylation could be a new therapeutic strategy against human tauopathies.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Min</LastName><ForeName>Sang-Won</ForeName><Initials>SW</Initials><AffiliationInfo><Affiliation>Gladstone Institute of Neurological Disease, San Francisco, California, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, University of California, San Francisco, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Xu</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Gladstone Institute of Neurological Disease, San Francisco, California, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, University of California, San Francisco, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tracy</LastName><ForeName>Tara E</ForeName><Initials>TE</Initials><AffiliationInfo><Affiliation>Gladstone Institute of Neurological Disease, San Francisco, California, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, University of California, San Francisco, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Yaqiao</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Gladstone Institute of Neurological Disease, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Yungui</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Gladstone Institute of Neurological Disease, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Chao</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Gladstone Institute of Neurological Disease, San Francisco, California, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, University of California, San Francisco, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shirakawa</LastName><ForeName>Kotaro</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Gladstone Institute of Virology and Immunology, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Minami</LastName><ForeName>S Sakura</ForeName><Initials>SS</Initials><AffiliationInfo><Affiliation>Gladstone Institute of Neurological Disease, San Francisco, California, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, University of California, San Francisco, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Defensor</LastName><ForeName>Erwin</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Stanford Institute for Neuro-Innovation and Translational Neurosciences, Stanford University School of Medicine, Stanford, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mok</LastName><ForeName>Sue Ann</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>Department of Pharmaceutical Chemistry, Institute for Neurodegenerative Disease, University of California, San Francisco, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sohn</LastName><ForeName>Peter Dongmin</ForeName><Initials>PD</Initials><AffiliationInfo><Affiliation>Gladstone Institute of Neurological Disease, San Francisco, California, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neuroscience Graduate Program, University of California, San Francisco, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schilling</LastName><ForeName>Birgit</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Buck Institute for Research on Aging, Novato, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cong</LastName><ForeName>Xin</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Buck Institute for Research on Aging, Novato, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ellerby</LastName><ForeName>Lisa</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Buck Institute for Research on Aging, Novato, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gibson</LastName><ForeName>Bradford W</ForeName><Initials>BW</Initials><AffiliationInfo><Affiliation>Buck Institute for Research on Aging, Novato, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Johnson</LastName><ForeName>Jeffrey</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Gladstone Institute of Cardiovascular Disease, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Krogan</LastName><ForeName>Nevan</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Gladstone Institute of Cardiovascular Disease, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shamloo</LastName><ForeName>Mehrdad</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Stanford Institute for Neuro-Innovation and Translational Neurosciences, Stanford University School of Medicine, Stanford, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gestwicki</LastName><ForeName>Jason</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Pharmaceutical Chemistry, Institute for Neurodegenerative Disease, University of California, San Francisco, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Masliah</LastName><ForeName>Eliezer</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, University of California, San Diego, San Diego, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Verdin</LastName><ForeName>Eric</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Gladstone Institute of Virology and Immunology, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gan</LastName><ForeName>Li</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Gladstone Institute of Neurological Disease, San Francisco, California, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, University of California, San Francisco, San Francisco, California, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neuroscience Graduate Program, University of California, San Francisco, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>1R01AG036884</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005131</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG036884</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RL1 NS062413</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS059690</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS40251</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R24 DK085610</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01AG030207</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 NS065780</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30NS065780</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG030207</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS062413</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AI027763</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 MH062512</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS040251</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>S10 RR024615</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>09</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Med</MedlineTA><NlmUniqueID>9502015</NlmUniqueID><ISSNLinking>1078-8956</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Drug Discov. 2015 Nov;14(11):748. doi: 10.1038/nrd4768.</RefSource><PMID Version="1">26514860</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000107" MajorTopicYN="N">Acetylation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001522" MajorTopicYN="N">Behavior, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="N">Neurodegenerative Diseases</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading></MeshHeadingList><CoiStatement><b>COMPETING FINANCIAL INTERESTS</b>. The authors declare no competing financial interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>4</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>8</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>9</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>9</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>1</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2016</Year><Month>4</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26390242</ArticleId><ArticleId IdType="mid">NIHMS717753</ArticleId><ArticleId IdType="pmc">PMC4598295</ArticleId><ArticleId IdType="doi">10.1038/nm.3951</ArticleId><ArticleId IdType="pii">nm.3951</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ludolph AC, et al. Tauopathies with parkinsonism: clinical spectrum, neuropathologic basis, biological markers, and treatment options. Eur J Neurol. 2009;16:297&#x2013;309.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2847416</ArticleId><ArticleId IdType="pubmed">19364361</ArticleId></ArticleIdList></Reference><Reference><Citation>Cairns NJ, et al. Neuropathologic diagnostic and nosologic criteria for frontotemporal lobar degeneration: consensus of the Consortium for Frontotemporal Lobar Degeneration. Acta neuropathologica. 2007;114:5&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2827877</ArticleId><ArticleId IdType="pubmed">17579875</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol Berl. 1991;82:239&#x2013;259.</Citation><ArticleIdList><ArticleId IdType="pubmed">1759558</ArticleId></ArticleIdList></Reference><Reference><Citation>Lasagna-Reeves CA, et al. Identification of oligomers at early stages of tau aggregation in Alzheimer&#x2019;s disease. FASEB journal : official publication of the Federation of American Societies for Experimental Biology. 2012;26:1946&#x2013;1959.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4046102</ArticleId><ArticleId IdType="pubmed">22253473</ArticleId></ArticleIdList></Reference><Reference><Citation>Ren Y, Sahara N. Characteristics of tau oligomers. Frontiers in neurology. 2013;4:102.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3715738</ArticleId><ArticleId IdType="pubmed">23882258</ArticleId></ArticleIdList></Reference><Reference><Citation>Maeda S, et al. Increased levels of granular tau oligomers: an early sign of brain aging and Alzheimer&#x2019;s disease. Neuroscience research. 2006;54:197&#x2013;201.</Citation><ArticleIdList><ArticleId IdType="pubmed">16406150</ArticleId></ArticleIdList></Reference><Reference><Citation>Lasagna-Reeves CA, et al. Tau oligomers impair memory and induce synaptic and mitochondrial dysfunction in wild-type mice. Molecular neurodegeneration. 2011;6:39.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3224595</ArticleId><ArticleId IdType="pubmed">21645391</ArticleId></ArticleIdList></Reference><Reference><Citation>Berger Z, et al. Accumulation of pathological tau species and memory loss in a conditional model of tauopathy. The Journal of neuroscience : the official journal of the Society for Neuroscience. 2007;27:3650&#x2013;3662.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672413</ArticleId><ArticleId IdType="pubmed">17409229</ArticleId></ArticleIdList></Reference><Reference><Citation>Santacruz K, et al. Tau suppression in a neurodegenerative mouse model improves memory function. Science. 2005;309:476&#x2013;481.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1574647</ArticleId><ArticleId IdType="pubmed">16020737</ArticleId></ArticleIdList></Reference><Reference><Citation>Sydow A, et al. Reversibility of Tau-related cognitive defects in a regulatable FTD mouse model. Journal of molecular neuroscience : MN. 2011;45:432&#x2013;437.</Citation><ArticleIdList><ArticleId IdType="pubmed">21822709</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Mandelkow E. Degradation of tau protein by autophagy and proteasomal pathways. Biochemical Society transactions. 2012;40:644&#x2013;652.</Citation><ArticleIdList><ArticleId IdType="pubmed">22817709</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee BH, et al. Enhancement of proteasome activity by a small-molecule inhibitor of USP14. Nature. 2010;467:179&#x2013;184.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2939003</ArticleId><ArticleId IdType="pubmed">20829789</ArticleId></ArticleIdList></Reference><Reference><Citation>Tai HC, et al. The synaptic accumulation of hyperphosphorylated tau oligomers in Alzheimer disease is associated with dysfunction of the ubiquitin-proteasome system. The American journal of pathology. 2012;181:1426&#x2013;1435.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3463637</ArticleId><ArticleId IdType="pubmed">22867711</ArticleId></ArticleIdList></Reference><Reference><Citation>Min SW, et al. Acetylation of tau inhibits its degradation and contributes to tauopathy. Neuron. 2010;67:953&#x2013;966.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3035103</ArticleId><ArticleId IdType="pubmed">20869593</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen TJ, et al. The acetylation of tau inhibits its function and promotes pathological tau aggregation. Nature communications. 2011;2:252.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3120096</ArticleId><ArticleId IdType="pubmed">21427723</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim GW, Yang XJ. Comprehensive lysine acetylomes emerging from bacteria to humans. Trends in biochemical sciences. 2010</Citation><ArticleIdList><ArticleId IdType="pubmed">21075636</ArticleId></ArticleIdList></Reference><Reference><Citation>Mandelkow EM, Mandelkow E. Biochemistry and cell biology of tau protein in neurofibrillary degeneration. Cold Spring Harbor perspectives in medicine. 2012;2:a006247.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3385935</ArticleId><ArticleId IdType="pubmed">22762014</ArticleId></ArticleIdList></Reference><Reference><Citation>Cook C, et al. Acetylation of the KXGS motifs in tau is a critical determinant in modulation of tau aggregation and clearance. Human molecular genetics. 2013</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3857946</ArticleId><ArticleId IdType="pubmed">23962722</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshiyama Y, et al. Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron. 2007;53:337&#x2013;351.</Citation><ArticleIdList><ArticleId IdType="pubmed">17270732</ArticleId></ArticleIdList></Reference><Reference><Citation>Jicha GA, Bowser R, Kazam IG, Davies P. Alz-50 and MC-1, a new monoclonal antibody raised to paired helical filaments, recognize conformational epitopes on recombinant tau. Journal of neuroscience research. 1997;48:128&#x2013;132.</Citation><ArticleIdList><ArticleId IdType="pubmed">9130141</ArticleId></ArticleIdList></Reference><Reference><Citation>Weaver CL, Espinoza M, Kress Y, Davies P. Conformational change as one of the earliest alterations of tau in Alzheimer&#x2019;s disease. Neurobiology of aging. 2000;21:719&#x2013;727.</Citation><ArticleIdList><ArticleId IdType="pubmed">11016541</ArticleId></ArticleIdList></Reference><Reference><Citation>Yeung F, et al. Regulation of the mitogen-activated protein kinase kinase (MEK)-1 by NAD-dependent deacetylases. Oncogene. 2014</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4182313</ArticleId><ArticleId IdType="pubmed">24681949</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang B, et al. Microtubule acetylation amplifies p38 kinase signalling and anti-inflammatory IL-10 production. Nature communications. 2014;5:3479.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4000527</ArticleId><ArticleId IdType="pubmed">24632940</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao Y, et al. p300-dependent acetylation of activating transcription factor 5 enhances C/EBPbeta transactivation of C/EBPalpha during 3T3-L1 differentiation. Molecular and cellular biology. 2014;34:315&#x2013;324.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3911509</ArticleId><ArticleId IdType="pubmed">24216764</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaworski T, et al. AAV-tau mediates pyramidal neurodegeneration by cell-cycle re-entry without neurofibrillary tangle formation in wild-type mice. PloS one. 2009;4:e7280.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2748684</ArticleId><ArticleId IdType="pubmed">19794916</ArticleId></ArticleIdList></Reference><Reference><Citation>Lecourtier L, et al. Intact neurobehavioral development and dramatic impairments of procedural-like memory following neonatal ventral hippocampal lesion in rats. Neuroscience. 2012;207:110&#x2013;123.</Citation><ArticleIdList><ArticleId IdType="pubmed">22322113</ArticleId></ArticleIdList></Reference><Reference><Citation>Takeuchi H, et al. P301S mutant human tau transgenic mice manifest early symptoms of human tauopathies with dementia and altered sensorimotor gating. PloS one. 2011;6:e21050.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3115982</ArticleId><ArticleId IdType="pubmed">21698260</ArticleId></ArticleIdList></Reference><Reference><Citation>Kasper LH, et al. CBP/p300 double null cells reveal effect of coactivator level and diversity on CREB transactivation. The EMBO journal. 2010;29:3660&#x2013;3672.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2982758</ArticleId><ArticleId IdType="pubmed">20859256</ArticleId></ArticleIdList></Reference><Reference><Citation>Kasper LH, Qu C, Obenauer JC, McGoldrick DJ, Brindle PK. Genome-wide and single-cell analyses reveal a context dependent relationship between CBP recruitment and gene expression. Nucleic acids research. 2014;42:11363&#x2013;11382.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4191404</ArticleId><ArticleId IdType="pubmed">25249627</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin Q, et al. Distinct roles of GCN5/PCAF-mediated H3K9ac and CBP/p300-mediated H3K18/27ac in nuclear receptor transactivation. The EMBO journal. 2011;30:249&#x2013;262.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3025463</ArticleId><ArticleId IdType="pubmed">21131905</ArticleId></ArticleIdList></Reference><Reference><Citation>Kouzarides T. Chromatin modifications and their function. Cell. 2007;128:693&#x2013;705.</Citation><ArticleIdList><ArticleId IdType="pubmed">17320507</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshiyama Y, Kojima A, Ishikawa C, Arai K. Anti-inflammatory action of donepezil ameliorates tau pathology, synaptic loss, and neurodegeneration in a tauopathy mouse model. Journal of Alzheimer&#x2019;s disease : JAD. 2010;22:295&#x2013;306.</Citation><ArticleIdList><ArticleId IdType="pubmed">20847440</ArticleId></ArticleIdList></Reference><Reference><Citation>Faizi M, et al. Thy1-hAPP(Lond/Swe+) mouse model of Alzheimer&#x2019;s disease displays broad behavioral deficits in sensorimotor, cognitive and social function. Brain and behavior. 2012;2:142&#x2013;154.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3345358</ArticleId><ArticleId IdType="pubmed">22574282</ArticleId></ArticleIdList></Reference><Reference><Citation>Grinberg LT, et al. Argyrophilic grain disease differs from other tauopathies by lacking tau acetylation. Acta neuropathologica. 2013;125:581&#x2013;593.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3692283</ArticleId><ArticleId IdType="pubmed">23371364</ArticleId></ArticleIdList></Reference><Reference><Citation>Irwin DJ, et al. Acetylated tau neuropathology in sporadic and hereditary tauopathies. The American journal of pathology. 2013;183:344&#x2013;351.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3730769</ArticleId><ArticleId IdType="pubmed">23885714</ArticleId></ArticleIdList></Reference><Reference><Citation>Irwin DJ, et al. Acetylated tau, a novel pathological signature in Alzheimer&#x2019;s disease and other tauopathies. Brain : a journal of neurology. 2012;135:807&#x2013;818.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3286338</ArticleId><ArticleId IdType="pubmed">22366796</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris M, et al. Tau post-translational modifications in wild-type and human amyloid precursor protein transgenic mice. Nature neuroscience. 2015;18:1183&#x2013;1189.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8049446</ArticleId><ArticleId IdType="pubmed">26192747</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith WL, DeWitt DL, Garavito RM. Cyclooxygenases: structural, cellular, and molecular biology. Annu Rev Biochem. 2000;69:145&#x2013;182.</Citation><ArticleIdList><ArticleId IdType="pubmed">10966456</ArticleId></ArticleIdList></Reference><Reference><Citation>in t&#x2019; Veld BA, et al. Nonsteroidal antiinflammatory drugs and the risk of Alzheimer&#x2019;s disease. N Engl J Med. 2001;345:1515&#x2013;1521.</Citation><ArticleIdList><ArticleId IdType="pubmed">11794217</ArticleId></ArticleIdList></Reference><Reference><Citation>Aubry S, et al. Assembly and interrogation of Alzheimer&#x2019;s disease genetic networks reveal novel regulators of progression. PloS one. 2015;10:e0120352.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4363671</ArticleId><ArticleId IdType="pubmed">25781952</ArticleId></ArticleIdList></Reference><Reference><Citation>Hawley SA, et al. The Ancient Drug Salicylate Directly Activates AMP-Activated Protein Kinase. Science. 2012</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3399766</ArticleId><ArticleId IdType="pubmed">22517326</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Qiu J, Wang X, Zhang Y, Xia M. AMP-activated protein kinase suppresses endothelial cell inflammation through phosphorylation of transcriptional coactivator p300. Arterioscler Thromb Vasc Biol. 2011;31:2897&#x2013;2908.</Citation><ArticleIdList><ArticleId IdType="pubmed">21940946</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim JY, Oh MA, Kim WH, Sohn HY, Park SI. AMP-activated protein kinase inhibits TGF-beta-induced fibrogenic responses of hepatic stellate cells by targeting transcriptional coactivator p300. Journal of cellular physiology. 2012;227:1081&#x2013;1089.</Citation><ArticleIdList><ArticleId IdType="pubmed">21567395</ArticleId></ArticleIdList></Reference><Reference><Citation>Greene WC, Chen LF. Regulation of NF-kappaB action by reversible acetylation. Novartis Foundation symposium. 2004;259:208&#x2013;217. discussion 218&#x2013;225.</Citation><ArticleIdList><ArticleId IdType="pubmed">15171256</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee H, et al. Ethanol selectively modulates inflammatory activation signaling of brain microglia. Journal of neuroimmunology. 2004;156:88&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pubmed">15465599</ArticleId></ArticleIdList></Reference><Reference><Citation>Apostolova LG, et al. Conversion of mild cognitive impairment to Alzheimer disease predicted by hippocampal atrophy maps. Archives of neurology. 2006;63:693&#x2013;699.</Citation><ArticleIdList><ArticleId IdType="pubmed">16682538</ArticleId></ArticleIdList></Reference><Reference><Citation>Kerchner GA, et al. Hippocampal CA1 apical neuropil atrophy in mild Alzheimer disease visualized with 7-T MRI. Neurology. 2010;75:1381&#x2013;1387.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3013485</ArticleId><ArticleId IdType="pubmed">20938031</ArticleId></ArticleIdList></Reference><Reference><Citation>Leung KK, et al. Cerebral atrophy in mild cognitive impairment and Alzheimer disease: rates and acceleration. Neurology. 2013;80:648&#x2013;654.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3590059</ArticleId><ArticleId IdType="pubmed">23303849</ArticleId></ArticleIdList></Reference><Reference><Citation>Reagan-Shaw S, Nihal M, Ahmad N. Dose translation from animal to human studies revisited. FASEB journal : official publication of the Federation of American Societies for Experimental Biology. 2008;22:659&#x2013;661.</Citation><ArticleIdList><ArticleId IdType="pubmed">17942826</ArticleId></ArticleIdList></Reference><Reference><Citation>Schilling B, et al. Platform-independent and label-free quantitation of proteomic data using MS1 extracted ion chromatograms in skyline: application to protein acetylation and phosphorylation. Molecular &amp; cellular proteomics : MCP. 2012;11:202&#x2013;214.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3418851</ArticleId><ArticleId IdType="pubmed">22454539</ArticleId></ArticleIdList></Reference><Reference><Citation>Shilov IV, et al. The Paragon Algorithm, a next generation search engine that uses sequence temperature values and feature probabilities to identify peptides from tandem mass spectra. Molecular &amp; cellular proteomics : MCP. 2007;6:1638&#x2013;1655.</Citation><ArticleIdList><ArticleId IdType="pubmed">17533153</ArticleId></ArticleIdList></Reference><Reference><Citation>Perkins DN, Pappin DJ, Creasy DM, Cottrell JS. Probability-based protein identification by searching sequence databases using mass spectrometry data. Electrophoresis. 1999;20:3551&#x2013;3567.</Citation><ArticleIdList><ArticleId IdType="pubmed">10612281</ArticleId></ArticleIdList></Reference><Reference><Citation>Pagans S, et al. SIRT1 regulates HIV transcription via Tat deacetylation. PLoS Biol. 2005;3:e41.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC546329</ArticleId><ArticleId IdType="pubmed">15719057</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen J, et al. SIRT1 Protects against Microglia-dependent Amyloid-{beta} Toxicity through Inhibiting NF-{kappa}B Signaling. The Journal of biological chemistry. 2005;280:40364&#x2013;40374.</Citation><ArticleIdList><ArticleId IdType="pubmed">16183991</ArticleId></ArticleIdList></Reference><Reference><Citation>Barghorn S, et al. Structure, microtubule interactions, and paired helical filament aggregation by tau mutants of frontotemporal dementias. Biochemistry. 2000;39:11714&#x2013;11721.</Citation><ArticleIdList><ArticleId IdType="pubmed">10995239</ArticleId></ArticleIdList></Reference><Reference><Citation>Moore CL, et al. Secondary nucleating sequences affect kinetics and thermodynamics of tau aggregation. Biochemistry. 2011;50:10876&#x2013;10886.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3237831</ArticleId><ArticleId IdType="pubmed">22085312</ArticleId></ArticleIdList></Reference><Reference><Citation>Winsor CP. The Gompertz Curve as a Growth Curve. Proceedings of the National Academy of Sciences of the United States of America. 1932;18:1&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1076153</ArticleId><ArticleId IdType="pubmed">16577417</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun A, Nguyen XV, Bing G. Comparative analysis of an improved thioflavin-s stain, Gallyas silver stain, and immunohistochemistry for neurofibrillary tangle demonstration on the same sections. The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society. 2002;50:463&#x2013;472.</Citation><ArticleIdList><ArticleId IdType="pubmed">11897799</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim SW, et al. Robust protective effects of a novel multimodal neuroprotectant oxopropanoyloxy benzoic acid (a salicylic acid/pyruvate ester) in the postischemic brain. Molecular pharmacology. 2011;79:220&#x2013;228.</Citation><ArticleIdList><ArticleId IdType="pubmed">21036874</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">2974227</PMID><DateCompleted><Year>1989</Year><Month>01</Month><Day>25</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>16</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0001-6322</ISSN><JournalIssue CitedMedium="Print"><Volume>76</Volume><Issue>6</Issue><PubDate><Year>1988</Year></PubDate></JournalIssue><Title>Acta neuropathologica</Title><ISOAbbreviation>Acta Neuropathol</ISOAbbreviation></Journal><ArticleTitle>Expression of the histocompatibility glycoprotein HLA-DR in neurological disease.</ArticleTitle><Pagination><StartPage>550</StartPage><EndPage>557</EndPage><MedlinePgn>550-7</MedlinePgn></Pagination><Abstract><AbstractText>Reactive microglia or macrophages expressing the histocompatibility glycoprotein HLA-DR were detected in many neurological diseases including Alzheimer's, Parkinson's, Pick's and Huntington's diseases, parkinsonism-dementia of Guam, amyotrophic lateral sclerosis, Shy-Drager syndrome, multiple sclerosis and AIDS encephalopathy. Reactive astrocytes, also present in these conditions, were established as a population distinct from the HLA-DR positive microglia by double immunostaining for glial fibrillary acidic protein and HLA-DR. A distinctive pattern of HLA-DR positive cells was seen in each disease entity. Areas known to contain pathology always stained positively, and, in several cases, reactive microglia appeared in areas that would otherwise not have been suspected of being involved in the pathological process. HLA-DR staining, which outlines the surface membranes of positive cells, was so strong that lesioned areas could frequently be identified in sections with the naked eye. In adjacent sections stained with H&amp;E or sections destained of HLA-DR and then restained with H&amp;E, gliosis was often hard to identify except on close microscopic inspection. The results suggest that HLA-DR staining may be a valuable addition to standard neuropathological methods and might be useful in investigating diseases where pathology has not yet been identified.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>McGeer</LastName><ForeName>P L</ForeName><Initials>PL</Initials><AffiliationInfo><Affiliation>Kinsmen Laboratory of Neurological Research, Department of Psychiatry, University of British Columbia, Vancouver, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Itagaki</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>McGeer</LastName><ForeName>E G</ForeName><Initials>EG</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Acta Neuropathol</MedlineTA><NlmUniqueID>0412041</NlmUniqueID><ISSNLinking>0001-6322</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006684">HLA-DR Antigens</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001927" MajorTopicYN="N">Brain Diseases</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006684" MajorTopicYN="N">HLA-DR Antigens</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006816" MajorTopicYN="N">Huntington Disease</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007150" MajorTopicYN="N">Immunohistochemistry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008264" MajorTopicYN="N">Macrophages</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009457" MajorTopicYN="N">Neuroglia</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1988</Year><Month>1</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1988</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1988</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">2974227</ArticleId><ArticleId IdType="doi">10.1007/BF00689592</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>J Neuroimmunol. 1985 Apr;8(1):1-14</Citation><ArticleIdList><ArticleId IdType="pubmed">3882754</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroscience. 1986 Mar;17(3):857-65</Citation><ArticleIdList><ArticleId IdType="pubmed">2422599</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 1973 Sep;23(9):912-7</Citation><ArticleIdList><ArticleId IdType="pubmed">4146891</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Pathol. 1987 Mar;126(3):403-10</Citation><ArticleIdList><ArticleId IdType="pubmed">3548405</ArticleId></ArticleIdList></Reference><Reference><Citation>Transplantation. 1981 Jan;31(1):75-8</Citation><ArticleIdList><ArticleId IdType="pubmed">7015604</ArticleId></ArticleIdList></Reference><Reference><Citation>Can J Neurol Sci. 1987 Aug;14(3 Suppl):363-72</Citation><ArticleIdList><ArticleId IdType="pubmed">2890425</ArticleId></ArticleIdList></Reference><Reference><Citation>J Immunol. 1986 Jun 1;136(11):4054-62</Citation><ArticleIdList><ArticleId IdType="pubmed">2422272</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 1984 Jun;34(6):741-5</Citation><ArticleIdList><ArticleId IdType="pubmed">6539435</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurol Sci. 1987 Aug;80(1):25-37</Citation><ArticleIdList><ArticleId IdType="pubmed">3302117</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neuroimmunol. 1986 Oct;12(4):265-77</Citation><ArticleIdList><ArticleId IdType="pubmed">3489735</ArticleId></ArticleIdList></Reference><Reference><Citation>J Immunol. 1984 May;132(5):2402-7</Citation><ArticleIdList><ArticleId IdType="pubmed">6425402</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neuroimmunol. 1983 Oct;5(2):197-205</Citation><ArticleIdList><ArticleId IdType="pubmed">6413533</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci Methods. 1987 Mar;19(3):183-92</Citation><ArticleIdList><ArticleId IdType="pubmed">2437408</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Neurol. 1986 Jun;19(6):525-35</Citation><ArticleIdList><ArticleId IdType="pubmed">3014994</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Pathol. 1925 Jan;1(1):77-90.15</Citation><ArticleIdList><ArticleId IdType="pubmed">19969634</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 1984 Aug 23-29;310(5979):688-91</Citation><ArticleIdList><ArticleId IdType="pubmed">6433204</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurol Neurosurg Psychiatry. 1984 Apr;47(4):417-8</Citation><ArticleIdList><ArticleId IdType="pubmed">6587009</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Res. 1987 Jul 7;415(1):49-62</Citation><ArticleIdList><ArticleId IdType="pubmed">3304532</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurosci Lett. 1987 Aug 18;79(1-2):195-200</Citation><ArticleIdList><ArticleId IdType="pubmed">3670729</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neuroimmunol. 1987 Apr;14(3):293-303</Citation><ArticleIdList><ArticleId IdType="pubmed">3494042</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Neuropathol. 1987;74(1):33-8</Citation><ArticleIdList><ArticleId IdType="pubmed">3310502</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 1986 Dec;36(12 ):1569-74</Citation><ArticleIdList><ArticleId IdType="pubmed">3491344</ArticleId></ArticleIdList></Reference><Reference><Citation>J Exp Med. 1987 Apr 1;165(4):1058-75</Citation><ArticleIdList><ArticleId IdType="pubmed">2435831</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Neuropathol. 1985;68(4):263-72</Citation><ArticleIdList><ArticleId IdType="pubmed">3879081</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 1987 Apr;84(7):2082-6</Citation><ArticleIdList><ArticleId IdType="pubmed">3550805</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">3263583</PMID><DateCompleted><Year>1988</Year><Month>11</Month><Day>30</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0197-4580</ISSN><JournalIssue CitedMedium="Print"><Volume>9</Volume><Issue>4</Issue><PubDate><Year>1988</Year><Season>Jul-Aug</Season></PubDate></JournalIssue><Title>Neurobiology of aging</Title><ISOAbbreviation>Neurobiol Aging</ISOAbbreviation></Journal><ArticleTitle>Expression of immune system-associated antigens by cells of the human central nervous system: relationship to the pathology of Alzheimer's disease.</ArticleTitle><Pagination><StartPage>339</StartPage><EndPage>349</EndPage><MedlinePgn>339-49</MedlinePgn></Pagination><Abstract><AbstractText>HLA-DR is a class II major histocompatibility complex antigen which in the periphery confers antigen presenting capability. We have previously shown that this marker is profusely expressed in cortex of elderly and Alzheimer's disease (AD) patients, as is the receptor for the lymphokine interleukin-2. We now report presence of additional immune-related antigens in AD, and distributional differences from normal elderly controls. In gray matter, HLA-DR immunoreactivity is normally sparse, except in AD where it co-localizes with virtually all neuritic plaques. HLA-DR positive T cells can be demonstrated in Alzheimer's disease brain tissue, as can instances of apposition between putative brain microglia and T cells. In addition, cells with the morphologic characteristics of astrocytes label for natural killer cell antigen (Leu-11), and apparent lymphocytes bearing T helper and T cytotoxic/suppressor cell antigens are observed. These and other data suggest that the glial proliferation and scavenger activity characteristic of Alzheimer's disease may occur in an immune context and may play an important role in the pathogenesis of the disorder.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rogers</LastName><ForeName>J</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>L. J. Roberts Center, Institute for Biogerontology Research, Sun City, AZ 85372.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Luber-Narod</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Styren</LastName><ForeName>S D</ForeName><Initials>SD</Initials></Author><Author ValidYN="Y"><LastName>Civin</LastName><ForeName>W H</ForeName><Initials>WH</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>1RO1 AG07367-01</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurobiol Aging</MedlineTA><NlmUniqueID>8100437</NlmUniqueID><ISSNLinking>0197-4580</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006681">HLA-D Antigens</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000911" MajorTopicYN="N">Antibodies, Monoclonal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006681" MajorTopicYN="N">HLA-D Antigens</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007150" MajorTopicYN="N">Immunohistochemistry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009454" MajorTopicYN="N">Neurofibrils</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009457" MajorTopicYN="N">Neuroglia</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013601" MajorTopicYN="N">T-Lymphocytes</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1988</Year><Month>7</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1988</Year><Month>7</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1988</Year><Month>7</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">3263583</ArticleId><ArticleId IdType="doi">10.1016/s0197-4580(88)80079-4</ArticleId><ArticleId IdType="pii">S0197-4580(88)80079-4</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">2565620</PMID><DateCompleted><Year>1989</Year><Month>06</Month><Day>02</Day></DateCompleted><DateRevised><Year>2019</Year><Month>09</Month><Day>19</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0340-6075</ISSN><JournalIssue CitedMedium="Print"><Volume>56</Volume><Issue>4</Issue><PubDate><Year>1989</Year></PubDate></JournalIssue><Title>Virchows Archiv. B, Cell pathology including molecular pathology</Title><ISOAbbreviation>Virchows Arch B Cell Pathol Incl Mol Pathol</ISOAbbreviation></Journal><ArticleTitle>Complement activation in amyloid plaques in Alzheimer's dementia.</ArticleTitle><Pagination><StartPage>259</StartPage><EndPage>262</EndPage><MedlinePgn>259-62</MedlinePgn></Pagination><Abstract><AbstractText>Amyloid plaques in Alzheimer's dementia contain complement factors C1q, C4 and C3. In the present study we demonstrate complement activation in amyloid plaques using immunoenzymatical techniques and specific antibodies against subunits of individual complement components and activated complement products. Amyloid plaques contain C1q and activated C3 fragments (C3c and C3d, g) but no C1s and C3a. These findings demonstrate that the complement components are not passively bound to the amyloid plaque structures but are the result of an activation process. The role of complement activation in the genesis of senile plaques is discussed.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Eikelenboom</LastName><ForeName>P</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Medical Faculty, Free University, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hack</LastName><ForeName>C E</ForeName><Initials>CE</Initials></Author><Author ValidYN="Y"><LastName>Rozemuller</LastName><ForeName>J M</ForeName><Initials>JM</Initials></Author><Author ValidYN="Y"><LastName>Stam</LastName><ForeName>F C</ForeName><Initials>FC</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Virchows Arch B Cell Pathol Incl Mol Pathol</MedlineTA><NlmUniqueID>9316922</NlmUniqueID><ISSNLinking>0340-6075</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003167" MajorTopicYN="Y">Complement Activation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007124" MajorTopicYN="N">Immunoenzyme Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007150" MajorTopicYN="N">Immunohistochemistry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1989</Year><Month>1</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1989</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1989</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">2565620</ArticleId><ArticleId IdType="doi">10.1007/BF02890024</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">26400934</PMID><DateCompleted><Year>2015</Year><Month>12</Month><Day>29</Day></DateCompleted><DateRevised><Year>2020</Year><Month>12</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>35</Volume><Issue>38</Issue><PubDate><Year>2015</Year><Month>Sep</Month><Day>23</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Complement C3-Deficient Mice Fail to Display Age-Related Hippocampal Decline.</ArticleTitle><Pagination><StartPage>13029</StartPage><EndPage>13042</EndPage><MedlinePgn>13029-42</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.1698-15.2015</ELocationID><Abstract><AbstractText>The complement system is part of the innate immune response responsible for removing pathogens and cellular debris, in addition to helping to refine CNS neuronal connections via microglia-mediated pruning of inappropriate synapses during brain development. However, less is known about the role of complement during normal aging. Here, we studied the role of the central complement component, C3, in synaptic health and aging. We examined behavior as well as electrophysiological, synaptic, and neuronal changes in the brains of C3-deficient male mice (C3 KO) compared with age-, strain-, and gender-matched C57BL/6J (wild-type, WT) control mice at postnatal day 30, 4 months, and 16 months of age. We found the following: (1) region-specific and age-dependent synapse loss in aged WT mice that was not observed in C3 KO mice; (2) age-dependent neuron loss in hippocampal CA3 (but not in CA1) that followed synapse loss in aged WT mice, neither of which were observed in aged C3 KO mice; and (3) significantly enhanced LTP and cognition and less anxiety in aged C3 KO mice compared with aged WT mice. Importantly, CA3 synaptic puncta were similar between WT and C3 KO mice at P30. Together, our results suggest a novel and prominent role for complement protein C3 in mediating aged-related and region-specific changes in synaptic function and plasticity in the aging brain. Significance statement: The complement cascade, part of the innate immune response to remove pathogens, also plays a role in synaptic refinement during brain development by the removal of weak synapses. We investigated whether complement C3, a central component, affects synapse loss during aging. Wild-type (WT) and C3 knock-out (C3 KO) mice were examined at different ages. The mice were similar at 1 month of age. However, with aging, WT mice lost synapses in specific brain regions, especially in hippocampus, an area important for memory, whereas C3 KO mice were protected. Aged C3 KO mice also performed better on learning and memory tests than aged WT mice. Our results suggest that complement C3, or its downstream signaling, is detrimental to synapses during aging.</AbstractText><CopyrightInformation>Copyright &#xa9; 2015 the authors 0270-6474/15/3513029-14$15.00/0.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Shi</LastName><ForeName>Qiaoqiao</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Colodner</LastName><ForeName>Kenneth J</ForeName><Initials>KJ</Initials><AffiliationInfo><Affiliation>Department of Neurology, F.M. Kirby Neurobiology Center, Boston Children's Hospital, and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Matousek</LastName><ForeName>Sarah B</ForeName><Initials>SB</Initials><AffiliationInfo><Affiliation>Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Merry</LastName><ForeName>Katherine</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Neurology, F.M. Kirby Neurobiology Center, Boston Children's Hospital, and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hong</LastName><ForeName>Soyon</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-5744-4871</Identifier><AffiliationInfo><Affiliation>Department of Neurology, F.M. Kirby Neurobiology Center, Boston Children's Hospital, and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kenison</LastName><ForeName>Jessica E</ForeName><Initials>JE</Initials><AffiliationInfo><Affiliation>Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Frost</LastName><ForeName>Jeffrey L</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Le</LastName><ForeName>Kevin X</ForeName><Initials>KX</Initials><AffiliationInfo><Affiliation>Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Shaomin</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dodart</LastName><ForeName>Jean-Cosme</ForeName><Initials>JC</Initials><Identifier Source="ORCID">0000-0002-6455-514X</Identifier><AffiliationInfo><Affiliation>Harvard NeuroDiscovery Center NeuroBehavior Laboratory Core, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Caldarone</LastName><ForeName>Barbara J</ForeName><Initials>BJ</Initials><AffiliationInfo><Affiliation>Harvard NeuroDiscovery Center NeuroBehavior Laboratory Core, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stevens</LastName><ForeName>Beth</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Neurology, F.M. Kirby Neurobiology Center, Boston Children's Hospital, and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lemere</LastName><ForeName>Cynthia A</ForeName><Initials>CA</Initials><Identifier Source="ORCID">0000-0002-2983-7870</Identifier><AffiliationInfo><Affiliation>Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital, clemere@partners.org.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D003176">Complement C3</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016704">Synapsins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016708">Synaptophysin</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 4.2.1.11</RegistryNumber><NameOfSubstance UI="D010751">Phosphopyruvate Hydratase</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000222" MajorTopicYN="N">Adaptation, Physiological</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003176" MajorTopicYN="N">Complement C3</DescriptorName><QualifierName UI="Q000172" MajorTopicYN="Y">deficiency</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003213" MajorTopicYN="N">Conditioning, Psychological</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019706" MajorTopicYN="N">Excitatory Postsynaptic Potentials</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005106" MajorTopicYN="N">Exploratory Behavior</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005239" MajorTopicYN="N">Fear</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018782" MajorTopicYN="N">Maze Learning</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009473" MajorTopicYN="N">Neuronal Plasticity</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010751" MajorTopicYN="N">Phosphopyruvate Hydratase</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013569" MajorTopicYN="N">Synapses</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016704" MajorTopicYN="N">Synapsins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016708" MajorTopicYN="N">Synaptophysin</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013574" MajorTopicYN="N">Synaptosomes</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">CA3</Keyword><Keyword MajorTopicYN="N">aging</Keyword><Keyword MajorTopicYN="N">cognition</Keyword><Keyword MajorTopicYN="N">complement C3</Keyword><Keyword MajorTopicYN="N">innate immunity</Keyword><Keyword MajorTopicYN="N">synapse</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>9</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>9</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>12</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2016</Year><Month>3</Month><Day>23</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26400934</ArticleId><ArticleId IdType="pmc">PMC6605437</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.1698-15.2015</ArticleId><ArticleId IdType="pii">35/38/13029</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Adams MM, Shi L, Linville MC, Forbes ME, Long AB, Bennett C, Newton IG, Carter CS, Sonntag WE, Riddle DR, Brunso-Bechtold JK. Caloric restriction and age affect synaptic proteins in hippocampal CA3 and spatial learning ability. Exp Neurol. 2008;211:141&#x2013;149. doi: 10.1016/j.expneurol.2008.01.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2008.01.016</ArticleId><ArticleId IdType="pmc">PMC2805131</ArticleId><ArticleId IdType="pubmed">18342310</ArticleId></ArticleIdList></Reference><Reference><Citation>Adams MM, Donohue HS, Linville MC, Iversen EA, Newton IG, Brunso-Bechtold JK. Age-related synapse loss in hippocampal CA3 is not reversed by caloric restriction. Neuroscience. 2010;171:373&#x2013;382. doi: 10.1016/j.neuroscience.2010.09.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroscience.2010.09.022</ArticleId><ArticleId IdType="pmc">PMC2995889</ArticleId><ArticleId IdType="pubmed">20854882</ArticleId></ArticleIdList></Reference><Reference><Citation>Aroniadou-Anderjaska V, Pidoplichko VI, Figueiredo TH, Almeida-Suhett CP, Prager EM, Braga MF. Presynaptic facilitation of glutamate release in the basolateral amygdala: a mechanism for the anxiogenic and seizurogenic function of GluK1 receptors. Neuroscience. 2012;221:157&#x2013;169. doi: 10.1016/j.neuroscience.2012.07.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroscience.2012.07.006</ArticleId><ArticleId IdType="pmc">PMC3443632</ArticleId><ArticleId IdType="pubmed">22796081</ArticleId></ArticleIdList></Reference><Reference><Citation>Baskerville KA, Kent C, Nicolle MM, Gallagher M, McKinney M. Aging causes partial loss of basal forebrain but no loss of pontine reticular cholinergic neurons. Neuroreport. 2006;17:1819&#x2013;1823. doi: 10.1097/WNR.0b013e32800fef5a.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/WNR.0b013e32800fef5a</ArticleId><ArticleId IdType="pubmed">17164671</ArticleId></ArticleIdList></Reference><Reference><Citation>Brunson KL, Eghbal-Ahmadi M, Bender R, Chen Y, Baram TZ. Long-term, progressive hippocampal cell loss and dysfunction induced by early-life administration of corticotropin-releasing hormone reproduce the effects of early-life stress. Proc Natl Acad Sci U S A. 2001;98:8856&#x2013;8861. doi: 10.1073/pnas.151224898.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.151224898</ArticleId><ArticleId IdType="pmc">PMC37525</ArticleId><ArticleId IdType="pubmed">11447269</ArticleId></ArticleIdList></Reference><Reference><Citation>Calhoun ME, Kurth D, Phinney AL, Long JM, Hengemihle J, Mouton PR, Ingram DK, Jucker M. Hippocampal neuron and synaptophysin-positive bouton number in aging C57BL/6 mice. Neurobiol Aging. 1998;19:599&#x2013;606. doi: 10.1016/S0197-4580(98)00098-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0197-4580(98)00098-0</ArticleId><ArticleId IdType="pubmed">10192220</ArticleId></ArticleIdList></Reference><Reference><Citation>Coleman PD, Flood DG. Neuron numbers and dendritic extent in normal aging and Alzheimer's disease. Neurobiol Aging. 1987;8:521&#x2013;545. doi: 10.1016/0197-4580(87)90127-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0197-4580(87)90127-8</ArticleId><ArticleId IdType="pubmed">3323927</ArticleId></ArticleIdList></Reference><Reference><Citation>Cribbs DH, Berchtold NC, Perreau V, Coleman PD, Rogers J, Tenner AJ, Cotman CW. Extensive innate immune gene activation accompanies brain aging, increasing vulnerability to cognitive decline and neurodegeneration: a microarray study. J Neuroinflammation. 2012;9:179. doi: 10.1186/1742-2094-9-179.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1742-2094-9-179</ArticleId><ArticleId IdType="pmc">PMC3419089</ArticleId><ArticleId IdType="pubmed">22824372</ArticleId></ArticleIdList></Reference><Reference><Citation>De Groot DMG BE. Numerical changes in rat hippocampal synapses: an effect of &#x2018;aging&#x2019;? Acta Stereol. 1987;6:53&#x2013;58.</Citation></Reference><Reference><Citation>Filali M, Lalonde R. Age-related cognitive decline and nesting behavior in an APPswe/PS1 bigenic model of Alzheimer's disease. Brain Res. 2009;1292:93&#x2013;99. doi: 10.1016/j.brainres.2009.07.066.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2009.07.066</ArticleId><ArticleId IdType="pubmed">19643098</ArticleId></ArticleIdList></Reference><Reference><Citation>Fu H, Liu B, Frost JL, Hong S, Jin M, Ostaszewski B, Shankar GM, Costantino IM, Carroll MC, Mayadas TN, Lemere CA. Complement component C3 and complement receptor type 3 contribute to the phagocytosis and clearance of fibrillar Abeta by microglia. Glia. 2012;60:993&#x2013;1003. doi: 10.1002/glia.22331.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/glia.22331</ArticleId><ArticleId IdType="pmc">PMC3325361</ArticleId><ArticleId IdType="pubmed">22438044</ArticleId></ArticleIdList></Reference><Reference><Citation>Fujita T. Evolution of the lectin-complement pathway and its role in innate immunity. Nat Rev Immunol. 2002;2:346&#x2013;353. doi: 10.1038/nri800.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri800</ArticleId><ArticleId IdType="pubmed">12033740</ArticleId></ArticleIdList></Reference><Reference><Citation>Geinisman Y, de Toledo-Morrell L, Morrell F. Loss of perforated synapses in the dentate gyrus: morphological substrate of memory deficit in aged rats. Proc Natl Acad Sci U S A. 1986;83:3027&#x2013;3031. doi: 10.1073/pnas.83.9.3027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.83.9.3027</ArticleId><ArticleId IdType="pmc">PMC323440</ArticleId><ArticleId IdType="pubmed">3458260</ArticleId></ArticleIdList></Reference><Reference><Citation>Geinisman Y, deToledo-Morrell L, Morrell F. Induction of long-term potentiation is associated with an increase in the number of axospinous synapses with segmented postsynaptic densities. Brain Res. 1991;566:77&#x2013;88. doi: 10.1016/0006-8993(91)91683-R.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0006-8993(91)91683-R</ArticleId><ArticleId IdType="pubmed">1814558</ArticleId></ArticleIdList></Reference><Reference><Citation>Geinisman Y, deToledo-Morrell L, Morrell F, Persina IS, Rossi M. Age-related loss of axospinous synapses formed by two afferent systems in the rat dentate gyrus as revealed by the unbiased stereological dissector technique. Hippocampus. 1992;2:437&#x2013;444. doi: 10.1002/hipo.450020411.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hipo.450020411</ArticleId><ArticleId IdType="pubmed">1308200</ArticleId></ArticleIdList></Reference><Reference><Citation>Geinisman Y, Detoledo-Morrell L, Morrell F, Persina IS, Beatty MA. Synapse restructuring associated with the maintenance phase of hippocampal long-term potentiation. J Comp Neurol. 1996;368:413&#x2013;423.</Citation><ArticleIdList><ArticleId IdType="pubmed">8725348</ArticleId></ArticleIdList></Reference><Reference><Citation>Geinisman Y, Ganeshina O, Yoshida R, Berry RW, Disterhoft JF, Gallagher M. Aging, spatial learning, and total synapse number in the rat CA1 stratum radiatum. Neurobiol Aging. 2004;25:407&#x2013;416. doi: 10.1016/j.neurobiolaging.2003.12.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2003.12.001</ArticleId><ArticleId IdType="pubmed">15123345</ArticleId></ArticleIdList></Reference><Reference><Citation>Gerstein H, O'Riordan K, Osting S, Schwarz M, Burger C. Rescue of synaptic plasticity and spatial learning deficits in the hippocampus of Homer1 knockout mice by recombinant Adeno-associated viral gene delivery of Homer1c. Neurobiol Learn Mem. 2012;97:17&#x2013;29. doi: 10.1016/j.nlm.2011.08.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nlm.2011.08.009</ArticleId><ArticleId IdType="pmc">PMC3496399</ArticleId><ArticleId IdType="pubmed">21945599</ArticleId></ArticleIdList></Reference><Reference><Citation>Himeda T, Mizuno K, Kato H, Araki T. Effects of age on immunohistochemical changes in the mouse hippocampus. Mech Ageing Dev. 2005;126:673&#x2013;677. doi: 10.1016/j.mad.2004.12.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mad.2004.12.004</ArticleId><ArticleId IdType="pubmed">15888321</ArticleId></ArticleIdList></Reference><Reference><Citation>Ippolito DM, Eroglu C. Quantifying synapses: an immunocytochemistry-based assay to quantify synapse number. J Vis Exp. 2010;pii:2270. doi: 10.3791/2270.</Citation><ArticleIdList><ArticleId IdType="doi">10.3791/2270</ArticleId><ArticleId IdType="pmc">PMC3159596</ArticleId><ArticleId IdType="pubmed">21113117</ArticleId></ArticleIdList></Reference><Reference><Citation>Irizarry MC, Soriano F, McNamara M, Page KJ, Schenk D, Games D, Hyman BT. Abeta deposition is associated with neuropil changes, but not with overt neuronal loss in the human amyloid precursor protein V717F (PDAPP) transgenic mouse. J Neurosci. 1997;17:7053&#x2013;7059.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6573263</ArticleId><ArticleId IdType="pubmed">9278541</ArticleId></ArticleIdList></Reference><Reference><Citation>Kerr DS, Campbell LW, Applegate MD, Brodish A, Landfield PW. Chronic stress-induced acceleration of electrophysiologic and morphometric biomarkers of hippocampal aging. J Neurosci. 1991;11:1316&#x2013;1324.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6575317</ArticleId><ArticleId IdType="pubmed">2027050</ArticleId></ArticleIdList></Reference><Reference><Citation>Kleinknecht KR, Bedenk BT, Kaltwasser SF, Gr&#xfc;necker B, Yen YC, Czisch M, Wotjak CT. Hippocampus-dependent place learning enables spatial flexibility in C57BL/6N mice. Front Behav Neurosci. 2012;6:87.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3530747</ArticleId><ArticleId IdType="pubmed">23293591</ArticleId></ArticleIdList></Reference><Reference><Citation>Landfield PW, Baskin RK, Pitler TA. Brain aging correlates: retardation by hormonal-pharmacological treatments. Science. 1981a;214:581&#x2013;584. doi: 10.1126/science.6270791.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.6270791</ArticleId><ArticleId IdType="pubmed">6270791</ArticleId></ArticleIdList></Reference><Reference><Citation>Landfield PW, Braun LD, Pitler TA, Lindsey JD, Lynch G. Hippocampal aging in rats: a morphometric study of multiple variables in semithin sections. Neurobiol Aging. 1981b;2:265&#x2013;275. doi: 10.1016/0197-4580(81)90034-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0197-4580(81)90034-8</ArticleId><ArticleId IdType="pubmed">7335145</ArticleId></ArticleIdList></Reference><Reference><Citation>Lemere CA, Spooner ET, Leverone JF, Mori C, Clements JD. Intranasal immunotherapy for the treatment of Alzheimer's disease: Escherichia coli LT and LT(R192G) as mucosal adjuvants. Neurobiol Aging. 2002;23:991&#x2013;1000. doi: 10.1016/S0197-4580(02)00127-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0197-4580(02)00127-6</ArticleId><ArticleId IdType="pubmed">12470794</ArticleId></ArticleIdList></Reference><Reference><Citation>Li D, Wang J, Yew DT, Lucy Forster E, Yao Z. Age-related alterations of Nestin-immunoreactive neurons in rat basal forebrain with aged memory deficit. Neurochem Int. 2008;53:270&#x2013;277. doi: 10.1016/j.neuint.2008.08.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuint.2008.08.006</ArticleId><ArticleId IdType="pubmed">18805450</ArticleId></ArticleIdList></Reference><Reference><Citation>Lian H, Yang L, Cole A, Sun L, Chiang AC, Fowler SW, Shim DJ, Rodriguez-Rivera J, Taglialatela G, Jankowsky JL, Lu HC, Zheng H. NFkappaB-activated astroglial release of complement C3 compromises neuronal morphology and function associated with Alzheimer's disease. Neuron. 2015;85:101&#x2013;115. doi: 10.1016/j.neuron.2014.11.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2014.11.018</ArticleId><ArticleId IdType="pmc">PMC4289109</ArticleId><ArticleId IdType="pubmed">25533482</ArticleId></ArticleIdList></Reference><Reference><Citation>Li S, Jin M, Koeglsperger T, Shepardson NE, Shankar GM, Selkoe DJ. Soluble A&#x3b2; oligomers inhibit long-term potentiation through a mechanism involving excessive activation of extrasynaptic NR2B-containing NMDA receptors. J Neurosci. 2011;31:6627&#x2013;6638. doi: 10.1523/JNEUROSCI.0203-11.2011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.0203-11.2011</ArticleId><ArticleId IdType="pmc">PMC3100898</ArticleId><ArticleId IdType="pubmed">21543591</ArticleId></ArticleIdList></Reference><Reference><Citation>Li S, Jin M, Zhang D, Yang T, Koeglsperger T, Fu H, Selkoe DJ. Environmental novelty activates beta2-adrenergic signaling to prevent the impairment of hippocampal LTP by Abeta oligomers. Neuron. 2013;77:929&#x2013;941. doi: 10.1016/j.neuron.2012.12.040.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2012.12.040</ArticleId><ArticleId IdType="pmc">PMC3596823</ArticleId><ArticleId IdType="pubmed">23473322</ArticleId></ArticleIdList></Reference><Reference><Citation>Magnusson KR, Scruggs B, Aniya J, Wright KC, Ontl T, Xing Y, Bai L. Age-related deficits in mice performing working memory tasks in a water maze. Behav Neurosci. 2003;117:485&#x2013;495. doi: 10.1037/0735-7044.117.3.485.</Citation><ArticleIdList><ArticleId IdType="doi">10.1037/0735-7044.117.3.485</ArticleId><ArticleId IdType="pubmed">12802877</ArticleId></ArticleIdList></Reference><Reference><Citation>Maier M, Peng Y, Jiang L, Seabrook TJ, Carroll MC, Lemere CA. Complement C3 deficiency leads to accelerated amyloid beta plaque deposition and neurodegeneration and modulation of the microglia/macrophage phenotype in amyloid precursor protein transgenic mice. J Neurosci. 2008;28:6333&#x2013;6341. doi: 10.1523/JNEUROSCI.0829-08.2008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.0829-08.2008</ArticleId><ArticleId IdType="pmc">PMC3329761</ArticleId><ArticleId IdType="pubmed">18562603</ArticleId></ArticleIdList></Reference><Reference><Citation>Meaney MJ, Aitken DH, van Berkel C, Bhatnagar S, Sapolsky RM. Effect of neonatal handling on age-related impairments associated with the hippocampus. Science. 1988;239:766&#x2013;768. doi: 10.1126/science.3340858.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.3340858</ArticleId><ArticleId IdType="pubmed">3340858</ArticleId></ArticleIdList></Reference><Reference><Citation>Morrison JH, Baxter MG. The ageing cortical synapse: hallmarks and implications for cognitive decline. Nat Rev Neurosci. 2012;13:240&#x2013;250.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3592200</ArticleId><ArticleId IdType="pubmed">22395804</ArticleId></ArticleIdList></Reference><Reference><Citation>Morrison JH, Hof PR. Selective vulnerability of corticocortical and hippocampal circuits in aging and Alzheimer's disease. Prog Brain Res. 2002;136:467&#x2013;486. doi: 10.1016/S0079-6123(02)36039-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0079-6123(02)36039-4</ArticleId><ArticleId IdType="pubmed">12143403</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohmi Y, Ohkawa Y, Tajima O, Sugiura Y, Furukawa K, Furukawa K. Ganglioside deficiency causes inflammation and neurodegeneration via the activation of complement system in the spinal cord. J Neuroinflammation. 2014;11:61. doi: 10.1186/1742-2094-11-61.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1742-2094-11-61</ArticleId><ArticleId IdType="pmc">PMC3986855</ArticleId><ArticleId IdType="pubmed">24673754</ArticleId></ArticleIdList></Reference><Reference><Citation>Perez-Alcazar M, Daborg J, Stokowska A, Wasling P, Bj&#xf6;refeldt A, Kalm M, Zetterberg H, Carlstr&#xf6;m KE, Blomgren K, Ekdahl CT, Hanse E, Pekna M. Altered cognitive performance and synaptic function in the hippocampus of mice lacking C3. Exp Neurol. 2014;253:154&#x2013;164. doi: 10.1016/j.expneurol.2013.12.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2013.12.013</ArticleId><ArticleId IdType="pubmed">24378428</ArticleId></ArticleIdList></Reference><Reference><Citation>Pistell PJ, Spangler EL, Kelly-Bell B, Miller MG, de Cabo R, Ingram DK. Age-associated learning and memory deficits in two mouse versions of the Stone T-maze. Neurobiol Aging. 2012;33:2431&#x2013;2439. doi: 10.1016/j.neurobiolaging.2011.12.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2011.12.004</ArticleId><ArticleId IdType="pmc">PMC3321391</ArticleId><ArticleId IdType="pubmed">22217418</ArticleId></ArticleIdList></Reference><Reference><Citation>Reichwald J, Danner S, Wiederhold KH, Staufenbiel M. Expression of complement system components during aging and amyloid deposition in APP transgenic mice. J Neuroinflammation. 2009;6:35. doi: 10.1186/1742-2094-6-35.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1742-2094-6-35</ArticleId><ArticleId IdType="pmc">PMC2784442</ArticleId><ArticleId IdType="pubmed">19917141</ArticleId></ArticleIdList></Reference><Reference><Citation>Rudy JW, Huff NC, Matus-Amat P. Understanding contextual fear conditioning: insights from a two-process model. Neurosci Biobehav Rev. 2004;28:675&#x2013;685. doi: 10.1016/j.neubiorev.2004.09.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neubiorev.2004.09.004</ArticleId><ArticleId IdType="pubmed">15555677</ArticleId></ArticleIdList></Reference><Reference><Citation>Rutten BP, Van der Kolk NM, Schafer S, van Zandvoort MA, Bayer TA, Steinbusch HW, Schmitz C. Age-related loss of synaptophysin immunoreactive presynaptic boutons within the hippocampus of APP751SL, PS1M146L, and APP751SL/PS1M146L transgenic mice. Am J Pathol. 2005;167:161&#x2013;173. doi: 10.1016/S0002-9440(10)62963-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0002-9440(10)62963-X</ArticleId><ArticleId IdType="pmc">PMC1603440</ArticleId><ArticleId IdType="pubmed">15972962</ArticleId></ArticleIdList></Reference><Reference><Citation>Sapolsky RM, Krey LC, McEwen BS. Prolonged glucocorticoid exposure reduces hippocampal neuron number: implications for aging. J Neurosci. 1985;5:1222&#x2013;1227.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6565052</ArticleId><ArticleId IdType="pubmed">3998818</ArticleId></ArticleIdList></Reference><Reference><Citation>Schafer DP, Lehrman EK, Kautzman AG, Koyama R, Mardinly AR, Yamasaki R, Ransohoff RM, Greenberg ME, Barres BA, Stevens B. Microglia sculpt postnatal neural circuits in an activity and complement-dependent manner. Neuron. 2012;74:691&#x2013;705. doi: 10.1016/j.neuron.2012.03.026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2012.03.026</ArticleId><ArticleId IdType="pmc">PMC3528177</ArticleId><ArticleId IdType="pubmed">22632727</ArticleId></ArticleIdList></Reference><Reference><Citation>Schliebs R, Arendt T. The significance of the cholinergic system in the brain during aging and in Alzheimer's disease. J Neural Transm. 2006;113:1625&#x2013;1644. doi: 10.1007/s00702-006-0579-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00702-006-0579-2</ArticleId><ArticleId IdType="pubmed">17039298</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheng M, Kim MJ. Postsynaptic signaling and plasticity mechanisms. Science. 2002;298:776&#x2013;780. doi: 10.1126/science.1075333.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1075333</ArticleId><ArticleId IdType="pubmed">12399578</ArticleId></ArticleIdList></Reference><Reference><Citation>Stephan AH, Madison DV, Mateos JM, Fraser DA, Lovelett EA, Coutellier L, Kim L, Tsai HH, Huang EJ, Rowitch DH, Berns DS, Tenner AJ, Shamloo M, Barres BA. A dramatic increase of C1q protein in the CNS during normal aging. J Neurosci. 2013;33:13460&#x2013;13474. doi: 10.1523/JNEUROSCI.1333-13.2013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.1333-13.2013</ArticleId><ArticleId IdType="pmc">PMC3742932</ArticleId><ArticleId IdType="pubmed">23946404</ArticleId></ArticleIdList></Reference><Reference><Citation>Stevens B, Allen NJ, Vazquez LE, Howell GR, Christopherson KS, Nouri N, Micheva KD, Mehalow AK, Huberman AD, Stafford B, Sher A, Litke AM, Lambris JD, Smith SJ, John SW, Barres BA. The classical complement cascade mediates CNS synapse elimination. Cell. 2007;131:1164&#x2013;1178. doi: 10.1016/j.cell.2007.10.036.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2007.10.036</ArticleId><ArticleId IdType="pubmed">18083105</ArticleId></ArticleIdList></Reference><Reference><Citation>Stoltzner SE, Grenfell TJ, Mori C, Wisniewski KE, Wisniewski TM, Selkoe DJ, Lemere CA. Temporal accrual of complement proteins in amyloid plaques in Down's syndrome with Alzheimer's disease. Am J Pathol. 2000;156:489&#x2013;499. doi: 10.1016/S0002-9440(10)64753-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0002-9440(10)64753-0</ArticleId><ArticleId IdType="pmc">PMC1850044</ArticleId><ArticleId IdType="pubmed">10666378</ArticleId></ArticleIdList></Reference><Reference><Citation>Stover KR, Brown RE. Age-related changes in visual acuity, learning and memory in the APPswe/PS1dE9 mouse model of Alzheimer's disease. Behav Brain Res. 2012;231:75&#x2013;85. doi: 10.1016/j.bbr.2012.02.044.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbr.2012.02.044</ArticleId><ArticleId IdType="pubmed">22409975</ArticleId></ArticleIdList></Reference><Reference><Citation>von Bohlen und Halbach O, Unsicker K. Morphological alterations in the amygdala and hippocampus of mice during ageing. Eur J Neurosci. 2002;16:2434&#x2013;2440. doi: 10.1046/j.1460-9568.2002.02405.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1460-9568.2002.02405.x</ArticleId><ArticleId IdType="pubmed">12492438</ArticleId></ArticleIdList></Reference><Reference><Citation>von Bohlen und Halbach O, Zacher C, Gass P, Unsicker K. Age-related alterations in hippocampal spines and deficiencies in spatial memory in mice. J Neurosci Res. 2006;83:525&#x2013;531. doi: 10.1002/jnr.20759.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jnr.20759</ArticleId><ArticleId IdType="pubmed">16447268</ArticleId></ArticleIdList></Reference><Reference><Citation>Wessels MR, Butko P, Ma M, Warren HB, Lage AL, Carroll MC. Studies of group B streptococcal infection in mice deficient in complement component C3 or C4 demonstrate an essential role for complement in both innate and acquired immunity. Proc Natl Acad Sci U S A. 1995;92:11490&#x2013;11494. doi: 10.1073/pnas.92.25.11490.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.92.25.11490</ArticleId><ArticleId IdType="pmc">PMC40427</ArticleId><ArticleId IdType="pubmed">8524789</ArticleId></ArticleIdList></Reference><Reference><Citation>West MJ, Gundersen HJ. Unbiased stereological estimation of the number of neurons in the human hippocampus. J Comp Neurol. 1990;296:1&#x2013;22. doi: 10.1002/cne.902960102.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cne.902960102</ArticleId><ArticleId IdType="pubmed">2358525</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong AA, Brown RE. Age-related changes in visual acuity, learning and memory in C57BL/6J and DBA/2J mice. Neurobiol Aging. 2007;28:1577&#x2013;1593. doi: 10.1016/j.neurobiolaging.2006.07.023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2006.07.023</ArticleId><ArticleId IdType="pubmed">17010477</ArticleId></ArticleIdList></Reference><Reference><Citation>Wyss-Coray T, Yan F, Lin AH, Lambris JD, Alexander JJ, Quigg RJ, Masliah E. Prominent neurodegeneration and increased plaque formation in complement-inhibited Alzheimer's mice. Proc Natl Acad Sci U S A. 2002;99:10837&#x2013;10842. doi: 10.1073/pnas.162350199.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.162350199</ArticleId><ArticleId IdType="pmc">PMC125059</ArticleId><ArticleId IdType="pubmed">12119423</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamada M, Takeshita T, Miura S, Murata K, Kimura Y, Ishii N, Nose M, Sakagami H, Kondo H, Tashiro F, Miyazaki JI, Sasaki H, Sugamura K. Loss of hippocampal CA3 pyramidal neurons in mice lacking STAM1. Mol Cell Biol. 2001;21:3807&#x2013;3819. doi: 10.1128/MCB.21.11.3807-3819.2001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/MCB.21.11.3807-3819.2001</ArticleId><ArticleId IdType="pmc">PMC87035</ArticleId><ArticleId IdType="pubmed">11340172</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu YF, Zhai F, Dai CF, Hu JJ. The relationship between age-related hearing loss and synaptic changes in the hippocampus of C57BL/6J mice. Exp Gerontol. 2011;46:716&#x2013;722. doi: 10.1016/j.exger.2011.04.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.exger.2011.04.007</ArticleId><ArticleId IdType="pubmed">21586320</ArticleId></ArticleIdList></Reference><Reference><Citation>Zabel MK, Kirsch WM. From development to dysfunction: microglia and the complement cascade in CNS homeostasis. Ageing Res Rev. 2013;12:749&#x2013;756. doi: 10.1016/j.arr.2013.02.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.arr.2013.02.001</ArticleId><ArticleId IdType="pmc">PMC3700678</ArticleId><ArticleId IdType="pubmed">23419464</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">5465843</PMID><DateCompleted><Year>1970</Year><Month>10</Month><Day>17</Day></DateCompleted><DateRevised><Year>2019</Year><Month>08</Month><Day>20</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0022-1422</ISSN><JournalIssue CitedMedium="Print"><Volume>25</Volume><Issue>3</Issue><PubDate><Year>1970</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Journal of gerontology</Title><ISOAbbreviation>J Gerontol</ISOAbbreviation></Journal><ArticleTitle>Rate of change on selective tests of intelligence: a twenty-year longitudinal study of aging.</ArticleTitle><Pagination><StartPage>171</StartPage><EndPage>176</EndPage><MedlinePgn>171-6</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Blum</LastName><ForeName>J E</ForeName><Initials>JE</Initials></Author><Author ValidYN="Y"><LastName>Jarvik</LastName><ForeName>L F</ForeName><Initials>LF</Initials></Author><Author ValidYN="Y"><LastName>Clark</LastName><ForeName>E T</ForeName><Initials>ET</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Gerontol</MedlineTA><NlmUniqueID>0374762</NlmUniqueID><ISSNLinking>0022-1422</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="Y">Aging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007360" MajorTopicYN="Y">Intelligence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007361" MajorTopicYN="N">Intelligence Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011247" MajorTopicYN="N">Pregnancy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014427" MajorTopicYN="N">Twins</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1970</Year><Month>7</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1970</Year><Month>7</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1970</Year><Month>7</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">5465843</ArticleId><ArticleId IdType="doi">10.1093/geronj/25.3.171</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">8035925</PMID><DateCompleted><Year>1994</Year><Month>08</Month><Day>15</Day></DateCompleted><DateRevised><Year>2019</Year><Month>05</Month><Day>14</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0028-3878</ISSN><JournalIssue CitedMedium="Print"><Volume>44</Volume><Issue>7</Issue><PubDate><Year>1994</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Neurology</Title><ISOAbbreviation>Neurology</ISOAbbreviation></Journal><ArticleTitle>The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part VI. Family history assessment: a multicenter study of first-degree relatives of Alzheimer's disease probands and nondemented spouse controls.</ArticleTitle><Pagination><StartPage>1253</StartPage><EndPage>1259</EndPage><MedlinePgn>1253-9</MedlinePgn></Pagination><Abstract><AbstractText>Although familial factors in Alzheimer's disease (AD) are well established, uniform family-history assessment in genetic and epidemiologic studies of AD is needed to reconcile the divergent estimates of the cumulative risk of this illness among relatives of AD probands. To answer the need, the Consortium to Establish a Registry for Alzheimer's Disease (CERAD) has developed a standardized Family History Assessment of AD to identify the presence of AD, Parkinson's disease (PD), and Down's syndrome (DS) in family members. This paper describes the use of this new assessment instrument in 118 patients with AD (estimated mean age at onset [+/- SD] = 64.5 +/- 7.7 years) and their nondemented spouses who were enrolled in 11 different CERAD sites in the U.S. The first-degree relatives of the probands with AD had a significantly greater cumulative risk (p &lt; 0.005) of AD or primary progressive dementia (24.8%) than did the relatives of spouse controls (15.2%). Furthermore, the cumulative risk for this disorder among female relatives of probands was significantly greater than that among male relatives. There were no differences between the families of probands and controls for the numbers of affected first-degree relatives with PD or DS. This is the first reported multicenter family-history study of AD, and it supports earlier reports of familial factors in AD and indicates a higher risk to female relatives of AD probands. The CERAD Family History Assessment instrument may be useful for further multicenter and epidemiologic studies designed to delineate familial factors associated with AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Silverman</LastName><ForeName>J M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Mt. Sinai School of Medicine, New York, NY.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Raiford</LastName><ForeName>K</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Edland</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Fillenbaum</LastName><ForeName>G</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Morris</LastName><ForeName>J C</ForeName><Initials>JC</Initials></Author><Author ValidYN="Y"><LastName>Clark</LastName><ForeName>C M</ForeName><Initials>CM</Initials></Author><Author ValidYN="Y"><LastName>Kukull</LastName><ForeName>W</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Heyman</LastName><ForeName>A</ForeName><Initials>A</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurology</MedlineTA><NlmUniqueID>0401060</NlmUniqueID><ISSNLinking>0028-3878</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D017668" MajorTopicYN="N">Age of Onset</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008393" MajorTopicYN="N">Marriage</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008499" MajorTopicYN="N">Medical Records</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012042" MajorTopicYN="Y">Registries</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012737" MajorTopicYN="N">Sex Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1994</Year><Month>7</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1994</Year><Month>7</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1994</Year><Month>7</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">8035925</ArticleId><ArticleId IdType="doi">10.1212/wnl.44.7.1253</ArticleId></ArticleIdList></PubmedData></PubmedArticle>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">26456686</PMID><DateCompleted><Year>2017</Year><Month>01</Month><Day>10</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1875-9777</ISSN><JournalIssue CitedMedium="Internet"><Volume>17</Volume><Issue>6</Issue><PubDate><Year>2015</Year><Month>Dec</Month><Day>03</Day></PubDate></JournalIssue><Title>Cell stem cell</Title><ISOAbbreviation>Cell Stem Cell</ISOAbbreviation></Journal><ArticleTitle>Directly Reprogrammed Human Neurons Retain Aging-Associated Transcriptomic Signatures and Reveal Age-Related Nucleocytoplasmic Defects.</ArticleTitle><Pagination><StartPage>705</StartPage><EndPage>718</EndPage><MedlinePgn>705-718</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.stem.2015.09.001</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1934-5909(15)00408-7</ELocationID><Abstract><AbstractText>Aging is a major risk factor for many human diseases, and in vitro generation of human neurons is an attractive approach for modeling aging-related brain disorders. However, modeling aging in differentiated human neurons has proved challenging. We generated neurons from human donors across a broad range of ages, either by iPSC-based reprogramming and differentiation or by direct conversion into induced neurons (iNs). While iPSCs and derived neurons did not retain aging-associated gene signatures, iNs displayed age-specific transcriptional profiles and revealed age-associated decreases in the nuclear transport receptor RanBP17. We detected an age-dependent loss of nucleocytoplasmic compartmentalization (NCC) in donor fibroblasts and corresponding iNs and found that reduced RanBP17 impaired NCC in young cells, while iPSC rejuvenation restored NCC in aged cells. These results show that iNs retain important aging-related signatures, thus allowing modeling of the aging process in vitro, and they identify impaired NCC as an important factor in human aging.</AbstractText><CopyrightInformation>Copyright &#xa9; 2015 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mertens</LastName><ForeName>Jerome</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Laboratory of Genetics, The Salk Institute for Biological Studies, 10010 North Torrey Pines Road, La Jolla, CA 92037, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Paquola</LastName><ForeName>Apu&#xe3; C M</ForeName><Initials>ACM</Initials><AffiliationInfo><Affiliation>Laboratory of Genetics, The Salk Institute for Biological Studies, 10010 North Torrey Pines Road, La Jolla, CA 92037, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ku</LastName><ForeName>Manching</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Next Generation Sequencing Core, The Salk Institute for Biological Studies, 10010 North Torrey Pines Road, La Jolla, CA 92037, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hatch</LastName><ForeName>Emily</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Molecular and Cell Biology Laboratory, The Salk Institute for Biological Studies, 10010 North Torrey Pines Road, La Jolla, CA 92037, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>B&#xf6;hnke</LastName><ForeName>Lena</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Laboratory of Genetics, The Salk Institute for Biological Studies, 10010 North Torrey Pines Road, La Jolla, CA 92037, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ladjevardi</LastName><ForeName>Shauheen</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Laboratory of Genetics, The Salk Institute for Biological Studies, 10010 North Torrey Pines Road, La Jolla, CA 92037, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McGrath</LastName><ForeName>Sean</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Laboratory of Genetics, The Salk Institute for Biological Studies, 10010 North Torrey Pines Road, La Jolla, CA 92037, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Campbell</LastName><ForeName>Benjamin</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Laboratory of Genetics, The Salk Institute for Biological Studies, 10010 North Torrey Pines Road, La Jolla, CA 92037, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Hyungjun</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Laboratory of Genetics, The Salk Institute for Biological Studies, 10010 North Torrey Pines Road, La Jolla, CA 92037, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Herdy</LastName><ForeName>Joseph R</ForeName><Initials>JR</Initials><AffiliationInfo><Affiliation>Laboratory of Genetics, The Salk Institute for Biological Studies, 10010 North Torrey Pines Road, La Jolla, CA 92037, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gon&#xe7;alves</LastName><ForeName>J Tiago</ForeName><Initials>JT</Initials><AffiliationInfo><Affiliation>Laboratory of Genetics, The Salk Institute for Biological Studies, 10010 North Torrey Pines Road, La Jolla, CA 92037, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Toda</LastName><ForeName>Tomohisa</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Laboratory of Genetics, The Salk Institute for Biological Studies, 10010 North Torrey Pines Road, La Jolla, CA 92037, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Yongsung</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Laboratory of Genetics, The Salk Institute for Biological Studies, 10010 North Torrey Pines Road, La Jolla, CA 92037, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Winkler</LastName><ForeName>J&#xfc;rgen</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Molecular Neurology, Friedrich-Alexander University Erlangen-N&#xfc;rnberg, 91054 Erlangen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yao</LastName><ForeName>Jun</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Membrane Biology, Tsinghua-Peking Joint Center for Life Sciences, McGovern Institute for Brain Research, School of Life Sciences, Tsinghua University, Beijing 100084, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hetzer</LastName><ForeName>Martin W</ForeName><Initials>MW</Initials><AffiliationInfo><Affiliation>Molecular and Cell Biology Laboratory, The Salk Institute for Biological Studies, 10010 North Torrey Pines Road, La Jolla, CA 92037, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gage</LastName><ForeName>Fred H</ForeName><Initials>FH</Initials><AffiliationInfo><Affiliation>Laboratory of Genetics, The Salk Institute for Biological Studies, 10010 North Torrey Pines Road, La Jolla, CA 92037, USA. Electronic address: gage@salk.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 CA014195</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005131</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>10</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cell Stem Cell</MedlineTA><NlmUniqueID>101311472</NlmUniqueID><ISSNLinking>1875-9777</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019006">Neural Cell Adhesion Molecules</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C417257">RanGTP-binding protein 17</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.6.5.2</RegistryNumber><NameOfSubstance UI="D020931">ran GTP-Binding Protein</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Cell Stem Cell. 2015 Dec 3;17(6):637-638. doi: 10.1016/j.stem.2015.11.009.</RefSource><PMID Version="1">26637936</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Stem Cell Investig. 2016 Apr 14;3:11. doi: 10.21037/sci.2016.04.02.</RefSource><PMID Version="1">27357142</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="Y">Aging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002467" MajorTopicYN="N">Cell Nucleus</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002469" MajorTopicYN="N">Cell Separation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D065150" MajorTopicYN="Y">Cellular Reprogramming</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003593" MajorTopicYN="N">Cytoplasm</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005347" MajorTopicYN="N">Fibroblasts</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005434" MajorTopicYN="N">Flow Cytometry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057026" MajorTopicYN="N">Induced Pluripotent Stem Cells</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="Y">cytology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007231" MajorTopicYN="N">Infant, Newborn</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019006" MajorTopicYN="N">Neural Cell Adhesion Molecules</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="Y">cytology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D059467" MajorTopicYN="N">Transcriptome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020931" MajorTopicYN="N">ran GTP-Binding Protein</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>4</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2015</Year><Month>6</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>9</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>10</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>10</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>1</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2018</Year><Month>5</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26456686</ArticleId><ArticleId IdType="mid">NIHMS937899</ArticleId><ArticleId IdType="pmc">PMC5929130</ArticleId><ArticleId IdType="doi">10.1016/j.stem.2015.09.001</ArticleId><ArticleId IdType="pii">S1934-5909(15)00408-7</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Adler AS, Sinha S, Kawahara TLA, Zhang JY, Segal E, Chang HY. Motif module map reveals enforcement of aging by continual NF-kappaB activity. Genes Dev. 2007;21:3244&#x2013;3257.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2113026</ArticleId><ArticleId IdType="pubmed">18055696</ArticleId></ArticleIdList></Reference><Reference><Citation>Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc B. 1995;57:289&#x2013;300.</Citation></Reference><Reference><Citation>Bl&#xf6;mer U, Naldini L, Kafri T, Trono D, Verma IM, Gage FH. Highly efficient and sustained gene transfer in adult neurons with a lentivirus vector. J Virol. 1997;71:6641&#x2013;6649.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC191942</ArticleId><ArticleId IdType="pubmed">9261386</ArticleId></ArticleIdList></Reference><Reference><Citation>Bozdag S, Li A, Riddick G, Kotliarov Y, Baysan M, Iwamoto FM, Cam MC, Kotliarova S, Fine HA. Age-specific signatures of glioblastoma at the genomic, genetic, and epigenetic levels. PLoS ONE. 2013;8:e62982.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3639162</ArticleId><ArticleId IdType="pubmed">23658659</ArticleId></ArticleIdList></Reference><Reference><Citation>Broad Institute TCGA Genome Data Analysis Center. Correlation between mRNAseq expression and clinical features. Broad Institute of MIT and Harvard; 2013a.   http://dx.doi.org/10.7908/C1J67F8Q.</Citation><ArticleIdList><ArticleId IdType="doi">10.7908/C1J67F8Q</ArticleId></ArticleIdList></Reference><Reference><Citation>Broad Institute TCGA Genome Data Analysis Center. Correlation between gene methylation status and clinical features. Broad Institute of MIT and Harvard; 2013b.   http://dx.doi.org/10.7908/C12B8W55.</Citation><ArticleIdList><ArticleId IdType="doi">10.7908/C12B8W55</ArticleId></ArticleIdList></Reference><Reference><Citation>Broad Institute TCGA Genome Data Analysis Center. Correlation between mRNA expression and clinical features. Broad Institute of MIT and Harvard; 2014.   http://dx.doi.org/10.7908/C1445K69.</Citation><ArticleIdList><ArticleId IdType="doi">10.7908/C1445K69</ArticleId></ArticleIdList></Reference><Reference><Citation>Burke SN, Barnes CA. Neural plasticity in the ageing brain. Nat Rev Neurosci. 2006;7:30&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">16371948</ArticleId></ArticleIdList></Reference><Reference><Citation>Capelson M, Hetzer MW. The role of nuclear pores in gene regulation, development and disease. EMBO Rep. 2009;10:697&#x2013;705.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2727434</ArticleId><ArticleId IdType="pubmed">19543230</ArticleId></ArticleIdList></Reference><Reference><Citation>Cho Y, Sloutsky R, Naegle KM, Cavalli V. Injury-induced HDAC5 nuclear export is essential for axon regeneration. Cell. 2013;155:894&#x2013;908.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3987749</ArticleId><ArticleId IdType="pubmed">24209626</ArticleId></ArticleIdList></Reference><Reference><Citation>Cummings J. The black book of Alzheimer&#x2019;s disease, part 1. Prim Psychiatry. 2008;15:66&#x2013;76.</Citation></Reference><Reference><Citation>D&#x2019;Angelo MA, Raices M, Panowski SH, Hetzer MW. Age-dependent deterioration of nuclear pore complexes causes a loss of nuclear integrity in postmitotic cells. Cell. 2009;136:284&#x2013;295.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2805151</ArticleId><ArticleId IdType="pubmed">19167330</ArticleId></ArticleIdList></Reference><Reference><Citation>Flachsbart F, Caliebe A, Kleindorp R, Blanch&#xe9; H, von Eller-Eberstein H, Nikolaus S, Schreiber S, Nebel A. Association of FOXO3A variation with human longevity confirmed in German centenarians. Proc Natl Acad Sci USA. 2009;106:2700&#x2013;2705.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2650329</ArticleId><ArticleId IdType="pubmed">19196970</ArticleId></ArticleIdList></Reference><Reference><Citation>Fraser HB, Khaitovich P, Plotkin JB, P&#xe4;&#xe4;bo S, Eisen MB. Aging and gene expression in the primate brain. PLoS Biol. 2005;3:e274.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1181540</ArticleId><ArticleId IdType="pubmed">16048372</ArticleId></ArticleIdList></Reference><Reference><Citation>Frobel J, Hemeda H, Lenz M, Abagnale G, Joussen S, Denecke B, &#x15c;ari&#x107; T, Zenke M, Wagner W. Epigenetic rejuvenation of mesenchymal stromal cells derived from induced pluripotent stem cells. Stem Cell Reports. 2014;3:414&#x2013;422.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4266008</ArticleId><ArticleId IdType="pubmed">25241740</ArticleId></ArticleIdList></Reference><Reference><Citation>Gladyshev VN. The origin of aging: imperfectness-driven non-random damage defines the aging process and control of lifespan. Trends Genet. 2013;29:506&#x2013;512.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3804915</ArticleId><ArticleId IdType="pubmed">23769208</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon LB, Rothman FG, L&#xf3;pez-Ot&#xed;n C, Misteli T. Progeria: a paradigm for translational medicine. Cell. 2014;156:400&#x2013;407.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6318797</ArticleId><ArticleId IdType="pubmed">24485450</ArticleId></ArticleIdList></Reference><Reference><Citation>Guenzel CA, H&#xe9;rate C, Benichou S. HIV-1 Vpr-a still &#x201c;enigmatic multitasker&#x201d;. Front Microbiol. 2014;5:127.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3978352</ArticleId><ArticleId IdType="pubmed">24744753</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanz S, Perlson E, Willis D, Zheng JQ, Massarwa R, Huerta JJ, Koltzenburg M, Kohler M, van-Minnen J, Twiss JL, Fainzilber M. Axoplasmic importins enable retrograde injury signaling in lesioned nerve. Neuron. 2003;40:1095&#x2013;1104.</Citation><ArticleIdList><ArticleId IdType="pubmed">14687545</ArticleId></ArticleIdList></Reference><Reference><Citation>Hennekam RCM. Hutchinson-Gilford progeria syndrome: review of the phenotype. Am J Med Genet A. 2006;140:2603&#x2013;2624.</Citation><ArticleIdList><ArticleId IdType="pubmed">16838330</ArticleId></ArticleIdList></Reference><Reference><Citation>Israel MA, Yuan SH, Bardy C, Reyna SM, Mu Y, Herrera C, Hefferan MP, Van Gorp S, Nazor KL, Boscolo FS, et al. Probing sporadic and familial Alzheimer&#x2019;s disease using induced pluripotent stem cells. Nature. 2012;482:216&#x2013;220.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3338985</ArticleId><ArticleId IdType="pubmed">22278060</ArticleId></ArticleIdList></Reference><Reference><Citation>Koch P, Bohlmann I, Sch&#xe4;fer M, Hansen-Hagge TE, Kiyoi H, Wilda M, Hameister H, Bartram CR, Janssen JWG. Identification of a novel putative Ran-binding protein and its close homologue. Biochem Biophys Res Commun. 2000;278:241&#x2013;249.</Citation><ArticleIdList><ArticleId IdType="pubmed">11071879</ArticleId></ArticleIdList></Reference><Reference><Citation>Koch P, Breuer P, Peitz M, Jungverdorben J, Kesavan J, Poppe D, Doerr J, Ladewig J, Mertens J, T&#xfc;ting T, et al. Excitation-induced ataxin-3 aggregation in neurons from patients with Machado-Joseph disease. Nature. 2011;480:543&#x2013;546.</Citation><ArticleIdList><ArticleId IdType="pubmed">22113611</ArticleId></ArticleIdList></Reference><Reference><Citation>Koch P, Tamboli IY, Mertens J, Wunderlich P, Ladewig J, St&#xfc;ber K, Esselmann H, Wiltfang J, Br&#xfc;stle O, Walter J. Presenilin-1 L166P mutant human pluripotent stem cell-derived neurons exhibit partial loss of &#x3b3;-secretase activity in endogenous amyloid-&#x3b2; generation. Am J Pathol. 2012;180:2404&#x2013;2416.</Citation><ArticleIdList><ArticleId IdType="pubmed">22510327</ArticleId></ArticleIdList></Reference><Reference><Citation>Ladewig J, Mertens J, Kesavan J, Doerr J, Poppe D, Glaue F, Herms S, Wernet P, K&#xf6;gler G, M&#xfc;ller FJ, et al. Small molecules enable highly efficient neuronal conversion of human fibroblasts. Nat Methods. 2012;9:575&#x2013;578.</Citation><ArticleIdList><ArticleId IdType="pubmed">22484851</ArticleId></ArticleIdList></Reference><Reference><Citation>Lapasset L, Milhavet O, Prieur A, Besnard E, Babled A, A&#xef;t-Hamou N, Leschik J, Pellestor F, Ramirez JM, De Vos J, et al. Rejuvenating senescent and centenarian human cells by reprogramming through the pluripotent state. Genes Dev. 2011;25:2248&#x2013;2253.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3219229</ArticleId><ArticleId IdType="pubmed">22056670</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee JH, Zhou S, Smas CM. Identification of RANBP16 and RANBP17 as novel interaction partners for the bHLH transcription factor E12. J Cell Biochem. 2010;111:195&#x2013;206.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2930062</ArticleId><ArticleId IdType="pubmed">20503194</ArticleId></ArticleIdList></Reference><Reference><Citation>Lehtinen MK, Yuan Z, Boag PR, Yang Y, Vill&#xe9;n J, Becker EBE, DiBacco S, de la Iglesia N, Gygi S, Blackwell TK, Bonni A. A conserved MST-FOXO signaling pathway mediates oxidative-stress responses and extends life span. Cell. 2006;125:987&#x2013;1001.</Citation><ArticleIdList><ArticleId IdType="pubmed">16751106</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu ML, Zang T, Zou Y, Chang JC, Gibson JR, Huber KM, Zhang CL. Small molecules enable neurogenin 2 to efficiently convert human fibroblasts into cholinergic neurons. Nat Commun. 2013;4:2183.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3843951</ArticleId><ArticleId IdType="pubmed">23873306</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu T, Pan Y, Kao SY, Li C, Kohane I, Chan J, Yankner BA. Gene regulation and DNA damage in the ageing human brain. Nature. 2004;429:883&#x2013;891.</Citation><ArticleIdList><ArticleId IdType="pubmed">15190254</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu T, Aron L, Zullo J, Pan Y, Kim H, Chen Y, Yang TH, Kim HM, Drake D, Liu XS, et al. REST and stress resistance in ageing and Alzheimer&#x2019;s disease. Nature. 2014;507:448&#x2013;454.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4110979</ArticleId><ArticleId IdType="pubmed">24670762</ArticleId></ArticleIdList></Reference><Reference><Citation>Maherali N, Sridharan R, Xie W, Utikal J, Eminli S, Arnold K, Stadtfeld M, Yachechko R, Tchieu J, Jaenisch R, et al. Directly reprogrammed fibroblasts show global epigenetic remodeling and widespread tissue contribution. Cell Stem Cell. 2007;1:55&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pubmed">18371336</ArticleId></ArticleIdList></Reference><Reference><Citation>Manukyan M, Singh PB. Epigenome rejuvenation: HP1&#x3b2; mobility as a measure of pluripotent and senescent chromatin ground states. Sci Rep. 2014;4:4789.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3999444</ArticleId><ArticleId IdType="pubmed">24763337</ArticleId></ArticleIdList></Reference><Reference><Citation>Marchetto MC, Brennand KJ, Boyer LF, Gage FH. Induced pluripotent stem cells (iPSCs) and neurological disease modeling: progress and promises. Hum Mol Genet. 2011;20(R2):R109&#x2013;R115.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4447776</ArticleId><ArticleId IdType="pubmed">21828073</ArticleId></ArticleIdList></Reference><Reference><Citation>Meissner A, Mikkelsen TS, Gu H, Wernig M, Hanna J, Sivachenko A, Zhang X, Bernstein BE, Nusbaum C, Jaffe DB, et al. Genome-scale DNA methylation maps of pluripotent and differentiated cells. Nature. 2008;454:766&#x2013;770.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2896277</ArticleId><ArticleId IdType="pubmed">18600261</ArticleId></ArticleIdList></Reference><Reference><Citation>Mertens J, St&#xfc;ber K, Poppe D, Doerr J, Ladewig J, Br&#xfc;stle O, Koch P. Embryonic stem cell-based modeling of tau pathology in human neurons. Am J Pathol. 2013a;182:1769&#x2013;1779.</Citation><ArticleIdList><ArticleId IdType="pubmed">23499461</ArticleId></ArticleIdList></Reference><Reference><Citation>Mertens J, St&#xfc;ber K, Wunderlich P, Ladewig J, Kesavan JC, Vandenberghe R, Vandenbulcke M, van Damme P, Walter J, Br&#xfc;stle O, Koch P. APP processing in human pluripotent stem cell-derived neurons is resistant to NSAID-based &#x3b3;-secretase modulation. Stem Cell Reports. 2013b;1:491&#x2013;498.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3871388</ArticleId><ArticleId IdType="pubmed">24371804</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller JD, Ganat YM, Kishinevsky S, Bowman RL, Liu B, Tu EY, Mandal PK, Vera E, Shim JW, Kriks S, et al. Human iPSC-based modeling of late-onset disease via progerin-induced aging. Cell Stem Cell. 2013;13:691&#x2013;705.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4153390</ArticleId><ArticleId IdType="pubmed">24315443</ArticleId></ArticleIdList></Reference><Reference><Citation>Murphy CT. Using whole-genome transcriptional analyses to identify molecular mechanisms of aging. Drug Discov Today Dis Mech. 2006;3:41&#x2013;46.</Citation></Reference><Reference><Citation>Musich PR, Zou Y. Genomic instability and DNA damage responses in progeria arising from defective maturation of prelamin A. Aging (Albany, NY) 2009;1:28&#x2013;37.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2765059</ArticleId><ArticleId IdType="pubmed">19851476</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen HN, Byers B, Cord B, Shcheglovitov A, Byrne J, Gujar P, Kee K, Sch&#xfc;le B, Dolmetsch RE, Langston W, et al. LRRK2 mutant iPSC-derived DA neurons demonstrate increased susceptibility to oxidative stress. Cell Stem Cell. 2011;8:267&#x2013;280.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3578553</ArticleId><ArticleId IdType="pubmed">21362567</ArticleId></ArticleIdList></Reference><Reference><Citation>Pang ZP, Yang N, Vierbuchen T, Ostermeier A, Fuentes DR, Yang TQ, Citri A, Sebastiano V, Marro S, S&#xfc;dhof TC, Wernig M. Induction of human neuronal cells by defined transcription factors. Nature. 2011;476:220&#x2013;223.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3159048</ArticleId><ArticleId IdType="pubmed">21617644</ArticleId></ArticleIdList></Reference><Reference><Citation>Peterson C, Gibson GE, Blass JP. Altered calcium uptake in cultured skin fibroblasts from patients with Alzheimer&#x2019;s disease. N Engl J Med. 1985;312:1063&#x2013;1065.</Citation><ArticleIdList><ArticleId IdType="pubmed">3982463</ArticleId></ArticleIdList></Reference><Reference><Citation>Rando TA, Chang HY. Aging, rejuvenation, and epigenetic reprogramming: resetting the aging clock. Cell. 2012;148:46&#x2013;57.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3336960</ArticleId><ArticleId IdType="pubmed">22265401</ArticleId></ArticleIdList></Reference><Reference><Citation>Reinhardt P, Schmid B, Burbulla LF, Sch&#xf6;ndorf DC, Wagner L, Glatza M, H&#xf6;ing S, Hargus G, Heck SA, Dhingra A, et al. Genetic correction of a LRRK2 mutation in human iPSCs links parkinsonian neurodegeneration to ERK-dependent changes in gene expression. Cell Stem Cell. 2013;12:354&#x2013;367.</Citation><ArticleIdList><ArticleId IdType="pubmed">23472874</ArticleId></ArticleIdList></Reference><Reference><Citation>Savas JN, Toyama BH, Xu T, Yates JR, 3rd, Hetzer MW. Extremely long-lived nuclear pore proteins in the rat brain. Science. 2012;335:942&#x2013;942.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3296478</ArticleId><ArticleId IdType="pubmed">22300851</ArticleId></ArticleIdList></Reference><Reference><Citation>Scaffidi P, Misteli T. Lamin A-dependent nuclear defects in human aging. Science. 2006;312:1059&#x2013;1063.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1855250</ArticleId><ArticleId IdType="pubmed">16645051</ArticleId></ArticleIdList></Reference><Reference><Citation>Suhr ST, Chang EA, Tjong J, Alcasid N, Perkins GA, Goissis MD, Ellisman MH, Perez GI, Cibelli JB. Mitochondrial rejuvenation after induced pluripotency. PLoS ONE. 2010;5:e14095.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2991355</ArticleId><ArticleId IdType="pubmed">21124794</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, Yamanaka S. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell. 2007;131:861&#x2013;872.</Citation><ArticleIdList><ArticleId IdType="pubmed">18035408</ArticleId></ArticleIdList></Reference><Reference><Citation>Toyama BH, Hetzer MW. Protein homeostasis: live long, won&#x2019;t prosper. Nat Rev Mol Cell Biol. 2013;14:55&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3570024</ArticleId><ArticleId IdType="pubmed">23258296</ArticleId></ArticleIdList></Reference><Reference><Citation>Toyama BH, Savas JN, Park SK, Harris MS, Ingolia NT, Yates JR, 3rd, Hetzer MW. Identification of long-lived proteins reveals exceptional stability of essential cellular structures. Cell. 2013;154:971&#x2013;982.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3788602</ArticleId><ArticleId IdType="pubmed">23993091</ArticleId></ArticleIdList></Reference><Reference><Citation>Vierbuchen T, Ostermeier A, Pang ZP, Kokubu Y, S&#xfc;dhof TC, Wernig M. Direct conversion of fibroblasts to functional neurons by defined factors. Nature. 2010;463:1035&#x2013;1041.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2829121</ArticleId><ArticleId IdType="pubmed">20107439</ArticleId></ArticleIdList></Reference><Reference><Citation>Willcox BJ, Donlon TA, He Q, Chen R, Grove JS, Yano K, Masaki KH, Willcox DC, Rodriguez B, Curb JD. FOXO3A genotype is strongly associated with human longevity. Proc Natl Acad Sci USA. 2008;105:13987&#x2013;13992.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2544566</ArticleId><ArticleId IdType="pubmed">18765803</ArticleId></ArticleIdList></Reference><Reference><Citation>Yankner BA, Lu T, Loerch P. The aging brain. Annu Rev Pathol. 2008;3:41&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pubmed">18039130</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">26468326</PMID><DateCompleted><Year>2016</Year><Month>08</Month><Day>23</Day></DateCompleted><DateRevised><Year>2015</Year><Month>10</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1946-6242</ISSN><JournalIssue CitedMedium="Internet"><Volume>7</Volume><Issue>309</Issue><PubDate><Year>2015</Year><Month>Oct</Month><Day>14</Day></PubDate></JournalIssue><Title>Science translational medicine</Title><ISOAbbreviation>Sci Transl Med</ISOAbbreviation></Journal><ArticleTitle>Loss of GPR3 reduces the amyloid plaque burden and improves memory in Alzheimer's disease mouse models.</ArticleTitle><Pagination><StartPage>309ra164</StartPage><MedlinePgn>309ra164</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1126/scitranslmed.aab3492</ELocationID><Abstract><AbstractText>The orphan G protein (heterotrimeric guanine nucleotide-binding protein)-coupled receptor (GPCR) GPR3 regulates activity of the &#x3b3;-secretase complex in the absence of an effect on Notch proteolysis, providing a potential therapeutic target for Alzheimer's disease (AD). However, given the vast resources required to develop and evaluate any new therapy for AD and the multiple failures involved in translational research, demonstration of the pathophysiological relevance of research findings in multiple disease-relevant models is necessary before initiating costly drug development programs. We evaluated the physiological consequences of loss of Gpr3 in four AD transgenic mouse models, including two that contain the humanized murine A&#x3b2; sequence and express similar amyloid precursor protein (APP) levels as wild-type mice, thereby reducing potential artificial phenotypes. Our findings reveal that genetic deletion of Gpr3 reduced amyloid pathology in all of the AD mouse models and alleviated cognitive deficits in APP/PS1 mice. Additional three-dimensional visualization and analysis of the amyloid plaque burden provided accurate information on the amyloid load, distribution, and volume in the structurally intact adult mouse brain. Analysis of 10 different regions in healthy human postmortem brain tissue indicated that GPR3 expression was stable during aging. However, two cohorts of human AD postmortem brain tissue samples showed a correlation between elevated GPR3 and AD progression. Collectively, these studies provide evidence that GPR3 mediates the amyloidogenic proteolysis of APP in four AD transgenic mouse models as well as the physiological processing of APP in wild-type mice, suggesting that GPR3 may be a potential therapeutic target for AD drug development.</AbstractText><CopyrightInformation>Copyright &#xa9; 2015, American Association for the Advancement of Science.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Yunhong</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>VIB Center for the Biology of Disease, 3000 Leuven, Belgium. KU Leuven Center for Human Genetics and Leuven Institute for Neurodegenerative Diseases, 3000 Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Skwarek-Maruszewska</LastName><ForeName>Aneta</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>VIB Center for the Biology of Disease, 3000 Leuven, Belgium. KU Leuven Center for Human Genetics and Leuven Institute for Neurodegenerative Diseases, 3000 Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Horr&#xe9;</LastName><ForeName>Katrien</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>VIB Center for the Biology of Disease, 3000 Leuven, Belgium. KU Leuven Center for Human Genetics and Leuven Institute for Neurodegenerative Diseases, 3000 Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vandewyer</LastName><ForeName>Elke</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>VIB Center for the Biology of Disease, 3000 Leuven, Belgium. KU Leuven Center for Human Genetics and Leuven Institute for Neurodegenerative Diseases, 3000 Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wolfs</LastName><ForeName>Leen</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>VIB Center for the Biology of Disease, 3000 Leuven, Belgium. KU Leuven Center for Human Genetics and Leuven Institute for Neurodegenerative Diseases, 3000 Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Snellinx</LastName><ForeName>An</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>VIB Center for the Biology of Disease, 3000 Leuven, Belgium. KU Leuven Center for Human Genetics and Leuven Institute for Neurodegenerative Diseases, 3000 Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saito</LastName><ForeName>Takashi</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Laboratory for Proteolytic Neuroscience, RIKEN Brain Science Institute, Wako-shi, 351-0198 Saitama, Japan. Japan Science and Technology Agency, 332-0012 Saitama, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Radaelli</LastName><ForeName>Enrico</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>VIB Center for the Biology of Disease, 3000 Leuven, Belgium. KU Leuven Center for Human Genetics and Leuven Institute for Neurodegenerative Diseases, 3000 Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Corthout</LastName><ForeName>Nikky</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>VIB Center for the Biology of Disease, 3000 Leuven, Belgium. KU Leuven Center for Human Genetics and Leuven Institute for Neurodegenerative Diseases, 3000 Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Colombelli</LastName><ForeName>Julien</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology, 08028 Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lo</LastName><ForeName>Adrian C</ForeName><Initials>AC</Initials><AffiliationInfo><Affiliation>Department of Psychology, Laboratory of Biological Psychology, University of Leuven, 3000 Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Van Aerschot</LastName><ForeName>Leen</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Psychology, Laboratory of Biological Psychology, University of Leuven, 3000 Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Callaerts-Vegh</LastName><ForeName>Zsuzsanna</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Psychology, Laboratory of Biological Psychology, University of Leuven, 3000 Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Trabzuni</LastName><ForeName>Daniah</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Departments of Molecular Neuroscience and Clinical Neuroscience, Reta Lila Weston Research Laboratories, Institute of Neurology, University College London, WC1N 3BG London, UK. Department of Genetics, King Faisal Specialist Hospital and Research Centre, 11211 Riyadh, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bossers</LastName><ForeName>Koen</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Netherlands Institute for Neuroscience, an Institute of the Royal Netherlands Academy of Arts and Sciences, 1105 BA Amsterdam, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Verhaagen</LastName><ForeName>Joost</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Netherlands Institute for Neuroscience, an Institute of the Royal Netherlands Academy of Arts and Sciences, 1105 BA Amsterdam, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ryten</LastName><ForeName>Mina</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Departments of Molecular Neuroscience and Clinical Neuroscience, Reta Lila Weston Research Laboratories, Institute of Neurology, University College London, WC1N 3BG London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Munck</LastName><ForeName>Sebastian</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>VIB Center for the Biology of Disease, 3000 Leuven, Belgium. KU Leuven Center for Human Genetics and Leuven Institute for Neurodegenerative Diseases, 3000 Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>D'Hooge</LastName><ForeName>Rudi</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Psychology, Laboratory of Biological Psychology, University of Leuven, 3000 Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Swaab</LastName><ForeName>Dick F</ForeName><Initials>DF</Initials><AffiliationInfo><Affiliation>Netherlands Institute for Neuroscience, an Institute of the Royal Netherlands Academy of Arts and Sciences, 1105 BA Amsterdam, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hardy</LastName><ForeName>John</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Departments of Molecular Neuroscience and Clinical Neuroscience, Reta Lila Weston Research Laboratories, Institute of Neurology, University College London, WC1N 3BG London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saido</LastName><ForeName>Takaomi C</ForeName><Initials>TC</Initials><AffiliationInfo><Affiliation>Laboratory for Proteolytic Neuroscience, RIKEN Brain Science Institute, Wako-shi, 351-0198 Saitama, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Strooper</LastName><ForeName>Bart</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>VIB Center for the Biology of Disease, 3000 Leuven, Belgium. KU Leuven Center for Human Genetics and Leuven Institute for Neurodegenerative Diseases, 3000 Leuven, Belgium. amantha.thathiah@cme.vib-kuleuven.be bart.destrooper@cme.vib-kuleuven.be.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thathiah</LastName><ForeName>Amantha</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>VIB Center for the Biology of Disease, 3000 Leuven, Belgium. KU Leuven Center for Human Genetics and Leuven Institute for Neurodegenerative Diseases, 3000 Leuven, Belgium. amantha.thathiah@cme.vib-kuleuven.be bart.destrooper@cme.vib-kuleuven.be.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>G0802462</GrantID><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>G0901254</GrantID><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Sci Transl Med</MedlineTA><NlmUniqueID>101505086</NlmUniqueID><ISSNLinking>1946-6234</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C092794">GPR3 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D043562">Receptors, G-Protein-Coupled</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017353" MajorTopicYN="N">Gene Deletion</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015870" MajorTopicYN="N">Gene Expression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D023421" MajorTopicYN="N">Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058225" MajorTopicYN="N">Plaque, Amyloid</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D043562" MajorTopicYN="N">Receptors, G-Protein-Coupled</DescriptorName><QualifierName UI="Q000172" MajorTopicYN="Y">deficiency</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>10</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>10</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>8</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26468326</ArticleId><ArticleId IdType="doi">10.1126/scitranslmed.aab3492</ArticleId><ArticleId IdType="pii">7/309/309ra164</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">26469250</PMID><DateCompleted><Year>2016</Year><Month>01</Month><Day>13</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1554-6578</ISSN><JournalIssue CitedMedium="Internet"><Volume>74</Volume><Issue>11</Issue><PubDate><Year>2015</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Journal of neuropathology and experimental neurology</Title><ISOAbbreviation>J Neuropathol Exp Neurol</ISOAbbreviation></Journal><ArticleTitle>Neuropsychological Markers of Cognitive Decline in Persons With Alzheimer Disease Neuropathology.</ArticleTitle><Pagination><StartPage>1086</StartPage><EndPage>1092</EndPage><MedlinePgn>1086-92</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/NEN.0000000000000254</ELocationID><Abstract><AbstractText>To evaluate cognitive performance among persons who did and did not develop clinical Alzheimer disease (AD) but had AD neuropathology at autopsy, we examined neuropsychological performance in cognitively healthy (Clinical Dementia Rating [CDR] = 0) participants who returned for at least 1 follow-up and died within 2 years of their last assessment. Nonprogressors remained at CDR = 0 until death; progressors developed symptomatic AD during life (CDR &gt; 0). Cognitive performance at baseline was compared between progressors and nonprogressors on a global cognitive composite and 4 domain-specific composites (episodic memory, language, attention/working memory, and executive function). Models adjusted for age, education, sex, and non-AD neuropathology. Progressors (n = 173) had worse performance than nonprogressors (n = 141) in nearly all cognitive domains. Progressors scored lower on composites of global cognition (P &lt; 0.001), executive function (P = 0.0006), language (P &lt; 0.0001), and episodic memory (P = 0.0006) but not on attention/working memory (P = 0.91). These data indicate that individuals with underlying AD neuropathology who are clinically healthy but who later develop symptomatic AD have worse performance in a wide range of domains versus individuals with underlying AD neuropathology who are clinically healthy but do not become symptomatic during life. Therefore, subtle cognitive decline at baseline may indicate an increased risk of progression to symptomatic AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hassenstab</LastName><ForeName>Jason</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>From the Knight Alzheimer's Disease Research Center, Department of Neurology (JH, CMR, NJC, JCM), Washington University School of Medicine, St. Louis, Missouri; and National Alzheimer's Coordinating Center (SEM, CM, WK), University of Washington, Seattle, Washington.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Monsell</LastName><ForeName>Sarah E</ForeName><Initials>SE</Initials></Author><Author ValidYN="Y"><LastName>Mock</LastName><ForeName>Charles</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Roe</LastName><ForeName>Catherine M</ForeName><Initials>CM</Initials></Author><Author ValidYN="Y"><LastName>Cairns</LastName><ForeName>Nigel J</ForeName><Initials>NJ</Initials></Author><Author ValidYN="Y"><LastName>Morris</LastName><ForeName>John C</ForeName><Initials>JC</Initials></Author><Author ValidYN="Y"><LastName>Kukull</LastName><ForeName>Walter</ForeName><Initials>W</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 AG013854</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG010124</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG023501</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005142</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005131</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG010133</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG016574</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005146</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K23 DK094982</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG035982</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG008702</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG016976</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG003991</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG008051</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005681</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG013846</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG026276</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>L30 DK092995</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005136</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG012300</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG016573</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG016570</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005134</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG008017</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG010161</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG025688</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005133</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005138</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG010129</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG019610</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG028383</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG033514</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U19 AG032438</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Neuropathol Exp Neurol</MedlineTA><NlmUniqueID>2985192R</NlmUniqueID><ISSNLinking>0022-3069</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001288" MajorTopicYN="N">Attention</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007802" MajorTopicYN="N">Language</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008568" MajorTopicYN="N">Memory</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009422" MajorTopicYN="N">Nervous System Diseases</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="Y">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>10</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>10</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2016</Year><Month>11</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26469250</ArticleId><ArticleId IdType="mid">NIHMS717503</ArticleId><ArticleId IdType="pmc">PMC4610245</ArticleId><ArticleId IdType="doi">10.1097/NEN.0000000000000254</ArticleId><ArticleId IdType="pii">00005072-201511000-00007</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bateman RJ, Xiong C, Benzinger TLS, et al. Clinical and biomarker changes in dominantly inherited Alzheimer&#x2019;s disease. N Engl J Med. 2012;367:795&#x2013;804.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3474597</ArticleId><ArticleId IdType="pubmed">22784036</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr, Knopman DS, Jagust WJ, et al. Tracking pathophysiological processes in Alzheimer&#x2019;s disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 2013;12:207&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3622225</ArticleId><ArticleId IdType="pubmed">23332364</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperling RA, Aisen PS, Beckett LA, et al. Toward defining the preclinical stages of Alzheimer&#x2019;s disease: recommendations from the National Institute on Aging-Alzheimer&#x2019;s Association workgroups on diagnostic guidelines for Alzheimer&#x2019;s disease. Alzheimers Dement. 2011;7:280&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3220946</ArticleId><ArticleId IdType="pubmed">21514248</ArticleId></ArticleIdList></Reference><Reference><Citation>Grober E, Hall CB, Lipton RB, et al. Memory impairment, executive dysfunction, and intellectual decline in preclinical Alzheimer&#x2019;s disease. J Int Neuropsychol Soc. 2008;14:266&#x2013;78.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2763488</ArticleId><ArticleId IdType="pubmed">18282324</ArticleId></ArticleIdList></Reference><Reference><Citation>Roe CM, Fagan AM, Grant EA, et al. Amyloid imaging and CSF biomarkers in predicting cognitive impairment up to 7.5 years later. Neurology. 2013;80:1784&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3719431</ArticleId><ArticleId IdType="pubmed">23576620</ArticleId></ArticleIdList></Reference><Reference><Citation>Howieson DB, Carlson NE, Moore MM, et al. Trajectory of mild cognitive impairment onset. J Int Neuropsychol Soc. 2008;14:192&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">18282317</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson DK, Storandt M, Morris JC, et al. Longitudinal study of the transition from healthy aging to Alzheimer disease. Arch Neurol. 2009;66:1254&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2795328</ArticleId><ArticleId IdType="pubmed">19822781</ArticleId></ArticleIdList></Reference><Reference><Citation>Beach TG, Monsell SE, Phillips LE, et al. Accuracy of the clinical diagnosis of Alzheimer disease at National Institute on Aging Alzheimer Disease Centers, 2005&#x2013;2010. J Neuropathol Exp Neurol. 2012;71:266&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3331862</ArticleId><ArticleId IdType="pubmed">22437338</ArticleId></ArticleIdList></Reference><Reference><Citation>Cure S, Abrams K, Belger M, et al. Systematic literature review and meta-analysis of diagnostic test accuracy in Alzheimer&#x2019;s disease and other dementia using autopsy as standard of truth. J Alzheimer&#x2019;s Dis. 2014;42:169&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pubmed">24840572</ArticleId></ArticleIdList></Reference><Reference><Citation>Ball M, Braak H, Coleman P, et al. Consensus Recommendations for the Postmortem Diagnosis of Alzheimer&#x2019;s Disease. Neurobiol Aging. 1997;18:S1&#x2013;S2.</Citation><ArticleIdList><ArticleId IdType="pubmed">9330978</ArticleId></ArticleIdList></Reference><Reference><Citation>Hyman BT, Phelps CH, Beach TG, et al. National Institute on Aging-Alzheimer&#x201d;s Association guidelines for the neuropathologic assessment of Alzheimer&#x201d;s disease. Alzheimer&#x2019;s Dement. 2012;8:1&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3266529</ArticleId><ArticleId IdType="pubmed">22265587</ArticleId></ArticleIdList></Reference><Reference><Citation>Monsell SE, Mock C, Hassenstab J, et al. Neuropsychological changes in asymptomatic persons with Alzheimer disease neuropathology. Neurology. 2014;83:434&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4132573</ArticleId><ArticleId IdType="pubmed">24951474</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC, Weintraub S, Chui HC, et al. The Uniform Data Set (UDS): clinical and cognitive variables and descriptive data from Alzheimer Disease Centers. Alzheimer Dis Assoc Disord. 2006;20:210&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">17132964</ArticleId></ArticleIdList></Reference><Reference><Citation>Beekly DL, Ramos EM, Lee WW, et al. The National Alzheimer&#x2019;s Coordinating Center (NACC) database: the uniform data set. Alzheimer Dis Assoc Disord. 2007;21:249&#x2013;58.</Citation><ArticleIdList><ArticleId IdType="pubmed">17804958</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology. 1993;43:2412&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">8232972</ArticleId></ArticleIdList></Reference><Reference><Citation>Montine TJ, Phelps CH, Beach TG, et al. National Institute on Aging&#x2013;Alzheimer&#x2019;s Association guidelines for the neuropathologic assessment of Alzheimer&#x2019;s disease: a practical approach. Acta Neuropathol. 2011;123:1&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3268003</ArticleId><ArticleId IdType="pubmed">22101365</ArticleId></ArticleIdList></Reference><Reference><Citation>Monsell SE, Mock C, Roe CM, et al. Comparison of symptomatic and asymptomatic persons with Alzheimer disease neuropathology. Neurology. 2013;80:2121&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3716351</ArticleId><ArticleId IdType="pubmed">23645594</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Alafuzoff I, Arzberger T, et al. Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol. 2006;112:389&#x2013;404.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3906709</ArticleId><ArticleId IdType="pubmed">16906426</ArticleId></ArticleIdList></Reference><Reference><Citation>Mirra SS, Heyman A, McKeel D, et al. The Consortium to Establish a Registry for Alzheimer&#x201d;s Disease (CERAD) Part II. Standardization of the neuropathologic assessment of Alzheimer&#x201d;s disease. Neurology. 1991;41:479&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">2011243</ArticleId></ArticleIdList></Reference><Reference><Citation>Thal DR, R&#xfc;b U, Orantes M, et al. Phases of A beta-deposition in the human brain and its relevance for the development of AD. Neurology. 2002;58:1791&#x2013;800.</Citation><ArticleIdList><ArticleId IdType="pubmed">12084879</ArticleId></ArticleIdList></Reference><Reference><Citation>Weintraub S, Salmon D, Mercaldo N, et al. The Alzheimer&#x201d;s Disease Centers&#x201d; Uniform Data Set (UDS): the neuropsychologic test battery. Alzheimer Dis Assoc Disord. 2009;23:91&#x2013;101.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2743984</ArticleId><ArticleId IdType="pubmed">19474567</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayden KM, Jones RN, Zimmer C, et al. Factor structure of the National Alzheimer&#x2019;s Coordinating Centers uniform dataset neuropsychological battery: an evaluation of invariance between and within groups over time. Alzheimer Dis Assoc Disord. 2011;25:128&#x2013;37.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3101374</ArticleId><ArticleId IdType="pubmed">21606904</ArticleId></ArticleIdList></Reference><Reference><Citation>Thal DR, Ghebremedhin E, Orantes M, et al. Vascular pathology in Alzheimer disease: correlation of cerebral amyloid angiopathy and arteriosclerosis/lipohyalinosis with cognitive decline. J Neuropathol Exp Neurol. 2003;62:1287&#x2013;301.</Citation><ArticleIdList><ArticleId IdType="pubmed">14692704</ArticleId></ArticleIdList></Reference><Reference><Citation>Pfeifer LA, White LR, Ross GW, et al. Cerebral amyloid angiopathy and cognitive function The HAAS autopsy study. Neurology. 2002;58:1629&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">12058090</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenberg SM, Gurol ME, Rosand J. Amyloid angiopathy-related vascular cognitive impairment. Stroke. 2004;35:2616&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">15459438</ArticleId></ArticleIdList></Reference><Reference><Citation>Balota DA, Tse C-S, Hutchison KA, et al. Predicting conversion to dementia of the Alzheimer&#x2019;s type in a healthy control sample: The power of errors in stroop color naming. Psychol Aging. 2010;25:208&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2886285</ArticleId><ArticleId IdType="pubmed">20230140</ArticleId></ArticleIdList></Reference><Reference><Citation>Tse C-S, Balota DA, Yap MJ, et al. Effects of healthy aging and early stage dementia of the Alzheimer&#x2019;s type on components of response time distributions in three attention tasks. Neuropsychol. 2010;24:300&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2864950</ArticleId><ArticleId IdType="pubmed">20438208</ArticleId></ArticleIdList></Reference><Reference><Citation>Storandt M, Mintun MA, Head D, et al. Cognitive decline and brain volume loss as signatures of cerebral amyloid-beta peptide deposition identified with Pittsburgh compound B: cognitive decline associated with Abeta deposition. Arch Neurol. 2009;66:1476&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2796577</ArticleId><ArticleId IdType="pubmed">20008651</ArticleId></ArticleIdList></Reference><Reference><Citation>Twamley EW, Ropacki SAL, Bondi MW. Neuropsychological and neuroimaging changes in preclinical Alzheimer&#x2019;s disease. J Int Neuropsychol Soc. 2006;12:707&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1621044</ArticleId><ArticleId IdType="pubmed">16961952</ArticleId></ArticleIdList></Reference><Reference><Citation>Driscoll I, Resnick SM, Troncoso JC, et al. Impact of Alzheimer&#x2019;s pathology on cognitive trajectories in nondemented elderly. Ann Neurol. 2006;60:688&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pubmed">17192929</ArticleId></ArticleIdList></Reference><Reference><Citation>Riley KP, Jicha GA, Davis D, et al. Prediction of preclinical Alzheimer&#x2019;s disease: longitudinal rates of change in cognition. J Alzheimers Dis. 2011;25:707&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3353267</ArticleId><ArticleId IdType="pubmed">21498903</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett DA, Wilson RS, Boyle PA, et al. Relation of neuropathology to cognition in persons without cognitive impairment. Ann Neurol. 2012;72:599&#x2013;609.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3490232</ArticleId><ArticleId IdType="pubmed">23109154</ArticleId></ArticleIdList></Reference><Reference><Citation>Price JL, McKeel DW, Buckles VD, et al. Neuropathology of nondemented aging: presumptive evidence for preclinical Alzheimer disease. Neurobiol Aging. 2009;30:1026&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2737680</ArticleId><ArticleId IdType="pubmed">19376612</ArticleId></ArticleIdList></Reference><Reference><Citation>Gauthier S, Wu L, Rosa-Neto P, et al. Prevention strategies for Alzheimer&#x2019;s disease. Transl Neurodegener. 2012;1:13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3514088</ArticleId><ArticleId IdType="pubmed">23210473</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">2353798</PMID><DateCompleted><Year>1990</Year><Month>07</Month><Day>16</Day></DateCompleted><DateRevised><Year>2024</Year><Month>12</Month><Day>19</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0364-5134</ISSN><JournalIssue CitedMedium="Print"><Volume>27</Volume><Issue>4</Issue><PubDate><Year>1990</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Annals of neurology</Title><ISOAbbreviation>Ann Neurol</ISOAbbreviation></Journal><ArticleTitle>The prevalence of dementia and Alzheimer's disease in Shanghai, China: impact of age, gender, and education.</ArticleTitle><Pagination><StartPage>428</StartPage><EndPage>437</EndPage><MedlinePgn>428-37</MedlinePgn></Pagination><Abstract><AbstractText>We report the prevalence rates for dementia and Alzheimer's disease (AD) obtained from a probability sample survey of 5,055 noninstitutionalized older persons in Shanghai, China. A two-stage procedure was used for case finding and case identification. A Chinese version of the Mini-Mental State Examination was used to determine cases of possible dementia. Three different cutoff points on this mental status test were used depending on the respondent's level of education. Clinical evaluations, based on functional assessments and psychiatric interview, medical and neurological examinations, three standardized mental status tests, and a selected group of psychometric tests, were made in the second stage of the study to ascertain the clinical diagnosis of dementia and AD utilizing the Diagnostic and Statistical Manual for Mental Disorders, edition 3 and National Institute of Neurological and Communicative Disorders and Stroke-Alzheimer's Disease and Related Disorders Association criteria, respectively. The prevalence rate of dementia in persons 65 years and older was 4.6%. Clinically diagnosed AD accounted for 65% of the subjects with dementia. These findings indicate that the prevalence of dementia in Shanghai is very much higher than figures published earlier for China and Japan, and at the lower part of the range of values reported for community residents in the United States and other Western countries, but less than half of that reported in the recently published survey of the elderly in East Boston. Increasing age, gender (female), and low education are each highly significant and independent risk factors for dementia. One hypothesis to explain the increased prevalence in elderly women who had received no formal education invokes the possibility of an effect of early deprivation, perhaps lowering brain "reserve," allowing the symptoms of dementia to appear at an earlier date during disease progression.</AbstractText></Abstract><AuthorList CompleteYN="N"><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>M Y</ForeName><Initials>MY</Initials><AffiliationInfo><Affiliation>Shanghai Institute of Mental Health, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Katzman</LastName><ForeName>R</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Salmon</LastName><ForeName>D</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Jin</LastName><ForeName>H</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Cai</LastName><ForeName>G J</ForeName><Initials>GJ</Initials></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Z Y</ForeName><Initials>ZY</Initials></Author><Author ValidYN="Y"><LastName>Qu</LastName><ForeName>G Y</ForeName><Initials>GY</Initials></Author><Author ValidYN="Y"><LastName>Grant</LastName><ForeName>I</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>E</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Levy</LastName><ForeName>P</ForeName><Initials>P</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>AG05131</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH 36408</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Ann Neurol</MedlineTA><NlmUniqueID>7707449</NlmUniqueID><ISSNLinking>0364-5134</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002681" MajorTopicYN="N" Type="Geographic">China</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003625" MajorTopicYN="N">Data Collection</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004522" MajorTopicYN="N">Educational Status</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012737" MajorTopicYN="N">Sex Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1990</Year><Month>4</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1990</Year><Month>4</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1990</Year><Month>4</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">2353798</ArticleId><ArticleId IdType="doi">10.1002/ana.410270412</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">26505746</PMID><DateCompleted><Year>2016</Year><Month>06</Month><Day>17</Day></DateCompleted><DateRevised><Year>2024</Year><Month>06</Month><Day>12</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1531-8249</ISSN><JournalIssue CitedMedium="Internet"><Volume>79</Volume><Issue>1</Issue><PubDate><Year>2016</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Annals of neurology</Title><ISOAbbreviation>Ann Neurol</ISOAbbreviation></Journal><ArticleTitle>Tau positron emission tomographic imaging in aging and early Alzheimer disease.</ArticleTitle><Pagination><StartPage>110</StartPage><EndPage>119</EndPage><MedlinePgn>110-9</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/ana.24546</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Detection of focal brain tau deposition during life could greatly facilitate accurate diagnosis of Alzheimer disease (AD), staging and monitoring of disease progression, and development of disease-modifying therapies.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We acquired tau positron emission tomography (PET) using (18)F T807 (AV1451), and amyloid-&#x3b2; PET using (11)C Pittsburgh compound B (PiB) in older clinically normal individuals, and symptomatic patients with mild cognitive impairment or mild AD dementia.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">We found abnormally high cortical (18)F T807 binding in patients with mild cognitive impairment and AD dementia compared to clinically normal controls. Consistent with the neuropathology literature, the presence of elevated neocortical (18)F T807 binding particularly in the inferior temporal gyrus was associated with clinical impairment. The association of cognitive impairment was stronger with inferior temporal (18)F T807 than with mean cortical (11)C PIB. Regional (18)F T807 was correlated with mean cortical (11)C PiB among both impaired and control subjects.</AbstractText><AbstractText Label="INTERPRETATION" NlmCategory="CONCLUSIONS">These findings suggest that (18)F T807 PET could have value as a biomarker that reflects both the progression of AD tauopathy and the emergence of clinical impairment.</AbstractText><CopyrightInformation>&#xa9; 2015 American Neurological Association.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Johnson</LastName><ForeName>Keith A</ForeName><Initials>KA</Initials><AffiliationInfo><Affiliation>Division of Nuclear Medicine and Molecular Imaging, Boston, MA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Boston, MA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Radiology, Massachusetts General Hospital, Boston, MA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Alzheimer Research and Treatment, Department of Neurology, Brigham and Women's Hospital, Boston, MA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Harvard Medical School, Boston, MA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schultz</LastName><ForeName>Aaron</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Nuclear Medicine and Molecular Imaging, Boston, MA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Alzheimer Research and Treatment, Department of Neurology, Brigham and Women's Hospital, Boston, MA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Athinoula A. Martinos Center for Biomedical Imaging, Boston, MA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Betensky</LastName><ForeName>Rebecca A</ForeName><Initials>RA</Initials><AffiliationInfo><Affiliation>Department of Medicine (Biostatistics Center), Massachusetts General Hospital, Boston, MA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Harvard School of Public Health, Boston, MA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Becker</LastName><ForeName>J Alex</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Division of Nuclear Medicine and Molecular Imaging, Boston, MA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Radiology, Massachusetts General Hospital, Boston, MA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sepulcre</LastName><ForeName>Jorge</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Division of Nuclear Medicine and Molecular Imaging, Boston, MA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Radiology, Massachusetts General Hospital, Boston, MA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Harvard Medical School, Boston, MA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Athinoula A. Martinos Center for Biomedical Imaging, Boston, MA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rentz</LastName><ForeName>Dorene</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Neurology, Boston, MA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Alzheimer Research and Treatment, Department of Neurology, Brigham and Women's Hospital, Boston, MA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Harvard Medical School, Boston, MA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mormino</LastName><ForeName>Elizabeth</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Neurology, Boston, MA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Alzheimer Research and Treatment, Department of Neurology, Brigham and Women's Hospital, Boston, MA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chhatwal</LastName><ForeName>Jasmeer</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurology, Boston, MA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Alzheimer Research and Treatment, Department of Neurology, Brigham and Women's Hospital, Boston, MA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Harvard Medical School, Boston, MA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Amariglio</LastName><ForeName>Rebecca</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Neurology, Boston, MA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Alzheimer Research and Treatment, Department of Neurology, Brigham and Women's Hospital, Boston, MA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Harvard Medical School, Boston, MA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Papp</LastName><ForeName>Kate</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Neurology, Boston, MA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Alzheimer Research and Treatment, Department of Neurology, Brigham and Women's Hospital, Boston, MA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Harvard Medical School, Boston, MA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marshall</LastName><ForeName>Gad</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Neurology, Boston, MA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Alzheimer Research and Treatment, Department of Neurology, Brigham and Women's Hospital, Boston, MA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Harvard Medical School, Boston, MA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Albers</LastName><ForeName>Mark</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology, Boston, MA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Harvard Medical School, Boston, MA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mauro</LastName><ForeName>Samantha</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Division of Nuclear Medicine and Molecular Imaging, Boston, MA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Radiology, Massachusetts General Hospital, Boston, MA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pepin</LastName><ForeName>Lesley</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Division of Nuclear Medicine and Molecular Imaging, Boston, MA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Radiology, Massachusetts General Hospital, Boston, MA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alverio</LastName><ForeName>Jonathan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Division of Nuclear Medicine and Molecular Imaging, Boston, MA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Radiology, Massachusetts General Hospital, Boston, MA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Judge</LastName><ForeName>Kelly</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Division of Nuclear Medicine and Molecular Imaging, Boston, MA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Radiology, Massachusetts General Hospital, Boston, MA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Philiossaint</LastName><ForeName>Marlie</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of Nuclear Medicine and Molecular Imaging, Boston, MA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Radiology, Massachusetts General Hospital, Boston, MA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shoup</LastName><ForeName>Timothy</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Division of Nuclear Medicine and Molecular Imaging, Boston, MA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Radiology, Massachusetts General Hospital, Boston, MA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yokell</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Division of Nuclear Medicine and Molecular Imaging, Boston, MA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Radiology, Massachusetts General Hospital, Boston, MA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Harvard Medical School, Boston, MA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dickerson</LastName><ForeName>Bradford</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Division of Nuclear Medicine and Molecular Imaging, Boston, MA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Boston, MA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Harvard Medical School, Boston, MA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Athinoula A. Martinos Center for Biomedical Imaging, Boston, MA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gomez-Isla</LastName><ForeName>Teresa</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Neurology, Boston, MA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Harvard Medical School, Boston, MA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hyman</LastName><ForeName>Bradley</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Neurology, Boston, MA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Harvard Medical School, Boston, MA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vasdev</LastName><ForeName>Neil</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Division of Nuclear Medicine and Molecular Imaging, Boston, MA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Radiology, Massachusetts General Hospital, Boston, MA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Harvard Medical School, Boston, MA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sperling</LastName><ForeName>Reisa</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Neurology, Boston, MA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Alzheimer Research and Treatment, Department of Neurology, Brigham and Women's Hospital, Boston, MA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Harvard Medical School, Boston, MA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Athinoula A. Martinos Center for Biomedical Imaging, Boston, MA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG037497</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG027435</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>M01 RR002635</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005134</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG00513421</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG010483</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K23 AG049087</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG046396</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG036694</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG024904</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U19 AG010483</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>12</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Ann Neurol</MedlineTA><NlmUniqueID>7707449</NlmUniqueID><ISSNLinking>0364-5134</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C475519">2-(4'-(methylamino)phenyl)-6-hydroxybenzothiazole</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000814">Aniline Compounds</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002243">Carbolines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013844">Thiazoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>J09QS3Z3WB</RegistryNumber><NameOfSubstance UI="C000591008">7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000814" MajorTopicYN="N">Aniline Compounds</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002243" MajorTopicYN="N">Carbolines</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002540" MajorTopicYN="N">Cerebral Cortex</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D060825" MajorTopicYN="N">Cognitive Dysfunction</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="N">Positron-Emission Tomography</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013702" MajorTopicYN="N">Temporal Lobe</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013844" MajorTopicYN="N">Thiazoles</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList><CoiStatement><b>Potential Conflict of Interests:</b> AS, RB, JAB, JS, DR, EM, JC, RA, KP, GM, SM, LP, JA, KJ, MP, TS, DY, and TG have no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>6</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2015</Year><Month>9</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>10</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>10</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>10</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>6</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2017</Year><Month>1</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26505746</ArticleId><ArticleId IdType="mid">NIHMS733591</ArticleId><ArticleId IdType="pmc">PMC4738026</ArticleId><ArticleId IdType="doi">10.1002/ana.24546</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hyman BT, Phelps CH, Beach TG, et al. National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease. Alzheimers Dement. 2012;8(1):1&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3266529</ArticleId><ArticleId IdType="pubmed">22265587</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson PT, Alafuzoff I, Bigio EH, et al. Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J Neuropathol Exp Neurol. 2012;71(5):362&#x2013;381.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3560290</ArticleId><ArticleId IdType="pubmed">22487856</ArticleId></ArticleIdList></Reference><Reference><Citation>Klunk WE, Engler H, Nordberg A, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol. 2004;55(3):306&#x2013;319.</Citation><ArticleIdList><ArticleId IdType="pubmed">14991808</ArticleId></ArticleIdList></Reference><Reference><Citation>Clark CM, Pontecorvo MJ, Beach TG, et al. Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-&#x3b2; plaques: a prospective cohort study. Lancet Neurol. 2012;11(8):669&#x2013;678.</Citation><ArticleIdList><ArticleId IdType="pubmed">22749065</ArticleId></ArticleIdList></Reference><Reference><Citation>Rinne JO, Wong DF, Wolk DA, et al. [(18)F]Flutemetamol PET imaging and cortical biopsy histopathology for fibrillar amyloid &#x3b2; detection in living subjects with normal pressure hydrocephalus: pooled analysis of four studies. Acta Neuropathol. 2012;124(6):833&#x2013;845.</Citation><ArticleIdList><ArticleId IdType="pubmed">23053137</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia C-F, Arteaga J, Chen G, et al. [(18)F]T807, a novel tau positron emission tomography imaging agent for Alzheimer's disease. Alzheimers Dement. 2013;9(6):666&#x2013;676.</Citation><ArticleIdList><ArticleId IdType="pubmed">23411393</ArticleId></ArticleIdList></Reference><Reference><Citation>Chien DT, Bahri S, Szardenings AK, et al. Early clinical PET imaging results with the novel PHF-tau radioligand [F-18]-T807. J Alzheimers Dis. 2013;34(2):457&#x2013;468.</Citation><ArticleIdList><ArticleId IdType="pubmed">23234879</ArticleId></ArticleIdList></Reference><Reference><Citation>Villemagne VL, Fodero-Tavoletti MT, Masters CL, Rowe CC. Tau imaging: early progress and future directions. Lancet Neurol. 2015;14(1):114&#x2013;124.</Citation><ArticleIdList><ArticleId IdType="pubmed">25496902</ArticleId></ArticleIdList></Reference><Reference><Citation>Okamura N, Furumoto S, Fodero-Tavoletti MT, et al. Non-invasive assessment of Alzheimer&#x2019;s disease neurofibrillary pathology using 18F-THK5105 PET. Brain. 2014;137:1762&#x2013;1771.</Citation><ArticleIdList><ArticleId IdType="pubmed">24681664</ArticleId></ArticleIdList></Reference><Reference><Citation>Harada R, Okamura N, Furumoto S, et al. Comparison of the binding characteristics of [18F]THK-523 and other amyloid imaging tracers to Alzheimer&#x2019;s disease pathology. Eur J Nucl Med Mol Imaging. 2013;40:125&#x2013;132.</Citation><ArticleIdList><ArticleId IdType="pubmed">23100049</ArticleId></ArticleIdList></Reference><Reference><Citation>Villemagne VL, Furumoto S, Fodero-Tavoletti MT, et al. In vivo evaluation of a novel tau imaging tracer for Alzheimer&#x2019;s disease. Eur J Nucl Med Mol Imaging. 2014;41:816&#x2013;826.</Citation><ArticleIdList><ArticleId IdType="pubmed">24514874</ArticleId></ArticleIdList></Reference><Reference><Citation>Yesavage JA, Brink TL, Rose TL, et al. Development and validation of a geriatric depression screening scale: a preliminary report. J Psychiatr Res. 1983;17:37&#x2013;49.</Citation><ArticleIdList><ArticleId IdType="pubmed">7183759</ArticleId></ArticleIdList></Reference><Reference><Citation>Wechsler D. WMS-R: Wechsler Memory Scale&#x2013;Revised. San Antonio, TX: Psychological Corp; 1987.</Citation></Reference><Reference><Citation>Folstein MF, Folstein SE, McHugh PR. &#x201c;Mini-mental state&#x201d;. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189&#x2013;198.</Citation><ArticleIdList><ArticleId IdType="pubmed">1202204</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology. 1993;43(11):2412&#x2013;2414.</Citation><ArticleIdList><ArticleId IdType="pubmed">8232972</ArticleId></ArticleIdList></Reference><Reference><Citation>Becker JA, Hedden T, Carmasin J, et al. Amyloid-&#x3b2; associated cortical thinning in clinically normal elderly. Ann Neurol. 2011;69(6):1032&#x2013;1042.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3117980</ArticleId><ArticleId IdType="pubmed">21437929</ArticleId></ArticleIdList></Reference><Reference><Citation>Amariglio RE, Becker JA, Carmasin J, et al. Subjective cognitive complaints and amyloid burden in cognitively normal older individuals. Neuropsychologia. 2012;50(12):2880&#x2013;2886.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3473106</ArticleId><ArticleId IdType="pubmed">22940426</ArticleId></ArticleIdList></Reference><Reference><Citation>Mormino EC, Betensky RA, Hedden T, et al. Amyloid and APOE e4 interact to influence short-term decline in preclinical Alzheimer disease. Neurology. 2014;82(20):1760&#x2013;1767.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4035706</ArticleId><ArticleId IdType="pubmed">24748674</ArticleId></ArticleIdList></Reference><Reference><Citation>Albert MS, Dekosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer&#x2018;s Association workgroups on diagnostic guidelines for Alzheimer&#x2019;s disease. 2011:270&#x2013;279.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3312027</ArticleId><ArticleId IdType="pubmed">21514249</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7(3):263&#x2013;269.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3312024</ArticleId><ArticleId IdType="pubmed">21514250</ArticleId></ArticleIdList></Reference><Reference><Citation>Shoup TM, Yokell DL, Rice PA, et al. A concise radiosynthesis of the tau radiopharmaceutical, [(18) F]T807. J Label Compd Radiopharm. 2013;56(14):736&#x2013;740. 2013.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4114396</ArticleId><ArticleId IdType="pubmed">24339014</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Alafuzoff I, Arzberger T, et al. Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta neuropatholog. 2006;112(4):389&#x2013;404.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3906709</ArticleId><ArticleId IdType="pubmed">16906426</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E. Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol Aging. 1997;18(4):351&#x2013;357.</Citation><ArticleIdList><ArticleId IdType="pubmed">9330961</ArticleId></ArticleIdList></Reference><Reference><Citation>Delacourte A, Sergeant N, Wattez A, et al. Tau aggregation in the hippocampal formation: an ageing or a pathological process? Exp Gerontol. 2002;37(10&#x2013;11):1291&#x2013;1296.</Citation><ArticleIdList><ArticleId IdType="pubmed">12470843</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischl B, Salat DH, van der Kouwe AJ, et al. Sequence-independent segmentation of magnetic resonance images. Neuroimage. 2004;23(Suppl 1):S69&#x2013;S84.</Citation><ArticleIdList><ArticleId IdType="pubmed">15501102</ArticleId></ArticleIdList></Reference><Reference><Citation>Logan J. Graphical analysis of reversible radioligand binding from time-activity measurements. J Cereb Blood Flow Metab. 1990;10(5):740&#x2013;747.</Citation><ArticleIdList><ArticleId IdType="pubmed">2384545</ArticleId></ArticleIdList></Reference><Reference><Citation>Hedden T, Van Dijk KRA, Becker JA, et al. Disruption of functional connectivity in clinically normal older adults harboring amyloid burden. Journal of Neurosci. 2009;29(40):12686&#x2013;12694.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2808119</ArticleId><ArticleId IdType="pubmed">19812343</ArticleId></ArticleIdList></Reference><Reference><Citation>Arriagada PV, Marzloff K, Hyman BT. Distribution of Alzheimer-type pathologic changes in nondemented elderly individuals matches the pattern in Alzheimer's disease. Neurology. 1992 Sep;42(9):1681&#x2013;1688.</Citation><ArticleIdList><ArticleId IdType="pubmed">1307688</ArticleId></ArticleIdList></Reference><Reference><Citation>Arriagada PV, Growdon JH, Hedley-Whyte ET, Hyman BT. Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease. Neurology. 1992 Mar;42(3 Pt 1):631&#x2013;639.</Citation><ArticleIdList><ArticleId IdType="pubmed">1549228</ArticleId></ArticleIdList></Reference><Reference><Citation>G&#xf3;mez-Isla T, Price JL, McKeel DW, Jr, Morris JC, Growdon JH, Hyman BT. Profound loss of layer II entorhinal cortex neurons occurs in very mild Alzheimer's disease. J Neurosci. 1996 Jul 15;16(14):4491&#x2013;4500.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6578866</ArticleId><ArticleId IdType="pubmed">8699259</ArticleId></ArticleIdList></Reference><Reference><Citation>Marquie M, Normandin M, Vanderburg C, et al. Towards the validation of novel PET tracer T807 on postmortem human brain tissue samples. In: Johnson KA, Jagust WJ, Klunk WE, Mathis CA, editors. Proceedings of the 9th Human Amyloid Imaging Conference; 2015 Jan 14&#x2013;16; Miami, FL. 2015.</Citation></Reference><Reference><Citation>Serrano-Pozo A, Qian J, Monsell SE, et al. Examination of the clinicopathologic continuum of Alzheimer disease in the autopsy cohort of the National Alzheimer Coordinating Center. J Neuropathol Exp Neurol. 2013 Dec;72(12):1182&#x2013;1192.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3962953</ArticleId><ArticleId IdType="pubmed">24226270</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson PT, Abner EL, Schmitt FA, et al. Brains with medial temporal lobe neurofibrillary tangles but no neuritic amyloid plaques are a diagnostic dilemma but may have pathogenetic aspects distinct from Alzheimer disease. J Neuropathol Exp Neurol. 2009;68(7):774&#x2013;784.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2725359</ArticleId><ArticleId IdType="pubmed">19535994</ArticleId></ArticleIdList></Reference><Reference><Citation>Crary JF, Trojanowski JQ, Schneider JA, et al. Primary age-related taupathy (PART): a common pathology associated with human aging. Acta Neuropathol. 2014;128(6):755&#x2013;766.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4257842</ArticleId><ArticleId IdType="pubmed">25348064</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">2804814</PMID><DateCompleted><Year>1989</Year><Month>12</Month><Day>20</Day></DateCompleted><DateRevised><Year>2019</Year><Month>08</Month><Day>28</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0317-1671</ISSN><JournalIssue CitedMedium="Print"><Volume>16</Volume><Issue>4 Suppl</Issue><PubDate><Year>1989</Year><Month>Nov</Month></PubDate></JournalIssue><Title>The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques</Title><ISOAbbreviation>Can J Neurol Sci</ISOAbbreviation></Journal><ArticleTitle>Immune system response in Alzheimer's disease.</ArticleTitle><Pagination><StartPage>516</StartPage><EndPage>527</EndPage><MedlinePgn>516-27</MedlinePgn></Pagination><Abstract><AbstractText>Involvement of the immune system in the pathogenesis of Alzheimer's disease was demonstrated in two ways: by the attachment of complement proteins to diseased tissue, and by the activation of cells associated with the immune system. Alzheimer brain tissue was stained immunohistochemically by antibodies to components of the classical, but not the alternative, complement pathway. Antibodies to C1q, C3d, and C4d stained senile plaques, dystrophic neurites, neuropil threads and some tangled neurons. Antibodies to a neoantigenic site on the C5b-9 membrane attack complex stained dystrophic neurites and many tangled neurons, but not senile plaques. Antibodies to Factor P and fraction Bb of Factor B, which are specific for the alternative complement pathway, did not stain Alzheimer brain tissue. The cellular immune response was evaluated by the presence of reactive microglia and by the infiltration of small numbers of T-cells into diseased brain tissue. Reactive microglia were identified by antibodies to HLA-DR, a class II major histocompatibility complex glycoprotein, and by enhanced staining with antibodies to leukocyte common antigen and the Fc gamma RI and Fc gamma RII receptors. T-cells were identified by antibodies to leukocyte common antigen, as well as the CD4 and CD8 surface proteins. Double immunostaining with antibodies to GFAP and MHC class I or class II antigens established that astrocytes, which are GFAP positive, do not express MHC antigens in Alzheimer's disease. Endothelial cells express MHC class I antigens while reactive microglia and some leukocytes express class II antigen.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>McGeer</LastName><ForeName>P L</ForeName><Initials>PL</Initials><AffiliationInfo><Affiliation>Kinsmen Laboratory of Neurological Research, Department of Psychiatry, University of B.C., Vancouver.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Akiyama</LastName><ForeName>H</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Itagaki</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>McGeer</LastName><ForeName>E G</ForeName><Initials>EG</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Can J Neurol Sci</MedlineTA><NlmUniqueID>0415227</NlmUniqueID><ISSNLinking>0317-1671</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003167" MajorTopicYN="Y">Complement Activation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1989</Year><Month>11</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1989</Year><Month>11</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1989</Year><Month>11</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">2804814</ArticleId><ArticleId IdType="doi">10.1017/s0317167100029863</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">26582899</PMID><DateCompleted><Year>2016</Year><Month>09</Month><Day>26</Day></DateCompleted><DateRevised><Year>2020</Year><Month>04</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1946-6242</ISSN><JournalIssue CitedMedium="Internet"><Volume>7</Volume><Issue>314</Issue><PubDate><Year>2015</Year><Month>Nov</Month><Day>18</Day></PubDate></JournalIssue><Title>Science translational medicine</Title><ISOAbbreviation>Sci Transl Med</ISOAbbreviation></Journal><ArticleTitle>The E3 ubiquitin ligase Idol controls brain LDL receptor expression, ApoE clearance, and A&#x3b2; amyloidosis.</ArticleTitle><Pagination><StartPage>314ra184</StartPage><MedlinePgn>314ra184</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1126/scitranslmed.aad1904</ELocationID><Abstract><AbstractText>Apolipoprotein E (ApoE) is an important modifier of Alzheimer's disease (AD) pathogenesis, and its abundance has been linked to the clearance of &#x3b2;-amyloid (A&#x3b2;) in the brain. The pathways that control the clearance of ApoE in the brain are incompletely understood. We report that Idol, an E3 ubiquitin ligase that targets the low-density lipoprotein receptor (LDLR) for degradation, is a critical determinant of brain ApoE metabolism and A&#x3b2; plaque biogenesis. Previous work has shown that Idol contributes minimally to the regulation of hepatic LDLR expression in mice. By contrast, we demonstrate that Idol is a primary physiological regulator of LDLR protein in the brain, controlling the clearance of both ApoE-containing high-density lipoprotein (HDL) particles and A&#x3b2;. We studied the consequences of loss of Idol expression in a transgenic mouse model of A&#x3b2; amyloidosis. Idol deficiency increased brain LDLR, decreased ApoE, decreased soluble and insoluble A&#x3b2;, reduced amyloid plaque burden, and ameliorated neuroinflammation. These findings identify Idol as a gatekeeper of LDLR-dependent ApoE and A&#x3b2; clearance in the brain and a potential enzyme target for therapeutic intervention in AD.</AbstractText><CopyrightInformation>Copyright &#xa9; 2015, American Association for the Advancement of Science.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Choi</LastName><ForeName>Jinkuk</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Howard Hughes Medical Institute, University of California, Los Angeles, Los Angeles, CA 90095, USA. Department of Pathology and Laboratory Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gao</LastName><ForeName>Jie</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Howard Hughes Medical Institute, University of California, Los Angeles, Los Angeles, CA 90095, USA. Department of Pathology and Laboratory Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Jaekwang</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Graduate School, Mayo Clinic College of Medicine, Jacksonville, FL 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hong</LastName><ForeName>Cynthia</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Howard Hughes Medical Institute, University of California, Los Angeles, Los Angeles, CA 90095, USA. Department of Pathology and Laboratory Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Jungsu</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Graduate School, Mayo Clinic College of Medicine, Jacksonville, FL 32224, USA. ptontonoz@mednet.ucla.edu kim.jungsu@mayo.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tontonoz</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Howard Hughes Medical Institute, University of California, Los Angeles, Los Angeles, CA 90095, USA. Department of Pathology and Laboratory Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA. ptontonoz@mednet.ucla.edu kim.jungsu@mayo.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>HL066088</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS069329</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><Acronym>HHMI</Acronym><Agency>Howard Hughes Medical Institute</Agency><Country>United States</Country></Grant><Grant><GrantID>K99 AG054736</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 HL066088</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 NS069329</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Sci Transl Med</MedlineTA><NlmUniqueID>101505086</NlmUniqueID><ISSNLinking>1946-6234</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001057">Apolipoproteins E</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011973">Receptors, LDL</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.3.2.27</RegistryNumber><NameOfSubstance UI="C542022">Mylip protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.3.2.27</RegistryNumber><NameOfSubstance UI="D044767">Ubiquitin-Protein Ligases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Ann Transl Med. 2016 Dec;4(24):536. doi: 10.21037/atm.2016.11.63.</RefSource><PMID Version="1">28149897</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="Y">enzymology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000686" MajorTopicYN="N">Amyloidosis</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="Y">enzymology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001057" MajorTopicYN="N">Apolipoproteins E</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="Y">enzymology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="N">Genetic Predisposition to Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058225" MajorTopicYN="N">Plaque, Amyloid</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059748" MajorTopicYN="N">Proteolysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011973" MajorTopicYN="N">Receptors, LDL</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D044767" MajorTopicYN="N">Ubiquitin-Protein Ligases</DescriptorName><QualifierName UI="Q000172" MajorTopicYN="N">deficiency</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList><CoiStatement><b>Competing interests:</b> UCLA holds a patent related to Idol of which P.T. is a co-inventor.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>11</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>11</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>9</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>4</Month><Day>13</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26582899</ArticleId><ArticleId IdType="mid">NIHMS1563350</ArticleId><ArticleId IdType="pmc">PMC7153735</ArticleId><ArticleId IdType="doi">10.1126/scitranslmed.aad1904</ArticleId><ArticleId IdType="pii">7/314/314ra184</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ballard C, Gauthier S, Corbett A, Brayne C, Aarsland D, Jones E, Alzheimer&#x2019;s disease. Lancet 377, 1019&#x2013;1031 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21371747</ArticleId></ArticleIdList></Reference><Reference><Citation>Blennow K, de Leon MJ, Zetterberg H, Alzheimer&#x2019;s disease. Lancet 368, 387&#x2013;403 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16876668</ArticleId></ArticleIdList></Reference><Reference><Citation>Holtzman DM, Morris JC, Goate AM, Alzheimer&#x2019;s disease: The challenge of the second century. Sci. Transl. Med 3, 77sr1 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3130546</ArticleId><ArticleId IdType="pubmed">21471435</ArticleId></ArticleIdList></Reference><Reference><Citation>Bertram L, Lill CM, Tanzi RE, The genetics of Alzheimer disease: Back to the future. Neuron 68, 270&#x2013;281 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20955934</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahley RW, Apolipoprotein E: Cholesterol transport protein with expanding role in cell biology. Science 240, 622&#x2013;630 (1988).</Citation><ArticleIdList><ArticleId IdType="pubmed">3283935</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim J, Basak JM, Holtzman DM, The role of apolipoprotein E in Alzheimer&#x2019;s disease. Neuron 63, 287&#x2013;303 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3044446</ArticleId><ArticleId IdType="pubmed">19679070</ArticleId></ArticleIdList></Reference><Reference><Citation>Bien-Ly N, Gillespie AK, Walker D, Yoon SY, Huang Y, Reducing human apolipoprotein E levels attenuates age-dependent A&#x3b2; accumulation in mutant human amyloid precursor protein transgenic mice. J. Neurosci 32, 4803&#x2013;4811 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3433173</ArticleId><ArticleId IdType="pubmed">22492035</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim J, Jiang H, Park S, Eltorai AEM, Stewart FR, Yoon H, Basak JM, Finn MB, Holtzman DM, Haploinsufficiency of human APOE reduces amyloid deposition in a mouse model of amyloid-b amyloidosis. J. Neurosci 31, 18007&#x2013;18012 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3257514</ArticleId><ArticleId IdType="pubmed">22159114</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim J, Eltorai AEM, Jiang H, Liao F, Verghese PB, Kim J, Stewart FR, Basak JM, Holtzman DM, Anti-apoE immunotherapy inhibits amyloid accumulation in a transgenic mouse model of A&#x3b2; amyloidosis. J. Exp. Med 209, 2149&#x2013;2156 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3501350</ArticleId><ArticleId IdType="pubmed">23129750</ArticleId></ArticleIdList></Reference><Reference><Citation>Wahrle SE, Jiang H, Parsadanian M, Kim J, Li A, Knoten A, Jain S, Hirsch-Reinshagen V, Wellington CL, Bales KR, Paul SM, Holtzman DM, Overexpression of ABCA1 reduces amyloid deposition in the PDAPP mouse model of Alzheimer disease. J. Clin. Invest 118, 671&#x2013;682 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2200302</ArticleId><ArticleId IdType="pubmed">18202749</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown MS, Goldstein JL, A receptor-mediated pathway for cholesterol homeostasis. Science 232, 34&#x2013;47 (1986).</Citation><ArticleIdList><ArticleId IdType="pubmed">3513311</ArticleId></ArticleIdList></Reference><Reference><Citation>Calkin AC, Lee SD, Kim J, Stijn CMWV, Wu X-H, Lusis AJ, Hong C, Tangirala RI, Tontonoz P, Transgenic expression of dominant-active IDOL in liver causes diet-induced hypercholesterolemia and atherosclerosis in mice. Circ. Res 115, 442&#x2013;449 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4119488</ArticleId><ArticleId IdType="pubmed">24935961</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong C, Marshall SM, McDaniel AL, Graham M, Layne JD, Cai L, Scotti E, Boyadjian R, Kim J, Chamberlain BT, Tangirala RK, Jung ME, Fong L, Lee R, Young SG, Temel RE, Tontonoz P, The LXR&#x2013;Idol axis differentially regulates plasma LDL levels in primates and mice. Cell Metab. 20, 910&#x2013;918 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4261644</ArticleId><ArticleId IdType="pubmed">25440061</ArticleId></ArticleIdList></Reference><Reference><Citation>Weissglas-Volkov D, Calkin AC, Tusie-Luna T, Sinsheimer JS, Zelcer N, Riba L, Tino AMV, Ordo&#xf1;ez-S&#xe1;nchez ML, Cruz-Bautista I, Aguilar-Salinas CA, Tontonoz P, Pajukanta P, The N342S MYLIP polymorphism is associated with high total cholesterol and increased LDL receptor degradation in humans. J. Clin. Invest 121, 3062&#x2013;3071 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3148733</ArticleId><ArticleId IdType="pubmed">21765216</ArticleId></ArticleIdList></Reference><Reference><Citation>Zelcer N, Hong C, Boyadjian R, Tontonoz P, LXR regulates cholesterol uptake through idol-dependent ubiquitination of the LDL receptor. Science 325, 100&#x2013;104 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2777523</ArticleId><ArticleId IdType="pubmed">19520913</ArticleId></ArticleIdList></Reference><Reference><Citation>Calkin AC, Goult BT, Zhang L, Fairall L, Hong C, Schwabe JWR, Tontonoz P, FERM-dependent E3 ligase recognition is a conserved mechanism for targeted degradation of lipoprotein receptors. Proc. Natl. Acad. Sci. U.S.A 108, 20107&#x2013;20112 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3250164</ArticleId><ArticleId IdType="pubmed">22109552</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang L, Fairall L, Goult BT, Calkin AC, Hong C, Millard CJ, Tontonoz P, Schwabe JWR, The IDOL&#x2013;UBE2D complex mediates sterol-dependent degradation of the LDL receptor. Genes Dev. 25, 1262&#x2013;1274 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3127428</ArticleId><ArticleId IdType="pubmed">21685362</ArticleId></ArticleIdList></Reference><Reference><Citation>Castellano JM, Deane R, Gottesdiener AJ, Verghese PB, Stewart FR, West T, Paoletti AC, Kasper TR, DeMattos RB, Zlokovic BV, Holtzman DM, Low-density lipoprotein receptor overexpression enhances the rate of brain-to-blood A&#x3b2; clearance in a mouse model of &#x3b2;-amyloidosis. Proc. Natl. Acad. Sci. U.S.A 109, 15502&#x2013;15507 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3458349</ArticleId><ArticleId IdType="pubmed">22927427</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim J, Castellano JM, Jiang H, Basak JM, Parsadanian M, Pham V, Mason SM, Paul SM, Holtzman DM, Overexpression of low-density lipoprotein receptor in the brain markedly inhibits amyloid deposition and increases extracellular A&#x3b2; clearance. Neuron 64, 632&#x2013;644 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2787195</ArticleId><ArticleId IdType="pubmed">20005821</ArticleId></ArticleIdList></Reference><Reference><Citation>Mosher KI, Wyss-Coray T, Microglial dysfunction in brain aging and Alzheimer&#x2019;s disease. Biochem. Pharmacol 88, 594&#x2013;604 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3972294</ArticleId><ArticleId IdType="pubmed">24445162</ArticleId></ArticleIdList></Reference><Reference><Citation>Solito E, Sastre M, Microglia function in Alzheimer&#x2019;s disease. Front. Pharmacol 3, 14 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3277080</ArticleId><ArticleId IdType="pubmed">22363284</ArticleId></ArticleIdList></Reference><Reference><Citation>Jankowsky JL, Fadale DJ, Anderson J, Xu GM, Gonzales V, Jenkins NA, Copeland NG, Lee MK, Younkin LH, Wagner SL, Younkin SG, Borchelt DR, Mutant presenilins specifically elevate the levels of the 42 residue &#x3b2;-amyloid peptide in vivo: Evidence for augmentation of a 42-specific g secretase. Hum. Mol. Genet 13, 159&#x2013;170 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">14645205</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyer-Luehmann M, Spires-Jones TL, Prada C, Garcia-Alloza M, de Calignon A, Rozkalne A, Koenigsknecht-Talboo J, Holtzman DM, Bacskai BJ, Hyman BT, Rapid appearance and local toxicity of amyloid-&#x3b2; plaques in a mouse model of Alzheimer&#x2019;s disease. Nature 451, 720&#x2013;724 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3264491</ArticleId><ArticleId IdType="pubmed">18256671</ArticleId></ArticleIdList></Reference><Reference><Citation>Wahrle SE, Jiang H, Parsadanian M, Hartman RE, Bales KR, Paul SM, Holtzman DM, Deletion of Abca1 increases A&#x3b2; deposition in the PDAPP transgenic mouse model of Alzheimer disease. J. Biol. Chem 280, 43236&#x2013;43242 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">16207708</ArticleId></ArticleIdList></Reference><Reference><Citation>Lai AY, McLaurin J, Mechanisms of amyloid-b peptide uptake by neurons: The role of lipid rafts and lipid raft-associated proteins. Int. J. Alzheimers Dis 2011, 548380 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3010653</ArticleId><ArticleId IdType="pubmed">21197446</ArticleId></ArticleIdList></Reference><Reference><Citation>Perry VH, Nicoll JAR, Holmes C, Microglia in neurodegenerative disease. Nat. Rev. Neurol 6, 193&#x2013;201 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20234358</ArticleId></ArticleIdList></Reference><Reference><Citation>Wyss-Coray T, Loike JD, Brionne TC, Lu E, Anankov R, Yan F, Silverstein SC, Husemann J, Adult mouse astrocytes degrade amyloid-&#x3b2; in vitro and in situ. Nat. Med 9, 453&#x2013;457 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">12612547</ArticleId></ArticleIdList></Reference><Reference><Citation>Basak JM, Verghese PB, Yoon H, Kim J, Holtzman DM, Low-density lipoprotein receptor represents an apolipoprotein E-independent pathway of A&#x3b2; uptake and degradation by astrocytes. J. Biol. Chem 287, 13959&#x2013;13971 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3340151</ArticleId><ArticleId IdType="pubmed">22383525</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang Q, Lee CYD, Mandrekar S, Wilkinson B, Cramer P, Zelcer N, Mann K, Lamb B, Willson TM, Collins JL, Richardson JC, Smith JD, Comery TA, Riddell D, Holtzman DM, Tontonoz P, Landreth GE, ApoE promotes the proteolytic degradation of A&#x3b2;. Neuron 58, 681&#x2013;693 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2493297</ArticleId><ArticleId IdType="pubmed">18549781</ArticleId></ArticleIdList></Reference><Reference><Citation>Pitas RE, Boyles JK, Lee SH, Hui D, Weisgraber KH, Lipoproteins and their receptors in the central nervous system. characterization of the lipoproteins in cerebrospinal fluid and identification of apolipoprotein B,E(LDL) receptors in the brain. J. Biol. Chem 262, 14352&#x2013;14360 (1987).</Citation><ArticleIdList><ArticleId IdType="pubmed">3115992</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanekiyo T, Xu H, Bu G, ApoE and A&#x3b2; in Alzheimer&#x2019;s disease: Accidental encounters or partners? Neuron 81, 740&#x2013;754 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3983361</ArticleId><ArticleId IdType="pubmed">24559670</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu C-C, Kanekiyo T, Xu H, Bu G, Apolipoprotein E and Alzheimer disease: Risk, mechanisms and therapy. Nat. Rev. Neurol 9, 106&#x2013;118 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3726719</ArticleId><ArticleId IdType="pubmed">23296339</ArticleId></ArticleIdList></Reference><Reference><Citation>Bales KR, Verina T, Dodel RC, Du Y, Altstiel L, Bender M, Hyslop P, Johnstone EM, Little SP, Cummins DJ, Piccardo P, Ghetti B, Paul SM, Lack of apolipoprotein E dramatically reduces amyloid &#x3b2;-peptide deposition. Nat. Genet 17, 263&#x2013;264 (1997).</Citation><ArticleIdList><ArticleId IdType="pubmed">9354781</ArticleId></ArticleIdList></Reference><Reference><Citation>Irizarry MC, Rebeck GW, Cheung B, Bales K, Paul SM, Holzman D, Hyman BT, Modulation of A&#x3b2; deposition in APP transgenic mice by an apolipoprotein E null background. Ann. N. Y. Acad. Sci 920, 171&#x2013;178 (2000).</Citation><ArticleIdList><ArticleId IdType="pubmed">11193147</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao D, Fukuchi K, Wan H, Kim H, Li L, Lack of LDL receptor aggravates learning deficits and amyloid deposits in Alzheimer transgenic mice. Neurobiol. Aging 27, 1632&#x2013;1643 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16236385</ArticleId></ArticleIdList></Reference><Reference><Citation>Fryer JD, DeMattos RB, McCormick LM, O&#x2019;Dell MA, Spinner ML, Bales KR, Paul SM, Sullivan PM, Parsadanian M, Bu G, Holtzman DM, The low density lipoprotein receptor regulates the level of central nervous system human and murine Apolipoprotein E but does not modify amyloid plaque pathology in PDAPP mice. J. Biol. Chem 280, 25754&#x2013;25759 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">15888448</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Q, Zerbinatti CV, Zhang J, Hoe H-S, Wang B, Cole SL, Herz J, Muglia L, Bu G, Amyloid precursor protein regulates brain apolipoprotein E and cholesterol metabolism through lipoprotein receptor LRP1. Neuron 56, 66&#x2013;78 (2007).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2045076</ArticleId><ArticleId IdType="pubmed">17920016</ArticleId></ArticleIdList></Reference><Reference><Citation>Chakrabarty P, Li A, Ceballos-Diaz C, Eddy JA, Funk CC, Moore B, DiNunno N, Rosario AM, Cruz PE, Verbeeck C, Sacino A, Nix S, Janus C, Price ND, Das P, Golde TE, IL-10 Alters immunoproteostasis in APP mice, increasing plaque burden and worsening cognitive behavior, Neuron 85, 519&#x2013;533 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4320003</ArticleId><ArticleId IdType="pubmed">25619653</ArticleId></ArticleIdList></Reference><Reference><Citation>Namba Y, Tomonaga M, Kawasaki H, Otomo E, Ikeda K, Apolipoprotein E immune-reactivity in cerebral amyloid deposits and neurofibrillary tangles in Alzheimer&#x2019;s disease and kuru plaque amyloid in Creutzfeldt-Jakob disease. Brain Res 541, 163&#x2013;166 (1991).</Citation><ArticleIdList><ArticleId IdType="pubmed">2029618</ArticleId></ArticleIdList></Reference><Reference><Citation>Verghese PB, Castellano JM, Garai K, Wang Y, Jiang H, Shah A, Bu G, Frieden C, Holtzman DM, ApoE influences amyloid-&#x3b2; (A&#x3b2;) clearance despite minimal apoE/A&#x3b2; association in physiological conditions. Proc. Natl. Acad. Sci. U.S.A 110, E1807&#x2013;E1816 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3651443</ArticleId><ArticleId IdType="pubmed">23620513</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu M, Wu G, Baysarowich J, Kavana M, Addona GH, Bierilo KK, Mudgett JS, Pavlovic G, Sitlani A, Renger JJ, Hubbard BK, Fisher TS, Zerbinatti CV, PCSK9 is not involved in the degradation of LDL receptors and BACE1 in the adult mouse brain. J. Lipid Res 51, 2611&#x2013;2618 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2918444</ArticleId><ArticleId IdType="pubmed">20453200</ArticleId></ArticleIdList></Reference><Reference><Citation>Rousselet E, Marcinkiewicz J, Kriz J, Zhou A, Hatten ME, Prat A, Seidah NG, PCSK9 reduces the protein levels of the LDL receptor in mouse brain during development and after ischemic stroke. J. Lipid Res 52, 1383&#x2013;1391 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3111744</ArticleId><ArticleId IdType="pubmed">21518694</ArticleId></ArticleIdList></Reference><Reference><Citation>Burns MP, Vardanian L, Pajoohesh-Ganji A, Wang L, Cooper M, Harris DC, Duff K, Rebeck GW, The effects of ABCA1 on cholesterol efflux and A&#x3b2; levels in vitro and in vivo. J. Neurochem 98, 792&#x2013;800 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16771834</ArticleId></ArticleIdList></Reference><Reference><Citation>Donkin JJ, Stukas S, Hirsch-Reinshagen V, Namjoshi D, Wilkinson A, May S, Chan J, Fan J, Collins J, Wellington CL, ATP-binding cassette transporter A1 mediates the beneficial effects of the liver X receptor agonist GW3965 on object recognition memory and amyloid burden in amyloid precursor protein/presenilin 1 mice. J. Biol. Chem 285, 34144&#x2013;34154 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2962513</ArticleId><ArticleId IdType="pubmed">20739291</ArticleId></ArticleIdList></Reference><Reference><Citation>Koldamova RP, Lefterov IM, Staufenbiel M, Wolfe D, Huang S, Glorioso JC, Walter M, Roth MG, Lazo JS, The liver X receptor ligand T0901317 decreases amyloid b production in vitro and in a mouse model of Alzheimer&#x2019;s disease. J. Biol. Chem 280, 4079&#x2013;4088 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">15557325</ArticleId></ArticleIdList></Reference><Reference><Citation>Lefterov I, Bookout A, Wang Z, Staufenbiel M, Mangelsdorf D, Koldamova R, Expression profiling in APP23 mouse brain: Inhibition of A&#x3b2; amyloidosis and inflammation in response to LXR agonist treatment. Mol. Neurodegener 2, 20 (2007).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2214725</ArticleId><ArticleId IdType="pubmed">17953774</ArticleId></ArticleIdList></Reference><Reference><Citation>Riddell DR, Zhou H, Comery TA, Kouranova E, Lo CF, Warwick HK, Ring RH, Kirksey Y, Aschmies S, Xu J, Kubek K, Hirst WD, Gonzales C, Chen Y, Murphy E, Leonard S, Vasylyev D, Oganesian A, Martone RL, Pangalos MN, Reinhart PH, Jacobsen JS, The LXR agonist TO901317 selectively lowers hippocampal A&#x3b2;42 and improves memory in the Tg2576 mouse model of Alzheimer&#x2019;s disease, Mol. Cell. Neurosci 34, 621&#x2013;628 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17336088</ArticleId></ArticleIdList></Reference><Reference><Citation>Vanmierlo T, Rutten K, Dederen J, Bloks VW, van LC Vark-van der Zee, F. Kuipers, A. Kiliaan, A. Blokland, E. J. G. Sijbrands, H. Steinbusch, J. Prickaerts, D. L&#xfc;tjohann, M. Mulder, Liver X receptor activation restores memory in aged AD mice without reducing amyloid. Neurobiol. Aging 32, 1262&#x2013;1272 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">19674815</ArticleId></ArticleIdList></Reference><Reference><Citation>Wahrle SE, Jiang H, Parsadanian M, Legleiter J, Han X, Fryer JD, Kowalewski T, Holtzman DM, ABCA1 is required for normal central nervous system ApoE levels and for lipidation of astrocyte-secreted apoE. J. Biol. Chem 279, 40987&#x2013;40993 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15269217</ArticleId></ArticleIdList></Reference><Reference><Citation>Zelcer N, Khanlou N, Clare R, Jiang Q, Reed-Geaghan EG, Landreth GE, Vinters HV, Tontonoz P, Attenuation of neuroinflammation and Alzheimer&#x2019;s disease pathology by liver X receptors. Proc. Natl. Acad. Sci. U.S.A 104, 10601&#x2013;10606 (2007).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1890560</ArticleId><ArticleId IdType="pubmed">17563384</ArticleId></ArticleIdList></Reference><Reference><Citation>Zelcer N, Tontonoz P, Liver X receptors as integrators of metabolic and inflammatory signaling. J. Clin. Invest 116, 607&#x2013;614 (2006).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1386115</ArticleId><ArticleId IdType="pubmed">16511593</ArticleId></ArticleIdList></Reference><Reference><Citation>Skaar JR, Pagan JK, Pagano M, SCF ubiquitin ligase-targeted therapies. Nat. Rev. Drug Discov 13, 889&#x2013;903 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4410837</ArticleId><ArticleId IdType="pubmed">25394868</ArticleId></ArticleIdList></Reference><Reference><Citation>Beaudoin III GMJ, Lee S-H, Singh D, Yuan Y, Ng Y-G, Reichardt LF, Arikkath J, Culturing pyramidal neurons from the early postnatal mouse hippocampus and cortex. Nat. Protoc 7, 1741&#x2013;1754 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22936216</ArticleId></ArticleIdList></Reference><Reference><Citation>Viviani B, Preparation and coculture of neurons and glial cells. Curr. Protoc. Cell Biol Chapter 2, Unit 2.7 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">18228481</ArticleId></ArticleIdList></Reference><Reference><Citation>Collins JL, Fivush AM, Watson MA, Galardi CM, Lewis MC, Moore LB, Parks DJ, Wilson JG, Tippin TK, Binz JG, Plunket KD, Morgan DG, Beaudet EJ, Whitney KD, Kliewer SA, Willson TM, Identification of a nonsteroidal liver X receptor agonist through parallel array synthesis of tertiary amines. J. Med. Chem 45, 1963&#x2013;1966 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">11985463</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim J, Yoon H, Ram&#xed;rez CM, Lee S-M, Hoe H-S, Fern&#xe1;ndez-Hernando C, Kim J, miR-106b impairs cholesterol efflux and increases A&#x3b2; levels by repressing ABCA1 expression. Exp. Neurol 235, 476&#x2013;483 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3328628</ArticleId><ArticleId IdType="pubmed">22119192</ArticleId></ArticleIdList></Reference><Reference><Citation>Li X, Kan H-Y, Lavrentiadou S, Krieger M, Zannis V, Reconstituted discoidal ApoE-phospholipid particles are ligands for the scavenger receptor BI. The amino-terminal 1&#x2013;165 domain of ApoE suffices for receptor binding. J. Biol. Chem 277, 21149&#x2013;21157 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">11861652</ArticleId></ArticleIdList></Reference><Reference><Citation>Matz CE, Jonas A, Micellar complexes of human apolipoprotein A-I with phosphatidylcholines and cholesterol prepared from cholate-lipid dispersions. J. Biol. Chem 257, 4535&#x2013;4540 (1982).</Citation><ArticleIdList><ArticleId IdType="pubmed">6802835</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">26714488</PMID><DateCompleted><Year>2016</Year><Month>09</Month><Day>20</Day></DateCompleted><DateRevised><Year>2019</Year><Month>01</Month><Day>09</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1758-9193</ISSN><JournalIssue CitedMedium="Internet"><Volume>7</Volume><PubDate><Year>2015</Year><Month>Dec</Month><Day>27</Day></PubDate></JournalIssue><Title>Alzheimer's research &amp; therapy</Title><ISOAbbreviation>Alzheimers Res Ther</ISOAbbreviation></Journal><ArticleTitle>Cognitive impact after short-term exposure to different proton pump inhibitors: assessment using CANTAB software.</ArticleTitle><Pagination><StartPage>79</StartPage><MedlinePgn>79</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">79</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s13195-015-0164-8</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Studies have shown that proton pump inhibitors (PPIs) increase the brain burden of amyloid-beta (A&#x3b2;) and also create vitamin B12 deficiency. However, these two phenomena have deleterious effect on cognition and Alzheimer's disease (AD). Since the use of PPIs has increased tremendously for the last few years, it is of great public health importance to investigate the cognitive impact of PPIs. Hence, the purpose of this study was to investigate the degree of neuropsychological association of each PPI with different cognitive functions.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Sixty volunteers of either gender were recruited and divided randomly into six groups: five test groups for five classes of PPIs and one control group. All the groups participated in the five computerized neuropsychological tests (nine subtests) of the Cambridge Neuropsychological Test Automated Battery twice: at the beginning of the study and 7 days thereafter.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">We found statistically and clinically significant impairment in visual memory, attention, executive function, and working and planning function. One-way analysis of variance findings showed that all PPIs had a similar negative impact on cognition. However, paired-samples t tests indicated that omeprazole showed significant (p&#x2009;&lt;&#x2009;0.05) results in seven subtests; lansoprazole and pantoprazole showed significant results in five subtests; and rabeprazole showed significant results in four subtests. Among five classes of PPIs, esomeprazole showed comparatively less impact on cognitive function with significant results in three subtests.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The present study reveals for the first time that different PPIs have varying degrees of influence on different cognitive domains and have associations with AD. These findings should be considered when balancing the risks and benefits of prescribing these medications. A study done for a longer period of time with a larger sample size might yield better results.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Akter</LastName><ForeName>Sanjida</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Pharmacy, School of Medicine, University of Asia Pacific, House no. 73, Road no. 5A, Dhanmondi, Dhaka, 1209, Bangladesh. sanjida2050@yahoo.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hassan</LastName><ForeName>Md Rajib</ForeName><Initials>MR</Initials><AffiliationInfo><Affiliation>Department of Pharmacy, School of Medicine, University of Asia Pacific, House no. 73, Road no. 5A, Dhanmondi, Dhaka, 1209, Bangladesh. rajib@uap-bd.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shahriar</LastName><ForeName>Mohammad</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Pharmacy, School of Medicine, University of Asia Pacific, House no. 73, Road no. 5A, Dhanmondi, Dhaka, 1209, Bangladesh. shahriar@uap-bd.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Akter</LastName><ForeName>Nahia</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Pharmacy, School of Medicine, University of Asia Pacific, House no. 73, Road no. 5A, Dhanmondi, Dhaka, 1209, Bangladesh. nahia_07@uap-bd.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abbas</LastName><ForeName>Md Golam</ForeName><Initials>MG</Initials><AffiliationInfo><Affiliation>Department of Molecular Neuroscience and Integrative Physiology, Graduate School of Medical Science, Kanazawa University, Kanazawa, Ishikawa, Japan. abbasgolam@yahoo.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bhuiyan</LastName><ForeName>Mohiuddin Ahmed</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Department of Pharmacy, School of Medicine, University of Asia Pacific, House no. 73, Road no. 5A, Dhanmondi, Dhaka, 1209, Bangladesh. mohiuddin@uap-bd.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>12</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Alzheimers Res Ther</MedlineTA><NlmUniqueID>101511643</NlmUniqueID></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053799">2-Pyridinylmethylsulfinylbenzimidazoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000897">Anti-Ulcer Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D054328">Proton Pump Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0K5C5T2QPG</RegistryNumber><NameOfSubstance UI="D064747">Lansoprazole</NameOfSubstance></Chemical><Chemical><RegistryNumber>32828355LL</RegistryNumber><NameOfSubstance UI="D064750">Rabeprazole</NameOfSubstance></Chemical><Chemical><RegistryNumber>D8TST4O562</RegistryNumber><NameOfSubstance UI="D000077402">Pantoprazole</NameOfSubstance></Chemical><Chemical><RegistryNumber>KG60484QX9</RegistryNumber><NameOfSubstance UI="D009853">Omeprazole</NameOfSubstance></Chemical><Chemical><RegistryNumber>N3PA6559FT</RegistryNumber><NameOfSubstance UI="D064098">Esomeprazole</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D053799" MajorTopicYN="N">2-Pyridinylmethylsulfinylbenzimidazoles</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000897" MajorTopicYN="N">Anti-Ulcer Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D064098" MajorTopicYN="N">Esomeprazole</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064747" MajorTopicYN="N">Lansoprazole</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009853" MajorTopicYN="N">Omeprazole</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000077402" MajorTopicYN="N">Pantoprazole</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D054328" MajorTopicYN="N">Proton Pump Inhibitors</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D064750" MajorTopicYN="N">Rabeprazole</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012984" MajorTopicYN="Y">Software</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>7</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>11</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>12</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>12</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>9</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2015</Year><Month>12</Month><Day>27</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26714488</ArticleId><ArticleId IdType="pmc">PMC4696341</ArticleId><ArticleId IdType="doi">10.1186/s13195-015-0164-8</ArticleId><ArticleId IdType="pii">10.1186/s13195-015-0164-8</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Heidelbaugh JJ, Kim AH, Chang R, Walker PC. Overutilization of proton-pump inhibitors: what the clinician needs to know. Ther Adv Gastroenterol. 2012;5:219&#x2013;32. doi: 10.1177/1756283X12437358.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1756283X12437358</ArticleId><ArticleId IdType="pmc">PMC3388523</ArticleId><ArticleId IdType="pubmed">22778788</ArticleId></ArticleIdList></Reference><Reference><Citation>Chubineh S, Birk J. Proton pump inhibitors: the good, the bad, and the unwanted. South Med J. 2012;105:613&#x2013;8. doi: 10.1097/SMJ.0b013e31826efbea.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/SMJ.0b013e31826efbea</ArticleId><ArticleId IdType="pubmed">23128806</ArticleId></ArticleIdList></Reference><Reference><Citation>Lew EA. Pharmacokinetic concerns in the selection of anti-ulcer therapy. Aliment Pharmacol Ther. 1999;13:11&#x2013;6. doi: 10.1046/j.1365-2036.1999.00034.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1365-2036.1999.00034.x</ArticleId><ArticleId IdType="pubmed">10555604</ArticleId></ArticleIdList></Reference><Reference><Citation>Norman A, Hawkey CJ. What you need to know when you prescribe a proton pump inhibitor. Frontline Gastroenterol. 2011;2:199&#x2013;205. doi: 10.1136/flgastro-2011-100006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/flgastro-2011-100006</ArticleId><ArticleId IdType="pmc">PMC5517237</ArticleId><ArticleId IdType="pubmed">28839610</ArticleId></ArticleIdList></Reference><Reference><Citation>Holt S, Howden CW. Omeprazole: overview and opinion. Digest Dis Sci. 1991;36:385&#x2013;93. doi: 10.1007/BF01298864.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF01298864</ArticleId><ArticleId IdType="pubmed">2007354</ArticleId></ArticleIdList></Reference><Reference><Citation>Ksi&#x105;dzyna D, Szel&#x105;g A, Paradowski L. Overuse of proton pump inhibitors. Pol Arch Med Wewn. 2015;125:289&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="pubmed">25790817</ArticleId></ArticleIdList></Reference><Reference><Citation>Forgacs I, Loganayagam A. Overprescribing proton pump inhibitors. BMJ. 2008;336:2&#x2013;3. doi: 10.1136/bmj.39406.449456.BE.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.39406.449456.BE</ArticleId><ArticleId IdType="pmc">PMC2174763</ArticleId><ArticleId IdType="pubmed">18174564</ArticleId></ArticleIdList></Reference><Reference><Citation>Naunton M, Peterson GM, Bleasel MD. Overuse of proton pump inhibitors. J Clin Pharm Ther. 2000;25:333&#x2013;40. doi: 10.1046/j.1365-2710.2000.00312.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1365-2710.2000.00312.x</ArticleId><ArticleId IdType="pubmed">11123484</ArticleId></ArticleIdList></Reference><Reference><Citation>Walker NM, McDonald J. An evaluation of the use of proton pump inhibitors. Pharm World Sci. 2001;23:116&#x2013;7. doi: 10.1023/A:1011278030001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1023/A:1011278030001</ArticleId><ArticleId IdType="pubmed">11468876</ArticleId></ArticleIdList></Reference><Reference><Citation>Grant K, Al-Adhami N, Tordoff J, Livesey J, Barbezat G, Reith D. Continuation of proton pump inhibitors from hospital to community. Pharm World Sci. 2006;28:189&#x2013;93. doi: 10.1007/s11096-006-9028-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11096-006-9028-4</ArticleId><ArticleId IdType="pubmed">17066244</ArticleId></ArticleIdList></Reference><Reference><Citation>Batuwitage BT, Kingham JGC, Morgan NE, Bartlett RL. Inappropriate prescribing of proton pump inhibitors in primary care. Postgrad Med J. 2007;83:66&#x2013;8. doi: 10.1136/pgmj.2006.051151.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/pgmj.2006.051151</ArticleId><ArticleId IdType="pmc">PMC2599965</ArticleId><ArticleId IdType="pubmed">17267683</ArticleId></ArticleIdList></Reference><Reference><Citation>Heidelbaugh JJ, Goldberg KL, Inadomi JM. Magnitude and economic impact of overutilization of antisecretory therapy in the ambulatory care setting. Am J Manag Care. 2010;16:e228&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">21250399</ArticleId></ArticleIdList></Reference><Reference><Citation>Heidelbaugh JJ, Inadomi JM. Magnitude and economic impact of inappropriate use of stress ulcer prophylaxis in non-ICU hospitalized patients. Am J Gastroenterol. 2006;101:2200&#x2013;5. doi: 10.1111/j.1572-0241.2006.00839.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1572-0241.2006.00839.x</ArticleId><ArticleId IdType="pubmed">16952283</ArticleId></ArticleIdList></Reference><Reference><Citation>Eid S, Boueiz A, Paranji S, Mativo C, Landis R, Abougergi MS. Patterns and predictors of proton pump inhibitor overuse among academic and non-academic hospitalists. Intern Med. 2010;49:2561&#x2013;8. doi: 10.2169/internalmedicine.49.4064.</Citation><ArticleIdList><ArticleId IdType="doi">10.2169/internalmedicine.49.4064</ArticleId><ArticleId IdType="pubmed">21139293</ArticleId></ArticleIdList></Reference><Reference><Citation>Laine L, Ahnen D, McClain C, Solcia E, Walsh JH. Review article: potential gastrointestinal effects of long-term acid suppression with proton pump inhibitors. Aliment Pharmacol Ther. 2000;14:651&#x2013;68. doi: 10.1046/j.1365-2036.2000.00768.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1365-2036.2000.00768.x</ArticleId><ArticleId IdType="pubmed">10848649</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomson AB, Sauve MD, Kassam N, Kamitakahara H. Safety of the long-term use of proton pump inhibitors. World J Gastroenterol. 2010;16:2323&#x2013;30. doi: 10.3748/wjg.v16.i19.2323.</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.v16.i19.2323</ArticleId><ArticleId IdType="pmc">PMC2874135</ArticleId><ArticleId IdType="pubmed">20480516</ArticleId></ArticleIdList></Reference><Reference><Citation>Haenisch B, von Holt K, Wiese B, Prokein J, Lange C, Ernst A, et al. Risk of dementia in elderly patients with the use of proton pump inhibitors. Eur Arch Psychiatry Clin Neurosci. 2015;265:419&#x2013;28. doi: 10.1007/s00406-014-0554-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00406-014-0554-0</ArticleId><ArticleId IdType="pubmed">25341874</ArticleId></ArticleIdList></Reference><Reference><Citation>Reitz C, Brayne C, Mayeux R. Epidemiology of Alzheimer disease. Nat Rev Neurol. 2011;7:137&#x2013;52. doi: 10.1038/nrneurol.2011.2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2011.2</ArticleId><ArticleId IdType="pmc">PMC3339565</ArticleId><ArticleId IdType="pubmed">21304480</ArticleId></ArticleIdList></Reference><Reference><Citation>Younkin SG. The role of A&#x3b2;42 in Alzheimer&#x2019;s disease. J Physiol Paris. 1998;92:289&#x2013;92. doi: 10.1016/S0928-4257(98)80035-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0928-4257(98)80035-1</ArticleId><ArticleId IdType="pubmed">9789825</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer&#x2019;s disease: progress and problems on the road to therapeutics. Science. 2002;297:353&#x2013;6. doi: 10.1126/science.1072994.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1072994</ArticleId><ArticleId IdType="pubmed">12130773</ArticleId></ArticleIdList></Reference><Reference><Citation>Badiola N, Alcalde V, Pujol A, M&#xfc;nter LM, Multhaup G, Lle&#xf3; A, et al. The proton-pump inhibitor lansoprazole enhances amyloid beta production. PLoS One. 2013;8:58837. doi: 10.1371/journal.pone.0058837.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0058837</ArticleId><ArticleId IdType="pmc">PMC3592824</ArticleId><ArticleId IdType="pubmed">23520537</ArticleId></ArticleIdList></Reference><Reference><Citation>Fallahzadeh MK, Borhani Haghighi A, Namazi MR. Proton pump inhibitors: predisposers to Alzheimer disease? J Clin Pharm Ther. 2010;35:125&#x2013;6. doi: 10.1111/j.1365-2710.2009.01100.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2710.2009.01100.x</ArticleId><ArticleId IdType="pubmed">20456731</ArticleId></ArticleIdList></Reference><Reference><Citation>Majumdar A, Capetillo-Zarate E, Cruz D, Gouras GK, Maxfield FR. Degradation of Alzheimer&#x2019;s amyloid fibrils by microglia requires delivery of ClC-7 to lysosomes. Mol Biol Cell. 2011;22:1664&#x2013;76. doi: 10.1091/mbc.E10-09-0745.</Citation><ArticleIdList><ArticleId IdType="doi">10.1091/mbc.E10-09-0745</ArticleId><ArticleId IdType="pmc">PMC3093319</ArticleId><ArticleId IdType="pubmed">21441306</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiarini A, Dal Pra I, Whitfield JF, Armato U. The killing of neurons by &#x3b2;-amyloid peptides, prions, and pro-inflammatory cytokines. Ital J Anat Embryol. 2006;111:221&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pubmed">17385278</ArticleId></ArticleIdList></Reference><Reference><Citation>Lam JR, Schneider JL, Zhao W, Corley DA. Proton pump inhibitor and histamine 2 receptor antagonist use and vitamin B12 deficiency. JAMA. 2013;310:2435&#x2013;42. doi: 10.1001/jama.2013.280490.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2013.280490</ArticleId><ArticleId IdType="pubmed">24327038</ArticleId></ArticleIdList></Reference><Reference><Citation>Heidelbaugh JJ. Proton pump inhibitors and risk of vitamin and mineral deficiency: evidence and clinical implications. Ther Adv Drug Saf. 2013;4:125&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4110863</ArticleId><ArticleId IdType="pubmed">25083257</ArticleId></ArticleIdList></Reference><Reference><Citation>Hammel I, Agarwal R, Manandhar L, Chiou C, Gill R, Pawlaczyk B, et al. Effects of long-term proton pump inhibitors on the quantitative levels of vitamin B12: an observational study. Biol Biomed Rep. 2012;2:230&#x2013;3.</Citation></Reference><Reference><Citation>O&#x2019;Leary F, Allman-Farinelli M, Samman S. Vitamin B12 status, cognitive decline and dementia: a systematic review of prospective cohort studies. Br J Nutr. 2012;108:1948&#x2013;61. doi: 10.1017/S0007114512004175.</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S0007114512004175</ArticleId><ArticleId IdType="pubmed">23084026</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith AD, Refsum H. Vitamin B-12 and cognition in the elderly. Am J Clin Nutr. 2009;89:707S&#x2013;11. doi: 10.3945/ajcn.2008.26947D.</Citation><ArticleIdList><ArticleId IdType="doi">10.3945/ajcn.2008.26947D</ArticleId><ArticleId IdType="pubmed">19116332</ArticleId></ArticleIdList></Reference><Reference><Citation>Vogiatzoglou A, Smith AD, Nurk E, Drevon CA, Ueland PM, Vollset SE, et al. Cognitive function in an elderly population: interaction between vitamin B12 status, depression, and apolipoprotein E &#x3b5;4: the Hordaland Homocysteine Study. Psychosom Med. 2013;75:20&#x2013;9. doi: 10.1097/PSY.0b013e3182761b6c.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/PSY.0b013e3182761b6c</ArticleId><ArticleId IdType="pubmed">23213264</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang HX, Wahlin A, Basun H, Fastbom J, Winblad B, Fratiglioni L. Vitamin B12 and folate in relation to the development of Alzheimer&#x2019;s disease. Neurology. 2001;56:1188&#x2013;94. doi: 10.1212/WNL.56.9.1188.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.56.9.1188</ArticleId><ArticleId IdType="pubmed">11342684</ArticleId></ArticleIdList></Reference><Reference><Citation>Hooshmand B, Solomon A, K&#xe5;reholt I, Leivisk&#xe4; J, Rusanen M, Ahtiluoto S, et al. Homocysteine and holotranscobalamin and the risk of Alzheimer disease: a longitudinal study. Neurology. 2010;75:1408&#x2013;14. doi: 10.1212/WNL.0b013e3181f88162.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e3181f88162</ArticleId><ArticleId IdType="pubmed">20956786</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith AD. The worldwide challenge of the dementias: a role for B vitamins and homocysteine? Food Nutr Bull. 2008;29:143&#x2013;72. doi: 10.1177/15648265080292S119.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/15648265080292S119</ArticleId><ArticleId IdType="pubmed">18709889</ArticleId></ArticleIdList></Reference><Reference><Citation>Reynolds E. Vitamin B12, folic acid, and the nervous system. Lancet Neurol. 2006;5:949&#x2013;60. doi: 10.1016/S1474-4422(06)70598-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(06)70598-1</ArticleId><ArticleId IdType="pubmed">17052662</ArticleId></ArticleIdList></Reference><Reference><Citation>McCracken C, Hudson P, Ellis R, McCaddon A. Methylmalonic acid and cognitive function in the Medical Research Council Cognitive Function and Ageing Study. Am J Clin Nutr. 2006;84:1406&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pubmed">17158424</ArticleId></ArticleIdList></Reference><Reference><Citation>Lue LF, Kuo YM, Roher AE, Brachova L, Shen Y, Sue L, et al. Soluble amyloid &#x3b2; peptide concentration as a predictor of synaptic change in Alzheimer&#x2019;s disease. Am J Pathol. 1999;155:853&#x2013;62. doi: 10.1016/S0002-9440(10)65184-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0002-9440(10)65184-X</ArticleId><ArticleId IdType="pmc">PMC1866907</ArticleId><ArticleId IdType="pubmed">10487842</ArticleId></ArticleIdList></Reference><Reference><Citation>Cognition C. Neuropsychological Test Automated Battery (CANTABeclipse) manual. Cambridge, UK: Cambridge Cognition; 2013.</Citation></Reference><Reference><Citation>De Jager CA, Milwain E, Budge MM. Early detection of isolated memory deficits in the elderly: the need for more sensitive neuropsychological tests. Psychol Med. 2002;32:483&#x2013;91. doi: 10.1017/S003329170200524X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S003329170200524X</ArticleId><ArticleId IdType="pubmed">11989993</ArticleId></ArticleIdList></Reference><Reference><Citation>Egerh&#xe1;zi A, Berecz R, Bart&#xf3;k E, Degrell I. Automated Neuropsychological Test Battery (CANTAB) in mild cognitive impairment and in Alzheimer&#x2019;s disease. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31:746&#x2013;51. doi: 10.1016/j.pnpbp.2007.01.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pnpbp.2007.01.011</ArticleId><ArticleId IdType="pubmed">17289240</ArticleId></ArticleIdList></Reference><Reference><Citation>Sahakian BJ, Morris RG, Evenden JL, Heald A, Levy R, Philpot M, et al. A comparative study of visuospatial memory and learning in Alzheimer-type dementia and Parkinson&#x2019;s disease. Brain. 1988;111:695&#x2013;718. doi: 10.1093/brain/111.3.695.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/111.3.695</ArticleId><ArticleId IdType="pubmed">3382917</ArticleId></ArticleIdList></Reference><Reference><Citation>Coull JT, Frith CD, Frackowiak RS, Grasby PM. A fronto-parietal network for rapid visual information processing: a PET study of sustained attention and working memory. Neuropsychologia. 1996;34:1085&#x2013;95. doi: 10.1016/0028-3932(96)00029-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0028-3932(96)00029-2</ArticleId><ArticleId IdType="pubmed">8904746</ArticleId></ArticleIdList></Reference><Reference><Citation>Soares FC, de Oliveira TC, de Macedo LD, Tom&#xe1;s AM, Pican&#xe7;o-Diniz DL, Bento-Torres J, et al. CANTAB object recognition and language tests to detect aging cognitive decline: an exploratory comparative study. Clin Interv Aging. 2014;10:37&#x2013;48.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4279672</ArticleId><ArticleId IdType="pubmed">25565785</ArticleId></ArticleIdList></Reference><Reference><Citation>Vin&#x163;an MA, Palade S, Cristea A, Benga I, Muresanu DF. A neuropsychological assessment, using computerized battery tests (CANTAB), in children with benign rolandic epilepsy before AED therapy. J Med Life. 2012;5:114&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3307071</ArticleId><ArticleId IdType="pubmed">22574100</ArticleId></ArticleIdList></Reference><Reference><Citation>Armstrong RA. &#x3b2;-amyloid deposition in the medial temporal lobe in elderly non-demented brains and in Alzheimer&#x2019;s disease. Dementia. 1995;6:121&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">7620523</ArticleId></ArticleIdList></Reference><Reference><Citation>Owen A, Sahakian BJ, Semple J, Polkey C, Robbins TW. Visual spatial short term recognition working memory and learning after temporal lobe excision, frontal lobe excision or amygdalo-hippocampectomy in man. Neuropsychologia. 1995;33:1&#x2013;24. doi: 10.1016/0028-3932(94)00098-A.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0028-3932(94)00098-A</ArticleId><ArticleId IdType="pubmed">7731533</ArticleId></ArticleIdList></Reference><Reference><Citation>Ossenkoppele R, Zwan MD, Tolboom N, van Assema DM, Adriaanse SF, Kloet RW, et al. Amyloid burden and metabolic function in early-onset Alzheimer&#x2019;s disease: parietal lobe involvement. Brain. 2012;135:2115&#x2013;25. doi: 10.1093/brain/aws113.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/aws113</ArticleId><ArticleId IdType="pubmed">22556189</ArticleId></ArticleIdList></Reference><Reference><Citation>Torgersen J, Flaatten H, Engelsen BA, Gramstad A. Clinical validation of Cambridge Neuropsychological Test Automated Battery in a Norwegian epilepsy population. J Behav Brain Sci. 2012;2:108&#x2013;16. doi: 10.4236/jbbs.2012.21013.</Citation><ArticleIdList><ArticleId IdType="doi">10.4236/jbbs.2012.21013</ArticleId></ArticleIdList></Reference><Reference><Citation>Howden CW. Vitamin B12 levels during prolonged treatment with proton pump inhibitors. J Clin Gastroenterol. 2000;30:29&#x2013;33. doi: 10.1097/00004836-200001000-00006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00004836-200001000-00006</ArticleId><ArticleId IdType="pubmed">10636207</ArticleId></ArticleIdList></Reference><Reference><Citation>Rizzo M, Anderson SW, Dawson J, Myers R, Ball K. Visual attention impairments in Alzheimer&#x2019;s disease. Neurology. 2000;54:1954&#x2013;9. doi: 10.1212/WNL.54.10.1954.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.54.10.1954</ArticleId><ArticleId IdType="pubmed">10822436</ArticleId></ArticleIdList></Reference><Reference><Citation>Jackson GR, Owsley C. Visual dysfunction, neurodegenerative diseases, and aging. Neurol Clin. 2003;21:709&#x2013;28. doi: 10.1016/S0733-8619(02)00107-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0733-8619(02)00107-X</ArticleId><ArticleId IdType="pubmed">13677819</ArticleId></ArticleIdList></Reference><Reference><Citation>Rabbitt P, Lowe C. Patterns of cognitive ageing. Psychol Res. 2000;63:308&#x2013;16. doi: 10.1007/s004269900009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s004269900009</ArticleId><ArticleId IdType="pubmed">11004884</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu T, Slotnick SD, Serences JT, Yantis S. Cortical mechanisms of feature-based attentional control. Cereb Cortex. 2003;13:1334&#x2013;43. doi: 10.1093/cercor/bhg080.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cercor/bhg080</ArticleId><ArticleId IdType="pubmed">14615298</ArticleId></ArticleIdList></Reference><Reference><Citation>Oishi K, Toma K, Bagarinao ET, Matsuo K, Nakai T, Chihara K, et al. Activation of the precuneus is related to reduced reaction time in serial reaction time tasks. Neurosci Res. 2005;52:37&#x2013;45. doi: 10.1016/j.neures.2005.01.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neures.2005.01.008</ArticleId><ArticleId IdType="pubmed">15811551</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">26774490</PMID><DateCompleted><Year>2016</Year><Month>10</Month><Day>20</Day></DateCompleted><DateRevised><Year>2020</Year><Month>12</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2211-1247</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>3</Issue><PubDate><Year>2016</Year><Month>Jan</Month><Day>26</Day></PubDate></JournalIssue><Title>Cell reports</Title><ISOAbbreviation>Cell Rep</ISOAbbreviation></Journal><ArticleTitle>Tet3 Reads 5-Carboxylcytosine through Its CXXC Domain and Is a Potential Guardian against Neurodegeneration.</ArticleTitle><Pagination><StartPage>493</StartPage><EndPage>505</EndPage><MedlinePgn>493-505</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.celrep.2015.12.044</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2211-1247(15)01485-0</ELocationID><Abstract><AbstractText>We report that the mammalian 5-methylcytosine (5mC) oxidase Tet3 exists as three major isoforms and characterized the full-length isoform containing an N-terminal CXXC domain (Tet3FL). This CXXC domain binds to unmethylated CpGs, but, unexpectedly, its highest affinity is toward 5-carboxylcytosine (5caC). We determined the crystal structure of the CXXC domain-5caC-DNA complex, revealing the structural basis of the binding specificity of this domain as a reader of CcaCG sequences. Mapping of Tet3FL in neuronal cells shows that Tet3FL is localized precisely at the transcription start sites (TSSs) of genes involved in lysosome function, mRNA processing, and key genes of the base excision repair pathway. Therefore, Tet3FL may function as a regulator of 5caC removal by base excision repair. Active removal of accumulating 5mC from the TSSs of genes coding for lysosomal proteins by Tet3FL in postmitotic neurons of the brain may be important for preventing neurodegenerative diseases.</AbstractText><CopyrightInformation>Copyright &#xa9; 2016 The Authors. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jin</LastName><ForeName>Seung-Gi</ForeName><Initials>SG</Initials><AffiliationInfo><Affiliation>Center for Epigenetics, Van Andel Research Institute, Grand Rapids, MI 49503, USA; Department of Cancer Biology, Beckman Research Institute of the City of Hope, Duarte, CA 91010, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Zhi-Min</ForeName><Initials>ZM</Initials><AffiliationInfo><Affiliation>Department of Biochemistry, University of California, Riverside, Riverside, CA 92521, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dunwell</LastName><ForeName>Thomas L</ForeName><Initials>TL</Initials><AffiliationInfo><Affiliation>Department of Cancer Biology, Beckman Research Institute of the City of Hope, Duarte, CA 91010, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Harter</LastName><ForeName>Matthew R</ForeName><Initials>MR</Initials><AffiliationInfo><Affiliation>Department of Biochemistry, University of California, Riverside, Riverside, CA 92521, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Xiwei</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Molecular and Cellular Biology, Beckman Research Institute of the City of Hope, Duarte, CA 91010, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Johnson</LastName><ForeName>Jennifer</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Center for Epigenetics, Van Andel Research Institute, Grand Rapids, MI 49503, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Zheng</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>The State Key Laboratory of Molecular Biology, Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences, Shanghai 200031, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Jiancheng</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, Beckman Research Institute of the City of Hope, Duarte, CA 91010, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Szab&#xf3;</LastName><ForeName>Piroska E</ForeName><Initials>PE</Initials><AffiliationInfo><Affiliation>Center for Epigenetics, Van Andel Research Institute, Grand Rapids, MI 49503, USA; Department of Molecular and Cellular Biology, Beckman Research Institute of the City of Hope, Duarte, CA 91010, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Qiang</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, Beckman Research Institute of the City of Hope, Duarte, CA 91010, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Guo-Liang</ForeName><Initials>GL</Initials><AffiliationInfo><Affiliation>The State Key Laboratory of Molecular Biology, Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences, Shanghai 200031, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Song</LastName><ForeName>Jikui</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Biochemistry, University of California, Riverside, Riverside, CA 92521, USA. Electronic address: jikui.song@ucr.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pfeifer</LastName><ForeName>Gerd P</ForeName><Initials>GP</Initials><AffiliationInfo><Affiliation>Center for Epigenetics, Van Andel Research Institute, Grand Rapids, MI 49503, USA; Department of Cancer Biology, Beckman Research Institute of the City of Hope, Duarte, CA 91010, USA. Electronic address: gerd.pfeifer@vai.org.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 MH094599</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS075393</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 GM064378</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>CA160965</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>GM064378</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS075393</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 CA160965</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH094599</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>01</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cell Rep</MedlineTA><NlmUniqueID>101573691</NlmUniqueID></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C560974">5-carboxylcytosine</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006657">Histones</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D020033">Protein Isoforms</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011518">Proto-Oncogene Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>8J337D1HZY</RegistryNumber><NameOfSubstance UI="D003596">Cytosine</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.13.11.-</RegistryNumber><NameOfSubstance UI="D049308">Dioxygenases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.13.11.-</RegistryNumber><NameOfSubstance UI="C551915">Tet3 protein, mouse</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D020816" MajorTopicYN="N">Amino Acid Motifs</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000595" MajorTopicYN="N">Amino Acid Sequence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018360" MajorTopicYN="N">Crystallography, X-Ray</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003596" MajorTopicYN="N">Cytosine</DescriptorName><QualifierName UI="Q000031" MajorTopicYN="Y">analogs &amp; derivatives</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019175" MajorTopicYN="N">DNA Methylation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004260" MajorTopicYN="N">DNA Repair</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004268" MajorTopicYN="N">DNA-Binding Proteins</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D049308" MajorTopicYN="N">Dioxygenases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057809" MajorTopicYN="N">HEK293 Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006657" MajorTopicYN="N">Histones</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008247" MajorTopicYN="N">Lysosomes</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008969" MajorTopicYN="N">Molecular Sequence Data</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009690" MajorTopicYN="N">Nucleic Acid Conformation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020033" MajorTopicYN="N">Protein Isoforms</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017434" MajorTopicYN="N">Protein Structure, Tertiary</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011518" MajorTopicYN="N">Proto-Oncogene Proteins</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D024363" MajorTopicYN="N">Transcription Initiation Site</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014981" MajorTopicYN="N">Xenopus</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>7</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2015</Year><Month>11</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>12</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>1</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>1</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>10</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2016</Year><Month>1</Month><Day>28</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26774490</ArticleId><ArticleId IdType="mid">NIHMS746652</ArticleId><ArticleId IdType="pmc">PMC4731272</ArticleId><ArticleId IdType="doi">10.1016/j.celrep.2015.12.044</ArticleId><ArticleId IdType="pii">S2211-1247(15)01485-0</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Blaschke K, Ebata KT, Karimi MM, Zepeda-Martinez JA, Goyal P, Mahapatra S, Tam A, Laird DJ, Hirst M, Rao A, et al. Vitamin C induces Tet-dependent DNA demethylation and a blastocyst-like state in ES cells. Nature. 2013;500:222&#x2013;226.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3893718</ArticleId><ArticleId IdType="pubmed">23812591</ArticleId></ArticleIdList></Reference><Reference><Citation>Coey CT, Fitzgerald ME, Maiti A, Reiter KH, Guzzo CM, Matunis MJ, Drohat AC. E2-mediated Small Ubiquitin-like Modifier (SUMO) Modification of Thymine DNA Glycosylase Is Efficient but Not Selective for the Enzyme-Product Complex. J. Biol. Chem. 2014;289:15810&#x2013;15819.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4140935</ArticleId><ArticleId IdType="pubmed">24753249</ArticleId></ArticleIdList></Reference><Reference><Citation>Cuervo AM, Dice JF. When lysosomes get old. Exp. Gerontol. 2000;35:119&#x2013;131.</Citation><ArticleIdList><ArticleId IdType="pubmed">10767573</ArticleId></ArticleIdList></Reference><Reference><Citation>Dumesic PA, Homer CM, Moresco JJ, Pack LR, Shanle EK, Coyle SM, Strahl BD, Fujimori DG, Yates JR, 3rd, Madhani HD. Product binding enforces the genomic specificity of a yeast polycomb repressive complex. Cell. 2015;160:204&#x2013;218.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4303595</ArticleId><ArticleId IdType="pubmed">25533783</ArticleId></ArticleIdList></Reference><Reference><Citation>Ficz G, Branco MR, Seisenberger S, Santos F, Krueger F, Hore TA, Marques CJ, Andrews S, Reik W. Dynamic regulation of 5-hydroxymethylcytosine in mouse ES cells and during differentiation. Nature. 2011;473:398&#x2013;402.</Citation><ArticleIdList><ArticleId IdType="pubmed">21460836</ArticleId></ArticleIdList></Reference><Reference><Citation>Gan-Or Z, Dion PA, Rouleau GA. Genetic perspective on the role of the Autophagy-Lysosome Pathway in Parkinson disease. Autophagy. 2015;11:1443&#x2013;1457.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4590678</ArticleId><ArticleId IdType="pubmed">26207393</ArticleId></ArticleIdList></Reference><Reference><Citation>Gu TP, Guo F, Yang H, Wu HP, Xu GF, Liu W, Xie ZG, Shi L, He X, Jin SG, et al. The role of Tet3 DNA dioxygenase in epigenetic reprogramming by oocytes. Nature. 2011;477:606&#x2013;610.</Citation><ArticleIdList><ArticleId IdType="pubmed">21892189</ArticleId></ArticleIdList></Reference><Reference><Citation>Guan X, Madabushi A, Chang DY, Fitzgerald ME, Shi G, Drohat AC, Lu AL. The human checkpoint sensor Rad9-Rad1-Hus1 interacts with and stimulates DNA repair enzyme TDG glycosylase. Nucleic Acids Res. 2007;35:6207&#x2013;6218.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2094074</ArticleId><ArticleId IdType="pubmed">17855402</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo F, Li X, Liang D, Li T, Zhu P, Guo H, Wu X, Wen L, Gu TP, Hu B, et al. Active and passive demethylation of male and female pronuclear DNA in the Mammalian zygote. Cell stem cell. 2014;15:447&#x2013;458.</Citation><ArticleIdList><ArticleId IdType="pubmed">25220291</ArticleId></ArticleIdList></Reference><Reference><Citation>Hackett JA, Sengupta R, Zylicz JJ, Murakami K, Lee C, Down TA, Surani MA. Germline DNA demethylation dynamics and imprint erasure through 5-hydroxymethylcytosine. Science. 2013;339:448&#x2013;452.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3847602</ArticleId><ArticleId IdType="pubmed">23223451</ArticleId></ArticleIdList></Reference><Reference><Citation>Hahn MA, Qiu R, Wu X, Li AX, Zhang H, Wang J, Jui J, Jin SG, Jiang Y, Pfeifer GP, et al. Dynamics of 5-hydroxymethylcytosine and chromatin marks in Mammalian neurogenesis. Cell Rep. 2013;3:291&#x2013;300.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3582786</ArticleId><ArticleId IdType="pubmed">23403289</ArticleId></ArticleIdList></Reference><Reference><Citation>Hahn MA, Szabo PE, Pfeifer GP. 5-Hydroxymethylcytosine: A stable or transient DNA modification? Genomics. 2014;104:314&#x2013;323.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4252803</ArticleId><ArticleId IdType="pubmed">25181633</ArticleId></ArticleIdList></Reference><Reference><Citation>Hansen KH, Bracken AP, Pasini D, Dietrich N, Gehani SS, Monrad A, Rappsilber J, Lerdrup M, Helin K. A model for transmission of the H3K27me3 epigenetic mark. Nat. Cell Biol. 2008;10:1291&#x2013;1300.</Citation><ArticleIdList><ArticleId IdType="pubmed">18931660</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardeland U, Steinacher R, Jiricny J, Schar P. Modification of the human thymine-DNA glycosylase by ubiquitin-like proteins facilitates enzymatic turnover. EMBO J. 2002;21:1456&#x2013;1464.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC125358</ArticleId><ArticleId IdType="pubmed">11889051</ArticleId></ArticleIdList></Reference><Reference><Citation>Hashimoto H, Liu Y, Upadhyay AK, Chang Y, Howerton SB, Vertino PM, Zhang X, Cheng X. Recognition and potential mechanisms for replication and erasure of cytosine hydroxymethylation. Nucleic Acids Res. 2012;40:4841&#x2013;4849.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3367191</ArticleId><ArticleId IdType="pubmed">22362737</ArticleId></ArticleIdList></Reference><Reference><Citation>Hashimoto H, Pais JE, Zhang X, Saleh L, Fu ZQ, Dai N, Correa IR, Jr., Zheng Y, Cheng X. Structure of a Naegleria Tet-like dioxygenase in complex with 5-methylcytosine DNA. Nature. 2014;506:391&#x2013;395.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4364404</ArticleId><ArticleId IdType="pubmed">24390346</ArticleId></ArticleIdList></Reference><Reference><Citation>Hashimoto H, Zhang X, Cheng X. Activity and crystal structure of human thymine DNA glycosylase mutant N140A with 5-carboxylcytosine DNA at low pH. DNA repair. 2013;12:535&#x2013;540.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3758246</ArticleId><ArticleId IdType="pubmed">23680598</ArticleId></ArticleIdList></Reference><Reference><Citation>Hassan AH, Prochasson P, Neely KE, Galasinski SC, Chandy M, Carrozza MJ, Workman JL. Function and selectivity of bromodomains in anchoring chromatin-modifying complexes to promoter nucleosomes. Cell. 2002;111:369&#x2013;379.</Citation><ArticleIdList><ArticleId IdType="pubmed">12419247</ArticleId></ArticleIdList></Reference><Reference><Citation>He YF, Li BZ, Li Z, Liu P, Wang Y, Tang Q, Ding J, Jia Y, Chen Z, Li L, et al. Tet-mediated formation of 5-carboxylcytosine and its excision by TDG in mammalian DNA. Science. 2011;333:1303&#x2013;1307.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3462231</ArticleId><ArticleId IdType="pubmed">21817016</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu L, Li Z, Cheng J, Rao Q, Gong W, Liu M, Shi YG, Zhu J, Wang P, Xu Y. Crystal structure of TET2-DNA complex: insight into TET-mediated 5mC oxidation. Cell. 2013;155:1545&#x2013;1555.</Citation><ArticleIdList><ArticleId IdType="pubmed">24315485</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu X, Zhang L, Mao SQ, Li Z, Chen J, Zhang RR, Wu HP, Gao J, Guo F, Liu W, et al. Tet and TDG Mediate DNA Demethylation Essential for Mesenchymal-to-Epithelial Transition in Somatic Cell Reprogramming. Cell Stem Cell. 2014;14:512&#x2013;522.</Citation><ArticleIdList><ArticleId IdType="pubmed">24529596</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang Y, Chavez L, Chang X, Wang X, Pastor WA, Kang J, Zepeda-Martinez JA, Pape UJ, Jacobsen SE, Peters B, et al. Distinct roles of the methylcytosine oxidases Tet1 and Tet2 in mouse embryonic stem cells. Proc. Natl. Acad. Sci. USA. 2014;111:1361&#x2013;1366.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3910590</ArticleId><ArticleId IdType="pubmed">24474761</ArticleId></ArticleIdList></Reference><Reference><Citation>Iqbal K, Jin SG, Pfeifer GP, Szabo PE. Reprogramming of the paternal genome upon fertilization involves genome-wide oxidation of 5-methylcytosine. Proc. Natl. Acad. Sci. USA. 2011;108:3642&#x2013;3647.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3048122</ArticleId><ArticleId IdType="pubmed">21321204</ArticleId></ArticleIdList></Reference><Reference><Citation>Ito S, D'Alessio AC, Taranova OV, Hong K, Sowers LC, Zhang Y. Role of Tet proteins in 5mC to 5hmC conversion, ES-cell self-renewal and inner cell mass specification. Nature. 2010;466:1129&#x2013;1133.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3491567</ArticleId><ArticleId IdType="pubmed">20639862</ArticleId></ArticleIdList></Reference><Reference><Citation>Ito S, Shen L, Dai Q, Wu SC, Collins LB, Swenberg JA, He C, Zhang Y. Tet proteins can convert 5-methylcytosine to 5-formylcytosine and 5-carboxylcytosine. Science. 2011;333:1300&#x2013;1303.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3495246</ArticleId><ArticleId IdType="pubmed">21778364</ArticleId></ArticleIdList></Reference><Reference><Citation>Khare T, Pai S, Koncevicius K, Pal M, Kriukiene E, Liutkeviciute Z, Irimia M, Jia P, Ptak C, Xia M, et al. 5-hmC in the brain is abundant in synaptic genes and shows differences at the exon-intron boundary. Nat. Struct. Mol. Biol. 2012;19:1037&#x2013;1043.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3465469</ArticleId><ArticleId IdType="pubmed">22961382</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein BJ, Piao L, Xi Y, Rincon-Arano H, Rothbart SB, Peng D, Wen H, Larson C, Zhang X, Zheng X, et al. The histone-H3K4-specific demethylase KDM5B binds to its substrate and product through distinct PHD fingers. Cell Rep. 2014;6:325&#x2013;335.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3918441</ArticleId><ArticleId IdType="pubmed">24412361</ArticleId></ArticleIdList></Reference><Reference><Citation>Klose RJ, Bird AP. Genomic DNA methylation: the mark and its mediators. Trends Biochem. Sci. 2006;31:89&#x2013;97.</Citation><ArticleIdList><ArticleId IdType="pubmed">16403636</ArticleId></ArticleIdList></Reference><Reference><Citation>Ko M, An J, Bandukwala HS, Chavez L, Aijo T, Pastor WA, Segal MF, Li H, Koh KP, Lahdesmaki H, et al. Modulation of TET2 expression and 5-methylcytosine oxidation by the CXXC domain protein IDAX. Nature. 2013;497:122&#x2013;126.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3643997</ArticleId><ArticleId IdType="pubmed">23563267</ArticleId></ArticleIdList></Reference><Reference><Citation>Ko M, Huang Y, Jankowska AM, Pape UJ, Tahiliani M, Bandukwala HS, An J, Lamperti ED, Koh KP, Ganetzky R, et al. Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2. Nature. 2010;468:839&#x2013;843.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3003755</ArticleId><ArticleId IdType="pubmed">21057493</ArticleId></ArticleIdList></Reference><Reference><Citation>Koh KP, Rao A. DNA methylation and methylcytosine oxidation in cell fate decisions. Curr. Opin. Cell Biol. 2013;25:152&#x2013;161.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3649866</ArticleId><ArticleId IdType="pubmed">23498662</ArticleId></ArticleIdList></Reference><Reference><Citation>Kriaucionis S, Heintz N. The nuclear DNA base 5-hydroxymethylcytosine is present in Purkinje neurons and the brain. Science. 2009;324:929&#x2013;930.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3263819</ArticleId><ArticleId IdType="pubmed">19372393</ArticleId></ArticleIdList></Reference><Reference><Citation>Lan F, Collins RE, De Cegli R, Alpatov R, Horton JR, Shi X, Gozani O, Cheng X, Shi Y. Recognition of unmethylated histone H3 lysine 4 links BHC80 to LSD1-mediated gene repression. Nature. 2007;448:718&#x2013;722.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2702779</ArticleId><ArticleId IdType="pubmed">17687328</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu N, Wang M, Deng W, Schmidt CS, Qin W, Leonhardt H, Spada F. Intrinsic and extrinsic connections of Tet3 dioxygenase with CXXC zinc finger modules. PloS One. 2013a;8:e62755.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3653909</ArticleId><ArticleId IdType="pubmed">23690950</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu N, Zhang Z, Wu H, Jiang Y, Meng L, Xiong J, Zhao Z, Zhou X, Li J, Li H, et al. Recognition of H3K9 methylation by GLP is required for efficient establishment of H3K9 methylation, rapid target gene repression, and mouse viability. Genes Dev. 2015;29:379&#x2013;393.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4335294</ArticleId><ArticleId IdType="pubmed">25637356</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu S, Wang J, Su Y, Guerrero C, Zeng Y, Mitra D, Brooks PJ, Fisher DE, Song H, Wang Y. Quantitative assessment of Tet-induced oxidation products of 5-methylcytosine in cellular and tissue DNA. Nucl. Acids Res. 2013b;41:6421&#x2013;6429.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3711458</ArticleId><ArticleId IdType="pubmed">23658232</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu X, Han D, Zhao BS, Song CX, Zhang LS, Dore LC, He C. Base-resolution maps of 5-formylcytosine and 5-carboxylcytosine reveal genome-wide DNA demethylation dynamics. Cell Res. 2015;25:386&#x2013;389.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4349244</ArticleId><ArticleId IdType="pubmed">25591929</ArticleId></ArticleIdList></Reference><Reference><Citation>Maiti A, Drohat AC. Thymine DNA glycosylase can rapidly excise 5-formylcytosine and 5-carboxylcytosine: potential implications for active demethylation of CpG sites. J. Biol. Chem. 2011;286:35334&#x2013;35338.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3195571</ArticleId><ArticleId IdType="pubmed">21862836</ArticleId></ArticleIdList></Reference><Reference><Citation>Margueron R, Justin N, Ohno K, Sharpe ML, Son J, Drury WJ, 3rd, Voigt P, Martin SR, Taylor WR, De Marco V, et al. Role of the polycomb protein EED in the propagation of repressive histone marks. Nature. 2009;461:762&#x2013;767.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3772642</ArticleId><ArticleId IdType="pubmed">19767730</ArticleId></ArticleIdList></Reference><Reference><Citation>McLean CY, Bristor D, Hiller M, Clarke SL, Schaar BT, Lowe CB, Wenger AM, Bejerano G. GREAT improves functional interpretation of cis-regulatory regions. Nat. Biotechnol. 2010;28:495&#x2013;501.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4840234</ArticleId><ArticleId IdType="pubmed">20436461</ArticleId></ArticleIdList></Reference><Reference><Citation>Minor EA, Court BL, Young JI, Wang G. Ascorbate induces ten-eleven translocation (Tet) methylcytosine dioxygenase-mediated generation of 5-hydroxymethylcytosine. J. Biol. Chem. 2013;288:13669&#x2013;13674.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3650403</ArticleId><ArticleId IdType="pubmed">23548903</ArticleId></ArticleIdList></Reference><Reference><Citation>M&#xfc;nzel M, Globisch D, Bruckl T, Wagner M, Welzmiller V, Michalakis S, Muller M, Biel M, Carell T. Quantification of the sixth DNA base hydroxymethylcytosine in the brain. Angew. Chem. Int. Ed. Engl. 2010;49:5375&#x2013;5377.</Citation><ArticleIdList><ArticleId IdType="pubmed">20583021</ArticleId></ArticleIdList></Reference><Reference><Citation>Palmieri M, Impey S, Kang H, di Ronza A, Pelz C, Sardiello M, Ballabio A. Characterization of the CLEAR network reveals an integrated control of cellular clearance pathways. Hum. Mol. Genet. 2011;20:3852&#x2013;3866.</Citation><ArticleIdList><ArticleId IdType="pubmed">21752829</ArticleId></ArticleIdList></Reference><Reference><Citation>Parsons JL, Tait PS, Finch D, Dianova II, Allinson SL, Dianov GL. CHIP-mediated degradation and DNA damage-dependent stabilization regulate base excision repair proteins. Mol. Cell. 2008;29:477&#x2013;487.</Citation><ArticleIdList><ArticleId IdType="pubmed">18313385</ArticleId></ArticleIdList></Reference><Reference><Citation>Peat JR, Dean W, Clark SJ, Krueger F, Smallwood SA, Ficz G, Kim JK, Marioni JC, Hore TA, Reik W. Genome-wide bisulfite sequencing in zygotes identifies demethylation targets and maps the contribution of TET3 oxidation. Cell Rep. 2014;9:1990&#x2013;2000.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4542306</ArticleId><ArticleId IdType="pubmed">25497087</ArticleId></ArticleIdList></Reference><Reference><Citation>Perera A, Eisen D, Wagner M, Laube SK, Kunzel AF, Koch S, Steinbacher J, Schulze E, Splith V, Mittermeier N, et al. TET3 Is Recruited by REST for Context-Specific Hydroxymethylation and Induction of Gene Expression. Cell Rep. 2015;11:283&#x2013;294.</Citation><ArticleIdList><ArticleId IdType="pubmed">25843715</ArticleId></ArticleIdList></Reference><Reference><Citation>Pfeifer GP, Kadam S, Jin SG. 5-hydroxymethylcytosine and its potential roles in development and cancer. Epigenetics Chromatin. 2013;6:10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3645968</ArticleId><ArticleId IdType="pubmed">23634848</ArticleId></ArticleIdList></Reference><Reference><Citation>Rottach A, Frauer C, Pichler G, Bonapace IM, Spada F, Leonhardt H. The multi-domain protein Np95 connects DNA methylation and histone modification. Nucleic Acids Res. 2010;38:1796&#x2013;1804.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2847221</ArticleId><ArticleId IdType="pubmed">20026581</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider L, Zhang J. Lysosomal function in macromolecular homeostasis and bioenergetics in Parkinson's disease. Mol. Neurodegener. 2010;5:14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2867960</ArticleId><ArticleId IdType="pubmed">20388210</ArticleId></ArticleIdList></Reference><Reference><Citation>Schondorf DC, Aureli M, McAllister FE, Hindley CJ, Mayer F, Schmid B, Sardi SP, Valsecchi M, Hoffmann S, Schwarz LK, et al. iPSC-derived neurons from GBA1-associated Parkinson's disease patients show autophagic defects and impaired calcium homeostasis. Nat. Commun. 2014;5:4028.</Citation><ArticleIdList><ArticleId IdType="pubmed">24905578</ArticleId></ArticleIdList></Reference><Reference><Citation>Settembre C, Di Malta C, Polito VA, Garcia Arencibia M, Vetrini F, Erdin S, Erdin SU, Huynh T, Medina D, Colella P, et al. TFEB links autophagy to lysosomal biogenesis. Science. 2011;332:1429&#x2013;1433.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3638014</ArticleId><ArticleId IdType="pubmed">21617040</ArticleId></ArticleIdList></Reference><Reference><Citation>Shacka JJ. Mouse models of neuronal ceroid lipofuscinoses: useful pre-clinical tools to delineate disease pathophysiology and validate therapeutics. Brain. Res. Bull. 2012;88:43&#x2013;57.</Citation><ArticleIdList><ArticleId IdType="pubmed">22502604</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen L, Inoue A, He J, Liu Y, Lu F, Zhang Y. Tet3 and DNA replication mediate demethylation of both the maternal and paternal genomes in mouse zygotes. Cell Stem Cell. 2014;15:459&#x2013;470.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4201500</ArticleId><ArticleId IdType="pubmed">25280220</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen L, Wu H, Diep D, Yamaguchi S, D'Alessio AC, Fung HL, Zhang K, Zhang Y. Genome-wide analysis reveals TET- and TDG-dependent 5-methylcytosine oxidation dynamics. Cell. 2013;153:692&#x2013;706.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3687516</ArticleId><ArticleId IdType="pubmed">23602152</ArticleId></ArticleIdList></Reference><Reference><Citation>Sidransky E, Nalls MA, Aasly JO, Aharon-Peretz J, Annesi G, Barbosa ER, Bar-Shira A, Berg D, Bras J, Brice A, et al. Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. N. Engl. J. Med. 2009;361:1651&#x2013;1661.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2856322</ArticleId><ArticleId IdType="pubmed">19846850</ArticleId></ArticleIdList></Reference><Reference><Citation>Sobol RW. CHIPping away at base excision repair. Molecular cell. 2008;29:413&#x2013;415.</Citation><ArticleIdList><ArticleId IdType="pubmed">18313379</ArticleId></ArticleIdList></Reference><Reference><Citation>Song J, Rechkoblit O, Bestor TH, Patel DJ. Structure of DNMT1-DNA complex reveals a role for autoinhibition in maintenance DNA methylation. Science. 2011;331:1036&#x2013;1040.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4689315</ArticleId><ArticleId IdType="pubmed">21163962</ArticleId></ArticleIdList></Reference><Reference><Citation>Stadler MB, Murr R, Burger L, Ivanek R, Lienert F, Scholer A, van Nimwegen E, Wirbelauer C, Oakeley EJ, Gaidatzis D, et al. DNA-binding factors shape the mouse methylome at distal regulatory regions. Nature. 2011;480:490&#x2013;495.</Citation><ArticleIdList><ArticleId IdType="pubmed">22170606</ArticleId></ArticleIdList></Reference><Reference><Citation>Szulwach KE, Li X, Li Y, Song CX, Wu H, Dai Q, Irier H, Upadhyay AK, Gearing M, Levey AI, et al. 5-hmC-mediated epigenetic dynamics during postnatal neurodevelopment and aging. Nature Neuroscience. 2011;14:1607&#x2013;1616.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3292193</ArticleId><ArticleId IdType="pubmed">22037496</ArticleId></ArticleIdList></Reference><Reference><Citation>Tahiliani M, Koh KP, Shen Y, Pastor WA, Bandukwala H, Brudno Y, Agarwal S, Iyer LM, Liu DR, Aravind L, et al. Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science. 2009;324:930&#x2013;935.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2715015</ArticleId><ArticleId IdType="pubmed">19372391</ArticleId></ArticleIdList></Reference><Reference><Citation>Torres IO, Kuchenbecker KM, Nnadi CI, Fletterick RJ, Kelly MJ, Fujimori DG. Histone demethylase KDM5A is regulated by its reader domain through a positive-feedback mechanism. Nat. Commun. 2015;6:6204.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5080983</ArticleId><ArticleId IdType="pubmed">25686748</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsunemoto K, Anzai M, Matsuoka T, Tokoro M, Shin SW, Amano T, Mitani T, Kato H, Hosoi Y, Saeki K, et al. Cis-acting elements (E-box and NBE) in the promoter region of three maternal genes (Histone H1oo, Nucleoplasmin 2, and Zygote Arrest 1) are required for oocyte-specific gene expression in the mouse. Mol. Reprod. Dev. 2008;75:1104&#x2013;1108.</Citation><ArticleIdList><ArticleId IdType="pubmed">18324673</ArticleId></ArticleIdList></Reference><Reference><Citation>Valinluck V, Sowers LC. Endogenous cytosine damage products alter the site selectivity of human DNA maintenance methyltransferase DNMT1. Cancer Res. 2007;67:946&#x2013;950.</Citation><ArticleIdList><ArticleId IdType="pubmed">17283125</ArticleId></ArticleIdList></Reference><Reference><Citation>Wen L, Li X, Yan L, Tan Y, Li R, Zhao Y, Wang Y, Xie J, Zhang Y, Song C, et al. Whole-genome analysis of 5-hydroxymethylcytosine and 5-methylcytosine at base resolution in the human brain. Genome Biol. 2014;15:R49.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4053808</ArticleId><ArticleId IdType="pubmed">24594098</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams K, Christensen J, Pedersen MT, Johansen JV, Cloos PA, Rappsilber J, Helin K. TET1 and hydroxymethylcytosine in transcription and DNA methylation fidelity. Nature. 2011;473:343&#x2013;348.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3408592</ArticleId><ArticleId IdType="pubmed">21490601</ArticleId></ArticleIdList></Reference><Reference><Citation>Wossidlo M, Nakamura T, Lepikhov K, Marques CJ, Zakhartchenko V, Boiani M, Arand J, Nakano T, Reik W, Walter J. 5-Hydroxymethylcytosine in the mammalian zygote is linked with epigenetic reprogramming. Nat. Commun. 2011;2:241.</Citation><ArticleIdList><ArticleId IdType="pubmed">21407207</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu H, Zhang Y. Reversing DNA methylation: mechanisms, genomics, and biological functions. Cell. 2014;156:45&#x2013;68.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3938284</ArticleId><ArticleId IdType="pubmed">24439369</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu Y, Wu F, Tan L, Kong L, Xiong L, Deng J, Barbera AJ, Zheng L, Zhang H, Huang S, et al. Genome-wide regulation of 5hmC, 5mC, and gene expression by Tet1 hydroxylase in mouse embryonic stem cells. Mol. Cell. 2011;42:451&#x2013;464.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3099128</ArticleId><ArticleId IdType="pubmed">21514197</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu Y, Xu C, Kato A, Tempel W, Abreu JG, Bian C, Hu Y, Hu D, Zhao B, Cerovina T, et al. Tet3 CXXC domain and dioxygenase activity cooperatively regulate key genes for Xenopus eye and neural development. Cell. 2012;151:1200&#x2013;1213.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3705565</ArticleId><ArticleId IdType="pubmed">23217707</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamaguchi S, Shen L, Liu Y, Sendler D, Zhang Y. Role of Tet1 in erasure of genomic imprinting. Nature. 2013;504:460&#x2013;464.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3957231</ArticleId><ArticleId IdType="pubmed">24291790</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin R, Mao SQ, Zhao B, Chong Z, Yang Y, Zhao C, Zhang D, Huang H, Gao J, Li Z, et al. Ascorbic acid enhances Tet-mediated 5-methylcytosine oxidation and promotes DNA demethylation in mammals. J. Am. Chem. Soc. 2013;135:10396&#x2013;10403.</Citation><ArticleIdList><ArticleId IdType="pubmed">23768208</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang K, Mosch K, Fischle W, Grewal SI. Roles of the Clr4 methyltransferase complex in nucleation, spreading and maintenance of heterochromatin. Nat. Struct. Mol. Biol. 2008;15:381&#x2013;388.</Citation><ArticleIdList><ArticleId IdType="pubmed">18345014</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang L, Lu X, Lu J, Liang H, Dai Q, Xu GL, Luo C, Jiang H, He C. Thymine DNA glycosylase specifically recognizes 5-carboxylcytosine-modified DNA. Nat. Chem. Biol. 2012;8:328&#x2013;330.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3307914</ArticleId><ArticleId IdType="pubmed">22327402</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">26806385</PMID><DateCompleted><Year>2017</Year><Month>12</Month><Day>18</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1552-5279</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><Issue>7</Issue><PubDate><Year>2016</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Alzheimer's &amp; dementia : the journal of the Alzheimer's Association</Title><ISOAbbreviation>Alzheimers Dement</ISOAbbreviation></Journal><ArticleTitle>Blood metabolite markers of preclinical Alzheimer's disease in two longitudinally followed cohorts of older individuals.</ArticleTitle><Pagination><StartPage>815</StartPage><EndPage>822</EndPage><MedlinePgn>815-22</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jalz.2015.12.008</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1552-5260(15)03032-0</ELocationID><Abstract><AbstractText Label="INTRODUCTION">Recently, quantitative metabolomics identified a panel of 10 plasma lipids that were highly predictive of conversion to Alzheimer's disease (AD) in cognitively normal older individuals (n&#xa0;=&#xa0;28, area under the curve [AUC]&#xa0;=&#xa0;0.92, sensitivity/specificity of 90%/90%).</AbstractText><AbstractText Label="METHODS">Quantitative targeted metabolomics in serum using an identical method as in the index study.</AbstractText><AbstractText Label="RESULTS">We failed to replicate these findings in a substantially larger study from two independent cohorts-the Baltimore Longitudinal Study of Aging ([BLSA], n&#xa0;=&#xa0;93, AUC&#xa0;=&#xa0;0.642, sensitivity/specificity of 51.6%/65.7%) and the Age, Gene/Environment Susceptibility-Reykjavik Study ([AGES-RS], n&#xa0;=&#xa0;100, AUC&#xa0;=&#xa0;0.395, sensitivity/specificity of 47.0%/36.0%). In analyses applying machine learning methods to all 187 metabolite concentrations assayed, we find a modest signal in the BLSA with distinct metabolites associated with the preclinical and symptomatic stages of AD, whereas the same methods gave poor classification accuracies in the AGES-RS samples.</AbstractText><AbstractText Label="DISCUSSION">We believe that ours is the largest blood biomarker study of preclinical AD to date. These findings underscore the importance of large-scale independent validation of index findings from biomarker studies with relatively small sample sizes.</AbstractText><CopyrightInformation>Published by Elsevier Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Casanova</LastName><ForeName>Ramon</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Biostatistical Sciences, Wake Forest School of Medicine, Winston-Salem, NC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Varma</LastName><ForeName>Sudhir</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>HiThru Analytics LLC, Laurel, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Simpson</LastName><ForeName>Brittany</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Clinical and Translational Neuroscience Unit, Laboratory of Behavioral Neuroscience, National Institute on Aging, National Institutes of Health, Baltimore, MD, USA; School of Medicine, University of Mississippi Medical Center, Jackson, MS, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Min</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute of Pharmaceutical Science, King's College, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>An</LastName><ForeName>Yang</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Laboratory of Behavioral Neuroscience, National Institute on Aging, National Institutes of Health, Baltimore, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saldana</LastName><ForeName>Santiago</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Biostatistical Sciences, Wake Forest School of Medicine, Winston-Salem, NC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Riveros</LastName><ForeName>Carlos</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>School of Electrical Engineering and Computer Science, University of Newcastle, Callaghan, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moscato</LastName><ForeName>Pablo</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>School of Electrical Engineering and Computer Science, University of Newcastle, Callaghan, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Griswold</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Center of Biostatistics and Bioinformatics, University of Mississippi Medical Center, Jackson, MS, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sonntag</LastName><ForeName>Denise</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>BIOCRATES Life Sciences AG, Innsbruck, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wahrheit</LastName><ForeName>Judith</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>BIOCRATES Life Sciences AG, Innsbruck, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Klavins</LastName><ForeName>Kristaps</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>BIOCRATES Life Sciences AG, Innsbruck, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jonsson</LastName><ForeName>Palmi V</ForeName><Initials>PV</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, University of Iceland, Reykjavik, Iceland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eiriksdottir</LastName><ForeName>Gudny</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Icelandic Heart Association, Kopavogur, Iceland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aspelund</LastName><ForeName>Thor</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, University of Iceland, Reykjavik, Iceland; Icelandic Heart Association, Kopavogur, Iceland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Launer</LastName><ForeName>Lenore J</ForeName><Initials>LJ</Initials><AffiliationInfo><Affiliation>Laboratory of Epidemiology, Demography and Biometry, National Institute on Aging, Bethesda, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gudnason</LastName><ForeName>Vilmundur</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, University of Iceland, Reykjavik, Iceland; Icelandic Heart Association, Kopavogur, Iceland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Legido Quigley</LastName><ForeName>Cristina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Institute of Pharmaceutical Science, King's College, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thambisetty</LastName><ForeName>Madhav</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Clinical and Translational Neuroscience Unit, Laboratory of Behavioral Neuroscience, National Institute on Aging, National Institutes of Health, Baltimore, MD, USA. Electronic address: thambisettym@mail.nih.gov.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>N01 AG012100</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005146</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>ZIA AG000200</GrantID><Acronym>ImNIH</Acronym><Agency>Intramural NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D052060">Research Support, N.I.H., Intramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>01</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Alzheimers Dement</MedlineTA><NlmUniqueID>101231978</NlmUniqueID><ISSNLinking>1552-5260</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Alzheimers Dement. 2017 May;13(5):608-609. doi: 10.1016/j.jalz.2016.11.004.</RefSource><PMID Version="1">28010950</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Alzheimers Dement. 2017 May;13(5):606-607. doi: 10.1016/j.jalz.2017.01.003.</RefSource><PMID Version="1">28119051</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015142" MajorTopicYN="N">Baltimore</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055432" MajorTopicYN="N">Metabolomics</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D062706" MajorTopicYN="Y">Prodromal Symptoms</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Biomarker</Keyword><Keyword MajorTopicYN="N">Machine learning</Keyword><Keyword MajorTopicYN="N">Metabolomics</Keyword><Keyword MajorTopicYN="N">Phospholipids</Keyword><Keyword MajorTopicYN="N">Preclinical Alzheimer's disease</Keyword></KeywordList><CoiStatement><b>Conflict of Interest:</b> The authors confirm that they do not have any conflicts of interest to disclose.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>10</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2015</Year><Month>11</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>12</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>1</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>1</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>12</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2017</Year><Month>7</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26806385</ArticleId><ArticleId IdType="mid">NIHMS748804</ArticleId><ArticleId IdType="pmc">PMC4947451</ArticleId><ArticleId IdType="doi">10.1016/j.jalz.2015.12.008</ArticleId><ArticleId IdType="pii">S1552-5260(15)03032-0</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, et al. The diagnosis of mild cognitive impairment due to Alzheimer&#x2019;s disease: recommendations from the National Institute on Aging-Alzheimer&#x2019;s Association workgroups on diagnostic guidelines for Alzheimer&#x2019;s disease. Alzheimer&#x2019;s &amp; dementia : the journal of the Alzheimer&#x2019;s Association. 2011;7:270&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3312027</ArticleId><ArticleId IdType="pubmed">21514249</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR, Jr, Kawas CH, et al. The diagnosis of dementia due to Alzheimer&#x2019;s disease: recommendations from the National Institute on Aging-Alzheimer&#x2019;s Association workgroups on diagnostic guidelines for Alzheimer&#x2019;s disease. Alzheimer&#x2019;s &amp; dementia : the journal of the Alzheimer&#x2019;s Association. 2011;7:263&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3312024</ArticleId><ArticleId IdType="pubmed">21514250</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, et al. Toward defining the preclinical stages of Alzheimer&#x2019;s disease: recommendations from the National Institute on Aging-Alzheimer&#x2019;s Association workgroups on diagnostic guidelines for Alzheimer&#x2019;s disease. Alzheimer&#x2019;s &amp; dementia : the journal of the Alzheimer&#x2019;s Association. 2011;7:280&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3220946</ArticleId><ArticleId IdType="pubmed">21514248</ArticleId></ArticleIdList></Reference><Reference><Citation>Trushina E, Mielke MM. Recent advances in the application of metabolomics to Alzheimer&#x2019;s Disease. Biochim Biophys Acta. 2014;1842:1232&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3842412</ArticleId><ArticleId IdType="pubmed">23816564</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewis GD, Gerszten RE. Toward metabolomic signatures of cardiovascular disease. Circ Cardiovasc Genet. 2010;3:119&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3010400</ArticleId><ArticleId IdType="pubmed">20407099</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenberg N, Grassano A, Thambisetty M, Lovestone S, Legido-Quigley C. A proposed metabolic strategy for monitoring disease progression in Alzheimer&#x2019;s disease. Electrophoresis. 2009;30:1235&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">19288586</ArticleId></ArticleIdList></Reference><Reference><Citation>Han X, Rozen S, Boyle SH, Hellegers C, Cheng H, Burke JR, et al. Metabolomics in early Alzheimer&#x2019;s disease: identification of altered plasma sphingolipidome using shotgun lipidomics. PloS one. 2011;6:e21643.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3136924</ArticleId><ArticleId IdType="pubmed">21779331</ArticleId></ArticleIdList></Reference><Reference><Citation>Oresic M, Hyotylainen T, Herukka SK, Sysi-Aho M, Mattila I, Seppanan-Laakso T, et al. Metabolome in progression to Alzheimer&#x2019;s disease. Transl Psychiatry. 2011;1:e57.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3309497</ArticleId><ArticleId IdType="pubmed">22832349</ArticleId></ArticleIdList></Reference><Reference><Citation>Sato Y, Nakamura T, Aoshima K, Oda Y. Quantitative and wide-ranging profiling of phospholipids in human plasma by two-dimensional liquid chromatography/mass spectrometry. Anal Chem. 2010;82:9858&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pubmed">21062019</ArticleId></ArticleIdList></Reference><Reference><Citation>Sato Y, Suzuki I, Nakamura T, Bernier F, Aoshima K, Oda Y. Identification of a new plasma biomarker of Alzheimer&#x2019;s disease using metabolomics technology. J Lipid Res. 2012;53:567&#x2013;76.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3276481</ArticleId><ArticleId IdType="pubmed">22203775</ArticleId></ArticleIdList></Reference><Reference><Citation>Trushina E, Dutta T, Persson XM, Mielke MM, Petersen RC. Identification of altered metabolic pathways in plasma and CSF in mild cognitive impairment and Alzheimer&#x2019;s disease using metabolomics. PloS one. 2013;8:e63644.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3658985</ArticleId><ArticleId IdType="pubmed">23700429</ArticleId></ArticleIdList></Reference><Reference><Citation>Whiley L, Sen A, Heaton J, Proitsi P, Garcia-Gomez D, Leung R, et al. Evidence of altered phosphatidylcholine metabolism in Alzheimer&#x2019;s disease. Neurobiol Aging. 2014;35:271&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5866043</ArticleId><ArticleId IdType="pubmed">24041970</ArticleId></ArticleIdList></Reference><Reference><Citation>Mapstone M, Cheema AK, Fiandaca MS, Zhong X, Mhyre TR, MacArthur LH, et al. Plasma phospholipids identify antecedent memory impairment in older adults. Nature medicine. 2014;20:415&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5360460</ArticleId><ArticleId IdType="pubmed">24608097</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferrucci L. The Baltimore Longitudinal Study of Aging (BLSA): a 50-year-long journey and plans for the future. J Gerontol A Biol Sci Med Sci. 2008;63:1416&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5004590</ArticleId><ArticleId IdType="pubmed">19126858</ArticleId></ArticleIdList></Reference><Reference><Citation>Harris TB, Launer LJ, Eiriksdottir G, Kjartansson O, Jonsson PV, Sigurdsson G, et al. Age, Gene/Environment Susceptibility-Reykjavik Study: multidisciplinary applied phenomics. American journal of epidemiology. 2007;165:1076&#x2013;87.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2723948</ArticleId><ArticleId IdType="pubmed">17351290</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawas C, Gray S, Brookmeyer R, Fozard J, Zonderman A. Age-specific incidence rates of Alzheimer&#x2019;s disease: the Baltimore Longitudinal Study of Aging. Neurology. 2000;54:2072&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">10851365</ArticleId></ArticleIdList></Reference><Reference><Citation>Shock NW Gerontology Research C. Normal human aging : the Baltimore longitudinal study of aging. [Baltimore, Md.]; Washington, D.C: U.S. Dept. of Health and Human Services, Public Health Service, National Institutes of Health, National Institute on Aging, Gerontology Research Center; 1984. For sale by the Supt. of Docs., U.S. G.P.O.</Citation></Reference><Reference><Citation>Qiu C, Cotch MF, Sigurdsson S, Jonsson PV, Jonsdottir MK, Sveinbjrnsdottir S, et al. Cerebral microbleeds, retinopathy, and dementia: the AGES-Reykjavik Study. Neurology. 2010;75:2221&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3013588</ArticleId><ArticleId IdType="pubmed">21172845</ArticleId></ArticleIdList></Reference><Reference><Citation>Koal T, Klavins K, Seppi D, Kemmler G, Humpel C. Sphingomyelin SM(d18:1/18:0) is significantly enhanced in cerebrospinal fluid samples dichotomized by pathological amyloid-beta42, tau, and phospho-tau-181 levels. Journal of Alzheimer&#x2019;s disease : JAD. 2015;44:1193&#x2013;201.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4699259</ArticleId><ArticleId IdType="pubmed">25408209</ArticleId></ArticleIdList></Reference><Reference><Citation>Bjorkqvist M, Ohlsson M, Minthon L, Hansson O. Evaluation of a previously suggested plasma biomarker panel to identify Alzheimer&#x2019;s disease. PloS one. 2012;7:e29868.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3261152</ArticleId><ArticleId IdType="pubmed">22279551</ArticleId></ArticleIdList></Reference><Reference><Citation>Ray S, Britschgi M, Herbert C, Takeda-Uchimura Y, Boxer A, Blennow K, et al. Classification and prediction of clinical Alzheimer&#x2019;s diagnosis based on plasma signaling proteins. Nature medicine. 2007;13:1359&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pubmed">17934472</ArticleId></ArticleIdList></Reference><Reference><Citation>Perlis RH. Translating biomarkers to clinical practice. Molecular psychiatry. 2011;16:1076&#x2013;87.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3752672</ArticleId><ArticleId IdType="pubmed">21709685</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu Z, Kastenmuller G, He Y, Belcredi P, Moller G, Prehn C, et al. Differences between human plasma and serum metabolite profiles. PloS one. 2011;6:e21230.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3132215</ArticleId><ArticleId IdType="pubmed">21760889</ArticleId></ArticleIdList></Reference><Reference><Citation>Breier M, Wahl S, Prehn C, Fugmann M, Ferrari U, Weise M, et al. Targeted metabolomics identifies reliable and stable metabolites in human serum and plasma samples. PloS one. 2014;9:e89728.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3933650</ArticleId><ArticleId IdType="pubmed">24586991</ArticleId></ArticleIdList></Reference><Reference><Citation>Thambisetty M, Lovestone S. Blood-based biomarkers of Alzheimer&#x2019;s disease: challenging but feasible. Biomark Med. 2010;4:65&#x2013;79.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2863057</ArticleId><ArticleId IdType="pubmed">20387303</ArticleId></ArticleIdList></Reference><Reference><Citation>Tzoulaki I, Ebbels TM, Valdes A, Elliott P, Ioannidis JP. Design and analysis of metabolomics studies in epidemiologic research: a primer on -omic technologies. American journal of epidemiology. 2014;180:129&#x2013;39.</Citation><ArticleIdList><ArticleId IdType="pubmed">24966222</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">26810632</PMID><DateCompleted><Year>2016</Year><Month>09</Month><Day>06</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>30</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-6157</ISSN><JournalIssue CitedMedium="Internet"><Volume>73</Volume><Issue>3</Issue><PubDate><Year>2016</Year><Month>Mar</Month></PubDate></JournalIssue><Title>JAMA neurology</Title><ISOAbbreviation>JAMA Neurol</ISOAbbreviation></Journal><ArticleTitle>Assessment of Eating Behavior Disturbance and Associated Neural Networks in Frontotemporal Dementia.</ArticleTitle><Pagination><StartPage>282</StartPage><EndPage>290</EndPage><MedlinePgn>282-90</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamaneurol.2015.4478</ELocationID><Abstract><AbstractText Label="IMPORTANCE" NlmCategory="OBJECTIVE">Abnormal eating behaviors are common in patients with frontotemporal dementia (FTD), yet their exact prevalence, severity, and underlying biological mechanisms are not understood.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To define the severity of abnormal eating behavior and sucrose preference and their neural correlates in patients with behavioral variant FTD (bvFTD) and semantic dementia.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS" NlmCategory="METHODS">Forty-nine patients with dementia (19 with bvFTD, 15 with semantic dementia, and 15 with Alzheimer disease) were recruited, and their eating behavior was compared with that of 25 healthy controls. The study was conducted from November 1, 2013, through May 31, 2015, and data analyzed from June 1 to August 31, 2015.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES" NlmCategory="METHODS">Patients participated in an ad libitum breakfast test meal, and their total caloric intake and food preferences were measured. Changes in eating behavior were also measured using the Appetite and Eating Habits Questionnaire (APEHQ) and the Cambridge Behavioral Inventory (CBI). Sucrose preference was tested by measuring liking ratings of 3 desserts of varying sucrose content (A: 26%, B: 39%, C: 60%). Voxel-based morphometry analysis of whole-brain 3-T high-resolution brain magnetic resonance imaging was used to determine the gray matter density changes across groups and their relations to eating behaviors.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Mean (SD) ages of patients in all 4 groups ranged from 62 (8.3) to 66 (8.4) years. At the ad libitum breakfast test meal, all patients with bvFTD had increased total caloric intake (mean, 1344 calories) compared with the Alzheimer disease (mean, 710 calories), semantic dementia (mean, 573 calories), and control groups (mean, 603 calories) (P &lt; .001). Patients with bvFTD and semantic dementia had a strong sucrose preference compared with the other groups. Increased caloric intake correlated with atrophy in discrete neural networks that differed between patients with bvFTD and semantic dementia but included the cingulate cortices, thalami, and cerebellum in patients with bvFTD, with the addition of the orbitofrontal cortices and nucleus accumbens in patients with semantic dementia. A distributed network of neural correlates was associated with sucrose preference in patients with FTD.</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE" NlmCategory="CONCLUSIONS">Marked hyperphagia is restricted to bvFTD, present in all patients with this diagnosis, and supports its diagnostic value. Differing neural networks control eating behavior in patients with bvFTD and semantic dementia and are likely responsible for the differences seen, with a similar network controlling sucrose preference. These networks share structures that control cognitive-reward, autonomic, neuroendocrine, and visual modulation of eating behavior. Delineating the neural networks involved in mediating these changes in eating behavior may enable treatment of these features in patients with complex medical needs and aid in our understanding of structures that control eating behavior in patients with FTD and healthy individuals.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ahmed</LastName><ForeName>Rebekah M</ForeName><Initials>RM</Initials><AffiliationInfo><Affiliation>Neuroscience Research Australia, Sydney2University of New South Wales, Sydney, Australia3Australian Research Council Centre of Excellence in Cognition and Its Disorders, University of New South Wales, Sydney, Australia4Brain and Mind Centre, Sydney Medica.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Irish</LastName><ForeName>Muireann</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Neuroscience Research Australia, Sydney2University of New South Wales, Sydney, Australia3Australian Research Council Centre of Excellence in Cognition and Its Disorders, University of New South Wales, Sydney, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Henning</LastName><ForeName>Elana</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>University of Cambridge Metabolic Research Laboratories and National Institute for Health Research Cambridge Biomedical Research Centre, Wellcome Trust-Medical Research Council Institute of Metabolic Science, Cambridge, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dermody</LastName><ForeName>Nadene</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Neuroscience Research Australia, Sydney.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bartley</LastName><ForeName>Lauren</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Neuroscience Research Australia, Sydney.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kiernan</LastName><ForeName>Matthew C</ForeName><Initials>MC</Initials><AffiliationInfo><Affiliation>Brain and Mind Centre, Sydney Medical School, University of Sydney, Sydney, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Piguet</LastName><ForeName>Olivier</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Neuroscience Research Australia, Sydney2University of New South Wales, Sydney, Australia3Australian Research Council Centre of Excellence in Cognition and Its Disorders, University of New South Wales, Sydney, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Farooqi</LastName><ForeName>Sadaf</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>University of Cambridge Metabolic Research Laboratories and National Institute for Health Research Cambridge Biomedical Research Centre, Wellcome Trust-Medical Research Council Institute of Metabolic Science, Cambridge, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hodges</LastName><ForeName>John R</ForeName><Initials>JR</Initials><AffiliationInfo><Affiliation>Neuroscience Research Australia, Sydney2University of New South Wales, Sydney, Australia3Australian Research Council Centre of Excellence in Cognition and Its Disorders, University of New South Wales, Sydney, Australia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Neurol</MedlineTA><NlmUniqueID>101589536</NlmUniqueID><ISSNLinking>2168-6149</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>JAMA Neurol. 2016 Mar;73(3):267-8. doi: 10.1001/jamaneurol.2015.4496.</RefSource><PMID Version="1">26810266</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001284" MajorTopicYN="N">Atrophy</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001068" MajorTopicYN="Y">Feeding and Eating Disorders</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057180" MajorTopicYN="Y">Frontotemporal Dementia</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009415" MajorTopicYN="N">Nerve Net</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>1</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>1</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>9</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26810632</ArticleId><ArticleId IdType="doi">10.1001/jamaneurol.2015.4478</ArticleId><ArticleId IdType="pii">2484444</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">26818518</PMID><DateCompleted><Year>2016</Year><Month>06</Month><Day>01</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>09</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>36</Volume><Issue>4</Issue><PubDate><Year>2016</Year><Month>Jan</Month><Day>27</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Rho Kinase Inhibition as a Therapeutic for Progressive Supranuclear Palsy and Corticobasal Degeneration.</ArticleTitle><Pagination><StartPage>1316</StartPage><EndPage>1323</EndPage><MedlinePgn>1316-23</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.2336-15.2016</ELocationID><Abstract><AbstractText Label="UNLABELLED">Progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD) are neurodegenerative four-repeat tauopathies with no cure. Mitigating pathogenic tau levels is a rational strategy for tauopathy treatment, but therapeutic targets with clinically available drugs are lacking. Here, we report that protein levels of the Rho-associated protein kinases (ROCK1 and ROCK2), p70 S6 kinase (S6K), and mammalian target of rapamycin (mTOR) were increased in PSP and CBD brains. RNAi depletion of ROCK1 or ROCK2 reduced tau mRNA and protein level in human neuroblastoma cells. However, additional phenotypes were observed under ROCK2 knockdown, including decreased S6K and phosphorylated mTOR levels. Pharmacologic inhibition of Rho kinases in neurons diminished detergent-soluble and -insoluble tau through a combination of autophagy enhancement and tau mRNA reduction. Fasudil, a clinically approved ROCK inhibitor, suppressed rough eye phenotype and mitigated pathogenic tau levels by inducing autophagic pathways in a Drosophila model of tauopathy. Collectively, these findings highlight the Rho kinases as rational therapeutic targets to combat tau accumulation in PSP and CBD.</AbstractText><AbstractText Label="SIGNIFICANCE STATEMENT" NlmCategory="CONCLUSIONS">Studies of progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD) suggest that mitigating pathogenic tau levels is a rational strategy for tauopathy treatment. In this report, the Rho-associated protein kinases (ROCK1 and ROCK2) are identified as novel drug targets for PSP and CBD. We show that elevated insoluble tau levels are associated with increased ROCK1 and ROCK2 in PSP and CBD brains, whereas experiments in cellular and animal models identify pharmacologic inhibition of ROCKs as a mechanism-based approach to reduce tau levels. Our study correlates bona fide changes in PSP and CBD brains with cellular models, identifies drug targets, and tests the therapeutic in vivo.</AbstractText><CopyrightInformation>Copyright &#xa9; 2016 the authors 0270-6474/16/361316-08$15.00/0.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gentry</LastName><ForeName>Erik G</ForeName><Initials>EG</Initials><AffiliationInfo><Affiliation>Center for Neurodegeneration and Experimental Therapeutics and Departments of Neurology.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Henderson</LastName><ForeName>Benjamin W</ForeName><Initials>BW</Initials><AffiliationInfo><Affiliation>Center for Neurodegeneration and Experimental Therapeutics and Departments of Neurology.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arrant</LastName><ForeName>Andrew E</ForeName><Initials>AE</Initials><AffiliationInfo><Affiliation>Center for Neurodegeneration and Experimental Therapeutics and Departments of Neurology.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gearing</LastName><ForeName>Marla</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-1959-7412</Identifier><AffiliationInfo><Affiliation>Departments of Pathology and Laboratory Medicine, and Neurology, Emory University School of Medicine, Atlanta, Georgia 30322, and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Feng</LastName><ForeName>Yangbo</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Medicinal Chemistry, Translational Research Institute, Scripps Research Institute, Jupiter, Florida 33458.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Riddle</LastName><ForeName>Nicole C</ForeName><Initials>NC</Initials><Identifier Source="ORCID">0000-0003-1827-9145</Identifier><AffiliationInfo><Affiliation>Biology, University of Alabama at Birmingham, Birmingham, Alabama 35294.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Herskowitz</LastName><ForeName>Jeremy H</ForeName><Initials>JH</Initials><AffiliationInfo><Affiliation>Center for Neurodegeneration and Experimental Therapeutics and Departments of Neurology, Neurobiology, and jhersko@uab.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>NS055077</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 NS061788</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG025688</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG025688</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R00 AG043552</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>5R00AG043552-04</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 NS055077</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004791">Enzyme Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.1.1</RegistryNumber><NameOfSubstance UI="C546842">MTOR protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="C515851">ROCK1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="C515852">ROCK2 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="D038762">Ribosomal Protein S6 Kinases, 70-kDa</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="D058570">TOR Serine-Threonine Kinases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="D054460">rho-Associated Kinases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D030801" MajorTopicYN="N">Animals, Genetically Modified</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001480" MajorTopicYN="N">Basal Ganglia Diseases</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004330" MajorTopicYN="N">Drosophila</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004791" MajorTopicYN="N">Enzyme Inhibitors</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015971" MajorTopicYN="N">Gene Expression Regulation, Enzymologic</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009410" MajorTopicYN="N">Nerve Degeneration</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009447" MajorTopicYN="N">Neuroblastoma</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D038762" MajorTopicYN="N">Ribosomal Protein S6 Kinases, 70-kDa</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013494" MajorTopicYN="N">Supranuclear Palsy, Progressive</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058570" MajorTopicYN="N">TOR Serine-Threonine Kinases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D054460" MajorTopicYN="N">rho-Associated Kinases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Drosophila</Keyword><Keyword MajorTopicYN="N">ROCK</Keyword><Keyword MajorTopicYN="N">Rho kinase</Keyword><Keyword MajorTopicYN="N">autophagy</Keyword><Keyword MajorTopicYN="N">tau</Keyword><Keyword MajorTopicYN="N">tauopathy</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>1</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>1</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>6</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2016</Year><Month>7</Month><Day>27</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26818518</ArticleId><ArticleId IdType="pmc">PMC4728727</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.2336-15.2016</ArticleId><ArticleId IdType="pii">36/4/1316</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Amano M, Chihara K, Kimura K, Fukata Y, Nakamura N, Matsuura Y, Kaibuchi K. Formation of actin stress fibers and focal adhesions enhanced by Rho-kinase. Science. 1997;275:1308&#x2013;1311. doi: 10.1126/science.275.5304.1308.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.275.5304.1308</ArticleId><ArticleId IdType="pubmed">9036856</ArticleId></ArticleIdList></Reference><Reference><Citation>An WL, Cowburn RF, Li L, Braak H, Alafuzoff I, Iqbal K, Iqbal IG, Winblad B, Pei JJ. Up-regulation of phosphorylated/activated p70 S6 kinase and its relationship to neurofibrillary pathology in Alzheimer's disease. Am J Pathol. 2003;163:591&#x2013;607. doi: 10.1016/S0002-9440(10)63687-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0002-9440(10)63687-5</ArticleId><ArticleId IdType="pmc">PMC1868198</ArticleId><ArticleId IdType="pubmed">12875979</ArticleId></ArticleIdList></Reference><Reference><Citation>Baker M, Litvan I, Houlden H, Adamson J, Dickson D, Perez-Tur J, Hardy J, Lynch T, Bigio E, Hutton M. Association of an extended haplotype in the tau gene with progressive supranuclear palsy. Hum Mol Genet. 1999;8:711&#x2013;715. doi: 10.1093/hmg/8.4.711.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/8.4.711</ArticleId><ArticleId IdType="pubmed">10072441</ArticleId></ArticleIdList></Reference><Reference><Citation>Bakhoum MF, Bakhoum CY, Ding Z, Carlton SM, Campbell GA, Jackson GR. Evidence for autophagic gridlock in aging and neurodegeneration. Transl Res. 2014;164:1&#x2013;12. doi: 10.1016/j.trsl.2014.01.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.trsl.2014.01.016</ArticleId><ArticleId IdType="pubmed">24561013</ArticleId></ArticleIdList></Reference><Reference><Citation>Bauer PO, Wong HK, Oyama F, Goswami A, Okuno M, Kino Y, Miyazaki H, Nukina N. Inhibition of Rho kinases enhances the degradation of mutant huntingtin. J Biol Chem. 2009;284:13153&#x2013;13164. doi: 10.1074/jbc.M809229200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M809229200</ArticleId><ArticleId IdType="pmc">PMC2676047</ArticleId><ArticleId IdType="pubmed">19278999</ArticleId></ArticleIdList></Reference><Reference><Citation>Berger Z, Ravikumar B, Menzies FM, Oroz LG, Underwood BR, Pangalos MN, Schmitt I, Wullner U, Evert BO, O'Kane CJ, Rubinsztein DC. Rapamycin alleviates toxicity of different aggregate-prone proteins. Hum Mol Genet. 2006;15:433&#x2013;442. doi: 10.1093/hmg/ddi458.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddi458</ArticleId><ArticleId IdType="pubmed">16368705</ArticleId></ArticleIdList></Reference><Reference><Citation>Bj&#xf8;rk&#xf8;y G, Lamark T, Brech A, Outzen H, Perander M, Overvatn A, Stenmark H, Johansen T. p62/SQSTM1 forms protein aggregates degraded by autophagy and has a protective effect on huntingtin-induced cell death. J Cell Biol. 2005;171:603&#x2013;614. doi: 10.1083/jcb.200507002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1083/jcb.200507002</ArticleId><ArticleId IdType="pmc">PMC2171557</ArticleId><ArticleId IdType="pubmed">16286508</ArticleId></ArticleIdList></Reference><Reference><Citation>Boland B, Kumar A, Lee S, Platt FM, Wegiel J, Yu WH, Nixon RA. Autophagy induction and autophagosome clearance in neurons: relationship to autophagic pathology in Alzheimer's disease. J Neurosci. 2008;28:6926&#x2013;6937. doi: 10.1523/JNEUROSCI.0800-08.2008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.0800-08.2008</ArticleId><ArticleId IdType="pmc">PMC2676733</ArticleId><ArticleId IdType="pubmed">18596167</ArticleId></ArticleIdList></Reference><Reference><Citation>Cairns NJ, Bigio EH, Mackenzie IR, Neumann M, Lee VM, Hatanpaa KJ, White CL, 3rd, Schneider JA, Grinberg LT, Halliday G, Duyckaerts C, Lowe JS, Holm IE, Tolnay M, Okamoto K, Yokoo H, Murayama S, Woulfe J, Munoz DG, Dickson DW, Ince PG, Trojanowski JQ, Mann DM. Neuropathologic diagnostic and nosologic criteria for frontotemporal lobar degeneration: consensus of the Consortium for Frontotemporal Lobar Degeneration. Acta Neuropathol. 2007;114:5&#x2013;22. doi: 10.1007/s00401-007-0237-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-007-0237-2</ArticleId><ArticleId IdType="pmc">PMC2827877</ArticleId><ArticleId IdType="pubmed">17579875</ArticleId></ArticleIdList></Reference><Reference><Citation>Castro-Alvarez JF, Gutierrez-Vargas J, Darnaud&#xe9;ry M, Cardona-G&#xf3;mez GP. ROCK inhibition prevents tau hyperphosphorylation and p25/CDK5 increase after global cerebral ischemia. Behav Neurosci. 2011;125:465&#x2013;472. doi: 10.1037/a0023167.</Citation><ArticleIdList><ArticleId IdType="doi">10.1037/a0023167</ArticleId><ArticleId IdType="pubmed">21517148</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiang GG, Abraham RT. Phosphorylation of mammalian target of rapamycin (mTOR) at Ser-2448 is mediated by p70S6 kinase. J Biol Chem. 2005;280:25485&#x2013;25490. doi: 10.1074/jbc.M501707200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M501707200</ArticleId><ArticleId IdType="pubmed">15899889</ArticleId></ArticleIdList></Reference><Reference><Citation>Conrad C, Andreadis A, Trojanowski JQ, Dickson DW, Kang D, Chen X, Wiederholt W, Hansen L, Masliah E, Thal LJ, Katzman R, Xia Y, Saitoh T. Genetic evidence for the involvement of tau in progressive supranuclear palsy. Ann Neurol. 1997;41:277&#x2013;281. doi: 10.1002/ana.410410222.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.410410222</ArticleId><ArticleId IdType="pubmed">9029080</ArticleId></ArticleIdList></Reference><Reference><Citation>Costa R, Speretta E, Crowther DC, Cardoso I. Testing the therapeutic potential of doxycycline in a Drosophila melanogaster model of Alzheimer disease. J Biol Chem. 2011;286:41647&#x2013;41655. doi: 10.1074/jbc.M111.274548.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M111.274548</ArticleId><ArticleId IdType="pmc">PMC3308874</ArticleId><ArticleId IdType="pubmed">21998304</ArticleId></ArticleIdList></Reference><Reference><Citation>Diner I, Hales CM, Bishof I, Rabenold L, Duong DM, Yi H, Laur O, Gearing M, Troncoso J, Thambisetty M, Lah JJ, Levey AI, Seyfried NT. Aggregation properties of the small nuclear ribonucleoprotein U1&#x2013;70K in Alzheimer disease. J Biol Chem. 2014;289:35296&#x2013;35313. doi: 10.1074/jbc.M114.562959.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M114.562959</ArticleId><ArticleId IdType="pmc">PMC4271217</ArticleId><ArticleId IdType="pubmed">25355317</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng Y, Yin Y, Weiser A, Griffin E, Cameron MD, Lin L, Ruiz C, Sch&#xfc;rer SC, Inoue T, Rao PV, Schr&#xf6;ter T, Lograsso P. Discovery of substituted 4-(pyrazol-4-yl)-phenylbenzodioxane-2-carboxamides as potent and highly selective Rho kinase (ROCK-II) inhibitors. J Med Chem. 2008;51:6642&#x2013;6645. doi: 10.1021/jm800986w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/jm800986w</ArticleId><ArticleId IdType="pmc">PMC3708311</ArticleId><ArticleId IdType="pubmed">18834107</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamano T, Yen SH, Gendron T, Ko LW, Kuriyama M. Pitavastatin decreases tau levels via the inactivation of Rho/ROCK. Neurobiol Aging. 2012;33:2306&#x2013;2320. doi: 10.1016/j.neurobiolaging.2011.10.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2011.10.020</ArticleId><ArticleId IdType="pubmed">22133277</ArticleId></ArticleIdList></Reference><Reference><Citation>Hauw JJ, Daniel SE, Dickson D, Horoupian DS, Jellinger K, Lantos PL, McKee A, Tabaton M, Litvan I. Preliminary NINDS neuropathologic criteria for Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy) Neurology. 1994;44:2015&#x2013;2019. doi: 10.1212/WNL.44.11.2015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.44.11.2015</ArticleId><ArticleId IdType="pubmed">7969952</ArticleId></ArticleIdList></Reference><Reference><Citation>Herskowitz JH, Seyfried NT, Gearing M, Kahn RA, Peng J, Levey AI, Lah JJ. Rho kinase II phosphorylation of the lipoprotein receptor LR11/SORLA alters amyloid-beta production. J Biol Chem. 2011;286:6117&#x2013;6127. doi: 10.1074/jbc.M110.167239.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M110.167239</ArticleId><ArticleId IdType="pmc">PMC3057792</ArticleId><ArticleId IdType="pubmed">21147781</ArticleId></ArticleIdList></Reference><Reference><Citation>Herskowitz JH, Offe K, Deshpande A, Kahn RA, Levey AI, Lah JJ. GGA1-mediated endocytic traffic of LR11/SorLA alters APP intracellular distribution and amyloid-beta production. Mol Biol Cell. 2012;23:2645&#x2013;2657. doi: 10.1091/mbc.E12-01-0014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1091/mbc.E12-01-0014</ArticleId><ArticleId IdType="pmc">PMC3395654</ArticleId><ArticleId IdType="pubmed">22621900</ArticleId></ArticleIdList></Reference><Reference><Citation>Herskowitz JH, Feng Y, Mattheyses AL, Hales CM, Higginbotham LA, Duong DM, Montine TJ, Troncoso JC, Thambisetty M, Seyfried NT, Levey AI, Lah JJ. Pharmacologic inhibition of ROCK2 suppresses amyloid-beta production in an Alzheimer's disease mouse model. J Neurosci. 2013;33:19086&#x2013;19098. doi: 10.1523/JNEUROSCI.2508-13.2013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.2508-13.2013</ArticleId><ArticleId IdType="pmc">PMC3850036</ArticleId><ArticleId IdType="pubmed">24305806</ArticleId></ArticleIdList></Reference><Reference><Citation>Holz MK, Blenis J. Identification of S6 kinase 1 as a novel mammalian target of rapamycin (mTOR)-phosphorylating kinase. J Biol Chem. 2005;280:26089&#x2013;26093. doi: 10.1074/jbc.M504045200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M504045200</ArticleId><ArticleId IdType="pubmed">15905173</ArticleId></ArticleIdList></Reference><Reference><Citation>Houlden H, Baker M, Morris HR, MacDonald N, Pickering-Brown S, Adamson J, Lees AJ, Rossor MN, Quinn NP, Kertesz A, Khan MN, Hardy J, Lantos PL, St George-Hyslop P, Munoz DG, Mann D, Lang AE, Bergeron C, Bigio EH, Litvan I, Bhatia KP, Dickson D, Wood NW, Hutton M. Corticobasal degeneration and progressive supranuclear palsy share a common tau haplotype. Neurology. 2001;56:1702&#x2013;1706. doi: 10.1212/WNL.56.12.1702.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.56.12.1702</ArticleId><ArticleId IdType="pubmed">11425937</ArticleId></ArticleIdList></Reference><Reference><Citation>Jackson GR, Wiedau-Pazos M, Sang TK, Wagle N, Brown CA, Massachi S, Geschwind DH. Human wild-type tau interacts with wingless pathway components and produces neurofibrillary pathology in Drosophila. Neuron. 2002;34:509&#x2013;519. doi: 10.1016/S0896-6273(02)00706-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0896-6273(02)00706-7</ArticleId><ArticleId IdType="pubmed">12062036</ArticleId></ArticleIdList></Reference><Reference><Citation>Kabeya Y, Mizushima N, Ueno T, Yamamoto A, Kirisako T, Noda T, Kominami E, Ohsumi Y, Yoshimori T. LC3, a mammalian homologue of yeast Apg8p, is localized in autophagosome membranes after processing. EMBO J. 2000;19:5720&#x2013;5728. doi: 10.1093/emboj/19.21.5720.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/emboj/19.21.5720</ArticleId><ArticleId IdType="pmc">PMC305793</ArticleId><ArticleId IdType="pubmed">11060023</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim BM, You MH, Chen CH, Lee S, Hong Y, Hong Y, Kimchi A, Zhou XZ, Lee TH. Death-associated protein kinase 1 has a critical role in aberrant tau protein regulation and function. Cell Death Dis. 2014;5:e1237. doi: 10.1038/cddis.2014.216.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/cddis.2014.216</ArticleId><ArticleId IdType="pmc">PMC4047864</ArticleId><ArticleId IdType="pubmed">24853415</ArticleId></ArticleIdList></Reference><Reference><Citation>Koch JC, T&#xf6;nges L, Barski E, Michel U, B&#xe4;hr M, Lingor P. ROCK2 is a major regulator of axonal degeneration, neuronal death and axonal regeneration in the CNS. Cell Death Dis. 2014;5:e1225. doi: 10.1038/cddis.2014.191.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/cddis.2014.191</ArticleId><ArticleId IdType="pmc">PMC4047920</ArticleId><ArticleId IdType="pubmed">24832597</ArticleId></ArticleIdList></Reference><Reference><Citation>Kouri N, Whitwell JL, Josephs KA, Rademakers R, Dickson DW. Corticobasal degeneration: a pathologically distinct 4R tauopathy. Nat Rev Neurol. 2011;7:263&#x2013;272. doi: 10.1038/nrneurol.2011.43.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2011.43</ArticleId><ArticleId IdType="pmc">PMC10006729</ArticleId><ArticleId IdType="pubmed">21487420</ArticleId></ArticleIdList></Reference><Reference><Citation>Kr&#xfc;ger U, Wang Y, Kumar S, Mandelkow EM. Autophagic degradation of tau in primary neurons and its enhancement by trehalose. Neurobiol Aging. 2012;33:2291&#x2013;2305. doi: 10.1016/j.neurobiolaging.2011.11.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2011.11.009</ArticleId><ArticleId IdType="pubmed">22169203</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu WK, Le TV, Adamson J, Baker M, Cookson N, Hardy J, Hutton M, Yen SH, Dickson DW. Relationship of the extended tau haplotype to tau biochemistry and neuropathology in progressive supranuclear palsy. Ann Neurol. 2001;50:494&#x2013;502. doi: 10.1002/ana.1159.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.1159</ArticleId><ArticleId IdType="pubmed">11601500</ArticleId></ArticleIdList></Reference><Reference><Citation>Miron M, Lasko P, Sonenberg N. Signaling from Akt to FRAP/TOR targets both 4E-BP and S6K in Drosophila melanogaster. Mol Cell Biol. 2003;23:9117&#x2013;9126. doi: 10.1128/MCB.23.24.9117-9126.2003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/MCB.23.24.9117-9126.2003</ArticleId><ArticleId IdType="pmc">PMC309682</ArticleId><ArticleId IdType="pubmed">14645523</ArticleId></ArticleIdList></Reference><Reference><Citation>Mizuno T, Amano M, Kaibuchi K, Nishida Y. Identification and characterization of Drosophila homolog of Rho-kinase. Gene. 1999;238:437&#x2013;444. doi: 10.1016/S0378-1119(99)00351-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0378-1119(99)00351-0</ArticleId><ArticleId IdType="pubmed">10570971</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakagawa O, Fujisawa K, Ishizaki T, Saito Y, Nakao K, Narumiya S. ROCK-I and ROCK-II, two isoforms of Rho-associated coiled-coil forming protein serine/threonine kinase in mice. FEBS Lett. 1996;392:189&#x2013;193. doi: 10.1016/0014-5793(96)00811-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0014-5793(96)00811-3</ArticleId><ArticleId IdType="pubmed">8772201</ArticleId></ArticleIdList></Reference><Reference><Citation>Nezis IP, Simonsen A, Sagona AP, Finley K, Gaumer S, Contamine D, Rusten TE, Stenmark H, Brech A. Ref(2)P, the Drosophila melanogaster homologue of mammalian p62, is required for the formation of protein aggregates in adult brain. J Cell Biol. 2008;180:1065&#x2013;1071. doi: 10.1083/jcb.200711108.</Citation><ArticleIdList><ArticleId IdType="doi">10.1083/jcb.200711108</ArticleId><ArticleId IdType="pmc">PMC2290837</ArticleId><ArticleId IdType="pubmed">18347073</ArticleId></ArticleIdList></Reference><Reference><Citation>Shibuya M, Hirai S, Seto M, Satoh S, Ohtomo E. Effects of fasudil in acute ischemic stroke: results of a prospective placebo-controlled double-blind trial. J Neurol Sci. 2005;238:31&#x2013;39. doi: 10.1016/j.jns.2005.06.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2005.06.003</ArticleId><ArticleId IdType="pubmed">16005902</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang Z, Bereczki E, Zhang H, Wang S, Li C, Ji X, Branca RM, Lehti&#xf6; J, Guan Z, Filipcik P, Xu S, Winblad B, Pei JJ. Mammalian target of rapamycin (mTor) mediates tau protein dyshomeostasis: implication for Alzheimer disease. J Biol Chem. 2013;288:15556&#x2013;15570. doi: 10.1074/jbc.M112.435123.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M112.435123</ArticleId><ArticleId IdType="pmc">PMC3668717</ArticleId><ArticleId IdType="pubmed">23585566</ArticleId></ArticleIdList></Reference><Reference><Citation>Togo T, Dickson DW. Tau accumulation in astrocytes in progressive supranuclear palsy is a degenerative rather than a reactive process. Acta Neuropathol. 2002;104:398&#x2013;402.</Citation><ArticleIdList><ArticleId IdType="pubmed">12200627</ArticleId></ArticleIdList></Reference><Reference><Citation>Verhoef LG, Lindsten K, Masucci MG, Dantuma NP. Aggregate formation inhibits proteasomal degradation of polyglutamine proteins. Hum Mol Genet. 2002;11:2689&#x2013;2700. doi: 10.1093/hmg/11.22.2689.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/11.22.2689</ArticleId><ArticleId IdType="pubmed">12374759</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Mandelkow E. Degradation of tau protein by autophagy and proteasomal pathways. Biochem Soc Trans. 2012;40:644&#x2013;652. doi: 10.1042/BST20120071.</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/BST20120071</ArticleId><ArticleId IdType="pubmed">22817709</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">26822146</PMID><DateCompleted><Year>2016</Year><Month>12</Month><Day>13</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>02</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1758-9193</ISSN><JournalIssue CitedMedium="Internet"><Volume>8</Volume><PubDate><Year>2016</Year><Month>Jan</Month><Day>29</Day></PubDate></JournalIssue><Title>Alzheimer's research &amp; therapy</Title><ISOAbbreviation>Alzheimers Res Ther</ISOAbbreviation></Journal><ArticleTitle>Double-blind, placebo-controlled, proof-of-concept trial of bexarotene Xin moderate Alzheimer's disease.</ArticleTitle><Pagination><StartPage>4</StartPage><MedlinePgn>4</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">4</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s13195-016-0173-2</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">We assessed the impact of retinoid X receptor&#xa0;(RXR) agonist bexarotene on brain amyloid measured by amyloid imaging in patients with Alzheimer's disease (AD) in a proof-of-concept trial.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Twenty patients with AD [Mini Mental State Examination (MMSE) score 10-20 inclusive] with positive florbetapir scans were randomized to receive 300&#xa0;mg of bexarotene or placebo for 4&#xa0;weeks. The amyloid imaging result was the primary outcome. Whole-population analyses and prespecified analyses by genotype [apolipoprotein E &#x3b5;4 (ApoE4) carriers and ApoE4 noncarriers] were conducted. Secondary outcomes included scores on the Alzheimer's Disease Assessment Scale-Cognitive subscale, Alzheimer's Disease Cooperative Study-Activities of Daily Living scale, MMSE, Clinical Dementia Rating scale, and Neuropsychiatric Inventory. Serum amyloid-&#x3b2; (A&#x3b2;) peptide sequences A&#x3b2;1-40 and A&#x3b2;1-42 measurements were collected as biomarker outcomes.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">There was no change in the composite or regional amyloid burden when all patients were included in the analysis. ApoE4 noncarriers showed a significant reduction in brain amyloid on the composite measure in five of six regional measurements. No change in amyloid burden was observed in ApoE4 carriers. There was a significant association between increased serum A&#x3b2;1-42 and reductions in brain amyloid in ApoE4 noncarriers (not in carriers). There were significant elevations in serum triglycerides in bexarotene-treated patients. There was no consistent change in any clinical measure.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The primary outcome of this trial was negative. The data suggest that bexarotene reduced brain amyloid and increased serum A&#x3b2;1-42 in ApoE4 noncarriers. Elevated triglycerides could represent a cardiovascular risk, and bexarotene should not be administered outside a research setting.&#xa0;RXR agonists warrant further investigations as AD therapies.</AbstractText><AbstractText Label="TRIAL REGISTRATION" NlmCategory="BACKGROUND">ClinicalTrials.gov identifier NCT01782742 . Registered 29 January 2013.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cummings</LastName><ForeName>Jeffrey L</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>Cleveland Clinic Lou Ruvo Center for Brain Health, 888 West Bonneville Avenue, Las Vegas, NV, 89106, USA. cumminj@ccf.org.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhong</LastName><ForeName>Kate</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Cleveland Clinic Lou Ruvo Center for Brain Health, 888 West Bonneville Avenue, Las Vegas, NV, 89106, USA. zhongk@ccf.org.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kinney</LastName><ForeName>Jefferson W</ForeName><Initials>JW</Initials><AffiliationInfo><Affiliation>Department of Psychology, University of Nevada, Las Vegas, NV, USA. jefferson.kinney@unlv.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Heaney</LastName><ForeName>Chelcie</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Psychology, University of Nevada, Las Vegas, NV, USA. chelcie.heaney@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moll-Tudla</LastName><ForeName>Joanne</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Cleveland Clinic Lou Ruvo Center for Brain Health, 888 West Bonneville Avenue, Las Vegas, NV, 89106, USA. mollj@ccf.org.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Joshi</LastName><ForeName>Abhinay</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Avid Pharmaceuticals, Philadelphia, PA, USA. joshi@avidrp.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pontecorvo</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Avid Pharmaceuticals, Philadelphia, PA, USA. pontecorvo@avidrp.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Devous</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Avid Pharmaceuticals, Philadelphia, PA, USA. devous@avidrp.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tang</LastName><ForeName>Anne</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Cleveland Clinic Quantitative Health Services, Cleveland, OH, USA. tanga@ccf.org.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bena</LastName><ForeName>James</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Cleveland Clinic Quantitative Health Services, Cleveland, OH, USA. benaj@ccf.org.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT01782742</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>P20 GM109025</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>01</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Alzheimers Res Ther</MedlineTA><NlmUniqueID>101511643</NlmUniqueID></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001057">Apolipoproteins E</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D047488">Retinoid X Receptors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013764">Tetrahydronaphthalenes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C078592">amyloid beta-protein (1-40)</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C075222">amyloid beta-protein (1-42)</NameOfSubstance></Chemical><Chemical><RegistryNumber>A61RXM4375</RegistryNumber><NameOfSubstance UI="D000077610">Bexarotene</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001057" MajorTopicYN="N">Apolipoproteins E</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000077610" MajorTopicYN="N">Bexarotene</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="N">Positron-Emission Tomography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D047488" MajorTopicYN="N">Retinoid X Receptors</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000819" MajorTopicYN="Y">agonists</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013764" MajorTopicYN="N">Tetrahydronaphthalenes</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>9</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>1</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>1</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>1</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2016</Year><Month>1</Month><Day>29</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26822146</ArticleId><ArticleId IdType="pmc">PMC4731943</ArticleId><ArticleId IdType="doi">10.1186/s13195-016-0173-2</ArticleId><ArticleId IdType="pii">10.1186/s13195-016-0173-2</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>James BD, Leurgans SE, Hebert LE, Scherr PA, Yaffe K, Bennett DA. Contribution of Alzheimer disease to mortality in the United States. Neurology. 2014;82:1045&#x2013;50. doi: 10.1212/WNL.0000000000000240.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000000240</ArticleId><ArticleId IdType="pmc">PMC3962992</ArticleId><ArticleId IdType="pubmed">24598707</ArticleId></ArticleIdList></Reference><Reference><Citation>Hurd MD, Martorell P, Delavande A, Mullen KJ, Langa KM. Monetary costs of dementia in the United States. N Engl J Med. 2013;368:1326&#x2013;34. doi: 10.1056/NEJMsa1204629.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMsa1204629</ArticleId><ArticleId IdType="pmc">PMC3959992</ArticleId><ArticleId IdType="pubmed">23550670</ArticleId></ArticleIdList></Reference><Reference><Citation>Association A&#x2019;s. 2015 Alzheimer&#x2019;s disease facts and figures. Alzheimers Dement. 2015;11:332&#x2013;84. doi: 10.1016/j.jalz.2015.02.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2015.02.003</ArticleId><ArticleId IdType="pubmed">25984581</ArticleId></ArticleIdList></Reference><Reference><Citation>Cummings JL, Morstorf T, Zhong K. Alzheimer&#x2019;s disease drug-development pipeline: few candidates, frequent failures. Alzheimers Res Ther. 2014;6:37. doi: 10.1186/alzrt269.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/alzrt269</ArticleId><ArticleId IdType="pmc">PMC4095696</ArticleId><ArticleId IdType="pubmed">25024750</ArticleId></ArticleIdList></Reference><Reference><Citation>Bohm C, Chen F, Sevalle J, Qamar S, Dodd R, Li Y, et al. Current and future implications of basic and translational research on amyloid-&#x3b2; peptide production and removal pathways. Mol Cell Neurosci. 2015;66:3&#x2013;11. doi: 10.1016/j.mcn.2015.02.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mcn.2015.02.016</ArticleId><ArticleId IdType="pmc">PMC4503820</ArticleId><ArticleId IdType="pubmed">25748120</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiang K, Koo EH. Emerging therapeutics for Alzheimer&#x2019;s disease. Annu Rev Pharmacol Toxicol. 2014;54:381&#x2013;405. doi: 10.1146/annurev-pharmtox-011613-135932.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-pharmtox-011613-135932</ArticleId><ArticleId IdType="pubmed">24392696</ArticleId></ArticleIdList></Reference><Reference><Citation>Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer&#x2019;s disease in late onset families. Science. 1993;261:921&#x2013;3. doi: 10.1126/science.8346443.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.8346443</ArticleId><ArticleId IdType="pubmed">8346443</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang Y. A&#x3b2;-independent roles of apolipoprotein E4 in the pathogenesis of Alzheimer&#x2019;s disease. Trends Mol Med. 2010;16:287&#x2013;94. doi: 10.1016/j.molmed.2010.04.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molmed.2010.04.004</ArticleId><ArticleId IdType="pubmed">20537952</ArticleId></ArticleIdList></Reference><Reference><Citation>Drzezga A, Grimmer T, Henriksen G, M&#xfc;hlau M, Perneczky R, Miederer I, et al. Effect of APOE genotype on amyloid plaque load and gray matter volume in Alzheimer disease. Neurology. 2009;72:1487&#x2013;94. doi: 10.1212/WNL.0b013e3181a2e8d0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e3181a2e8d0</ArticleId><ArticleId IdType="pubmed">19339712</ArticleId></ArticleIdList></Reference><Reference><Citation>Peuralinna T, Tanskanen M, M&#xe4;kel&#xe4; M, Polvikoski T, Paetau A, Kalimo H, et al. APOE and A&#x3b2;PP gene variation in cortical and cerebrovascular amyloid-&#x3b2; pathology and Alzheimer&#x2019;s disease: a population-based analysis. J Alzheimers Dis. 2011;26:377&#x2013;85.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3516850</ArticleId><ArticleId IdType="pubmed">21654062</ArticleId></ArticleIdList></Reference><Reference><Citation>Koldamova R, Fitz NF, Lefterov I. ATP-binding cassette transporter A1: from metabolism to neurodegeneration. Neurobiol Dis. 2014;72:13&#x2013;21. doi: 10.1016/j.nbd.2014.05.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2014.05.007</ArticleId><ArticleId IdType="pmc">PMC4302328</ArticleId><ArticleId IdType="pubmed">24844148</ArticleId></ArticleIdList></Reference><Reference><Citation>Tai LM, Koster KP, Luo J, Lee SH, Wang YT, Collins NC, et al. Amyloid-&#x3b2; pathology and APOE genotype modulate retinoid X receptor agonist activity in vivo. J Biol Chem. 2014;289:30538&#x2013;55. doi: 10.1074/jbc.M114.600833.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M114.600833</ArticleId><ArticleId IdType="pmc">PMC4215234</ArticleId><ArticleId IdType="pubmed">25217640</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao J, Fu Y, Liu CC, Shinohara M, Nielsen HM, Dong Q, et al. Retinoic acid isomers facilitate apolipoprotein E production and lipidation in astrocytes through the retinoid X receptor/retinoic acid receptor pathway. J Biol Chem. 2014;289:11282&#x2013;92. doi: 10.1074/jbc.M113.526095.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M113.526095</ArticleId><ArticleId IdType="pmc">PMC4036266</ArticleId><ArticleId IdType="pubmed">24599963</ArticleId></ArticleIdList></Reference><Reference><Citation>Cramer PE, Cirrito JR, Wesson DW, Lee CY, Karlo JC, Zinn AE, et al. ApoE-directed therapeutics rapidly clear &#x3b2;-amyloid and reverse deficits in AD mouse models. Science. 2012;335:1503&#x2013;6. doi: 10.1126/science.1217697.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1217697</ArticleId><ArticleId IdType="pmc">PMC3651582</ArticleId><ArticleId IdType="pubmed">22323736</ArticleId></ArticleIdList></Reference><Reference><Citation>Balducci C, Paladini A, Micotti E, Tolomeo D, La Vitola P, Grigoli E, et al. The continuing failure of bexarotene in Alzheimer&#x2019;s disease mice. J Alzheimers Dis. 2015;46:471&#x2013;82. doi: 10.3233/JAD-150029.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-150029</ArticleId><ArticleId IdType="pubmed">25777514</ArticleId></ArticleIdList></Reference><Reference><Citation>Veeraraghavalu K, Zhang C, Miller S, Hefendehl JK, Rajapaksha TW, Ulrich J, et al. Comment on &#x201c;ApoE-directed therapeutics rapidly clear &#x3b2;-amyloid and reverse deficits in AD mouse models&#x201d;. Science. 2013;340:924. doi: 10.1126/science.1235505.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1235505</ArticleId><ArticleId IdType="pubmed">23704555</ArticleId></ArticleIdList></Reference><Reference><Citation>Fitz NF, Cronican AA, Lefterov I, Koldamova R. Comment on &#x201c;ApoE-directed therapeutics rapidly clear &#x3b2;-amyloid and reverse deficits in AD mouse models&#x201d;. Science. 2013;340:924. doi: 10.1126/science.1235809.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1235809</ArticleId><ArticleId IdType="pmc">PMC4086452</ArticleId><ArticleId IdType="pubmed">23704552</ArticleId></ArticleIdList></Reference><Reference><Citation>Price AR, Xu G, Siemienski ZB, Smithson LA, Borchelt DR, Golde TE, et al. Comment on &#x201c;ApoE-directed therapeutics rapidly clear &#x3b2;-amyloid and reverse deficits in AD mouse models&#x201d;. Science. 2013;340:924. doi: 10.1126/science.1234089.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1234089</ArticleId><ArticleId IdType="pubmed">23704553</ArticleId></ArticleIdList></Reference><Reference><Citation>Tesseur I, Lo AC, Roberfroid A, Dietvorst S, Van Broeck B, Borgers M, et al. Comment on &#x201c;ApoE-directed therapeutics rapidly clear &#x3b2;-amyloid and reverse deficits in AD mouse models&#x201d;. Science. 2013;340:924. doi: 10.1126/science.1233937.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1233937</ArticleId><ArticleId IdType="pubmed">23704554</ArticleId></ArticleIdList></Reference><Reference><Citation>Farol LT, Hymes KB. Bexarotene: a clinical review. Expert Rev Anticancer Ther. 2004;4:180&#x2013;8. doi: 10.1586/14737140.4.2.180.</Citation><ArticleIdList><ArticleId IdType="doi">10.1586/14737140.4.2.180</ArticleId><ArticleId IdType="pubmed">15056048</ArticleId></ArticleIdList></Reference><Reference><Citation>Appleby BS, Nacopoulos D, Milano N, Zhong K, Cummings JL. A review: treatment of Alzheimer&#x2019;s disease discovered in repurposed agents. Dement Geriatr Cogn Disord. 2013;35:1&#x2013;22. doi: 10.1159/000345791.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000345791</ArticleId><ArticleId IdType="pubmed">23307039</ArticleId></ArticleIdList></Reference><Reference><Citation>Graeppi-Dulac J, Vlaeminck-Guillem V, Perier-Muzet M, Dalle S, Orgiazzi J. Endocrine side-effects of anti-cancer drugs: the impact of retinoids on the thyroid axis. Eur J Endocrinol. 2014;170:R253&#x2013;62. doi: 10.1530/EJE-13-0920.</Citation><ArticleIdList><ArticleId IdType="doi">10.1530/EJE-13-0920</ArticleId><ArticleId IdType="pubmed">24616413</ArticleId></ArticleIdList></Reference><Reference><Citation>LaFerla FM. Preclinical success against Alzheimer&#x2019;s disease with an old drug. N Engl J Med. 2012;367:570&#x2013;2. doi: 10.1056/NEJMcibr1204890.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMcibr1204890</ArticleId><ArticleId IdType="pubmed">22873540</ArticleId></ArticleIdList></Reference><Reference><Citation>Lowenthal J, Hull SC, Pearson SD. The ethics of early evidence&#x2014;preparing for a possible breakthrough in Alzheimer&#x2019;s disease. N Engl J Med. 2012;367:488&#x2013;90. doi: 10.1056/NEJMp1203104.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMp1203104</ArticleId><ArticleId IdType="pmc">PMC3469579</ArticleId><ArticleId IdType="pubmed">22873528</ArticleId></ArticleIdList></Reference><Reference><Citation>Strittmatter WJ. Old drug, new hope for Alzheimer&#x2019;s disease. Science. 2012;335:1447&#x2013;8. doi: 10.1126/science.1220725.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1220725</ArticleId><ArticleId IdType="pubmed">22442467</ArticleId></ArticleIdList></Reference><Reference><Citation>de Vries-van der Weij J, de Haan W, Hu L, Kuif M, Oei HL, van der Hoorn JW, et al. Bexarotene induces dyslipidemia by increased very low-density lipoprotein production and cholesteryl ester transfer protein-mediated reduction of high-density lipoprotein. Endocrinology. 2009;150:2368&#x2013;75. doi: 10.1210/en.2008-1540.</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/en.2008-1540</ArticleId><ArticleId IdType="pubmed">19147676</ArticleId></ArticleIdList></Reference><Reference><Citation>Pierrot N, Lhommel R, Quenon L, Hanseeuw B, Dricot L, Sindic C, et al. Targretin improves cognitive and biological markers in a patient with Alzheimer&#x2019;s disease. J Alzheimers Dis. 2015;49:271&#x2013;6. doi: 10.3233/JAD-150405.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-150405</ArticleId><ArticleId IdType="pubmed">26444777</ArticleId></ArticleIdList></Reference><Reference><Citation>Cummings JL. Optimizing phase II of drug development for disease-modifying compounds. Alzheimers Dement. 2008;4:S15&#x2013;20. doi: 10.1016/j.jalz.2007.10.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2007.10.002</ArticleId><ArticleId IdType="pubmed">18631992</ArticleId></ArticleIdList></Reference><Reference><Citation>Cummings JL. Biomarkers in Alzheimer&#x2019;s disease drug development. Alzheimers Dement. 2011;7:e13&#x2013;44. doi: 10.1016/j.jalz.2010.06.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2010.06.004</ArticleId><ArticleId IdType="pubmed">21550318</ArticleId></ArticleIdList></Reference><Reference><Citation>Cook D, Brown D, Alexander R, March R, Morgan P, Satterthwaite G, et al. Lessons learned from the fate of AstraZeneca&#x2019;s drug pipeline: a five-dimensional framework. Nat Rev Drug Discov. 2014;13:419&#x2013;31. doi: 10.1038/nrd4309.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrd4309</ArticleId><ArticleId IdType="pubmed">24833294</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer&#x2019;s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer&#x2019;s Disease. Neurology. 1984;34:939&#x2013;44. doi: 10.1212/WNL.34.7.939.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.34.7.939</ArticleId><ArticleId IdType="pubmed">6610841</ArticleId></ArticleIdList></Reference><Reference><Citation>Folstein MF, Folstein SE, McHugh PR. &#x201c;Mini-mental state&#x201d;: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189&#x2013;98. doi: 10.1016/0022-3956(75)90026-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0022-3956(75)90026-6</ArticleId><ArticleId IdType="pubmed">1202204</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen K, Roontiva A, Thiyyagura P, Lee W, Liu X, Ayutyanont N, et al. Improved power to characterize longitudinal amyloid-&#x3b2; PET changes and evaluate amyloid-modifying treatments using a cerebral white matter reference region. J Nucl Med. 2015;56:560&#x2013;6. doi: 10.2967/jnumed.114.149732.</Citation><ArticleIdList><ArticleId IdType="doi">10.2967/jnumed.114.149732</ArticleId><ArticleId IdType="pubmed">25745091</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer&#x2019;s disease. Am J Psychiatry. 1984;141:1356&#x2013;64. doi: 10.1176/ajp.141.11.1356.</Citation><ArticleIdList><ArticleId IdType="doi">10.1176/ajp.141.11.1356</ArticleId><ArticleId IdType="pubmed">6496779</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology. 1993;43:2412&#x2013;4. doi: 10.1212/WNL.43.11.2412-a.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.43.11.2412-a</ArticleId><ArticleId IdType="pubmed">8232972</ArticleId></ArticleIdList></Reference><Reference><Citation>Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology. 1994;44:2308&#x2013;14. doi: 10.1212/WNL.44.12.2308.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.44.12.2308</ArticleId><ArticleId IdType="pubmed">7991117</ArticleId></ArticleIdList></Reference><Reference><Citation>Galasko D, Bennett D, Sano M, Ernesto C, Thomas R, Grundman M, et al. An inventory to assess activities of daily living for clinical trials in Alzheimer&#x2019;s disease: the Alzheimer&#x2019;s Disease Cooperative Study. Alzheimer Dis Assoc Disord. 1997;11:S33&#x2013;9. doi: 10.1097/00002093-199700112-00005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00002093-199700112-00005</ArticleId><ArticleId IdType="pubmed">9236950</ArticleId></ArticleIdList></Reference><Reference><Citation>Calero O, Hortiguela R, Bullido MJ, Calero M. Apolipoprotein E genotyping method by real time PCR, a fast and cost-effective alternative to the TaqMan and FRET assays. J Neurosci Methods. 2009;183:238&#x2013;40. doi: 10.1016/j.jneumeth.2009.06.033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jneumeth.2009.06.033</ArticleId><ArticleId IdType="pubmed">19583979</ArticleId></ArticleIdList></Reference><Reference><Citation>Clark CM, Schneider JA, Bedell BJ, Beach TG, Bilker WB, Mintun MA, et al. Use of florbetapir-PET for imaging &#x3b2;-amyloid pathology. JAMA. 2011;305:275&#x2013;83. doi: 10.1001/jama.2010.2008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2010.2008</ArticleId><ArticleId IdType="pmc">PMC7041965</ArticleId><ArticleId IdType="pubmed">21245183</ArticleId></ArticleIdList></Reference><Reference><Citation>Landau SM, Fero A, Baker SL, Koeppe R, Mintun M, Chen K, et al. Measurement of longitudinal &#x3b2;-amyloid change with 18F-florbetapir PET and standardized uptake value ratios. J Nucl Med. 2015;56:567&#x2013;74. doi: 10.2967/jnumed.114.148981.</Citation><ArticleIdList><ArticleId IdType="doi">10.2967/jnumed.114.148981</ArticleId><ArticleId IdType="pmc">PMC5313473</ArticleId><ArticleId IdType="pubmed">25745095</ArticleId></ArticleIdList></Reference><Reference><Citation>Dubois B, Feldman HH, Jacova C, Hampel H, Molinuevo JL, Blennow K, et al. Advancing research diagnostic criteria for Alzheimer&#x2019;s disease: the IWG-2 criteria. Lancet Neurol. 2014;13:614&#x2013;29. doi: 10.1016/S1474-4422(14)70090-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(14)70090-0</ArticleId><ArticleId IdType="pubmed">24849862</ArticleId></ArticleIdList></Reference><Reference><Citation>Youmans KL, Tai LM, Nwabuisi-Heath E, Jungbauer L, Kanekiyo T, Gan M, et al. APOE4-specific changes in A&#x3b2; accumulation in a new transgenic mouse model of Alzheimer disease. J Biol Chem. 2012;287:41774&#x2013;86. doi: 10.1074/jbc.M112.407957.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M112.407957</ArticleId><ArticleId IdType="pmc">PMC3516726</ArticleId><ArticleId IdType="pubmed">23060451</ArticleId></ArticleIdList></Reference><Reference><Citation>Michaelson DM. APOE &#x3b5;4: the most prevalent yet understudied risk factor for Alzheimer&#x2019;s disease. Alzheimers Dement. 2014;10:861&#x2013;8. doi: 10.1016/j.jalz.2014.06.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2014.06.015</ArticleId><ArticleId IdType="pubmed">25217293</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">26843562</PMID><DateCompleted><Year>2016</Year><Month>07</Month><Day>06</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1526-632X</ISSN><JournalIssue CitedMedium="Internet"><Volume>86</Volume><Issue>9</Issue><PubDate><Year>2016</Year><Month>Mar</Month><Day>01</Day></PubDate></JournalIssue><Title>Neurology</Title><ISOAbbreviation>Neurology</ISOAbbreviation></Journal><ArticleTitle>Amyloid pathology and axonal injury after brain trauma.</ArticleTitle><Pagination><StartPage>821</StartPage><EndPage>828</EndPage><MedlinePgn>821-8</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1212/WNL.0000000000002413</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To image &#x3b2;-amyloid (A&#x3b2;) plaque burden in long-term survivors of traumatic brain injury (TBI), test whether traumatic axonal injury and A&#x3b2; are correlated, and compare the spatial distribution of A&#x3b2; to Alzheimer disease (AD).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Patients 11 months to 17 years after moderate-severe TBI underwent (11)C-Pittsburgh compound B ((11)C-PiB)-PET, structural and diffusion MRI, and neuropsychological examination. Healthy aged controls and patients with AD underwent PET and structural MRI. Binding potential (BPND) images of (11)C-PiB, which index A&#x3b2; plaque density, were computed using an automatic reference region extraction procedure. Voxelwise and regional differences in BPND were assessed. In TBI, a measure of white matter integrity, fractional anisotropy, was estimated and correlated with (11)C-PiB BPND.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Twenty-eight participants (9 with TBI, 9 controls, 10 with AD) were assessed. Increased (11)C-PiB BPND was found in TBI vs controls in the posterior cingulate cortex and cerebellum. Binding in the posterior cingulate cortex increased with decreasing fractional anisotropy of associated white matter tracts and increased with time since injury. Compared to AD, binding after TBI was lower in neocortical regions but increased in the cerebellum.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Increased A&#x3b2; burden was observed in TBI. The distribution overlaps with, but is distinct from, that of AD. This suggests a mechanistic link between TBI and the development of neuropathologic features of dementia, which may relate to axonal damage produced by the injury.</AbstractText><CopyrightInformation>&#xa9; 2016 American Academy of Neurology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Scott</LastName><ForeName>Gregory</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>From the Division of Brain Sciences (G.S., A.F.R., P.E., P.H., J.C., R.L., S.M.G., R.A.H., P.M.M., D.J.B., D.J.S.), Department of Medicine, Imperial College London; Institute of Psychiatry, Psychology &amp; Neuroscience (P.H., M.V., F.E.T.), King's College London; Institute of Neurology (R.J.G.), University College London, UK; MedTech West at Sahlgrenska University Hospital (R.A.H.), University of Gothenburg, Sweden; and Institute of Clinical Medicine (D.J.B.), Aarhus University, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ramlackhansingh</LastName><ForeName>Anil F</ForeName><Initials>AF</Initials><AffiliationInfo><Affiliation>From the Division of Brain Sciences (G.S., A.F.R., P.E., P.H., J.C., R.L., S.M.G., R.A.H., P.M.M., D.J.B., D.J.S.), Department of Medicine, Imperial College London; Institute of Psychiatry, Psychology &amp; Neuroscience (P.H., M.V., F.E.T.), King's College London; Institute of Neurology (R.J.G.), University College London, UK; MedTech West at Sahlgrenska University Hospital (R.A.H.), University of Gothenburg, Sweden; and Institute of Clinical Medicine (D.J.B.), Aarhus University, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Edison</LastName><ForeName>Paul</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>From the Division of Brain Sciences (G.S., A.F.R., P.E., P.H., J.C., R.L., S.M.G., R.A.H., P.M.M., D.J.B., D.J.S.), Department of Medicine, Imperial College London; Institute of Psychiatry, Psychology &amp; Neuroscience (P.H., M.V., F.E.T.), King's College London; Institute of Neurology (R.J.G.), University College London, UK; MedTech West at Sahlgrenska University Hospital (R.A.H.), University of Gothenburg, Sweden; and Institute of Clinical Medicine (D.J.B.), Aarhus University, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hellyer</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>From the Division of Brain Sciences (G.S., A.F.R., P.E., P.H., J.C., R.L., S.M.G., R.A.H., P.M.M., D.J.B., D.J.S.), Department of Medicine, Imperial College London; Institute of Psychiatry, Psychology &amp; Neuroscience (P.H., M.V., F.E.T.), King's College London; Institute of Neurology (R.J.G.), University College London, UK; MedTech West at Sahlgrenska University Hospital (R.A.H.), University of Gothenburg, Sweden; and Institute of Clinical Medicine (D.J.B.), Aarhus University, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cole</LastName><ForeName>James</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>From the Division of Brain Sciences (G.S., A.F.R., P.E., P.H., J.C., R.L., S.M.G., R.A.H., P.M.M., D.J.B., D.J.S.), Department of Medicine, Imperial College London; Institute of Psychiatry, Psychology &amp; Neuroscience (P.H., M.V., F.E.T.), King's College London; Institute of Neurology (R.J.G.), University College London, UK; MedTech West at Sahlgrenska University Hospital (R.A.H.), University of Gothenburg, Sweden; and Institute of Clinical Medicine (D.J.B.), Aarhus University, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Veronese</LastName><ForeName>Mattia</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>From the Division of Brain Sciences (G.S., A.F.R., P.E., P.H., J.C., R.L., S.M.G., R.A.H., P.M.M., D.J.B., D.J.S.), Department of Medicine, Imperial College London; Institute of Psychiatry, Psychology &amp; Neuroscience (P.H., M.V., F.E.T.), King's College London; Institute of Neurology (R.J.G.), University College London, UK; MedTech West at Sahlgrenska University Hospital (R.A.H.), University of Gothenburg, Sweden; and Institute of Clinical Medicine (D.J.B.), Aarhus University, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leech</LastName><ForeName>Rob</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>From the Division of Brain Sciences (G.S., A.F.R., P.E., P.H., J.C., R.L., S.M.G., R.A.H., P.M.M., D.J.B., D.J.S.), Department of Medicine, Imperial College London; Institute of Psychiatry, Psychology &amp; Neuroscience (P.H., M.V., F.E.T.), King's College London; Institute of Neurology (R.J.G.), University College London, UK; MedTech West at Sahlgrenska University Hospital (R.A.H.), University of Gothenburg, Sweden; and Institute of Clinical Medicine (D.J.B.), Aarhus University, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Greenwood</LastName><ForeName>Richard J</ForeName><Initials>RJ</Initials><AffiliationInfo><Affiliation>From the Division of Brain Sciences (G.S., A.F.R., P.E., P.H., J.C., R.L., S.M.G., R.A.H., P.M.M., D.J.B., D.J.S.), Department of Medicine, Imperial College London; Institute of Psychiatry, Psychology &amp; Neuroscience (P.H., M.V., F.E.T.), King's College London; Institute of Neurology (R.J.G.), University College London, UK; MedTech West at Sahlgrenska University Hospital (R.A.H.), University of Gothenburg, Sweden; and Institute of Clinical Medicine (D.J.B.), Aarhus University, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Turkheimer</LastName><ForeName>Federico E</ForeName><Initials>FE</Initials><AffiliationInfo><Affiliation>From the Division of Brain Sciences (G.S., A.F.R., P.E., P.H., J.C., R.L., S.M.G., R.A.H., P.M.M., D.J.B., D.J.S.), Department of Medicine, Imperial College London; Institute of Psychiatry, Psychology &amp; Neuroscience (P.H., M.V., F.E.T.), King's College London; Institute of Neurology (R.J.G.), University College London, UK; MedTech West at Sahlgrenska University Hospital (R.A.H.), University of Gothenburg, Sweden; and Institute of Clinical Medicine (D.J.B.), Aarhus University, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gentleman</LastName><ForeName>Steve M</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>From the Division of Brain Sciences (G.S., A.F.R., P.E., P.H., J.C., R.L., S.M.G., R.A.H., P.M.M., D.J.B., D.J.S.), Department of Medicine, Imperial College London; Institute of Psychiatry, Psychology &amp; Neuroscience (P.H., M.V., F.E.T.), King's College London; Institute of Neurology (R.J.G.), University College London, UK; MedTech West at Sahlgrenska University Hospital (R.A.H.), University of Gothenburg, Sweden; and Institute of Clinical Medicine (D.J.B.), Aarhus University, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Heckemann</LastName><ForeName>Rolf A</ForeName><Initials>RA</Initials><AffiliationInfo><Affiliation>From the Division of Brain Sciences (G.S., A.F.R., P.E., P.H., J.C., R.L., S.M.G., R.A.H., P.M.M., D.J.B., D.J.S.), Department of Medicine, Imperial College London; Institute of Psychiatry, Psychology &amp; Neuroscience (P.H., M.V., F.E.T.), King's College London; Institute of Neurology (R.J.G.), University College London, UK; MedTech West at Sahlgrenska University Hospital (R.A.H.), University of Gothenburg, Sweden; and Institute of Clinical Medicine (D.J.B.), Aarhus University, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Matthews</LastName><ForeName>Paul M</ForeName><Initials>PM</Initials><AffiliationInfo><Affiliation>From the Division of Brain Sciences (G.S., A.F.R., P.E., P.H., J.C., R.L., S.M.G., R.A.H., P.M.M., D.J.B., D.J.S.), Department of Medicine, Imperial College London; Institute of Psychiatry, Psychology &amp; Neuroscience (P.H., M.V., F.E.T.), King's College London; Institute of Neurology (R.J.G.), University College London, UK; MedTech West at Sahlgrenska University Hospital (R.A.H.), University of Gothenburg, Sweden; and Institute of Clinical Medicine (D.J.B.), Aarhus University, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brooks</LastName><ForeName>David J</ForeName><Initials>DJ</Initials><AffiliationInfo><Affiliation>From the Division of Brain Sciences (G.S., A.F.R., P.E., P.H., J.C., R.L., S.M.G., R.A.H., P.M.M., D.J.B., D.J.S.), Department of Medicine, Imperial College London; Institute of Psychiatry, Psychology &amp; Neuroscience (P.H., M.V., F.E.T.), King's College London; Institute of Neurology (R.J.G.), University College London, UK; MedTech West at Sahlgrenska University Hospital (R.A.H.), University of Gothenburg, Sweden; and Institute of Clinical Medicine (D.J.B.), Aarhus University, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sharp</LastName><ForeName>David J</ForeName><Initials>DJ</Initials><AffiliationInfo><Affiliation>From the Division of Brain Sciences (G.S., A.F.R., P.E., P.H., J.C., R.L., S.M.G., R.A.H., P.M.M., D.J.B., D.J.S.), Department of Medicine, Imperial College London; Institute of Psychiatry, Psychology &amp; Neuroscience (P.H., M.V., F.E.T.), King's College London; Institute of Neurology (R.J.G.), University College London, UK; MedTech West at Sahlgrenska University Hospital (R.A.H.), University of Gothenburg, Sweden; and Institute of Clinical Medicine (D.J.B.), Aarhus University, Denmark. david.sharp@imperial.ac.uk.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>G1100810</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/L022141/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MC_U120085814</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>G0701951</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>NIHR-RP-011-048</GrantID><Acronym>DH_</Acronym><Agency>Department of Health</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MC_U120036861</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>G0900897</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>G1100809</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>02</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurology</MedlineTA><NlmUniqueID>0401060</NlmUniqueID><ISSNLinking>0028-3878</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Neurology. 2016 Mar 1;86(9):798-9. doi: 10.1212/WNL.0000000000002426.</RefSource><PMID Version="1">26843567</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017772" MajorTopicYN="N">Amyloid Neuropathies</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001369" MajorTopicYN="N">Axons</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001930" MajorTopicYN="N">Brain Injuries</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D056324" MajorTopicYN="N">Diffusion Tensor Imaging</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064847" MajorTopicYN="N">Multimodal Imaging</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="N">Positron-Emission Tomography</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015203" MajorTopicYN="N">Reproducibility of Results</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012680" MajorTopicYN="N">Sensitivity and Specificity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014018" MajorTopicYN="N">Tissue Distribution</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>4</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>9</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>2</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>2</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>7</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2016</Year><Month>3</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26843562</ArticleId><ArticleId IdType="pmc">PMC4793784</ArticleId><ArticleId IdType="doi">10.1212/WNL.0000000000002413</ArticleId><ArticleId IdType="pii">WNL.0000000000002413</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Fleminger S, Ponsford J. Long term outcome after traumatic brain injury. BMJ 2005;331:1419&#x2013;1420.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1315633</ArticleId><ArticleId IdType="pubmed">16356951</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitnall L, McMillan TM, Murray GD, Teasdale GM. Disability in young people and adults after head injury: 5&#x2013;7 year follow up of a prospective cohort study. J Neurol Neurosurg Psychiatry 2006;77:640&#x2013;645.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2117429</ArticleId><ArticleId IdType="pubmed">16614025</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith DH, Johnson VE, Stewart W. Chronic neuropathologies of single and repetitive TBI: substrates of dementia? Nat Rev Neurol 2013;9:211&#x2013;221.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4513655</ArticleId><ArticleId IdType="pubmed">23458973</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson VE, Stewart W, Smith DH. Widespread tau and amyloid-beta pathology many years after a single traumatic brain injury in humans. Brain Pathol 2012;22:142&#x2013;149.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3979351</ArticleId><ArticleId IdType="pubmed">21714827</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson VE, Stewart W, Smith DH. Axonal pathology in traumatic brain injury. Exp Neurol 2013;246:35&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3979341</ArticleId><ArticleId IdType="pubmed">22285252</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson VE, Stewart W, Smith DH. Traumatic brain injury and amyloid-beta pathology: a link to Alzheimer's disease? Nat Rev Neurosci 2010;11:361&#x2013;370.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3979339</ArticleId><ArticleId IdType="pubmed">20216546</ArticleId></ArticleIdList></Reference><Reference><Citation>Quigley H, Colloby SJ, O'Brien JT. PET imaging of brain amyloid in dementia: a review. Int J Geriatr Psychiatry 2011;26:991&#x2013;999.</Citation><ArticleIdList><ArticleId IdType="pubmed">21905095</ArticleId></ArticleIdList></Reference><Reference><Citation>Rowe CC, Ng S, Ackermann U, et al. Imaging beta-amyloid burden in aging and dementia. Neurology 2007;68:1718&#x2013;1725.</Citation><ArticleIdList><ArticleId IdType="pubmed">17502554</ArticleId></ArticleIdList></Reference><Reference><Citation>Ikonomovic MD, Klunk WE, Abrahamson EE, et al. Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease. Brain 2008;131:1630&#x2013;1645.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2408940</ArticleId><ArticleId IdType="pubmed">18339640</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong YT, Veenith T, Dewar D, et al. Amyloid imaging with carbon 11&#x2013;labeled Pittsburgh compound B for traumatic brain injury. JAMA Neurol 2014;71:23&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4084932</ArticleId><ArticleId IdType="pubmed">24217171</ArticleId></ArticleIdList></Reference><Reference><Citation>Mac Donald CL, Dikranian K, Bayly P, Holtzman D, Brody D. Diffusion tensor imaging reliably detects experimental traumatic axonal injury and indicates approximate time of injury. J Neurosci 2007;27:11869&#x2013;11876.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2562788</ArticleId><ArticleId IdType="pubmed">17978027</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharp DJ, Ham TE. Investigating white matter injury after mild traumatic brain injury. Curr Opin Neurol 2011;24:558&#x2013;563.</Citation><ArticleIdList><ArticleId IdType="pubmed">21986682</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharp DJ, Scott G, Leech R. Network dysfunction after traumatic brain injury. Nat Rev Neurol 2014;10:156&#x2013;166.</Citation><ArticleIdList><ArticleId IdType="pubmed">24514870</ArticleId></ArticleIdList></Reference><Reference><Citation>Magnoni S, Mac Donald CL, Esparza TJ, et al. Quantitative assessments of traumatic axonal injury in human brain: concordance of microdialysis and advanced MRI. Brain 2015;138:2263&#x2013;2277.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4840950</ArticleId><ArticleId IdType="pubmed">26084657</ArticleId></ArticleIdList></Reference><Reference><Citation>Malec JF, Brown AW, Leibson CL, et al. The Mayo classification system for traumatic brain injury severity. J Neurotrauma 2007;24:1417&#x2013;1424.</Citation><ArticleIdList><ArticleId IdType="pubmed">17892404</ArticleId></ArticleIdList></Reference><Reference><Citation>Ikoma Y, Edison P, Ramlackhansingh A, Brooks DJ, Turkheimer FE. Reference region automatic extraction in dynamic [11C]-PIB. J Cereb Blood Flow Metab 2013;33:1725&#x2013;1731.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3824180</ArticleId><ArticleId IdType="pubmed">23921900</ArticleId></ArticleIdList></Reference><Reference><Citation>Ashburner J. A fast diffeomorphic image registration algorithm. Neuroimage 2007;38:95&#x2013;113.</Citation><ArticleIdList><ArticleId IdType="pubmed">17761438</ArticleId></ArticleIdList></Reference><Reference><Citation>Heckemann RA, Keihaninejad S, Aljabar P, Rueckert D, Hajnal JV, Hammers A. Improving intersubject image registration using tissue-class information benefits robustness and accuracy of multi-atlas based anatomical segmentation. Neuroimage 2010;51:221&#x2013;227.</Citation><ArticleIdList><ArticleId IdType="pubmed">20114079</ArticleId></ArticleIdList></Reference><Reference><Citation>Frisoni GB, Jack CR. Harmonization of magnetic resonance-based manual hippocampal segmentation: a mandatory step for wide clinical use. Alzheimers Dement 2011;7:171&#x2013;174.</Citation><ArticleIdList><ArticleId IdType="pubmed">21414554</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith SM, Jenkinson M, Woolrich MW, et al. Advances in functional and structural MR image analysis and implementation as FSL. Neuroimage 2004;23(suppl 1):S208&#x2013;S219.</Citation><ArticleIdList><ArticleId IdType="pubmed">15501092</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith SM, Jenkinson M, Johansen-Berg H, et al. Tract-based spatial statistics: voxelwise analysis of multi-subject diffusion data. Neuroimage 2006;31:1487&#x2013;1505.</Citation><ArticleIdList><ArticleId IdType="pubmed">16624579</ArticleId></ArticleIdList></Reference><Reference><Citation>Hua K, Zhang J, Wakana S, et al. Tract probability maps in stereotaxic spaces: analyses of white matter anatomy and tract-specific quantification. Neuroimage 2008;39:336&#x2013;347.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2724595</ArticleId><ArticleId IdType="pubmed">17931890</ArticleId></ArticleIdList></Reference><Reference><Citation>Blumbergs PC, Jones NR, North JB. Diffuse axonal injury in head trauma. J Neurol Neurosurg Psychiatry 1989;52:838&#x2013;841.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1031929</ArticleId><ArticleId IdType="pubmed">2769276</ArticleId></ArticleIdList></Reference><Reference><Citation>Thal DR, Rub U, Orantes M, Braak H. Phases of A beta-deposition in the human brain and its relevance for the development of AD. Neurology 2002;58:1791&#x2013;1800.</Citation><ArticleIdList><ArticleId IdType="pubmed">12084879</ArticleId></ArticleIdList></Reference><Reference><Citation>Tosun D, Schuff N, Mathis CA, Jagust W, Weiner MW. Spatial patterns of brain amyloid-beta burden and atrophy rate associations in mild cognitive impairment. Brain 2011;134:1077&#x2013;1088.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3069703</ArticleId><ArticleId IdType="pubmed">21429865</ArticleId></ArticleIdList></Reference><Reference><Citation>Stein T, Montenigro P, Alvarez V, et al. Beta-amyloid deposition in chronic traumatic encephalopathy. Acta Neuropathol 2015;130:21&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4529056</ArticleId><ArticleId IdType="pubmed">25943889</ArticleId></ArticleIdList></Reference><Reference><Citation>Cole JH, Leech R, Sharp DJ; Alzheimer's Disease Neuroimaging Initiative. Prediction of brain age suggests accelerated atrophy after traumatic brain injury. Ann Neurol 2015;77:571&#x2013;581.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4403966</ArticleId><ArticleId IdType="pubmed">25623048</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson VE, Stewart JE, Begbie FD, Trojanowski JQ, Smith DH, Stewart W. Inflammation and white matter degeneration persist for years after a single traumatic brain injury. Brain 2013;136:28&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3562078</ArticleId><ArticleId IdType="pubmed">23365092</ArticleId></ArticleIdList></Reference><Reference><Citation>Harris JA, Devidze N, Verret L, et al. Transsynaptic progression of amyloid-beta-induced neuronal dysfunction within the entorhinal-hippocampal network. Neuron 2010;68:428&#x2013;441.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3050043</ArticleId><ArticleId IdType="pubmed">21040845</ArticleId></ArticleIdList></Reference><Reference><Citation>Polymenidou M, Cleveland DW. Prion-like spread of protein aggregates in neurodegeneration. J Exp Med 2012;209:889&#x2013;893.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3348110</ArticleId><ArticleId IdType="pubmed">22566400</ArticleId></ArticleIdList></Reference><Reference><Citation>Raj A, Kuceyeski A, Weiner M. A network diffusion model of disease progression in dementia. Neuron 2012;73:1204&#x2013;1215.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3623298</ArticleId><ArticleId IdType="pubmed">22445347</ArticleId></ArticleIdList></Reference><Reference><Citation>Crossley NA, Mechelli A, Scott J, et al. The hubs of the human connectome are generally implicated in the anatomy of brain disorders. Brain 2014;137:2382&#x2013;2395.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4107735</ArticleId><ArticleId IdType="pubmed">25057133</ArticleId></ArticleIdList></Reference><Reference><Citation>Ponsford J, McLaren A, Schonberger M, et al. The association between apolipoprotein E and traumatic brain injury severity and functional outcome in a rehabilitation sample. J Neurotrauma 2011;28:1683&#x2013;1692.</Citation><ArticleIdList><ArticleId IdType="pubmed">21651315</ArticleId></ArticleIdList></Reference><Reference><Citation>Rowe CC, Villemagne VL. Brain amyloid imaging. J Nucl Med 2011;52:1733&#x2013;1740.</Citation><ArticleIdList><ArticleId IdType="pubmed">21917849</ArticleId></ArticleIdList></Reference><Reference><Citation>Rowe CC, Ellis KA, Rimajova M, et al. Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) Study of Aging. Neurobiol Aging 2010;31:1275&#x2013;1283.</Citation><ArticleIdList><ArticleId IdType="pubmed">20472326</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein A, Andersson J, Ardekani BA, et al. Evaluation of 14 nonlinear deformation algorithms applied to human brain MRI registration. Neuroimage 2009;46:786&#x2013;802.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2747506</ArticleId><ArticleId IdType="pubmed">19195496</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">26842965</PMID><DateCompleted><Year>2016</Year><Month>06</Month><Day>15</Day></DateCompleted><DateRevised><Year>2024</Year><Month>01</Month><Day>04</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2041-1723</ISSN><JournalIssue CitedMedium="Internet"><Volume>7</Volume><PubDate><Year>2016</Year><Month>Feb</Month><Day>04</Day></PubDate></JournalIssue><Title>Nature communications</Title><ISOAbbreviation>Nat Commun</ISOAbbreviation></Journal><ArticleTitle>ALS-associated mutant FUS induces selective motor neuron degeneration through toxic gain of function.</ArticleTitle><Pagination><StartPage>10465</StartPage><MedlinePgn>10465</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">10465</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/ncomms10465</ELocationID><Abstract><AbstractText>Mutations in FUS cause amyotrophic lateral sclerosis (ALS), including some of the most aggressive, juvenile-onset forms of the disease. FUS loss-of-function and toxic gain-of-function mechanisms have been proposed to explain how mutant FUS leads to motor neuron degeneration, but neither has been firmly established in the pathogenesis of ALS. Here we characterize a series of transgenic FUS mouse lines that manifest progressive, mutant-dependent motor neuron degeneration preceded by early, structural and functional abnormalities at the neuromuscular junction. A novel, conditional FUS knockout mutant reveals that postnatal elimination of FUS has no effect on motor neuron survival or function. Moreover, endogenous FUS does not contribute to the onset of the ALS phenotype induced by mutant FUS. These findings demonstrate that FUS-dependent motor degeneration is not due to loss of FUS function, but to the gain of toxic properties conferred by ALS mutations.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sharma</LastName><ForeName>Aarti</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurology, Center for Motor Neuron Biology and Disease, Columbia University, 630 W 168th Street, P&amp;S Building, Room 5-423, New York, New York 10032, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lyashchenko</LastName><ForeName>Alexander K</ForeName><Initials>AK</Initials><AffiliationInfo><Affiliation>Department of Neurology, Center for Motor Neuron Biology and Disease, Columbia University, 630 W 168th Street, P&amp;S Building, Room 5-423, New York, New York 10032, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Lei</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Neurology, Center for Motor Neuron Biology and Disease, Columbia University, 630 W 168th Street, P&amp;S Building, Room 5-423, New York, New York 10032, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nasrabady</LastName><ForeName>Sara Ebrahimi</ForeName><Initials>SE</Initials><AffiliationInfo><Affiliation>Department of Pathology and Cell Biology, Center for Motor Neuron Biology and Disease, Columbia University, New York, New York 10032, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Elmaleh</LastName><ForeName>Margot</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology, Center for Motor Neuron Biology and Disease, Columbia University, 630 W 168th Street, P&amp;S Building, Room 5-423, New York, New York 10032, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mendelsohn</LastName><ForeName>Monica</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Pathology and Cell Biology, Center for Motor Neuron Biology and Disease, Columbia University, New York, New York 10032, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nemes</LastName><ForeName>Adriana</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Howard Hughes Medical Institute, Columbia University, New York, New York 10032, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tapia</LastName><ForeName>Juan Carlos</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Columbia University, New York, New York 10032, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mentis</LastName><ForeName>George Z</ForeName><Initials>GZ</Initials><AffiliationInfo><Affiliation>Department of Pathology and Cell Biology, Center for Motor Neuron Biology and Disease, Columbia University, New York, New York 10032, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shneider</LastName><ForeName>Neil A</ForeName><Initials>NA</Initials><AffiliationInfo><Affiliation>Department of Neurology, Center for Motor Neuron Biology and Disease, Columbia University, 630 W 168th Street, P&amp;S Building, Room 5-423, New York, New York 10032, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>T32 NS064928</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS07377</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 GM007367</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS078375</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 NS064928-06</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><Agency>Howard Hughes Medical Institute</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 DK057521</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS078375</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>02</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nat Commun</MedlineTA><NlmUniqueID>101528555</NlmUniqueID><ISSNLinking>2041-1723</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000599550">FUS protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D034702">RNA-Binding Protein FUS</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002470" MajorTopicYN="N">Cell Survival</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018613" MajorTopicYN="N">Microscopy, Confocal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008854" MajorTopicYN="N">Microscopy, Electron</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009046" MajorTopicYN="N">Motor Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018482" MajorTopicYN="N">Muscle, Skeletal</DescriptorName><QualifierName UI="Q000294" MajorTopicYN="N">innervation</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009410" MajorTopicYN="N">Nerve Degeneration</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009469" MajorTopicYN="N">Neuromuscular Junction</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D034702" MajorTopicYN="N">RNA-Binding Protein FUS</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013116" MajorTopicYN="N">Spinal Cord</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>7</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>12</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>2</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>2</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>6</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2016</Year><Month>2</Month><Day>4</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26842965</ArticleId><ArticleId IdType="pmc">PMC4742863</ArticleId><ArticleId IdType="doi">10.1038/ncomms10465</ArticleId><ArticleId IdType="pii">ncomms10465</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Andersen P. M. &amp; Al-Chalabi A. Clinical genetics of amyotrophic lateral sclerosis: what do we really know? Nat. Rev. Neurol. 7, 603&#x2013;615 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21989245</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M. et al.. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 314, 130&#x2013;133 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">17023659</ArticleId></ArticleIdList></Reference><Reference><Citation>Kabashi E. et al.. TARDBP mutations in individuals with sporadic and familial amyotrophic lateral sclerosis. Nat. Genet. 40, 572&#x2013;574 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18372902</ArticleId></ArticleIdList></Reference><Reference><Citation>Vance C. et al.. Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6. Science 323, 1208&#x2013;1211 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4516382</ArticleId><ArticleId IdType="pubmed">19251628</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwiatkowski T. J. Jr. et al.. Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. Science 323, 1205&#x2013;1208 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19251627</ArticleId></ArticleIdList></Reference><Reference><Citation>Lagier-Tourenne C. &amp; Cleveland D. W. Rethinking ALS: the FUS about TDP-43. Cell 136, 1001&#x2013;1004 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3110083</ArticleId><ArticleId IdType="pubmed">19303844</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim H. J. et al.. Mutations in prion-like domains in hnRNPA2B1 and hnRNPA1 cause multisystem proteinopathy and ALS. Nature 495, 467&#x2013;473 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3756911</ArticleId><ArticleId IdType="pubmed">23455423</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng H., Gao K. &amp; Jankovic J. The role of FUS gene variants in neurodegenerative diseases. Nat. Rev. Neurol. 10, 337&#x2013;348 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24840975</ArticleId></ArticleIdList></Reference><Reference><Citation>Zakaryan R. P. &amp; Gehring H. Identification and characterization of the nuclear localization/retention signal in the EWS proto-oncoprotein. J. Mol. Biol. 363, 27&#x2013;38 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16965792</ArticleId></ArticleIdList></Reference><Reference><Citation>Conte A. et al.. P525L FUS mutation is consistently associated with a severe form of juvenile amyotrophic lateral sclerosis. Neuromuscul. Disord. 22, 73&#x2013;75 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">21907581</ArticleId></ArticleIdList></Reference><Reference><Citation>Rademakers R. et al.. Fus gene mutations in familial and sporadic amyotrophic lateral sclerosis. Muscle Nerve 42, 170&#x2013;176 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2969843</ArticleId><ArticleId IdType="pubmed">20544928</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackenzie I. R., Rademakers R. &amp; Neumann M. TDP-43 and FUS in amyotrophic lateral sclerosis and frontotemporal dementia. Lancet Neurol. 9, 995&#x2013;1007 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20864052</ArticleId></ArticleIdList></Reference><Reference><Citation>Sabatelli M. et al.. Mutations in the 3&#x2032; untranslated region of FUS causing FUS overexpression are associated with amyotrophic lateral sclerosis. Hum. Mol. Genet. 22, 4748&#x2013;4755 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23847048</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitchell J. C. et al.. Overexpression of human wild-type FUS causes progressive motor neuron degeneration in an age- and dose-dependent fashion. Acta Neuropathol. 125, 273&#x2013;288 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3549237</ArticleId><ArticleId IdType="pubmed">22961620</ArticleId></ArticleIdList></Reference><Reference><Citation>Lagier-Tourenne C. et al.. Divergent roles of ALS-linked proteins FUS/TLS and TDP-43 intersect in processing long pre-mRNAs. Nat. Neurosci. 15, 1488&#x2013;1497 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3586380</ArticleId><ArticleId IdType="pubmed">23023293</ArticleId></ArticleIdList></Reference><Reference><Citation>Sama R. R., Ward C. L. &amp; Bosco D. A. Functions of FUS/TLS From DNA Repair to Stress Response: Implications for ALS. ASN Neuro 6, 1&#x2013;18 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4189536</ArticleId><ArticleId IdType="pubmed">25289647</ArticleId></ArticleIdList></Reference><Reference><Citation>Fujii R. et al.. The RNA binding protein TLS is translocated to dendritic spines by mGluR5 activation and regulates spine morphology. Curr. Biol. 15, 587&#x2013;593 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">15797031</ArticleId></ArticleIdList></Reference><Reference><Citation>Husi H., Ward M. A., Choudhary J. S., Blackstock W. P. &amp; Grant S. G. Proteomic analysis of NMDA receptor-adhesion protein signaling complexes. Nat. Neurosci. 3, 661&#x2013;669 (2000).</Citation><ArticleIdList><ArticleId IdType="pubmed">10862698</ArticleId></ArticleIdList></Reference><Reference><Citation>Belly A., Moreau-Gachelin F., Sadoul R. &amp; Goldberg Y. Delocalization of the multifunctional RNA splicing factor TLS/FUS in hippocampal neurones: exclusion from the nucleus and accumulation in dendritic granules and spine heads. Neurosci. Lett. 379, 152&#x2013;157 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">15843054</ArticleId></ArticleIdList></Reference><Reference><Citation>Alami N. H. et al.. Axonal transport of TDP-43 mRNA granules is impaired by ALS-causing mutations. Neuron 81, 536&#x2013;543 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3939050</ArticleId><ArticleId IdType="pubmed">24507191</ArticleId></ArticleIdList></Reference><Reference><Citation>Nomura T. et al.. Intranuclear aggregation of mutant FUS/TLS as a molecular pathomechanism of amyotrophic lateral sclerosis. J. Biol. Chem. 289, 1192&#x2013;1202 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3887186</ArticleId><ArticleId IdType="pubmed">24280224</ArticleId></ArticleIdList></Reference><Reference><Citation>De Paola V., Arber S. &amp; Caroni P. AMPA receptors regulate dynamic equilibrium of presynaptic terminals in mature hippocampal networks. Nat. Neurosci. 6, 491&#x2013;500 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">12692557</ArticleId></ArticleIdList></Reference><Reference><Citation>O'Gorman S., Dagenais N. A., Qian M. &amp; Marchuk Y. Protamine-Cre recombinase transgenes efficiently recombine target sequences in the male germ line of mice, but not in embryonic stem cells. Proc. Natl Acad. Sci. USA 94, 14602&#x2013;14607 (1997).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC25067</ArticleId><ArticleId IdType="pubmed">9405659</ArticleId></ArticleIdList></Reference><Reference><Citation>Hewitt C. et al.. Novel FUS/TLS mutations and pathology in familial and sporadic amyotrophic lateral sclerosis. Arch. Neurol. 67, 455&#x2013;461 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20385912</ArticleId></ArticleIdList></Reference><Reference><Citation>Bernhardt R. &amp; Matus A. Light and electron microscopic studies of the distribution of microtubule-associated protein 2 in rat brain: a difference between dendritic and axonal cytoskeletons. J.Comparat. Neurol. 226, 203&#x2013;221 (1984).</Citation><ArticleIdList><ArticleId IdType="pubmed">6736300</ArticleId></ArticleIdList></Reference><Reference><Citation>Bloom G. S., Schoenfeld T. A. &amp; Vallee R. B. Widespread distribution of the major polypeptide component of MAP 1 (microtubule-associated protein 1) in the nervous system. J. Cell Biol. 98, 320&#x2013;330 (1984).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2112990</ArticleId><ArticleId IdType="pubmed">6368569</ArticleId></ArticleIdList></Reference><Reference><Citation>Migheli A., Butler M., Brown K. &amp; Shelanski M. L. Light and electron microscope localization of the microtubule-associated tau protein in rat brain. J. Neurosci. 8, 1846&#x2013;1851 (1988).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6569338</ArticleId><ArticleId IdType="pubmed">3133453</ArticleId></ArticleIdList></Reference><Reference><Citation>Caceres A. et al.. Differential subcellular localization of tubulin and the microtubule-associated protein MAP2 in brain tissue as revealed by immunocytochemistry with monoclonal hybridoma antibodies. J. Neurosci. 4, 394&#x2013;410 (1984).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6564908</ArticleId><ArticleId IdType="pubmed">6699682</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanning K. C., Kaplan A. &amp; Henderson C. E. Motor neuron diversity in development and disease. Annu. Rev. Neurosci. 33, 409&#x2013;440 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20367447</ArticleId></ArticleIdList></Reference><Reference><Citation>Ince P., Shaw P., Slade J., Jones C. &amp; Hudgson P. Familial amyotrophic lateral sclerosis with a mutation in exon 4 of the Cu/Zn superoxide dismutase gene: pathological and immunocytochemical changes. Acta Neuropathol. 92, 7 (1996).</Citation><ArticleIdList><ArticleId IdType="pubmed">8891072</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawamata T., Akiyama H., Yamada T. &amp; McGeer P. L. Immunologic reactions in amyotrophic lateral sclerosis brain and spinal cord tissue. Am. J. Pathol. 140, 691&#x2013;707 (1992).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1886170</ArticleId><ArticleId IdType="pubmed">1347673</ArticleId></ArticleIdList></Reference><Reference><Citation>Almer G., Vukosavic S., Romero N. &amp; Przedborski S. Inducible nitric oxide synthase up-regulation in a transgenic mouse model of familial amyotrophic lateral sclerosis. J. Neurochem. 72, 2415&#x2013;2425 (1999).</Citation><ArticleIdList><ArticleId IdType="pubmed">10349851</ArticleId></ArticleIdList></Reference><Reference><Citation>Bruijn L. I. et al.. ALS-linked SOD1 mutant G85R mediates damage to astrocytes and promotes rapidly progressive disease with SOD1-containing inclusions. Neuron 18, 327&#x2013;338 (1997).</Citation><ArticleIdList><ArticleId IdType="pubmed">9052802</ArticleId></ArticleIdList></Reference><Reference><Citation>Hall E. D., Oostveen J. A. &amp; Gurney M. E. Relationship of microglial and astrocytic activation to disease onset and progression in a transgenic model of familial ALS. Glia 23, 249&#x2013;256 (1998).</Citation><ArticleIdList><ArticleId IdType="pubmed">9633809</ArticleId></ArticleIdList></Reference><Reference><Citation>Dengler R. et al.. Amyotrophic lateral sclerosis: macro-EMG and twitch forces of single motor units. Muscle Nerve 13, 545&#x2013;550 (1990).</Citation><ArticleIdList><ArticleId IdType="pubmed">2366827</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischer L. R. et al.. Amyotrophic lateral sclerosis is a distal axonopathy: evidence in mice and man. Exp. Neurol. 185, 232&#x2013;240 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">14736504</ArticleId></ArticleIdList></Reference><Reference><Citation>Pun S., Santos A. F., Saxena S., Xu L. &amp; Caroni P. Selective vulnerability and pruning of phasic motoneuron axons in motoneuron disease alleviated by CNTF. Nat. Neurosci. 9, 408&#x2013;419 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16474388</ArticleId></ArticleIdList></Reference><Reference><Citation>Frey D. et al.. Early and selective loss of neuromuscular synapse subtypes with low sprouting competence in motoneuron diseases. J. Neurosci. 20, 2534&#x2013;2542 (2000).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6772256</ArticleId><ArticleId IdType="pubmed">10729333</ArticleId></ArticleIdList></Reference><Reference><Citation>Wichterle H. &amp; Peljto M. Differentiation of mouse embryonic stem cells to spinal motor neurons. Curr. Protoc. Stem Cell Biol. Chapter 1, Unit 1H.1.1&#x2013;1H.1.9 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18770634</ArticleId></ArticleIdList></Reference><Reference><Citation>Magrane J., Cortez C., Gan W. B. &amp; Manfredi G. Abnormal mitochondrial transport and morphology are common pathological denominators in SOD1 and TDP43 ALS mouse models. Hum. Mol. Genet. 23, 1413&#x2013;1424 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3929084</ArticleId><ArticleId IdType="pubmed">24154542</ArticleId></ArticleIdList></Reference><Reference><Citation>Hicks G. G. et al.. Fus deficiency in mice results in defective B-lymphocyte development and activation, high levels of chromosomal instability and perinatal death. Nat. Genet. 24, 175&#x2013;179 (2000).</Citation><ArticleIdList><ArticleId IdType="pubmed">10655065</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruzankina Y. et al.. Deletion of the developmentally essential gene ATR in adult mice leads to age-related phenotypes and stem cell loss. Cell Stem Cell 1, 113&#x2013;126 (2007).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2920603</ArticleId><ArticleId IdType="pubmed">18371340</ArticleId></ArticleIdList></Reference><Reference><Citation>Kato M. et al.. Cell-free formation of RNA granules: low complexity sequence domains form dynamic fibers within hydrogels. Cell 149, 753&#x2013;767 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6347373</ArticleId><ArticleId IdType="pubmed">22579281</ArticleId></ArticleIdList></Reference><Reference><Citation>Han T. W. et al.. Cell-free formation of RNA granules: bound RNAs identify features and components of cellular assemblies. Cell 149, 768&#x2013;779 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22579282</ArticleId></ArticleIdList></Reference><Reference><Citation>Ilieva H., Polymenidou M. &amp; Cleveland D. W. Non-cell autonomous toxicity in neurodegenerative disorders: ALS and beyond. J. Cell Biol. 187, 761&#x2013;772 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2806318</ArticleId><ArticleId IdType="pubmed">19951898</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang S. H. et al.. Degeneration and impaired regeneration of gray matter oligodendrocytes in amyotrophic lateral sclerosis. Nat. Neurosci. 16, 571&#x2013;579 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3637847</ArticleId><ArticleId IdType="pubmed">23542689</ArticleId></ArticleIdList></Reference><Reference><Citation>Frakes A. E. et al.. Microglia induce motor neuron death via the classical NF-kappaB pathway in amyotrophic lateral sclerosis. Neuron 81, 1009&#x2013;1023 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3978641</ArticleId><ArticleId IdType="pubmed">24607225</ArticleId></ArticleIdList></Reference><Reference><Citation>Boillee S. et al.. Onset and progression in inherited ALS determined by motor neurons and microglia. Science 312, 1389&#x2013;1392 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16741123</ArticleId></ArticleIdList></Reference><Reference><Citation>Schaefer A. M., Sanes J. R. &amp; Lichtman J. W. A compensatory subpopulation of motor neurons in a mouse model of amyotrophic lateral sclerosis. J. Comp. Neurol. 490, 209&#x2013;219 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">16082680</ArticleId></ArticleIdList></Reference><Reference><Citation>Bosco D. A., Brady S., Morfini G. &amp; Sama R. R.
Investigating a gain of toxic function of ALS-linked mutant FUS/TLS in the squid axoplasm model of axonal transport. ALS Therapy Alliance. http://alstherapyalliance.org/index.php/research/current-projects.html (2012).</Citation></Reference><Reference><Citation>Groen E. J. et al.. ALS-associated mutations in FUS disrupt the axonal distribution and function of SMN. Hum. Mol. Genet. 22, 3690&#x2013;3704 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23681068</ArticleId></ArticleIdList></Reference><Reference><Citation>Machamer J. B. &amp; Lloyd T. in Drosophila Genetics: 54th Annual Drosophila Research Conference (Washington, DC, 2013).</Citation></Reference><Reference><Citation>Sephton C. F. et al.. Activity-dependent FUS dysregulation disrupts synaptic homeostasis. Proc. Natl Acad. Sci. USA 111, E4769&#x2013;E4778 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4226112</ArticleId><ArticleId IdType="pubmed">25324524</ArticleId></ArticleIdList></Reference><Reference><Citation>Yasuda K. et al.. The RNA-binding protein Fus directs translation of localized mRNAs in APC-RNP granules. J. Cell Biol. 203, 737&#x2013;746 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3857475</ArticleId><ArticleId IdType="pubmed">24297750</ArticleId></ArticleIdList></Reference><Reference><Citation>Jung H., Yoon B. C. &amp; Holt C. E. Axonal mRNA localization and local protein synthesis in nervous system assembly, maintenance and repair. Nat. Rev. Neurosci. 13, 308&#x2013;324 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3682205</ArticleId><ArticleId IdType="pubmed">22498899</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J. W., Brent J. R., Tomlinson A., Shneider N. A. &amp; McCabe B. D. The ALS-associated proteins FUS and TDP-43 function together to affect Drosophila locomotion and life span. J. Clin. Invest. 121, 4118&#x2013;4126 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3195475</ArticleId><ArticleId IdType="pubmed">21881207</ArticleId></ArticleIdList></Reference><Reference><Citation>Kabashi E. et al.. FUS and TARDBP but not SOD1 interact in genetic models of amyotrophic lateral sclerosis. PLoS Genet. 7, e1002214 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3150442</ArticleId><ArticleId IdType="pubmed">21829392</ArticleId></ArticleIdList></Reference><Reference><Citation>Dormann D. et al.. ALS-associated fused in sarcoma (FUS) mutations disrupt Transportin-mediated nuclear import. EMBO J. 29, 2841&#x2013;2857 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2924641</ArticleId><ArticleId IdType="pubmed">20606625</ArticleId></ArticleIdList></Reference><Reference><Citation>Qiu H. et al.. ALS-associated mutation FUS-R521C causes DNA damage and RNA splicing defects. J. Clin. Invest. 124, 981&#x2013;999 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3938263</ArticleId><ArticleId IdType="pubmed">24509083</ArticleId></ArticleIdList></Reference><Reference><Citation>Dini Modigliani S., Morlando M., Errichelli L., Sabatelli M. &amp; Bozzoni I. An ALS-associated mutation in the FUS 3&#x2032;-UTR disrupts a microRNA-FUS regulatory circuitry. Nat. Commun. 5, 4335 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">25004804</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang C. et al.. FUS transgenic rats develop the phenotypes of amyotrophic lateral sclerosis and frontotemporal lobar degeneration. PLoS Genet. 7, e1002011 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3048370</ArticleId><ArticleId IdType="pubmed">21408206</ArticleId></ArticleIdList></Reference><Reference><Citation>Qin H., Lim L. Z., Wei Y. &amp; Song J. TDP-43 N terminus encodes a novel ubiquitin-like fold and its unfolded form in equilibrium that can be shifted by binding to ssDNA. Proc. Natl Acad. Sci. USA 111, 18619&#x2013;18624 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4284588</ArticleId><ArticleId IdType="pubmed">25503365</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwon I. et al.. Poly-dipeptides encoded by the C9orf72 repeats bind nucleoli, impede RNA biogenesis, and kill cells. Science 345, 1139&#x2013;1145 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4459787</ArticleId><ArticleId IdType="pubmed">25081482</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwon I. et al.. Phosphorylation-regulated binding of RNA polymerase II to fibrous polymers of low-complexity domains. Cell 155, 1049&#x2013;1060 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4010232</ArticleId><ArticleId IdType="pubmed">24267890</ArticleId></ArticleIdList></Reference><Reference><Citation>Hippenmeyer S. et al.. A developmental switch in the response of DRG neurons to ETS transcription factor signaling. PLoS Biol. 3, e159 (2005).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1084331</ArticleId><ArticleId IdType="pubmed">15836427</ArticleId></ArticleIdList></Reference><Reference><Citation>Tapia J. C. et al.. High-contrast en bloc staining of neuronal tissue for field emission scanning electron microscopy. Nat. Protoc. 7, 193&#x2013;206 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3701260</ArticleId><ArticleId IdType="pubmed">22240582</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">26863354</PMID><DateCompleted><Year>2016</Year><Month>02</Month><Day>24</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1533-4406</ISSN><JournalIssue CitedMedium="Internet"><Volume>374</Volume><Issue>6</Issue><PubDate><Year>2016</Year><Month>Feb</Month><Day>11</Day></PubDate></JournalIssue><Title>The New England journal of medicine</Title><ISOAbbreviation>N Engl J Med</ISOAbbreviation></Journal><ArticleTitle>Incidence of Dementia over Three Decades in the Framingham Heart Study.</ArticleTitle><Pagination><StartPage>523</StartPage><EndPage>532</EndPage><MedlinePgn>523-32</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1056/NEJMoa1504327</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The prevalence of dementia is expected to soar as the average life expectancy increases, but recent estimates suggest that the age-specific incidence of dementia is declining in high-income countries. Temporal trends are best derived through continuous monitoring of a population over a long period with the use of consistent diagnostic criteria. We describe temporal trends in the incidence of dementia over three decades among participants in the Framingham Heart Study.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Participants in the Framingham Heart Study have been under surveillance for incident dementia since 1975. In this analysis, which included 5205 persons 60 years of age or older, we used Cox proportional-hazards models adjusted for age and sex to determine the 5-year incidence of dementia during each of four epochs. We also explored the interactions between epoch and age, sex, apolipoprotein E &#x3b5;4 status, and educational level, and we examined the effects of these interactions, as well as the effects of vascular risk factors and cardiovascular disease, on temporal trends.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The 5-year age- and sex-adjusted cumulative hazard rates for dementia were 3.6 per 100 persons during the first epoch (late 1970s and early 1980s), 2.8 per 100 persons during the second epoch (late 1980s and early 1990s), 2.2 per 100 persons during the third epoch (late 1990s and early 2000s), and 2.0 per 100 persons during the fourth epoch (late 2000s and early 2010s). Relative to the incidence during the first epoch, the incidence declined by 22%, 38%, and 44% during the second, third, and fourth epochs, respectively. This risk reduction was observed only among persons who had at least a high school diploma (hazard ratio, 0.77; 95% confidence interval, 0.67 to 0.88). The prevalence of most vascular risk factors (except obesity and diabetes) and the risk of dementia associated with stroke, atrial fibrillation, or heart failure have decreased over time, but none of these trends completely explain the decrease in the incidence of dementia.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Among participants in the Framingham Heart Study, the incidence of dementia has declined over the course of three decades. The factors contributing to this decline have not been completely identified. (Funded by the National Institutes of Health.).</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Satizabal</LastName><ForeName>Claudia L</ForeName><Initials>CL</Initials><AffiliationInfo><Affiliation>From the Boston University Schools of Medicine (C.L.S., A.S.B., V.C., S.S.) and Public Health (A.S.B.), Boston, and the Framingham Heart Study, Framingham (C.L.S., A.S.B., V.C., S.S.) - all in Massachusetts; and Inserm Unit&#xe9; 1219 and CIC 1401-EC (Clinical Epidemiology) and University of Bordeaux, ISPED (Bordeaux School of Public Health) - both in Bordeaux, France (G.C., C.D.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beiser</LastName><ForeName>Alexa S</ForeName><Initials>AS</Initials></Author><Author ValidYN="Y"><LastName>Chouraki</LastName><ForeName>Vincent</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Ch&#xea;ne</LastName><ForeName>Genevi&#xe8;ve</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Dufouil</LastName><ForeName>Carole</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Seshadri</LastName><ForeName>Sudha</ForeName><Initials>S</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>N01-HC-25195</GrantID><Acronym>HC</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS017950</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG054076</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HHSN268201500001C</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG033193</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG049607</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG08122</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG008122</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HHSN268201500001I</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG033040</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG049505</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>N01 HC025195</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG033193</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS017950</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG010129</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>N Engl J Med</MedlineTA><NlmUniqueID>0255562</NlmUniqueID><ISSNLinking>0028-4793</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Dtsch Med Wochenschr. 2016 Apr;141(8):528</RefSource></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>BMJ. 2016 Feb 15;352:i912. doi: 10.1136/bmj.i912.</RefSource><PMID Version="1">26879962</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>MMW Fortschr Med. 2016 Apr 14;158(7):35.</RefSource><PMID Version="1">27183660</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>N Engl J Med. 2016 Jul 7;375(1):93-4. doi: 10.1056/NEJMc1604823.</RefSource><PMID Version="1">27406362</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>N Engl J Med. 2016 Jul 7;375(1):92-3. doi: 10.1056/NEJMc1604823.</RefSource><PMID Version="1">27406363</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>N Engl J Med. 2016 Jul 7;375(1):93. doi: 10.1056/NEJMc1604823.</RefSource><PMID Version="1">27406364</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001281" MajorTopicYN="N">Atrial Fibrillation</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015140" MajorTopicYN="N">Dementia, Vascular</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004522" MajorTopicYN="N">Educational Status</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006333" MajorTopicYN="N">Heart Failure</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008404" MajorTopicYN="N" Type="Geographic">Massachusetts</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016016" MajorTopicYN="N">Proportional Hazards Models</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020521" MajorTopicYN="N">Stroke</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>2</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>2</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>2</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2016</Year><Month>8</Month><Day>11</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26863354</ArticleId><ArticleId IdType="mid">NIHMS762894</ArticleId><ArticleId IdType="pmc">PMC4943081</ArticleId><ArticleId IdType="doi">10.1056/NEJMoa1504327</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Sousa RM, Ferri CP, Acosta D, et al. Contribution of chronic diseases to disability in elderly people in countries with low and middle incomes: a 10/66 Dementia Research Group population-based survey. Lancet. 2009;374:1821&#x2013;1830.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2854331</ArticleId><ArticleId IdType="pubmed">19944863</ArticleId></ArticleIdList></Reference><Reference><Citation>Sousa RM, Ferri CP, Acosta D, et al. The contribution of chronic diseases to the prevalence of dependence among older people in Latin America, China and India: a 10/66 Dementia Research Group population-based survey. BMC Geriatr. 2010;10:53.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2923155</ArticleId><ArticleId IdType="pubmed">20691064</ArticleId></ArticleIdList></Reference><Reference><Citation>Harwood RH, Sayer AA, Hirschfeld M. Current and future worldwide prevalence of dependency, its relationship to total population, and dependency ratios. Bull World Health Organ. 2004;82:251&#x2013;258.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2585969</ArticleId><ArticleId IdType="pubmed">15259253</ArticleId></ArticleIdList></Reference><Reference><Citation>Prince M, Bryce R, Albanese E, Wimo A, Ribeiro W, Ferri CP. The global prevalence of dementia: a systematic review and metaanalysis. Alzheimers Dement. 2013;9:63&#x2013;75.e2.</Citation><ArticleIdList><ArticleId IdType="pubmed">23305823</ArticleId></ArticleIdList></Reference><Reference><Citation>Hurd MD, Martorell P, Delavande A, Mullen KJ, Langa KM. Monetary costs of dementia in the United States. N Engl J Med. 2013;368:1326&#x2013;1334.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3959992</ArticleId><ArticleId IdType="pubmed">23550670</ArticleId></ArticleIdList></Reference><Reference><Citation>Schrijvers EM, Verhaaren BF, Koudstaal PJ, Hofman A, Ikram MA, Breteler MM. Is dementia incidence declining? Trends in dementia incidence since 1990 in the Rotterdam Study. Neurology. 2012;78:1456&#x2013;1463.</Citation><ArticleIdList><ArticleId IdType="pubmed">22551732</ArticleId></ArticleIdList></Reference><Reference><Citation>Rocca WA, Petersen RC, Knopman DS, et al. Trends in the incidence and prevalence of Alzheimer&#x2019;s disease, dementia, and cognitive impairment in the United States. Alzheimers Dement. 2011;7:80&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3026476</ArticleId><ArticleId IdType="pubmed">21255746</ArticleId></ArticleIdList></Reference><Reference><Citation>Matthews FE, Arthur A, Barnes LE, et al. A two-decade comparison of prevalence of dementia in individuals aged 65 years and older from three geographical areas of England: results of the Cognitive Function and Ageing Study I and II. Lancet. 2013;382:1405&#x2013;1412.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3906607</ArticleId><ArticleId IdType="pubmed">23871492</ArticleId></ArticleIdList></Reference><Reference><Citation>Qiu C, von Strauss E, B&#xe4;ckman L, Winblad B, Fratiglioni L. Twenty-year changes in dementia occurrence suggest decreasing incidence in central Stockholm, Sweden. Neurology. 2013;80:1888&#x2013;1894.</Citation><ArticleIdList><ArticleId IdType="pubmed">23596063</ArticleId></ArticleIdList></Reference><Reference><Citation>Manton KC, Gu XL, Ukraintseva SV. Declining prevalence of dementia in the U.S. elderly population. Adv Gerontol. 2005;16:30&#x2013;37.</Citation><ArticleIdList><ArticleId IdType="pubmed">16075674</ArticleId></ArticleIdList></Reference><Reference><Citation>Hebert LE, Bienias JL, Aggarwal NT, et al. Change in risk of Alzheimer disease over time. Neurology. 2010;75:786&#x2013;791.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2938969</ArticleId><ArticleId IdType="pubmed">20805524</ArticleId></ArticleIdList></Reference><Reference><Citation>Dawber TR, Meadors GF, Moore FE., Jr Epidemiological approaches to heart disease: the Framingham Study. Am J Public Health Nations Health. 1951;41:279&#x2013;281.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1525365</ArticleId><ArticleId IdType="pubmed">14819398</ArticleId></ArticleIdList></Reference><Reference><Citation>Kannel WB, Feinleib M, McNamara PM, Garrison RJ, Castelli WP. An investigation of coronary heart disease in families: the Framingham offspring study. Am J Epidemiol. 1979;110:281&#x2013;290.</Citation><ArticleIdList><ArticleId IdType="pubmed">474565</ArticleId></ArticleIdList></Reference><Reference><Citation>Seshadri S, Wolf PA, Beiser A, et al. Lifetime risk of dementia and Alzheimer&#x2019;s disease. The impact of mortality on risk estimates in the Framingham Study. Neurology. 1997;49:1498&#x2013;1504.</Citation><ArticleIdList><ArticleId IdType="pubmed">9409336</ArticleId></ArticleIdList></Reference><Reference><Citation>Seshadri S, Beiser A, Au R, et al. Operationalizing diagnostic criteria for Alzheimer&#x2019;s disease and other age-related cognitive impairment-Part 2. Alzheimers Dement. 2011;7:35&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3039838</ArticleId><ArticleId IdType="pubmed">21255742</ArticleId></ArticleIdList></Reference><Reference><Citation>Farmer ME, White LR, Kittner SJ, et al. Neuropsychological test performance in Framingham: a descriptive study. Psychol Rep. 1987;60:1023&#x2013;1040.</Citation><ArticleIdList><ArticleId IdType="pubmed">3628637</ArticleId></ArticleIdList></Reference><Reference><Citation>Folstein MF, Folstein SE, McHugh PR. &#x201c;Mini-mental state&#x201d;: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189&#x2013;198.</Citation><ArticleIdList><ArticleId IdType="pubmed">1202204</ArticleId></ArticleIdList></Reference><Reference><Citation>Au R, Seshadri S, Wolf PA, et al. New norms for a new generation: cognitive performance in the Framingham offspring cohort. Exp Aging Res. 2004;30:333&#x2013;358.</Citation><ArticleIdList><ArticleId IdType="pubmed">15371099</ArticleId></ArticleIdList></Reference><Reference><Citation>Winblad B, Palmer K, Kivipelto M, et al. Mild cognitive impairment &#x2014; beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. J Intern Med. 2004;256:240&#x2013;246.</Citation><ArticleIdList><ArticleId IdType="pubmed">15324367</ArticleId></ArticleIdList></Reference><Reference><Citation>Au R, Seshadri S, Knox K, et al. The Framingham Brain Donation Program: neuropathology along the cognitive continuum. Curr Alzheimer Res. 2012;9:673&#x2013;686.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3622706</ArticleId><ArticleId IdType="pubmed">22471865</ArticleId></ArticleIdList></Reference><Reference><Citation>Diagnostic and statistical manual of mental disorders: DSM-IV. 4th. Washington, DC: American Psychiatric Association; 1994.</Citation></Reference><Reference><Citation>McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer&#x2019;s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer&#x2019;s Disease. Neurology. 1984;34:939&#x2013;944.</Citation><ArticleIdList><ArticleId IdType="pubmed">6610841</ArticleId></ArticleIdList></Reference><Reference><Citation>Bachman DL, Wolf PA, Linn R, et al. Prevalence of dementia and probable senile dementia of the Alzheimer type in the Framingham Study. Neurology. 1992;42:115&#x2013;119.</Citation><ArticleIdList><ArticleId IdType="pubmed">1734291</ArticleId></ArticleIdList></Reference><Reference><Citation>Rom&#xe1;n GC, Tatemichi TK, Erkinjuntti T, et al. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology. 1993;43:250&#x2013;260.</Citation><ArticleIdList><ArticleId IdType="pubmed">8094895</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee EW, Wei LJ, Amato DA, Leurgans S. Cox-type regression analysis for large numbers of small groups of correlated failure time observations. In: Klein JP, Goel PK, editors. Survival analysis: state of the art. Dordrecht, The Netherlands: Kluwer Academic; 1992. pp. 237&#x2013;247.</Citation></Reference><Reference><Citation>Wolf PA, D&#x2019;Agostino RB, Belanger AJ, Kannel WB. Probability of stroke: a risk profile from the Framingham Study. Stroke. 1991;22:312&#x2013;318.</Citation><ArticleIdList><ArticleId IdType="pubmed">2003301</ArticleId></ArticleIdList></Reference><Reference><Citation>Seidell JC. Obesity, insulin resistance and diabetes &#x2014; a worldwide epidemic. Br J Nutr. 2000;83(Suppl 1):S5&#x2013;S8.</Citation><ArticleIdList><ArticleId IdType="pubmed">10889785</ArticleId></ArticleIdList></Reference><Reference><Citation>K&#xf6;vari E, Herrmann FR, Bouras C, Gold G. Amyloid deposition is decreasing in aging brains: an autopsy study of 1,599 older people. Neurology. 2014;82:326&#x2013;331.</Citation><ArticleIdList><ArticleId IdType="pubmed">24363129</ArticleId></ArticleIdList></Reference><Reference><Citation>Evans DA, Bennett DA, Wilson RS, et al. Incidence of Alzheimer disease in a biracial urban community: relation to apolipoprotein E allele status. Arch Neurol. 2003;60:185&#x2013;189.</Citation><ArticleIdList><ArticleId IdType="pubmed">12580702</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawas C, Gray S, Brookmeyer R, Fozard J, Zonderman A. Age-specific incidence rates of Alzheimer&#x2019;s disease: the Baltimore Longitudinal Study of Aging. Neurology. 2000;54:2072&#x2013;2077.</Citation><ArticleIdList><ArticleId IdType="pubmed">10851365</ArticleId></ArticleIdList></Reference><Reference><Citation>Seshadri S, Wolf PA. Lifetime risk of stroke and dementia: current concepts, and estimates from the Framingham Study. Lancet Neurol. 2007;6:1106&#x2013;1114.</Citation><ArticleIdList><ArticleId IdType="pubmed">18031707</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu YT, Fratiglioni L, Matthews FE, et al. Dementia in western Europe: epidemiological evidence and implications for policy making. Lancet Neurol. 2015;15:116&#x2013;124.</Citation><ArticleIdList><ArticleId IdType="pubmed">26300044</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathillas J, L&#xf6;vheim H, Gustafson Y. Increasing prevalence of dementia among very old people. Age Ageing. 2011;40:243&#x2013;249.</Citation><ArticleIdList><ArticleId IdType="pubmed">21258087</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan KY, Wang W, Wu JJ, et al. Epidemiology of Alzheimer&#x2019;s disease and other forms of dementia in China, 1990&#x2013;2010: a systematic review and analysis. Lancet. 2013;381:2016&#x2013;2023.</Citation><ArticleIdList><ArticleId IdType="pubmed">23746902</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu YT, Brayne C, Matthews FE. Prevalence of dementia in East Asia: a synthetic review of time trends. Int J Geriatr Psychiatry. 2015;30:793&#x2013;801.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4510821</ArticleId><ArticleId IdType="pubmed">25963138</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferri CP, Prince M, Brayne C, et al. Global prevalence of dementia: a Delphi consensus study. Lancet. 2005;366:2112&#x2013;2117.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2850264</ArticleId><ArticleId IdType="pubmed">16360788</ArticleId></ArticleIdList></Reference><Reference><Citation>Barnes DE, Yaffe K. The projected effect of risk factor reduction on Alzheimer&#x2019;s disease prevalence. Lancet Neurol. 2011;10:819&#x2013;828.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3647614</ArticleId><ArticleId IdType="pubmed">21775213</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">26874595</PMID><DateCompleted><Year>2016</Year><Month>12</Month><Day>15</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>07</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1552-5279</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><Issue>3</Issue><PubDate><Year>2016</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Alzheimer's &amp; dementia : the journal of the Alzheimer's Association</Title><ISOAbbreviation>Alzheimers Dement</ISOAbbreviation></Journal><ArticleTitle>Inequalities in dementia incidence between six racial and ethnic groups over 14&#xa0;years.</ArticleTitle><Pagination><StartPage>216</StartPage><EndPage>224</EndPage><MedlinePgn>216-24</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jalz.2015.12.007</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1552-5260(15)03031-9</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Reducing racial/ethnic disparities is a primary objective of the National Alzheimer's Plan (NAPA), yet direct comparisons within large samples representing diversity of the United States are lacking.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Dementia incidence from January 1, 2000 to December 31, 2013 and a 25-year cumulative risk in 274,283 health care members aged 64+ (n&#xa0;=&#xa0;18,778 African-American, n&#xa0;=&#xa0;4543 American Indian/Alaska Native [AIAN], n&#xa0;=&#xa0;21,000 Latino, n&#xa0;=&#xa0;440 Pacific Islander, n&#xa0;=&#xa0;206,490 white, n&#xa0;=&#xa0;23,032 Asian-Americans). Cox proportional hazard models were adjusted for age, sex, medical utilization, and comorbidities.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Dementia incidence (n&#xa0;=&#xa0;59,555) was highest for African-Americans (26.6/1000 person-years) and AIANs (22.2/1000 person-years); intermediate for Latinos (19.6/1000 person-years), Pacific Islanders (19.6/1000 person-years), and whites (19.3/1000 person-years) and lowest among Asian-Americans (15.2/1000 person-years). Risk was 65% greater for African-Americans (hazard ratio&#xa0;=&#xa0;1.65; 95% confidence interval&#xa0;=&#xa0;1.58-1.72) versus Asian-Americans. Cumulative 25-year risk at age 65 was as follows: 38% African-Americans, 35% AIANs, 32% Latino, 25% Pacific Islanders, 30% white, and 28% Asian-Americans.</AbstractText><AbstractText Label="DISCUSSION" NlmCategory="CONCLUSIONS">Dementia rates varied over 60% between groups, providing a comprehensive benchmark for the NAPA goal of reducing disparities.</AbstractText><CopyrightInformation>Copyright &#xa9; 2016 The Alzheimer's Association. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mayeda</LastName><ForeName>Elizabeth Rose</ForeName><Initials>ER</Initials><AffiliationInfo><Affiliation>Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Glymour</LastName><ForeName>M Maria</ForeName><Initials>MM</Initials><AffiliationInfo><Affiliation>Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Quesenberry</LastName><ForeName>Charles P</ForeName><Initials>CP</Initials><AffiliationInfo><Affiliation>Kaiser Permanente Division of Research, Oakland, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Whitmer</LastName><ForeName>Rachel A</ForeName><Initials>RA</Initials><AffiliationInfo><Affiliation>Kaiser Permanente Division of Research, Oakland, CA, USA; Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA, USA. Electronic address: Rachel.Whitmer@kp.org.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 AG015272</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30-AG15272</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>02</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Alzheimers Dement</MedlineTA><NlmUniqueID>101231978</NlmUniqueID><ISSNLinking>1552-5260</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001741" MajorTopicYN="N">Black or African American</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003695" MajorTopicYN="N">Delivery of Health Care</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000208" MajorTopicYN="Y">ethnology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005006" MajorTopicYN="N">Ethnicity</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006630" MajorTopicYN="N">Hispanic or Latino</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007198" MajorTopicYN="N">Indians, North American</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016016" MajorTopicYN="N">Proportional Hazards Models</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012737" MajorTopicYN="N">Sex Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012959" MajorTopicYN="N">Socioeconomic Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D044465" MajorTopicYN="N">White People</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Cohort</Keyword><Keyword MajorTopicYN="N">Dementia</Keyword><Keyword MajorTopicYN="N">Disparities</Keyword><Keyword MajorTopicYN="N">Epidemiology</Keyword><Keyword MajorTopicYN="N">Ethnicity</Keyword><Keyword MajorTopicYN="N">Race</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>8</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2015</Year><Month>11</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>12</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2017</Year><Month>3</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>2</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>2</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>12</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26874595</ArticleId><ArticleId IdType="mid">NIHMS761058</ArticleId><ArticleId IdType="pmc">PMC4969071</ArticleId><ArticleId IdType="doi">10.1016/j.jalz.2015.12.007</ArticleId><ArticleId IdType="pii">S1552-5260(15)03031-9</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>US Department of Health and Human Services. National plan to address Alzheimer&#x2019;s disease: 2014 update. Washington, DC: 2014.</Citation></Reference><Reference><Citation>Montine TJ, Koroshetz WJ, Babcock D, Dickson DW, Galpern WR, Glymour MM, et al. Recommendations of the Alzheimer&#x2019;s Disease&#x2013;Related Dementias Conference. Neurology. 2014;83:851&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4155046</ArticleId><ArticleId IdType="pubmed">25080517</ArticleId></ArticleIdList></Reference><Reference><Citation>Lines LM, Wiener JM. RACIAL AND ETHNIC DISPARITIES IN ALZHEIMER&#x2019;S DISEASE: A Literature Review. 2014</Citation></Reference><Reference><Citation>Alzheimer&#x2019;s Association. 2015 Alzheimer&#x2019;s disease facts and figures. Alzheimer&#x2019;s &amp; Dementia. 2015;11:332&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">25984581</ArticleId></ArticleIdList></Reference><Reference><Citation>Yaffe K, Falvey C, Harris TB, Newman A, Satterfield S, Koster A, et al. Effect of socioeconomic disparities on incidence of dementia among biracial older adults: prospective study. Bmj. 2013;347:f7051.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3898154</ArticleId><ArticleId IdType="pubmed">24355614</ArticleId></ArticleIdList></Reference><Reference><Citation>Byrd DA, Sanchez D, Manly JJ. Neuropsychological test performance among Caribbean-born and Us-born African American elderly: The role of age, education and reading level. Journal of Clinical and Experimental Neuropsychology. 2005;27:1056&#x2013;69.</Citation><ArticleIdList><ArticleId IdType="pubmed">16207624</ArticleId></ArticleIdList></Reference><Reference><Citation>Meng X, D&#x2019;Arcy C. Education and dementia in the context of the cognitive reserve hypothesis: a systematic review with meta-analyses and qualitative analyses. PLoS One. 2012;7:e38268.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3366926</ArticleId><ArticleId IdType="pubmed">22675535</ArticleId></ArticleIdList></Reference><Reference><Citation>Glymour MM, Manly JJ. Lifecourse social conditions and racial and ethnic patterns of cognitive aging. Neuropsychology review. 2008;18:223&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pubmed">18815889</ArticleId></ArticleIdList></Reference><Reference><Citation>Erkinjuntti T, Ostbye T, Steenhuis R, Hachinski V. The effect of different diagnostic criteria on the prevalence of dementia. The New England journal of medicine. 1997;337:1667&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pubmed">9385127</ArticleId></ArticleIdList></Reference><Reference><Citation>Weuve J, Proust-Lima C, Power MC, Gross AL, Hofer SM, Thi&#xe9;baut R, et al. Guidelines for reporting methodological challenges and evaluating potential bias in dementia research. Alzheimer&#x2019;s &amp; Dementia. 2015;11:1098&#x2013;109.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4655106</ArticleId><ArticleId IdType="pubmed">26397878</ArticleId></ArticleIdList></Reference><Reference><Citation>Glymour MM, Kosheleva A, Wadley VG, Weiss C, Manly JJ. Geographic distribution of dementia mortality: elevated mortality rates for black and white Americans by place of birth. Alzheimer disease and associated disorders. 2011;25:196&#x2013;202.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3383774</ArticleId><ArticleId IdType="pubmed">21297428</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang M-X, Cross P, Andrews H, Jacobs D, Small S, Bell K, et al. Incidence of AD in African-Americans, Caribbean hispanics, and caucasians in northern Manhattan. Neurology. 2001;56:49&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pubmed">11148235</ArticleId></ArticleIdList></Reference><Reference><Citation>Shadlen MF, Siscovick D, Fitzpatrick AL, Dulberg C, Kuller LH, Jackson S. Education, Cognitive Test Scores, and Black-White Differences in Dementia Risk. Journal of the American Geriatrics Society. 2006;54:898&#x2013;905.</Citation><ArticleIdList><ArticleId IdType="pubmed">16776783</ArticleId></ArticleIdList></Reference><Reference><Citation>Evans DA, Bennett DA, Wilson RS, Bienias JL, Morris MC, Scherr PA, et al. Incidence of Alzheimer disease in a biracial urban community: relation to apolipoprotein E allele status. Archives of Neurology. 2003;60:185&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">12580702</ArticleId></ArticleIdList></Reference><Reference><Citation>Plassman BL, Langa KM, Fisher GG, Heeringa SG, Weir DR, Ofstedal MB, et al. Prevalence of dementia in the United States: the aging, demographics, and memory study. Neuroepidemiology. 2007;29:125.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2705925</ArticleId><ArticleId IdType="pubmed">17975326</ArticleId></ArticleIdList></Reference><Reference><Citation>Haan MN, Mungas DM, Gonzalez HM, Ortiz TA, Acharya A, Jagust WJ. Prevalence of dementia in older latinos: the influence of type 2 diabetes mellitus, stroke and genetic factors. Journal of the American Geriatrics Society. 2003;51:169&#x2013;77.</Citation><ArticleIdList><ArticleId IdType="pubmed">12558712</ArticleId></ArticleIdList></Reference><Reference><Citation>White L, Petrovitch H, Ross GW, Masaki KH, Abbott RD, Teng EL, et al. Prevalence of dementia in older Japanese-American men in Hawaii: the Honolulu-Asia aging study. JAMA : the journal of the American Medical Association. 1996;276:955&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pubmed">8805729</ArticleId></ArticleIdList></Reference><Reference><Citation>Borenstein AR, Wu Y, Bowen JD, McCormick WC, Uomoto J, McCurry SM, et al. Incidence rates of dementia, Alzheimer disease, and vascular dementia in the Japanese American population in Seattle, WA: the Kame Project. Alzheimer disease and associated disorders. 2014;28:23&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4036673</ArticleId><ArticleId IdType="pubmed">24045327</ArticleId></ArticleIdList></Reference><Reference><Citation>Hummer RA, Benjamins MR, Rogers RG. Racial and Ethnic Disparities in Health and Mortality Among the U.S. Elderly Population. In: Anderson N, Bulatao R, Cohen B, editors. Critical perspectives on racial and ethnic differences in health in late life. Washington D.C: National Academies Press; 2004. p. 53.</Citation><ArticleIdList><ArticleId IdType="pubmed">20669464</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon NP, Kaplan GA. Some evidence refuting the HMO &#x201c;favorable selection&#x201d; hypothesis: the case of Kaiser Permanente. Advances in health economics and health services research. 1991;12:19&#x2013;39.</Citation><ArticleIdList><ArticleId IdType="pubmed">10122802</ArticleId></ArticleIdList></Reference><Reference><Citation>Krieger N. Overcoming the absence of socioeconomic data in medical records: validation and application of a census-based methodology. American journal of public health. 1992;82:703&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1694121</ArticleId><ArticleId IdType="pubmed">1566949</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon NP. Similarity of the Kaiser Permanente Senior Member Population in Northern California to the Non-Kaiser Permanente Covered and General Population of Seniors in Northern California: Statistics from the 2009 California Health Interview Survey. Kaiser Permanente Northern California Division of Research. 2012</Citation></Reference><Reference><Citation>UCLA Center for Health Policy Research. 2001 California Health Interview Survey. Los Angeles, CA:</Citation></Reference><Reference><Citation>Whitmer RA, Karter AJ, Yaffe K, Quesenberry CP, Jr, Selby JV. Hypoglycemic episodes and risk of dementia in older patients with type 2 diabetes mellitus. JAMA : the journal of the American Medical Association. 2009;301:1565&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2782622</ArticleId><ArticleId IdType="pubmed">19366776</ArticleId></ArticleIdList></Reference><Reference><Citation>Mayeda ER, Karter AJ, Huang ES, Moffet HH, Haan MN, Whitmer RA. Racial/ethnic differences in dementia risk among older type 2 diabetic patients: the diabetes and aging study. Diabetes care. 2014;37:1009&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3964496</ArticleId><ArticleId IdType="pubmed">24271192</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitmer R, Sidney S, Selby J, Johnston SC, Yaffe K. Midlife cardiovascular risk factors and risk of dementia in late life. Neurology. 2005;64:277&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pubmed">15668425</ArticleId></ArticleIdList></Reference><Reference><Citation>Exalto LG, Biessels GJ, Karter AJ, Huang ES, Katon WJ, Minkoff JR, et al. Risk score for prediction of 10 year dementia risk in individuals with type 2 diabetes: a cohort study. The Lancet Diabetes &amp; Endocrinology. 2013;1:183&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4429783</ArticleId><ArticleId IdType="pubmed">24622366</ArticleId></ArticleIdList></Reference><Reference><Citation>Katon WJ, Lin EH, Williams LH, Ciechanowski P, Heckbert SR, Ludman E, et al. Comorbid depression is associated with an increased risk of dementia diagnosis in patients with diabetes: a prospective cohort study. Journal of general internal medicine. 2010;25:423&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2855007</ArticleId><ArticleId IdType="pubmed">20108126</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor DH, Fillenbaum GG, Ezell ME. The accuracy of medicare claims data in identifying Alzheimer&#x2019;s disease. Journal of clinical epidemiology. 2002;55:929&#x2013;37.</Citation><ArticleIdList><ArticleId IdType="pubmed">12393082</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang ES, Laiteerapong N, Liu JY, John PM, Moffet HH, Karter AJ. Rates of complications and mortality in older patients with diabetes mellitus: the diabetes and aging study. JAMA internal medicine. 2014;174:251&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3950338</ArticleId><ArticleId IdType="pubmed">24322595</ArticleId></ArticleIdList></Reference><Reference><Citation>Julious SA. Using confidence intervals around individual means to assess statistical significance between two means. Pharmaceutical Statistics. 2004;3:217&#x2013;22.</Citation></Reference><Reference><Citation>Beiser A, D&#x2019;Agostino RB, Seshadri S, Sullivan LM, Wolf PA. Computing estimates of incidence, including lifetime risk: Alzheimer&#x2019;s disease in the Framingham Study. The Practical Incidence Estimators (PIE) macro. Statistics in medicine. 2000;19:1495&#x2013;522.</Citation><ArticleIdList><ArticleId IdType="pubmed">10844714</ArticleId></ArticleIdList></Reference><Reference><Citation>Haan MN, Miller JW, Aiello AE, Whitmer RA, Jagust WJ, Mungas DM, Homocysteine B, et al. vitamins, and the incidence of dementia and cognitive impairment: results from the Sacramento Area Latino Study on Aging. The American journal of clinical nutrition. 2007;85:511&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1892349</ArticleId><ArticleId IdType="pubmed">17284751</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonzalez HM, Tarraf W, Gouskova N, Gallo LC, Penedo FJ, Davis SM, et al. Neurocognitive function among middle-aged and older Hispanic/Latinos: results from the Hispanic Community Health Study/Study of Latinos. Archives of clinical neuropsychology : the official journal of the National Academy of Neuropsychologists. 2015;30:68&#x2013;77.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4351363</ArticleId><ArticleId IdType="pubmed">25451561</ArticleId></ArticleIdList></Reference><Reference><Citation>Elias MF, Beiser A, Wolf PA, Au R, White RF, D&#x2019;Agostino RB. The preclinical phase of Alzheimer disease: a 22-year prospective study of the Framingham Cohort. Archives of Neurology. 2000;57:808&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pubmed">10867777</ArticleId></ArticleIdList></Reference><Reference><Citation>Ennis SR, Rios-Vargas M, Albert NG. 2010 Census Briefs. US Department of Commerce, Economics, and Statistics Administration, US Census Bureau; Washington D.C.: 2011. This Hispanic population: 2010.</Citation></Reference><Reference><Citation>Sentell TL, Valcour N, Ahn HJ, Miyamura J, Nakamoto B, Chow D, et al. High Rates of Native Hawaiian and Older Japanese Adults Hospitalized with Dementia in Hawai &#x2018;i. Journal of the American Geriatrics Society. 2014</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4300272</ArticleId><ArticleId IdType="pubmed">25537987</ArticleId></ArticleIdList></Reference><Reference><Citation>Hendrie HC, Hall KS, Pillay N, Rodgers D, Prince C, Norton J, et al. Alzheimer&#x2019;s disease is rare in Cree. International psychogeriatrics / IPA. 1993;5:5&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pubmed">8499574</ArticleId></ArticleIdList></Reference><Reference><Citation>Barnes DE, Yaffe K. The projected effect of risk factor reduction on Alzheimer&#x2019;s disease prevalence. Lancet neurology. 2011;10:819&#x2013;28.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3647614</ArticleId><ArticleId IdType="pubmed">21775213</ArticleId></ArticleIdList></Reference><Reference><Citation>Kivipelto M, Helkala E-L, Laakso MP, H&#xe4;nninen T, Hallikainen M, Alhainen K, et al. Midlife vascular risk factors and Alzheimer&#x2019;s disease in later life: longitudinal, population based study. Bmj. 2001;322:1447&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC32306</ArticleId><ArticleId IdType="pubmed">11408299</ArticleId></ArticleIdList></Reference><Reference><Citation>Debette S, Seshadri S, Beiser A, Au R, Himali JJ, Palumbo C, et al. Midlife vascular risk factor exposure accelerates structural brain aging and cognitive decline. Neurology. 2011;77:461&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3146307</ArticleId><ArticleId IdType="pubmed">21810696</ArticleId></ArticleIdList></Reference><Reference><Citation>Gorelick PB, Scuteri A, Black SE, DeCarli C, Greenberg SM, Iadecola C, et al. Vascular contributions to cognitive impairment and dementia a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2011;42:2672&#x2013;713.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3778669</ArticleId><ArticleId IdType="pubmed">21778438</ArticleId></ArticleIdList></Reference><Reference><Citation>UCLA Center for Health Policy Research. 2011-2012 California Health Interview Survey. Los Angeles, CA:</Citation></Reference><Reference><Citation>Burchard EG, Ziv E, Coyle N, Gomez SL, Tang H, Karter AJ, et al. The importance of race and ethnic background in biomedical research and clinical practice. New England Journal of Medicine. 2003;348:1170&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">12646676</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang M-X, Stern Y, Marder K, Bell K, Gurland B, Lantigua R, et al. The APOE-&#x2208; 4 allele and the risk of Alzheimer disease among African Americans, whites, and Hispanics. JAMA : the journal of the American Medical Association. 1998;279:751&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">9508150</ArticleId></ArticleIdList></Reference><Reference><Citation>Maestre G, Ottman R, Stern Y, Gurland B, Chun M, Tang MX, et al. Apolipoprotein E and Alzheimer&#x2019;s disease: ethnic variation in genotypic risks. Annals of neurology. 1995;37:254&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">7847867</ArticleId></ArticleIdList></Reference><Reference><Citation>Marden JR, Walter S, Tchetgen Tchetgen EJ, Kawachi I, Glymour MM. Validation of a polygenic risk score for dementia in black and white individuals. Brain and behavior. 2014;4:687&#x2013;97.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4107377</ArticleId><ArticleId IdType="pubmed">25328845</ArticleId></ArticleIdList></Reference><Reference><Citation>Ch&#xea;ne G, Beiser A, Au R, Preis SR, Wolf PA, Dufouil C, et al. Gender and incidence of dementia in the Framingham Heart Study from mid-adult life. Alzheimer&#x2019;s &amp; Dementia. 2015;11:310&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4092061</ArticleId><ArticleId IdType="pubmed">24418058</ArticleId></ArticleIdList></Reference><Reference><Citation>Clark PC, Kutner NG, Goldstein FC, Peterson-Hazen S, Garner V, Zhang R, et al. Impediments to timely diagnosis of Alzheimer&#x2019;s disease in African Americans. Journal of the American Geriatrics Society. 2005;53:2012&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">16274388</ArticleId></ArticleIdList></Reference><Reference><Citation>Fitten LJ, Ortiz F, Pont&#xf3;n M. Frequency of Alzheimer&#x2019;s disease and other dementias in a community outreach sample of Hispanics. Journal of the American Geriatrics Society. 2001;49:1301&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">11890488</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">26933687</PMID><DateCompleted><Year>2016</Year><Month>04</Month><Day>24</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>02</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2375-2548</ISSN><JournalIssue CitedMedium="Print"><Volume>2</Volume><Issue>2</Issue><PubDate><Year>2016</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Science advances</Title><ISOAbbreviation>Sci Adv</ISOAbbreviation></Journal><ArticleTitle>An anticancer drug suppresses the primary nucleation reaction that initiates the production of the toxic A&#x3b2;42 aggregates linked with Alzheimer's disease.</ArticleTitle><Pagination><StartPage>e1501244</StartPage><MedlinePgn>e1501244</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e1501244</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1126/sciadv.1501244</ELocationID><Abstract><AbstractText>The conversion of the &#x3b2;-amyloid (A&#x3b2;) peptide into pathogenic aggregates is linked to the onset and progression of Alzheimer's disease. Although this observation has prompted an extensive search for therapeutic agents to modulate the concentration of A&#x3b2; or inhibit its aggregation, all clinical trials with these objectives have so far failed, at least in part because of a lack of understanding of the molecular mechanisms underlying the process of aggregation and its inhibition. To address this problem, we describe a chemical kinetics approach for rational drug discovery, in which the effects of small molecules on the rates of specific microscopic steps in the self-assembly of A&#x3b2;42, the most aggregation-prone variant of A&#x3b2;, are analyzed quantitatively. By applying this approach, we report that bexarotene, an anticancer drug approved by the U.S. Food and Drug Administration, selectively targets the primary nucleation step in A&#x3b2;42 aggregation, delays the formation of toxic species in neuroblastoma cells, and completely suppresses A&#x3b2;42 deposition and its consequences in a Caenorhabditis elegans model of A&#x3b2;42-mediated toxicity. These results suggest that the prevention of the primary nucleation of A&#x3b2;42 by compounds such as bexarotene could potentially reduce the risk of onset of Alzheimer's disease and, more generally, that our strategy provides a general framework for the rational identification of a range of candidate drugs directed against neurodegenerative disorders.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Habchi</LastName><ForeName>Johnny</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Chemistry, University of Cambridge, Cambridge CB2 1EW, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arosio</LastName><ForeName>Paolo</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Chemistry, University of Cambridge, Cambridge CB2 1EW, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Perni</LastName><ForeName>Michele</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Chemistry, University of Cambridge, Cambridge CB2 1EW, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Costa</LastName><ForeName>Ana Rita</ForeName><Initials>AR</Initials><AffiliationInfo><Affiliation>Department of Chemistry, University of Cambridge, Cambridge CB2 1EW, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yagi-Utsumi</LastName><ForeName>Maho</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Chemistry, University of Cambridge, Cambridge CB2 1EW, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Joshi</LastName><ForeName>Priyanka</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0003-3419-2875</Identifier><AffiliationInfo><Affiliation>Department of Chemistry, University of Cambridge, Cambridge CB2 1EW, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chia</LastName><ForeName>Sean</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Chemistry, University of Cambridge, Cambridge CB2 1EW, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cohen</LastName><ForeName>Samuel I A</ForeName><Initials>SI</Initials><AffiliationInfo><Affiliation>Department of Chemistry, University of Cambridge, Cambridge CB2 1EW, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>M&#xfc;ller</LastName><ForeName>Martin B D</ForeName><Initials>MB</Initials><AffiliationInfo><Affiliation>University of Groningen, University Medical Centre Groningen, European Research Institute for the Biology of Aging, 9700 AD Groningen, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Linse</LastName><ForeName>Sara</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0001-9629-7109</Identifier><AffiliationInfo><Affiliation>Department of Biochemistry and Structural Biology, Center for Molecular Protein Science, Lund University, PO Box 124, 221 00 Lund, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nollen</LastName><ForeName>Ellen A A</ForeName><Initials>EA</Initials><AffiliationInfo><Affiliation>University of Groningen, University Medical Centre Groningen, European Research Institute for the Biology of Aging, 9700 AD Groningen, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dobson</LastName><ForeName>Christopher M</ForeName><Initials>CM</Initials><AffiliationInfo><Affiliation>Department of Chemistry, University of Cambridge, Cambridge CB2 1EW, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Knowles</LastName><ForeName>Tuomas P J</ForeName><Initials>TP</Initials><AffiliationInfo><Affiliation>Department of Chemistry, University of Cambridge, Cambridge CB2 1EW, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vendruscolo</LastName><ForeName>Michele</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Chemistry, University of Cambridge, Cambridge CB2 1EW, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>02</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Sci Adv</MedlineTA><NlmUniqueID>101653440</NlmUniqueID><ISSNLinking>2375-2548</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011994">Recombinant Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013764">Tetrahydronaphthalenes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C075222">amyloid beta-protein (1-42)</NameOfSubstance></Chemical><Chemical><RegistryNumber>1EQV5MLY3D</RegistryNumber><NameOfSubstance UI="D013654">Taurine</NameOfSubstance></Chemical><Chemical><RegistryNumber>5K8EAX0G53</RegistryNumber><NameOfSubstance UI="C001355">tramiprosate</NameOfSubstance></Chemical><Chemical><RegistryNumber>A61RXM4375</RegistryNumber><NameOfSubstance UI="D000077610">Bexarotene</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000595" MajorTopicYN="N">Amino Acid Sequence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D030801" MajorTopicYN="N">Animals, Genetically Modified</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000077610" MajorTopicYN="N">Bexarotene</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017173" MajorTopicYN="N">Caenorhabditis elegans</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055808" MajorTopicYN="N">Drug Discovery</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D066298" MajorTopicYN="N">In Vitro Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007700" MajorTopicYN="N">Kinetics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D023421" MajorTopicYN="N">Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008969" MajorTopicYN="N">Molecular Sequence Data</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055503" MajorTopicYN="N">Protein Multimerization</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011994" MajorTopicYN="N">Recombinant Proteins</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013654" MajorTopicYN="N">Taurine</DescriptorName><QualifierName UI="Q000031" MajorTopicYN="N">analogs &amp; derivatives</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013764" MajorTopicYN="N">Tetrahydronaphthalenes</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">chemical kinetics</Keyword><Keyword MajorTopicYN="N">molecular mechanisms</Keyword><Keyword MajorTopicYN="N">neurodegeneration</Keyword><Keyword MajorTopicYN="N">protein misfolding</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>9</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>12</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>3</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>3</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>3</Month><Day>5</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2016</Year><Month>2</Month><Day>12</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26933687</ArticleId><ArticleId IdType="pmc">PMC4758743</ArticleId><ArticleId IdType="doi">10.1126/sciadv.1501244</ArticleId><ArticleId IdType="pii">1501244</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Alzheimer&#x2019;s Association, 2012 Alzheimer&#x2019;s disease facts and figures. Alzheimer&#x2019;s Dement. 8, 131&#x2013;168 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22404854</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiti F., Dobson C. M., Protein misfolding, functional amyloid, and human disease. Annu. Rev. Biochem. 75, 333&#x2013;366 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16756495</ArticleId></ArticleIdList></Reference><Reference><Citation>Dobson C. M., Protein folding and misfolding. Nature 426, 884&#x2013;890 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">14685248</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe D. J., Folding proteins in fatal ways. Nature 426, 900&#x2013;904 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">14685251</ArticleId></ArticleIdList></Reference><Reference><Citation>Haass C., Selkoe D. J., Soluble protein oligomers in neurodegeneration: Lessons from the Alzheimer&#x2019;s amyloid &#x3b2;-peptide. Nat. Rev. Mol. Cell Biol. 8, 101&#x2013;112 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17245412</ArticleId></ArticleIdList></Reference><Reference><Citation>Balch W. E., Morimoto R. I., Dillin A., Kelly J. W., Adapting proteostasis for disease intervention. Science 319, 916&#x2013;919 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18276881</ArticleId></ArticleIdList></Reference><Reference><Citation>Hartl F. U., Bracher A., Hayer-Hartl M., Molecular chaperones in protein folding and proteostasis. Nature 475, 324&#x2013;332 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21776078</ArticleId></ArticleIdList></Reference><Reference><Citation>Eisenberg D., Jucker M., The amyloid state of proteins in human diseases. Cell 148, 1188&#x2013;1203 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3353745</ArticleId><ArticleId IdType="pubmed">22424229</ArticleId></ArticleIdList></Reference><Reference><Citation>Knowles T. P. J., Vendruscolo M., Dobson C. M., The amyloid state and its association with protein misfolding diseases. Nat. Rev. Mol. Cell Biol. 15, 384&#x2013;396 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24854788</ArticleId></ArticleIdList></Reference><Reference><Citation>Habchi J., Tompa P., Longhi S., Uversky V. N., Introducing protein intrinsic disorder. Chem. Rev. 114, 6561&#x2013;6588 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24739139</ArticleId></ArticleIdList></Reference><Reference><Citation>Bieschke J., Natural compounds may open new routes to treatment of amyloid diseases. Neurotherapeutics 10, 429&#x2013;439 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3701768</ArticleId><ArticleId IdType="pubmed">23670234</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen J., Armstrong A. H., Koehler A. N., Hecht M. H., Small molecule microarrays enable the discovery of compounds that bind the Alzheimer&#x2019;s A&#x3b2; peptide and reduce its cytotoxicity. J. Am. Chem. Soc. 132, 17015&#x2013;17022 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3063105</ArticleId><ArticleId IdType="pubmed">21062056</ArticleId></ArticleIdList></Reference><Reference><Citation>Ito M., Johansson J., Str&#xf6;mberg R., Nilsson L., Effects of ligands on unfolding of the amyloid &#x3b2;-peptide central helix: Mechanistic insights from molecular dynamics simulations. PLOS One 7, e30510 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3264620</ArticleId><ArticleId IdType="pubmed">22291970</ArticleId></ArticleIdList></Reference><Reference><Citation>Kroth H., Ansaloni A., Varisco Y., Jan A., Sreenivasachary N., Rezaei-Ghaleh N., Giriens V., Lohmann S., L&#xf3;pez-Deber M. P., Adolfsson O., Pihlgren M., Paganetti P., Froestl W., Nagel-Steger L., Willbold D., Schrader T., Zweckstetter M., Pfeifer A., Lashuel H. A., Muhs A., Discovery and structure activity relationship of small molecule inhibitors of toxic &#x3b2;-amyloid-42 fibril formation. J. Biol. Chem. 287, 34786&#x2013;34800 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3464581</ArticleId><ArticleId IdType="pubmed">22891248</ArticleId></ArticleIdList></Reference><Reference><Citation>Necula M., Kayed R., Milton S., Glabe C. G., Small molecule inhibitors of aggregation indicate that amyloid &#x3b2; oligomerization and fibrillization pathways are independent and distinct. J. Biol. Chem. 282, 10311&#x2013;10324 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17284452</ArticleId></ArticleIdList></Reference><Reference><Citation>Nie Q., Du X., Geng M., Small molecule inhibitors of amyloid &#x3b2; peptide aggregation as a potential therapeutic strategy for Alzheimer&#x2019;s disease. Acta Pharmacol. Sin. 32, 545&#x2013;551 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4002509</ArticleId><ArticleId IdType="pubmed">21499284</ArticleId></ArticleIdList></Reference><Reference><Citation>Porat Y., Abramowitz A., Gazit E., Inhibition of amyloid fibril formation by polyphenols: Structural similarity and aromatic interactions as a common inhibition mechanism. Chem. Biol. Drug Des. 67, 27&#x2013;37 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16492146</ArticleId></ArticleIdList></Reference><Reference><Citation>Sinha S., Lopes D. H. J., Du Z., Pang E. S., Shanmugam A., Lomakin A., Talbiersky P., Tennstaedt A., McDaniel K., Bakshi R., Kuo P.-Y., Ehrmann M., Benedek G. B., Loo J. A., Kl&#xe4;rner F.-G., Schrader T., Wang C., Bitan G., Lysine-specific molecular tweezers are broad-spectrum inhibitors of assembly and toxicity of amyloid proteins. J. Am. Chem. Soc. 133, 16958&#x2013;16969 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3210512</ArticleId><ArticleId IdType="pubmed">21916458</ArticleId></ArticleIdList></Reference><Reference><Citation>Abelein A., Lang L., Lendel C., Gr&#xe4;slund A., Danielsson J., Transient small molecule interactions kinetically modulate amyloid &#x3b2; peptide self-assembly. FEBS Lett. 586, 3991&#x2013;3995 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">23058290</ArticleId></ArticleIdList></Reference><Reference><Citation>Lansbury P. T., Lashuel H. A., A century-old debate on protein aggregation and neurodegeneration enters the clinic. Nature 443, 774&#x2013;779 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">17051203</ArticleId></ArticleIdList></Reference><Reference><Citation>Cummings J. L., Morstorf T., Zhong K., Alzheimer&#x2019;s disease drug-development pipeline: Few candidates, frequent failures. Alzheimer&#x2019;s Res. Ther. 6, 37 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4095696</ArticleId><ArticleId IdType="pubmed">25024750</ArticleId></ArticleIdList></Reference><Reference><Citation>Arosio P., Cukalevski R., Frohm B., Knowles T. P. J., Linse S., Quantification of the concentration of A&#x3b2;42 propagons during the lag phase by an amyloid chain reaction assay. J. Am. Chem. Soc. 136, 219&#x2013;225 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24313551</ArticleId></ArticleIdList></Reference><Reference><Citation>Butterfield S. M., Lashuel H. A., Amyloidogenic protein&#x2013;membrane interactions: Mechanistic insight from model systems. Angew. Chem. Int. Ed. 49, 5628&#x2013;5654 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20623810</ArticleId></ArticleIdList></Reference><Reference><Citation>Campioni S., Mannini B., Zampagni M., Pensalfini A., Parrini C., Evangelisti E., Relini A., Stefani M., Dobson C. M., Cecchi C., Chiti F., A causative link between the structure of aberrant protein oligomers and their toxicity. Nat. Chem. Biol. 6, 140&#x2013;147 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20081829</ArticleId></ArticleIdList></Reference><Reference><Citation>Shankar G. M., Li S., Mehta T. H., Garcia-Munoz A., Shepardson N. E., Smith I., Brett F. M., Farrell M. A., Rowan M. J., Lemere C. A., Regan C. M., Walsh D. M., Sabatini B. L., Selkoe D. J., Amyloid-&#x3b2; protein dimers isolated directly from Alzheimer&#x2019;s brains impair synaptic plasticity and memory. Nat. Med. 14, 837&#x2013;842 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2772133</ArticleId><ArticleId IdType="pubmed">18568035</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh D. M., Selkoe D. J., A&#x3b2; oligomers&#x2014;A decade of discovery. J. Neurochem. 101, 1172&#x2013;1184 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17286590</ArticleId></ArticleIdList></Reference><Reference><Citation>Mannini B., Mulvihill E., Sgromo C., Cascella R., Khodarahmi R., Ramazzotti M., Dobson C. M., Cecchi C., Chiti F., Toxicity of protein oligomers is rationalized by a function combining size and surface hydrophobicity. ACS Chem. Biol. 9, 2309&#x2013;2317 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">25079908</ArticleId></ArticleIdList></Reference><Reference><Citation>Arosio P., Vendruscolo M., Dobson C. M., Knowles T. P. J., Chemical kinetics for drug discovery to combat protein aggregation diseases. Trends Pharmacol. Sci. 35, 127&#x2013;135 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24560688</ArticleId></ArticleIdList></Reference><Reference><Citation>Knowles T. P. J., Waudby C. A., Devlin G. L., Cohen S. I. A., Aguzzi A., Vendruscolo M., Terentjev E. M., Welland M. E., Dobson C. M., An analytical solution to the kinetics of breakable filament assembly. Science 326, 1533&#x2013;1537 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">20007899</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen S. I. A., Linse S., Luheshi L. M., Hellstrand E., White D. A., Rajah L., Otzen D. E., Vendruscolo M., Dobson C. M., Knowles T. P. J., Proliferation of amyloid-&#x3b2;42 aggregates occurs through a secondary nucleation mechanism. Proc. Natl. Acad. Sci. U.S.A. 110, 9758&#x2013;9763 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3683769</ArticleId><ArticleId IdType="pubmed">23703910</ArticleId></ArticleIdList></Reference><Reference><Citation>Hellstrand E., Boland B., Walsh D. M., Linse S., Amyloid &#x3b2;-protein aggregation produces highly reproducible kinetic data and occurs by a two-phase process. ACS Chem. Neurosci. 1, 13&#x2013;18 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3368626</ArticleId><ArticleId IdType="pubmed">22778803</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen S. I. A., Vendruscolo M., Dobson C. M., Knowles T. P. J., From macroscopic measurements to microscopic mechanisms of protein aggregation. J. Mol. Biol. 421, 160&#x2013;171 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22406275</ArticleId></ArticleIdList></Reference><Reference><Citation>Hajduk P. J., Galloway W. R. J. D., Spring D. R., Drug discovery: A question of library design. Nature 470, 42&#x2013;43 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21293363</ArticleId></ArticleIdList></Reference><Reference><Citation>Rees D. C., Congreve M., Murray C. W., Carr R., Fragment-based lead discovery. Nat. Rev. Drug Discov. 3, 660&#x2013;672 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15286733</ArticleId></ArticleIdList></Reference><Reference><Citation>Appleby B. S., Cummings J. L., Discovering new treatments for Alzheimer&#x2019;s disease by repurposing approved medications. Curr. Top. Med. Chem. 13, 2306&#x2013;2327 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">24059463</ArticleId></ArticleIdList></Reference><Reference><Citation>Corbett A., Williams G., Ballard C., Drug repositioning: An opportunity to develop novel treatments for Alzheimer&#x2019;s disease. Pharmaceuticals 6, 1304&#x2013;1321 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3817602</ArticleId><ArticleId IdType="pubmed">24275851</ArticleId></ArticleIdList></Reference><Reference><Citation>Caltagirone C., Ferrannini L., Marchionni N., Nappi G., Scapagnini G., Trabucchi M., The potential protective effect of tramiprosate (homotaurine) against Alzheimer&#x2019;s disease: A review. Aging Clin. Exp. Res. 24, 580&#x2013;587 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22961121</ArticleId></ArticleIdList></Reference><Reference><Citation>Bomben V., Holth J., Reed J., Cramer P., Landreth G., Noebels J., Bexarotene reduces network excitability in models of Alzheimer&#x2019;s disease and epilepsy. Neurobiol. Aging 35, 2091&#x2013;2095 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4053509</ArticleId><ArticleId IdType="pubmed">24767949</ArticleId></ArticleIdList></Reference><Reference><Citation>Cramer P. E., Cirrito J. R., Wesson D. W., Lee C. Y. D., Karlo J. C., Zinn A. E., Casali B. T., Restivo J. L., Goebel W. D., James M. J., Brunden K. R., Wilson D. A., Landreth G. E., ApoE-directed therapeutics rapidly clear &#x3b2;-amyloid and reverse deficits in AD mouse models. Science 335, 1503&#x2013;1506 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3651582</ArticleId><ArticleId IdType="pubmed">22323736</ArticleId></ArticleIdList></Reference><Reference><Citation>Fitz N. F., Cronican A. A., Lefterov I., Koldamova R., Comment on &#x201c;ApoE-directed therapeutics rapidly clear &#x3b2;-amyloid and reverse deficits in AD mouse models&#x201d;. Science 340, 924-c (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4086452</ArticleId><ArticleId IdType="pubmed">23704552</ArticleId></ArticleIdList></Reference><Reference><Citation>Price A. R., Xu G., Siemienski Z. B., Smithson L. A., Borchelt D. R., Golde T. E., Felsenstein K. M., Comment on &#x201c;ApoE-directed therapeutics rapidly clear &#x3b2;-amyloid and reverse deficits in AD mouse models&#x201d;. Science 340, 924-d (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23704553</ArticleId></ArticleIdList></Reference><Reference><Citation>Tesseur I., Lo A. C., Roberfroid A., Dietvorst S., Van Broeck B., Borgers M., Gijsen H., Moechars D., Mercken M., Kemp J., D&#x2019;Hooge R., De Strooper B., Comment on &#x201c;ApoE-directed therapeutics rapidly clear &#x3b2;-amyloid and reverse deficits in AD mouse models&#x201d;. Science 340, 924-e (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23704554</ArticleId></ArticleIdList></Reference><Reference><Citation>Veeraraghavalu K., Zhang C., Miller S., Hefendehl J. K., Rajapaksha T. W., Ulrich J., Jucker M., Holtzman D. M., Tanzi R. E., Vassar R., Sisodia S. S., , Comment on &#x201c;ApoE-directed therapeutics rapidly clear &#x3b2;-amyloid and reverse deficits in AD mouse models&#x201d;. Science 340, 924-f (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23704555</ArticleId></ArticleIdList></Reference><Reference><Citation>LaClair K. D., Manaye K. F., Lee D. L., Allard J. S., Savonenko A. V., Troncoso J. C., Wong P. C., Treatment with bexarotene, a compound that increases apolipoprotein-E, provides no cognitive benefit in mutant APP/PS1 mice. Mol. Neurodegener. 8, 18 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3693923</ArticleId><ArticleId IdType="pubmed">23764200</ArticleId></ArticleIdList></Reference><Reference><Citation>Fantini J., Di Scala C., Yahi N., Troadec J.-D., Sadelli K., Chahinian H., Garmy N., Bexarotene blocks calcium-permeable ion channels formed by neurotoxic Alzheimer&#x2019;s &#x3b2;-amyloid peptides. ACS Chem. Neurosci. 5, 216&#x2013;224 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4058752</ArticleId><ArticleId IdType="pubmed">24383913</ArticleId></ArticleIdList></Reference><Reference><Citation>McColl G., Roberts B. R., Pukala T. L., Kenche V. B., Roberts C. M., Link C. D., Ryan T. M., Masters C. L., Barnham K. J., Bush A. I., Cherny R. A., Utility of an improved model of amyloid-beta (A&#x3b2;1-42) toxicity in Caenorhabditis elegans for drug screening for Alzheimer&#x2019;s disease. Mol. Neurodegener. 7, 57 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3519830</ArticleId><ArticleId IdType="pubmed">23171715</ArticleId></ArticleIdList></Reference><Reference><Citation>Olzscha H., Schermann S. M., Woerner A. C., Pinkert S., Hecht M. H., Tartaglia G. G., Vendruscolo M., Hayer-Hartl M., Hartl F. U., Vabulas R. M., Amyloid-like aggregates sequester numerous metastable proteins with essential cellular functions. Cell 144, 67&#x2013;78 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21215370</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen S. I. A., Arosio P., Presto J., Kurudenkandy F. R., Biverst&#xe5;l H., Dolfe L., Dunning C., Yang X., Frohm B., Vendruscolo M., Johansson J., Dobson C. M., Fisahn A., Knowles T. P. J., Linse S., A molecular chaperone breaks the catalytic cycle that generates toxic A&#x3b2; oligomers. Nat. Struct. Mol. Biol. 22, 207&#x2013;213 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4595974</ArticleId><ArticleId IdType="pubmed">25686087</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperling R. A., Aisen P. S., Beckett L. A., Bennett D. A., Craft S., Fagan A. M., Iwatsubo T., Jack C. R. Jr, Kaye J., Montine T. J., Park D. C., Reiman E. M., Rowe C. C., Siemers E., Stern Y., Yaffe K., Carrillo M. C., Thies B., Morrison-Bogorad M., Wagster M. V., Phelps C. H., Toward defining the preclinical stages of Alzheimer&#x2019;s disease: Recommendations from the National Institute on Aging-Alzheimer&#x2019;s Association workgroups on diagnostic guidelines for Alzheimer&#x2019;s disease. Alzheimer&#x2019;s Dement. 7, 280&#x2013;292 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3220946</ArticleId><ArticleId IdType="pubmed">21514248</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe D. J., Resolving controversies on the path to Alzheimer&#x2019;s therapeutics. Nat. Med. 17, 1060&#x2013;1065 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21900936</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh D. M., Thulin E., Minogue A. M., Gustavsson N., Pang E., Teplow D. B., Linse S., A facile method for expression and purification of the Alzheimer&#x2019;s disease-associated amyloid &#x3b2;-peptide. FEBS J. 276, 1266&#x2013;1281 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2702495</ArticleId><ArticleId IdType="pubmed">19175671</ArticleId></ArticleIdList></Reference><Reference><Citation>Roychaudhuri R., Yang M., Hoshi M. M., Teplow D. B., Amyloid &#x3b2;-protein assembly and Alzheimer disease. J. Biol. Chem. 284, 4749&#x2013;4753 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3837440</ArticleId><ArticleId IdType="pubmed">18845536</ArticleId></ArticleIdList></Reference><Reference><Citation>Brenner S., The genetics of Caenorhabditis elegans. Genetics 77, 71&#x2013;94 (1974).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1213120</ArticleId><ArticleId IdType="pubmed">4366476</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">26884167</PMID><DateCompleted><Year>2016</Year><Month>08</Month><Day>03</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>31</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1091-6490</ISSN><JournalIssue CitedMedium="Internet"><Volume>113</Volume><Issue>9</Issue><PubDate><Year>2016</Year><Month>Mar</Month><Day>01</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>The adaptive immune system restrains Alzheimer's disease pathogenesis by modulating microglial function.</ArticleTitle><Pagination><StartPage>E1316</StartPage><EndPage>E1325</EndPage><MedlinePgn>E1316-25</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1073/pnas.1525466113</ELocationID><Abstract><AbstractText>The innate immune system is strongly implicated in the pathogenesis of Alzheimer's disease (AD). In contrast, the role of adaptive immunity in AD remains largely unknown. However, numerous clinical trials are testing vaccination strategies for AD, suggesting that T and B cells play a pivotal role in this disease. To test the hypothesis that adaptive immunity influences AD pathogenesis, we generated an immune-deficient AD mouse model that lacks T, B, and natural killer (NK) cells. The resulting "Rag-5xfAD" mice exhibit a greater than twofold increase in &#x3b2;-amyloid (A&#x3b2;) pathology. Gene expression analysis of the brain implicates altered innate and adaptive immune pathways, including changes in cytokine/chemokine signaling and decreased Ig-mediated processes. Neuroinflammation is also greatly exacerbated in Rag-5xfAD mice as indicated by a shift in microglial phenotype, increased cytokine production, and reduced phagocytic capacity. In contrast, immune-intact 5xfAD mice exhibit elevated levels of nonamyloid reactive IgGs in association with microglia, and treatment of Rag-5xfAD mice or microglial cells with preimmune IgG enhances A&#x3b2; clearance. Last, we performed bone marrow transplantation studies in Rag-5xfAD mice, revealing that replacement of these missing adaptive immune populations can dramatically reduce AD pathology. Taken together, these data strongly suggest that adaptive immune cell populations play an important role in restraining AD pathology. In contrast, depletion of B cells and their appropriate activation by T cells leads to a loss of adaptive-innate immunity cross talk and accelerated disease progression.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Marsh</LastName><ForeName>Samuel E</ForeName><Initials>SE</Initials><Identifier Source="ORCID">0000-0002-3012-6945</Identifier><AffiliationInfo><Affiliation>Department of Neurobiology and Behavior, University of California, Irvine, CA 92697; Sue and Bill Gross Stem Cell Research Center, University of California, Irvine, CA 92697;</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abud</LastName><ForeName>Edsel M</ForeName><Initials>EM</Initials><AffiliationInfo><Affiliation>Department of Neurobiology and Behavior, University of California, Irvine, CA 92697; Sue and Bill Gross Stem Cell Research Center, University of California, Irvine, CA 92697;</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lakatos</LastName><ForeName>Anita</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Institute for Memory Impairments and Neurological Disorders, University of California, Irvine, CA 92697;</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Karimzadeh</LastName><ForeName>Alborz</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Sue and Bill Gross Stem Cell Research Center, University of California, Irvine, CA 92697; Department of Molecular Biology and Biochemistry, University of California, Irvine, CA 92697;</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yeung</LastName><ForeName>Stephen T</ForeName><Initials>ST</Initials><AffiliationInfo><Affiliation>Institute for Memory Impairments and Neurological Disorders, University of California, Irvine, CA 92697;</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Davtyan</LastName><ForeName>Hayk</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Molecular Immunology, Institute for Molecular Medicine, Huntington Beach, CA 92647.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fote</LastName><ForeName>Gianna M</ForeName><Initials>GM</Initials><AffiliationInfo><Affiliation>Department of Neurobiology and Behavior, University of California, Irvine, CA 92697; Sue and Bill Gross Stem Cell Research Center, University of California, Irvine, CA 92697;</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lau</LastName><ForeName>Lydia</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Institute for Memory Impairments and Neurological Disorders, University of California, Irvine, CA 92697;</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weinger</LastName><ForeName>Jason G</ForeName><Initials>JG</Initials><AffiliationInfo><Affiliation>Department of Molecular Biology and Biochemistry, University of California, Irvine, CA 92697;</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lane</LastName><ForeName>Thomas E</ForeName><Initials>TE</Initials><AffiliationInfo><Affiliation>Sue and Bill Gross Stem Cell Research Center, University of California, Irvine, CA 92697; Institute for Memory Impairments and Neurological Disorders, University of California, Irvine, CA 92697; Department of Molecular Biology and Biochemistry, University of California, Irvine, CA 92697;</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Inlay</LastName><ForeName>Matthew A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Sue and Bill Gross Stem Cell Research Center, University of California, Irvine, CA 92697; Department of Molecular Biology and Biochemistry, University of California, Irvine, CA 92697;</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Poon</LastName><ForeName>Wayne W</ForeName><Initials>WW</Initials><AffiliationInfo><Affiliation>Institute for Memory Impairments and Neurological Disorders, University of California, Irvine, CA 92697;</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blurton-Jones</LastName><ForeName>Mathew</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurobiology and Behavior, University of California, Irvine, CA 92697; Sue and Bill Gross Stem Cell Research Center, University of California, Irvine, CA 92697; Institute for Memory Impairments and Neurological Disorders, University of California, Irvine, CA 92697; mblurton@uci.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>T32 GM008620</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG048099</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1AG048099</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 NS082174</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG000538</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG016573</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 AG00096-30</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 AG000096</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>02</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007074">Immunoglobulin G</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000222" MajorTopicYN="Y">Adaptation, Physiological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007074" MajorTopicYN="N">Immunoglobulin G</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010587" MajorTopicYN="N">Phagocytosis</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer&#x2019;s</Keyword><Keyword MajorTopicYN="N">IgG</Keyword><Keyword MajorTopicYN="N">amyloid</Keyword><Keyword MajorTopicYN="N">inflammation</Keyword><Keyword MajorTopicYN="N">microglia</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>2</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>2</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>8</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2016</Year><Month>2</Month><Day>16</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26884167</ArticleId><ArticleId IdType="pmc">PMC4780638</ArticleId><ArticleId IdType="doi">10.1073/pnas.1525466113</ArticleId><ArticleId IdType="pii">1525466113</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Alzheimer&#x2019;s Association 2014 Alzheimer&#x2019;s disease facts and figures. Alzheimers Dement. 2014;10(2):e47&#x2013;e92.</Citation><ArticleIdList><ArticleId IdType="pubmed">24818261</ArticleId></ArticleIdList></Reference><Reference><Citation>McAlpine FE, Tansey MG. Neuroinflammation and tumor necrosis factor signaling in the pathophysiology of Alzheimer&#x2019;s disease. J Inflamm Res. 2008;1:29&#x2013;39.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3218716</ArticleId><ArticleId IdType="pubmed">22096345</ArticleId></ArticleIdList></Reference><Reference><Citation>Maier M, et al. Complement C3 deficiency leads to accelerated amyloid beta plaque deposition and neurodegeneration and modulation of the microglia/macrophage phenotype in amyloid precursor protein transgenic mice. J Neurosci. 2008;28(25):6333&#x2013;6341.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3329761</ArticleId><ArticleId IdType="pubmed">18562603</ArticleId></ArticleIdList></Reference><Reference><Citation>Wyss-Coray T, Rogers J. Inflammation in Alzheimer disease&#x2014;a brief review of the basic science and clinical literature. Cold Spring Harb Perspect Med. 2012;2(1):a006346.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3253025</ArticleId><ArticleId IdType="pubmed">22315714</ArticleId></ArticleIdList></Reference><Reference><Citation>Guillot-Sestier MV, Town T. Innate immunity in Alzheimer&#x2019;s disease: A complex affair. CNS Neurol Disord Drug Targets. 2013;12(5):593&#x2013;607.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3792655</ArticleId><ArticleId IdType="pubmed">23574177</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee CY, Landreth GE. The role of microglia in amyloid clearance from the AD brain. J Neural Transm (Vienna) 2010;117(8):949&#x2013;960.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3653296</ArticleId><ArticleId IdType="pubmed">20552234</ArticleId></ArticleIdList></Reference><Reference><Citation>Mosher KI, Wyss-Coray T. Microglial dysfunction in brain aging and Alzheimer&#x2019;s disease. Biochem Pharmacol. 2014;88(4):594&#x2013;604.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3972294</ArticleId><ArticleId IdType="pubmed">24445162</ArticleId></ArticleIdList></Reference><Reference><Citation>Heneka MT, et al. Neuroinflammation in Alzheimer&#x2019;s disease. Lancet Neurol. 2015;14(4):388&#x2013;405.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5909703</ArticleId><ArticleId IdType="pubmed">25792098</ArticleId></ArticleIdList></Reference><Reference><Citation>Hickman SE, Allison EK, El Khoury J. Microglial dysfunction and defective beta-amyloid clearance pathways in aging Alzheimer&#x2019;s disease mice. J Neurosci. 2008;28(33):8354&#x2013;8360.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2597474</ArticleId><ArticleId IdType="pubmed">18701698</ArticleId></ArticleIdList></Reference><Reference><Citation>Krabbe G, et al. Functional impairment of microglia coincides with beta-amyloid deposition in mice with Alzheimer-like pathology. PLoS One. 2013;8(4):e60921.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3620049</ArticleId><ArticleId IdType="pubmed">23577177</ArticleId></ArticleIdList></Reference><Reference><Citation>Bradshaw EM, et al. Alzheimer Disease Neuroimaging Initiative CD33 Alzheimer&#x2019;s disease locus: Altered monocyte function and amyloid biology. Nat Neurosci. 2013;16(7):848&#x2013;850.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3703870</ArticleId><ArticleId IdType="pubmed">23708142</ArticleId></ArticleIdList></Reference><Reference><Citation>Griciuc A, et al. Alzheimer&#x2019;s disease risk gene CD33 inhibits microglial uptake of amyloid beta. Neuron. 2013;78(4):631&#x2013;643.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3706457</ArticleId><ArticleId IdType="pubmed">23623698</ArticleId></ArticleIdList></Reference><Reference><Citation>Guerreiro R, et al. Alzheimer Genetic Analysis Group TREM2 variants in Alzheimer&#x2019;s disease. N Engl J Med. 2013;368(2):117&#x2013;127.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3631573</ArticleId><ArticleId IdType="pubmed">23150934</ArticleId></ArticleIdList></Reference><Reference><Citation>Jay TR, et al. TREM2 deficiency eliminates TREM2+ inflammatory macrophages and ameliorates pathology in Alzheimer&#x2019;s disease mouse models. J Exp Med. 2015;212(3):287&#x2013;295.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4354365</ArticleId><ArticleId IdType="pubmed">25732305</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, et al. TREM2 lipid sensing sustains the microglial response in an Alzheimer&#x2019;s disease model. Cell. 2015;160(6):1061&#x2013;1071.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4477963</ArticleId><ArticleId IdType="pubmed">25728668</ArticleId></ArticleIdList></Reference><Reference><Citation>Pellican&#xf2; M, et al. Immune profiling of Alzheimer patients. J Neuroimmunol. 2012;242(1-2):52&#x2013;59.</Citation><ArticleIdList><ArticleId IdType="pubmed">22153977</ArticleId></ArticleIdList></Reference><Reference><Citation>Baruch K, et al. Breaking immune tolerance by targeting Foxp3(+) regulatory T cells mitigates Alzheimer&#x2019;s disease pathology. Nat Commun. 2015;6:7967.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4557123</ArticleId><ArticleId IdType="pubmed">26284939</ArticleId></ArticleIdList></Reference><Reference><Citation>Zenaro E, et al. Neutrophils promote Alzheimer&#x2019;s disease-like pathology and cognitive decline via LFA-1 integrin. Nat Med. 2015;21(8):880&#x2013;886.</Citation><ArticleIdList><ArticleId IdType="pubmed">26214837</ArticleId></ArticleIdList></Reference><Reference><Citation>Oakley H, et al. Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer&#x2019;s disease mutations: Potential factors in amyloid plaque formation. J Neurosci. 2006;26(40):10129&#x2013;10140.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6674618</ArticleId><ArticleId IdType="pubmed">17021169</ArticleId></ArticleIdList></Reference><Reference><Citation>Dranoff G. Cytokines in cancer pathogenesis and cancer therapy. Nat Rev Cancer. 2004;4(1):11&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pubmed">14708024</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiman EM, et al. Brain imaging and fluid biomarker analysis in young adults at genetic risk for autosomal dominant Alzheimer&#x2019;s disease in the presenilin 1 E280A kindred: A case-control study. Lancet Neurol. 2012;11(12):1048&#x2013;1056.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4181671</ArticleId><ArticleId IdType="pubmed">23137948</ArticleId></ArticleIdList></Reference><Reference><Citation>Potter R, et al. Increased in vivo amyloid-&#x3b2;42 production, exchange, and loss in presenilin mutation carriers. Sci Transl Med. 2013;5(189):189ra77.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3838868</ArticleId><ArticleId IdType="pubmed">23761040</ArticleId></ArticleIdList></Reference><Reference><Citation>Mawuenyega KG, et al. Decreased clearance of CNS beta-amyloid in Alzheimer&#x2019;s disease. Science. 2010;330(6012):1774.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3073454</ArticleId><ArticleId IdType="pubmed">21148344</ArticleId></ArticleIdList></Reference><Reference><Citation>Wildsmith KR, Holley M, Savage JC, Skerrett R, Landreth GE. Evidence for impaired amyloid &#x3b2; clearance in Alzheimer&#x2019;s disease. Alzheimers Res Ther. 2013;5(4):33.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3978761</ArticleId><ArticleId IdType="pubmed">23849219</ArticleId></ArticleIdList></Reference><Reference><Citation>Tarasoff-Conway JM, et al. Clearance systems in the brain&#x2014;implications for Alzheimer disease. Nat Rev Neurol. 2015;11(8):457&#x2013;470.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4694579</ArticleId><ArticleId IdType="pubmed">26195256</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, et al. An RNA-sequencing transcriptome and splicing database of glia, neurons, and vascular cells of the cerebral cortex. J Neurosci. 2014;34(36):11929&#x2013;11947.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4152602</ArticleId><ArticleId IdType="pubmed">25186741</ArticleId></ArticleIdList></Reference><Reference><Citation>Chakrabarty P, et al. IL-10 alters immunoproteostasis in APP mice, increasing plaque burden and worsening cognitive behavior. Neuron. 2015;85(3):519&#x2013;533.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4320003</ArticleId><ArticleId IdType="pubmed">25619653</ArticleId></ArticleIdList></Reference><Reference><Citation>Guillot-Sestier MV, et al. Il10 deficiency rebalances innate immunity to mitigate Alzheimer-like pathology. Neuron. 2015;85(3):534&#x2013;548.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4352138</ArticleId><ArticleId IdType="pubmed">25619654</ArticleId></ArticleIdList></Reference><Reference><Citation>Guillot-Sestier MV, Doty KR, Town T. Innate immunity fights Alzheimer&#x2019;s disease. Trends Neurosci. 2015;38(11):674&#x2013;681.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4641041</ArticleId><ArticleId IdType="pubmed">26549882</ArticleId></ArticleIdList></Reference><Reference><Citation>Leinenga G, G&#xf6;tz J. Scanning ultrasound removes amyloid-&#x3b2; and restores memory in an Alzheimer&#x2019;s disease mouse model. Sci Transl Med. 2015;7(278):278ra33.</Citation><ArticleIdList><ArticleId IdType="pubmed">25761889</ArticleId></ArticleIdList></Reference><Reference><Citation>Deane R, et al. apoE isoform-specific disruption of amyloid beta peptide clearance from mouse brain. J Clin Invest. 2008;118(12):4002&#x2013;4013.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2582453</ArticleId><ArticleId IdType="pubmed">19033669</ArticleId></ArticleIdList></Reference><Reference><Citation>Zlokovic BV. Cerebrovascular effects of apolipoprotein E: Implications for Alzheimer disease. JAMA Neurol. 2013;70(4):440&#x2013;444.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4414030</ArticleId><ArticleId IdType="pubmed">23400708</ArticleId></ArticleIdList></Reference><Reference><Citation>Elmore MR, et al. Colony-stimulating factor 1 receptor signaling is necessary for microglia viability, unmasking a microglia progenitor cell in the adult brain. Neuron. 2014;82(2):380&#x2013;397.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4161285</ArticleId><ArticleId IdType="pubmed">24742461</ArticleId></ArticleIdList></Reference><Reference><Citation>Davtyan H, et al. DNA prime-protein boost increased the titer, avidity and persistence of anti-Abeta antibodies in wild-type mice. Gene Ther. 2010;17(2):261&#x2013;271.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2820600</ArticleId><ArticleId IdType="pubmed">19865176</ArticleId></ArticleIdList></Reference><Reference><Citation>Davtyan H, Petrushina I, Ghochikyan A. Immunotherapy for Alzheimer&#x2019;s disease: DNA- and protein-based epitope vaccines. Methods Mol Biol. 2014;1143:259&#x2013;281.</Citation><ArticleIdList><ArticleId IdType="pubmed">24715293</ArticleId></ArticleIdList></Reference><Reference><Citation>Koenigsknecht-Talboo J, Landreth GE. Microglial phagocytosis induced by fibrillar beta-amyloid and IgGs are differentially regulated by proinflammatory cytokines. J Neurosci. 2005;25(36):8240&#x2013;8249.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725530</ArticleId><ArticleId IdType="pubmed">16148231</ArticleId></ArticleIdList></Reference><Reference><Citation>Garc&#xed;a-Garc&#xed;a E, Rosales C. Signal transduction during Fc receptor-mediated phagocytosis. J Leukoc Biol. 2002;72(6):1092&#x2013;1108.</Citation><ArticleIdList><ArticleId IdType="pubmed">12488490</ArticleId></ArticleIdList></Reference><Reference><Citation>Sudduth TL, Greenstein A, Wilcock DM. Intracranial injection of Gammagard, a human IVIg, modulates the inflammatory response of the brain and lowers A&#x3b2; in APP/PS1 mice along a different time course than anti-A&#x3b2; antibodies. J Neurosci. 2013;33(23):9684&#x2013;9692.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3839584</ArticleId><ArticleId IdType="pubmed">23739965</ArticleId></ArticleIdList></Reference><Reference><Citation>Knight EM, Gandy S. Immunomodulation and AD&#x2014;down but not out. J Clin Immunol. 2014;34(Suppl 1):S70&#x2013;S73.</Citation><ArticleIdList><ArticleId IdType="pubmed">24781637</ArticleId></ArticleIdList></Reference><Reference><Citation>Relkin N. Clinical trials of intravenous immunoglobulin for Alzheimer&#x2019;s disease. J Clin Immunol. 2014;34(Suppl 1):S74&#x2013;S79.</Citation><ArticleIdList><ArticleId IdType="pubmed">24760112</ArticleId></ArticleIdList></Reference><Reference><Citation>Counts SE, et al. Intravenous immunoglobulin (IVIG) treatment exerts antioxidant and neuropreservatory effects in preclinical models of Alzheimer&#x2019;s disease. J Clin Immunol. 2014;34(Suppl 1):S80&#x2013;S85.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4293701</ArticleId><ArticleId IdType="pubmed">24760109</ArticleId></ArticleIdList></Reference><Reference><Citation>Jord&#xe3;o JF, et al. Amyloid-&#x3b2; plaque reduction, endogenous antibody delivery and glial activation by brain-targeted, transcranial focused ultrasound. Exp Neurol. 2013;248:16&#x2013;29.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4000699</ArticleId><ArticleId IdType="pubmed">23707300</ArticleId></ArticleIdList></Reference><Reference><Citation>Burgess A, et al. Alzheimer disease in a mouse model: MR imaging-guided focused ultrasound targeted to the hippocampus opens the blood-brain barrier and improves pathologic abnormalities and behavior. Radiology. 2014;273(3):736&#x2013;745.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4314115</ArticleId><ArticleId IdType="pubmed">25222068</ArticleId></ArticleIdList></Reference><Reference><Citation>Carrillo MC, et al. Can we prevent Alzheimer&#x2019;s disease? Secondary &#x201c;prevention&#x201d; trials in Alzheimer&#x2019;s disease. Alzheimers Dement. 2013;9(2):123&#x2013;131.e1.</Citation><ArticleIdList><ArticleId IdType="pubmed">23411394</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu E, et al. Bapineuzumab 301 and 302 Clinical Trial Investigators Amyloid-&#x3b2; 11C-PiB-PET imaging results from 2 randomized bapineuzumab phase 3 AD trials. Neurology. 2015;85(8):692&#x2013;700.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4553028</ArticleId><ArticleId IdType="pubmed">26208959</ArticleId></ArticleIdList></Reference><Reference><Citation>Ances BM, Ellis RJ. Dementia and neurocognitive disorders due to HIV-1 infection. Semin Neurol. 2007;27(1):86&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pubmed">17226745</ArticleId></ArticleIdList></Reference><Reference><Citation>Brew BJ, Pemberton L, Blennow K, Wallin A, Hagberg L. CSF amyloid beta42 and tau levels correlate with AIDS dementia complex. Neurology. 2005;65(9):1490&#x2013;1492.</Citation><ArticleIdList><ArticleId IdType="pubmed">16275845</ArticleId></ArticleIdList></Reference><Reference><Citation>Soontornniyomkij V, et al. Cerebral &#x3b2;-amyloid deposition predicts HIV-associated neurocognitive disorders in APOE &#x3b5;4 carriers. AIDS. 2012;26(18):2327&#x2013;2335.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3576852</ArticleId><ArticleId IdType="pubmed">23018443</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu W, Banchereau J. The antigen presenting cells instruct plasma cell differentiation. Front Immunol. 2014;4:504.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3880943</ArticleId><ArticleId IdType="pubmed">24432021</ArticleId></ArticleIdList></Reference><Reference><Citation>Sakaguchi S, Yamaguchi T, Nomura T, Ono M. Regulatory T cells and immune tolerance. Cell. 2008;133(5):775&#x2013;787.</Citation><ArticleIdList><ArticleId IdType="pubmed">18510923</ArticleId></ArticleIdList></Reference><Reference><Citation>Poduslo JF, Curran GL, Berg CT. Macromolecular permeability across the blood&#x2013;nerve and blood&#x2013;brain barriers. Proc Natl Acad Sci USA. 1994;91(12):5705&#x2013;5709.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC44065</ArticleId><ArticleId IdType="pubmed">8202551</ArticleId></ArticleIdList></Reference><Reference><Citation>Fuller JP, Stavenhagen JB, Teeling JL. New roles for Fc receptors in neurodegeneration-the impact on immunotherapy for Alzheimer&#x2019;s disease. Front Neurosci. 2014;8:235.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4139653</ArticleId><ArticleId IdType="pubmed">25191216</ArticleId></ArticleIdList></Reference><Reference><Citation>Ransohoff RM, Engelhardt B. The anatomical and cellular basis of immune surveillance in the central nervous system. Nat Rev Immunol. 2012;12(9):623&#x2013;635.</Citation><ArticleIdList><ArticleId IdType="pubmed">22903150</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwartz M, Baruch K. The resolution of neuroinflammation in neurodegeneration: Leukocyte recruitment via the choroid plexus. EMBO J. 2014;33(1):7&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3990679</ArticleId><ArticleId IdType="pubmed">24357543</ArticleId></ArticleIdList></Reference><Reference><Citation>Baruch K, et al. Aging. Aging-induced type I interferon response at the choroid plexus negatively affects brain function. Science. 2014;346(6205):89&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4869326</ArticleId><ArticleId IdType="pubmed">25147279</ArticleId></ArticleIdList></Reference><Reference><Citation>Bergen AA, Kaing S, Ten Brink JB, Gorgels TG, Janssen SF. Netherlands Brain Bank Gene expression and functional annotation of human choroid plexus epithelium failure in Alzheimer&#x2019;s disease. BMC Genomics. 2015;16(1):956.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4647590</ArticleId><ArticleId IdType="pubmed">26573292</ArticleId></ArticleIdList></Reference><Reference><Citation>Schlachetzki F, Zhu C, Pardridge WM. Expression of the neonatal Fc receptor (FcRn) at the blood-brain barrier. J Neurochem. 2002;81(1):203&#x2013;206.</Citation><ArticleIdList><ArticleId IdType="pubmed">12067234</ArticleId></ArticleIdList></Reference><Reference><Citation>Deane R, et al. IgG-assisted age-dependent clearance of Alzheimer&#x2019;s amyloid beta peptide by the blood-brain barrier neonatal Fc receptor. J Neurosci. 2005;25(50):11495&#x2013;11503.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6726020</ArticleId><ArticleId IdType="pubmed">16354907</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao X, et al. Defective lymphoid development in mice lacking expression of the common cytokine receptor gamma chain. Immunity. 1995;2(3):223&#x2013;238.</Citation><ArticleIdList><ArticleId IdType="pubmed">7697543</ArticleId></ArticleIdList></Reference><Reference><Citation>Blurton-Jones M, et al. Neural stem cells improve cognition via BDNF in a transgenic model of Alzheimer disease. Proc Natl Acad Sci USA. 2009;106(32):13594&#x2013;13599.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2715325</ArticleId><ArticleId IdType="pubmed">19633196</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmued L, et al. Introducing Amylo-Glo, a novel fluorescent amyloid specific histochemical tracer especially suited for multiple labeling and large scale quantification studies. J Neurosci Methods. 2012;209(1):120&#x2013;126.</Citation><ArticleIdList><ArticleId IdType="pubmed">22705750</ArticleId></ArticleIdList></Reference><Reference><Citation>Webster SD, et al. Antibody-mediated phagocytosis of the amyloid beta-peptide in microglia is differentially modulated by C1q. J Immunol. 2001;166(12):7496&#x2013;7503.</Citation><ArticleIdList><ArticleId IdType="pubmed">11390503</ArticleId></ArticleIdList></Reference><Reference><Citation>Blasi E, Barluzzi R, Bocchini V, Mazzolla R, Bistoni F. Immortalization of murine microglial cells by a v-raf/v-myc carrying retrovirus. J Neuroimmunol. 1990;27(2-3):229&#x2013;237.</Citation><ArticleIdList><ArticleId IdType="pubmed">2110186</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">26888431</PMID><DateCompleted><Year>2016</Year><Month>12</Month><Day>13</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>02</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1946-6242</ISSN><JournalIssue CitedMedium="Internet"><Volume>8</Volume><Issue>326</Issue><PubDate><Year>2016</Year><Month>Feb</Month><Day>17</Day></PubDate></JournalIssue><Title>Science translational medicine</Title><ISOAbbreviation>Sci Transl Med</ISOAbbreviation></Journal><ArticleTitle>Chronic administration of an HDAC inhibitor treats both neurological and systemic Niemann-Pick type C disease in a mouse model.</ArticleTitle><Pagination><StartPage>326ra23</StartPage><MedlinePgn>326ra23</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1126/scitranslmed.aad9407</ELocationID><Abstract><AbstractText>Histone deacetylase inhibitors (HDACi) are approved for treating rare cancers and are of interest as potential therapies for neurodegenerative disorders. We evaluated a triple combination formulation (TCF) comprising the pan-HDACi vorinostat, the caging agent 2-hydroxypropyl-&#x3b2;-cyclodextrin (HPBCD), and polyethylene glycol (PEG) for treating a mouse model (the Npc1(nmf164) mouse) of Niemann-Pick type C (NPC) disease, a difficult-to-treat cerebellar disorder. Vorinostat alone showed activity in cultured primary cells derived from Npc1(nmf164) mice but did not improve animal survival. However, low-dose, once-weekly intraperitoneal injections of the TCF containing vorinostat increased histone acetylation in the mouse brain, preserved neurites and Purkinje cells, delayed symptoms of neurodegeneration, and extended mouse life span from 4 to almost 9 months. We demonstrate that the TCF boosted the ability of HDACi to cross the blood-brain barrier and was not toxic even when used long term. Further, the TCF enabled dose reduction, which has been a major challenge in HDACi therapy. TCF simultaneously treats neurodegenerative and systemic symptoms of Niemann-Pick type C disease in a mouse model.</AbstractText><CopyrightInformation>Copyright &#xa9; 2016, American Association for the Advancement of Science.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Alam</LastName><ForeName>Md Suhail</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>Boler-Parseghian Center for Rare and Neglected Diseases, University of Notre Dame, Notre Dame, IN 46556, USA. Department of Biological Sciences, University of Notre Dame, 103 Galvin Life Sciences, Notre Dame, IN 46556, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Getz</LastName><ForeName>Michelle</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Boler-Parseghian Center for Rare and Neglected Diseases, University of Notre Dame, Notre Dame, IN 46556, USA. Department of Biological Sciences, University of Notre Dame, 103 Galvin Life Sciences, Notre Dame, IN 46556, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Haldar</LastName><ForeName>Kasturi</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Boler-Parseghian Center for Rare and Neglected Diseases, University of Notre Dame, Notre Dame, IN 46556, USA. Department of Biological Sciences, University of Notre Dame, 103 Galvin Life Sciences, Notre Dame, IN 46556, USA. khaldar@nd.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Sci Transl Med</MedlineTA><NlmUniqueID>101505086</NlmUniqueID><ISSNLinking>1946-6234</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D056572">Histone Deacetylase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006877">Hydroxamic Acids</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D047392">beta-Cyclodextrins</NameOfSubstance></Chemical><Chemical><RegistryNumber>1I96OHX6EK</RegistryNumber><NameOfSubstance UI="D000073738">2-Hydroxypropyl-beta-cyclodextrin</NameOfSubstance></Chemical><Chemical><RegistryNumber>3WJQ0SDW1A</RegistryNumber><NameOfSubstance UI="D011092">Polyethylene Glycols</NameOfSubstance></Chemical><Chemical><RegistryNumber>58IFB293JI</RegistryNumber><NameOfSubstance UI="D000077337">Vorinostat</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000073738" MajorTopicYN="N">2-Hydroxypropyl-beta-cyclodextrin</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001812" MajorTopicYN="N">Blood-Brain Barrier</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005347" MajorTopicYN="N">Fibroblasts</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D056572" MajorTopicYN="N">Histone Deacetylase Inhibitors</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006877" MajorTopicYN="N">Hydroxamic Acids</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007249" MajorTopicYN="N">Inflammation</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008099" MajorTopicYN="N">Liver</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009410" MajorTopicYN="N">Nerve Degeneration</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D052556" MajorTopicYN="N">Niemann-Pick Disease, Type C</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011092" MajorTopicYN="N">Polyethylene Glycols</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011689" MajorTopicYN="N">Purkinje Cells</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012333" MajorTopicYN="N">RNA, Messenger</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013154" MajorTopicYN="N">Spleen</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016019" MajorTopicYN="N">Survival Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077337" MajorTopicYN="N">Vorinostat</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D047392" MajorTopicYN="N">beta-Cyclodextrins</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>2</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>2</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26888431</ArticleId><ArticleId IdType="doi">10.1126/scitranslmed.aad9407</ArticleId><ArticleId IdType="pii">8/326/326ra23</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">26888450</PMID><DateCompleted><Year>2016</Year><Month>12</Month><Day>23</Day></DateCompleted><DateRevised><Year>2024</Year><Month>05</Month><Day>24</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2045-2322</ISSN><JournalIssue CitedMedium="Internet"><Volume>6</Volume><PubDate><Year>2016</Year><Month>Feb</Month><Day>18</Day></PubDate></JournalIssue><Title>Scientific reports</Title><ISOAbbreviation>Sci Rep</ISOAbbreviation></Journal><ArticleTitle>Chronic consumption of a western diet induces robust glial activation in aging mice and in a mouse model of Alzheimer's disease.</ArticleTitle><Pagination><StartPage>21568</StartPage><MedlinePgn>21568</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">21568</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/srep21568</ELocationID><Abstract><AbstractText>Studies have assessed individual components of a western diet, but no study has assessed the long-term, cumulative effects of a western diet on aging and Alzheimer's disease (AD). Therefore, we have formulated the first western-style diet that mimics the fat, carbohydrate, protein, vitamin and mineral levels of western diets. This diet was fed to aging C57BL/6J (B6) mice to identify phenotypes that may increase susceptibility to AD, and to APP/PS1 mice, a mouse model of AD, to determine the effects of the diet in AD. Astrocytosis and microglia/monocyte activation were dramatically increased in response to diet and was further increased in APP/PS1 mice fed the western diet. This increase in glial responses was associated with increased plaque burden in the hippocampus. Interestingly, given recent studies highlighting the importance of TREM2 in microglia/monocytes in AD susceptibility and progression, B6 and APP/PS1 mice fed the western diet showed significant increases TREM2+ microglia/monocytes. Therefore, an increase in TREM2+ microglia/monocytes may underlie the increased risk from a western diet to age-related neurodegenerative diseases such as Alzheimer's disease. This study lays the foundation to fully investigate the impact of a western diet on glial responses in aging and Alzheimer's disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Graham</LastName><ForeName>Leah C</ForeName><Initials>LC</Initials><AffiliationInfo><Affiliation>The Jackson Laboratory, 600 Main St, Bar Harbor, ME, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Graduate Program in Genetics, Sackler School of Graduate Biomedical Sciences, Tufts University, 136 Harrison Avenue, Boston, MA 02111, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Harder</LastName><ForeName>Jeffrey M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>The Jackson Laboratory, 600 Main St, Bar Harbor, ME, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Soto</LastName><ForeName>Ileana</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>The Jackson Laboratory, 600 Main St, Bar Harbor, ME, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Vries</LastName><ForeName>Wilhelmine N</ForeName><Initials>WN</Initials><AffiliationInfo><Affiliation>The Jackson Laboratory, 600 Main St, Bar Harbor, ME, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Howard Hughes Medical Institute, 600 Main St, Bar Harbor, ME, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>John</LastName><ForeName>Simon W M</ForeName><Initials>SW</Initials><AffiliationInfo><Affiliation>The Jackson Laboratory, 600 Main St, Bar Harbor, ME, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Graduate Program in Genetics, Sackler School of Graduate Biomedical Sciences, Tufts University, 136 Harrison Avenue, Boston, MA 02111, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Howard Hughes Medical Institute, 600 Main St, Bar Harbor, ME, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Ophthalmology, Tufts University School of Medicine, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Howell</LastName><ForeName>Gareth R</ForeName><Initials>GR</Initials><AffiliationInfo><Affiliation>The Jackson Laboratory, 600 Main St, Bar Harbor, ME, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Graduate Program in Genetics, Sackler School of Graduate Biomedical Sciences, Tufts University, 136 Harrison Avenue, Boston, MA 02111, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 EY011721</GrantID><Acronym>EY</Acronym><Agency>NEI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R29 EY011721</GrantID><Acronym>EY</Acronym><Agency>NEI NIH HHS</Agency><Country>United States</Country></Grant><Grant><Agency>Howard Hughes Medical Institute</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 EY021525</GrantID><Acronym>EY</Acronym><Agency>NEI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>EY021525</GrantID><Acronym>EY</Acronym><Agency>NEI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>EY011721</GrantID><Acronym>EY</Acronym><Agency>NEI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>02</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sci Rep</MedlineTA><NlmUniqueID>101563288</NlmUniqueID><ISSNLinking>2045-2322</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D066273" MajorTopicYN="N">Diet, Western</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005911" MajorTopicYN="N">Gliosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>9</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>1</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>2</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>2</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>12</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2016</Year><Month>2</Month><Day>18</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26888450</ArticleId><ArticleId IdType="pmc">PMC4757836</ArticleId><ArticleId IdType="doi">10.1038/srep21568</ArticleId><ArticleId IdType="pii">srep21568</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Braak H. &amp; Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 82, 239&#x2013;259, 10.1007/BF00308809 (1991).</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF00308809</ArticleId><ArticleId IdType="pubmed">1759558</ArticleId></ArticleIdList></Reference><Reference><Citation>Bero A. W. et al. Neuronal activity regulates the regional vulnerability to amyloid-beta deposition. Nat Neurosci 14, 750&#x2013;756, 10.1038/nn.2801 (2011).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.2801</ArticleId><ArticleId IdType="pmc">PMC3102784</ArticleId><ArticleId IdType="pubmed">21532579</ArticleId></ArticleIdList></Reference><Reference><Citation>Hooli B. V. et al. Role of common and rare APP DNA sequence variants in Alzheimer disease. Neurology 78, 1250&#x2013;1257, 10.1212/WNL.0b013e3182515972 (2012).</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e3182515972</ArticleId><ArticleId IdType="pmc">PMC3324321</ArticleId><ArticleId IdType="pubmed">22491860</ArticleId></ArticleIdList></Reference><Reference><Citation>Thinakaran G.
et al.
Stable Association of Presenilin Derivatives and Absence of Presenilin Interactions with APP. Neurobiology of Disease
4, 438&#x2013;453, http://dx.doi.org/10.1006/nbdi.1998.0171 (1998).</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/nbdi.1998.0171</ArticleId><ArticleId IdType="pubmed">9666482</ArticleId></ArticleIdList></Reference><Reference><Citation>Genin E.
et al.
APOE and Alzheimer disease: a major gene with semi-dominant inheritance. Mol Psychiatry
16, 903&#x2013;907, http://www.nature.com/mp/journal/v16/n9/suppinfo/mp201152s1.html (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3162068</ArticleId><ArticleId IdType="pubmed">21556001</ArticleId></ArticleIdList></Reference><Reference><Citation>Harold D. et al. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer&#x2019;s disease. Nat Genet 41, 1088&#x2013;1093, 10.1038/ng.440 (2009).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.440</ArticleId><ArticleId IdType="pmc">PMC2845877</ArticleId><ArticleId IdType="pubmed">19734902</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert J.-C. et al. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer&#x2019;s disease. Nat Genet 45, 1452&#x2013;1458, 10.1038/ng.2802http://www.nature.com/ng/journal/v45/n12/abs/ng.2802.html - supplementary-information (2013).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.2802http://www.nature.com/ng/journal/v45/n12/abs/ng.2802.html</ArticleId><ArticleId IdType="pmc">PMC3896259</ArticleId><ArticleId IdType="pubmed">24162737</ArticleId></ArticleIdList></Reference><Reference><Citation>Ogden C. L., Carroll M. D., Kit B. K. &amp; Flegal K. M. PRevalence of childhood and adult obesity in the united states, 2011&#x2013;2012. JAMA 311, 806&#x2013;814, 10.1001/jama.2014.732 (2014).</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2014.732</ArticleId><ArticleId IdType="pmc">PMC4770258</ArticleId><ArticleId IdType="pubmed">24570244</ArticleId></ArticleIdList></Reference><Reference><Citation>Kivipelto M., Ngandu T., Fratiglioni L. et al. OBesity and vascular risk factors at midlife and the risk of dementia and alzheimer disease. Archives of Neurology 62, 1556&#x2013;1560, 10.1001/archneur.62.10.1556 (2005).</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneur.62.10.1556</ArticleId><ArticleId IdType="pubmed">16216938</ArticleId></ArticleIdList></Reference><Reference><Citation>Qizilbash N. et al. BMI and risk of dementia in two million people over two decades: a retrospective cohort study. The Lancet Diabetes &amp; Endocrinology, 10.1016/S2213-8587(15)00033-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-8587(15)00033-9</ArticleId><ArticleId IdType="pubmed">25866264</ArticleId></ArticleIdList></Reference><Reference><Citation>Cordain L. et al. Origins and evolution of the Western diet: health implications for the 21st century. The American Journal of Clinical Nutrition 81, 341&#x2013;354 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">15699220</ArticleId></ArticleIdList></Reference><Reference><Citation>Allison D. B., Fontaine K. R., Manson J. E., Stevens J. &amp; VanItallie T. B. Annual deaths attributable to obesity in the United States. Jama 282, 1530&#x2013;1538 (1999).</Citation><ArticleIdList><ArticleId IdType="pubmed">10546692</ArticleId></ArticleIdList></Reference><Reference><Citation>Hedley A. A. et al. Prevalence of overweight and obesity among US children, adolescents, and adults, 1999&#x2013;2002. Jama 291, 2847&#x2013;2850 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15199035</ArticleId></ArticleIdList></Reference><Reference><Citation>Popkin B. M., Adair L. S. &amp; Ng S. W. Global nutrition transition and the pandemic of obesity in developing countries. Nutrition reviews 70, 3&#x2013;21 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3257829</ArticleId><ArticleId IdType="pubmed">22221213</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO J. &amp; Consultation, F. E. Diet, nutrition and the prevention of chronic diseases. WHO technical report series, 1&#x2013;60 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">12768890</ArticleId></ArticleIdList></Reference><Reference><Citation>Association A. D. Evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes and related complications. Clinical Diabetes 20, 53&#x2013;64 (2002).</Citation></Reference><Reference><Citation>Pistell P. J. et al. Cognitive impairment following high fat diet consumption is associated with brain inflammation. Journal of neuroimmunology 219, 25&#x2013;32, 10.1016/j.jneuroim.2009.11.010 (2010).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jneuroim.2009.11.010</ArticleId><ArticleId IdType="pmc">PMC2823983</ArticleId><ArticleId IdType="pubmed">20004026</ArticleId></ArticleIdList></Reference><Reference><Citation>Oksman M. et al. Impact of different saturated fatty acid, polyunsaturated fatty acid and cholesterol containing diets on beta-amyloid accumulation in APP/PS1 transgenic mice. Neurobiol Dis 23, 563&#x2013;572, 10.1016/j.nbd.2006.04.013 (2006).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2006.04.013</ArticleId><ArticleId IdType="pubmed">16765602</ArticleId></ArticleIdList></Reference><Reference><Citation>Valladolid-Acebes I. et al. High-fat diets impair spatial learning in the radial-arm maze in mice. Neurobiology of learning and memory 95, 80&#x2013;85 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21093599</ArticleId></ArticleIdList></Reference><Reference><Citation>Knight E. M., Martins I. V. A., G&#xfc;m&#xfc;sg&#xf6;z S., Allan S. M. &amp; Lawrence C. B. High-fat diet-induced memory impairment in triple-transgenic Alzheimer&#x2019;s disease (3xTgAD) mice is independent of changes in amyloid and tau pathology(). Neurobiology of Aging 35, 1821&#x2013;1832, 10.1016/j.neurobiolaging.2014.02.010 (2014).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2014.02.010</ArticleId><ArticleId IdType="pmc">PMC4024197</ArticleId><ArticleId IdType="pubmed">24630364</ArticleId></ArticleIdList></Reference><Reference><Citation>Shie F.-S., Jin L.-W., Cook D. G., Leverenz J. B. &amp; LeBoeuf R. C. Diet-induced hypercholesterolemia enhances brain A&#x3b2; accumulation in transgenic mice. Neuroreport 13, 455&#x2013;459 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">11930160</ArticleId></ArticleIdList></Reference><Reference><Citation>Julien C. et al. High-fat diet aggravates amyloid-beta and tau pathologies in the 3xTg-AD mouse model. Neurobiology of aging 31, 1516&#x2013;1531 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">18926603</ArticleId></ArticleIdList></Reference><Reference><Citation>Campbell T. M. II The China study: the most comprehensive study of nutrition ever conducted and the startling implications for diet, weight loss and long-term health. (BenBella Books, Inc., 2004).</Citation></Reference><Reference><Citation>Naderali E. K., Ratcliffe S. H. &amp; Dale M. C. Review: Obesity and Alzheimer&#x2019;s Disease: A Link Between Body Weight and Cognitive Function in Old Age. American Journal of Alzheimer&#x2019;s Disease and Other Dementias 24, 445&#x2013;449, 10.1177/1533317509348208 (2009).</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1533317509348208</ArticleId><ArticleId IdType="pmc">PMC10846277</ArticleId><ArticleId IdType="pubmed">19801534</ArticleId></ArticleIdList></Reference><Reference><Citation>Heneka M., O&#x2019;Banion M. K., Terwel D. &amp; Kummer M. Neuroinflammatory processes in Alzheimer&#x2019;s disease. J Neural Transm 117, 919&#x2013;947, 10.1007/s00702-010-0438-z (2010).</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00702-010-0438-z</ArticleId><ArticleId IdType="pubmed">20632195</ArticleId></ArticleIdList></Reference><Reference><Citation>Ankeny D. P. &amp; Popovich P. G.
Mechanisms and implications of adaptive immune responses after traumatic spinal cord injury. Neuroscience
158, 1112&#x2013;1121, http://dx.doi.org/10.1016/j.neuroscience.2008.07.001 (2009).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroscience.2008.07.001</ArticleId><ArticleId IdType="pmc">PMC2661571</ArticleId><ArticleId IdType="pubmed">18674593</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagareddy Prabhakara R.
et al.
Adipose Tissue Macrophages Promote Myelopoiesis and Monocytosis in Obesity. Cell Metabolism
19, 821&#x2013;835, http://dx.doi.org/10.1016/j.cmet.2014.03.029 (2014).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmet.2014.03.029</ArticleId><ArticleId IdType="pmc">PMC4048939</ArticleId><ArticleId IdType="pubmed">24807222</ArticleId></ArticleIdList></Reference><Reference><Citation>Levinson R. Obesity: Recruiting inflammatory cells to fat. Nature medicine 20, 594&#x2013;594, 10.1038/nm.3603 (2014).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.3603</ArticleId></ArticleIdList></Reference><Reference><Citation>Jay T. R. et al. TREM2 deficiency eliminates TREM2+ inflammatory macrophages and ameliorates pathology in Alzheimer&#x2019;s disease mouse models. J Exp Med 212, 287&#x2013;295, 10.1084/jem.20142322 (2015).</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20142322</ArticleId><ArticleId IdType="pmc">PMC4354365</ArticleId><ArticleId IdType="pubmed">25732305</ArticleId></ArticleIdList></Reference><Reference><Citation>Jonsson T. et al. Variant of TREM2 associated with the risk of Alzheimer&#x2019;s disease. New England Journal of Medicine 368, 107&#x2013;116 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3677583</ArticleId><ArticleId IdType="pubmed">23150908</ArticleId></ArticleIdList></Reference><Reference><Citation>Perry V. H., Cunningham C. &amp; Holmes C. Systemic infections and inflammation affect chronic neurodegeneration. Nature Reviews Immunology 7, 161&#x2013;167 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17220915</ArticleId></ArticleIdList></Reference><Reference><Citation>Frank S. et al. TREM2 is upregulated in amyloid plaque-associated microglia in aged APP23 transgenic mice. Glia 56, 1438&#x2013;1447, 10.1002/glia.20710 (2008).</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/glia.20710</ArticleId><ArticleId IdType="pubmed">18551625</ArticleId></ArticleIdList></Reference><Reference><Citation>Salminen A., Ojala J., Kauppinen A., Kaarniranta K. &amp; Suuronen T.
Inflammation in Alzheimer&#x2019;s disease: Amyloid-&#x3b2; oligomers trigger innate immunity defence via pattern recognition receptors. Progress in Neurobiology
87, 181&#x2013;194, http://dx.doi.org/10.1016/j.pneurobio.2009.01.001 (2009).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pneurobio.2009.01.001</ArticleId><ArticleId IdType="pubmed">19388207</ArticleId></ArticleIdList></Reference><Reference><Citation>Jankowsky J. L. et al. Mutant presenilins specifically elevate the levels of the 42 residue beta-amyloid peptide in vivo: evidence for augmentation of a 42-specific gamma-secretase. Human Molecular Genetics 13, 159&#x2013;170, 10.1093/hmg/ddh019 (2004).</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddh019</ArticleId><ArticleId IdType="pubmed">14645205</ArticleId></ArticleIdList></Reference><Reference><Citation>Jankowsky J. L.
et al.
Co-expression of multiple transgenes in mouse CNS: a comparison of strategies. Biomolecular Engineering
17, 157&#x2013;165, http://dx.doi.org/10.1016/S1389-0344(01)00067-3 (2001).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1389-0344(01)00067-3</ArticleId><ArticleId IdType="pubmed">11337275</ArticleId></ArticleIdList></Reference><Reference><Citation>Jay T. R. et al. TREM2 deficiency eliminates TREM2+ inflammatory macrophages and ameliorates pathology in Alzheimer&#x2019;s disease mouse models. The Journal of experimental medicine 212, 287&#x2013;295 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4354365</ArticleId><ArticleId IdType="pubmed">25732305</ArticleId></ArticleIdList></Reference><Reference><Citation>Clee S. M. &amp; Attie A. D. The genetic landscape of type 2 diabetes in mice. Endocrine reviews 28, 48&#x2013;83, 10.1210/er.2006-0035 (2007).</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/er.2006-0035</ArticleId><ArticleId IdType="pubmed">17018838</ArticleId></ArticleIdList></Reference><Reference><Citation>Elias M. F., Elias P. K., Sullivan L. M., Wolf P. A. &amp; D&#x2019;Agostino R. B.
Obesity, diabetes and cognitive deficit: The Framingham Heart Study. Neurobiology of Aging
26, 11&#x2013;16, http://dx.doi.org/10.1016/j.neurobiolaging.2005.08.019 (2005).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2005.08.019</ArticleId><ArticleId IdType="pubmed">16223549</ArticleId></ArticleIdList></Reference><Reference><Citation>Sj&#xf6;gren K. et al. Body Fat Content Can Be Predicted In Vivo in Mice Using a Modified Dual-Energy X-Ray Absorptiometry Technique. The Journal of Nutrition 131, 2963&#x2013;2966 (2001).</Citation><ArticleIdList><ArticleId IdType="pubmed">11694626</ArticleId></ArticleIdList></Reference><Reference><Citation>Jackson H., Soto I., Graham L., Carter G. &amp; Howell G. Clustering of transcriptional profiles identifies changes to insulin signaling as an early event in a mouse model of Alzheimer&#x2019;s disease. BMC Genomics 14, 831 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3907022</ArticleId><ArticleId IdType="pubmed">24274089</ArticleId></ArticleIdList></Reference><Reference><Citation>Burgess B. L.
et al.
Elevated plasma triglyceride levels precede amyloid deposition in Alzheimer&#x2019;s disease mouse models with abundant A&#x3b2; in plasma. Neurobiology of Disease
24, 114&#x2013;127, http://dx.doi.org/10.1016/j.nbd.2006.06.007 (2006).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2006.06.007</ArticleId><ArticleId IdType="pubmed">16899370</ArticleId></ArticleIdList></Reference><Reference><Citation>Richner M., Bach G. &amp; West M. J.
Over expression of amyloid beta-protein reduces the number of neurons in the striatum of APPswe/PS1&#x394;E9. Brain Research
1266, 87&#x2013;92, http://dx.doi.org/10.1016/j.brainres.2009.02.025 (2009).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2009.02.025</ArticleId><ArticleId IdType="pubmed">19245800</ArticleId></ArticleIdList></Reference><Reference><Citation>Rupp N. J., Wegenast-Braun B. M., Radde R., Calhoun M. E. &amp; Jucker M.
Early onset amyloid lesions lead to severe neuritic abnormalities and local, but not global neuron loss in APPPS1 transgenic mice. Neurobiology of Aging
32, 2324.e2321-2324.e2326, http://dx.doi.org/10.1016/j.neurobiolaging.2010.08.014 (2011).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2010.08.014</ArticleId><ArticleId IdType="pubmed">20970889</ArticleId></ArticleIdList></Reference><Reference><Citation>Blanchard V.
et al.
Time sequence of maturation of dystrophic neurites associated with A&#x3b2; deposits in APP/PS1 transgenic mice. Experimental Neurology
184, 247&#x2013;263, http://dx.doi.org/10.1016/S0014-4886(03)00252-8 (2003).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0014-4886(03)00252-8</ArticleId><ArticleId IdType="pubmed">14637096</ArticleId></ArticleIdList></Reference><Reference><Citation>Wirths O., Weis J., Szczygielski J., Multhaup G. &amp; Bayer T. A. Axonopathy in an APP/PS1 transgenic mouse model of Alzheimer&#x2019;s disease. Acta Neuropathol 111, 312&#x2013;319 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16520967</ArticleId></ArticleIdList></Reference><Reference><Citation>Guillot-Sestier M.-V.
et al.
Il10 Deficiency Rebalances Innate Immunity to Mitigate Alzheimer-Like Pathology. Neuron
85, 534&#x2013;548, http://dx.doi.org/10.1016/j.neuron.2014.12.068 (2015).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2014.12.068</ArticleId><ArticleId IdType="pmc">PMC4352138</ArticleId><ArticleId IdType="pubmed">25619654</ArticleId></ArticleIdList></Reference><Reference><Citation>Cardona A. E.
et al.
Control of microglial neurotoxicity by the fractalkine receptor. Nature neuroscience
9, 917&#x2013;924, http://www.nature.com/neuro/journal/v9/n7/suppinfo/nn1715_S1.html (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16732273</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsieh C. L. et al. A role for TREM2 ligands in the phagocytosis of apoptotic neuronal cells by microglia. Journal of Neurochemistry 109, 1144&#x2013;1156, 10.1111/j.1471-4159.2009.06042.x (2009).</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2009.06042.x</ArticleId><ArticleId IdType="pmc">PMC3087597</ArticleId><ArticleId IdType="pubmed">19302484</ArticleId></ArticleIdList></Reference><Reference><Citation>Esser N., Legrand-Poels S., Piette J., Scheen A. J. &amp; Paquot N.
Inflammation as a link between obesity, metabolic syndrome and type 2 diabetes. Diabetes Research and Clinical Practice
105, 141&#x2013;150, http://dx.doi.org/10.1016/j.diabres.2014.04.006 (2014).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.diabres.2014.04.006</ArticleId><ArticleId IdType="pubmed">24798950</ArticleId></ArticleIdList></Reference><Reference><Citation>Fakhouri T. H. &amp; Statistics, N. C. f. H. Prevalence of obesity among older adults in the United States, 2007&#x2013;2010. (Citeseer, 2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">23102091</ArticleId></ArticleIdList></Reference><Reference><Citation>Norton S., Matthews F. E., Barnes D. E., Yaffe K. &amp; Brayne C. Potential for primary prevention of Alzheimer&#x2019;s disease: an analysis of population-based data. The Lancet Neurology 13, 788&#x2013;794, 10.1016/s1474-4422(14)70136-x (2014).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s1474-4422(14)70136-x</ArticleId><ArticleId IdType="pubmed">25030513</ArticleId></ArticleIdList></Reference><Reference><Citation>Cornelis M. C. et al. Obesity susceptibility loci and uncontrolled eating, emotional eating and cognitive restraint behaviors in men and women. Obesity 22, E135&#x2013;E141 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3858422</ArticleId><ArticleId IdType="pubmed">23929626</ArticleId></ArticleIdList></Reference><Reference><Citation>Comuzzie A. G. &amp; Allison D. B. The search for human obesity genes. Science 280, 1374&#x2013;1377 (1998).</Citation><ArticleIdList><ArticleId IdType="pubmed">9603720</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopes da Silva S.
et al.
Plasma nutrient status of patients with Alzheimer&#x2019;s disease: Systematic review and meta-analysis. Alzheimer&#x2019;s &amp; Dementia
10, 485&#x2013;502, http://dx.doi.org/10.1016/j.jalz.2013.05.1771 (2014).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2013.05.1771</ArticleId><ArticleId IdType="pubmed">24144963</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanoski S. E. &amp; Davidson T. L. Western diet consumption and cognitive impairment: links to hippocampal dysfunction and obesity. Physiology &amp; behavior 103, 59&#x2013;68 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3056912</ArticleId><ArticleId IdType="pubmed">21167850</ArticleId></ArticleIdList></Reference><Reference><Citation>James M. J., Gibson R. A. &amp; Cleland L. G. Dietary polyunsaturated fatty acids and inflammatory mediator production. The American Journal of Clinical Nutrition 71, 343s&#x2013;348s (2000).</Citation><ArticleIdList><ArticleId IdType="pubmed">10617994</ArticleId></ArticleIdList></Reference><Reference><Citation>Valdearcos M. et al. Microglia Dictate the Impact of Saturated Fat Consumption on Hypothalamic Inflammation and Neuronal Function. Cell Reports 9, 2124&#x2013;2138, 10.1016/j.celrep.2014.11.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2014.11.018</ArticleId><ArticleId IdType="pmc">PMC4617309</ArticleId><ArticleId IdType="pubmed">25497089</ArticleId></ArticleIdList></Reference><Reference><Citation>Myles I. A. Fast food fever: reviewing the impacts of the Western diet on immunity. Nutrition journal 13, 61 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4074336</ArticleId><ArticleId IdType="pubmed">24939238</ArticleId></ArticleIdList></Reference><Reference><Citation>Brochard V. et al. Infiltration of CD4+ lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease. The Journal of clinical investigation 119, 182 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2613467</ArticleId><ArticleId IdType="pubmed">19104149</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamasaki R. et al. Differential roles of microglia and monocytes in the inflamed central nervous system. The Journal of experimental medicine 211, 1533&#x2013;1549 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4113947</ArticleId><ArticleId IdType="pubmed">25002752</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaftel S. S. et al. Chronic Interleukin-1&#x3b2; Expression in Mouse Brain Leads to Leukocyte Infiltration and Neutrophil-Independent Blood&#x2013;Brain Barrier Permeability without Overt Neurodegeneration. The Journal of Neuroscience 27, 9301&#x2013;9309, 10.1523/jneurosci.1418-07.2007 (2007).</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/jneurosci.1418-07.2007</ArticleId><ArticleId IdType="pmc">PMC6673122</ArticleId><ArticleId IdType="pubmed">17728444</ArticleId></ArticleIdList></Reference><Reference><Citation>Ownby R. Neuroinflammation and Cognitive Aging. Curr Psychiatry Rep 12, 39&#x2013;45, 10.1007/s11920-009-0082-1 (2010).</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11920-009-0082-1</ArticleId><ArticleId IdType="pubmed">20425309</ArticleId></ArticleIdList></Reference><Reference><Citation>Guerreiro R. et al. TREM2 variants in Alzheimer&#x2019;s disease. New England Journal of Medicine 368, 117&#x2013;127 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3631573</ArticleId><ArticleId IdType="pubmed">23150934</ArticleId></ArticleIdList></Reference><Reference><Citation>Ulrich J. D. et al. Altered microglial response to Abeta plaques in APPPS1-21 mice heterozygous for TREM2. Mol Neurodegener 9, 20 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4049806</ArticleId><ArticleId IdType="pubmed">24893973</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">26892305</PMID><DateCompleted><Year>2016</Year><Month>07</Month><Day>26</Day></DateCompleted><DateRevised><Year>2019</Year><Month>12</Month><Day>10</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2041-1723</ISSN><JournalIssue CitedMedium="Internet"><Volume>7</Volume><PubDate><Year>2016</Year><Month>Feb</Month><Day>19</Day></PubDate></JournalIssue><Title>Nature communications</Title><ISOAbbreviation>Nat Commun</ISOAbbreviation></Journal><ArticleTitle>Antibody-based PET imaging of amyloid beta in mouse models of Alzheimer's disease.</ArticleTitle><Pagination><StartPage>10759</StartPage><MedlinePgn>10759</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">10759</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/ncomms10759</ELocationID><Abstract><AbstractText>Owing to their specificity and high-affinity binding, monoclonal antibodies have potential as positron emission tomography (PET) radioligands and are currently used to image various targets in peripheral organs. However, in the central nervous system, antibody uptake is limited by the blood-brain barrier (BBB). Here we present a PET ligand to be used for diagnosis and evaluation of treatment effects in Alzheimer's disease. The amyloid &#x3b2; (A&#x3b2;) antibody mAb158 is radiolabelled and conjugated to a transferrin receptor antibody to enable receptor-mediated transcytosis across the BBB. PET imaging of two different mouse models with A&#x3b2; pathology clearly visualize A&#x3b2; in the brain. The PET signal increases with age and correlates closely with brain A&#x3b2; levels. Thus, we demonstrate that antibody-based PET ligands can be successfully used for brain imaging.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sehlin</LastName><ForeName>Dag</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0002-9430-3859</Identifier><AffiliationInfo><Affiliation>Department of Public Health and Caring Sciences/Geriatrics, Uppsala University, Rudbeck Laboratory, 75185 Uppsala, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fang</LastName><ForeName>Xiaotian T</ForeName><Initials>XT</Initials><AffiliationInfo><Affiliation>Department of Public Health and Caring Sciences/Geriatrics, Uppsala University, Rudbeck Laboratory, 75185 Uppsala, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cato</LastName><ForeName>Linda</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Public Health and Caring Sciences/Geriatrics, Uppsala University, Rudbeck Laboratory, 75185 Uppsala, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Antoni</LastName><ForeName>Gunnar</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Medicinal Chemistry, Preclinical PET Platform, Uppsala University, 75123 Uppsala, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>PET Centre, Uppsala University Hospital, 75185 Uppsala, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lannfelt</LastName><ForeName>Lars</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Public Health and Caring Sciences/Geriatrics, Uppsala University, Rudbeck Laboratory, 75185 Uppsala, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Syv&#xe4;nen</LastName><ForeName>Stina</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Public Health and Caring Sciences/Geriatrics, Uppsala University, Rudbeck Laboratory, 75185 Uppsala, Sweden.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D023362">Evaluation Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>02</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nat Commun</MedlineTA><NlmUniqueID>101528555</NlmUniqueID><ISSNLinking>2041-1723</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000911" MajorTopicYN="N">Antibodies, Monoclonal</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="N">Positron-Emission Tomography</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011859" MajorTopicYN="N">Radiography</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>L.L. is a founder of BioArctic Neuroscience and has shares in the company. The remaining authors declare no competing financial interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>6</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>1</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>2</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>2</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>7</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2016</Year><Month>2</Month><Day>19</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26892305</ArticleId><ArticleId IdType="pmc">PMC4762893</ArticleId><ArticleId IdType="doi">10.1038/ncomms10759</ArticleId><ArticleId IdType="pii">ncomms10759</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Klunk W. E. et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann. Neurol. 55, 306&#x2013;319 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">14991808</ArticleId></ArticleIdList></Reference><Reference><Citation>Fagan A. M. et al. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann. Neurol. 59, 512&#x2013;519 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16372280</ArticleId></ArticleIdList></Reference><Reference><Citation>Engler H. et al. In vivo amyloid imaging with PET in frontotemporal dementia. Eur. J. Nucl. Med. Mol. Imaging 35, 100&#x2013;106 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">17846768</ArticleId></ArticleIdList></Reference><Reference><Citation>Rabinovici G. D. et al. 11C-PIB PET imaging in Alzheimer disease and frontotemporal lobar degeneration. Neurology 68, 1205&#x2013;1212 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17420404</ArticleId></ArticleIdList></Reference><Reference><Citation>Engler H. et al. Two-year follow-up of amyloid deposition in patients with Alzheimer's disease. Brain 129, 2856&#x2013;2866 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16854944</ArticleId></ArticleIdList></Reference><Reference><Citation>Terry R. D. et al. Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann. Neurol. 30, 572&#x2013;580 (1991).</Citation><ArticleIdList><ArticleId IdType="pubmed">1789684</ArticleId></ArticleIdList></Reference><Reference><Citation>McLean C. A. et al. Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann. Neurol. 46, 860&#x2013;866 (1999).</Citation><ArticleIdList><ArticleId IdType="pubmed">10589538</ArticleId></ArticleIdList></Reference><Reference><Citation>N&#xe4;slund J. et al. Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline. JAMA 283, 1571&#x2013;1577 (2000).</Citation><ArticleIdList><ArticleId IdType="pubmed">10735393</ArticleId></ArticleIdList></Reference><Reference><Citation>Fukumoto H. et al. High-molecular-weight beta-amyloid oligomers are elevated in cerebrospinal fluid of Alzheimer patients. FASEB J. 24, 2716&#x2013;2726 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20339023</ArticleId></ArticleIdList></Reference><Reference><Citation>Esparza T. J. et al. Amyloid-beta oligomerization in Alzheimer dementia versus high-pathology controls. Ann. Neurol. 73, 104&#x2013;119 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3563737</ArticleId><ArticleId IdType="pubmed">23225543</ArticleId></ArticleIdList></Reference><Reference><Citation>Lannfelt L., Relkin N. R. &amp; Siemers E. R. Amyloid-&#x3b2;-directed immunotherapy for Alzheimer's disease. J. Intern. Med. 275, 284&#x2013;295 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4238820</ArticleId><ArticleId IdType="pubmed">24605809</ArticleId></ArticleIdList></Reference><Reference><Citation>Goure W. F., Krafft G. A., Jerecic J. &amp; Hefti F. Targeting the proper amyloid-beta neuronal toxins: a path forward for Alzheimer's disease immunotherapeutics. Alzheimers Res. Ther. 6, 42 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4100318</ArticleId><ArticleId IdType="pubmed">25045405</ArticleId></ArticleIdList></Reference><Reference><Citation>Lannfelt L. et al. Perspectives on future Alzheimer therapies: amyloid-beta protofibrils&#x2014;a new target for immunotherapy with BAN2401 in Alzheimer's disease. Alzheimers Res. Ther. 6, 16 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4054967</ArticleId><ArticleId IdType="pubmed">25031633</ArticleId></ArticleIdList></Reference><Reference><Citation>Viola K. L. &amp; Klein W. L. Amyloid beta oligomers in Alzheimer's disease pathogenesis, treatment, and diagnosis. Acta Neuropathol. 129, 183&#x2013;206 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4390393</ArticleId><ArticleId IdType="pubmed">25604547</ArticleId></ArticleIdList></Reference><Reference><Citation>Viola K. L. et al. Towards non-invasive diagnostic imaging of early-stage Alzheimer's disease. Nat. Nanotechnol. 10, 91&#x2013;98 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4300856</ArticleId><ArticleId IdType="pubmed">25531084</ArticleId></ArticleIdList></Reference><Reference><Citation>Salvadores N., Shahnawaz M., Scarpini E., Tagliavini F. &amp; Soto C. Detection of misfolded Abeta oligomers for sensitive biochemical diagnosis of Alzheimer's disease. Cell Rep. 7, 261&#x2013;268 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24656814</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang-Dietrich L. et al. The amyloid-beta oligomer count in cerebrospinal fluid is a biomarker for Alzheimer's disease. J. Alzheimers Dis. 34, 985&#x2013;994 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23313925</ArticleId></ArticleIdList></Reference><Reference><Citation>Sehlin D. et al. Large aggregates are the major soluble Abeta species in AD brain fractionated with density gradient ultracentrifugation. PLoS ONE 7, e32014 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3280222</ArticleId><ArticleId IdType="pubmed">22355408</ArticleId></ArticleIdList></Reference><Reference><Citation>Nilsberth C. et al. The &#x2018;Arctic' APP mutation (E693G) causes Alzheimer's disease by enhanced Abeta protofibril formation. Nat. Neurosci. 4, 887&#x2013;893 (2001).</Citation><ArticleIdList><ArticleId IdType="pubmed">11528419</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh D. M. et al. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416, 535&#x2013;539 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">11932745</ArticleId></ArticleIdList></Reference><Reference><Citation>Klyubin I. et al. Amyloid beta protein dimer-containing human CSF disrupts synaptic plasticity: prevention by systemic passive immunization. J. Neurosci. 28, 4231&#x2013;4237 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2685151</ArticleId><ArticleId IdType="pubmed">18417702</ArticleId></ArticleIdList></Reference><Reference><Citation>Shankar G. M. et al. Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat. Med. 14, 837&#x2013;842 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2772133</ArticleId><ArticleId IdType="pubmed">18568035</ArticleId></ArticleIdList></Reference><Reference><Citation>Fowler S. W. et al. Genetic modulation of soluble Abeta rescues cognitive and synaptic impairment in a mouse model of Alzheimer's disease. J. Neurosci. 34, 7871&#x2013;7885 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4044248</ArticleId><ArticleId IdType="pubmed">24899710</ArticleId></ArticleIdList></Reference><Reference><Citation>van Dongen G. A., Poot A. J. &amp; Vugts D. J. PET imaging with radiolabeled antibodies and tyrosine kinase inhibitors: immuno-PET and TKI-PET. Tumour Biol. 33, 607&#x2013;615 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3342498</ArticleId><ArticleId IdType="pubmed">22270450</ArticleId></ArticleIdList></Reference><Reference><Citation>Englund H. et al. Sensitive ELISA detection of amyloid-beta protofibrils in biological samples. J. Neurochem. 103, 334&#x2013;345 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17623042</ArticleId></ArticleIdList></Reference><Reference><Citation>Sehlin D. et al. Heavy-chain complementarity-determining regions determine conformation selectivity of anti-abeta antibodies. Neurodegener. Dis. 8, 117&#x2013;123 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">20714111</ArticleId></ArticleIdList></Reference><Reference><Citation>Magnusson K. et al. Specific uptake of an amyloid-beta protofibril-binding antibody-tracer in AbetaPP transgenic mouse brain. J. Alzheimers Dis. 37, 29&#x2013;40 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23780660</ArticleId></ArticleIdList></Reference><Reference><Citation>Tucker S. et al. The murine version of BAN2401 (mAb158) selectively reduces amyloid-beta protofibrils in brain and cerebrospinal fluid of tg-ArcSwe mice. J. Alzheimers Dis. 43, 575&#x2013;588 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">25096615</ArticleId></ArticleIdList></Reference><Reference><Citation>Lord A. et al. The Arctic Alzheimer mutation facilitates early intraneuronal Abeta aggregation and senile plaque formation in transgenic mice. Neurobiol. Aging 27, 67&#x2013;77 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16298242</ArticleId></ArticleIdList></Reference><Reference><Citation>Poduslo J. F., Curran G. L. &amp; Berg C. T. Macromolecular permeability across the blood-nerve and blood-brain barriers. Proc. Natl Acad. Sci. USA 91, 5705&#x2013;5709 (1994).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC44065</ArticleId><ArticleId IdType="pubmed">8202551</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu D. &amp; Pardridge W. M. Neuroprotection with noninvasive neurotrophin delivery to the brain. Proc. Natl Acad. Sci. USA 96, 254&#x2013;259 (1999).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC15126</ArticleId><ArticleId IdType="pubmed">9874805</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu Y. J. et al. Boosting brain uptake of a therapeutic antibody by reducing its affinity for a transcytosis target. Sci. Transl. Med. 3, 84ra44 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21613623</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu Y. J. et al. Therapeutic bispecific antibodies cross the blood-brain barrier in nonhuman primates. Sci. Transl. Med. 6, 261ra154 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">25378646</ArticleId></ArticleIdList></Reference><Reference><Citation>Niewoehner J. et al. Increased brain penetration and potency of a therapeutic antibody using a monovalent molecular shuttle. Neuron 81, 49&#x2013;60 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24411731</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee H. J., Engelhardt B., Lesley J., Bickel U. &amp; Pardridge W. M. Targeting rat anti-mouse transferrin receptor monoclonal antibodies through blood-brain barrier in mouse. J. Pharmacol. Exp. Ther. 292, 1048&#x2013;1052 (2000).</Citation><ArticleIdList><ArticleId IdType="pubmed">10688622</ArticleId></ArticleIdList></Reference><Reference><Citation>Kissel K. et al. Immunohistochemical localization of the murine transferrin receptor (TfR) on blood-tissue barriers using a novel anti-TfR monoclonal antibody. Histochem. Cell Biol. 110, 63&#x2013;72 (1998).</Citation><ArticleIdList><ArticleId IdType="pubmed">9681691</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee H. J., Zhang Y., Zhu C., Duff K. &amp; Pardridge W. M. Imaging brain amyloid of Alzheimer disease in vivo in transgenic mice with an Abeta peptide radiopharmaceutical. J. Cereb. Blood Flow Metab. 22, 223&#x2013;231 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">11823720</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y. &amp; Pardridge W. M. Delivery of beta-galactosidase to mouse brain via the blood-brain barrier transferrin receptor. J. Pharmacol. Exp. Ther. 313, 1075&#x2013;1081 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">15718287</ArticleId></ArticleIdList></Reference><Reference><Citation>Boado R. J., Zhang Y., Wang Y. &amp; Pardridge W. M. Engineering and expression of a chimeric transferrin receptor monoclonal antibody for blood-brain barrier delivery in the mouse. Biotechnol. Bioeng. 102, 1251&#x2013;1258 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2729652</ArticleId><ArticleId IdType="pubmed">18942151</ArticleId></ArticleIdList></Reference><Reference><Citation>Cabezon I. et al. Trafficking of gold nanoparticles coated with the 8D3 anti-transferrin receptor antibody at the mouse blood-brain barrier. Mol. Pharm. 12, 4137&#x2013;4145 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26440359</ArticleId></ArticleIdList></Reference><Reference><Citation>Koffie R. M. et al. Oligomeric amyloid &#x3b2; associates with postsynaptic densities and correlates with excitatory synapse loss near senile plaques. Proc. Natl Acad. Sci. USA 106, 4012&#x2013;4017 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2656196</ArticleId><ArticleId IdType="pubmed">19228947</ArticleId></ArticleIdList></Reference><Reference><Citation>Philipson O. et al. A highly insoluble state of Abeta similar to that of Alzheimer's disease brain is found in Arctic APP transgenic mice. Neurobiol. Aging 30, 1393&#x2013;1405 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">18192084</ArticleId></ArticleIdList></Reference><Reference><Citation>Lord A. et al. An amyloid-beta protofibril-selective antibody prevents amyloid formation in a mouse model of Alzheimer's disease. Neurobiol. Dis. 36, 425&#x2013;434 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19703562</ArticleId></ArticleIdList></Reference><Reference><Citation>Bussiere T. et al. Morphological characterization of thioflavin-S-positive amyloid plaques in transgenic Alzheimer mice and effect of passive Abeta immunotherapy on their clearance. Am. J. Pathol. 165, 987&#x2013;995 (2004).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1618604</ArticleId><ArticleId IdType="pubmed">15331422</ArticleId></ArticleIdList></Reference><Reference><Citation>Ingelsson M. et al. Early Abeta accumulation and progressive synaptic loss, gliosis, and tangle formation in AD brain. Neurology 62, 925&#x2013;931 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15037694</ArticleId></ArticleIdList></Reference><Reference><Citation>Sch&#xf6;ll M. et al. Low PiB PET retention in presence of pathologic CSF biomarkers in Arctic APP mutation carriers. Neurology 79, 229&#x2013;236 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22700814</ArticleId></ArticleIdList></Reference><Reference><Citation>von Pawel-Rammingen U., Johansson B. P. &amp; Bjorck L. IdeS, a novel streptococcal cysteine proteinase with unique specificity for immunoglobulin G. EMBO J. 21, 1607&#x2013;1615 (2002).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC125946</ArticleId><ArticleId IdType="pubmed">11927545</ArticleId></ArticleIdList></Reference><Reference><Citation>Lord A. et al. Amyloid-beta protofibril levels correlate with spatial learning in Arctic Alzheimer's disease transgenic mice. FEBS J. 276, 995&#x2013;1006 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2752010</ArticleId><ArticleId IdType="pubmed">19215301</ArticleId></ArticleIdList></Reference><Reference><Citation>Kahle P. J. et al. Subcellular localization of wild-type and Parkinson's disease-associated mutant alpha-synuclein in human and transgenic mouse brain. J. Neurosci. 20, 6365&#x2013;6373 (2000).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6772969</ArticleId><ArticleId IdType="pubmed">10964942</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenwood F. C., Hunter W. M. &amp; Glover J. S. The preparation of I-131-labelled human growth hormone of high specific radioactivity. Biochem. J. 89, 114&#x2013;123 (1963).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1202279</ArticleId><ArticleId IdType="pubmed">14097352</ArticleId></ArticleIdList></Reference><Reference><Citation>Bolton A. E. &amp; Hunter W. M. The labelling of proteins to high specific radioactivities by conjugation to a 125I-containing acylating agent. Biochem. J. 133, 529&#x2013;539 (1973).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1177731</ArticleId><ArticleId IdType="pubmed">4733239</ArticleId></ArticleIdList></Reference><Reference><Citation>Loening A. M. &amp; Gambhir S. S. AMIDE: a free software tool for multimodality medical image analysis. Mol. Imaging 2, 131&#x2013;137 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">14649056</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma Y. et al. A three-dimensional digital atlas database of the adult C57BL/6 J mouse brain by magnetic resonance microscopy. Neuroscience 135, 1203&#x2013;1215 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">16165303</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">26905201</PMID><DateCompleted><Year>2016</Year><Month>12</Month><Day>13</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2213-6711</ISSN><JournalIssue CitedMedium="Internet"><Volume>6</Volume><Issue>3</Issue><PubDate><Year>2016</Year><Month>Mar</Month><Day>08</Day></PubDate></JournalIssue><Title>Stem cell reports</Title><ISOAbbreviation>Stem Cell Reports</ISOAbbreviation></Journal><ArticleTitle>Functional Neurons Generated from T Cell-Derived Induced Pluripotent Stem Cells for Neurological Disease Modeling.</ArticleTitle><Pagination><StartPage>422</StartPage><EndPage>435</EndPage><MedlinePgn>422-35</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.stemcr.2016.01.010</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2213-6711(16)00027-8</ELocationID><Abstract><AbstractText>Modeling of neurological diseases using induced pluripotent stem cells (iPSCs) derived from the somatic cells of patients has provided a means of elucidating pathogenic mechanisms and performing drug screening. T cells are an ideal source of patient-specific iPSCs because they can be easily obtained from samples. Recent studies indicated that iPSCs retain an epigenetic memory relating to their cell of origin that restricts their differentiation potential. The classical method of differentiation via embryoid body formation was not suitable for T cell-derived iPSCs (TiPSCs). We developed a neurosphere-based robust differentiation protocol, which enabled TiPSCs to differentiate into functional neurons, despite differences in global gene expression between TiPSCs and adult human dermal fibroblast-derived iPSCs. Furthermore, neurons derived from TiPSCs generated from a juvenile patient with Parkinson's disease exhibited several Parkinson's disease phenotypes. Therefore, we conclude that TiPSCs are a useful tool for modeling neurological diseases.</AbstractText><CopyrightInformation>Copyright &#xa9; 2016 The Authors. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Matsumoto</LastName><ForeName>Takuya</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Physiology, Keio University School of Medicine, Shinjuku-ku, Tokyo 160-8582, Japan; Institute for Innovation, Ajinomoto Co., Inc., Kawasaki-ku, Kanagawa 210-8681, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fujimori</LastName><ForeName>Koki</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Physiology, Keio University School of Medicine, Shinjuku-ku, Tokyo 160-8582, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Andoh-Noda</LastName><ForeName>Tomoko</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Physiology, Keio University School of Medicine, Shinjuku-ku, Tokyo 160-8582, Japan; Division of Medicine and Engineering Science, University of Yamanashi, Interdisciplinary Graduate School of Medicine and Engineering, Kofu, Yamanashi 400-8511, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ando</LastName><ForeName>Takayuki</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Physiology, Keio University School of Medicine, Shinjuku-ku, Tokyo 160-8582, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kuzumaki</LastName><ForeName>Naoko</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Physiology, Keio University School of Medicine, Shinjuku-ku, Tokyo 160-8582, Japan; Department of Pharmacology, Hoshi University, Pharmacy and Pharmaceutical Sciences, Shinagawa-ku, Tokyo 142-8501, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Toyoshima</LastName><ForeName>Manabu</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Laboratory for Molecular Psychiatry, RIKEN Brain Science Institute, Wako, Saitama 351-0198, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tada</LastName><ForeName>Hirobumi</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Physiology, Yokohama City University Graduate School of Medicine, Kanazawa-ku, Kanagawa 236-0027, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Imaizumi</LastName><ForeName>Kent</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Physiology, Keio University School of Medicine, Shinjuku-ku, Tokyo 160-8582, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ishikawa</LastName><ForeName>Mitsuru</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Physiology, Keio University School of Medicine, Shinjuku-ku, Tokyo 160-8582, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yamaguchi</LastName><ForeName>Ryo</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Physiology, Keio University School of Medicine, Shinjuku-ku, Tokyo 160-8582, Japan; Regenerative &amp; Cellular Medicine Office, Sumitomo Dainippon Pharma Co., Ltd, Chuo-ku, Kobe 650-0047, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Isoda</LastName><ForeName>Miho</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Physiology, Keio University School of Medicine, Shinjuku-ku, Tokyo 160-8582, Japan; Regenerative &amp; Cellular Medicine Office, Sumitomo Dainippon Pharma Co., Ltd, Chuo-ku, Kobe 650-0047, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Zhi</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Physiology, Keio University School of Medicine, Shinjuku-ku, Tokyo 160-8582, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sato</LastName><ForeName>Shigeto</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurology, Juntendo University School of Medicine, Bunkyo-ku, Tokyo 113-8431, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kobayashi</LastName><ForeName>Tetsuro</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Dermatology, Keio University, School of Medicine, Shinjuku-ku, Tokyo 160-8582, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ohtaka</LastName><ForeName>Manami</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Biotechnology Research Institute for Drug Discovery, National Institute of Advanced Industrial Science and Technology (AIST), Tsukuba, Ibaraki 305-8565, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nishimura</LastName><ForeName>Ken</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Biotechnology Research Institute for Drug Discovery, National Institute of Advanced Industrial Science and Technology (AIST), Tsukuba, Ibaraki 305-8565, Japan; Laboratory of Gene Regulation, University of Tsukuba, Faculty of Medicine, Tsukuba, Ibaraki 305-8575, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kurosawa</LastName><ForeName>Hiroshi</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Division of Medicine and Engineering Science, University of Yamanashi, Interdisciplinary Graduate School of Medicine and Engineering, Kofu, Yamanashi 400-8511, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yoshikawa</LastName><ForeName>Takeo</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Laboratory for Molecular Psychiatry, RIKEN Brain Science Institute, Wako, Saitama 351-0198, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Takahashi</LastName><ForeName>Takuya</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Physiology, Yokohama City University Graduate School of Medicine, Kanazawa-ku, Kanagawa 236-0027, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nakanishi</LastName><ForeName>Mahito</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Biotechnology Research Institute for Drug Discovery, National Institute of Advanced Industrial Science and Technology (AIST), Tsukuba, Ibaraki 305-8565, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ohyama</LastName><ForeName>Manabu</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Dermatology, Keio University, School of Medicine, Shinjuku-ku, Tokyo 160-8582, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hattori</LastName><ForeName>Nobutaka</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Neurology, Juntendo University School of Medicine, Bunkyo-ku, Tokyo 113-8431, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Akamatsu</LastName><ForeName>Wado</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Physiology, Keio University School of Medicine, Shinjuku-ku, Tokyo 160-8582, Japan; Center for Genomic and Regenerative Medicine, Juntendo University, School of Medicine, Bunkyo-ku, Tokyo 113-8431, Japan. Electronic address: awado@juntendo.ac.jp.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Okano</LastName><ForeName>Hideyuki</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Physiology, Keio University School of Medicine, Shinjuku-ku, Tokyo 160-8582, Japan. Electronic address: hidokano@a2.keio.jp.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>02</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Stem Cell Reports</MedlineTA><NlmUniqueID>101611300</NlmUniqueID><ISSNLinking>2213-6711</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005347" MajorTopicYN="N">Fibroblasts</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057026" MajorTopicYN="N">Induced Pluripotent Stem Cells</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="Y">cytology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055495" MajorTopicYN="Y">Neurogenesis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="Y">cytology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D061251" MajorTopicYN="N">Primary Cell Culture</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013601" MajorTopicYN="N">T-Lymphocytes</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="Y">cytology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>12</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2016</Year><Month>1</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>1</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>2</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>2</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2016</Year><Month>2</Month><Day>18</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26905201</ArticleId><ArticleId IdType="pmc">PMC4788773</ArticleId><ArticleId IdType="doi">10.1016/j.stemcr.2016.01.010</ArticleId><ArticleId IdType="pii">S2213-6711(16)00027-8</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Aoi T., Yae K., Nakagawa M., Ichisaka T., Okita K., Takahashi K., Chiba T., Yamanaka S. Generation of pluripotent stem cells from adult mouse liver and stomach cells. Science. 2008;321:699&#x2013;702.</Citation><ArticleIdList><ArticleId IdType="pubmed">18276851</ArticleId></ArticleIdList></Reference><Reference><Citation>Brennand K.J., Simone A., Jou J., Gelboin-Burkhart C., Tran N., Sangar S., Li Y., Mu Y., Chen G., Yu D. Modelling schizophrenia using human induced pluripotent stem cells. Nature. 2011;473:221&#x2013;225.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3392969</ArticleId><ArticleId IdType="pubmed">21490598</ArticleId></ArticleIdList></Reference><Reference><Citation>Chambers S.M., Fasano C.A., Papapetrou E.P., Tomishima M., Sadelain M., Studer L. Highly efficient neural conversion of human ES and iPS cells by dual inhibition of SMAD signaling. Nat. Biotechnol. 2009;27:275&#x2013;280.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2756723</ArticleId><ArticleId IdType="pubmed">19252484</ArticleId></ArticleIdList></Reference><Reference><Citation>Clarke L., van der Kooy D. Low oxygen enhances primitive and definitive neural stem cell colony formation by inhibiting distinct cell death pathways. Stem Cells. 2009;27:1879&#x2013;1886.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2771103</ArticleId><ArticleId IdType="pubmed">19544448</ArticleId></ArticleIdList></Reference><Reference><Citation>Fusaki N., Ban H., Nishiyama A., Saeki K., Hasegawa M. Efficient induction of transgene-free human pluripotent stem cells using a vector based on Sendai virus, an RNA virus that does not integrate into the host genome. Proc. Jpn. Acad. Ser. B Phys. Biol. Sci. 2009;85:348&#x2013;362.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3621571</ArticleId><ArticleId IdType="pubmed">19838014</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanks M., Wurst W., Anson-Cartwright L., Auerbach A.B., Joyner A.L. Rescue of the En-1 mutant phenotype by replacement of En-1 with En-2. Science. 1995;269:679&#x2013;682.</Citation><ArticleIdList><ArticleId IdType="pubmed">7624797</ArticleId></ArticleIdList></Reference><Reference><Citation>Hunt P., Gulisano M., Cook M., Sham M.H., Faiella A., Wilkinson D., Boncinelli E., Krumlauf R. A distinct Hox code for the branchial region of the vertebrate head. Nature. 1991;353:861&#x2013;864.</Citation><ArticleIdList><ArticleId IdType="pubmed">1682814</ArticleId></ArticleIdList></Reference><Reference><Citation>Imaizumi Y., Okano H. Modeling human neurological disorders with induced pluripotent stem cells. J.&#xa0;Neurochem. 2014;129:388&#x2013;399.</Citation><ArticleIdList><ArticleId IdType="pubmed">24286589</ArticleId></ArticleIdList></Reference><Reference><Citation>Imaizumi Y., Okada Y., Akamatsu W., Koike M., Kuzumaki N., Hayakawa H., Nihira T., Kobayashi T., Ohyama M., Sato S. Mitochondrial dysfunction associated with increased oxidative stress and alpha-synuclein accumulation in PARK2 iPSC-derived neurons and postmortem brain tissue. Mol. Brain. 2012;5:35.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3546866</ArticleId><ArticleId IdType="pubmed">23039195</ArticleId></ArticleIdList></Reference><Reference><Citation>Itskovitz-Eldor J., Schuldiner M., Karsenti D., Eden A., Yanuka O., Amit M., Soreq H., Benvenisty N. Differentiation of human embryonic stem cells into embryoid bodies compromising the three embryonic germ layers. Mol. Med. 2000;6:88&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1949933</ArticleId><ArticleId IdType="pubmed">10859025</ArticleId></ArticleIdList></Reference><Reference><Citation>Kajiwara M., Aoi T., Okita K., Takahashi R., Inoue H., Takayama N., Endo H., Eto K., Toguchida J., Uemoto S. Donor-dependent variations in hepatic differentiation from human-induced pluripotent stem cells. Proc. Natl. Acad. Sci. USA. 2012;109:12538&#x2013;12543.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3411998</ArticleId><ArticleId IdType="pubmed">22802639</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim K., Doi A., Wen B., Ng K., Zhao R., Cahan P., Kim J., Aryee M.J., Ji H., Ehrlich L.I. Epigenetic memory in induced pluripotent stem cells. Nature. 2010;467:285&#x2013;290.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3150836</ArticleId><ArticleId IdType="pubmed">20644535</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim K., Zhao R., Doi A., Ng K., Unternaehrer J., Cahan P., Huo H., Loh Y.H., Aryee M.J., Lensch M.W. Donor cell type can influence the epigenome and differentiation potential of human induced pluripotent stem cells. Nat. Biotechnol. 2011;29:1117&#x2013;1119.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3357310</ArticleId><ArticleId IdType="pubmed">22119740</ArticleId></ArticleIdList></Reference><Reference><Citation>Koch P., Opitz T., Steinbeck J.A., Ladewig J., Brustle O. A rosette-type, self-renewing human ES cell-derived neural stem cell with potential for in&#xa0;vitro instruction and synaptic integration. Proc. Natl. Acad. Sci. USA. 2009;106:3225&#x2013;3230.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2651316</ArticleId><ArticleId IdType="pubmed">19218428</ArticleId></ArticleIdList></Reference><Reference><Citation>Loh Y.H., Hartung O., Li H., Guo C., Sahalie J.M., Manos P.D., Urbach A., Heffner G.C., Grskovic M., Vigneault F. Reprogramming of T&#xa0;cells from human peripheral blood. Cell Stem Cell. 2010;7:15&#x2013;19.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2913590</ArticleId><ArticleId IdType="pubmed">20621044</ArticleId></ArticleIdList></Reference><Reference><Citation>Mack A.A., Kroboth S., Rajesh D., Wang W.B. Generation of induced pluripotent stem cells from CD34+ cells across blood drawn from multiple donors with non-integrating episomal vectors. PLoS One. 2011;6:e27956.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3222670</ArticleId><ArticleId IdType="pubmed">22132178</ArticleId></ArticleIdList></Reference><Reference><Citation>Marchetto M.C., Gage F.H. Modeling brain disease in a dish: really? Cell Stem Cell. 2012;10:642&#x2013;645.</Citation><ArticleIdList><ArticleId IdType="pubmed">22704498</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishimura K., Sano M., Ohtaka M., Furuta B., Umemura Y., Nakajima Y., Ikehara Y., Kobayashi T., Segawa H., Takayasu S. Development of defective and persistent Sendai virus vector: a unique gene delivery/expression system ideal for cell reprogramming. J.&#xa0;Biol. Chem. 2011;286:4760&#x2013;4771.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3039346</ArticleId><ArticleId IdType="pubmed">21138846</ArticleId></ArticleIdList></Reference><Reference><Citation>Nori S., Okada Y., Yasuda A., Tsuji O., Takahashi Y., Kobayashi Y., Fujiyoshi K., Koike M., Uchiyama Y., Ikeda E. Grafted human-induced pluripotent stem-cell-derived neurospheres promote motor functional recovery after spinal cord injury in mice. Proc. Natl. Acad. Sci. USA. 2011;108:16825&#x2013;16830.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3189018</ArticleId><ArticleId IdType="pubmed">21949375</ArticleId></ArticleIdList></Reference><Reference><Citation>Okita K., Yamakawa T., Matsumura Y., Sato Y., Amano N., Watanabe A., Goshima N., Yamanaka S. An efficient nonviral method to generate integration-free human-induced pluripotent stem cells from cord blood and peripheral blood cells. Stem Cells. 2013;31:458&#x2013;466.</Citation><ArticleIdList><ArticleId IdType="pubmed">23193063</ArticleId></ArticleIdList></Reference><Reference><Citation>Oliver G., Mailhos A., Wehr R., Copeland N.G., Jenkins N.A., Gruss P. Six3, a murine homologue of the sine oculis gene, demarcates the most anterior border of the developing neural plate and is expressed during eye development. Development. 1995;121:4045&#x2013;4055.</Citation><ArticleIdList><ArticleId IdType="pubmed">8575305</ArticleId></ArticleIdList></Reference><Reference><Citation>Panopoulos A.D., Yanes O., Ruiz S., Kida Y.S., Diep D., Tautenhahn R., Herrerias A., Batchelder E.M., Plongthongkum N., Lutz M. The metabolome of induced pluripotent stem cells reveals metabolic changes occurring in somatic cell reprogramming. Cell Res. 2012;22:168&#x2013;177.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3252494</ArticleId><ArticleId IdType="pubmed">22064701</ArticleId></ArticleIdList></Reference><Reference><Citation>Polo J.M., Liu S., Figueroa M.E., Kulalert W., Eminli S., Tan K.Y., Apostolou E., Stadtfeld M., Li Y., Shioda T. Cell type of origin influences the molecular and functional properties of&#xa0;mouse induced pluripotent stem cells. Nat. Biotechnol. 2010;28:848&#x2013;855.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3148605</ArticleId><ArticleId IdType="pubmed">20644536</ArticleId></ArticleIdList></Reference><Reference><Citation>Seki T., Yuasa S., Oda M., Egashira T., Yae K., Kusumoto D., Nakata H., Tohyama S., Hashimoto H., Kodaira M. Generation of induced pluripotent stem cells from human terminally differentiated circulating T&#xa0;cells. Cell Stem Cell. 2010;7:11&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pubmed">20621043</ArticleId></ArticleIdList></Reference><Reference><Citation>Shimura H., Hattori N., Kubo S., Mizuno Y., Asakawa S., Minoshima S., Shimizu N., Iwai K., Chiba T., Tanaka K. Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase. Nat. Genet. 2000;25:302&#x2013;305.</Citation><ArticleIdList><ArticleId IdType="pubmed">10888878</ArticleId></ArticleIdList></Reference><Reference><Citation>Simeone A., Acampora D., Gulisano M., Stornaiuolo A., Boncinelli E. Nested expression domains of four homeobox genes in developing rostral brain. Nature. 1992;358:687&#x2013;690.</Citation><ArticleIdList><ArticleId IdType="pubmed">1353865</ArticleId></ArticleIdList></Reference><Reference><Citation>Song B., Niclis J.C., Alikhan M.A., Sakkal S., Sylvain A., Kerr P.G., Laslett A.L., Bernard C.A., Ricardo S.D. Generation of induced pluripotent stem cells from human kidney mesangial cells. J.&#xa0;Am. Soc. Nephrol. 2011;22:1213&#x2013;1220.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3137569</ArticleId><ArticleId IdType="pubmed">21566060</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi K., Tanabe K., Ohnuki M., Narita M., Ichisaka T., Tomoda K., Yamanaka S. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell. 2007;131:861&#x2013;872.</Citation><ArticleIdList><ArticleId IdType="pubmed">18035408</ArticleId></ArticleIdList></Reference><Reference><Citation>Tropepe V., Hitoshi S., Sirard C., Mak T.W., Rossant J., van der Kooy D. Direct neural fate specification from embryonic stem cells: a primitive mammalian neural stem cell stage acquired through a default mechanism. Neuron. 2001;30:65&#x2013;78.</Citation><ArticleIdList><ArticleId IdType="pubmed">11343645</ArticleId></ArticleIdList></Reference><Reference><Citation>Watanabe K., Ueno M., Kamiya D., Nishiyama A., Matsumura M., Wataya T., Takahashi J.B., Nishikawa S., Nishikawa S., Muguruma K. A ROCK inhibitor permits survival of dissociated human embryonic stem cells. Nat. Biotechnol. 2007;25:681&#x2013;686.</Citation><ArticleIdList><ArticleId IdType="pubmed">17529971</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang S.Z., Li H.F., Ma L.X., Qian W.J., Wang Z.F., Wu Z.Y. Urine-derived induced pluripotent stem cells as a modeling tool for paroxysmal kinesigenic dyskinesia. Biol. Open. 2015;4:1744&#x2013;1752.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4736025</ArticleId><ArticleId IdType="pubmed">26621826</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou T., Benda C., Duzinger S., Huang Y., Li X., Li Y., Guo X., Cao G., Chen S., Hao L. Generation of induced pluripotent stem cells from urine. J.&#xa0;Am. Soc. Nephrol. 2011;22:1221&#x2013;1228.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3137570</ArticleId><ArticleId IdType="pubmed">21636641</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Z., Kohda K., Ibata K., Kohyama J., Akamatsu W., Yuzaki M., Okano H.J., Sasaki E., Okano H. Reprogramming non-human primate somatic cells into functional neuronal cells by defined factors. Mol. Brain. 2014;7:24.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4021617</ArticleId><ArticleId IdType="pubmed">24694048</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">26900927</PMID><DateCompleted><Year>2016</Year><Month>08</Month><Day>18</Day></DateCompleted><DateRevised><Year>2020</Year><Month>11</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1546-1726</ISSN><JournalIssue CitedMedium="Internet"><Volume>19</Volume><Issue>4</Issue><PubDate><Year>2016</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Nature neuroscience</Title><ISOAbbreviation>Nat Neurosci</ISOAbbreviation></Journal><ArticleTitle>Hyperactive somatostatin interneurons contribute to excitotoxicity in neurodegenerative disorders.</ArticleTitle><Pagination><StartPage>557</StartPage><EndPage>559</EndPage><MedlinePgn>557-559</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/nn.4257</ELocationID><Abstract><AbstractText>Amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) are overlapping neurodegenerative disorders whose pathogenesis remains largely unknown. Using TDP-43(A315T) mice, an ALS and FTD model with marked cortical pathology, we found that hyperactive somatostatin interneurons disinhibited layer 5 pyramidal neurons (L5-PNs) and contributed to their excitotoxicity. Focal ablation of somatostatin interneurons efficiently restored normal excitability of L5-PNs and alleviated neurodegeneration, suggesting a new therapeutic target for ALS and FTD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Zhang</LastName><ForeName>Wen</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, 333 Cassell Drive, Baltimore, MD 21224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Zhang</LastName><ForeName>Lifeng</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, 333 Cassell Drive, Baltimore, MD 21224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liang</LastName><ForeName>Bo</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, 333 Cassell Drive, Baltimore, MD 21224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schroeder</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>The Jackson Laboratory, 600 Main Street, Bar Harbor, ME 04609, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Zhong-Wei</ForeName><Initials>ZW</Initials><AffiliationInfo><Affiliation>The Jackson Laboratory, 600 Main Street, Bar Harbor, ME 04609, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cox</LastName><ForeName>Gregory A</ForeName><Initials>GA</Initials><AffiliationInfo><Affiliation>The Jackson Laboratory, 600 Main Street, Bar Harbor, ME 04609, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Yun</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, 333 Cassell Drive, Baltimore, MD 21224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Da-Ting</ForeName><Initials>DT</Initials><AffiliationInfo><Affiliation>Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, 333 Cassell Drive, Baltimore, MD 21224, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Jackson Laboratory, 600 Main Street, Bar Harbor, ME 04609, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 NS064013</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 NS075382</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>1R21NS075382-01A1</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><Agency>Intramural NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D052060">Research Support, N.I.H., Intramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>02</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Neurosci</MedlineTA><NlmUniqueID>9809671</NlmUniqueID><ISSNLinking>1097-6256</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000598624">TARDBP protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>51110-01-1</RegistryNumber><NameOfSubstance UI="D013004">Somatostatin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004268" MajorTopicYN="N">DNA-Binding Proteins</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053444" MajorTopicYN="N">Inhibitory Postsynaptic Potentials</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007395" MajorTopicYN="N">Interneurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="N">Neurodegenerative Diseases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009924" MajorTopicYN="N">Organ Culture Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017966" MajorTopicYN="N">Pyramidal Cells</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013004" MajorTopicYN="N">Somatostatin</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>11</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>1</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>2</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>2</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>8</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2016</Year><Month>8</Month><Day>22</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26900927</ArticleId><ArticleId IdType="mid">NIHMS756731</ArticleId><ArticleId IdType="pmc">PMC4811704</ArticleId><ArticleId IdType="doi">10.1038/nn.4257</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Vucic S, Kiernan MC. Curr Mol Med. 2009;9:255&#x2013;272.</Citation><ArticleIdList><ArticleId IdType="pubmed">19355908</ArticleId></ArticleIdList></Reference><Reference><Citation>Ravits JM, La Spada AR. Neurology. 2009;73:805&#x2013;811.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2739608</ArticleId><ArticleId IdType="pubmed">19738176</ArticleId></ArticleIdList></Reference><Reference><Citation>Rothstein JD. Ann Neurol. 2009;65(Suppl 1):S3&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">19191304</ArticleId></ArticleIdList></Reference><Reference><Citation>Perry JJ, Shin DS, Tainer JA. Adv Exp Med Biol. 2010;685:9&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">20687491</ArticleId></ArticleIdList></Reference><Reference><Citation>Seeley WW. Curr Opin Neurol. 2008;21:701&#x2013;707.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2909835</ArticleId><ArticleId IdType="pubmed">18989116</ArticleId></ArticleIdList></Reference><Reference><Citation>Kabashi E, et al. Nat Genet. 2008;40:572&#x2013;574.</Citation><ArticleIdList><ArticleId IdType="pubmed">18372902</ArticleId></ArticleIdList></Reference><Reference><Citation>Sreedharan J, et al. Science. 2008;319:1668&#x2013;1672.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7116650</ArticleId><ArticleId IdType="pubmed">18309045</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M, et al. Science. 2006;314:130&#x2013;133.</Citation><ArticleIdList><ArticleId IdType="pubmed">17023659</ArticleId></ArticleIdList></Reference><Reference><Citation>Baloh RH. Curr Opin Neurol. 2012;25:701&#x2013;707.</Citation><ArticleIdList><ArticleId IdType="pubmed">23041957</ArticleId></ArticleIdList></Reference><Reference><Citation>Ling SC, Polymenidou M, Cleveland DW. Neuron. 2013;79:416&#x2013;438.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4411085</ArticleId><ArticleId IdType="pubmed">23931993</ArticleId></ArticleIdList></Reference><Reference><Citation>Enterzari-Taher M, Eisen A, Stewart H, Nakajima M. Muscle Nerve. 1997;20:65&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pubmed">8995585</ArticleId></ArticleIdList></Reference><Reference><Citation>Ziemann U, et al. Neurology. 1997;49:1292&#x2013;1298.</Citation><ArticleIdList><ArticleId IdType="pubmed">9371911</ArticleId></ArticleIdList></Reference><Reference><Citation>Zanette G, et al. J Neurol. 2002;249:1723&#x2013;1728.</Citation><ArticleIdList><ArticleId IdType="pubmed">12529797</ArticleId></ArticleIdList></Reference><Reference><Citation>Karandreas N, et al. Amyotroph Lateral Scler. 2007;8:112&#x2013;118.</Citation><ArticleIdList><ArticleId IdType="pubmed">17453640</ArticleId></ArticleIdList></Reference><Reference><Citation>Vucic S, Nicholson GA, Kiernan MC. Brain. 2008;131:1540&#x2013;1550.</Citation><ArticleIdList><ArticleId IdType="pubmed">18469020</ArticleId></ArticleIdList></Reference><Reference><Citation>Wegorzewska I, Bell S, Cairns NJ, Miller TM, Baloh RH. Proc Natl Acad Sci U S A. 2009;106:18809&#x2013;18814.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2762420</ArticleId><ArticleId IdType="pubmed">19833869</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin RC, Matesic DF, Connor JA. Ann N Y Acad Sci. 1997;825:134&#x2013;145.</Citation><ArticleIdList><ArticleId IdType="pubmed">9369982</ArticleId></ArticleIdList></Reference><Reference><Citation>Kubota Y. Curr Opin Neurobiol. 2014;26:7&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pubmed">24650498</ArticleId></ArticleIdList></Reference><Reference><Citation>Pfeffer CK, Xue M, He M, Huang ZJ, Scanziani M. Nat Neurosci. 2013;16:1068&#x2013;1076.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3729586</ArticleId><ArticleId IdType="pubmed">23817549</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu H, Jeong HY, Tremblay R, Rudy B. Neuron. 2013;77:155&#x2013;167.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3556168</ArticleId><ArticleId IdType="pubmed">23312523</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang W, Peterson M, Beyer B, Frankel WN, Zhang ZW. Loss of MeCP2 from forebrain excitatory neurons leads to cortical hyperexcitation and seizures. The Journal of neuroscience : the official journal of the Society for Neuroscience. 2014;34:2754&#x2013;2763.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3921436</ArticleId><ArticleId IdType="pubmed">24523563</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang G, Pan F, Parkhurst CN, Grutzendler J, Gan WB. Thinned-skull cranial window technique for long-term imaging of the cortex in live mice. Nat Protoc. 2010;5:201&#x2013;208.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4690457</ArticleId><ArticleId IdType="pubmed">20134419</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang LF, et al. Imaging glioma initiation in vivo through a polished and reinforced thin-skull cranial window. J. Vis. Exp. 2012 DOI: 10.3791/4201.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3529512</ArticleId><ArticleId IdType="pubmed">23207870</ArticleId></ArticleIdList></Reference><Reference><Citation>Pronichev IV, Lenkov DN. Functional mapping of the motor cortex of the white mouse by a microstimulation method. Neurosci Behav Physiol. 1998;28:80&#x2013;85.</Citation><ArticleIdList><ArticleId IdType="pubmed">9513982</ArticleId></ArticleIdList></Reference><Reference><Citation>Tricoire L, et al. A blueprint for the spatiotemporal origins of mouse hippocampal interneuron diversity. The Journal of neuroscience : the official journal of the Society for Neuroscience. 2011;31:10948&#x2013;10970.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3163481</ArticleId><ArticleId IdType="pubmed">21795545</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakamura M, et al. Signaling complex formation of phospholipase Cbeta4 with metabotropic glutamate receptor type 1alpha and 1,4,5-trisphosphate receptor at the perisynapse and endoplasmic reticulum in the mouse brain. The European journal of neuroscience. 2004;20:2929&#x2013;2944.</Citation><ArticleIdList><ArticleId IdType="pubmed">15579147</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaur P, Karolina DS, Sepramaniam S, Armugam A, Jeyaseelan K. Expression profiling of RNA transcripts during neuronal maturation and ischemic injury. PloS one. 2014;9:e103525.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4111601</ArticleId><ArticleId IdType="pubmed">25061880</ArticleId></ArticleIdList></Reference><Reference><Citation>Stum M, et al. An assessment of mechanisms underlying peripheral axonal degeneration caused by aminoacyl-tRNA synthetase mutations. Molecular and cellular neurosciences. 2011;46:432&#x2013;443.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3030653</ArticleId><ArticleId IdType="pubmed">21115117</ArticleId></ArticleIdList></Reference><Reference><Citation>Huckleberry KA, et al. Behavioral experience induces zif268 expression in mature granule cells but suppresses its expression in immature granule cells. Frontiers in systems neuroscience. 2015;9:118.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4543859</ArticleId><ArticleId IdType="pubmed">26347620</ArticleId></ArticleIdList></Reference><Reference><Citation>Teixeira FK, et al. ATP synthase promotes germ cell differentiation independent of oxidative phosphorylation. Nature cell biology. 2015;17:689&#x2013;696.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4573567</ArticleId><ArticleId IdType="pubmed">25915123</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">26911640</PMID><DateCompleted><Year>2016</Year><Month>08</Month><Day>18</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1526-632X</ISSN><JournalIssue CitedMedium="Internet"><Volume>86</Volume><Issue>12</Issue><PubDate><Year>2016</Year><Month>Mar</Month><Day>22</Day></PubDate></JournalIssue><Title>Neurology</Title><ISOAbbreviation>Neurology</ISOAbbreviation></Journal><ArticleTitle>Effect of intellectual enrichment on AD biomarker trajectories: Longitudinal imaging study.</ArticleTitle><Pagination><StartPage>1128</StartPage><EndPage>1135</EndPage><MedlinePgn>1128-35</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1212/WNL.0000000000002490</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To investigate the effect of age, sex, APOE4 genotype, and lifestyle enrichment (education/occupation, midlife cognitive activity, and midlife physical activity) on Alzheimer disease (AD) biomarker trajectories using longitudinal imaging data (brain &#x3b2;-amyloid load via Pittsburgh compound B PET and neurodegeneration via (18)fluorodeoxyglucose (FDG) PET and structural MRI) in an elderly population without dementia.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">In the population-based longitudinal Mayo Clinic Study of Aging, we studied 393 participants without dementia (340 clinically normal, 53 mild cognitive impairment; 70 years and older) who had cognitive and physical activity measures and at least 2 visits with imaging biomarkers. We dichotomized participants into high (&#x2265;14 years) and low (&lt;14 years) education levels using the median. For the entire cohort and the 2 education strata, we built linear mixed models to investigate the effect of the predictors on each of the biomarker outcomes.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Age was associated with amyloid and neurodegeneration trajectories; APOE4 status appears to influence only the amyloid and FDG trajectories but not hippocampal volume trajectory. In the high-education stratum, high midlife cognitive activity was associated with lower amyloid deposition in APOE4 carriers. APOE4 status was associated with lower FDG uptake in the entire cohort and in participants with lower education but not the high-education cohort.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">There were minimal effects of lifestyle enrichment on AD biomarker trajectories (specifically rates). Lifetime intellectual enrichment (high education, high midlife cognitive activity) is associated with lower amyloid in APOE4 carriers. High education is protective from the APOE4 effect on FDG metabolism. Differing education levels may explain the conflicting results seen in the literature.</AbstractText><CopyrightInformation>&#xa9; 2016 American Academy of Neurology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Vemuri</LastName><ForeName>Prashanthi</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>From the Departments of Radiology (P.V., V.J.L., J.L.G., M.L.S., C.R.J.), Health Sciences Research (T.G.L., S.A.P., M.M.M., R.O.R., W.A.R.), Neurology (D.S.K., M.M.M., R.O.R., W.A.R., R.C.P.), and Psychology (M.M., Y.E.G.), Mayo Clinic, Rochester, MN; and Departments of Psychiatry (Y.E.G.) and Neurology (Y.E.G.), Mayo Clinic, Scottsdale, AZ. vemuri.prashanthi@mayo.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lesnick</LastName><ForeName>Timothy G</ForeName><Initials>TG</Initials><AffiliationInfo><Affiliation>From the Departments of Radiology (P.V., V.J.L., J.L.G., M.L.S., C.R.J.), Health Sciences Research (T.G.L., S.A.P., M.M.M., R.O.R., W.A.R.), Neurology (D.S.K., M.M.M., R.O.R., W.A.R., R.C.P.), and Psychology (M.M., Y.E.G.), Mayo Clinic, Rochester, MN; and Departments of Psychiatry (Y.E.G.) and Neurology (Y.E.G.), Mayo Clinic, Scottsdale, AZ.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Przybelski</LastName><ForeName>Scott A</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>From the Departments of Radiology (P.V., V.J.L., J.L.G., M.L.S., C.R.J.), Health Sciences Research (T.G.L., S.A.P., M.M.M., R.O.R., W.A.R.), Neurology (D.S.K., M.M.M., R.O.R., W.A.R., R.C.P.), and Psychology (M.M., Y.E.G.), Mayo Clinic, Rochester, MN; and Departments of Psychiatry (Y.E.G.) and Neurology (Y.E.G.), Mayo Clinic, Scottsdale, AZ.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Knopman</LastName><ForeName>David S</ForeName><Initials>DS</Initials><AffiliationInfo><Affiliation>From the Departments of Radiology (P.V., V.J.L., J.L.G., M.L.S., C.R.J.), Health Sciences Research (T.G.L., S.A.P., M.M.M., R.O.R., W.A.R.), Neurology (D.S.K., M.M.M., R.O.R., W.A.R., R.C.P.), and Psychology (M.M., Y.E.G.), Mayo Clinic, Rochester, MN; and Departments of Psychiatry (Y.E.G.) and Neurology (Y.E.G.), Mayo Clinic, Scottsdale, AZ.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Machulda</LastName><ForeName>Mary</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>From the Departments of Radiology (P.V., V.J.L., J.L.G., M.L.S., C.R.J.), Health Sciences Research (T.G.L., S.A.P., M.M.M., R.O.R., W.A.R.), Neurology (D.S.K., M.M.M., R.O.R., W.A.R., R.C.P.), and Psychology (M.M., Y.E.G.), Mayo Clinic, Rochester, MN; and Departments of Psychiatry (Y.E.G.) and Neurology (Y.E.G.), Mayo Clinic, Scottsdale, AZ.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lowe</LastName><ForeName>Val J</ForeName><Initials>VJ</Initials><AffiliationInfo><Affiliation>From the Departments of Radiology (P.V., V.J.L., J.L.G., M.L.S., C.R.J.), Health Sciences Research (T.G.L., S.A.P., M.M.M., R.O.R., W.A.R.), Neurology (D.S.K., M.M.M., R.O.R., W.A.R., R.C.P.), and Psychology (M.M., Y.E.G.), Mayo Clinic, Rochester, MN; and Departments of Psychiatry (Y.E.G.) and Neurology (Y.E.G.), Mayo Clinic, Scottsdale, AZ.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mielke</LastName><ForeName>Michelle M</ForeName><Initials>MM</Initials><AffiliationInfo><Affiliation>From the Departments of Radiology (P.V., V.J.L., J.L.G., M.L.S., C.R.J.), Health Sciences Research (T.G.L., S.A.P., M.M.M., R.O.R., W.A.R.), Neurology (D.S.K., M.M.M., R.O.R., W.A.R., R.C.P.), and Psychology (M.M., Y.E.G.), Mayo Clinic, Rochester, MN; and Departments of Psychiatry (Y.E.G.) and Neurology (Y.E.G.), Mayo Clinic, Scottsdale, AZ.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Roberts</LastName><ForeName>Rosebud O</ForeName><Initials>RO</Initials><AffiliationInfo><Affiliation>From the Departments of Radiology (P.V., V.J.L., J.L.G., M.L.S., C.R.J.), Health Sciences Research (T.G.L., S.A.P., M.M.M., R.O.R., W.A.R.), Neurology (D.S.K., M.M.M., R.O.R., W.A.R., R.C.P.), and Psychology (M.M., Y.E.G.), Mayo Clinic, Rochester, MN; and Departments of Psychiatry (Y.E.G.) and Neurology (Y.E.G.), Mayo Clinic, Scottsdale, AZ.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gunter</LastName><ForeName>Jeffrey L</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>From the Departments of Radiology (P.V., V.J.L., J.L.G., M.L.S., C.R.J.), Health Sciences Research (T.G.L., S.A.P., M.M.M., R.O.R., W.A.R.), Neurology (D.S.K., M.M.M., R.O.R., W.A.R., R.C.P.), and Psychology (M.M., Y.E.G.), Mayo Clinic, Rochester, MN; and Departments of Psychiatry (Y.E.G.) and Neurology (Y.E.G.), Mayo Clinic, Scottsdale, AZ.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Senjem</LastName><ForeName>Matthew L</ForeName><Initials>ML</Initials><AffiliationInfo><Affiliation>From the Departments of Radiology (P.V., V.J.L., J.L.G., M.L.S., C.R.J.), Health Sciences Research (T.G.L., S.A.P., M.M.M., R.O.R., W.A.R.), Neurology (D.S.K., M.M.M., R.O.R., W.A.R., R.C.P.), and Psychology (M.M., Y.E.G.), Mayo Clinic, Rochester, MN; and Departments of Psychiatry (Y.E.G.) and Neurology (Y.E.G.), Mayo Clinic, Scottsdale, AZ.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Geda</LastName><ForeName>Yonas E</ForeName><Initials>YE</Initials><AffiliationInfo><Affiliation>From the Departments of Radiology (P.V., V.J.L., J.L.G., M.L.S., C.R.J.), Health Sciences Research (T.G.L., S.A.P., M.M.M., R.O.R., W.A.R.), Neurology (D.S.K., M.M.M., R.O.R., W.A.R., R.C.P.), and Psychology (M.M., Y.E.G.), Mayo Clinic, Rochester, MN; and Departments of Psychiatry (Y.E.G.) and Neurology (Y.E.G.), Mayo Clinic, Scottsdale, AZ.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rocca</LastName><ForeName>Walter A</ForeName><Initials>WA</Initials><AffiliationInfo><Affiliation>From the Departments of Radiology (P.V., V.J.L., J.L.G., M.L.S., C.R.J.), Health Sciences Research (T.G.L., S.A.P., M.M.M., R.O.R., W.A.R.), Neurology (D.S.K., M.M.M., R.O.R., W.A.R., R.C.P.), and Psychology (M.M., Y.E.G.), Mayo Clinic, Rochester, MN; and Departments of Psychiatry (Y.E.G.) and Neurology (Y.E.G.), Mayo Clinic, Scottsdale, AZ.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Petersen</LastName><ForeName>Ronald C</ForeName><Initials>RC</Initials><AffiliationInfo><Affiliation>From the Departments of Radiology (P.V., V.J.L., J.L.G., M.L.S., C.R.J.), Health Sciences Research (T.G.L., S.A.P., M.M.M., R.O.R., W.A.R.), Neurology (D.S.K., M.M.M., R.O.R., W.A.R., R.C.P.), and Psychology (M.M., Y.E.G.), Mayo Clinic, Rochester, MN; and Departments of Psychiatry (Y.E.G.) and Neurology (Y.E.G.), Mayo Clinic, Scottsdale, AZ.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jack</LastName><ForeName>Clifford R</ForeName><Initials>CR</Initials><Suffix>Jr</Suffix><AffiliationInfo><Affiliation>From the Departments of Radiology (P.V., V.J.L., J.L.G., M.L.S., C.R.J.), Health Sciences Research (T.G.L., S.A.P., M.M.M., R.O.R., W.A.R.), Neurology (D.S.K., M.M.M., R.O.R., W.A.R., R.C.P.), and Psychology (M.M., Y.E.G.), Mayo Clinic, Rochester, MN; and Departments of Psychiatry (Y.E.G.) and Neurology (Y.E.G.), Mayo Clinic, Scottsdale, AZ.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01-AG041851</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG041851</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01-AG037551</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>C06 RR018898</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01-AG024904</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG034676</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01-AG032438</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG11378</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG016574</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG011378</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG16574/P1</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01-HL096917</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG06786</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R00 AG37573</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01-AG011378</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R00 AG037573</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG006786</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>02</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurology</MedlineTA><NlmUniqueID>0401060</NlmUniqueID><ISSNLinking>0028-3878</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053327">Apolipoprotein E4</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053327" MajorTopicYN="N">Apolipoprotein E4</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D060825" MajorTopicYN="N">Cognitive Dysfunction</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004522" MajorTopicYN="N">Educational Status</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009043" MajorTopicYN="N">Motor Activity</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009790" MajorTopicYN="N">Occupations</DescriptorName><QualifierName UI="Q000639" MajorTopicYN="Y">trends</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011159" MajorTopicYN="Y">Population Surveillance</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D040242" MajorTopicYN="Y">Risk Reduction Behavior</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>6</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>11</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>2</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>2</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>8</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2016</Year><Month>3</Month><Day>22</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26911640</ArticleId><ArticleId IdType="pmc">PMC4820132</ArticleId><ArticleId IdType="doi">10.1212/WNL.0000000000002490</ArticleId><ArticleId IdType="pii">WNL.0000000000002490</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Wilson RS, Mendes De Leon CF, Barnes LL, et al. Participation in cognitively stimulating activities and risk of incident Alzheimer disease. JAMA 2002;287:742&#x2013;748.</Citation><ArticleIdList><ArticleId IdType="pubmed">11851541</ArticleId></ArticleIdList></Reference><Reference><Citation>Verghese J, Lipton RB, Katz MJ, et al. Leisure activities and the risk of dementia in the elderly. N Engl J Med 2003;348:2508&#x2013;2516.</Citation><ArticleIdList><ArticleId IdType="pubmed">12815136</ArticleId></ArticleIdList></Reference><Reference><Citation>Soldan A, Pettigrew C, Li S, et al. Relationship of cognitive reserve and cerebrospinal fluid biomarkers to the emergence of clinical symptoms in preclinical Alzheimer's disease. Neurobiol Aging 2013;34:2827&#x2013;2834.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3823238</ArticleId><ArticleId IdType="pubmed">23916061</ArticleId></ArticleIdList></Reference><Reference><Citation>Almeida RP, Schultz SA, Austin BP, et al. Effect of cognitive reserve on age-related changes in cerebrospinal fluid biomarkers of Alzheimer disease. JAMA Neurol 2015;72:699&#x2013;706.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4639566</ArticleId><ArticleId IdType="pubmed">25893879</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson RS, Boyle PA, Yu L, Barnes LL, Schneider JA, Bennett DA. Life-span cognitive activity, neuropathologic burden, and cognitive aging. Neurology 2013;81:314&#x2013;321.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3772831</ArticleId><ArticleId IdType="pubmed">23825173</ArticleId></ArticleIdList></Reference><Reference><Citation>Landau SM, Marks SM, Mormino EC, et al. Association of lifetime cognitive engagement and low beta-amyloid deposition. Arch Neurol 2012;69:623&#x2013;629.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3747737</ArticleId><ArticleId IdType="pubmed">22271235</ArticleId></ArticleIdList></Reference><Reference><Citation>Matthews DC, Davies M, Murray J, et al. Physical activity, Mediterranean diet and biomarkers-assessed risk of Alzheimer's: a multi-modality brain imaging study. Adv J Mol Imaging 2014;4:43&#x2013;57.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4294269</ArticleId><ArticleId IdType="pubmed">25599008</ArticleId></ArticleIdList></Reference><Reference><Citation>Wirth M, Haase CM, Villeneuve S, Vogel J, Jagust WJ. Neuroprotective pathways: lifestyle activity, brain pathology, and cognition in cognitively normal older adults. Neurobiol Aging 2014;35:1873&#x2013;1882.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4019766</ArticleId><ArticleId IdType="pubmed">24656834</ArticleId></ArticleIdList></Reference><Reference><Citation>Head D, Bugg JM, Goate AM, et al. Exercise engagement as a moderator of the effects of APOE genotype on amyloid deposition. Arch Neurol 2012;69:636&#x2013;643.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3583203</ArticleId><ArticleId IdType="pubmed">22232206</ArticleId></ArticleIdList></Reference><Reference><Citation>Wirth M, Villeneuve S, La Joie R, Marks SM, Jagust WJ. Gene-environment interactions: lifetime cognitive activity, APOE genotype, and beta-amyloid burden. J Neurosci 2014;34:8612&#x2013;8617.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4061397</ArticleId><ArticleId IdType="pubmed">24948815</ArticleId></ArticleIdList></Reference><Reference><Citation>Rocca WA, Yawn BP, St Sauver JL, Grossardt BR, Melton LJ. History of the Rochester epidemiology project: half a century of medical records linkage in a US population. Mayo Clin Proc 2012;87:1202&#x2013;1213.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3541925</ArticleId><ArticleId IdType="pubmed">23199802</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen RC, Roberts RO, Knopman DS, et al. Prevalence of mild cognitive impairment is higher in men: the Mayo Clinic Study of Aging. Neurology 2010;75:889&#x2013;897.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2938972</ArticleId><ArticleId IdType="pubmed">20820000</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberts RO, Geda YE, Knopman DS, et al. The incidence of MCI differs by subtype and is higher in men: the Mayo Clinic Study of Aging. Neurology 2012;78:342&#x2013;351.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3280046</ArticleId><ArticleId IdType="pubmed">22282647</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr, Bernstein MA, Fox NC, et al. The Alzheimer's Disease Neuroimaging Initiative (ADNI): MRI methods. J Magn Reson Imaging 2008;27:685&#x2013;691.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2544629</ArticleId><ArticleId IdType="pubmed">18302232</ArticleId></ArticleIdList></Reference><Reference><Citation>Reuter M, Schmansky NJ, Rosas HD, Fischl B. Within-subject template estimation for unbiased longitudinal image analysis. Neuroimage 2012;61:1402&#x2013;1418.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3389460</ArticleId><ArticleId IdType="pubmed">22430496</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr, Wiste HJ, Weigand SD, et al. Age, sex, and APOE epsilon4 effects on memory, brain structure, and beta-amyloid across the adult life span. JAMA Neurol 2015;72:511&#x2013;519.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4428984</ArticleId><ArticleId IdType="pubmed">25775353</ArticleId></ArticleIdList></Reference><Reference><Citation>Lowe VJ, Kemp BJ, Jack CR, Jr, et al. Comparison of 18F-FDG and PiB PET in cognitive impairment. J Nucl Med 2009;50:878&#x2013;886.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2886669</ArticleId><ArticleId IdType="pubmed">19443597</ArticleId></ArticleIdList></Reference><Reference><Citation>Senjem ML, Gunter JL, Shiung MM, Petersen RC, Jack CR., Jr Comparison of different methodological implementations of voxel-based morphometry in neurodegenerative disease. Neuroimage 2005;26:600&#x2013;608.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2739382</ArticleId><ArticleId IdType="pubmed">15907317</ArticleId></ArticleIdList></Reference><Reference><Citation>Tzourio-Mazoyer N, Landeau B, Papathanassiou D, et al. Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain. Neuroimage 2002;15:273&#x2013;289.</Citation><ArticleIdList><ArticleId IdType="pubmed">11771995</ArticleId></ArticleIdList></Reference><Reference><Citation>Landau SM, Harvey D, Madison CM, et al. Comparing predictors of conversion and decline in mild cognitive impairment. Neurology 2010;75:230&#x2013;238.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2906178</ArticleId><ArticleId IdType="pubmed">20592257</ArticleId></ArticleIdList></Reference><Reference><Citation>Vemuri P, Lesnick TG, Przybelski SA, et al. Effect of lifestyle activities on Alzheimer disease biomarkers and cognition. Ann Neurol 2012;72:730&#x2013;738.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3539211</ArticleId><ArticleId IdType="pubmed">23280791</ArticleId></ArticleIdList></Reference><Reference><Citation>Ainsworth BE, Haskell WL, Herrmann SD, et al. 2011 compendium of physical activities: a second update of codes and MET values. Med Sci Sports Exerc 2011;43:1575&#x2013;1581.</Citation><ArticleIdList><ArticleId IdType="pubmed">21681120</ArticleId></ArticleIdList></Reference><Reference><Citation>Ainsworth BE, Haskell WL, Herrmann SD, et al. 
The compendium of physical activities tracking guide [online]. Available at: https://sites.google.com/site/compendiumofphysicalactivities/. Accessed February 20, 2015.</Citation></Reference><Reference><Citation>Schelldorfer J, Buhlmann P, Van De Geer S. Estimation for high-dimensional linear mixed-effects models using &#x2113;1-penalization. Scand J Stat 2011;38:197&#x2013;214.</Citation></Reference><Reference><Citation>Villemagne VL, Burnham S, Bourgeat P, et al. Amyloid beta deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study. Lancet Neurol 2013;12:357&#x2013;367.</Citation><ArticleIdList><ArticleId IdType="pubmed">23477989</ArticleId></ArticleIdList></Reference><Reference><Citation>Sojkova J, Zhou Y, An Y, et al. Longitudinal patterns of beta-amyloid deposition in nondemented older adults. Arch Neurol 2011;68:644&#x2013;649.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3136195</ArticleId><ArticleId IdType="pubmed">21555640</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown B, Peiffer J, Taddei K, et al. Physical activity and amyloid-&#x3b2; plasma and brain levels: results from the Australian Imaging, Biomarkers and Lifestyle Study of Ageing. Mol Psychiatry 2013;18:875&#x2013;881.</Citation><ArticleIdList><ArticleId IdType="pubmed">22889922</ArticleId></ArticleIdList></Reference><Reference><Citation>Kivipelto M, Rovio S, Ngandu T, et al. Apolipoprotein E &#x25b;4 magnifies lifestyle risks for dementia: a population-based study. J Cell Mol Med 2008;12:2762&#x2013;2771.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3828889</ArticleId><ArticleId IdType="pubmed">18318693</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodrigue KM, Rieck JR, Kennedy KM, Devous MD, Diaz-Arrastia R, Park DC. Risk factors for &#x3b2;-amyloid deposition in healthy aging: vascular and genetic effects. JAMA Neurol 2013;70:600&#x2013;606.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3968915</ArticleId><ArticleId IdType="pubmed">23553344</ArticleId></ArticleIdList></Reference><Reference><Citation>Head D, Bugg JM, Goate AM, et al. Exercise engagement as a moderator of the effects of APOE genotype on amyloid deposition. Arch Neurol 2012;69:636&#x2013;643.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3583203</ArticleId><ArticleId IdType="pubmed">22232206</ArticleId></ArticleIdList></Reference><Reference><Citation>Jansen WJ, Ossenkoppele R, Knol DL, et al. Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. JAMA 2015;313:1924&#x2013;1938.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4486209</ArticleId><ArticleId IdType="pubmed">25988462</ArticleId></ArticleIdList></Reference><Reference><Citation>Protas HD, Chen K, Langbaum JB, et al. Posterior cingulate glucose metabolism, hippocampal glucose metabolism, and hippocampal volume in cognitively normal, late-middle-aged persons at 3 levels of genetic risk for Alzheimer disease. JAMA Neurol 2013;70:320&#x2013;325.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3745014</ArticleId><ArticleId IdType="pubmed">23599929</ArticleId></ArticleIdList></Reference><Reference><Citation>Kantarci K, Senjem ML, Lowe VJ, et al. Effects of age on the glucose metabolic changes in mild cognitive impairment. AJNR Am J Neuroradiol 2010;31:1247&#x2013;1253.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2890033</ArticleId><ArticleId IdType="pubmed">20299441</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiman EM, Caselli RJ, Chen K, Alexander GE, Bandy D, Frost J. Declining brain activity in cognitively normal apolipoprotein E epsilon 4 heterozygotes: a foundation for using positron emission tomography to efficiently test treatments to prevent Alzheimer's disease. Proc Natl Acad Sci USA 2001;98:3334&#x2013;3339.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC30654</ArticleId><ArticleId IdType="pubmed">11248079</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr, Petersen RC, Xu Y, et al. Rates of hippocampal atrophy correlate with change in clinical status in aging and AD. Neurology 2000;55:484&#x2013;489.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2724764</ArticleId><ArticleId IdType="pubmed">10953178</ArticleId></ArticleIdList></Reference><Reference><Citation>Carlson NE, Moore MM, Dame A, et al. Trajectories of brain loss in aging and the development of cognitive impairment. Neurology 2008;70:828&#x2013;833.</Citation><ArticleIdList><ArticleId IdType="pubmed">18046010</ArticleId></ArticleIdList></Reference><Reference><Citation>Jak AJ, Houston WS, Nagel BJ, Corey-Bloom J, Bondi MW. Differential cross-sectional and longitudinal impact of APOE genotype on hippocampal volumes in nondemented older adults. Dement Geriatr Cogn Disord 2007;23:382&#x2013;389.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2084479</ArticleId><ArticleId IdType="pubmed">17389798</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr, Petersen RC, Xu YC, et al. Hippocampal atrophy and apolipoprotein E genotype are independently associated with Alzheimer's disease. Ann Neurol 1998;43:303&#x2013;310.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2752747</ArticleId><ArticleId IdType="pubmed">9506546</ArticleId></ArticleIdList></Reference><Reference><Citation>Vemuri P, Lesnick TG, Przybelski SA, et al. Association of lifetime intellectual enrichment with cognitive decline in the older population. JAMA Neurol 2014;71:1017&#x2013;1024.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4266551</ArticleId><ArticleId IdType="pubmed">25054282</ArticleId></ArticleIdList></Reference><Reference><Citation>Phillips C, Baktir MA, Srivatsan M, Salehi A. Neuroprotective effects of physical activity on the brain: a closer look at trophic factor signaling. Front Cell Neurosci 2014;8:170.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4064707</ArticleId><ArticleId IdType="pubmed">24999318</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">26916334</PMID><DateCompleted><Year>2016</Year><Month>10</Month><Day>14</Day></DateCompleted><DateRevised><Year>2024</Year><Month>01</Month><Day>09</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2051-5960</ISSN><JournalIssue CitedMedium="Internet"><Volume>4</Volume><PubDate><Year>2016</Year><Month>Feb</Month><Day>25</Day></PubDate></JournalIssue><Title>Acta neuropathologica communications</Title><ISOAbbreviation>Acta Neuropathol Commun</ISOAbbreviation></Journal><ArticleTitle>Age-dependent neuroinflammation and cognitive decline in a novel Ala152Thr-Tau transgenic mouse model of PSP and AD.</ArticleTitle><Pagination><StartPage>17</StartPage><MedlinePgn>17</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">17</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s40478-016-0281-z</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Mutations of Tau are associated with several neurodegenerative disorders. Recently, the Tau mutation A152T was described as a novel risk factor for frontotemporal dementia spectrum disorders and Alzheimer disease. In vitro Tau-A152T shows a decreased binding to microtubules and a reduced tendency to form abnormal fibers.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">To study the effects of this mutation we generated a mouse model expressing human full-length Tau with this mutation (hTau40(AT)). At young age (2-3 months) immunohistological analysis reveals pathological Tau conformation and Tau-hyperphosphorylation combined with Tau missorting into the somatodendritic compartment of neurons. With increasing age there is Tau aggregation including co-aggregates of endogenous mouse Tau and exogenous human Tau, accompanied by loss of synapses (especially presynaptic failure) and neurons. From ~10&#xa0;months onwards the mice show a prominent neuroinflammatory response as judged by activation of microglia and astrocytes. This progressive neuroinflammation becomes visible by in vivo bioluminescence imaging after crossbreeding of hTau40(AT) mice and Gfap-luciferase reporter mice. In contrast to other Tau-transgenic models and Alzheimer disease patients with reduced protein clearance, hTau40(AT) mice show a strong induction of autophagy. Although Tau-hyperphosphorylation and aggregation is also present in spinal cord and motor cortex (due to the Thy1.2 promoter), neuromotor performance is not affected. Deficits in spatial reference memory are manifest at ~16&#xa0;months and are accompanied by neuronal death.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The hTau40(AT) mice mimic pathological hallmarks of tauopathies including a cognitive phenotype combined with pronounced neuroinflammation visible by bioluminescence. Thus the mice are suitable for mechanistic studies of Tau induced toxicity and in vivo validation of neuroprotective compounds.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sydow</LastName><ForeName>Astrid</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), Ludwig-Erhard-Allee 2, 53175, Bonn, Germany. sydow@mpasmb.desy.de.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Max-Planck-Institute for Metabolism Research, Hamburg Outstation, c/o DESY, Notkestrasse 85, 22607, Hamburg, Germany. sydow@mpasmb.desy.de.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hochgr&#xe4;fe</LastName><ForeName>Katja</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Max-Planck-Institute for Metabolism Research, Hamburg Outstation, c/o DESY, Notkestrasse 85, 22607, Hamburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>K&#xf6;nen</LastName><ForeName>Stefanie</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), Ludwig-Erhard-Allee 2, 53175, Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cadinu</LastName><ForeName>Daniela</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Max-Planck-Institute for Metabolism Research, Hamburg Outstation, c/o DESY, Notkestrasse 85, 22607, Hamburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Matenia</LastName><ForeName>Dorthe</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), Ludwig-Erhard-Allee 2, 53175, Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Petrova</LastName><ForeName>Olga</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), Ludwig-Erhard-Allee 2, 53175, Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Joseph</LastName><ForeName>Maria</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), Ludwig-Erhard-Allee 2, 53175, Bonn, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Max-Planck-Institute for Metabolism Research, Hamburg Outstation, c/o DESY, Notkestrasse 85, 22607, Hamburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dennissen</LastName><ForeName>Frank Johannes</ForeName><Initials>FJ</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), Ludwig-Erhard-Allee 2, 53175, Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mandelkow</LastName><ForeName>Eva-Maria</ForeName><Initials>EM</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), Ludwig-Erhard-Allee 2, 53175, Bonn, Germany. mandelkow@mpasmb.desy.de.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Max-Planck-Institute for Metabolism Research, Hamburg Outstation, c/o DESY, Notkestrasse 85, 22607, Hamburg, Germany. mandelkow@mpasmb.desy.de.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CAESAR Research Center, Ludwig-Erhard-Allee 2, 53175, Bonn, Germany. mandelkow@mpasmb.desy.de.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>02</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Acta Neuropathol Commun</MedlineTA><NlmUniqueID>101610673</NlmUniqueID><ISSNLinking>2051-5960</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016207">Cytokines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C110853">Gt(ROSA)26Sor non-coding RNA, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009419">Nerve Tissue Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D022661">RNA, Untranslated</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>2ZD004190S</RegistryNumber><NameOfSubstance UI="D013912">Threonine</NameOfSubstance></Chemical><Chemical><RegistryNumber>OF5P57N2ZX</RegistryNumber><NameOfSubstance UI="D000409">Alanine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="Y">Aging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000409" MajorTopicYN="N">Alanine</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001253" MajorTopicYN="N">Astrocytes</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D049229" MajorTopicYN="N">Dendritic Spines</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004660" MajorTopicYN="N">Encephalitis</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008569" MajorTopicYN="N">Memory Disorders</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009419" MajorTopicYN="N">Nerve Tissue Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011030" MajorTopicYN="N">Pneumothorax</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D022661" MajorTopicYN="N">RNA, Untranslated</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013912" MajorTopicYN="N">Threonine</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>1</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>1</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>2</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>2</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>10</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2016</Year><Month>2</Month><Day>25</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26916334</ArticleId><ArticleId IdType="pmc">PMC4766625</ArticleId><ArticleId IdType="doi">10.1186/s40478-016-0281-z</ArticleId><ArticleId IdType="pii">10.1186/s40478-016-0281-z</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, Cole GM, et al. Inflammation and Alzheimer's disease. Neurobiol Aging. 2000;21:383&#x2013;421. doi: 10.1016/S0197-4580(00)00124-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0197-4580(00)00124-X</ArticleId><ArticleId IdType="pmc">PMC3887148</ArticleId><ArticleId IdType="pubmed">10858586</ArticleId></ArticleIdList></Reference><Reference><Citation>Amor S, Peferoen LA, Vogel DY, Breur M, van der Valk P, Baker D, et al. Inflammation in neurodegenerative diseases--an update. Immunology. 2014;142:151&#x2013;66. doi: 10.1111/imm.12233.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/imm.12233</ArticleId><ArticleId IdType="pmc">PMC4008224</ArticleId><ArticleId IdType="pubmed">24329535</ArticleId></ArticleIdList></Reference><Reference><Citation>Ando K, Leroy K, Heraud C, Yilmaz Z, Authelet M, Suain V, et al. Accelerated human mutant tau aggregation by knocking out murine tau in a transgenic mouse model. Am. J. Pathol. 2011;178:803&#x2013;16. doi: 10.1016/j.ajpath.2010.10.034.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajpath.2010.10.034</ArticleId><ArticleId IdType="pmc">PMC3069830</ArticleId><ArticleId IdType="pubmed">21281813</ArticleId></ArticleIdList></Reference><Reference><Citation>Andreadis A, Brown WM, Kosik KS. Structure and novel exons of the human tau gene. Biochemistry. 1992;31:10626&#x2013;33. doi: 10.1021/bi00158a027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/bi00158a027</ArticleId><ArticleId IdType="pubmed">1420178</ArticleId></ArticleIdList></Reference><Reference><Citation>Augustinack JC, Schneider A, Mandelkow EM, Hyman BT. Specific tau phosphorylation sites correlate with severity of neuronal cytopathology in Alzheimer's disease. Acta Neuropathol. 2002;103:26&#x2013;35. doi: 10.1007/s004010100423.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s004010100423</ArticleId><ArticleId IdType="pubmed">11837744</ArticleId></ArticleIdList></Reference><Reference><Citation>Avital A, Goshen I, Kamsler A, Segal M, Iverfeldt K, Richter-Levin G, et al. Impaired interleukin-1 signaling is associated with deficits in hippocampal memory processes and neural plasticity. Hippocampus. 2003;13:826&#x2013;34. doi: 10.1002/hipo.10135.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hipo.10135</ArticleId><ArticleId IdType="pubmed">14620878</ArticleId></ArticleIdList></Reference><Reference><Citation>Bajic N, Jenner P, Ballard CG, Francis PT. Proteasome inhibition leads to early loss of synaptic proteins in neuronal culture. J Neural Transm. 2012;119:1467&#x2013;76. doi: 10.1007/s00702-012-0816-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00702-012-0816-9</ArticleId><ArticleId IdType="pubmed">22592936</ArticleId></ArticleIdList></Reference><Reference><Citation>Baker M, Litvan I, Houlden H, Adamson J, Dickson D, Perez-Tur J, et al. Association of an extended haplotype in the tau gene with progressive supranuclear palsy. Hum Mol Genet. 1999;8:711&#x2013;5. doi: 10.1093/hmg/8.4.711.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/8.4.711</ArticleId><ArticleId IdType="pubmed">10072441</ArticleId></ArticleIdList></Reference><Reference><Citation>Barger SW, Van Eldik LJ. S100 beta stimulates calcium fluxes in glial and neuronal cells. J Biol Chem. 1992;267:9689&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pubmed">1315768</ArticleId></ArticleIdList></Reference><Reference><Citation>Bellucci A, Westwood AJ, Ingram E, Casamenti F, Goedert M, Spillantini MG. Induction of inflammatory mediators and microglial activation in mice transgenic for mutant human P301S tau protein. Am. J. Pathol. 2004;165:1643&#x2013;52. doi: 10.1016/S0002-9440(10)63421-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0002-9440(10)63421-9</ArticleId><ArticleId IdType="pmc">PMC1618683</ArticleId><ArticleId IdType="pubmed">15509534</ArticleId></ArticleIdList></Reference><Reference><Citation>Beraud D, Maguire-Zeiss KA. Misfolded alpha-synuclein and Toll-like receptors: therapeutic targets for Parkinson's disease. Parkinsonism Relat Disord. 2012;18(Suppl 1):S17&#x2013;20. doi: 10.1016/S1353-8020(11)70008-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1353-8020(11)70008-6</ArticleId><ArticleId IdType="pmc">PMC3500631</ArticleId><ArticleId IdType="pubmed">22166424</ArticleId></ArticleIdList></Reference><Reference><Citation>Bergeron C, Pollanen MS, Weyer L, Lang AE. Cortical degeneration in progressive supranuclear palsy. A comparison with cortical-basal ganglionic degeneration. J Neuropathol Exp Neurol. 1997;56:726&#x2013;34. doi: 10.1097/00005072-199706000-00010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00005072-199706000-00010</ArticleId><ArticleId IdType="pubmed">9184663</ArticleId></ArticleIdList></Reference><Reference><Citation>Binder LI, Guillozet-Bongaarts AL, Garcia-Sierra F, Berry RW. Tau, tangles, and Alzheimer's disease. Biochim Biophys Acta. 1739;2005:216&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pubmed">15615640</ArticleId></ArticleIdList></Reference><Reference><Citation>Bouabe H, Okkenhaug K. Gene targeting in mice: a review. Methods Mol Biol. 2013;1064:315&#x2013;36. doi: 10.1007/978-1-62703-601-6_23.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-1-62703-601-6_23</ArticleId><ArticleId IdType="pmc">PMC4524968</ArticleId><ArticleId IdType="pubmed">23996268</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82:239&#x2013;59. doi: 10.1007/BF00308809.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF00308809</ArticleId><ArticleId IdType="pubmed">1759558</ArticleId></ArticleIdList></Reference><Reference><Citation>Buee L, Bussiere T, Buee-Scherrer V, Delacourte A, Hof PR. Tau protein isoforms, phosphorylation and role in neurodegenerative disorders. Brain Res Brain Res Rev. 2000;33:95&#x2013;130. doi: 10.1016/S0165-0173(00)00019-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0165-0173(00)00019-9</ArticleId><ArticleId IdType="pubmed">10967355</ArticleId></ArticleIdList></Reference><Reference><Citation>Bugiani O, Mancardi GL, Brusa A, Ederli A. The fine structure of subcortical neurofibrillary tangles in progressive supranuclear palsy. Acta Neuropathol. 1979;45:147&#x2013;52. doi: 10.1007/BF00691893.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF00691893</ArticleId><ArticleId IdType="pubmed">419938</ArticleId></ArticleIdList></Reference><Reference><Citation>Caroni P. Overexpression of growth-associated proteins in the neurons of adult transgenic mice. J Neurosci Methods. 1997;71:3&#x2013;9. doi: 10.1016/S0165-0270(96)00121-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0165-0270(96)00121-5</ArticleId><ArticleId IdType="pubmed">9125370</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen J, Kanai Y, Cowan NJ, Hirokawa N. Projection domains of MAP2 and tau determine spacings between microtubules in dendrites and axons. Nature. 1992;360:674&#x2013;7. doi: 10.1038/360674a0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/360674a0</ArticleId><ArticleId IdType="pubmed">1465130</ArticleId></ArticleIdList></Reference><Reference><Citation>Coppola G, Chinnathambi S, Lee JJ, Dombroski BA, Baker MC, Soto-Ortolaza AI, et al. Evidence for a role of the rare p.A152T variant in MAPT in increasing the risk for FTD-spectrum and Alzheimer's diseases. Hum Mol Genet. 2012;21:3500&#x2013;12. doi: 10.1093/hmg/dds161.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/dds161</ArticleId><ArticleId IdType="pmc">PMC3392107</ArticleId><ArticleId IdType="pubmed">22556362</ArticleId></ArticleIdList></Reference><Reference><Citation>Cuervo AM, Wong E. Chaperone-mediated autophagy: roles in disease and aging. Cell Res. 2014;24:92&#x2013;104. doi: 10.1038/cr.2013.153.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/cr.2013.153</ArticleId><ArticleId IdType="pmc">PMC3879702</ArticleId><ArticleId IdType="pubmed">24281265</ArticleId></ArticleIdList></Reference><Reference><Citation>de Calignon A, Polydoro M, Suarez-Calvet M, William C, Adamowicz DH, Kopeikina KJ, et al. Propagation of tau pathology in a model of early Alzheimer's disease. Neuron. 2012;73:685&#x2013;97. doi: 10.1016/j.neuron.2011.11.033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2011.11.033</ArticleId><ArticleId IdType="pmc">PMC3292759</ArticleId><ArticleId IdType="pubmed">22365544</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickson DW, Kouri N, Murray ME, Josephs KA. Neuropathology of frontotemporal lobar degeneration-tau (FTLD-tau) J Mol Neurosci. 2011;45:384&#x2013;9. doi: 10.1007/s12031-011-9589-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12031-011-9589-0</ArticleId><ArticleId IdType="pmc">PMC3208128</ArticleId><ArticleId IdType="pubmed">21720721</ArticleId></ArticleIdList></Reference><Reference><Citation>Ding H, Dolan PJ, Johnson GV. Histone deacetylase 6 interacts with the microtubule-associated protein tau. J Neurochem. 2008;106:2119&#x2013;30. doi: 10.1111/j.1471-4159.2008.05564.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2008.05564.x</ArticleId><ArticleId IdType="pmc">PMC2574575</ArticleId><ArticleId IdType="pubmed">18636984</ArticleId></ArticleIdList></Reference><Reference><Citation>Ding Q, Dimayuga E, Markesbery WR, Keller JN. Proteasome inhibition induces reversible impairments in protein synthesis. FASEB J. 2006;20:1055&#x2013;63. doi: 10.1096/fj.05-5495com.</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fj.05-5495com</ArticleId><ArticleId IdType="pubmed">16770004</ArticleId></ArticleIdList></Reference><Reference><Citation>Ding WX, Ni HM, Gao W, Yoshimori T, Stolz DB, Ron D, et al. Linking of autophagy to ubiquitin-proteasome system is important for the regulation of endoplasmic reticulum stress and cell viability. Am. J. Pathol. 2007;171:513&#x2013;24. doi: 10.2353/ajpath.2007.070188.</Citation><ArticleIdList><ArticleId IdType="doi">10.2353/ajpath.2007.070188</ArticleId><ArticleId IdType="pmc">PMC1934546</ArticleId><ArticleId IdType="pubmed">17620365</ArticleId></ArticleIdList></Reference><Reference><Citation>Dong C, Upadhya SC, Ding L, Smith TK, Hegde AN. Proteasome inhibition enhances the induction and impairs the maintenance of late-phase long-term potentiation. Learn Mem. 2008;15:335&#x2013;47. doi: 10.1101/lm.984508.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/lm.984508</ArticleId><ArticleId IdType="pmc">PMC2364605</ArticleId><ArticleId IdType="pubmed">18441292</ArticleId></ArticleIdList></Reference><Reference><Citation>Doorn KJ, Moors T, Drukarch B, van de Berg W, Lucassen PJ, van Dam AM. Microglial phenotypes and toll-like receptor 2 in the substantia nigra and hippocampus of incidental Lewy body disease cases and Parkinson's disease patients. Acta Neuropathol Commun. 2014;2:90.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4224021</ArticleId><ArticleId IdType="pubmed">25099483</ArticleId></ArticleIdList></Reference><Reference><Citation>Du J, Liang Y, Xu F, Sun B, Wang Z. Trehalose rescues Alzheimer's disease phenotypes in APP/PS1 transgenic mice. J Pharm Pharmacol. 2013;65:1753&#x2013;6. doi: 10.1111/jphp.12108.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jphp.12108</ArticleId><ArticleId IdType="pubmed">24236985</ArticleId></ArticleIdList></Reference><Reference><Citation>Eckermann K, Mocanu MM, Khlistunova I, Biernat J, Nissen A, Hofmann A, et al. The beta-propensity of Tau determines aggregation and synaptic loss in inducible mouse models of tauopathy. J Biol Chem. 2007;282:31755&#x2013;65. doi: 10.1074/jbc.M705282200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M705282200</ArticleId><ArticleId IdType="pubmed">17716969</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernandez-Botran R, Ahmed Z, Crespo FA, Gatenbee C, Gonzalez J, Dickson DW, et al. Cytokine expression and microglial activation in progressive supranuclear palsy. Parkinsonism Relat Disord. 2011;17:683&#x2013;8. doi: 10.1016/j.parkreldis.2011.06.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.parkreldis.2011.06.007</ArticleId><ArticleId IdType="pmc">PMC3196843</ArticleId><ArticleId IdType="pubmed">21741294</ArticleId></ArticleIdList></Reference><Reference><Citation>Fong H, Wang C, Knoferle J, Walker D, Balestra ME, Tong LM, et al. Genetic correction of tauopathy phenotypes in neurons derived from human induced pluripotent stem cells. Stem Cell Rep. 2013;1:226&#x2013;34. doi: 10.1016/j.stemcr.2013.08.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.stemcr.2013.08.001</ArticleId><ArticleId IdType="pmc">PMC3849235</ArticleId><ArticleId IdType="pubmed">24319659</ArticleId></ArticleIdList></Reference><Reference><Citation>Friedrich G, Soriano P. Promoter traps in embryonic stem cells: a genetic screen to identify and mutate developmental genes in mice. Genes Dev. 1991;5:1513&#x2013;23. doi: 10.1101/gad.5.9.1513.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/gad.5.9.1513</ArticleId><ArticleId IdType="pubmed">1653172</ArticleId></ArticleIdList></Reference><Reference><Citation>Gerlai R, Wojtowicz JM, Marks A, Roder J. Overexpression of a calcium-binding protein, S100 beta, in astrocytes alters synaptic plasticity and impairs spatial learning in transgenic mice. Learn Mem. 1995;2:26&#x2013;39. doi: 10.1101/lm.2.1.26.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/lm.2.1.26</ArticleId><ArticleId IdType="pubmed">10467564</ArticleId></ArticleIdList></Reference><Reference><Citation>Glaser EM, Van der Loos H. Analysis of thick brain sections by obverse-reverse computer microscopy: application of a new, high clarity Golgi-Nissl stain. J Neurosci Methods. 1981;4:117&#x2013;25. doi: 10.1016/0165-0270(81)90045-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0165-0270(81)90045-5</ArticleId><ArticleId IdType="pubmed">6168870</ArticleId></ArticleIdList></Reference><Reference><Citation>Goedert M, Jakes R. Mutations causing neurodegenerative tauopathies. Biochim Biophys Acta. 1739;2005:240&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pubmed">15615642</ArticleId></ArticleIdList></Reference><Reference><Citation>Gorlovoy P, Larionov S, Pham TT, Neumann H. Accumulation of tau induced in neurites by microglial proinflammatory mediators. FASEB J. 2009;23:2502&#x2013;13. doi: 10.1096/fj.08-123877.</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fj.08-123877</ArticleId><ArticleId IdType="pubmed">19289607</ArticleId></ArticleIdList></Reference><Reference><Citation>Graff-Radford J, Whitwell JL, Dickson DW, Josephs KA. Pallidonigroluysian atrophy associated with p.A152T variant in MAPT. Parkinsonism Relat Disord. 2013;19:838&#x2013;41. doi: 10.1016/j.parkreldis.2013.04.023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.parkreldis.2013.04.023</ArticleId><ArticleId IdType="pubmed">23692670</ArticleId></ArticleIdList></Reference><Reference><Citation>Griffin WS, Sheng JG, Royston MC, Gentleman SM, McKenzie JE, Graham DI, et al. Glial-neuronal interactions in Alzheimer's disease: the potential role of a 'cytokine cycle' in disease progression. Brain Pathol. 1998;8:65&#x2013;72. doi: 10.1111/j.1750-3639.1998.tb00136.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1750-3639.1998.tb00136.x</ArticleId><ArticleId IdType="pmc">PMC8098321</ArticleId><ArticleId IdType="pubmed">9458167</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanger DP, Anderton BH, Noble W. Tau phosphorylation: the therapeutic challenge for neurodegenerative disease. Trends Mol Med. 2009;15:112&#x2013;9. doi: 10.1016/j.molmed.2009.01.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molmed.2009.01.003</ArticleId><ArticleId IdType="pubmed">19246243</ArticleId></ArticleIdList></Reference><Reference><Citation>Harris JA, Koyama A, Maeda S, Ho K, Devidze N, Dubal DB, et al. Human P301L-mutant tau expression in mouse entorhinal-hippocampal network causes tau aggregation and presynaptic pathology but no cognitive deficits. PLoS One. 2012;7 doi: 10.1371/journal.pone.0045881.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0045881</ArticleId><ArticleId IdType="pmc">PMC3454317</ArticleId><ArticleId IdType="pubmed">23029293</ArticleId></ArticleIdList></Reference><Reference><Citation>Hasegawa M, Smith MJ, Goedert M. Tau proteins with FTDP-17 mutations have a reduced ability to promote microtubule assembly. FEBS Lett. 1998;437:207&#x2013;10. doi: 10.1016/S0014-5793(98)01217-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0014-5793(98)01217-4</ArticleId><ArticleId IdType="pubmed">9824291</ArticleId></ArticleIdList></Reference><Reference><Citation>Heneka MT, O'Banion MK. Inflammatory processes in Alzheimer's disease. J Neuroimmunol. 2007;184:69&#x2013;91. doi: 10.1016/j.jneuroim.2006.11.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jneuroim.2006.11.017</ArticleId><ArticleId IdType="pubmed">17222916</ArticleId></ArticleIdList></Reference><Reference><Citation>Heneka MT, Wiesinger H, Dumitrescu-Ozimek L, Riederer P, Feinstein DL, Klockgether T. Neuronal and glial coexpression of argininosuccinate synthetase and inducible nitric oxide synthase in Alzheimer disease. J Neuropathol Exp Neurol. 2001;60:906&#x2013;16. doi: 10.1093/jnen/60.9.906.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jnen/60.9.906</ArticleId><ArticleId IdType="pubmed">11556547</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirsch EC, Hunot S. Neuroinflammation in Parkinson's disease: a target for neuroprotection? Lancet Neurol. 2009;8:382&#x2013;97. doi: 10.1016/S1474-4422(09)70062-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(09)70062-6</ArticleId><ArticleId IdType="pubmed">19296921</ArticleId></ArticleIdList></Reference><Reference><Citation>Hochgr&#xe4;fe K, Mandelkow EM. Making the brain glow: in vivo bioluminescence imaging to study neurodegeneration. Mol Neurobiol. 2013;47:868&#x2013;82. doi: 10.1007/s12035-012-8379-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-012-8379-1</ArticleId><ArticleId IdType="pubmed">23192390</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang Q, Figueiredo-Pereira ME. Ubiquitin/proteasome pathway impairment in neurodegeneration: therapeutic implications. Apoptosis. 2010;15:1292&#x2013;311. doi: 10.1007/s10495-010-0466-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10495-010-0466-z</ArticleId><ArticleId IdType="pmc">PMC2908192</ArticleId><ArticleId IdType="pubmed">20131003</ArticleId></ArticleIdList></Reference><Reference><Citation>Hutton M, Lendon CL, Rizzu P, Baker M, Froelich S, Houlden H, et al. Association of missense and 5'-splice-site mutations in tau with the inherited dementia FTDP-17. Nature. 1998;393:702&#x2013;5. doi: 10.1038/31508.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/31508</ArticleId><ArticleId IdType="pubmed">9641683</ArticleId></ArticleIdList></Reference><Reference><Citation>Illenberger S, Zheng-Fischhofer Q, Preuss U, Stamer K, Baumann K, Trinczek B, et al. The endogenous and cell cycle-dependent phosphorylation of tau protein in living cells: implications for Alzheimer's disease. Mol Biol Cell. 1998;9:1495&#x2013;512. doi: 10.1091/mbc.9.6.1495.</Citation><ArticleIdList><ArticleId IdType="doi">10.1091/mbc.9.6.1495</ArticleId><ArticleId IdType="pmc">PMC25374</ArticleId><ArticleId IdType="pubmed">9614189</ArticleId></ArticleIdList></Reference><Reference><Citation>Ittner LM, Ke YD, Delerue F, Bi M, Gladbach A, van Eersel J, et al. Dendritic function of tau mediates amyloid-beta toxicity in Alzheimer's disease mouse models. Cell. 2010;142:387&#x2013;97. doi: 10.1016/j.cell.2010.06.036.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2010.06.036</ArticleId><ArticleId IdType="pubmed">20655099</ArticleId></ArticleIdList></Reference><Reference><Citation>Iyer A, Lapointe NE, Zielke K, Berdynski M, Guzman E, Barczak A, et al. A novel MAPT mutation, G55R, in a frontotemporal dementia patient leads to altered Tau function. PLoS One. 2013;8 doi: 10.1371/journal.pone.0076409.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0076409</ArticleId><ArticleId IdType="pmc">PMC3785453</ArticleId><ArticleId IdType="pubmed">24086739</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeganathan S, von Bergen M, Brutlach H, Steinhoff HJ, Mandelkow E. Global hairpin folding of tau in solution. Biochemistry. 2006;45:2283&#x2013;93. doi: 10.1021/bi0521543.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/bi0521543</ArticleId><ArticleId IdType="pubmed">16475817</ArticleId></ArticleIdList></Reference><Reference><Citation>Jicha GA, Berenfeld B, Davies P. Sequence requirements for formation of conformational variants of tau similar to those found in Alzheimer's disease. J Neurosci Res. 1999;55:713&#x2013;23. doi: 10.1002/(SICI)1097-4547(19990315)55:6&lt;713::AID-JNR6&gt;3.0.CO;2-G.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/(SICI)1097-4547(19990315)55:6&lt;713::AID-JNR6&gt;3.0.CO;2-G</ArticleId><ArticleId IdType="pubmed">10220112</ArticleId></ArticleIdList></Reference><Reference><Citation>Josephs KA, Hodges JR, Snowden JS, Mackenzie IR, Neumann M, Mann DM, et al. Neuropathological background of phenotypical variability in frontotemporal dementia. Acta Neuropathol. 2011;122:137&#x2013;53. doi: 10.1007/s00401-011-0839-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-011-0839-6</ArticleId><ArticleId IdType="pmc">PMC3232515</ArticleId><ArticleId IdType="pubmed">21614463</ArticleId></ArticleIdList></Reference><Reference><Citation>Kara E, Ling H, Pittman AM, Shaw K, de Silva R, Simone R, et al. The MAPT p.A152T variant is a risk factor associated with tauopathies with atypical clinical and neuropathological features. Neurobiol Aging. 2012;33:2231 e2237&#x2013;2231 e2214.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3657164</ArticleId><ArticleId IdType="pubmed">22595371</ArticleId></ArticleIdList></Reference><Reference><Citation>Korolchuk VI, Menzies FM, Rubinsztein DC. Mechanisms of cross-talk between the ubiquitin-proteasome and autophagy-lysosome systems. FEBS Lett. 2010;584:1393&#x2013;8. doi: 10.1016/j.febslet.2009.12.047.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.febslet.2009.12.047</ArticleId><ArticleId IdType="pubmed">20040365</ArticleId></ArticleIdList></Reference><Reference><Citation>Kovacs GG, Wohrer A, Strobel T, Botond G, Attems J, Budka H. Unclassifiable tauopathy associated with an A152T variation in MAPT exon 7. Clin Neuropathol. 2011;30:3&#x2013;10. doi: 10.5414/NPP30003.</Citation><ArticleIdList><ArticleId IdType="doi">10.5414/NPP30003</ArticleId><ArticleId IdType="pubmed">21176711</ArticleId></ArticleIdList></Reference><Reference><Citation>Kr&#xfc;ger U, Wang Y, Kumar S, Mandelkow EM. Autophagic degradation of tau in primary neurons and its enhancement by trehalose. Neurobiol Aging. 2012;33:2291&#x2013;305. doi: 10.1016/j.neurobiolaging.2011.11.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2011.11.009</ArticleId><ArticleId IdType="pubmed">22169203</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee MJ, Lee JH, Rubinsztein DC. Tau degradation: the ubiquitin-proteasome system versus the autophagy-lysosome system. Prog Neurobiol. 2013;105:49&#x2013;59. doi: 10.1016/j.pneurobio.2013.03.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pneurobio.2013.03.001</ArticleId><ArticleId IdType="pubmed">23528736</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee SE, Tartaglia MC, Yener G, Genc S, Seeley WW, Sanchez-Juan P, et al. Neurodegenerative disease phenotypes in carriers of MAPT p.A152T, a risk factor for frontotemporal dementia spectrum disorders and Alzheimer disease. Alzheimer Dis Assoc Disord. 2013;27:302&#x2013;9. doi: 10.1097/WAD.0b013e31828cc357.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/WAD.0b013e31828cc357</ArticleId><ArticleId IdType="pmc">PMC3796183</ArticleId><ArticleId IdType="pubmed">23518664</ArticleId></ArticleIdList></Reference><Reference><Citation>Leroy K, Bretteville A, Schindowski K, Gilissen E, Authelet M, De Decker R, et al. Early axonopathy preceding neurofibrillary tangles in mutant tau transgenic mice. Am. J. Pathol. 2007;171:976&#x2013;92. doi: 10.2353/ajpath.2007.070345.</Citation><ArticleIdList><ArticleId IdType="doi">10.2353/ajpath.2007.070345</ArticleId><ArticleId IdType="pmc">PMC1959508</ArticleId><ArticleId IdType="pubmed">17690183</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewis J, McGowan E, Rockwood J, Melrose H, Nacharaju P, Van Slegtenhorst M, et al. Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein. Nat Genet. 2000;25:402&#x2013;5. doi: 10.1038/78078.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/78078</ArticleId><ArticleId IdType="pubmed">10932182</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu L, Drouet V, Wu JW, Witter MP, Small SA, Clelland C, et al. Trans-synaptic spread of tau pathology in vivo. PLoS One. 2012;7 doi: 10.1371/journal.pone.0031302.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0031302</ArticleId><ArticleId IdType="pmc">PMC3270029</ArticleId><ArticleId IdType="pubmed">22312444</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez-Salon M, Alonso M, Vianna MR, Viola H, Mello e Souza T, Izquierdo I, et al. The ubiquitin-proteasome cascade is required for mammalian long-term memory formation. Eur J Neurosci. 2001;14:1820&#x2013;6. doi: 10.1046/j.0953-816x.2001.01806.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.0953-816x.2001.01806.x</ArticleId><ArticleId IdType="pubmed">11860477</ArticleId></ArticleIdList></Reference><Reference><Citation>Low P, Varga A, Pircs K, Nagy P, Szatmari Z, Sass M, et al. Impaired proteasomal degradation enhances autophagy via hypoxia signaling in Drosophila. BMC Cell Biol. 2013;14:29. doi: 10.1186/1471-2121-14-29.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2121-14-29</ArticleId><ArticleId IdType="pmc">PMC3700814</ArticleId><ArticleId IdType="pubmed">23800266</ArticleId></ArticleIdList></Reference><Reference><Citation>Lyman M, Lloyd DG, Ji X, Vizcaychipi MP, Ma D. Neuroinflammation: the role and consequences. Neurosci Res. 2014;79:1&#x2013;12. doi: 10.1016/j.neures.2013.10.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neures.2013.10.004</ArticleId><ArticleId IdType="pubmed">24144733</ArticleId></ArticleIdList></Reference><Reference><Citation>Magnani E, Fan J, Gasparini L, Golding M, Williams M, Schiavo G, et al. Interaction of tau protein with the dynactin complex. EMBO J. 2007;26:4546&#x2013;54. doi: 10.1038/sj.emboj.7601878.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.emboj.7601878</ArticleId><ArticleId IdType="pmc">PMC2063488</ArticleId><ArticleId IdType="pubmed">17932487</ArticleId></ArticleIdList></Reference><Reference><Citation>Majumder S, Caccamo A, Medina DX, Benavides AD, Javors MA, Kraig E, et al. Lifelong rapamycin administration ameliorates age-dependent cognitive deficits by reducing IL-1beta and enhancing NMDA signaling. Aging Cell. 2012;11:326&#x2013;35. doi: 10.1111/j.1474-9726.2011.00791.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1474-9726.2011.00791.x</ArticleId><ArticleId IdType="pmc">PMC3306461</ArticleId><ArticleId IdType="pubmed">22212527</ArticleId></ArticleIdList></Reference><Reference><Citation>Majumder S, Richardson A, Strong R, Oddo S. Inducing autophagy by rapamycin before, but not after, the formation of plaques and tangles ameliorates cognitive deficits. PLoS One. 2011;6 doi: 10.1371/journal.pone.0025416.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0025416</ArticleId><ArticleId IdType="pmc">PMC3182203</ArticleId><ArticleId IdType="pubmed">21980451</ArticleId></ArticleIdList></Reference><Reference><Citation>Mandelkow EM, Mandelkow E. Biochemistry and cell biology of tau protein in neurofibrillary degeneration. Cold Spring Harb Perspect Med. 2012;2:a006247. doi: 10.1101/cshperspect.a006247.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/cshperspect.a006247</ArticleId><ArticleId IdType="pmc">PMC3385935</ArticleId><ArticleId IdType="pubmed">22762014</ArticleId></ArticleIdList></Reference><Reference><Citation>Metcalf DJ, Garcia-Arencibia M, Hochfeld WE, Rubinsztein DC. Autophagy and misfolded proteins in neurodegeneration. Exp Neurol. 2012;238:22&#x2013;8. doi: 10.1016/j.expneurol.2010.11.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2010.11.003</ArticleId><ArticleId IdType="pmc">PMC3463804</ArticleId><ArticleId IdType="pubmed">21095248</ArticleId></ArticleIdList></Reference><Reference><Citation>Middeldorp J, Hol EM. GFAP in health and disease. Prog Neurobiol. 2011;93:421&#x2013;43. doi: 10.1016/j.pneurobio.2011.01.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pneurobio.2011.01.005</ArticleId><ArticleId IdType="pubmed">21219963</ArticleId></ArticleIdList></Reference><Reference><Citation>Mishra A, Kim HJ, Shin AH, Thayer SA. Synapse loss induced by interleukin-1beta requires pre- and post-synaptic mechanisms. J Neuroimmune Pharmacol. 2012;7:571&#x2013;8. doi: 10.1007/s11481-012-9342-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11481-012-9342-7</ArticleId><ArticleId IdType="pmc">PMC3415563</ArticleId><ArticleId IdType="pubmed">22311599</ArticleId></ArticleIdList></Reference><Reference><Citation>Mittal S, Ganesh S. Protein quality control mechanisms and neurodegenerative disorders: Checks, balances and deadlocks. Neurosci Res. 2010;68:159&#x2013;66. doi: 10.1016/j.neures.2010.08.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neures.2010.08.002</ArticleId><ArticleId IdType="pubmed">20708043</ArticleId></ArticleIdList></Reference><Reference><Citation>Mocanu MM, Nissen A, Eckermann K, Khlistunova I, Biernat J, Drexler D, et al. The potential for beta-structure in the repeat domain of tau protein determines aggregation, synaptic decay, neuronal loss, and coassembly with endogenous Tau in inducible mouse models of tauopathy. J Neurosci. 2008;28:737&#x2013;48. doi: 10.1523/JNEUROSCI.2824-07.2008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.2824-07.2008</ArticleId><ArticleId IdType="pmc">PMC6670355</ArticleId><ArticleId IdType="pubmed">18199773</ArticleId></ArticleIdList></Reference><Reference><Citation>Morishima-Kawashima M, Hasegawa M, Takio K, Suzuki M, Yoshida H, Titani K, et al. Proline-directed and non-proline-directed phosphorylation of PHF-tau. J Biol Chem. 1995;270:823&#x2013;9. doi: 10.1074/jbc.270.2.823.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.270.2.823</ArticleId><ArticleId IdType="pubmed">7822317</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris R. Developments of a water-maze procedure for studying spatial learning in the rat. J Neurosci Methods. 1984;11:47&#x2013;60. doi: 10.1016/0165-0270(84)90007-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0165-0270(84)90007-4</ArticleId><ArticleId IdType="pubmed">6471907</ArticleId></ArticleIdList></Reference><Reference><Citation>Mrak RE, Griffin WS. Interleukin-1, neuroinflammation, and Alzheimer's disease. Neurobiol Aging. 2001;22:903&#x2013;8. doi: 10.1016/S0197-4580(01)00287-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0197-4580(01)00287-1</ArticleId><ArticleId IdType="pubmed">11754997</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M, Tolnay M, Mackenzie IR. The molecular basis of frontotemporal dementia. Expert Rev Mol Med. 2009;11 doi: 10.1017/S1462399409001136.</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S1462399409001136</ArticleId><ArticleId IdType="pubmed">19638255</ArticleId></ArticleIdList></Reference><Reference><Citation>Pan T, Kondo S, Le W, Jankovic J. The role of autophagy-lysosome pathway in neurodegeneration associated with Parkinson's disease. Brain. 2008;131:1969&#x2013;78. doi: 10.1093/brain/awm318.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awm318</ArticleId><ArticleId IdType="pubmed">18187492</ArticleId></ArticleIdList></Reference><Reference><Citation>Pandey UB, Nie Z, Batlevi Y, McCray BA, Ritson GP, Nedelsky NB, et al. HDAC6 rescues neurodegeneration and provides an essential link between autophagy and the UPS. Nature. 2007;447:859&#x2013;63. doi: 10.1038/nature05853.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature05853</ArticleId><ArticleId IdType="pubmed">17568747</ArticleId></ArticleIdList></Reference><Reference><Citation>Pennanen L, Wolfer DP, Nitsch RM, Gotz J. Impaired spatial reference memory and increased exploratory behavior in P301L tau transgenic mice. Genes Brain Behav. 2006;5:369&#x2013;79. doi: 10.1111/j.1601-183X.2005.00165.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1601-183X.2005.00165.x</ArticleId><ArticleId IdType="pubmed">16879631</ArticleId></ArticleIdList></Reference><Reference><Citation>Perry VH, Nicoll JA, Holmes C. Microglia in neurodegenerative disease. Nat Rev Neurol. 2010;6:193&#x2013;201. doi: 10.1038/nrneurol.2010.17.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2010.17</ArticleId><ArticleId IdType="pubmed">20234358</ArticleId></ArticleIdList></Reference><Reference><Citation>Pintado C, Gavilan MP, Gavilan E, Garcia-Cuervo L, Gutierrez A, Vitorica J, et al. Lipopolysaccharide-induced neuroinflammation leads to the accumulation of ubiquitinated proteins and increases susceptibility to neurodegeneration induced by proteasome inhibition in rat hippocampus. J Neuroinflammation. 2012;9:87. doi: 10.1186/1742-2094-9-87.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1742-2094-9-87</ArticleId><ArticleId IdType="pmc">PMC3462674</ArticleId><ArticleId IdType="pubmed">22559833</ArticleId></ArticleIdList></Reference><Reference><Citation>Politis M, Su P, Piccini P. Imaging of microglia in patients with neurodegenerative disorders. Front Pharmacol. 2012;3:96. doi: 10.3389/fphar.2012.00096.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2012.00096</ArticleId><ArticleId IdType="pmc">PMC3361961</ArticleId><ArticleId IdType="pubmed">22661951</ArticleId></ArticleIdList></Reference><Reference><Citation>Poorkaj P, Muma NA, Zhukareva V, Cochran EJ, Shannon KM, Hurtig H, et al. An R5L tau mutation in a subject with a progressive supranuclear palsy phenotype. Ann Neurol. 2002;52:511&#x2013;6. doi: 10.1002/ana.10340.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.10340</ArticleId><ArticleId IdType="pubmed">12325083</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramsden M, Kotilinek L, Forster C, Paulson J, McGowan E, SantaCruz K, et al. Age-dependent neurofibrillary tangle formation, neuron loss, and memory impairment in a mouse model of human tauopathy (P301L) J. Neurosci. 2005;25:10637&#x2013;47. doi: 10.1523/JNEUROSCI.3279-05.2005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.3279-05.2005</ArticleId><ArticleId IdType="pmc">PMC6725849</ArticleId><ArticleId IdType="pubmed">16291936</ArticleId></ArticleIdList></Reference><Reference><Citation>Ricobaraza A, Cuadrado-Tejedor M, Marco S, Perez-Otano I, Garcia-Osta A. Phenylbutyrate rescues dendritic spine loss associated with memory deficits in a mouse model of Alzheimer disease. Hippocampus. 2010. doi:10.1002/hipo.20883</Citation><ArticleIdList><ArticleId IdType="pubmed">21069780</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodriguez-Navarro JA, Rodriguez L, Casarejos MJ, Solano RM, Gomez A, Perucho J, et al. Trehalose ameliorates dopaminergic and tau pathology in parkin deleted/tau overexpressing mice through autophagy activation. Neurobiol Dis. 2010;39:423&#x2013;38. doi: 10.1016/j.nbd.2010.05.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2010.05.014</ArticleId><ArticleId IdType="pubmed">20546895</ArticleId></ArticleIdList></Reference><Reference><Citation>Rohrer JD, Paviour D, Vandrovcova J, Hodges J, de Silva R, Rossor MN. Novel L284R MAPT mutation in a family with an autosomal dominant progressive supranuclear palsy syndrome. Neurodegener Dis. 2011;8:149&#x2013;52. doi: 10.1159/000319454.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000319454</ArticleId><ArticleId IdType="pmc">PMC3078284</ArticleId><ArticleId IdType="pubmed">20838030</ArticleId></ArticleIdList></Reference><Reference><Citation>Santacruz K, Lewis J, Spires T, Paulson J, Kotilinek L, Ingelsson M, et al. Tau suppression in a neurodegenerative mouse model improves memory function. Science. 2005;309:476&#x2013;81. doi: 10.1126/science.1113694.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1113694</ArticleId><ArticleId IdType="pmc">PMC1574647</ArticleId><ArticleId IdType="pubmed">16020737</ArticleId></ArticleIdList></Reference><Reference><Citation>Schindowski K, Bretteville A, Leroy K, Begard S, Brion JP, Hamdane M, et al. Alzheimer's disease-like tau neuropathology leads to memory deficits and loss of functional synapses in a novel mutated tau transgenic mouse without any motor deficits. Am. J. Pathol. 2006;169:599&#x2013;616. doi: 10.2353/ajpath.2006.060002.</Citation><ArticleIdList><ArticleId IdType="doi">10.2353/ajpath.2006.060002</ArticleId><ArticleId IdType="pmc">PMC1698785</ArticleId><ArticleId IdType="pubmed">16877359</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheng JG, Ito K, Skinner RD, Mrak RE, Rovnaghi CR, Van Eldik LJ, et al. In vivo and in vitro evidence supporting a role for the inflammatory cytokine interleukin-1 as a driving force in Alzheimer pathogenesis. Neurobiol Aging. 1996;17:761&#x2013;6. doi: 10.1016/0197-4580(96)00104-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0197-4580(96)00104-2</ArticleId><ArticleId IdType="pmc">PMC3886636</ArticleId><ArticleId IdType="pubmed">8892349</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheng JG, Zhu SG, Jones RA, Griffin WS, Mrak RE. Interleukin-1 promotes expression and phosphorylation of neurofilament and tau proteins in vivo. Exp Neurol. 2000;163:388&#x2013;91. doi: 10.1006/exnr.2000.7393.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/exnr.2000.7393</ArticleId><ArticleId IdType="pmc">PMC3886634</ArticleId><ArticleId IdType="pubmed">10833312</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi CS, Kehrl JH. TRAF6 and A20 regulate lysine 63-linked ubiquitination of Beclin-1 to control TLR4-induced autophagy. Sci Signal. 2010;3:ra42.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6335036</ArticleId><ArticleId IdType="pubmed">20501938</ArticleId></ArticleIdList></Reference><Reference><Citation>Spittaels K, Van den Haute C, Van Dorpe J, Bruynseels K, Vandezande K, Laenen I, et al. Prominent axonopathy in the brain and spinal cord of transgenic mice overexpressing four-repeat human tau protein. Am. J. Pathol. 1999;155:2153&#x2013;65. doi: 10.1016/S0002-9440(10)65533-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0002-9440(10)65533-2</ArticleId><ArticleId IdType="pmc">PMC1866931</ArticleId><ArticleId IdType="pubmed">10595944</ArticleId></ArticleIdList></Reference><Reference><Citation>Stalder M, Phinney A, Probst A, Sommer B, Staufenbiel M, Jucker M. Association of microglia with amyloid plaques in brains of APP23 transgenic mice. Am. J. Pathol. 1999;154:1673&#x2013;84. doi: 10.1016/S0002-9440(10)65423-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0002-9440(10)65423-5</ArticleId><ArticleId IdType="pmc">PMC1866618</ArticleId><ArticleId IdType="pubmed">10362792</ArticleId></ArticleIdList></Reference><Reference><Citation>Sumpter R, Jr, Levine B. Autophagy and innate immunity: triggering, targeting and tuning. Semin Cell Dev Biol. 2010;21:699&#x2013;711. doi: 10.1016/j.semcdb.2010.04.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.semcdb.2010.04.003</ArticleId><ArticleId IdType="pmc">PMC2930105</ArticleId><ArticleId IdType="pubmed">20403453</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun A, Nguyen XV, Bing G. Comparative analysis of an improved thioflavin-s stain, Gallyas silver stain, and immunohistochemistry for neurofibrillary tangle demonstration on the same sections. J Histochem Cytochem. 2002;50:463&#x2013;72. doi: 10.1177/002215540205000403.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/002215540205000403</ArticleId><ArticleId IdType="pubmed">11897799</ArticleId></ArticleIdList></Reference><Reference><Citation>Sydow A, Van der Jeugd A, Zheng F, Ahmed T, Balschun D, Petrova O, et al. Tau-induced defects in synaptic plasticity, learning, and memory are reversible in transgenic mice after switching off the toxic Tau mutant. J Neurosci. 2011;31:2511&#x2013;25. doi: 10.1523/JNEUROSCI.5245-10.2011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.5245-10.2011</ArticleId><ArticleId IdType="pmc">PMC6623704</ArticleId><ArticleId IdType="pubmed">21325519</ArticleId></ArticleIdList></Reference><Reference><Citation>Takeda S, Wegmann S, Cho H, DeVos SL, Commins C, Roe AD, et al. Neuronal uptake and propagation of a rare phosphorylated high-molecular-weight tau derived from Alzheimer's disease brain. Nat Commun. 2015;6:8490. doi: 10.1038/ncomms9490.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms9490</ArticleId><ArticleId IdType="pmc">PMC4608380</ArticleId><ArticleId IdType="pubmed">26458742</ArticleId></ArticleIdList></Reference><Reference><Citation>Tamguney G, Francis KP, Giles K, Lemus A, DeArmond SJ, Prusiner SB. Measuring prions by bioluminescence imaging. Proc Natl Acad Sci U S A. 2009;106:15002&#x2013;6. doi: 10.1073/pnas.0907339106.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0907339106</ArticleId><ArticleId IdType="pmc">PMC2736416</ArticleId><ArticleId IdType="pubmed">19706444</ArticleId></ArticleIdList></Reference><Reference><Citation>Tarawneh R, Holtzman DM. The clinical problem of symptomatic Alzheimer disease and mild cognitive impairment. Cold Spring Harb Perspect Med. 2012;2:a006148. doi: 10.1101/cshperspect.a006148.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/cshperspect.a006148</ArticleId><ArticleId IdType="pmc">PMC3331682</ArticleId><ArticleId IdType="pubmed">22553492</ArticleId></ArticleIdList></Reference><Reference><Citation>Tatebayashi Y, Miyasaka T, Chui DH, Akagi T, Mishima K, Iwasaki K, et al. Tau filament formation and associative memory deficit in aged mice expressing mutant (R406W) human tau. Proc Natl Acad Sci U S A. 2002;99:13896&#x2013;901. doi: 10.1073/pnas.202205599.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.202205599</ArticleId><ArticleId IdType="pmc">PMC129794</ArticleId><ArticleId IdType="pubmed">12368474</ArticleId></ArticleIdList></Reference><Reference><Citation>Tellez-Nagel I, Wisniewski HM. Ultrastructure of neurofibrillary tangles in Steele-Richardson-Olszewski syndrome. Arch Neurol. 1973;29:324&#x2013;7. doi: 10.1001/archneur.1973.00490290064007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneur.1973.00490290064007</ArticleId><ArticleId IdType="pubmed">4743882</ArticleId></ArticleIdList></Reference><Reference><Citation>Terry RD, Masliah E, Salmon DP, Butters N, DeTeresa R, Hill R, et al. Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol. 1991;30:572&#x2013;80. doi: 10.1002/ana.410300410.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.410300410</ArticleId><ArticleId IdType="pubmed">1789684</ArticleId></ArticleIdList></Reference><Reference><Citation>Terwel D, Lasrado R, Snauwaert J, Vandeweert E, Van Haesendonck C, Borghgraef P, et al. Changed conformation of mutant Tau-P301L underlies the moribund tauopathy, absent in progressive, nonlethal axonopathy of Tau-4R/2N transgenic mice. J Biol Chem. 2005;280:3963&#x2013;73. doi: 10.1074/jbc.M409876200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M409876200</ArticleId><ArticleId IdType="pubmed">15509565</ArticleId></ArticleIdList></Reference><Reference><Citation>Van der Jeugd A, Hochgr&#xe4;fe K, Ahmed T, Decker JM, Sydow A, Hofmann A, et al. Cognitive defects are reversible in inducible mice expressing pro-aggregant full-length human Tau. Acta Neuropathol. 2012;123:787&#x2013;805. doi: 10.1007/s00401-012-0987-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-012-0987-3</ArticleId><ArticleId IdType="pmc">PMC4979687</ArticleId><ArticleId IdType="pubmed">22532069</ArticleId></ArticleIdList></Reference><Reference><Citation>von Bergen M, Barghorn S, Li L, Marx A, Biernat J, Mandelkow EM, et al. Mutations of tau protein in frontotemporal dementia promote aggregation of paired helical filaments by enhancing local beta-structure. J Biol Chem. 2001;276:48165&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pubmed">11606569</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang M-VM, Kruger U, Kaushik S, Wong E, Mandelkow EM, Cuervo AM, et al. Tau fragmentation, aggregation and clearance: the dual role of lysosomal processing. Hum Mol Genet. 2009;18:4153&#x2013;70. doi: 10.1093/hmg/ddp367.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddp367</ArticleId><ArticleId IdType="pmc">PMC2758146</ArticleId><ArticleId IdType="pubmed">19654187</ArticleId></ArticleIdList></Reference><Reference><Citation>Wes PD, Easton A, Corradi J, Barten DM, Devidze N, DeCarr LB, et al. Tau overexpression impacts a neuroinflammation gene expression network perturbed in Alzheimer's disease. PLoS One. 2014;9 doi: 10.1371/journal.pone.0106050.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0106050</ArticleId><ArticleId IdType="pmc">PMC4143352</ArticleId><ArticleId IdType="pubmed">25153994</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolfe MS. The role of tau in neurodegenerative diseases and its potential as a therapeutic target. Scientifica (Cairo) 2012;2012:796024.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3820460</ArticleId><ArticleId IdType="pubmed">24278740</ArticleId></ArticleIdList></Reference><Reference><Citation>Wszolek ZK, Slowinski J, Golan M, Dickson DW. Frontotemporal dementia and parkinsonism linked to chromosome 17. Folia Neuropathol. 2005;43:258&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pubmed">16416390</ArticleId></ArticleIdList></Reference><Reference><Citation>Yi JJ, Ehlers MD. Ubiquitin and protein turnover in synapse function. Neuron. 2005;47:629&#x2013;32. doi: 10.1016/j.neuron.2005.07.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2005.07.008</ArticleId><ArticleId IdType="pubmed">16129392</ArticleId></ArticleIdList></Reference><Reference><Citation>Yirmiya R, Goshen I. Immune modulation of learning, memory, neural plasticity and neurogenesis. Brain Behav Immun. 2011;25:181&#x2013;213. doi: 10.1016/j.bbi.2010.10.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbi.2010.10.015</ArticleId><ArticleId IdType="pubmed">20970492</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshiyama Y, Higuchi M, Zhang B, Huang SM, Iwata N, Saido TC, et al. Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron. 2007;53:337&#x2013;51. doi: 10.1016/j.neuron.2007.01.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2007.01.010</ArticleId><ArticleId IdType="pubmed">17270732</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu L, Ramboz S, Hewitt D, Boring L, Grass DS, Purchio AF. Non-invasive imaging of GFAP expression after neuronal damage in mice. Neurosci Lett. 2004;367:210&#x2013;2. doi: 10.1016/j.neulet.2004.06.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neulet.2004.06.020</ArticleId><ArticleId IdType="pubmed">15331155</ArticleId></ArticleIdList></Reference><Reference><Citation>Zimmer ER, Leuzy A, Benedet AL, Breitner J, Gauthier S, Rosa-Neto P. Tracking neuroinflammation in Alzheimer's disease: the role of positron emission tomography imaging. J Neuroinflammation. 2014;11:120. doi: 10.1186/1742-2094-11-120.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1742-2094-11-120</ArticleId><ArticleId IdType="pmc">PMC4099095</ArticleId><ArticleId IdType="pubmed">25005532</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">26923602</PMID><DateCompleted><Year>2017</Year><Month>01</Month><Day>10</Day></DateCompleted><DateRevised><Year>2017</Year><Month>09</Month><Day>03</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2211-1247</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>9</Issue><PubDate><Year>2016</Year><Month>Mar</Month><Day>08</Day></PubDate></JournalIssue><Title>Cell reports</Title><ISOAbbreviation>Cell Rep</ISOAbbreviation></Journal><ArticleTitle>Specific Inhibition of &#x3b2;-Secretase Processing of the Alzheimer Disease Amyloid Precursor Protein.</ArticleTitle><Pagination><StartPage>2127</StartPage><EndPage>2141</EndPage><MedlinePgn>2127-2141</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.celrep.2016.01.076</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2211-1247(16)30075-4</ELocationID><Abstract><AbstractText>Development of disease-modifying therapeutics is urgently needed for treating Alzheimer disease (AD). AD is characterized by toxic &#x3b2;-amyloid (A&#x3b2;) peptides produced by &#x3b2;- and &#x3b3;-secretase-mediated cleavage of the amyloid precursor protein (APP). &#x3b2;-secretase inhibitors reduce A&#x3b2; levels, but mechanism-based side effects arise because they also inhibit &#x3b2;-cleavage of non-amyloid substrates like Neuregulin. We report that &#x3b2;-secretase has a higher affinity for Neuregulin than it does for APP. Kinetic studies demonstrate that the affinities and catalytic efficiencies of &#x3b2;-secretase are higher toward non-amyloid substrates than toward APP. We show that non-amyloid substrates are processed by &#x3b2;-secretase in an endocytosis-independent manner. Exploiting this compartmentalization of substrates, we specifically target the endosomal &#x3b2;-secretase by an endosomally targeted &#x3b2;-secretase inhibitor, which blocked cleavage of APP but not non-amyloid substrates in many cell systems, including induced pluripotent stem cell (iPSC)-derived neurons. &#x3b2;-secretase inhibitors can be designed to specifically inhibit the Alzheimer process, enhancing their potential as AD therapeutics without undesired side effects.</AbstractText><CopyrightInformation>Copyright &#xa9; 2016 The Authors. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ben Halima</LastName><ForeName>Saoussen</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Systems and Cell Biology of Neurodegeneration, Institute of Regenerative Medicine, University of Zurich, Wagistrasse 12, 8952&#xa0;Schlieren,&#xa0;Switzerland; Graduate Program in Neuroscience, Neuroscience Center Zurich, 8057 Zurich, Switzerland; Graduate Program of the Zurich Center for Integrative Human Physiology, University of Zurich, 8057 Zurich, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mishra</LastName><ForeName>Sabyashachi</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Biochemistry, University of Zurich, 8057 Zurich, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Raja</LastName><ForeName>K Muruga Poopathi</ForeName><Initials>KMP</Initials><AffiliationInfo><Affiliation>Department of Physical Chemistry, School of Chemistry, Madurai Kamaraj University, Tamil Nadu 625002, Madurai, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Willem</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Biomedical Center, Ludwig-Maximilians-University, 81337 Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baici</LastName><ForeName>Antonio</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Biochemistry, University of Zurich, 8057 Zurich, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Simons</LastName><ForeName>Kai</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Max Planck Institute of Molecular Cell Biology and Genetics, 01307 Dresden, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Br&#xfc;stle</LastName><ForeName>Oliver</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Institute of Reconstructive Neurobiology, University of Bonn, 53127 Bonn, Germany; German Center for Neurodegenerative Diseases, 53175 Bonn, Germany; Life &amp; Brain, 53127 Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Koch</LastName><ForeName>Philipp</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Institute of Reconstructive Neurobiology, University of Bonn, 53127 Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Haass</LastName><ForeName>Christian</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Biomedical Center, Ludwig-Maximilians-University, 81337 Munich, Germany; German Center for Neurodegenerative Diseases, 53175 Bonn, Germany; Munich Cluster for Systems Neurology (SyNergy), 81377 Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Caflisch</LastName><ForeName>Amedeo</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Biochemistry, University of Zurich, 8057 Zurich, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rajendran</LastName><ForeName>Lawrence</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Systems and Cell Biology of Neurodegeneration, Institute of Regenerative Medicine, University of Zurich, Wagistrasse 12, 8952&#xa0;Schlieren,&#xa0;Switzerland; Graduate Program in Neuroscience, Neuroscience Center Zurich, 8057 Zurich, Switzerland; Graduate Program of the Zurich Center for Integrative Human Physiology, University of Zurich, 8057 Zurich, Switzerland. Electronic address: rajendran@bli.uzh.ch.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>02</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cell Rep</MedlineTA><NlmUniqueID>101573691</NlmUniqueID></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C094131">NRG1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D020890">Neuregulin-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C414614">OM99-2</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009842">Oligopeptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.-</RegistryNumber><NameOfSubstance UI="D016282">Aspartic Acid Endopeptidases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.46</RegistryNumber><NameOfSubstance UI="C509280">BACE1 protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000201" MajorTopicYN="Y">enzymology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053829" MajorTopicYN="N">Amyloid Precursor Protein Secretases</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016282" MajorTopicYN="N">Aspartic Acid Endopeptidases</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004705" MajorTopicYN="N">Endocytosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011992" MajorTopicYN="N">Endosomes</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006056" MajorTopicYN="N">Golgi Apparatus</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057026" MajorTopicYN="N">Induced Pluripotent Stem Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007700" MajorTopicYN="N">Kinetics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D056004" MajorTopicYN="N">Molecular Dynamics Simulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020890" MajorTopicYN="N">Neuregulin-1</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009842" MajorTopicYN="N">Oligopeptides</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011499" MajorTopicYN="N">Protein Processing, Post-Translational</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D021381" MajorTopicYN="N">Protein Transport</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059748" MajorTopicYN="N">Proteolysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013379" MajorTopicYN="N">Substrate Specificity</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">APP</Keyword><Keyword MajorTopicYN="N">Alzheimer disease</Keyword><Keyword MajorTopicYN="N">BACE</Keyword><Keyword MajorTopicYN="N">Neuregulin</Keyword><Keyword MajorTopicYN="N">amyloid</Keyword><Keyword MajorTopicYN="N">membrane trafficking</Keyword><Keyword MajorTopicYN="N">molecular dynamics</Keyword><Keyword MajorTopicYN="N">secretase</Keyword><Keyword MajorTopicYN="N">subcellular compartmentalization</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2013</Year><Month>4</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2015</Year><Month>11</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>1</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>3</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>3</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>1</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26923602</ArticleId><ArticleId IdType="doi">10.1016/j.celrep.2016.01.076</ArticleId><ArticleId IdType="pii">S2211-1247(16)30075-4</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">26941262</PMID><DateCompleted><Year>2017</Year><Month>09</Month><Day>13</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Electronic-Print"><Journal><ISSN IssnType="Electronic">1757-4684</ISSN><JournalIssue CitedMedium="Internet"><Volume>8</Volume><Issue>5</Issue><PubDate><Year>2016</Year><Month>May</Month></PubDate></JournalIssue><Title>EMBO molecular medicine</Title><ISOAbbreviation>EMBO Mol Med</ISOAbbreviation></Journal><ArticleTitle>sTREM2 cerebrospinal fluid levels are a potential biomarker for microglia activity in early-stage Alzheimer's disease and associate with neuronal injury markers.</ArticleTitle><Pagination><StartPage>466</StartPage><EndPage>476</EndPage><MedlinePgn>466-76</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.15252/emmm.201506123</ELocationID><Abstract><AbstractText>TREM2 is an innate immune receptor expressed on the surface of microglia. Loss-of-function mutations of TREM2 are associated with increased risk of Alzheimer's disease (AD). TREM2 is a type-1 protein with an ectodomain that is proteolytically cleaved and released into the extracellular space as a soluble variant (sTREM2), which can be measured in the cerebrospinal fluid (CSF). In this cross-sectional multicenter study, we investigated whether CSF levels of sTREM2 are changed during the clinical course of AD, and in cognitively normal individuals with suspected non-AD pathology (SNAP). CSF sTREM2 levels were higher in mild cognitive impairment due to AD than in all other AD groups and controls. SNAP individuals also had significantly increased CSF sTREM2 compared to controls. Moreover, increased CSF sTREM2 levels were associated with higher CSF total tau and phospho-tau181P, which are markers of neuronal degeneration and tau pathology. Our data demonstrate that CSF sTREM2 levels are increased in the early symptomatic phase of AD, probably reflecting a corresponding change of the microglia activation status in response to neuronal degeneration.</AbstractText><CopyrightInformation>&#xa9; 2016 The Authors. Published under the terms of the CC BY 4.0 license.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Su&#xe1;rez-Calvet</LastName><ForeName>Marc</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>BioMedical Center (BMC), Biochemistry, Ludwig-Maximilians-University Munich, Munich, Germany German Center for Neurodegenerative Diseases (DZNE) Munich, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kleinberger</LastName><ForeName>Gernot</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>BioMedical Center (BMC), Biochemistry, Ludwig-Maximilians-University Munich, Munich, Germany Munich Cluster for Systems Neurology (SyNergy), Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Araque Caballero</LastName><ForeName>Miguel &#xc1;ngel</ForeName><Initials>M&#xc1;</Initials><AffiliationInfo><Affiliation>Institute for Stroke and Dementia Research, Klinikum der Universit&#xe4;t M&#xfc;nchen, Ludwig-Maximilians-University Munich, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brendel</LastName><ForeName>Matthias</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Nuclear Medicine, Klinikum der Universit&#xe4;t M&#xfc;nchen, Ludwig-Maximilians-University Munich, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rominger</LastName><ForeName>Axel</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Munich Cluster for Systems Neurology (SyNergy), Munich, Germany Department of Nuclear Medicine, Klinikum der Universit&#xe4;t M&#xfc;nchen, Ludwig-Maximilians-University Munich, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alcolea</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Neurology, Institut d'Investigacions Biom&#xe8;diques Hospital de la Santa Creu i Sant Pau Universitat Aut&#xf2;noma de Barcelona, Barcelona, Spain Center for Networked Biomedical Research for Neurodegenerative Diseases, CIBERNED, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fortea</LastName><ForeName>Juan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurology, Institut d'Investigacions Biom&#xe8;diques Hospital de la Santa Creu i Sant Pau Universitat Aut&#xf2;noma de Barcelona, Barcelona, Spain Center for Networked Biomedical Research for Neurodegenerative Diseases, CIBERNED, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lle&#xf3;</LastName><ForeName>Alberto</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurology, Institut d'Investigacions Biom&#xe8;diques Hospital de la Santa Creu i Sant Pau Universitat Aut&#xf2;noma de Barcelona, Barcelona, Spain Center for Networked Biomedical Research for Neurodegenerative Diseases, CIBERNED, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blesa</LastName><ForeName>Rafael</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Neurology, Institut d'Investigacions Biom&#xe8;diques Hospital de la Santa Creu i Sant Pau Universitat Aut&#xf2;noma de Barcelona, Barcelona, Spain Center for Networked Biomedical Research for Neurodegenerative Diseases, CIBERNED, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gispert</LastName><ForeName>Juan Domingo</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>Clinical and Neuroimaging Departments, Barcelona Beta Brain Research Center Pasqual Maragall Foundation, Barcelona, Spain Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red de Bioingenier&#xed;a, Biomateriales y Nanomedicina (CIBER-BBN), Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>S&#xe1;nchez-Valle</LastName><ForeName>Raquel</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Alzheimer's Disease and Other Cognitive Disorders Unit, Neurology Service, ICN Hospital Clinic i Universitari, Barcelona, Spain Institut d'Investigacions Biom&#xe8;diques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Antonell</LastName><ForeName>Anna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Alzheimer's Disease and Other Cognitive Disorders Unit, Neurology Service, ICN Hospital Clinic i Universitari, Barcelona, Spain Institut d'Investigacions Biom&#xe8;diques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rami</LastName><ForeName>Lorena</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Alzheimer's Disease and Other Cognitive Disorders Unit, Neurology Service, ICN Hospital Clinic i Universitari, Barcelona, Spain Institut d'Investigacions Biom&#xe8;diques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Molinuevo</LastName><ForeName>Jos&#xe9; L</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>Clinical and Neuroimaging Departments, Barcelona Beta Brain Research Center Pasqual Maragall Foundation, Barcelona, Spain Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red de Bioingenier&#xed;a, Biomateriales y Nanomedicina (CIBER-BBN), Barcelona, Spain Alzheimer's Disease and Other Cognitive Disorders Unit, Neurology Service, ICN Hospital Clinic i Universitari, Barcelona, Spain Institut d'Investigacions Biom&#xe8;diques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brosseron</LastName><ForeName>Frederic</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Trasch&#xfc;tz</LastName><ForeName>Andreas</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Neurology Department, Universit&#xe4;tsklinikum Bonn, Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Heneka</LastName><ForeName>Michael T</ForeName><Initials>MT</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany Neurology Department, Universit&#xe4;tsklinikum Bonn, Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Struyfs</LastName><ForeName>Hanne</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Reference Center for Biological Markers of Dementia (BIODEM), Laboratory of Neurochemistry and Behavior, Institute Born-Bunge University of Antwerp, Antwerp, Belgium Department of Neurology and Memory Clinic, Hospital Network Antwerp (ZNA) Middelheim and Hoge Beuken, Antwerp, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Engelborghs</LastName><ForeName>Sebastiaan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Reference Center for Biological Markers of Dementia (BIODEM), Laboratory of Neurochemistry and Behavior, Institute Born-Bunge University of Antwerp, Antwerp, Belgium Department of Neurology and Memory Clinic, Hospital Network Antwerp (ZNA) Middelheim and Hoge Beuken, Antwerp, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sleegers</LastName><ForeName>Kristel</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Neurodegenerative Brain Diseases Group, Department of Molecular Genetics, VIB, Antwerp, Belgium Laboratory of Neurogenetics, Institute Born-Bunge University of Antwerp, Antwerp, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Van Broeckhoven</LastName><ForeName>Christine</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Neurodegenerative Brain Diseases Group, Department of Molecular Genetics, VIB, Antwerp, Belgium Laboratory of Neurogenetics, Institute Born-Bunge University of Antwerp, Antwerp, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zetterberg</LastName><ForeName>Henrik</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Clinical Neurochemistry Lab, Institute of Neuroscience and Physiology The Sahlgrenska Academy at the University of Gothenburg, M&#xf6;lndal, Sweden Reta Lila Weston Laboratories and Department of Molecular Neuroscience, UCL Institute of Neurology, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nellg&#xe5;rd</LastName><ForeName>Bengt</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Anaesthesiology and Intensive Care, Institute of Clinical Sciences Sahlgrenska Academy Gothenburg University, Gothenburg, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blennow</LastName><ForeName>Kaj</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Clinical Neurochemistry Lab, Institute of Neuroscience and Physiology The Sahlgrenska Academy at the University of Gothenburg, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Crispin</LastName><ForeName>Alexander</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Institute of Medical Informatics, Biometry, and Epidemiology, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ewers</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute for Stroke and Dementia Research, Klinikum der Universit&#xe4;t M&#xfc;nchen, Ludwig-Maximilians-University Munich, Munich, Germany michael.ewers@med.uni-muenchen.de christian.haass@mail03.med.uni-muenchen.de.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Haass</LastName><ForeName>Christian</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>BioMedical Center (BMC), Biochemistry, Ludwig-Maximilians-University Munich, Munich, Germany German Center for Neurodegenerative Diseases (DZNE) Munich, Munich, Germany Munich Cluster for Systems Neurology (SyNergy), Munich, Germany michael.ewers@med.uni-muenchen.de christian.haass@mail03.med.uni-muenchen.de.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>321366</GrantID><Acronym>ERC_</Acronym><Agency>European Research Council</Agency><Country>International</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>05</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>EMBO Mol Med</MedlineTA><NlmUniqueID>101487380</NlmUniqueID><ISSNLinking>1757-4676</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008562">Membrane Glycoproteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011971">Receptors, Immunologic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C498715">TREM2 protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>EMBO Mol Med. 2016 May 02;8(5):437-8. doi: 10.15252/emmm.201606245.</RefSource><PMID Version="1">26976613</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002555" MajorTopicYN="N">Cerebrospinal Fluid</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008562" MajorTopicYN="N">Membrane Glycoproteins</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011971" MajorTopicYN="N">Receptors, Immunologic</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer's disease</Keyword><Keyword MajorTopicYN="N">TREM2</Keyword><Keyword MajorTopicYN="N">biomarkers</Keyword><Keyword MajorTopicYN="N">microglia</Keyword><Keyword MajorTopicYN="N">neurodegeneration</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>3</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>3</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>9</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2016</Year><Month>5</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26941262</ArticleId><ArticleId IdType="pmc">PMC5120370</ArticleId><ArticleId IdType="doi">10.15252/emmm.201506123</ArticleId><ArticleId IdType="pii">emmm.201506123</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, Gamst A, Holtzman DM, Jagust WJ, Petersen RC et&#xa0;al (2011) The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging&#x2010;Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7: 270&#x2013;279</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3312027</ArticleId><ArticleId IdType="pubmed">21514249</ArticleId></ArticleIdList></Reference><Reference><Citation>Alcolea D, Carmona&#x2010;Iragui M, Su&#xe1;rez&#x2010;Calvet M, S&#xe1;nchez&#x2010;Saudin&#xf3;s MB, Sala I, Ant&#xf3;n&#x2010;Aguirre S, Blesa R, Clarim&#xf3;n J, Fortea J, Lle&#xf3; A (2014) Relationship between &#x3b2;&#x2010;secretase, inflammation and core cerebrospinal fluid biomarkers for Alzheimer's disease. J Alzheimers Dis 42: 157&#x2013;167</Citation><ArticleIdList><ArticleId IdType="pubmed">24820015</ArticleId></ArticleIdList></Reference><Reference><Citation>Antonell A, Fortea J, Rami L, Bosch B, Balasa M, S&#xe1;nchez&#x2010;Valle R, Iranzo A, Molinuevo JL, Llad&#xf3; A (2011) Different profiles of Alzheimer's disease cerebrospinal fluid biomarkers in controls and subjects with subjective memory complaints. J Neural Transm 118: 259&#x2013;262</Citation><ArticleIdList><ArticleId IdType="pubmed">21161712</ArticleId></ArticleIdList></Reference><Reference><Citation>Blennow K, Hampel H, Weiner M, Zetterberg H (2010) Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol 6: 131&#x2013;144</Citation><ArticleIdList><ArticleId IdType="pubmed">20157306</ArticleId></ArticleIdList></Reference><Reference><Citation>Borroni B, Ferrari F, Galimberti D, Nacmias B, Barone C, Bagnoli S, Fenoglio C, Piaceri I, Archetti S, Bonvicini C et&#xa0;al (2013) Heterozygous TREM2 mutations in frontotemporal dementia. Neurobiol Aging 35: 934.e7&#x2013;e10</Citation><ArticleIdList><ArticleId IdType="pubmed">24139279</ArticleId></ArticleIdList></Reference><Reference><Citation>Bouchon A, Hern&#xe1;ndez&#x2010;Munain C, Cella M, Colonna M (2001) A DAP12&#x2010;mediated pathway regulates expression of CC chemokine receptor 7 and maturation of human dendritic cells. J Exp Med 194: 1111&#x2013;1122</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2193511</ArticleId><ArticleId IdType="pubmed">11602640</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E (1997) Frequency of stages of Alzheimer&#x2010;related lesions in different age categories. Neurobiol Aging 18: 351&#x2013;357</Citation><ArticleIdList><ArticleId IdType="pubmed">9330961</ArticleId></ArticleIdList></Reference><Reference><Citation>Brosseron F, Krauthausen M, Kummer M, Heneka MT (2014) Body fluid cytokine levels in mild cognitive impairment and Alzheimer's disease: a comparative overview. Mol Neurobiol 50: 534&#x2013;544</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4182618</ArticleId><ArticleId IdType="pubmed">24567119</ArticleId></ArticleIdList></Reference><Reference><Citation>Clark CM, Xie S, Chittams J, Ewbank D, Peskind E, Galasko D, Morris JC, McKeel DW, Farlow M, Weitlauf SL et&#xa0;al (2003) Cerebrospinal fluid tau and beta&#x2010;amyloid: how well do these biomarkers reflect autopsy&#x2010;confirmed dementia diagnoses? Arch Neurol 60: 1696&#x2013;1702</Citation><ArticleIdList><ArticleId IdType="pubmed">14676043</ArticleId></ArticleIdList></Reference><Reference><Citation>Craig&#x2010;Schapiro R, Kuhn M, Xiong C, Pickering EH, Liu J, Misko TP, Perrin RJ, Bales KR, Soares H, Fagan AM et&#xa0;al (2011) Multiplexed immunoassay panel identifies novel CSF biomarkers for Alzheimer's disease diagnosis and prognosis. PLoS ONE 6: e18850</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3079734</ArticleId><ArticleId IdType="pubmed">21526197</ArticleId></ArticleIdList></Reference><Reference><Citation>Cuyvers E, Bettens K, Philtjens S, Van Langenhove T, Gijselinck I, van der Zee J, Engelborghs S, Vandenbulcke M, Van Dongen J, Geerts N et&#xa0;al (2014) Investigating the role of rare heterozygous TREM2 variants in Alzheimer's disease and frontotemporal dementia. Neurobiol Aging 35: 726.e11&#x2013;e19</Citation><ArticleIdList><ArticleId IdType="pubmed">24119542</ArticleId></ArticleIdList></Reference><Reference><Citation>Galimberti D, Fenoglio C, Lovati C, Venturelli E, Guidi I, Corr&#xe0; B, Scalabrini D, Clerici F, Mariani C, Bresolin N et&#xa0;al (2006a) Serum MCP&#x2010;1 levels are increased in mild cognitive impairment and mild Alzheimer's disease. Neurobiol Aging 27: 1763&#x2013;1768</Citation><ArticleIdList><ArticleId IdType="pubmed">16307829</ArticleId></ArticleIdList></Reference><Reference><Citation>Galimberti D, Schoonenboom N, Scheltens P, Fenoglio C, Bouwman F, Venturelli E, Guidi I, Blankenstein MA, Bresolin N, Scarpini E (2006b) Intrathecal chemokine synthesis in mild cognitive impairment and Alzheimer disease. Arch Neurol 63: 538&#x2013;543</Citation><ArticleIdList><ArticleId IdType="pubmed">16606766</ArticleId></ArticleIdList></Reference><Reference><Citation>Guerreiro R, Wojtas A, Bras J, Carrasquillo M, Rogaeva E, Majounie E, Cruchaga C, Sassi C, Kauwe JS, Younkin S et&#xa0;al (2013a) TREM2 variants in Alzheimer's disease. N Engl J Med 368: 117&#x2013;127</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3631573</ArticleId><ArticleId IdType="pubmed">23150934</ArticleId></ArticleIdList></Reference><Reference><Citation>Guerreiro RJ, Lohmann E, Br&#xe1;s JM, Gibbs JR, Rohrer JD, Gurunlian N, Dursun B, Bilgic B, Hanagasi H, Gurvit H et&#xa0;al (2013b) Using exome sequencing to reveal mutations in TREM2 presenting as a frontotemporal dementia&#x2010;like syndrome without bone involvement. JAMA Neurol 70: 78&#x2013;84</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4001789</ArticleId><ArticleId IdType="pubmed">23318515</ArticleId></ArticleIdList></Reference><Reference><Citation>Heneka MT, Carson MJ, El Khoury J, Landreth GE, Brosseron F, Feinstein DL, Jacobs AH, Wyss&#x2010;Coray T, Vitorica J, Ransohoff RM et&#xa0;al (2015) Neuroinflammation in Alzheimer's disease. Lancet Neurol 14: 388&#x2013;405</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5909703</ArticleId><ArticleId IdType="pubmed">25792098</ArticleId></ArticleIdList></Reference><Reference><Citation>Heslegrave A, Heywood W, Paterson R, Magdalinou N, Svensson J, Johansson P, &#xd6;hrfelt A, Blennow K, Hardy J, Schott J et&#xa0;al (2016) Increased cerebrospinal fluid soluble TREM2 concentration in Alzheimer's disease. Mol Neurodegener 11: 1&#x2013;7</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4709982</ArticleId><ArticleId IdType="pubmed">26754172</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsieh CL, Koike M, Spusta SC, Niemi EC, Yenari M, Nakamura MC, Seaman WE (2009) A role for TREM2 ligands in the phagocytosis of apoptotic neuronal cells by microglia. J Neurochem 109: 1144&#x2013;1156</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3087597</ArticleId><ArticleId IdType="pubmed">19302484</ArticleId></ArticleIdList></Reference><Reference><Citation>Hulette CM, Welsh&#x2010;Bohmer KA, Murray MG, Saunders AM, Mash DC, McIntyre LM (1998) Neuropathological and neuropsychological changes in &#x2018;normal&#x2019; aging: evidence for preclinical Alzheimer disease in cognitively normal individuals. J Neuropathol Exp Neurol 57: 1168&#x2013;1174</Citation><ArticleIdList><ArticleId IdType="pubmed">9862640</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Knopman DS, Weigand SD, Wiste HJ, Vemuri P, Lowe V, Kantarci K, Gunter JL, Senjem ML, Ivnik RJ et&#xa0;al (2012) An operational approach to National Institute on Aging&#x2010;Alzheimer's Association criteria for preclinical Alzheimer disease. Ann Neurol 71: 765&#x2013;775</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3586223</ArticleId><ArticleId IdType="pubmed">22488240</ArticleId></ArticleIdList></Reference><Reference><Citation>Jay TR, Miller CM, Cheng PJ, Graham LC, Bemiller S, Broihier ML, Xu G, Margevicius D, Karlo JC, Sousa GL et&#xa0;al (2015) TREM2 deficiency eliminates TREM2 + inflammatory macrophages and ameliorates pathology in Alzheimer's disease mouse models. J Exp Med 212: 2&#x2013;10</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4354365</ArticleId><ArticleId IdType="pubmed">25732305</ArticleId></ArticleIdList></Reference><Reference><Citation>Jonsson T, Stefansson H, Steinberg S, Jonsdottir I, Jonsson PV, Snaedal J, Bjornsson S, Huttenlocher J, Levey AI, Lah JJ et&#xa0;al (2013) Variant of TREM2 associated with the risk of Alzheimer's disease. N Engl J Med 368: 107&#x2013;116</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3677583</ArticleId><ArticleId IdType="pubmed">23150908</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiialainen A, Hovanes K, Paloneva J, Kopra O, Peltonen L (2005) Dap12 and Trem2, molecules involved in innate immunity and neurodegeneration, are co&#x2010;expressed in the CNS. Neurobiol Dis 18: 314&#x2013;322</Citation><ArticleIdList><ArticleId IdType="pubmed">15686960</ArticleId></ArticleIdList></Reference><Reference><Citation>Kleinberger G, Yamanishi Y, Su&#xe1;rez&#x2010;Calvet M, Czirr E, Lohmann E, Cuyvers E, Struyfs H, Pettkus N, Wenninger&#x2010;Weinzierl A, Mazaheri F et&#xa0;al (2014) TREM2 mutations implicated in neurodegeneration impair cell surface transport and phagocytosis. Sci Transl Med 6: 243ra86</Citation><ArticleIdList><ArticleId IdType="pubmed">24990881</ArticleId></ArticleIdList></Reference><Reference><Citation>Klesney&#x2010;Tait J, Turnbull IR, Colonna M (2006) The TREM receptor family and signal integration. Nat Immunol 7: 1266&#x2013;1273</Citation><ArticleIdList><ArticleId IdType="pubmed">17110943</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu B, Le KX, Park MA, Wang S, Belanger AP, Dubey S, Frost JL, Holton P, Reiser V, Jones PA et&#xa0;al (2015) In vivo detection of age&#x2010; and disease&#x2010;related increases in neuroinflammation by 18F&#x2010;GE180 TSPO microPET Imaging in wild&#x2010;type and Alzheimer's transgenic mice. J Neurosci 35: 15716&#x2013;15730</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6705465</ArticleId><ArticleId IdType="pubmed">26609163</ArticleId></ArticleIdList></Reference><Reference><Citation>Matarin M, Salih DA, Yasvoina M, Cummings DM, Guelfi S, Liu W, Nahaboo Solim MA, Moens TG, Paublete RM, Ali SS et&#xa0;al (2015) A genome&#x2010;wide gene&#x2010;expression analysis and database in transgenic mice during development of amyloid or tau pathology. Cell Rep 10: 633&#x2013;644</Citation><ArticleIdList><ArticleId IdType="pubmed">25620700</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattsson N, Andreasson U, Persson S, Arai H, Batish SD, Bernardini S, Bocchio&#x2010;Chiavetto L, Blankenstein MA, Carrillo MC, Chalbot S et&#xa0;al (2011) The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers. Alzheimers Dement 7: 386&#x2013;395.e6</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3710290</ArticleId><ArticleId IdType="pubmed">21784349</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR, Kawas CH, Klunk WE, Koroshetz WJ, Manly JJ, Mayeux R et&#xa0;al (2011) The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging&#x2010;Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7: 263&#x2013;269</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3312024</ArticleId><ArticleId IdType="pubmed">21514250</ArticleId></ArticleIdList></Reference><Reference><Citation>Molinuevo JL, Blennow K, Dubois B, Engelborghs S, Lewczuk P, Perret&#x2010;Liaudet A, Teunissen CE, Parnetti L (2014) The clinical use of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: a consensus paper from the Alzheimer's Biomarkers Standardization Initiative. Alzheimers Dement 10: 808&#x2013;817</Citation><ArticleIdList><ArticleId IdType="pubmed">25150736</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC, Storandt M, McKeel DW, Rubin EH, Price JL, Grant EA, Berg L (1996) Cerebral amyloid deposition and diffuse plaques in &#x2018;normal&#x2019; aging: evidence for presymptomatic and very mild Alzheimer's disease. Neurology 46: 707&#x2013;719</Citation><ArticleIdList><ArticleId IdType="pubmed">8618671</ArticleId></ArticleIdList></Reference><Reference><Citation>Mosher KI, Wyss&#x2010;Coray T (2014) Microglial dysfunction in brain aging and Alzheimer's disease. Biochem Pharmacol 88: 594&#x2013;604</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3972294</ArticleId><ArticleId IdType="pubmed">24445162</ArticleId></ArticleIdList></Reference><Reference><Citation>Motta M, Imbesi R, Di Rosa M, Stivala F, Malaguarnera L (2007) Altered plasma cytokine levels in Alzheimer's disease: correlation with the disease progression. Immunol Lett 114: 46&#x2013;51</Citation><ArticleIdList><ArticleId IdType="pubmed">17949824</ArticleId></ArticleIdList></Reference><Reference><Citation>Paloneva J, Manninen T, Christman G, Hovanes K, Mandelin J, Adolfsson R, Bianchin M, Bird T, Miranda R, Salmaggi A et&#xa0;al (2002) Mutations in two genes encoding different subunits of a receptor signaling complex result in an identical disease phenotype. Am J Hum Genet 71: 656&#x2013;662</Citation><ArticleIdList><ArticleId IdType="pmc">PMC379202</ArticleId><ArticleId IdType="pubmed">12080485</ArticleId></ArticleIdList></Reference><Reference><Citation>Paloneva J, Mandelin J, Kiialainen A, Bohling T, Prudlo J, Hakola P, Haltia M, Konttinen YT, Peltonen L (2003) DAP12/TREM2 deficiency results in impaired osteoclast differentiation and osteoporotic features. J Exp Med 198: 669&#x2013;675</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2194176</ArticleId><ArticleId IdType="pubmed">12925681</ArticleId></ArticleIdList></Reference><Reference><Citation>Piccio L, Buonsanti C, Cella M, Tassi I, Schmidt RE, Fenoglio C, Rinker J, Naismith RT, Panina&#x2010;Bordignon P, Passini N et&#xa0;al (2008) Identification of soluble TREM&#x2010;2 in the cerebrospinal fluid and its association with multiple sclerosis and CNS inflammation. Brain 131: 3081&#x2013;3091</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2577803</ArticleId><ArticleId IdType="pubmed">18790823</ArticleId></ArticleIdList></Reference><Reference><Citation>
Piccio L, Deming Y, Del&#x2010;&#xc1;guila JL, Ghezzi L, Holtzman DM, Fagan AM, Fenoglio C, Galimberti D, Borroni B, Cruchaga C (2016) Cerebrospinal fluid soluble TREM2 is higher in Alzheimer disease and associated with mutation status. Acta Neuropathol doi:10.1007/s00401&#x2010;016&#x2010;1533&#x2010;5
</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-016-1533-5</ArticleId><ArticleId IdType="pmc">PMC4867123</ArticleId><ArticleId IdType="pubmed">26754641</ArticleId></ArticleIdList></Reference><Reference><Citation>Price JL, Morris JC (1999) Tangles and plaques in nondemented aging and &#x2018;preclinical&#x2019; Alzheimer's disease. Ann Neurol 45: 358&#x2013;368</Citation><ArticleIdList><ArticleId IdType="pubmed">10072051</ArticleId></ArticleIdList></Reference><Reference><Citation>Rayaprolu S, Mullen B, Baker M, Lynch T, Finger E, Seeley WW, Hatanpaa KJ, Lomen&#x2010;Hoerth C, Kertesz A, Bigio EH et&#xa0;al (2013) TREM2 in neurodegeneration: evidence for association of the p. R47H variant with frontotemporal dementia and Parkinson's disease. Mol Neurodegener 8: 19</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3691612</ArticleId><ArticleId IdType="pubmed">23800361</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmid CD, Sautkulis LN, Danielson PE, Cooper J, Hasel KW, Hilbush BS, Sutcliffe JG, Carson MJ (2002) Heterogeneous expression of the triggering receptor expressed on myeloid cells&#x2010;2 on adult murine microglia. J Neurochem 83: 1309&#x2013;1320</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2637869</ArticleId><ArticleId IdType="pubmed">12472885</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaw LM, Vanderstichele H, Knapik&#x2010;Czajka M, Clark CM, Aisen PS, Petersen RC, Blennow K, Soares H, Simon A, Lewczuk P et&#xa0;al (2009) Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol 65: 403&#x2013;413</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2696350</ArticleId><ArticleId IdType="pubmed">19296504</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, Iwatsubo T, Jack CR, Kaye J, Montine TJ et&#xa0;al (2011) Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging&#x2010;Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7: 280&#x2013;292</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3220946</ArticleId><ArticleId IdType="pubmed">21514248</ArticleId></ArticleIdList></Reference><Reference><Citation>Streit WJ, Xue QS, Tischer J, Bechmann I (2014) Microglial pathology. Acta Neuropathol Commun 2: 142</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4180960</ArticleId><ArticleId IdType="pubmed">25257319</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi K, Rochford CD, Neumann H (2005) Clearance of apoptotic neurons without inflammation by microglial triggering receptor expressed on myeloid cells&#x2010;2. J Exp Med 201: 647&#x2013;657</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2213053</ArticleId><ArticleId IdType="pubmed">15728241</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanzi RE (2015) TREM2 and risk of Alzheimer's disease &#x2014; friend or foe? N Engl J Med 372: 2564&#x2013;2565</Citation><ArticleIdList><ArticleId IdType="pubmed">26107057</ArticleId></ArticleIdList></Reference><Reference><Citation>Van der Mussele S, Fransen E, Struyfs H, Luyckx J, Mari&#xeb;n P, Saerens J, Somers N, Goeman J, De Deyn PP, Engelborghs S (2014) Depression in&#xa0;mild cognitive impairment is associated with progression to Alzheimer's disease: a longitudinal study. J Alzheimers Dis 42: 1239&#x2013;1250</Citation><ArticleIdList><ArticleId IdType="pubmed">25024328</ArticleId></ArticleIdList></Reference><Reference><Citation>Vanderstichele H, Bibl M, Engelborghs S, Le Bastard N, Lewczuk P, Molinuevo JL, Parnetti L, Perret&#x2010;Liaudet A, Shaw LM, Teunissen C et&#xa0;al (2012) Standardization of preanalytical aspects of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: a consensus paper from the Alzheimer's Biomarkers Standardization Initiative. Alzheimers Dement 8: 65&#x2013;73</Citation><ArticleIdList><ArticleId IdType="pubmed">22047631</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Cella M, Mallinson K, Ulrich JD, Young KL, Robinette ML, Gilfillan S, Krishnan GM, Sudhakar S, Zinselmeyer BH et&#xa0;al (2015) TREM2 lipid sensing sustains the microglial response in an Alzheimer's disease model. Cell 160: 1061&#x2013;1071</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4477963</ArticleId><ArticleId IdType="pubmed">25728668</ArticleId></ArticleIdList></Reference><Reference><Citation>Winblad B, Palmer K, Kivipelto M, Jelic V, Fratiglioni L, Wahlund L, Nordberg A, B&#xe4;ckman L, Albert M, Almkvist O et&#xa0;al (2004) Mild cognitive impairment&#x2013;beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. J Intern Med 256: 240&#x2013;246</Citation><ArticleIdList><ArticleId IdType="pubmed">15324367</ArticleId></ArticleIdList></Reference><Reference><Citation>Wunderlich P, Glebov K, Kemmerling N, Tien NT, Neumann H, Walter J (2013) Sequential proteolytic processing of the triggering receptor expressed on myeloid cells&#x2010;2 (TREM2) protein by ectodomain shedding and &#x3b3;&#x2010;secretase&#x2010;dependent intramembranous cleavage. J Biol Chem 288: 33027&#x2013;33036</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3829152</ArticleId><ArticleId IdType="pubmed">24078628</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">26938442</PMID><DateCompleted><Year>2016</Year><Month>07</Month><Day>13</Day></DateCompleted><DateRevised><Year>2024</Year><Month>03</Month><Day>24</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1097-4199</ISSN><JournalIssue CitedMedium="Internet"><Volume>89</Volume><Issue>5</Issue><PubDate><Year>2016</Year><Month>Mar</Month><Day>02</Day></PubDate></JournalIssue><Title>Neuron</Title><ISOAbbreviation>Neuron</ISOAbbreviation></Journal><ArticleTitle>PET Imaging of Tau Deposition in the Aging Human Brain.</ArticleTitle><Pagination><StartPage>971</StartPage><EndPage>982</EndPage><MedlinePgn>971-982</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.neuron.2016.01.028</ELocationID><Abstract><AbstractText>Tau pathology is a hallmark of Alzheimer's disease (AD) but also occurs in normal cognitive aging. Using the tau PET agent (18)F-AV-1451, we examined retention patterns in cognitively normal older people in relation to young controls and AD patients. Age and &#x3b2;-amyloid (measured using PiB PET) were differentially associated with tau tracer retention in healthy aging. Older age was related to increased tracer retention in regions of the medial temporal lobe, which predicted worse episodic memory performance. PET detection of tau in other isocortical regions required the presence of cortical &#x3b2;-amyloid and was associated with decline in global cognition. Furthermore, patterns of tracer retention corresponded well with Braak staging of neurofibrillary tau pathology. The present study defined patterns of tau tracer retention in normal aging in relation to age, cognition, and &#x3b2;-amyloid deposition.</AbstractText><CopyrightInformation>Copyright &#xa9; 2016 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Sch&#xf6;ll</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Helen Wills Neuroscience Institute, University of California Berkeley, Berkeley, California, 94720, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>MedTech West and the Department of Clinical Neuroscience and Rehabilitation, University of Gothenburg, 405 30 Gothenburg, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Lockhart</LastName><ForeName>Samuel N</ForeName><Initials>SN</Initials><AffiliationInfo><Affiliation>Helen Wills Neuroscience Institute, University of California Berkeley, Berkeley, California, 94720, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schonhaut</LastName><ForeName>Daniel R</ForeName><Initials>DR</Initials><AffiliationInfo><Affiliation>Department of Neurology, Memory and Aging Center, University of California San Francisco, San Francisco, California, 94158, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>O'Neil</LastName><ForeName>James P</ForeName><Initials>JP</Initials><AffiliationInfo><Affiliation>Lawrence Berkeley National Laboratory, Berkeley, California, 94720, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Janabi</LastName><ForeName>Mustafa</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Lawrence Berkeley National Laboratory, Berkeley, California, 94720, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ossenkoppele</LastName><ForeName>Rik</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Helen Wills Neuroscience Institute, University of California Berkeley, Berkeley, California, 94720, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Memory and Aging Center, University of California San Francisco, San Francisco, California, 94158, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology &amp; Alzheimer Center, Neuroscience Campus Amsterdam, VU University Medical Center, 1081 HV Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baker</LastName><ForeName>Suzanne L</ForeName><Initials>SL</Initials><AffiliationInfo><Affiliation>Lawrence Berkeley National Laboratory, Berkeley, California, 94720, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vogel</LastName><ForeName>Jacob W</ForeName><Initials>JW</Initials><AffiliationInfo><Affiliation>Helen Wills Neuroscience Institute, University of California Berkeley, Berkeley, California, 94720, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Faria</LastName><ForeName>Jamie</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Lawrence Berkeley National Laboratory, Berkeley, California, 94720, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schwimmer</LastName><ForeName>Henry D</ForeName><Initials>HD</Initials><AffiliationInfo><Affiliation>Helen Wills Neuroscience Institute, University of California Berkeley, Berkeley, California, 94720, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rabinovici</LastName><ForeName>Gil D</ForeName><Initials>GD</Initials><AffiliationInfo><Affiliation>Helen Wills Neuroscience Institute, University of California Berkeley, Berkeley, California, 94720, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Memory and Aging Center, University of California San Francisco, San Francisco, California, 94158, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Lawrence Berkeley National Laboratory, Berkeley, California, 94720, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jagust</LastName><ForeName>William J</ForeName><Initials>WJ</Initials><AffiliationInfo><Affiliation>Helen Wills Neuroscience Institute, University of California Berkeley, Berkeley, California, 94720, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Lawrence Berkeley National Laboratory, Berkeley, California, 94720, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG034570</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG023501</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG034570</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50-AG23501</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG045611</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>F32 AG050389</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01-AG045611</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neuron</MedlineTA><NlmUniqueID>8809320</NlmUniqueID><ISSNLinking>0896-6273</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C475519">2-(4'-(methylamino)phenyl)-6-hydroxybenzothiazole</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000814">Aniline Compounds</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001057">Apolipoproteins E</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005026">Ethylene Glycols</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013844">Thiazoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>6867Q6IKOD</RegistryNumber><NameOfSubstance UI="C545186">florbetapir</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="Y">Aging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000814" MajorTopicYN="N">Aniline Compounds</DescriptorName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001057" MajorTopicYN="N">Apolipoproteins E</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005026" MajorTopicYN="N">Ethylene Glycols</DescriptorName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="Y">Positron-Emission Tomography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013844" MajorTopicYN="N">Thiazoles</DescriptorName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">PET</Keyword><Keyword MajorTopicYN="N">aging</Keyword><Keyword MajorTopicYN="N">amyloid</Keyword><Keyword MajorTopicYN="N">memory</Keyword><Keyword MajorTopicYN="N">tau</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>10</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2015</Year><Month>12</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>1</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2017</Year><Month>3</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>3</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>3</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>7</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26938442</ArticleId><ArticleId IdType="mid">NIHMS754405</ArticleId><ArticleId IdType="pmc">PMC4779187</ArticleId><ArticleId IdType="doi">10.1016/j.neuron.2016.01.028</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Alafuzoff I, Arzberger T, Al-Sarraj S, Bodi I, Bogdanovic N, Braak H, Bugiani O, Del Tredici K, Ferrer I, Gelpi E, et al. Staging of neurofibrillary pathology in Alzheimer's disease: a study of the BrainNet Europe Consortium. Brain Pathol. 2008;18:484&#x2013;496.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2659377</ArticleId><ArticleId IdType="pubmed">18371174</ArticleId></ArticleIdList></Reference><Reference><Citation>Arriagada PV, Growdon JH, Hedley-Whyte ET, Hyman BT. Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease. Neurology. 1992;42:631&#x2013;639.</Citation><ArticleIdList><ArticleId IdType="pubmed">1549228</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett DA, Schneider JA, Arvanitakis Z, Kelly JF, Aggarwal NT, Shah RC, Wilson RS. Neuropathology of older persons without cognitive impairment from two community-based studies. Neurology. 2006;66:1837&#x2013;1844.</Citation><ArticleIdList><ArticleId IdType="pubmed">16801647</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett DA, Wilson RS, Boyle PA, Buchman AS, Schneider JA. Relation of neuropathology to cognition in persons without cognitive impairment. Ann Neurol. 2012;72:599&#x2013;609.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3490232</ArticleId><ArticleId IdType="pubmed">23109154</ArticleId></ArticleIdList></Reference><Reference><Citation>Bouras C, Hof PR, Giannakopoulos P, Michel JP, Morrison JH. Regional distribution of neurofibrillary tangles and senile plaques in the cerebral cortex of elderly patients: a quantitative evaluation of a one-year autopsy population from a geriatric hospital. Cereb. Cortex. 1994;4:138&#x2013;150.</Citation><ArticleIdList><ArticleId IdType="pubmed">8038565</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Alafuzoff I, Arzberger T, Kretzschmar H, Del Tredici K. Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol. 2006;112:389&#x2013;404.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3906709</ArticleId><ArticleId IdType="pubmed">16906426</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82:239&#x2013;259.</Citation><ArticleIdList><ArticleId IdType="pubmed">1759558</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E. Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol. Aging. 1997;18:351&#x2013;357.</Citation><ArticleIdList><ArticleId IdType="pubmed">9330961</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E, Bohl J, Reintjes R. Age, neurofibrillary changes, A beta-amyloid and the onset of Alzheimer's disease. Neurosci. Lett. 1996;210:87&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pubmed">8783279</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Thal DR, Ghebremedhin E, Del Tredici K. Stages of the pathologic process in Alzheimer disease: age categories from 1 to 100 years. J. Neuropathol. Exp. Neurol. 2011;70:960&#x2013;969.</Citation><ArticleIdList><ArticleId IdType="pubmed">22002422</ArticleId></ArticleIdList></Reference><Reference><Citation>Chien DT, Bahri S, Szardenings AK, Walsh JC, Mu F, Su M-Y, Shankle WR, Elizarov A, Kolb HC. Early clinical PET imaging results with the novel PHF-tau radioligand [F-18]-T807. J. Alz. Dis. 2013;34:457&#x2013;468.</Citation><ArticleIdList><ArticleId IdType="pubmed">23234879</ArticleId></ArticleIdList></Reference><Reference><Citation>Crary JF, Trojanowski JQ, Schneider JA, Abisambra JF, Abner EL, Alafuzoff I, Arnold SE, Attems J, Beach TG, Bigio EH, et al. Primary age-related tauopathy (PART): a common pathology associated with human aging. Acta Neuropathol. 2014;128:755&#x2013;766.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4257842</ArticleId><ArticleId IdType="pubmed">25348064</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis DG, Schmitt FA, Wekstein DR, Markesbery WR. Alzheimer neuropathologic alterations in aged cognitively normal subjects. J. Neuropathol. Exp. Neurol. 1999;58:376&#x2013;388.</Citation><ArticleIdList><ArticleId IdType="pubmed">10218633</ArticleId></ArticleIdList></Reference><Reference><Citation>Deary IJ, Corley J, Gow AJ, Harris SE, Houlihan LM, Marioni RE, Penke L, Rafnsson SB, Starr JM. Age-associated cognitive decline. Br. Med. Bull. 2009;92:135&#x2013;152.</Citation><ArticleIdList><ArticleId IdType="pubmed">19776035</ArticleId></ArticleIdList></Reference><Reference><Citation>Duyckaerts C, Braak H, Brion JP, Buee L, Del Tredici K, Goedert M, Halliday G, Neumann M, Spillantini MG, Tolnay M, et al. PART is part of Alzheimer disease. Acta Neuropathol. 2015;129:749&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4405349</ArticleId><ArticleId IdType="pubmed">25628035</ArticleId></ArticleIdList></Reference><Reference><Citation>Elman JA, Oh H, Madison CM, Baker SL, Vogel JW, Marks SM, Crowley S, O&#x2019;Neil JP, Jagust WJ. Neural compensation in older people with brain amyloid-&#x3b2; deposition. Nat. Neurosci. 2014;17:1316&#x2013;1318.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4177011</ArticleId><ArticleId IdType="pubmed">25217827</ArticleId></ArticleIdList></Reference><Reference><Citation>Fagan AM, Roe CM, Xiong C, Mintun MA, Morris JC, Holtzman DM. Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. Arch. Neurol. 2007;64:343&#x2013;349.</Citation><ArticleIdList><ArticleId IdType="pubmed">17210801</ArticleId></ArticleIdList></Reference><Reference><Citation>Fornicola W, Pelcovits A, Li B-X, Heath J, Perry G, Castellani RJ. Alzheimer Disease Pathology in Middle Age Reveals a Spatial-Temporal Disconnect Between Amyloid-&#x3b2; and Phosphorylated Tau. Open Neurol. J. 2014;8:22&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4303956</ArticleId><ArticleId IdType="pubmed">25628768</ArticleId></ArticleIdList></Reference><Reference><Citation>Fox LM, William CM, Adamowicz DH, Pitstick R, Carlson GA, Spires-Jones TL, Hyman BT. Soluble tau species, not neurofibrillary aggregates, disrupt neural system integration in a tau transgenic model. J. Neuropathol. Exp. Neurol. 2011;70:588&#x2013;595.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3118928</ArticleId><ArticleId IdType="pubmed">21666499</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghoshal N, Garc&#xed;a-Sierra F, Wuu J, Leurgans S, Bennett DA, Berry RW, Binder LI. Tau conformational changes correspond to impairments of episodic memory in mild cognitive impairment and Alzheimer's disease. Exp. Neurol. 2002;177:475&#x2013;493.</Citation><ArticleIdList><ArticleId IdType="pubmed">12429193</ArticleId></ArticleIdList></Reference><Reference><Citation>Guillozet AL, Weintraub S, Mash DC, Mesulam M-M. Neurofibrillary tangles, amyloid, and memory in aging and mild cognitive impairment. Arch. Neurol. 2003;60:729&#x2013;736.</Citation><ArticleIdList><ArticleId IdType="pubmed">12756137</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoover BR, Reed MN, Su J, Penrod RD, Kotilinek LA, Grant MK, Pitstick R, Carlson GA, Lanier LM, Yuan L-L, et al. Tau mislocalization to dendritic spines mediates synaptic dysfunction independently of neurodegeneration. Neuron. 2010;68:1067&#x2013;1081.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3026458</ArticleId><ArticleId IdType="pubmed">21172610</ArticleId></ArticleIdList></Reference><Reference><Citation>Hyman BT, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Carrillo MC, Dickson DW, Duyckaerts C, Frosch MP, Masliah E, et al. National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease. Alz. Dement. 2012;8:1&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3266529</ArticleId><ArticleId IdType="pubmed">22265587</ArticleId></ArticleIdList></Reference><Reference><Citation>Ihaka R, Gentleman R. R: a language for data analysis and graphics. J. Comp. Graph. Stat. 1996;5:299&#x2013;314.</Citation></Reference><Reference><Citation>Jack CR, Knopman DS, Jagust WJ, Petersen RC, Weiner MW, Aisen PS, Shaw LM, Vemuri P, Wiste HJ, Weigand SD, et al. Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 2013;12:207&#x2013;216.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3622225</ArticleId><ArticleId IdType="pubmed">23332364</ArticleId></ArticleIdList></Reference><Reference><Citation>Jellinger KA, Alafuzoff I, Attems J, Beach TG, Cairns NJ, Crary JF, Dickson DW, Hof PR, Hyman BT, Jack CR, et al. PART, a distinct tauopathy, different from classical sporadic Alzheimer disease. Acta Neuropathol. 2015;129:757&#x2013;762.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4534004</ArticleId><ArticleId IdType="pubmed">25778618</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson KA, Schultz A, Betensky RA, Becker JA, Sepulcre J, Rentz D, Mormino E, Chhatwal J, Amariglio R, Papp K, et al. Tau PET imaging in aging and early Alzheimer's disease. Ann Neurol. 2015 Oct 27;</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4738026</ArticleId><ArticleId IdType="pubmed">26505746</ArticleId></ArticleIdList></Reference><Reference><Citation>Landau SM, Mintun MA, Joshi AD, Koeppe RA, Petersen RC, Aisen PS, Weiner MW, Jagust WJ, Initiative, A. a. s. D. N. Amyloid deposition, hypometabolism, and longitudinal cognitive decline. Ann. Neurol. 2012;72:578&#x2013;586.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3786871</ArticleId><ArticleId IdType="pubmed">23109153</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu L, Drouet V, Wu JW, Witter MP, Small SA, Clelland C, Duff K. Trans-synaptic spread of tau pathology in vivo. PLoS ONE. 2012;7:e31302.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3270029</ArticleId><ArticleId IdType="pubmed">22312444</ArticleId></ArticleIdList></Reference><Reference><Citation>Logan J, Fowler JS, Volkow ND, Wang GJ, Ding YS, Alexoff DL. Distribution volume ratios without blood sampling from graphical analysis of PET data. J. Cereb. Blood Flow Metab. 1996;16:834&#x2013;840.</Citation><ArticleIdList><ArticleId IdType="pubmed">8784228</ArticleId></ArticleIdList></Reference><Reference><Citation>Marquie M, Normandin MD, Vanderburg CR, Costantino I, Bien EA, Rycyna LG, Klunk WE, Mathis CA, Ikonomovic MD, Debnath ML, et al. Validating novel tau PET tracer [F-18]-AV-1451 (T807) on postmortem brain tissue. Ann. Neurol. 2015:1&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4900162</ArticleId><ArticleId IdType="pubmed">26344059</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathis CA, Wang Y, Holt DP, Huang G.-f., Debnath ML, Klunk WE. Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents. J. Med. Chem. 2003;46:2740&#x2013;2754.</Citation><ArticleIdList><ArticleId IdType="pubmed">12801237</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR, Kawas CH, Klunk WE, Koroshetz WJ, Manly JJ, Mayeux R, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alz. Dement. 2011;7:263&#x2013;269.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3312024</ArticleId><ArticleId IdType="pubmed">21514250</ArticleId></ArticleIdList></Reference><Reference><Citation>Menkes-Caspi N, Yamin HG, Kellner V, Spires-Jones TL, Cohen D, Stern EA. Pathological Tau Disrupts Ongoing Network Activity. Neuron. 2015</Citation><ArticleIdList><ArticleId IdType="pubmed">25704951</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitchell TW, Mufson EJ, Schneider JA, Cochran EJ, Nissanov J, Han L-Y, Bienias JL, Lee VMY, Trojanowski JQ, Bennett DA, et al. Parahippocampal tau pathology in healthy aging, mild cognitive impairment, and early Alzheimer's disease. Ann. Neurol. 2002;51:182&#x2013;189.</Citation><ArticleIdList><ArticleId IdType="pubmed">11835374</ArticleId></ArticleIdList></Reference><Reference><Citation>Mormino EC, Brandel MG, Madison CM, Rabinovici GD, Marks S, Baker SL, Jagust WJ. Not quite PIB-positive, not quite PIB-negative: slight PIB elevations in elderly normal control subjects are biologically relevant. Neuroimage. 2012;59:1152&#x2013;1160.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3230690</ArticleId><ArticleId IdType="pubmed">21884802</ArticleId></ArticleIdList></Reference><Reference><Citation>Mormino EC, Kluth JT, Madison CM, Rabinovici GD, Baker SL, Miller BL, Koeppe RA, Mathis CA, Weiner MW, Jagust WJ, et al. Episodic memory loss is related to hippocampal-mediated beta-amyloid deposition in elderly subjects. Brain. 2009;132:1310&#x2013;1323.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2677792</ArticleId><ArticleId IdType="pubmed">19042931</ArticleId></ArticleIdList></Reference><Reference><Citation>Mormino EC, Smiljic A, Hayenga AO, Onami SH, Greicius MD, Rabinovici GD, Janabi M, Baker SL, Yen IV, Madison CM, et al. Relationships between &#x3b2;-amyloid and functional connectivity in different components of the default mode network in aging. Cereb. Cortex. 2011;21:2399&#x2013;2407.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3169663</ArticleId><ArticleId IdType="pubmed">21383234</ArticleId></ArticleIdList></Reference><Reference><Citation>Murray ME, Graff-Radford NR, Ross OA, Petersen RC, Duara R, Dickson DW. Neuropathologically defined subtypes of Alzheimer's disease with distinct clinical characteristics: a retrospective study. Lancet Neurol. 2011;10:785&#x2013;796.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3175379</ArticleId><ArticleId IdType="pubmed">21802369</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson PT, Alafuzoff I, Bigio EH, Bouras C, Braak H, Cairns NJ, Castellani RJ, Crain BJ, Davies P, Del Tredici K, et al. Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J. Neuropathol. Exp. Neurol. 2012;71:362&#x2013;381.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3560290</ArticleId><ArticleId IdType="pubmed">22487856</ArticleId></ArticleIdList></Reference><Reference><Citation>Ossenkoppele R, Cohn-Sheehy BI, La Joie R, Vogel JW, M&#xf6;ller C, Lehmann M, van Berckel BNM, Seeley WW, Pijnenburg YA, Gorno-Tempini ML, et al. Atrophy patterns in early clinical stages across distinct phenotypes of Alzheimer's disease. Hum. Brain Mapp. 2015a</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4692964</ArticleId><ArticleId IdType="pubmed">26260856</ArticleId></ArticleIdList></Reference><Reference><Citation>Ossenkoppele R, Pijnenburg YAL, Perry DC, Cohn-Sheehy BI, Scheltens NME, Vogel JW, Kramer JH, van der Vlies AE, Joie RL, Rosen HJ, et al. The behavioural/dysexecutive variant of Alzheimer's disease: clinical, neuroimaging and pathological features. Brain. 2015b;138:2732&#x2013;2749.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4623840</ArticleId><ArticleId IdType="pubmed">26141491</ArticleId></ArticleIdList></Reference><Reference><Citation>Ossenkoppele R, Schonhaut DR, Baker SL, O&#x2019;Neil JP, Janabi M, Ghosh PM, Santos M, Miller ZA, Bettcher BM, Gorno-Tempini ML, et al. Tau, amyloid, and hypometabolism in a patient with posterior cortical atrophy. Ann. Neurol. 2015c;77:338&#x2013;342.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4382124</ArticleId><ArticleId IdType="pubmed">25448043</ArticleId></ArticleIdList></Reference><Reference><Citation>Price JC, Klunk WE, Lopresti BJ, Lu X, Hoge JA, Ziolko SK, Holt DP, Meltzer CC, Dekosky ST, Mathis CA. Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh Compound-B. J. Cereb. Blood Flow Metab. 2005;25:1528&#x2013;1547.</Citation><ArticleIdList><ArticleId IdType="pubmed">15944649</ArticleId></ArticleIdList></Reference><Reference><Citation>Price JL, Morris JC. Tangles and plaques in nondemented aging and preclinical Alzheimer's disease. Ann. Neurol. 1999;45:358&#x2013;368.</Citation><ArticleIdList><ArticleId IdType="pubmed">10072051</ArticleId></ArticleIdList></Reference><Reference><Citation>Rolstad S, Berg AI, Bjerke M, Johansson B, Zetterberg H, Wallin A. Cerebrospinal fluid biomarkers mirror rate of cognitive decline. J. Alz. Dis. 2013;34:949&#x2013;956.</Citation><ArticleIdList><ArticleId IdType="pubmed">23313924</ArticleId></ArticleIdList></Reference><Reference><Citation>Rousset OG, Ma Y, Evans AC. Correction for partial volume effects in PET: principle and validation. J. Nucl. Med. 1998;39:904&#x2013;911.</Citation><ArticleIdList><ArticleId IdType="pubmed">9591599</ArticleId></ArticleIdList></Reference><Reference><Citation>Serrano-Pozo A, Frosch MP, Masliah E, Hyman BT. Neuropathological alterations in Alzheimer disease. Cold Spring Harb. Perspect. Med. 2011;1:a006189.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3234452</ArticleId><ArticleId IdType="pubmed">22229116</ArticleId></ArticleIdList></Reference><Reference><Citation>Sj&#xf6;gren M, Vanderstichele H, Agren H, Zachrisson O, Edsbagge M, Wikkels&#xf8; C, Skoog I, Wallin A, Wahlund L-O, Marcusson J, et al. Tau and Abeta42 in cerebrospinal fluid from healthy adults 21-93 years of age: establishment of reference values. Clin. Chem. 2001;47:1776&#x2013;1781.</Citation><ArticleIdList><ArticleId IdType="pubmed">11568086</ArticleId></ArticleIdList></Reference><Reference><Citation>Small SA, Duff K. Linking Abeta and tau in late-onset Alzheimer's disease: a dual pathway hypothesis. Neuron. 2008;60:534&#x2013;542.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2692134</ArticleId><ArticleId IdType="pubmed">19038212</ArticleId></ArticleIdList></Reference><Reference><Citation>Spires-Jones TL, Hyman BT. The Intersection of Amyloid Beta and Tau at Synapses in Alzheimer's Disease. Neuron. 2014;82:756&#x2013;771.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4135182</ArticleId><ArticleId IdType="pubmed">24853936</ArticleId></ArticleIdList></Reference><Reference><Citation>Tomlinson BE, Blessed G, Roth M. Observations on the brains of non-demented old people. J. Neurol. Sci. 1968;7:331&#x2013;356.</Citation><ArticleIdList><ArticleId IdType="pubmed">5707082</ArticleId></ArticleIdList></Reference><Reference><Citation>Tong J, Meyer JH, Furukawa Y, Boileau I, Chang L-J, Wilson AA, Houle S, Kish SJ. Distribution of monoamine oxidase proteins in human brain: implications for brain imaging studies. J. Cereb. Blood Flow Metab. 2013;33:863&#x2013;871.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3677103</ArticleId><ArticleId IdType="pubmed">23403377</ArticleId></ArticleIdList></Reference><Reference><Citation>Tromp D, Dufour A, Lithfous S, Pebayle T, Despr&#xe9;s O. Episodic memory in normal aging and Alzheimer disease: Insights from imaging and behavioral studies. Ageing Res. Rev. 2015</Citation><ArticleIdList><ArticleId IdType="pubmed">26318058</ArticleId></ArticleIdList></Reference><Reference><Citation>van Rossum IA, Visser PJ, Knol DL, van der Flier WM, Teunissen CE, Barkhof F, Blankenstein MA, Scheltens P. Injury markers but not amyloid markers are associated with rapid progression from mild cognitive impairment to dementia in Alzheimer's disease. J. Alz. Dis. 2012;29:319&#x2013;327.</Citation><ArticleIdList><ArticleId IdType="pubmed">22233766</ArticleId></ArticleIdList></Reference><Reference><Citation>Villemagne VL, Burnham S, Bourgeat P, Brown B, Ellis KA, Salvado O, Szoeke C, Macaulay SL, Martins R, Maruff P, et al. Amyloid beta deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study. Lancet Neurol. 2013;12:357&#x2013;67.</Citation><ArticleIdList><ArticleId IdType="pubmed">23477989</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia C-F, Arteaga J, Chen G, Gangadharmath U, Gomez LF, Kasi D, Lam C, Liang Q, Liu C, Mocharla VP, et al. [(18)F]T807, a novel tau positron emission tomography imaging agent for Alzheimer's disease. Alz. Dement. 2013;9:666&#x2013;676.</Citation><ArticleIdList><ArticleId IdType="pubmed">23411393</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">26936940</PMID><DateCompleted><Year>2017</Year><Month>05</Month><Day>08</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1460-2156</ISSN><JournalIssue CitedMedium="Internet"><Volume>139</Volume><Issue>Pt 5</Issue><PubDate><Year>2016</Year><Month>May</Month></PubDate></JournalIssue><Title>Brain : a journal of neurology</Title><ISOAbbreviation>Brain</ISOAbbreviation></Journal><ArticleTitle>Regional profiles of the candidate tau PET ligand 18F-AV-1451 recapitulate key features of Braak histopathological stages.</ArticleTitle><Pagination><StartPage>1539</StartPage><EndPage>1550</EndPage><MedlinePgn>1539-50</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/brain/aww023</ELocationID><Abstract><AbstractText>SEE THAL AND VANDENBERGHE DOI101093/BRAIN/AWW057 FOR A SCIENTIFIC COMMENTARY ON THIS ARTICLE: Post-mortem Braak staging of neurofibrillary tau tangle topographical distribution is one of the core neuropathological criteria for the diagnosis of Alzheimer's disease. The recent development of positron emission tomography tracers targeting neurofibrillary tangles has enabled the distribution of tau pathology to be imaged in living subjects. Methods for extraction of classic Braak staging from in vivo imaging of neurofibrillary tau tangles have not yet been explored. Standardized uptake value ratio images were calculated from 80-100 minute (18)F-AV-1451 (also known as T807) positron emission tomography scans obtained from n = 14 young reference subjects (age 21-39 years, Mini-Mental State Examination 29-30) and n = 173 older test subjects (age 50-95 years) comprising amyloid negative cognitively normal (n = 42), clinically-diagnosed mild cognitive impairment (amyloid positive, n = 47, and amyloid negative, n = 40) and Alzheimer's disease (amyloid positive, n = 28, and amyloid negative, n = 16). We defined seven regions of interest in anterior temporal lobe and occipital lobe sections corresponding closely to those used as decision points in Braak staging. An algorithm based on the Braak histological staging procedure was applied to estimate Braak stages directly from the region of interest profiles in each subject. Quantitative region-based analysis of (18)F-AV-1451 images yielded region of interest and voxel level profiles that mirrored key features of neuropathological tau progression including profiles consistent with Braak stages 0 through VI. A simple set of decision rules enabled plausible Braak stages corresponding to stereotypical progression patterns to be objectively estimated in 149 (86%) of test subjects. An additional 12 (7%) subjects presented with predefined variant profiles (relative sparing of the hippocampus and/or occipital lobe). The estimated Braak stage was significantly associated with amyloid status, diagnostic category and measures of global cognition. In vivo (18)F-AV-1451 positron emission tomography images across the Alzheimer's disease spectrum could be classified into patterns similar to those prescribed by Braak neuropathological staging of tau pathology.</AbstractText><CopyrightInformation>&#xa9; The Author (2016). Published by Oxford University Press on behalf of the Guarantors of Brain. All rights reserved. For Permissions, please email: journals.permissions@oup.com.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Schwarz</LastName><ForeName>Adam J</ForeName><Initials>AJ</Initials><AffiliationInfo><Affiliation>Tailored Therapeutics, Eli Lilly and Company, Indianapolis, IN 46285, USA a.schwarz@lilly.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Peng</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Tailored Therapeutics, Eli Lilly and Company, Indianapolis, IN 46285, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miller</LastName><ForeName>Bradley B</ForeName><Initials>BB</Initials><AffiliationInfo><Affiliation>Tailored Therapeutics, Eli Lilly and Company, Indianapolis, IN 46285, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shcherbinin</LastName><ForeName>Sergey</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Tailored Therapeutics, Eli Lilly and Company, Indianapolis, IN 46285, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dickson</LastName><ForeName>James</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Avid Radiopharmaceuticals, Philadelphia, PA 19104, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Navitsky</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Avid Radiopharmaceuticals, Philadelphia, PA 19104, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Joshi</LastName><ForeName>Abhinay D</ForeName><Initials>AD</Initials><AffiliationInfo><Affiliation>Avid Radiopharmaceuticals, Philadelphia, PA 19104, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Devous</LastName><ForeName>Michael D</ForeName><Initials>MD</Initials><Suffix>Sr</Suffix><AffiliationInfo><Affiliation>Avid Radiopharmaceuticals, Philadelphia, PA 19104, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mintun</LastName><ForeName>Mark S</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>Avid Radiopharmaceuticals, Philadelphia, PA 19104, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>03</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Brain</MedlineTA><NlmUniqueID>0372537</NlmUniqueID><ISSNLinking>0006-8950</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002243">Carbolines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>J09QS3Z3WB</RegistryNumber><NameOfSubstance UI="C000591008">7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Brain. 2016 May;139(Pt 5):1318-20. doi: 10.1093/brain/aww057.</RefSource><PMID Version="1">27189579</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000465" MajorTopicYN="N">Algorithms</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002243" MajorTopicYN="N">Carbolines</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D060825" MajorTopicYN="N">Cognitive Dysfunction</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016874" MajorTopicYN="N">Neurofibrillary Tangles</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D059906" MajorTopicYN="N">Neuroimaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009778" MajorTopicYN="N">Occipital Lobe</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="N">Positron-Emission Tomography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013702" MajorTopicYN="N">Temporal Lobe</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">18F-AV-1451</Keyword><Keyword MajorTopicYN="N">Braak staging</Keyword><Keyword MajorTopicYN="N">imaging</Keyword><Keyword MajorTopicYN="N">positron emission tomography (PET)</Keyword><Keyword MajorTopicYN="N">tau</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>9</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>1</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>3</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>3</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>5</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26936940</ArticleId><ArticleId IdType="doi">10.1093/brain/aww023</ArticleId><ArticleId IdType="pii">aww023</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">26931567</PMID><DateCompleted><Year>2017</Year><Month>09</Month><Day>07</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>03</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1469-3178</ISSN><JournalIssue CitedMedium="Internet"><Volume>17</Volume><Issue>4</Issue><PubDate><Year>2016</Year><Month>Apr</Month></PubDate></JournalIssue><Title>EMBO reports</Title><ISOAbbreviation>EMBO Rep</ISOAbbreviation></Journal><ArticleTitle>Expression of A152T human tau causes age-dependent neuronal dysfunction and loss in transgenic mice.</ArticleTitle><Pagination><StartPage>530</StartPage><EndPage>551</EndPage><MedlinePgn>530-51</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.15252/embr.201541438</ELocationID><Abstract><AbstractText>A152T-variant human tau (hTau-A152T) increases risk for tauopathies, including Alzheimer's disease. Comparing mice with regulatable expression of hTau-A152T or wild-type hTau (hTau-WT), we find age-dependent neuronal loss, cognitive impairments, and spontaneous nonconvulsive epileptiform activity primarily in hTau-A152T mice. However, overexpression of either hTau species enhances neuronal responses to electrical stimulation of synaptic inputs and to an epileptogenic chemical. hTau-A152T mice have higher hTau protein/mRNA ratios in brain, suggesting that A152T increases production or decreases clearance of hTau protein. Despite their functional abnormalities, aging hTau-A152T mice show no evidence for accumulation of insoluble tau aggregates, suggesting that their dysfunctions are caused by soluble tau. In human amyloid precursor protein (hAPP) transgenic mice, co-expression of hTau-A152T enhances risk of early death and epileptic activity, suggesting copathogenic interactions between hTau-A152T and amyloid-&#x3b2; peptides or other hAPP metabolites. Thus, the A152T substitution may augment risk for neurodegenerative diseases by increasing hTau protein levels, promoting network hyperexcitability, and synergizing with the adverse effects of other pathogenic factors.</AbstractText><CopyrightInformation>&#xa9; 2016 The Authors. Published under the terms of the CC BY NC ND 4.0 license.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Maeda</LastName><ForeName>Sumihiro</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Gladstone Institute of Neurological Disease, San Francisco, CA, USA Department of Neurology, University of California, San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Djukic</LastName><ForeName>Biljana</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Gladstone Institute of Neurological Disease, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Taneja</LastName><ForeName>Praveen</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Gladstone Institute of Neurological Disease, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Gui-Qiu</ForeName><Initials>GQ</Initials><AffiliationInfo><Affiliation>Gladstone Institute of Neurological Disease, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lo</LastName><ForeName>Iris</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Gladstone Institute of Neurological Disease, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Davis</LastName><ForeName>Allyson</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Gladstone Institute of Neurological Disease, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Craft</LastName><ForeName>Ryan</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Gladstone Institute of Neurological Disease, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guo</LastName><ForeName>Weikun</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Gladstone Institute of Neurological Disease, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Xin</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Gladstone Institute of Neurological Disease, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Gladstone Institute of Neurological Disease, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ponnusamy</LastName><ForeName>Ravikumar</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Gladstone Institute of Neurological Disease, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gill</LastName><ForeName>T Michael</ForeName><Initials>TM</Initials><AffiliationInfo><Affiliation>Gladstone Institute of Neurological Disease, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Masliah</LastName><ForeName>Eliezer</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, University of California, San Diego, La Jolla, CA, USA Department of Pathology, University of California, San Diego, La Jolla, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mucke</LastName><ForeName>Lennart</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Gladstone Institute of Neurological Disease, San Francisco, CA, USA Department of Neurology, University of California, San Francisco, San Francisco, CA, USA lennart.mucke@gladstone.ucsf.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>C06 RR018928</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 NS065780</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005131</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS041787</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>03</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>EMBO Rep</MedlineTA><NlmUniqueID>100963049</NlmUniqueID><ISSNLinking>1469-221X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>EMBO Rep. 2024 Nov;25(11):5212-5215. doi: 10.1038/s44319-024-00212-8.</RefSource><PMID Version="1">39363060</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="Y">Aging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D060825" MajorTopicYN="N">Cognitive Dysfunction</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057180" MajorTopicYN="N">Frontotemporal Dementia</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D024801" MajorTopicYN="N">Tauopathies</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">A152T</Keyword><Keyword MajorTopicYN="N">Alzheimer's disease</Keyword><Keyword MajorTopicYN="N">frontotemporal dementia</Keyword><Keyword MajorTopicYN="N">hyperexcitability</Keyword><Keyword MajorTopicYN="N">tau</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>9</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>1</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>3</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>3</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>9</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2016</Year><Month>3</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26931567</ArticleId><ArticleId IdType="pmc">PMC4818780</ArticleId><ArticleId IdType="doi">10.15252/embr.201541438</ArticleId><ArticleId IdType="pii">embr.201541438</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Morris M, Maeda S, Vossel K, Mucke L (2011) The many faces of tau. Neuron 70: 410&#x2013;426</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3319390</ArticleId><ArticleId IdType="pubmed">21555069</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang Y, Mucke L (2012) Alzheimer mechanisms and therapeutic strategies. Cell 148: 1204&#x2013;1222</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3319071</ArticleId><ArticleId IdType="pubmed">22424230</ArticleId></ArticleIdList></Reference><Reference><Citation>Irwin DJ, Cairns NJ, Grossman M, McMillan CT, Lee EB, Van Deerlin VM, Lee VM, Trojanowski JQ (2015) Frontotemporal lobar degeneration: defining phenotypic diversity through personalized medicine. Acta Neuropathol 129: 469&#x2013;491</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4369168</ArticleId><ArticleId IdType="pubmed">25549971</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee VM, Goedert M, Trojanowski JQ (2001) Neurodegenerative tauopathies. Annu Rev Neurosci 24: 1121&#x2013;1159</Citation><ArticleIdList><ArticleId IdType="pubmed">11520930</ArticleId></ArticleIdList></Reference><Reference><Citation>Grundke&#x2010;Iqbal I, Iqbal K, Quinlan M, Tung YC, Zaidi MS, Wisniewski HM (1986) Microtubule&#x2010;associated protein tau. A component of Alzheimer paired helical filaments. J Biol Chem 261: 6084&#x2013;6089</Citation><ArticleIdList><ArticleId IdType="pubmed">3084478</ArticleId></ArticleIdList></Reference><Reference><Citation>Kosik KS, Joachim CL, Selkoe DJ (1986) Microtubule&#x2010;associated protein tau (t) is a major antigenic component of paired helical filaments in Alzheimer disease. Proc Natl Acad Sci USA 83: 4044&#x2013;4048</Citation><ArticleIdList><ArticleId IdType="pmc">PMC323662</ArticleId><ArticleId IdType="pubmed">2424016</ArticleId></ArticleIdList></Reference><Reference><Citation>Kondo J, Honda T, Mori H, Hamada Y, Miura R, Ogawara M, Ihara Y (1988) The carboxyl third of tau is tightly bound to paired helical filaments. Neuron 1: 827&#x2013;834</Citation><ArticleIdList><ArticleId IdType="pubmed">2483105</ArticleId></ArticleIdList></Reference><Reference><Citation>Nukina N, Ihara Y (1986) One of the antigenic determinants of paired helical filaments is related to tau protein. J Biochem 99: 1541&#x2013;1544</Citation><ArticleIdList><ArticleId IdType="pubmed">2423512</ArticleId></ArticleIdList></Reference><Reference><Citation>Wood JG, Mirra SS, Pollock NJ, Binder LI (1986) Neurofibrillary tangles of Alzheimer disease share antigenic determinants with the axonal microtubule&#x2010;associated protein tau (t). Proc Natl Acad Sci USA 83: 4040&#x2013;4043</Citation><ArticleIdList><ArticleId IdType="pmc">PMC323661</ArticleId><ArticleId IdType="pubmed">2424015</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee VM, Balin BJ, Otvos L Jr, Trojanowski JQ (1991) A68: a major subunit of paired helical filaments and derivatized forms of normal Tau. Science 251: 675&#x2013;678</Citation><ArticleIdList><ArticleId IdType="pubmed">1899488</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E (1991) Neuropathological stageing of Alzheimer&#x2010;related changes. Acta Neuropathol 82: 239&#x2013;259</Citation><ArticleIdList><ArticleId IdType="pubmed">1759558</ArticleId></ArticleIdList></Reference><Reference><Citation>Giannakopoulos P, Herrmann FR, Bussiere T, Bouras C, Kovari E, Perl DP, Morrison JH, Gold G, Hof PR (2003) Tangle and neuron numbers, but not amyloid load, predict cognitive status in Alzheimer's disease. Neurology 60: 1495&#x2013;1500</Citation><ArticleIdList><ArticleId IdType="pubmed">12743238</ArticleId></ArticleIdList></Reference><Reference><Citation>Hyman BT, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Carrillo MC, Dickson DW, Duyckaerts C, Frosch MP, Masliah E et al (2012) National Institute on Aging&#x2010;Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease. Alzheimers Dement 8: 1&#x2013;13</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3266529</ArticleId><ArticleId IdType="pubmed">22265587</ArticleId></ArticleIdList></Reference><Reference><Citation>Wagshal D, Sankaranarayanan S, Guss V, Hall T, Berisha F, Lobach I, Karydas A, Voltarelli L, Scherling C, Heuer H et al (2015) Divergent CSF tau alterations in two common tauopathies: Alzheimer's disease and progressive supranuclear palsy. J Neurol Neurosurg Psychiatry 86: 244&#x2013;250</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4256124</ArticleId><ArticleId IdType="pubmed">24899730</ArticleId></ArticleIdList></Reference><Reference><Citation>Maruyama M, Shimada H, Suhara T, Shinotoh H, Ji B, Maeda J, Zhang MR, Trojanowski JQ, Lee VM, Ono M et al (2013) Imaging of tau pathology in a tauopathy mouse model and in Alzheimer patients compared to normal controls. Neuron 79: 1094&#x2013;1108</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3809845</ArticleId><ArticleId IdType="pubmed">24050400</ArticleId></ArticleIdList></Reference><Reference><Citation>Chien DT, Bahri S, Szardenings AK, Walsh JC, Mu F, Su MY, Shankle WR, Elizarov A, Kolb HC (2013) Early clinical PET imaging results with the novel PHF&#x2010;tau radioligand [F&#x2010;18]&#x2010;T807. J Alzheimers Dis 34: 457&#x2013;468</Citation><ArticleIdList><ArticleId IdType="pubmed">23234879</ArticleId></ArticleIdList></Reference><Reference><Citation>Okamura N, Furumoto S, Fodero&#x2010;Tavoletti MT, Mulligan RS, Harada R, Yates P, Pejoska S, Kudo Y, Masters CL, Yanai K et al (2014) Non&#x2010;invasive assessment of Alzheimer's disease neurofibrillary pathology using 18F&#x2010;THK5105 PET. Brain 137: 1762&#x2013;1771</Citation><ArticleIdList><ArticleId IdType="pubmed">24681664</ArticleId></ArticleIdList></Reference><Reference><Citation>Reed LA, Wszolek ZK, Hutton M (2001) Phenotypic correlations in FTDP&#x2010;17. Neurobiol Aging 22: 89&#x2013;107</Citation><ArticleIdList><ArticleId IdType="pubmed">11164280</ArticleId></ArticleIdList></Reference><Reference><Citation>Boeve BF, Hutton M (2008) Refining frontotemporal dementia with parkinsonism linked to chromosome 17: introducing FTDP&#x2010;17 (MAPT) and FTDP&#x2010;17 (PGRN). Arch Neurol 65: 460&#x2013;464</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2746630</ArticleId><ArticleId IdType="pubmed">18413467</ArticleId></ArticleIdList></Reference><Reference><Citation>Goedert M, Ghetti B, Spillantini MG (2012) Frontotemporal dementia: implications for understanding Alzheimer disease. Cold Spring Harb Perspect Med 2: a006254</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3281593</ArticleId><ArticleId IdType="pubmed">22355793</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryman DC, Acosta&#x2010;Baena N, Aisen PS, Bird T, Danek A, Fox NC, Goate A, Frommelt P, Ghetti B, Langbaum JB et al (2014) Symptom onset in autosomal dominant Alzheimer disease: a systematic review and meta&#x2010;analysis. Neurology 83: 253&#x2013;260</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4117367</ArticleId><ArticleId IdType="pubmed">24928124</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanders DW, Kaufman SK, DeVos SL, Sharma AM, Mirbaha H, Li A, Barker SJ, Foley AC, Thorpe JR, Serpell LC et al (2014) Distinct tau prion strains propagate in cells and mice and define different tauopathies. Neuron 82: 1271&#x2013;1288</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4171396</ArticleId><ArticleId IdType="pubmed">24857020</ArticleId></ArticleIdList></Reference><Reference><Citation>Coppola G, Chinnathambi S, Lee JJ, Dombroski BA, Baker MC, Soto&#x2010;Ortolaza AI, Lee SE, Klein E, Huang AY, Sears R et al (2012) Evidence for a role of the rare p. A152T variant in MAPT in increasing the risk for FTD&#x2010;spectrum and Alzheimer's diseases. Hum Mol Genet 21: 3500&#x2013;3512</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3392107</ArticleId><ArticleId IdType="pubmed">22556362</ArticleId></ArticleIdList></Reference><Reference><Citation>Kara E, Ling H, Pittman AM, Shaw K, de Silva R, Simone R, Holton JL, Warren JD, Rohrer JD, Xiromerisiou G et al (2012) The MAPT p.A152T variant is a risk factor associated with tauopathies with atypical clinical and neuropathological features. Neurobiol Aging 33: 2231 e7&#x2013;2231 e14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3657164</ArticleId><ArticleId IdType="pubmed">22595371</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee SE, Tartaglia MC, Yener G, Genc S, Seeley WW, Sanchez&#x2010;Juan P, Moreno F, Mendez MF, Klein E, Rademakers R et al (2013) Neurodegenerative disease phenotypes in carriers of MAPT p. A152T, a risk factor for frontotemporal dementia spectrum disorders and Alzheimer disease. Alzheimer Dis Assoc Disord 27: 302&#x2013;309</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3796183</ArticleId><ArticleId IdType="pubmed">23518664</ArticleId></ArticleIdList></Reference><Reference><Citation>Kovacs GG, Wohrer A, Strobel T, Botond G, Attems J, Budka H (2011) Unclassifiable tauopathy associated with an A152T variation in MAPT exon 7. Clin Neuropathol 30: 3&#x2013;10</Citation><ArticleIdList><ArticleId IdType="pubmed">21176711</ArticleId></ArticleIdList></Reference><Reference><Citation>Klopotowska D, Strzadala L, Matuszyk J (2008) Inducibility of doxycycline&#x2010;regulated gene in neural and neuroendocrine cells strongly depends on the appropriate choice of a tetracycline&#x2010;responsive promoter. Neurochem Int 52: 221&#x2013;229</Citation><ArticleIdList><ArticleId IdType="pubmed">17618706</ArticleId></ArticleIdList></Reference><Reference><Citation>Mayford M, Bach ME, Huang YY, Wang L, Hawkins RD, Kandel ER (1996) Control of memory formation through regulated expression of a CaMKII transgene. Science 274: 1678&#x2013;1683</Citation><ArticleIdList><ArticleId IdType="pubmed">8939850</ArticleId></ArticleIdList></Reference><Reference><Citation>Harris JA, Koyama A, Maeda S, Ho K, Devidze N, Dubal DB, Yu G&#x2010;Q, Masliah E, Mucke L (2012) Human P301L&#x2010;mutant tau expression in mouse entorhinal&#x2010;hippocampal network causes tau aggregation and presynaptic pathology but no cognitive deficits. PLoS One 7: e45881</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3454317</ArticleId><ArticleId IdType="pubmed">23029293</ArticleId></ArticleIdList></Reference><Reference><Citation>Barten DM, Cadelina GW, Hoque N, DeCarr LB, Guss VL, Yang L, Sankaranarayanan S, Wes PD, Flynn ME, Meredith JE et al (2011) Tau transgenic mice as models for cerebrospinal fluid tau biomarkers. J Alzheimers Dis 24(Suppl 2): 127&#x2013;141</Citation><ArticleIdList><ArticleId IdType="pubmed">21422517</ArticleId></ArticleIdList></Reference><Reference><Citation>SantaCruz K, Lewis J, Spires T, Paulson J, Kotilinek L, Ingelsson M, Guimaraes A, DeTure M, Ramsden M, McGowan E et al (2005) Tau suppression in a neurodegenerative mouse model improves memory function. Science 309: 476&#x2013;481</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1574647</ArticleId><ArticleId IdType="pubmed">16020737</ArticleId></ArticleIdList></Reference><Reference><Citation>Delerue F, White M, Ittner LM (2014) Inducible, tightly regulated and non&#x2010;leaky neuronal gene expression in mice. Transgenic Res 23: 225&#x2013;233</Citation><ArticleIdList><ArticleId IdType="pubmed">24214494</ArticleId></ArticleIdList></Reference><Reference><Citation>West MJ, Coleman PD, Flood DG, Troncoso JC (1994) Differences in the pattern of hippocampal neuronal loss in normal ageing and Alzheimer's disease. Lancet 344: 769&#x2013;772</Citation><ArticleIdList><ArticleId IdType="pubmed">7916070</ArticleId></ArticleIdList></Reference><Reference><Citation>Otvos L Jr, Feiner L, Lang E, Szendrei GI, Goedert M, Lee VM (1994) Monoclonal antibody PHF&#x2010;1 recognizes tau protein phosphorylated at serine residues 396 and 404. J Neurosci Res 39: 669&#x2013;673</Citation><ArticleIdList><ArticleId IdType="pubmed">7534834</ArticleId></ArticleIdList></Reference><Reference><Citation>Porzig R, Singer D, Hoffmann R (2007) Epitope mapping of mAbs AT8 and Tau5 directed against hyperphosphorylated regions of the human tau protein. Biochem Biophys Res Commun 358: 644&#x2013;649</Citation><ArticleIdList><ArticleId IdType="pubmed">17499212</ArticleId></ArticleIdList></Reference><Reference><Citation>Sydow A, Van der Jeugd A, Zheng F, Ahmed T, Balschun D, Petrova O, Drexler D, Zhou L, Rune G, Mandelkow E et al (2011) Tau&#x2010;induced defects in synaptic plasticity, learning, and memory are reversible in transgenic mice after switching off the toxic Tau mutant. J Neurosci 31: 2511&#x2013;2525</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6623704</ArticleId><ArticleId IdType="pubmed">21325519</ArticleId></ArticleIdList></Reference><Reference><Citation>Maeda S, Sahara N, Saito Y, Murayama M, Yoshiike Y, Kim H, Miyasaka T, Murayama S, Ikai A, Takashima A (2007) Granular tau oligomers as intermediates of tau filaments. Biochemistry 46: 3856&#x2013;3861</Citation><ArticleIdList><ArticleId IdType="pubmed">17338548</ArticleId></ArticleIdList></Reference><Reference><Citation>Weaver CL, Espinoza M, Kress Y, Davies P (2000) Conformational change as one of the earliest alterations of tau in Alzheimer's disease. Neurobiol Aging 21: 719&#x2013;727</Citation><ArticleIdList><ArticleId IdType="pubmed">11016541</ArticleId></ArticleIdList></Reference><Reference><Citation>Cunningham C, Deacon R, Wells H, Boche D, Waters S, Diniz CP, Scott H, Rawlins JN, Perry VH (2003) Synaptic changes characterize early behavioural signs in the ME7 model of murine prion disease. Eur J Neurosci 17: 2147&#x2013;2155</Citation><ArticleIdList><ArticleId IdType="pubmed">12786981</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin L, Chen G, Kuang H, Wang D, Tsien JZ (2007) Neural encoding of the concept of nest in the mouse brain. Proc Natl Acad Sci USA 104: 6066&#x2013;6071</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1851617</ArticleId><ArticleId IdType="pubmed">17389405</ArticleId></ArticleIdList></Reference><Reference><Citation>Heller HC, Salehi A, Chuluun B, Das D, Lin B, Moghadam S, Garner CC, Colas D (2014) Nest building is impaired in the Ts65Dn mouse model of Down syndrome and rescued by blocking 5HT2a receptors. Neurobiol Learn Mem 116: 162&#x2013;171</Citation><ArticleIdList><ArticleId IdType="pubmed">25463650</ArticleId></ArticleIdList></Reference><Reference><Citation>Han HJ, Allen CC, Buchovecky CM, Yetman MJ, Born HA, Marin MA, Rodgers SP, Song BJ, Lu HC, Justice MJ et al (2012) Strain background influences neurotoxicity and behavioral abnormalities in mice expressing the tetracycline transactivator. J Neurosci 32: 10574&#x2010;10586</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3431916</ArticleId><ArticleId IdType="pubmed">22855807</ArticleId></ArticleIdList></Reference><Reference><Citation>Abbott LF, Regehr WG (2004) Synaptic computation. Nature 431: 796&#x2013;803</Citation><ArticleIdList><ArticleId IdType="pubmed">15483601</ArticleId></ArticleIdList></Reference><Reference><Citation>Zucker RS, Regehr WG (2002) Short&#x2010;term synaptic plasticity. Annu Rev Physiol 64: 355&#x2013;405</Citation><ArticleIdList><ArticleId IdType="pubmed">11826273</ArticleId></ArticleIdList></Reference><Reference><Citation>Vossel KA, Beagle AJ, Rabinovici GD, Shu H, Lee SE, Naasan G, Hegde M, Cornes SB, Henry ML, Nelson AB et al (2013) Seizures and epileptiform activity in the early stages of Alzheimer disease. JAMA Neurol 70: 1158&#x2013;1166</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4013391</ArticleId><ArticleId IdType="pubmed">23835471</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanchez PE, Zhu L, Verret L, Vossel KA, Orr AG, Cirrito JR, Devidze N, Ho K, Yu G&#x2010;Q, Palop JJ et al (2012) Levetiracetam suppresses neuronal network dysfunction and reverses synaptic and cognitive deficits in an Alzheimer's disease model. Proc Natl Acad Sci USA 109: E2895&#x2013;E2903</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3479491</ArticleId><ArticleId IdType="pubmed">22869752</ArticleId></ArticleIdList></Reference><Reference><Citation>Palop JJ, Mucke L (2010) Amyloid&#x2010;beta&#x2010;induced neuronal dysfunction in Alzheimer's disease: from synapses toward neural networks. Nat Neurosci 13: 812&#x2013;818</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3072750</ArticleId><ArticleId IdType="pubmed">20581818</ArticleId></ArticleIdList></Reference><Reference><Citation>Palop JJ, Mucke L (2009) Epilepsy and cognitive impairments in Alzheimer disease. Arch Neurol 66: 435&#x2013;440</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2812914</ArticleId><ArticleId IdType="pubmed">19204149</ArticleId></ArticleIdList></Reference><Reference><Citation>Palop JJ, Chin J, Roberson ED, Wang J, Thwin MT, Bien&#x2010;Ly N, Yoo J, Ho KO, Yu G&#x2010;Q, Kreitzer A et al (2007) Aberrant excitatory neuronal activity and compensatory remodeling of inhibitory hippocampal circuits in mouse models of Alzheimer's disease. Neuron 55: 697&#x2013;711</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8055171</ArticleId><ArticleId IdType="pubmed">17785178</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberson ED, Halabisky B, Yoo JW, Yao J, Chin J, Yan F, Wu T, Hamto P, Devidze N, Yu G&#x2010;Q et al (2011) Amyloid&#x2010;&#x3b2;/Fyn&#x2010;induced synaptic, network, and cognitive impairments depend on tau levels in multiple mouse models of Alzheimer's disease. J Neurosci 31: 700&#x2013;711</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3325794</ArticleId><ArticleId IdType="pubmed">21228179</ArticleId></ArticleIdList></Reference><Reference><Citation>Verret L, Mann EO, Hang GB, Barth AM, Cobos I, Ho K, Devidze N, Masliah E, Kreitzer AC, Mody I et al (2012) Inhibitory interneuron deficit links altered network activity and cognitive dysfunction in Alzheimer model. Cell 149: 708&#x2013;721</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3375906</ArticleId><ArticleId IdType="pubmed">22541439</ArticleId></ArticleIdList></Reference><Reference><Citation>Suberbielle E, Sanchez PE, Kravitz AV, Wang X, Ho K, Eilertson K, Devidze N, Kreitzer AC, Mucke L (2013) Physiologic brain activity causes DNA double&#x2010;strand breaks in neurons, with exacerbation by amyloid&#x2010;&#x3b2;. Nat Neurosci 16: 613&#x2013;621</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3637871</ArticleId><ArticleId IdType="pubmed">23525040</ArticleId></ArticleIdList></Reference><Reference><Citation>Orr AG, Hsiao EC, Wang MM, Ho K, Kim DH, Wang X, Guo W, Kang J, Yu GQ, Adame A et al (2015) Astrocytic adenosine receptor A2A and Gs&#x2010;coupled signaling regulate memory. Nat Neurosci 18: 423&#x2013;434</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4340760</ArticleId><ArticleId IdType="pubmed">25622143</ArticleId></ArticleIdList></Reference><Reference><Citation>Mucke L, Masliah E, Yu G&#x2010;Q, Mallory M, Rockenstein E, Tatsuno G, Hu K, Kholodenko D, Johnson&#x2010;Wood K, McConlogue L (2000) High&#x2010;level neuronal expression of A&#x3b2;1&#x2010;42 in wild&#x2010;type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J Neurosci 20: 4050&#x2013;4058</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6772621</ArticleId><ArticleId IdType="pubmed">10818140</ArticleId></ArticleIdList></Reference><Reference><Citation>Chin J, Palop JJ, Puoliv&#xe4;li J, Massaro C, Bien&#x2010;Ly N, Gerstein H, Scearce&#x2010;Levie K, Masliah E, Mucke L (2005) Fyn kinase induces synaptic and cognitive impairments in a transgenic mouse model of Alzheimer's disease. J Neurosci 25: 9694&#x2013;9703</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725734</ArticleId><ArticleId IdType="pubmed">16237174</ArticleId></ArticleIdList></Reference><Reference><Citation>Chin J, Palop JJ, Yu G&#x2010;Q, Kojima N, Masliah E, Mucke L (2004) Fyn kinase modulates synaptotoxicity, but not aberrant sprouting, in human amyloid precursor protein transgenic mice. J Neurosci 24: 4692&#x2013;4697</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6729387</ArticleId><ArticleId IdType="pubmed">15140940</ArticleId></ArticleIdList></Reference><Reference><Citation>Labbe C, Ogaki K, Lorenzo&#x2010;Betancor O, Soto&#x2010;Ortolaza AI, Walton RL, Rayaprolu S, Fujioka S, Murray ME, Heckman MG, McCarthy A et al (2015) Role for the microtubule&#x2010;associated protein tau variant p.A152T in risk of alpha&#x2010;synucleinopathies. Neurology 85: 1680&#x2013;1686</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4653108</ArticleId><ArticleId IdType="pubmed">26333800</ArticleId></ArticleIdList></Reference><Reference><Citation>Desikan RS, Schork AJ, Wang Y, Witoelar A, Sharma M, McEvoy LK, Holland D, Brewer JB, Chen CH, Thompson WK et al (2015) Genetic overlap between Alzheimer's disease and Parkinson's disease at the MAPT locus. Mol Psychiatry 20: 1588&#x2013;1595</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4539304</ArticleId><ArticleId IdType="pubmed">25687773</ArticleId></ArticleIdList></Reference><Reference><Citation>Monti G, Meletti S (2015) Emotion recognition in temporal lobe epilepsy: a systematic review. Neurosci Biobehav Rev 55: 280&#x2013;293</Citation><ArticleIdList><ArticleId IdType="pubmed">25999121</ArticleId></ArticleIdList></Reference><Reference><Citation>Fong H, Wang C, Knoferle J, Walker D, Balestra ME, Tong LM, Leung L, Ring KL, Seeley WW, Karydas A et al (2013) Genetic correction of tauopathy phenotypes in neurons derived from human induced pluripotent stem cells. Stem Cell Rep 1: 226&#x2013;234</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3849235</ArticleId><ArticleId IdType="pubmed">24319659</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Martinez&#x2010;Vicente M, Kruger U, Kaushik S, Wong E, Mandelkow EM, Cuervo AM, Mandelkow E (2009) Tau fragmentation, aggregation and clearance: the dual role of lysosomal processing. Hum Mol Genet 18: 4153&#x2013;4170</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2758146</ArticleId><ArticleId IdType="pubmed">19654187</ArticleId></ArticleIdList></Reference><Reference><Citation>de Calignon A, Fox LM, Pitstick R, Carlson GA, Bacskai BJ, Spires&#x2010;Jones TL, Hyman BT (2010) Caspase activation precedes and leads to tangles. Nature 464: 1201&#x2013;1204</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3091360</ArticleId><ArticleId IdType="pubmed">20357768</ArticleId></ArticleIdList></Reference><Reference><Citation>LaPointe NE, Morfini G, Pigino G, Gaisina IN, Kozikowski AP, Binder LI, Brady ST (2009) The amino terminus of tau inhibits kinesin&#x2010;dependent axonal transport: implications for filament toxicity. J Neurosci Res 87: 440&#x2013;451</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2739042</ArticleId><ArticleId IdType="pubmed">18798283</ArticleId></ArticleIdList></Reference><Reference><Citation>Quintanilla RA, Matthews&#x2010;Roberson TA, Dolan PJ, Johnson GV (2009) Caspase&#x2010;cleaved tau expression induces mitochondrial dysfunction in immortalized cortical neurons: implications for the pathogenesis of Alzheimer disease. J Biol Chem 284: 18754&#x2013;18766</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2707209</ArticleId><ArticleId IdType="pubmed">19389700</ArticleId></ArticleIdList></Reference><Reference><Citation>Lang AE, Riherd Methner DN, Ferreira A (2014) Neuronal degeneration, synaptic defects, and behavioral abnormalities in tau45&#x2010;230 transgenic mice. Neuroscience 275: 322&#x2013;339</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4122686</ArticleId><ArticleId IdType="pubmed">24952329</ArticleId></ArticleIdList></Reference><Reference><Citation>Hochgrafe K, Sydow A, Mandelkow EM (2013) Regulatable transgenic mouse models of Alzheimer disease: onset, reversibility and spreading of Tau pathology. FEBS J 280: 4371&#x2013;4381</Citation><ArticleIdList><ArticleId IdType="pubmed">23517246</ArticleId></ArticleIdList></Reference><Reference><Citation>Devos SL, Goncharoff DK, Chen G, Kebodeaux CS, Yamada K, Stewart FR, Schuler DR, Maloney SE, Wozniak DF, Rigo F et al (2013) Antisense reduction of tau in adult mice protects against seizures. J Neurosci 33: 12887&#x2013;12897</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3728694</ArticleId><ArticleId IdType="pubmed">23904623</ArticleId></ArticleIdList></Reference><Reference><Citation>Spittaels K, Van den Haute C, Van Dorpe J, Bruynseels K, Vandezande K, Laenen I, Geerts H, Mercken M, Sciot R, Van Lommel A et al (1999) Prominent axonopathy in the brain and spinal cord of transgenic mice overexpressing four&#x2010;repeat human tau protein. Am J Pathol 155: 2153&#x2013;2165</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1866931</ArticleId><ArticleId IdType="pubmed">10595944</ArticleId></ArticleIdList></Reference><Reference><Citation>Probst A, G&#xf6;tz J, Wiederhold KH, Tolnay M, Mistl C, Jaton AL, Hong M, Ishihara T, Lee VMY, Trojanowski JQ et al (2000) Axonopathy and amyotrophy in mice transgenic for human four&#x2010;repeat tau protein. Acta Neuropathol (Berl) 99: 469&#x2013;481</Citation><ArticleIdList><ArticleId IdType="pubmed">10805089</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang B, Higuchi M, Yoshiyama Y, Ishihara T, Forman MS, Martinez D, Joyce S, Trojanowski JQ, Lee VM (2004) Retarded axonal transport of R406W mutant tau in transgenic mice with a neurodegenerative tauopathy. J Neurosci 24: 4657&#x2013;4667</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6729383</ArticleId><ArticleId IdType="pubmed">15140937</ArticleId></ArticleIdList></Reference><Reference><Citation>Kimura T, Yamashita S, Fukuda T, Park JM, Murayama M, Mizoroki T, Yoshiike Y, Sahara N, Takashima A (2007) Hyperphosphorylated tau in parahippocampal cortex impairs place learning in aged mice expressing wild&#x2010;type human tau. EMBO J 26: 5143&#x2013;5152</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2140104</ArticleId><ArticleId IdType="pubmed">18007595</ArticleId></ArticleIdList></Reference><Reference><Citation>G&#xf6;tz J, Probst A, Spillantini MG, Sch&#xe4;fer T, Jakes R, B&#xfc;rki K, Goedert M (1995) Somatodendritic localization and hyperphosphorylation of tau protein in transgenic mice expressing the longest human brain tau isoform. EMBO J 14: 1304&#x2013;1313</Citation><ArticleIdList><ArticleId IdType="pmc">PMC398215</ArticleId><ArticleId IdType="pubmed">7729409</ArticleId></ArticleIdList></Reference><Reference><Citation>Duff K, Knight H, Refolo LM, Sanders S, Yu X, Picciano M, Malester B, Hutton M, Adamson J, Goedert M et al (2000) Characterization of pathology in transgenic mice over&#x2010;expressing human genomic and cDNA tau transgenes. Neurobiol Dis 7: 87&#x2013;98</Citation><ArticleIdList><ArticleId IdType="pubmed">10783293</ArticleId></ArticleIdList></Reference><Reference><Citation>Decker JM, Kruger L, Sydow A, Dennissen F, Siskova Z, Mandelkow E, Mandelkow EM (2016) The Tau/A152T mutation, a risk factor for frontotemporal spectrum disorders, leads to NR2B receptor&#x2010;mediated excitotoxicity. EMBO Rep 17: 552&#x2013;569</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4818782</ArticleId><ArticleId IdType="pubmed">26931569</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee G, Newman ST, Gard DL, Band H, Panchamoorthy G (1998) Tau interacts with src&#x2010;family non&#x2010;receptor tyrosine kinases. J Cell Sci 111(Pt 21): 3167&#x2013;3177</Citation><ArticleIdList><ArticleId IdType="pubmed">9763511</ArticleId></ArticleIdList></Reference><Reference><Citation>Ittner LM, Ke YD, Delerue F, Bi M, Gladbach A, van Eersel J, Wolfing H, Chieng BC, Christie MJ, Napier IA et al (2010) Dendritic function of tau mediates amyloid&#x2010;beta toxicity in Alzheimer's disease mouse models. Cell 142: 387&#x2013;397</Citation><ArticleIdList><ArticleId IdType="pubmed">20655099</ArticleId></ArticleIdList></Reference><Reference><Citation>Patterson KR, Remmers C, Fu Y, Brooker S, Kanaan NM, Vana L, Ward S, Reyes JF, Philibert K, Glucksman MJ et al (2011) Characterization of prefibrillar Tau oligomers in vitro and in Alzheimer disease. J Biol Chem 286: 23063&#x2013;23076</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3123074</ArticleId><ArticleId IdType="pubmed">21550980</ArticleId></ArticleIdList></Reference><Reference><Citation>Van der Jeugd A, Hochgrafe K, Ahmed T, Decker JM, Sydow A, Hofmann A, Wu D, Messing L, Balschun D, D'Hooge R et al (2012) Cognitive defects are reversible in inducible mice expressing pro&#x2010;aggregant full&#x2010;length human Tau. Acta Neuropathol 123: 787&#x2013;805</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4979687</ArticleId><ArticleId IdType="pubmed">22532069</ArticleId></ArticleIdList></Reference><Reference><Citation>Chong SA, Benilova I, Shaban H, De Strooper B, Devijver H, Moechars D, Eberle W, Bartic C, Van Leuven F, Callewaert G (2011) Synaptic dysfunction in hippocampus of transgenic mouse models of Alzheimer's disease: a multi&#x2010;electrode array study. Neurobiol Dis 44: 284&#x2013;291</Citation><ArticleIdList><ArticleId IdType="pubmed">21807097</ArticleId></ArticleIdList></Reference><Reference><Citation>Levenga J, Krishnamurthy P, Rajamohamedsait H, Wong H, Franke TF, Cain P, Sigurdsson EM, Hoeffer CA (2013) Tau pathology induces loss of GABAergic interneurons leading to altered synaptic plasticity and behavioral impairments. Acta Neuropathol Commun 1: 34</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3893396</ArticleId><ArticleId IdType="pubmed">24252661</ArticleId></ArticleIdList></Reference><Reference><Citation>Decker JM, Kruger L, Sydow A, Zhao S, Frotscher M, Mandelkow E, Mandelkow EM (2015) Pro&#x2010;aggregant Tau impairs mossy fiber plasticity due to structural changes and Ca(++) dysregulation. Acta Neuropathol Commun 3: 23</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4384391</ArticleId><ArticleId IdType="pubmed">25853683</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar S, Tepper K, Kaniyappan S, Biernat J, Wegmann S, Mandelkow EM, Muller DJ, Mandelkow E (2014) Stages and conformations of the Tau repeat domain during aggregation and its effect on neuronal toxicity. J Biol Chem 289: 20318&#x2013;20332</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4106345</ArticleId><ArticleId IdType="pubmed">24825901</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberson ED, Scearce&#x2010;Levie K, Palop JJ, Yan F, Cheng IH, Wu T, Gerstein H, Yu G&#x2010;Q, Mucke L (2007) Reducing endogenous tau ameliorates amyloid &#x3b2;&#x2010;induced deficits in an Alzheimer's disease mouse model. Science 316: 750&#x2013;754</Citation><ArticleIdList><ArticleId IdType="pubmed">17478722</ArticleId></ArticleIdList></Reference><Reference><Citation>Holth JK, Bomben VC, Reed JG, Inoue T, Younkin L, Younkin SG, Pautler RG, Botas J, Noebels JL (2013) Tau loss attenuates neuronal network hyperexcitability in mouse and Drosophila genetic models of epilepsy. J Neurosci 33: 1651&#x2013;1659</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3711605</ArticleId><ArticleId IdType="pubmed">23345237</ArticleId></ArticleIdList></Reference><Reference><Citation>Gheyara AL, Ponnusamy R, Djukic B, Craft RJ, Ho K, Guo W, Finucane MM, Sanchez PE, Mucke L (2014) Tau reduction prevents disease in a mouse model of Dravet syndrome. Ann Neurol 76: 443&#x2013;456</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4338764</ArticleId><ArticleId IdType="pubmed">25042160</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia&#x2010;Cabrero AM, Guerrero&#x2010;Lopez R, Giraldez BG, Llorens&#x2010;Martin M, Avila J, Serratosa JM, Sanchez MP (2013) Hyperexcitability and epileptic seizures in a model of frontotemporal dementia. Neurobiol Dis 58: 200&#x2013;208</Citation><ArticleIdList><ArticleId IdType="pubmed">23774255</ArticleId></ArticleIdList></Reference><Reference><Citation>Qizilbash N, Gregson J, Johnson ME, Pearce N, Douglas I, Wing K, Evans SJ, Pocock SJ (2015) BMI and risk of dementia in two million people over two decades: a retrospective cohort study. Lancet Diabetes Endocrinol 3: 431&#x2013;436</Citation><ArticleIdList><ArticleId IdType="pubmed">25866264</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris M, Hamto P, Adame A, Devidze N, Masliah E, Mucke L (2013) Age&#x2010;appropriate cognition and subtle dopamine&#x2010;independent motor deficits in aged tau knockout mice. Neurobiol Aging 34: 1523&#x2013;1529</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3596503</ArticleId><ArticleId IdType="pubmed">23332171</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewis J, Dickson DW, Lin WL, Chisholm L, Corral A, Jones G, Yen SH, Sahara N, Skipper L, Yager D et al (2001) Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science 293: 1487&#x2013;1491</Citation><ArticleIdList><ArticleId IdType="pubmed">11520987</ArticleId></ArticleIdList></Reference><Reference><Citation>Oddo S, Caccamo A, Shepherd JD, Murphy MP, Golde TE, Kayed R, Metherate R, Mattson MP, Akbari Y, LaFerla FM (2003) Triple&#x2010;transgenic model of Alzheimer's disease with plaques and tangles: intracellular Ab and synaptic dysfunction. Neuron 39: 409&#x2013;421</Citation><ArticleIdList><ArticleId IdType="pubmed">12895417</ArticleId></ArticleIdList></Reference><Reference><Citation>Grueninger F, Bohrmann B, Czech C, Ballard TM, Frey JR, Weidensteiner C, von Kienlin M, Ozmen L (2010) Phosphorylation of Tau at S422 is enhanced by Abeta in TauPS2APP triple transgenic mice. Neurobiol Dis 37: 294&#x2013;306</Citation><ArticleIdList><ArticleId IdType="pubmed">19781645</ArticleId></ArticleIdList></Reference><Reference><Citation>Platt B, Drever B, Koss D, Stoppelkamp S, Jyoti A, Plano A, Utan A, Merrick G, Ryan D, Melis V et al (2011) Abnormal cognition, sleep, EEG and brain metabolism in a novel knock&#x2010;in Alzheimer mouse, PLB1. PLoS One 6: e27068</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3214038</ArticleId><ArticleId IdType="pubmed">22096518</ArticleId></ArticleIdList></Reference><Reference><Citation>Seino Y, Kawarabayashi T, Wakasaya Y, Watanabe M, Takamura A, Yamamoto&#x2010;Watanabe Y, Kurata T, Abe K, Ikeda M, Westaway D et al (2010) Amyloid beta accelerates phosphorylation of tau and neurofibrillary tangle formation in an amyloid precursor protein and tau double&#x2010;transgenic mouse model. J Neurosci Res 88: 3547&#x2013;3554</Citation><ArticleIdList><ArticleId IdType="pubmed">20936700</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshiyama Y, Higuchi M, Zhang B, Huang SM, Iwata N, Saido TC, Maeda J, Suhara T, Trojanowski JQ, Lee VM (2007) Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron 53: 337&#x2013;351</Citation><ArticleIdList><ArticleId IdType="pubmed">17270732</ArticleId></ArticleIdList></Reference><Reference><Citation>Overk CR, Cartier A, Shaked G, Rockenstein E, Ubhi K, Spencer B, Price DL, Patrick C, Desplats P, Masliah E (2014) Hippocampal neuronal cells that accumulate alpha&#x2010;synuclein fragments are more vulnerable to Abeta oligomer toxicity via mGluR5&#x2013;implications for dementia with Lewy bodies. Mol Neurodegener 9: 18</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4041038</ArticleId><ArticleId IdType="pubmed">24885390</ArticleId></ArticleIdList></Reference><Reference><Citation>Gallyas F (1971) Silver staining of Alzheimer's neurofibrillary changes by means of physical development. Acta Morphol Acad Sci Hung 19: 1&#x2013;8</Citation><ArticleIdList><ArticleId IdType="pubmed">4107507</ArticleId></ArticleIdList></Reference><Reference><Citation>Ting JT, Daigle TL, Chen Q, Feng G (2014) Acute brain slice methods for adult and aging animals: application of targeted patch clamp analysis and optogenetics. Methods Mol Biol 1183: 221&#x2013;242</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4219416</ArticleId><ArticleId IdType="pubmed">25023312</ArticleId></ArticleIdList></Reference><Reference><Citation>Castillo PE, Weisskopf MG, Nicoll RA (1994) The role of Ca2 + channels in hippocampal mossy fiber synaptic transmission and long&#x2010;term potentiation. Neuron 12: 261&#x2013;269</Citation><ArticleIdList><ArticleId IdType="pubmed">8110457</ArticleId></ArticleIdList></Reference><Reference><Citation>Calixto E, Thiels E, Klann E, Barrionuevo G (2003) Early maintenance of hippocampal mossy fiber&#x2013;long&#x2010;term potentiation depends on protein and RNA synthesis and presynaptic granule cell integrity. J Neurosci 23: 4842&#x2013;4849</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6741163</ArticleId><ArticleId IdType="pubmed">12832506</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">26931569</PMID><DateCompleted><Year>2017</Year><Month>09</Month><Day>07</Day></DateCompleted><DateRevised><Year>2021</Year><Month>01</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1469-3178</ISSN><JournalIssue CitedMedium="Internet"><Volume>17</Volume><Issue>4</Issue><PubDate><Year>2016</Year><Month>Apr</Month></PubDate></JournalIssue><Title>EMBO reports</Title><ISOAbbreviation>EMBO Rep</ISOAbbreviation></Journal><ArticleTitle>The Tau/A152T mutation, a risk factor for frontotemporal-spectrum disorders, leads to NR2B receptor-mediated excitotoxicity.</ArticleTitle><Pagination><StartPage>552</StartPage><EndPage>569</EndPage><MedlinePgn>552-69</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.15252/embr.201541439</ELocationID><Abstract><AbstractText>We report on a novel transgenic mouse model expressing human full-length Tau with the Tau mutation A152T (hTau(AT)), a risk factor for FTD-spectrum disorders including PSP and CBD Brain neurons reveal pathological Tau conformation, hyperphosphorylation, mis-sorting, aggregation, neuronal degeneration, and progressive loss, most prominently in area CA3 of the hippocampus. The mossy fiber pathway shows enhanced basal synaptic transmission without changes in short- or long-term plasticity. In organotypic hippocampal slices, extracellular glutamate increases early above control levels, followed by a rise in neurotoxicity. These changes are normalized by inhibiting neurotransmitter release or by blocking voltage-gated sodium channels. CA3 neurons show elevated intracellular calcium during rest and after activity induction which is sensitive to NR2B antagonizing drugs, demonstrating a pivotal role of extrasynaptic NMDA receptors. Slices show pronounced epileptiform activity and axonal sprouting of mossy fibers. Excitotoxic neuronal death is ameliorated by ceftriaxone, which stimulates astrocytic glutamate uptake via the transporter EAAT2/GLT1. In summary, hTau(AT) causes excitotoxicity mediated by NR2B-containing NMDA receptors due to enhanced extracellular glutamate.</AbstractText><CopyrightInformation>&#xa9; 2016 The Authors.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Decker</LastName><ForeName>Jochen Martin</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kr&#xfc;ger</LastName><ForeName>Lars</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sydow</LastName><ForeName>Astrid</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany Max-Planck-Institute for Metabolism Research (Cologne), Hamburg Outstation, Hamburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dennissen</LastName><ForeName>Frank Ja</ForeName><Initials>FJ</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Siskova</LastName><ForeName>Zuzana</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mandelkow</LastName><ForeName>Eckhard</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany Max-Planck-Institute for Metabolism Research (Cologne), Hamburg Outstation, Hamburg, Germany Caesar Research Center, Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mandelkow</LastName><ForeName>Eva-Maria</ForeName><Initials>EM</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany Max-Planck-Institute for Metabolism Research (Cologne), Hamburg Outstation, Hamburg, Germany Caesar Research Center, Bonn, Germany eva.mandelkow@dzne.de.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>03</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>EMBO Rep</MedlineTA><NlmUniqueID>100963049</NlmUniqueID><ISSNLinking>1469-221X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D003470">Culture Media</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C121001">NR2B NMDA receptor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016194">Receptors, N-Methyl-D-Aspartate</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>3KX376GY7L</RegistryNumber><NameOfSubstance UI="D018698">Glutamic Acid</NameOfSubstance></Chemical><Chemical><RegistryNumber>SY7Q814VUP</RegistryNumber><NameOfSubstance UI="D002118">Calcium</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D056654" MajorTopicYN="N">CA3 Region, Hippocampal</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002118" MajorTopicYN="N">Calcium</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003470" MajorTopicYN="N">Culture Media</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057180" MajorTopicYN="N">Frontotemporal Dementia</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018698" MajorTopicYN="N">Glutamic Acid</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009473" MajorTopicYN="N">Neuronal Plasticity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009924" MajorTopicYN="N">Organ Culture Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016194" MajorTopicYN="N">Receptors, N-Methyl-D-Aspartate</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009435" MajorTopicYN="N">Synaptic Transmission</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">CA3</Keyword><Keyword MajorTopicYN="N">NR2B</Keyword><Keyword MajorTopicYN="N">Tau</Keyword><Keyword MajorTopicYN="N">excitotoxicity</Keyword><Keyword MajorTopicYN="N">frontotemporal&#x2010;spectrum disorders</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>9</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>1</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>3</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>3</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>9</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2017</Year><Month>4</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26931569</ArticleId><ArticleId IdType="pmc">PMC4818782</ArticleId><ArticleId IdType="doi">10.15252/embr.201541439</ArticleId><ArticleId IdType="pii">embr.201541439</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Goedert M, Crowther RA, Spillantini MG (1998) Tau mutations cause frontotemporal dementias. Neuron 21: 955&#x2013;958</Citation><ArticleIdList><ArticleId IdType="pubmed">9856453</ArticleId></ArticleIdList></Reference><Reference><Citation>Barghorn S, Zheng&#x2010;Fischhofer Q, Ackmann M, Biernat J, von Bergen M, Mandelkow EM, Mandelkow E (2000) Structure, microtubule interactions, and paired helical filament aggregation by tau mutants of frontotemporal dementias. Biochemistry 39: 11714&#x2013;11721</Citation><ArticleIdList><ArticleId IdType="pubmed">10995239</ArticleId></ArticleIdList></Reference><Reference><Citation>
Hong M, Zhukareva V, Vogelsberg&#x2010;Ragaglia V, Wszolek Z, Reed L, Miller BI, Geschwind DH, Bird TD, McKeel D, Goate A
<i>et al</i> (1998) Mutation&#x2010;specific functional impairments in distinct tau isoforms of hereditary FTDP&#x2010;17. Science
282: 1914&#x2013;1917
</Citation><ArticleIdList><ArticleId IdType="pubmed">9836646</ArticleId></ArticleIdList></Reference><Reference><Citation>Kovacs GG, Molnar K, Laszlo L, Strobel T, Botond G, Honigschnabl S, Reiner&#x2010;Concin A, Palkovits M, Fischer P, Budka H (2011) A peculiar constellation of tau pathology defines a subset of dementia in the elderly. Acta Neuropathol 122: 205&#x2013;222</Citation><ArticleIdList><ArticleId IdType="pubmed">21437732</ArticleId></ArticleIdList></Reference><Reference><Citation>
Kara E, Ling H, Pittman AM, Shaw K, deSilva
R
, Simone R, Holton JL, Warren JD, Rohrer JD, Xiromerisiou G
<i>et al</i> (2012) The MAPT p.A152T variant is a risk factor associated with tauopathies with atypical clinical and neuropathological features. Neurobiol Aging
33: 2231 e7&#x2013;2231 e14
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3657164</ArticleId><ArticleId IdType="pubmed">22595371</ArticleId></ArticleIdList></Reference><Reference><Citation>
Lee SE, Tartaglia MC, Yener G, Genc S, Seeley WW, Sanchez&#x2010;Juan P, Moreno F, Mendez MF, Klein E, Rademakers R
<i>et al</i> (2013) Neurodegenerative disease phenotypes in carriers of MAPT p. A152T, a risk factor for frontotemporal dementia spectrum disorders and Alzheimer disease. Alzheimer Dis Assoc Disord
27: 302&#x2013;309
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3796183</ArticleId><ArticleId IdType="pubmed">23518664</ArticleId></ArticleIdList></Reference><Reference><Citation>
Coppola G, Chinnathambi S, Lee JJ, Dombroski BA, Baker MC, Soto&#x2010;Ortolaza AI, Lee SE, Klein E, Huang AY, Sears R
<i>et al</i> (2012) Evidence for a role of the rare p. A152T variant in MAPT in increasing the risk for FTD&#x2010;spectrum and Alzheimer's diseases. Hum Mol Genet
21: 3500&#x2013;3512
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3392107</ArticleId><ArticleId IdType="pubmed">22556362</ArticleId></ArticleIdList></Reference><Reference><Citation>Binder LI, Frankfurter A, Rebhun LI (1985) The distribution of tau in the mammalian central nervous system. J Cell Biol 101: 1371&#x2013;1378</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2113928</ArticleId><ArticleId IdType="pubmed">3930508</ArticleId></ArticleIdList></Reference><Reference><Citation>Brion JP, Guilleminot J, Couchie D, Flament&#x2010;Durand J, Nunez J (1988) Both adult and juvenile tau microtubule&#x2010;associated proteins are axon specific in the developing and adult rat cerebellum. Neuroscience 25: 139&#x2013;146</Citation><ArticleIdList><ArticleId IdType="pubmed">3134623</ArticleId></ArticleIdList></Reference><Reference><Citation>Gotz J, Ittner LM, Kins S (2006) Do axonal defects in tau and amyloid precursor protein transgenic animals model axonopathy in Alzheimer's disease? J Neurochem 98: 993&#x2013;1006</Citation><ArticleIdList><ArticleId IdType="pubmed">16787410</ArticleId></ArticleIdList></Reference><Reference><Citation>Thies E, Mandelkow EM (2007) Missorting of tau in neurons causes degeneration of synapses that can be rescued by the kinase MARK2/Par&#x2010;1. J Neurosci 27: 2896&#x2013;2907</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672561</ArticleId><ArticleId IdType="pubmed">17360912</ArticleId></ArticleIdList></Reference><Reference><Citation>
Hoover BR, Reed MN, Su J, Penrod RD, Kotilinek LA, Grant MK, Pitstick R, Carlson GA, Lanier LM, Yuan LL
<i>et al</i> (2010) Tau mislocalization to dendritic spines mediates synaptic dysfunction independently of neurodegeneration. Neuron
68: 1067&#x2013;1081
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3026458</ArticleId><ArticleId IdType="pubmed">21172610</ArticleId></ArticleIdList></Reference><Reference><Citation>
Ittner LM, Ke YD, Delerue F, Bi M, Gladbach A, van Eersel J, Wolfing H, Chieng BC, Christie MJ, Napier IA
<i>et al</i> (2010) Dendritic function of tau mediates amyloid&#x2010;beta toxicity in Alzheimer's disease mouse models. Cell
142: 387&#x2013;397
</Citation><ArticleIdList><ArticleId IdType="pubmed">20655099</ArticleId></ArticleIdList></Reference><Reference><Citation>
Polydoro M, Dzhala VI, Pooler AM, Nicholls SB, McKinney AP, Sanchez L, Pitstick R, Carlson GA, Staley KJ, Spires&#x2010;Jones TL
<i>et al</i> (2014) Soluble pathological tau in the entorhinal cortex leads to presynaptic deficits in an early Alzheimer's disease model. Acta Neuropathol
127: 257&#x2013;270
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3946978</ArticleId><ArticleId IdType="pubmed">24271788</ArticleId></ArticleIdList></Reference><Reference><Citation>
Decker JM, Kruger L, Sydow A, Zhao S, Frotscher M, Mandelkow E, Mandelkow EM (2015) Pro&#x2010;aggregant Tau impairs mossy fiber plasticity due to structural changes and Ca<sup>2+</sup> dysregulation. Acta Neuropathol Commun
3: 23
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4384391</ArticleId><ArticleId IdType="pubmed">25853683</ArticleId></ArticleIdList></Reference><Reference><Citation>Messing L, Decker JM, Joseph M, Mandelkow E, Mandelkow EM (2013) Cascade of tau toxicity in inducible hippocampal brain slices and prevention by aggregation inhibitors. Neurobiol Aging 34: 1343&#x2013;1354</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4984976</ArticleId><ArticleId IdType="pubmed">23158765</ArticleId></ArticleIdList></Reference><Reference><Citation>Zempel H, Thies E, Mandelkow E, Mandelkow EM (2010) Abeta oligomers cause localized Ca(2+) elevation, missorting of endogenous Tau into dendrites, Tau phosphorylation, and destruction of microtubules and spines. J Neurosci 30: 11938&#x2013;11950</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6633549</ArticleId><ArticleId IdType="pubmed">20826658</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris M, Maeda S, Vossel K, Mucke L (2011) The many faces of tau. Neuron 70: 410&#x2013;426</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3319390</ArticleId><ArticleId IdType="pubmed">21555069</ArticleId></ArticleIdList></Reference><Reference><Citation>Vossel KA, Xu JC, Fomenko V, Miyamoto T, Suberbielle E, Knox JA, Ho K, Kim DH, Yu GQ, Mucke L (2015) Tau reduction prevents Abeta&#x2010;induced axonal transport deficits by blocking activation of GSK3beta. J Cell Biol 209: 419&#x2013;433</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4427789</ArticleId><ArticleId IdType="pubmed">25963821</ArticleId></ArticleIdList></Reference><Reference><Citation>
Roberson ED, Halabisky B, Yoo JW, Yao J, Chin J, Yan F, Wu T, Hamto P, Devidze N, Yu GQ
<i>et al</i> (2011) Amyloid&#x2010;beta/Fyn&#x2010;induced synaptic, network, and cognitive impairments depend on tau levels in multiple mouse models of Alzheimer's disease. J Neurosci
31: 700&#x2013;711
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3325794</ArticleId><ArticleId IdType="pubmed">21228179</ArticleId></ArticleIdList></Reference><Reference><Citation>
Holth JK, Bomben VC, Reed JG, Inoue T, Younkin L, Younkin SG, Pautler RG, Botas J, Noebels JL (2013) Tau loss attenuates neuronal network hyperexcitability in mouse and <i>Drosophila</i> genetic models of epilepsy. J Neurosci
33: 1651&#x2013;1659
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3711605</ArticleId><ArticleId IdType="pubmed">23345237</ArticleId></ArticleIdList></Reference><Reference><Citation>Hauw JJ, Daniel SE, Dickson D, Horoupian DS, Jellinger K, Lantos PL, McKee A, Tabaton M, Litvan I (1994) Preliminary NINDS neuropathologic criteria for Steele&#x2010;Richardson&#x2010;Olszewski syndrome (progressive supranuclear palsy). Neurology 44: 2015&#x2013;2019</Citation><ArticleIdList><ArticleId IdType="pubmed">7969952</ArticleId></ArticleIdList></Reference><Reference><Citation>Amadoro G, Ciotti MT, Costanzi M, Cestari V, Calissano P, Canu N (2006) NMDA receptor mediates tau&#x2010;induced neurotoxicity by calpain and ERK/MAPK activation. Proc Natl Acad Sci USA 103: 2892&#x2013;2897</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1413822</ArticleId><ArticleId IdType="pubmed">16477009</ArticleId></ArticleIdList></Reference><Reference><Citation>Nilsen LH, Rae C, Ittner LM, Gotz J, Sonnewald U (2013) Glutamate metabolism is impaired in transgenic mice with tau hyperphosphorylation. J Cereb Blood Flow Metab 33: 684&#x2013;691</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3652703</ArticleId><ArticleId IdType="pubmed">23340677</ArticleId></ArticleIdList></Reference><Reference><Citation>Hunsberger HC, Rudy CC, Batten SR, Gerhardt GA, Reed MN (2015) P301L tau expression affects glutamate release and clearance in the hippocampal trisynaptic pathway. J Neurochem 132: 169&#x2013;182</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4302046</ArticleId><ArticleId IdType="pubmed">25319522</ArticleId></ArticleIdList></Reference><Reference><Citation>Nygaard TG, Duvoisin RC, Manocha M, Chokroverty S (1989) Seizures in progressive supranuclear palsy. Neurology 39: 138&#x2013;140</Citation><ArticleIdList><ArticleId IdType="pubmed">2909902</ArticleId></ArticleIdList></Reference><Reference><Citation>
Maeda S, Djukic B, Taneja P, Yu G, Lo I, Davis A, Craft R, Guo W, Wang X, Kim D
<i>et al</i> (2016) Expression of A152T human tau causes age&#x2010;dependent neuronal dysfunction and loss in transgenic mice. EMBO Rep
17: 530&#x2013;551
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4818780</ArticleId><ArticleId IdType="pubmed">26931567</ArticleId></ArticleIdList></Reference><Reference><Citation>Bouabe H, Okkenhaug K (2013) A protocol for construction of gene targeting vectors and generation of homologous recombinant embryonic stem cells. Methods Mol Biol 1064: 337&#x2013;354</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4526796</ArticleId><ArticleId IdType="pubmed">23996269</ArticleId></ArticleIdList></Reference><Reference><Citation>
Mocanu MM, Nissen A, Eckermann K, Khlistunova I, Biernat J, Drexler D, Petrova O, Schonig K, Bujard H, Mandelkow E
<i>et al</i> (2008) The potential for beta&#x2010;structure in the repeat domain of tau protein determines aggregation, synaptic decay, neuronal loss, and coassembly with endogenous Tau in inducible mouse models of tauopathy. J Neurosci
28: 737&#x2013;748
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6670355</ArticleId><ArticleId IdType="pubmed">18199773</ArticleId></ArticleIdList></Reference><Reference><Citation>
Siskova Z, Justus D, Kaneko H, Friedrichs D, Henneberg N, Beutel T, Pitsch J, Schoch S, Becker A, von der Kammer H
<i>et al</i> (2014) Dendritic structural degeneration is functionally linked to cellular hyperexcitability in a mouse model of Alzheimer's disease. Neuron
84: 1023&#x2013;1033
</Citation><ArticleIdList><ArticleId IdType="pubmed">25456500</ArticleId></ArticleIdList></Reference><Reference><Citation>Foster KA, McLaughlin N, Edbauer D, Phillips M, Bolton A, Constantine&#x2010;Paton M, Sheng M (2010) Distinct roles of NR2A and NR2B cytoplasmic tails in long&#x2010;term potentiation. J Neurosci 30: 2676&#x2013;2685</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2840640</ArticleId><ArticleId IdType="pubmed">20164351</ArticleId></ArticleIdList></Reference><Reference><Citation>Barria A, Malinow R (2002) Subunit&#x2010;specific NMDA receptor trafficking to synapses. Neuron 35: 345&#x2013;353</Citation><ArticleIdList><ArticleId IdType="pubmed">12160751</ArticleId></ArticleIdList></Reference><Reference><Citation>Barria A, Malinow R (2005) NMDA receptor subunit composition controls synaptic plasticity by regulating binding to CaMKII. Neuron 48: 289&#x2013;301</Citation><ArticleIdList><ArticleId IdType="pubmed">16242409</ArticleId></ArticleIdList></Reference><Reference><Citation>Korinek M, Kapras V, Vyklicky V, Adamusova E, Borovska J, Vales K, Stuchlik A, Horak M, Chodounska H, Vyklicky L Jr (2011) Neurosteroid modulation of N&#x2010;methyl&#x2010;D&#x2010;aspartate receptors: molecular mechanism and behavioral effects. Steroids 76: 1409&#x2013;1418</Citation><ArticleIdList><ArticleId IdType="pubmed">21925193</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia P, Chen HS, Zhang D, Lipton SA (2010) Memantine preferentially blocks extrasynaptic over synaptic NMDA receptor currents in hippocampal autapses. J Neurosci 30: 11246&#x2013;11250</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2932667</ArticleId><ArticleId IdType="pubmed">20720132</ArticleId></ArticleIdList></Reference><Reference><Citation>Cull&#x2010;Candy SG, Leszkiewicz DN (2004) Role of distinct NMDA receptor subtypes at central synapses. Sci STKE 2004: re16</Citation><ArticleIdList><ArticleId IdType="pubmed">15494561</ArticleId></ArticleIdList></Reference><Reference><Citation>Cull&#x2010;Candy S, Brickley S, Farrant M (2001) NMDA receptor subunits: diversity, development and disease. Curr Opin Neurobiol 11: 327&#x2013;335</Citation><ArticleIdList><ArticleId IdType="pubmed">11399431</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardingham GE, Bading H (2010) Synaptic versus extrasynaptic NMDA receptor signalling: implications for neurodegenerative disorders. Nat Rev Neurosci 11: 682&#x2013;696</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2948541</ArticleId><ArticleId IdType="pubmed">20842175</ArticleId></ArticleIdList></Reference><Reference><Citation>Paoletti P, Bellone C, Zhou Q (2013) NMDA receptor subunit diversity: impact on receptor properties, synaptic plasticity and disease. Nat Rev Neurosci 14: 383&#x2013;400</Citation><ArticleIdList><ArticleId IdType="pubmed">23686171</ArticleId></ArticleIdList></Reference><Reference><Citation>Parsons MP, Raymond LA (2014) Extrasynaptic NMDA receptor involvement in central nervous system disorders. Neuron 82: 279&#x2013;293</Citation><ArticleIdList><ArticleId IdType="pubmed">24742457</ArticleId></ArticleIdList></Reference><Reference><Citation>
Talantova M, Sanz&#x2010;Blasco S, Zhang X, Xia P, Akhtar MW, Okamoto S, Dziewczapolski G, Nakamura T, Cao G, Pratt AE
<i>et al</i> (2013) Abeta induces astrocytic glutamate release, extrasynaptic NMDA receptor activation, and synaptic loss. Proc Natl Acad Sci USA
110: E2518&#x2013;E2527
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3704025</ArticleId><ArticleId IdType="pubmed">23776240</ArticleId></ArticleIdList></Reference><Reference><Citation>Hara MR, Snyder SH (2007) Cell signaling and neuronal death. Annu Rev Pharmacol Toxicol 47: 117&#x2013;141</Citation><ArticleIdList><ArticleId IdType="pubmed">16879082</ArticleId></ArticleIdList></Reference><Reference><Citation>
Mantamadiotis T, Lemberger T, Bleckmann SC, Kern H, Kretz O, Martin Villalba A, Tronche F, Kellendonk C, Gau D, Kapfhammer J
<i>et al</i> (2002) Disruption of CREB function in brain leads to neurodegeneration. Nat Genet
31: 47&#x2013;54
</Citation><ArticleIdList><ArticleId IdType="pubmed">11967539</ArticleId></ArticleIdList></Reference><Reference><Citation>Barco A, Bailey CH, Kandel ER (2006) Common molecular mechanisms in explicit and implicit memory. J Neurochem 97: 1520&#x2013;1533</Citation><ArticleIdList><ArticleId IdType="pubmed">16805766</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuste R, Bonhoeffer T (2001) Morphological changes in dendritic spines associated with long&#x2010;term synaptic plasticity. Annu Rev Neurosci 24: 1071&#x2013;1089</Citation><ArticleIdList><ArticleId IdType="pubmed">11520928</ArticleId></ArticleIdList></Reference><Reference><Citation>Nabavi S, Fox R, Proulx CD, Lin JY, Tsien RY, Malinow R (2014) Engineering a memory with LTD and LTP. Nature 511: 348&#x2013;352</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4210354</ArticleId><ArticleId IdType="pubmed">24896183</ArticleId></ArticleIdList></Reference><Reference><Citation>
Rothstein JD, Patel S, Regan MR, Haenggeli C, Huang YH, Bergles DE, Jin L, Dykes Hoberg M, Vidensky S, Chung DS
<i>et al</i> (2005) Beta&#x2010;lactam antibiotics offer neuroprotection by increasing glutamate transporter expression. Nature
433: 73&#x2013;77
</Citation><ArticleIdList><ArticleId IdType="pubmed">15635412</ArticleId></ArticleIdList></Reference><Reference><Citation>Morgan JI, Cohen DR, Hempstead JL, Curran T (1987) Mapping patterns of c&#x2010;fos expression in the central nervous system after seizure. Science 237: 192&#x2013;197</Citation><ArticleIdList><ArticleId IdType="pubmed">3037702</ArticleId></ArticleIdList></Reference><Reference><Citation>Ronesi JA, Collins KA, Hays SA, Tsai NP, Guo W, Birnbaum SG, Hu JH, Worley PF, Gibson JR, Huber KM (2012) Disrupted Homer scaffolds mediate abnormal mGluR5 function in a mouse model of fragile X syndrome. Nat Neurosci 15: 431&#x2013;440, S1</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3288402</ArticleId><ArticleId IdType="pubmed">22267161</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang AH, Alger BE (2015) Homer protein&#x2010;metabotropic glutamate receptor binding regulates endocannabinoid signaling and affects hyperexcitability in a mouse model of fragile X syndrome. J Neurosci 35: 3938&#x2013;3945</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4348189</ArticleId><ArticleId IdType="pubmed">25740522</ArticleId></ArticleIdList></Reference><Reference><Citation>Danbolt NC (2001) Glutamate uptake. Prog Neurobiol 65: 1&#x2013;105</Citation><ArticleIdList><ArticleId IdType="pubmed">11369436</ArticleId></ArticleIdList></Reference><Reference><Citation>Moddel G, Jacobson B, Ying Z, Janigro D, Bingaman W, Gonzalez&#x2010;Martinez J, Kellinghaus C, Prayson RA, Najm IM (2005) The NMDA receptor NR2B subunit contributes to epileptogenesis in human cortical dysplasia. Brain Res 1046: 10&#x2013;23</Citation><ArticleIdList><ArticleId IdType="pubmed">15890316</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Z, Hall AM, Kelinske M, Roberson ED (2014) Seizure resistance without parkinsonism in aged mice after tau reduction. Neurobiol Aging 35: 2617&#x2013;2624</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4171213</ArticleId><ArticleId IdType="pubmed">24908165</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu CS, Liu AC, Chen J, Pan ZY, Wan Q, Li ZQ, Wang ZF (2015) Overactivation of NR2B&#x2010;containing NMDA receptors through entorhinal&#x2010;hippocampal connection initiates accumulation of hyperphosphorylated tau in rat hippocampus after transient middle cerebral artery occlusion (MCAO). J Neurochem 134: 566&#x2013;577</Citation><ArticleIdList><ArticleId IdType="pubmed">25903928</ArticleId></ArticleIdList></Reference><Reference><Citation>
Van der Jeugd A, Hochgrafe K, Ahmed T, Decker JM, Sydow A, Hofmann A, Wu D, Messing L, Balschun D, D'Hooge R
<i>et al</i> (2012) Cognitive defects are reversible in inducible mice expressing pro&#x2010;aggregant full&#x2010;length human Tau. Acta Neuropathol
123: 787&#x2013;805
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4979687</ArticleId><ArticleId IdType="pubmed">22532069</ArticleId></ArticleIdList></Reference><Reference><Citation>
Sydow A, Van der Jeugd A, Zheng F, Ahmed T, Balschun D, Petrova O, Drexler D, Zhou L, Rune G, Mandelkow E
<i>et al</i> (2011) Tau&#x2010;induced defects in synaptic plasticity, learning, and memory are reversible in transgenic mice after switching off the toxic Tau mutant. J Neurosci
31: 2511&#x2013;2525
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6623704</ArticleId><ArticleId IdType="pubmed">21325519</ArticleId></ArticleIdList></Reference><Reference><Citation>
Furukawa K, Wang Y, Yao PJ, Fu W, Mattson MP, Itoyama Y, Onodera H, D'Souza I, Poorkaj PH, Bird TD
<i>et al</i> (2003) Alteration in calcium channel properties is responsible for the neurotoxic action of a familial frontotemporal dementia tau mutation. J Neurochem
87: 427&#x2013;436
</Citation><ArticleIdList><ArticleId IdType="pubmed">14511120</ArticleId></ArticleIdList></Reference><Reference><Citation>
Vossel KA, Beagle AJ, Rabinovici GD, Shu H, Lee SE, Naasan G, Hegde M, Cornes SB, Henry ML, Nelson AB
<i>et al</i> (2013) Seizures and epileptiform activity in the early stages of Alzheimer disease. JAMA Neurol
70: 1158&#x2013;1166
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4013391</ArticleId><ArticleId IdType="pubmed">23835471</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruan YW, Lei Z, Fan Y, Zou B, Xu ZC (2009) Diversity and fluctuation of spine morphology in CA1 pyramidal neurons after transient global ischemia. J Neurosci Res 87: 61&#x2013;68</Citation><ArticleIdList><ArticleId IdType="pubmed">18709659</ArticleId></ArticleIdList></Reference><Reference><Citation>
Bano D, Young KW, Guerin CJ, Lefeuvre R, Rothwell NJ, Naldini L, Rizzuto R, Carafoli E, Nicotera P (2005) Cleavage of the plasma membrane Na<sup>+</sup>/Ca<sup>2+</sup> exchanger in excitotoxicity. Cell
120: 275&#x2013;285
</Citation><ArticleIdList><ArticleId IdType="pubmed">15680332</ArticleId></ArticleIdList></Reference><Reference><Citation>
Fong H, Wang C, Knoferle J, Walker D, Balestra ME, Tong LM, Leung L, Ring KL, Seeley WW, Karydas A
<i>et al</i> (2013) Genetic correction of tauopathy phenotypes in neurons derived from human induced pluripotent stem cells. Stem Cell Reports
1: 226&#x2013;234
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3849235</ArticleId><ArticleId IdType="pubmed">24319659</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberson ED, Scearce&#x2010;Levie K, Palop JJ, Yan F, Cheng IH, Wu T, Gerstein H, Yu GQ, Mucke L (2007) Reducing endogenous tau ameliorates amyloid beta&#x2010;induced deficits in an Alzheimer's disease mouse model. Science 316: 750&#x2013;754</Citation><ArticleIdList><ArticleId IdType="pubmed">17478722</ArticleId></ArticleIdList></Reference><Reference><Citation>Masliah E, Alford M, Mallory M, Rockenstein E, Moechars D, Van Leuven F (2000) Abnormal glutamate transport function in mutant amyloid precursor protein transgenic mice. Exp Neurol 163: 381&#x2013;387</Citation><ArticleIdList><ArticleId IdType="pubmed">10833311</ArticleId></ArticleIdList></Reference><Reference><Citation>Rothstein JD, Van Kammen M, Levey AI, Martin LJ, Kuncl RW (1995) Selective loss of glial glutamate transporter GLT&#x2010;1 in amyotrophic lateral sclerosis. Ann Neurol 38: 73&#x2013;84</Citation><ArticleIdList><ArticleId IdType="pubmed">7611729</ArticleId></ArticleIdList></Reference><Reference><Citation>Untergasser A, Nijveen H, Rao X, Bisseling T, Geurts R, Leunissen JA (2007) Primer3Plus, an enhanced web interface to Primer3. Nucleic Acids Res 35: W71&#x2013;W74</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1933133</ArticleId><ArticleId IdType="pubmed">17485472</ArticleId></ArticleIdList></Reference><Reference><Citation>Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A, Speleman F (2002) Accurate normalization of real&#x2010;time quantitative RT&#x2010;PCR data by geometric averaging of multiple internal control genes. Genome Biol 3: RESEARCH0034</Citation><ArticleIdList><ArticleId IdType="pmc">PMC126239</ArticleId><ArticleId IdType="pubmed">12184808</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramakers C, Ruijter JM, Deprez RH, Moorman AF (2003) Assumption&#x2010;free analysis of quantitative real&#x2010;time polymerase chain reaction (PCR) data. Neurosci Lett 339: 62&#x2013;66</Citation><ArticleIdList><ArticleId IdType="pubmed">12618301</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E (1991) Neuropathological stageing of Alzheimer&#x2010;related changes. Acta Neuropathol 82: 239&#x2013;259</Citation><ArticleIdList><ArticleId IdType="pubmed">1759558</ArticleId></ArticleIdList></Reference><Reference><Citation>Siskova Z, Page A, O'Connor V, Perry VH (2009) Degenerating synaptic boutons in prion disease: microglia activation without synaptic stripping. Am J Pathol 175: 1610&#x2013;1621</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2751557</ArticleId><ArticleId IdType="pubmed">19779137</ArticleId></ArticleIdList></Reference><Reference><Citation>Glaser EM, Van der Loos H (1981) Analysis of thick brain sections by obverse&#x2010;reverse computer microscopy: application of a new, high clarity Golgi&#x2010;Nissl stain. J Neurosci Methods 4: 117&#x2013;125</Citation><ArticleIdList><ArticleId IdType="pubmed">6168870</ArticleId></ArticleIdList></Reference><Reference><Citation>Ricobaraza A, Cuadrado&#x2010;Tejedor M, Marco S, Perez&#x2010;Otano I, Garcia&#x2010;Osta A (2012) Phenylbutyrate rescues dendritic spine loss associated with memory deficits in a mouse model of Alzheimer disease. Hippocampus 22: 1040&#x2013;1050</Citation><ArticleIdList><ArticleId IdType="pubmed">21069780</ArticleId></ArticleIdList></Reference><Reference><Citation>Stoppini L, Buchs PA, Muller D (1991) A simple method for organotypic cultures of nervous tissue. J Neurosci Methods 37: 173&#x2013;182</Citation><ArticleIdList><ArticleId IdType="pubmed">1715499</ArticleId></ArticleIdList></Reference><Reference><Citation>
Grynkiewicz G, Poenie M, Tsien RY (1985) A new generation of Ca<sup>2+</sup> indicators with greatly improved fluorescence properties. J Biol Chem
260: 3440&#x2013;3450
</Citation><ArticleIdList><ArticleId IdType="pubmed">3838314</ArticleId></ArticleIdList></Reference><Reference><Citation>Behrens CJ, van den Boom LP, de Hoz L, Friedman A, Heinemann U (2005) Induction of sharp wave&#x2010;ripple complexes in vitro and reorganization of hippocampal networks. Nat Neurosci 8: 1560&#x2013;1567</Citation><ArticleIdList><ArticleId IdType="pubmed">16222227</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">26948379</PMID><DateCompleted><Year>2016</Year><Month>09</Month><Day>20</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>21</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2041-1723</ISSN><JournalIssue CitedMedium="Internet"><Volume>7</Volume><PubDate><Year>2016</Year><Month>Mar</Month><Day>07</Day></PubDate></JournalIssue><Title>Nature communications</Title><ISOAbbreviation>Nat Commun</ISOAbbreviation></Journal><ArticleTitle>Increased amyloidogenic APP processing in APOE &#x25b;4-negative individuals with cerebral &#x3b2;-amyloidosis.</ArticleTitle><Pagination><StartPage>10918</StartPage><MedlinePgn>10918</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">10918</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/ncomms10918</ELocationID><Abstract><AbstractText>Increased APP (amyloid precursor protein) processing causes &#x3b2;-amyloid (A&#x3b2;) accumulation in autosomal dominant Alzheimer's disease (AD), but it is unclear if it also affects sporadic A&#x3b2; accumulation. We tested healthy controls and patients with mild cognitive symptoms (N=331) in the BioFINDER study, using cerebrospinal fluid (CSF) A&#x3b2;40 as a surrogate for amyloidogenic APP processing. We find that levels of brain A&#x3b2; fibrils (measured by 18F-flutemetamol PET) are independently associated with high CSF A&#x3b2;40 (P&lt;0.001) and APOE &#x25b;4 (P&lt;0.001). The association between CSF A&#x3b2;40 and brain A&#x3b2; is stronger in APOE &#x25b;4-negative than in positive people (P=0.0080). The results are similar for CSF A&#x3b2;38 and for a combination of CSF A&#x3b2;38 and CSF A&#x3b2;40. In conclusion, sporadic A&#x3b2; accumulation may be partly associated with increased amyloidogenic APP production, especially in APOE &#x25b;4-negative subjects. The risk for sporadic AD may consequently depend on increased A&#x3b2; production, in addition to decreased A&#x3b2; clearance.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mattsson</LastName><ForeName>Niklas</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Clinical Memory Research Unit, Department of Clinical Sciences Malm&#xf6;, Lund University, Simrisbanv&#xe4;gen 14, Malm&#xf6; 212 24, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Memory Clinic, Sk&#xe5;ne University Hospital, Simrisbanv&#xe4;gen 14, Malm&#xf6; 212 24, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Sk&#xe5;ne University Hospital, Getingev&#xe4;gen 4, Lund 222 41, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Insel</LastName><ForeName>Philip S</ForeName><Initials>PS</Initials><AffiliationInfo><Affiliation>Clinical Memory Research Unit, Department of Clinical Sciences Malm&#xf6;, Lund University, Simrisbanv&#xe4;gen 14, Malm&#xf6; 212 24, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Imaging of Neurodegenerative Diseases, Department of Radiology and Biomedical Imaging, San Francisco Veterans Affairs Medical Center (SFVAMC) campus, 4150 Clement Street, University of California, San Francisco, California 94121, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Palmqvist</LastName><ForeName>Sebastian</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Clinical Memory Research Unit, Department of Clinical Sciences Malm&#xf6;, Lund University, Simrisbanv&#xe4;gen 14, Malm&#xf6; 212 24, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Sk&#xe5;ne University Hospital, Getingev&#xe4;gen 4, Lund 222 41, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stomrud</LastName><ForeName>Erik</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Clinical Memory Research Unit, Department of Clinical Sciences Malm&#xf6;, Lund University, Simrisbanv&#xe4;gen 14, Malm&#xf6; 212 24, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Memory Clinic, Sk&#xe5;ne University Hospital, Simrisbanv&#xe4;gen 14, Malm&#xf6; 212 24, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Westen</LastName><ForeName>Danielle</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Clinical Sciences, Diagnostic Radiology, Lund University, Box 117, Lund 221 00, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Medical Imaging and Physiology, Sk&#xe5;ne University Hospital, Getingev&#xe4;gen 4, Lund 222 41, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Minthon</LastName><ForeName>Lennart</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Clinical Memory Research Unit, Department of Clinical Sciences Malm&#xf6;, Lund University, Simrisbanv&#xe4;gen 14, Malm&#xf6; 212 24, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Memory Clinic, Sk&#xe5;ne University Hospital, Simrisbanv&#xe4;gen 14, Malm&#xf6; 212 24, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zetterberg</LastName><ForeName>Henrik</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Molecular Neuroscience, UCL Institute of Neurology, Queen Square, London WC1N 3BG, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Neurochemistry Laboratory, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at University of Gothenburg, M&#xf6;lndal 431 80, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blennow</LastName><ForeName>Kaj</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Clinical Neurochemistry Laboratory, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at University of Gothenburg, M&#xf6;lndal 431 80, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hansson</LastName><ForeName>Oskar</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Clinical Memory Research Unit, Department of Clinical Sciences Malm&#xf6;, Lund University, Simrisbanv&#xe4;gen 14, Malm&#xf6; 212 24, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Memory Clinic, Sk&#xe5;ne University Hospital, Simrisbanv&#xe4;gen 14, Malm&#xf6; 212 24, Sweden.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>03</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nat Commun</MedlineTA><NlmUniqueID>101528555</NlmUniqueID><ISSNLinking>2041-1723</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053327">Apolipoprotein E4</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000686" MajorTopicYN="N">Amyloidosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053327" MajorTopicYN="N">Apolipoprotein E4</DescriptorName><QualifierName UI="Q000172" MajorTopicYN="Y">deficiency</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002555" MajorTopicYN="N">Cerebrospinal Fluid</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>N.M., P.S.I., S.P., E.S., L.H. and O.H. report no conflicts of interest. K.B. has served as a consultant for Eli Lilly, Novartis, Roche Diagnostics and Sanofi-Aventis, and at Advisory Boards for IBL International and lecturing for Fujirebio Europe and Lundbeck. K.B. and H.Z. are co-founders of Brain Biomarker Solutions in Gothenburg AB, a GU Holding-based platform company at the University of Gothenburg.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>8</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>2</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>3</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>3</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>9</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2016</Year><Month>3</Month><Day>7</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26948379</ArticleId><ArticleId IdType="pmc">PMC4786682</ArticleId><ArticleId IdType="doi">10.1038/ncomms10918</ArticleId><ArticleId IdType="pii">ncomms10918</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bateman R. J. et al. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N. Engl. J. Med. 367, 795&#x2013;804 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3474597</ArticleId><ArticleId IdType="pubmed">22784036</ArticleId></ArticleIdList></Reference><Reference><Citation>Villemagne V. L. et al. Amyloid &#x3b2; deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study. Lancet Neurol. 12, 357&#x2013;367 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23477989</ArticleId></ArticleIdList></Reference><Reference><Citation>Jansen W. J. et al. Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. JAMA. 313, 1924&#x2013;1938 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4486209</ArticleId><ArticleId IdType="pubmed">25988462</ArticleId></ArticleIdList></Reference><Reference><Citation>Klunk W. E. et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann. Neurol. 55, 306&#x2013;319 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">14991808</ArticleId></ArticleIdList></Reference><Reference><Citation>Blennow K., Mattsson N., Sch&#xf6;ll M., Hansson O. &amp; Zetterberg H. Amyloid biomarkers in Alzheimer's disease. Trends Pharmacol. Sci. 36, 297&#x2013;309 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25840462</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy J. &amp; Selkoe D. J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297, 353&#x2013;356 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">12130773</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris J. C. et al. APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. Ann. Neurol. 67, 122&#x2013;131 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2830375</ArticleId><ArticleId IdType="pubmed">20186853</ArticleId></ArticleIdList></Reference><Reference><Citation>Castellano J. M. et al. Human apoE isoforms differentially regulate brain amyloid-beta peptide clearance. Sci. Transl. Med. 3, 89ra57 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3192364</ArticleId><ArticleId IdType="pubmed">21715678</ArticleId></ArticleIdList></Reference><Reference><Citation>Ward A. et al. Prevalence of apolipoprotein E4 genotype and homozygotes (APOE e4/4) among patients diagnosed with Alzheimer's disease: a systematic review and meta-analysis. Neuroepidemiology 38, 1&#x2013;17 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22179327</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiman E. M. et al. Brain imaging and fluid biomarker analysis in young adults at genetic risk for autosomal dominant Alzheimer's disease in the presenilin 1 E280A kindred: a case-control study. Lancet Neurol. 11, 1048&#x2013;1056 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4181671</ArticleId><ArticleId IdType="pubmed">23137948</ArticleId></ArticleIdList></Reference><Reference><Citation>Moore S. et al. APP metabolism regulates tau proteostasis in human cerebral cortex neurons. Cell Rep. 11, 689&#x2013;696 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4431668</ArticleId><ArticleId IdType="pubmed">25921538</ArticleId></ArticleIdList></Reference><Reference><Citation>Fagan A. M. et al. Cerebrospinal fluid tau and ptau(181) increase with cortical amyloid deposition in cognitively normal individuals: implications for future clinical trials of Alzheimer's disease. EMBO Mol. Med. 1, 371&#x2013;380 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2806678</ArticleId><ArticleId IdType="pubmed">20049742</ArticleId></ArticleIdList></Reference><Reference><Citation>Palmqvist S. et al. Accuracy of brain amyloid detection in clinical practice using cerebrospinal fluid &#x3b2;-amyloid 42: a cross-validation study against amyloid positron emission tomography. JAMA Neurol. 71, 1282&#x2013;1289 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">25155658</ArticleId></ArticleIdList></Reference><Reference><Citation>Mawuenyega K. G. et al. Decreased clearance of CNS beta-amyloid in Alzheimer's disease. Science 330, 1774 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3073454</ArticleId><ArticleId IdType="pubmed">21148344</ArticleId></ArticleIdList></Reference><Reference><Citation>Michaelson D. M. APOE &#x25b;4: the most prevalent yet understudied risk factor for Alzheimer's disease. Alzheimers Dement. 10, 861&#x2013;868 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">25217293</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu J.-T., Tan L. &amp; Hardy J. Apolipoprotein E in Alzheimer's disease: an update. Annu. Rev. Neurosci. 37, 79&#x2013;100 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24821312</ArticleId></ArticleIdList></Reference><Reference><Citation>Jonsson T. et al. A mutation in APP protects against Alzheimer's disease and age-related cognitive decline. Nature 488, 96&#x2013;99 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22801501</ArticleId></ArticleIdList></Reference><Reference><Citation>Li J. et al. Effect of human cerebrospinal fluid sampling frequency on amyloid-&#x3b2; levels. Alzheimers Dement. 8, 295&#x2013;303 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22047633</ArticleId></ArticleIdList></Reference><Reference><Citation>Selnes P. et al. Effects of cerebrovascular disease on amyloid precursor protein metabolites in cerebrospinal fluid. Cerebrospinal. Fluid. Res. 7, 10 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2921347</ArticleId><ArticleId IdType="pubmed">20673341</ArticleId></ArticleIdList></Reference><Reference><Citation>Brun A. &amp; Englund E. A white matter disorder in dementia of the Alzheimer type: a pathoanatomical study. Ann. Neurol. 19, 253&#x2013;262 (1986).</Citation><ArticleIdList><ArticleId IdType="pubmed">3963770</ArticleId></ArticleIdList></Reference><Reference><Citation>Hedden T. et al. Disruption of functional connectivity in clinically normal older adults harboring amyloid burden. J. Neurosci. 29, 12686&#x2013;12694 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2808119</ArticleId><ArticleId IdType="pubmed">19812343</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert J.-C. &amp; Amouyel P. Genetics of Alzheimer's disease: new evidences for an old hypothesis? Curr. Opin. Genet. Dev. 21, 295&#x2013;301 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21371880</ArticleId></ArticleIdList></Reference><Reference><Citation>Snitz B. E. et al. Amyloid-&#x3b2; Imaging in Older Adults Presenting to a Memory Clinic with Subjective Cognitive Decline: A Pilot Study. J. Alzheimers Dis. 48, (Suppl 1): S151&#x2013;S159 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4675050</ArticleId><ArticleId IdType="pubmed">26402082</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosen C. et al. Cerebrospinal fluid profiles of amyloid beta-related biomarkers in Alzheimer's disease. Neuromolecular. Med. 14, 65&#x2013;73 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22350541</ArticleId></ArticleIdList></Reference><Reference><Citation>Nilsson L.-G. et al. The betula prospective cohort study: memory, health, and aging. Neuropsychol. Dev. Cogn. B Aging Neuropsychol. Cogn. 4, 1&#x2013;32 (1997).</Citation></Reference><Reference><Citation>Delis D. C., Kaplan E. &amp; Kramer J. H. Delis-Kaplan executive function system TM: Examiner's Manual The Psychological Corporation (2001).</Citation></Reference><Reference><Citation>Strauss E., Sherman E. M. &amp; Spreen O. A Compendium of Neuropsychological Tests. Administration, Norms, and Commentary &#x2013; third edition Oxford University Press (2006).</Citation></Reference><Reference><Citation>Meyers J. E. &amp; Meyers K. R. Rey Complex Figure Test and Recognition Trial Psychological Resources, Inc. (1995).</Citation></Reference><Reference><Citation>Wechsler D. Wechsler Adult Intelligence Scale 4th edn, (ed. Psykologif&#xf6;rlaget A. B.) (Pearson, Inc., 2008; Harcourt Assessment, Swedish version, 2010).</Citation></Reference><Reference><Citation>Petersen R. C. Mild cognitive impairment as a diagnostic entity. J. Intern. Med. 256, 183&#x2013;194 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15324362</ArticleId></ArticleIdList></Reference><Reference><Citation>Koole M. et al. Whole-body biodistribution and radiation dosimetry of 18F-GE067: a radioligand for in vivo brain amyloid imaging. J. Nucl. Med. 50, 818&#x2013;822 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19372469</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelissen N. et al. Phase 1 study of the Pittsburgh compound B derivative 18F-flutemetamol in healthy volunteers and patients with probable Alzheimer disease. J. Nucl. Med. 50, 1251&#x2013;1259 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19617318</ArticleId></ArticleIdList></Reference><Reference><Citation>Lundqvist R. et al. Implementation and validation of an adaptive template registration method for 18F-flutemetamol imaging data. J. Nucl. Med. 54, 1472&#x2013;1478 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23740104</ArticleId></ArticleIdList></Reference><Reference><Citation>Thurfjell L. et al. Automated quantification of 18F-flutemetamol PET activity for categorizing scans as negative or positive for brain amyloid: concordance with visual image reads. J. Nucl. Med. 55, 1623&#x2013;1628 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">25146124</ArticleId></ArticleIdList></Reference><Reference><Citation>Blennow K., Hampel H., Weiner M. &amp; Zetterberg H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat. Rev. Neurol. 6, 131&#x2013;144 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20157306</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt P. et al. An automated tool for detection of FLAIR-hyperintense white-matter lesions in multiple sclerosis. NeuroImage 59, 3774&#x2013;3783 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22119648</ArticleId></ArticleIdList></Reference><Reference><Citation>Brinkmalm G. et al. An online nano-LC-ESI-FTICR-MS method for comprehensive characterization of endogenous fragments from amyloid beta and amyloid precursor protein in human and cat cerebrospinal fluid. J. Mass. Spectrom. 47, 591&#x2013;603 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22576872</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">26950006</PMID><DateCompleted><Year>2017</Year><Month>08</Month><Day>29</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>22</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1546-1726</ISSN><JournalIssue CitedMedium="Internet"><Volume>19</Volume><Issue>5</Issue><PubDate><Year>2016</Year><Month>May</Month></PubDate></JournalIssue><Title>Nature neuroscience</Title><ISOAbbreviation>Nat Neurosci</ISOAbbreviation></Journal><ArticleTitle>Genetically targeted magnetic control of the nervous system.</ArticleTitle><Pagination><StartPage>756</StartPage><EndPage>761</EndPage><MedlinePgn>756-761</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/nn.4265</ELocationID><Abstract><AbstractText>Optogenetic and chemogenetic actuators are critical for deconstructing the neural correlates of behavior. However, these tools have several limitations, including invasive modes of stimulation or slow on/off kinetics. We have overcome these disadvantages by synthesizing a single-component, magnetically sensitive actuator, "Magneto," comprising the cation channel TRPV4 fused to the paramagnetic protein ferritin. We validated noninvasive magnetic control over neuronal activity by demonstrating remote stimulation of cells using in vitro calcium imaging assays, electrophysiological recordings in brain slices, in vivo electrophysiological recordings in the brains of freely moving mice, and behavioral outputs in zebrafish and mice. As proof of concept, we used Magneto to delineate a causal role of striatal dopamine receptor 1 neurons in mediating reward behavior in mice. Together our results present Magneto as an actuator capable of remotely controlling circuits associated with complex animal behaviors.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wheeler</LastName><ForeName>Michael A</ForeName><Initials>MA</Initials><Identifier Source="ORCID">0000-0002-0689-6384</Identifier><AffiliationInfo><Affiliation>Department of Biology, University of Virginia, Charlottesville, Virginia, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neuroscience Graduate Program, University of Virginia, Charlottesville, Virginia, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Smith</LastName><ForeName>Cody J</ForeName><Initials>CJ</Initials><AffiliationInfo><Affiliation>Department of Biology, University of Virginia, Charlottesville, Virginia, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ottolini</LastName><ForeName>Matteo</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology, University of Virginia, Charlottesville, Virginia, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barker</LastName><ForeName>Bryan S</ForeName><Initials>BS</Initials><AffiliationInfo><Affiliation>Neuroscience Graduate Program, University of Virginia, Charlottesville, Virginia, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Anesthesiology, University of Virginia, Charlottesville, Virginia, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Purohit</LastName><ForeName>Aarti M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Department of Biology, University of Virginia, Charlottesville, Virginia, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grippo</LastName><ForeName>Ryan M</ForeName><Initials>RM</Initials><AffiliationInfo><Affiliation>Department of Biology, University of Virginia, Charlottesville, Virginia, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gaykema</LastName><ForeName>Ronald P</ForeName><Initials>RP</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology, University of Virginia, Charlottesville, Virginia, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Spano</LastName><ForeName>Anthony J</ForeName><Initials>AJ</Initials><AffiliationInfo><Affiliation>Department of Biology, University of Virginia, Charlottesville, Virginia, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beenhakker</LastName><ForeName>Mark P</ForeName><Initials>MP</Initials><AffiliationInfo><Affiliation>Department of Pharmacology, University of Virginia, Charlottesville, Virginia, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kucenas</LastName><ForeName>Sarah</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Biology, University of Virginia, Charlottesville, Virginia, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cell Biology, University of Virginia, Charlottesville, Virginia, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Patel</LastName><ForeName>Manoj K</ForeName><Initials>MK</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology, University of Virginia, Charlottesville, Virginia, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deppmann</LastName><ForeName>Christopher D</ForeName><Initials>CD</Initials><AffiliationInfo><Affiliation>Department of Biology, University of Virginia, Charlottesville, Virginia, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cell Biology, University of Virginia, Charlottesville, Virginia, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biomedical Engineering, University of Virginia, Charlottesville, Virginia, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>G&#xfc;ler</LastName><ForeName>Ali D</ForeName><Initials>AD</Initials><AffiliationInfo><Affiliation>Department of Biology, University of Virginia, Charlottesville, Virginia, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>F32 NS087791</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>S10 RR025616</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 GM008136</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS072388</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 GM008328</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS072212</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS075157</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>03</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Neurosci</MedlineTA><NlmUniqueID>9809671</NlmUniqueID><ISSNLinking>1097-6256</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D050916">TRPV Cation Channels</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C486577">Trpv4 protein, rat</NameOfSubstance></Chemical><Chemical><RegistryNumber>9007-73-2</RegistryNumber><NameOfSubstance UI="D005293">Ferritins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Neurosci. 2016 May;17(5):262-3. doi: 10.1038/nrn.2016.42.</RefSource><PMID Version="1">27040906</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Nat Neurosci. 2020 Sep;23(9):1051-1054. doi: 10.1038/s41593-019-0472-6.</RefSource><PMID Version="1">31570860</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Nat Neurosci. 2020 Sep;23(9):1044-1046. doi: 10.1038/s41593-019-0474-4.</RefSource><PMID Version="1">31570861</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Nat Neurosci. 2020 Sep;23(9):1047-1050. doi: 10.1038/s41593-019-0473-5.</RefSource><PMID Version="1">31570862</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Nat Neurosci. 2020 Sep;23(9):1041-1043. doi: 10.1038/s41593-019-0475-3.</RefSource><PMID Version="1">31570863</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001522" MajorTopicYN="N">Behavior, Animal</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003342" MajorTopicYN="N">Corpus Striatum</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D059290" MajorTopicYN="N">Dopaminergic Neurons</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005293" MajorTopicYN="N">Ferritins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008280" MajorTopicYN="N">Magnetics</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012201" MajorTopicYN="N">Reward</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D050916" MajorTopicYN="N">TRPV Cation Channels</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015027" MajorTopicYN="N">Zebrafish</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>12</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>2</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>3</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>3</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>8</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2016</Year><Month>9</Month><Day>7</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26950006</ArticleId><ArticleId IdType="mid">NIHMS759068</ArticleId><ArticleId IdType="pmc">PMC4846560</ArticleId><ArticleId IdType="doi">10.1038/nn.4265</ArticleId><ArticleId IdType="pii">nn.4265</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Zemelman BV, Lee Ga, Ng M, Miesenb&#xf6;ck G. Selective photostimulation of genetically chARGed neurons. Neuron. 2002;33:15&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pubmed">11779476</ArticleId></ArticleIdList></Reference><Reference><Citation>Boyden ES, Zhang F, Bamberg E, Nagel G, Deisseroth K. Millisecond-timescale, genetically targeted optical control of neural activity. Nat. Neurosci. 2005;8:1263&#x2013;1268.</Citation><ArticleIdList><ArticleId IdType="pubmed">16116447</ArticleId></ArticleIdList></Reference><Reference><Citation>Gradinaru V, Mogri M, Thompson KR, Henderson JM, Deisseroth K. Optical deconstruction of parkinsonian neural circuitry. Science. 2009;324:354&#x2013;359.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6744370</ArticleId><ArticleId IdType="pubmed">19299587</ArticleId></ArticleIdList></Reference><Reference><Citation>Sternson SM, Roth BL. Chemogenetic Tools to Interrogate Brain Functions. Annu. Rev. Neurosci. 2014:387&#x2013;407.</Citation><ArticleIdList><ArticleId IdType="pubmed">25002280</ArticleId></ArticleIdList></Reference><Reference><Citation>Alexander GM, et al. Remote control of neuronal activity in transgenic mice expressing evolved G protein-coupled receptors. Neuron. 2009;63:27&#x2013;39.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2751885</ArticleId><ArticleId IdType="pubmed">19607790</ArticleId></ArticleIdList></Reference><Reference><Citation>G&#xfc;ler AD, et al. Transient activation of specific neurons in mice by selective expression of the capsaicin receptor. Nat. Commun. 2012;3:746.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3592340</ArticleId><ArticleId IdType="pubmed">22434189</ArticleId></ArticleIdList></Reference><Reference><Citation>Bernstein JG, Garrity Pa, Boyden ES. Optogenetics and thermogenetics: Technologies for controlling the activity of targeted cells within intact neural circuits. Curr. Opin. Neurobiol. 2012;22:61&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3292652</ArticleId><ArticleId IdType="pubmed">22119320</ArticleId></ArticleIdList></Reference><Reference><Citation>Hughes S, McBain S, Dobson J, El Haj AJ. Selective activation of mechanosensitive ion channels using magnetic particles. J. R. Soc. Interface. 2008;5:855&#x2013;863.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2495030</ArticleId><ArticleId IdType="pubmed">18077244</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang H, Delikanli S, Zeng H, Ferkey DM, Pralle A. Remote control of ion channels and neurons through magnetic-field heating of nanoparticles. Nat. Nanotechnol. 2010;5:602&#x2013;606.</Citation><ArticleIdList><ArticleId IdType="pubmed">20581833</ArticleId></ArticleIdList></Reference><Reference><Citation>Stanley Sa, et al. Radio-wave heating of iron oxide nanoparticles can regulate plasma glucose in mice. Science. 2012;336:604&#x2013;608.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3646550</ArticleId><ArticleId IdType="pubmed">22556257</ArticleId></ArticleIdList></Reference><Reference><Citation>Stanley Sa, Sauer J, Kane RS, Dordick JS, Friedman JM. Remote regulation of glucose homeostasis in mice using genetically encoded nanoparticles. Nat. Med. 2015;21:92&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4894538</ArticleId><ArticleId IdType="pubmed">25501906</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen R, Romero G, Christiansen MG, Mohr A, Anikeeva P. Wireless magnetothermal deep brain stimulation. Science. 2015;347:1477&#x2013;1480.</Citation><ArticleIdList><ArticleId IdType="pubmed">25765068</ArticleId></ArticleIdList></Reference><Reference><Citation>Stanley Sa, Sauer J, Kane RS, Dordick JS, Friedman JM. Remote regulation of glucose homeostasis in mice using genetically encoded nanoparticles. Nat. Med. 2015;21:92&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4894538</ArticleId><ArticleId IdType="pubmed">25501906</ArticleId></ArticleIdList></Reference><Reference><Citation>Loukin S, Zhou X, Su Z, Saimi Y, Kung C. Wild-type and brachyolmia-causing mutant TRPV4 channels respond directly to stretch force. J. Biol. Chem. 2010;285:27176&#x2013;27181.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2930716</ArticleId><ArticleId IdType="pubmed">20605796</ArticleId></ArticleIdList></Reference><Reference><Citation>Liedtke W, et al. Vanilloid receptor-related osmotically activated channel (VR-OAC), a candidate vertebrate osmoreceptor. Cell. 2000;103:525&#x2013;535.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2211528</ArticleId><ArticleId IdType="pubmed">11081638</ArticleId></ArticleIdList></Reference><Reference><Citation>G&#xfc;ler AD, et al. Heat-evoked activation of the ion channel, TRPV4. J. Neurosci. 2002;22:6408&#x2013;6414.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6758176</ArticleId><ArticleId IdType="pubmed">12151520</ArticleId></ArticleIdList></Reference><Reference><Citation>Stanley S. Biological nanoparticles and their influence on organisms. Curr. Opin. Biotechnol. 2014;28:69&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pubmed">24832077</ArticleId></ArticleIdList></Reference><Reference><Citation>Iordanova B, Robison CS, Ahrens ET. Design and characterization of a chimeric ferritin with enhanced iron loading and transverse NMR relaxation rate. J. Biol. Inorg. Chem. 2010;15:957&#x2013;965.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2936821</ArticleId><ArticleId IdType="pubmed">20401622</ArticleId></ArticleIdList></Reference><Reference><Citation>Lei L, et al. A TRPV4 channel C-terminal folding recognition domain critical for trafficking and function. J. Biol. Chem. 2013;288:10427&#x2013;10439.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3624425</ArticleId><ArticleId IdType="pubmed">23457335</ArticleId></ArticleIdList></Reference><Reference><Citation>Hofherr A, Fakler B, Kl&#xf6;cker N. Selective Golgi export of Kir2.1 controls the stoichiometry of functional Kir2.x channel heteromers. J. Cell Sci. 2005;118:1935&#x2013;1943.</Citation><ArticleIdList><ArticleId IdType="pubmed">15827083</ArticleId></ArticleIdList></Reference><Reference><Citation>Gradinaru V, et al. Molecular and Cellular Approaches for Diversifying and Extending Optogenetics. Cell. 2010;141:154&#x2013;165.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4160532</ArticleId><ArticleId IdType="pubmed">20303157</ArticleId></ArticleIdList></Reference><Reference><Citation>Lytton J, Westlin M, Hanley MR. Thapsigargin inhibits the sarcoplasmic or endoplasmic reticulum Ca-ATPase family of calcium pumps. J. Biol. Chem. 1991;266:17067&#x2013;17071.</Citation><ArticleIdList><ArticleId IdType="pubmed">1832668</ArticleId></ArticleIdList></Reference><Reference><Citation>Phan MN, et al. Functional characterization of TRPV4 as an osmotically sensitive ion channel in porcine articular chondrocytes. Arthritis Rheum. 2009;60:3028&#x2013;3037.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2846816</ArticleId><ArticleId IdType="pubmed">19790068</ArticleId></ArticleIdList></Reference><Reference><Citation>Sohal VS, Zhang F, Yizhar O, Deisseroth K. Parvalbumin neurons and gamma rhythms enhance cortical circuit performance. Nature. 2009;459:698&#x2013;702.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3969859</ArticleId><ArticleId IdType="pubmed">19396159</ArticleId></ArticleIdList></Reference><Reference><Citation>Andermann P, Ungos J, Raible DW. Neurogenin1 defines zebrafish cranial sensory ganglia precursors. Dev. Biol. 2002;251:45&#x2013;58.</Citation><ArticleIdList><ArticleId IdType="pubmed">12413897</ArticleId></ArticleIdList></Reference><Reference><Citation>Douglass AD, Kraves S, Deisseroth K, Schier AF, Engert F. Escape Behavior Elicited by Single, Channelrhodopsin-2-Evoked Spikes in Zebrafish Somatosensory Neurons. Curr. Biol. 2008;18:1133&#x2013;1137.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2891506</ArticleId><ArticleId IdType="pubmed">18682213</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian L, et al. Imaging neural activity in worms, flies and mice with improved GCaMP calcium indicators. Nat. Methods. 2009;6:875&#x2013;881.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2858873</ArticleId><ArticleId IdType="pubmed">19898485</ArticleId></ArticleIdList></Reference><Reference><Citation>Wyart C, et al. Optogenetic dissection of a behavioural module in the vertebrate spinal cord. Nature. 2009;461:407&#x2013;410.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2770190</ArticleId><ArticleId IdType="pubmed">19759620</ArticleId></ArticleIdList></Reference><Reference><Citation>Sagasti A, Guido MR, Raible DW, Schier AF. Repulsive Interactions Shape the Morphologies and Functional Arrangement of Zebrafish Peripheral Sensory Arbors. Curr. Biol. 2005;15:804&#x2013;814.</Citation><ArticleIdList><ArticleId IdType="pubmed">15886097</ArticleId></ArticleIdList></Reference><Reference><Citation>Hersch SM, et al. Electron microscopic analysis of D1 and D2 dopamine receptor proteins in the dorsal striatum and their synaptic relationships with motor corticostriatal afferents. J. Neurosci. 1995;15:5222&#x2013;5237.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6577913</ArticleId><ArticleId IdType="pubmed">7623147</ArticleId></ArticleIdList></Reference><Reference><Citation>Berke JD, Okatan M, Skurski J, Eichenbaum HB. Oscillatory Entrainment of Striatal Neurons in Freely-Moving Rats. Neuron. 2004;43:883&#x2013;896.</Citation><ArticleIdList><ArticleId IdType="pubmed">15363398</ArticleId></ArticleIdList></Reference><Reference><Citation>Wise Ra. Dopamine, learning and motivation. Nat. Rev. Neurosci. 2004;5:483&#x2013;494.</Citation><ArticleIdList><ArticleId IdType="pubmed">15152198</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsai H-C, et al. Phasic firing in dopaminergic neurons is sufficient for behavioral conditioning. Science. 2009;324:1080&#x2013;1084.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5262197</ArticleId><ArticleId IdType="pubmed">19389999</ArticleId></ArticleIdList></Reference><Reference><Citation>Lobo MK, et al. Cell type-specific loss of BDNF signaling mimics optogenetic control of cocaine reward. Science. 2010;330:385&#x2013;390.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3011229</ArticleId><ArticleId IdType="pubmed">20947769</ArticleId></ArticleIdList></Reference><Reference><Citation>Zengin-Toktas Y, et al. Motivational properties of D2 and D3 dopamine receptors agonists and cocaine, but not with D1 dopamine receptors agonist and l-dopa, in bilateral 6-OHDA-lesioned rat. Neuropharmacology. 2013;70:74&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pubmed">23347953</ArticleId></ArticleIdList></Reference><Reference><Citation>Gore BB, Zweifel LS. Genetic Reconstruction of Dopamine D1 Receptor Signaling in the Nucleus Accumbens Facilitates Natural and Drug Reward Responses. J. Neurosci. 2013;33:8640&#x2013;8649.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3684445</ArticleId><ArticleId IdType="pubmed">23678109</ArticleId></ArticleIdList></Reference><Reference><Citation>Stuber GD, Britt JP, Bonci A. Optogenetic modulation of neural circuits that underlie reward seeking. Biol. Psychiatry. 2012;71:1061&#x2013;1067.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3332148</ArticleId><ArticleId IdType="pubmed">22196983</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeong JW, et al. Wireless Optofluidic Systems for Programmable In Vivo Pharmacology and Optogenetics. Cell. 2015;162:662&#x2013;674.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4525768</ArticleId><ArticleId IdType="pubmed">26189679</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Neil RG, Heller S. The mechanosensitive nature of TRPV channels. Pflugers Arch. 2005;451:193&#x2013;203.</Citation><ArticleIdList><ArticleId IdType="pubmed">15909178</ArticleId></ArticleIdList></Reference><Reference><Citation>Liedtke W, Kim C. Functionality of the TRPV subfamily of TRP ion channels: add mechano-TRP and osmo-TRP to the lexicon! Cell. Mol. Life Sci. 2005;62:2985&#x2013;3001.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11139190</ArticleId><ArticleId IdType="pubmed">16314934</ArticleId></ArticleIdList></Reference><Reference><Citation>Matthews BD, et al. Ultra-rapid activation of TRPV4 ion channels by mechanical forces applied to cell surface beta1 integrins. Integr. Biol. (Camb) 2010;2:435&#x2013;442.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3147167</ArticleId><ArticleId IdType="pubmed">20725677</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Methods-only References</Title><Reference><Citation>Kimmel CB, Ballard WW, Kimmel SR, Ullmann B, Schilling TF. Stages of embryonic development of the zebrafish. Dev. Dyn. 1995;203:253&#x2013;310.</Citation><ArticleIdList><ArticleId IdType="pubmed">8589427</ArticleId></ArticleIdList></Reference><Reference><Citation>McFarland TJ, et al. Evaluation of a novel short polyadenylation signal as an alternative to the SV40 polyadenylation signal. Plasmid. 2006;56:62&#x2013;67.</Citation><ArticleIdList><ArticleId IdType="pubmed">16472858</ArticleId></ArticleIdList></Reference><Reference><Citation>Wheeler Ma, et al. TNF-&#x3b1;/TNFR1 Signaling Is Required for the Development and Function of Primary Nociceptors. Neuron. 2014;82:587&#x2013;602.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4046273</ArticleId><ArticleId IdType="pubmed">24811380</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith CJ, Morris AD, Welsh TG, Kucenas S. Contact-Mediated Inhibition Between Oligodendrocyte Progenitor Cells and Motor Exit Point Glia Establishes the Spinal Cord Transition Zone. PLoS Biol. 2014;12:e1001961.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4181976</ArticleId><ArticleId IdType="pubmed">25268888</ArticleId></ArticleIdList></Reference><Reference><Citation>Hargus NJ, Nigam A, Bertram EH, Patel MK. Evidence for a role of Nav1.6 in facilitating increases in neuronal hyperexcitability during epileptogenesis. J. Neurophysiol. 2013;110:1144&#x2013;1157.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3763090</ArticleId><ArticleId IdType="pubmed">23741036</ArticleId></ArticleIdList></Reference><Reference><Citation>Quintana A, et al. Lack of GPR88 enhances medium spiny neuron activity and alters motor- and cue-dependent behaviors. Nat. Neurosci. 2012;15:1547&#x2013;1555.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3483418</ArticleId><ArticleId IdType="pubmed">23064379</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen S, Chiu CN, McArthur KL, Fetcho JR, Prober Da. TRP channel mediated neuronal activation and ablation in freely behaving zebrafish. Nat. Methods. 2015;8:1&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4851460</ArticleId><ArticleId IdType="pubmed">26657556</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">26982728</PMID><DateCompleted><Year>2016</Year><Month>04</Month><Day>27</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1476-4687</ISSN><JournalIssue CitedMedium="Internet"><Volume>531</Volume><Issue>7595</Issue><PubDate><Year>2016</Year><Month>Mar</Month><Day>24</Day></PubDate></JournalIssue><Title>Nature</Title><ISOAbbreviation>Nature</ISOAbbreviation></Journal><ArticleTitle>Memory retrieval by activating engram cells in mouse models of early Alzheimer's disease.</ArticleTitle><Pagination><StartPage>508</StartPage><EndPage>512</EndPage><MedlinePgn>508-12</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/nature17172</ELocationID><Abstract><AbstractText>Alzheimer's disease (AD) is a neurodegenerative disorder characterized by progressive memory decline and subsequent loss of broader cognitive functions. Memory decline in the early stages of AD is mostly limited to episodic memory, for which the hippocampus has a crucial role. However, it has been uncertain whether the observed amnesia in the early stages of AD is due to disrupted encoding and consolidation of episodic information, or an impairment in the retrieval of stored memory information. Here we show that in transgenic mouse models of early AD, direct optogenetic activation of hippocampal memory engram cells results in memory retrieval despite the fact that these mice are amnesic in long-term memory tests when natural recall cues are used, revealing a retrieval, rather than a storage impairment. Before amyloid plaque deposition, the amnesia in these mice is age-dependent, which correlates with a progressive reduction in spine density of hippocampal dentate gyrus engram cells. We show that optogenetic induction of long-term potentiation at perforant path synapses of dentate gyrus engram cells restores both spine density and long-term memory. We also demonstrate that an ablation of dentate gyrus engram cells containing restored spine density prevents the rescue of long-term memory. Thus, selective rescue of spine density in engram cells may lead to an effective strategy for treating memory loss in the early stages of AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Roy</LastName><ForeName>Dheeraj S</ForeName><Initials>DS</Initials><AffiliationInfo><Affiliation>RIKEN-MIT Center for Neural Circuit Genetics at the Picower Institute for Learning and Memory, Department of Biology and Department of Brain and Cognitive Sciences, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arons</LastName><ForeName>Autumn</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>RIKEN-MIT Center for Neural Circuit Genetics at the Picower Institute for Learning and Memory, Department of Biology and Department of Brain and Cognitive Sciences, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Howard Hughes Medical Institute, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mitchell</LastName><ForeName>Teryn I</ForeName><Initials>TI</Initials><AffiliationInfo><Affiliation>RIKEN-MIT Center for Neural Circuit Genetics at the Picower Institute for Learning and Memory, Department of Biology and Department of Brain and Cognitive Sciences, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pignatelli</LastName><ForeName>Michele</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>RIKEN-MIT Center for Neural Circuit Genetics at the Picower Institute for Learning and Memory, Department of Biology and Department of Brain and Cognitive Sciences, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ryan</LastName><ForeName>Tom&#xe1;s J</ForeName><Initials>TJ</Initials><AffiliationInfo><Affiliation>RIKEN-MIT Center for Neural Circuit Genetics at the Picower Institute for Learning and Memory, Department of Biology and Department of Brain and Cognitive Sciences, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Howard Hughes Medical Institute, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tonegawa</LastName><ForeName>Susumu</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>RIKEN-MIT Center for Neural Circuit Genetics at the Picower Institute for Learning and Memory, Department of Biology and Department of Brain and Cognitive Sciences, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Howard Hughes Medical Institute, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Acronym>HHMI</Acronym><Agency>Howard Hughes Medical Institute</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>03</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nature</MedlineTA><NlmUniqueID>0410462</NlmUniqueID><ISSNLinking>0028-0836</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C054369">MAPT protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053764">Presenilin-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nature. 2016 Mar 24;531(7595):450-1. doi: 10.1038/nature17312.</RefSource><PMID Version="1">26982731</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Neuroscience. 2016 Jun 21;326:v-vii. doi: 10.1016/j.neuroscience.2016.04.012.</RefSource><PMID Version="1">27085990</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000647" MajorTopicYN="N">Amnesia</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049229" MajorTopicYN="N">Dendritic Spines</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018891" MajorTopicYN="N">Dentate Gyrus</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="Y">cytology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="Y">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D061345" MajorTopicYN="N">Early Medical Intervention</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017774" MajorTopicYN="N">Long-Term Potentiation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D061212" MajorTopicYN="N">Memory, Episodic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057567" MajorTopicYN="N">Memory, Long-Term</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D062308" MajorTopicYN="N">Optogenetics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058225" MajorTopicYN="N">Plaque, Amyloid</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053764" MajorTopicYN="N">Presenilin-1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013569" MajorTopicYN="N">Synapses</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019076" MajorTopicYN="N">Transgenes</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList><OtherID Source="NLM">HHMIMS755852</OtherID><CoiStatement>The authors declare no competing financial interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>8</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>1</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>3</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>3</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>4</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2016</Year><Month>9</Month><Day>16</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26982728</ArticleId><ArticleId IdType="mid">NIHMS755852</ArticleId><ArticleId IdType="pmc">PMC4847731</ArticleId><ArticleId IdType="doi">10.1038/nature17172</ArticleId><ArticleId IdType="pii">nature17172</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Selkoe DJ. Alzheimer&#x2019;s disease: genes, proteins, and therapy. Physiol Rev. 2001;81:741&#x2013;766.</Citation><ArticleIdList><ArticleId IdType="pubmed">11274343</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ. Alzheimer&#x2019;s disease is a synaptic failure. Science. 2002;298:789&#x2013;791.</Citation><ArticleIdList><ArticleId IdType="pubmed">12399581</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacobsen JS, et al. Early-onset behavioral and synaptic deficits in a mouse model of Alzheimer&#x2019;s disease. Proc Natl Acad Sci USA. 2006;103:5161&#x2013;5166.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1405622</ArticleId><ArticleId IdType="pubmed">16549764</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsia AY, et al. Plaque-independent disruption of neural circuits in Alzheimer&#x2019;s disease mouse models. Proc Natl Acad Sci USA. 1999;96:3228&#x2013;3233.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC15924</ArticleId><ArticleId IdType="pubmed">10077666</ArticleId></ArticleIdList></Reference><Reference><Citation>Mucke L, et al. High-level neuronal expression of A&#x3b2;1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J Neurosci. 2000;20:4050&#x2013;4058.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6772621</ArticleId><ArticleId IdType="pubmed">10818140</ArticleId></ArticleIdList></Reference><Reference><Citation>Terry RD, et al. Physical basis of cognitive alterations in Alzheimer&#x2019;s disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol. 1991;30:572&#x2013;580.</Citation><ArticleIdList><ArticleId IdType="pubmed">1789684</ArticleId></ArticleIdList></Reference><Reference><Citation>Granholm E, Butters N. Associative encoding and retrieval in Alzheimer&#x2019;s and Huntington&#x2019;s disease. Brain Cognition. 1988;7:335&#x2013;347.</Citation><ArticleIdList><ArticleId IdType="pubmed">2969744</ArticleId></ArticleIdList></Reference><Reference><Citation>Hodges JR, Salmon DP, Butters N. Differential impairment of semantic and episodic memory in Alzheimer&#x2019;s and Huntington&#x2019;s diseases: a controlled prospective study. J Neurol Neurosurg Psychiatry. 1990;53:1089&#x2013;1095.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC488322</ArticleId><ArticleId IdType="pubmed">2149861</ArticleId></ArticleIdList></Reference><Reference><Citation>Weintraub S, Wicklund AH, Salmon DP. The neuropsychological profile of Alzheimer disease. Cold Spring Harb Perspect Med. 2012;2:a006171.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3312395</ArticleId><ArticleId IdType="pubmed">22474609</ArticleId></ArticleIdList></Reference><Reference><Citation>Jankowsky JL, et al. Mutant presenilins specifically elevate the levels of the 42 residue &#x3b2;-amyloid peptide in vivo: evidence for augmentation of a 42-residue &#x3b3; secretase. Hum Mol Genet. 2004;13:159&#x2013;170.</Citation><ArticleIdList><ArticleId IdType="pubmed">14645205</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu XL, et al. Optogenetic stimulation of a hippocampal engram activates fear memory recall. Nature. 2012;484:381&#x2013;385.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3331914</ArticleId><ArticleId IdType="pubmed">22441246</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramirez S, et al. Creating a false memory in the hippocampus. Science. 2013;341:387&#x2013;391.</Citation><ArticleIdList><ArticleId IdType="pubmed">23888038</ArticleId></ArticleIdList></Reference><Reference><Citation>Redondo RL, et al. Bidirectional switch of the valence associated with a hippocampal contextual memory engram. Nature. 2014;513:426&#x2013;430.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4169316</ArticleId><ArticleId IdType="pubmed">25162525</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryan TJ, Roy DS, Pignatelli M, Arons A, Tonegawa S. Engram cells retain memory under retrograde amnesia. Science. 2015;348:1007&#x2013;1013.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5583719</ArticleId><ArticleId IdType="pubmed">26023136</ArticleId></ArticleIdList></Reference><Reference><Citation>Denny CA, et al. Hippocampal memory traces are differentially modulated by experience, time, and adult neurogenesis. Neuron. 2014;83:189&#x2013;201.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4169172</ArticleId><ArticleId IdType="pubmed">24991962</ArticleId></ArticleIdList></Reference><Reference><Citation>Harris JA, et al. Transsynaptic progression of amyloid-&#x3b2;-induced neuronal dysfunction within the entorhinal-hippocampal network. Neuron. 2010;68:428&#x2013;441.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3050043</ArticleId><ArticleId IdType="pubmed">21040845</ArticleId></ArticleIdList></Reference><Reference><Citation>Hyman BT, Van Hoesen GW, Kromer LJ, Damasio AR. Perforant pathway changes and the memory impairment of Alzheimer&#x2019;s disease. Ann Neurol. 1986;20:472&#x2013;481.</Citation><ArticleIdList><ArticleId IdType="pubmed">3789663</ArticleId></ArticleIdList></Reference><Reference><Citation>Oddo S, et al. Triple-transgenic model of Alzheimer&#x2019;s disease with plaques and tangles: intracellular A&#x3b2; and synaptic dysfunction. Neuron. 2003;39:409&#x2013;421.</Citation><ArticleIdList><ArticleId IdType="pubmed">12895417</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodriguez JJ, et al. Impaired adult neurogenesis in the dentate gyrus of a triple transgenic mouse model of Alzheimer&#x2019;s disease. PLoS One. 2008;3:e2935.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2492828</ArticleId><ArticleId IdType="pubmed">18698410</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin JY, Lin MZ, Steinbach P, Tsien RY. Characterization of engineered channelrhodopsin variants with improved properties and kinetics. Biophys J. 2009;96:1803&#x2013;1814.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2717302</ArticleId><ArticleId IdType="pubmed">19254539</ArticleId></ArticleIdList></Reference><Reference><Citation>Maletic-Savatic M, Malinow R, Svoboda K. Rapid dendritic morphogenesis in CA1 hippocampal dendrites induced by synaptic plasticity. Science. 1999;283:1923&#x2013;1927.</Citation><ArticleIdList><ArticleId IdType="pubmed">10082466</ArticleId></ArticleIdList></Reference><Reference><Citation>Engert F, Bonhoeffer T. Dendritic spine changes associated with hippocampal long-term synaptic plasticity. Nature. 1999;399:66&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pubmed">10331391</ArticleId></ArticleIdList></Reference><Reference><Citation>Nabavi S, et al. Engineering a memory with LTD and LTP. Nature. 2014;511:348&#x2013;352.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4210354</ArticleId><ArticleId IdType="pubmed">24896183</ArticleId></ArticleIdList></Reference><Reference><Citation>Tamamaki N, Nojyo Y. Projection of the entorhinal layer II neurons in the rat as revealed by intracellular pressure-injection of neurobiotin. Hippocampus. 1993;3:471&#x2013;480.</Citation><ArticleIdList><ArticleId IdType="pubmed">8269038</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhan C, et al. Acute and long-term suppression of feeding behavior by POMC neurons in the brainstem and hypothalamus, respectively. J Neurosci. 2013;33:3624&#x2013;3632.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6619547</ArticleId><ArticleId IdType="pubmed">23426689</ArticleId></ArticleIdList></Reference><Reference><Citation>Tonegawa S, Liu X, Ramirez S, Redondo RL. Memory engram cells have come of age. Neuron. 2015;87:918&#x2013;931.</Citation><ArticleIdList><ArticleId IdType="pubmed">26335640</ArticleId></ArticleIdList></Reference><Reference><Citation>Cisse M, et al. Reversing EphB2 depletion rescues cognitive functions in Alzheimer model. Nature. 2011;469:47&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3030448</ArticleId><ArticleId IdType="pubmed">21113149</ArticleId></ArticleIdList></Reference><Reference><Citation>Reijmers LG, Perkins BL, Matsuo N, Mayford M. Localization of a stable neural correlate of associative memory. Science. 2007;317:1230&#x2013;1233.</Citation><ArticleIdList><ArticleId IdType="pubmed">17761885</ArticleId></ArticleIdList></Reference><Reference><Citation>Urlinger S, et al. Exploring the sequence space for tetracycline-dependent transcriptional activators: novel mutations yield expanded range and sensitivity. Proc Natl Acad Sci USA. 2000;97:7963&#x2013;7968.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC16653</ArticleId><ArticleId IdType="pubmed">10859354</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">26988102</PMID><DateCompleted><Year>2017</Year><Month>09</Month><Day>13</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Electronic-Print"><Journal><ISSN IssnType="Electronic">1757-4684</ISSN><JournalIssue CitedMedium="Internet"><Volume>8</Volume><Issue>5</Issue><PubDate><Year>2016</Year><Month>May</Month></PubDate></JournalIssue><Title>EMBO molecular medicine</Title><ISOAbbreviation>EMBO Mol Med</ISOAbbreviation></Journal><ArticleTitle>Generation and deposition of A&#x3b2;43 by the virtually inactive presenilin-1 L435F mutant contradicts the presenilin loss-of-function hypothesis of Alzheimer's disease.</ArticleTitle><Pagination><StartPage>458</StartPage><EndPage>465</EndPage><MedlinePgn>458-65</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.15252/emmm.201505952</ELocationID><Abstract><AbstractText>As stated by the prevailing amyloid cascade hypothesis, Alzheimer's disease (AD) is caused by the aggregation and cerebral deposition of long amyloid-&#x3b2; peptide (A&#x3b2;) species, which are released from a C-terminal amyloid precursor protein fragment by &#x3b3;-secretase. Mutations in its catalytic subunit presenilin-1 (PS1) increase the A&#x3b2;42 to A&#x3b2;40 ratio and are the major cause of familial AD (FAD). An opposing hypothesis states that loss of essential presenilin functions underlies the disease. A major argument for this hypothesis is the observation that the nearly inactive PS1 L435F mutant, paradoxically, causes FAD We now show that the very little A&#x3b2; generated by PS1 L435F consists primarily of A&#x3b2;43, a highly amyloidogenic species which was overlooked in previous studies of this mutant. We further demonstrate that the generation of A&#x3b2;43 is not due to a trans-dominant effect of this mutant on WT presenilin. Furthermore, we found A&#x3b2;43-containing plaques in brains of patients with this mutation. The aberrant generation of A&#x3b2;43 by this particular mutant provides a direct objection against the presenilin hypothesis.</AbstractText><CopyrightInformation>&#xa9; 2016 The Authors. Published under the terms of the CC BY 4.0 license.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kretner</LastName><ForeName>Benedikt</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Biomedical Center, Metabolic Biochemistry, Ludwig-Maximilians-University Munich, Munich, Germany DZNE - German Center for Neurodegenerative Diseases, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Trambauer</LastName><ForeName>Johannes</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Biomedical Center, Metabolic Biochemistry, Ludwig-Maximilians-University Munich, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fukumori</LastName><ForeName>Akio</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>DZNE - German Center for Neurodegenerative Diseases, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mielke</LastName><ForeName>Janina</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Center for Neuropathology and Prion Research, Ludwig-Maximilians-University Munich, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kuhn</LastName><ForeName>Peer-Hendrik</ForeName><Initials>PH</Initials><AffiliationInfo><Affiliation>DZNE - German Center for Neurodegenerative Diseases, Munich, Germany Neuroproteomics, Klinikum rechts der Isar and Institute for Advanced Study, Technische Universit&#xe4;t M&#xfc;nchen, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kremmer</LastName><ForeName>Elisabeth</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Munich Cluster for Systems Neurology (SyNergy), Munich, Germany Institute of Molecular Immunology, Helmholtz Zentrum M&#xfc;nchen, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Giese</LastName><ForeName>Armin</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Center for Neuropathology and Prion Research, Ludwig-Maximilians-University Munich, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lichtenthaler</LastName><ForeName>Stefan F</ForeName><Initials>SF</Initials><AffiliationInfo><Affiliation>DZNE - German Center for Neurodegenerative Diseases, Munich, Germany Neuroproteomics, Klinikum rechts der Isar and Institute for Advanced Study, Technische Universit&#xe4;t M&#xfc;nchen, Munich, Germany Munich Cluster for Systems Neurology (SyNergy), Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Haass</LastName><ForeName>Christian</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Biomedical Center, Metabolic Biochemistry, Ludwig-Maximilians-University Munich, Munich, Germany DZNE - German Center for Neurodegenerative Diseases, Munich, Germany Munich Cluster for Systems Neurology (SyNergy), Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arzberger</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>DZNE - German Center for Neurodegenerative Diseases, Munich, Germany Center for Neuropathology and Prion Research, Ludwig-Maximilians-University Munich, Munich, Germany Department of Psychiatry and Psychotherapy, Ludwig-Maximilians-University Munich, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Steiner</LastName><ForeName>Harald</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Biomedical Center, Metabolic Biochemistry, Ludwig-Maximilians-University Munich, Munich, Germany DZNE - German Center for Neurodegenerative Diseases, Munich, Germany harald.steiner@med.uni-muenchen.de.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>321366</GrantID><Acronym>ERC_</Acronym><Agency>European Research Council</Agency><Country>International</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>05</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>EMBO Mol Med</MedlineTA><NlmUniqueID>101487380</NlmUniqueID><ISSNLinking>1757-4676</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D050505">Mutant Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C508853">PSEN1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053764">Presenilin-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C098994">amyloid beta-protein (1-43)</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005625" MajorTopicYN="N">Frontal Lobe</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007150" MajorTopicYN="N">Immunohistochemistry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008853" MajorTopicYN="N">Microscopy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D050505" MajorTopicYN="N">Mutant Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053764" MajorTopicYN="N">Presenilin-1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer's disease</Keyword><Keyword MajorTopicYN="N">amyloid&#x2010;&#x3b2; peptide 43</Keyword><Keyword MajorTopicYN="N">neurodegeneration</Keyword><Keyword MajorTopicYN="N">presenilin</Keyword><Keyword MajorTopicYN="N">&#x3b3;&#x2010;secretase</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>3</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>3</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>9</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2016</Year><Month>5</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26988102</ArticleId><ArticleId IdType="pmc">PMC5119496</ArticleId><ArticleId IdType="doi">10.15252/emmm.201505952</ArticleId><ArticleId IdType="pii">emmm.201505952</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Burnouf S, Gorsky MK, Dols J, Gronke S, Partridge L (2015) A&#x3b2;43 is neurotoxic and primes aggregation of A&#x3b2;40 in&#xa0;vivo. Acta Neuropathol 130: 35&#x2013;47</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4469414</ArticleId><ArticleId IdType="pubmed">25862636</ArticleId></ArticleIdList></Reference><Reference><Citation>Capell A, Saffrich R, Olivo JC, Meyn L, Walter J, Grunberg J, Mathews P, Nixon R, Dotti C, Haass C (1997) Cellular expression and proteolytic processing of presenilin proteins is developmentally regulated during neuronal differentiation. J Neurochem 69: 2432&#x2013;2440</Citation><ArticleIdList><ArticleId IdType="pubmed">9375676</ArticleId></ArticleIdList></Reference><Reference><Citation>Chavez&#x2010;Gutierrez L, Bammens L, Benilova I, Vandersteen A, Benurwar M, Borgers M, Lismont S, Zhou L, Van Cleynenbreugel S, Esselmann H et&#xa0;al (2012) The mechanism of &#x3b3;&#x2010;secretase dysfunction in familial Alzheimer disease. EMBO J 31: 2261&#x2013;2274</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3364747</ArticleId><ArticleId IdType="pubmed">22505025</ArticleId></ArticleIdList></Reference><Reference><Citation>Citron M, Oltersdorf T, Haass C, McConlogue L, Hung AY, Seubert P, Vigo&#x2010;Pelfrey C, Lieberburg I, Selkoe DJ (1992) Mutation of the &#x3b2;&#x2010;amyloid precursor protein in familial Alzheimer's disease increases &#x3b2;&#x2010;protein production. Nature 360: 672&#x2013;674</Citation><ArticleIdList><ArticleId IdType="pubmed">1465129</ArticleId></ArticleIdList></Reference><Reference><Citation>Edbauer D, Winkler E, Regula JT, Pesold B, Steiner H, Haass C (2003) Reconstitution of &#x3b3;&#x2010;secretase activity. Nat Cell Biol 5: 486&#x2013;488</Citation><ArticleIdList><ArticleId IdType="pubmed">12679784</ArticleId></ArticleIdList></Reference><Reference><Citation>Godbolt AK, Beck JA, Collinge J, Garrard P, Warren JD, Fox NC, Rossor MN (2004) A presenilin 1 R278I mutation presenting with language impairment. Neurology 63: 1702&#x2013;1704</Citation><ArticleIdList><ArticleId IdType="pubmed">15534260</ArticleId></ArticleIdList></Reference><Reference><Citation>Haass C, Selkoe DJ (2007) Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid &#x3b2;&#x2010;peptide. Nat Rev Mol Cell Biol 8: 101&#x2013;112</Citation><ArticleIdList><ArticleId IdType="pubmed">17245412</ArticleId></ArticleIdList></Reference><Reference><Citation>Heilig EA, Xia W, Shen J, Kelleher RJ 3rd (2010) A presenilin&#x2010;1 mutation identified in familial Alzheimer disease with cotton wool plaques causes a nearly complete loss of &#x3b3;&#x2010;secretase activity. J Biol Chem 285: 22350&#x2013;22359</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2903357</ArticleId><ArticleId IdType="pubmed">20460383</ArticleId></ArticleIdList></Reference><Reference><Citation>Heilig EA, Gutti U, Tai T, Shen J, Kelleher RJ 3rd (2013) Trans&#x2010;dominant negative effects of pathogenic PSEN1 mutations on &#x3b3;&#x2010;secretase activity and A&#x3b2; production. J Neurosci 33: 11606&#x2013;11617</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3724549</ArticleId><ArticleId IdType="pubmed">23843529</ArticleId></ArticleIdList></Reference><Reference><Citation>Iizuka T, Shoji M, Harigaya Y, Kawarabayashi T, Watanabe M, Kanai M, Hirai S (1995) Amyloid &#x3b2;&#x2010;protein ending at Thr43 is a minor component of some diffuse plaques in the Alzheimer's disease brain, but is not found in cerebrovascular amyloid. Brain Res 702: 275&#x2013;278</Citation><ArticleIdList><ArticleId IdType="pubmed">8846089</ArticleId></ArticleIdList></Reference><Reference><Citation>Irizarry MC, Soriano F, McNamara M, Page KJ, Schenk D, Games D, Hyman BT (1997) A&#x3b2; deposition is associated with neuropil changes, but not with overt neuronal loss in the human amyloid precursor protein V717F (PDAPP) transgenic mouse. J Neurosci 17: 7053&#x2013;7059</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6573263</ArticleId><ArticleId IdType="pubmed">9278541</ArticleId></ArticleIdList></Reference><Reference><Citation>Jonsson T, Atwal JK, Steinberg S, Snaedal J, Jonsson PV, Bjornsson S, Stefansson H, Sulem P, Gudbjartsson D, Maloney J et&#xa0;al (2012) A mutation in APP protects against Alzheimer's disease and age&#x2010;related cognitive decline. Nature 488: 96&#x2013;99</Citation><ArticleIdList><ArticleId IdType="pubmed">22801501</ArticleId></ArticleIdList></Reference><Reference><Citation>Kretner B, Fukumori A, Kuhn PH, Perez&#x2010;Revuelta BI, Lichtenthaler SF, Haass C, Steiner H (2013) Important functional role of residue x of the presenilin GxGD protease active site motif for APP substrate cleavage specificity and substrate selectivity of &#x3b3;&#x2010;secretase. J Neurochem 125: 144&#x2013;156</Citation><ArticleIdList><ArticleId IdType="pubmed">23237322</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuhn PH, Wang H, Dislich B, Colombo A, Zeitschel U, Ellwart JW, Kremmer E, Rossner S, Lichtenthaler SF (2010) ADAM10 is the physiologically relevant, constitutive &#x3b1;&#x2010;secretase of the amyloid precursor protein in primary neurons. EMBO J 29: 3020&#x2013;3032</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2944055</ArticleId><ArticleId IdType="pubmed">20676056</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuperstein I, Broersen K, Benilova I, Rozenski J, Jonckheere W, Debulpaep M, Vandersteen A, Segers&#x2010;Nolten I, Van Der Werf K, Subramaniam V et&#xa0;al (2010) Neurotoxicity of Alzheimer's disease A&#x3b2; peptides is induced by small changes in the A&#x3b2;42 to A&#x3b2;40 ratio. EMBO J 29: 3408&#x2013;3420</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2957213</ArticleId><ArticleId IdType="pubmed">20818335</ArticleId></ArticleIdList></Reference><Reference><Citation>Lichtenthaler SF, Haass C, Steiner H (2011) Regulated intramembrane proteolysis&#x2013;lessons from amyloid precursor protein processing. J Neurochem 117: 779&#x2013;796</Citation><ArticleIdList><ArticleId IdType="pubmed">21413990</ArticleId></ArticleIdList></Reference><Reference><Citation>Meng P, Yoshida H, Tanji K, Matsumiya T, Xing F, Hayakari R, Wang L, Tsuruga K, Tanaka H, Mimura J et&#xa0;al (2015) Carnosic acid attenuates apoptosis induced by amyloid&#x2010;&#x3b2; 1&#x2010;42 or 1&#x2010;43 in SH&#x2010;SY5Y human neuroblastoma cells. Neurosci Res 94: 1&#x2013;9</Citation><ArticleIdList><ArticleId IdType="pubmed">25510380</ArticleId></ArticleIdList></Reference><Reference><Citation>Moehlmann T, Winkler E, Xia X, Edbauer D, Murrell J, Capell A, Kaether C, Zheng H, Ghetti B, Haass C et&#xa0;al (2002) Presenilin&#x2010;1 mutations of leucine 166 equally affect the generation of the Notch and APP intracellular domains independent of their effect on A&#x3b2;42 production. Proc Natl Acad Sci USA 99: 8025&#x2013;8030</Citation><ArticleIdList><ArticleId IdType="pmc">PMC123014</ArticleId><ArticleId IdType="pubmed">12048239</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakaya Y, Yamane T, Shiraishi H, Wang HQ, Matsubara E, Sato T, Dolios G, Wang R, De Strooper B, Shoji M et&#xa0;al (2005) Random mutagenesis of presenilin&#x2010;1 identifies novel mutants exclusively generating long amyloid &#x3b2;&#x2010;peptides. J Biol Chem 280: 19070&#x2013;19077</Citation><ArticleIdList><ArticleId IdType="pubmed">15764596</ArticleId></ArticleIdList></Reference><Reference><Citation>Page RM, Baumann K, Tomioka M, Perez&#x2010;Revuelta BI, Fukumori A, Jacobsen H, Flohr A, Luebbers T, Ozmen L, Steiner H et&#xa0;al (2008) Generation of A&#x3b2;38 and A&#x3b2;42 is independently and differentially affected by FAD&#x2010;associated presenilin 1 mutations and &#x3b3;&#x2010;secretase modulation. J Biol Chem 283: 677&#x2013;683</Citation><ArticleIdList><ArticleId IdType="pubmed">17962197</ArticleId></ArticleIdList></Reference><Reference><Citation>Parvathy S, Davies P, Haroutunian V, Purohit DP, Davis KL, Mohs RC, Park H, Moran TM, Chan JY, Buxbaum JD (2001) Correlation between A&#x3b2;x&#x2010;40&#x2010;, A&#x3b2;x&#x2010;42&#x2010;, and A&#x3b2;x&#x2010;43&#x2010;containing amyloid plaques and cognitive decline. Arch Neurol 58: 2025&#x2013;2032</Citation><ArticleIdList><ArticleId IdType="pubmed">11735776</ArticleId></ArticleIdList></Reference><Reference><Citation>Saito T, Suemoto T, Brouwers N, Sleegers K, Funamoto S, Mihira N, Matsuba Y, Yamada K, Nilsson P, Takano J et&#xa0;al (2011) Potent amyloidogenicity and pathogenicity of A&#x3b2;43. Nat Neurosci 14: 1023&#x2013;1032</Citation><ArticleIdList><ArticleId IdType="pubmed">21725313</ArticleId></ArticleIdList></Reference><Reference><Citation>Sandebring A, Welander H, Winblad B, Graff C, Tjernberg LO (2013) The pathogenic A&#x3b2;43 is enriched in familial and sporadic Alzheimer disease. PLoS One 8: e55847</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3569467</ArticleId><ArticleId IdType="pubmed">23409063</ArticleId></ArticleIdList></Reference><Reference><Citation>Sastre M, Steiner H, Fuchs K, Capell A, Multhaup G, Condron MM, Teplow DB, Haass C (2001) Presenilin&#x2010;dependent &#x3b3;&#x2010;secretase processing of &#x3b2;&#x2010;amyloid precursor protein at a site corresponding to the S3 cleavage of Notch. EMBO Rep 2: 835&#x2013;841</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1084035</ArticleId><ArticleId IdType="pubmed">11520861</ArticleId></ArticleIdList></Reference><Reference><Citation>Saura CA, Choi SY, Beglopoulos V, Malkani S, Zhang D, Shankaranarayana Rao BS, Chattarji S, Kelleher RJ 3rd, Kandel ER, Duff K et&#xa0;al (2004) Loss of presenilin function causes impairments of memory and synaptic plasticity followed by age&#x2010;dependent neurodegeneration. Neuron 42: 23&#x2013;36</Citation><ArticleIdList><ArticleId IdType="pubmed">15066262</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheuner D, Eckman C, Jensen M, Song X, Citron M, Suzuki N, Bird TD, Hardy J, Hutton M, Kukull W et&#xa0;al (1996) Secreted amyloid &#x3b2;&#x2010;protein similar to that in the senile plaques of Alzheimer's disease is increased in&#xa0;vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nat Med 2: 864&#x2013;870</Citation><ArticleIdList><ArticleId IdType="pubmed">8705854</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen J, Kelleher RJ 3rd (2007) The presenilin hypothesis of Alzheimer's disease: evidence for a loss&#x2010;of&#x2010;function pathogenic mechanism. Proc Natl Acad Sci USA 104: 403&#x2013;409</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1766397</ArticleId><ArticleId IdType="pubmed">17197420</ArticleId></ArticleIdList></Reference><Reference><Citation>Shirotani K, Tomioka M, Kremmer E, Haass C, Steiner H (2007) Pathological activity of familial Alzheimer's disease&#x2010;associated mutant presenilin can be executed by six different &#x3b3;&#x2010;secretase complexes. Neurobiol Dis 27: 102&#x2013;107</Citation><ArticleIdList><ArticleId IdType="pubmed">17560791</ArticleId></ArticleIdList></Reference><Reference><Citation>Steiner H, Romig H, Grim MG, Philipp U, Pesold B, Citron M, Baumeister R, Haass C (1999) The biological and pathological function of the presenilin&#x2010;1 &#x2206;exon 9 mutation is independent of its defect to undergo proteolytic processing. J Biol Chem 274: 7615&#x2013;7618</Citation><ArticleIdList><ArticleId IdType="pubmed">10075646</ArticleId></ArticleIdList></Reference><Reference><Citation>Steiner H, Kostka M, Romig H, Basset G, Pesold B, Hardy J, Capell A, Meyn L, Grim MG, Baumeister R et&#xa0;al (2000) Glycine 384 is required for presenilin&#x2010;1 function and is conserved in polytopic bacterial aspartyl proteases. Nat Cell Biol 2: 848&#x2013;851</Citation><ArticleIdList><ArticleId IdType="pubmed">11056541</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang B, Yang W, Wen W, Sun J, Su B, Liu B, Ma D, Lv D, Wen Y, Qu T et&#xa0;al (2010) &#x3b3;&#x2010;Secretase gene mutations in familial acne inversa. Science 330: 1065</Citation><ArticleIdList><ArticleId IdType="pubmed">20929727</ArticleId></ArticleIdList></Reference><Reference><Citation>Weggen S, Beher D (2012) Molecular consequences of amyloid precursor protein and presenilin mutations causing autosomal&#x2010;dominant Alzheimer's disease. Alzheimers Res Ther 4: 9</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3334542</ArticleId><ArticleId IdType="pubmed">22494386</ArticleId></ArticleIdList></Reference><Reference><Citation>Welander H, Franberg J, Graff C, Sundstrom E, Winblad B, Tjernberg LO (2009) A&#x3b2;43 is more frequent than A&#x3b2;40 in amyloid plaque cores from Alzheimer disease brains. J Neurochem 110: 697&#x2013;706</Citation><ArticleIdList><ArticleId IdType="pubmed">19457079</ArticleId></ArticleIdList></Reference><Reference><Citation>Wiltfang J, Smirnov A, Schnierstein B, Kelemen G, Matthies U, Klafki HW, Staufenbiel M, Huther G, Ruther E, Kornhuber J (1997) Improved electrophoretic separation and immunoblotting of &#x3b2;&#x2010;amyloid (A&#x3b2;) peptides 1&#x2010;40, 1&#x2010;42, and 1&#x2010;43. Electrophoresis 18: 527&#x2013;532</Citation><ArticleIdList><ArticleId IdType="pubmed">9150936</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia D, Watanabe H, Wu B, Lee SH, Li Y, Tsvetkov E, Bolshakov VY, Shen J, Kelleher RJ 3rd (2015) Presenilin&#x2010;1 knockin mice reveal loss&#x2010;of&#x2010;function mechanism for familial Alzheimer's disease. Neuron 85: 967&#x2013;981</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4358812</ArticleId><ArticleId IdType="pubmed">25741723</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamasaki A, Eimer S, Okochi M, Smialowska A, Kaether C, Baumeister R, Haass C, Steiner H (2006) The GxGD motif of presenilin contributes to catalytic function and substrate identification of &#x3b3;&#x2010;secretase. J Neurosci 26: 3821&#x2013;3828</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6674133</ArticleId><ArticleId IdType="pubmed">16597736</ArticleId></ArticleIdList></Reference><Reference><Citation>Zou K, Liu J, Watanabe A, Hiraga S, Liu S, Tanabe C, Maeda T, Terayama Y, Takahashi S, Michikawa M et&#xa0;al (2013) A&#x3b2;43 is the earliest&#x2010;depositing A&#x3b2; species in APP transgenic mouse brain and is converted to A&#x3b2;41 by two active domains of ACE. Am J Pathol 182: 2322&#x2013;2331</Citation><ArticleIdList><ArticleId IdType="pubmed">23562443</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">1669714</PMID><DateCompleted><Year>1994</Year><Month>02</Month><Day>25</Day></DateCompleted><DateRevised><Year>2019</Year><Month>10</Month><Day>28</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1015-6305</ISSN><JournalIssue CitedMedium="Print"><Volume>1</Volume><Issue>4</Issue><PubDate><Year>1991</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Brain pathology (Zurich, Switzerland)</Title><ISOAbbreviation>Brain Pathol</ISOAbbreviation></Journal><ArticleTitle>Amyloid precursor protein (APP) and beta A4 amyloid in the etiology of Alzheimer's disease: precursor-product relationships in the derangement of neuronal function.</ArticleTitle><Pagination><StartPage>241</StartPage><EndPage>251</EndPage><MedlinePgn>241-51</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Beyreuther</LastName><ForeName>K</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Center for Molecular Biology, University of Heidelberg, Federal Republic of Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Masters</LastName><ForeName>C L</ForeName><Initials>CL</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Brain Pathol</MedlineTA><NlmUniqueID>9216781</NlmUniqueID><ISSNLinking>1015-6305</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000682">Amyloid</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000682" MajorTopicYN="N">Amyloid</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001923" MajorTopicYN="N">Brain Chemistry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008954" MajorTopicYN="N">Models, Biological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016874" MajorTopicYN="N">Neurofibrillary Tangles</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009928" MajorTopicYN="N">Organ Specificity</DescriptorName></MeshHeading></MeshHeadingList><NumberOfReferences>127</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1991</Year><Month>7</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1991</Year><Month>7</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1991</Year><Month>7</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">1669714</ArticleId><ArticleId IdType="doi">10.1111/j.1750-3639.1991.tb00667.x</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">27033548</PMID><DateCompleted><Year>2016</Year><Month>06</Month><Day>07</Day></DateCompleted><DateRevised><Year>2024</Year><Month>03</Month><Day>26</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1095-9203</ISSN><JournalIssue CitedMedium="Internet"><Volume>352</Volume><Issue>6286</Issue><PubDate><Year>2016</Year><Month>May</Month><Day>06</Day></PubDate></JournalIssue><Title>Science (New York, N.Y.)</Title><ISOAbbreviation>Science</ISOAbbreviation></Journal><ArticleTitle>Complement and microglia mediate early synapse loss in Alzheimer mouse models.</ArticleTitle><Pagination><StartPage>712</StartPage><EndPage>716</EndPage><MedlinePgn>712-716</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1126/science.aad8373</ELocationID><Abstract><AbstractText>Synapse loss in Alzheimer's disease (AD) correlates with cognitive decline. Involvement of microglia and complement in AD has been attributed to neuroinflammation, prominent late in disease. Here we show in mouse models that complement and microglia mediate synaptic loss early in AD. C1q, the initiating protein of the classical complement cascade, is increased and associated with synapses before overt plaque deposition. Inhibition of C1q, C3, or the microglial complement receptor CR3 reduces the number of phagocytic microglia, as well as the extent of early synapse loss. C1q is necessary for the toxic effects of soluble &#x3b2;-amyloid (A&#x3b2;) oligomers on synapses and hippocampal long-term potentiation. Finally, microglia in adult brains engulf synaptic material in a CR3-dependent process when exposed to soluble A&#x3b2; oligomers. Together, these findings suggest that the complement-dependent pathway and microglia that prune excess synapses in development are inappropriately activated and mediate synapse loss in AD.</AbstractText><CopyrightInformation>Copyright &#xa9; 2016, American Association for the Advancement of Science.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hong</LastName><ForeName>Soyon</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>F.M. Kirby Neurobiology Center, Boston Children's Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Beja-Glasser</LastName><ForeName>Victoria F</ForeName><Initials>VF</Initials><AffiliationInfo><Affiliation>F.M. Kirby Neurobiology Center, Boston Children's Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Nfonoyim</LastName><ForeName>Bianca M</ForeName><Initials>BM</Initials><AffiliationInfo><Affiliation>F.M. Kirby Neurobiology Center, Boston Children's Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Frouin</LastName><ForeName>Arnaud</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>F.M. Kirby Neurobiology Center, Boston Children's Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Shaomin</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Ann Romney Center for Neurologic Diseases, Department of Neurology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ramakrishnan</LastName><ForeName>Saranya</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>F.M. Kirby Neurobiology Center, Boston Children's Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Merry</LastName><ForeName>Katherine M</ForeName><Initials>KM</Initials><AffiliationInfo><Affiliation>F.M. Kirby Neurobiology Center, Boston Children's Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shi</LastName><ForeName>Qiaoqiao</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Ann Romney Center for Neurologic Diseases, Department of Neurology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rosenthal</LastName><ForeName>Arnon</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Alector Inc., 953 Indiana St, San Francisco, California 94107, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Annexon Biosciences, 280 Utah Avenue Suite 110, South San Francisco, California 94080, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Anatomy, University of California San Francisco, California 94143, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barres</LastName><ForeName>Ben A</ForeName><Initials>BA</Initials><AffiliationInfo><Affiliation>Department of Neurobiology, Stanford University School of Medicine, Palo Alto, California 94305, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lemere</LastName><ForeName>Cynthia A</ForeName><Initials>CA</Initials><AffiliationInfo><Affiliation>Ann Romney Center for Neurologic Diseases, Department of Neurology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Selkoe</LastName><ForeName>Dennis J</ForeName><Initials>DJ</Initials><AffiliationInfo><Affiliation>Ann Romney Center for Neurologic Diseases, Department of Neurology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Prothena Biosciences, Dublin, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stevens</LastName><ForeName>Beth</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>F.M. Kirby Neurobiology Center, Boston Children's Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, Massachusetts 02142, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P01 AG015379</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01NS083845</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 AG000222</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 NS083845</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG006173</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 HD090255</GrantID><Acronym>HD</Acronym><Agency>NICHD NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>1RF1AG051496A</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS083845</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG000222</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG051496</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>03</Month><Day>31</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Science</MedlineTA><NlmUniqueID>0404511</NlmUniqueID><ISSNLinking>0036-8075</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000076122">Disks Large Homolog 4 Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C501447">Dlg4 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016177">Macrophage-1 Antigen</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008565">Membrane Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016708">Synaptophysin</NameOfSubstance></Chemical><Chemical><RegistryNumber>80295-33-6</RegistryNumber><NameOfSubstance UI="D015922">Complement C1q</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.4.8</RegistryNumber><NameOfSubstance UI="D051528">Guanylate Kinases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Neurosci. 2016 Jun;17(6):336. doi: 10.1038/nrn.2016.52.</RefSource><PMID Version="1">27098771</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D056547" MajorTopicYN="N">CA1 Region, Hippocampal</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015922" MajorTopicYN="N">Complement C1q</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003171" MajorTopicYN="N">Complement Pathway, Classical</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000076122" MajorTopicYN="N">Disks Large Homolog 4 Protein</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051528" MajorTopicYN="N">Guanylate Kinases</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017774" MajorTopicYN="N">Long-Term Potentiation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016177" MajorTopicYN="N">Macrophage-1 Antigen</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008565" MajorTopicYN="N">Membrane Proteins</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010587" MajorTopicYN="N">Phagocytosis</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058225" MajorTopicYN="N">Plaque, Amyloid</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013569" MajorTopicYN="N">Synapses</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016708" MajorTopicYN="N">Synaptophysin</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015854" MajorTopicYN="N">Up-Regulation</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>11</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>3</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>4</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>4</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>6</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2016</Year><Month>11</Month><Day>6</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27033548</ArticleId><ArticleId IdType="mid">NIHMS825491</ArticleId><ArticleId IdType="pmc">PMC5094372</ArticleId><ArticleId IdType="doi">10.1126/science.aad8373</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hong S, Dissing-Olesen L, Stevens B. New insights on the role of microglia in synaptic pruning in health and disease. Curr Opin Neurobiol. 2016 doi:10.1016/j.conb.2015.12.004.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5479435</ArticleId><ArticleId IdType="pubmed">26745839</ArticleId></ArticleIdList></Reference><Reference><Citation>Wyss-Coray T, Rogers J. Inflammation in Alzheimer disease-a brief review of the basic science and clinical literature. Cold Spring Harbor Perspectives in Medicine. 2012;2:a006346.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3253025</ArticleId><ArticleId IdType="pubmed">22315714</ArticleId></ArticleIdList></Reference><Reference><Citation>Benoit ME, et al. C1q-induced LRP1B and GPR6 proteins expressed early in Alzheimer disease mouse models, are essential for the C1q-mediated protection against amyloid-&#x3b2; neurotoxicity. Journal of Biological Chemistry. 2013;288:654&#x2013;665.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3537064</ArticleId><ArticleId IdType="pubmed">23150673</ArticleId></ArticleIdList></Reference><Reference><Citation>Mucke L, Selkoe DJ. Neurotoxicity of Amyloid &#x3b2;-Protein: Synaptic and Network Dysfunction. Cold Spring Harbor Perspectives in Medicine. 2012;2:a006338.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3385944</ArticleId><ArticleId IdType="pubmed">22762015</ArticleId></ArticleIdList></Reference><Reference><Citation>Stevens B, et al. The classical complement cascade mediates CNS synapse elimination. Cell. 2007;131:1164&#x2013;1178.</Citation><ArticleIdList><ArticleId IdType="pubmed">18083105</ArticleId></ArticleIdList></Reference><Reference><Citation>Schafer DP, et al. Microglia Sculpt Postnatal Neural Circuits in an Activity and Complement-Dependent Manner. Neuron. 2012;74:691&#x2013;705.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3528177</ArticleId><ArticleId IdType="pubmed">22632727</ArticleId></ArticleIdList></Reference><Reference><Citation>Bialas AR, Stevens B. TGF-&#x3b2; signaling regulates neuronal C1q expression and developmental synaptic refinement. Nat Neurosci. 2013;16:1773&#x2013;1782.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3973738</ArticleId><ArticleId IdType="pubmed">24162655</ArticleId></ArticleIdList></Reference><Reference><Citation>DeKosky ST, Scheff SW. Synapse loss in frontal cortex biopsies in Alzheimer's disease: correlation with cognitive severity. Ann Neurol. 1990;27:457&#x2013;464.</Citation><ArticleIdList><ArticleId IdType="pubmed">2360787</ArticleId></ArticleIdList></Reference><Reference><Citation>Terry RD, et al. Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol. 1991;30:572&#x2013;580.</Citation><ArticleIdList><ArticleId IdType="pubmed">1789684</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong S, Wilton D, Stevens B, Richardson DS. Structured Illumination Microscopy for the investigation of synaptic structure and function. Methods in Molecular Biology; Synapse Development: Methods and Protocols</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5479421</ArticleId><ArticleId IdType="pubmed">27943190</ArticleId></ArticleIdList></Reference><Reference><Citation>Mucke L, et al. High-Level Neuronal Expression of Abeta 1-42 in Wild-Type Human Amyloid Protein Precursor Transgenic Mice: Synaptotoxicity without Plaque Formation. Journal of Neuroscience. 2000;20:4050.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6772621</ArticleId><ArticleId IdType="pubmed">10818140</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong S, et al. Dynamic Analysis of Amyloid -Protein in Behaving Mice Reveals Opposing Changes in ISF versus Parenchymal A during Age-Related Plaque Formation. Journal of Neuroscience. 2011;31:15861&#x2013;15869.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3227224</ArticleId><ArticleId IdType="pubmed">22049429</ArticleId></ArticleIdList></Reference><Reference><Citation>Stephan AH, et al. A Dramatic Increase of C1q Protein in the CNS during Normal Aging. Journal of Neuroscience. 2013;33:13460&#x2013;13474.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3742932</ArticleId><ArticleId IdType="pubmed">23946404</ArticleId></ArticleIdList></Reference><Reference><Citation>Harris JA, et al. Many neuronal and behavioral impairments in transgenic mouse models of Alzheimer's disease are independent of caspase cleavage of the amyloid precursor protein. J Neurosci. 2010;30:372&#x2013;381.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3064502</ArticleId><ArticleId IdType="pubmed">20053918</ArticleId></ArticleIdList></Reference><Reference><Citation>Jankowsky JL, et al. Mutant presenilins specifically elevate the levels of the 42 residue beta-amyloid peptide in vivo: evidence for augmentation of a 42-specific gamma secretase. Hum. Mol. Genet. 2004;13:159&#x2013;170.</Citation><ArticleIdList><ArticleId IdType="pubmed">14645205</ArticleId></ArticleIdList></Reference><Reference><Citation>Botto M, et al. Homozygous C1q deficiency causes glomerulonephritis associated with multiple apoptotic bodies. Nat Genet. 1998;19:56&#x2013;59.</Citation><ArticleIdList><ArticleId IdType="pubmed">9590289</ArticleId></ArticleIdList></Reference><Reference><Citation>Freir DB, et al. A&#x3b2; oligomers inhibit synapse remodelling necessary for memory consolidation. Neurobiology of Aging. 2011;32:2211&#x2013;2218.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2891223</ArticleId><ArticleId IdType="pubmed">20097446</ArticleId></ArticleIdList></Reference><Reference><Citation>Wessels MR, et al. Studies of group B streptococcal infection in mice deficient in complement component C3 or C4 demonstrate an essential role for complement in both innate and acquired immunity. Proc Natl Acad Sci USA. 1995;92:11490&#x2013;11494.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC40427</ArticleId><ArticleId IdType="pubmed">8524789</ArticleId></ArticleIdList></Reference><Reference><Citation>Schafer DP, Lehrman EK, Heller CT, Stevens B. An engulfment assay: a protocol to assess interactions between CNS phagocytes and neurons. J Vis Exp. 2014 doi:10.3791/51482.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4188069</ArticleId><ArticleId IdType="pubmed">24962472</ArticleId></ArticleIdList></Reference><Reference><Citation>Ebihara T, Kawabata I, Usui S, Sobue K, Okabe S. Synchronized formation and remodeling of postsynaptic densities: long-term visualization of hippocampal neurons expressing postsynaptic density proteins tagged with green fluorescent protein. Journal of Neuroscience. 2003;23:2170&#x2013;2181.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6742042</ArticleId><ArticleId IdType="pubmed">12657676</ArticleId></ArticleIdList></Reference><Reference><Citation>Coxon A, et al. A Novel Role for the &#x3b2;2 Integrin CD11b/CD18 in Neutrophil Apoptosis: A Homeostatic Mechanism in Inflammation. Immunity. 1996;5:653&#x2013;666.</Citation><ArticleIdList><ArticleId IdType="pubmed">8986723</ArticleId></ArticleIdList></Reference><Reference><Citation>Butovsky O, et al. Identification of a unique TGF-&#x3b2;&#x2013;dependent molecular and functional signature in microglia. Nat Neurosci. 2013;17:131&#x2013;143.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4066672</ArticleId><ArticleId IdType="pubmed">24316888</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ. Alzheimer's disease is a synaptic failure. Science. 2002;298:789&#x2013;791.</Citation><ArticleIdList><ArticleId IdType="pubmed">12399581</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheff SW, Price DA, Schmitt FA, Mufson EJ. Hippocampal synaptic loss in early Alzheimer's disease and mild cognitive impairment. Neurobiology of Aging. 2006;27:1372&#x2013;1384.</Citation><ArticleIdList><ArticleId IdType="pubmed">16289476</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheff SW, Price DA, Schmitt FA, DeKosky ST, Mufson EJ. Synaptic alterations in CA1 in mild Alzheimer disease and mild cognitive impairment. Neurology. 2007;68:1501&#x2013;1508.</Citation><ArticleIdList><ArticleId IdType="pubmed">17470753</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong S, et al. Soluble A&#x3b2; Oligomers Are Rapidly Sequestered from Brain ISF In Vivo and Bind GM1 Ganglioside on Cellular Membranes. Neuron. 2014 doi:10.1016/j.neuron.2014.02.027.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4129520</ArticleId><ArticleId IdType="pubmed">24685176</ArticleId></ArticleIdList></Reference><Reference><Citation>Stephan AH, Barres BA, Stevens B. The complement system: an unexpected role in synaptic pruning during development and disease. Annu. Rev. Neurosci. 2012;35:369&#x2013;389.</Citation><ArticleIdList><ArticleId IdType="pubmed">22715882</ArticleId></ArticleIdList></Reference><Reference><Citation>Datwani A, et al. Classical MHCI molecules regulate retinogeniculate refinement and limit ocular dominance plasticity. Neuron. 2009;64:463&#x2013;470.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2787480</ArticleId><ArticleId IdType="pubmed">19945389</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim T, et al. Human LilrB2 Is a -Amyloid Receptor and Its Murine Homolog PirB Regulates Synaptic Plasticity in an Alzheimer's Model. Science. 2013;341:1399&#x2013;1404.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3853120</ArticleId><ArticleId IdType="pubmed">24052308</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee H, et al. Synapse elimination and learning r. Nature. 2014:1&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4016165</ArticleId><ArticleId IdType="pubmed">24695230</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">27030596</PMID><DateCompleted><Year>2016</Year><Month>12</Month><Day>19</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>09</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1946-6242</ISSN><JournalIssue CitedMedium="Internet"><Volume>8</Volume><Issue>332</Issue><PubDate><Year>2016</Year><Month>Mar</Month><Day>30</Day></PubDate></JournalIssue><Title>Science translational medicine</Title><ISOAbbreviation>Sci Transl Med</ISOAbbreviation></Journal><ArticleTitle>Neuronal heparan sulfates promote amyloid pathology by modulating brain amyloid-&#x3b2; clearance and aggregation in Alzheimer's disease.</ArticleTitle><Pagination><StartPage>332ra44</StartPage><MedlinePgn>332ra44</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1126/scitranslmed.aad3650</ELocationID><Abstract><AbstractText>Accumulation of amyloid-&#x3b2; (A&#x3b2;) peptide in the brain is the first critical step in the pathogenesis of Alzheimer's disease (AD). Studies in humans suggest that A&#x3b2; clearance from the brain is frequently impaired in late-onset AD. A&#x3b2; accumulation leads to the formation of A&#x3b2; aggregates, which injure synapses and contribute to eventual neurodegeneration. Cell surface heparan sulfates (HSs), expressed on all cell types including neurons, have been implicated in several features in the pathogenesis of AD including its colocalization with amyloid plaques and modulatory role in A&#x3b2; aggregation. We show that removal of neuronal HS by conditional deletion of the Ext1 gene, which encodes an essential glycosyltransferase for HS biosynthesis, in postnatal neurons of amyloid model APP/PS1 mice led to a reduction in both A&#x3b2; oligomerization and the deposition of amyloid plaques. In vivo microdialysis experiments also detected an accelerated rate of A&#x3b2; clearance in the brain interstitial fluid, suggesting that neuronal HS either inhibited or represented an inefficient pathway for A&#x3b2; clearance. We found that the amounts of various HS proteoglycans (HSPGs) were increased in postmortem human brain tissues from AD patients, suggesting that this pathway may contribute directly to amyloid pathogenesis. Our findings have implications for AD pathogenesis and provide insight into therapeutic interventions targeting A&#x3b2;-HSPG interactions.</AbstractText><CopyrightInformation>Copyright &#xa9; 2016, American Association for the Advancement of Science.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Chia-Chen</ForeName><Initials>CC</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Na</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yamaguchi</LastName><ForeName>Yu</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA 92037, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cirrito</LastName><ForeName>John R</ForeName><Initials>JR</Initials><AffiliationInfo><Affiliation>Department of Neurology, Hope Center for Neurological Disorders, Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kanekiyo</LastName><ForeName>Takahisa</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Holtzman</LastName><ForeName>David M</ForeName><Initials>DM</Initials><AffiliationInfo><Affiliation>Department of Neurology, Hope Center for Neurological Disorders, Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bu</LastName><ForeName>Guojun</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA. Fujian Provincial Key Laboratory of Neurodegenerative Disease and Aging Research, Institute of Neuroscience, College of Medicine, Xiamen University, Xiamen, Fujian 361100, China. bu.guojun@mayo.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 AG028383</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50AG016574</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01AG046205</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 NS074969</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG027924</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01AG027924</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG046205</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01AG035355</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG016574</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS088496</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG042513</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG051504</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG035355</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01NS088496</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01NS074969</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01AG042513</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG046205</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Sci Transl Med</MedlineTA><NlmUniqueID>101505086</NlmUniqueID><ISSNLinking>1946-6234</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000682">Amyloid</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>9050-30-0</RegistryNumber><NameOfSubstance UI="D006497">Heparitin Sulfate</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Neurosurgery. 2016 Aug;79(2):N12-3. doi: 10.1227/NEU.0000000000001291.</RefSource><PMID Version="1">27428635</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000682" MajorTopicYN="N">Amyloid</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006497" MajorTopicYN="N">Heparitin Sulfate</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000098" MajorTopicYN="N">blood supply</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007249" MajorTopicYN="N">Inflammation</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D066263" MajorTopicYN="N">Protein Aggregation, Pathological</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList><CoiStatement><b>Competing interests:</b> DH is on the scientific advisory boards of Genentech, AstraZeneca, Neurophage, and Denali, and has consulted for Eli Lilly, AbbVie, Novartis, Ono Pharma. DH is a cofounder of C2N Diagnostics LLC and has equity in the company. The other authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>9</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>3</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>4</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>4</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>12</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2017</Year><Month>7</Month><Day>17</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27030596</ArticleId><ArticleId IdType="mid">NIHMS877653</ArticleId><ArticleId IdType="pmc">PMC5512541</ArticleId><ArticleId IdType="doi">10.1126/scitranslmed.aad3650</ArticleId><ArticleId IdType="pii">8/332/332ra44</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer&#x2019;s disease: progress and problems on the road to therapeutics. Science. 2002;297:353&#x2013;356.</Citation><ArticleIdList><ArticleId IdType="pubmed">12130773</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ. Deciphering the genesis and fate of amyloid beta-protein yields novel therapies for Alzheimer disease. J Clin Invest. 2002;110:1375&#x2013;1381.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC151820</ArticleId><ArticleId IdType="pubmed">12438432</ArticleId></ArticleIdList></Reference><Reference><Citation>Vassar R, Bennett BD, Babu-Khan S, Kahn S, Mendiaz EA, Denis P, Teplow DB, Ross S, Amarante P, Loeloff R, Luo Y, Fisher S, Fuller J, Edenson S, Lile J, Jarosinski MA, Biere AL, Curran E, Burgess T, Louis JC, Collins F, Treanor J, Rogers G, Citron M. Beta-secretase cleavage of Alzheimer&#x2019;s amyloid precursor protein by the transmembrane aspartic protease BACE. Science. 1999;286:735&#x2013;741.</Citation><ArticleIdList><ArticleId IdType="pubmed">10531052</ArticleId></ArticleIdList></Reference><Reference><Citation>Kimberly WT, LaVoie MJ, Ostaszewski BL, Ye W, Wolfe MS, Selkoe DJ. Gamma-secretase is a membrane protein complex comprised of presenilin, nicastrin, Aph-1, and Pen-2. Proc Natl Acad Sci U S A. 2003;100:6382&#x2013;6387.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC164455</ArticleId><ArticleId IdType="pubmed">12740439</ArticleId></ArticleIdList></Reference><Reference><Citation>Goate A. Segregation of a missense mutation in the amyloid beta-protein precursor gene with familial Alzheimer&#x2019;s disease. J Alzheimers Dis. 2006;9:341&#x2013;347.</Citation><ArticleIdList><ArticleId IdType="pubmed">16914872</ArticleId></ArticleIdList></Reference><Reference><Citation>Bu G. Apolipoprotein E and its receptors in Alzheimer&#x2019;s disease: pathways, pathogenesis and therapy. Nat Rev Neurosci. 2009;10:333&#x2013;344.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2908393</ArticleId><ArticleId IdType="pubmed">19339974</ArticleId></ArticleIdList></Reference><Reference><Citation>Mucke L, Selkoe DJ. Neurotoxicity of amyloid beta-protein: synaptic and network dysfunction. Cold Spring Harb Perspect Med. 2012;2:a006338.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3385944</ArticleId><ArticleId IdType="pubmed">22762015</ArticleId></ArticleIdList></Reference><Reference><Citation>Cirrito JR, May PC, O&#x2019;Dell MA, Taylor JW, Parsadanian M, Cramer JW, Audia JE, Nissen JS, Bales KR, Paul SM, DeMattos RB, Holtzman DM. In vivo assessment of brain interstitial fluid with microdialysis reveals plaque-associated changes in amyloid-beta metabolism and half-life. J Neurosci. 2003;23:8844&#x2013;8853.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6740389</ArticleId><ArticleId IdType="pubmed">14523085</ArticleId></ArticleIdList></Reference><Reference><Citation>Bateman RJ, Munsell LY, Morris JC, Swarm R, Yarasheski KE, Holtzman DM. Human amyloid-beta synthesis and clearance rates as measured in cerebrospinal fluid in vivo. Nat Med. 2006;12:856&#x2013;861.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2983090</ArticleId><ArticleId IdType="pubmed">16799555</ArticleId></ArticleIdList></Reference><Reference><Citation>Mawuenyega KG, Sigurdson W, Ovod V, Munsell L, Kasten T, Morris JC, Yarasheski KE, Bateman RJ. Decreased clearance of CNS beta-amyloid in Alzheimer&#x2019;s disease. Science. 2010;330:1774.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3073454</ArticleId><ArticleId IdType="pubmed">21148344</ArticleId></ArticleIdList></Reference><Reference><Citation>Park PW, Reizes O, Bernfield M. Cell surface heparan sulfate proteoglycans: selective regulators of ligand-receptor encounters. J Biol Chem. 2000;275:29923&#x2013;29926.</Citation><ArticleIdList><ArticleId IdType="pubmed">10931855</ArticleId></ArticleIdList></Reference><Reference><Citation>Sarrazin S, Lamanna WC, Esko JD. Heparan sulfate proteoglycans. Cold Spring Harb Perspect Biol. 2011;3</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3119907</ArticleId><ArticleId IdType="pubmed">21690215</ArticleId></ArticleIdList></Reference><Reference><Citation>Bishop JR, Schuksz M, Esko JD. Heparan sulphate proteoglycans fine-tune mammalian physiology. Nature. 2007;446:1030&#x2013;1037.</Citation><ArticleIdList><ArticleId IdType="pubmed">17460664</ArticleId></ArticleIdList></Reference><Reference><Citation>Lind T, Tufaro F, McCormick C, Lindahl U, Lidholt K. The putative tumor suppressors EXT1 and EXT2 are glycosyltransferases required for the biosynthesis of heparan sulfate. J Biol Chem. 1998;273:26265&#x2013;26268.</Citation><ArticleIdList><ArticleId IdType="pubmed">9756849</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin X, Wei G, Shi Z, Dryer L, Esko JD, Wells DE, Matzuk MM. Disruption of gastrulation and heparan sulfate biosynthesis in EXT1-deficient mice. Dev Biol. 2000;224:299&#x2013;311.</Citation><ArticleIdList><ArticleId IdType="pubmed">10926768</ArticleId></ArticleIdList></Reference><Reference><Citation>Cotman SL, Halfter W, Cole GJ. Agrin binds to beta-amyloid (Abeta), accelerates abeta fibril formation, and is localized to Abeta deposits in Alzheimer&#x2019;s disease brain. Mol Cell Neurosci. 2000;15:183&#x2013;198.</Citation><ArticleIdList><ArticleId IdType="pubmed">10673326</ArticleId></ArticleIdList></Reference><Reference><Citation>van Horssen J, Otte-Holler I, David G, Maat-Schieman ML, van den Heuvel LP, Wesseling P, de Waal RM, Verbeek MM. Heparan sulfate proteoglycan expression in cerebrovascular amyloid beta deposits in Alzheimer&#x2019;s disease and hereditary cerebral hemorrhage with amyloidosis (Dutch) brains. Acta Neuropathol. 2001;102:604&#x2013;614.</Citation><ArticleIdList><ArticleId IdType="pubmed">11761721</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Gool D, David G, Lammens M, Baro F, Dom R. Heparan sulfate expression patterns in the amyloid deposits of patients with Alzheimer&#x2019;s and Lewy body type dementia. Dementia. 1993;4:308&#x2013;314.</Citation><ArticleIdList><ArticleId IdType="pubmed">8136893</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang GL, Zhang X, Wang XM, Li JP. Towards understanding the roles of heparan sulfate proteoglycans in Alzheimer&#x2019;s disease. Biomed Res Int. 2014;2014 516028.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4135094</ArticleId><ArticleId IdType="pubmed">25157361</ArticleId></ArticleIdList></Reference><Reference><Citation>Watanabe N, Araki W, Chui DH, Makifuchi T, Ihara Y, Tabira T. Glypican-1 as an Abeta binding HSPG in the human brain: its localization in DIG domains and possible roles in the pathogenesis of Alzheimer&#x2019;s disease. Faseb J. 2004;18:1013&#x2013;1015.</Citation><ArticleIdList><ArticleId IdType="pubmed">15084524</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng F, Ruscher K, Fransson LA, Mani K. Non-toxic amyloid beta formed in the presence of glypican-1 or its deaminatively generated heparan sulfate degradation products. Glycobiology. 2013;23:1510&#x2013;1519.</Citation><ArticleIdList><ArticleId IdType="pubmed">24026238</ArticleId></ArticleIdList></Reference><Reference><Citation>Brunden KR, Richter-Cook NJ, Chaturvedi N, Frederickson RC. pH-dependent binding of synthetic beta-amyloid peptides to glycosaminoglycans. J Neurochem. 1993;61:2147&#x2013;2154.</Citation><ArticleIdList><ArticleId IdType="pubmed">8245966</ArticleId></ArticleIdList></Reference><Reference><Citation>Sandwall E, O&#x2019;Callaghan P, Zhang X, Lindahl U, Lannfelt L, Li JP. Heparan sulfate mediates amyloid-beta internalization and cytotoxicity. Glycobiology. 2010;20:533&#x2013;541.</Citation><ArticleIdList><ArticleId IdType="pubmed">20053627</ArticleId></ArticleIdList></Reference><Reference><Citation>Bergamaschini L, Donarini C, Rossi E, De Luigi A, Vergani C, De Simoni MG. Heparin attenuates cytotoxic and inflammatory activity of Alzheimer amyloid-beta in vitro. Neurobiol Aging. 2002;23:531&#x2013;536.</Citation><ArticleIdList><ArticleId IdType="pubmed">12009502</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanekiyo T, Zhang J, Liu Q, Liu CC, Zhang L, Bu G. Heparan sulphate proteoglycan and the low-density lipoprotein receptor-related protein 1 constitute major pathways for neuronal amyloid-beta uptake. J Neurosci. 2011;31:1644&#x2013;1651.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3272839</ArticleId><ArticleId IdType="pubmed">21289173</ArticleId></ArticleIdList></Reference><Reference><Citation>Jendresen CB, Cui H, Zhang X, Vlodavsky I, Nilsson LN, Li JP. Overexpression of heparanase lowers the amyloid burden in amyloid-beta precursor protein transgenic mice. J Biol Chem. 2015;290:5053&#x2013;5064.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4335241</ArticleId><ArticleId IdType="pubmed">25548284</ArticleId></ArticleIdList></Reference><Reference><Citation>Inatani M, Irie F, Plump AS, Tessier-Lavigne M, Yamaguchi Y. Mammalian brain morphogenesis and midline axon guidance require heparan sulfate. Science. 2003;302:1044&#x2013;1046.</Citation><ArticleIdList><ArticleId IdType="pubmed">14605369</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsien JZ, Chen DF, Gerber D, Tom C, Mercer EH, Anderson DJ, Mayford M, Kandel ER, Tonegawa S. Subregion- and cell type-restricted gene knockout in mouse brain. Cell. 1996;87:1317&#x2013;1326.</Citation><ArticleIdList><ArticleId IdType="pubmed">8980237</ArticleId></ArticleIdList></Reference><Reference><Citation>Jankowsky JL, Fadale DJ, Anderson J, Xu GM, Gonzales V, Jenkins NA, Copeland NG, Lee MK, Younkin LH, Wagner SL, Younkin SG, Borchelt DR. Mutant presenilins specifically elevate the levels of the 42 residue beta-amyloid peptide in vivo: evidence for augmentation of a 42-specific gamma secretase. Hum Mol Genet. 2004;13:159&#x2013;170.</Citation><ArticleIdList><ArticleId IdType="pubmed">14645205</ArticleId></ArticleIdList></Reference><Reference><Citation>Irie F, Badie-Mahdavi H, Yamaguchi Y. Autism-like socio-communicative deficits and stereotypies in mice lacking heparan sulfate. Proc Natl Acad Sci U S A. 2012;109:5052&#x2013;5056.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3323986</ArticleId><ArticleId IdType="pubmed">22411800</ArticleId></ArticleIdList></Reference><Reference><Citation>van Horssen J, Wesseling P, van den Heuvel LP, de Waal RM, Verbeek MM. Heparan sulphate proteoglycans in Alzheimer&#x2019;s disease and amyloid-related disorders. Lancet Neurol. 2003;2:482&#x2013;492.</Citation><ArticleIdList><ArticleId IdType="pubmed">12878436</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Callaghan P, Sandwall E, Li JP, Yu H, Ravid R, Guan ZZ, van Kuppevelt TH, Nilsson LN, Ingelsson M, Hyman BT, Kalimo H, Lindahl U, Lannfelt L, Zhang X. Heparan sulfate accumulation with Abeta deposits in Alzheimer&#x2019;s disease and Tg2576 mice is contributed by glial cells. Brain Pathol. 2008;18:548&#x2013;561.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2856073</ArticleId><ArticleId IdType="pubmed">18422760</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia-Alloza M, Robbins EM, Zhang-Nunes SX, Purcell SM, Betensky RA, Raju S, Prada C, Greenberg SM, Bacskai BJ, Frosch MP. Characterization of amyloid deposition in the APPswe/PS1dE9 mouse model of Alzheimer disease. Neurobiol Dis. 2006;24:516&#x2013;524.</Citation><ArticleIdList><ArticleId IdType="pubmed">17029828</ArticleId></ArticleIdList></Reference><Reference><Citation>Youmans KL, Tai LM, Kanekiyo T, Stine WB, Jr, Michon SC, Nwabuisi-Heath E, Manelli AM, Fu Y, Riordan S, Eimer WA, Binder L, Bu G, Yu C, Hartley DM, LaDu MJ. Intraneuronal Abeta detection in 5xFAD mice by a new Abeta-specific antibody. Mol Neurodegener. 2012;7:8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3355009</ArticleId><ArticleId IdType="pubmed">22423893</ArticleId></ArticleIdList></Reference><Reference><Citation>Timmer NM, Herbert MK, Kleinovink JW, Kiliaan AJ, De Waal RM, Verbeek MM. Limited expression of heparan sulphate proteoglycans associated with Abeta deposits in the APPswe/PS1dE9 mouse model for Alzheimer&#x2019;s disease. Neuropathol Appl Neurobiol. 2010;36:478&#x2013;486.</Citation><ArticleIdList><ArticleId IdType="pubmed">20831743</ArticleId></ArticleIdList></Reference><Reference><Citation>Verbeek MM, Otte-Holler I, van den Born J, van den Heuvel LP, David G, Wesseling P, de Waal RM. Agrin is a major heparan sulfate proteoglycan accumulating in Alzheimer&#x2019;s disease brain. Am J Pathol. 1999;155:2115&#x2013;2125.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1866925</ArticleId><ArticleId IdType="pubmed">10595940</ArticleId></ArticleIdList></Reference><Reference><Citation>Rauch SM, Huen K, Miller MC, Chaudry H, Lau M, Sanes JR, Johanson CE, Stopa EG, Burgess RW. Changes in brain beta-amyloid deposition and aquaporin 4 levels in response to altered agrin expression in mice. J Neuropathol Exp Neurol. 2011;70:1124&#x2013;1137.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3223604</ArticleId><ArticleId IdType="pubmed">22082664</ArticleId></ArticleIdList></Reference><Reference><Citation>Youmans KL, Leung S, Zhang J, Maus E, Baysac K, Bu G, Vassar R, Yu C, LaDu MJ. Amyloid-beta42 alters apolipoprotein E solubility in brains of mice with five familial AD mutations. J Neurosci Methods. 2011;196:51&#x2013;59.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3049315</ArticleId><ArticleId IdType="pubmed">21219931</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ. Soluble oligomers of the amyloid beta-protein impair synaptic plasticity and behavior. Behav Brain Res. 2008;192:106&#x2013;113.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2601528</ArticleId><ArticleId IdType="pubmed">18359102</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia W, Yang T, Shankar G, Smith IM, Shen Y, Walsh DM, Selkoe DJ. A specific enzyme-linked immunosorbent assay for measuring beta-amyloid protein oligomers in human plasma and brain tissue of patients with Alzheimer disease. Arch Neurol. 2009;66:190&#x2013;199.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3618974</ArticleId><ArticleId IdType="pubmed">19204155</ArticleId></ArticleIdList></Reference><Reference><Citation>Castillo GM, Lukito W, Wight TN, Snow AD. The sulfate moieties of glycosaminoglycans are critical for the enhancement of beta-amyloid protein fibril formation. J Neurochem. 1999;72:1681&#x2013;1687.</Citation><ArticleIdList><ArticleId IdType="pubmed">10098877</ArticleId></ArticleIdList></Reference><Reference><Citation>Wyss-Coray T. Inflammation in Alzheimer disease: driving force, bystander or beneficial response? Nat Med. 2006;12:1005&#x2013;1015.</Citation><ArticleIdList><ArticleId IdType="pubmed">16960575</ArticleId></ArticleIdList></Reference><Reference><Citation>Rubio-Perez JM, Morillas-Ruiz JM. A review: inflammatory process in Alzheimer&#x2019;s disease, role of cytokines. ScientificWorldJournal. 2012;2012 756357.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3330269</ArticleId><ArticleId IdType="pubmed">22566778</ArticleId></ArticleIdList></Reference><Reference><Citation>Cirrito JR, Disabato BM, Restivo JL, Verges DK, Goebel WD, Sathyan A, Hayreh D, D&#x2019;Angelo G, Benzinger T, Yoon H, Kim J, Morris JC, Mintun MA, Sheline YI. Serotonin signaling is associated with lower amyloid-beta levels and plaques in transgenic mice and humans. Proc Natl Acad Sci U S A. 2011;108:14968&#x2013;14973.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3169155</ArticleId><ArticleId IdType="pubmed">21873225</ArticleId></ArticleIdList></Reference><Reference><Citation>Bero AW, Yan P, Roh JH, Cirrito JR, Stewart FR, Raichle ME, Lee JM, Holtzman DM. Neuronal activity regulates the regional vulnerability to amyloid-beta deposition. Nat Neurosci. 2011;14:750&#x2013;756.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3102784</ArticleId><ArticleId IdType="pubmed">21532579</ArticleId></ArticleIdList></Reference><Reference><Citation>Weller RO, Subash M, Preston SD, Mazanti I, Carare RO. Perivascular drainage of amyloid-beta peptides from the brain and its failure in cerebral amyloid angiopathy and Alzheimer&#x2019;s disease. Brain Pathol. 2008;18:253&#x2013;266.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8095597</ArticleId><ArticleId IdType="pubmed">18363936</ArticleId></ArticleIdList></Reference><Reference><Citation>Snow AD, Sekiguchi RT, Nochlin D, Kalaria RN, Kimata K. Heparan sulfate proteoglycan in diffuse plaques of hippocampus but not of cerebellum in Alzheimer&#x2019;s disease brain. Am J Pathol. 1994;144:337&#x2013;347.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1887140</ArticleId><ArticleId IdType="pubmed">8311117</ArticleId></ArticleIdList></Reference><Reference><Citation>Snow AD, Mar H, Nochlin D, Kimata K, Kato M, Suzuki S, Hassell J, Wight TN. The presence of heparan sulfate proteoglycans in the neuritic plaques and congophilic angiopathy in Alzheimer&#x2019;s disease. Am J Pathol. 1988;133:456&#x2013;463.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1880818</ArticleId><ArticleId IdType="pubmed">2974240</ArticleId></ArticleIdList></Reference><Reference><Citation>Donahue JE, Berzin TM, Rafii MS, Glass DJ, Yancopoulos GD, Fallon JR, Stopa EG. Agrin in Alzheimer&#x2019;s disease: altered solubility and abnormal distribution within microvasculature and brain parenchyma. Proc Natl Acad Sci U S A. 1999;96:6468&#x2013;6472.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC26905</ArticleId><ArticleId IdType="pubmed">10339611</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang Y, Mucke L. Alzheimer mechanisms and therapeutic strategies. Cell. 2012;148:1204&#x2013;1222.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3319071</ArticleId><ArticleId IdType="pubmed">22424230</ArticleId></ArticleIdList></Reference><Reference><Citation>Holtzman DM, Morris JC, Goate AM. Alzheimer&#x2019;s disease: the challenge of the second century. Sci Transl Med. 2011;3:77sr71.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3130546</ArticleId><ArticleId IdType="pubmed">21471435</ArticleId></ArticleIdList></Reference><Reference><Citation>Citron M, Oltersdorf T, Haass C, McConlogue L, Hung AY, Seubert P, Vigo-Pelfrey C, Lieberburg I, Selkoe DJ. Mutation of the beta-amyloid precursor protein in familial Alzheimer&#x2019;s disease increases beta-protein production. Nature. 1992;360:672&#x2013;674.</Citation><ArticleIdList><ArticleId IdType="pubmed">1465129</ArticleId></ArticleIdList></Reference><Reference><Citation>Campion D, Dumanchin C, Hannequin D, Dubois B, Belliard S, Puel M, Thomas-Anterion C, Michon A, Martin C, Charbonnier F, Raux G, Camuzat A, Penet C, Mesnage V, Martinez M, Clerget-Darpoux F, Brice A, Frebourg T. Early-onset autosomal dominant Alzheimer disease: prevalence, genetic heterogeneity, and mutation spectrum. Am J Hum Genet. 1999;65:664&#x2013;670.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1377972</ArticleId><ArticleId IdType="pubmed">10441572</ArticleId></ArticleIdList></Reference><Reference><Citation>Iozzo RV. Heparan sulfate proteoglycans: intricate molecules with intriguing functions. J Clin Invest. 2001;108:165&#x2013;167.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC203034</ArticleId><ArticleId IdType="pubmed">11457866</ArticleId></ArticleIdList></Reference><Reference><Citation>Turnbull J, Powell A, Guimond S. Heparan sulfate: decoding a dynamic multifunctional cell regulator. Trends Cell Biol. 2001;11:75&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pubmed">11166215</ArticleId></ArticleIdList></Reference><Reference><Citation>Holmes BB, DeVos SL, Kfoury N, Li M, Jacks R, Yanamandra K, Ouidja MO, Brodsky FM, Marasa J, Bagchi DP, Kotzbauer PT, Miller TM, Papy-Garcia D, Diamond MI. Heparan sulfate proteoglycans mediate internalization and propagation of specific proteopathic seeds. Proc Natl Acad Sci U S A. 2013;110:E3138&#x2013;3147.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3746848</ArticleId><ArticleId IdType="pubmed">23898162</ArticleId></ArticleIdList></Reference><Reference><Citation>Bame KJ, Danda J, Hassall A, Tumova S. Abeta(1-40) prevents heparanase-catalyzed degradation of heparan sulfate glycosaminoglycans and proteoglycans in vitro. A role for heparan sulfate proteoglycan turnover in Alzheimer&#x2019;s disease. J Biol Chem. 1997;272:17005&#x2013;17011.</Citation><ArticleIdList><ArticleId IdType="pubmed">9202014</ArticleId></ArticleIdList></Reference><Reference><Citation>Cirrito JR, Deane R, Fagan AM, Spinner ML, Parsadanian M, Finn MB, Jiang H, Prior JL, Sagare A, Bales KR, Paul SM, Zlokovic BV, Piwnica-Worms D, Holtzman DM. P-glycoprotein deficiency at the blood-brain barrier increases amyloid-beta deposition in an Alzheimer disease mouse model. J Clin Invest. 2005;115:3285&#x2013;3290.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1257538</ArticleId><ArticleId IdType="pubmed">16239972</ArticleId></ArticleIdList></Reference><Reference><Citation>Farris W, Schutz SG, Cirrito JR, Shankar GM, Sun X, George A, Leissring MA, Walsh DM, Qiu WQ, Holtzman DM, Selkoe DJ. Loss of neprilysin function promotes amyloid plaque formation and causes cerebral amyloid angiopathy. Am J Pathol. 2007;171:241&#x2013;251.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1941603</ArticleId><ArticleId IdType="pubmed">17591969</ArticleId></ArticleIdList></Reference><Reference><Citation>Miners JS, Baig S, Palmer J, Palmer LE, Kehoe PG, Love S. Abeta-degrading enzymes in Alzheimer&#x2019;s disease. Brain Pathol. 2008;18:240&#x2013;252.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8095507</ArticleId><ArticleId IdType="pubmed">18363935</ArticleId></ArticleIdList></Reference><Reference><Citation>Saido T, Leissring MA. Proteolytic degradation of amyloid beta-protein. Cold Spring Harb Perspect Med. 2012;2:a006379.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3367539</ArticleId><ArticleId IdType="pubmed">22675659</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta-Bansal R, Frederickson RC, Brunden KR. Proteoglycan-mediated inhibition of A beta proteolysis. A potential cause of senile plaque accumulation. J Biol Chem. 1995;270:18666&#x2013;18671.</Citation><ArticleIdList><ArticleId IdType="pubmed">7629198</ArticleId></ArticleIdList></Reference><Reference><Citation>Sagare AP, Bell RD, Zlokovic BV. Neurovascular dysfunction and faulty amyloid beta-peptide clearance in Alzheimer disease. Cold Spring Harb Perspect Med. 2012;2</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3475405</ArticleId><ArticleId IdType="pubmed">23028132</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanekiyo T, Xu H, Bu G. ApoE and Abeta in Alzheimer&#x2019;s disease: accidental encounters or partners? Neuron. 2014;81:740&#x2013;754.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3983361</ArticleId><ArticleId IdType="pubmed">24559670</ArticleId></ArticleIdList></Reference><Reference><Citation>Bergamaschini L, Rossi E, Storini C, Pizzimenti S, Distaso M, Perego C, De Luigi A, Vergani C, De Simoni MG. Peripheral treatment with enoxaparin, a low molecular weight heparin, reduces plaques and beta-amyloid accumulation in a mouse model of Alzheimer&#x2019;s disease. J Neurosci. 2004;24:4181&#x2013;4186.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6729286</ArticleId><ArticleId IdType="pubmed">15115813</ArticleId></ArticleIdList></Reference><Reference><Citation>van Horssen J, Wesseling P, van den Heuvel LP, de Waal RM, Verbeek MM. Heparan sulphate proteoglycans in Alzheimer&#x2019;s disease and amyloid-related disorders. Lancet Neurol. 2003;2:482&#x2013;492.</Citation><ArticleIdList><ArticleId IdType="pubmed">12878436</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanekiyo T, Cirrito JR, Liu CC, Shinohara M, Li J, Schuler DR, Holtzman DM, Bu G. Neuronal clearance of amyloid-beta by endocytic receptor LRP1. J Neurosci. 2013;33:19276&#x2013;19283.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3850043</ArticleId><ArticleId IdType="pubmed">24305823</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu X, Crick SL, Bu G, Frieden C, Pappu RV, Lee JM. Amyloid seeds formed by cellular uptake, concentration, and aggregation of the amyloid-beta peptide. Proc Natl Acad Sci U S A. 2009;106:20324&#x2013;20329.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2787156</ArticleId><ArticleId IdType="pubmed">19910533</ArticleId></ArticleIdList></Reference><Reference><Citation>Li J, Kanekiyo T, Shinohara M, Zhang Y, LaDu MJ, Xu H, Bu G. Differential regulation of amyloid-beta endocytic trafficking and lysosomal degradation by apolipoprotein E isoforms. J Biol Chem. 2012;287:44593&#x2013;44601.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3531774</ArticleId><ArticleId IdType="pubmed">23132858</ArticleId></ArticleIdList></Reference><Reference><Citation>Watts JC, Condello C, Stohr J, Oehler A, Lee J, DeArmond SJ, Lannfelt L, Ingelsson M, Giles K, Prusiner SB. Serial propagation of distinct strains of Abeta prions from Alzheimer&#x2019;s disease patients. Proc Natl Acad Sci U S A. 2014;111:10323&#x2013;10328.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4104857</ArticleId><ArticleId IdType="pubmed">24982139</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyer-Luehmann M, Coomaraswamy J, Bolmont T, Kaeser S, Schaefer C, Kilger E, Neuenschwander A, Abramowski D, Frey P, Jaton AL, Vigouret JM, Paganetti P, Walsh DM, Mathews PM, Ghiso J, Staufenbiel M, Walker LC, Jucker M. Exogenous induction of cerebral beta-amyloidogenesis is governed by agent and host. Science. 2006;313:1781&#x2013;1784.</Citation><ArticleIdList><ArticleId IdType="pubmed">16990547</ArticleId></ArticleIdList></Reference><Reference><Citation>Song HL, Shim S, Kim DH, Won SH, Joo S, Kim S, Jeon NL, Yoon SY. beta-Amyloid is transmitted via neuronal connections along axonal membranes. Ann Neurol. 2014;75:88&#x2013;97.</Citation><ArticleIdList><ArticleId IdType="pubmed">24114864</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo JL, Covell DJ, Daniels JP, Iba M, Stieber A, Zhang B, Riddle DM, Kwong LK, Xu Y, Trojanowski JQ, Lee VM. Distinct alpha-synuclein strains differentially promote tau inclusions in neurons. Cell. 2013;154:103&#x2013;117.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3820001</ArticleId><ArticleId IdType="pubmed">23827677</ArticleId></ArticleIdList></Reference><Reference><Citation>Futamura M, Dhanasekaran P, Handa T, Phillips MC, Lund-Katz S, Saito H. Two-step mechanism of binding of apolipoprotein E to heparin: implications for the kinetics of apolipoprotein E-heparan sulfate proteoglycan complex formation on cell surfaces. J Biol Chem. 2005;280:5414&#x2013;5422.</Citation><ArticleIdList><ArticleId IdType="pubmed">15583000</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu CC, Kanekiyo T, Xu H, Bu G. Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nat Rev Neurol. 2013;9:106&#x2013;118.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3726719</ArticleId><ArticleId IdType="pubmed">23296339</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu CC, Tsai CW, Deak F, Rogers J, Penuliar M, Sung YM, Maher JN, Fu Y, Li X, Xu H, Estus S, Hoe HS, Fryer JD, Kanekiyo T, Bu G. Deficiency in LRP6-mediated Wnt signaling contributes to synaptic abnormalities and amyloid pathology in Alzheimer&#x2019;s disease. Neuron. 2014;84:63&#x2013;77.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4199382</ArticleId><ArticleId IdType="pubmed">25242217</ArticleId></ArticleIdList></Reference><Reference><Citation>Grear KE, Ling IF, Simpson JF, Furman JL, Simmons CR, Peterson SL, Schmitt FA, Markesbery WR, Liu Q, Crook JE, Younkin SG, Bu G, Estus S. Expression of SORL1 and a novel SORL1 splice variant in normal and Alzheimers disease brain. Mol Neurodegener. 2009;4:46.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2776013</ArticleId><ArticleId IdType="pubmed">19889229</ArticleId></ArticleIdList></Reference><Reference><Citation>Das P, Verbeeck C, Minter L, Chakrabarty P, Felsenstein K, Kukar T, Maharvi G, Fauq A, Osborne BA, Golde TE. Transient pharmacologic lowering of Abeta production prior to deposition results in sustained reduction of amyloid plaque pathology. Mol Neurodegener. 2012;7:39.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3477045</ArticleId><ArticleId IdType="pubmed">22892055</ArticleId></ArticleIdList></Reference><Reference><Citation>Tay WM, Bryant JG, Martin PK, Nix AJ, Cusack BM, Rosenberry TL. A mass spectrometric approach for characterization of amyloid-beta aggregates and identification of their post-translational modifications. Biochemistry. 2012;51:3759&#x2013;3766.</Citation><ArticleIdList><ArticleId IdType="pubmed">22506642</ArticleId></ArticleIdList></Reference><Reference><Citation>Rangachari V, Moore BD, Reed DK, Sonoda LK, Bridges AW, Conboy E, Hartigan D, Rosenberry TL. Amyloid-beta(1-42) rapidly forms protofibrils and oligomers by distinct pathways in low concentrations of sodium dodecylsulfate. Biochemistry. 2007;46:12451&#x2013;12462.</Citation><ArticleIdList><ArticleId IdType="pubmed">17910477</ArticleId></ArticleIdList></Reference><Reference><Citation>Chakrabarty P, Ceballos-Diaz C, Beccard A, Janus C, Dickson D, Golde TE, Das P. IFN-gamma promotes complement expression and attenuates amyloid plaque deposition in amyloid beta precursor protein transgenic mice. J Immunol. 2010;184:5333&#x2013;5343.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3798002</ArticleId><ArticleId IdType="pubmed">20368278</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">27041503</PMID><DateCompleted><Year>2017</Year><Month>06</Month><Day>19</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1097-4199</ISSN><JournalIssue CitedMedium="Internet"><Volume>90</Volume><Issue>2</Issue><PubDate><Year>2016</Year><Month>Apr</Month><Day>20</Day></PubDate></JournalIssue><Title>Neuron</Title><ISOAbbreviation>Neuron</ISOAbbreviation></Journal><ArticleTitle>Acetylated Tau Obstructs KIBRA-Mediated Signaling in Synaptic Plasticity and Promotes Tauopathy-Related Memory Loss.</ArticleTitle><Pagination><StartPage>245</StartPage><EndPage>260</EndPage><MedlinePgn>245-60</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.neuron.2016.03.005</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0896-6273(16)00184-7</ELocationID><Abstract><AbstractText>Tau toxicity has been implicated in the emergence of synaptic dysfunction in Alzheimer's disease (AD), but the mechanism by which tau alters synapse physiology and leads to cognitive decline is unclear. Here we report abnormal acetylation of K274 and K281 on tau, identified in AD brains, promotes memory loss and disrupts synaptic plasticity by reducing postsynaptic KIdney/BRAin (KIBRA) protein, a memory-associated protein. Transgenic mice expressing human tau with lysine-to-glutamine mutations to mimic K274 and K281 acetylation (tauKQ) exhibit AD-related memory deficits and impaired hippocampal long-term potentiation (LTP). TauKQ reduces synaptic KIBRA levels and disrupts activity-induced postsynaptic actin remodeling and AMPA receptor insertion. The LTP deficit was rescued by promoting actin polymerization or by KIBRA expression. In AD patients with dementia, we found enhanced tau acetylation is linked to loss of KIBRA. These findings suggest a novel mechanism by which pathogenic tau causes synaptic dysfunction and cognitive decline in AD pathogenesis.</AbstractText><CopyrightInformation>Copyright &#xa9; 2016 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tracy</LastName><ForeName>Tara E</ForeName><Initials>TE</Initials><AffiliationInfo><Affiliation>Gladstone Institute of Neurological Disease, San Francisco, CA 91458, USA; Department of Neurology, University of California, San Francisco, San Francisco, CA 91458, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sohn</LastName><ForeName>Peter Dongmin</ForeName><Initials>PD</Initials><AffiliationInfo><Affiliation>Gladstone Institute of Neurological Disease, San Francisco, CA 91458, USA; Neuroscience Graduate Program, University of California, San Francisco, San Francisco, CA 91458, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Minami</LastName><ForeName>S Sakura</ForeName><Initials>SS</Initials><AffiliationInfo><Affiliation>Gladstone Institute of Neurological Disease, San Francisco, CA 91458, USA; Department of Neurology, University of California, San Francisco, San Francisco, CA 91458, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Chao</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Gladstone Institute of Neurological Disease, San Francisco, CA 91458, USA; Department of Neurology, University of California, San Francisco, San Francisco, CA 91458, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Min</LastName><ForeName>Sang-Won</ForeName><Initials>SW</Initials><AffiliationInfo><Affiliation>Gladstone Institute of Neurological Disease, San Francisco, CA 91458, USA; Department of Neurology, University of California, San Francisco, San Francisco, CA 91458, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Yaqiao</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Gladstone Institute of Neurological Disease, San Francisco, CA 91458, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Yungui</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Gladstone Institute of Neurological Disease, San Francisco, CA 91458, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Le</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Gladstone Institute of Neurological Disease, San Francisco, CA 91458, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lo</LastName><ForeName>Iris</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Gladstone Institute of Neurological Disease, San Francisco, CA 91458, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ponnusamy</LastName><ForeName>Ravikumar</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Gladstone Institute of Neurological Disease, San Francisco, CA 91458, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cong</LastName><ForeName>Xin</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Buck Institute for Research on Aging, Novato, CA 94945, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schilling</LastName><ForeName>Birgit</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Buck Institute for Research on Aging, Novato, CA 94945, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ellerby</LastName><ForeName>Lisa M</ForeName><Initials>LM</Initials><AffiliationInfo><Affiliation>Buck Institute for Research on Aging, Novato, CA 94945, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huganir</LastName><ForeName>Richard L</ForeName><Initials>RL</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gan</LastName><ForeName>Li</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Gladstone Institute of Neurological Disease, San Francisco, CA 91458, USA; Department of Neurology, University of California, San Francisco, San Francisco, CA 91458, USA; Neuroscience Graduate Program, University of California, San Francisco, San Francisco, CA 91458, USA. Electronic address: lgan@gladstone.ucsf.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>F32 AG043301</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG036884</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RL1 NS062413</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS036715</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 NS065780</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG030207</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG051390</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS040251</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>C06 RR018928</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>03</Month><Day>31</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neuron</MedlineTA><NlmUniqueID>8809320</NlmUniqueID><ISSNLinking>0896-6273</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000199">Actins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002352">Carrier Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D047908">Intracellular Signaling Peptides and Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010750">Phosphoproteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018091">Receptors, AMPA</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C539495">Wwc1 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Neuron. 2016 Apr 20;90(2):205-6. doi: 10.1016/j.neuron.2016.04.008.</RefSource><PMID Version="1">27100190</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000107" MajorTopicYN="N">Acetylation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000199" MajorTopicYN="N">Actins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002352" MajorTopicYN="N">Carrier Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D047908" MajorTopicYN="N">Intracellular Signaling Peptides and Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017774" MajorTopicYN="N">Long-Term Potentiation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008569" MajorTopicYN="N">Memory Disorders</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009473" MajorTopicYN="N">Neuronal Plasticity</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010750" MajorTopicYN="N">Phosphoproteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D061251" MajorTopicYN="N">Primary Cell Culture</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018091" MajorTopicYN="N">Receptors, AMPA</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="Y">Signal Transduction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>9</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2016</Year><Month>1</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>2</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>4</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>4</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>6</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2017</Year><Month>4</Month><Day>20</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27041503</ArticleId><ArticleId IdType="mid">NIHMS774312</ArticleId><ArticleId IdType="pmc">PMC4859346</ArticleId><ArticleId IdType="doi">10.1016/j.neuron.2016.03.005</ArticleId><ArticleId IdType="pii">S0896-6273(16)00184-7</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ally BA, Hussey EP, Ko PC, Molitor RJ. Pattern separation and pattern completion in Alzheimer&#x2019;s disease: evidence of rapid forgetting in amnestic mild cognitive impairment. Hippocampus. 2013;23:1246&#x2013;1258.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4310474</ArticleId><ArticleId IdType="pubmed">23804525</ArticleId></ArticleIdList></Reference><Reference><Citation>Andorfer C, Kress Y, Espinoza M, de Silva R, Tucker KL, Barde YA, Duff K, Davies P. Hyperphosphorylation and aggregation of tau in mice expressing normal human tau isoforms. Journal of neurochemistry. 2003;86:582&#x2013;590.</Citation><ArticleIdList><ArticleId IdType="pubmed">12859672</ArticleId></ArticleIdList></Reference><Reference><Citation>Aubry S, Shin W, Crary JF, Lefort R, Qureshi YH, Lefebvre C, Califano A, Shelanski ML. Assembly and interrogation of Alzheimer&#x2019;s disease genetic networks reveal novel regulators of progression. PloS one. 2015;10:e0120352.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4363671</ArticleId><ArticleId IdType="pubmed">25781952</ArticleId></ArticleIdList></Reference><Reference><Citation>Burgess JD, Pedraza O, Graff-Radford NR, Hirpa M, Zou F, Miles R, Nguyen T, Li M, Lucas JA, Ivnik RJ, et al. Association of common KIBRA variants with episodic memory and AD risk. Neurobiology of aging. 2011;32:557, e551&#x2013;559.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3065956</ArticleId><ArticleId IdType="pubmed">21185624</ArticleId></ArticleIdList></Reference><Reference><Citation>Buther K, Plaas C, Barnekow A, Kremerskothen J. KIBRA is a novel substrate for protein kinase Czeta. Biochemical and biophysical research communications. 2004;317:703&#x2013;707.</Citation><ArticleIdList><ArticleId IdType="pubmed">15081397</ArticleId></ArticleIdList></Reference><Reference><Citation>Capani F, Martone ME, Deerinck TJ, Ellisman MH. Selective localization of high concentrations of F-actin in subpopulations of dendritic spines in rat central nervous system: a three-dimensional electron microscopic study. The Journal of comparative neurology. 2001;435:156&#x2013;170.</Citation><ArticleIdList><ArticleId IdType="pubmed">11391638</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen TJ, Friedmann D, Hwang AW, Marmorstein R, Lee VM. The microtubule-associated tau protein has intrinsic acetyltransferase activity. Nature structural &amp; molecular biology. 2013;20:756&#x2013;762.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3827724</ArticleId><ArticleId IdType="pubmed">23624859</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen TJ, Guo JL, Hurtado DE, Kwong LK, Mills IP, Trojanowski JQ, Lee VM. The acetylation of tau inhibits its function and promotes pathological tau aggregation. Nature communications. 2011;2:252.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3120096</ArticleId><ArticleId IdType="pubmed">21427723</ArticleId></ArticleIdList></Reference><Reference><Citation>Cook C, Carlomagno Y, Gendron TF, Dunmore J, Scheffel K, Stetler C, Davis M, Dickson D, Jarpe M, DeTure M, et al. Acetylation of the KXGS motifs in tau is a critical determinant in modulation of tau aggregation and clearance. Human molecular genetics. 2014;23:104&#x2013;116.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3857946</ArticleId><ArticleId IdType="pubmed">23962722</ArticleId></ArticleIdList></Reference><Reference><Citation>Corneveaux JJ, Liang WS, Reiman EM, Webster JA, Myers AJ, Zismann VL, Joshipura KD, Pearson JV, Hu-Lince D, Craig DW, et al. Evidence for an association between KIBRA and late-onset Alzheimer&#x2019;s disease. Neurobiology of aging. 2010;31:901&#x2013;909.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2913703</ArticleId><ArticleId IdType="pubmed">18789830</ArticleId></ArticleIdList></Reference><Reference><Citation>Correas I, Padilla R, Avila J. The tubulin-binding sequence of brain microtubule-associated proteins, tau and MAP-2, is also involved in actin binding. The Biochemical journal. 1990;269:61&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1131531</ArticleId><ArticleId IdType="pubmed">2115775</ArticleId></ArticleIdList></Reference><Reference><Citation>Crary JF, Shao CY, Mirra SS, Hernandez AI, Sacktor TC. Atypical protein kinase C in neurodegenerative disease I: PKMzeta aggregates with limbic neurofibrillary tangles and AMPA receptors in Alzheimer disease. Journal of neuropathology and experimental neurology. 2006;65:319&#x2013;326.</Citation><ArticleIdList><ArticleId IdType="pubmed">16691113</ArticleId></ArticleIdList></Reference><Reference><Citation>Cunningham CC, Leclerc N, Flanagan LA, Lu M, Janmey PA, Kosik KS. Microtubule-associated protein 2c reorganizes both microtubules and microfilaments into distinct cytological structures in an actin-binding protein-280-deficient melanoma cell line. The Journal of cell biology. 1997;136:845&#x2013;857.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2132495</ArticleId><ArticleId IdType="pubmed">9049250</ArticleId></ArticleIdList></Reference><Reference><Citation>Decker JM, Kruger L, Sydow A, Zhao S, Frotscher M, Mandelkow E, Mandelkow EM. Pro-aggregant Tau impairs mossy fiber plasticity due to structural changes and Ca++ dysregulation. Acta neuropathologica communications. 2015;3:23.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4384391</ArticleId><ArticleId IdType="pubmed">25853683</ArticleId></ArticleIdList></Reference><Reference><Citation>DeKosky ST, Scheff SW. Synapse loss in frontal cortex biopsies in Alzheimer&#x2019;s disease: correlation with cognitive severity. Annals of neurology. 1990;27:457&#x2013;464.</Citation><ArticleIdList><ArticleId IdType="pubmed">2360787</ArticleId></ArticleIdList></Reference><Reference><Citation>Drier EA, Tello MK, Cowan M, Wu P, Blace N, Sacktor TC, Yin JC. Memory enhancement and formation by atypical PKM activity in Drosophila melanogaster. Nature neuroscience. 2002;5:316&#x2013;324.</Citation><ArticleIdList><ArticleId IdType="pubmed">11914720</ArticleId></ArticleIdList></Reference><Reference><Citation>DuBoff B, Gotz J, Feany MB. Tau promotes neurodegeneration via DRP1 mislocalization in vivo. Neuron. 2012;75:618&#x2013;632.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3428596</ArticleId><ArticleId IdType="pubmed">22920254</ArticleId></ArticleIdList></Reference><Reference><Citation>Duning K, Schurek EM, Schluter M, Bayer M, Reinhardt HC, Schwab A, Schaefer L, Benzing T, Schermer B, Saleem MA, et al. KIBRA modulates directional migration of podocytes. Journal of the American Society of Nephrology: JASN. 2008;19:1891&#x2013;1903.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2551571</ArticleId><ArticleId IdType="pubmed">18596123</ArticleId></ArticleIdList></Reference><Reference><Citation>Frandemiche ML, De Seranno S, Rush T, Borel E, Elie A, Arnal I, Lante F, Buisson A. Activity-dependent tau protein translocation to excitatory synapse is disrupted by exposure to amyloid-beta oligomers. The Journal of neuroscience: the official journal of the Society for Neuroscience. 2014;34:6084&#x2013;6097.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6608293</ArticleId><ArticleId IdType="pubmed">24760868</ArticleId></ArticleIdList></Reference><Reference><Citation>Fukazawa Y, Saitoh Y, Ozawa F, Ohta Y, Mizuno K, Inokuchi K. Hippocampal LTP is accompanied by enhanced F-actin content within the dendritic spine that is essential for late LTP maintenance in vivo. Neuron. 2003;38:447&#x2013;460.</Citation><ArticleIdList><ArticleId IdType="pubmed">12741991</ArticleId></ArticleIdList></Reference><Reference><Citation>Fulga TA, Elson-Schwab I, Khurana V, Steinhilb ML, Spires TL, Hyman BT, Feany MB. Abnormal bundling and accumulation of F-actin mediates tau-induced neuronal degeneration in vivo. Nature cell biology. 2007;9:139&#x2013;148.</Citation><ArticleIdList><ArticleId IdType="pubmed">17187063</ArticleId></ArticleIdList></Reference><Reference><Citation>Gamblin TC, Chen F, Zambrano A, Abraha A, Lagalwar S, Guillozet AL, Lu M, Fu Y, Garcia-Sierra F, LaPointe N, et al. Caspase cleavage of tau: linking amyloid and neurofibrillary tangles in Alzheimer&#x2019;s disease. Proceedings of the National Academy of Sciences of the United States of America. 2003;100:10032&#x2013;10037.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC187753</ArticleId><ArticleId IdType="pubmed">12888622</ArticleId></ArticleIdList></Reference><Reference><Citation>Giannakopoulos P, Herrmann FR, Bussiere T, Bouras C, Kovari E, Perl DP, Morrison JH, Gold G, Hof PR. Tangle and neuron numbers, but not amyloid load, predict cognitive status in Alzheimer&#x2019;s disease. Neurology. 2003;60:1495&#x2013;1500.</Citation><ArticleIdList><ArticleId IdType="pubmed">12743238</ArticleId></ArticleIdList></Reference><Reference><Citation>Grinberg LT, Wang X, Wang C, Sohn PD, Theofilas P, Sidhu M, Arevalo JB, Heinsen H, Huang EJ, Rosen H, et al. Argyrophilic grain disease differs from other tauopathies by lacking tau acetylation. Acta neuropathologica. 2013;125:581&#x2013;593.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3692283</ArticleId><ArticleId IdType="pubmed">23371364</ArticleId></ArticleIdList></Reference><Reference><Citation>Hecht A, Laroche T, Strahl-Bolsinger S, Gasser SM, Grunstein M. Histone H3 and H4 N-termini interact with SIR3 and SIR4 proteins: a molecular model for the formation of heterochromatin in yeast. Cell. 1995;80:583&#x2013;592.</Citation><ArticleIdList><ArticleId IdType="pubmed">7867066</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoover BR, Reed MN, Su J, Penrod RD, Kotilinek LA, Grant MK, Pitstick R, Carlson GA, Lanier LM, Yuan LL, et al. Tau mislocalization to dendritic spines mediates synaptic dysfunction independently of neurodegeneration. Neuron. 2010;68:1067&#x2013;1081.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3026458</ArticleId><ArticleId IdType="pubmed">21172610</ArticleId></ArticleIdList></Reference><Reference><Citation>Irwin DJ, Cohen TJ, Grossman M, Arnold SE, McCarty-Wood E, Van Deerlin VM, Lee VM, Trojanowski JQ. Acetylated tau neuropathology in sporadic and hereditary tauopathies. The American journal of pathology. 2013;183:344&#x2013;351.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3730769</ArticleId><ArticleId IdType="pubmed">23885714</ArticleId></ArticleIdList></Reference><Reference><Citation>Irwin DJ, Cohen TJ, Grossman M, Arnold SE, Xie SX, Lee VM, Trojanowski JQ. Acetylated tau, a novel pathological signature in Alzheimer&#x2019;s disease and other tauopathies. Brain: a journal of neurology. 2012;135:807&#x2013;818.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3286338</ArticleId><ArticleId IdType="pubmed">22366796</ArticleId></ArticleIdList></Reference><Reference><Citation>Ittner LM, Ke YD, Delerue F, Bi M, Gladbach A, van Eersel J, Wolfing H, Chieng BC, Christie MJ, Napier IA, et al. Dendritic function of tau mediates amyloid-beta toxicity in Alzheimer&#x2019;s disease mouse models. Cell. 2010;142:387&#x2013;397.</Citation><ArticleIdList><ArticleId IdType="pubmed">20655099</ArticleId></ArticleIdList></Reference><Reference><Citation>Jain S, Yoon SY, Zhu L, Brodbeck J, Dai J, Walker D, Huang Y. Arf4 determines dentate gyrus-mediated pattern separation by regulating dendritic spine development. PloS one. 2012;7:e46340.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3457985</ArticleId><ArticleId IdType="pubmed">23050017</ArticleId></ArticleIdList></Reference><Reference><Citation>Johannsen S, Duning K, Pavenstadt H, Kremerskothen J, Boeckers TM. Temporal-spatial expression and novel biochemical properties of the memory-related protein KIBRA. Neuroscience. 2008;155:1165&#x2013;1173.</Citation><ArticleIdList><ArticleId IdType="pubmed">18672031</ArticleId></ArticleIdList></Reference><Reference><Citation>Julien C, Tremblay C, Emond V, Lebbadi M, Salem N, Jr, Bennett DA, Calon F. Sirtuin 1 reduction parallels the accumulation of tau in Alzheimer disease. Journal of neuropathology and experimental neurology. 2009;68:48&#x2013;58.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2813570</ArticleId><ArticleId IdType="pubmed">19104446</ArticleId></ArticleIdList></Reference><Reference><Citation>Kremerskothen J, Plaas C, Buther K, Finger I, Veltel S, Matanis T, Liedtke T, Barnekow A. Characterization of KIBRA, a novel WW domain-containing protein. Biochemical and biophysical research communications. 2003;300:862&#x2013;867.</Citation><ArticleIdList><ArticleId IdType="pubmed">12559952</ArticleId></ArticleIdList></Reference><Reference><Citation>Kremerskothen J, Plaas C, Kindler S, Frotscher M, Barnekow A. Synaptopodin, a molecule involved in the formation of the dendritic spine apparatus, is a dual actin/alpha-actinin binding protein. Journal of neurochemistry. 2005;92:597&#x2013;606.</Citation><ArticleIdList><ArticleId IdType="pubmed">15659229</ArticleId></ArticleIdList></Reference><Reference><Citation>Krucker T, Siggins GR, Halpain S. Dynamic actin filaments are required for stable long-term potentiation (LTP) in area CA1 of the hippocampus. Proceedings of the National Academy of Sciences of the United States of America. 2000;97:6856&#x2013;6861.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC18765</ArticleId><ArticleId IdType="pubmed">10823894</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y, Peng L, Seto E, Huang S, Qiu Y. Modulation of histone deacetylase 6 (HDAC6) nuclear import and tubulin deacetylase activity through acetylation. The Journal of biological chemistry. 2012;287:29168&#x2013;29174.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3436516</ArticleId><ArticleId IdType="pubmed">22778253</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu W, Man H, Ju W, Trimble WS, MacDonald JF, Wang YT. Activation of synaptic NMDA receptors induces membrane insertion of new AMPA receptors and LTP in cultured hippocampal neurons. Neuron. 2001;29:243&#x2013;254.</Citation><ArticleIdList><ArticleId IdType="pubmed">11182095</ArticleId></ArticleIdList></Reference><Reference><Citation>Makuch L, Volk L, Anggono V, Johnson RC, Yu Y, Duning K, Kremerskothen J, Xia J, Takamiya K, Huganir RL. Regulation of AMPA receptor function by the human memory-associated gene KIBRA. Neuron. 2011;71:1022&#x2013;1029.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3200575</ArticleId><ArticleId IdType="pubmed">21943600</ArticleId></ArticleIdList></Reference><Reference><Citation>McHugh TJ, Jones MW, Quinn JJ, Balthasar N, Coppari R, Elmquist JK, Lowell BB, Fanselow MS, Wilson MA, Tonegawa S. Dentate gyrus NMDA receptors mediate rapid pattern separation in the hippocampal network. Science (New York, NY) 2007;317:94&#x2013;99.</Citation><ArticleIdList><ArticleId IdType="pubmed">17556551</ArticleId></ArticleIdList></Reference><Reference><Citation>Min SW, Chen X, Tracy TE, Li Y, Zhou Y, Wang C, Shirakawa K, Minami SS, Defensor E, Mok SA, et al. Critical role of acetylation in tau-mediated neurodegeneration and cognitive deficits. Nature medicine. 2015;21:1154&#x2013;1162.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4598295</ArticleId><ArticleId IdType="pubmed">26390242</ArticleId></ArticleIdList></Reference><Reference><Citation>Min SW, Cho SH, Zhou Y, Schroeder S, Haroutunian V, Seeley WW, Huang EJ, Shen Y, Masliah E, Mukherjee C, et al. Acetylation of tau inhibits its degradation and contributes to tauopathy. Neuron. 2010;67:953&#x2013;966.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3035103</ArticleId><ArticleId IdType="pubmed">20869593</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris M, Knudsen GM, Maeda S, Trinidad JC, Ioanoviciu A, Burlingame AL, Mucke L. Tau post-translational modifications in wild-type and human amyloid precursor protein transgenic mice. Nature neuroscience 2015</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8049446</ArticleId><ArticleId IdType="pubmed">26192747</ArticleId></ArticleIdList></Reference><Reference><Citation>Mucke L, Masliah E, Yu GQ, Mallory M, Rockenstein EM, Tatsuno G, Hu K, Kholodenko D, Johnson-Wood K, McConlogue L. High-level neuronal expression of abeta 1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. The Journal of neuroscience: the official journal of the Society for Neuroscience. 2000;20:4050&#x2013;4058.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6772621</ArticleId><ArticleId IdType="pubmed">10818140</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakashiba T, Cushman JD, Pelkey KA, Renaudineau S, Buhl DL, McHugh TJ, Rodriguez Barrera V, Chittajallu R, Iwamoto KS, McBain CJ, et al. Young dentate granule cells mediate pattern separation, whereas old granule cells facilitate pattern completion. Cell. 2012;149:188&#x2013;201.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3319279</ArticleId><ArticleId IdType="pubmed">22365813</ArticleId></ArticleIdList></Reference><Reference><Citation>Oku Y, Huganir RL. AGAP3 and Arf6 regulate trafficking of AMPA receptors and synaptic plasticity. The Journal of neuroscience: the official journal of the Society for Neuroscience. 2013;33:12586&#x2013;12598.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3728681</ArticleId><ArticleId IdType="pubmed">23904596</ArticleId></ArticleIdList></Reference><Reference><Citation>Papassotiropoulos A, Stephan DA, Huentelman MJ, Hoerndli FJ, Craig DW, Pearson JV, Huynh KD, Brunner F, Corneveaux J, Osborne D, et al. Common Kibra alleles are associated with human memory performance. Science (New York, NY) 2006;314:475&#x2013;478.</Citation><ArticleIdList><ArticleId IdType="pubmed">17053149</ArticleId></ArticleIdList></Reference><Reference><Citation>Rissman RA, Poon WW, Blurton-Jones M, Oddo S, Torp R, Vitek MP, LaFerla FM, Rohn TT, Cotman CW. Caspase-cleavage of tau is an early event in Alzheimer disease tangle pathology. The Journal of clinical investigation. 2004;114:121&#x2013;130.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC437967</ArticleId><ArticleId IdType="pubmed">15232619</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodriguez-Rodriguez E, Infante J, Llorca J, Mateo I, Sanchez-Quintana C, Garcia-Gorostiaga I, Sanchez-Juan P, Berciano J, Combarros O. Age-dependent association of KIBRA genetic variation and Alzheimer&#x2019;s disease risk. Neurobiology of aging. 2009;30:322&#x2013;324.</Citation><ArticleIdList><ArticleId IdType="pubmed">17707552</ArticleId></ArticleIdList></Reference><Reference><Citation>Santacruz K, Lewis J, Spires T, Paulson J, Kotilinek L, Ingelsson M, Guimaraes A, DeTure M, Ramsden M, McGowan E, et al. Tau suppression in a neurodegenerative mouse model improves memory function. Science. 2005;309:476&#x2013;481.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1574647</ArticleId><ArticleId IdType="pubmed">16020737</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider A, Huentelman MJ, Kremerskothen J, Duning K, Spoelgen R, Nikolich K. KIBRA: A New Gateway to Learning and Memory? Frontiers in aging neuroscience. 2010;2:4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2874402</ArticleId><ArticleId IdType="pubmed">20552044</ArticleId></ArticleIdList></Reference><Reference><Citation>Scroggins BT, Robzyk K, Wang D, Marcu MG, Tsutsumi S, Beebe K, Cotter RJ, Felts S, Toft D, Karnitz L, et al. An acetylation site in the middle domain of Hsp90 regulates chaperone function. Molecular cell. 2007;25:151&#x2013;159.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1839984</ArticleId><ArticleId IdType="pubmed">17218278</ArticleId></ArticleIdList></Reference><Reference><Citation>Serrano P, Yao Y, Sacktor TC. Persistent phosphorylation by protein kinase Mzeta maintains late-phase long-term potentiation. The Journal of neuroscience: the official journal of the Society for Neuroscience. 2005;25:1979&#x2013;1984.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6726070</ArticleId><ArticleId IdType="pubmed">15728837</ArticleId></ArticleIdList></Reference><Reference><Citation>Spange S, Wagner T, Heinzel T, Kramer OH. Acetylation of non-histone proteins modulates cellular signalling at multiple levels. The international journal of biochemistry &amp; cell biology. 2009;41:185&#x2013;198.</Citation><ArticleIdList><ArticleId IdType="pubmed">18804549</ArticleId></ArticleIdList></Reference><Reference><Citation>Sydow A, Van der Jeugd A, Zheng F, Ahmed T, Balschun D, Petrova O, Drexler D, Zhou L, Rune G, Mandelkow E, et al. Tau-induced defects in synaptic plasticity, learning, and memory are reversible in transgenic mice after switching off the toxic Tau mutant. The Journal of neuroscience: the official journal of the Society for Neuroscience. 2011;31:2511&#x2013;2525.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6623704</ArticleId><ArticleId IdType="pubmed">21325519</ArticleId></ArticleIdList></Reference><Reference><Citation>Van der Jeugd A, Hochgrafe K, Ahmed T, Decker JM, Sydow A, Hofmann A, Wu D, Messing L, Balschun D, D&#x2019;Hooge R, et al. Cognitive defects are reversible in inducible mice expressing pro-aggregant full-length human Tau. Acta neuropathologica. 2012;123:787&#x2013;805.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4979687</ArticleId><ArticleId IdType="pubmed">22532069</ArticleId></ArticleIdList></Reference><Reference><Citation>Vogt-Eisele A, Kruger C, Duning K, Weber D, Spoelgen R, Pitzer C, Plaas C, Eisenhardt G, Meyer A, Vogt G, et al. KIBRA (KIdney/BRAin protein) regulates learning and memory and stabilizes Protein kinase Mzeta. Journal of neurochemistry. 2014;128:686&#x2013;700.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3947452</ArticleId><ArticleId IdType="pubmed">24117625</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang YH, Tsay YG, Tan BC, Lo WY, Lee SC. Identification and characterization of a novel p300-mediated p53 acetylation site, lysine 305. The Journal of biological chemistry. 2003;278:25568&#x2013;25576.</Citation><ArticleIdList><ArticleId IdType="pubmed">12724314</ArticleId></ArticleIdList></Reference><Reference><Citation>Warmus BA, Sekar DR, McCutchen E, Schellenberg GD, Roberts RC, McMahon LL, Roberson ED. Tau-mediated NMDA receptor impairment underlies dysfunction of a selectively vulnerable network in a mouse model of frontotemporal dementia. The Journal of neuroscience: the official journal of the Society for Neuroscience. 2014;34:16482&#x2013;16495.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4252555</ArticleId><ArticleId IdType="pubmed">25471585</ArticleId></ArticleIdList></Reference><Reference><Citation>Wesnes KA, Annas P, Basun H, Edgar C, Blennow K. Performance on a pattern separation task by Alzheimer&#x2019;s patients shows possible links between disrupted dentate gyrus activity and apolipoprotein E in4 status and cerebrospinal fluid amyloid-beta42 levels. Alzheimer&#x2019;s research &amp; therapy. 2014;6:20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4054957</ArticleId><ArticleId IdType="pubmed">24735568</ArticleId></ArticleIdList></Reference><Reference><Citation>Yassa MA, Stark SM, Bakker A, Albert MS, Gallagher M, Stark CE. High-resolution structural and functional MRI of hippocampal CA3 and dentate gyrus in patients with amnestic Mild Cognitive Impairment. NeuroImage. 2010;51:1242&#x2013;1252.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2909476</ArticleId><ArticleId IdType="pubmed">20338246</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshiyama Y, Higuchi M, Zhang B, Huang SM, Iwata N, Saido TC, Maeda J, Suhara T, Trojanowski JQ, Lee VM. Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron. 2007;53:337&#x2013;351.</Citation><ArticleIdList><ArticleId IdType="pubmed">17270732</ArticleId></ArticleIdList></Reference><Reference><Citation>Zempel H, Mandelkow E. Lost after translation: missorting of Tau protein and consequences for Alzheimer disease. Trends in neurosciences. 2014;37:721&#x2013;732.</Citation><ArticleIdList><ArticleId IdType="pubmed">25223701</ArticleId></ArticleIdList></Reference><Reference><Citation>Zempel H, Thies E, Mandelkow E, Mandelkow EM. Abeta oligomers cause localized Ca(2+) elevation, missorting of endogenous Tau into dendrites, Tau phosphorylation, and destruction of microtubules and spines. The Journal of neuroscience: the official journal of the Society for Neuroscience. 2010;30:11938&#x2013;11950.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6633549</ArticleId><ArticleId IdType="pubmed">20826658</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang L, Yang S, Wennmann DO, Chen Y, Kremerskothen J, Dong J. KIBRA: In the brain and beyond. Cellular signalling. 2014;26:1392&#x2013;1399.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4032603</ArticleId><ArticleId IdType="pubmed">24642126</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>